PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Johnston, S; Wilkes, GJ; Thompson, JA; Ziman, M; Brightwell, R				Johnston, Steven; Wilkes, Garry J.; Thompson, Jennifer A.; Ziman, Mel; Brightwell, Richard			Inhaled methoxyflurane and intranasal fentanyl for prehospital management of visceral pain in an Australian ambulance service	EMERGENCY MEDICINE JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS MORPHINE; EMERGENCY-DEPARTMENT; ANALGESIA; TITRATION; EFFICACY; SAFETY; TRAUMA	Objective This study analysed the analgesic effect and changes in vital signs associated with administration of inhaled Methoxyflurane (MTX) and/or intranasal Fentanyl (INF) for prehospital management of visceral pain. Method A retrospective, observational study reviewing 1024 randomly selected records of patients with presumed visceral pain administered MTX (465), INF (397) or both (162) by the Western Australian Ambulance Service between January 2004 and February 2006. Clinical variables assessed included systolic blood pressure, pulse rate, respiration rate and Glasgow Coma Scale score. Pain was assessed utilising Visual/Verbal Analogue Scale pain scores. Results Overall effects on vital signs appeared favourable 5 min after use and at hospital arrival with either agent alone or in combination. As sole agents, MTX produced the greatest initial pain scores reduction (2.0 (1.7 to 2.2) vs 1.6 (1.4 to 1.8)) (mean (95% CI), and INF provided greater pain reduction by hospital arrival (3.2 (2.9 to 3.5) vs 2.5 (2.1 to 2.9)). While both agents were effective, INF provided a greater pain score reduction for cardiac (3.0 (2.6 to 3.4) vs 2.3 (1.8 to 2.8)), female (3.4 (2.9 to 4.0) v 2.5 (2.0 to 3.0)) and age 75+ patients (3.2 (2.5 to 3.8) vs 1.8 (1.0 to 2.5)). Combined use of agents was not advantageous. Conclusions MTX and INF are effective agents for providing visceral pain analgesia in the prehospital setting. While MTX provided a more rapid onset of pain relief, INF provided superior analgesia after subsequent doses and in female, cardiac and older patients.	[Johnston, Steven; Wilkes, Garry J.; Brightwell, Richard] Edith Cowan Univ, Sch Nursing Midwifery & Postgrad Med, Perth, WA 6027, Australia; [Johnston, Steven; Wilkes, Garry J.; Brightwell, Richard] St John Ambulance, Western Australia Ambulance Serv, Belmont, MA, Australia; [Wilkes, Garry J.] Univ Western Australia, Rural Clin Sch, Perth, WA 6009, Australia; [Thompson, Jennifer A.; Ziman, Mel] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Perth, WA, Australia	Johnston, S (reprint author), Edith Cowan Univ, Sch Nursing Midwifery & Postgrad Med, 270 Joondalup Dr, Perth, WA 6027, Australia.	steven.johnston@ecu.edu.au		Ziman, Mel/0000-0001-7527-3538			Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; *AUSTR GOV NAT OCC, 2010, 1003199574 NOHSC AUS; Babl Franz E, 2006, Emerg Med Australas, V18, P404, DOI 10.1111/j.1742-6723.2006.00874.x; BLEDSOE BE, 2005, PRE HOSP EMERGENCY P; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P77, DOI 10.1046/j.1442-2026.2002.00288.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; Buntine P, 2007, EMERG MED AUSTRALAS, V19, P509, DOI 10.1111/j.1742-6723.2007.01017.x; CHAMBERS JA, 1993, ARCH EMERG MED, V10, P187; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; DONOHOO E, 2006, MIMS ANN, P486; FLYNN M, 2002, SIRENS, V7, P2; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Giamberardino MA, 2000, PROG PAIN RES MANAG, V16, P523; GIAMBERARDINO MA, PAIN CLIN UPDATES 20, V13; Grindlay J, 2009, EMERG MED AUSTRALAS, V21, P4, DOI 10.1111/j.1742-6723.2009.01153.x; Jaslow David, 2007, EMS Mag, V36, P105; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Kelly A M, 2001, Emerg Med (Fremantle), V13, P57, DOI 10.1046/j.1442-2026.2001.00179.x; KENNA JG, 1995, ANESTH ANALG, V81, pS51, DOI 10.1097/00000539-199512001-00008; Lord Bill A, 2003, Prehosp Disaster Med, V18, P353; MAZZE RI, 1973, BRIT J ANAESTH, V45, P394, DOI 10.1093/bja/45.4.394; McLennan J V, 2007, J R Army Med Corps, V153, P111; MISTOVICH J, 2003, BRADYS PREHOSPITAL A; *NIOSH, 2005, POCK GUID CHEM HAZ; PACKER KJ, 1969, BRIT J ANAESTH, V41, P1080, DOI 10.1093/bja/41.12.1080; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Silfvast T, 2001, Eur J Emerg Med, V8, P275, DOI 10.1097/00063110-200112000-00005; SONG S, PAIN CLIN UPDATE 199, V7; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Thomas SH, 2007, AM J EMERG MED, V25, P842, DOI 10.1016/j.ajem.2007.02.010; TINTINALLI JE, 2000, EMERGENCY MED COMPRE; TOOMATH RJ, 1987, NEW ZEAL MED J, V100, P707; Wilkes G, 2006, CAN J EMERG MED, V8, pS103	38	37	37	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	JAN	2011	28	1					57	63		10.1136/emj.2009.078717			7	Emergency Medicine	Emergency Medicine	696PR	WOS:000285454400019	20466829				2020-06-30	J	Mitzelfelt, JD; DuPree, JP; Seo, DO; Carter, CS; Morgan, D				Mitzelfelt, Jeremiah D.; DuPree, Jameson P.; Seo, Dong-oh; Carter, Christy S.; Morgan, Drake			Effects of chronic fentanyl administration on physical performance of aged rats	EXPERIMENTAL GERONTOLOGY			English	Article						Locomotor activity; Rotarod; Grip strength; Body composition; Osmotic minipump	OLDER-ADULTS; WEIGHT-LOSS; TRANSDERMAL FENTANYL; BODY-COMPOSITION; ELDERLY-PATIENTS; NONCANCER PAIN; INCREASED FOOD; WATER-INTAKE; MANAGEMENT; OPIOIDS	There is growing concern over the increasing use of opioids to treat chronic pain in the elderly primarily because of the potential increased sensitivity to the adverse side effects. Here, we use a preclinical model (male Brown Norway X F344 rats aged 12, 18, 24, and 30 months) to describe the outcome of chronic fentanyl administration (1.0 mg/kg/day) on various physiological and behavioral measures. Continuous fentanyl administration resulted in an initial decrease in food consumption, followed by the development of tolerance to this effect over a 4-week period and a subsequent increase in food consumption during withdrawal. This change in food consumption was associated with decreases in body weight (predominantly due to a loss of fat mass) that was maintained through early withdrawal. After 1 month of withdrawal, only the 12-month old animals had fully regained body weight Fentanyl administration resulted in a decrease in grip strength and an increase in locomotor activity that did not differ across age groups. There was no effect of fentanyl administration on rotarod performance. These results demonstrate that while there is a delayed recovery of body mass with age, the observed changes in behavioral responses are uniform across ages. (c) 2010 Elsevier Inc. All rights reserved.	[Mitzelfelt, Jeremiah D.; Morgan, Drake] Univ Florida, Dept Psychiat, Coll Med, Gainesville, FL 32610 USA; [DuPree, Jameson P.; Seo, Dong-oh; Carter, Christy S.; Morgan, Drake] Univ Florida, Inst Aging, Coll Med, Gainesville, FL 32610 USA; [Carter, Christy S.] Univ Florida, Dept Aging & Geriatr Res, Coll Med, Gainesville, FL 32610 USA	Morgan, D (reprint author), Univ Florida, Dept Psychiat, Coll Med, POB 100183, Gainesville, FL 32610 USA.	drakem@ufl.edu	Morgan, Drake/F-6664-2012; Carter, Christy/E-6630-2011; Morgan, Drake/A-6373-2008; Seo, Dong-oh/AAJ-1676-2020	Seo, Dong-oh/0000-0003-0315-4489	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21DA023022]; US Public HealthUnited States Public Health Service [R01AG24526]; T32 training grant [AG00196]; University of FloridaUniversity of Florida; University of Florida Claude D. Pepper Older Americans Independence Center [P30AG028740]	This research was primarily supported by a grant from the NIH (R21DA023022 to DM). We would like to thank Alex Bibbey, Greg Foremny, Gebreyes Kassu, and Sheila Quintana for assistance with data collection. CSC was supported by US Public Health grant R01AG24526. JDM was supported by a T32 training grant (AG00196) and the University of Florida Alumni Fellowship. This article was used in partial fulfillment for the requirements of the doctoral degree at the University of Florida for the first author. Additional support was provided by the University of Florida Claude D. Pepper Older Americans Independence Center grant P30AG028740.	Agarwal S, 2007, PAIN MED, V8, P554, DOI 10.1111/j.1526-4637.2006.00246.x; ALTURI S, 2003, PAIN PHYSICIAN, V6, P233; Auret K, 2005, DRUG AGING, V22, P641, DOI 10.2165/00002512-200522080-00002; Bell JS, 2009, AM J GERIATR PHARMAC, V7, P355, DOI 10.1016/j.amjopharm.2009.11.006; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Bhambhani Y, 2010, EUR J APPL PHYSIOL, V109, P241, DOI 10.1007/s00421-009-1332-y; Binsack Ralf, 2006, J Zhejiang Univ Sci B, V7, P892, DOI 10.1631/jzus.2006.B0892; Bodnar RJ, 2004, PEPTIDES, V25, P697, DOI 10.1016/j.peptides.2004.01.006; Brixner Diana I, 2006, J Pain Palliat Care Pharmacother, V20, P5; Byas-Smith MG, 2005, CLIN J PAIN, V21, P345, DOI 10.1097/01.ajp.0000125244.29279.c1; Carter CS, 2004, J GERONTOL A-BIOL, V59, P416; Carter CS, 2002, J GERONTOL A-BIOL, V57, pB177, DOI 10.1093/gerona/57.5.B177; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Chen RZ, 2004, EUR J PHARMACOL, V495, P63, DOI 10.1016/j.ejphar.2004.05.025; Chodosh J, 2004, J AM GERIATR SOC, V52, P756, DOI 10.1111/j.1532-5415.2004.52214.x; de Leon-Casasola OA, 2008, CLIN J PAIN, V24, pS3, DOI 10.1097/AJP.0b013e31816b589f; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Delgado-Guay MO, 2008, ONCOLOGY-NY, V22, P148; Donald IP, 2004, RHEUMATOLOGY, V43, P1256, DOI 10.1093/rheumatology/keh298; Fine PG, 2004, CLIN J PAIN, V20, P220, DOI 10.1097/00002508-200407000-00003; Fine PG, 2001, CLIN GERIATR MED, V17, P479, DOI 10.1016/S0749-0690(05)70081-1; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Forster MJ, 1999, NEUROBIOL AGING, V20, P167, DOI 10.1016/S0197-4580(99)00041-X; Fox PL, 1999, CAN MED ASSOC J, V160, P329; Gagliese L, 2009, J PAIN, V10, P343, DOI 10.1016/j.jpain.2008.10.013; Gianni W, 2010, ARCH GERONTOL GERIAT, V51, P273, DOI 10.1016/j.archger.2009.11.016; Glass MJ, 1999, NEUROPEPTIDES, V33, P360, DOI 10.1054/npep.1999.0050; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Helme RD, 2001, CLIN GERIATR MED, V17, P417, DOI 10.1016/S0749-0690(05)70078-1; Herndon CM, 2002, PHARMACOTHERAPY, V22, P240, DOI 10.1592/phco.22.3.240.33552; Hong JY, 2010, J KOREAN MED SCI, V25, P287, DOI 10.3346/jkms.2010.25.2.287; Hutchinson K, 2007, EUR J PAIN, V11, P93, DOI 10.1016/j.ejpain.2006.01.003; KHALLOUKBOUSSELMAME R, 1994, EUR NEUROPSYCHOPHARM, V4, P137, DOI 10.1016/0924-977X(94)90007-8; Lee JS, 2005, AM J CLIN NUTR, V82, P644; LEVINE AS, 1988, PHARMACOL BIOCHEM BE, V29, P495, DOI 10.1016/0091-3057(88)90010-X; Li P, 2010, BIOCHEM PHARMACOL, V79, P1015, DOI 10.1016/j.bcp.2009.11.003; Lin JJ, 2007, CLIN J PAIN, V23, P799, DOI 10.1097/AJP.0b013e3181565cf1; Locher JL, 2007, J GERONTOL A-BIOL, V62, P1389, DOI 10.1093/gerona/62.12.1389; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS63; Marcell TJ, 2003, J GERONTOL A-BIOL, V58, P911, DOI 10.1093/gerona/58.10.M911; MCLAUGHLIN CL, 1983, PHARMACOL BIOCHEM BE, V19, P235, DOI 10.1016/0091-3057(83)90045-X; McNeill JA, 2004, J PAIN SYMPTOM MANAG, V28, P47, DOI 10.1016/j.jpainsymman.2003.11.005; Miller SL, 2008, J NUTR HEALTH AGING, V12, P487, DOI 10.1007/BF02982710; Morgan D, 2008, EXP CLIN PSYCHOPHARM, V16, P367, DOI 10.1037/a0013520; Moser VC, 2000, NEUROTOXICOLOGY, V21, P989; Paddon-Jones D, 2008, AM J CLIN NUTR, V87, p1558S; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Potter J, 2004, LUNG CANCER-J IASLC, V43, P247, DOI 10.1016/j.lungcan.2003.08.030; Powell KR, 2001, DRUG ALCOHOL DEPEN, V62, P83, DOI 10.1016/S0376-8716(00)00167-8; Rao Arati, 2004, J Natl Cancer Inst Monogr, P150; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; RAUHALA P, 1995, EUR J PHARMACOL, V285, P69, DOI 10.1016/0014-2999(95)00392-X; Ritchie CS, 2008, J GERONTOL A-BIOL, V63, P67, DOI 10.1093/gerona/63.1.67; Rustoen T, 2005, CLIN J PAIN, V21, P513, DOI 10.1097/01.ajp.0000146217.31780.ef; SANGER DJ, 1981, PSYCHOPHARMACOLOGY, V74, P217, DOI 10.1007/BF00427097; Scudds RJ, 2000, J GERONTOL A-BIOL, V55, pM393, DOI 10.1093/gerona/55.7.M393; Swegle JM, 2006, AM FAM PHYSICIAN, V74, P1347; Thomas E, 2004, PAIN, V110, P361, DOI 10.1016/j.pain.2004.04.017; Thomason TE, 1998, J PAIN SYMPTOM MANAG, V15, P275, DOI 10.1016/S0885-3924(98)00016-5; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Trujillo KA, 2004, PHARMACOL BIOCHEM BE, V79, P661, DOI 10.1016/j.pbb.2004.09.017; Wilder-Smith OHG, 2005, EUR J PAIN, V9, P137, DOI 10.1016/j.ejpain.2004.07.011; Yuan Chun-Su, 2009, J Opioid Manag, V5, P213; Zarit SH, 2004, GERONTOLOGIST, V44, P459, DOI 10.1093/geront/44.4.459	65	2	3	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	JAN	2011	46	1					65	72		10.1016/j.exger.2010.10.004			8	Geriatrics & Gerontology	Geriatrics & Gerontology	710UP	WOS:000286542800010	20951790	Green Accepted			2020-06-30	J	Correia, LM; Bonilha, DQ; Gomes, GF; Brito, JR; Nakao, FS; Lenz, L; Rohr, MRS; Ferrari, AP; Della Libera, E				Correia, Lucianna Motta; Bonilha, Danielle Queiroz; Gomes, Gustavo Flores; Brito, Juliana Ramos; Nakao, Frank Shigueo; Lenz, Luciano; Silveira Rohr, Maria Rachel; Ferrari, Angelo P.; Della Libera, Ermelindo			Sedation during upper GI endoscopy in cirrhotic outpatients: a randomized, controlled trial comparing propofol and fentanyl with midazolam and fentanyl	GASTROINTESTINAL ENDOSCOPY			English	Article							NURSE-ADMINISTERED PROPOFOL; CONSCIOUS SEDATION; ESOPHAGEAL-VARICES; DEEP SEDATION; MEPERIDINE; ENCEPHALOPATHY; PHARMACOKINETICS; GUIDELINES; ANESTHESIA	Background: Patients with liver cirrhosis frequently undergo diagnostic or therapeutic upper GI endoscopy (UGIE), and the liver disease might impair the metabolism of drugs usually administered for sedation. Objective and Setting: To compare sedation with a combination of propofol plus fentanyl and midazolam plus fentanyl in cirrhotic outpatients undergoing UGIE. Design: A prospective, randomized, controlled trial was conducted between February 2008 and February 2009. Main Outcomes Measurements: Efficacy (proportion of complete procedures using the initial proposed sedation scheme), safety (occurrence of sedation-related complications), and recovery time were measured. Results: Two hundred ten cirrhotic patients referred for UGIE were randomized to 2 groups: midazolam group (0.05 mg/kg plus fentanyl 50 mu g intravenously) or propofol group (0.25 mg/kg plus fentanyl 50 mu g intravenously). There were no differences between groups regarding age, sex, weight, etiology of cirrhosis, and Child-Pugh or American Society of Anesthesiologists classification. Sedation with propofol was more efficacious (100% vs 88.2%; P < .001) and had a shorter recovery time than sedation with midazolam (16.23 +/- 6.84 minutes and 27.40 +/- 17.19 minutes, respectively; P < .001). Complication rates were similar in both groups (14% vs 7.3%; P = .172). Limitations: Single-blind study; sample size. Conclusion: Both sedation schemes were safe in this setting. Sedation with propofol plus fentanyl was more efficacious with a shorter recovery time compared with midazolam plus fentanyl. Therefore, the former scheme is an alternative when sedating cirrhotic patients undergoing UGIE. (Gastrointest Enclose 2011;73:45-51.)	[Correia, Lucianna Motta; Bonilha, Danielle Queiroz; Gomes, Gustavo Flores; Brito, Juliana Ramos; Nakao, Frank Shigueo; Lenz, Luciano; Silveira Rohr, Maria Rachel; Ferrari, Angelo P.; Della Libera, Ermelindo] Univ Fed Sao Paulo, Disciplina Gastroenterol Clin, BR-04023900 Sao Paulo, Brazil	Della Libera, E (reprint author), Univ Fed Sao Paulo, Disciplina Gastroenterol Clin, Rua Botucatu 740,2 Andar,Vila Clementino, BR-04023900 Sao Paulo, Brazil.		libera, ermelindo/K-3785-2012; Lenz, Luciano/H-4184-2016	libera, ermelindo/0000-0002-1098-7975; Lenz, Luciano/0000-0002-7945-8158			Amoros A, 2009, GASTROINTEST ENDOSC, V70, P262, DOI 10.1016/j.gie.2008.10.038; Assy N, 1999, GASTROINTEST ENDOSC, V49, P690, DOI 10.1016/S0016-5107(99)70283-X; Carey Elizabeth J, 2004, Gastrointest Endosc Clin N Am, V14, P369, DOI 10.1016/j.giec.2004.01.003; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Chutkan R, 2004, GASTROINTEST ENDOSC, V60, P167, DOI 10.1016/S0016-5107(04)01699-2; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; de Franchis R, 2005, J HEPATOL, V43, P167, DOI 10.1016/j.jhep.2005.05.009; DeWitt J, 2008, GASTROINTEST ENDOSC, V68, P499, DOI 10.1016/j.gie.2008.02.092; Faigel DO, 2002, GASTROINTEST ENDOSC, V56, P613; Heuss Ludwig T, 2008, Gastrointest Endosc Clin N Am, V18, P727, DOI 10.1016/j.giec.2008.06.007; Horiuchi A, 2009, AM J GASTROENTEROL, V104, P1650, DOI 10.1038/ajg.2009.250; Horn Ed, 2004, Gastrointest Endosc Clin N Am, V14, P247, DOI 10.1016/j.giec.2004.01.001; Hourmand-Ollivier I, 2003, AM J GASTROENTEROL, V98, P1450; Khanna Sudeep, 2003, Indian J Gastroenterol, V22, P56; Lee SY, 2004, J KOREAN MED SCI, V19, P536, DOI 10.3346/jkms.2004.19.4.536; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; MACGILCHRIST AJ, 1986, GUT, V27, P190, DOI 10.1136/gut.27.2.190; Madhotra R, 2003, AM J GASTROENTEROL, V98, P807, DOI 10.1016/S0002-9270(03)00038-8; Mancuso CE, 2004, PHARMACOTHERAPY, V24, P1177, DOI 10.1592/phco.24.13.1177.38089; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; PENTIKAINEN PJ, 1989, J CLIN PHARMACOL, V29, P272, DOI 10.1002/j.1552-4604.1989.tb03327.x; Qadeer MA, 2008, CLIN GASTROENTEROL H, V6, P102, DOI 10.1016/j.cgh.2007.10.005; Rex DK, 2008, GASTROINTEST ENDOSC, V18, pix; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Rex Douglas K, 2008, Gastrointest Endosc Clin N Am, V18, P717, DOI 10.1016/j.giec.2008.06.002; Riphaus A, 2009, ENDOSCOPY, V41, P787, DOI 10.1055/s-0029-1215035; Riphaus A, 2009, SCAND J GASTROENTERO, V44, P1244, DOI 10.1080/00365520903194591; Saeian K, 2002, AM J GASTROENTEROL, V97, P2246; Thuluvath PJ, 2009, GASTROINTEST ENDOSC, V70, P269, DOI 10.1016/j.gie.2009.01.029; Vargo JJ, 2009, GASTROINTEST ENDOSC, V70, P1053, DOI 10.1016/j.gie.2009.07.020; Vasudevan AE, 2002, AM J GASTROENTEROL, V97, P1717; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Weston BR, 2003, AM J GASTROENTEROL, V98, P2440, DOI 10.1016/S0002-9270(03)01701-5; Zuccaro G, 2006, GASTROINTEST ENDOSC, V63, P95, DOI 10.1016/j.gie.2005.10.007	35	42	45	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	JAN	2011	73	1					45	51		10.1016/j.gie.2010.09.025			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	702QO	WOS:000285909400007	21184869				2020-06-30	J	Leung, J; Mann, S; Siao-Salera, R; Ransibrahmanakul, K; Lim, B; Canete, W; Samson, L; Gutierrez, R; Leung, FW				Leung, Joseph; Mann, Surinder; Siao-Salera, Rodelei; Ransibrahmanakul, Kanat; Lim, Brian; Canete, Wilhelmina; Samson, Laramie; Gutierrez, Rebeck; Leung, Felix W.			A randomized, controlled trial to confirm the beneficial effects of the water method on US veterans undergoing colonoscopy with the option of on-demand sedation	GASTROINTESTINAL ENDOSCOPY			English	Article							UNSEDATED COLONOSCOPY; SCREENING COLONOSCOPY; WARM WATER; TIME REQUIREMENTS; CO2 INSUFFLATION; AIR INSUFFLATION; PROPOFOL; ENDOSCOPY; INFUSION; MIDAZOLAM	Background: Sedation for colonoscopy discomfort imposes a recovery-time burden on patients. The water method permitted 52% of patients accepting on-demand sedation to complete colonoscopy without sedation. On-site and at-home recovery times were not reported. Objective: To confirm the beneficial effect of the water method and document the patient recovery-time burden. Design: Randomized, controlled trial, with single-blinded, intent-to-treat analysis. Setting: Veterans Affairs outpatient endoscopy unit. Patients: This study involved veterans accepting on-demand sedation for screening and surveillance colonoscopy. Intervention: Air versus water method for colonoscope insertion. Main Outcome Measurements: Proportion of patients completing colonoscopy without sedation, cecal intubation rate, medication requirement, maximum discomfort (0 = none, 10 = severe), procedure-related and patient-related outcomes. Results: One hundred veterans were randomized to the air (n = 50) or water (n = 50) method. The proportions of patients who could complete colonoscopy without sedation in the water group (78%) and the air group (54%) were significantly different (P = .011, Fisher exact test), but the cecal intubation rate was similar (100% in both groups). Secondary analysis (data as Mean [SD]) shows that the water method produced a reduction in medication requirement: fentanyl, 12.5 (26.8) mu g versus 24.0 (30.7) mu g; midazolam, 0.5 (1.1) mg versus 0.94 (1.20) mg; maximum discomfort, 2.3 (1.7) versus 4.9 (2.0); recovery time on site, 8.4 (6.8) versus 12.3 (9.4) minutes; and recovery time at home, 4.5 (9.2) versus 10.9 (14.0) hours (P = .049; P = .06; P = .0012; P = .0199; and P = .0048, respectively, t test). Limitations: Single Veterans Affairs site, predominantly male population, unblinded examiners. Conclusion: This randomized, controlled trial confirms the reported beneficial effects of the water method. The combination of the water method with on-demand sedation minimizes the patient recovery-time burden. (Clinical trial registration number: NCT00920751.) (Gastrointest Enclose 201173:103-10.)	[Leung, Felix W.] VAGLAHS, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA; [Leung, Joseph; Mann, Surinder; Ransibrahmanakul, Kanat] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA; [Lim, Brian] Kaiser Permanente, Riverside Med Ctr, Riverside, CA USA; [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, North Hills, CA USA	Leung, FW (reprint author), VAGLAHS, Sepulveda Ambulatory Care Ctr, 111G,16111 Plummer St, North Hills, CA 91343 USA.	felix.leung@va.gov			C.W. Law Research Fund; Veterans Affairs Northern California Healthcare SystemUS Department of Veterans Affairs; Veterans Affairs Greater Los Angeles Healthcare System; American College of Gastroenterology Clinical Research Award	The study was supported in part by the C.W. Law Research Fund (J.L.). Research support came from the Veterans Affairs Northern California Healthcare System and Veterans Affairs Greater Los Angeles Healthcare System, statistical support from the Clinical and Translational Science Center University of California Davis, and partial support from an American College of Gastroenterology Clinical Research Award (F.W.L.). No other financial relationships relevant to this publication were disclosed.	Baumann UA, 1999, ENDOSCOPY, V31, P314; Brocchi E, 2008, AM J GASTROENTEROL, V103, P581, DOI 10.1111/j.1572-0241.2007.01693.x; Church JM, 2002, GASTROINTEST ENDOSC, V56, P672, DOI 10.1067/mge.2002.128916; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, pAB127; Davila ML, 2009, GASTROINTEST ENDOSC, V70, P511, DOI 10.1016/j.gie.2009.05.022; Denberg TD, 2005, J GEN INTERN MED, V20, P989, DOI 10.1111/j.1525-1497.2005.00164.x; Doubeni CA, 2009, CANCER EPIDEM BIOMAR, V18, P2170, DOI 10.1158/1055-9965.EPI-09-0104; FALCHUK ZM, 1984, NEW ENGL J MED, V310, P598; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; Gasparovic S, 2003, ACTA MED AUST, V30, P13, DOI 10.1046/j.1563-2571.2003.02050.x; Hamamoto N, 2002, GASTROINTEST ENDOSC, V56, P825, DOI 10.1067/mge.2002.129608; HERMAN FN, 1990, DIS COLON RECTUM, V33, P70, DOI 10.1007/BF02053206; Hoffman MS, 1998, J CLIN GASTROENTEROL, V26, P279, DOI 10.1097/00004836-199806000-00013; Jonas DE, 2008, MED DECIS MAKING, V28, P56, DOI 10.1177/0272989X07309643; Jonas DE, 2007, AM J GASTROENTEROL, V102, P2401, DOI 10.1111/j.1572-0241.2007.01387.x; Leung FW, 2008, DIGEST DIS SCI, V53, P2847, DOI 10.1007/s10620-008-0259-1; Leung FW, 2008, DIGEST DIS SCI, V53, P1462, DOI 10.1007/s10620-007-0025-9; Leung FW, 2008, GASTROINTEST ENDOSC, V67, P718, DOI 10.1016/j.gie.2007.11.040; Leung FW, 2010, WORLD J GASTRO ENDOS, V2, P81, DOI 10.4253/wjge.v2.i3.81; Leung FW, 2010, GASTROINTEST ENDOSC, V72, P693, DOI 10.1016/j.gie.2010.05.020; Leung FW, 2009, GASTROINTEST ENDOSC, V69, P1354, DOI 10.1016/j.gie.2008.12.234; Leung FW, 2009, GASTROINTEST ENDOSC, V69, P546, DOI 10.1016/j.gie.2008.08.014; Leung JV, 2007, ALIMENT PHARM THERAP, V26, P627, DOI 10.1111/j.1365-2036.2007.03404.x; Leung JW, 2009, GASTROINTEST ENDOSC, V70, P505, DOI 10.1016/j.gie.2008.12.253; Leung JW, 2009, DIGEST DIS SCI, V54, P1997, DOI 10.1007/s10620-008-0576-4; Mizukami T, 2007, DIGEST ENDOSC, V19, P43, DOI 10.1111/j.1443-1661.2007.00670.x; Ng JM, 2001, GASTROINTEST ENDOSC, V54, P8, DOI 10.1067/mge.2001.116110; Petrini JL, 2009, GASTROINTEST ENDOSC, V69, P567, DOI 10.1016/j.gie.2008.10.027; Ramakrishnan S, 2004, J ROY SOC MED, V97, P432, DOI 10.1258/jrsm.97.9.432; Rex DK, 1999, GASTROINTEST ENDOSC, V49, P554, DOI 10.1016/S0016-5107(99)70381-0; Riss S, 2009, WIEN KLIN WOCHENSCHR, V121, P464, DOI 10.1007/s00508-009-1202-y; Russell LB, 2009, MED CARE, V47, pS89, DOI 10.1097/MLR.0b013e31819bc077; Siddiqui AA, 2009, GASTROINTEST ENDOSC, V69, P700, DOI 10.1016/j.gie.2008.09.047; Tohda G, 2006, ENDOSCOPY, V38, P360, DOI 10.1055/s-2005-921192; Uraoka T, 2009, WORLD J GASTROENTERO, V15, P5186, DOI 10.3748/wjg.15.5186; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Wasan SK, 2009, GASTROINTEST ENDOSC, V69, P551, DOI 10.1016/j.gie.2008.10.045; Williams CB, 1996, PRACTICAL GASTROINTE, P187; Wong JCH, 2008, ANZ J SURG, V78, P871, DOI 10.1111/j.1445-2197.2008.04683.x; Zuccaro GJr, 2003, COLONOSCOPY PRINCIPL, P229	40	55	57	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	JAN	2011	73	1					103	110		10.1016/j.gie.2010.09.020			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	702QO	WOS:000285909400015	21184876				2020-06-30	J	Patel, SH; Zakowski, MI; Ramanathan, S				Patel, S. H.; Zakowski, M. I.; Ramanathan, S.			Accidental local anesthetic overdose due to epidural pump malfunction	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter									[Patel, S. H.; Zakowski, M. I.; Ramanathan, S.] Cedars Sinai Med Ctr, Dept Anesthesiol, Los Angeles, CA 90048 USA	Patel, SH (reprint author), Cedars Sinai Med Ctr, Dept Anesthesiol, Los Angeles, CA 90048 USA.	sramanathan1@gmail.com					*ECRI I, 2008, REC CURL MED CMS PAI; GROVER ER, 1992, ANAESTHESIA, V47, P402, DOI 10.1111/j.1365-2044.1992.tb02221.x; RITHALIA SVS, 1984, INTENSIVE CARE WORLD, V1, P54; Santos A. C., 2009, OBSTET ANESTHESIA PR, P247	4	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2011	20	1					93	94		10.1016/j.ijoa.2010.07.016			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	725WG	WOS:000287677000023	21074403				2020-06-30	J	Moon, JM; Chun, BJ				Moon, Jeong Mi; Chun, Byeong Jo			FENTANYL INTOXICATION CAUSED BY ABUSE OF TRANSDERMAL FENTANYL	JOURNAL OF EMERGENCY MEDICINE			English	Article						fentanyl; transdermal administration; respiratory insufficiency; opioid; pain	PAIN; PHARMACOKINETICS; OPIOIDS	Fentanyl has an analgesic effect 100 times greater than that of morphine; therefore, transdermal administration of fentanyl has been widely used to control pain. Due to misconceptions regarding the proper use of fentanyl, its simple method of administration, and the absence of regulatory rules regarding its use, both medical providers and non-medical providers have abused fentanyl. We report on three cases of fentanyl intoxication and suggest solutions to prevent its abuse in the future. Three patients were intoxicated by transdermal fentanyl, which resulted in respiratory depression. Two of these cases were attributed to non-medical use of the drug and the other occurred while using fentanyl as directed by medical personnel. Physicians should use transdermal fentanyl only to control chronic pain, and rules should be established to prevent abuse of fentanyl that occurs due to its ease of use and the absence of any established policy regarding the prescription and disposal of this drug. (C) 2011 Elsevier Inc.	[Moon, Jeong Mi; Chun, Byeong Jo] Chonnam Natl Univ Hosp, Dept Emergency Med, Kwangju, South Korea	Chun, BJ (reprint author), Chonnam Natl Univ, Sch Med, Dept Emergency Med, 8 Hakdong Donggu, Kwangju 501757, South Korea.			moon, jeongmi/0000-0002-9182-5475; jeon, byeongjo/0000-0002-5240-4213			Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; BULLINGHAM RES, 1983, OPIATE ANALGESIA; DESIO JM, 1993, ANESTHESIOLOGY, V79, P1139, DOI 10.1097/00000542-199311000-00036; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; NELSON LS, 1998, GOLDFRANKS TOXICOLOG, P901; NIGHTINGALE SL, 1990, JAMA-J AM MED ASSOC, V264, P1802, DOI 10.1001/jama.264.14.1802; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Yerasi AB, 1997, AM J HEALTH-SYST PH, V54, P85, DOI 10.1093/ajhp/54.1.85	14	14	14	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	JAN	2011	40	1					37	40		10.1016/j.jemermed.2007.10.075			4	Emergency Medicine	Emergency Medicine	712CY	WOS:000286643500008	18455903				2020-06-30	J	Lin, BF; Huang, YS; Kuo, CP; Ju, DT; Lu, CH; Cherng, CH; Wu, CT				Lin, Bo-Feng; Huang, Yuan-Shiou; Kuo, Chang-Po; Ju, Da-Tong; Lu, Chueng-He; Cherng, Chen-Hwan; Wu, Ching-Tang			Comparison of A-Line Autoregressive Index and Observer Assessment of Alertness/Sedation Scale for Monitored Anesthesia Care With Target-controlled Infusion of Propofol in Patients Undergoing Percutaneous Vertebroplasty	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						percutaneous vertebroplasty; auditory-evoked potential; Observer Assessment of Alertness/Sedation scale; monitored anesthetic care; target-controlled infusion	EVOKED POTENTIAL INDEX; BISPECTRAL INDEX; REMIFENTANIL; SEDATION; PERFORMANCE; MIDAZOLAM; CONSCIOUSNESS; INDICATOR; INDUCTION; SYSTEM	Background: Percutaneous vertebroplasty (PV) with monitored anesthesia care (MAC) is a growing trend. Without adequate sedation, patient movement can affect and even interrupt the procedure during MAC. The aim of this study was to compare the performance of the auditory-evoked potential (AEP) index and the Observer Assessment of Alertness/Sedation (OAA/S) scale as indicators of depth of sedation in patients undergoing PV. Methods: Two hundred and twenty patients in ASA II to III, aged 43 to 92 years, undergoing elective PV with MAC, were randomly allocated to the AEP or the OAA/S group (n = 110 each). Initially, all patients received 1 mu g/kg of fentanyl and 0.02 mg/kg of midazolam intravenously and sedation with a target-controlled infusion (TCI) of propofol at a target concentration of 1.2 mu g/mL. The concentration for the propofol TCI was adjusted in 0.2 mu g/mL increments or decrements according to the A-Line autoregressive index (AAI) or the OAA/S scale. A blinded study nurse recorded the measured parameters. Results: Some parameters were significantly different in the AEP group compared with the OAA/S group: lower AAI, lower OAA/S score, lower respiratory rates, and higher end-tidal carbon dioxide pressure were noted from local anesthetic infiltration to bone cement implantation, fewer patients whose movements affected the procedure (10 vs. 36, respectively, P < 0.001), and more adjustments of TCI (twice vs. once, respectively, P < 0.006). The surgeons' satisfaction was greater for the AEP group than for the OAA/S group. Conclusions: TCI propofol with AEP monitoring can provide less patient movement, better sedation, and higher surgeon satisfaction in patients during prone-position PV procedures than can TCI propofol with OAA/S monitoring.	[Lin, Bo-Feng; Huang, Yuan-Shiou; Kuo, Chang-Po; Lu, Chueng-He; Cherng, Chen-Hwan; Wu, Ching-Tang] TriServ Gen Hosp, Dept Anesthesiol, Natl Def Med Ctr, Taipei 114, Taiwan; [Ju, Da-Tong] TriServ Gen Hosp, Dept Neurosurg, Natl Def Med Ctr, Taipei 114, Taiwan	Wu, CT (reprint author), TriServ Gen Hosp, Dept Anesthesiol, Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.	wuchingtang@msn.com		Ju, Da-Tong/0000-0003-1055-1597	Tri-Service General Hospital of Taiwan, Republic of China [TSGH-C97-129]	Supported by grants from Tri-Service General Hospital (TSGH-C97-129) of Taiwan, Republic of China.	Absalom AR, 2001, BRIT J ANAESTH, V87, P778, DOI 10.1093/bja/87.5.778; Barawi M, 2000, GASTROINTEST ENDOSC, V51, P365, DOI 10.1016/S0016-5107(00)70376-2; Casati A, 1999, CAN J ANAESTH, V46, P235, DOI 10.1007/BF03012602; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Eastwood PR, 2005, ANESTHESIOLOGY, V103, P470, DOI 10.1097/00000542-200509000-00007; Fanti L, 2004, GASTROINTEST ENDOSC, V60, P361, DOI 10.1016/S0016-5107(04)01713-4; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Huang YY, 2007, EUR J ANAESTH, V24, P252, DOI 10.1017/S0265021506001633; Jensen ME, 1997, AM J NEURORADIOL, V18, P1897; Layton KF, 2007, AM J NEURORADIOL, V28, P683; Litvan H, 2002, ANESTHESIOLOGY, V97, P351, DOI 10.1097/00000542-200208000-00011; Luginbuhl M, 2008, CURR OPIN ANESTHESIO, V21, P504, DOI 10.1097/ACO.0b013e328303be62; Nieuwenhuijs DJF, 2003, ANESTHESIOLOGY, V98, P312, DOI 10.1097/00000542-200302000-00008; Ohara Takeshi, 2003, Masui, V52, P740; Rehberg B, 2008, ANESTH ANALG, V107, P117, DOI 10.1213/ane.0b013e31816f1965; Schmidt GN, 2003, ANESTH ANALG, V97, P139, DOI 10.1213/01.ANE.0000065546.78919.82; Schraag S, 1999, ANESTH ANALG, V89, P1311, DOI 10.1213/00000539-199911000-00045; Struys MMRF, 2003, ANESTHESIOLOGY, V99, P802, DOI 10.1097/00000542-200310000-00010; Struys MMRF, 2002, ANESTHESIOLOGY, V96, P803, DOI 10.1097/00000542-200204000-00006; van Oud-Alblas HJB, 2008, ANESTH ANALG, V107, P1683, DOI 10.1213/ane.0b013e3181852d94; von Delius S, 2009, AM J GASTROENTEROL, V104, P318, DOI 10.1038/ajg.2008.73; WHITE M, 1990, ANAESTHESIA, V45, P204, DOI 10.1111/j.1365-2044.1990.tb14685.x	22	3	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2011	23	1					6	11		10.1097/ANA.0b013e3181ecbdbf			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	692FC	WOS:000285137200002	20706141				2020-06-30	J	Skrablin, S; Grgic, O; Mihaljevic, S; Blajic, J				Skrablin, S.; Grgic, O.; Mihaljevic, S.; Blajic, J.			Comparison of intermittent and continuous epidural analgesia on delivery and progression of labour	JOURNAL OF OBSTETRICS AND GYNAECOLOGY			English	Article						Continuous; epidural analgesia; intermittent; length of labour; maternal outcome; neonatal outcome; operative delivery	CONTINUOUS-INFUSION; BOLUS	In this study, 205 nulliparous parturients were enrolled to receive either intermittent (n = 101) or continuous (n = 104) type of epidural analgesia in labour. The primary outcome was rate of caesarean deliveries, whereas secondary outcomes included rate of fundal pressure manoeuvres, duration of labour from application of analgesia, dose of anaesthetic and short-term maternal and neonatal outcome between two groups. Rate of caesarean deliveries was significantly increased in the continuous group (15/104 vs 5/101, p = 0.02), as well as rate of fundal pressure manoeuvres (24/104 vs 11/101, p = 0.02) and dose of fentanyl (100 [100-300] vs 187.5 [125-450] mu g, p < 0.001 and levobupivacaine (40 [40-60] vs 75 [50-90] ml, p < 0.001). Duration of labour from analgesia to delivery was not significantly different between the two groups (414 +/- 101 vs 432 +/- 94 min, p = 0.12).	[Skrablin, S.; Blajic, J.] Univ Zagreb, Dept Obstet & Gynecol, Sch Med, Zagreb 10000, Croatia; [Grgic, O.] Univ Zagreb, Clin Hosp Sestre Milosrdnice, Zagreb 10000, Croatia	Grgic, O (reprint author), Univ Zagreb, Dept Obstet & Gynecol, Sch Med, Vinogradska 29, Zagreb 10000, Croatia.	ozren.grgic@gmail.com					Boutros A, 1999, INT J OBSTET ANESTH, V8, P236, DOI 10.1016/S0959-289X(99)80103-4; Driver I, 1996, EUR J ANAESTH, V13, P515, DOI 10.1046/j.1365-2346.1996.d01-388.x; EDDLESTON JM, 1992, BRIT J ANAESTH, V69, P154, DOI 10.1093/bja/69.2.154; Eltzschig HK, 2003, NEW ENGL J MED, V348, P319, DOI 10.1056/NEJMra021276; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; Halpern S, 2005, CURR OPIN ANESTHESIO, V18, P247, DOI 10.1097/01.aco.0000169229.75938.c8; LAMONT RF, 1989, ANAESTHESIA, V44, P893, DOI 10.1111/j.1365-2044.1989.tb09142.x; Quinn A. J., 1993, Journal of Obstetrics and Gynaecology (Abingdon), V13, P171, DOI 10.3109/01443619309151817; Salim R, 2005, OBSTET GYNECOL, V106, P301, DOI 10.1097/01.AOG.0000171109.53832.8d; SMEDSTAD KG, 1988, CAN J ANAESTH, V35, P234, DOI 10.1007/BF03010616; Torvaldsen S, 2004, COCHRANE DATABASE SY; Vallejo MC, 2007, J PAIN, V8, P970, DOI 10.1016/j.jpain.2007.07.002; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a	13	1	1	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0144-3615	1364-6893		J OBSTET GYNAECOL	J. Obstet. Gynaecol.		2011	31	2					134	138		10.3109/01443615.2010.542840			5	Obstetrics & Gynecology	Obstetrics & Gynecology	717XP	WOS:000287081600010	21281028				2020-06-30	J	Passik, SD; Messina, J; Golsorkhi, A; Xie, F				Passik, Steven D.; Messina, John; Golsorkhi, Anthony; Xie, Fang			Aberrant Drug-Related Behavior Observed During Clinical Studies Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet for Breakthrough Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Chronic pain; fentanyl buccal tablet (FBT); breakthrough pain (BTP); opioid; aberrant drug-related behavior; drug abuse	NONMALIGNANT PAIN; NONCANCER PAIN; ABUSE; VALIDATION; ADDICTION; HISTORY; RISK	Context. Information on aberrant drug-related behaviors in the clinical study setting is limited. Objectives. This retrospective analysis was designed to identify the types and frequency of aberrant drug-related behaviors (including misuse and abuse) and associated patient characteristics in opioid-tolerant patients with chronic pain. Methods. Data from opioid-tolerant patients participating in clinical studies of fentanyl buccal tablet (FBT) for breakthrough pain (up to 18 months of clinical study case-report forms) were retrospectively reviewed and coded for abuse, overdose, and aberrant behavior. Aberrant behaviors were categorized as those involving FBT (overuse, lost or stolen study drug) and those not involving FBT (patients seeking prescriptions from other sources, not returning for follow-up). Results. Of the 1,160 patients evaluated, 10 (<1%) patients had an abuse-related event, 18 (<2%) had a positive urine drug screening (nonprescribed drug or illicit substance), and 12 (1%) had an event consistent with opioid overdose; 124 (11%) had aberrant behaviors related to FBT, and 68 (6%) had aberrant behaviors that were not. Aberrant behaviors were more frequent in men (odds ratio [OR]: 1.5; 95% confidence interval [CI]: 1.1, 2.1; P < 0.01), in patients 42 years or younger (OR: 2.5; 95% CI: 1.6, 4.0; P < 0.01), and in patients 43 years to 49 years (OR: 1.9; 95% CI: 1.2, 3.1; P < 0.01). Conclusion. The incidence of drug abuse events and aberrant drug-related behaviors was relatively low, probably because of the implementation of universal precautions and the controlled clinical study setting. Even in this setting, events occurred, highlighting the limits of screening and the need for ongoing monitoring of aberrant behavior. J Pain Symptom Manage 2011;41:116-125. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Passik, Steven D.] Mem Sloan Kettering Canc Ctr, New York, NY 10022 USA; [Messina, John; Golsorkhi, Anthony; Xie, Fang] Cephalon Inc, Frazer, PA USA	Passik, SD (reprint author), Mem Sloan Kettering Canc Ctr, 641 Lexington Ave,7th Floor, New York, NY 10022 USA.	passiks@mskcc.org			Cephalon, Inc.	This study was sponsored by Cephalon, Inc. Writing assistance was provided by Peloton Advantage, LLC, funded by Cephalon, Inc.	Ballantyne JC, 2003, ONCOLOGIST, V8, P567, DOI 10.1634/theoncologist.8-6-567; Butler SF, 2007, PAIN, V130, P144, DOI 10.1016/j.pain.2007.01.014; Chabal C, 1997, CLIN J PAIN, V13, P150, DOI 10.1097/00002508-199706000-00009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Cicero TJ, 2009, PAIN, V144, P20, DOI 10.1016/j.pain.2009.01.026; Dunbar SA, 1996, J PAIN SYMPTOM MANAG, V11, P163, DOI 10.1016/0885-3924(95)00165-4; Farrar JT, 2008, PAIN MED, V9, P102; Fine PG, J PAIN SYMPTOM MANAG, pXX; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; Gourlay DL, 2008, J ADDICT DIS, V27, P23, DOI 10.1080/10550880802122570; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI 10.1016/j.jpainsymman.2004.04.007; Passik Steven D, 2002, J Pain Palliat Care Pharmacother, V16, P39; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2007, CLIN J PAIN, V23, P287, DOI 10.1097/AJP.0b013e31802b582f; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Trescot Andrea M, 2006, Pain Physician, V9, P1; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x; World Health Organization, 1990, CANC PAIN REL PALL C; Wu SM, 2006, J PAIN SYMPTOM MANAG, V32, P342, DOI 10.1016/j.jpainsymman.2006.05.010	21	38	39	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JAN	2011	41	1					116	125		10.1016/j.jpainsymman.2010.03.012			10	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	704LB	WOS:000286053400013	20580202	Bronze			2020-06-30	J	van der Linde, HJ; Van Deuren, B; Somers, Y; Teisman, A; Drinkenburg, WH; Gallacher, DJ				van der Linde, H. J.; Van Deuren, B.; Somers, Y.; Teisman, A.; Drinkenburg, W. H.; Gallacher, D. J.			EEG in the FEAB model: Measurement of electroencephalographical burst suppression and seizure liability in safety pharmacology	JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS			English	Article						Burst suppression; Depth of anaesthesia; Dog; EEG; Safety pharmacology; Seizures	EPILEPTIC SEIZURES; ANESTHESIA; ETOMIDATE; PROPOFOL; DEPTH; RATS; MICE; DOGS	Introduction: The purpose of this study was to explore the integration of electroencephalographical (EEG) measurements into the fentanyl/etomidate-anaesthetised Beagle (FEAB) model in order to detect burst suppression and/or seizure development caused by compounds, prior to new molecular entity (NME) declaration. Detecting such unfavourable side effects prevents their being found in conscious animals at a later stage of safety evaluation. In addition, this has the advantage of performing safety studies on the three vital organ systems (cardiovascular system, respiratory system and central nervous system) within one and the same animal model. Methods: Dogs were anaesthetized and instrumented according to the FEAB model requirements, and in addition three needle electrodes were placed on the cranium and a one lead EEG signal was measured. The raw signal was analysed by the Narcotrend (R) (MonitorTechnik, Bad Bramstedt, Germany) for depth of anaesthesia registration, visually analysed for burst suppression ratio calculation after different anaesthetics (pentobarbital and etomidate), and spiking and seizure activity were quantified after intravenous administration of different proconvulsant agents: pentylenetetrazole (PTZ), bicuculline (BCC), bupropion (BUP) and pilocarpine (PIL). Results: High doses of pentobarbital (60 mg/kg over 10 min) and etomidate (6 mg/kg over 10 min) induced dose-dependent burst suppression of 98 +/- 2% and 61 +/- 16%. respectively. Infusions of PTZ (1.5 mg/kg/min), BCC (0.0625 mg/kg/min), BUP (0.5 mg/kg/min) and PIL (5 mg/kg/min) induced dose-dependent spiking and seizures: the thresholds were 34 +/- 2, 0.15 +/- 0.03, 10.0 +/- 1 and 144 +/- 9 mg/kg, respectively. In PTZ-treated dogs, spiking and seizures could be abolished with diazepam (2 mg/kg i.v.) or with propofol (4 mg/kg i.v.). Discussion: The present study showed that a one lead EEG can be used reliably in the FLAB model to estimate the depth of anaesthesia, and to detect burst suppression and seizure risk in safety pharmacology studies. (C) 2010 Elsevier Inc. All rights reserved.	[van der Linde, H. J.; Drinkenburg, W. H.] Johnson & Johnson Pharmaceut Res & Dev, Div Janssen Pharmaceut NV, Neurosci Discovery Res, B-2340 Beerse, Belgium	van der Linde, HJ (reprint author), Johnson & Johnson Pharmaceut Res & Dev, Div Janssen Pharmaceut NV, Neurosci Discovery Res, Turnhoutseweg 30, B-2340 Beerse, Belgium.	hvdlinde@its.jnj.com		Drinkenburg, Wilhelmus/0000-0002-1095-7995			Berendt M, 1999, ACTA NEUROL SCAND, V99, P276, DOI 10.1111/j.1600-0404.1999.tb00676.x; Blum AS, 2009, J CLIN NEUROPHYSIOL, V26, P309, DOI 10.1097/WNP.0b013e3181b7f14d; CHAPPLE DJ, 1987, BRIT J ANAESTH, V59, P218, DOI 10.1093/bja/59.2.218; Doyle PW, 1999, BRIT J ANAESTH, V83, P580; Drinkenburg WH, 2004, ESSENTIALS APPL EEG, P131; Duermueller Niklaus, 2007, Journal of Pharmacological and Toxicological Methods, V56, P234, DOI 10.1016/j.vascn.2007.03.006; Easter A, 2009, DRUG DISCOV TODAY, V14, P876, DOI 10.1016/j.drudis.2009.06.003; Erdil F, 2009, J ECT, V25, P174, DOI 10.1097/YCT.0b013e3181903fa5; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; GASTAUT H, 1970, EPILEPSIA, V11, P102, DOI 10.1111/j.1528-1157.1970.tb03871.x; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; Kreuer S, 2006, BEST PRACT RES-CLIN, V20, P111, DOI 10.1016/j.bpa.2005.08.010; Kreuer S, 2001, ANAESTHESIST, V50, P921, DOI 10.1007/s00101-001-0242-0; Kumar S. S., 2007, CURRENT RES INFORM P, V8, P2; Mandhane SN, 2007, SEIZURE-EUR J EPILEP, V16, P636, DOI 10.1016/j.seizure.2007.05.005; Maromi N., 2009, EPILEPSY CURR, V9, P91; MODICA PA, 1992, CAN J ANAESTH, V39, P236, DOI 10.1007/BF03008783; Otto KA, 2008, LAB ANIM-UK, V42, P45, DOI 10.1258/la.2007.006025; POLLACK GM, 1985, J PHARMACOL METHOD, V13, P135, DOI 10.1016/0160-5402(85)90057-9; Porsolt RD, 2002, FUND CLIN PHARMACOL, V16, P197, DOI 10.1046/j.1472-8206.2002.00061.x; SEBEL PS, 1981, ANESTHESIOLOGY, V55, P203, DOI 10.1097/00000542-198109000-00004; Sloan TB, 1998, J CLIN NEUROPHYSIOL, V15, P217, DOI 10.1097/00004691-199805000-00005; STERIADE M, 1994, ELECTROEN CLIN NEURO, V90, P1, DOI 10.1016/0013-4694(94)90108-2; Tutka P, 2005, EPILEPSY RES, V64, P13, DOI 10.1016/j.eplepsyres.2005.01.006; Van Deuren Bruno, 2009, Journal of Pharmacological and Toxicological Methods, V60, P11, DOI 10.1016/j.vascn.2009.04.195; VANNESS PC, 1990, EPILEPSIA, V31, P61; Vijn PCM, 1998, BRIT J ANAESTH, V81, P415, DOI 10.1093/bja/81.3.415; Watson PL, 2008, CRIT CARE MED, V36, P3171, DOI 10.1097/CCM.0b013e318186b9ce; Zijlmans M, 2002, EPILEPSIA, V43, P847, DOI 10.1046/j.1528-1157.2002.37801.x	29	14	14	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1056-8719			J PHARMACOL TOXICOL	J. Pharmacol. Toxicol. Methods	JAN-FEB	2011	63	1					96	101		10.1016/j.vascn.2010.06.002			6	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	717TS	WOS:000287070900013	20601023				2020-06-30	J	Baumgartner, C; Koenighaus, H; Ebner, J; Henke, J; Schuster, T; Erhardt, W				Baumgartner, C.; Koenighaus, H.; Ebner, J.; Henke, J.; Schuster, T.; Erhardt, W.			Comparison of dipyrone/propofol versus fentanyl/propofol anaesthesia during surgery in rabbits	LABORATORY ANIMALS			English	Article						Dipyrone; metamizol; fentanyl; analgesia; cardiovascular; rabbits; propofol; anaesthesia	PROPOFOL-FENTANYL ANESTHESIA; HEART-RATE; PHARMACOKINETICS; MECHANISM; KETAMINE; DRUGS	In this study, the investigation of the intraoperative effects of dipyrone (metamizol) on heart rate (HR), mean arterial pressure (MAP) and analgesic efficacy in rabbits is described for the first time. This was carried out to evaluate the cardiovascular stability achieved using dipyrone compared with fentanyl. In this prospective study, 17 female New Zealand White rabbits were randomly allocated to either one of two groups: dipyrone/propofol (DP) or fentanyl/propofol (FP). Anaesthesia was induced in both groups using propofol to effect (4.0-8.0 mg/kg intravenously) until the swallowing reflex was lost for intubation. After induction, anaesthesia was maintained with continuous infusion of propofol 1.5-1.7 mg/kg/min intravenously. Analgesics were then injected in defined boluses of either dipyrone 65 mg/kg or fentanyl 0.0053 mg/kg. After surgical tolerance, defined as loss of the ear pinch reflex and loss of the anterior and posterior pedal withdrawal reflex, was achieved, two surgical procedures were performed. The surgical procedures (implantation of either a pacemaker or an electrocardiogram transmitter), both require a comparable level of analgesic depth. During and after surgery, clinical variables, such as MAP, HR, peripheral arterial oxygen saturation (SpO(2)) and end-tidal CO2 (PE'CO2) were recorded simultaneously every 2 min. Eight time points were chosen for comparison: baseline, surgical tolerance (ST), values at 10, 20 and 30 min after reaching ST, values at the end of propofol infusion (El) and data at 10 and 20 min after El. Both FP and DP combinations provided effective anaesthesia and analgesia in rabbits. In both groups a significant decrease of HR and MAP was measured. The results of this study indicate that the non-opioid drug dipyrone produces similar analgesic and even better cardiovascular effects by trend in rabbits. Therefore we conclude that dipyrone in combination with propofol can be used as an alternative to FP for intraoperative analgesia.	[Baumgartner, C.; Henke, J.] Tech Univ Munich, Klinikum Rechts Isar, Ctr Preclin Res, D-81675 Munich, Germany; [Koenighaus, H.; Erhardt, W.] Tech Univ Munich, Working Grp Expt Surg, Inst Expt Oncol & Therapeut Res, D-81675 Munich, Germany; [Ebner, J.] Trigen GmbH, Martinsried, Germany; [Schuster, T.] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Stat & Epidemiol, D-81675 Munich, Germany	Baumgartner, C (reprint author), Tech Univ Munich, Klinikum Rechts Isar, Ctr Preclin Res, Ismaninger Str 22, D-81675 Munich, Germany.	christine.baumgartner@lrz.tu-muenchen.de					Aeschbacher G., 1992, Veterinary Surgery, V21, P159; Aguirre-Banuelos P, 1999, J PHARMACOL TOXICOL, V42, P79, DOI 10.1016/S1056-8719(00)00046-0; Avellaneda C, 2000, EUR J ANAESTH, V17, P85, DOI 10.1046/j.1365-2346.2000.00607.x; BELLER JP, 1988, BRIT J ANAESTH, V61, P583, DOI 10.1093/bja/61.5.583; BORKOWSKI GL, 1990, LAB ANIM SCI, V40, P270; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Clemm A, 2008, THESIS LUDWIG MAXIMI; COCKSHOTT ID, 1985, POSTGRAD MED J, V61, P45; DEMBINSKAKIEC A, 1976, ADV PROSTAG THROMB R, V1, P99; DEUTSCHMAN CS, 1994, ANESTH ANALG, V79, P373; EGAN TD, 1991, ANESTH ANALG, V73, P818; Ergun H, 1999, GEN PHARMACOL, V33, P237, DOI 10.1016/S0306-3623(99)00013-0; Erhardt W, 2004, ANAESTHESIE ANALGESI, P125; Erhardt W, 2004, ANAESTHESIE ANALGESI, P432; Erhardt W, 2004, ANAESTHESIE ANALGESI, P31; Fish RE, 1997, ANESTHESIA ANALGESIA, P8; Freye E, 1991, OPIOIDE MEDIZIN, P108; Haberstroh J, 2004, ANASTHESIE ANALGESIE, P629; Henke J, 2004, ANAESTHESIE ANALGESI, P370; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; HESS R, 1971, J PHARMACOL EXP THER, V179, P474; Hess W, 1976, ANAESTHESIST, V25, P10; Hoigne R, 1986, Agents Actions Suppl, V19, P189; Kramer M, 1986, Agents Actions Suppl, V19, P225; Liehmann L, 2006, VET ANAESTH ANALG, V33, P158, DOI 10.1111/j.1467-2995.2005.00251.x; Lipman NS, 1997, ANESTHESIA ANALGESIA, p[209, 19]; Maier C, 1997, SCHMERZTHERAPIE BUCH, P307; Mastronardi P, 2001, Minerva Anestesiol, V67, P332; MAYER M, 1990, ANAESTHESIST, V39, P609; Murphy KL, 2010, VET ANAESTH ANALG, V37, P222, DOI 10.1111/j.1467-2995.2009.00525.x; Richter T., 2007, P AUT M ASS VET AN E, P53; SAMAIN E, 1989, EUR J ANAESTH, V6, P321; Schug SA, 2007, BEST PRACT RES-CLIN, V21, P15, DOI 10.1016/j.bpa.2006.12.002; SHIMADA SG, 1994, AGENTS ACTIONS, V41, P188, DOI 10.1007/BF02001915; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Tortorici V, 1996, BRAIN RES, V725, P106, DOI 10.1016/S0006-8993(96)00196-5; VANWIJNGAARDEN I, 1968, LIFE SCI PT 1 PHYSI, V7, P1239, DOI 10.1016/0024-3205(68)90236-1; WHELAN G, 1995, LAB ANIM, V29, P83, DOI 10.1258/002367795780740384	38	10	10	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	JAN	2011	45	1					38	44		10.1258/la.2010.010091			7	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	801HI	WOS:000293428800005	21088031				2020-06-30	J	Kim, KS; Simon, L				Kim, Kwang Seok; Simon, Laurent			Transport mechanisms in oral transmucosal drug delivery: Implications for pain management	MATHEMATICAL BIOSCIENCES			English	Article						Transmucosal delivery; Fentanyl citrate; Controlled release device; Diffusion	FENTANYL CITRATE; IN-VITRO; ABSORPTION; DIFFUSION; SEDATION	The mechanism for the oral transmucosal delivery of fentanyl citrate (OTFC) was investigated in this work. A developed mathematical model included the following transport characteristics: dissolution of the fentanyl citrate lozenge, diffusion through the saliva and oral mucosal membrane and equilibrium between adjacent layers. An orthogonal-collocation-based solution procedure was adopted to discretize the governing equations and boundary conditions. The Mathematica (R) built-in function, NDSolve, was applied to integrate the equations with respect to time. Simulations were conducted with a 200 mu g-dosage. A novel fabrication method, aimed at maintaining a high flux for a prolonged period of time, was proposed based on the calculated delivery rate and cumulative amount of medicament absorbed into the systemic circulation. The model allows drug manufacturers to decide when to replace the unit based on estimated drug concentrations in the saliva and the mucosal membrane. Both the model and solution strategies were validated using serum fentanyl citrate concentration collected from adult subjects. The predicted profiles, based on parameters obtained from the literature, agree well with the experimental data. (C) 2010 Elsevier Inc. All rights reserved.	[Kim, Kwang Seok; Simon, Laurent] New Jersey Inst Technol, Otto H York Dept Chem Biol & Pharmaceut Engn, Newark, NJ 07102 USA	Simon, L (reprint author), New Jersey Inst Technol, Otto H York Dept Chem Biol & Pharmaceut Engn, Newark, NJ 07102 USA.	laurent.simon@njit.edu					Andersson M, 1997, INT J PHARM, V157, P199, DOI 10.1016/S0378-5173(97)00243-3; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; CHIOU CT, 1985, ENVIRON SCI TECHNOL, V19, P57, DOI 10.1021/es00131a005; COLLINS LMC, 1987, J DENT RES, V66, P1300, DOI 10.1177/00220345870660080201; del Consuelo ID, 2005, PHARM RES-DORDR, V22, P1525, DOI 10.1007/s11095-005-6020-y; Finlayson B, 1980, NONLINEAR ANAL CHEM; GAINER JL, 1994, IND ENG CHEM RES, V33, P2341, DOI 10.1021/ie00034a013; Hallworth S, 2003, ANESTH ANALG, V96, P1234; Howell TK, 2002, ANAESTHESIA, V57, P798; LIND GH, 1991, ANN EMERG MED, V20, P1117, DOI 10.1016/S0196-0644(05)81387-3; Mazzobre MF, 2005, CARBOHYD RES, V340, P1207, DOI 10.1016/j.carres.2004.12.038; Mystakidou K, 2007, INT J NANOMED, V2, P49, DOI 10.2147/nano.2007.2.1.49; PATHER SI, 2008, MODIFIED RELEASE DRU, V1, P53; Petelin M, 1998, INT J PHARM, V173, P193, DOI 10.1016/S0378-5173(98)00232-4; Rim JE, 2005, ANN BIOMED ENG, V33, P1422, DOI 10.1007/s10439-005-5788-6; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Schutzman SA, 1996, ANN EMERG MED, V28, P385, DOI 10.1016/S0196-0644(96)70001-X; Shaiova L, 2004, SUPPORT CARE CANCER, V12, P268, DOI 10.1007/s00520-004-0595-4; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; SUBBARAO K, 1995, J CONTROL RELEASE, V37, P251; WONG RC, 2005, DRUGS ABUSE	21	5	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-5564	1879-3134		MATH BIOSCI	Math. Biosci.	JAN	2011	229	1					93	100		10.1016/j.mbs.2010.11.002			8	Biology; Mathematical & Computational Biology	Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology	715CX	WOS:000286859100009	21095195				2020-06-30	J	Erturk, E; Bostan, H; Eroglu, A				Erturk, Engin; Bostan, Habib; Eroglu, Ahmet			Epidural Analgesia and Vaginal Delivery in a Patient with Aortic Stenosis and Insufficiency	MEDICAL PRINCIPLES AND PRACTICE			English	Article						Epidural analgesia; Vaginal delivery; Aortic stenosis; Aortic insufficiency; Ropivacaine	CESAREAN-SECTION; ANESTHESIA; PREGNANCY	Objective: To report a successful vaginal delivery using slow infusion of epidural analgesia in a patient with both severe aortic stenosis and insufficiency. Clinical Presentation and Intervention: A 26-year-old primigravid patient presented to our hospital for delivery. She had aortic stenosis and insufficiency due to rheumatic fever. Although the obstetrician recommended cesarean section owing to her cardiac status, she insisted upon vaginal delivery. We performed low-dose epidural analgesia with 10 ml of 0.125% ropivacaine and 20 mu g fentanyl. She had spontaneous vaginal delivery without complication. Conclusion: This case showed that in spite of the cardiac pathology, vaginal delivery under low-dose slow infusion of epidural analgesia was successful and therefore may be a safe alternative to cesarean section for cardiac patients. Copyright (C) 2011 S. Karger AG, Basel	[Erturk, Engin; Bostan, Habib; Eroglu, Ahmet] Karadeniz Tech Univ, Dept Anesthesiol & Intens Care, Fac Med, Trabzon, Turkey	Erturk, E (reprint author), Karadeniz Tech Univ, Dept Anesthesiol & Intens Care, Fac Med, Trabzon, Turkey.	engin_md@yahoo.com	Eroglu, Ahmet/B-1414-2012	Eroglu, Ahmet/0000-0002-0396-1582; Erturk, Engin/0000-0002-5864-1754			ARIAS F, 1978, J REPROD MED, V20, P229; Brighouse D, 1998, ANAESTHESIA, V53, P107, DOI 10.1046/j.1365-2044.1998.00398.x; Dua S, 2006, INT J OBSTET ANESTH, V15, P250, DOI 10.1016/j.ijoa.2005.10.016; Gomar C, 2005, CURR OPIN ANESTHESIO, V18, P507, DOI 10.1097/01.aco.0000183108.27297.3c; HESS W, 1995, ANAESTHESIST, V44, P395, DOI 10.1007/s001010050167; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; Moghbeli Nazanin, 2008, Congenit Heart Dis, V3, P308, DOI 10.1111/j.1747-0803.2008.00207.x; Suntharalingam G, 2001, INT J OBSTET ANESTH, V10, P129, DOI 10.1054/ijoa.2000.0720; Whitfield A, 1998, ANAESTHESIA, V53, P109, DOI 10.1046/j.1365-2044.1998.00399.x; Xia VW, 2006, J CLIN ANESTH, V18, P142, DOI 10.1016/j.jclinane.2005.06.007	10	2	2	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1011-7571			MED PRIN PRACT	Med. Princ. Pract.		2011	20	6					574	576		10.1159/000330027			3	Medicine, General & Internal	General & Internal Medicine	832ZO	WOS:000295850400016	21986019	Bronze			2020-06-30	J	Raehal, KM; Bohn, LM				Raehal, Kirsten M.; Bohn, Laura M.			The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics	NEUROPHARMACOLOGY			English	Article						Opioid; G protein-coupled receptor; Mu opioid receptor; Antinociception; Withdrawal; Functional selectivity	AGONIST-SPECIFIC REGULATION; MORPHINE-INDUCED ANALGESIA; RECEPTOR-KNOCKOUT MICE; TAIL-SKIN TEMPERATURE; BETA-ARRESTIN; IN-VITRO; GASTROINTESTINAL TRANSIT; FUNCTIONAL SELECTIVITY; REDUCES TOLERANCE; DESENSITIZATION	Ligands acting at the same receptor can differentially activate distinct signal transduction pathways, which in turn, can have diverse functional consequences. Further, receptors expressed in different tissues may utilize intracellular signaling proteins in response to a ligand differently as well. The mu opioid receptor (MOR), which mediates many of the pharmacological actions of opiate therapeutics, is also subject to differential signaling in response to diverse agonists. To study the effect of diverse agonists on MOR signaling, we examined the effects of chronic opiate treatment on two distinct physiological endpoints, antinociceptive tolerance and physical dependence, in mice lacking the intracellular regulatory molecule, beta arrestin2. While beta arrestin2 knockout (beta arr2-KO) mice do not become tolerant to the antinociceptive effects of chronic morphine in a hot plate test, tolerance develops to the same degree in both wild type and beta arr2-KO mice following chronic infusion with methadone, fentanyl, and oxycodone. Studies here also assess the severity of withdrawal signs precipitated by naloxone following chronic infusions at three different doses of each opiate agonist. While there are no differences in withdrawal responses between genotypes at the highest dose of morphine tested (48 mg/kg/day), the beta arr2-KO mice display several less severe withdrawal responses when the infusion dose is lowered (12 or 24 mg/kg/day). Chronic infusion of methadone, fentanyl, and oxycodone all lead to equivalent naloxone-precipitated withdrawal responses in both genotypes at all doses tested. These results lend further evidence that distinct agonists can differentially impact on opioid-mediated responses in vivo in a beta arrestin2-dependent manner. (C) 2010 Elsevier Ltd. All rights reserved.	[Bohn, Laura M.] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL 33458 USA; Scripps Res Inst, Dept Neurosci, Jupiter, FL 33458 USA	Bohn, LM (reprint author), Scripps Res Inst, Dept Mol Therapeut, 130 Scripps Way, Jupiter, FL 33458 USA.	lbohn@scripps.edu	Bohn, Laura/A-7483-2014	Bohn, Laura/0000-0002-6474-8179	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA021952, DA14600, DA18860]	This work was supported by the National Institute on Drug Abuse grants DA021952 (K.M.R), DA14600 and DA18860 (L.M.B.)	Aceto M.D., 1997, NIDA RES MONOGR, V19997, P338; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Arttamangkul S, 2008, MOL PHARMACOL, V74, P972, DOI 10.1124/mol.108.048512; Bailey CP, 2006, TRENDS PHARMACOL SCI, V27, P558, DOI 10.1016/j.tips.2006.09.006; BERGE OG, 1988, NEUROSCI LETT, V86, P284, DOI 10.1016/0304-3940(88)90497-1; Berrendero F, 2003, EUR J NEUROSCI, V17, P315, DOI 10.1046/j.1460-9568.2003.02439.x; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Bohn LM, 2002, J NEUROSCI, V22, P10494; Bostrom E, 2008, ANESTHESIOLOGY, V108, P495, DOI 10.1097/ALN.0b013e318164cf9e; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; DYKSTRA LA, 1985, BEHAVIORAL PHARM CUR, P111; Feng P, 2006, EUR J PHARMACOL, V534, P250, DOI 10.1016/j.ejphar.2006.01.048; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Gabra BH, 2008, BRAIN RES, V1217, P70, DOI 10.1016/j.brainres.2008.04.036; He L, 2005, CURR BIOL, V15, P1028, DOI 10.1016/j.cub.2005.04.052; Kaiko RF, 1996, CLIN PHARMACOL THER, V59, P52, DOI 10.1016/S0009-9236(96)90024-7; Kalvass JC, 2007, J PHARMACOL EXP THER, V323, P346, DOI 10.1124/jpet.107.119560; Keith DE, 1998, MOL PHARMACOL, V53, P377; Kenakin T, 2007, MOL PHARMACOL, V72, P1393, DOI 10.1124/mol.107.040352; Kest B, 2002, NEUROSCIENCE, V115, P463, DOI 10.1016/S0306-4522(02)00458-X; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kim JA, 2008, CURR BIOL, V18, P129, DOI 10.1016/j.cub.2007.12.057; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Lemberg KK, 2006, ANESTHESIOLOGY, V105, P801, DOI 10.1097/00000542-200610000-00027; Madia PA, 2009, PSYCHOPHARMACOLOGY, V207, P413, DOI 10.1007/s00213-009-1673-6; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mogil JS, 2001, METH NE FRO NEUROSCI, P11; Raehal KM, 2009, DRUG ALCOHOL DEPEN, V104, P187, DOI 10.1016/j.drugalcdep.2009.04.011; Roy S, 1998, MOL BRAIN RES, V56, P281, DOI 10.1016/S0169-328X(98)00051-5; Schmid CL, 2009, PHARMACOL THERAPEUT, V121, P285, DOI 10.1016/j.pharmthera.2008.11.005; Smith FL, 2006, PHARMACOL RES, V54, P474, DOI 10.1016/j.phrs.2006.09.007; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; TJOLSEN A, 1989, J NEUROSCI METH, V26, P259, DOI 10.1016/0165-0270(89)90124-6; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Virk MS, 2008, MOL PHARMACOL, V73, P1301, DOI 10.1124/mol.107.042952; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YOBURN BC, 1995, PHARMACOL BIOCHEM BE, V51, P535, DOI 10.1016/0091-3057(94)00375-S; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842	44	99	103	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JAN	2011	60	1					58	65		10.1016/j.neuropharm.2010.08.003			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	703PA	WOS:000285989500008	20713067	Green Accepted			2020-06-30	J	Wang, Y; Yan, M; He, JG; Zhu, YM; Hu, XS; Li, X; Wu, WD				Wang, Y.; Yan, M.; He, J. G.; Zhu, Y. M.; Hu, X. S.; Li, X.; Wu, W. D.			A Randomized Comparison of Target-Controlled Infusion of Remifentanil and Propofol with Desflurane and Fentanyl for Laryngeal Surgery	ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES			English	Article						Target-controlled infusion; Remifentanil; Propofol; Direct laryngoscopic surgery	BISPECTRAL INDEX; PHARMACOKINETICS; ANESTHESIA; PHARMACODYNAMICS; PROFILE	Aims: To compare the clinical profile of target-controlled infusion (TCI) of remifentanil (REM) + propofol (PRO) with fentanyl (FEN) bolus infusion with desflurane (DES) inhalation in direct laryngoscopic surgery. Methods: Sixty patients who were scheduled to undergo laryngoscopic surgery were randomly assigned to two groups (n = 30, respectively). One group of patients received a TCI of REM + PRO anesthetic treatment, while the patients in the other group received a bolus infusion of FEN and DES inhalation treatment. The hemodynamics, recovery profiles and unexpected events that occurred in both groups were recorded. Results:The hemodynamics of the patients in the TCI group was more stable during tracheal intubation, direct laryngoscope insertion and extubation. The mean arterial pressure was also significantly lower in the TCI group compared with the FEN/DES group. The TCI group also showed faster recovery profiles (e.g. a shorter time needed for response to verbal commands, autonomous breathing, tracheal extubation and orientation recovery). The FEN/DES group had lower Stewart recovery scores during the first 15 min determined at the postanesthesia care unit. However, there were no significant differences regarding the occurrence of unexpected events and postoperative complications between the two groups. Conclusions: TCI of REM + PRO anesthesia appears to be a reasonable alternative to FEN bolus infusion combined with DES inhalation during direct laryngoscopic surgery. Copyright (C) 2011 S. Karger AG, Basel	[Wang, Y.; Yan, M.; Zhu, Y. M.; Hu, X. S.; Li, X.; Wu, W. D.] Zhejiang Univ, Sch Med, Dept Anesthesiol, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China; [He, J. G.] Zhejiang Univ, Sch Med, Dept Otorhinolaryngol, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China	Wu, WD (reprint author), Zhejiang Univ, Sch Med, Dept Anesthesiol, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.	weidongw@yahoo.com					Absalom AR, 2003, BRIT J ANAESTH, V90, P737, DOI 10.1093/bja/aeg137; Apfelbaum JL, 2002, ANESTHESIOLOGY, V97, P66, DOI 10.1097/00000542-200207000-00010; Avramov Michail N., 1998, Anesthesia and Analgesia, V87, P666, DOI 10.1097/00000539-199809000-00033; BUERKLE H, 1996, ANESTHESIA ANALGESIA, V84, P646; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Guarracino F, 2005, Minerva Anestesiol, V71, P335; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Gurses E, 2004, ANESTH ANALG, V98, P128, DOI 10.1213/01.ANE.0000090314.43496.1D; Howie MB, 2001, ANESTH ANALG, V92, P1084; Leone M, 2004, BRIT J ANAESTH, V93, P660, DOI 10.1093/bja/aeh250; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Minto CF, 1997, ANESTHESIOLOGY, V86, P24, DOI 10.1097/00000542-199701000-00005; Passot S, 2002, ANESTH ANALG, V94, P1212, DOI 10.1097/00000539-200205000-00030; Servin F. S., 2008, V182, P283, DOI 10.1007/978-3-540-74806-9_14; Struys MMRF, 2001, ANESTHESIOLOGY, V95, P6, DOI 10.1097/00000542-200107000-00007; Twersky RS, 2001, J CLIN ANESTH, V13, P407, DOI 10.1016/S0952-8180(01)00292-6; Wormald PJ, 2005, AM J RHINOL, V19, P514, DOI 10.1177/194589240501900516	20	3	3	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND				ORL-J OTO-RHIN-LARYN	ORL-J. Oto-Rhino-Laryngol. Relat. Spec.		2011	73	1					47	52		10.1159/000322598			6	Otorhinolaryngology	Otorhinolaryngology	713FJ	WOS:000286720100007	21212710				2020-06-30	J	Fukushima, S; Takenami, T; Yagishita, S; Nara, Y; Hoka, S; Okamoto, H				Fukushima, Sayano; Takenami, Tamie; Yagishita, Saburo; Nara, Yoshihiro; Hoka, Sumio; Okamoto, Hirotsugu			Neurotoxicity of Intrathecally Administered Fentanyl in a Rat Spinal Model	PAIN MEDICINE			English	Article						Intrathecally Administered Fentanyl; Neurotoxicity; Rat Spinal Model; Inflammatory Mass	INFLAMMATORY MASSES; SUFENTANIL; MORPHINE; PHARMACOLOGY; INFUSION; SHEEP; PAIN	Objective. Intrathecally administered fentanyl rarely causes drug tolerance or formation of inflammatory masses and might therefore be a suitable treatment option for chronic pain. However, the neurotoxicity of intrathecally administered fentanyl remains to be clarified. We examined the histological changes, neurodysfunction, and side effects of intrathecal fentanyl in rats. Design. The rats received fentanyl at 0.12 mu L/g body weight (0, 50, 1,000, 2,000, and 5,000 mu g/mL in saline) via an intrathecal catheter. Seven days after the injection, the spinal cord with both roots were removed for histological examination. The neurological function was evaluated by monitoring walking behavior and latencies to radiant heat. Side effects were also recorded. Results. No histological abnormalities were observed in the spinal cord, anterior and posterior roots, cauda equina nerves, or arachnoid membrane. Formation of white neomembrane was noted around the catheter in some animals, but there was no significant difference in the incidence among the groups. The sensory threshold was significantly higher at 1 and 2 hours after injection in the 50 and 5,000 mu g/mL groups, respectively. However, there was no significant difference in the sensory threshold among the five groups at 7 days postinjection. All of the rats walked normally within 4 hours even after injection of 5,000 mu g/mL fentanyl. The incidence of apnea, muscular rigidity, and bradycardia increased significantly at >= 1,000 mu g/mL dose. Conclusions. The side effects of intrathecally administered fentanyl were concentration-dependent, although no neuronal tissue damage, inflammation, or irreversible neurodysfunction were observed even at 5,000 mu g/mL.	[Takenami, Tamie] Kitasato Univ, Dept Anesthesiol, Sch Med, Minami Ku, Kanagawa 2520374, Japan; [Yagishita, Saburo] Kanagawa Rehabil Ctr, Dept Pathol, Kanagawa, Japan	Takenami, T (reprint author), Kitasato Univ, Dept Anesthesiol, Sch Med, Minami Ku, 1-15-1 Kitasato, Kanagawa 2520374, Japan.	takenami@med.kitasato-u.ac.jp					Allen JW, 2006, ANESTHESIOLOGY, V105, P590, DOI 10.1097/00000542-200609000-00025; Auroy Y, 2002, ANESTHESIOLOGY, V97, P1274, DOI 10.1097/00000542-200211000-00034; Bailey P.L., 2000, ANESTHESIA, P273; Deer T, 2008, NEUROMODULATION, V11, P77, DOI 10.1111/j.1525-1403.2008.00147.x; Deer TR, 2010, PAIN PHYSICIAN, V13, pE175; Gradert TL, 2003, ANESTHESIOLOGY, V99, P188, DOI 10.1097/00000542-200307000-00029; RAWAL N, 1991, ANESTHESIOLOGY, V75, P1025, DOI 10.1097/00000542-199112000-00015; SABBE MB, 1994, ANESTHESIOLOGY, V81, P899, DOI 10.1097/00000542-199410000-00017; Takenami T, 2005, REGION ANESTH PAIN M, V30, P464, DOI 10.1016/j.rapm.2005.05.005; Takenami T, 2000, REGION ANESTH PAIN M, V25, P372, DOI 10.1053/rapm.2000.6444; Thimineur MA, 2004, PAIN, V109, P242, DOI 10.1016/j.pain.2004.01.003; Waara-Wolleat KL, 2006, PAIN MED, V7, P251, DOI 10.1111/j.1526-4637.2006.00155.x; Yaksh TL, 2002, PAIN MED, V3, P300, DOI 10.1046/j.1526-4637.2002.02048.x; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009	15	6	7	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.		2011	12	5					717	725		10.1111/j.1526-4637.2011.01084.x			9	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	762OM	WOS:000290489300007	21463467	Bronze			2020-06-30	J	Terui, K; Omoto, A; Osada, H; Hishiki, T; Saito, T; Sato, Y; Mitsunaga, T; Yoshida, H				Terui, Keita; Omoto, Akiko; Osada, Hisao; Hishiki, Tomoro; Saito, Takeshi; Sato, Yoshiharu; Mitsunaga, Tetsuya; Yoshida, Hideo			Influence of fetal stabilization on postnatal status of patients with congenital diaphragmatic hernia	PEDIATRIC SURGERY INTERNATIONAL			English	Article						Congenital diaphragmatic hernia; Fetal diagnosis; Pulmonary hypoplasia; Pulmonary hypertension; Prenatal diagnosis	SURVIVAL RATE; VENTILATION; INFANTS	Purpose Fetal stabilization (FS) is a way to decrease stresses to the fetus during the perinatal period to control persistent pulmonary hypertension in neonates (PPHN). Although FS in congenital diaphragmatic hernia (CDH) patients has been reported, the effect of FS has not been evaluated sufficiently. The present study retrospectively evaluated influences of FS on the postnatal status of CDH patients. Methods Twenty-three cases of prenatally diagnosed CDH which were treated after birth in our institution from April 1998 to March 2010 were reviewed. From April 1998 to May 2007, FS was performed by administration of fentanyl and midazolam to the mother before subsequent cesarean section (FS group, n = 10). Beginning from June 2007, FS was discontinued (non-FS, n = 13). Results At the first postnatal estimation, flow pattern of the ductus arteriosus had no difference between two groups. The oxygenation index of the FS group was significantly higher than that in the non-FS group (p = 0.045). Only the non-FS group had correlations between estimated standardized lung volume (% lung volume) and alveolar-arterial oxygen tension difference (p = 0.022), and between % lung volume and the oxygenation index (p = 0.0037). Conclusion During the period immediately after birth, FS had no obvious therapeutic effect on PPHN, and had a negative impact on respiratory status.	[Terui, Keita; Hishiki, Tomoro; Saito, Takeshi; Sato, Yoshiharu; Mitsunaga, Tetsuya; Yoshida, Hideo] Chiba Univ, Grad Sch Med, Dept Pediat Surg, Chiba 2608677, Japan; [Omoto, Akiko; Osada, Hisao] Chiba Univ Hosp, Dept Maternal Fetal Med, Chiba, Japan	Terui, K (reprint author), Chiba Univ, Grad Sch Med, Dept Pediat Surg, 1-8-1 Inohana, Chiba 2608677, Japan.	kta@cc.rim.or.jp		Terui, Keita/0000-0003-4315-5179			Bagolan P, 2004, J PEDIATR SURG, V39, P313, DOI 10.1016/j.jpedsurg.2003.11.009; BARRIER G, 1987, NEONATAL MED, P154; Betremieux P, 2004, PRENATAL DIAG, V24, P487, DOI 10.1002/pd.909; Boloker J, 2002, J PEDIATR SURG, V37, P357, DOI 10.1053/jpsu.2002.30834; Coakley FV, 2000, RADIOLOGY, V216, P107, DOI 10.1148/radiology.216.1.r00jn44107; Downard CD, 2003, J PEDIATR SURG, V38, P729, DOI 10.1016/jpsu.2003.50194; IWANAKA T, 1994, J OBSTET GYNAECOL, V20, P115; Javid PJ, 2004, J PEDIATR SURG, V39, P657, DOI 10.1016/j.jpedsurg.2004.01.022; Masumoto K, 2006, PEDIATR SURG INT, V25, P487, DOI 10.1007/s00383-009-2370-6; Migliazza L, 2007, J PEDIATR SURG, V42, P1526, DOI 10.1016/j.jpedsurg.2007.04.015; Okawada M, 2006, PEDIATR SURG INT, V22, P925, DOI 10.1007/s00383-006-1759-8; Osada H, 2004, RADIOLOGY, V231, P887, DOI 10.1148/radiol.2313021689; Scott L, 2004, J PEDIATR SURG, V39, P661, DOI 10.1016/j.jpedsurg.2004.01.032; Senzaki Hideaki, 1994, Acta Paediatrica Japonica, V36, P497; Stege G, 2003, PEDIATRICS, V112, P532, DOI 10.1542/peds.112.3.532; Suita S, 1999, J PEDIATR SURG, V34, P1652, DOI 10.1016/S0022-3468(99)90637-1; Tanabe M, 2000, EUR J PEDIATR SURG, V10, P92, DOI 10.1055/s-2008-1072333; Uesugi T, 2007, PEDIATR SURG INT, V23, P961, DOI 10.1007/s00383-007-1978-7; VACANTI JP, 1984, J PEDIATR SURG, V19, P672, DOI 10.1016/S0022-3468(84)80351-6	19	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-0358			PEDIATR SURG INT	Pediatr. Surg. Int.	JAN	2011	27	1					29	33		10.1007/s00383-010-2723-1			5	Pediatrics; Surgery	Pediatrics; Surgery	707ZR	WOS:000286330600005	20842386				2020-06-30	J	Wuethrich, PY; Henning, A; Schweizerhof, M; Kessler, TM; Burkhard, FC				Wuethrich, Patrick Y.; Henning, Armin; Schweizerhof, Matthias; Kessler, Thomas M.; Burkhard, Fiona C.			Postvoid Residuals Remain Unchanged in Patients With Postoperative Thoracic Epidural Analgesia After Thoracotomy	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							ASSOCIATION SYMPTOM INDEX; URINARY-TRACT-INFECTION; LOW-DOSE INFUSION; DOUBLE-BLIND; RETENTION; FENTANYL; BUPIVACAINE; SURGERY; HYPERPLASIA; SPECIFICITY	Background and Objectives: We found in previous studies that thoracic epidural analgesia (TEA) after open renal surgery via lumbotomy significantly impaired bladder function with decreased detrusor contractility and increased postvoid residuals under urodynamic assessment. Here we evaluated the effect of TEA on bladder emptying in patients undergoing thoracotomy. Methods: In a prospective, follow-up study, 13 men and 13 women with an International Prostate Symptom Score of less than 7 and with a postvoid residual of less than 100 mL underwent sonographic assessment of the postvoid residual the day before thoracotomy without TEA and 2 days postoperatively under TEA. The epidural catheter was inserted at level T4/5 or 5/6. Continuous epidural analgesia was maintained with a mixture of bupivacaine 1 mg/mL, epinephrine 2 mu g/mL, and fentanyl 2 mu g/mL. Primary outcome was the difference in postvoid residual before versus during TEA. Results: The postvoid residual did not change significantly preoperatively and postoperatively in men (P = 0.09) and women (P = 0.18). However, a significant decrease in bladder capacity at strong desire to void and voided volumes was observed in women. Of the 3 male patients with an initial International Prostate Symptom Score of 3 or greater and less than 7, all developed a postvoid residual of greater than 100 mL and were older than 50 years. Conclusions: Most patients after thoracotomy had unchanged postvoid residuals under TEA. Our study design does not allow us to determine cause and effect or to make conclusions that are based on comparative, randomized data. However, our observations do yield a hypothesis-generating basis for future clinical trials.	[Wuethrich, Patrick Y.] Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, CH-3010 Bern, Switzerland; [Henning, Armin; Schweizerhof, Matthias] Univ Hosp Bern, Dept Thorac Surg, CH-3010 Bern, Switzerland; [Kessler, Thomas M.; Burkhard, Fiona C.] Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland	Wuethrich, PY (reprint author), Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, CH-3010 Bern, Switzerland.	patrick.wuethrich@insel.ch	Burkhard, Fiona/AAE-4524-2020				Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Basse L, 2000, REGION ANESTH PAIN M, V25, P498, DOI 10.1053/rapm.2000.9537; CHAI TC, 1993, J UROLOGY, V150, P1710, DOI 10.1016/S0022-5347(17)35874-3; CHANCELLOR MB, 1993, J UROLOGY, V150, P1706, DOI 10.1016/S0022-5347(17)35872-X; Chapple CR, 2008, EUR UROL, V54, P563, DOI 10.1016/j.eururo.2008.03.109; Chia Yuan-Yi, 2009, Acta Anaesthesiol Taiwan, V47, P173, DOI 10.1016/S1875-4597(09)60051-5; Curatolo M, 2000, ANESTHESIOLOGY, V92, P325, DOI 10.1097/00000542-200002000-00012; Fenton AS, 2005, UROLOGY, V65, P1055, DOI 10.1016/j.urology.2004.12.018; HAMPSON SJ, 1992, BRIT J UROL, V70, P506; Ladak SSJ, 2009, PAIN MANAG NURS, V10, P94, DOI 10.1016/j.pmn.2008.08.001; Madersbacher S, 1999, NEUROUROL URODYNAM, V18, P173, DOI 10.1002/(SICI)1520-6777(1999)18:3<173::AID-NAU3>3.3.CO;2-D; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2002, ANESTH ANALG, V94, P1598, DOI 10.1097/00000539-200206000-00044; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; Saint S, 1999, J AM GERIATR SOC, V47, P1453, DOI 10.1111/j.1532-5415.1999.tb01567.x; Saint S, 2000, AM J INFECT CONTROL, V28, P68, DOI 10.1016/S0196-6553(00)90015-4; Saito M, 2001, J UROLOGY, V165, P1745, DOI 10.1016/S0022-5347(05)66406-3; Saito Motoaki, 1998, Life Sciences, V62, P149; Saito M, 2010, MOL CELL BIOCHEM, V333, P109, DOI 10.1007/s11010-009-0210-6; Shimizu S, 2009, BJU INT, V104, P713, DOI 10.1111/j.1464-410X.2009.08471.x; Wuethrich PY, 2010, ANESTHESIOLOGY, V112, P1345, DOI 10.1097/ALN.0b013e3181d4f4fe; WUETHRICH PY, 2010, NEUROUROL URODY 0629; Zaouter C, 2009, REGION ANESTH PAIN M, V34, P542, DOI 10.1097/AAP.0b013e3181ae9fac	24	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JAN-FEB	2011	36	1					46	50		10.1097/AAP.0b013e3182030828			5	Anesthesiology	Anesthesiology	792TW	WOS:000292774300011	21455089				2020-06-30	J	Sert, H; Muslu, B; Usta, B; Colak, N; Demircioglu, RI; Gozdemir, M				Sert, Huseyin; Muslu, Bunyamin; Usta, Burhanettin; Colak, Necmettin; Demircioglu, Ruveyda Irem; Gozdemir, Muhammet			A Comparison of Articaine and Fentanyl-Supplemented Articaine for Hemodialysis Fistula Creation under Ultrasound-Guided Axillary Block	RENAL FAILURE			English	Article						Hemodialysis fistula creation; renal failure; axillary plexus block; articaine; ultrasound guidance	BRACHIAL-PLEXUS BLOCK; RENAL-FAILURE; ANESTHESIA; ANALGESIA; LIDOCAINE; SURGERY; PHARMACOKINETICS; PROLONGS	The aim of this prospective randomized, double-blinded study was to evaluate the effect of fentanyl addition to articaine on the duration of sensory as well as motor blocks, and the duration of analgesia during hemodialysis fistula creation under ultrasound-guided axillary block. Fifty patients were randomly allocated to two groups, an articaine group (A), receiving 40 mL of articaine HCI (20 mg/mL) with 2 mL of isotonic sodium chloride solution, and an articaine-fentanyl group (AF), receiving 40 mL of articaine HCI (20 mg/mL) with 2 mL (100 mu g) of fentanyl. The onset as well as the duration of sensory and motor blocks, the time necessary for first analgesic administration, the hemodynamic parameters, and the side effects were recorded. Three patients in Group A and two patients in Group AF due to incomplete block were excluded from the study. The duration of sensory and motor blocks was significantly longer in the AF group than in the A group. The first time for analgesic need was also significantly longer in group AF (363 +/- 134 min) than in group A (244 +/- 84 min) (p = 0.001). The addition of fentanyl did not improve the onset of sensory and motor block times. Hemodynamic parameters were similar in the two groups. In conclusion, the addition of fentanyl to articaine in axillary block prolongs the duration of sensory and motor blocks, as well as the time of first analgesic requirement.	[Sert, Huseyin; Muslu, Bunyamin; Usta, Burhanettin; Demircioglu, Ruveyda Irem; Gozdemir, Muhammet] Fatih Univ, Dept Anesthesiol, Fac Med, TR-06520 Ankara, Turkey; [Colak, Necmettin] Fatih Univ, Dept Cardiovasc Surg, Fac Med, TR-06520 Ankara, Turkey	Sert, H (reprint author), Fatih Univ, Dept Anesthesiol, Fac Med, Alparslan Turkes Caddesi 57, TR-06520 Ankara, Turkey.	drhuseyinsert@yahoo.com					DAVIS WJ, 1991, MAYO CLIN PROC, V66, P470, DOI 10.1016/S0025-6196(12)62386-6; EULEFELD F, 1980, Regional-Anaesthesie, V3, P1; FLETCHER D, 1994, REGION ANESTH, V19, P183; Jamnig D, 2003, ACUTE PAIN, V5, P51; Janzen PRM, 2001, ANESTH ANALG, V93, P187; Johnson ME, 2000, MAYO CLIN PROC, V75, P921, DOI 10.4065/75.9.921; Karakaya D, 2001, REGION ANESTH PAIN M, V26, P434, DOI 10.1053/rapm.2001.24675; KARDASH K, 1995, REGION ANESTH, V20, P311; Klein SM, 2005, ANESTH ANALG, V101, P1663, DOI 10.1213/01.ANE.0000184187.02887.24; LADURON PM, 1984, BRAIN RES, V294, P157, DOI 10.1016/0006-8993(84)91322-2; Mercadante S, 1997, J PAIN SYMPTOM MANAG, V13, P241, DOI 10.1016/S0885-3924(97)00076-6; MOUQUET C, 1989, ANESTHESIOLOGY, V70, P909, DOI 10.1097/00000542-198906000-00005; Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028; Oertel R, 1997, CLIN PHARMACOKINET, V33, P417, DOI 10.2165/00003088-199733060-00002; RACZ H, 1991, ANESTH ANALG, V72, P769; Rodriguez J, 2001, EUR J ANAESTH, V18, P171, DOI 10.1046/j.0265-0215.2000.00806.x; Simon MAM, 1999, INT J CLIN PHARM TH, V37, P598; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; VANOSS GECJM, 1989, EUR J ANAESTH, V6, P49	19	3	4	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0886-022X			RENAL FAILURE	Ren. Fail.		2011	33	3					280	284		10.3109/0886022X.2011.560502			5	Urology & Nephrology	Urology & Nephrology	734GX	WOS:000288323700005	21401351	Bronze			2020-06-30	J	Psatha, E; Alibhai, HI; Jimenez-Lozano, A; Armitage-Chan, E; Brodbelt, DC				Psatha, Evdokia; Alibhai, Hatim Ik; Jimenez-Lozano, Angeles; Armitage-Chan, Elizabeth; Brodbelt, David C.			Clinical efficacy and cardiorespiratory effects of alfaxalone, or diazepam/fentanyl for induction of anaesthesia in dogs that are a poor anaesthetic risk	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alfaxalone; anaesthesia; diazepam; dog; fentanyl; high risk	BLOOD-PRESSURE; HEART-RATE; PROPOFOL; THIOPENTONE; DIAZEPAM; AGENT; CATS; PHARMACOKINETICS; KETAMINE; MEDETOMIDINE	Objective To evaluate the clinical efficacy and cardiorespiratory effects of alfaxalone as an anaesthetic induction agent in dogs with moderate to severe systemic disease. Study design Randomized prospective clinical study. Animals Forty dogs of physical status ASA III-V referred for various surgical procedures. Methods Dogs were pre-medicated with intramuscular methadone (0.2 mg kg-1) and allocated randomly to one of two treatment groups for induction of anaesthesia: alfaxalone (ALF) 1-2 mg kg-1 administered intravenously (IV) over 60 seconds or fentanyl 5 mu g kg-1 with diazepam 0.2 mg kg-1 +/- propofol 1-2 mg kg-1 (FDP) IV to allow endotracheal intubation. Anaesthesia was maintained with isoflurane in oxygen and fentanyl infusion following both treatments. All dogs were mechanically ventilated to maintain normocapnia. Systolic blood pressure (SAP) was measured by Doppler ultrasound before and immediately after anaesthetic induction, but before isoflurane administration. Parameters recorded every 5 minutes throughout subsequent anaesthesia were heart and respiratory rates, end-tidal partial pressure of carbon dioxide and isoflurane, oxygen saturation of haemoglobin and invasive systolic, diastolic and mean arterial blood pressure. Quality of anaesthetic induction and recovery were recorded. Continuous variables were assessed for normality and analyzed with the Mann Whitney U test. Repeated measures were log transformed and analyzed with repeated measures anova (p < 0.05). Results Treatment groups were similar for continuous and categorical data. Anaesthetic induction quality was good following both treatments. Pre-induction and post-induction systolic blood pressure did not differ between treatments and there was no significant change after induction. The parameters measured throughout the subsequent anaesthetic procedures did not differ between treatments. Quality of recovery was very, quite or moderately smooth. Conclusions and clinical relevance Induction of anaesthesia with alfaxalone resulted in similar cardiorespiratory effects when compared to the fentanyl-diazepam-propofol combination and is a clinically acceptable induction agent in sick dogs.	[Psatha, Evdokia; Alibhai, Hatim Ik; Jimenez-Lozano, Angeles; Armitage-Chan, Elizabeth; Brodbelt, David C.] Queen Mother Hosp, Royal Vet Coll, Hatfield, Herts, England	Psatha, E (reprint author), VRCC Vet Referrals, 1 Bramston Way, Southfields SS15 6TP, Essex, England.	psathae@yahoo.co.uk	Brodbelt, David/C-6005-2009	Brodbelt, David/0000-0001-5628-4194; Armitage-Chan, Elizabeth/0000-0001-9632-4955	Vetoquinol UK	The authors wish to acknowledge the financial support of Vetoquinol UK and the assistance of Mr Chris Seymour in making constructive comments during the formulation of this paper.	Absalom A, 1999, ANAESTHESIA, V54, P861; Ambros B, 2008, AM J VET RES, V69, P1391, DOI 10.2460/ajvr.69.11.1391; BLAKE DW, 1981, J AUTONOM NERV SYST, V3, P55, DOI 10.1016/0165-1838(81)90030-8; Blancquaert JP, 1986, EUR J PHARM THER, V21, P380; BOMZON L, 1981, J SMALL ANIM PRACT, V22, P769, DOI 10.1111/j.1748-5827.1981.tb00584.x; Bowdle TA, 2004, ANESTH ANALG, V98, P1692, DOI 10.1213/01.ANE.0000114085.20751.20; Braun C, 2007, J AM ANIM HOSP ASSOC, V43, P8, DOI 10.5326/0430008; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Brodbelt DC, 2006, VET REC, V158, P563, DOI 10.1136/vr.158.16.563; CHILD KJ, 1971, BRIT J ANAESTH, V43, P2, DOI 10.1093/bja/43.1.2-a; Clarke KW, 1990, VET ANAESTH ANALG, V17, P4; Clutton RE, 2007, MANUAL CANINE FELINE, P200; CORBETT HR, 1977, AUST VET PRACT, V7, P184; Covey-Crump GL, 2008, VET ANAESTH ANALG, V35, P463, DOI 10.1111/j.1467-2995.2008.00408.x; England GC, 1989, ACTA VET SCAND, V85, P179; Fayyaz S, 2009, VET ANAESTH ANALG, V36, P110, DOI 10.1111/j.1467-2995.2008.00437.x; Ferre PJ, 2006, VET ANAESTH ANALG, V33, P229, DOI 10.1111/j.1467-2995.2005.00264.x; GARDOCKI JF, 1964, TOXICOL APPL PHARM, V6, P48, DOI 10.1016/0041-008X(64)90021-3; GILLIES GWA, 1989, ANAESTHESIA, V44, P386, DOI 10.1111/j.1365-2044.1989.tb11333.x; GOODCHILD CS, 1989, BRIT J ANAESTH, V63, P87, DOI 10.1093/bja/63.1.87; Hall L., 2001, VET ANAESTHESIA, P77; Hall LW, 2001, VET ANAESTHESIA, P29; Hall LW, 2001, VET ANAESTHESIA, P75; HASKINS SC, 1986, AM J VET RES, V47, P795; Hellebrekers LJ, 1991, VET ANAESTH ANALG, V18, P191; ILKIW JE, 1992, AM J VET RES, V53, P2323; Ko JCH, 2006, J AM ANIM HOSP ASSOC, V42, P18, DOI 10.5326/0420018; Maddern K, 2010, VET ANAESTH ANALG, V37, P7, DOI 10.1111/j.1467-2995.2009.00503.x; Monteiro ER, 2009, VET ANAESTH ANALG, V36, P25, DOI 10.1111/j.1467-2995.2008.00424.x; MORGAN DWT, 1989, VET REC, V124, P31, DOI 10.1136/vr.124.2.31; Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x; Muir W, 2009, VET ANAESTH ANALG, V36, P42, DOI 10.1111/j.1467-2995.2008.00428.x; Murison PJ, 2001, J SMALL ANIM PRACT, V42, P71, DOI 10.1111/j.1748-5827.2001.tb01995.x; Murrell JC, 2007, MANUAL CANINE FELINE, P120; MUZI M, 1992, ANESTH ANALG, V74, P877; NIMMO GR, 1994, ANAESTHESIA, V49, P485, DOI 10.1111/j.1365-2044.1994.tb03517.x; NOLAN A, 1993, BRIT J ANAESTH, V70, P546, DOI 10.1093/bja/70.5.546; Nolan A. M., 1991, Journal of Veterinary Anaesthesia, V18, P30; PRIANO LL, 1981, ANESTHESIOLOGY, V55, P236, DOI 10.1097/00000542-198109000-00009; PRUNEAU D, 1984, EUR J PHARMACOL, V105, P343, DOI 10.1016/0014-2999(84)90629-0; Sano T, 2003, J VET MED SCI, V65, P641, DOI 10.1292/jvms.65.641; Sawyer DC, 2004, VET ANAESTH ANALG, V31, P27, DOI 10.1111/j.1467-2995.2004.00141.x; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; SMITH JA, 1993, J AM VET MED ASSOC, V202, P1111; Spens HJ, 1996, BRIT J ANAESTH, V77, P194, DOI 10.1093/bja/77.2.194; STANLEY TH, 1980, CAN ANAESTH SOC J, V27, P53; TAYLOR MB, 1986, ANAESTHESIA, V41, P816, DOI 10.1111/j.1365-2044.1986.tb13123.x; Tournadre JP, 2000, ACTA ANAESTH SCAND, V44, P231, DOI 10.1034/j.1399-6576.2000.440303.x; Veterinary Medicines Directorate, 2009, 15 VET MED DIR, P5; WATKINS SB, 1987, VET REC, V120, P326, DOI 10.1136/vr.120.14.326; Whittem T, 2008, J VET PHARMACOL THER, V31, P571, DOI 10.1111/j.1365-2885.2008.00998.x	51	31	32	1	28	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2011	38	1					24	36		10.1111/j.1467-2995.2010.00577.x			13	Veterinary Sciences	Veterinary Sciences	704LR	WOS:000286055000003	21214707				2020-06-30	J	Kokubun, H; Matoba, M; Yamada, Y; Yago, K				Kokubun, Hideya; Matoba, Motohiro; Yamada, Yasuhiko; Yago, Kazuo			Solutions for the Clinical Problems of Analgesics for Cancer Pain Treatment in Japan	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Review						cancer pain; appropriate usage; fentanyl; morphine; oxcodone; acetaminophen	CONTROLLED-RELEASE OXYCODONE; PERFORMANCE LIQUID-CHROMATOGRAPHY; WORLD-HEALTH-ORGANIZATION; TRANSDERMAL FENTANYL; RENAL-FAILURE; DOUBLE-BLIND; ELECTROCHEMICAL DETECTION; MORPHINE GLUCURONIDES; PHARMACOKINETICS; ACETAMINOPHEN	The pain experienced by cancer patients can be managed in 70-90% of cases by the World Health Organisation protocol for cancer pain. However, cancer pain treatment in Japan is not sufficiently effective. To use medicine safely and effectively, various problems must be solved. Therefore, in this study, appropriate usage of cancer pain treatment was examined. We were able to use acetaminophen suppositories (800 mg each) in cancer pain patients. It was suggested that high serum concentrations of oxycodone and hydrocotarnine might be observed in geriatric patients or in the state of decreased hepatic blood flow, making dose adjustment is necessary for such patients. We also clarified that the conversion ratio from oral oxycodone to intravenous ocycodone/hydrocotarnine was 0.71 +/- 0.12. In addition, we clarified the pharmacokinetics of controlled-release oxycodone in patients with cancer pain. Moreover, the findings of our study indicate that in the steady state, the serum concentrations of fentanyl are not maintained at a constant level for 3 days following the use of transdermal fentanyl. We established a method of appropriately passing a nasal duct for sustained release of fine granules of morphine sulfate. Resolution of the clinical problems associated with cancer pain treatments is anticipated to allow the proper use of cancer pain treatments in Japan.	[Kokubun, Hideya; Yago, Kazuo] Kitasato Univ Hosp, Dept Pharm, Minami Ku, Kanagawa 2520375, Japan; [Matoba, Motohiro] Natl Canc Ctr, Dept Palliat Med & Psychooncol, Chuo Ku, Tokyo 1040045, Japan; [Yamada, Yasuhiko] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Clin Evaluat Drug Efficacy, Tokyo 1920392, Japan	Kokubun, H (reprint author), Kitasato Univ Hosp, Dept Pharm, Minami Ku, 1-15-1 Kitasato, Kanagawa 2520375, Japan.	kokubun@kitasato-u.ac.jp					Amrican Pain Society, 2005, GUID MAN CANC PAIN A, P53; Anderson DT, 2002, J ANAL TOXICOL, V26, P448, DOI 10.1093/jat/26.7.448; Anderson P.O., 2001, HDB CLIN DRUG DATA, P16; Angst MS, 2000, ANESTHESIOLOGY, V92, P1473, DOI 10.1097/00000542-200005000-00038; [Anonymous], 2001, JAPANESE PHARMACOPOE, pC; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Benziger DP, 1996, J PHARM SCI, V85, P407, DOI 10.1021/js950403a; BONICA JJ, 1990, [No title captured], P400; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Bruera E, 1989, J Pain Symptom Manage, V4, P3, DOI 10.1016/0885-3924(89)90057-2; CLARK R, 1973, LANCET, V1, P66; COVINGTON EC, 1989, PSYCHOSOMATICS, V30, P226, DOI 10.1016/S0033-3182(89)72306-9; Dahan A, 2004, ANESTHESIOLOGY, V101, P1201, DOI 10.1097/00000542-200411000-00021; DECONNO F, 1994, PAIN, V57, P161, DOI 10.1016/0304-3959(94)90219-4; DO JH, 2004, J KOREAN RHEUM ASS, V11, P14; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Genf World Health Organization, 1986, CANC PAIN REL; GROND S, 1991, J PAIN SYMPTOM MANAG, V6, P411, DOI 10.1016/0885-3924(91)90039-7; Hanks G., 1999, OXFORD TXB PALLIATIV, P342; Heiskanen T, 1998, CLIN PHARMACOL THER, V64, P603, DOI 10.1016/S0009-9236(98)90051-0; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Kaiko R.F., 2005, SYMPTOM MANAGEMENT C, V16, P57; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; KANE RL, 1984, LANCET, V1, P890; Kokubun H, 2005, ANAL SCI, V21, P337, DOI 10.2116/analsci.21.337; Kokubun H, 2007, J PHARM HLTH CARE SC, V33, P200; Kokubun H., 2007, JAPANESE J CANC CHEM, V34, P2255; Kokubun H., 2006, PALLATIVE CARE RES, V1, P311; Kokubun H., 2004, J JAPANESE SOC HOSP, V40, P1011; Kokubun H., 2003, J NEW REMEDIES CLIN, V52, P461; Kokubun H, 2008, YAKUGAKU ZASSHI, V128, P447, DOI 10.1248/yakushi.128.447; Kokubun H, 2007, BIOL PHARM BULL, V30, P2173, DOI 10.1248/bpb.30.2173; Kurtovic J, 2003, J INTERN MED, V253, P240, DOI 10.1046/j.1365-2796.2003.01097.x; LEOW KP, 1992, CLIN PHARMACOL THER, V52, P487, DOI 10.1038/clpt.1992.176; MALAN J, 1985, BRIT J CLIN PHARMACO, V19, P843, DOI 10.1111/j.1365-2125.1985.tb02726.x; Mandema JW, 1996, BRIT J CLIN PHARMACO, V42, P747, DOI 10.1046/j.1365-2125.1996.00481.x; Maruyama M., 2005, JAPANESE J PALLIATIV, V17, P65; Matoba M., 2007, PAIN CLINIC, V28, P1131; Matoba M., 2007, CLIN GASTROENTEROLOG, V22, P173; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P448, DOI 10.1016/S0885-3924(01)00289-5; Mercadante S, 1999, PALLIATIVE MED, V13, P95, DOI 10.1191/026921699678158579; Mizuguchi K., 2001, MED DRUG J, V37, P2389; Mizuguchi K., 2001, MED DRUG J, V37, P2403; Moore A, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; Nakamura K., 2007, JAPANESE J CANC CHEM, V34, P1449; Nishikawa Y., 1987, JAPANESE J INTENSIVE, V11, P483; Numata C., 2005, JPN J PHARM HLTH CAR, V31, P599; Okushima K., 1925, OKAYAMA MED J, V425, P612; OSBORNE R, 1993, CLIN PHARMACOL THER, V54, P158, DOI 10.1038/clpt.1993.127; Otis J, 2006, CURR MED RES OPIN, V22, P1493, DOI 10.1185/030079906X115540; Ozaki M., 2004, MED DRUG J, V40, P302; Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002; Pauli-Magnus C, 1999, NEPHROL DIAL TRANSPL, V14, P903, DOI 10.1093/ndt/14.4.903; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; Peng YR, 2005, J PAIN SYMPTOM MANAG, V30, P7, DOI 10.1016/j.jpainsymman.2005.05.002; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1587, DOI 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X; POYHIA R, 1991, BRIT J CLIN PHARMACO, V32, P516, DOI 10.1111/j.1365-2125.1991.tb03942.x; Prescott L F, 2000, Am J Ther, V7, P99, DOI 10.1097/00045391-200007020-00007; PRICE LM, 1991, J FORENSIC SCI, V36, P930; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RAWLINS MD, 1977, EUR J CLIN PHARMACOL, V11, P283, DOI 10.1007/BF00607678; Reder RF, 1996, CLIN THER, V18, P95, DOI 10.1016/S0149-2918(96)80182-2; Reid CM, 2006, ARCH INTERN MED, V166, P837, DOI 10.1001/archinte.166.8.837; Robertson SA, 2005, J VET PHARMACOL THER, V28, P87, DOI 10.1111/j.1365-2885.2004.00628.x; Shinoda S, 2007, BIOL PHARM BULL, V30, P157, DOI 10.1248/bpb.30.157; Shionogi & Co.  Ltd., 2001, OXYCONTIN TABL PROD; SJOGREN P, 1993, ACTA ANAESTH SCAND, V37, P780, DOI 10.1111/j.1399-6576.1993.tb03809.x; SMITH MT, 1991, THER DRUG MONIT, V13, P126, DOI 10.1097/00007691-199103000-00007; Stjernsward J, 1996, J PAIN SYMPTOM MANAG, V12, P65, DOI 10.1016/0885-3924(96)00109-1; Sunshine A, 1996, J CLIN PHARMACOL, V36, P595, DOI 10.1002/j.1552-4604.1996.tb04223.x; Suzuki T., 2006, J PAIN CLIN MED, V6, P136; Tallgren M, 1997, CLIN PHARMACOL THER, V61, P655, DOI 10.1016/S0009-9236(97)90100-4; Tsuneto S., 1996, JAPANESE J HOSPICE P, V6, P482; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; Uetsuka K., 1947, NIPPON YAKURIGAKU ZA, V42, P137; van der Marel CD, 2001, CLIN PHARMACOL THER, V70, P82, DOI 10.1067/mcp.2001.116794; WALTERSACK I, 1989, ARZNEIMITTEL-FORSCH, V39-1, P719; WEINSTEIN SH, 1979, J PHARM SCI, V68, P527, DOI 10.1002/jps.2600680441; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904; YAMAOKA K, 1983, J PHARMACOBIO-DYNAM, V6, P595; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; Yomiya Kinomi, 2007, Nihon Rinsho, V65, P49	86	0	0	0	5	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	JAN	2011	131	1					113	127		10.1248/yakushi.131.113			15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	699XY	WOS:000285697400016	21212621	Bronze			2020-06-30	J	Yildiz, A; Gokmen, N; Kucukguclu, S; Yurt, A; Olson, D; Rouse, ED; Moore, C; Dicle, O; Renshaw, PF				Yildiz, Aysegul; Gokmen, Necati; Kucukguclu, Semih; Yurt, Aysegul; Olson, David; Rouse, Elizabeth D.; Moore, Constance; Dicle, Oguz; Renshaw, Perry F.			In vivo proton magnetic resonance spectroscopic examination of benzodiazepine action in humans	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Benzodiazepine; Midazolam; H-1 MRS; Healthy volunteers; Human brain	CINGULATE CORTEX; BRAIN; SEDATION	In an examination of the effect of benzodiazepines on brain chemistry, 44 healthy controls underwent a short echo-time proton magnetic resonance spectroscopy (H-1 MRS) session after induced sedation with intravenous midazolam (0.03 mg/kg) plus fentanyl (2 mu g/kg). The regions of interest were the anterior cingulate cortex, right basal ganglia, right frontal lobe, and right hippocampus. Twenty-five of these subjects underwent the second H-1 MRS session while awake. The measured H-1 MRS metabolites included N-acetylaspartate, creatine-containing compounds (PCr+Cr), choline-containing compounds, myo-inositol, and glutamate plus glutamine, which were quantified both as absolute values and metabolite/PCr+Cr ratios. The results were analyzed using independent group t tests and repeated measures analysis of variance (ANOVA, with alpha values set at 0.025 to minimize the risk of false-positive findings arising from multiple comparisons. No significant difference between subjects under midazolam plus fentanyl induced sedation and awake could be detected with unpaired analyses. Paired comparisons by ANOVA with repeated measures found that neither drug (midazolam plus fentanyl) nor the drug by time (interval between two scan times) interaction had a significant effect on the quantified metabolites. These findings encourage utilization of benzodiazepine-induced brief sedation during in vivo H-1 MRS experiments of the brain, and may help with elucidation of state-dependent neurochemical alterations during the course of bipolar and schizoaffective disorders. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Yildiz, Aysegul] Dokuz Eylul Univ, Dept Psychiat, Izmir, Turkey; [Gokmen, Necati; Kucukguclu, Semih] Dokuz Eylul Univ, Dept Anesthesiol, Izmir, Turkey; [Yurt, Aysegul; Dicle, Oguz] Dokuz Eylul Univ, Dept Radiol, Izmir, Turkey; [Olson, David; Rouse, Elizabeth D.; Moore, Constance] Harvard Univ, McLean Hosp, Sch Med, Brain Imaging Ctr, Belmont, MA 02178 USA; [Renshaw, Perry F.] Univ Utah, Inst Brain, Salt Lake City, UT USA; [Renshaw, Perry F.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Yildiz, A (reprint author), Dokuz Eylul Univ, Dept Psychiat, Mithatpasa Cad 479, Izmir, Turkey.	agul_yildiz@hotmail.com	Gokmen, Necati/J-9761-2019; Gokmen, Necati/B-1775-2008; Yurt, Aysegul/S-1509-2016	Gokmen, Necati/0000-0002-3225-7666; Gokmen, Necati/0000-0002-3225-7666; Yurt, Aysegul/0000-0001-6512-4950; Gokmen, Necati/0000-0003-1835-4133	American Psychiatric Association/Astra Zeneca Young Minds in Psychiatry Award; Harvard Medical School; Bipolar Research Center; Stanley Foundation, Belmont, MA; International Sleep Research Foundation, Houston, TX;  [MH 58681]	Funding source: This study was supported in part by the American Psychiatric Association/Astra Zeneca Young Minds in Psychiatry Award to A. Yildiz, and research grants from Harvard Medical School, the Bipolar Research Center, Stanley Foundation, Belmont, MA (A. Yildiz), the International Sleep Research Foundation, Houston, TX (A. Yildiz), and MH 58681 (P.F. Renshaw).	Auer DP, 2000, BIOL PSYCHIAT, V47, P305, DOI 10.1016/S0006-3223(99)00159-6; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; BLANSHARD HJ, 1999, POSTANESTHESIA CARE, P110; Brambilla P, 2002, NEUROPSYCHOPHARMACOL, V26, P546, DOI 10.1016/S0893-133X(01)00388-8; BUNIATIAN HC, 1965, J NEUROCHEM, V12, P695, DOI 10.1111/j.1471-4159.1965.tb06783.x; BURAU T, 1997, ANN M INT SOC MAGN R; DEICKEN RF, 1992, BIOL PSYCHIAT, V32, P628, DOI 10.1016/0006-3223(92)90077-D; Fountoulakis KN, 2008, BRAIN RES REV, V59, P9, DOI 10.1016/j.brainresrev.2008.04.005; Glitz Debra A, 2002, Semin Clin Neuropsychiatry, V7, P269, DOI 10.1053/scnp.2002.35226; Goddard AW, 2004, AM J PSYCHIAT, V161, P2186, DOI 10.1176/appi.ajp.161.12.2186; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Heinke W, 2002, BRIT J ANAESTH, V89, P112, DOI 10.1093/bja/aef155; Kato T, 1998, J NEUROPSYCH CLIN N, V10, P133, DOI 10.1176/jnp.10.2.133; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Moore Gregory J, 2002, Psychopharmacol Bull, V36, P5; Nutt DJ, 2001, BRIT J PSYCHIAT, V179, P390, DOI 10.1192/bjp.179.5.390; Ongur D, 2008, BIOL PSYCHIAT, V64, P718, DOI 10.1016/j.biopsych.2008.05.014; PROMMER EE, 2008, J PAIN SYMPTOM MANAG, V36, P5; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Schaffer CB, 2007, J NEUROPSYCH CLIN N, V19, P449, DOI 10.1176/appi.neuropsych.19.4.449; Scherk H, 2009, WORLD J BIOL PSYCHIA, V10, P285, DOI 10.3109/15622970701472086; Soares JC, 1997, J PSYCHIATR RES, V31, P393, DOI 10.1016/S0022-3956(97)00016-2; Stanley JA, 2000, BIOL PSYCHIAT, V48, P357, DOI 10.1016/S0006-3223(00)00949-5; STANLEY JA, 1995, MAGNET RESON MED, V34, P17, DOI 10.1002/mrm.1910340105; STRAKOWSKI SM, 1994, INT J PSYCHIAT MED, V24, P305, DOI 10.2190/CM8E-46R5-9AJL-03FN; Yildiz-Yesiloglu A, 2006, PROG NEURO-PSYCHOPH, V30, P969, DOI 10.1016/j.pnpbp.2006.03.012	28	6	6	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	DEC 30	2010	184	3					162	170		10.1016/j.pscychresns.2010.07.004			9	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	694UO	WOS:000285324700005	21036017				2020-06-30	J	Mercadante, S; Porzio, G; Ferrera, P; Aielli, F; Adile, C; Ficorella, C				Mercadante, Sebastiano; Porzio, Gianpiero; Ferrera, Patrizia; Aielli, Federica; Adile, Claudio; Ficorella, Corrado			Low doses of transdermal fentanyl in opioid-naive patients with cancer pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Cancer pain; Opioids; Trandermal fentanyl	RELEASE ORAL MORPHINE; EFFICACY CLINICAL-TRIAL; ANALGESIC LADDER; TTS-FENTANYL; MANAGEMENT; TOLERABILITY; TITRATION; QUALITY; CODEINE; SAFETY	Objective: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain. Methods: This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 mu g/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. Results: Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a mean of 1.7 days after the start of TS fentanyl therapy. Significant differences in TD fentanyl doses were observed during the study period (P = 0.03). Mean doses were doubled 4 weeks after starting the treatment. The level of adverse effects was acceptable in most patients and only a minority of patients discontinued the treatment (13.8%). Conclusion: Low doses of TD fentanyl were well tolerated and effective. Observations from this study suggest that randomized, controlled, double-blind studies of TD fentanyl 12 mu g/h in opioid-naive patients with cancer pain may be warranted.	[Mercadante, Sebastiano; Ferrera, Patrizia; Adile, Claudio] La Maddalena Canc Ctr, Anaesthesia & Intens Care Unit, I-90146 Palermo, Italy; [Mercadante, Sebastiano; Ferrera, Patrizia; Adile, Claudio] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Mercadante, Sebastiano] Univ Palermo, Palermo, Italy; [Porzio, Gianpiero; Aielli, Federica] Aquila Vita Home Care Serv, Laquila, Italy; [Ficorella, Corrado] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anaesthesia & Intens Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	03sebelle@gmail.com		Porzio, Giampiero/0000-0002-9875-9220; Adile, Claudio/0000-0002-0664-3520; AIELLI, Federica/0000-0003-2785-0702	PfizerPfizer; Sanofi-AventisSanofi-Aventis; JanssenJohnson & Johnson USAJanssen Biotech Inc; Grunenthal; Mundipharma; Cephalon; Qx Pharma; GwPharma; Prostrakan; Nycomed; Dompe	Prof. Mercadante received fees for advisory boards or lectures from the following companies: Pfizer, Sanofi-Aventis, Janssen, Grunenthal, Mundipharma, Cephalon, Qx Pharma, GwPharma, Prostrakan, Nycomed and Dompe.	ADDINGTONHALL JM, 1990, BRIT J CANCER, V62, P695, DOI 10.1038/bjc.1990.360; De Conno F, 2008, PALLIATIVE MED, V22, P214, DOI 10.1177/0269216308088692; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; JANSSEN LP, IMPORTANT DRUG WARNI; Koizumi W, 2004, JPN J CLIN ONCOL, V34, P608, DOI 10.1093/jjco/hyh104; Maltoni M, 2005, SUPPORT CARE CANCER, V13, P888, DOI 10.1007/s00520-005-0807-6; Marinangeli F, 2004, J PAIN SYMPTOM MANAG, V27, P409, DOI 10.1016/j.jpainsymman.2003.10.006; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V31, P242, DOI 10.1016/j.jpainsymman.2006.01.001; Mercadante S, 2009, CLIN THER, V25, P1517; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2007, EUR J PAIN, V11, P823, DOI 10.1016/j.ejpain.2007.01.003; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; Otis J, 2006, CURR MED RES OPIN, V22, P1493, DOI 10.1185/030079906X115540; TAWKFIK MO, 2004, CURR MED RES OPIN, V20, P259; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; World Health Organization, 1990, CANC PAIN REL PALL C	20	10	12	2	4	LIBRAPHARM/INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	DEC	2010	26	12					2765	2768		10.1185/03007995.2010.532545			4	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	680GI	WOS:000284220000007	21034376				2020-06-30	J	Hostynek, JJ; Maibach, HI				Hostynek, Jurij J.; Maibach, Howard I.			Fentanyl transdermal patches: overview of cutaneous adverse effects in humans	CUTANEOUS AND OCULAR TOXICOLOGY			English	Article							FATAL ANAPHYLACTIC REACTION; EPIDURAL FENTANYL; POSTOPERATIVE ANALGESIA; CANCER PAIN; PROPOFOL; PLACEBO; MODEL	Using Medline, Embase, and the Science Citation Index, we summarize the cutaneous adverse effects of transdermal and parenteral fentanyl. The fentanyl transdermal therapeutic system (TTS; patch) provides continuous systemic delivery of fentanyl (N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl) propanamide), a potent opioid analgesic, for 72 hours. Clinical studies of fentanyl TTSs demonstrated varying rates of irritation at the application site, ranging from none to 42%, with a median of 25%. Most descriptions of skin reactions included erythema at the application site, indicating irritant dermatitis. Skin testing in 2 subjects receiving parenteral doses concluded that although immunoglobulin E (IgE) antibodies to fentanyl exist, few cases of immediate-type allergic reactions to fentanyl have been substantiated. Comparing the reactions to anesthetic agents during allergenic testing demonstrated positive "wheal and flare" to fentanyl in only 1 of 50 patients (2%). Pruritus has been frequently reported during administration of epidural fentanyl, but allergenicity has not been shown. The few case reports of possible anaphylactic reactions to fentanyl have not clearly demonstrated fentanyl as the causal agent. In addition, transdermal and intravenous/epidural routes of administration may not be comparable because of large differences in plasma concentrations: When these results are taken together, fentanyl (TTS) has shown limited skin intolerance.</.	[Hostynek, Jurij J.; Maibach, Howard I.] Univ Calif San Francisco, UCSF Sch Med, Dept Dermatol, San Francisco, CA 94143 USA	Hostynek, JJ (reprint author), Univ Calif San Francisco, UCSF Sch Med, Dept Dermatol, 90 Med Ctr Way,Surge Bldg, San Francisco, CA 94143 USA.	jurij.hostynek65@gmail.com					BENEZRA C, 1985, J INVEST DERMATOL, V85, P351, DOI 10.1111/1523-1747.ep12276961; BENNETT MJ, 1986, CAN J ANAESTH, V33, P75, DOI 10.1007/BF03010913; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P635, DOI 10.1016/S0196-0644(89)80517-7; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Girgis Y, 2001, ANAESTHESIA, V56, P1016, DOI 10.1046/j.1365-2044.2001.02279-25.x; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; HAYDEN JJR, 1974, Anesth Prog, V21, P3; Hostynek JJ, 1999, IN VITRO MOL TOXICOL, V12, P203; Konarzewski W, 2001, ANAESTHESIA, V56, P497, DOI 10.1046/j.1365-2044.2001.02047-22.x; LEVIN CY, 2007, MARZULLI MAIBACHS DE, P101; LEVY JH, 1989, ANESTHESIOLOGY, V70, P756, DOI 10.1097/00000542-198905000-00008; LEYNADIER F, 1987, BRIT J ANAESTH, V59, P683, DOI 10.1093/bja/59.6.683; LYTLE SA, 1991, J AM OSTEOPATH ASSOC, V91, P547; MAGEE PS, 1994, QUANT STRUCT-ACT REL, V13, P22, DOI 10.1002/qsar.19940130106; Mancuso G, 2001, J EUR ACAD DERMATOL, V15, P70, DOI 10.1046/j.1468-3083.2001.00203.x; Mertes PM, 2002, ANAESTHESIA, V57, P821; PEVNY Y, 1981, ANAESTHESIST, V30, P400; SHIPTON EA, 1984, S AFR MED J, V66, P61; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; STOUKIDES CA, 1992, CLIN PHARMACY, V11, P222; VALLEY MA, 1992, ANESTHESIOLOGY, V76, P1056, DOI 10.1097/00000542-199206000-00029; ZUCKERPINCHOFF B, 1993, ANESTHESIOLOGY, V79, P1152	23	3	3	1	5	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1556-9527			CUTAN OCUL TOXICOL	Cutan. Ocul. Toxicol.	DEC	2010	29	4					241	246		10.3109/15569527.2010.492487			6	Ophthalmology; Toxicology	Ophthalmology; Toxicology	673UH	WOS:000283688500003	20550459				2020-06-30	J	Ali, AR; El Ghoneimy, MN				Ali, Ashgan Raouf; El Ghoneimy, Mohamed N.			Dexmedetomidine versus fentanyl as adjuvant to propofol: comparative study in children undergoing extracorporeal shock wave lithotripsy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						dexmedetomidine; intravenous anaesthetic; paediatric extracorporeal shock wave lithotripsy; propofol	INTRAVENOUS DEXMEDETOMIDINE; BISPECTRAL INDEX; PROCEDURAL SEDATION; ANESTHESIA; EXPERIENCE; INFUSION; RECOVERY; HUMANS	Background The present study was designed to compare the efficacy, tolerability and safety of dexmedetomidine and fentanyl when combined with propofol during extracorporeal shock wave lithotripsy in children. Methods Fifty children aged 3-8 years, the American Society of Anesthesiologists status I and II, scheduled for elective extracorporeal shock wave lithotripsy were randomly allocated to receive a loading dose 0.7 mu gkg(-1) over 10 min followed by maintenance infusion 0.3 mu gkg(-1)h(-1) of either dexmedetomidine in propofol/dexmedetomidine group or fentanyl in propofol/fentanyl group (n=25 each). The target drug infusion rates were adjusted to keep the haemodynamics within +/- 20% from the baseline values. All patients received propofol infusion to maintain bispectral index values (40-60) throughout the procedure. Induction and maintenance doses of propofol were recorded. Total doses of both studied drugs were calculated. Perioperative haemodynamics, incidence of intraprocedural and postprocedural complications and time to first analgesic requirement were recorded. Results The propofol requirement was significantly lower in the propofol/dexmedetomidine group than that in propofol/fentanyl group during induction and maintenance of anaesthesia (P<0.0001). Total doses of fentanyl and dexmedetomidine were 0.961 (0.1) mu gkg(-1) and 0.925 (0.07) mu gkg(-1), respectively. Mean arterial pressure and heart rate were significantly decreased compared to the baseline throughout the procedure in both groups and increased significantly relative to both baseline and the other group at 30 min in the propofol/fentanyl group and 60 min in the propofol/dexmedetomidine group in the recovery area (P<0.05). In propofol/dexmedetomidine group, the incidence of intraprocedural hypoventilation was significantly lower (P=0.016) and time to first analgesic requirement was significantly longer (P<0.0001) than that in propofol/fentanyl group. Conclusion Both propofol/fentanyl and propofol/dexmedetomidine combinations at mentioned dose regimen were effective and well tolerated for children undergoing extracorporeal shock wave lithotripsy. However, propofol/dexmedetomidine combination was accompanied with less propofol consumption, prolonged analgesia and lower incidence of intraprocedural and postprocedural complications. Eur J Anaesthesiol 2010;27:1058-1064	[Ali, Ashgan Raouf] Cairo Univ, Dept Anaesthesiol, Fac Med, Cairo, Egypt; [El Ghoneimy, Mohamed N.] Cairo Univ, Dept Urol, Fac Med, Cairo, Egypt	Ali, AR (reprint author), Cairo Univ, Dept Anaesthesiol, Fac Med, Cairo, Egypt.	ashganraouf@yahoo.com			Department of Anaesthesiology, Kasr El-Aini Hospital, Cairo, Egypt	This work was supported by the Department of Anaesthesiology, Kasr El-Aini Hospital, Cairo, Egypt.	AHO MS, 1991, ANESTH ANALG, V73, P112; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Aldridge RD, 2006, PEDIATR ANESTH, V16, P236, DOI 10.1111/j.1460-9592.2005.01839.x; Ard J, 2003, J NEUROSURG ANESTH, V15, P263, DOI 10.1097/00008506-200307000-00015; Bannister CF, 2001, ANESTH ANALG, V92, P877; Basar H, 2003, J ENDOUROL, V17, P3, DOI 10.1089/089277903321196706; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Brinkmann OA, 2001, EUR UROL, V39, P591, DOI 10.1159/000052509; BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; Dutta S, 2001, J PHARM SCI-US, V90, P172, DOI 10.1002/1520-6017(200102)90:2<172::AID-JPS8>3.0.CO;2-J; Erden IA, 2007, SAUDI MED J, V28, P364; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; Ganesh Arjunan, 2004, Curr Opin Anaesthesiol, V17, P229, DOI 10.1097/00001503-200406000-00006; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; Kaygusuz K, 2008, ANESTH ANALG, V106, P114, DOI 10.1213/01.ane.0000296453.75494.64; Koroglu A, 2006, ANESTH ANALG, V103, P63, DOI 10.1213/01.ane.0000219592.82598.AA; Kundra P, 1998, ANESTH ANALG, V87, P52, DOI 10.1097/00000539-199807000-00012; Landau EH, 2001, J UROLOGY, V165, P2316, DOI 10.1016/S0022-5347(05)66193-9; Mason KP, 2006, ANESTH ANALG, V103, P57, DOI 10.1213/01.ane.0000216293.16613.15; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; NEWMAN DM, 1986, J UROLOGY, V136, P238, DOI 10.1016/S0022-5347(17)44826-9; Peden CJ, 2001, ANAESTHESIA, V56, P408, DOI 10.1046/j.1365-2044.2001.01553.x; Powers KS, 2005, PEDIATRICS, V115, P1666, DOI 10.1542/peds.2004-1979; Talke P, 2000, ANESTH ANALG, V90, P834, DOI 10.1213/00000539-200004000-00011; Tobias JD, 2002, PAEDIATR ANAESTH, V12, P171, DOI 10.1046/j.1460-9592.2002.00805.x; Turgut N, 2008, MINERVA ANESTESIOL, V74, P469; Ugur G, 2003, PAEDIATR ANAESTH, V13, P85, DOI 10.1046/j.1460-9592.2003.09672.x; Unsal A, 2001, SCAND J UROL NEPHROL, V35, P502; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Weber A, 1998, EUR UROL, V34, P85, DOI 10.1159/000019690; Whyte SD, 2004, ANESTH ANALG, V98, P1644; Yang Chih-Ping, 2002, Acta Anaesthesiol Sin, V40, P9	40	13	16	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	DEC	2010	27	12					1058	1064		10.1097/EJA.0b013e32833e6e2d			7	Anesthesiology	Anesthesiology	678TT	WOS:000284104500007	20805754				2020-06-30	J	Apan, A; Aykac, E; Kazkayasi, M; Doganci, N; Tahran, FD				Apan, Alparslan; Aykac, Esra; Kazkayasi, Mustafa; Doganci, Nur; Tahran, Filiz Datli			Magnesium sulphate infusion is not effective on discomfort or emergence phenomenon in paediatric adenoidectomy/tonsillectomy	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Sevoflurane; Emergence; Agitation; Magnesium sulphate; Infusion	SEVOFLURANE ANESTHESIA; AGITATION; CHILDREN; RECOVERY; PROPOFOL; FENTANYL; INDUCTION; CLONIDINE	Objective: This study was performed to evaluate the possible influence of magnesium sulphate which has sedative and analgesic properties on sevoflurane-induced emergence agitation in paediatric patients undergoing adenoidectomy with or without tonsillectomy. Methods: One hundred and ten paediatric patients aged between 3 and 16 years were randomly allocated to the study. Propofol 2-2.5 mg kg(-1), vecuronium 0.1 mg kg(-1) and fentanyl 1 mu g kg(-1) were used for induction of anesthesia and sevoflurane at 1 MAC with nitrous oxide in oxygen (35%) mixture was administered as maintenance. Magnesium sulfate 30 mg kg(-1) in saline (20 mL) in the Group M, or equal volume of saline for controls (Group C) was started 10 min before and infused until the end of the operation. Recovery characteristics included time to extubation, eyes open, emergence and interaction. Patients were evaluated using Modified Aldrete Score (MAS), Pain/Discomfort Scale and Agitation Score. Side effects were determined during emergence and in the recovery. Results: Time to open eyes was significantly higher in the magnesium treatment group (Group C: 7.7 +/- 3.5, Group M: 12.7 +/- 17.5 min, p = 0.001). Agitation score was significantly lower in Group M at the 60th min (Group C: 1.3 +/- 0.7, Group M: 1.0 +/- 0.3, p = 0.005). Agitation or pain/discomfort scores in the resting observation periods were the same. The initial MAS value was lower in Group M (Group C: 5.0 +/- 1.9, Group M: 4.0 +/- 1.7, p = 0.003). There was no significant difference between groups regarding side effects. Conclusion: Magnesium sulphate infusion has no influence on sevoflurane-induced discomfort or emergence agitation. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Apan, Alparslan; Aykac, Esra] Kirikkale Univ, Fac Med, Dept Anaesthesiol, Kirikkale, Turkey; [Kazkayasi, Mustafa; Tahran, Filiz Datli] Kirikkale Univ, Fac Med, Dept Ear Nose & Throat Surg, Kirikkale, Turkey	Apan, A (reprint author), Urankent THK Bloklari E-2 Blok,15 Yenimahalle, Ankara, Turkey.	alpaslanapan@gmail.com					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Altan A, 2005, BRIT J ANAESTH, V94, P438, DOI 10.1093/bja/aei070; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Arai YCP, 2005, ACTA ANAESTH SCAND, V49, P698, DOI 10.1111/j.1399-6576.2005.00700.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; FERRARI LR, 2006, CLIN ANESTH, P998; Galinkin JL, 2000, ANESTHESIOLOGY, V93, pU227; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Lankinen U, 2006, ANESTH ANALG, V102, P1383, DOI 10.1213/01.ane.0000205745.84044.31; Oh AY, 2005, ACTA ANAESTH SCAND, V49, P297, DOI 10.1111/j.1399-6576.2005.00687.x; Picard V, 2000, ACTA ANAESTH SCAND, V44, P307, DOI 10.1034/j.1399-6576.2000.440315.x; RYU RJ, 2008, BRIT J ANAESTH, V100, P398; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; Viitanen H, 1999, CAN J ANAESTH, V46, P21, DOI 10.1007/BF03012509; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	19	13	13	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	DEC	2010	74	12					1367	1371		10.1016/j.ijporl.2010.09.004			5	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	692TA	WOS:000285176800005	20880596				2020-06-30	J	Li, SQ; Liu, YQ; Tan, F; Chen, JL; Chen, LH				Li Shaoqing; Liu Yuqi; Tan Fang; Chen Junliang; Chen Lianhua			Efficacy of manual jet ventilation using Manujet III for bronchoscopic airway foreign body removal in children	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Airway foreign body; Manual jet ventilation; Rigid bronchoscopy	SURGERY; BODIES	Objectives: To evaluate the efficacy of a manual jet ventilation device for bronchoscopic removal of foreign bodies in children. Methods: 360 children aged from 10 months to 12 years old undergoing rigid bronchoscopy for airway foreign body (FB) removal from February 2005 to June 2009 were included in the study. Patients were randomly divided into three groups of 120 patients per group (S, P and J). In group S. anesthesia was induced with propofol and gamma-hydroxybutyrate sodium and maintained by intermittent bolus administration of propofol; the patients were breathing spontaneously throughout the procedure. In group P. anesthesia was induced with propofol (4-5 mg/kg), fentanyl (1-2 mu g/kg) and succinylcholine (2 mg/kg). Mechanical ventilation was performed through the side arm of the rigid bronchoscope. In group J, the patient received propofol, fentanyl and succinylcholine as the same doses administered in group P. and manual jet ventilation was performed by using the Manujet III device. Condition for insertion of bronchoscope, occurrence of hypoxemia, successful rate of FB removal, the duration of the operation, the time of emergence and recovery from anesthesia, and perioperative complications (adverse events) were recorded. Results: Groups P and J had significantly higher rates of successful bronchoscope insertion (P < 0.05), significantly higher success rates for FB removal (P < 0.05), and lower incidences of hypoxemia during intra- and post-operative periods when compared with groups. Perioperative complications were lower (P < 0.05), duration of operation was shorter, and emergence from anesthesia was faster (P < 0.05) in groups P and J when compared with group S. Incidences of hypoxemia were lower in Group J when compared with Group P (P < 0.05). Conclusion: This study confirmed the safety and efficacy of performing manual jet ventilation with Manujet III in foreign body removal by rigid bronchoscopy in children. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Li Shaoqing; Liu Yuqi; Tan Fang; Chen Junliang; Chen Lianhua] Fudan Univ, Dept Anesthesiol, Eye Ear Nose & Throat Hosp, Shanghai 200031, Peoples R China	Chen, LH (reprint author), Fudan Univ, Dept Anesthesiol, Eye Ear Nose & Throat Hosp, Shanghai 200031, Peoples R China.	chenlianhua@citiz.net					BARR NL, 1971, ARCHIV OTOLARYNGOL, V93, P606; Bourgain JL, 2001, BRIT J ANAESTH, V87, P870, DOI 10.1093/bja/87.6.870; Divisi D, 2007, THORAC CARDIOV SURG, V55, P249, DOI 10.1055/s-2006-924714; James E, 2006, CONTIN ED ANAESTH CR, V6, P111; OULTON JL, 1971, ANESTHESIOLOGY, V35, P540, DOI 10.1097/00000542-197111000-00017; Rezaie-Majd A, 2006, BRIT J ANAESTH, V96, P650, DOI 10.1093/bja/ael074; SANDERS RD, 1967, DEL MED J, V39, P170; SPOEREL WE, 1971, BRIT J ANAESTH, V43, P932, DOI 10.1093/bja/43.10.932; TAN F, LARYNGOSCOP IN PRESS; The Difficult Airway Society, FAIL VENT GUID; Tomaske M, 2006, PEDIATR ANESTH, V16, P123, DOI 10.1111/j.1460-9592.2005.01714.x; Yadav S. P. S., 2007, SMJ Singapore Medical Journal, V48, P850	12	10	12	1	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	DEC	2010	74	12					1401	1404		10.1016/j.ijporl.2010.09.018			4	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	692TA	WOS:000285176800012	20951443				2020-06-30	J	Nakada, T; Ikeda, D; Yokota, M; Kawahara, K				Nakada, Takeo; Ikeda, Daisuke; Yokota, Miyuki; Kawahara, Kazuo			Analysis of the cost-effectiveness of remifentanil-based general anesthesia: a survey of clinical economics under the Japanese health care system	JOURNAL OF ANESTHESIA			English	Article						Remifentanil; Cost-effectiveness; Clinical economics; Fentanyl	POSTOPERATIVE NAUSEA; SEVOFLURANE; PROPOFOL; SURGERY; DESFLURANE	Remifentanil has been available in Japan for 3 years. The use of this new opioid is considered a useful adjuvant to general anesthesia. Knowing the exact cost-effectiveness of remifentanil should lead to improved anesthetic outcomes with a reasonable cost. This single-blinded, prospective, randomized study compared the cost of remifentanil-based general anesthesia combined with isoflurane, sevoflurane, or propofol with fentanyl-based conventional techniques in 210 women who underwent breast surgeries. Remifentanil-based general anesthesia was no more expensive than fentanyl-based conventional anesthesia. Postoperative nausea and vomiting was significantly less frequent after remifentanil-based than fentanyl-based anesthesia. This study shows that remifentanil-based general anesthesia is no more expensive than conventional fentanyl-based anesthesia under the Japanese health care system because of the small difference in price between remifentanil and fentanyl.	[Nakada, Takeo; Ikeda, Daisuke; Kawahara, Kazuo] Tokyo Med & Dent Univ, Dept Hlth Policy Sci, Grad Sch, Bunkyo Ku, Tokyo 1138519, Japan; [Yokota, Miyuki] Canc Inst Hosp, Div Anesthesia & Pain Med, Tokyo, Japan; [Nakada, Takeo] Tohjun Hosp, Div Anesthesia, Tokyo, Japan	Nakada, T (reprint author), Tokyo Med & Dent Univ, Dept Hlth Policy Sci, Grad Sch, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	tmnakada@yahoo.com.sg					Abenstein JP, 2004, ANESTH ANALG, V98, P750, DOI 10.1213/01.ANE.0000100945.56081.AC; Beers RA, 2000, ANESTH ANALG, V91, P1420, DOI 10.1097/00000539-200012000-00022; Boldt J, 1998, ANESTH ANALG, V86, P504, DOI 10.1097/00000539-199803000-00010; Croinin Donall F, 2002, Curr Opin Anaesthesiol, V15, P359, DOI 10.1097/00001503-200206000-00014; Fernandez-Guisasola J, 2010, ANAESTHESIA, V65, P379, DOI 10.1111/j.1365-2044.2010.06249.x; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; Kharasch ED, 2006, TOXICOL SCI, V90, P419, DOI 10.1093/toxsci/kfj088; Lockwood GG, 2001, BRIT J ANAESTH, V87, P559, DOI 10.1093/bja/87.4.559; Loop T, 2002, ACTA ANAESTH SCAND, V46, P1251, DOI 10.1034/j.1399-6576.2002.461013.x; *ORG EC COOP DEV, OECD HLTH DAT 2009 H; Ravishankara AR, 2009, SCIENCE, V326, P123, DOI 10.1126/science.1176985; Servin F. S., 2008, V182, P283, DOI 10.1007/978-3-540-74806-9_14; Unal Y, 2009, SAUDI MED J, V30, P778; *US FDA, 20478S006 NDA US FOO	14	6	7	0	2	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	DEC	2010	24	6					832	837		10.1007/s00540-010-1006-2			6	Anesthesiology	Anesthesiology	692LD	WOS:000285153400002	20827560				2020-06-30	J	Yano, T; Okubo, S; Naruo, H; Iwasaki, T; Tsuneyoshi, I				Yano, Takeshi; Okubo, Shigeaki; Naruo, Hiroaki; Iwasaki, Tatsuma; Tsuneyoshi, Isao			Comparisons of two different doses of fentanyl for procedural analgesia during epidural catheter placement: a double-blind prospective, randomized, placebo-controlled study	JOURNAL OF ANESTHESIA			English	Article						Procedural pain; Epidural anesthesia; Fentanyl; Procedural analgesia	ANESTHESIA; INFUSION	The purpose of this study was to investigate the effect of fentanyl on analgesic properties and respiratory responses during an epidural procedure. Sixty patients premedicated with oral brotizolam 0.25 mg were allocated to receive procedural analgesia with saline or 25 or 50 mu g of fentanyl. Five minutes after administration, an epidural procedure was started. Pain assessments were made immediately after the epidural catheter placement using a visual analog scale. The lowest SpO(2) levels during the procedure were recorded to evaluate respiratory depression, and cardiovascular complications were also recorded. The pain scores were significantly lower in the 25 and 50 mu g fentanyl groups than in the placebo group (P < 0.01). There was no difference in pain assessment between the 25 and 50 mu g fentanyl groups. The lowest SpO(2) value of the 50 mu g fentanyl group was significantly lower than those of the other groups (P < 0.001). Seven of 20 cases in the 50 mu g fentanyl group needed oxygen administration because of a decreased SpO(2) value (< 94%). No cardiovascular complications were observed in any group during the entire study period. Thus, intravenous fentanyl at a dose of 25 mu g provides effective procedural analgesia without the risk of hypoxemia during an epidural procedure in a patient with preanesthetic medication.	[Yano, Takeshi; Tsuneyoshi, Isao] Miyazaki Univ, Dept Anesthesiol, Sch Med, Miyazaki 8891692, Japan; [Okubo, Shigeaki] Miyazaki Med Assoc Hosp, Dept Anesthesiol, Miyazaki, Japan; [Naruo, Hiroaki] Miyazaki Prefectural Nichinan Hosp, Dept Anesthesiol, Miyazaki, Japan; [Iwasaki, Tatsuma] Miyakonojo Hosp, Dept Anesthesiol, Natl Hosp Org, Miyazaki, Japan	Yano, T (reprint author), Miyazaki Univ, Dept Anesthesiol, Sch Med, 5200 Kihara, Miyazaki 8891692, Japan.	plant9458@yahoo.co.jp					Bahn EL, 2005, EMERG MED CLIN N AM, V23, P503, DOI 10.1016/j.emc.2004.12.013; Bromage PR, 1998, REGION ANESTH PAIN M, V23, P104, DOI 10.1016/S1098-7339(98)90120-1; Drasner K, 2004, ANESTH ANALG, V99, P578, DOI 10.1213/01.ANE.0000130390.54989.86; GAJRAJ NM, 1995, ANAESTHESIA, V50, P740, DOI 10.1111/j.1365-2044.1995.tb06110.x; Hernandez-Gancedo Carmen, 2007, J Clin Monit Comput, V21, P295, DOI 10.1007/s10877-007-9087-7; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; Horlocker TT, 2003, ANESTH ANALG, V96, P1547, DOI 10.1213/01.ANE.0000057600.31380.75; Kudo Masaru, 2005, Anesth Prog, V52, P95, DOI 10.2344/0003-3006(2005)52[95:IIPFDL]2.0.CO;2; NIMMO WS, 1985, BRIT J ANAESTH, V57, P250, DOI 10.1093/bja/57.3.250; Oda A, 2000, CAN J ANAESTH, V47, P910, DOI 10.1007/BF03019675; ORSER B, 1988, CAN J ANAESTH, V35, P503, DOI 10.1007/BF03026900; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Ueta K, 2003, ANESTH ANALG, V96, P1079, DOI 10.1213/01.ANE.0000055364.39576.FF; Vadalouca A, 2009, PAIN PRACT, V9, P181, DOI 10.1111/j.1533-2500.2009.00271.x; Van den Bussche E, 2007, EUR J PAIN, V11, P275, DOI 10.1016/j.ejpain.2006.03.002	15	2	2	0	1	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	DEC	2010	24	6					966	969		10.1007/s00540-010-1016-0			4	Anesthesiology	Anesthesiology	692LD	WOS:000285153400029	20811917				2020-06-30	J	Kunisawa, T; Nagashima, M; Suzuki, A; Takahata, O; Iwasaki, H				Kunisawa, Takayuki; Nagashima, Michio; Suzuki, Akihiro; Takahata, Osamu; Iwasaki, Hiroshi			Accidental injection of remifentanil can cause a much more dangerous situation than the same dose of fentanyl	JOURNAL OF ANESTHESIA			English	Letter							PHARMACOKINETICS		[Kunisawa, Takayuki; Suzuki, Akihiro; Takahata, Osamu; Iwasaki, Hiroshi] Asahikawa Med Coll, Dept Anesthesiol & Crit Care Med, Asahikawa, Hokkaido 0788510, Japan; [Kunisawa, Takayuki] Asahikawa Med Coll Hosp, Surg Operat Dept, Asahikawa, Hokkaido, Japan; [Nagashima, Michio] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; [Nagashima, Michio] Harvard Univ, Sch Med, Boston, MA USA	Kunisawa, T (reprint author), Asahikawa Med Coll, Dept Anesthesiol & Crit Care Med, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	taka.kunisawa@nifty.ne.jp					Fukuda K, 2009, MILLERS ANESTHESIA, P769; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; TERADA T, 2009, JPN J ANESTHESIOL, V58, P1512	4	2	2	0	0	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	DEC	2010	24	6					970	971		10.1007/s00540-010-1008-0			2	Anesthesiology	Anesthesiology	692LD	WOS:000285153400030	20721610				2020-06-30	J	McMeniman, TJ; McMeniman, PJ; Myers, PT; Hayes, DA; Cavdarski, A; Wong, MS; Wilson, AJ; Jones, MA; Watts, MC				McMeniman, Timothy J.; McMeniman, Peter J.; Myers, Peter T.; Hayes, David A.; Cavdarski, Alex; Wong, Man Shun; Wilson, Adrian J.; Jones, Mark A.; Watts, Mark C.		Brisbane Orthopaedic Sports Med Ct	Femoral Nerve Block vs Fascia Iliaca Block for Total Knee Arthroplasty Postoperative Pain Control A Prospective, Randomized Controlled Trial	JOURNAL OF ARTHROPLASTY			English	Article						TKA; anesthesia; fascia iliaca nerve; femoral nerve; nerve block	REGIONAL ANESTHESIA; EPIDURAL ANALGESIA; 3-IN-ONE BLOCK; REHABILITATION; COMPLICATIONS; FRACTURES; MORPHINE	Femoral nerve block (FNB) is an accepted mode of analgesia for lower limb procedures but has a documented complication rate This study compared femoral nerve and fascia iliaca regional anesthesia for total knee arthroplasty (TKA) using fentanyl consumption as the primary outcome measure Ninety-eight primary unilateral TKA patients were blinded and randomized into fascia iliaca block (FIB) (n = 51) or FNB (n = 47) groups No significant differences were found in analgesia use (fentanyl and tramadol) at 12 and 36 hours in pain nausea and range of motion between the groups There was one case of paresthesia in the femoral nerve in the FNB group Fascia iliaca block is as effective as FNB as part of a multimodal anesthetic regimen for TKA	[McMeniman, Timothy J.; McMeniman, Peter J.; Myers, Peter T.; Hayes, David A.; Wilson, Adrian J.; Watts, Mark C.] Brisbane Orthopaed & Sports Med Ctr, Brisbane, Qld, Australia; [Cavdarski, Alex] Wickham Terrace Anaesthesia, Brisbane, Qld, Australia; [Wong, Man Shun] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; [Jones, Mark A.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia; [Watts, Mark C.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia	Watts, MC (reprint author), Brisbane Private Hosp, Brisbane Orthoped & Sports Med Ctr, Specialist Ctr, Level 5,259 Wickham Tce, Brisbane, Qld 4000, Australia.		Myers, Peter T/J-4825-2017; Jones, Mark/I-2720-2016	Jones, Mark/0000-0001-6858-9710			Allen HW, 1998, ANESTH ANALG, V87, P93, DOI 10.1097/00000539-199807000-00020; Atchabahian A, 2001, ANESTHESIOLOGY, V94, P534, DOI 10.1097/00000542-200103000-00029; Auroy Y, 2002, ANESTHESIOLOGY, V97, P1274, DOI 10.1097/00000542-200211000-00034; Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Chelly JE, 2001, J ARTHROPLASTY, V16, P436, DOI 10.1054/arth.2001.23622; COUTO JJC, 2005, INJURY, V36, P505; Foss NB, 2007, ANESTHESIOLOGY, V106, P773, DOI 10.1097/01.anes.0000264764.56544.d2; Fowler SJ, 2008, BRIT J ANAESTH, V100, P154, DOI 10.1093/bja/aem373; Ganapathy S, 1999, ANESTH ANALG, V89, P1197, DOI 10.1213/00000539-199911000-00021; Grant CRK, 2008, CONTIN ED ANAESTH CR, V8, P56; Johr M, 1987, Reg Anaesth, V10, P37; Lopez S, 2003, REGION ANESTH PAIN M, V28, P203, DOI 10.1053/rapm.2003.50134; Morau D, 2003, REGION ANESTH PAIN M, V28, P309, DOI 10.1016/S1098-7339(03)00183-4; Newson R, 2004, STATA J, V4, P379, DOI 10.1177/1536867X0400400402; Ozen M, 2006, AGRI, V18, P44; Shelley BG, 2006, REGION ANESTH PAIN M, V31, P582, DOI 10.1016/j.rapm.2006.08.009; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; Stevens M, 2007, ANAESTH INTENS CARE, V35, P949, DOI 10.1177/0310057X0703500615; Szczukowski MJ, 2004, J ARTHROPLASTY, V19, P720, DOI 10.1016/j.arth.2004.02.043; Wang H, 2002, REGION ANESTH PAIN M, V27, P139, DOI 10.1053/rapm.2002.29253; Wathen JE, 2007, ANN EMERG MED, V50, P162, DOI 10.1016/j.annemergmed.2006.09.006	22	21	26	0	3	CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS	PHILADELPHIA	CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA	0883-5403	1532-8406		J ARTHROPLASTY	J. Arthroplast.	DEC	2010	25	8					1246	1249		10.1016/j.arth.2009.11.018			4	Orthopedics	Orthopedics	687BT	WOS:000284749500012	20178889				2020-06-30	J	Gunaydin, B; Tan, ED				Gunaydin, Berrin; Tan, Ece D.			Intrathecal hyperbaric or isobaric bupivacaine and ropivacaine with fentanyl for elective caesarean section	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE			English	Article						Surgery; caesarean section; anaesthetic technique; combined spinal epidural; local anaesthetics; bupivacaine; ropivacaine	SPINAL ANESTHETIC SOLUTIONS; EPIDURAL ANESTHESIA; BODY-TEMPERATURE; DELIVERY; PLAIN; LEVOBUPIVACAINE; POSITION; DENSITY	Objective. We aimed to investigate the efficacy of either plain or hyperbaric solutions of intrathecal bupivacaine and ropivacaine on maternal block characteristics, complications, side effects and neonatal parameters to find out which is superior in a single study. Methods. One hundred and three term parturients were randomly assigned to receive intrathecal 10 mg hyperbaric bupivacaine (Group Bh), 10 mg plain bupivacaine (Group Bp), 15 mg hyperbaric ropivacaine prepared with dextrose 30% (Group Rh) or 15 mg plain ropivacaine (Group Rp) coadministered with fentanyl 20 mu g. Sensory and motor block characteristics, analgesia duration, ephedrine consumption, and neonatal and maternal parameters were recorded. Results. Time to maximum cephalad spread of sensory block was longer in Group Rp than both bupivacaine groups. Time to achieve sensory block at T6 dermatome was similar between both hyperbaric groups (Group Bh:4.5 +/- 1.6, Group Rh:4.6 +/- 1.1, p > 0.05) but Group Rp needed significantly longer time (7.5 +/- 5.5 min, p = 0.003) than both hyperbaric groups. Duration of motor block was shorter in ropivacaine groups (Group Rh: 90.6 +/- 17.3, Group Rp 121.6 +/- 33.7) vs. bupivacaine groups (Group Bh: 140.2 +/- 33.3, Group Bp: 149.7 +/- 46.0); Group Rh being shorter than Group Rp (p < 0.05). Ephedrine consumption was less in Groups Rh (20.0 +/- 11.9 mg) and Rp (18.3 +/- 12.4 mg) vs. Groups Bh (30.0 +/- 14.9 mg) and Bp (27.8 +/- 15.4 mg) (p = 0.006). Conclusions. Intrathecal hyperbaric ropivacaine 15 mg with fentanyl 20 mu g for CSE is suitable since it provides early motor recovery leading to faster patient ambulation, rapid onset of sensory block with less ephedrine.	[Gunaydin, Berrin; Tan, Ece D.] Gazi Univ, Fac Med, Dept Anaesthesiol, TR-06500 Ankara, Turkey	Gunaydin, B (reprint author), Gazi Univ, Fac Med, Dept Anaesthesiol, TR-06500 Ankara, Turkey.	gunaydin@gazi.edu.tr					Chen Xin-zhong, 2006, J Zhejiang Univ Sci B, V7, P992, DOI 10.1631/jzus.2006.B0992; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Chung CJ, 2001, ANESTH ANALG, V93, P157; Coppejans HC, 2006, ANESTH ANALG, V102, P243, DOI 10.1213/01.ane.0000189049.11005.26; Danelli G, 2004, REGION ANESTH PAIN M, V29, P221, DOI 10.1016/j.rapm.2004.02.003; Dyer Robert A, 2004, Curr Opin Anaesthesiol, V17, P301, DOI 10.1097/01.aco.0000137088.29861.64; Gautier P, 2003, BRIT J ANAESTH, V91, P684, DOI 10.1093/bja/aeg251; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; HORLOCKER TT, 1993, ANESTH ANALG, V76, P1015; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Khaw KS, 2001, ANESTHESIOLOGY, V95, P1346, DOI 10.1097/00000542-200112000-00011; Lui ACP, 1998, CAN J ANAESTH, V45, P297, DOI 10.1007/BF03012018; McLeod GA, 2004, BRIT J ANAESTH, V92, P547, DOI 10.1093/bja/aeh094; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; Stienstra Rudolf, 2001, Current Topics in Medicinal Chemistry, V1, P215, DOI 10.2174/1568026013395218; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014; Wille M, 2004, Acta Anaesthesiol Belg, V55, P251; Yun EM, 1998, ANESTH ANALG, V87, P614, DOI 10.1097/00000539-199809000-00023	19	10	10	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1476-7058			J MATERN-FETAL NEO M	J. Matern.-Fetal Neonatal Med.	DEC	2010	23	12					1481	1486		10.3109/14767051003678051			6	Obstetrics & Gynecology	Obstetrics & Gynecology	678LH	WOS:000284075000021	20230319				2020-06-30	J	Ogawa, N; Higashi, K; Nagase, H; Endo, T; Moribe, K; Loftsson, T; Yamamoto, K; Ueda, H				Ogawa, Noriko; Higashi, Kenjirou; Nagase, Hiromasa; Endo, Tomohiro; Moribe, Kunikazu; Loftsson, Thorsteinn; Yamamoto, Keiji; Ueda, Haruhisa			Effects of Cogrinding with beta-Cyclodextrin on the Solid State Fentanyl	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						milling; physicochemical properties; FTIR; solid state NMR; inclusion compounds; X-ray powder diffractometry; crystallization; cyclodextrins; thermal analysis; interaction	CAMBRIDGE STRUCTURAL DATABASE; CRYSTAL-STRUCTURES; INCLUSION COMPLEXES; ALPHA-CYCLODEXTRIN; (Z)-TETRADEC-7-ENOIC ACID; GAMMA-CYCLODEXTRIN; MESOPOROUS SILICA; BREAKTHROUGH PAIN; TRIDECANOIC ACID; GROUND MIXTURES	Fentanyl base and beta-cyclodextrin (beta-CD) were coground at 1: 1 and 1: 2 molar ratios (fentanyl: beta-CD) and the physicochemical characteristics of the mixtures were studied using differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), solid state (13)C nuclear magnetic resonance (NMR) spectroscopy and powder X-ray diffraction (PXRD) measurement. Additionally, portions of the coground samples were exposed to high relative humidity to investigate fentanyl and beta-CD interactions. The results of DSC and PXRD analyses indicate that the ground mixtures are in an amorphous state, and the FTIR measurements show hydrogen bonding interactions between fentanyl and beta-CD. Solid state (13)C NMR indicates that a fentanyl/beta-CD inclusion compound is formed in the humidified mixture. Furthermore, PXRD data from the humidified mixtures are similar to the PXRD patterns from the inclusion complex. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:5019-5029, 2010	[Ogawa, Noriko; Nagase, Hiromasa; Endo, Tomohiro; Ueda, Haruhisa] Hoshi Univ, Dept Phys Chem, Shinagawa Ku, Tokyo 1428501, Japan; [Higashi, Kenjirou; Moribe, Kunikazu; Yamamoto, Keiji] Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; [Loftsson, Thorsteinn] Univ Iceland, Fac Pharm, IS-107 Reykjavik, Iceland	Ogawa, N (reprint author), Hoshi Univ, Dept Phys Chem, Shinagawa Ku, 4-41 Ebara,2 Chome, Tokyo 1428501, Japan.	n-ogawa@hoshi.ac.jp	Loftsson, Thorsteinn/N-3438-2013	Loftsson, Thorsteinn/0000-0002-9439-1553	Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	The authors thank Mr. Masaki Uemura and Mr. Kousuke Makita for their experimental work. This study was supported in part by a research grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Ayala-Zavala JF, 2008, J INCL PHENOM MACRO, V60, P359, DOI 10.1007/s10847-007-9385-1; Braga D, 2004, ANGEW CHEM INT EDIT, V43, P4002, DOI 10.1002/anie.200301721; Bruno IJ, 2002, ACTA CRYSTALLOGR B, V58, P389, DOI 10.1107/S0108768102003324; Caira MR, 2001, REV ROUM CHIM, V46, P371; Cunha-Silva L, 2004, NEW J CHEM, V28, P200, DOI 10.1039/b309491j; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fernandes CM, 2002, EUR J PHARM SCI, V15, P79, DOI 10.1016/S0928-0987(01)00208-1; Frisch M. J., 2004, GAUSSIAN 03 REVISION; GIDLEY MJ, 1988, J AM CHEM SOC, V110, P3820, DOI 10.1021/ja00220a016; Guitton J, 1997, J CHROMATOGR B, V693, P59, DOI 10.1016/S0378-4347(97)00050-9; HAYASHI S, 1991, J CHEM PHYS, V94, P4446, DOI 10.1063/1.460634; Hedges AR, 1998, CHEM REV, V98, P2035, DOI 10.1021/cr970014w; HEYES SJ, 1992, CARBOHYD RES, V233, P1, DOI 10.1016/S0008-6215(00)90916-9; Holvoet C, 2003, INT J PHARM, V265, P13, DOI 10.1016/S0378-5173(03)00368-5; Jimeno ML, 2003, CHEM PHARM BULL, V51, P929; KAWANO K, 1985, YAKUGAKU ZASSHI, V105, P1071, DOI 10.1248/yakushi1947.105.11_1071; Kuo SW, 2001, MACROMOLECULES, V34, P5224, DOI 10.1021/ma010517a; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Macrae CF, 2008, J APPL CRYSTALLOGR, V41, P466, DOI 10.1107/S0021889807067908; Macrae CF, 2006, J APPL CRYSTALLOGR, V39, P453, DOI 10.1107/S0021 88980600731X; Makedonopoulou S, 1998, CHEM COMMUN, P2133, DOI 10.1039/a804057e; Makedonopoulou S, 2000, J INCL PHENOM MACRO, V36, P191, DOI 10.1023/A:1008055904136; MENTZAFOS D, 1991, ACTA CRYSTALLOGR B, V47, P746, DOI 10.1107/S010876819100366X; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mollica G, 2006, PHARM RES-DORDR, V23, P2129, DOI 10.1007/s11095-006-9044-z; MORIBE K, 1995, CHEM PHARM BULL, V43, P666; NAGAOKA S, 1983, J CHEM PHYS, V79, P4694, DOI 10.1063/1.445610; NAKAI Y, 1984, CHEM PHARM BULL, V32, P685; NAKAI Y, 1986, CHEM PHARM BULL, V34, P2178; NAKAI Y, 1986, YAKUGAKU ZASSHI, V106, P420, DOI 10.1248/yakushi1947.106.5_420; Nishiwaki A, 2009, INT J PHARMACEUT, V378, P17, DOI 10.1016/j.ijpharm.2009.05.023; OGAWA N, 2009, ANAL SCI XRAY STRUC, V25, P83; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Pereira CCL, 2007, ORGANOMETALLICS, V26, P4220, DOI 10.1021/om7003749; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Prodduturi S, 2009, PHARM RES-DORD, V26, P1344, DOI 10.1007/s11095-009-9843-0; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Shenderovich IG, 2003, J PHYS CHEM B, V107, P11924, DOI 10.1021/jp0349740; STREISAND JB, 1998, ANESTHESIOLOGY, V88, P310; SZEJTLI J, 1996, COMPREHENSIVE SUPRAM, V3, P5; Szente L, 1999, ADV DRUG DELIVER REV, V36, P17, DOI 10.1016/S0169-409X(98)00092-1; Taylor R, 2001, ACTA CRYSTALLOGR B, V57, P815, DOI 10.1107/S010876810101360X; Uekama K, 1998, CHEM REV, V98, P2045, DOI 10.1021/cr970025p; Wang EJ, 2007, CARBOHYD RES, V342, P1530, DOI 10.1016/j.carres.2007.04.008	45	21	22	0	25	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0022-3549			J PHARM SCI-US	J. Pharm. Sci.	DEC	2010	99	12					5019	5029		10.1002/jps.22193			11	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	680HG	WOS:000284222400023	20821388				2020-06-30	J	Hagelberg, NM; Olkkola, KT				Hagelberg, Nora M.; Olkkola, Klaus T.			Fentanyl for breakthrough cancer pain - what's new?	PAIN			English	Editorial Material							CROSSOVER TRIAL; DOUBLE-BLIND; OPEN-LABEL; INTRANASAL; CITRATE; PHARMACOKINETICS; TOLERABILITY; EFFICACY; SPRAY		[Hagelberg, Nora M.] Univ Turku, Dept Anaesthesiol Intens Care Emergency Care & Pa, FI-20521 Turku, Finland; Turku Univ Hosp, FI-20521 Turku, Finland	Hagelberg, NM (reprint author), Univ Turku, Dept Anaesthesiol Intens Care Emergency Care & Pa, POB 52, FI-20521 Turku, Finland.	nora.hagelberg@tyks.fi		Olkkola, Klaus/0000-0001-7872-8665			Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farr SJ, 2006, ADV DRUG DELIVER REV, V58, P1076, DOI 10.1016/j.addr.2006.07.013; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Jekunen AP, 2006, J CLIN ONCOL 1, V24, P8629; Katz N, 2009, CLIN J PAIN, V25, P797, DOI 10.1097/AJP.0b013e3181b12dec; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028	12	3	3	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	DEC	2010	151	3					565	566		10.1016/j.pain.2010.08.026			2	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	673KC	WOS:000283657300004	20817402				2020-06-30	J	Portenoy, RK; Burton, AW; Gabrail, N; Taylor, D				Portenoy, Russell K.; Burton, Allen W.; Gabrail, Nashat; Taylor, Donald		Fentanyl Pectin Nasal Spray 043 St	A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain	PAIN			English	Article						Breakthrough pain; Cancer pain; Fentanyl Pectin Nasal Spray; Intranasal opioid; Rapidonset opioid	DOSE-TITRATION; DRUG-DELIVERY; OPEN-LABEL; CITRATE; PHARMACOKINETICS; TOLERABILITY; DEFINITION; PREVALENCE; XEROSTOMIA; PERCEPTION	This randomized, double-blind, crossover study assessed the efficacy and tolerability of a new rapid onset nasal fentanyl formulation (Fentanyl Pectin Nasal Spray; FPNS) for breakthrough cancer pain (BTCP). Eighty-three of 114 patients experiencing one to four BTCP episodes/day while taking >= 60 mg/day of oral morphine or equivalent successfully identified an effective dose of FPNS during a titration phase and entered a double-blind phase in which 10 BTCP episodes were treated with this effective dose (7) or placebo (3). Compared with placebo, FPNS significantly improved mean summed pain intensity difference (SPID) from 10 min (P < 0.05) until 60 min (P < 0.0001), including the primary endpoint at 30 min (P < 0.0001). FPNS significantly improved pain intensity (PI) scores as early as 5 min (P < 0.05); pain intensity difference (PID) from 10 min (P < 0.01); and pain relief (PR) scores from 10 min (P < 0.001). More patients showed a clinically meaningful (>= 2-point reduction in PI) pain reduction from 10 min onward (P <= 0.01) and 90.6% of the FPNS-treated versus 80.0% of placebo-treated BTCP episodes did not require rescue medication (P < 0.001). Approximately 70% of patients were satisfied or very satisfied with the convenience and ease of use of FPNS. Only 5.3% of patients withdrew from treatment due to adverse events, no significant nasal effects were reported, and 87% of patients elected to continue open-label treatment post-study. In this short-term study, FPNS was safe, well tolerated, and rapidly efficacious for BTCP. (C) 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Portenoy, Russell K.] Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA; [Burton, Allen W.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Gabrail, Nashat] Gabrail Canc Ctr, Canton, OH USA; [Taylor, Donald] Georgia Ctr Canc Pain Management & Palliat Med, Marietta, GA USA	Portenoy, RK (reprint author), Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, 1st Ave & 16th St, New York, NY 10003 USA.	rportenoy@chpnet.org			Archimedes Development Ltd; Archimedes Pharmaceuticals; Baxter Healthcare Corporation; Cephalon; Forest Laboratories; Tempurpedic; WyethWyeth; G.W. Pharmaceuticals; King Pharma; Pfizer IncPfizer; Purdue; Tempur-Pedic Corporation; United BioSource Corp.; MedtronicMedtronic	This study was sponsored by Archimedes Development Ltd. The authors wish to acknowledge the technical and editorial support provided by ApotheCom.; In the past year, R. K. P. has also served as a consultant for Ameritox, Cephalon, CNSBio, Grupo Ferrer, Nicox, Purdue Pharma, and Xenon, and his department has received research grants from Archimedes Pharmaceuticals, Baxter Healthcare Corporation, Cephalon, Forest Laboratories, Tempurpedic, and Wyeth, G.W. Pharmaceuticals, King Pharma, Pfizer Inc, Purdue, Tempur-Pedic Corporation, United BioSource Corp., and Wyeth. In the past year, A. W. B. has also received research grants from Medtronic and has served on the speakers bureau of Elan. N.G. and D. T. have no other disclosures to report for the past year.	Bennett D, 2005, MANAGEMENT PHARM THE, V30, P354; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2001, J PAIN SYMPTOM MANAG, V22, P820, DOI 10.1016/S0885-3924(01)00318-9; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Gordon S R, 1985, Gerodontics, V1, P125; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lemmens HJM, 2006, CONTEMP CLIN TRIALS, V27, P165, DOI 10.1016/j.cct.2005.10.005; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Ploner M, 2010, P NATL ACAD SCI USA, V107, P355, DOI 10.1073/pnas.0906186106; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Straube S, 2008, BRIT J CLIN PHARMACO, V66, P266, DOI 10.1111/j.1365-2125.2008.03200.x; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Watson A, 2009, PAIN, V145, P24, DOI 10.1016/j.pain.2009.04.003; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]	30	103	111	0	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	DEC	2010	151	3					617	624		10.1016/j.pain.2010.07.028			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	673KC	WOS:000283657300013	20800358				2020-06-30	J	Rabbitts, JA; Groenewald, CB; Dietz, NM; Morales, C; Rasanen, J				Rabbitts, Jennifer A.; Groenewald, Cornelius B.; Dietz, Niki M.; Morales, Carmen; Raesaenen, Jukka			Perioperative opioid requirements are decreased in hypoxic children living at altitude	PEDIATRIC ANESTHESIA			English	Article						hypoxia; opioid; pain < PACU; altitude; children; Peru	BARORECEPTOR STIMULATION; INTERMITTENT HYPOXIA; RECURRENT HYPOXEMIA; CHRONIC PAIN; SENSITIVITY; RATS	P>Objectives: To investigate the effect of altitude on perioperative opioid requirements in otherwise healthy children. Aim: To investigate whether children living and having surgery at high altitude received different doses of fentanyl than those living and having surgery at sea level. Background: Recent studies in animals (Anesthesiology, 105, 2006 and 715) and children with obstructive sleep apnea (Anesthesiology, 105, 2006 and 665; Anesthesiology 100, 2004 and 806) suggest that analgesic effects of exogenous opioids are enhanced by hypoxia. However, the effects of hypoxia on perioperative narcotic requirements in otherwise healthy children have not been previously reported. Methods/materials: We reviewed retrospectively the opioid requirements of pediatric patients who underwent cleft lip or palate surgery during Smile Network International mission trips to Cusco and Lima, Peru between 2007 and 2009. Patients who had surgery at high altitude were compared to those who had surgery at sea level. All patients received a standardized anesthetic with intravenous fentanyl as the only perioperative opioid. Results: Hundred and two patients had surgery at 3399 m above sea level (masl) (Cusco) and 169 patients had surgery at 150 masl (Lima). Patients at high altitude had significantly lower baseline oxygen saturations (92 +/- 4% vs 98 +/- 3%; P < 0.001) and received 40% less opioid (1.2 +/- 0.8 vs 2.0 +/- 1.4 mu g center dot kg-1 per h; P < 0.001) compared to patients at sea level. Conclusions: Opioid administration was reduced in otherwise healthy children with altitude-induced chronic hypoxia when compared to non-hypoxic children undergoing similar operations under similar anesthetic regimens. Whether this difference is due to altitude or altitude-induced hypoxia, requires further study.	[Rabbitts, Jennifer A.; Groenewald, Cornelius B.; Dietz, Niki M.; Raesaenen, Jukka] Mayo Clin, Dept Anesthesiol, Rochester, MN USA; [Morales, Carmen] San Martin de Porres Univ, Unit Org Qual, Sch Midwifery & Nursing, Lima, Peru	Rabbitts, JA (reprint author), Mayo Fdn Educ & Res, Dept Anesthesiol, 200 1st St SW, Rochester, MN 55905 USA.	rabbitts.jennifer@mayo.edu					Bernardi L, 1998, CLIN SCI, V95, P565, DOI 10.1042/cs0950565; Bernardi L, 2007, P ANN INT IEEE EMBS, P6679; Brown KA, 2004, ANESTHESIOLOGY, V100, P806, DOI 10.1097/00000542-200404000-00009; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; Brown KA, 2009, ANESTHESIOLOGY, V110, P922, DOI 10.1097/ALN.0b013e31819c480a; Bruehl S, 2004, NEUROSCI BIOBEHAV R, V28, P395, DOI 10.1016/j.neubiorev.2004.06.004; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Chung OY, 2008, PAIN, V138, P87, DOI 10.1016/j.pain.2007.11.011; Claydon VE, 2004, EXP PHYSIOL, V89, P565, DOI 10.1113/expphysiol.2004.027698; DROSTE C, 1994, BIOL PSYCHOL, V37, P101, DOI 10.1016/0301-0511(94)90025-6; Duschek S, 2007, INT J PSYCHOPHYSIOL, V65, P193, DOI 10.1016/j.ijpsycho.2007.03.012; Gulli G, 2007, EXP PHYSIOL, V92, P427, DOI 10.1113/expphysiol.2006.035519; Hainsworth R, 2007, CLIN AUTON RES, V17, P13, DOI 10.1007/s10286-006-0395-7; Laferriere A, 2003, BRAIN RES BULL, V59, P307, DOI 10.1016/S0361-9230(02)00915-2; Moore JP, 2006, EXP PHYSIOL, V91, P907, DOI 10.1113/expphysiol.2005.033084; Moss IR, 2006, ANESTHESIOLOGY, V105, P715, DOI 10.1097/00000542-200610000-00017; RAU H, 1994, PSYCHOPHYSIOLOGY, V31, P480, DOI 10.1111/j.1469-8986.1994.tb01051.x; SAAVEDRA JM, 1981, EXPERIENTIA, V37, P1002, DOI 10.1007/BF01971804	18	10	10	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	DEC	2010	20	12					1078	1083		10.1111/j.1460-9592.2010.03453.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	683OQ	WOS:000284485500003	21199116				2020-06-30	J	Gupta, A; Bathla, S; Saini, S; Kamal, G				Gupta, Aikta; Bathla, Sapna; Saini, Suman; Kamal, Geeta			Response to Anesthetic management of a rare case of Shprintzen-Goldberg craniosynostosis syndrome	PEDIATRIC ANESTHESIA			English	Letter									[Gupta, Aikta; Bathla, Sapna; Saini, Suman; Kamal, Geeta] CNBC, Dept Anaesthesia, Delhi, India	Gupta, A (reprint author), CNBC, Dept Anaesthesia, Delhi, India.	aiktab@rediffmail.com					Gupta AK, 2010, PEDIATR ANESTH, V20, P771, DOI 10.1111/j.1460-9592.2010.03340.x	1	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	DEC	2010	20	12					1138	1138		10.1111/j.1460-9592.2010.03451.x			1	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	683OQ	WOS:000284485500014	21199127				2020-06-30	J	Banks, ML; Folk, JE; Rice, KC; Negus, SS				Banks, Matthew L.; Folk, John E.; Rice, Kenner C.; Negus, S. Stevens			Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Delta opioid receptor; Mu opioid receptor; NMDA receptor; Interaction; Antinociception; Rhesus monkey	SPINAL-CORD; QUANTITATIVE AUTORADIOGRAPHY; PHARMACOLOGICAL MODULATION; BEHAVIORAL PHARMACOLOGY; THERMAL NOCICEPTION; RAT-BRAIN; PAIN; MORPHINE; RECEPTORS; SNC80	Mu-opioid receptor agonists such as fentanyl are effective analgesics, but their clinical use is limited by untoward effects. Adjunct medications may improve the effectiveness and/or safety of opioid analgesics. This study compared interactions between fentanyl and either the noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine or the delta-opioid receptor agonist SNC162 [(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-phenyl)methyl]-N,N-diethylbenzamide] in two behavioral assays in rhesus monkeys. An assay of thermal nociception evaluated tail-withdrawal latencies from water heated to 50 and 54 C. An assay of schedule-controlled responding evaluated response rates maintained under a fixed-ratio 30 schedule of food presentation. Effects of each drug alone and of three mixtures of ketamine + fentanyl (22:1, 65:1. 195:1 ketamine/fentanyl) or SNC162 + fentanyl (59:1, 176:1, 528:1 SNC162/fentanyl) were evaluated in each assay. All drugs and mixtures dose-dependently decreased rates of food-maintained responding, and drug proportions in the mixtures were based on relative potencies in this assay. Ketamine and SNC162 were inactive in the assay of thermal antinociception, but fentanyl and all mixtures produced dose-dependent antinociception. Drug interactions were evaluated using dose-addition and dose-ratio analysis. Dose-addition analysis revealed that interactions for all ketamine/fentanyl mixtures were additive in both assays. SNC162/fentanyl interactions were usually additive, but one mixture (176:1) produced synergistic antinociception at 50 C. Dose-ratio analysis indicated that ketamine failed to improve the relative potency of fentanyl to produce antinociception vs. rate suppression, whereas two SNC162/fentanyl mixtures (59:1 and 176:1) increased the relative potency of fentanyl to produce antinociception. These results suggest that delta agonists may produce more selective enhancement than ketamine of mu agonist-induced antinociception. (C) 2010 Elsevier Inc. All rights reserved.	[Banks, Matthew L.; Negus, S. Stevens] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Folk, John E.; Rice, Kenner C.] NIDA, Chem Biol Res Branch, NIH, DHHS, Bethesda, MD 20892 USA; [Folk, John E.; Rice, Kenner C.] NIAAA, NIH, DHHS, Bethesda, MD USA	Negus, SS (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, 410 N 12th St,POB 980613, Richmond, VA 23298 USA.	ssnegus@vcu.edu	Banks, Matthew L/K-4429-2014	Banks, Matthew L/0000-0003-4949-5246	 [R01-DA011460];  [T32-DA007027]	We appreciate the technical assistance of Ember Morrissey and Crystal Reyns. This research was supported by grants R01-DA011460 and T32-DA007027.	ADAMS JU, 1993, J PHARMACOL EXP THER, V266, P1261; Allen RM, 2002, J PHARMACOL EXP THER, V300, P435, DOI 10.1124/jpet.300.2.435; Baker AK, 2002, PHARMACOL BIOCHEM BE, V74, P73, DOI 10.1016/S0091-3057(02)00961-9; Bell RF, 2003, J PAIN SYMPTOM MANAG, V26, P867, DOI 10.1016/S0885-3924(03)00311-7; Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939; Brown DG, 2006, CURR TOP MED CHEM, V6, P749, DOI 10.2174/156802606777057571; Butelman ER, 2003, J PHARMACOL EXP THER, V306, P1106, DOI 10.1124/jpet.103.052381; Carstensen M, 2010, BRIT J ANAESTH, V104, P401, DOI 10.1093/bja/aeq041; DAMBISYA YM, 1994, METHOD FIND EXP CLIN, V16, P179; Dickenson AH, 1997, GEN PHARMACOL-VASC S, V28, P633, DOI 10.1016/S0306-3623(96)00359-X; Do Carmo GP, 2008, J PHARMACOL EXP THER, V326, P939, DOI 10.1124/jpet.108.138180; DYKSTRA LA, 1986, J PHARMACOL METHOD, V15, P263, DOI 10.1016/0160-5402(86)90056-2; FRANCE CP, 1989, J PHARMACOL EXP THER, V250, P197; Furst S, 1999, BRAIN RES BULL, V48, P129, DOI 10.1016/S0361-9230(98)00159-2; Gatch MB, 1998, PSYCHOPHARMACOLOGY, V135, P99, DOI 10.1007/s002130050490; HEYMAN JS, 1989, EUR J PHARMACOL, V169, P43, DOI 10.1016/0014-2999(89)90815-7; HEYMAN JS, 1987, BRAIN RES, V420, P100, DOI 10.1016/0006-8993(87)90244-7; Hoffmann VLH, 2003, PHARMACOL BIOCHEM BE, V74, P933, DOI 10.1016/S0091-3057(03)00020-0; Holtman JR, 2008, PHARMACOL BIOCHEM BE, V90, P769, DOI 10.1016/j.pbb.2008.05.019; Jutkiewicz EM, 2004, J PHARMACOL EXP THER, V309, P173, DOI 10.1124/jpet.103.061242; Kalb RG, 1997, J COMP NEUROL, V384, P200, DOI 10.1002/(SICI)1096-9861(19970728)384:2<200::AID-CNE3>3.0.CO;2-5; KENAKIN TP, PHARM ANAL DRUG RECE; Kollender Y, 2008, EUR J CANCER, V44, P954, DOI 10.1016/j.ejca.2008.02.021; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; Mugnaini M, 1996, BRIT J PHARMACOL, V119, P819, DOI 10.1111/j.1476-5381.1996.tb15746.x; Nadeson R, 2002, BRIT J ANAESTH, V88, P685, DOI 10.1093/bja/88.5.685; Negus SS, 2008, EXP CLIN PSYCHOPHARM, V16, P386, DOI 10.1037/a0013088; Negus SS, 2009, EUR J PHARMACOL, V602, P92, DOI 10.1016/j.ejphar.2008.11.004; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 1998, J PHARMACOL EXP THER, V286, P362; ONeill SJ, 1997, J PHARMACOL EXP THER, V282, P271; Pelissier T, 2003, EUR J PHARMACOL, V477, P23, DOI 10.1016/S0014-2999(03)02192-7; Roth JE, 1996, J PHARMACOL EXP THER, V277, P1823; Schulte H, 2004, ANESTH ANALG, V98, P1574; Schulte H, 2003, ACTA ANAESTH SCAND, V47, P1020, DOI 10.1034/j.1399-6576.2003.00204.x; Stevenson GW, 2005, J PHARMACOL EXP THER, V314, P221, DOI 10.1124/jpet.104.082685; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; STEWART PE, 1993, J PHARMACOL EXP THER, V266, P820; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; TALLARIDA R, 2000, DRUG SYNERGISM DOSE; Tallarida RJ, 2007, PHARMACOL THERAPEUT, V113, P197, DOI 10.1016/j.pharmthera.2006.08.002; TUCKER AP, 2005, [No title captured], V5, P2; WESSINGER WD, 1986, NEUROSCI BIOBEHAV R, V10, P103, DOI 10.1016/0149-7634(86)90021-7	43	15	15	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	DEC	2010	97	2					205	212		10.1016/j.pbb.2010.07.019			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	680ON	WOS:000284244400004	20678514	Green Accepted			2020-06-30	J	Romero, A; Miranda, HF; Puig, MM				Romero, Asuncion; Miranda, Hugo F.; Puig, Margarita M.			Antinociceptive effects of morphine, fentanyl, tramadol and their combination, in morphine-tolerant mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Opioid agonist; Hot plate; Antinociception; Morphine tolerance; Drug interaction; Isobolographic analysis	OPIOID RECEPTOR DESENSITIZATION; BREAKTHROUGH PAIN; SYNERGY; ENDOCYTOSIS; CLONIDINE; PHOSPHORYLATION; RESPONSES	The development of morphine-tolerance after chronic administration, reduces analgesic efficacy and is a significant clinical problem in some patients; may be managed clinically by increasing the doses of morphine and/or the administration of a second mu-opioid agonist. In morphine-tolerant mice, we investigated the presence of an interaction when two opioids are administered simultaneously. We determined the antinociceptive effects of morphine (M), fentanyl (FEN), and tramadol (TRM) individually and combined in a 1:1 proportion, based on their potency. Nociceptive thresholds were evaluated in CD1 mice using the hot plate test. Morphine tolerance was induced by the subcutaneous implantation of a 75 mg morphine pellet, whereas control animals received a placebo pellet; the experiments were performed three days later. In both ( placebo and morphine pellets), dose-response curves for M, FEN and TRM, individually and combined were obtained, and the doses that produced 50% inhibition (ED50) were determined. Sustained exposure to morphine induced a significant decrease in antinociceptive potency to acute M or FEN administration (tolerance), which was of a lesser magnitude after acute TRM: in these experiments the analysis of the interaction between chronic morphine and each opioid, demonstrated functional antagonism. The simultaneous administration of two opioids in morphine-tolerant mice, demonstrated antagonism for the M:FEN combination, whereas the effects of TRM combined with M or FEN, remained additive. The results suggest that during morphine-tolerance. TRM could be a useful drug to induce effective analgesia when combined with FEN or M. (C) 2010 Elsevier Inc. All rights reserved.	[Romero, Asuncion; Puig, Margarita M.] Univ Autonoma Barcelona, Hosp Mar, Physiopatholol & Pain Management Res Grp, Dept Anesthesiol,IMIM, Barcelona, Spain; [Miranda, Hugo F.] Univ Chile, Dept Pharmacol, ICBM, Sch Med, Santiago, Chile	Romero, A (reprint author), Dr Aiguader 88, E-08003 Barcelona, Spain.	mromero@imim.es; hmiranda@med.uchile.cl; MPuigR@hospitaldelmar.cat	Romero, Asuncion/L-6030-2014	Romero, Asuncion/0000-0002-5182-1672	Fondo de Investigaciones SanitariasInstituto de Salud Carlos III; Instituto de Salud Carlos III, Madrid, SpainInstituto de Salud Carlos III [PI 060669, PS09/01270]; La Marato de TV3 [071110]; Endowed Chair in Pain Management UAB-IMAS-MENARINI (MMP)	We are grateful to Ms. Carolina Zamora for her excellent technical help, and Marta Pulido, MD, for editing the manuscript and editorial assistance. Financial support for this study was provided by grants from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid, Spain (PI 060669 and PS09/01270), La Marato de TV3 (071110) and the Endowed Chair in Pain Management UAB-IMAS-MENARINI (MMP).	Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Bredeloux P, 2006, BEHAV BRAIN RES, V175, P399, DOI 10.1016/j.bbr.2006.09.016; CARTER RB, 1991, PAIN, V47, P211, DOI 10.1016/0304-3959(91)90207-E; Castane A, 2006, NEUROPHARMACOLOGY, V51, P631, DOI 10.1016/j.neuropharm.2006.05.005; CAUDLE RM, 1993, PAIN, V55, P313, DOI 10.1016/0304-3959(93)90006-B; Contet C, 2006, NEUROPSYCHOPHARMACOL, V31, P1733, DOI 10.1038/sj.npp.1300934; Cristiano M. P., 2008, Autonomic & Autacoid Pharmacology, V28, P103, DOI 10.1111/j.1474-8673.2008.00423.x; Devulder J, 2009, BRIT J ANAESTH, V103, P576, DOI 10.1093/bja/aep253; Dighe SV, 2009, PHARMACOL BIOCHEM BE, V92, P537, DOI 10.1016/j.pbb.2009.02.004; Dursteler C, 2006, EUR J PAIN, V10, P629, DOI 10.1016/j.ejpain.2005.10.002; Fairbanks CA, 1999, J PHARMACOL EXP THER, V288, P1107; Fernandez-Duenas V, 2007, J PHARMACOL EXP THER, V322, P360, DOI 10.1124/jpet.106.118901; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hernandez L, 2009, BRAIN RES, V1248, P31, DOI 10.1016/j.brainres.2008.10.065; Jordan BA, 2003, MOL PHARMACOL, V64, P1317, DOI 10.1124/mol.64.6.1317; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Le Bars D, 2001, PHARMACOL REV, V53, P597; Leppert W, 2009, PHARMACOL REP, V61, P978, DOI 10.1016/S1734-1140(09)70159-8; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Minami K, 2007, J PHARMACOL SCI, V103, P253, DOI 10.1254/jphs.CR0060032; MURGA G, 1994, ANAESTHESIA, V49, P999, DOI 10.1111/j.1365-2044.1994.tb04323.x; Nemirovsky A, 2001, ANESTH ANALG, V93, P197; OSSIPOV MH, 1990, LIFE SCI, V47, pPL71, DOI 10.1016/0024-3205(90)90530-5; Pol O, 1997, BRIT J PHARMACOL, V122, P1216, DOI 10.1038/sj.bjp.0701472; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; RAFFA RB, 1996, RAIN REV, V3, P249; Richebe P, 2009, CAN J ANAESTH, V56, P969, DOI 10.1007/s12630-009-9202-y; Romero A, 2010, PHARMACOL RES, V61, P511, DOI 10.1016/j.phrs.2010.02.011; Ross FB, 2000, PAIN, V84, P421, DOI 10.1016/S0304-3959(99)00230-4; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin NE, 2009, CURR MED RES OPIN, V25, P2133, DOI 10.1185/03007990903120158; SUTTERS KA, 1990, BRAIN RES, V530, P290, DOI 10.1016/0006-8993(90)91297-T; TALLARIDA R, 2000, DRUG SYNERGISM DOSE; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Tumati S, 2009, J PHARMACOL EXP THER, V330, P810, DOI 10.1124/jpet.109.151704; Vissers KCP, 2010, PAIN PRACT, V10, P85, DOI 10.1111/j.1533-2500.2009.00335.x; Wilson SG, 2001, BEHAV BRAIN RES, V125, P65, DOI 10.1016/S0166-4328(01)00281-9; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang Y, 2009, NEUROSCI BIOBEHAV R, V33, P1192, DOI 10.1016/j.neubiorev.2009.03.007; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	44	13	13	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	DEC	2010	97	2					363	369		10.1016/j.pbb.2010.09.005			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	680ON	WOS:000284244400025	20843476				2020-06-30	J	Garg, A; Solas, DW; Takahashi, LH; Cassella, JV				Garg, Anuradha; Solas, Dennis W.; Takahashi, Lori H.; Cassella, James V.			Forced degradation of fentanyl: Identification and analysis of impurities and degradants	JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS			English	Article						Fentanyl; Forced degradation; Degradants; Impurities; Validation; Structural alerts	ASSAY	Fentanyl. N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide is a rapid-acting, powerful opioid analgesic used extensively for anesthesia and chronic pain management. A forced degradation study of fentanyl active pharmaceutical ingredient (API) was performed using light, acid, base, heat and oxidation. Under acidic conditions, fentanyl was shown to degrade to N-phenyl-1-(2-phenylethyl)-piperidin-4-amine (PPA(1)). Fentanyl was stable to light exposure and base treatment with no degradation observed. Oxidation with hydrogen peroxide produced fentanyl N-oxide by rapidly oxidizing the nitrogen on the piperidine ring. Five degradants were formed during thermal degradation of fentanyl The two known degradants included propionanilide (PRP(2)) and norfentanyl (NRF(3)) The three unknown degradants were first identified by mass using LC/MS, and postulated compounds were synthesized and confirmed by LC/MS and (1)H NMR. These degradants were identified as 1-phenethylpyridinium salt (1-PEP(4)), 1-phenethyl-1H-pyridin-2-one (1-PPO(5)), and 1-styryl-1H-pyridin-2-one (1-SPO(6)). In addition to the seven degradants, three known process impurities, acetyl fentanyl, pyruvyl fentanyl and butyryl fentanyl were also detected by reverse-phase high performance liquid chromatography (HPLC) with UV detection All degradants and impurities were identified and confirmed using authentic materials Method validation was performed for the assay of fentanyl and its related compounds in accordance to ICH guideline Q2(R1), and the method was demonstrated to be specific, linear (r > 0 999 for fentanyl assay and r > 0 996 for related compounds), accurate (recovery > 99 6% for fentanyl assay and recovery > 91 0 for related compounds), precise (%RSD <0.8% for fentanyl assay and <4 8% for related compounds), sensitive (limit of detection = 008 mu g/mL or 0 016% of nominal concentration), robust and suitable for its intended use The chemical structures for the degradants and impurities were submitted to three in silico toxicity programs to identify any structural alerts. (C) 2010 Elsevier B.V. All rights reserved	[Garg, Anuradha; Solas, Dennis W.; Takahashi, Lori H.; Cassella, James V.] Alexza Pharmaceut, Analyt Res & Dev, Mountain View, CA 94043 USA	Garg, A (reprint author), Alexza Pharmaceut, Analyt Res & Dev, 2091 Stierlin Court, Mountain View, CA 94043 USA.						Bailey AB, 2005, REGUL TOXICOL PHARM, V42, P225, DOI 10.1016/j.yrtph.2005.04.006; Benigni R, 2008, MUTAT RES-REV MUTAT, V659, P248, DOI 10.1016/j.mrrev.2008.05.003; Bhattacharyya L., 2005, PHARMACOPEIAL FORUM, V31, P960; CHEN J, 2006, 2006 AAPS ANN M EXP; *EU EMEA CHMP, 2007, GUID LIM GEN IMP; *EUR PHARM, 2005, FENT MON, P1584; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; MARCH J, 1977, ADV ORG CHEM, P895; Matthews EJ, 2008, TOXICOL MECH METHOD, V18, P189, DOI 10.1080/15376510701857379; Nishikawa RK, 2009, J ANAL TOXICOL, V33, P418, DOI 10.1093/jat/33.8.418; Rabinowitz JD, 2004, J PHARMACOL EXP THER, V309, P769, DOI 10.1124/jpet.103.062893; *US FDA, 2008, GUID IND DRAFT GEN C	12	24	25	2	57	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0731-7085			J PHARMACEUT BIOMED	J. Pharm. Biomed. Anal.	NOV 2	2010	53	3					325	334		10.1016/j.jpba.2010.04.004			10	Chemistry, Analytical; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	632PD	WOS:000280435800015	20462721				2020-06-30	J	Saunders, M; Adelgais, K; Nelson, D				Saunders, Mary; Adelgais, Kathleen; Nelson, Douglas			Use of Intranasal Fentanyl for the Relief of Pediatric Orthopedic Trauma Pain	ACADEMIC EMERGENCY MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ORAL TRANSMUCOSAL FENTANYL; POSTOPERATIVE PAIN; INTRAMUSCULAR MEPERIDINE; CONSCIOUS SEDATION; LACERATION REPAIR; CHILDREN; ANALGESIA; EMERGENCY; SUFENTANIL	Objectives: The objective was to evaluate the use of a single 2 mu g/kg dose of intranasal fentanyl as analgesia for painful orthopedic injuries in children presenting to a pediatric emergency department (ED). Methods: This was a prospective, nonblinded interventional trial, in a convenience sample of patients 3 to 18 years of age seen in a tertiary care pediatric ED. All had clinically suspected fractures and were treated between July and November 2006. Eligible patients had moderate to severe pain based on initial pain scores using the Wong Baker Faces Scale (VVBS) for patients aged 3-8 years or the Visual Analog Scale (VAS) for patients aged 9-18 years. All enrolled patients received fentanyl via intranasal atomization. Pain scores were obtained at baseline and at 10, 20, and 30 minutes after intranasal fentanyl administration. Satisfaction scores were obtained using a 100-mm VAS. Vital signs and adverse events were recorded. Results: Eighty-one patients were enrolled, 28 in the VAS group and 53 in the WBS group. The mean patient age was 8 years. Fracture locations included forearm, 38 (47%); supracondylar, 16 (20%); clavicle, 7 (9%); tibia/fibula, 5 (6%); and other, 15 (18%). In the WBS group, the median pain scores decreased from five faces (interquartile range [IQR] = 4-6) at baseline to three faces (IQR = 2-5) at 10 minutes, two faces (IQR = 1-4) at 20 minutes, and two faces (IQR = 1-3) at 30 minutes. The mean pain score in the VAS group at baseline was 70 mm (95% confidence interval [CI] = 63 to 77 mm). In this group, the pain scores decreased by a mean of 21 mm (95% CI = 14 to 28 mm) at 10 minutes, 25 mm (95% CI = 15 to 34 mm) at 20 minutes, and 27 mm (95% CI = 16 to 37 mm) at 30 minutes. Mean satisfaction scores were 79 mm for providers, 74 mm for parents, and 62 mm for patients. No adverse events were recorded. Conclusions: Intranasal fentanyl at a dose of 2 mu g/kg provides effective analgesia for pediatric ED patients with painful orthopedic trauma within 10 minutes of administration.	[Saunders, Mary] Med Coll Wisconsin, Dept Pediat Emergency Med, Milwaukee, WI 53226 USA; [Adelgais, Kathleen; Nelson, Douglas] Univ Utah, Dept Pediat Emergency Med, Salt Lake City, UT USA	Saunders, M (reprint author), Carepoint PC, Carepoint Pediat Div, Greenwood Village, CO USA.	mary.saunders@yahoo.com					*AM AC PED SUBC MA, 2001, PEDIATRICS, V108, pA24; BATES BA, 1994, ANN EMERG MED, V24, P646, DOI 10.1016/S0196-0644(94)70274-8; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Bulloch B, 2002, ACAD EMERG MED, V9, P199, DOI 10.1197/aemj.9.3.199; Chambers CT, 1999, PAIN, V83, P25, DOI 10.1016/S0304-3959(99)00086-X; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; HENDERSON JM, 1988, ANESTHESIOLOGY, V68, P671, DOI 10.1097/00000542-198805000-00003; Kain ZN, 2006, PEDIATRICS, V118, P651, DOI 10.1542/peds.2005-2920; KARL HW, 1992, ANESTHESIOLOGY, V76, P209, DOI 10.1097/00000542-199202000-00009; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; LEBARON S, 1984, J CONSULT CLIN PSYCH, V52, P729, DOI 10.1037/0022-006X.52.5.729; Magaret ND, 2002, ACAD EMERG MED, V9, P1379, DOI 10.1111/j.1553-2712.2002.tb01606.x; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Pappas AL, 2003, ANESTH ANALG, V96, P1621, DOI 10.1213/01.ANE.0000064206.51296.1D; Powell CV, 2001, ANN EMERG MED, V37, P28; RALLEY FE, 1989, CAN J ANAESTH, V36, P491, DOI 10.1007/BF03005372; Roelofse J A, 2004, Anesth Prog, V51, P114; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; Schutzman SA, 1996, ANN EMERG MED, V28, P385, DOI 10.1016/S0196-0644(96)70001-X; Singer AJ, 2008, ANN EMERG MED, V52, P41, DOI 10.1016/j.annemergmed.2008.01.336; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405; Wilson JA, 1997, J ACCID EMERG MED, V14, P70; *WOLF TOR MED INC, MAD NAS; Wong D L, 1988, Pediatr Nurs, V14, P9; Zempsky WT, 2004, PEDIATRICS, V114, P1348, DOI 10.1542/peds.2004-1752	30	52	54	1	4	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	NOV	2010	17	11					1155	1161		10.1111/j.1553-2712.2010.00905.x			7	Emergency Medicine	Emergency Medicine	676UW	WOS:000283945100006	21175512				2020-06-30	J	Trinity, JD; Amann, M; McDaniel, J; Fjeldstad, AS; Barrett-O'Keefe, Z; Runnels, S; Morgan, DE; Wray, DW; Richardson, RS				Trinity, Joel D.; Amann, Markus; McDaniel, John; Fjeldstad, Anette S.; Barrett-O'Keefe, Zachary; Runnels, Sean; Morgan, David E.; Wray, D. Walter; Richardson, Russell S.			Limb movement-induced hyperemia has a central hemodynamic component: evidence from a neural blockade study	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						afferent nerve fiber; blood flow; hemodynamics	STATIC MUSCULAR-CONTRACTION; SKELETAL-MUSCLE; BLOOD-FLOW; CARDIAC-OUTPUT; HEART-RATE; GROUP-III; EXERCISE HYPEREMIA; ARTERIAL-PRESSURE; DYNAMIC EXERCISE; RESPONSES	Trinity JD, Amann M, McDaniel J, Fjeldstad AS, Barrett-O'Keefe Z, Runnels S, Morgan DE, Wray DW, Richardson RS. Limb movement-induced hyperemia has a central hemodynamic component: evidence from a neural blockade study. Am J Physiol Heart Circ Physiol 299: H1693-H1700, 2010. First published August 27, 2010; doi:10.1152/ajpheart.00482.2010.-The purpose of this investigation was to partially remove feedback from type III/IV skeletal muscle afferents and determine how this feedback influences the central and peripheral hemodynamic responses to passive leg movement. Heart rate (HR), stroke volume (SV), cardiac output (CO), mean arterial pressure, leg vascular conductance (LVC), and leg blood flow (LBF) were measured during 2 min of passive knee extension in eight young men before and after intrathecal fentanyl injection. Passive movement increased HR by 14 beats/min from baseline to maximal response during control (CON) (65 +/- 4 to 79 +/- 5 beats/min, P < 0.05), whereas HR did not significantly increase with the fentanyl block (BLK). LBF and LVC increased in both conditions; however, these increases were attenuated and delayed during BLK [% change from baseline to maximum, LBF: CON 295 +/- 109 vs. BLK 210 +/- 86%, (P < 0.05); LVC: CON 322 +/- 40% vs. BLK 231 +/- 32%, (P < 0.04)]. In CON, HR, SV, CO, and LVC increased contributing to the hyperemic response. However, under BLK conditions, statistically insignificant increases in HR and SV combined to yield a small, but significant, increase in CO and an attenuated hyperemic response. Therefore, partially blocking skeletal muscle afferent feedback blunts the central hemodynamic response due to passive limb movement, which then results in an attenuated and delayed movement-induced hyperemia. In combination, these findings provide evidence that limb movement-induced hyperemia has a significant central hemodynamic component induced by peripheral nerve activation.	[Trinity, Joel D.; Amann, Markus; Fjeldstad, Anette S.; Wray, D. Walter; Richardson, Russell S.] Univ Utah, Dept Med, Div Geriatr, Salt Lake City, UT 84112 USA; [Runnels, Sean; Morgan, David E.] Univ Utah, Dept Anesthesiol, Salt Lake City, UT 84112 USA; [Barrett-O'Keefe, Zachary; Wray, D. Walter; Richardson, Russell S.] Univ Utah, Dept Exercise & Sport Sci, Salt Lake City, UT 84112 USA; [Trinity, Joel D.; McDaniel, John; Wray, D. Walter; Richardson, Russell S.] Univ Utah, Ctr Geriatr Res Educ & Clin, George E Whalen Vet Affairs Med Ctr, Salt Lake City, UT 84112 USA	Trinity, JD (reprint author), VA Med Ctr, Bldg 2,RM 1D29A,500 Foothill Dr, Salt Lake City, UT 84148 USA.	joel.trinity@utah.edu		Amann, Markus/0000-0002-4012-8880	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K99 HL103786, K99 HL103786-02, K99 HL103786-01]		Adreani CM, 1997, J APPL PHYSIOL, V82, P1811; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; BERKENBOSCH A, 1989, J APPL PHYSIOL, V66, P2168; Clifford PS, 2006, J PHYSIOL-LONDON, V572, P561, DOI 10.1113/jphysiol.2005.099507; COOTE JH, 1970, J PHYSIOL-LONDON, V208, P261, DOI 10.1113/jphysiol.1970.sp009118; de Vaal JB, 2005, BRIT J ANAESTH, V95, P326, DOI 10.1093/bja/aei189; de Wilde RBP, 2009, ANAESTHESIA, V64, P762, DOI 10.1111/j.1365-2044.2009.05934.x; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; Gladwell VF, 2002, J PHYSIOL-LONDON, V540, P1095, DOI 10.1113/jphysiol.2001.013486; Gonzalez-Alonso J, 2008, J PHYSIOL-LONDON, V586, P2405, DOI 10.1113/jphysiol.2008.152058; Hellsten Y, 2008, AM J PHYSIOL-REG I, V294, pR975, DOI 10.1152/ajpregu.00677.2007; HILL JM, 1990, J APPL PHYSIOL, V68, P2466; KALIA M, 1981, CIRC RES, V48, P48; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; KAUFMAN MP, 1984, CARDIOVASC RES, V18, P663, DOI 10.1093/cvr/18.11.663; KAUFMAN MP, 1983, J APPL PHYSIOL, V55, P105; Kenfack MA, 2004, CLIN SCI, V106, P365, DOI 10.1042/CS20030303; Kirby BS, 2007, J PHYSIOL-LONDON, V583, P861, DOI 10.1113/jphysiol.2007.131250; KOLLER A, 1989, MICROCIRC ENDOTH LYM, V5, P519; KOLLER A, 1990, AM J PHYSIOL, V258, pH916; Kooijman M, 2008, J PHYSIOL-LONDON, V586, P1137, DOI 10.1113/jphysiol.2007.145722; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; LAUGHLIN MH, 1987, AM J PHYSIOL, V253, pH993; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; McDaniel J, 2010, J APPL PHYSIOL, V108, P76, DOI 10.1152/japplphysiol.00895.2009; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; MENSE S, 1993, PAIN, V54, P241, DOI 10.1016/0304-3959(93)90027-M; MENSE S, 1988, NEUROSCIENCE, V26, P1023, DOI 10.1016/0306-4522(88)90117-0; NOBREGA ACL, 1995, J APPL PHYSIOL, V79, P1405; NOBREGA ACL, 1993, MED SCI SPORT EXER, V25, P37; NOBREGA ACL, 1994, MED SCI SPORT EXER, V26, P709; Nurhayati Y, 1998, MED SCI SPORT EXER, V30, P234, DOI 10.1097/00005768-199802000-00010; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; POMEROY G, 1986, BRAIN RES, V381, P385, DOI 10.1016/0006-8993(86)90095-8; SATO A, 1981, J AUTONOM NERV SYST, V4, P231, DOI 10.1016/0165-1838(81)90047-3; Segal SS, 2000, ACTA PHYSIOL SCAND, V168, P511, DOI 10.1046/j.1365-201x.2000.00703.x; SHERIFF DD, 1993, AM J PHYSIOL, V265, pH1227; Sugawara J, 2003, ACTA PHYSIOL SCAND, V179, P361, DOI 10.1046/j.0001-6772.2003.01211.x; Ter Woerds W, 2006, PHYS THER, V86, P636, DOI 10.1093/ptj/86.5.636; Tschakovsky ME, 2004, J APPL PHYSIOL, V97, P739, DOI 10.1152/japplphysiol.00185.2004; van Lieshout JJ, 2003, EUR J APPL PHYSIOL, V90, P131, DOI 10.1007/s00421-003-0901-8; Wray DW, 2005, J PHYSIOL-LONDON, V565, P1053, DOI 10.1113/jphysiol.2005.084327; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pharmtox.25.1.433; YAKSH TL, 1981, PAIN, V11, P293, DOI 10.1016/0304-3959(81)90633-3	46	32	32	0	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	NOV	2010	299	5					H1693	H1700		10.1152/ajpheart.00482.2010			8	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	673HB	WOS:000283649000047	20802133	Green Published			2020-06-30	J	Fine, PG; Messina, J; Xie, F; Rathmell, J				Fine, Perry G.; Messina, John; Xie, Fang; Rathmell, James			Long-Term Safety and Tolerability of Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain An 18-Month Study	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Fentanyl buccal tablet; opioid; long-term safety	CHRONIC NONCANCER PAIN; CLINICAL-PRACTICE GUIDELINE; AMERICAN ACADEMY; TREATED PATIENTS; DOUBLE-BLIND; BACK-PAIN; PREVALENCE; EFFICACY; PRESCRIPTIONS; RELEASE	Context Breakthrough pain (BTP) is highly prevalent in patients with chronic cancer and noncancer pain, commonly requiring treatment with short-acting or rapid-onset opioids. This is the first report of an analysis of long-term safety from combined clinical trials of a rapid-onset transmucosal formulation of fentanyl, the fentanyl buccal tablet (FBT). Objectives This long-term (18-month), open-label study assessed the safety and tolerability of FBT for the treatment of BTP in a large cohort (n = 646) of opioid-tolerant patients receiving around-the-clock (ATC) opioids for persistant noncancer pain. Methods This was a long-term, multicenter, open-label safety study that accepted patients naive to FBT (new patients) as well as rollover patients from one of two previous short-term, randomized, placebo-controlled studies involving opioid-tolerant adults with chronic noncancer pain. All patients gave written informed consent, and the study was conducted according to Good Clinical Practice and with Independent Ethics Committee or Institutional Review Board approval. Results During maintenance treatment, 70 of 646 patients (11%) discontinued because of adverse events (AEs), 69 of 646 (11%) because of withdrawn consent, and 57 of 646 (9%) because of noncompliance. A total of 571 of 646 patients (88%) had one or more AEs; most were mild to moderate in intensity and typical of AEs associated with opioid use in a noncancer chronic pain population. Serious AEs were seen in 118 of 646 patients (18%); most were considered by the investigators to be unrelated or unlikely to be related to FBT. There were six deaths (three myocardial infarction, two cardiac arrest, and one pneumonia) that were considered by investigators to be unrelated or unlikely to be related to FBT. There were two reports of accidental overdose contained within nine reports of nonfatal overdose (FBT and/or ATC and/or other medications). Four patients had AEs of abuse or drug dependence, two in association with FBT. Drug withdrawal syndrome occurred in 23 patients after discontinuation of FBT alone or in combination with other opioids. Secondary assessments showed that average pain ratings, as assessed by the Brief Pain Inventory, remained relatively stable throughout the study and that consistent improvements were noted in functional measures. Conclusion FBT was generally safe and well tolerated, with self-reported functional improvement observed in most of the opioid-tolerant patients with BTP in association with chronic noncancer pain. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Fine, Perry G.] Univ Utah, Dept Anesthesiol, Pain Management Ctr, Salt Lake City, UT 84109 USA; [Messina, John; Xie, Fang] Cephalon Inc, Frazer, PA USA; [Rathmell, James] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA	Fine, PG (reprint author), Univ Utah, Dept Anesthesiol, Pain Management Ctr, Suite 200,615 Arapeen Dr, Salt Lake City, UT 84109 USA.						*AM AC PAIN MED AM, 1997, [No title captured]; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; *FED STAT MED BOAR, 1998, [No title captured]; Kalso E, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-39; Katz N, 2007, CURR MED RES OPIN, V23, P117, DOI 10.1185/030079906X162692; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; McNair D, 1992, POMS MANUAL PROFILE; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; MURPHY K, 2009, J PAIN S1, V10, pS58; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Olsen Y, 2006, J PAIN, V7, P225, DOI 10.1016/j.jpain.2005.11.006; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2007, CLIN J PAIN, V23, P287, DOI 10.1097/AJP.0b013e31802b582f; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Rauck Richard L, 2006, J Opioid Manag, V2, P155; Russell IJ, 2008, PAIN, V136, P432, DOI 10.1016/j.pain.2008.02.024; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Trescot Andrea M, 2006, Pain Physician, V9, P1; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220	29	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	NOV	2010	40	5					747	760		10.1016/j.jpainsymman.2010.02.009			14	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	686BI	WOS:000284671400011	20594801	Bronze			2020-06-30	J	Issandoh, S				Issandoh, Samuel			A Cautionary Tale From Critical Care Resolution of Myoclonus After Fentanyl Rotation to Hydromorphone	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Issandoh, S (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.			Glare, Paul/0000-0001-6850-7025			CALLAGHER R, 2007, CAN FAM PHYSICIAN, V53, P126; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Hagen N, 1997, J PAIN SYMPTOM MANAG, V14, P51, DOI 10.1016/S0885-3924(97)00001-8; Horton Robert, 2009, J Pain Symptom Manage, V37, pe2, DOI 10.1016/j.jpainsymman.2009.02.230; Latronico N, 2005, CURR OPIN CRIT CARE, V11, P381, DOI 10.1097/01.ccx.0000168530.30702.3e; Okon TR, 2008, J PAIN SYMPTOM MANAG, V35, P327, DOI 10.1016/j.jpainsymman.2007.04.023; Riechelmann RP, 2008, J PAIN SYMPTOM MANAG, V35, P535, DOI 10.1016/j.jpainsymman.2007.06.009; Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Wright AWE, 2001, LIFE SCI, V69, P409, DOI 10.1016/S0024-3205(01)01133-X; 1996, ANESTH ANALG, V82, P167; 2005, MOL PHARM, V67, P665; 2002, J PAIN SYMPTOM MANAG, V21, P284; 2005, BIOL PHARM B, V28, P2026; 2008, PAIN, V71, P5	16	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	NOV	2010	40	5					E4	E6		10.1016/j.jpainsymman.2010.08.005			3	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	686BI	WOS:000284671400019	20932710	Bronze			2020-06-30	J	Hirsh, I; Lerner, A; Shnaider, I; Reuveni, A; Pacht, A; Segol, O; Pizov, R				Hirsh, Irina; Lerner, Aaron; Shnaider, Ilia; Reuveni, Amit; Pacht, Avi; Segol, Ori; Pizov, Reuven			Remifentanil Versus Fentanyl for Esophagogastroduodenoscopy in Children	JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION			English	Article						children; esophagogastroduodenoscopy; remifentanil; sedation	DEEP SEDATION; PROPOFOL; MIDAZOLAM; ANESTHESIA	Objectives: We compared sedation by propofol combined with either fentanyl or remifentanil in pediatric outpatients undergoing diagnostic esophagogastroduodenoscopy. Patients and Methods: Forty-two children scheduled for esophagogastroduodenoscopy in our institution were randomly assigned to receive 2 mg/kg propofol plus either 1 mu g/kg bolus of fentanyl (group F; n = 20) or 0.5 mu g/kg bolus of remifentanil (group R; n = 22). Cardiorespiratory parameters, sedation level, adverse effects related to the drugs and/or to the procedure, ease of performance for the endoscopist, and time to awakening were analyzed. Results: There were no clinically significant changes in hemodynamics. Apnea periods >20 seconds and decreases in SaO(2) < 90% occurred more frequently in group R (31.8% vs 0%, P < 0.01, and 27.3% vs 5.0%, P > 0.05, respectively). Children in group R had significantly shorter average time to awakening: 9.5 +/- 5.6 vs 16.5 +/- 10.5 minutes (P = 0.01), and received a significantly lower total dose of propofol (P = 0.034). Adverse effects within the first 24 hours postprocedure occurred less frequently in group R (P = 0.03). Conclusions: Remifentanil in combination with propofol provides good analgesic and sedative effects, which were shorter lasting compared with fentanyl-based sedation, and caused fewer delayed adverse effects. The use of remifentanil was associated with respiratory depression, emphasizing the need for experienced anesthesiologists.	[Hirsh, Irina; Shnaider, Ilia; Reuveni, Amit; Pizov, Reuven] Lady Davis Carmel Med Ctr, Dept Anesthesiol Crit Care & Pain Med, IL-34362 Haifa, Israel; [Segol, Ori] Lady Davis Carmel Med Ctr, Dept Gastroenterol, IL-34362 Haifa, Israel; [Lerner, Aaron; Pacht, Avi] Lady Davis Carmel Med Ctr, Pediat Gastroenterol & Nutr Unit, IL-34362 Haifa, Israel; Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel	Hirsh, I (reprint author), Lady Davis Carmel Med Ctr, Dept Anesthesiol Crit Care & Pain Med, 7 Michal St, IL-34362 Haifa, Israel.	hi767682@yahoo.com			Lady Davis Carmel Medical Center	The work was supported by the Lady Davis Carmel Medical Center Research Fund.	AMENT ME, 1995, GASTROINTEST ENDOSC, V41, P173, DOI 10.1016/S0016-5107(05)80607-8; Cravero JP, 2004, ANESTH ANALG, V99, P1355, DOI 10.1213/01.ANE.0000134810.60270.E8; Davis PJ, 2005, CLIN PHARMACOKINET, V44, P787, DOI 10.2165/00003088-200544080-00002; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Drover DR, 2004, ANESTHESIOLOGY, V100, P1382, DOI 10.1097/00000542-200406000-00008; Duthie DJR, 1998, BRIT J ANAESTH, V81, P51; FREYE E, 2008, OPIOIDS MED COMPREHE, P109; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Keidan I, 2001, PAEDIATR ANAESTH, V11, P297, DOI 10.1046/j.1460-9592.2001.00662.x; Khoshoo V, 2003, J PEDIATR GASTR NUTR, V37, P146, DOI 10.1097/00005176-200308000-00012; MATINEZ JL, 2002, J PEDIAT GASTROENTER, V35, P51; Montes RG, 2000, J PEDIATR GASTR NUTR, V31, P41, DOI 10.1097/00005176-200007000-00010; Paspatis GA, 2006, J PEDIATR GASTR NUTR, V43, P195, DOI 10.1097/01.mpg.0000228099.04702.39; Rama-Maceiras P, 2005, ACTA ANAESTH SCAND, V49, P305, DOI 10.1111/j.1399-6576.2005.00650.x; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Tolia V, 2000, J PEDIATR GASTR NUTR, V30, P477, DOI 10.1097/00005176-200005000-00003; Xu ZY, 2008, J CLIN ANESTH, V20, P352, DOI 10.1016/j.jclinane.2008.03.006	17	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-2116	1536-4801		J PEDIATR GASTR NUTR	J. Pediatr. Gastroenterol. Nutr.	NOV	2010	51	5					618	621		10.1097/MPG.0b013e3181ddaeb3			4	Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics	Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics	671UM	WOS:000283536900013	20808251				2020-06-30	J	Rampersad, S; Jimenez, N; Bradford, H; Seidel, K; Lynn, A				Rampersad, Sally; Jimenez, Nathalia; Bradford, Heidi; Seidel, Kristy; Lynn, Anne			Two-agent analgesia versus acetaminophen in children having bilateral myringotomies and tubes surgery	PEDIATRIC ANESTHESIA			English	Article						ear tube surgery; children; postoperative analgesia; emergence agitation; intranasal fentanyl; intramuscular ketorolac	SEVOFLURANE ANESTHESIA; EMERGENCE CHARACTERISTICS; PEDIATRIC-PATIENTS; INTRANASAL FENTANYL; HALOTHANE; PLACEMENT; KETOROLAC; INSERTION; DESFLURANE; AGITATION	P>Objectives: The objective of this study was to determine whether the incidence of emergence agitation (EA) can be reduced by adding an additional, faster onset, non-IV analgesic, intranasal fentanyl or intramuscular (im) ketorolac to rectal acetaminophen. Aim: To compare the incidence of EA after analgesia with two agents vs acetaminophen alone in pediatric patients after bilateral myringotomy procedures (BM&T). Background: Anesthesia for BM&T is usually performed with volatile anesthetics as a single agent without securing intravenous access. The anesthetic agent most commonly used is sevoflurane; however, EA has been reported in up to 67% of patients. Emergence agitation is distressing for parents, can impair the ability of nursing staff to adequately monitor the child, and can result in a child injuring him/herself if it is severe. Methods/Materials: A standardized anesthetic was used with oral midazolam premedication and sevoflurane for induction, and maintenance of anesthesia. All patients received 40 mg center dot kg-1 rectal acetaminophen, group 1 received acetaminophen alone, group 2 received acetaminophen and 1 mcg center dot kg-1 of intranasal fentanyl, and group 3 received acetaminophen and 1 mg center dot kg-1 of intramuscular ketorolac. Incidence of EA was compared using chi-square test between the acetaminophen group alone vs the two-agent analgesia groups combined. Results: There were no differences in demographic and clinical characteristics between the two groups. There were no statistically significant differences between the three groups for the incidence of EA at any time point during recovery from anesthesia nor were there any significant differences in pain scores or side effects. No significant side effects because of the administration of a second analgesic agent were reported. Conclusions: We conclude that two-agent analgesia is not superior to acetaminophen alone for decreasing the incidence of EA after inhalation anesthesia with sevoflurane for BM&T surgery. Our overall incidence of EA was low compared to previous studies, which could potentially have decreased our ability to detect differences between groups.	[Rampersad, Sally; Jimenez, Nathalia; Bradford, Heidi; Lynn, Anne] Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Rampersad, Sally; Jimenez, Nathalia; Lynn, Anne] Univ Washington, Sch Med, Seattle, WA USA; [Seidel, Kristy] Seattle Childrens Hosp, Biostat Serv, Seattle, WA USA	Rampersad, S (reprint author), W9824 Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, 4800 Sand Point Way NE, Seattle, WA 98105 USA.	sally.rampersad@seattlechildrens.org		Jimenez, Nathalia/0000-0002-6785-8330	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM086270]		Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Bajwa SA, 2010, PEDIATR ANESTH, V20, P704, DOI 10.1111/j.1460-9592.2010.03328.x; BeanLijewski JD, 1997, PAEDIATR ANAESTH, V7, P131, DOI 10.1046/j.1460-9592.1997.d01-47.x; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2001, ANESTH ANALG, V93, P88; Cravero JP, 2000, J CLIN ANESTH, V12, P397, DOI 10.1016/S0952-8180(00)00180-X; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Kol IO, 2008, CLIN THER, V30, P175, DOI 10.1016/j.clinthera.2008.01.008; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; OROBELLO PW, 1991, INT J PEDIATR OTORHI, V21, P51, DOI 10.1016/0165-5876(91)90059-K; Pappas AL, 2003, ANESTH ANALG, V96, P1621, DOI 10.1213/01.ANE.0000064206.51296.1D; RICE ASC, 1991, ANAESTHESIA, V46, P541, DOI 10.1111/j.1365-2044.1991.tb09651.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224	19	15	15	1	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2010	20	11					1028	1035		10.1111/j.1460-9592.2010.03427.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	669VL	WOS:000283378200009	20964769	Green Accepted			2020-06-30	J	Dzikiti, BT; Stegmann, FG; Dzikiti, LN; Hellebrekers, LJ				Dzikiti, Brighton T.; Stegmann, Frik G.; Dzikiti, Loveness N.; Hellebrekers, Ludo J.			Total intravenous anaesthesia (TIVA) with propofol-fentanyl and propofol-midazolam combinations in spontaneously-breathing goats	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; constant rate infusion; fentanyl; goat; midazolam; propofol	PHARMACOKINETICS; MORPHINE	Objective To compare the efficacy and cardiopulmonary effects of propofol and fentanyl, with propofol and midazolam for total intravenous anaesthesia. Study design Prospective, randomized, crossover experimental study. Animals Six goats; three does and three wethers. Methods Goats received either fentanyl 0.02 mg kg-1 (treatment FP) or midazolam 0.3 mg kg-1 (treatment MP) intravenously. One minute later anaesthesia was induced with propofol, then maintained by constant rate infusion of propofol 12.0 mg kg-1 hour-1 and fentanyl 0.02 mg kg-1 hour-1 (treatment FP) or propofol 12.0 mg kg-1 hour-1 and midazolam 0.3 mg kg-1 hour-1 (treatment MP) for 90 minutes. Response to noxious stimulus was tested every 10 minutes and propofol dose adjusted to prevent purposeful movement. Cardiopulmonary parameters were measured continuously, and arterial blood-gas analysis performed intermittently. Recovery was timed and quality scored. Results are presented as median (IQR). Results Differences in the propofol induction dose [4.00 (3.96-4.01) and 3.97 (3.91-4.00) mg kg-1 for treatments FP and MP, respectively] were not significant. Quality of induction in both groups was smooth. The median propofol dose for maintenance was less (p = 0.004) with treatment FP (12.0 mg kg-1 hour-1) than MP (18.0 mg kg-1 hour-1). Cardiopulmonary function was well maintained with both treatments. Recovery times in minutes from the end of anaesthetic infusion for treatments FP and MP respectively were; to extubation 3.0 (3.0-3.0) and 4.5 (3.3-5.0); to sternal position, 4.5 (3.3-5.0) and 5.0 (5.0-6.5) and to standing 13.0 (10.3-15.0) and 15.0 (11.3-17.3). Quality of recovery was acceptable in both groups, but abnormal behavioural signs were observed after treatment FP. Conclusions and clinical relevance Total intravenous anaesthesia with propofol and fentanyl or propofol and midazolam, at the doses studied, in spontaneously-breathing, oxygen-supplemented goats is practicable. Recovery from the fentanyl-propofol combination is not always smooth.	[Dzikiti, Brighton T.; Stegmann, Frik G.] Univ Pretoria, Compan Anim Clin Studies Dept, ZA-0110 Onderstepoort, South Africa; [Dzikiti, Loveness N.] Univ Pretoria, Sch Hlth Syst & Publ Hlth, ZA-0110 Onderstepoort, South Africa; [Hellebrekers, Ludo J.] Univ Utrecht, Sect Vet Anaesthesiol, Utrecht, Netherlands	Dzikiti, BT (reprint author), Univ Pretoria, Compan Anim Clin Studies Dept, P Bag X04, ZA-0110 Onderstepoort, South Africa.	brighton.dzikiti@up.ac.za	Dzikiti, T/N-8696-2014	Dzikiti, Tarisai Brighton/0000-0002-8050-8597; Stegmann, Frik/0000-0002-6122-4847			Bettschart-Wolfensberger R, 2000, J VET MED A, V47, P341, DOI 10.1046/j.1439-0442.2000.00289.x; Cao JL, 2002, ACTA PHARMACOL SIN, V23, P685; Carroll GL, 1999, AM J VET RES, V60, P986; Doherty TJ, 2004, VET ANAESTH ANALG, V31, P97, DOI 10.1111/j.1467-2987.2004.00156.x; Dzikiti TB, 2009, J S AFR VET ASSOC, V80, P10; Larenza MP, 2005, AM J VET RES, V66, P2135, DOI 10.2460/ajvr.2005.66.2135; Pablo LS, 1997, J AM VET MED ASSOC, V211, P86; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Stegmann G F, 2001, Vet Anaesth Analg, V28, P49, DOI 10.1046/j.1467-2987.2000.00034.x	9	13	15	0	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2010	37	6					519	525		10.1111/j.1467-2995.2010.00568.x			7	Veterinary Sciences	Veterinary Sciences	662OH	WOS:000282816900005	21072973				2020-06-30	J	Pekcan, Z; Koc, B				Pekcan, Zeynep; Koc, Bahattin			The post-operative analgesic effects of epidurally administered morphine and transdermal fentanyl patch after ovariohysterectomy in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; dog; epidural morphine; extradural morphine; fentanyl patch	ORTHOPEDIC-SURGERY; PAIN; BUPIVACAINE; SCALE; MEDETOMIDINE; COMBINATION; MANAGEMENT; ANESTHESIA; BEHAVIOR	Objective To investigate the analgesic and side effects of epidural morphine or a fentanyl patch after ovariohysterectomy in dogs. Study design Prospective, randomized clinical study. Animals Twenty female mongrel dogs undergoing ovariohysterectomy. Methods The dogs were allocated to one of two groups: epidural morphine or transdermal fentanyl patch. Anaesthesia was induced with propofol and maintained with isoflurane. Morphine (0.1 mg kg-1) was administered epidurally in the epidural morphine group and a transdermal fentanyl patch was applied 24 hours before the operation in the fentanyl patch group. The heart rate, respiratory rate, body temperature, plasma cortisol concentration, and sedation and analgesia scores were recorded during the 24 hour post-operative period. Adverse effects such as vomiting, anorexia, skin reactions, urinary retention, and time to start licking the surgical site were also recorded. p < 0.05 was considered significant. Statistical analyses utilized anova for repeated measures, Friedman tests, Mann-Whitney U-tests and independent sample t-tests as relevant. Results Pain scores were lower in the epidural group than in the fentanyl group at all post-operative times. The dogs in the epidural morphine group were calm and relaxed, whereas discomfort and vocalization were recorded in the fentanyl patch group. The sedation scores were higher in the fentanyl patch group throughout the 12 hour period. Salivation and anorexia lasted longer in the fentanyl patch group than in the epidural morphine group. Plasma cortisol concentrations were high in the early post-operative period in both groups. The fentanyl patch group had higher cortisol concentrations than the epidural morphine group. Slight erythema was recorded in two dogs when the patches were removed. Conclusion and clinical relevance Epidurally administered morphine provided better analgesia and caused fewer adverse effects than the fentanyl patch after ovariohysterectomy in dogs.	[Pekcan, Zeynep] Kirikkale Univ, Fac Vet Med, Dept Surg, TR-71451 Yahsihan, Kirikkale, Turkey; [Koc, Bahattin] Ankara Univ, Dept Surg, Fac Vet Med, TR-06100 Ankara, Turkey	Pekcan, Z (reprint author), Kirikkale Univ, Fac Vet Med, Dept Surg, TR-71451 Yahsihan, Kirikkale, Turkey.	vetzeynep@yahoo.com					Acosta AD, 2005, AM J VET RES, V66, P54, DOI 10.2460/ajvr.2005.66.54; Conzemius MG, 1997, J AM VET MED ASSOC, V210, P1619; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Fink R., 2001, PAIN MANAGEMENT ANIM, P53; Firth AM, 1999, J AM VET MED ASSOC, V214, P651; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Grisneaux E, 1999, J AM VET MED ASSOC, V215, P1105; Hendrix PK, 1996, J AM VET MED ASSOC, V209, P598; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Holton L, 2001, VET REC, V148, P525, DOI 10.1136/vr.148.17.525; Holton LL, 1998, J SMALL ANIM PRACT, V39, P469, DOI 10.1111/j.1748-5827.1998.tb03681.x; Ko JCH, 2000, J AM VET MED ASSOC, V217, P509, DOI 10.2460/javma.2000.217.509; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Lafuente MP, 2005, JAVMA-J AM VET MED A, V227, P1768, DOI 10.2460/javma.2005.227.1768; Lucas AN, 2001, J AM VET MED ASSOC, V218, P884, DOI 10.2460/javma.2001.218.884; Mathews KA, 2000, VET CLIN N AM-SMALL, V30, P729, DOI 10.1016/S0195-5616(08)70004-4; Novello L, 2006, VET SURG, V35, P191, DOI 10.1111/j.1532-950X.2006.00131.x; Pacharinsak C, 2003, J VET PHARMACOL THER, V26, P71, DOI 10.1046/j.1365-2885.2003.00452.x; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; PASCOE PJ, 1993, VET SURG, V22, P141, DOI 10.1111/j.1532-950X.1993.tb01689.x; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Schmiedt CW, 2007, VET ANAESTH ANALG, V34, P70, DOI 10.1111/j.1467-2995.2006.00302.x; Sibanda S, 2006, VET ANAESTH ANALG, V33, P246, DOI 10.1111/j.1467-2995.2005.00261.x; Thurmon JC, 1996, LUMB JONES VET ANEST, P40; Torske KE, 2000, VET CLIN N AM-SMALL, V30, P859, DOI 10.1016/S0195-5616(08)70011-1; Troncy E, 2002, J AM VET MED ASSOC, V221, P666, DOI 10.2460/javma.2002.221.666; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x	28	24	24	0	15	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2010	37	6					557	565		10.1111/j.1467-2995.2010.00571.x			9	Veterinary Sciences	Veterinary Sciences	662OH	WOS:000282816900010	21040380				2020-06-30	J	Ghitza, UE; Preston, KL; Epstein, DH; Kuwabara, H; Endres, CJ; Bencherif, B; Boyd, SJ; Copersino, ML; Frost, JJ; Gorelick, DA				Ghitza, Udi E.; Preston, Kenzie L.; Epstein, David H.; Kuwabara, Hiroto; Endres, Christopher J.; Bencherif, Badreddine; Boyd, Susan J.; Copersino, Marc L.; Frost, J. James; Gorelick, David A.			Brain Mu-Opioid Receptor Binding Predicts Treatment Outcome in Cocaine-Abusing Outpatients	BIOLOGICAL PSYCHIATRY			English	Article						Addiction; cocaine; dependence; mu-opioid receptor; positron emission tomography (PET); treatment	ADDICTION; SEEKING; REINSTATEMENT; DEPENDENCE; DENSITY; RELAPSE; USERS; PET; MEN	Background: Cocaine users not seeking treatment have increased regional brain mu-opioid receptor (mOR) binding that correlates with cocaine craving and tendency to relapse. In cocaine-abusing outpatients in treatment, the relationship of mOR binding and treatment outcome is unknown. Methods: We determined whether regional brain mOR binding before treatment correlates with outcome and compared it with standard clinical predictors of outcome. Twenty-five individuals seeking outpatient treatment for cocaine abuse or dependence (DSM-IV) received up to 12 weeks of cognitive-behavioral therapy and cocaine abstinence reinforcement, whereby each cocaine-free urine was reinforced with vouchers redeemable for goods. Regional brain mOR binding was measured before treatment using positron emission tomography with [C-11]-carfentanil (a selective mOR agonist). Main outcome measures were: 1) overall percentage of urines positive for cocaine during first month of treatment; and 2) longest duration (weeks) of abstinence from cocaine during treatment, all verified by urine toxicology. Results: Elevated mOR binding in the medial frontal and middle frontal gyri before treatment correlated with greater cocaine use during treatment. Elevated mOR binding in the anterior cingulate, medial frontal, middle frontal, middle temporal, and sublobar insular gyri correlated with shorter duration of cocaine abstinence during treatment. Regional mOR binding contributed significant predictive power for treatment outcome beyond that of standard clinical variables such as baseline drug and alcohol use. Conclusions: Elevated mOR binding in brain regions associated with reward sensitivity is a significant independent predictor of treatment outcome in cocaine-abusing outpatients, suggesting a key role for the brain endogenous opioid system in cocaine addiction.	[Ghitza, Udi E.] NIDA, Intramural Res Program, Clin Pharmacol & Therapeut Res Branch, NIH,Dept Hlth & Human Serv,Ctr Clin Trials Networ, Bethesda, MD 20892 USA; [Gorelick, David A.] NIDA, Off Sci Director, NIH, US Dept HHS, Bethesda, MD 20892 USA; [Kuwabara, Hiroto; Endres, Christopher J.; Bencherif, Badreddine; Frost, J. James] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Kuwabara, Hiroto; Endres, Christopher J.; Bencherif, Badreddine; Frost, J. James] Johns Hopkins Univ, Sch Med, Dept Radiol Sci & Neurosci, Baltimore, MD 21205 USA	Ghitza, UE (reprint author), NIDA, Intramural Res Program, Clin Pharmacol & Therapeut Res Branch, NIH,Dept Hlth & Human Serv,Ctr Clin Trials Networ, 6001 Execut Blvd,Room 3109,MSC 9557, Bethesda, MD 20892 USA.	ghitzau@nida.nih.gov	Preston, Kenzie L/J-5830-2013	Preston, Kenzie L/0000-0003-0603-2479	National Institutes of Health, National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DA-09479]	This study was supported in pail by the Intramural Research Program of the National Institutes of Health, National Institute on Drug Abuse and in part by National Institutes of Health Grant R01 DA-09479 to JIF.	Ahmadi J, 2006, AM J ADDICTION, V15, P434, DOI 10.1080/10550490600998476; ASHBURNER J, 2003, HUMAN BRAIN FUNCTION, P655; Berrendero F, 2010, NEUROSCI BIOBEHAV RE; Bossert JM, 2005, EUR J PHARMACOL, V526, P36, DOI 10.1016/j.ejphar.2005.09.030; BROWN RA, 1984, J CONSULT CLIN PSYCH, V52, P774, DOI 10.1037/0022-006X.52.5.774; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Epstein DH, 2003, PSYCHOL ADDICT BEHAV, V17, P73, DOI 10.1037/0893-164X.17.1.73; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P571, DOI 10.1037/0022-3514.50.3.571; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789; Gerrits MAFM, 2005, EUR NEUROPSYCHOPHARM, V15, P297, DOI 10.1016/j.euroneuro.2004.11.004; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Gorelick DA, 2008, PSYCHOPHARMACOLOGY, V200, P475, DOI 10.1007/s00213-008-1225-5; Guardia J, 2000, AM J PSYCHIAT, V157, P127, DOI 10.1176/ajp.157.1.127; Jayaram-Lindstrom N, 2008, AM J PSYCHIAT, V165, P1442, DOI 10.1176/appi.ajp.2008.08020304; Knapp WP, 2007, COCHRANE DB SYST REV, V3; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; MARLATT GA, 1988, J CONSULT CLIN PSYCH, V56, P715, DOI 10.1037/0022-006X.56.5.715; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; Montoya ID, 2004, CLIN PHARMACOL THER, V75, P34, DOI 10.1016/j.clpt.2003.09.004; Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926; Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009; Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761; POLINE JB, 1995, J COMPUT ASSIST TOMO, V19, P788, DOI 10.1097/00004728-199509000-00017; Poling J, 2007, AM J DRUG ALCOHOL AB, V33, P191, DOI 10.1080/00952990701199416; Reiber C, 2002, DRUG ALCOHOL DEPEN, V68, P35, DOI 10.1016/S0376-8716(02)00103-5; ROBINS LN, 1995, [No title captured]; ROUSSEEUW RJ, 1987, ROBUST REGRESSION OU; Schmahl CG, 2004, BIOL PSYCHIAT, V55, P759, DOI 10.1016/j.biopsych.2003.11.007; Simmons D, 2009, NEUROPSYCHOPHARMACOL, V34, P1946, DOI 10.1038/npp.2009.28; Tang XC, 2005, J NEUROSCI, V25, P4512, DOI 10.1523/JNEUROSCI.0685-05.2005; Unterwald EM, 2001, ANN NY ACAD SCI, V937, P74; Wong DF, 2006, NEUROPSYCHOPHARMACOL, V31, P2716, DOI 10.1038/sj.npp.1301194; Yasuno F, 2007, BIOL PSYCHIAT, V61, P1252, DOI 10.1016/j.biopsych.2006.06.028; ZACHARY RA, 1986, SHIPLEY I LIVING SCA; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	41	42	45	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	OCT 15	2010	68	8					697	703		10.1016/j.biopsych.2010.05.003			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	664XJ	WOS:000282997000004	20579973	Green Accepted			2020-06-30	J	Watabiki, T; Nagakura, Y; Wegner, K; Kakimoto, S; Tozier, NA; Malkmus, SA; Yaksh, TL				Watabiki, Tomonari; Nagakura, Yukinori; Wegner, Kirsten; Kakimoto, Shuichiro; Tozier, Nicolle A.; Malkmus, Shelle A.; Yaksh, Tony L.			Assessment of canine sensory function by using sine-wave electrical stimuli paradigm	PHYSIOLOGY & BEHAVIOR			English	Article						Transcutaneous electrical stimulation; Sine-wave; Current threshold; Dog; Fentanyl; Neurometer; Sensory function; Pharmacokinetics-pharmacodynamics; Non-invasive	CURRENT PERCEPTION THRESHOLD; QUANTITATIVE ASSESSMENT; CONSCIOUS DOGS; RAT MODEL; FIBERS; WITHDRAWAL; CLONIDINE; LIDOCAINE; FENTANYL; EFFICACY	The paradigm of sine-wave electrical stimuli has been used for sensory neurological assessment in humans. In the present study, we applied the paradigm to the dog for the quantitative assessment of sensory function. Sine-wave electrical current stimuli at frequencies of 2000, 250, and 5 Hz were delivered to bipolar electrodes attached to the skin surface of the hind paws. The stimulation intensity was gradually increased, and the minimum intensity required to elicit the lifting behavior in the stimulated paw was determined as current threshold (CT) for each of the three frequencies. Dogs consistently showed the lifting behavior at CTs without showing aversive behaviors such as vocalization and wriggling. The baseline CTs (mean +/- SEM, n = 12) were 4430 +/- 110 mu A for CT2000, 2215 +/- 173 mu A for CT250, and 2305 +/- 152 mu A for CT5. The CTs immediately increased after bolus intravenous injection of fentanyl at 10 mu g/kg, although the significant increase disappeared within 1 h. The time course for the as was parallel to that of plasma fentanyl concentration. In conclusion, the present study applied the paradigm of transcutaneous sine-wave electrical stimuli to the dog, and used the hind paw lifting as endpoint behavior. This paradigm is simple, non-invasive, useful in the assessment of sensory function, and can be adapted to investigate the pharmacokinetics/pharmacodynamics relation of drugs. Further studies are needed to give the conclusive interpretation of the endpoint behavior. (C) 2010 Elsevier Inc. All rights reserved.	[Watabiki, Tomonari; Nagakura, Yukinori; Kakimoto, Shuichiro] Astellas Pharma Inc, Drug Discovery Res, Ibaraki 3058585, Japan; [Wegner, Kirsten; Tozier, Nicolle A.; Malkmus, Shelle A.; Yaksh, Tony L.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA	Nagakura, Y (reprint author), Astellas Pharma Inc, Drug Discovery Res, 21 Miyukigaoka, Ibaraki 3058585, Japan.	yukinori.nagakura@jp.astellas.com	Yaksh, Tony/D-4119-2009	Nagakura, Yukinori/0000-0003-3264-8808			Abouassaly R, 2008, J UROLOGY, V179, P1167, DOI 10.1016/j.juro.2007.10.027; Angst MS, 2001, ANESTHESIOLOGY, V94, P63, DOI 10.1097/00000542-200101000-00014; Bergadano A, 2006, AM J VET RES, V67, P882, DOI 10.2460/ajvr.67.5.882; COVINO BG, 1980, PAIN, V9, P141, DOI DOI 10.1016/0304-3959(80)90002-0; Kiso T, 2001, J PHARMACOL EXP THER, V297, P352; Koga K, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-13; KOLTZENBURG M, 1992, PAIN, V51, P207, DOI 10.1016/0304-3959(92)90262-A; Kroin JS, 1996, ANESTH ANALG, V82, P627, DOI 10.1097/00000539-199603000-00035; KuKanich B, 2005, AM J VET RES, V66, P1616, DOI 10.2460/ajvr.2005.66.1616; LIU S, 1995, ANESTHESIOLOGY, V82, P60, DOI 10.1097/00000542-199501000-00009; Ma DQ, 1998, ANESTH ANALG, V87, P211, DOI 10.1097/00000539-199807000-00043; Matsumoto M, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-16; Matsumoto M, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-25; Nagakura Y, 2008, PAIN, V139, P569, DOI 10.1016/j.pain.2008.06.014; Nagakura Y, 2008, PAIN, V134, P293, DOI 10.1016/j.pain.2007.04.030; Oda M, 2005, J PHARMACOL EXP THER, V312, P1132, DOI 10.1124/jpet.104.076893; Oishi M, 2002, INTERNAL MED, V41, P819, DOI 10.2169/internalmedicine.41.819; Raj P P, 2001, Pain Pract, V1, P53; Sakura S, 1998, BRIT J ANAESTH, V81, P718, DOI 10.1093/bja/81.5.718; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005; Wegner K, 2008, J NEUROSCI METH, V168, P88, DOI 10.1016/j.jneumeth.2007.09.019; YAKSH TL, 1994, FUND APPL TOXICOL, V23, P319, DOI 10.1006/faat.1994.1112; Yamashita T, 2002, SPINE, V27, P1567, DOI 10.1097/00007632-200207150-00016	24	4	4	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	OCT 5	2010	101	3					327	330		10.1016/j.physbeh.2010.05.019			4	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	657CL	WOS:000282389300003	20570687				2020-06-30	J	Kushikata, T; Yoshida, H; Kudo, M; Kudo, T; Hirota, K				Kushikata, Tetsuya; Yoshida, Hitoshi; Kudo, Mihoko; Kudo, Tsuyoshi; Hirota, Kazuyoshi			Plasma orexin A increases at emergence from sevoflurane-fentanyl anesthesia in patients undergoing ophthalmologic surgery	NEUROSCIENCE LETTERS			English	Article						Sevoflurane; Orexin A; Cortisol; Catecholamine; Hypothalamic-pituitary-adrenal axis	NEUROENDOCRINE STRESS-RESPONSE; PITUITARY-ADRENAL AXIS; GENERAL-ANESTHESIA; BRAIN; RAT; NARCOLEPSY; PROPOFOL; NEURONS	Central orexinergic and noradrenergic neurons are involved in the control of sleep and wakefulness. In addition, previous reports suggest that both neurons may have an important role to play in general anesthesia. In the present study, we have determined whether general anesthesia would affect plasma orexin A (OXA) and norepinephrine concentrations. Twelve patients scheduled for elective ophthalmic surgery under general anesthesia with sevoflurane, fentanyl and vecuronium were studied. Arterial blood was collected before and 1 and 2 h after induction of anesthesia and at emergence to measure plasma OXA, cortisol, norepinephrine and epinephrine concentrations. During anesthesia the inhalational concentration of sevoflurane was changed to maintain the bispectral index between 40 and 50. Plasma OXA, cortisol, norepinephrine and epinephrine did not change during anesthesia but significantly increased after emergence compared to pre-anesthesia (from 14.8 +/- 1.7 to 21.4 +/- 1.7 pM, p < 0.01, from 26.5 +/- 5.2 to 52.8 +/- 6.0 pM, p < 0.01, from 263 +/- 46 to 513 +/- 89 pM, p < 0.01, and from 1239 +/- 120 to 1631 +/- 203 pM, p < 0.01, respectively). There were significant correlations of plasma OXA with cortisol (r = 0.334, p < 0.05) and epinephrine (r = 0.292, p < 0.05) but not with norepinephrine. In conclusion we found that plasma OXA significantly increased at emergence from sevoflurane-fentanyl anesthesia and this was probably via activation of the hypothalamic-pituitary-adrenal axis. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Kushikata, Tetsuya; Yoshida, Hitoshi; Kudo, Mihoko; Kudo, Tsuyoshi; Hirota, Kazuyoshi] Hirosaki Univ, Grad Sch Med, Dept Anesthesiol, Aomori 0368562, Japan	Hirota, K (reprint author), Hirosaki Univ, Grad Sch Med, Dept Anesthesiol, 5 Zaifu Cho, Aomori 0368562, Japan.	hirotak@cc.hirosaki-u.ac.jp	Hirota, Kazuyoshi/S-3292-2019		Ministry of Education, Science and Culture in JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17390423]	This study was funded by grant-in-aid for scientific research (No. 17390423) from the Ministry of Education, Science and Culture in Japan.	Dong HL, 2009, NEUROPEPTIDES, V43, P179, DOI 10.1016/j.npep.2009.04.006; He Y, 2007, ANESTH ANALG, V104, P338, DOI 10.1213/01.ane.0000252413.62821.2e; Higuchi S, 2002, NEUROSCI LETT, V318, P61, DOI 10.1016/S0304-3940(01)02476-4; Hirota K, 2001, BRIT J ANAESTH, V87, P811, DOI 10.1093/bja/87.6.811; Ihn CH, 2009, J INT MED RES, V37, P1760, DOI 10.1177/147323000903700612; Kastin AJ, 1999, J PHARMACOL EXP THER, V289, P219; Kelz MB, 2008, P NATL ACAD SCI USA, V105, P1309, DOI 10.1073/pnas.0707146105; Kirchgessner AL, 2002, ENDOCR REV, V23, P1, DOI 10.1210/er.23.1.1; Kuru M, 2000, NEUROREPORT, V11, P1977, DOI 10.1097/00001756-200006260-00034; Kushikata T, 2003, NEUROSCIENCE, V121, P855, DOI 10.1016/S0306-4522(03)00554-2; Kushikata T, 2010, BRIT J ANAESTH, V104, P723, DOI 10.1093/bja/aeq098; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Marana E, 2008, ACTA ANAESTH SCAND, V52, P541, DOI 10.1111/j.1399-6576.2008.01589.x; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Ouedraogo R, 2003, DIABETES, V52, P111, DOI 10.2337/diabetes.52.1.111; RUDD BT, 1963, J ENDOCRINOL, V27, P317, DOI 10.1677/joe.0.0270317; Russell SH, 2001, J NEUROENDOCRINOL, V13, P561, DOI 10.1046/j.1365-2826.2001.00672.x; Sakurai S, 2005, CHEST, V127, P731, DOI 10.1378/chest.127.3.731; Spinazzi R, 2006, PHARMACOL REV, V58, P46, DOI 10.1124/pr.58.1.4; Taheri S, 1999, FEBS LETT, V457, P157, DOI 10.1016/S0014-5793(99)01030-3; Tose R, 2009, ANESTH ANALG, V108, P491, DOI 10.1213/ane.0b013e31819000c8; Winsky-Sommerer R, 2004, J NEUROSCI, V24, P11439, DOI 10.1523/JNEUROSCI.3459-04.2004	22	8	9	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 4	2010	482	3					212	215		10.1016/j.neulet.2010.07.037			4	Neurosciences	Neurosciences & Neurology	652WG	WOS:000282041000007	20655366				2020-06-30	J	Shear, ML; Adler, JN; Shewakramani, S; Ilgen, J; Soremekun, OA; Nelson, S; Thomas, SH				Shear, Melissa L.; Adler, Jonathan N.; Shewakramani, Sanjay; Ilgen, Jon; Soremekun, Olanrewaju A.; Nelson, Sara; Thomas, Stephen H.			Transbuccal fentanyl for rapid relief of orthopedic pain in the ED	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							DOSE PROPORTIONALITY; HEALTHY-VOLUNTEERS; LACERATION REPAIR; BUCCAL TABLETS; DOUBLE-BLIND; ANALGESIA; EMERGENCY; TRAUMA; FRACTURES; CHILDREN	Objectives: This study's objectives were to assess administration of a rapidly dissolving transbuccal fentanyl tablet to patients in emergency department (ED) with orthopedic extremity pain. The main end point was time required to achieve a 2-point drop on a 0 to 10 pain scale. Methods: In this double-blind trial, subjects received either transbuccal fentanyl, 100 mu g, and a swallowed placebo, or a swallowed oxycodone/acetaminophen, 5/325-mg pill, and a nonanalgesic transbuccal comparator. Pain assessment occurred every 5 minutes for an hour, and vital signs were monitored for 2 hours. Results: Transbuccal fentanyl was associated with faster pain relief onset (median, 10 vs 35 minutes; P < .0001). Secondary end points (pain relief magnitude, rescue medication rate, subject preference for medication on future visit) favored transbuccal fentanyl. No vital sign abnormalities or significant side effects occurred in the ED or on 100% next-day follow-up. Conclusions: Transbuccal fentanyl shows promise for continued investigation as a means to safely provide rapid and effective pain relief for ED patients. (C) 2010 Elsevier Inc. All rights reserved.	[Thomas, Stephen H.] Univ Oklahoma, Sch Community Med, OU Schusterman Ctr, Dept Emergency Med, Tulsa, OK 74135 USA; [Shear, Melissa L.; Adler, Jonathan N.; Shewakramani, Sanjay; Ilgen, Jon; Soremekun, Olanrewaju A.; Nelson, Sara] Massachusetts Gen Hosp, Emergency Serv, Boston, MA 02114 USA; [Shear, Melissa L.; Adler, Jonathan N.; Shewakramani, Sanjay; Ilgen, Jon; Soremekun, Olanrewaju A.; Nelson, Sara] Harvard Univ, Sch Med, Boston, MA 02114 USA	Thomas, SH (reprint author), Univ Oklahoma, Sch Community Med, OU Schusterman Ctr, Dept Emergency Med, Tulsa, OK 74135 USA.	stephen-thomas@ouhsc.edu			Harvard Medical School Division of Emergency Medicine	Unrestricted grant from the Harvard Medical School Division of Emergency Medicine.	Abbuhl Frederick B, 2003, Prehosp Emerg Care, V7, P445; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P77, DOI 10.1046/j.1442-2026.2002.00288.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; Chang AK, 2006, ANN EMERG MED, V48, P164, DOI 10.1016/j.annemergmed.2006.03.005; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P635, DOI 10.1016/S0196-0644(89)80517-7; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; FRIEDLAND LR, 1994, ANN EMERG MED, V23, P203, DOI 10.1016/S0196-0644(94)70031-1; Fulda Gerard J, 2005, J Trauma, V59, P383, DOI 10.1097/01.ta.0000179452.70520.1b; Fullerton-Gleason Lynne, 2002, Prehosp Emerg Care, V6, P411, DOI 10.1080/10903120290938049; GAMIS AS, 1989, ANN EMERG MED, V18, P177, DOI 10.1016/S0196-0644(89)80110-6; Gammaitoni AR, 2003, J CLIN PHARMACOL, V43, P296, DOI 10.1177/0091270003251147; Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301-620X.82B5.9899; Grant PS, 2006, AM J EMERG MED, V24, P806, DOI 10.1016/j.ajem.2006.05.004; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; Kober A, 2002, ANESTH ANALG, V95, P723, DOI 10.1097/00000539-200209000-00035; KRAUSS W, 2007, PREHOSP EMERG CARE, V11, P133; Kurtz T, 2006, PREHOSP EMERG CARE, V10, P140; Lee C, 2005, EMERG MED J, V22, P660, DOI 10.1136/emj.2005.024489; Manning BJ, 2004, INJURY, V35, P121, DOI 10.1016/S0020-1383(03)00073-1; Marco CA, 2005, ACAD EMERG MED, V12, P282, DOI 10.1197/j.aem.2004.12.005; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; McLean Samuel A, 2004, Prehosp Emerg Care, V8, P155, DOI 10.1016/j.prehos.2003.12.006; PIANTADOSI S, 1997, CLIN TRIALS METHODOL; Pointer James E, 2005, Prehosp Emerg Care, V9, P377, DOI 10.1080/10903120500253805; Safdar B, 2006, ANN EMERG MED, V48, P173, DOI 10.1016/j.annemergmed.2006.03.013; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; Schutzman SA, 1996, ANN EMERG MED, V28, P385, DOI 10.1016/S0196-0644(96)70001-X; SELBST SM, 1992, DRUG SAFETY, V7, P8, DOI 10.2165/00002018-199207010-00003; Sobel RM, 2002, AM J EMERG MED, V20, P126, DOI 10.1053/ajem.2002.31143; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; THOMAS SH, 1996, AIR MED J, V15, P57; Vassiliadis John, 2002, Emerg Med (Fremantle), V14, P261, DOI 10.1046/j.1442-2026.2002.00341.x; Vergnion M, 2001, ANESTH ANALG, V92, P1543; Webster LR, 2006, EXPERT OPIN INV DRUG, V15, P1469, DOI 10.1517/13543784.15.11.1469; White L J, 2000, Prehosp Emerg Care, V4, P205, DOI 10.1080/10903120090941209; ZIMMER GD, EMERGENCY MED COMPRE, pCH36	43	6	6	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	OCT	2010	28	8					847	852		10.1016/j.ajem.2009.04.011			6	Emergency Medicine	Emergency Medicine	660TV	WOS:000282669300001	20887903				2020-06-30	J	Ahern, BJ; Soma, LR; Rudy, JA; Uboh, CE; Schaer, TP				Ahern, Benjamin J.; Soma, Lawrence R.; Rudy, Jeffrey A.; Uboh, Cornelius E.; Schaer, Thomas P.			Pharmacokinetics of fentanyl administered transdermally and intravenously in sheep	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							SPECTROMETRIC SCREENING METHOD; MASS-SPECTROMETRY; HUMAN PLASMA; HORSES; SYSTEM; SUFENTANIL; CATS; FORMULATION; ONYCHECTOMY; ALFENTANIL	Objective-To investigate the pharmacokinetics of fentanyl administered transdermally and IV in sheep. Animals-21 adult female sheep. Procedures-Fentanyl was administered IV to 6 healthy sheep. Transdermal fentanyl patches (TFPs) were applied to 15 sheep 12 hours prior to general anesthesia and surgery. Serial blood samples were collected for 18 hours after IV injection and 84 hours after TFP application. Fentanyl concentrations were quantified via liquid chromatography mass spectrometry, and pharmacokinetic values were estimated. Results-All sheep completed the study without complications. Following a dose of 2.5 mu g/kg administered IV, the p half-life was 3.08 hours (range, 2.20 to 3.36 hours), volume of distribution at steady state was 8.86 L/kg (range, 5.55 to 15.04 L/kg), and systemic clearance was 3.62 L/kg/h (range, 2.51 to 5.39 L/kg/h). The TFPs were applied at a mean dose of 2.05 mu g/kg/h. Time to maximum plasma concentration and maximal concentration were 12 hours (range, 4 to 24 hours) and 1.30 ng/mL (range, 0.62 to 2.73 ng/mL), respectively. Fentanyl concentrations were maintained at > 0.5 ng/mL for 40 hours after TFP application. Conclusions and Clinical Relevance-IV administration of fentanyl resulted in a short half-life. Application of a TFP resulted in stable blood fentanyl concentrations in sheep. (Am J Vet Res 2010;71:1127-1132)	[Ahern, Benjamin J.; Schaer, Thomas P.] Univ Penn, Comparat Orthopaed Res Lab, Kennett Sq, PA 19348 USA; [Soma, Lawrence R.; Uboh, Cornelius E.; Schaer, Thomas P.] Univ Penn, Dept Clin Studies, New Bolton Ctr, Sch Vet Med, Kennett Sq, PA 19348 USA; [Rudy, Jeffrey A.; Uboh, Cornelius E.] W Chester Univ, Penn Equine Toxicol & Res Ctr, W Chester, PA 19382 USA	Schaer, TP (reprint author), Univ Penn, Comparat Orthopaed Res Lab, Kennett Sq, Kennett Sq, PA 19348 USA.	tpschaer@vet.upenn.edu	Schaer, Thomas/F-4519-2010; Ahern, Benjamin J/M-1193-2015; Ahern, Benjamin/J-2602-2016	Schaer, Thomas/0000-0002-4340-8212; Ahern, Benjamin J/0000-0001-5527-8964; Ahern, Benjamin/0000-0001-5527-8964			Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; BAGGOT JD, 1977, PRINCIPLES DRUG DISP, P170; BERMAN M, 1956, J APPL PHYS, V27, P1361, DOI 10.1063/1.1722264; BOSTON RC, 1981, COMPUT PROG BIOMED, V13, P111, DOI 10.1016/0010-468X(81)90089-1; Carroll GL, 1999, AM J VET RES, V60, P986; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; GABRIELSSON J, 2000, PHARMACOKINETIC PHAR, P81; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Grubb TL, 2005, AM J VET RES, V66, P907, DOI 10.2460/ajvr.2005.66.907; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; *INT ORG STAND, 1999, 17025 ISOIEC CASC CO; KYLES A, 1998, COMPEND CONTIN ED PR, P721; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Posner LP, 2007, VET ANAESTH ANALG, V34, P40, DOI 10.1111/j.1467-2995.2006.00287.x; Romans CW, 2005, JAVMA-J AM VET MED A, V227, P89, DOI 10.2460/javma.2005.227.89; Shafford HL, 2004, VET ANAESTH ANALG, V31, P20, DOI 10.1111/j.1467-2995.2004.00126.x; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Stefanovski D, 2003, METABOLISM, V52, P1153, DOI 10.1016/S0026-0495(03)00144-6; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Van Nimmen NFJ, 2004, J CHROMATOGR A, V1035, P249, DOI 10.1016/j.chroma.2004.02.074; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Wastney M. E., 1999, INVESTIGATING BIOL S, P129; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12	32	22	22	0	14	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	OCT	2010	71	10					1127	1132		10.2460/ajvr.71.10.1127			6	Veterinary Sciences	Veterinary Sciences	657IW	WOS:000282407400003	20919897				2020-06-30	J	Patel, A; Davidson, M; Tran, MCJ; Quraishi, H; Schoenberg, C; Sant, M; Lin, A; Sun, XR				Patel, Anuradha; Davidson, Melissa; Tran, Minh C. J.; Quraishi, Huma; Schoenberg, Catherine; Sant, Manasee; Lin, Albert; Sun, Xiuru			Dexmedetomidine Infusion for Analgesia and Prevention of Emergence Agitation in Children with Obstructive Sleep Apnea Syndrome Undergoing Tonsillectomy and Adenoidectomy	ANESTHESIA AND ANALGESIA			English	Article							DOSE DEXMEDETOMIDINE; REDUCES AGITATION; ADENOTONSILLECTOMY; SEVOFLURANE; ANESTHESIA; DELIRIUM; METAANALYSIS; MORPHINE; PAIN	BACKGROUND: Dexmedetomidine, a specific alpha(2) agonist, has an analgesic-sparing effect and reduces emergence agitation. We compared an intraoperative dexmedetomidine infusion with bolus fentanyl to reduce perioperative opioid use and decrease emergence agitation in children with obstructive sleep apnea syndrome undergoing adenotonsillectomy (T&A). METHODS: One hundred twenty-two patients with obstructive sleep apnea syndrome undergoing T&A, ages 2 to 10 years, completed this prospective, randomized, U. S. Food and Drug Administration-approved study. After mask induction with sevoflurane, group D received IV dexmedetomidine 2 mu g . kg(-1) over 10 minutes, followed by 0.7 mu g . kg(-1) . h(-1), and group F received IV fentanyl bolus 1 mu g . kg(-1). Anesthesia was maintained with sevoflurane, oxygen, and nitrous oxide. Fentanyl 0.5 to 1 mu g . kg(-1) was given to subjects in both groups for an increase in heart rate or systolic blood pressure 30% above preincision values that continued for 5 minutes. Observers in the postanesthesia care unit (PACU) were blinded to treatment groups. Pain was evaluated using the objective pain score in the PACU on arrival, at 5 minutes, at 15 minutes, then every 15 minutes for 120 minutes. Emergence agitation was evaluated at the same intervals by 2 scales: the Pediatric Anesthesia Emergence Delirium scale and a 5-point scale described by Cole. Morphine (0.05 to 0.1 mg . kg(-1)) was given for pain (score >4) or severe agitation (score 4 or 5) lasting more than 5 minutes. RESULTS: In group D, 9.8% patients needed intraoperative rescue fentanyl in comparison with 36% in group F (P = 0.001). Mean systolic blood pressure and heart rate were significantly lower in group D (P < 0.05). Minimum alveolar concentration values were significantly different between the 2 groups (P = 0.015). The median objective pain score was 3 for group D and 5 for group F (P = 0.001). In group D, 10 (16.3%) patients required rescue morphine, in comparison with 29 (47.5%) in group F (P = 0.002). The frequency of severe emergence agitation on arrival in the PACU was 18% in group D and 45.9% in group F (P = 0.004); at 5 minutes and at 15 minutes, it was lower in group D (P = 0.028). The duration of agitation on the Cole scale was statistically lower in group D (P = 0.004). In group D, 18% of patients and 40.9% in group F had an episode of SPO2 below 95% (P = 0.01). CONCLUSIONS: An intraoperative infusion of dexmedetomidine combined with inhalation anesthetics provided satisfactory intraoperative conditions for T&A without adverse hemodynamic effects. Postoperative opioid requirements were significantly reduced, and the incidence and duration of severe emergence agitation was lower with fewer patients having desaturation episodes. (Anesth Analg 2010;111:1004-10)	[Patel, Anuradha; Davidson, Melissa; Tran, Minh C. J.; Schoenberg, Catherine; Sant, Manasee; Lin, Albert; Sun, Xiuru] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Anesthesiol & Perioperat Med, Newark, NJ 07101 USA; [Quraishi, Huma] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Otolaryngol, Newark, NJ 07101 USA	Patel, A (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Anesthesiol & Perioperat Med, Med Sci Bldg,E-581,185 S Orange Ave, Newark, NJ 07101 USA.	patelan@umdnj.edu			Hospira Worldwide, Lake Forest, Illinois	Financial support was provided by an Institutional Cost of Drug support grant from Hospira Worldwide, Lake Forest, Illinois.	Afman CE, 2006, OTOLARYNG HEAD NECK, V134, P181, DOI 10.1016/j.otohns.2005.11.010; Brown KA, 2001, PAEDIATR ANAESTH, V11, P385, DOI 10.1046/j.1460-9592.2001.00719.x; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Dawson C, 2004, ANESTHESIOLOGY, V100, P894, DOI 10.1097/00000542-200404000-00020; Deutsch E, 2007, PEDIATR ANESTH, V17, P438, DOI 10.1111/j.1460-9592.2006.02139.x; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Erhan OL, 2007, INT J PEDIATR OTORHI, V71, P735, DOI 10.1016/j.ijporl.2007.01.008; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Hullett BJ, 2006, PEDIATR ANESTH, V16, P648, DOI 10.1111/j.1460-9592.2005.01827.x; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Marret E, 2003, ANESTHESIOLOGY, V98, P1497; Mason KP, 2008, PEDIATR ANESTH, V18, P403, DOI 10.1111/j.1460-9592.2008.02468.x; MCCOLLEY SA, 1992, ARCH OTOLARYNGOL, V118, P940; Petroz GC, 2006, ANESTHESIOLOGY, V105, P1098, DOI 10.1097/00000542-200612000-00009; Sanders JC, 2006, ANESTH ANALG, V103, P1115, DOI 10.1213/01.ane.0000244318.77377.67; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61	26	107	126	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2010	111	4					1004	1010		10.1213/ANE.0b013e3181ee82fa			7	Anesthesiology	Anesthesiology	656EY	WOS:000282310200030	20705788				2020-06-30	J	Kuczkowski, KM; Fernandez, CL				Kuczkowski, Krzysztof M.; Fernandez, Claudia L.			Labor analgesia for the morbidly obese woman involved in a minor motor vehicle accident and unaware of pregnancy until full term and labor	ARCHIVES OF GYNECOLOGY AND OBSTETRICS			English	Letter									[Kuczkowski, Krzysztof M.] Univ Med Ctr El Paso, Dept Anesthesiol, El Paso, TX USA; [Kuczkowski, Krzysztof M.] Univ Med Ctr El Paso, Dept Obstet & Gynecol, El Paso, TX USA; [Fernandez, Claudia L.] Juan A Fernandez Hosp, Dept Anesthesiol, Buenos Aires, DF, Argentina	Kuczkowski, KM (reprint author), Univ Med Ctr El Paso, Dept Anesthesiol, 4800 Alberta Ave, El Paso, TX USA.	kmkuczkowski@gmail.com					Farah N, 2009, OBESITY FACTS, V2, P352, DOI 10.1159/000261951; Kuczkowski KM, 2005, ACTA ANAESTH BELG, V56, P13; Roofthooft E, 2009, CURR OPIN ANESTHESIO, V22, P341, DOI 10.1097/ACO.0b013e328329a5b8	3	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-0067			ARCH GYNECOL OBSTET	Arch. Gynecol. Obstet.	OCT	2010	282	4					463	464		10.1007/s00404-010-1445-x			2	Obstetrics & Gynecology	Obstetrics & Gynecology	652AL	WOS:000281972100020	20339858				2020-06-30	J	Hong, JY; Han, SW; Kim, WO; Kim, EJ; Kil, HK				Hong, J. -Y.; Han, S. W.; Kim, W. O.; Kim, E. J.; Kil, H. K.			Effect of dexamethasone in combination with caudal analgesia on postoperative pain control in day-case paediatric orchiopexy	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia; caudal; anaesthesia recovery period; analgesia; postoperative; dexamethasone; surgery; day case; surgery; urological; paediatric; orchiopexy	LOCAL-ANESTHETICS; CHILDREN; TONSILLECTOMY; BLOCK; BUPIVACAINE; SURGERY	Dexamethasone has a powerful anti-inflammatory action and has demonstrated reduced morbidity after surgery. The aim of this study was to examine the effects of a single i.v. dose of dexamethasone in combination with caudal block on postoperative analgesia in children. Seventy-seven children (aged 1-5 yr) undergoing day-case orchiopexy were included in this prospective, randomized, double-blinded study at a single university hospital. After inhalation induction of general anaesthesia, children received either dexamethasone 0.5 mg kg(-1) (maximum 10 mg) (n=39) or the same volume of saline (n=38) i.v. A caudal anaesthetic block was then performed using 1.5 ml kg(-1) of ropivacaine 0.15% in all patients. After surgery, rescue analgesic consumption, pain scores, and adverse effects were evaluated for 24 h. Significantly, fewer patients in the dexamethasone group required fentanyl for rescue analgesia (7.9% vs 38.5%) in the post-anaesthetic care unit or acetaminophen (23.7% vs 64.1%) after discharge compared with the control group. The time to first administration of oral acetaminophen was significantly longer in the dexamethasone group (646 vs 430 min). Postoperative pain scores were lower in the dexamethasone group and the incidence of adverse effects was similar in both groups. Intravenous dexamethasone 0.5 mg kg(-1) in combination with a caudal block augmented the intensity and duration of postoperative analgesia without adverse effects in children undergoing day-case paediatric orchiopexy. Trial registration: ClinicalTrials.gov. The number of registration: NCT01041378.	[Hong, J. -Y.; Kim, W. O.; Kim, E. J.; Kil, H. K.] Yonsei Univ, Coll Med, Severance Hosp, Dept Anesthesiol & Pain Med,Anesthesia & Pain Res, Seoul 120752, South Korea; [Han, S. W.] Yonsei Univ, Coll Med, Severance Hosp, Dept Urol,Urol Sci Inst, Seoul 120752, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Severance Hosp, Dept Anesthesiol & Pain Med,Anesthesia & Pain Res, 250 Seongsanno, Seoul 120752, South Korea.	jenyhongg@hanmail.net; hkkil@yuhs.ac		Han, Sang Won/0000-0003-0941-1300			Agrawal D, 2004, ANN EMERG MED, V43, P247, DOI 10.1016/S0196-0644(03)00721-2; Ansermino M, 2003, PAEDIATR ANAESTH, V13, P561, DOI 10.1046/j.1460-9592.2003.01048.x; Beyer J E, 1990, J Pain Symptom Manage, V5, P350, DOI 10.1016/0885-3924(90)90029-J; Bisgaard T, 2003, ANN SURG, V238, P651, DOI 10.1097/01.sla.0000094390.82352.cb; BROMAGE PR, 1975, BRIT J ANAESTH, V47, P199; Constant I, 1998, BRIT J ANAESTH, V80, P294; Crellin D, 2007, PEDIATR ANESTH, V17, P720, DOI 10.1111/j.1460-9592.2007.02218.x; DiTomasso R A, 1991, Fam Med, V23, P127; Ferreira SH, 1997, BRIT J PHARMACOL, V121, P883, DOI 10.1038/sj.bjp.0701211; Giannoni C, 2002, OTOLARYNG HEAD NECK, V126, P307, DOI 10.1067/mhn.2002.122700; Hanasono MM, 2004, ARCH OTOLARYNGOL, V130, P917, DOI 10.1001/archotol.130.8.917; HARGREAVES KM, 1990, CLIN PHARMACOL THER, V48, P168, DOI 10.1038/clpt.1990.132; Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6; HONG D, 1993, PAIN, V55, P171, DOI 10.1016/0304-3959(93)90146-G; Hong JY, 2009, ANESTH ANALG, V109, P1073, DOI 10.1213/ane.0b013e3181b20c52; Kjetil H, 2007, ANESTH ANALG, V105, P481, DOI 10.1213/01.ane.0000267261.61444.69; Mohamed SK, 2009, EUR ARCH OTO-RHINO-L, V266, P1815, DOI 10.1007/s00405-009-0937-4; Park JH, 2006, ANAESTHESIA, V61, P946, DOI 10.1111/j.1365-2044.2006.04795.x; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Semple D, 1996, ANAESTHESIA, V51, P1170, DOI 10.1111/j.1365-2044.1996.tb15063.x; SHIMMER BP, 1996, GOODMAN GILMANS PHAR, P1459; Silvani P, 2006, MINERVA ANESTESIOL, V72, P453; SKJELBRED P, 1982, EUR J CLIN PHARMACOL, V23, P141, DOI 10.1007/BF00545968; TARBELL SE, 1992, PAIN, V50, P273, DOI 10.1016/0304-3959(92)90031-6; Vosdoganis F, 1999, ANAESTH INTENS CARE, V27, P489, DOI 10.1177/0310057X9902700509; Willis Martha H W, 2003, Pediatr Nurs, V29, P195; WOLF AR, 1990, BRIT J ANAESTH, V64, P430, DOI 10.1093/bja/64.4.430; Wolf AR, 1999, BRIT J ANAESTH, V82, P319, DOI 10.1093/bja/82.3.319	28	34	37	1	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	OCT	2010	105	4					506	510		10.1093/bja/aeq187			5	Anesthesiology	Anesthesiology	651TR	WOS:000281950500017	20659915	Bronze			2020-06-30	J	Palmer, RB				Palmer, Robert B.			Fentanyl in postmortem forensic toxicology	CLINICAL TOXICOLOGY			English	Review						Postmortem; Opioid; Transdermal; Postmortem redistribution (PMR); Necrokinetic; Forensic toxicology; Overdose; Poisoning	DELAYED RESPIRATORY DEPRESSION; TRANSDERMAL FENTANYL; DRUG REDISTRIBUTION; INTRAVENOUS MISUSE; PHARMACOKINETICS; BLOOD; ABUSE; PATCHES; METABOLISM; DEATH	Context. Fentanyl is a powerful opioid used for the induction of anesthesia as well as for the management of severe pain. In recent years, transdermal fentanyl "patches" have become popular for outpatient management of chronic pain. The high potency and outpatient availability of fentanyl has also made it a highly sought-after drug of abuse. Deaths in which fentanyl is detected challenge medical examiners who must decide whether a given case represents therapeutic administration or overdose. Objectives. The current review seeks to present data about fentanyl that are relevant to the interpretation of postmortem blood and tissue fentanyl concentrations as well as to highlight areas which can be helpful or misleading in the evaluation of deaths potentially related to fentanyl exposure. Methods. Standard searching of the PubMed database for studies, case series, and case reports involving fentanyl kinetics, chemistry, and postmortem behavior was performed. Search terms typically included "postmortem" and "fentanyl," as well as "kinetics" and "analysis," where appropriate. Additional references were located as citations from reviewed papers or as conference abstracts. Results and Conclusions. The postmortem behavior of fentanyl is influenced heavily by pH changes and the antemortem kinetic behavior of the drug, especially, by its distribution. Postmortem blood fentanyl concentrations do not correlate directly with antemortem blood concentrations. Without adequate evaluation of kinetic data, investigative information and consideration of postmortem changes, misinterpretation of postmortem fentanyl results is likely.</.	[Palmer, Robert B.] PLLC, Toxicol Associates, Denver, CO 80210 USA; [Palmer, Robert B.] Univ Colorado, Sch Med, Denver, CO USA; [Palmer, Robert B.] Rocky Mt Poison & Drug Ctr, Med Toxicol Serv, Denver, CO USA	Palmer, RB (reprint author), PLLC, Toxicol Associates, 2555 S Downing, Denver, CO 80210 USA.	rpalmer@toxicologyassoc.com					ADAMS AP, 1978, BRIT MED J, V1, P278, DOI 10.1136/bmj.1.6108.278; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 2009, Med Lett Drugs Ther, V51, P64; Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Barrueto F, 2004, VET HUM TOXICOL, V46, P30; BASELT RC, 2008, METHADONE DISPOSITIO, P941; BASELT RC, 2008, FENTANYL DISPOSITION, P616; Biedrzycki OJ, 2009, AM J FOREN MED PATH, V30, P188, DOI 10.1097/PAF.0b013e318187de71; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Caplehorn JRM, 2002, DRUG ALCOHOL REV, V21, P329, DOI 10.1080/0959523021000023171; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; CASPI J, 1988, CRIT CARE MED, V16, P238, DOI 10.1097/00003246-198803000-00006; CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; CHEN NBW, 1999, AM AC FOR SCI AAFS A; CHRISTIAN CM, 1983, ANESTHESIOLOGY, V58, P275, DOI 10.1097/00000542-198303000-00015; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Dalpe-Scott M, 1995, CAN SOC FORENSIC SCI, V28, P113; DUARTE LD, 2009, EUR J CLIN PHARM; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Feierman DE, 2000, ACTA ANAESTH SCAND, V44, P560, DOI 10.1034/j.1399-6576.2000.00513.x; Felgate HE., 1988, B INT ASS FOR TOX, V19, P32; Ferner RE, 2008, BRIT J CLIN PHARMACO, V66, P430, DOI 10.1111/j.1365-2125.2008.03231.x; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; Gerostamoulos J, 2000, J FORENSIC SCI, V45, P843; Glidewell RN, 2009, J CLIN SLEEP MED, V5, P63; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GROBOSCH T, 2007, TOXICHEM KRIMTECH, V74, P59; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; HABERER JP, 1982, BRIT J ANAESTH, V54, P1267, DOI 10.1093/bja/54.12.1267; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; Hargrove VM, 2008, J ANAL TOXICOL, V32, P621, DOI 10.1093/jat/32.8.621; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Hilberg T, 1999, J FORENSIC SCI, V44, P3; Hilberg T, 1999, J FORENSIC SCI, V44, P956; HILBERG T, 1992, INT J LEGAL MED, V105, P87, DOI 10.1007/BF02340830; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; *JANSS PHARM PROD, 2007, FENT TRANSD SYST FUL, P1; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Jones G, 2008, POSTMORTEM TOXICOLOG, P113; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kaferstein H, 2000, FORENSIC SCI INT, V113, P353, DOI 10.1016/S0379-0738(00)00224-3; KEMP PM, 2001, SW ASS TOX SAT ANN M; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; KLAUSNER JM, 1988, ARCH SURG-CHICAGO, V123, P66; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lafreniere NM, 2009, FORENSIC SCI INT, V185, P100, DOI 10.1016/j.forsciint.2008.12.019; Langford AM, 1997, J FORENSIC SCI, V42, P88; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; LEVINE B, 1989, SOC FOR TOX SOFT ANN; LEVINE B, 1987, AM AC FOR SCI AAFS A; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Menahem S, 2004, J AM BOARD FAM PRACT, V17, P388, DOI 10.3122/jabfm.17.5.388; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Milroy CM, 2000, J CLIN PATHOL, V53, P277, DOI 10.1136/jcp.53.4.277; Moore C, 2008, FORENSIC SCI INT, V176, P47, DOI 10.1016/j.forsciint.2007.06.027; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; *MYL PHARM I, 2008, FENT TRANSD SYST FUL, P1; *MYL PHARM INC, 2005, FENT TRANSD SYST FUL, P1; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Oda Y, 1999, BRIT J ANAESTH, V82, P900; Oechsler Stephanie, 2009, Archiv fuer Kriminologie, V224, P26; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; PRODDUTURI S, 2006, FDA SCI FOR, V1; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; SAWYER WR, 1988, J FORENSIC SCI, V33, P1439; SCHNEIDER E, 1985, N-S ARCH PHARMACOL, V331, P359, DOI 10.1007/BF00500820; Schneir AB, 2001, CLIN TOXICOL, V39, P487; SEBEL PS, 1987, EUR J CLIN PHARMACOL, V32, P529, DOI 10.1007/BF00637682; SHEPHERD MF, 1992, ANN PHARMACOTHER, V26, P510, DOI 10.1177/106002809202600412; Skopp G, 1997, J FORENSIC SCI, V42, P486; *SOFT, 2006, SOFT AAFS FOR TOX LA, P1; SOUTHWELL D, 1984, INT J PHARM, V18, P299, DOI 10.1016/0378-5173(84)90145-5; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thomasy SM, 2008, J ANAL TOXICOL, V32, P754, DOI 10.1093/jat/32.9.754; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Turock MK, 2009, AM J EMERG MED, V27, P237, DOI 10.1016/j.ajem.2008.09.043; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Waters CM, 1999, J PHARMACOL EXP THER, V288, P157; WATTS VW, 1990, J ANAL TOXICOL, V14, P266, DOI 10.1093/jat/14.5.266; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Wiesbrock Urs O., 2008, Archiv fuer Kriminologie, V222, P23; Winek CL, 2001, FORENSIC SCI INT, V122, P107, DOI 10.1016/S0379-0738(01)00483-2; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x	116	24	24	0	39	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	OCT	2010	48	8					771	784		10.3109/15563650.2010.525514			14	Toxicology	Toxicology	670PV	WOS:000283440700001	20969499				2020-06-30	J	Panni, MK; George, RB; Allen, TK; Olufolabi, AJ; Schultz, JR; Okumura, M; Columb, MO; Habib, AS				Panni, M. K.; George, R. B.; Allen, T. K.; Olufolabi, A. J.; Schultz, J. R.; Okumura, M.; Columb, M. O.; Habib, A. S.			Minimum effective dose of spinal ropivacaine with and without fentanyl for postpartum tubal ligation	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						MLAD; Postpartum tubal ligation; Ropivacaine; Fentanyl	INTRATHECAL BUPIVACAINE; RELATIVE POTENCIES; CERVICAL CERCLAGE; MOTOR BLOCK; ANESTHESIA; LABOR; ANALGESIA; LIDOCAINE	Background: Ropivacaine may be the ideal spinal anesthetic for postpartum tubal ligation due to its medium duration of action, low incidence of side effects and possibly reduced post-anesthetic care unit (PACU) stay. Methods: Two prospective up-down sequential allocation studies were performed using hyperbaric spinal ropivacaine via a combined spinal-epidural anesthetic technique for patients undergoing postpartum tubal ligation. The first study was performed using an initial dose of 12.5 mg hyperbaric ropivacaine, which was adjusted in testing intervals of 0.5 mg. The second study used an initial dose of 16 mg hyperbaric ropivacaine, a testing interval of 1.0 mg, and a fixed dose of fentanyl 10 mu g. The need to supplement the block with intravenous or epidural agents was defined as a failure. Failures were treated with epidural lidocaine. Results: The first and second studies recruited 24 and 17 patients, respectively. The median effective dose (ED50) for hyperbaric spinal ropivacaine was 16.4 mg (95% CI 13.7-19) with an ED95 estimate of 21.9 mg. The median effective dose of spinal ropivacaine with fentanyl 10 mu g was 17.0 mg (95% CI 15.4-18.7) with an ED95 estimate of 21.3 mg. When data were combined, the overall ED50 for ropivacaine was 16.7 mg (95% CI 15.1-18.4) with an ED95 estimate of 22.5 mg (95% CI 16.3-28.8). A T8 block was not achieved in 4 patients receiving spinal ropivacaine alone, and 1 patient receiving spinal ropivacaine with fentanyl. The majority (82%) of patients who did not receive epidural local anesthetic supplementation had recovery of motor block within 60 min following PACU admission. Conclusion: Spinal hyperbaric ropivacaine 22 mg with or without fentanyl 10 mu g could be used for postpartum tubal ligation surgery. (C) 2010 Elsevier Ltd. All rights reserved.	[Panni, M. K.; George, R. B.; Allen, T. K.; Olufolabi, A. J.; Schultz, J. R.; Okumura, M.; Habib, A. S.] Duke Univ, Med Ctr, Dept Anesthesiol, Div Womens Anesthesia, Durham, NC 27710 USA; [Columb, M. O.] S Manchester Univ Hosp NHS Trust, Acute Intens Care Unit, Wythenshawe, England	Panni, MK (reprint author), Univ Florida, Dept Anesthesiol, Coll Med Jacksonville, 655 W 8th St, Jacksonville, FL 32209 USA.	Moeen.Panni@jax.ufl.edu	George, Ronald B/S-9312-2019; Columb, Malachy/F-9588-2016; Habib, Ashraf/K-4889-2019	George, Ronald B/0000-0002-1848-036X; Columb, Malachy/0000-0001-7837-4262; Habib, Ashraf/0000-0002-6980-1856			Arndt JA, 2002, ANESTHESIOLOGY, V97, P1042, DOI 10.1097/00000542-200210000-00071; Beilin Y, 2003, ANESTH ANALG, V97, P56, DOI 10.1213/01.ANE.0000068940.36040.54; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; Camorcia M, 2007, ANESTH ANALG, V104, P904, DOI 10.1213/01.ane.0000256912.54023.79; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Columb MO, 2006, INT J OBSTET ANESTH, V15, P129, DOI 10.1016/j.ijoa.2005.09.010; Graham AC, 2001, ANAESTHESIA, V56, P470, DOI 10.1046/j.1365-2044.2001.01524-6.x; Huber AW, 2007, EUR J OBSTET GYN R B, V134, P105, DOI 10.1016/j.ejogrb.2006.06.016; Huffnagle SL, 2002, REGION ANESTH PAIN M, V27, P284, DOI 10.1053/rapm.2002.31210; James ML, 2005, ANESTH ANALG, V100, P897, DOI 10.1213/01.ANE.0000146651.78258.83; Munnur Uma, 2005, Crit Care Med, V33, pS259, DOI 10.1097/01.CCM.0000183502.45419.C9; PICCININO LJ, 1998, FAMILY PLANNING PERS, V30, P46; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Wang LZ, 2007, BRIT J ANAESTH, V98, P792, DOI 10.1093/bja/aem101; Zaric D, 2005, ANESTH ANALG, V100, P1811, DOI 10.1213/01.ANE.0000136844.87857.78	17	3	4	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2010	19	4					390	394		10.1016/j.ijoa.2010.06.011			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	676JO	WOS:000283907400008	20832280				2020-06-30	J	Yousef, AA; Amr, YM				Yousef, A. A.; Amr, Y. M.			The effect of adding magnesium sulphate to epidural bupivacaine and fentanyl in elective caesarean section using combined spinal-epidural anaesthesia: a prospective double blind randomised study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Combined spinal-epidural anaesthesia; Epidural magnesium sulphate; Caesarean section	CONTROLLED-TRIAL; ANALGESIA; BLOCK; PAIN	Background: Combined spinal-epidural anaesthesia is commonly used for elective caesarean section. Intrathecal injection produces rapid onset with minimal doses of local anaesthetic and epidural administration can be used to prolong the block. Our study examined the effects of adding magnesium sulphate to epidural bupivacaine and fentanyl in patients undergoing elective caesarean section using combined spinal-epidural anaesthesia. Methods: Women ASA physical status I or II at term were recruited. All received 2 mL intrathecal 0.5% hyperbaric bupivacaine, 10 mL epidural 0.25% plain bupivacaine with fentanyl 100 mu g, and were randomly allocated to receive either 10 mL of epidural 0.9% sodium chloride or 10 mL epidural 5% magnesium sulphate. The quality of surgical anaesthesia, incidence of hypotension, Apgar scores, intraoperative pain assessment, onset of postoperative pain, sedation scores and side effects were recorded in the postoperative period. Results: Ninety women were recruited. There was no difference in the time taken for the block to reach T4 sensory level, time to reach the highest level of sensory block, time interval between first neuraxial injection and onset of surgery between the groups. Women who received magnesium had greater motor block and muscle relaxation (P < 0.05). Apgar scores were 7 or more in almost all neonates in both groups. There was no significant difference in the incidence of hypotension, nausea and vomiting and duration of motor blockade between the groups. Women who received magnesium showed less shivering and later onset of post operative pain (P < 0.05). Conclusion: The addition of magnesium to epidural bupivacaine and fentanyl in women undergoing elective caesarean section with combined spinal-epidural anaesthesia improved intraoperative conditions and the quality of postoperative analgesia. (C) 2010 Elsevier Ltd. All rights reserved.	[Yousef, A. A.; Amr, Y. M.] Tanta Univ, Fac Med, Dept Anesthesia, Tanta, Egypt	Yousef, AA (reprint author), Tanta Univ, Fac Med, Dept Anesthesia, Tanta, Egypt.	Ayman.yousef@rocketmail.com					Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; Bilir A, 2007, BRIT J ANAESTH, V98, P519, DOI 10.1093/bja/aem029; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; CARRIE LES, 1990, BRIT J ANAESTH, V65, P225, DOI 10.1093/bja/65.2.225; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Goodman EJ, 2006, INT J OBSTET ANESTH, V15, P63, DOI 10.1016/j.ijoa.2005.06.009; LEJUSTE MJLR, 1985, S AFR MED J, V68, P367; Lysakowski C, 2007, ANESTH ANALG, V104, P1532, DOI 10.1213/01.ane.0000261250.59984.cd; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; POCKETT S, 1995, ANESTH ANALG, V80, P173, DOI 10.1097/00000539-199501000-00026; WOLFF CJ, 1991, [No title captured], V44, P293	13	41	44	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2010	19	4					401	404		10.1016/j.ijoa.2010.07.019			4	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	676JO	WOS:000283907400010	20833531				2020-06-30	J	Lee, KH; Nam, SH; Yoo, SY; Jung, CW; Bae, SS; Lee, JR				Lee, Kook-Hyun; Nam, Soon-Ho; Yoo, Seung-Yeon; Jung, Chul-Woo; Bae, Seng-Sim; Lee, Jeong-Rim			Vecuronium requirement during liver transplantation under sevoflurane anesthesia	JOURNAL OF ANESTHESIA			English	Article						Liver transplantation; Sevoflurane; Vecuronium	INDUCED NEUROMUSCULAR BLOCK; AUGMENTATION; ISOFLURANE; PROPOFOL; TIME	In liver transplantation patients under intravenous anesthesia, the vecuronium dose is known to be reduced, especially during the anhepatic phase. Volatile anesthetics potentiate a muscle relaxation effect of neuromuscular blocking agents, so the vecuronium dose is supposed to further decrease if sevoflurane is used during liver transplantation. The purpose of this study was to determine the appropriate dose of vecuronium at each phase of liver transplantation under sevoflurane anesthesia. Thirty-five patients scheduled for living donor liver transplantation because of liver cirrhosis were enrolled in this study. They were anesthetized with 1 MAC of sevoflurane and intermittent administration of fentanyl. Continuous infusion of vecuronium (0.5 mg/ml) was used for muscle relaxation, which was adjusted every 15 min for consistent muscle relaxation aimed at T1/Tc of 0.1 monitored by ulnar nerve stimulation. Vecuronium infusion was stopped after hepatic artery anastomosis was finished. The infusion rate of each operative phase-dissection, anhepatic, and neohepatic-was calculated and analyzed by one-way analysis of variance. The recovery time from train-of-four (TOF) count 1 to TOF ratio 25% was also measured. The vecuronium infusion rate of each operation phase for adequate muscle relaxation was as follows: 0.033 +/- A 0.009 mg/kg/h during dissection phase, 0.031 +/- A 0.009 mg/kg/h during anhepatic phase, and 0.026 +/- A 0.006 mg/kg/h during early neohepatic phase. There was a statistically significant difference between doses at each phase (P = 0.033). The recovery time from TOF count 1 to TOF ratio 25% was 103 +/- A 29 min. The required vecuronium dose in all phases was less than the known dose in the anhepatic phase (0.036 mg/kg/h) under midazolam-fentanyl anesthesia. In addition, the vecuronium infusion dose was not reduced in the anhepatic phase compared to the dissection phases.	[Nam, Soon-Ho; Lee, Jeong-Rim] Yonsei Univ, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Coll Med, Seoul 120752, South Korea; [Lee, Kook-Hyun; Yoo, Seung-Yeon; Jung, Chul-Woo; Bae, Seng-Sim] Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea	Lee, JR (reprint author), Yonsei Univ, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Coll Med, 250 Seongsan No, Seoul 120752, South Korea.	leejeongrim@gmail.com	Lee, Kook Hyun/J-5573-2012; Jung, Chul-Woo/J-5651-2012	Lee, Jeong-Rim/0000-0002-7425-0462			Adachi Takehiko, 2003, J Anesth, V17, P116, DOI 10.1007/s005400300027; Ahmed AAK, 1999, CAN J ANAESTH, V46, P429, DOI 10.1007/BF03012941; CANNON JE, 1987, ANESTHESIOLOGY, V67, P503, DOI 10.1097/00000542-198710000-00010; Lowry DW, 1998, ANESTH ANALG, V87, P936, DOI 10.1097/00000539-199810000-00036; LUKIN CL, 1995, ANESTH ANALG, V80, P526, DOI 10.1097/00000539-199503000-00016; Motamed C, 2002, CAN J ANAESTH, V49, P907, DOI 10.1007/BF03016872; OKELLY B, 1991, ANESTH ANALG, V73, P794; Segawa H, 2006, INT ANESTHESIOL CLIN, V44, P111, DOI 10.1097/01.aia.0000210799.60630.d2; Suzuki T, 1999, BRIT J ANAESTH, V83, P485; Wulf H, 1998, BRIT J ANAESTH, V80, P308	10	1	1	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2010	24	5					683	686		10.1007/s00540-010-0982-6			4	Anesthesiology	Anesthesiology	661CU	WOS:000282701400004	20607311				2020-06-30	J	Okutani, R; Arashi, D; Tsujii, K				Okutani, Ryu; Arashi, Daisuke; Tsujii, Kenji			Anesthetic case in a child with congenital neuromuscular disease with uniform type 1 fibers (CNMDU1)	JOURNAL OF ANESTHESIA			English	Article						Congenital neuromuscular disease with uniform type 1 fibers (CNMDU1); General anesthesia; Malignant hyperthermia	CENTRAL CORE DISEASE; MALIGNANT HYPERTHERMIA; MUTATION; MYOPATHY; PATIENT; MUSCLE; GENE	Congenital neuromuscular disease with uniform type 1 fibers (CNMDU1) is an extremely rare, non-progressive, congenital neuromuscular disorder. Although the etiology is unknown, ryanodine receptor gene mutation is reportedly involved. No descriptions of anesthetic practice in patients with this disease have been reported around the world. We report a case of safe perioperative management with general anesthesia, using total intravenous anesthesia, propofol, fentanyl and a non-depolarizing muscle relaxant but avoiding the use of any inhaled anesthetics or depolarizing muscle relaxants to prevent malignant hyperthermia and postoperative respiratory failure, during anesthetic management for cranioplasty for premature synostosis of the cranial sutures in a pediatric patient of CNMDU1.	[Okutani, Ryu; Arashi, Daisuke; Tsujii, Kenji] Osaka City Gen Hosp, Dept Anesthesiol, Miyakojima Ku, Osaka 5340021, Japan; [Okutani, Ryu; Arashi, Daisuke; Tsujii, Kenji] Childrens Hosp, Miyakojima Ku, Osaka 5340021, Japan	Okutani, R (reprint author), Osaka City Gen Hosp, Dept Anesthesiol, Miyakojima Ku, 2-13-22 Miyakojima Hondori, Osaka 5340021, Japan.	ryu0909@kcat.zaq.ne.jp					ARAKI A, 1991, No To Hattatsu, V23, P295; Foster RN, 2008, ANAESTHESIA, V63, P544, DOI 10.1111/j.1365-2044.2007.05411.x; Girard T, 2008, ANESTH ANALG, V107, P1953, DOI 10.1213/ane.0b013e3181857903; Huang Miao-Ling, 1998, Acta Paediatrica Sinica, V39, P62; JONG YJ, 1991, BRAIN DEV-JPN, V13, P444, DOI 10.1016/S0387-7604(12)80046-5; Jung EY, 1997, PEDIATR NEUROL, V16, P56, DOI 10.1016/S0887-8994(96)00231-7; Kaufmann A, 2008, ANESTHESIOLOGY, V109, P457, DOI 10.1097/ALN.0b013e318182a93b; Kitagawa Y, 2000, SCAND J PLAST RECONS, V34, P391; Korematsu S, 2006, BRAIN DEV-JPN, V28, P63, DOI 10.1016/j.braindev.2005.04.007; Na SJ, 2004, YONSEI MED J, V45, P150, DOI 10.3349/ymj.2004.45.1.150; OH SJ, 1983, ARCH NEUROL-CHICAGO, V40, P147, DOI 10.1001/archneur.1983.04050030041007; PELLEGRINI G, 1985, NEUROPEDIATRICS, V16, P162, DOI 10.1055/s-2008-1059533; Sakamoto HM, 2006, BRAIN DEV-JPN, V28, P202, DOI 10.1016/j.braindev.2005.06.008; Sato I, 2008, NEUROLOGY, V70, P114, DOI 10.1212/01.wnl.0000269792.63927.86; Shepherd S, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.014274; Shimohata T, 2006, EUR J NEUROL, V13, pE10, DOI 10.1111/j.1468-1331.2006.01454.x; SPAGNOLI LG, 1985, ITAL J NEUROL SCI, V6, P317, DOI 10.1007/BF02232009; TAKEDA S, 1986, CLIN NEUROL, V26, P119; Tojo M, 2000, BRAIN DEV-JPN, V22, P262, DOI 10.1016/S0387-7604(00)00108-X; Wappler F, 2001, EUR J ANAESTH, V18, P632, DOI 10.1046/j.1365-2346.2001.00888.x	20	0	0	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2010	24	5					797	800		10.1007/s00540-010-0977-3			4	Anesthesiology	Anesthesiology	661CU	WOS:000282701400025	20585812				2020-06-30	J	Kaufman, MP				Kaufman, Marc P.			Control of breathing during dynamic exercise by thin fiber muscle afferents	JOURNAL OF APPLIED PHYSIOLOGY			English	Editorial Material							GROUP-III; SKELETAL-MUSCLE; RESPONSES; CONTRACTION; CIRCULATION; RESPIRATION; LOCOMOTION; DISTENSION; NEURONS; REFLEX		Penn State Coll Med, Inst Heart & Vasc, Hershey, PA 17033 USA	Kaufman, MP (reprint author), Penn State Coll Med, Inst Heart & Vasc, Hershey, PA 17033 USA.	mkaufman@hmc.psu.edu					Adreani CM, 1997, J APPL PHYSIOL, V82, P1811; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; ELDRIDGE FL, 1985, RESP PHYSIOL, V59, P313, DOI 10.1016/0034-5687(85)90136-7; ELDRIDGE FL, 1981, SCIENCE, V211, P844, DOI 10.1126/science.7466362; Haouzi P, 1999, J APPL PHYSIOL, V87, P545; Haouzi P, 2004, J APPL PHYSIOL, V96, P407, DOI 10.1152/japplphysiol.00597.2003; KAUFMAN MP, 1983, J APPL PHYSIOL, V55, P105; Light AR, 2008, J NEUROPHYSIOL, V100, P1184, DOI 10.1152/jn.01344.2007; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; MITCHELL JH, 1983, ANNU REV PHYSIOL, V45, P229, DOI 10.1146/annurev.ph.45.030183.001305; NOBREGA ACL, 1993, MED SCI SPORT EXER, V25, P37; PAINTAL AS, 1960, J PHYSIOL-LONDON, V152, P250, DOI 10.1113/jphysiol.1960.sp006486; Plowey ED, 2002, AM J PHYSIOL-REG I, V283, pR1008, DOI 10.1152/ajpregu.00075.2002; WALDROP TG, 1996, HDB PHYSIOL 12, P333	14	11	11	0	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	OCT	2010	109	4					947	948		10.1152/japplphysiol.00892.2010			2	Physiology; Sport Sciences	Physiology; Sport Sciences	695BF	WOS:000285344900002	20689092				2020-06-30	J	Amann, M; Blain, GM; Proctor, LT; Sebranek, JJ; Pegelow, DF; Dempsey, JA				Amann, Markus; Blain, Gregory M.; Proctor, Lester T.; Sebranek, Joshua J.; Pegelow, David F.; Dempsey, Jerome A.			Group III and IV muscle afferents contribute to ventilatory and cardiovascular response to rhythmic exercise in humans	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						hyperpnea; control of breathing; neural feedback	SPINAL-CORD TRANSMISSION; PRESSOR-RESPONSE; DYNAMIC EXERCISE; EPIDURAL-ANESTHESIA; DORSAL-HORN; CARDIORESPIRATORY RESPONSE; RESPIRATORY RESPONSES; INTRATHECAL FENTANYL; STATIC EXERCISE; CENTRAL COMMAND	We investigated the role of somatosensory feedback on cardioventilatory responses to rhythmic exercise in five men. In a double-blind, placebo-controlled design, subjects performed the same leg cycling exercise (50/100/150/325 +/- 19 W, 3 min each) under placebo conditions (interspinous saline, L-3-L-4) and with lumbar intrathecal fentanyl impairing central projection of spinal opioid receptor-sensitive muscle afferents. Quadriceps strength was similar before and after fentanyl administration. To evaluate whether a cephalad migration of fentanyl affected cardioventilatory control centers in the brain stem, we compared resting ventilatory responses to hypercapnia (HCVR) and cardioventilatory responses to arm vs. leg cycling exercise after each injection. Similar HCVR and minor effects of fentanyl on cardioventilatory responses to arm exercise excluded direct medullary effects of fentanyl. Central command during leg exercise was estimated via quadriceps electromyogram. No differences between conditions were found in resting heart rate (HR), ventilation [minute ventilation ((V) over dotE)], or mean arterial pressure (MAP). Quadriceps electromyogram, O-2 consumption ((V) over dotO(2)), and plasma lactate were similar in both conditions at the four steady-state workloads. Compared with placebo, a substantial hypoventilation during fentanyl exercise was indicated by the 8-17% reduction in (V) over dotE/CO2 production ((V) over dotCO(2)) secondary to a reduced breathing frequency, leading to average increases of 4-7 Torr in end-tidal PCO2 (P < 0.001) and a reduced hemoglobin saturation (-3 +/- 1%; P < 0.05) at the heaviest workload (similar to 90% maximal (V) over dotO(2)) with fentanyl. HR was reduced 2-8%, MAP 8-13%, and ratings of perceived exertion by 13% during fentanyl vs. placebo exercise (P < 0.05). These findings demonstrate the essential contribution of muscle afferent feedback to the ventilatory, cardiovascular, and perceptual responses to rhythmic exercise in humans, even in the presence of unaltered contributions from other major inputs to cardioventilatory control.	[Amann, Markus] Univ Utah, Dept Internal Med, VA Med Ctr, Salt Lake City, UT 84148 USA; [Amann, Markus; Blain, Gregory M.; Pegelow, David F.; Dempsey, Jerome A.] Univ Wisconsin, John Rankin Lab Pulm Med, Madison, WI USA; [Proctor, Lester T.; Sebranek, Joshua J.] Univ Wisconsin, Dept Anesthesiol, Madison, WI USA	Amann, M (reprint author), Univ Utah, Dept Internal Med, VA Med Ctr, GRECC 182,500 Foothill Dr, Salt Lake City, UT 84148 USA.	markus.amann@utah.edu		Amann, Markus/0000-0002-4012-8880	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-15469]	This work was supported by National Heart, Lung, and Blood Institute R01 Grant HL-15469.	ADAMS L, 1984, J PHYSIOL-LONDON, V355, P85, DOI 10.1113/jphysiol.1984.sp015408; Adreani CM, 1997, J APPL PHYSIOL, V82, P1811; Amann M, 2004, MED SCI SPORT EXER, V36, P613, DOI 10.1249/01.MSS.0000122076.21804.10; Amann M, 2007, J PHYSIOL-LONDON, V581, P389, DOI 10.1113/jphysiol.2007.129700; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Amann M, 2008, J APPL PHYSIOL, V105, P1714, DOI 10.1152/japplphysiol.90456.2008; ASMUSSEN E, 1965, ACTA PHYSIOL SCAND, V63, P343, DOI 10.1111/j.1748-1716.1965.tb04073.x; ASMUSSEN E, 1967, CIRC RES, V20, pI2; ASMUSSEN E, 1943, ACTA PHYSIOL SCAND, V6, P168, DOI DOI 10.1111/J.1748-1716.1943.TB02838.X; Babenco HD, 2000, ANESTHESIOLOGY, V92, P393, DOI 10.1097/00000542-200002000-00020; BENNETT FM, 1988, J APPL PHYSIOL, V65, P2011; BESSE D, 1990, BRAIN RES, V521, P15, DOI 10.1016/0006-8993(90)91519-M; BESSE D, 1991, BRAIN RES, V548, P287, DOI 10.1016/0006-8993(91)91134-M; Borg G, 1998, BORGS PERCEIVED EXER; BROWN DR, 1990, J APPL PHYSIOL, V68, P2312; Caringi D, 1998, AM J PHYSIOL-HEART C, V274, pH139; CLARK JM, 1980, J APPL PHYSIOL, V48, P1065; COOTE JH, 1971, J PHYSIOL-LONDON, V215, P789, DOI 10.1113/jphysiol.1971.sp009498; CRAIG AD, 1995, J COMP NEUROL, V361, P225, DOI 10.1002/cne.903610204; CROSS BA, 1982, J PHYSIOL-LONDON, V329, P37, DOI 10.1113/jphysiol.1982.sp014289; Darques JL, 1998, NEUROSCI LETT, V257, P109; Darques JL, 1997, BRAIN RES, V750, P147, DOI 10.1016/S0006-8993(96)01341-8; Eiken O, 1987, Acta Physiol Scand Suppl, V566, P1; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; ELDRIDGE FL, 1985, RESP PHYSIOL, V59, P313, DOI 10.1016/0034-5687(85)90136-7; Farina D, 2004, J APPL PHYSIOL, V96, P1486, DOI 10.1152/japplphysiol.01070.2003; FERNANDES A, 1990, J PHYSIOL-LONDON, V420, P281, DOI 10.1113/jphysiol.1990.sp017912; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; FREUND PR, 1979, AM J PHYSIOL, V237, pH433; FRIEDMAN DB, 1993, J PHYSIOL-LONDON, V470, P681, DOI 10.1113/jphysiol.1993.sp019882; GALBO H, 1987, J PHYSIOL-LONDON, V389, P557, DOI 10.1113/jphysiol.1987.sp016672; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Grant GJ, 1996, J CLIN ANESTH, V8, P99, DOI 10.1016/0952-8180(95)00174-3; Guz A, 1997, RESP PHYSIOL, V109, P197, DOI 10.1016/S0034-5687(97)00050-9; HILL JM, 1990, J APPL PHYSIOL, V68, P2466; HORNBEIN TF, 1969, J APPL PHYSIOL, V27, P476; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; INNES JA, 1992, J PHYSIOL-LONDON, V448, P551, DOI 10.1113/jphysiol.1992.sp019057; KALIA M, 1981, CIRC RES, V48, P48; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; KAO FF, 1963, REGULATION HUMAN RES, P461; Keenan KG, 2005, J APPL PHYSIOL, V98, P120, DOI 10.1152/japplphysiol.00894.2004; KOZELKA JW, 1987, J APPL PHYSIOL, V62, P1186; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; LAMB TW, 1968, RESP PHYSIOL, V6, P88; LEVINE S, 1979, J APPL PHYSIOL, V47, P126; Marcora S, 2009, J APPL PHYSIOL, V106, P2060, DOI 10.1152/japplphysiol.90378.2008; MATEIKA JH, 1995, EUR J APPL PHYSIOL O, V71, P1, DOI 10.1007/BF00511228; MATEIKA JH, 1994, EUR J APPL PHYSIOL, V68, P54, DOI 10.1007/BF00599242; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; MENSE S, 1988, NEUROSCIENCE, V26, P1023, DOI 10.1016/0306-4522(88)90117-0; MITCHELL GS, 1990, J APPL PHYSIOL, V69, P718; MITCHELL JH, 1989, J PHYSIOL-LONDON, V417, P13, DOI 10.1113/jphysiol.1989.sp017787; Morin D, 2002, J NEUROSCI, V22, P4756, DOI 10.1523/JNEUROSCI.22-11-04756.2002; OCHWADT B, 1959, PFLUG ARCH GES PHYS, V269, P613, DOI 10.1007/BF00362415; PAN LG, 1990, J APPL PHYSIOL, V69, P1821; POMEROY G, 1986, BRAIN RES, V381, P385, DOI 10.1016/0006-8993(86)90095-8; Poon CS, 2007, RESP PHYSIOL NEUROBI, V159, P1, DOI 10.1016/j.resp.2007.02.020; PUNNEN S, 1984, NEUROPHARMACOLOGY, V23, P939, DOI 10.1016/0028-3908(84)90008-X; ROWELL LB, 1990, J APPL PHYSIOL, V69, P407; ROWELL LB, 1976, J APPL PHYSIOL, V41, P693; SATO A, 1981, J AUTONOM NERV SYST, V4, P231, DOI 10.1016/0165-1838(81)90047-3; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Shannon MT, 1998, J CLIN ANESTH, V10, P452, DOI 10.1016/S0952-8180(98)00058-0; Smith SA, 2003, J PHYSIOL-LONDON, V551, P1013, DOI 10.1113/jphysiol.2003.044925; Standl TG, 2001, ANESTHESIOLOGY, V94, P230, DOI 10.1097/00000542-200102000-00011; Sun SY, 1996, GEN PHARMACOL, V27, P1187, DOI 10.1016/S0306-3623(96)00055-9; Swenson JD, 2001, REGION ANESTH PAIN M, V26, P306, DOI 10.1053/ramp.2001.25069; Thornton JM, 2001, J PHYSIOL-LONDON, V533, P823, DOI 10.1111/j.1469-7793.2001.00823.x; TIBES U, 1977, CIRC RES, V41, P332, DOI 10.1161/01.RES.41.3.332; WALDROP TG, 1986, RESP PHYSIOL, V64, P317, DOI 10.1016/0034-5687(86)90125-8; WALDROP TG, 1996, HDB PHYSIOL 12, P333; WEISSMAN ML, 1980, J APPL PHYSIOL, V49, P239; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Winchester PK, 2000, J PHYSIOL-LONDON, V527, P193, DOI 10.1111/j.1469-7793.2000.00193.x; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pharmtox.25.1.433; YAKSH TL, 1981, PAIN, V11, P293, DOI 10.1016/0304-3959(81)90633-3; Yamamoto WS, 1977, MUSCULAR EXERCISE LU, P137	81	195	196	4	31	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	OCT	2010	109	4					966	976		10.1152/japplphysiol.00462.2010			11	Physiology; Sport Sciences	Physiology; Sport Sciences	695BF	WOS:000285344900006	20634355	Green Published			2020-06-30	J	Karanikolas, M; Aretha, D; Kiekkas, P; Monantera, G; Tsolakis, I; Filos, KS				Karanikolas, M.; Aretha, D.; Kiekkas, P.; Monantera, G.; Tsolakis, I.; Filos, K. S.			Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article						fentanyl; haemodialysis; opioids; pain; patient control analgesia; peripheral vascular disease	DIALYSIS PATIENTS; RENAL-FAILURE; QUESTIONNAIRE; EFFICACY; DISEASE; SAFETY	Background and objective: Use of opioids is common in perioperative haemodialysis patients because they often suffer from intractable ischaemic or neuropathic lower extremity pain. Intravenous (IV) fentanyl, patient-controlled analgesia (PCA) does not appear to have been evaluated in this setting; hence this study. Methods and results: This is a prospective, single-centre study. IV fentanyl PCA was used for pain control in 16 patients with lower extremity, neuropathic/ischaemic pain, scheduled for major lower extremity amputation. IV fentanyl PCA was used before and after amputation in eight patients, before but not after amputation in seven patients, and until death in one terminal cancer patient who chose to forgo surgery. Pain intensity was assessed with the Visual Analogue Scale (VAS) and the McGill Pain Questionnaire. Depth of sedation was assessed on a 4-point scale. Ischaemic pain scores were high before fentanyl PCA started, but decreased significantly and remained low with fentanyl PCA use (P < 0 center dot 001). Phantom pain scores were low (VAS < 4). Respiratory depression was not a problem in any patient. Conclusions: Concerns about accumulation of active opioid metabolites make provision of adequate analgesia problematic in haemodialysis patients scheduled for amputation, and emergency surgery. Our data on a small patient population suggest that IV fentanyl PCA is safe and effective for severe pain in haemodialysis patients.	[Karanikolas, M.] Univ Patras, Sch Med, Dept Anaesthesiol & Crit Care Med, GR-26110 Patras, Greece; [Aretha, D.; Kiekkas, P.; Monantera, G.] Patras Univ Hosp, Dept Anaesthesiol & Crit Care Med, Patras, Greece; [Tsolakis, I.] Univ Patras, Sch Med, Dept Vasc Surg, GR-26110 Patras, Greece; [Filos, K. S.] Univ Patras, Sch Med, Dept Anesthesiol & Crit Care Med, GR-26110 Patras, Greece	Aretha, D (reprint author), 76 Stratigou Konstantinopoulou Str, Patras 26331, Greece.	adaretha@yahoo.gr	Karanikolas, Menelaos/O-5928-2017	Karanikolas, Menelaos/0000-0001-8541-7988			Akmal M, 2001, AM J KIDNEY DIS, V38, pS195, DOI 10.1053/ajkd.2001.27443; Bastani B, 1997, NEPHROL DIAL TRANSPL, V12, P2802, DOI 10.1093/ndt/12.12.2802; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Joh J, 1998, ANESTH ANALG, V86, P447, DOI 10.1097/00000539-199802000-00049; Koehntop DE, 1997, PHARMACOTHERAPY, V17, P746; Liang Shi-wei, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1663; Marchettini P, 2006, CURR NEUROPHARMACOL, V4, P175, DOI 10.2174/157015906778019536; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MELZACK R, 1985, PAIN, V23, P201, DOI 10.1016/0304-3959(85)90060-0; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mercadante S, 1997, J PAIN SYMPTOM MANAG, V13, P241, DOI 10.1016/S0885-3924(97)00076-6; Murphy EJ, 2005, ANAESTH INTENS CARE, V33, P311, DOI 10.1177/0310057X0503300306; Murtagh FEM, 2006, J REN CARE, V32, P93, DOI 10.1111/j.1755-6686.2006.tb00459.x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Ruggiero A, 2007, SUPPORT CARE CANCER, V15, P569, DOI 10.1007/s00520-006-0193-8; Saha HHT, 2007, PERITON DIALYSIS INT, V27, pS210	17	8	11	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-4727	1365-2710		J CLIN PHARM THER	J. Clin. Pharm. Ther.	OCT	2010	35	5					603	608		10.1111/j.1365-2710.2009.01114.x			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	649TF	WOS:000281796100010	20831684				2020-06-30	J	Moritz, S; Schmidt, C; Bucher, M; Wiesenack, C; Zimmermann, M; Schebesch, KM; Kasprzak, P; Metz, C				Moritz, Stefan; Schmidt, Christoph; Bucher, Michael; Wiesenack, Christoph; Zimmermann, Markus; Schebesch, Karl-Michael; Kasprzak, Piotr; Metz, Christoph			Neuromonitoring in Carotid Surgery: Are the Results Obtained in Awake Patients Transferable to Patients Under Sevoflurane/Fentanyl Anesthesia?	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						carotid endarterectomy; neuromonitoring; regional anesthesia; general anesthesia	CEREBRAL-BLOOD-FLOW; SOMATOSENSORY-EVOKED POTENTIALS; NEAR-INFRARED SPECTROSCOPY; TRANSCRANIAL DOPPLER; STUMP PRESSURE; REGIONAL ANESTHESIA; GENERAL-ANESTHESIA; SELECTING PATIENTS; RANDOMIZED-TRIAL; ENDARTERECTOMY	Background: Diagnostic accuracy studies of neuromonitoring devices during carotid endarterectomy in awake patients are limited by the question of the transferability to anesthetized patients. This study was designed to compare the different neuromonitoring parameters in patients under regional and general anesthesia with stump pressure as the primary endpoint and the courses of cerebral blood flow velocity (Vmca) measured by transcranial Doppler sonography, regional cerebral oxygen saturation (rSO(2)) measured by near-infrared spectroscopy, and the amplitude of somatosensory evoked potentials (SEP) as the secondary endpoints. Materials and Methods: Ninety-six patients undergoing carotid endarterectomy were randomized to regional (n = 48) or sevoflurane/fentanyl anesthesia (n = 48) group. Absolute and relative changes of Vmca and rSO(2) and the SEP amplitude were recorded at baseline, during carotid artery clamping, and after declamping. Intergroup differences (beta) were calculated by generalized estimation equations and linear regression analysis. Results: Mean arterial pressure (P < 0.001) and heart rate (P < 0.001) were significantly higher in the regional anesthesia group. SP did not differ between both the groups (beta = - 1.6; P = 0.71). Vmca (beta = 9.2; P < 0.01) and rSO(2) (beta = 4.1; P < 0.01) values were higher in the awake patients. After adjustment for mean arterial pressure, the differences of Vmca remained consistent (beta = 9.3; P < 0.01) whereas these of rSO(2) during clamping (beta = 2.9; P = 0.105) and during reperfusion (beta = 2.7; P = 0.095) disappeared. No significant differences were found for Vmca(%) (beta = - 1.0; P = 0.80), rSO(2)(%) (beta = - 1.4; P = 1.8) and SEP (beta = - 2.6; P = 0.29). Conclusion: Carotid artery clamping leads to similar results of stump pressure and similar relative changes of transcranial Doppler sonography, near-infrared spectroscopy, and SEP monitoring in patients under regional and sevoflurane/fentanyl anesthesia.	[Moritz, Stefan; Schmidt, Christoph; Bucher, Michael; Metz, Christoph] Univ Halle Wittenberg, Dept Anesthesiol, D-06120 Halle, Germany; [Kasprzak, Piotr] Univ Regensburg, Dept Vasc Surg, D-8400 Regensburg, Germany; [Wiesenack, Christoph; Zimmermann, Markus] Univ Regensburg, Dept Anesthesiol, D-8400 Regensburg, Germany; [Schebesch, Karl-Michael] Univ Regensburg, Dept Neurosurg, D-8400 Regensburg, Germany; [Metz, Christoph] Klinikum Freising, Dept Anesthesiol, Freising Weihenstephan, Germany	Moritz, S (reprint author), Univ Halle Wittenberg, Dept Anesthesiol, Ernst Grube Str 40, D-06120 Halle, Germany.	moritz.stefan@yahoo.de	Kasprzak, Piotr/G-5897-2014				[Anonymous], 1995, JAMA, V273, P1421; [Anonymous], 1998, LANCET, V351, P1379; Banoub M, 2003, ANESTHESIOLOGY, V99, P716, DOI 10.1097/00000542-200309000-00029; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Beese U, 1998, STROKE, V29, P2032, DOI 10.1161/01.STR.29.10.2032; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bond R, 2003, STROKE, V34, P824, DOI 10.1161/01.STR.0000059381.17983.77; Brauer P, 1998, J NEUROSURG ANESTH, V10, P80, DOI 10.1097/00008506-199804000-00003; Cao P, 1997, J VASC SURG, V26, P973, DOI 10.1016/S0741-5214(97)70009-0; Davies LK, 2006, J CARDIOTHOR VASC AN, V20, P450, DOI 10.1053/j.jvca.2006.03.004; Fielmuth S, 2008, EUR J ANAESTH, V25, P648, DOI 10.1017/S0265021508003967; Green RM, 1997, J VASC SURG, V26, P979; Guarracino F, 2008, CURR OPIN ANESTHESIO, V21, P50, DOI 10.1097/ACO.0b013e3282f3f499; HALSEY JH, 1992, STROKE, V23, P1583, DOI 10.1161/01.STR.23.11.1583; Hans SS, 2007, J VASC SURG, V45, P511, DOI 10.1016/j.jvs.2006.11.035; Jacques F, 2009, ANN VASC SURG, V23, P324, DOI 10.1016/j.avsg.2008.05.015; Kaisti KK, 2002, ANESTHESIOLOGY, V96, P1358, DOI 10.1097/00000542-200206000-00015; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; McCarthy RJ, 2002, EUR J VASC ENDOVASC, V24, P215, DOI 10.1053/ejvs.2002.1715; McCarthy RJ, 2001, EUR J VASC ENDOVASC, V21, P408, DOI 10.1053/ejvs.2001.1341; McCleary AJ, 1996, EUR J VASC ENDOVASC, V12, P173, DOI 10.1016/S1078-5884(96)80103-1; McCulloch TJ, 2007, ANESTHESIOLOGY, V106, P56, DOI 10.1097/00000542-200701000-00012; Mestrum R, 2009, EUR J ANAESTH, V26, P260, DOI 10.1097/EJA.0b013e3283240427; Moritz S, 2007, ANESTHESIOLOGY, V107, P563, DOI 10.1097/01.anes.0000281894.69422.ff; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Samra SK, 2000, ANESTHESIOLOGY, V93, P964, DOI 10.1097/00000542-200010000-00015; Samra SK, 1996, STROKE, V27, P49, DOI 10.1161/01.STR.27.1.49; Sbarigia E, 1999, J VASC SURG, V30, P131, DOI 10.1016/S0741-5214(99)70185-0; SPENCER MP, 1992, STROKE, V23, P1439, DOI 10.1161/01.STR.23.10.1439; Sternbach Y, 2002, J VASC SURG, V35, P333, DOI 10.1067/mva.2002.121579; Tomura N, 2005, AM J NEURORADIOL, V26, P1937; WERNER C, 1991, ANESTH ANALG, V72, P177, DOI 10.1213/00000539-199102000-00006; WILLIAMS IM, 1994, BRIT J SURG, V81, P960, DOI 10.1002/bjs.1800810711; Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	36	13	13	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2010	22	4					288	295		10.1097/ANA.0b013e3181e16e14			8	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	650ER	WOS:000281832500001	20479662				2020-06-30	J	Liang, CC; Chang, SD; Wong, SY; Chang, YL; Cheng, PJ				Liang, Ching-Chung; Chang, Shuenn-Dhy; Wong, Shu-Yam; Chang, Yao-Lung; Cheng, Po-Jen			Effects of postoperative analgesia on postpartum urinary retention in women undergoing cesarean delivery	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						cesarean section; postoperative analgesia; postpartum; urinary retention	EPIDURAL ANALGESIA; SECTION; MORPHINE; VOLUME; FLOW	Aim: Various analgesics and administration methods are used to provide women undergoing cesarean delivery pain relief after surgery. We compared three methods of postoperative analgesia regarding the incidence of postpartum urinary retention (PUR) in primiparous women undergoing elective cesarean delivery. Methods: We estimated post-void residual bladder volume after the first postpartum micturition among 150 parturient women. Risk factors stratified for PUR defined by 150-mL post-void residual bladder volume were analyzed. Obstetric parameters and prevalence of lower urinary tract symptoms after surgery were compared among three groups of parturient women given different postoperative analgesia: epidural bolus morphine (EBM), patient-controlled epidural analgesia (PCEA) with ropivacaine-fentanyl, and intramuscular pethidine. Results: The incidence of PUR was higher in the group given EBM (33.3%) than the groups receiving ropivacaine-fentanyl by PCEA (15%) or intramuscular pethidine (16.7%) (P = 0.038). Eighteen (12%) parturient women needed bladder catheterization to resolve their urinary retention at 1 day postpartum but all achieved spontaneous micturition prior to hospital discharge. The need for catheterization was also increased in the group with EBM (21.7%) in comparison with the other two groups (6.7% and 3.3%, respectively, P = 0.011). At the 3-month follow up, six women (4%) had obstructive voiding problems and seven women (4.7%) had irritating voiding problems. At the 1-year follow up, only one woman in the EBM group had incomplete emptying and another in the PCEA group had urinary incontinence. Conclusion: Epidural analgesia with morphine was significantly associated with post-cesarean urinary retention. Nonetheless, it was not detrimental to later urinary function.	[Liang, Ching-Chung; Chang, Shuenn-Dhy; Chang, Yao-Lung; Cheng, Po-Jen] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Linkou Med Ctr, Tao Yuan, Taiwan; [Wong, Shu-Yam] Chang Gung Mem Hosp, Dept Anesthesiol, Tao Yuan, Taiwan; [Liang, Ching-Chung; Chang, Shuenn-Dhy; Wong, Shu-Yam; Chang, Yao-Lung; Cheng, Po-Jen] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan	Liang, CC (reprint author), Chang Gung Mem Hosp, Dept Obstet & Gynecol, Linkou Med Ctr, 5 Fu Shin St, Tao Yuan, Taiwan.	ccjoliang@cgmh.org.tw			Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPG 33048, CMRPG 370321]	This work was supported by a Medical Research Project Grant CMRPG 33048 and CMRPG 370321 from Chang Gung Memorial Hospital. We would like to thank Doctors Ho-Yen Chueh and Sheng-Huan Chen for their assistance in accomplishing this study.	Barrington JW, 2001, INT UROGYNECOL J PEL, V12, P373, DOI 10.1007/PL00004044; BATES CP, 1980, BRIT J UROL, V52, P348, DOI 10.1111/j.1464-410X.1980.tb03058.x; Chai AHL, 2008, INT UROGYNECOL J, V19, P537, DOI 10.1007/s00192-007-0470-1; Demaria F, 2004, INT UROGYNECOL J, V15, P281, DOI 10.1007/s00192-004-1159-3; DRAY A, 1984, J PHARMACOL EXP THER, V231, P254; EVRON S, 1985, PAIN, V23, P135, DOI 10.1016/0304-3959(85)90055-7; GHONEIM MA, 1975, BRIT J UROL, V47, P663, DOI 10.1111/j.1464-410X.1975.tb04034.x; Glavind K, 2003, INT UROGYNECOL J PEL, V14, P119, DOI 10.1007/s00192-002-1014-3; KERMANS G, 1986, Acta Urologica Belgica, V54, P376; Liang CC, 2007, INT J GYNECOL OBSTET, V99, P229, DOI 10.1016/j.ijgo.2007.05.037; Liang CC, 2002, INT J OBSTET ANESTH, V11, P164, DOI 10.1054/ijoa.2002.0951; Liang CC, 2007, INT UROGYNECOL J, V18, P537, DOI 10.1007/s00192-006-0195-6; Mack AJ, 1969, BR J UROL, V41, P448; Yip SK, 2004, ACTA OBSTET GYN SCAN, V83, P881, DOI 10.1111/j.0001-6349.2004.00460.x	14	13	14	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	OCT	2010	36	5					991	995		10.1111/j.1447-0756.2010.01252.x			5	Obstetrics & Gynecology	Obstetrics & Gynecology	656ZK	WOS:000282379500011	20846254				2020-06-30	J	Janvier, A; Martinez, JL; Barrington, K; Lavoie, J				Janvier, A.; Martinez, J. L.; Barrington, K.; Lavoie, J.			Anesthetic technique and postoperative outcome in preterm infants undergoing PDA closure	JOURNAL OF PERINATOLOGY			English	Article						anaesthesia; postoperative instability; preterm infant; ligation of ductus arteriosus	PATENT DUCTUS-ARTERIOSUS; INTENSIVE-CARE UNIT; FENTANYL ANESTHESIA; STRESS RESPONSES; CARDIAC-SURGERY; PAIN; LIGATION; BIRTH; SUFENTANIL; ANALGESIA	Objective: To describe the various anesthetic techniques used for surgical closure of PDA in premature infants at the Montreal Children's Hospital and assess their impact on postoperative outcome. Study Design: The charts of all preterms who underwent PDA ligation during a 21-month period were reviewed for preoperative status, intraoperative anesthetic management and postoperative outcome. We determined the associations between independent variables and two postoperative outcome variables: unstable postoperative respiratory course (UPRC) and hypotension. Result: The mean weight at surgery of the 33 infants was 1.031 +/- 0.29 kg. All infants, but one, received intraoperative opioids. Eight patients presented UPRC. Mean fentanyl doses were 5.3 +/- 2.6 mcg kg(-1) for patients with UPRC vs 22.6 +/- 16.6 mcg kg(-1) for patients without UPRC (P = 0.004). Applying the receiver-operator characteristic curve (ROC), 10.5 mcg kg(-1) of fentanyl was established as the dose that discriminated and identified patients who experienced UPRC. The postnatal and postmenstrual age of the patient, birthweight, current weight, ventilator settings preoperatively, previous courses of indomethacin, sex and preoperative creatinine, were not correlated with the dose of fentanyl equivalent used. Logistic regression did not show a relationship between any of the previously mentioned factors and receiving a fentanyl equivalent of > 10.5 mcg kg(-1). The only factor associated with the total fentanyl equivalent dose (as a continuous variable) or receiving < 10.5 mcg kg(-1) (as a dichotomous variable) was the identity of the anesthetist involved, P < 0.001. Conclusion: We conclude that the use of at least 10.5 mcg kg(-1) of fentanyl equivalent as a component of the anesthetic regimen for surgical closure of a PDA in premature infants, avoids an unstable postoperative respiratory course. Journal of Perinatology (2010) 30, 677-682; doi: 10.1038/jp.2010.24; published online 18 March 2010	[Janvier, A.; Barrington, K.] Ste Justine Hosp, Dept Neonatol, Montreal, PQ, Canada; [Martinez, J. L.; Lavoie, J.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Anesthesia, Montreal, PQ, Canada	Barrington, K (reprint author), Univ Montreal, NICU, CHU Ste Justine, 3175 Cote Ste Catherine, Montreal, PQ, Canada.	keith.barrington@umontreal.ca		Barrington, Keith/0000-0001-9669-5094			ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; Anand KJS, 1999, PHYSIOL BEHAV, V66, P627, DOI 10.1016/S0031-9384(98)00338-2; Anand KJS, 2000, BIOL NEONATE, V77, P69, DOI 10.1159/000014197; Anand KJS, 2004, ANESTHESIOLOGY, V101, P527, DOI 10.1097/00000542-200408000-00033; ANAND KJS, 1987, LANCET, V1, P243; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Barker DP, 1996, ARCH DIS CHILD-FETAL, V75, pF187, DOI 10.1136/fn.75.3.F187; Bhutta AT, 2002, CLIN PERINATOL, V29, P357, DOI 10.1016/S0095-5108(02)00011-8; Brant J M, 2001, Clin J Oncol Nurs, V5, P163; Buskila D, 2003, ARCH PEDIAT ADOL MED, V157, P1079, DOI 10.1001/archpedi.157.11.1079; CASS LJ, 1994, ANAESTHESIA, V49, P879, DOI 10.1111/j.1365-2044.1994.tb04264.x; COLLINS C, 1985, ANESTH ANALG, V64, P1078; CONN A W, 1960, Can Anaesth Soc J, V7, P169; Duncan HP, 2000, BRIT J ANAESTH, V84, P556, DOI 10.1093/bja/84.5.556; GERHARDT T, 1980, BIOL NEONATE, V38, P96; GHOSH PK, 1985, THORAX, V40, P533, DOI 10.1136/thx.40.7.533; GREGORY G, 1994, PEDIAT ANESTHESIA, P351; Grunau RE, 2001, PEDIATRICS, V107, P105, DOI 10.1542/peds.107.1.105; HACK M, 2000, SEMIN NEONATOL, V5, P80; HICKEY PR, 1985, ANESTH ANALG, V64, P1137; HICKEY PR, 1984, ANESTH ANALG, V63, P117; Kumar RK, 2004, CATHETER CARDIO INTE, V62, P266, DOI 10.1002/ccd.20039; Laughon MM, 2004, CURR OPIN PEDIATR, V16, P146, DOI 10.1097/00008480-200404000-00005; Litmann R., 2004, PEDIAT ANESTHESIA RE, P73; Olney JW, 2004, ANESTHESIOLOGY, V101, P273, DOI 10.1097/00000542-200408000-00004; OVERLANDER TF, 2000, PEDIATRICS, V105, pE6; Peters JWB, 2003, PEDIATRICS, V111, P129, DOI 10.1542/peds.111.1.129; Porter FL, 1999, J DEV BEHAV PEDIATR, V20, P253, DOI 10.1097/00004703-199908000-00008; Reynolds L, 2004, PAIN, V110, P182, DOI 10.1016/j.pain.2004.03.024; ROBINSON S, 1981, ANESTH ANALG, V60, P331; Rosen H, 2005, NAT REV DRUG DISCOV, V4, P381, DOI 10.1038/nrd1721; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Rushing S, 2004, SEMIN PERINATOL, V28, P444, DOI 10.1053/j.semperi.2004.10.007; Schmidt B, 2001, NEW ENGL J MED, V344, P1966, DOI 10.1056/NEJM200106283442602; Shew SB, 2000, J PEDIATR SURG, V35, P1277, DOI 10.1053/jpsu.2000.0350001; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; Taddio A, 2002, CLIN PERINATOL, V29, P493, DOI 10.1016/S0095-5108(02)00017-9; TAYLOR RL, 1986, AM J SURG, V152, P704, DOI 10.1016/0002-9610(86)90453-8; Wyllie Jonathan, 2003, Semin Neonatol, V8, P425, DOI 10.1016/S1084-2756(03)00121-0	39	9	10	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	OCT	2010	30	10					677	682		10.1038/jp.2010.24			6	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	655UG	WOS:000282275300009	20237487	Bronze			2020-06-30	J	Buchanan, D				Buchanan, Deans			Sinus bradycardia related to methadone in a patient with myeloma receiving thalidomide therapy	PALLIATIVE MEDICINE			English	Letter									Royal Victoria Hosp, NHS Tayside, Dundee DD1 1SP, Scotland	Buchanan, D (reprint author), Royal Victoria Hosp, NHS Tayside, Roxburghe House, Dundee DD1 1SP, Scotland.	deansbuchanan@nhs.net					Ashwath ML, 2005, J EMERG MED, V29, P73, DOI 10.1016/j.jemermed.2004.10.022; Davis MP, 2001, SUPPORT CARE CANCER, V9, P73, DOI 10.1007/s005200000180; Fahdi IE, 2004, AM J CARDIOL, V93, P1052, DOI 10.1016/j.amjcard.2003.12.061; Guay DRP, 2009, CLIN MED INSIGHTS-TH, V1, P1073; Karir V, 2002, PHARMACOTHERAPY, V22, P1196, DOI 10.1592/phco.22.13.1196.33511; Morley JS, 1998, PAIN REV, V5, P51, DOI 10.1191/096813098673619329; Wheeler AD, 2006, PEDIATR CRIT CARE ME, V7, P83, DOI 10.1097/01.PCC.0000192337.00842.1E; Wilcock Andrew, 2009, Curr Opin Support Palliat Care, V3, P252, DOI 10.1097/SPC.0b013e328332e0a4	8	2	3	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.	OCT	2010	24	7					742	743		10.1177/0269216310373526			2	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	657SM	WOS:000282432600012	20921094				2020-06-30	J	Heard, C; Smith, J; Creighton, P; Joshi, P; Feldman, D; Lerman, J				Heard, Christopher; Smith, Jayson; Creighton, Paul; Joshi, Prashant; Feldman, Doron; Lerman, Jerrold			A comparison of four sedation techniques for pediatric dental surgery	PEDIATRIC ANESTHESIA			English	Article						pediatrics; sedation; dentistry	ADVERSE EVENTS; ORAL MIDAZOLAM; CHILDREN; SYRUP	P>Background: We prospectively assessed the efficacy and side effects of four sedation techniques in our dental clinic: oral midazolam, intranasal (IN) midazolam, IN midazolam combined with oral transmucosal fentanyl citrate (OTFC), and IN midazolam combined with IN sufentanil. Materials & Methods: With IRB approval, a nonrandomized open label study of moderate sedation in children undergoing dental surgery was administered during a 6 -month period. The sedation regimen was rotated daily at the anesthesiologist's discretion. Each sedation was monitored by a research nurse who assessed the quality of sedation and the frequency of complications. All children were monitored during the procedure and recovery for at least 20 min, before discharge based on the University of Michigan Sedation and Ohio State behavior rating scores. Results: One hundred and two children were sedated in the dental clinic during this period. The sedation was successful in 73% (range 64% to 88%) of the children. The time to onset was greatest with OTFC (37 min) and least with IN midazolam (17 min) compared with the other two groups (20 and 30 min). Recovery after OTFC was prolonged (39 min) significantly compared with the other three groups (26.5-30 min). Efficacy of sedation and frequency of complications (9% incidence of nausea and 6% of mild hemoglobin desaturation) were similar among the groups. Conclusions: All four sedation regimens were equally effective in this cohort of healthy children. The onset and recovery with OTFC was significantly delayed compared with the other regimens. The frequency of side effects was small; there were no side effects in the PO midazolam group.	[Heard, Christopher; Feldman, Doron; Lerman, Jerrold] Women & Childrens Hosp Buffalo, Dept Anesthesiol, Buffalo, NY 14222 USA; [Heard, Christopher; Joshi, Prashant] Women & Childrens Hosp Buffalo, Div Pediat Crit Care, Buffalo, NY 14222 USA; [Heard, Christopher; Feldman, Doron; Lerman, Jerrold] Univ Rochester, Dept Anesthesiol, Rochester, NY 14627 USA; [Heard, Christopher; Smith, Jayson; Creighton, Paul] Women & Childrens Hosp Buffalo, Dept Pediat & Community Dent, Buffalo, NY 14222 USA	Heard, C (reprint author), Women & Childrens Hosp Buffalo, Dept Anesthesiol, 219 Bryant St, Buffalo, NY 14222 USA.	cheard@upa.chob.edu	Heard, Christopher/M-4254-2015	Lerman, Jerrold/0000-0003-4408-9847			Costa PSS, 2010, ANESTH ANALG, V110, P110, DOI 10.1213/ANE.0b013e3181bdc63d; Cote CJ, 2002, ANESTH ANALG, V94, P37; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; Cravero JP, 2006, PEDIATRICS, V118, P1087, DOI 10.1542/peds.2006-0313; Day PF, 2006, EUR ARCH PAEDIATR DE, V7, P228, DOI 10.1007/BF03262557; Eid Hani, 2002, J Clin Pediatr Dent, V26, P179; Haas D A, 1996, Anesth Prog, V43, P1; Kain ZN, 2007, ANESTHESIOLOGY, V107, P545, DOI 10.1097/01.anes.0000281895.81168.c3; Lochary Margaret E., 1993, Pediatric Dentistry, V15, P348; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Marshall J, 2000, J CLIN PHARMACOL, V40, P578; MCMILLAN CO, 1992, CAN J ANAESTH, V39, P545, DOI 10.1007/BF03008315; Ng MW, 2004, PEDIATR DENT, V26, P180; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Primosch RE, 2005, PEDIATR DENT, V27, P401; Roelofse J A, 2004, Anesth Prog, V51, P114; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Torres-Perez Javier, 2007, J Clin Pediatr Dent, V31, P183; WIGHTMAN M, 2005, SEDATION ANESTHESIA	19	10	11	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	OCT	2010	20	10					924	930		10.1111/j.1460-9592.2010.03402.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	651TK	WOS:000281949800003	20849497				2020-06-30	J	Cicero, TJ; Ellis, MS; Paradis, A; Ortbal, Z				Cicero, Theodore J.; Ellis, Matthew S.; Paradis, Alethea; Ortbal, Zachary			Determinants of fentanyl and other potent mu opioid agonist misuse in opioid-dependent individuals	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						fentanyl; mu opioid agonists; abuse; pain management; opioid exposure	MEDICAL USE; ABUSE; ANALGESICS; TRENDS; ADDICTION; STATES	Purpose Based on preclinical and clinical abuse liability assessments, fentanyl and other potent mu opioid agonists (e.g., hydromorphone and morphine) should be the most misused opioids if accessibility in the real world were not an issue. Since the latter is seldom true, we postulated that there would be a significant mismatch between actual and predicted rates of misuse. Methods We recruited 1818 prescription-opioid dependent patients entering drug treatment programs to complete an anonymous survey, covering drug use and health related issues. Results Hydrocodone and oxycodone products were the drugs of choice in 75% of patients, whereas potent pc opioid agonists (fentanyl, hydromorphone, and morphine), with the greatest predicted abuse potential, were very rarely chosen (<5% each). Most unexpectedly, the rank order of the actual drug of choice and the preferred drug in an ideal world were highly correlated. The reason most commonly given for the failure to endorse fentanyl, for example, as an actual or preferred drug, was fear of toxicity and overdose. We found few differences in drug use patterns between a subset of high-risk, impaired health care professionals (N = 196), and all other patients other than source of drug (forged prescriptions and doctors more common and dealers much less common in the HC sample). Conclusions These results indicate that it should not be assumed - particularly for new drug formulations that a high potential for abuse will result in actual abuse; and, most importantly, that the hesitancy to use potent opioids because of fears of abuse may be misguided. Copyright (C) 2010 John Wiley & Sons, Ltd.	[Cicero, Theodore J.; Ellis, Matthew S.; Paradis, Alethea; Ortbal, Zachary] Washington Univ, Dept Psychiat, St Louis, MO 63110 USA	Cicero, TJ (reprint author), Washington Univ, Dept Psychiat, Campus Box 8134,660 S Euclid Ave, St Louis, MO 63110 USA.	Cicerot@wustl.edu		Ellis, Matthew/0000-0003-3753-9651	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5 R01 DA20791-04]; RADARS Registered System; RADARSRegistered System	This research was supported in part by NIH grant 5 R01 DA20791-04 and an unrestricted grant from the RADARS (R) System.	[Anonymous], 1994, DIAGN STAT MAN MENT; Baldisseri MR, 2007, CRIT CARE MED, V35, pS106, DOI 10.1097/01.CCM.0000252918.87746.96; Baylon GJ, 2000, J CLIN PSYCHOPHARM, V20, P597, DOI 10.1097/00004714-200012000-00002; Broadbear JH, 2004, PSYCHOPHARMACOLOGY, V176, P398, DOI 10.1007/s00213-004-1891-x; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; Cicero T. J, 2008, ADV PAIN MANAGE, V2, P17; Cicero TJ, 2007, DRUG ALCOHOL DEPEN, V91, P115, DOI 10.1016/j.drugalcdep.2007.05.008; Cicero TJ, 2007, PHARMACOEPIDEM DR S, V16, P827, DOI 10.1002/pds.1452; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; CLARK HW, 2006, SUBSTANCE ABUSE MENT; DOMINO K, 2005, JAMA-J AM MED ASSOC, V293, P1513; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; Fodale V, 2008, EXPERT OPIN DRUG SAF, V7, P213, DOI [10.1517/14740338.7.3.213, 10.1517/14740338.7.3.213 ]; Greenwald MK, 2008, DRUG ALCOHOL DEPEN, V93, P103, DOI 10.1016/j.drugalcdep.2007.09.002; Griffiths RR, 2003, DRUG ALCOHOL DEPEN, V70, pS41, DOI 10.1016/S0376-8716(03)00098-X; HURSH SR, 1995, J EXP ANAL BEHAV, V64, P373, DOI 10.1901/jeab.1995.64-373; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; JOSEPH D, 2005, DRUGS ABUSE US DEP J; Kalvass JC, 2007, J PHARMACOL EXP THER, V323, P346, DOI 10.1124/jpet.107.119560; Katz N, 2008, CLIN J PAIN, V24, P528, DOI 10.1097/AJP.0b013e318167a087; Maher-Brisen P, 2007, AM J NURS, V107, P78, DOI 10.1097/01.NAJ.0000282302.49183.67; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; Novak S, 2004, PAIN MED, V5, P59, DOI 10.1111/j.1526-4637.2004.04001.x; PCHELINTSEV MV, 1991, PHARMACOL BIOCHEM BE, V39, P873, DOI 10.1016/0091-3057(91)90046-5; Pooler D, 2009, J ADDICT DIS, V28, P113, DOI 10.1080/10550880902772415; PORTENOY RK, 2004, [No title captured], P863; Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; Sellers Edward M, 2006, J Opioid Manag, V2, P219; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019	29	18	18	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	OCT	2010	19	10					1057	1063		10.1002/pds.1989			7	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	667OB	WOS:000283202300009	20597128	Green Accepted			2020-06-30	J	Middleton, PM; Simpson, PM; Sinclair, G; Dobbins, TA; Bendall, JC				Middleton, Paul M.; Simpson, Paul M.; Sinclair, Gary; Dobbins, Timothy A.; Bendall, Jason C.			EFFECTIVENESS OF MORPHINE, FENTANYL, AND METHOXYFLURANE IN THE PREHOSPITAL SETTING	PREHOSPITAL EMERGENCY CARE			English	Article						prehospital; pain; analgesia; morphine; fentanyl; methoxyflurane	RANDOMIZED CONTROLLED-TRIAL; VISUAL ANALOG SCALE; INTRANASAL FENTANYL; INTRAVENOUS MORPHINE; ORAL MORPHINE; PAIN; ANALGESIA; GENDER; CARE; ACUPRESSURE	Objective. To compare the effectiveness of intravenous (IV) morphine, intranasal (IN) fentanyl, and inhaled methoxyflurane when administered by paramedics to patients with moderate to severe pain. Methods. We conducted a retrospective comparative study of adult patients with moderate to severe pain treated by paramedics from the Ambulance Service of New South Wales who received IV morphine, IN fentanyl, or inhaled methoxyflurane either alone or in combination between January 1, 2004, and November 30, 2006. We used multivariate logistic regression to analyze data extracted from a clinical database containing routinely entered information from patient health care records. The primary outcome measure was effective analgesia, defined as a reduction in pain severity of >= 30% of initial pain score using an 11-point verbal numeric rating scale (VNRS-11). Results. The study population comprised 52,046 patients aged between 16 and 100 years with VNRS-11 scores of >= 5. All analgesic agents were effective in the majority of patients (81.8%, 80.0%, and 59.1% for morphine, fentanyl, and methoxyflurane, respectively). There was very strong evidence that methoxyflurane was inferior to both morphine and fentanyl (p < 0.0001). There was strong evidence that morphine was more effective than fentanyl (p = 0.002). There was no evidence that combination analgesia was better than either fentanyl or morphine alone. Conclusion. Inhaled methoxyflurane, IN fentanyl, and IV morphine are all effective analgesic agents in the out-of-hospital setting. Morphine and fentanyl are significantly more effective analgesic agents than methoxyflurane. Morphine appears to be more effective than IN fentanyl; however, the benefit of IV morphine may be offset to some degree by the ability to administer IN fentanyl without the need for IV access.	[Middleton, Paul M.; Simpson, Paul M.; Sinclair, Gary; Bendall, Jason C.] Ambulance Res Inst, Ambulance Serv New S Wales, Rozelle, NSW 2039, Australia; [Dobbins, Timothy A.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	Middleton, PM (reprint author), Ambulance Res Inst, Ambulance Serv New S Wales, Locked Bag 105, Rozelle, NSW 2039, Australia.	pmmiddleton@ambulance.nsw.gov.au	Dobbins, Timothy/I-5819-2013; Simpson, Paul/N-7447-2019; Middleton, Paul M/A-9084-2012	Dobbins, Timothy/0000-0003-1841-9056; Simpson, Paul/0000-0003-3875-0061; Middleton, Paul M/0000-0003-0760-1098; Bendall, A/Prof Jason/0000-0002-8688-2192			Affleck G, 1999, PAIN, V83, P601, DOI 10.1016/S0304-3959(99)00167-0; Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; *AMB SERV NEW S WA, 2008, AMB SERV NEW S WAL P; *AMB SERV NEW S WA, 2006, ANN REP 2006 07 AMB; Babl Franz E, 2006, Emerg Med Australas, V18, P404, DOI 10.1111/j.1742-6723.2006.00874.x; Barker R, 2006, ACAD EMERG MED, V13, P19, DOI 10.1197/j.aem.2005.07.014; Bertalanffy A, 2005, ACAD EMERG MED, V12, P607, DOI 10.1197/j.aem.2005.01.013; Bertalanffy P, 2006, BJOG-INT J OBSTET GY, V113, P1031, DOI 10.1111/j.1471-0528.2006.01030.x; Black IH, 2009, PREHOSP EMERG CARE, V13, P223, DOI 10.1080/10903120802290778; Borland ML, 2009, EMERG MED AUSTRALAS, V21, P246, DOI 10.1111/j.1742-6723.2009.01192.x; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Buntine P, 2007, EMERG MED AUSTRALAS, V19, P509, DOI 10.1111/j.1742-6723.2007.01017.x; Cepeda MS, 2003, PAIN, V105, P151, DOI 10.1016/S0304-3959(03)00176-3; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Colwell C, 2009, PREHOSP EMERG CARE, V13, P237, DOI 10.1080/10903120802706138; Edwards RR, 1999, CLIN J PAIN, V15, P233, DOI 10.1097/00002508-199909000-00011; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Lang T, 2007, AM J EMERG MED, V25, P887, DOI 10.1016/j.ajem.2007.01.016; Lang T, 2007, J TRAUMA, V62, P184, DOI 10.1097/01.ta.0000197176.75598.fc; Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; Manjushree R, 2002, CAN J ANAESTH, V49, P190; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; Nuhr M, 2004, SPINE, V29, P1499, DOI 10.1097/01.BRS.0000131439.87553.99; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Silfvast T, 2001, Eur J Emerg Med, V8, P275, DOI 10.1097/00063110-200112000-00005; Unruh AM, 1999, CLIN J PAIN, V15, P31, DOI 10.1097/00002508-199903000-00006; Ward M E, 1997, Prehosp Disaster Med, V12, P158; Woollard M, 2004, EMERG MED J, V21, P362, DOI 10.1136/emj.2004.014324	36	43	43	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	OCT-DEC	2010	14	4					439	447		10.3109/10903127.2010.497896			9	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	663QE	WOS:000282901800005	20809687				2020-06-30	J	Jamstorp, E; Forsgren, J; Bredenberg, S; Engqvist, H; Stromme, M				Jamstorp, Erik; Forsgren, Johan; Bredenberg, Susanne; Engqvist, Hakan; Stromme, Maria			Mechanically strong geopolymers offer new possibilities in treatment of chronic pain	JOURNAL OF CONTROLLED RELEASE			English	Article						Geopolymers; Porous; Abuse-secured; Opioids; Chronic pain; Fentanyl		We propose that a clay derived class of materials, known as geopolymers, may solve the problem of finding materials for controlled release with the right combination of properties necessary for a safe and sustained oral delivery of highly potent opioids. We show that the opioid Fentanyl, and its structurally similar sedative Zolpidem, can be embedded into metakaolin based geopolymer pellets to provide prolonged release dosage forms with mechanical strengths of the same order of magnitude as that of human teeth. The results presented in the current work may open up new opportunities for future development of drug delivery for high potency drugs employing high-strength and variable-pore-structure geopolymers and materials alike. (c) 2010 Elsevier B.V. All rights reserved.	[Engqvist, Hakan] Uppsala Univ, Angstrom Lab, Dept Engn Sci, Div Appl Mat Sci, SE-75121 Uppsala, Sweden; [Jamstorp, Erik; Forsgren, Johan; Stromme, Maria] Uppsala Univ, Angstrom Lab, Dept Engn Sci, Div Nanotechnol & Funct Mat, SE-75121 Uppsala, Sweden; [Bredenberg, Susanne] Orexo AB, SE-75105 Uppsala, Sweden	Engqvist, H (reprint author), Uppsala Univ, Angstrom Lab, Dept Engn Sci, Div Appl Mat Sci, POB 534, SE-75121 Uppsala, Sweden.	hakan.engqvist@angstrom.uu.se; maria.stromme@angstrom.uu.se	Berg, Erik J./AAG-9424-2020; Forsgren, Johan/D-3627-2009; J. Berg, Erik/G-4999-2017	Berg, Erik J./0000-0001-5653-0383; J. Berg, Erik/0000-0001-5653-0383; Engqvist, Hakan/0000-0001-9529-650X	VinnovaVinnova; Uppsala BIO-X	The Swedish funding agency Vinnova and Uppsala BIO-X are greatly acknowledged for financial support of this project and Orexo AB is acknowledged for supplying the active substances and making their equipment available to us.	[Anonymous], 58332002 ISO; Auerbach S.M., 2003, HDB ZEOLITE SCI TECH; Aulton M. E., 2002, PHARM SCI DOSAGE FOR; Bakharev T, 2005, CEMENT CONCRETE RES, V35, P658, DOI 10.1016/j.cemconres.2004.06.005; Barsoum MW, 2006, J AM CERAM SOC, V89, P3788, DOI 10.1111/j.1551-2916.2006.01308.x; Bortnovsky O, 2008, J AM CERAM SOC, V91, P3052, DOI 10.1111/j.1551-2916.2008.02577.x; Brinker C.J., 1990, SOL GEL SCI PHYS CHE; Callister W.D., 1997, MAT SCI ENG INTRO; Chen J, 2000, J CONTROL RELEASE, V64, P39, DOI 10.1016/S0168-3659(99)00139-X; Crank J., 1975, MATH DIFFUSION; DAVIDOVITS J, 1991, J THERM ANAL, V37, P1633, DOI 10.1007/BF01912193; Davidovits J, 1988, PYRAMIDS ENIGMA SOLV; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Duxson P, 2007, J MATER SCI, V42, P2917, DOI 10.1007/s10853-006-0637-z; Duxson P, 2005, COLLOID SURFACE A, V269, P47, DOI 10.1016/j.colsurfa.2005.06.060; Duxson P, 2007, CEMENT CONCRETE RES, V37, P1590, DOI 10.1016/j.cemconres.2007.08.018; Fernandez-Jimenez A, 2007, J MATER SCI, V42, P3055, DOI 10.1007/s10853-006-0584-8; Forsgren J, 2010, J PHARM SCI-US, V99, P219, DOI 10.1002/jps.21814; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Komnitsas K, 2007, MINER ENG, V20, P1261, DOI 10.1016/j.mineng.2007.07.011; Kralj M, 2003, EMBO REP, V4, P1008, DOI 10.1038/sj.embor.7400017; Kriven WM, 2003, CERAM TRANS, V153, P227; KYDONIEUS A, 1992, TREATISE CONTROLLED; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Oudadesse H, 2007, J MATER SCI, V42, P3092, DOI 10.1007/s10853-006-0524-7; Palomo A, 1999, CEMENT CONCRETE RES, V29, P997, DOI 10.1016/S0008-8846(99)00074-5; Ranade VV, 2003, DRUG DELIVERY SYSTEM; Rice R.W., 1998, POROSITY CERAMICS; Riley J, 2004, PALLIATIVE MED, V18, P19, DOI 10.1191/0269216304pm856oa; Rohrig Timothy P, 2005, Forensic Sci Med Pathol, V1, P81, DOI 10.1385/FSMP:1:2:081; ROSSLER M, 1985, CEMENT CONCRETE RES, V15, P320; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; SIMMONDS MA, 1992, J PAIN SYMPTOM MA S3, V7, P36; Sloan Paul, 2006, Expert Opin Drug Deliv, V3, P489, DOI 10.1517/17425247.3.4.489; Steveson M, 2005, J MATER SCI, V40, P2023, DOI 10.1007/s10853-005-1226-2; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; *US PHARM CONV INC, 1997, US PHARM USP; Vogel S, 2003, COMP BIOMECHANICS LI; World Health Organization, 1996, CANC PAIN REL GUID O; YUEN KH, 1993, INT J PHARMACEUT, V97, P61, DOI 10.1016/0378-5173(93)90127-2; Zhang HY, 2006, MICROPOR MESOPOR MAT, V88, P312, DOI 10.1016/j.micromeso.2005.09.026	43	19	19	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-3659	1873-4995		J CONTROL RELEASE	J. Control. Release	SEP 15	2010	146	3					370	377		10.1016/j.jconrel.2010.05.029			8	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	657FH	WOS:000282398100014	20685295				2020-06-30	J	Bekhit, MH				Bekhit, Mary Hanna			Opioid-Induced Hyperalgesia and Tolerance	AMERICAN JOURNAL OF THERAPEUTICS			English	Article						opioid; hyperalgesia; tolerance; NMDA; ketamine; nitric oxide; rostral ventromedial medulla; tonic descending facilitation; central sensitization; neuronal plasticity; cholecystokinin; dynorphin; neuroinflammation	ROSTRAL VENTROMEDIAL MEDULLA; INDUCED ABNORMAL PAIN; POSTOPERATIVE PAIN; MORPHINE-TOLERANCE; FENTANYL; KETAMINE; FACILITATION; MECHANISMS; ABSTINENCE; NEURONS	We have all encountered the following postanesthesia care unit dilemma a myriad of times. As the attending covering the postanesthesia care unit, the anesthesiologist will be confronted not infrequently with the following clinical scenario: "He needed 500 mu g fentanyl in the operating room for a toe amputation and has received 20 mg morphine, and he's still complaining of severe pain .... Do you think he may need more morphine?" Opiates do prevail as first-line therapy for moderate to severe surgical and chronic pain states. However, their use may actually confound the clinical picture postoperatively, because opiate exposure counterintuitively may actually trigger exaggerated pain sensation. When assessing a patient experiencing exaggerated postoperative or chronic pain, several questions should come to mind. First, is this patient experiencing tolerance or hyperalgesia induced by opiate therapy? Second, does the management differ for the two etiologies? Third, what underlying mechanisms, both at the neuroanatomic and molecular/chemical levels, underlie the two processes? Fourth, how does the recent literature on opiate-induced hyperalgesia influence previously accepted views of pre-emptive analgesia? Fifth, what treatment modalities exist for opiate-induced hyperalgesia? Most importantly, sixth, how can opiate-induced hyperalgesia be prevented? In this literature review, we aim to address these questions and to hopefully change the current perception and management of perioperative and chronic pain states with opiates.	Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Dept Anesthesiol, Los Angeles, CA 90095 USA	Bekhit, MH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Dept Anesthesiol, 757 Westwood Plaza,Suite 3225, Los Angeles, CA 90095 USA.	mbekhit@mednet.ucla.edu					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bilsky EJ, 1996, PAIN, V68, P229, DOI 10.1016/S0304-3959(96)03185-5; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; Chang G, 2007, MED CLIN N AM, V91, P199, DOI 10.1016/j.mcna.2006.10.003; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; DeLeo JA, 2004, NEUROSCIENTIST, V10, P40, DOI 10.1177/1073858403259950; Eisenach JC, 2000, ANESTHESIOLOGY, V92, P308, DOI 10.1097/00000542-200002000-00009; FIELDS HL, 1983, J NEUROSCI, V3, P2545; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; KAPLAN H, 1991, J NEUROSCI, V11, P1433; Kissin I, 2000, ANESTH ANALG, V91, P110, DOI 10.1097/00000539-200007000-00021; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Li XQ, 2002, ANESTH ANALG, V95, P979, DOI 10.1097/00000539-200210000-00035; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; MORGAN MM, 1994, J NEUROPHYSIOL, V72, P1161; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Ossipov MH, 2003, LIFE SCI, V73, P783, DOI 10.1016/S0024-3205(03)00410-7; RANNEY D, 1996, ONT INT PAIN C WAT N; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Toda N, 2009, ANESTHESIOLOGY, V110, P166, DOI 10.1097/ALN.0b013e31819146a9; Vanderah TW, 2007, MED CLIN N AM, V91, P1, DOI 10.1016/j.mcna.2006.10.006; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001	31	62	70	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	SEP-OCT	2010	17	5					498	510		10.1097/MJT.0b013e3181ed83a0			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	650KC	WOS:000281847100009	20844348				2020-06-30	J	Lim, Y; Chakravarty, S; Ocampo, CE; Sia, AT				Lim, Y.; Chakravarty, S.; Ocampo, C. E.; Sia, A. T.			Comparison of automated intermittent low volume bolus with continuous infusion for labour epidural analgesia	ANAESTHESIA AND INTENSIVE CARE			English	Article						epidural analgesia; combined spinal epidural; continuous epidural infusion; epidural boluses	CATHETERS; FENTANYL	Delivery of local anaesthetics via automated intermittent bolus has been shown to improve epidural analgesia compared to delivery via continuous epidural infusion. However, the optimal bolus volume has not been investigated. This randomised, double-blind study compared the analgesic efficacy of automated intermittent bolus (volume 2.5 ml every 15 minutes) with that of a continuous epidural infusion (10 ml/hour) for the maintenance of labour epidural analgesia, to determine whether the advantages previously demonstrated for automated intermittent bolus over continuous epidural infusion are retained at this low bolus volume. With the approval of the Hospital Ethics Committee, we recruited 50 parturients who received combined spinal epidural analgesia with intrathecal ropivacaine 2 mg and fentanyl 15 mg. For epidural maintenance, participants were randomised to either the automated intermittent bolus group (2.5 ml automated intermittent epidural boluses of ropivacaine 0.1% plus fentanyl 2 mu g/ml delivered over a two-minute period every 15 minutes) or the continuous epidural infusion group (continuous epidural infusion of ropivacaine 0.1% plus fentanyl 2 mu g/ml at 10 ml/hour). The primary study outcome was the incidence of pain during labour that required management with supplemental epidural analgesia. There were no significant differences between the two regimens in terms of breakthrough pain (automated intermittent bolus 36% [9/25] vs continuous epidural infusion 32% [8/25], P=0.77). At the doses used in this study, maintenance of labour analgesia using automated intermittent bolus at a bolus volume of 2.5 ml every 15 minutes does not decrease the incidence of breakthrough pain or improve analgesic efficacy compared to continuous epidural infusion.	[Lim, Y.; Chakravarty, S.; Ocampo, C. E.; Sia, A. T.] Kandang Kerbau Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore 229899, Singapore	Lim, Y (reprint author), Kandang Kerbau Womens & Childrens Hosp, Dept Womens Anaesthesia, 100 Bukit Timah Rd, Singapore 229899, Singapore.	YVEL6@hotmail.com					Boutros A, 1999, INT J OBSTET ANESTH, V8, P236, DOI 10.1016/S0959-289X(99)80103-4; Christiaens F, 1998, REGION ANESTH PAIN M, V23, P134, DOI 10.1097/00115550-199823020-00004; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; DAngelo R, 1997, ANESTH ANALG, V84, P1276, DOI 10.1097/00000539-199706000-00019; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; POWER I, 1988, ANAESTHESIA, V43, P876; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Yokoyama M, 2004, ANESTHESIOLOGY, V100, P1504, DOI 10.1097/00000542-200406000-00024	11	14	16	0	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	SEP	2010	38	5					894	899		10.1177/0310057X1003800514			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	651GW	WOS:000281916700014	20865875	Bronze			2020-06-30	J	Hong, JY; Kim, WO; Koo, BN; Cho, JS; Suk, EH; Kil, HK				Hong, Jeong-Yeon; Kim, Won Oak; Koo, Bon Nyeo; Cho, Jin Sun; Suk, Eun H.; Kil, Hae Keum			Fentanyl-sparing Effect of Acetaminophen as a Mixture of Fentanyl in Intravenous Parent-/Nurse-controlled Analgesia after Pediatric Ureteroneocystostomy	ANESTHESIOLOGY			English	Article							PATIENT-CONTROLLED ANALGESIA; PARACETAMOL ACETAMINOPHEN; VESICOURETERAL REFLUX; RECTAL PARACETAMOL; CHILDREN; PHARMACOKINETICS; PROPACETAMOL; SAFETY; KETOROLAC; EFFICACY	Background: Although acetaminophen has been used widely and is well tolerated in children, its efficacy and safety have not been clarified when combined with an opioid in intravenous parent-/nurse-controlled postoperative analgesia. Methods: Sixty-three children (aged 6-24 months) who had undergone elective ureteroneocystostomies were enrolled in this prospective, randomized, double-blinded study. After the surgery, an analgesic pump was programmed to deliver fentanyl at a basal infusion rate of 0.25 mu g . kg(-1) . h(-1) and 0.25 mu g/kg bolus after a loading dose of 0.5 mu g/kg. In the fentanyl-acetaminophen group, acetaminophen was coadministered as a solution mixture at a basal infusion rate of 1.5 mg . kg(-1) . h(-1) and 1.5 mg/kg bolus after a loading dose of 15 mg/kg, whereas saline was administered to the fentanyl group. Results: Postoperative pain scores were similar between the two groups. The total dose (micrograms per kilogram per day, mean +/- SD) of fentanyl at postoperative days 1 (8.3 +/- 3.7 vs. 18.1 +/- 4.6, P = 0.021) and 2 (7.0 +/- 2.4 vs. 16.6, P = 0.042) was significantly less in the fentanyl-acetaminophen group compared with that in the fentanyl group. The incidences of vomiting (16.1 vs. 56.3%, P = 0.011) and sedation (9.7 vs. 46.9%, P = 0.019) were significantly lower in the fentanyl-acetaminophen group than those in the fentanyl group. Conclusions: Acetaminophen has significant fentanyl-sparing effects and reduces side effects when combined with fentanyl in intravenous parent-/nurse-controlled analgesia for postoperative pediatric pain management.	[Hong, Jeong-Yeon; Kim, Won Oak; Koo, Bon Nyeo; Cho, Jin Sun; Kil, Hae Keum] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea; [Suk, Eun H.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, 250 Seongsanno, Seoul 120752, South Korea.	hkkil@yuhs.ac		Cho, Jin Sun/0000-0002-5408-4188			Agrawal D, 2004, ANN EMERG MED, V43, P247, DOI 10.1016/S0196-0644(03)00721-2; Anderson BJ, 2005, PEDIATR ANESTH, V15, P282, DOI 10.1111/j.1460-9592.2005.01455.x; Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; Anghelescu DL, 2005, ANESTH ANALG, V101, P1623, DOI 10.1213/01.ANE.0000184198.13285.33; Choi SH, 2008, J KOREAN MED SCI, V23, P122, DOI 10.3346/jkms.2008.23.1.122; Cobby TF, 1999, BRIT J ANAESTH, V83, P253, DOI 10.1093/bja/83.2.253; Czarnecki ML, 2008, CLIN J PAIN, V24, P817, DOI 10.1097/AJP.0b013e3181773b69; DELBOS A, 1995, J PAIN SYMPTOM MANAG, V10, P279, DOI 10.1016/0885-3924(95)00004-I; ELLSWORTH PI, 1995, J PEDIATR SURG, V30, P600, DOI 10.1016/0022-3468(95)90141-8; Feierman DE, 2000, ACTA ANAESTH SCAND, V44, P560, DOI 10.1034/j.1399-6576.2000.00513.x; Gaitan G, 2005, LIFE SCI, V77, P85, DOI 10.1016/j.lfs.2004.12.022; GAUKROGER PB, 1989, ANAESTH INTENS CARE, V17, P264, DOI 10.1177/0310057X8901700304; Gibb IA, 2008, ARCH DIS CHILD, V93, P241, DOI 10.1136/adc.2007.126896; Gill AM, 1996, ANN PHARMACOTHER, V30, P125, DOI 10.1177/106002809603000202; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Monitto CL, 2000, ANESTH ANALG, V91, P573, DOI 10.1213/00000539-200009000-00014; Palmer GM, 2008, BRIT J ANAESTH, V101, P523, DOI 10.1093/bja/aen208; Palmer GM, 2007, ANAESTH INTENS CARE, V35, P702, DOI 10.1177/0310057X0703500507; Park JM, 2000, ANESTH ANALG, V91, P11, DOI 10.1097/00000539-200007000-00003; Prins SA, 2008, PEDIATR ANESTH, V18, P582, DOI 10.1111/j.1460-9592.2008.02619.x; Remy C, 2005, BRIT J ANAESTH, V94, P505, DOI 10.1093/bja/aei085; REUNANEN M, 1995, J UROLOGY, V154, P2156, DOI 10.1016/S0022-5347(01)66720-X; Symons JA, 2008, CLIN J PAIN, V24, P647, DOI 10.1097/AJP.0b013e3181706ca2; VETTER TR, 1994, J CLIN ANESTH, V6, P110, DOI 10.1016/0952-8180(94)90006-X; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Wilson-Smith EM, 2009, PEDIATR ANESTH, V19, P329, DOI 10.1111/j.1460-9592.2009.02947.x; Wong D L, 1988, Pediatr Nurs, V14, P9	27	30	30	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2010	113	3					672	677		10.1097/ALN.0b013e3181e2c34b			6	Anesthesiology	Anesthesiology	642WL	WOS:000281251600022	20693884	Bronze			2020-06-30	J	Kuczkowski, KM; Fernandez, CL; Drobnik, L; Chandra, S				Kuczkowski, Krzysztof M.; Fernandez, Claudia L.; Drobnik, Leon; Chandra, Susilo			Anesthesia for cesarean section in a parturient with Charcot-Marie-Tooth disease: unresolved controversies	ARCHIVES OF GYNECOLOGY AND OBSTETRICS			English	Letter									[Kuczkowski, Krzysztof M.] Univ Med Ctr El Paso, Dept Anesthesiol, El Paso, TX USA; [Kuczkowski, Krzysztof M.] Univ Med Ctr El Paso, Dept Obstet & Gynecol, El Paso, TX USA; [Fernandez, Claudia L.] Juan A Fernandez Hosp, Dept Anesthesiol, Buenos Aires, DF, Argentina; [Drobnik, Leon] Karol Marcinkowski Med Univ, Dept Anesthesiol, Poznan, Poland; [Chandra, Susilo] Univ Indonesia, Dept Anesthesiol, Jakarta, Indonesia	Kuczkowski, KM (reprint author), Univ Med Ctr El Paso, Dept Anesthesiol, 4800 Alberta Ave, El Paso, TX USA.	kmkuczkowski@gmail.com					Argov Z, 2009, NEUROMUSCULAR DISORD, V19, P675, DOI 10.1016/j.nmd.2009.07.004; Brock Macy, 2009, AANA J, V77, P335; Hoff JM, 2005, NEUROLOGY, V64, P459, DOI 10.1212/01.WNL.0000150933.65709.96; Pareyson D, 2009, LANCET NEUROL, V8, P654, DOI 10.1016/S1474-4422(09)70110-3; Szigeti K, 2009, EUR J HUM GENET, V17, P703, DOI 10.1038/ejhg.2009.31	5	1	1	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-0067			ARCH GYNECOL OBSTET	Arch. Gynecol. Obstet.	SEP	2010	282	3					347	348		10.1007/s00404-010-1417-1			2	Obstetrics & Gynecology	Obstetrics & Gynecology	634XD	WOS:000280618600019	20229081				2020-06-30	J	Bang, SR; Yu, SK; Kim, TH				Bang, Si Ra; Yu, Su Kyung; Kim, Tae Hyeong			Can Gabapentin Help Reduce Postoperative Pain in Arthroscopic Rotator Cuff Repair? A Prospective, Randomized, Double-Blind Study	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article							PATIENT-CONTROLLED ANALGESIA; SURGERY; MANAGEMENT; INFUSION; PREGABALIN; DRUGS	Purpose: The aim of the study was to determine the effect of low-dose gabapentin on postoperative pain management in patients undergoing arthroscopic rotator cuff repair. Methods: This randomized, double-blinded, placebo-controlled study included 46 patients. The patients were divided into 2 groups according to the drug administered 2 hours before surgery, either 300 mg of gabapentin or placebo. The primary outcome measure was the visual analog scale (VAS) score at 2, 6, 12, and 24 hours postoperatively. The secondary outcome measures were fentanyl consumption and side effects during the first 2 hours in the postanesthesia care unit and then at 6 and 24 hours postoperatively. The patients were evaluated for side effects including nausea, vomiting, respiratory depression, dizziness, drowsiness, voiding difficulty, and pruritus. Results: The VAS scores at 2, 6, and 12 hours postoperatively were significantly lower in the gabapentin group than in the placebo group (P = .023, P = .019, and P = .022, respectively). The consumption of fentanyl, over a period of 24 hours, was not different in the comparisons between the groups (P = .686). The incidence of side effects was similar in the 2 groups. Conclusions: A single dose of 300 mg of gabapentin reduced the VAS score during the first 24 hours postoperatively in patients undergoing shoulder arthroscopic rotator cuff repair, without significant side effects when compared with placebo. However, the fentanyl consumption did not differ between the gabapentin and placebo groups. Level of Evidence: Level I, randomized controlled trial.	[Bang, Si Ra; Yu, Su Kyung; Kim, Tae Hyeong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea	Kim, TH (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, 50 Ilwon Dong, Seoul, South Korea.	bluecar.kim@samsung.com					Al-Mujadi H, 2006, CAN J ANAESTH, V53, P268, DOI 10.1007/BF03022214; Barber FA, 2002, ARTHROSCOPY, V18, P76, DOI 10.1053/jars.2002.25976; Borgeat Alain, 2002, Best Pract Res Clin Anaesthesiol, V16, P211, DOI 10.1053/bean.2002.0234; Cho NS, 2007, AM J SPORT MED, V35, P75, DOI 10.1177/0363546506291632; Ciccone WJ, 2008, ARTHROSCOPY, V24, P14, DOI 10.1016/j.arthro.2007.07.021; Coghlan JA, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-56; Dahl JB, 2004, ACTA ANAESTH SCAND, V48, P1130, DOI 10.1111/j.1399-6576.2004.00484.x; Hayashida K, 2007, ANESTHESIOLOGY, V106, P557, DOI 10.1097/00000542-200703000-00021; Ho KY, 2006, PAIN, V126, P91, DOI 10.1016/j.pain.2006.06.018; Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316; Lanas Angel, 2006, Chin J Dig Dis, V7, P127, DOI 10.1111/j.1443-9573.2006.00257.x; Menigaux C, 2005, ANESTH ANALG, V100, P1394, DOI 10.1213/01.ANE.0000152010.74739.B8; Moiniche S, 2003, ANESTH ANALG, V96, P68, DOI 10.1213/01.ANE.0000040583.65135.57; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Oh JH, 2009, ARTHROSCOPY, V25, P30, DOI 10.1016/j.arthro.2008.08.010; Pandey CK, 2004, CAN J ANAESTH, V51, P358, DOI 10.1007/BF03018240; Pannu N, 2008, CRIT CARE MED, V36, pS216, DOI 10.1097/CCM.0b013e318168e375; Rees JL, 2008, J BONE JOINT SURG BR, V90B, P827, DOI 10.1302/0301-620X.90B7.19874; Taylor CP, 2009, PAIN, V142, P13, DOI 10.1016/j.pain.2008.11.019; Turan A, 2006, ANESTH ANALG, V102, P175, DOI 10.1213/01.ane.0000184824.43411.63	20	38	38	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063	1526-3231		ARTHROSCOPY	Arthroscopy	SEP	2010	26	9		1			S106	S111		10.1016/j.arthro.2009.11.010			6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	645EQ	WOS:000281434100014	20810085				2020-06-30	J	Inomata, S; Maeda, T; Shimizu, T; Satsumae, T; Tanaka, M				Inomata, S.; Maeda, T.; Shimizu, T.; Satsumae, T.; Tanaka, M.			Effects of fentanyl infusion on tracheal intubation and emergence agitation in preschool children anaesthetized with sevoflurane	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics opioid, fentanyl; anaesthetics volatile, sevoflurane; paediatrics; potency, anaesthetic, MAC	PEDIATRIC-PATIENTS; ANESTHESIA; HALOTHANE; RECOVERY; SURGERY; MYRINGOTOMY; PREVENTION; DESFLURANE; CLONIDINE; PROPOFOL	Background. Sevoflurane can be used as a sole agent for intubation in children, but studies have suggested that it is associated with emergence agitation. Fentanyl infusions can be used both to facilitate intubation and decrease emergence agitation. We investigated the effects of fentanyl on conditions at intubation and on emergence from sevoflurane anaesthesia without confounding nitrous oxide or premedication. Methods. IRB approval and informed consent were obtained. Subjects comprised 150 ASA physical status I or II (age, 2-6 yr). Anaesthesia was induced with sevoflurane in oxygen and maintained using a predetermined concentration of sevoflurane. Subjects were randomly allocated to receive one of three doses of fentanyl: vehicle only (control group), a bolus dose of 1 mu g kg(-1) followed by a continuous infusion of 0.5 mu g kg(-1) h(-1) (F1 group), or a bolus dose of 2 mu g kg(-1) followed by a continuous infusion of 1 mu g kg(-1) h(-1) (F2 group). Sevoflurane minimum alveolar concentration for tracheal intubation (MAC(TI)) and emergence agitation score were assessed. Results. MAC(TI) values were 2.49%, 1.61%, and 1.16% in control, F1, and F2 groups, respectively (P<0.05). Agitation scores were 11.5, 7.0, and 2.6 in control, F1, and F2 groups, respectively (P<0.05). Conclusions. Fentanyl infusion consisting of a bolus dose of 2 mu g kg(-1) followed by a continuous infusion of 1 mu g kg(-1) h(-1) facilitates tracheal intubation and smooth emergence in children anaesthetized using sevoflurane.	[Inomata, S.; Maeda, T.; Shimizu, T.; Satsumae, T.; Tanaka, M.] Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan	Inomata, S (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan.	inomatas@md.tsukuba.ac.jp					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Fazi L, 2001, ANESTH ANALG, V92, P56; Galford RE, 1992, PROBLEMS ANESTHESIOL, P341; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Inomata S, 2000, BRIT J ANAESTH, V85, P700, DOI 10.1093/bja/85.5.700; INOMATA S, 1994, ANESTHESIOLOGY, V80, P93, DOI 10.1097/00000542-199401000-00016; Katoh T, 1999, BRIT J ANAESTH, V82, P561; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Li Y, 2008, J NEUROSCI, V28, P2814, DOI 10.1523/JNEUROSCI.5447-07.2008; Rose JB, 1999, BRIT J ANAESTH, V83, P104; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; TOMI K, 1993, BRIT J ANAESTH, V70, P684, DOI 10.1093/bja/70.6.684; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012	21	17	26	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	SEP	2010	105	3					361	367		10.1093/bja/aeq168			7	Anesthesiology	Anesthesiology	653FQ	WOS:000282074300017	20627877	Bronze			2020-06-30	J	Arslan, M; Canturk, M; Ornek, D; Gamli, M; Pala, Y; Dikmen, B; Basaran, M				Arslan, Mahmut; Canturk, Mehmet; Ornek, Dilsen; Gamli, Mehmet; Pala, Yasar; Dikmen, Bayazit; Basaran, Meleksah			Regional intravenous anesthesia in knee arthroscopy	CLINICS			English	Article						Regional Intravenous Anesthesia; RIVA; Arthroscopy; Prilocaine; Analgesia; Motor block	INDUCED METHEMOGLOBINEMIA; BIER BLOCK; KETAMINE; SURGERY; FOOT; ANKLE	OBJECTIVE: The goal of the study was to investigate the regional intravenous anesthesia procedure in knee arthroscopy and to evaluate the effects of adding ketamine over the anesthesia block charactery and tourniquet pain. MATERIAL/METHOD: Forty American Society of Anesthesiologists (ASA) II patients who received knee arthroscopy were enrolled. After monitoring, a peripheral IV line was inserted. The venous blood in the lower extremity was evacuated with a bandage, and the proximal cuff of the double-cuff tourniquet was inflated. The patients were randomly split into two groups. While Group P received 80 ml 0.5% prilocaine, Group PK received 0.15 mg/kg ketamine (80 ml in total) via the dorsum of the foot. We recorded onset time of the sensory block, end time of the sensory block, presence of the motor block, the time when the patient verbally reported tourniquet pain and surgical pain, duration of tourniquet tolerance, fentanyl consumption during the operation, time to first analgesic requirement, methemoglobin values at 60 minutes, operative conditions, 24-hour analgesic consumption, discharge time, and hemodynamic parameters. RESULTS: The body mass index (BMI) of the patients who required general anesthesia was significantly higher than the BMI of other patients. The onset time of the sensory block was shorter for those in Group PK, but the time to first analgesic requirement was longer. CONCLUSION: Regional intravenous anesthesia using the doses and volumes commonly used in knee arthroscopy may be an inadequate block among patients with high BMI values. Moreover, the addition of ketamine to the local anesthetic solution may produce a partial solution by shortening the onset of sensory block and prolonging the time until the first analgesic is required.	[Arslan, Mahmut; Canturk, Mehmet; Ornek, Dilsen; Gamli, Mehmet; Pala, Yasar; Dikmen, Bayazit; Basaran, Meleksah] Ankara Numune Training & Res Hosp, Minist Hlth, Ankara, Turkey; [Arslan, Mahmut; Canturk, Mehmet; Ornek, Dilsen; Gamli, Mehmet; Pala, Yasar; Dikmen, Bayazit; Basaran, Meleksah] Anesthesiol & Reanimat Dept, Ankara, Turkey	Arslan, M (reprint author), Ankara Numune Training & Res Hosp, Minist Hlth, Ankara, Turkey.	dilsenpinar@yahoo.com	canturk, mehmet/H-8631-2018	canturk, mehmet/0000-0003-4753-3341; Ornek, Dilsen/0000-0002-3300-4839			Al-Metwalli R, 2002, CAN J ANAESTH, V49, P687, DOI 10.1007/BF03017446; AMIOT JF, 1985, ANAESTHESIA, V40, P899, DOI 10.1111/j.1365-2044.1985.tb11056.x; BROWN EM, 1989, CAN J ANAESTH, V36, P307, DOI 10.1007/BF03010770; CARLTON SM, 1995, NEUROSCI LETT, V197, P25, DOI 10.1016/0304-3940(95)11889-5; Chilvers CR, 1997, CAN J ANAESTH, V44, P1152, DOI 10.1007/BF03013336; Coleman MD, 1996, DRUG SAFETY, V14, P394, DOI 10.2165/00002018-199614060-00005; DAVIES JAH, 1989, ANAESTHESIA, V44, P902, DOI 10.1111/j.1365-2044.1989.tb09144.x; DURRANI Z, 1989, ANESTH ANALG, V68, P328; FRENKEL C, 1992, BRIT J ANAESTH, V69, P292, DOI 10.1093/bja/69.3.292; HALL AH, 1986, MED TOXICOL ADV DRUG, V1, P253, DOI 10.1007/BF03259842; Henderson CL, 1997, ANESTH ANALG, V85, P858, DOI 10.1097/00000539-199710000-00027; HILGENHURST G, 1990, REGION ANESTH, V15, P2; Hirota K, 1996, BRIT J ANAESTH, V77, P441, DOI 10.1093/bja/77.4.441; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P58, DOI 10.1053/rapm.2003.50037; KIM DD, 1993, ORTHOPEDICS, V16, P1109; LEHMAN WL, 1984, J BONE JOINT SURG AM, V66A, P1056, DOI 10.2106/00004623-198466070-00012; NUSBAUM LM, 1986, ANESTHESIOLOGY, V64, P91, DOI 10.1097/00000542-198601000-00014; SCHUERG R, 1990, Regional-Anaesthesie, V13, P118	18	5	5	0	4	HOSPITAL CLINICAS, UNIV SAO PAULO	SAO PAULO	FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL	1807-5932			CLINICS	Clinics	SEP	2010	65	9					831	835		10.1590/S1807-59322010000900003			5	Medicine, General & Internal	General & Internal Medicine	675TK	WOS:000283858300003	21049208	DOAJ Gold			2020-06-30	J	Helliwell, L				Helliwell, L.			INTRANASAL FENTANYL OR DIAMORPHINE VERSUS INTRAVENOUS MORPHINE FOR ANALGESIA IN ADULTS	EMERGENCY MEDICINE JOURNAL			English	Editorial Material																Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006	3	1	1	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	SEP	2010	27	9					715	716		10.1136/emj.2010.101204			2	Emergency Medicine	Emergency Medicine	644OS	WOS:000281389300018	20798100				2020-06-30	J	Mirski, MA; Lewin, JJ; LeDroux, S; Thompson, C; Murakami, P; Zink, EK; Griswold, M				Mirski, Marek A.; Lewin, John J., III; LeDroux, Shannon; Thompson, Carol; Murakami, Peter; Zink, Elizabeth K.; Griswold, Michael			Cognitive improvement during continuous sedation in critically ill, awake and responsive patients: the Acute Neurological ICU Sedation Trial (ANIST)	INTENSIVE CARE MEDICINE			English	Article						Critical care; Sedation; Cognition; Dexmedetomidine; Propofol; Awake	INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; PROPOFOL; DEXMEDETOMIDINE; DELIRIUM; RELIABILITY; MIDAZOLAM; FENTANYL; DISPOSITION	Most anxiolytics and sedative regimens in the intensive care unit (ICU) impair intellectual function, reducing patient autonomy, and often add to patient morbidity. Using an ICU-validated cognitive assessment tool Adapted Cognitive Exam (ACE), we performed a comparison between dexmedetomidine (DEX) and propofol (PRO) to evaluate which sedative regimen offered the least decrement in intellectual capacity. This was a prospective, randomized, double-blinded study of 30 awake and intubated brain-injured (BI, n = 18) and non-BI (12) ICU patients. Each patient received fentanyl/PRO and fentanyl/DEX titrated to a calm, awake state using a crossover design. Cognitive testing was performed at each study period using the validated 100-point Hopkins ACE cognitive battery. Sedation with PRO diminished adjusted ACE scores (100-point exam) by a mean of -12.4 (95% CI -8.3 to -16.5, p < 0.001) while DEX, in contrast, improved ACE scores (6.8, 95% CI 1.2-12.4, p < 0.018). The difference in the change of ACE score between DEX versus PRO, our primary endpoint, was 19.2 (95% CI 12.3-26.1 p < 0.001) in favor of an improved ACE score on DEX. Patients with BI required less sedative, but effects of PRO and DEX on cognition were not changed. No serious adverse events occurred. Modest bradycardia was noted post hoc with DEX (-7.7 bpm, p < 0.01). ICU patients may be offered sedation without necessarily compromising arousal or cognition. Alleviation of anxiety and agitation can singly and effectively improve mental engagement and performance if overt forebrain dysfunction is avoided. Higher ACE scores with DEX may be a consequence of the intellect-sparing yet calming effect of this drug.	[Mirski, Marek A.; Lewin, John J., III] Johns Hopkins Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Lewin, John J., III] Johns Hopkins Med, Dept Pharm, Baltimore, MD 21287 USA; [Mirski, Marek A.; LeDroux, Shannon; Zink, Elizabeth K.] Johns Hopkins Med, Dept Neurol, Baltimore, MD 21287 USA; [Thompson, Carol; Murakami, Peter; Griswold, Michael] Johns Hopkins Med, Dept Biostat, Baltimore, MD 21287 USA	Mirski, MA (reprint author), Johns Hopkins Med, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Meyer 8-140, Baltimore, MD 21287 USA.	mmirski1@jhmi.edu			Johns Hopkins & Bayview pharmacists Laura Wachter,; Annette Rowden	The authors would like to acknowledge the support of the Johns Hopkins & Bayview pharmacists Laura Wachter, Annette Rowden, Henry Choi, and Jim Monolakis, the neuroscience ICU nurses, especially Gail Biba, Patricia Trionfo, Theresa Blair, and Chris Boileau, and DSMB Committee ChairDr. Brent Petty.; ANIST was an investigator-initiated research study funded in part from a grant from Hospira. There was no input as to hypothesis, trial design, data acquisition, or analysis from the study sponsor. Partial support also was courtesy of The Gannaway Fund, an internal institutional philanthropic gift fund for research.	Cook D, 2001, CRIT CARE MED, V29, pN24, DOI 10.1097/00003246-200102001-00005; De Wolf AM, 2001, ANESTH ANALG, V93, P1205, DOI 10.1097/00000539-200111000-00031; Diggle PJ, 2002, ANAL LONGITUDINAL DA; DYCK JB, 1993, ANESTHESIOLOGY, V78, P821, DOI 10.1097/00000542-199305000-00003; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Garcia R, 2004, STAT MED, V23, P3773, DOI 10.1002/sim.2072; GEPTS E, 1987, ANESTH ANALG, V66, P1256; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; Hogarth D Kyle, 2004, Curr Opin Crit Care, V10, P40, DOI 10.1097/00075198-200402000-00007; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Martin Eike, 2003, J Intensive Care Med, V18, P29, DOI 10.1177/0885066602239122; Mirski MA, 2009, YEARB INTENSIVE CARE, P881, DOI 10.1007/978-3-540-92276-6_80; MIRSKI MA, 1995, CRIT CARE MED, V23, P2038, DOI 10.1097/00003246-199512000-00013; Mirski M, 2008, CRIT CARE MED, V36, pA125; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Robinson BRH, 2008, J TRAUMA, V65, P517, DOI 10.1097/TA.0b013e318181b8f6; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Soja SL, 2008, INTENS CARE MED, V34, P1263, DOI 10.1007/s00134-008-1031-x; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; Veselis RA, 1997, ANESTHESIOLOGY, V87, P749, DOI 10.1097/00000542-199710000-00007; Vree TB, 1997, CLIN DRUG INVEST, V13, P145, DOI 10.2165/00044011-199713030-00004; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495	32	55	66	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2010	36	9					1505	1513		10.1007/s00134-010-1874-9			9	Critical Care Medicine	General & Internal Medicine	638PV	WOS:000280908000008	20376430				2020-06-30	J	Mullaji, A; Kanna, R; Shetty, GM; Chavda, V; Singh, DP				Mullaji, Arun; Kanna, Raj; Shetty, Gautam M.; Chavda, Vipul; Singh, D. P.			Efficacy of Periarticular Injection of Bupivacaine, Fentanyl, and Methylprednisolone in Total Knee Arthroplasty A Prospective, Randomized Trial	JOURNAL OF ARTHROPLASTY			English	Article						total knee arthroplasty; periarticular injection; pain score; knee flexion; extensor lag	MORPHINE AND/OR BUPIVACAINE; INTRAARTICULAR MORPHINE; PAIN MANAGEMENT; PLUS METHYLPREDNISOLONE; POSTOPERATIVE PAIN; HOSPITAL STAY; REDUCES PAIN; TOTAL HIP; ANALGESIA; REPLACEMENT	We evaluated the efficacy of periarticular infiltration of corticosteroid, opioid, and a local anesthetic by comparing pain scores, knee flexion, and quadriceps function on the day of surgery, first postoperative day, day of discharge, and 2 and 4 weeks after surgery between the infiltrated and the noninfiltrated knee in 40 patients undergoing simultaneous bilateral computer-assisted total knee arthroplasty who were randomized to receive the injection in the right or left knee. In comparison to the noninfiltrated side, the infiltrated knee showed significantly lower pain scores, significantly greater active flexion up to 4 weeks, and superior quadriceps recovery up to 2 weeks after surgery. This simple and inexpensive technique can significantly reduce pain and hasten functional recovery in the first month after total knee arthroplasty.	[Mullaji, Arun; Chavda, Vipul] Arthrit Clin, Bombay 400036, Maharashtra, India; [Mullaji, Arun; Kanna, Raj; Shetty, Gautam M.] Breach Candy Hosp, Dept Orthopaed Surg, Bombay, Maharashtra, India; [Singh, D. P.] Tata Inst Social Sci, Ctr Res Methodol, Bombay, Maharashtra, India	Mullaji, A (reprint author), Arthrit Clin, 101 Cornelian,Cumballa Hill, Bombay 400036, Maharashtra, India.		SHETTY, GAUTAM/AAJ-3128-2020; teng, yj/C-4440-2011				AKERMAN B, 1988, ANESTH ANALG, V67, P943; Badner NH, 1997, REGION ANESTH, V22, P347, DOI 10.1016/S1098-7339(97)80010-7; Badner NH, 1996, J BONE JOINT SURG AM, V78A, P734, DOI 10.2106/00004623-199605000-00013; BIRD HA, 1998, RHEUMATOLOGY; Browne C, 2004, J ARTHROPLASTY, V19, P377, DOI 10.1016/j.arth.2003.10.012; Busch CA, 2006, J BONE JOINT SURG AM, V88A, P959, DOI 10.2106/JBJS.E.00344; Buvanendran A, 2003, JAMA-J AM MED ASSOC, V290, P2411, DOI 10.1001/jama.290.18.2411; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Catterall W.A., 2006, GOODMAN GILMANS PHAR, P369; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6; Kizilkaya M, 2005, EUR J ANAESTH, V22, P603, DOI 10.1017/S0265021505001018; Kizilkaya M, 2004, ANESTH ANALG, V98, P1062, DOI 10.1213/01.ANE.0000103185.18333.68; Klasen JA, 1999, ACTA ANAESTH SCAND, V43, P1021, DOI 10.1034/j.1399-6576.1999.431009.x; Kligman M, 2002, CAN J ANAESTH, V49, P380, DOI 10.1007/BF03017326; LOMBARDI AV, 2004, CLIN ORTHOP RELAT R, V428, P125; Mauerhan DR, 1997, J ARTHROPLASTY, V12, P546, DOI 10.1016/S0883-5403(97)90178-9; Mirzai H, 2002, SPINE, V27, P343, DOI 10.1097/00007632-200202150-00003; Parfitt K., 1999, COMPLETE DRUG REFERE, P1010; Parvataneni HK, 2007, J ARTHROPLASTY, V22, P33, DOI 10.1016/j.arth.2007.03.034; Parvataneni Hari K, 2007, Instr Course Lect, V56, P125; Peersman G, 2001, Clin Orthop Relat Res, P15, DOI 10.1097/00003086-200111000-00003; Peters CL, 2006, J ARTHROPLASTY, V21, P132, DOI 10.1016/j.arth.2006.04.017; Prasad N, 2005, ARCH ORTHOP TRAUM SU, V125, P381, DOI 10.1007/s00402-005-0813-7; Ranawat AS, 2007, J ARTHROPLASTY, V22, P12, DOI 10.1016/j.arth.2007.05.040; Rasmussen S, 1998, PAIN, V78, P131, DOI 10.1016/S0304-3959(98)00123-7; Rasmussen S, 2004, ACTA ORTHOP SCAND, V75, P606, DOI 10.1080/00016470410001501; Rasmussen S, 2002, ACTA ORTHOP SCAND, V73, P175, DOI 10.1080/000164702753671768; Ritter MA, 1999, J BONE JOINT SURG BR, V81B, P301, DOI 10.1302/0301-620X.81B2.9110; Salerno A, 2006, J BONE JOINT SURG AM, V88A, P1361, DOI 10.2106/JBJS.D.03018; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Sauerland S, 2000, DRUG SAFETY, V23, P449, DOI 10.2165/00002018-200023050-00007; Schimmer BP, 2006, GOODMAN GILMANS PHAR, P1587; Soderlund A, 1997, ACTA ANAESTH SCAND, V41, P6, DOI 10.1111/j.1399-6576.1997.tb04606.x; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Strichartz GR, 1994, ANESTHESIA, V1, P489; Tanaka N, 2001, J ARTHROPLASTY, V16, P306, DOI 10.1054/arth.2001.21496; Varkel V, 1999, CAN J ANAESTH, V46, P867, DOI 10.1007/BF03012977; Vendittoli PA, 2006, J BONE JOINT SURG AM, V88A, P282, DOI 10.2106/JBJS.E.00173; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	41	72	77	1	13	CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS	PHILADELPHIA	CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA	0883-5403	1532-8406		J ARTHROPLASTY	J. Arthroplast.	SEP	2010	25	6					851	857		10.1016/j.arth.2009.09.007			7	Orthopedics	Orthopedics	649FF	WOS:000281752500003	20022457				2020-06-30	J	Pandey, RK; Padmanabhan, MY; Saksena, AK; Chandra, G				Pandey, R. K.; Padmanabhan, M. Y.; Saksena, A. K.; Chandra, Girish			Midazolam-Fentanyl Analgo-Sedation in Pediatric Dental Patients - A Pilot Study	JOURNAL OF CLINICAL PEDIATRIC DENTISTRY			English	Article							ORAL TRANSMUCOSAL FENTANYL; PROCEDURAL SEDATION; LIDOCAINE; CHILDREN	Objective: The objective of this study was to comparatively evaluate the effectiveness of submucosal fentanyl when administered in conjunction with oral midazolam during pediatric procedural sedations. Study design: Twenty three uncooperative ASA type I children who net the selection criteria were randomly assigned to receive either submucosal fentanyl (3 mu g/kg) or placebo, along with oral midazolam (0.5mg/kg). A triple blind, 2-stage cross-over design was adopted so that each child received both the regimens. Results: Transient oxygen desaturation was observed in 4 children who were sedated with the combination of oral midazolam and submucosal fentanyl. The overall success was 73.91% with oral midazolam and submucosal fentanyl regimen and 47.83% for oral midazolam and submucosal placebo regimen. The chances of 'satisfactorily completing a 45 minute dental procedure in an uncooperative pediatric patient was 2.8 times more, when submucosal fentanyl was used along with oral midazolam. Conclusion: Submucosal fentanyl appears to improve the short working time associated with oral midazolam. But the oxygen desaturation associated with this regimen necessitates further studies to evaluate the efficacy of this combination at relatively lower doses before being used routinely for pediatric procedural sedation and analgesia.	[Pandey, R. K.] CSM Med Univ, Fac Dent Sci, Dept Pedodont & Prevent Dent, Lucknow, Uttar Pradesh, India; [Padmanabhan, M. Y.] Sri Ramakrishna Dent Coll & Hosp, Dept Pedodont & Prevent Dent, Coimbatore, Tamil Nadu, India; [Saksena, A. K.] CSM Med Univ, Dept Pharmacol, Lucknow, Uttar Pradesh, India; [Chandra, Girish] CSM Med Univ, Dept Anesthesiol, Lucknow, Uttar Pradesh, India	Padmanabhan, MY (reprint author), Care of Radhakrishnan V, 21-1 Rangaswamy St, Coimbatore 641002, Tamil Nadu, India.	dentistpad@rediffmail.com					American Academy on Pediatrics, 2008, Pediatr Dent, V30, P143; ASHBURN MA, 1990, CAN J ANAESTH, V37, P857, DOI 10.1007/BF03006621; Aubuchon RW, 1982, PEDIAT DENT, V4, P171; Cathers JW, 2005, PEDIATR DENT, V27, P395; Cherng CH, 2001, REGION ANESTH PAIN M, V26, P523, DOI 10.1053/rapm.2001.27852; Citerio G, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-19; Farrar Mark W, 2002, Anesthesiol Clin North Am, V20, P59, DOI 10.1016/S0889-8537(03)00055-5; FLACKE JW, 1987, ANESTH ANALG, V66, P723; Flood RG, 2003, EMERG MED CLIN N AM, V21, P121, DOI 10.1016/S0733-8627(02)00084-6; Kaplan Richard F, 2002, Anesthesiol Clin North Am, V20, P181, DOI 10.1016/S0889-8537(03)00060-9; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; da Silva PSL, 2007, PEDIATR ANESTH, V17, P358, DOI 10.1111/j.1460-9592.2006.02099.x; Matharu L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003877.pub3; Moore P A, 2000, Anesth Prog, V47, P29; Movafegh A, 2009, ANESTH ANALG, V109, P1679, DOI 10.1213/ANE.0b013e3181b9e904; Nathan John E, 2002, Pediatr Dent, V24, P129; Pandey RK, 2010, J CLIN PEDIATR DENT, V35, P105, DOI 10.17796/jcpd.35.1.t275680587226k66; Schmitt Marian, 1994, Pediatric Dentistry, V16, P190; Silver Thomas, 1994, Pediatric Dentistry, V16, P350; Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7	21	4	4	0	0	JOURNAL PEDODONTICS INC	BIRMINGHAM	5724 HIGHWAY 280 EAST, BIRMINGHAM, AL 35242 USA	1053-4628	1557-5268		J CLIN PEDIATR DENT	J. Clin. Pediatr. Dent.	FAL	2010	35	1					105	110		10.17796/jcpd.35.1.t275680587226k66			6	Dentistry, Oral Surgery & Medicine; Pediatrics	Dentistry, Oral Surgery & Medicine; Pediatrics	692AL	WOS:000285123800018	21189774				2020-06-30	J	Holleran, RS				Holleran, Renee S.			WHAT IS WRONG WITH THIS PICTURE?	JOURNAL OF EMERGENCY NURSING			English	Editorial Material										Holleran, RS (reprint author), 7236 Cypress Way, Salt Lake City, UT USA.	reneeflightnurse@msn.com					[Anonymous], HEALTHDAY NEWS; [Anonymous], US TODAY; Baehren DF, 2010, ANN EMERG MED, V56, P19, DOI 10.1016/j.annemergmed.2009.12.011; BARRY DT, J PAIN IN PRESS	4	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0099-1767			J EMERG NURS	J. Emerg. Nurs.	SEP	2010	36	5			SI		396	397		10.1016/j.jen.2010.08.005			2	Emergency Medicine; Nursing	Emergency Medicine; Nursing	657FS	WOS:000282399200002	20837205				2020-06-30	J	Cooreman, S; Deprez, C; Martens, F; Van Bocxlaer, J; Croes, K				Cooreman, Sarah; Deprez, Christa; Martens, Frank; Van Bocxlaer, Jan; Croes, Kathleen			A comprehensive LC-MS-based quantitative analysis of fentanyl-like drugs in plasma and urine	JOURNAL OF SEPARATION SCIENCE			English	Article						Fentanyl; Fentanyl-like drugs; LC-MS/MS; Quantification; Toxicology	CHROMATOGRAPHY-MASS SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOLID-PHASE MICROEXTRACTION; GAS-CHROMATOGRAPHY; ULTRAVIOLET DETECTION; MAJOR METABOLITES; SUFENTANIL; ALFENTANIL; IDENTIFICATION; REMIFENTANIL	Fentanyl, norfentanyl, alfentanil, sufentanil, remifentanil and 3-methylfentanyl are potent, short-acting, synthetic narcotic analgesics that are not revealed in standard opiate immunoassays. In this article, a fully validated analytical method for the determination of these fentanyl-type compounds in plasma and urine is presented, consisting of a liquid-liquid extraction followed by a LC-MS/MS analysis using electrospray ionisation in the positive ionisation mode. Fentanyl-d(5) and norfentanyl-d(5) were used as internal standards. The lower LOQ in plasma and urine was 0.1 ng/mL for fentanyl, norfentanyl, alfentanil, remifentanil and 3-methylfentanyl, and 0.2 ng/mL for sufentanil. The method proved linear over a concentration range of 0.2-50 ng/mL for sufentanil and 0.1-50 ng/mL for all other analytes, with correlation coefficients of 0.998 or better. The analytical procedure showed excellent selectivity and precision (all CVs below 15%) for all analytes. Accuracy was good, except for sufentanil, where deviations of more than 15% from nominal concentrations were observed. No matrix effects were observed, and stability of stock and internal standard solutions was within acceptability limits.	[Cooreman, Sarah; Deprez, Christa; Martens, Frank; Croes, Kathleen] AZ Groeninge Hosp, Kortrijk, Belgium; [Van Bocxlaer, Jan] Univ Ghent, Lab Med Biochem & Clin Anal, Fac Pharmaceut Sci, B-9000 Ghent, Belgium	Croes, K (reprint author), AZ Groeninge, Lab, Reepkaai 4, B-8500 Kortrijk, Belgium.	kathleen.croes@azgroeninge.be					Bagheri H, 2007, J PHARMACEUT BIOMED, V43, P1763, DOI 10.1016/j.jpba.2006.12.016; BASELT RC, 2002, [No title captured]; Beers R, 2004, CNS DRUGS, V18, P1085, DOI 10.2165/00023210-200418150-00004; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Dufresne C, 2001, THER DRUG MONIT, V23, P550, DOI 10.1097/00007691-200110000-00009; *FDA CDER, 2001, GUID IND BIOAN METH; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; GOLDFRANK LR, 2002, GOLDFRANKS TOXICOLOG, P901; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; ISENSCHMID D, 2007, CLIN FORENSIC TOXICO, P1; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; MICHIELS M, 1983, J PHARM PHARMACOL, V35, P86, DOI 10.1111/j.2042-7158.1983.tb04275.x; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Paradis C, 2002, THER DRUG MONIT, V24, P768, DOI 10.1097/00007691-200212000-00014; Peer CJ, 2007, J ANAL TOXICOL, V31, P515, DOI 10.1093/jat/31.8.515; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Roper J, 2006, CONTEMP SECUR STUD, P1; Schmidt R, 2006, J CHROMATOGR B, V836, P98, DOI 10.1016/j.jchromb.2006.03.052; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5	26	25	27	1	28	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1615-9306	1615-9314		J SEP SCI	J. Sep. Sci.	SEP	2010	33	17-18					2654	2662		10.1002/jssc.201000330			9	Chemistry, Analytical	Chemistry	660BJ	WOS:000282612900013	20658494				2020-06-30	J	Ohta, M; Wakuno, A; Okada, J; Kodaira, K; Nagata, S; Ito, M; Oku, K				Ohta, Minoru; Wakuno, Ai; Okada, Jun; Kodaira, Kazumichi; Nagata, Shun-ichi; Ito, Motoki; Oku, Kazuomi			Effects of Intravenous Fentanyl Administration on End-Tidal Sevoflurane Concentrations in Thoroughbred Racehorses undergoing Orthopedic Surgery	JOURNAL OF VETERINARY MEDICAL SCIENCE			English	Article						analgesia; fentanyl; racehorse; sevoflurane	MINIMUM ALVEOLAR CONCENTRATION; TRANSDERMAL FENTANYL; GENERAL-ANESTHESIA; ISOFLURANE; PHARMACOKINETICS; ALFENTANIL; ANALGESIA; HALOTHANE; MORPHINE; DOGS	To evaluate the effects of IV fentanyl administration on the end-tidal sevoflurane concentration (ETSEVO) in thoroughbred racehorses, the ETSEVO required for internal fixation of longitudinal fractures was compared between horses anesthetized with sevoflurane-fentanyl (Group SF; n=9) and those anesthetized with sevoflurane alone (Group S; n=9). The loading dose of fentanyl (5.0 mu g/kg) was administered over 15 min followed by a maintenance dose of fentanyl (0.1 mu g/kg/min) throughout the operation in Group SF. The mean ETSEVO during the operation in Group SF (2.6 +/- 0.2%) was significantly lower than in Group S (3.0 +/- 0.3%). The plasma fentanyl concentrations (6.12 +/- 0.88 to 7.78 +/- 1.12 ng/ml) in 7 out of 9 horses in Group SF were stable and did not change significantly throughout the operation. The mean dobutamine infusion rate required for maintaining a mean arterial blood pressure between 60 and 80 mmHg during the operation in Group SF (0.56 +/- 0.30 mu g/kg/min) was significantly lower than in Group S (0.90 +/- 0.16 mu g/kg/min). The qualities of the recoveries were clinically acceptable, and serious complications were not observed in either group. In conclusion, continuous IV fentanyl administration reduced the sevoflurane requirement by 13% in thoroughbred racehorses undergoing orthopedic surgery; however, fentanyl was considered to be less effective in horses compared with other species.	[Ohta, Minoru; Wakuno, Ai; Okada, Jun; Kodaira, Kazumichi; Ito, Motoki; Oku, Kazuomi] Japan Racing Assoc, Ritto Training Ctr, Racehorse Clin, Ritto, Shiga 5203085, Japan; [Nagata, Shun-ichi] Lab Racing Chem, Analyt Chem Sect, Utsunomiya, Tochigi 3200851, Japan	Ohta, M (reprint author), Japan Racing Assoc, Ritto Training Ctr, Racehorse Clin, 1028 Misono, Ritto, Shiga 5203085, Japan.	Minoru_Ota@jra.go.jp					Aida H, 1996, VET SURG, V25, P164, DOI 10.1111/j.1532-950X.1996.tb01393.x; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grosenbaugh DA, 1998, AM J VET RES, V59, P101; Hellyer PW, 2003, VET ANAESTH ANALG, V30, P172, DOI 10.1046/j.1467-2995.2003.00143.x; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; Mama KR, 1996, AM J VET RES, V57, P512; Matthews NS, 1998, VET SURG, V27, P480, DOI 10.1111/j.1532-950X.1998.tb00160.x; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MOON PF, 1995, ANESTHESIOLOGY, V83, P535, DOI 10.1097/00000542-199509000-00012; Ohta M, 2000, J VET MED SCI, V62, P1017, DOI 10.1292/jvms.62.1017; PASCOE PJ, 1993, AM J VET RES, V54, P1327; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Sanchez LC, 2007, J VET INTERN MED, V21, P1067; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Steffey EP, 2005, AM J VET RES, V66, P606, DOI 10.2460/ajvr.2005.66.606; Steffey EP, 2003, AM J VET RES, V64, P166, DOI 10.2460/ajvr.2003.64.166; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; Wilson D, 2006, JAVMA-J AM VET MED A, V228, P1042, DOI 10.2460/javma.228.7.1042	23	5	7	0	3	JAPAN SOC VET SCI	TOKYO	UNIV TOKYO, 1-1-1 YAYOI, BUNKYO-KU, TOKYO, 103, JAPAN	0916-7250	1347-7439		J VET MED SCI	J. Vet. Med. Sci.	SEP	2010	72	9					1107	1111		10.1292/jvms.09-0285			5	Veterinary Sciences	Veterinary Sciences	662CS	WOS:000282785100002	20379087	Bronze			2020-06-30	J	Kilgallon, CP; Lamberski, N; Larsen, RS				Kilgallon, Conor P.; Lamberski, Nadine; Larsen, R. Scott			COMPARISON OF THIAFENANTIL-XYLAZINE AND CARFENTANIL-XYLAZINE FOR IMMOBILIZATION OF GEMSBOK (ORYX GAZELLA)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Anesthesic quality; carfentanil; gemsbok; Oryx gazella; thiafentanil	MEDETOMIDINE; COMBINATION; ANESTHESIA; KETAMINE; A3080	This study compared immobilization of gemsbok (Oryx gazella) using thiafentanil-xylazine (TX) versus carfentanil-xylazine (CX). Twelve adult gemsboks were divided into two groups. TX and CX. Each group received either 6 mg thiafentanil (0.036 mu g/kg (0.032-0.040 mu g/kg) and 20 mg xylazine (TX) or 3.6 mg carfentanil (0.021 mu g/kg (0.017-0.024 mu g/kg) and 20 mg xylazine (CX). Once handled, physiologic measurements were taken every 5 min for 20 min. There were few physiologic differences between the groups, although TX gemsboks were more hypertensive. Quality of induction, quality of recovery, depth of anesthesia, and muscle relaxation were subjectively assessed. Although TX gemsboks showed a trend for more-rapid induction and recovery postantagonist administration, this difference was not statistically significant. Similarly, there was a trend for TX animals to have smoother inductions and improved immobilization quality, but only the quality of induction was significantly different. These trends suggest that TX is preferable to CX when anesthetizing adult gemsboks.	[Kilgallon, Conor P.; Lamberski, Nadine] Zool Soc San Diego, Escondido, CA 92027 USA; [Larsen, R. Scott] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA; [Larsen, R. Scott] Univ Calif Davis, Sch Vet Med, Wildlife Hlth Ctr, Davis, CA 95616 USA	Kilgallon, CP (reprint author), Zool Soc San Diego, San Diego Wild Anim Pk,15500 San Pasqual Valley R, Escondido, CA 92027 USA.	conchubhair2001@yahoo.co.uk					Ball Ray L., 2007, P613, DOI 10.1002/9780470376478.ch54; Burroughs R.E.J., 1993, P348; Citino SB, 2002, J WILDLIFE DIS, V38, P457, DOI 10.7589/0090-3558-38.2.457; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; HASKINS SC, 2007, LUMB JONES VET ANESH, P731	6	7	7	0	6	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2010	41	3					567	571		10.1638/2010-0021.1			5	Veterinary Sciences	Veterinary Sciences	651EC	WOS:000281906500031	20945664				2020-06-30	J	Bachiocco, V; Mondardini, MC				Bachiocco, Valeria; Mondardini, Maria Cristina			Julia's placebo effect	PAIN			English	Article						Placebo analgesia; Infant; Conditioning; Expectancy; Learning; Memory	TRACHEAL AGENESIS; OPIOID ACTIVITY; PAIN; ANALGESIA; HABITUATION; MANAGEMENT; RESPONSES; INFANTS; SYSTEMS; BRAIN	Placebo analgesia is the occurrence of an analgesic drug effect without drugs. The response is learned through conditioning and mediated by expectancy. It lies on the up-regulation of the pain-modulating areas and the down-regulation of the pain-encoding regions. A further mechanism is the retrieval of the brain circuit activity previously excited by drugs. We describe the case of an infant affected by a tracheal agenesis who underwent a series of operative and diagnostic bronchoscopies for which she received midazolam and fentanyl. After 61 procedures the infant showed a somatosensory response which in our interpretation reflected a placebo effect. Ontogenetic considerations and specific observations indicate that the infant had the appropriate competences in her learning and memory systems and nociceptive and antinociceptive circuits for the placebo effect to take place. Generalizing, the introduction of placebo manipulation in infant pain management may be taken into consideration; its approach through observational and experimental studies is the preliminary target. (C) 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Bachiocco, Valeria; Mondardini, Maria Cristina] Univ Bologna, S Orsola Hosp, Anaesthesia & Intens Care Unit, Bologna, Italy	Bachiocco, V (reprint author), Vicolo Broglio 6, I-640125 Bologna, Italy.	valebachiocco@libero.it					Amanzio M, 1999, J NEUROSCI, V19, P484; Baroncini-Cornea S, 2004, PEDIATR ANESTH, V14, P774, DOI 10.1111/j.1460-9592.2004.01281.x; Bartocci M, 2006, PAIN, V122, P109, DOI 10.1016/j.pain.2006.01.015; Benedetti F, 1996, PAIN, V64, P535, DOI 10.1016/0304-3959(95)00179-4; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; BOOTZIN RR, 1985, PLACEBO THEORY RES M, P196; Carbajal R, 2005, ARCH PEDIATRIE, V12, P110, DOI 10.1016/j.arcped.2004.06.005; Chen E, 2000, PEDIATR CLIN N AM, V47, P513, DOI 10.1016/S0031-3955(05)70223-6; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; CRAIG KD, 1988, PAIN RES CLIN MANAGE, V3, P317; CUNHA TM, 2007, [No title captured], P67; Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014; Enck P, 2008, NEURON, V59, P195, DOI 10.1016/j.neuron.2008.06.030; Fitzgerald M, 2001, NEUROSCIENTIST, V7, P246, DOI 10.1177/107385840100700309; Fitzgerald M, 2005, NAT REV NEUROSCI, V6, P507, DOI 10.1038/nrn1701; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Gebhart GF, 2004, NEUROSCI BIOBEHAV R, V27, P729, DOI 10.1016/j.neubiorev.2003.11.008; Herlenius E, 2001, EARLY HUM DEV, V65, P21, DOI 10.1016/S0378-3782(01)00189-X; James DK, 2002, ULTRASOUND OBST GYN, V20, P431, DOI 10.1046/j.1469-0705.2002.00845.x; Lieberman MD, 2004, NEUROIMAGE, V22, P447, DOI 10.1016/j.neuroimage.2004.01.037; McNamara F, 1999, SLEEP, V22, P320; MILNE RJ, 1991, EXP BRAIN RES, V87, P438; Nunnally JC, 1994, PSYCHOMETRIC THEORY, P3, DOI DOI 10.1080/13607860500090011; Olney JW, 2004, TRENDS PHARMACOL SCI, V25, P135, DOI 10.1016/j.tips.2004.01.002; Oppido G, 2004, J THORAC CARDIOV SUR, V127, P283, DOI 10.1016/S0022-5223(03)01298-4; Price DD, 1997, PLACEBO EFFECT INTER, P117; PRICE DD, 1999, PROGR PAIN RES MANAG, V15, P137; Richmond J, 2007, DEV REV, V27, P349, DOI 10.1016/j.dr.2007.04.002; Sheese BE, 2008, INFANT BEHAV DEV, V31, P501, DOI 10.1016/j.infbeh.2008.02.001; SIEGEL S, 2002, [No title captured], P133; Slater R, 2006, J NEUROSCI, V26, P3662, DOI 10.1523/JNEUROSCI.0348-06.2006; Slonim AD, 1999, CHEST, V116, P1802, DOI 10.1378/chest.116.6.1802; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; Tursky B., 1985, PLACEBO THEORY RES M, P229; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; WICKRAMASEKERA I, 1985, [No title captured], P255; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005	39	4	4	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	SEP	2010	150	3					582	585		10.1016/j.pain.2010.05.023			4	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	648FE	WOS:000281675000032	20705216				2020-06-30	J	Chen, JY; Li, WX; Hu, XA; Wang, DD				Chen, Jiayao; Li, Wenxian; Hu, Xiao; Wang, Dingding			Emergence agitation after cataract surgery in children: a comparison of midazolam, propofol and ketamine	PEDIATRIC ANESTHESIA			English	Article						anesthesia; pediatric; emergence; agitation; midazolam; propofol; ketamine	SEVOFLURANE GENERAL-ANESTHESIA; RECOVERY CHARACTERISTICS; PEDIATRIC ANESTHESIA; HALOTHANE; DESFLURANE; PREVENTION; MYRINGOTOMY; DELIRIUM; BEHAVIOR; FENTANYL	P>Objectives: The aim of this study was to determine whether the concurrent use of either of a subhypnotic dose of midazolam, propofol or ketamine with fentanyl just before discontinuing the sevoflurane anesthesia would effectively sedate the children as they recovered and significantly decrease the incidence and severity of emergence agitation and would not delay patient awakening and discharge. Background: Postoperative emergence agitation may occur in children after general anesthesia with volatile anesthetics. Children who undergo cataract surgery after sevoflurane induction and sevoflurane-remifentanil maintenance may experience this type of agitation. Methods/Materials: In 120 un-premedicated children aged 1-7 years, mask induction with sevoflurane was performed and they were then randomly assigned to one of the three antiagitation postoperative groups (n = 40). We studied the postoperative antiagitation effects of subhypnotic doses of midazolam combined with fentanyl, propofol with fentanyl or ketamine with fentanyl administered just before discontinuing the sevoflurane anesthesia. A score for the level of agitation can be assigned based on the recovery mental state (RMS) scale and the recently published pediatric anesthesia emergence delirium scale (PAED). Postoperative factors assessed included emergence behaviors, the time to eye opening, the time to discharge from the postanesthesia care unit (PACU) to the ward. Results: There were significantly more agitated children in the ketamine-group when compared to the midazolam-group or to the propofol-group at all time P < 0.05), especially at 10 and 15 min. The PAED scale showed a significant advantage for midazolam-fentanyl [5 (2-15)] and propofol-fentanyl [6 (3-15)] versus ketamine-fentanyl [10 (3-20)] (P < 0.05). The time to discharge from the PACU to the ward was not significantly different among the groups. Conclusions: Intravenous administration of a subhypnotic dose of midazolam or propofol in addition to a low dose of fentanyl just before discontinuing the sevoflurane anesthesia was both effective on decreasing the incidence and severity of emergence agitation in children undergoing cataract extraction without significant delaying recovery time and discharge. The effect of midazolam was clearer than that seen with propofol.	[Chen, Jiayao; Li, Wenxian; Hu, Xiao; Wang, Dingding] Fudan Univ, Dept Anesthesiol, EENT Hosp, Shanghai 200031, Peoples R China	Li, WX (reprint author), Fudan Univ, Dept Anesthesiol, EENT Hosp, 83 Fenyang Rd, Shanghai 200031, Peoples R China.	wenxianli66@gmail.com					Abu-Shahwan I, 2008, PEDIATR ANESTH, V18, P55, DOI 10.1111/j.1460-9592.2007.02376.x; Abu-Shahwan I, 2007, PEDIATR ANESTH, V17, P846, DOI 10.1111/j.1460-9592.2007.02298.x; Ansermino JM, 2005, PEDIATR ANESTH, V15, P115, DOI 10.1111/j.1460-9592.2004.01397.x; Aouad MT, 2005, CURR OPIN ANESTHESIO, V18, P614, DOI 10.1097/01.aco.0000188420.84763.35; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; Breschan C, 2007, PEDIATR ANESTH, V17, P347, DOI 10.1111/j.1460-9592.2006.02101.x; Briggs VD, 2005, PEDIATR ANESTH, V15, P9, DOI 10.1111/j.1460-9592.2005.01360.x; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; da Silva LM, 2008, J PEDIAT-BRAZIL, V84, P107, DOI [10.2223/JPED.1763, 10.1590/S0021-75572008000200004]; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Nishina Kahoru, 2002, Curr Opin Anaesthesiol, V15, P309, DOI 10.1097/00001503-200206000-00006; Sander-Kiesling A, 2002, PAEDIATR ANAESTH, V12, P429, DOI 10.1046/j.1460-9592.2002.00862.x; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; Veyckemans F, 2001, Curr Opin Anaesthesiol, V14, P339, DOI 10.1097/00001503-200106000-00010; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08; Yamashita M, 2003, PAEDIATR ANAESTH, V13, P641, DOI 10.1046/j.1460-9592.2003.00986_2.x	28	36	40	0	10	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	SEP	2010	20	9					873	879		10.1111/j.1460-9592.2010.03375.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	639TZ	WOS:000280998700012	20716081				2020-06-30	J	Richards, MJ; Eisses, M				Richards, Michael J.; Eisses, Michael			Dexmedetomidine as a postoperative sedative after congenital cardiac surgery-Consideration of the anesthetic management has an important role	PEDIATRIC CRITICAL CARE MEDICINE			English	Letter							OPEN-HEART-SURGERY; FENTANYL; CHILDREN; INFANTS		[Richards, Michael J.; Eisses, Michael] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA	Richards, MJ (reprint author), Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.						Chrysostomou C, 2009, PEDIATR CRIT CARE ME, V10, P654, DOI 10.1097/PCC.0b013e3181a00b7a; Duncan HP, 2000, BRIT J ANAESTH, V84, P556, DOI 10.1093/bja/84.5.556; Humphreys N, 2005, ANESTHESIOLOGY, V103, P1113, DOI 10.1097/00000542-200512010-00003; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Munro HM, 2007, PEDIATR ANESTH, V17, P109, DOI 10.1111/j.1460-9592.2006.02031.x	5	1	1	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2010	11	5					645	646		10.1097/PCC.0b013e3181e28b42			2	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	647PA	WOS:000281629300024	20823746				2020-06-30	J	Wichitnithad, W; McManus, TJ; Callery, PS				Wichitnithad, Wisut; McManus, Terence J.; Callery, Patrick S.			Identification of isobaric product ions in electrospray ionization mass spectra of fentanyl using multistage mass spectrometry and deuterium labeling	RAPID COMMUNICATIONS IN MASS SPECTROMETRY			English	Article							THERMAL-BEHAVIOR; ANALOGS; CONFIRMATION; PLASMA; MPTP	Isobaric product ions cannot be differentiated by exact mass determinations, although in some cases deuterium labeling can provide useful structural information for identifying isobaric ions. Proposed fragmentation pathways of fentanyl were investigated by electrospray ionization ion trap mass spectrometry coupled with deuterium labeling experiments and spectra of regiospecific deuterium labeled analogs. The major product ion of fentanyl under tandem mass spectrometry (MS/MS) conditions (m/z 188) was accounted for by a neutral loss of N-phenylpropanamide. 1-(2-Phenylethyl)1,2,3,6-tetrahydropyridine (1) was proposed as the structure of the product ion. However, further fragmentation (MS3) of the fentanyl m/z 188 ion gave product ions that were different from the product ion in the MS/MS fragmentation of synthesized 1, suggesting that the m/z 188 product ion from fentanyl includes an isobaric structure different from the structure of 1. MS/MS fragmentation of fentanyl in deuterium oxide moved one of the isobars to 1 Da higher mass, and left the other isobar unchanged in mass. Multistage mass spectral data from deuterium-labeled proposed isobaric structures provided support for two fragmentation pathways. The results illustrate the utility of multistage mass spectrometry and deuterium labeling in structural assignment of isobaric product ions. Copyright (C) 2010 John Wiley & Sons, Ltd.	[Callery, Patrick S.] W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Wichitnithad, Wisut] Chulalongkorn Univ, Dept Pharmaceut Technol Program, Bangkok 10330, Thailand; [McManus, Terence J.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	Callery, PS (reprint author), W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA.	pcallery@hsc.wvu.edu			Thailand Research FundThailand Research Fund (TRF) [PHD/0217/2548]	Financial support from the Thailand Research Fund through the Royal Golden Jubilee PhD Program (Grant No. PHD/0217/2548) to W. Wichitnithad is acknowledged. The triple quadrupole data were generated in the Clinical Pharmacology Core Facility of the Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA.	CHENG MT, 1982, ANAL CHEM, V54, P2204, DOI 10.1021/ac00250a016; Cui L, 2002, LIQ CRYST, V29, P1121, DOI 10.1080/02678290210155589; EFANGE SMN, 1990, J MED CHEM, V33, P3133, DOI 10.1021/jm00174a007; KALGUTKAR AS, 1992, J MED CHEM, V35, P4165, DOI 10.1021/jm00100a023; KALGUTKAR AS, 1994, J MED CHEM, V37, P944, DOI 10.1021/jm00033a012; Kaufmann A, 2009, RAPID COMMUN MASS SP, V23, P985, DOI 10.1002/rcm.3959; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; Mabic S, 1997, J LABELLED COMPD RAD, V39, P409; Manral L, 2009, J THERM ANAL CALORIM, V96, P531, DOI 10.1007/s10973-008-9211-z; Peer CJ, 2008, J ANAL TOXICOL, V32, P709, DOI 10.1093/jat/32.8.709; Pihlainen K, 2005, J MASS SPECTROM, V40, P539, DOI 10.1002/jms.831; Prakash C, 2007, MASS SPECTROM REV, V26, P340, DOI 10.1002/mas.20128; Sugasawa S, 1941, BER DTSCH CHEM GES, V74, P459, DOI 10.1002/cber.19410740317; Takashina Y, 2009, J CLIN PHARM THER, V34, P523, DOI 10.1111/j.1365-2710.2009.01033.x; Thurlkill RL, 2005, J CARDIOTHOR VASC AN, V19, P759, DOI 10.1053/j.jvca.2004.11.039; Wong SC, 2010, J MED TOXICOL, V6, P9, DOI 10.1007/s13181-010-0031-8	17	9	9	2	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0951-4198	1097-0231		RAPID COMMUN MASS SP	Rapid Commun. Mass Spectrom.	SEP	2010	24	17					2547	2553		10.1002/rcm.4673			7	Biochemical Research Methods; Chemistry, Analytical; Spectroscopy	Biochemistry & Molecular Biology; Chemistry; Spectroscopy	644ED	WOS:000281355000009	20740529				2020-06-30	J	Devillier, P; Grassin-Delyle, S; Naline, E; Buenestado, A; Blouquit-Laye, S; Advenier, C				Devillier, Philippe; Grassin-Delyle, Stanislas; Naline, Emmanuel; Buenestado, Amparo; Blouquit-Laye, Sabine; Advenier, Charles			Intranasal Delivery of Systemic Drugs: a New Route for Opioid Drugs.	THERAPIE			French	Article						nose; drugs; absorption; morphinic; fentanyl	TRANSMUCOSAL FENTANYL CITRATE; HYDROMORPHONE HYDROCHLORIDE; BREAKTHROUGH PAIN; DOUBLE-BLIND; NASAL SPRAY; OPEN-LABEL; MU-G; PHARMACOKINETICS; BIOAVAILABILITY; BUTORPHANOL	Intranasal Delivery of Systemic Drugs: a New Route for Opioid Drugs. The intranasal delivery of drugs is widely used for the local treatment of rhinitis or nasal polyposis. This route of delivery could represent an interesting alternative for systemic drugs with low digestive absorption. The nasal mucosa acts as an anatomical obstacle hard to get over, except for compounds with low molecular weight or highly lipophilic. Among morphinic drugs, fentanyl, very lipophilic, is rapidly absorbed via intranasal administration with a bioavailability close to 90%. This route of delivery for fentanyl is a new alternative for the treatment of breakthrough pain and gives the opportunity to discuss on the interest and the limits of nasal route administration of drugs, particularly of opioids.	[Devillier, Philippe; Grassin-Delyle, Stanislas; Naline, Emmanuel; Buenestado, Amparo; Blouquit-Laye, Sabine; Advenier, Charles] Univ St Quentin Yvelines, Hop Foch, URPES EA 220, F-92150 Suresnes, France	Devillier, P (reprint author), Univ St Quentin Yvelines, Hop Foch, URPES EA 220, 11 Rue Guillaume Lenoir, F-92150 Suresnes, France.	p.devillier@hopital-foch.org					Amidi M, 2010, ADV DRUG DELIVER REV, V62, P59, DOI 10.1016/j.addr.2009.11.009; Arora P, 2002, DRUG DISCOV TODAY, V7, P967, DOI 10.1016/S1359-6446(02)02452-2; Cheng TJ, 2007, J CHEM INF MODEL, V47, P2140, DOI 10.1021/ci700257y; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coda BA, 2003, ANESTH ANALG, V97, P117, DOI 10.1213/01.ANE.0000066311.40978.4F; Costantino HR, 2007, INT J PHARMACEUT, V337, P1, DOI 10.1016/j.ijpharm.2007.03.025; Dale O, 2002, CLIN PHARMACOL THER, V72, P536, DOI 10.1067/mcp.2002.128386; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Davis GA, 2005, AM J HEALTH-SYST PH, V62, P48, DOI 10.1093/ajhp/62.1.48; Davis GA, 2004, CLIN DRUG INVEST, V24, P633, DOI 10.2165/00044011-200424110-00002; Davis GA, 2004, PHARMACOTHERAPY, V24, P26, DOI 10.1592/phco.24.1.26.34810; Davis SS, 2003, CLIN PHARMACOKINET, V42, P1107, DOI 10.2165/00003088-200342130-00003; Fitzgibbon D, 2003, PAIN, V106, P309, DOI 10.1016/S0304-3959(03)00318-X; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; *HAUT AUT SANT, 2010, INST SYNTH AV COMM T; Illum L, 2002, J PHARMACOL EXP THER, V301, P391, DOI 10.1124/jpet.301.1.391; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x; LECORRE P, 2001, LETT PHARM, V15, P167; Lin HX, 2005, EUR J PHARM SCI, V26, P203, DOI 10.1016/j.ejps.2005.06.003; Loder E, 2006, CEPHALALGIA, V26, P89, DOI 10.1111/j.1468-2982.2005.00951.x; Marttin E, 1998, ADV DRUG DELIVER REV, V29, P13, DOI 10.1016/S0169-409X(97)00059-8; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Nave R, 2009, 6 C EUR FED IASP CHA; PARAB PV, 1988, BIOPHARM DRUG DISPOS, V9, P187, DOI 10.1002/bod.2510090207; Pavis H, 2002, J PAIN SYMPTOM MANAG, V24, P598, DOI 10.1016/S0885-3924(02)00522-5; Robbins L, 1993, Headache, V33, P220; Rudy AC, 2004, ANESTH ANALG, V99, P1379, DOI 10.1213/01.ANE.0000132927.47528.8B; SHYU WC, 1993, EUR J CLIN PHARMACOL, V45, P559, DOI 10.1007/BF00315315; Soane RJ, 1999, INT J PHARMACEUT, V178, P55, DOI 10.1016/S0378-5173(98)00367-6; Stoker DG, 2008, PAIN MED, V9, P3, DOI 10.1111/j.1526-4637.2007.00300.x; Wermeling DP, 2005, CLIN THER, V27, P430, DOI 10.1016/j.clinthera.2005.04.002; Wermeling DR, 2005, J CLIN PHARMACOL, V45, P969, DOI 10.1177/0091270005278057; Zeppetella G., 2006, COCHRANE DB SYST REV, V1, pCD004311	38	3	3	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0040-5957	1958-5578		THERAPIE	Therapie	SEP-OCT	2010	65	5					475	481		10.2515/therapie/2010052			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	693RE	WOS:000285242100010	21144483				2020-06-30	J	Prossin, AR; Love, TM; Koeppe, RA; Zubieta, JK; Silk, KR				Prossin, Alan R.; Love, Tiffany M.; Koeppe, Robert A.; Zubieta, Jon-Kar; Silk, Kenneth R.			Dysregulation of Regional Endogenous Opioid Function in Borderline Personality Disorder	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							VENTRAL TEGMENTAL AREA; AFFECTIVE INSTABILITY; GLUCOSE-METABOLISM; RECEPTOR-BINDING; UP-REGULATION; STRESS; COMORBIDITY; RESPONSES; DOPAMINE; EMOTION	Objective: Borderline personality disorder is characterized by a lack of effective regulation of emotional responses. The authors investigated the role of the endogenous opioid system and mu-opioid receptors in emotion regulation in borderline personality disorder. Method: Mu-opioid receptor availability in vivo (nondisplaceable binding potential, or BPND) was measured with positron emission tomography and the selective radiotracer [C-11]carfentanil during neutral and sustained sadness states in 18 un-medicated female patients with borderline personality disorder and 14 healthy female comparison subjects. Results: Patients showed greater regional mu-opioid BPND than did comparison subjects at baseline (neutral state) bilaterally in the orbitofrontal cortex, caudate, and nucleus accumbens and in the left amygdala, but lower BPND in the posterior thalamus. Sadness induction was associated with greater reductions in BPND (endogenous opioid system activation) in the patient group than in the comparison group in the pregenual anterior cingulate, left orbitofrontal cortex, left ventral pallidum, left amygdala, and left inferior temporal cortex. Patients showed evidence of endogenous opioid system deactivation in the left nucleus accumbens, the hypothalamus, and the right hippocampus/parahippocampus relative to comparison subjects. Correlations of baseline measures with the Dissociative Experiences Scale and endogenous opioid system activation with the Barratt Impulsiveness Scale did not remain significant after correction for multiple comparisons. Conclusions: Differences exist between patients with borderline personality disorder and comparison subjects in baseline in vivo p-opioid receptor concentrations and in the endogenous opioid system response to a negative emotional challenge that can be related to some of the clinical characteristics of patients with borderline personality disorder. The regional network involved is implicated in the representation and regulation of emotion and stress responses.	[Silk, Kenneth R.] Univ Michigan, Dept Psychiat, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA	Silk, KR (reprint author), Univ Michigan, Dept Psychiat, Mol & Behav Neurosci Inst, Box 5769,Rachel Upjohn Bldg,4250 Plymouth Rd, Ann Arbor, MI 48109 USA.	ksilk@umich.edu	Love, Tiffany/W-8427-2019; Prossin, Alan/K-2967-2015	Love, Tiffany/0000-0001-9299-3190; Prossin, Alan/0000-0003-1262-522X	Borderline Personality Disorder Research Foundation; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 MH 069612]	Supported by a grant from the Borderline Personality Disorder Research Foundation to Dr. Silk and NIMH grant R21 MH 069612 to Dr. Zubieta.	Barr CS, 2008, P NATL ACAD SCI USA, V105, P5277, DOI 10.1073/pnas.0710225105; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; Bohus MJ, 1999, J CLIN PSYCHIAT, V60, P598, DOI 10.4088/JCP.v60n0906; Brady LS, 1999, MOL BRAIN RES, V68, P193, DOI 10.1016/S0169-328X(99)00090-X; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Costa P.T., 1992, REVISED NEO PERSONAL; DeLaFuente JM, 1997, J PSYCHIATR RES, V31, P531, DOI 10.1016/S0022-3956(97)00001-0; Driessen M, 2000, ARCH GEN PSYCHIAT, V57, P1115, DOI 10.1001/archpsyc.57.12.1115; Drolet G, 2001, PROG NEURO-PSYCHOPH, V25, P729, DOI 10.1016/S0278-5846(01)00161-0; First M., 1996, STRUCTURED CLIN INTE; First M.B., 1995, STRUCTURED CLIN INTE; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Grant BF, 2008, J CLIN PSYCHIAT, V69, P533, DOI 10.4088/JCP.v69n0404; Herpertz S, 1997, J AFFECT DISORDERS, V44, P31, DOI 10.1016/S0165-0327(97)01444-4; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; Jolas T, 2000, NEUROSCIENCE, V95, P433; Juengling FD, 2003, J PSYCHIAT RES, V37, P109, DOI 10.1016/S0022-3956(02)00084-5; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Koenigsberg HW, 2002, AM J PSYCHIAT, V159, P784, DOI 10.1176/appi.ajp.159.5.784; Lange C, 2005, PSYCHIAT RES-NEUROIM, V139, P115, DOI 10.1016/j.pscychresns.2005.05.003; Leibenluft E, 1987, J PERSONALITY DISORD, V1, P317, DOI DOI 10.1521/PEDI.1987.1.4.317; LINEHAN MM, 1994, AM J PSYCHIAT, V151, P1771; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Love TM, 2009, ARCH GEN PSYCHIAT, V66, P1124, DOI 10.1001/archgenpsychiatry.2009.134; Ludascher P, 2007, PSYCHIAT RES, V149, P291, DOI 10.1016/j.psychres.2005.04.009; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; Minzenberg MJ, 2007, PSYCHIAT RES-NEUROIM, V155, P231, DOI 10.1016/j.pscychresns.2007.03.006; Narendran R, 2004, SYNAPSE, V52, P188, DOI 10.1002/syn.20013; New AS, 2008, PSYCHIAT CLIN N AM, V31, P441, DOI 10.1016/j.psc.2008.03.011; Nikulina EM, 2005, NEUROPSYCHOPHARMACOL, V30, P1096, DOI 10.1038/sj.npp.1300658; Ribeiro SC, 2005, PROG NEURO-PSYCHOPH, V29, P1264, DOI 10.1016/j.pnpbp.2005.08.011; Schmahl C, 2006, J PSYCHIATR RES, V40, P419, DOI 10.1016/j.jpsychires.2005.08.011; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Siever LJ, 2002, BIOL PSYCHIAT, V51, P964, DOI 10.1016/S0006-3223(02)01326-4; Silbersweig D, 2007, AM J PSYCHIAT, V164, P1832, DOI 10.1176/appi.ajp.2007.06010126; Silk KR, 2000, PSYCHIAT CLIN N AM, V23, P61, DOI 10.1016/S0193-953X(05)70143-X; Skodol AE, 2002, BIOL PSYCHIAT, V51, P936, DOI 10.1016/S0006-3223(02)01324-0; Smith APR, 2005, LEARN MEMORY, V12, P472, DOI 10.1101/lm.84305; Smith KS, 2007, J NEUROSCI, V27, P1594, DOI 10.1523/JNEUROSCI.4205-06.2007; Soloff PH, 2007, BIOL PSYCHIAT, V62, P580, DOI 10.1016/j.biopsych.2006.10.022; Soloff PH, 2003, PSYCHIAT RES-NEUROIM, V123, P153, DOI 10.1016/S0925-4927(03)00064-7; Svingos AL, 2001, SYNAPSE, V41, P221, DOI 10.1002/syn.1079; Tobler PN, 2005, SCIENCE, V307, P1642, DOI 10.1126/science.1105370; Tom SM, 2007, SCIENCE, V315, P515, DOI 10.1126/science.1134239; Wagner S, 2009, J PSYCHIATR RES, V43, P1067, DOI 10.1016/j.jpsychires.2009.03.004; Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zanarini MC, 2004, AM J PSYCHIAT, V161, P2108, DOI 10.1176/appi.ajp.161.11.2108; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	53	78	79	0	19	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	AUG	2010	167	8					925	933		10.1176/appi.ajp.2010.09091348			9	Psychiatry	Psychiatry	634OS	WOS:000280593400009	20439388	Green Accepted			2020-06-30	J	Short, TG				Short, Timothy G.			Using Response Surfaces to Expand the Utility of MAC	ANESTHESIA AND ANALGESIA			English	Editorial Material							REMIFENTANIL; MODEL; LARYNGOSCOPY; ANESTHESIA; HALOTHANE; PROPOFOL		Auckland City Hosp, Dept Anaesthesia & Perioperat Med, Auckland, New Zealand	Short, TG (reprint author), Auckland City Hosp, Dept Anaesthesia & Perioperat Med, Pk Rd, Auckland, New Zealand.	tims@adhb.govt.nz					Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Chan MTV, 1996, ANESTHESIOLOGY, V85, P782, DOI 10.1097/00000542-199610000-00013; FREI FJ, 1991, BRIT J ANAESTH, V66, P331, DOI 10.1093/bja/66.3.331; Johnson KB, 2008, ANESTH ANALG, V106, P471, DOI 10.1213/ane.0b013e3181606c62; Johnson KB, 2010, ANESTH ANALG, V111, P387, DOI 10.1213/ANE.0b013e3181afe31c; Liem EB, 2004, ANESTHESIOLOGY, V101, P279, DOI 10.1097/00000542-200408000-00006; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; Mapleson WW, 1996, BRIT J ANAESTH, V76, P179; MERKEL G, 1963, ANESTHESIOLOGY, V24, P346, DOI 10.1097/00000542-196305000-00016; Minto CF, 1997, ANESTHESIOLOGY, V86, P24, DOI 10.1097/00000542-199701000-00005; Minto CF, 2000, ANESTHESIOLOGY, V92, P1603, DOI 10.1097/00000542-200006000-00017; MUNSON ES, 1965, ANESTHESIOLOGY, V26, P134, DOI 10.1097/00000542-196503000-00003; Short TG, 2002, ANESTHESIOLOGY, V96, P400, DOI 10.1097/00000542-200202000-00027; Syroid ND, 2002, ANESTHESIOLOGY, V96, P565, DOI 10.1097/00000542-200203000-00010; Syroid ND, 2010, ANESTH ANALG, V111, P380, DOI 10.1213/ane.0b013e3181b11289	15	10	10	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2010	111	2					249	251		10.1213/ANE.0b013e3181e5f0ce			3	Anesthesiology	Anesthesiology	633CZ	WOS:000280478400001	20664083				2020-06-30	J	Syroid, ND; Johnson, KB; Pace, NL; Westenskow, DR; Tyler, D; Bruhschwein, F; Albert, RW; Roalstad, S; Costy-Bennett, S; Egan, TD				Syroid, Noah D.; Johnson, Ken B.; Pace, Nathan L.; Westenskow, Dwayne R.; Tyler, Diane; Bruehschwein, Frederike; Albert, Robert W.; Roalstad, Shelly; Costy-Bennett, Samuel; Egan, Talmage D.			Response Surface Model Predictions of Emergence and Response to Pain in the Recovery Room: An Evaluation of Patients Emerging from an Isoflurane and Fentanyl Anesthetic	ANESTHESIA AND ANALGESIA			English	Article							SEVOFLURANE REQUIREMENTS; ALVEOLAR CONCENTRATION; CONCENTRATION-AWAKE; INHALATION ANESTHESIA; SYSTEM MODEL; REMIFENTANIL; VOLUNTEERS; MAC; PHARMACOKINETICS; HYPERALGESIA	INTRODUCTION: Sevoflurane-remifentanil interaction models that predict responsiveness and response to painful stimuli have been evaluated in patients undergoing elective surgery. Preliminary evaluations of model predictions were found to be consistent with observations in patients anesthetized with sevoflurane, remifentanil, and fentanyl. This study explored the feasibility of adapting the predictions of sevoflurane-remifentanil interaction models to an isoflurane-fentanyl anesthetic. We hypothesized that model predictions adapted for isoflurane and fentanyl are consistent with observed patient responses and are similar to the predictions observed in our previous work with sevoflurane-remifentanil/fentanyl anesthetics. METHODS: Twenty-five patients scheduled for elective surgery received a fentanyl-isoflurane anesthetic. Model predictions of unresponsiveness were recorded at emergence, and predictions of a response to noxious stimulus were recorded when patients first required analgesics in the recovery room. Model predictions were compared with observations with graphical and temporal analyses. Results were also compared with our previous predictions after the administration of a sevoflurane-remifentanil/fentanyl anesthetic. RESULTS: Although patients were anesthetized, model predictions indicated a high likelihood that patients would be unresponsive (>= 99%). After the termination of the anesthetic, model predictions of responsiveness well described the actual fraction of patients observed to be responsive during emergence. Half of the patients woke within 2 min of the 50% model-predicted probability of unresponsiveness; 70% woke within 4 min. Similarly, predictions of a response to a noxious stimulus were consistent with the number of patients who required fentanyl in the recovery room. Model predictions after the administration of an isoflurane-fentanyl anesthetic were similar to model predictions after a sevoflurane-remifentanil/fentanyl anesthetic. DISCUSSION: The results confirmed our study hypothesis; model predictions for unresponsiveness and no response to painful stimuli, adapted to isoflurane-fentanyl were consistent with observations. These results were similar to our previous study comparing model predictions and patient observations after a sevoflurane-remifentanil/fentanyl anesthetic. (Anesth Analg 2010;111:380-6)	[Syroid, Noah D.; Johnson, Ken B.; Pace, Nathan L.; Westenskow, Dwayne R.; Tyler, Diane; Bruehschwein, Frederike; Roalstad, Shelly; Egan, Talmage D.] Univ Utah, Dept Anesthesiol, Salt Lake City, UT 84132 USA; [Syroid, Noah D.; Johnson, Ken B.; Pace, Nathan L.; Westenskow, Dwayne R.; Tyler, Diane; Bruehschwein, Frederike; Roalstad, Shelly; Egan, Talmage D.] Univ Utah, Dept Biomed Engn, Salt Lake City, UT 84132 USA; [Syroid, Noah D.; Johnson, Ken B.; Westenskow, Dwayne R.; Albert, Robert W.; Costy-Bennett, Samuel; Egan, Talmage D.] Appl Med Visualizat LLC, Salt Lake City, UT USA	Syroid, ND (reprint author), Univ Utah, Dept Anesthesiol, 30 N,1900 E,Room SOM 3C44, Salt Lake City, UT 84132 USA.	noah.syroid@hsc.utah.edu			General Electric HealthcareGE Healthcare; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2R44GM066615-02]	Supported in part by a research grant from General Electric Healthcare and National Institutes of Health SBIR Phase II grant no. 2R44GM066615-02.	CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cox D. R., 1984, ANAL SURVIVAL DATA; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Eger II EI, 2003, PHARM INHALED ANESTH; Goto T, 2000, ANESTHESIOLOGY, V93, P1188, DOI 10.1097/00000542-200011000-00009; GRECO WR, 1995, PHARMACOL REV, V47, P331; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hood DD, 2003, ANESTH ANALG, V97, P810, DOI 10.1213/01.ANE.0000078811.80093.88; Inomata Shinichi, 1999, Anesthesia and Analgesia, V89, P204, DOI 10.1097/00000539-199907000-00037; Johnson KB, 2008, ANESTH ANALG, V106, P471, DOI 10.1213/ane.0b013e3181606c62; Johnson KB, 2010, ANESTH ANALG, V111, P387, DOI 10.1213/ANE.0b013e3181afe31c; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; KATOH T, 1993, ANESTH ANALG, V77, P1012; KATOH T, 1993, ANESTH ANALG, V76, P348; KATOH T, 1987, ANESTHESIOLOGY, V66, P301, DOI 10.1097/00000542-198703000-00006; KIMURA T, 1994, ANESTH ANALG, V79, P378; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; LEROU JGC, 1991, ANESTHESIOLOGY, V75, P345, DOI 10.1097/00000542-199108000-00025; Lerou JGC, 2001, BRIT J ANAESTH, V86, P12, DOI 10.1093/bja/86.1.12; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; SCHELLER MS, 1988, CAN J ANAESTH, V35, P153, DOI 10.1007/BF03010656; Schmidt S, 2007, CLIN J PAIN, V23, P605, DOI 10.1097/AJP.0b013e318122d1e4; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; STEVENS WC, 1975, ANESTHESIOLOGY, V42, P197, DOI 10.1097/00000542-197502000-00014; Suzuki A, 1998, ANESTH ANALG, V86, P179, DOI 10.1097/00000539-199801000-00035; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23; ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P261, DOI 10.1097/00000542-199402000-00005	32	14	15	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999	1526-7598		ANESTH ANALG	Anesth. Analg.	AUG	2010	111	2					380	386		10.1213/ane.0b013e3181b11289			7	Anesthesiology	Anesthesiology	633CZ	WOS:000280478400021	19820239	Green Accepted			2020-06-30	J	Johnson, KB; Syroid, ND; Gupta, DK; Manyam, SC; Pace, NL; LaPierre, CD; Egan, TD; White, JL; Tyler, D; Westenskow, DR				Johnson, Ken B.; Syroid, Noah D.; Gupta, Dhanesh K.; Manyam, Sandeep C.; Pace, Nathan L.; LaPierre, Cris D.; Egan, Talmage D.; White, Julia L.; Tyler, Diane; Westenskow, Dwayne R.			An Evaluation of Remifentanil-Sevoflurane Response Surface Models in Patients Emerging from Anesthesia: Model Improvement Using Effect-Site Sevoflurane Concentrations	ANESTHESIA AND ANALGESIA			English	Article							INHALATION ANESTHESIA; CONTROLLED INFUSION; SYSTEM MODEL; PHARMACODYNAMICS; ISOFLURANE; MIDAZOLAM; SYNERGY; PHARMACOKINETICS; COMPUTER; FENTANYL	INTRODUCTION: We previously reported models that characterized the synergistic interaction between remifentanil and sevoflurane in blunting responses to verbal and painful stimuli. This preliminary study evaluated the ability of these models to predict a return of responsiveness during emergence from anesthesia and a response to tibial pressure when patients required analgesics in the recovery room. We hypothesized that model predictions would be consistent with observed responses. We also hypothesized that under non-steady-state conditions, accounting for the lag time between sevoflurane effect-site concentration (Ce) and end-tidal (ET) concentration would improve predictions. METHODS: Twenty patients received a sevoflurane, remifentanil, and fentanyl anesthetic. Two model predictions of responsiveness were recorded at emergence: an ET-based and a Ce-based prediction. Similarly, 2 predictions of a response to noxious stimuli were recorded when patients first required analgesics in the recovery room. Model predictions were compared with observations with graphical and temporal analyses. RESULTS: While patients were anesthetized, model predictions indicated a high likelihood that patients would be unresponsive (>= 99%). However, after termination of the anesthetic, models exhibited a wide range of predictions at emergence (1%-97%). Although wide, the Ce-based predictions of responsiveness were better distributed over a percentage ranking of observations than the ET-based predictions. For the ET-based model, 45% of the patients awoke within 2 min of the 50% model predicted probability of unresponsiveness and 65% awoke within 4 min. For the Ce-based model, 45% of the patients awoke within 1 min of the 50% model predicted probability of unresponsiveness and 85% awoke within 3.2 min. Predictions of a response to a painful stimulus in the recovery room were similar for the Ce- and ET-based models. DISCUSSION: Results confirmed, in part, our study hypothesis; accounting for the lag time between Ce and ET sevoflurane concentrations improved model predictions of responsiveness but had no effect on predicting a response to a noxious stimulus in the recovery room. These models may be useful in predicting events of clinical interest but large-scale evaluations with numerous patients are needed to better characterize model performance. (Anesth Analg 2010;111:387-94)	[Johnson, Ken B.; Syroid, Noah D.; Pace, Nathan L.; LaPierre, Cris D.; Egan, Talmage D.; White, Julia L.; Tyler, Diane; Westenskow, Dwayne R.] Univ Utah, Dept Anesthesiol, Salt Lake City, UT 84132 USA; [Johnson, Ken B.; Syroid, Noah D.; Pace, Nathan L.; LaPierre, Cris D.; Egan, Talmage D.; White, Julia L.; Tyler, Diane; Westenskow, Dwayne R.] Univ Utah, Dept Biomed Engn, Salt Lake City, UT 84132 USA; [Gupta, Dhanesh K.] Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, Chicago, IL 60611 USA; [Manyam, Sandeep C.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA	Johnson, KB (reprint author), Univ Utah, Dept Anesthesiol, 30 N,1900 E,Room 3C444, Salt Lake City, UT 84132 USA.	ken.b.johnson@hsc.utah.edu			General Electric HealthcareGE Healthcare; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2R44GM06615-02]	Supported in part by a research grant from General Electric Healthcare and NIH Health General Medicine SBIR Phase I grant no. 2R44GM06615-02.	Albrecht S, 1999, CLIN PHARMACOL THER, V65, P630, DOI 10.1016/S0009-9236(99)90084-X; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cox D. R., 1984, ANAL SURVIVAL DATA; EFRON B, 1982, JACKKNIFE BOOTSTRAP, P27; Egan TD, 2003, ANESTHESIOLOGY, V99, P1214, DOI 10.1097/00000542-200311000-00031; GRECO WR, 1995, PHARMACOL REV, V47, P331; GRECO WR, 1990, CANCER RES, V50, P5318; Johnson KB, 2008, ANESTH ANALG, V106, P471, DOI 10.1213/ane.0b013e3181606c62; Kern SE, 2004, ANESTHESIOLOGY, V100, P1373, DOI 10.1097/00000542-200406000-00007; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; LEROU JGC, 1991, ANESTHESIOLOGY, V75, P345, DOI 10.1097/00000542-199108000-00025; Lerou JGC, 2001, BRIT J ANAESTH, V86, P12, DOI 10.1093/bja/86.1.12; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; Minto C, 2003, ADV EXP MED BIOL, V523, P35; Sakata DJ, 2007, ANESTH ANALG, V104, P587, DOI 10.1213/01.ane.0000255074.96657.39; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Schumacher PM, 2007, ANESTHESIOLOGY, V107, pA17; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Somma J, 1998, ANESTHESIOLOGY, V89, P1430, DOI 10.1097/00000542-199812000-00021; Syroid ND, 2002, ANESTHESIOLOGY, V96, P565, DOI 10.1097/00000542-200203000-00010; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23	21	22	24	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2010	111	2					387	394		10.1213/ANE.0b013e3181afe31c			8	Anesthesiology	Anesthesiology	633CZ	WOS:000280478400022	19820241	Green Accepted			2020-06-30	J	Khafagy, HF; Refaat, AI; El-sabae, HH; Youssif, MA				Khafagy, Hanan F.; Refaat, Ahmed I.; El-sabae, Hossam H.; Youssif, Maha A.			Efficacy of epidural dexamethasone versus fentanyl on postoperative analgesia	JOURNAL OF ANESTHESIA			English	Article						Epidural; Dexamethasone; Fentanyl; Bupivacaine; Analgesia	LAPAROSCOPIC CHOLECYSTECTOMY; PAIN; NAUSEA; MANAGEMENT; STEROIDS; METHYLPREDNISOLONE; GLUCOCORTICOIDS; SURGERY	Dexamethasone has analgesic, anti-inflammatory, and antiemetic effects. This prospective, randomized, double-blind, controlled study was designed to evaluate the efficacy of adding dexamethasone versus fentanyl to epidural bupivacaine on postoperative analgesia. Ninety patients ASA I-II scheduled for lower abdominal surgeries were randomly allocated into three groups to receive a total of 10 mL epidural plain bupivacaine 0.25% in the control group (group B), with either 50 mu g fentanyl in group BF or 4 mg dexamethasone in group BD. Patients then received general anesthesia. Sedation, satisfaction, and visual analogue pain scores (VAS) were measured postoperatively. Meperidine was administered when VAS a parts per thousand yen4. Intraoperative fentanyl dose, postoperative meperidine consumption, and the time to first analgesic requirement were recorded. Intraoperative fentanyl requirements were comparable among groups. Time to first analgesic requirement was significantly prolonged (5.2 times) in the BF group and (4.8 times) in the BD group compared with group B (p < 0.01). There was significant reduction in postoperative meperidine consumption during the first 24 h in the BF and BD groups (65, 62.5% respectively) in comparison with group B (p < 0.01). VAS scores were significantly lower and patient satisfaction score was significantly higher in the BF and BD groups compared with group B (p < 0.01). Postoperative nausea was significantly lower in the BD group versus the B and BF groups (p < 0.05). This study revealed that epidural bupivacaine-dexamethasone admixture had almost the same analgesic potency as bupivacaine-fentanyl with opioid-sparing and antiemetic effects. Further studies are required to evaluate the optimum dose of epidural dexamethasone for postoperative analgesia.	[Khafagy, Hanan F.; Refaat, Ahmed I.; El-sabae, Hossam H.; Youssif, Maha A.] Theodor Bilharz Res Inst, Minist High Educ & Sci Res, Dept Anesthesiol, Giza 12411, Egypt	Khafagy, HF (reprint author), Theodor Bilharz Res Inst, Minist High Educ & Sci Res, Dept Anesthesiol, POB 30 Imbaba, Giza 12411, Egypt.	hananfkhafagy993@hotmail.com					Aasboe V, 1998, ANESTH ANALG, V87, P319, DOI 10.1097/00000539-199808000-00015; Aminmansour B, 2006, SPINE, V31, P2415, DOI 10.1097/01.brs.0000238668.49035.19; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; BAXENDALE BR, 1993, ANAESTHESIA, V48, P961; Bisgaard T, 2003, ANN SURG, V238, P651, DOI 10.1097/01.sla.0000094390.82352.cb; Blanloeil Y, 2001, BRIT J ANAESTH, V87, P635, DOI 10.1093/bja/87.4.635; BROCKWAY MS, 1991, BRIT J ANAESTH, V66, P31, DOI 10.1093/bja/66.1.31; BROWN FW, 1977, CLIN ORTHOP RELAT R, P72; Fujii Y, 1998, EUR J ANAESTH, V15, P342, DOI 10.1097/00003643-199805000-00017; Fujii Y, 1999, ANESTH ANALG, V89, P476, DOI 10.1097/00000539-199908000-00043; GALANDIUK S, 1993, ANN SURG, V218, P419, DOI 10.1097/00000658-199310000-00003; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; JOHANSSON A, 1990, ACTA ANAESTH SCAND, V34, P335, DOI 10.1111/j.1399-6576.1990.tb03097.x; Jokela RM, 2009, ANESTH ANALG, V109, P607, DOI 10.1213/ane.0b013e3181ac0f5c; Kroin JS, 2000, NEUROSURGERY, V46, P178; MAILLEFERT JF, 1995, REV RHUM, V62, P429; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; NORMAN GR, 2008, BIOSTATISTICS BAR ES; PIEN LC, 1988, J ALLERGY CLIN IMMUN, V82, P696, DOI 10.1016/0091-6749(88)90985-2; Price C, 2005, HEALTH TECHNOL ASSES, V9, P1; Reinhart DJ, 1997, CAN J ANAESTH, V44, P377, DOI 10.1007/BF03014457; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sauerland S, 2000, DRUG SAFETY, V23, P449, DOI 10.2165/00002018-200023050-00007; Shang AB, 2003, DRUGS, V63, P855, DOI 10.2165/00003495-200363090-00002; Thomas S, 2006, CAN J ANAESTH, V53, P899, DOI 10.1007/BF03022833; Vardy J, 2006, BRIT J CANCER, V94, P1011, DOI 10.1038/sj.bjc.6603048; Wang YL, 1997, ANESTH ANALG, V84, P376, DOI 10.1097/00000539-199702000-00025; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	29	33	34	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	AUG	2010	24	4					531	536		10.1007/s00540-010-0949-7			6	Anesthesiology	Anesthesiology	635IG	WOS:000280648200005	20467878				2020-06-30	J	Burkhart, CS; Dell-Kuster, S; Gamberini, M; Moeckli, A; Grapow, M; Filipovic, M; Seeberger, MD; Monsch, AU; Strebel, SP; Steiner, LA				Burkhart, Christoph S.; Dell-Kuster, Salome; Gamberini, Melanie; Moeckli, Ariane; Grapow, Martin; Filipovic, Miodrag; Seeberger, Manfred D.; Monsch, Andreas U.; Strebel, Stephan P.; Steiner, Luzius A.			Modifiable and Nonmodifiable Risk Factors for Postoperative Delirium After Cardiac Surgery With Cardiopulmonary Bypass	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						delirium; cardiac surgical procedures; risk factors; fentanyl; mechanical ventilation	CONFUSION ASSESSMENT METHOD; INTENSIVE-CARE UNIT; GRAFT-SURGERY; PREDICTORS; COMPLICATIONS; INFLAMMATION; MEDICATIONS; EXTUBATION; SYSTEM	Objectives: Postoperative delirium after cardiac surgery is associated with increased morbidity and mortality as well as prolonged stay in both the intensive care unit and the hospital. The authors sought to identify modifiable risk factors associated with the development of postoperative delirium in elderly patients after elective cardiac surgery in order to be able to design follow-up studies aimed at the prevention of delirium by optimizing perioperative management. Design: A post hoc analysis of data from patients enrolled in a randomized controlled trial was performed. Setting: A single university hospital. Participants: One hundred thirteen patients aged 65 or older undergoing elective cardiac surgery with cardiopulmonary bypass. Interventions: None. Measurements and Mains Results: Screening for delirium was performed using the Confusion Assessment Method (CAM) on the first 6 postoperative days. A multivariable logistic regression model was developed to identify significant risk factors and to control for confounders. Delirium developed in 35 of 113 patients (30%). The multivariable model showed the maximum value of C-reactive protein measured postoperatively, the dose of fentanyl per kilogram of body weight administered intraoperatively, and the duration of mechanical ventilation to be independently associated with delirium. Conclusions: In this post hoc analysis, larger doses of fentanyl administered intraoperatively and longer duration of mechanical ventilation were associated with postoperative delirium in the elderly after cardiac surgery. Prospective randomized trials should be performed to test the hypotheses that a reduced dose of fentanyl administered intraoperatively, the use of a different opioid, or weaning protocols aimed at early extubation prevent delirium in these patients. (C) 2010 Elsevier Inc. All rights reserved.	[Burkhart, Christoph S.; Dell-Kuster, Salome; Gamberini, Melanie; Moeckli, Ariane; Filipovic, Miodrag; Seeberger, Manfred D.; Strebel, Stephan P.; Steiner, Luzius A.] Univ Basel Hosp, Dept Anesthesia & Intens Care Med, CH-4031 Basel, Switzerland; [Grapow, Martin] Univ Basel Hosp, Div Cardiac Surg, CH-4031 Basel, Switzerland; [Steiner, Luzius A.] Univ Hosp Ctr, Dept Anaesthesia, Lausanne, Switzerland; [Steiner, Luzius A.] Univ Lausanne, Lausanne, Switzerland	Burkhart, CS (reprint author), Univ Basel Hosp, Dept Anesthesia & Intens Care Med, CH-4031 Basel, Switzerland.	cburkhart@uhbs.ch	Dell-Kuster, Salome/P-2653-2019; Monsch, Andreas U/C-8309-2019; Dell-Kuster, Salome/H-4259-2017; Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019; Seeberger, Manfred D/J-2847-2019	Dell-Kuster, Salome/0000-0001-7219-7138; Monsch, Andreas U/0000-0003-1692-1560; Dell-Kuster, Salome/0000-0001-7219-7138; Seeberger, Manfred/0000-0002-2358-7233; Burkhart, Christoph/0000-0002-9288-117X	Novartis Switzerland; Society for Research in Anesthesia and Critical Care Medicine of the Department of Anesthesia and Intensive Care Medicine, University Hospital Basel, Basel, Switzerland	Supported in part by an unrestricted research grant from Novartis Switzerland and the Society for Research in Anesthesia and Critical Care Medicine of the Department of Anesthesia and Intensive Care Medicine, University Hospital Basel, Basel, Switzerland.	Aldemir M, 2001, CRIT CARE, V5, P265, DOI 10.1186/cc1044; Banach M, 2008, MED SCI MONITOR, V14, pCR286; Bucerius J, 2004, J THORAC CARDIOV SUR, V127, P57, DOI 10.1016/S0022-5223(03)01281-9; Cheng DCH, 1996, J THORAC CARDIOV SUR, V112, P755, DOI 10.1016/S0022-5223(96)70062-4; Cheng DCH, 2001, ANESTH ANALG, V92, P1094; Chew ML, 2008, J AM GERIATR SOC, V56, P1333, DOI 10.1111/j.1532-5415.2008.01737.x; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Dumas A, 1999, J CARDIOTHOR VASC AN, V13, P130, DOI 10.1016/S1053-0770(99)90074-5; Ebert AD, 2001, J CARDIOTHOR VASC AN, V15, P15, DOI 10.1053/jcan.2001.20211; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gamberini M, 2009, CRIT CARE MED, V37, P1762, DOI 10.1097/CCM.0b013e31819da780; Girard TD, 2008, CRIT CARE, V12, DOI 10.1186/cc6149; Gunaydin B, 1998, Ann Thorac Cardiovasc Surg, V4, P12; Han L, 2001, ARCH INTERN MED, V161, P1099, DOI 10.1001/archinte.161.8.1099; Herrmann M, 1999, EUR J CARDIO-THORAC, V16, P513, DOI 10.1016/S1010-7940(99)00245-6; Ille R, 2007, CARDIOVASC REVASCULA, V8, P166, DOI 10.1016/j.carrev.2006.12.001; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Katznelson R, 2009, ANESTHESIOLOGY, V110, P67, DOI 10.1097/ALN.0b013e318190b4d9; Kazmierski J, 2006, GEN HOSP PSYCHIAT, V28, P536, DOI 10.1016/j.genhosppsych.2006.08.007; KURODA Y, 1993, ANESTH ANALG, V76, P222, DOI 10.1213/00000539-199302000-00004; Leung JM, 2006, NEUROLOGY, V67, P1251, DOI 10.1212/01.wnl.0000233831.87781.a9; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; Mathew JP, 2007, J AM COLL CARDIOL, V49, P1934, DOI 10.1016/j.jacc.2007.01.080; McKhann GM, 2002, ARCH NEUROL-CHICAGO, V59, P1422, DOI 10.1001/archneur.59.9.1422; Nashef SAM, 1999, EUR J CARDIO-THORAC, V16, P9, DOI 10.1016/S1010-7940(99)00134-7; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Norkiene I, 2007, SCAND CARDIOVASC J, V41, P180, DOI 10.1080/14017430701302490; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Paparella D, 2002, EUR J CARDIO-THORAC, V21, P232, DOI 10.1016/S1010-7940(01)01099-5; Santos FS, 2004, INT PSYCHOGERIATR, V16, P175, DOI 10.1017/S1041610204000365; SLOGOFF S, 1982, ANESTH ANALG, V61, P903; Tan MC, 2008, AM J GERIAT PSYCHIAT, V16, P575, DOI 10.1097/JGP.0b013e318172b418; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676	35	78	82	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	AUG	2010	24	4					555	559		10.1053/j.jvca.2010.01.003			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	636IS	WOS:000280726000004	20227891				2020-06-30	J	Saitoh, Y; Oshima, T; Nakata, Y				Saitoh, Yuhji; Oshima, Tsutomu; Nakata, Yoshinori			Acceleromyographic monitoring of neuromuscular block over the orbicularis orris muscle in anesthetized patients receiving vecuronium	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Acceleromyography; Monitoring; Train-of-four; Orbicularis oris muscle; Vecuromum	CORRUGATOR SUPERCILII MUSCLE; FEMALE-PATIENTS; ADDUCTOR POLLICIS; DOSE-RESPONSE; TIME-COURSE; OCULI; ROCURONIUM; STIMULATION; DIAPHRAGM; TWITCH	Study Objective: To evaluate the level of neuromuscular block acceleromyographically over the orbicularis oris muscle Design: Prospective, randomized, controlled study Setting: Operating room of a university-affiliated hospital. Patients: 36 adult, ASA physical status I and II women scheduled for mastectomy with air-oxygen-isoflurane-fentanyl anesthesia Interventions: Patients were randomized to two groups In the orbicularis oris group (n=18). the facial nerve was stimulated and movement of the orbicularis oils muscle was measured acceleromyographically In the control group (n=18). adduction of the thumb was quantified mechanically Measurements: Onset and recovery of neuromuscular block caused by vecuronium 0 1 mg/kg were compared between the groups Main Results: Time to onset of neuromuscular block in the orbicularis oris group was significantly shorter than in the control group (176 52 vs 220 34 sec. mean SI), P = 0 004) Times to return of the first, second, third, or fourth (TI, T2, T3, or T4) response of train-of four (TOE). and recovery of TI/control were comparable between the groups Train-of-four ratio (T4/TI) in the orbicularis oris group was significantly higher than in the control group 50 to 120 minutes after vecuronium administration (P < 0 05) Conclusion: Depth of neuromuscular block can be assessed acceleromyographically, over the orbicularis oils muscle Onset of neuromuscular block is quicker and recovery of TOF ratio is faster over the orbicularis oris muscle than at the thumb in patients receiving vecuronium (C) 2010 Elsevier Inc All rights reserved	[Saitoh, Yuhji] Tsujinaka Hosp Kashiwanoha, Dept Anesthesiol, Chiba 2770871, Japan; [Oshima, Tsutomu] Japanese Fdn Canc Res, Canc Inst Hosp, Div Anesthesia, Tokyo 1358550, Japan; [Nakata, Yoshinori] Teikyo Univ, Sch Med, Dept Anesthesia & Crit Care, Tokyo 1738605, Japan	Saitoh, Y (reprint author), Tsujinaka Hosp Kashiwanoha, Dept Anesthesiol, Chiba 2770871, Japan.						Baykara N, 2003, J CLIN ANESTH, V15, P446, DOI 10.1016/S0952-8180(03)00110-7; BROWNER WS, 2001, DESIGNING CLIN RES E, P65; BRULL S, 1995, ANESTHESIOLOGY, V83, P802; DEBAENE B, 1995, ANESTH ANALG, V80, P360, DOI 10.1097/00000539-199502000-00026; ERIKSSON LI, 1991, ACTA ANAESTH SCAND, V35, P247, DOI 10.1111/j.1399-6576.1991.tb03282.x; Fuchs-Buder T, 2007, ACTA ANAESTH SCAND, V51, P789, DOI 10.1111/j.1399-6576.2007.01352.x; Gatke MR, 2002, ACTA ANAESTH SCAND, V46, P1124, DOI 10.1034/j.1399-6576.2002.460911.x; Hemmerling TM, 2000, BRIT J ANAESTH, V85, P856, DOI 10.1093/bja/85.6.856; Hemmerling TM, 2003, CAN J ANAESTH, V50, P779, DOI 10.1007/BF03019373; Hemmerling TM, 2002, BRIT J ANAESTH, V88, P389, DOI 10.1093/bja/88.3.389; IBEBUNJO C, 1993, BRIT J ANAESTH, V71, P732, DOI 10.1093/bja/71.5.732; KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015; Larsen PB, 2002, ACTA ANAESTH SCAND, V46, P1131, DOI 10.1034/j.1399-6576.2002.460912.x; Plaud B, 2001, ANESTHESIOLOGY, V95, P96, DOI 10.1097/00000542-200107000-00019; SAITOH Y, 1995, CAN J ANAESTH, V42, P992, DOI 10.1007/BF03011071; Saitoh Y, 2003, CAN J ANAESTH, V50, P342, DOI 10.1007/BF03021030; SAITOH Y, 1993, BRIT J ANAESTH, V70, P402, DOI 10.1093/bja/70.4.402; SCHWARTING S, 1982, ORL J OTO-RHINO-LARY, V44, P51, DOI 10.1159/000275567; SEMPLE P, 1994, BRIT J ANAESTH, V72, P190, DOI 10.1093/bja/72.2.190; VIBYMOGENSEN J, 1988, ACTA ANAESTH SCAND, V32, P45; Xue FS, 1998, BRIT J ANAESTH, V80, P720, DOI 10.1093/bja/80.6.720; Xue FS, 1997, ANESTH ANALG, V85, P667, DOI 10.1097/00000539-199709000-00033	22	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2010	22	5					318	323		10.1016/j.jclinane.2009.09.004			6	Anesthesiology	Anesthesiology	633US	WOS:000280532800003	20650376				2020-06-30	J	Subwongcharoen, S; Udompornmongkol, V				Subwongcharoen, Somboon; Udompornmongkol, Vachira			A Randomized Control Trial of Levobupivacaine, Bupivacaine Versus Placebo Extraperitoneal Infusion in Totally Extraperitoneal Laparoscopic Inguinal Hernioplasty	JOURNAL OF SURGICAL RESEARCH			English	Article						laparoscopic; hernioplasty; levobupivacaine; bupivacaine; hernia; extraperitoneal; visual analogue pain scores; postoperative analgesia; pain; randomized control trial	HERNIA REPAIR; ANALGESIA; HERNIORRHAPHY; INFILTRATION; ANESTHESIA; TEP	Background. Totally extraperitoneal (TEP) laparoscopic inguinal hernioplasty procedure is significantly less painful than open repair, but it is not completely painless. The aim of this study was to compare the effect of extraperitoneal infusion of 0.25% levobupivacaine, 0.25% bupivacaine, and placebo in patients undergoing TEP procedure in terms of pain reduction. Methods. Twenty patients were included in each group for TEP procedure. Group A received 40 mL of 0.9% normal saline, group B received 40 mL of 0.25% bupivacaine, and group C received 40 mL of 0.25% levobupivacaine infused into the extraperitoneal space before closing. Postoperative pain was assessed at 4, 8, 12, 24, 36, and 48 h postoperatively. Analgesic requirement, complications, and overall satisfaction were also recorded. Results. The demographic and surgical characteristics of the patients did not significantly differ among groups. There were no statistical differences among groups in postoperative pain scores, total IV-PCA morphine requirement, complications, and overall satisfaction. Conclusion. Extraperitoneal infusion 40 mL of 0.25% bupivacaine or 0.25% levobupivacaine following TEP procedure did not show any benefit over placebo in terms of pain reduction. (C) 2010 Elsevier Inc. All rights reserved.	[Subwongcharoen, Somboon] Rangsit Univ, Dept Surg, Rajavithi Hosp, Bangkok 10400, Thailand; [Udompornmongkol, Vachira] Rangsit Univ, Dept Anesthesiol, Rajavithi Hosp, Bangkok 10400, Thailand	Subwongcharoen, S (reprint author), Rangsit Univ, Dept Surg, Rajavithi Hosp, Phayathai Rd, Bangkok 10400, Thailand.	somboonsub@hotmail.com			Rajavithi Research Fund	The authors gratefully acknowledge the Rajavithi Research Fund for generous financial support. The authors thank the nursing staff of Rajavithi Hospital for their assistance with the data collection. Gratitude is extended to Dr. Chulaluk Komoltri, Department of Research Development, Mahidol University, for her assistance with the power calculation and the statistical analysis of the data. Much appreciation goes to Dr. Rina Patramanon, Khon Kaen University, for her language assistance.	ABDELBASET AA, 2005, EG J ANAESTH, V21, P151; Bar-Dayan A, 2004, SURG ENDOSC, V18, P1079, DOI 10.1007/s00464-003-8214-x; Bay-Nielsen M, 1999, BRIT J ANAESTH, V82, P280, DOI 10.1093/bja/82.2.280; Foster RH, 2000, DRUGS, V59, P551, DOI 10.2165/00003495-200059030-00013; GOULDING ST, 1995, AMBUL SURG, V3, P75; Ivani G, 2001, Minerva Anestesiol, V67, P20; Juul P, 1999, BRIT J SURG, V86, P316, DOI 10.1046/j.1365-2168.1999.01053.x; Katkhouda N, 1999, SURG ENDOSC, V13, P1243, DOI 10.1007/PL00011163; Kingsnorth AN, 2002, EUR J SURG, V168, P391, DOI 10.1080/110241502320789069; Lal P, 2003, SURG ENDOSC, V17, P850, DOI 10.1007/s00464-002-8575-6; Lau H, 2002, SURG ENDOSC, V16, P159, DOI 10.1007/s00464-001-8106-x; Nixon SJ, 2005, SURG-J R COLL SURG E, V3, P281, DOI 10.1016/S1479-666X(05)80093-9; O'Riordain DS, 1998, AM J SURG, V176, P254, DOI 10.1016/S0002-9610(98)00151-2; O'Riordain DS, 1999, SURG ENDOSC-ULTRAS, V13, P914, DOI 10.1007/s004649901133; Saff GN, 1998, ANESTH ANALG, V87, P377, DOI 10.1097/00000539-199808000-00026; SHENFELD O, 1995, J UROLOGY, V153, P185, DOI 10.1097/00005392-199501000-00073	16	5	5	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	AUG	2010	162	2					279	283		10.1016/j.jss.2009.01.030			5	Surgery	Surgery	633JZ	WOS:000280499500021	19457494				2020-06-30	J	Ruangkittisakul, A; Ballanyi, K				Ruangkittisakul, Araya; Ballanyi, Klaus			Methylxanthine reversal of opioid-evoked inspiratory depression via phosphodiesterase-4 blockade	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Breathing; Caffeine; PDE; Respiratory rhythm; Rolipram; Theophylline	STEM-SPINAL CORD; INDUCED RESPIRATORY DEPRESSION; PRE-BOTZINGER COMPLEX; BRAIN-STEM; NEWBORN RATS; IN-VITRO; RHYTHM GENERATION; ADENOSINERGIC MODULATION; PREBOTZINGER COMPLEX; CEREBROSPINAL-FLUID	Hypothetic mechanisms for respirogenic methylxanthine actions include blockade of adenosine receptors or phosphodiesterase-4 (PDE4) in inspiratory pre-Botzinger complex (preBotC) networks. Here, we studied this by analyzing stimulating caffeine and theophylline actions on p.-opioid-depressed inspiratory-related rhythm in the ventrolateral aspect of rat brainstem slices. The methylxanthines restored DAMGO (0.5-1 mu M) depressed rhythm only at >1 mM, which is similar to 10-fold higher than selective for adenosine receptors. Adenosine receptor blockers did neither counter DAMGO inhibition nor change control rhythm, similar to adenosine (0.1-2.5 mM). The specific PDE4 blocker rolipram (5 mu M) restored DAMGO-depressed rhythm incompletely, but effectively reversed similar inhibition by clinical p.-agonist (fentanyl, 0.1 mu M). At 0.25 mu M, rolipram boosted incomplete recovery by 1 mM theophylline of DAMGO-depressed rhythm. Findings indicate that methylxanthines excite rhythmogenic preBotC networks via blockade of cAMP dependent PDE4 and suggest that specific PDE4 inhibitors (plus low methylxanthine doses) stimulate breathing effectively. We discuss why methylxanthine doses for preBotC stimulation need to be higher than those for respirogenic effects in vivo. (C) 2010 Elsevier B.V. All rights reserved.	[Ballanyi, Klaus] Univ Alberta, Dept Physiol, Fac Med & Dent, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Perinatal Res Ctr, Fac Med & Dent, Edmonton, AB T6G 2S2, Canada	Ballanyi, K (reprint author), Univ Alberta, Dept Physiol, Fac Med & Dent, 232D Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	klaus.ballanyi@ualberta.ca	Ungpakawa, Araya/J-3849-2013	Ungpakawa, Araya/0000-0002-9606-8557	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Heritage Foundation for Medical Research (AHFMR)Alberta Heritage Foundation for Medical Research	This study was supported by the Canadian Institutes of Health Research (CIHR) and the Alberta Heritage Foundation for Medical Research (AHFMR). We thank Lucia Secchia for expert technical assistance.	Ballanyi K, 1999, PROG NEUROBIOL, V59, P583, DOI 10.1016/S0301-0082(99)00009-X; Ballanyi K, 2004, J EXP BIOL, V207, P3201, DOI 10.1242/jeb.01106; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; BALLANYI K, 2009, EUR J PHYSL, V458, P571; Ballanyi Klaus, 2004, Current Neuropharmacology, V2, P221, DOI 10.2174/1570159043476828; Ballanyi K, 2009, RESP PHYSIOL NEUROBI, V168, P158, DOI 10.1016/j.resp.2009.04.020; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Bhatia J, 2000, CLIN PEDIATR, V39, P327, DOI 10.1177/000992280003900602; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Black AM, 2008, BRAIN RES, V1219, P136, DOI 10.1016/j.brainres.2008.04.066; BOBON D, 1988, EUR ARCH PSY CLIN N, V238, P2, DOI 10.1007/BF00381071; Boison D, 2005, NEUROSCIENTIST, V11, P25, DOI 10.1177/1073858404269112; Brockhaus J, 2000, NEUROSCIENCE, V96, P359, DOI 10.1016/S0306-4522(99)00544-8; Comer A M, 2001, Paediatr Drugs, V3, P61, DOI 10.2165/00128072-200103010-00005; Conde SV, 2006, J NEUROCHEM, V98, P616, DOI 10.1111/j.1471-4159.2006.03912.x; Crain SM, 2000, PAIN, V84, P121, DOI 10.1016/S0304-3959(99)00223-7; DAL PV, 2000, [No title captured], V35, P463; Daly JW, 2007, CELL MOL LIFE SCI, V64, P2153, DOI 10.1007/s00018-007-7051-9; Dutschmann M, 2004, RESP PHYSIOL NEUROBI, V143, P155, DOI 10.1016/j.resp.2004.04.015; ELDRIDGE FL, 1985, J APPL PHYSIOL, V59, P1428; Feldman JL, 2006, NAT REV NEUROSCI, V7, P232, DOI 10.1038/nrn1871; FELDMAN JL, 1986, [No title captured], V4, P463; FLEISCHHACKER WW, 1992, NEUROPSYCHOBIOLOGY, V26, P59, DOI 10.1159/000118897; Fredholm BB, 1999, PHARMACOL REV, V51, P83; Giembycz MA, 2008, BRIT J PHARMACOL, V155, P288, DOI 10.1038/bjp.2008.297; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; Goshgarian HG, 2009, RESP PHYSIOL NEUROBI, V169, P85, DOI 10.1016/j.resp.2009.06.005; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; Greer JJ, 2009, RESP PHYSIOL NEUROBI, V168, P153, DOI 10.1016/j.resp.2009.02.011; Guyenet PG, 2008, J APPL PHYSIOL, V105, P404, DOI 10.1152/japplphysiol.90452.2008; HEDNER T, 1985, BIOL NEONATE, V47, P323; HENDERSONSMART DJ, 2001, COCHRANE DB SYST REV, V3; Herlenius E, 1999, J PHYSIOL-LONDON, V518, P159, DOI 10.1111/j.1469-7793.1999.0159r.x; Herlenius E, 1997, PEDIATR RES, V42, P46, DOI 10.1203/00006450-199707000-00008; Herlenius E, 2002, PEDIATR RES, V51, P4, DOI 10.1203/00006450-200201000-00004; Horn EM, 1998, RESP PHYSIOL, V114, P201, DOI 10.1016/S0034-5687(98)00087-5; JAVAHERI S, 1988, J APPL PHYSIOL, V64, P1837; KANDEL ER, 1991, PRINCIPLES NEUROSCIE; KAPLAN GB, 1993, J PHARMACOL EXP THER, V266, P1563; KAWAI A, 1995, RESP PHYSIOL, V100, P25, DOI 10.1016/0034-5687(94)00124-I; Koos BJ, 2005, AM J PHYSIOL-REG I, V288, pR1185, DOI 10.1152/ajpregu.00723.2004; LEWIS AB, 1981, CIRCULATION, V64, P893, DOI 10.1161/01.CIR.64.5.893; Magkos F, 2005, CRIT REV FOOD SCI, V45, P535, DOI 10.1080/1040-830491379245; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Manzke T, 2009, PHILOS T R SOC B, V364, P2589, DOI 10.1098/rstb.2009.0068; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; Menniti FS, 2006, NAT REV DRUG DISCOV, V5, P660, DOI 10.1038/nrd2058; Montandon G, 2008, RESP PHYSIOL NEUROBI, V164, P87, DOI 10.1016/j.resp.2008.07.013; NAKAZONO T, 1992, CHEM PHARM BULL, V40, P2510; O'Donnell JM, 2004, TRENDS PHARMACOL SCI, V25, P158, DOI 10.1016/j.tips.2004.01.003; Onimaru H, 2009, RESP PHYSIOL NEUROBI, V168, P13, DOI 10.1016/j.resp.2009.03.007; Pace RW, 2007, J PHYSIOL-LONDON, V580, P485, DOI 10.1113/jphysiol.2006.124602; Panaitescu B, 2009, NEUROSCI LETT, V456, P25, DOI 10.1016/j.neulet.2009.03.074; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Pena F, 2006, CURR MED CHEM, V13, P2681, DOI 10.2174/092986706778201602; Ptak K, 2009, J NEUROSCI, V29, P3720, DOI 10.1523/JNEUROSCI.5271-08.2009; Rekling JC, 1996, J NEUROPHYSIOL, V75, P811; Richter DW, 1997, RESP PHYSIOL, V110, P113, DOI 10.1016/S0034-5687(97)00077-7; Ruangkittisakul A, 2008, J NEUROSCI, V28, P2447, DOI 10.1523/JNEUROSCI.1926-07.2008; Ruangkittisakul A, 2007, J PHYSIOL-LONDON, V584, P489, DOI 10.1113/jphysiol.2007.142760; Ruangkittisakul A, 2006, J NEUROSCI, V26, P11870, DOI 10.1523/JNEUROSCI.3357-06.2006; Ruangkittisakul A, 2006, NEUROSCI LETT, V401, P194, DOI 10.1016/j.neulet.2006.03.015; RUNOLD M, 1986, J APPL PHYSIOL, V61, P255; Saadani-Makki F, 2004, NEUROSCIENCE, V127, P505, DOI 10.1016/j.neuroscience.2004.05.006; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; SAWYNOK J, 1995, DRUGS, V49, P37, DOI 10.2165/00003495-199549010-00004; Schmidt B, 2006, NEW ENGL J MED, V354, P2112, DOI 10.1056/NEJMoa054065; SCOTT AIF, 1991, EUR J CLIN PHARMACOL, V40, P127; SINGH GK, 1994, EUR HEART J, V15, P377, DOI 10.1093/oxfordjournals.eurheartj.a060506; Spina D, 2008, BRIT J PHARMACOL, V155, P308, DOI 10.1038/bjp.2008.307; Subramanian HH, 2008, J NEUROSCI, V28, P12274, DOI 10.1523/JNEUROSCI.4168-08.2008; Takita K, 2000, BRAIN RES, V884, P201, DOI 10.1016/S0006-8993(00)02921-8; Tanabe A, 2005, NEUROSCI LETT, V375, P19, DOI 10.1016/j.neulet.2004.10.058; TURMEN T, 1979, J PEDIATR-US, V95, P644, DOI 10.1016/S0022-3476(79)80788-X; UKENA D, 1993, BIOCHEM PHARMACOL, V45, P847, DOI 10.1016/0006-2952(93)90168-V; VanDam RJ, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-95; Vickroy TW, 2008, J VET PHARMACOL THER, V31, P156, DOI 10.1111/j.1365-2885.2008.00942.x; WESSBERG P, 1984, EUR J PHARMACOL, V106, P59, DOI 10.1016/0014-2999(84)90678-2; Wilken B, 2000, J APPL PHYSIOL, V89, P2015; Zhang HT, 2000, NEUROPSYCHOPHARMACOL, V23, P198, DOI 10.1016/S0893-133X(00)00108-1; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784	82	18	18	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	JUL 31	2010	172	3					94	105		10.1016/j.resp.2010.04.025			12	Physiology; Respiratory System	Physiology; Respiratory System	631VX	WOS:000280379700002	20444435				2020-06-30	J	Fernandez-Duenas, V; Ciruela, F; Gandia, J; Sanchez, S; Planas, E; Poveda, R				Fernandez-Duenas, Victor; Ciruela, Francisco; Gandia, Jorge; Sanchez, Silvia; Planas, Eulalia; Poveda, Raquel			Histamine H-3 receptor activation potentiates peripheral opioid-mediated antinociception: Substance P role in peripheral inflammation in mice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Nociception; Inflammation; Fentanyl; Histamine H-3 receptor agonist; Substance P; Synergy	MAST-CELLS; RAT MODEL; C-FIBERS; BP 2-94; PAIN; AGONIST; RELEASE; MORPHINE; IMMUNE; HYPERALGESIA	Opioids provide effective analgesia in adult patients with painful inflammatory diseases. The proposed mechanism of action is the activation of peripheral opioid receptors, which may be up-regulated in such conditions. Here, by using a chronic inflammation model, namely subplantar injection of Complete Freund's adjuvant, we show a peripheral synergistic interaction between the histamine H-3 receptor agonist R-(alpha)-methylhistamine and fentanyl on the inhibition of thermal hyperalgesia and of peripheral substance P accumulation. Firstly, dose-related effects obtained for the subplantar antinociceptive effect of fentanyl (0.05-1 mu g) in the presence of a fixed dose of R-(alpha)-methylhistamine (12.5 mu g) showed a shift to the left when compared to that obtained with fentanyl alone. In a similar way, the subcutaneous administration of fentanyl (0.005-0.1 mg/kg) plus a fixed dose of R-(alpha)-methylhistamine (0.5 mg/kg) induced a supra additive effect on the inhibition of substance P accumulation in the hind-paw skin of inflamed mice. Interestingly, when a neurokinin-1 receptor antagonist was co-administered, the antinociceptive effects of the combined treatment were potentiated. The peripheral adjuvant effect of R-(alpha)-methylhistamine on fentanyl antinociception and inhibition of substance P accumulation was also demonstrated by means of opioid and histamine H-3 receptors selective antagonists: first, naloxone blockade of fentanyl-mediated effects were partially reversed by co-administration of R-(alpha)-methylhistamine, and second, thioperamide partially antagonised the combined R-(alpha)-methylhistamine/fentanyl effects. Overall, our results clearly show that R-(alpha)-methylhistamine enhances fentanyl effects at peripheral sites, and that the control of substance P levels might be one of the mechanisms responsible of such interaction. (C) 2010 Elsevier B.V. All rights reserved.	[Fernandez-Duenas, Victor; Ciruela, Francisco; Gandia, Jorge; Sanchez, Silvia; Planas, Eulalia; Poveda, Raquel] Univ Barcelona, Fac Med, Dept Patol & Terapeut Expt, Unitat Farmacol, Barcelona 08907, Spain	Fernandez-Duenas, V (reprint author), Univ Barcelona, Fac Med, Dept Patol & Terapeut Expt, Unitat Farmacol, Campus Bellvitge,Pavello Govern Av Feixa Llarga S, Barcelona 08907, Spain.	vfernandez@ub.edu	Fernandez-Duenas, Victor/E-5337-2014; Gandia, Jorge/P-3373-2016; Ciruela, F./A-5096-2013	Fernandez-Duenas, Victor/0000-0001-7834-2965; Gandia, Jorge/0000-0003-1711-8075; Ciruela, F./0000-0003-0832-3739	Ministerio de Ciencia e InnovacionInstituto de Salud Carlos IIISpanish Government [SAF2008-01462, CSD2008-00005]; Comissio Recerca de Bellvitge (University of Barcelona)	The authors belong to the "Neuropharmacology and Pain" accredited research group (Generalitat de Catalunya, 2009 SGR 232). This work was supported by grants SAF2008-01462 and Consolider-Ingenio CSD2008-00005 from Ministerio de Ciencia e Innovacion to FC, and ACESB from Comissio Recerca de Bellvitge (University of Barcelona) to VF and RP. The authors acknowledge Ms. S. Sanchez for the technical assistance.	ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; Bianchi M, 2008, EUR J PAIN, V12, P284, DOI 10.1016/j.ejpain.2007.06.005; Boerzsei R, 2008, NEUROSCIENCE, V152, P82, DOI 10.1016/j.neuroscience.2007.12.005; Buvanendran A, 2007, BEST PRACT RES-CLIN, V21, P31, DOI 10.1016/j.bpa.2006.12.003; Cannon KE, 2003, EUR J PHARMACOL, V470, P139, DOI 10.1016/S0014-2999(03)01737-0; Cannon KE, 2007, PAIN, V129, P76, DOI 10.1016/j.pain.2006.09.039; Cerinic Marco Matucci, 1998, Current Opinion in Rheumatology, V10, P220, DOI 10.1097/00002281-199805000-00011; DELAUNOIS A, 1995, EUR J PHARMACOL, V277, P243, DOI 10.1016/0014-2999(95)00085-Y; Dimitriadou V, 1997, NEUROSCIENCE, V77, P829, DOI 10.1016/S0306-4522(96)00488-5; DRAY A, 1995, BRIT J ANAESTH, V75, P125, DOI 10.1093/bja/75.2.125; Farzin D, 2002, PHARMACOL BIOCHEM BE, V72, P751, DOI 10.1016/S0091-3057(02)00748-7; Fernandez-Duenas V, 2008, EUR J PAIN, V12, P157, DOI 10.1016/j.ejpain.2007.03.485; Fernandez-Duenas V, 2007, J PHARMACOL EXP THER, V322, P360, DOI 10.1124/jpet.106.118901; Ferre S, 2007, TRENDS NEUROSCI, V30, P440, DOI 10.1016/j.tins.2007.07.001; Goodwin Jeremy L R, 2009, Curr Rheumatol Rep, V11, P5; Helyes Zsuzsanna, 2003, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V2, P191, DOI 10.2174/1568014033483806; Hernandez L, 2009, BRAIN RES, V1248, P31, DOI 10.1016/j.brainres.2008.10.065; Huang L, 2007, REGION ANESTH PAIN M, V32, P124, DOI 10.1016/j.rapm.2006.11.009; Imamura M, 1996, CIRC RES, V78, P863, DOI 10.1161/01.RES.78.5.863; Janson W., 2003, Current Pharmaceutical Biotechnology, V4, P270, DOI 10.2174/1389201033489766; Jensen MK, 2006, EUR J PAIN, V10, P423, DOI 10.1016/j.ejpain.2005.06.001; Labuz D, 2006, J NEUROSCI, V26, P4350, DOI 10.1523/JNEUROSCI.4349-05.2006; MAGGI CA, 1995, PROG NEUROBIOL, V45, P1, DOI 10.1016/0301-0082(94)E0017-B; MALMBERGAIELLO P, 1994, BRIT J PHARMACOL, V111, P1269, DOI 10.1111/j.1476-5381.1994.tb14883.x; Mcleod RL, 1998, J PHARMACOL EXP THER, V287, P43; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; Mobarakeh JI, 2009, NEUROPHARMACOLOGY, V57, P409, DOI 10.1016/j.neuropharm.2009.06.036; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Nemmar A, 1999, EUR J PHARMACOL, V371, P23, DOI 10.1016/S0014-2999(99)00176-4; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; OHKUBO T, 1995, EUR J PHARMACOL, V273, P83, DOI 10.1016/0014-2999(94)00668-W; OLUYOMI AO, 1991, NEUROPHARMACOLOGY, V30, P1021, DOI 10.1016/0028-3908(91)90115-R; OWEN SM, 1994, AGENTS ACTIONS, V41, pC62, DOI 10.1007/BF02007768; Perrot S, 2001, ANESTHESIOLOGY, V94, P870, DOI 10.1097/00000542-200105000-00027; Poveda R, 2006, EUR J PHARMACOL, V541, P53, DOI 10.1016/j.ejphar.2006.05.008; Przewlocki R, 2001, EUR J PHARMACOL, V429, P79, DOI 10.1016/S0014-2999(01)01308-5; Rittner HL, 2008, BRIT J ANAESTH, V101, P40, DOI 10.1093/bja/aen078; Rouleau A, 2000, J PHARMACOL EXP THER, V295, P219; Rouleau A, 1997, J PHARMACOL EXP THER, V281, P1085; Sluka KA, 1997, BRIT J PHARMACOL, V120, P1263, DOI 10.1038/sj.bjp.0701044; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Stein C, 2001, Z RHEUMATOL, V60, P416, DOI 10.1007/s003930170004; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; TALLARIDA RJ, 1992, PAIN, V49, P93, DOI 10.1016/0304-3959(92)90193-F; White D M, 1997, J Peripher Nerv Syst, V2, P191; Wilder-Smith CH, 2001, PAIN, V91, P23, DOI 10.1016/S0304-3959(00)00414-0; YONEHARA N, 1992, REGUL PEPTIDES, V38, P13, DOI 10.1016/0167-0115(92)90068-6; Yonehara N, 2001, PAIN, V92, P259, DOI 10.1016/S0304-3959(01)00264-0; Zampeli E, 2009, BRIT J PHARMACOL, V157, P24, DOI 10.1111/j.1476-5381.2009.00151.x	49	8	8	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JUL 25	2010	638	1-3					72	77		10.1016/j.ejphar.2010.04.022			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	616NU	WOS:000279216900012	20435034				2020-06-30	J	Zheng, H; Chu, J; Zeng, Y; Loh, HH; Law, PY				Zheng, Hui; Chu, Ji; Zeng, Yan; Loh, Horace H.; Law, Ping-Yee			Yin Yang 1 Phosphorylation Contributes to the Differential Effects of mu-Opioid Receptor Agonists on MicroRNA-190 Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; F-ACTIN; DENDRITIC SPINE; MECHANISMS; NEUROGENESIS; TALIN2; BACE1	mu-Opioid receptor regulates microRNA-190 (miR-190) in an agonist-dependent manner; fentanyl, but not morphine, decreases the miR-190 level in rat primary hippocampal neuron cultures and in mouse hippocampi. In this study, the correlation between the cellular content of miR-190 and the mRNA level of its host gene, talin2, suggested that fentanyl decreases the miR-190 level by inhibiting the transcription of talin2. Fentanyl-induced beta-arrestin2-mediated ERK phosphorylation led to the phosphorylation of Yin Yang 1(YY1). In addition, YY1 phosphorylation impaired the association of YY1 with the -208 to -200 region on the Talin2 promoter, and this association was essential for YY1 to stimulate the transcription of talin2. Thus, fentanyl decreased the transcription of talin2 and subsequently the cellular level of miR-190 by inducing YY1 phosphorylation. In contrast, because morphine induces ERK phosphorylation via the protein kinase C pathway, morphine did not induce YY1 phosphorylation and had no effect on the transcription of talin2 and the cellular content of miR-190. This study therefore delineates a signaling pathway that mediates the effects of fentanyl on miR-190 expression.	[Zheng, Hui; Chu, Ji; Zeng, Yan; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Zheng, H (reprint author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zhen0091@umn.edu		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA007339, DA016674, DA000564, DA011806, K05-DA70544, K05-DA00513]	This work was supported, in whole or in part, by National Institutes of Health Grants DA007339, DA016674, DA000564, and DA011806.; Recipient of National Institutes of Health Grant K05-DA70544.; Recipient of National Institutes of Health Grant K05-DA00513.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Capani F, 2001, J COMP NEUROL, V435, P156, DOI 10.1002/cne.1199; Christie BR, 2006, HIPPOCAMPUS, V16, P199, DOI 10.1002/hipo.20151; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Fukazawa' Y, 2003, NEURON, V38, P447, DOI 10.1016/S0896-6273(03)00206-X; Garzon R, 2006, P NATL ACAD SCI USA, V103, P5078, DOI 10.1073/pnas.0600587103; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; He Y, 2008, J NEUROCHEM, V106, P1493, DOI 10.1111/j.1471-4159.2008.05486.x; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Nishizaki T, 2007, NEW DIAM FRONT C TEC, V17, P21; Nowak K, 2006, J NEUROCHEM, V96, P1696, DOI 10.1111/j.1471-4159.2006.03692.x; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Senetar MA, 2007, CELL MOTIL CYTOSKEL, V64, P157, DOI 10.1002/cm.20173; Seo HM, 1996, J NEUROSCI, V16, P4102; Seo S, 2007, EMBO J, V26, P5093, DOI 10.1038/sj.emboj.7601923; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Stockley JH, 2008, CELL MOL LIFE SCI, V65, P3265, DOI 10.1007/s00018-008-8271-3; Tamada A, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-29; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Tsuchiya S, 2006, J PHARMACOL SCI, V101, P267, DOI 10.1254/jphs.CPJ06013X; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Yue R, 2009, CELL, V139, P535, DOI 10.1016/j.cell.2009.08.038; Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	37	48	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2010	285	29					21994	22002		10.1074/jbc.M110.112607			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	622YF	WOS:000279702200012	20457614	Bronze, Green Published			2020-06-30	J	Verplaetse, R; Tytgat, J				Verplaetse, Ruth; Tytgat, Jan			Development and validation of a sensitive ultra performance liquid chromatography tandem mass spectrometry method for the analysis of fentanyl and its major metabolite norfentanyl in urine and whole blood in forensic context	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						LC-MS/MS; High pH mobile phase; UFLC or UPLC; Fentanyl; Norfentanyl; Post-mortem samples	SOLID-PHASE EXTRACTION; MEDICAL-EXAMINERS-OFFICE; 9 BASIC PHARMACEUTICALS; PH MOBILE PHASES; HUMAN-PLASMA; ELECTROSPRAY-IONIZATION; TRANSDERMAL PATCHES; GAS-CHROMATOGRAPHY; MS/MS ANALYSIS; LC-MS/MS	Fentanyl and its major metabolite norfentanyl often occur in low doses in biological samples. Therefore, a highly sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method has been developed and fully validated. Sample preparation was performed on a mixed-mode cation exchange solid phase extraction (SPE) cartridge with an additional alkaline wash step to decrease matrix effects and thus increase sensitivity. Ionization of fentanyl and norfentanyl with electrospray ionization (ESI) was more efficient than atmospheric pressure chemical ionization (APCI). The use of a mobile phase of high pH resulted in higher ESI signals than the conventional low pH mobile phases. In the final method, gradient elution with 10 mM ammonium bicarbonate (pH 9) and methanol was performed. A comparison of columns with different internal diameter and/or smaller particles showed optimal resolution and sensitivity when an Acquity C18 column (1.7 mu m, 2.1 mm x 50 mm) was used. Deuterium labeled internal standards were used, but with careful evaluation of their stability since loss of deuteriums was seen. With limits of detection of 0.25 pg/ml for fentanyl and 2.5 pg/ml for norfentanyl in urine and 5 pg/ml for fentanyl and norfentanyl in whole blood the presented method is highly appropriate for the analysis of fentanyl and norfentanyl in forensic urine and blood samples. (C) 2010 Elsevier B.V. All rights reserved.	[Verplaetse, Ruth; Tytgat, Jan] KULeuven, Toxicol Lab, B-3000 Leuven, Belgium	Verplaetse, R (reprint author), KULeuven, Toxicol Lab, Campus Gasthuisberg O&N 2,POB 922,Herestr 49, B-3000 Leuven, Belgium.	ruth.verplaetse@pharm.kuleuven.be; jan.tytgat@pharm.kuleuven.be	Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022			Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; BASELT RC, 1995, [No title captured]; BERG T, 2008, J CHROMATOGR B; Bruins AP, 1998, J CHROMATOGR A, V794, P345, DOI 10.1016/S0021-9673(97)01110-2; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; Chavez-Eng CM, 2002, J CHROMATOGR B, V767, P117, DOI 10.1016/S0378-4347(01)00552-7; CHEN XH, 1992, J ANAL TOXICOL, V16, P351, DOI 10.1093/jat/16.6.351; Cheng YF, 2001, RAPID COMMUN MASS SP, V15, P141, DOI 10.1002/1097-0231(20010130)15:2<141::AID-RCM201>3.0.CO;2-I; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; Churchwell MI, 2005, J CHROMATOGR B, V825, P134, DOI 10.1016/j.jchromb.2005.05.037; Clarke S.D., 1996, PHARM SCI, V2, P203; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Delatour C, 2005, RAPID COMMUN MASS SP, V19, P1359, DOI 10.1002/rcm.1923; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Dong MW, 2003, J CHROMATOGR A, V987, P283, DOI 10.1016/S0021-9673(02)01961-1; Drummer OH, 2004, FORENSIC SCI INT, V142, P101, DOI 10.1016/j.forsciint.2004.02.013; DRUMMER OH, 2001, FORENSIC PATHOLOGY D, P235; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Espada A, 2004, J CHROMATOGR A, V1030, P43, DOI 10.1016/j.chroma.2003.12.027; Feierman DE, 1996, ANESTH ANALG, V82, P936, DOI 10.1097/00000539-199605000-00008; FRINCKE JM, 1980, DRUG METAB DISPOS, V8, P425; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; Guitton J, 1997, J CHROMATOGR B, V693, P59, DOI 10.1016/S0378-4347(97)00050-9; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kaferstein H, 2000, FORENSIC SCI INT, V113, P353, DOI 10.1016/S0379-0738(00)00224-3; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Klinke HB, 2007, SCAND J CLIN LAB INV, V67, P778, DOI 10.1080/00365510701449362; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lafreniere NM, 2009, FORENSIC SCI INT, V185, P100, DOI 10.1016/j.forsciint.2008.12.019; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; LU C, 2009, BIOMED CHRO IN PRESS; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; Mansoori BA, 1997, RAPID COMMUN MASS SP, V11, P1120, DOI 10.1002/(SICI)1097-0231(19970630)11:10<1120::AID-RCM976>3.3.CO;2-H; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Matuszewski BK, 1998, ANAL CHEM, V70, P882, DOI 10.1021/ac971078+; Moore C, 2008, FORENSIC SCI INT, V176, P47, DOI 10.1016/j.forsciint.2007.06.027; Musshoff F, 2006, J MASS SPECTROM, V41, P633, DOI 10.1002/jms.1021; Novakova L, 2006, J SEP SCI, V29, P2433, DOI 10.1002/jssc.200600147; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; Peer CJ, 2007, J ANAL TOXICOL, V31, P515, DOI 10.1093/jat/31.8.515; Peng L, 2008, J CHROMATOGR A, V1179, P131, DOI 10.1016/j.chroma.2007.11.048; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; POLETTINI A, 2006, APPL LC MS TOXICOLOG; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; SAAR E, 2008, ANAL BIOANAL CHEM; Sachs H, 1996, INT J LEGAL MED, V109, P213, DOI 10.1007/BF01225521; SCHWARTZ JG, 1994, AM J FOREN MED PATH, V15, P236, DOI 10.1097/00000433-199409000-00011; SELAVKA CM, 1995, J FORENSIC SCI, V40, P681; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Skulska Agnieszka, 2005, Przegl Lek, V62, P581; Skulska Agnieszka, 2007, Przegl Lek, V64, P263; Stout PR, 1998, DRUG METAB DISPOS, V26, P689; Sutlovic Davorka, 2007, Arhiv za Higijenu Rada i Toksikologiju, V58, P317, DOI 10.2478/v10004-007-0023-5; Takashina Y, 2009, J CLIN PHARM THER, V34, P523, DOI 10.1111/j.1365-2710.2009.01033.x; Taylor PJ, 2005, CLIN BIOCHEM, V38, P328, DOI 10.1016/j.clinbiochem.2004.11.007; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; Van De Steene JC, 2008, J AM SOC MASS SPECTR, V19, P713, DOI [10.1016/j.jasms.2008.01.01.3, 10.1016/j.jasms.2008.01.013]; Van De Steene JC, 2006, J CHROMATOGR A, V1123, P71, DOI 10.1016/j.chroma.2006.05.013; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; Wieling J, 2002, CHROMATOGRAPHIA, V55, pS107, DOI 10.1007/BF02493365; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Zhou SL, 2000, J AM SOC MASS SPECTR, V11, P961, DOI 10.1016/S1044-0305(00)00174-4; Zhou SL, 1996, J CHROMATOGR A, V755, P189, DOI 10.1016/S0021-9673(96)00617-6	85	30	32	1	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	JUL 15	2010	878	22					1987	1996		10.1016/j.jchromb.2010.05.033			10	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	629OU	WOS:000280210300012	20542478				2020-06-30	J	Shokry, M; Manaa, EM; Shoukry, RA; Shokeir, MH; Elsedfy, GO; El-Aziz, AESA				Shokry, Mahmoud; Manaa, Essam M.; Shoukry, Randa Ali; Shokeir, Mohamed Hossam; Elsedfy, Ghada O.; El-Aziz, Abd El-Salam Abd			Effects of intrapartum epidural analgesia at high altitudes: maternal, fetal, and neonatal outcomes. A randomized controlled trial of two formulations of analgesics	ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA			English	Article						Labor; epidural analgesia; high altitudes; Doppler indices; Apgar score	MIDDLE CEREBRAL-ARTERY; LABOR ANALGESIA; LOCAL-ANESTHETICS; NULLIPAROUS WOMEN; ROPIVACAINE; BUPIVACAINE; LEVOBUPIVACAINE; METAANALYSIS; PREGNANCIES; MULTICENTER	Objectives. To investigate whether intrapartum epidural analgesics (bupivacaine or ropivacaine) have an influence (safety and efficacy) on mothers, fetuses, or newborns at high altitudes (2,200 m above the sea level). Design. Prospective randomized trial. Setting. A tertiary referral hospital in Aseer region, Saudi Arabia. Population. Eighty parturient women with normal full term pregnancy (37-40 weeks) were randomly allocated to a group receiving epidural bupivacaine 0.125% and the other receiving ropivacaine 0.2%, with fentanyl 100 mu g given to both groups. Methods. Intra-and postpartum clinical management of the pregnant women and newborns and fetal Doppler assessments were performed. Main outcome measures. Severity of pain, onset and duration of analgesia, and occurrence of motor blockade were primary outcomes. Progress of labor, need for oxytocin augmentation, mode of delivery, and neonatal condition were secondary outcomes. Results. Demographic, labor characteristics, and neonatal outcomes of the two groups were comparable. The onset of analgesia was relatively more rapid for ropivacaine group (p = 0.067). Duration of analgesia after the first bolus dose was longer and the need for supplemental epidural analgesic doses was lesser in the bupivacaine group (p = 0.041 and 0.045, respectively). In both groups, the fetal umbilical and middle cerebral artery pulsatility indices showed significant change when compared to the baseline of the same group. Conclusion. At high altitudes, no major advantage was found for epidural ropivacaine over bupivacaine in addition to fentanyl for labor analgesia and no harmful effects of the medications were found on mothers, fetuses, or newborns.	[Shokry, Mahmoud; Shoukry, Randa Ali] Assiut Univ, Dept Obstet & Gynecol, Fac Med, Assiut 71515, Egypt; [Shokry, Mahmoud; Elsedfy, Ghada O.] Saudi German Hosp, Dept Obstet & Gynecol, Aseer, Saudi Arabia; [Shokry, Mahmoud; Elsedfy, Ghada O.] Saudi German Hosp, Dept Pediat, Aseer, Saudi Arabia; [Manaa, Essam M.] Assiut Univ, Dept Anesthesia, Fac Med, Assiut 71515, Egypt; [Shoukry, Randa Ali; Shokeir, Mohamed Hossam] Ain Shams Univ, Dept Anesthesia, Fac Med, Cairo, Egypt; [Shoukry, Randa Ali; Shokeir, Mohamed Hossam] Saudi German Hosp, Dept Anesthesia, Aseer, Saudi Arabia; [Elsedfy, Ghada O.] Assiut Univ, Dept Pediat, Fac Med, Assiut 71515, Egypt; [El-Aziz, Abd El-Salam Abd] Saudi German Hosp, Dept Radiol, Aseer, Saudi Arabia	Shokry, M (reprint author), Assiut Univ, Dept Obstet & Gynecol, Fac Med, Assiut 71515, Egypt.	mshromih@yahoo.com		Shokeir, Mohamed Hossameldin/0000-0002-4282-4214; Shoukry, Randa/0000-0001-8631-7356			*AM SOC AN, 2002, ANAESTH INTENSIVE CA, V30, P633; ARIAS F, 1994, AM J OBSTET GYNECOL, V171, P1541, DOI 10.1016/0002-9378(94)90398-0; Beilin Y, 2007, ANESTH ANALG, V105, P756, DOI 10.1213/01.ane.0000278131.73472.f4; Benhamou D, 2003, ANESTHESIOLOGY, V99, P1383, DOI 10.1097/00000542-200312000-00022; Bolukbasi D, 2005, INT J OBSTET ANESTH, V14, P288, DOI 10.1016/j.ijoa.2005.04.007; Brancato RM, 2008, JOGNN-J OBST GYN NEO, V37, P4, DOI [10.1111/j.1552-6909.2007.00205.x, 10.1111/J.1552-6909.2007.00205.x]; Camorcia M, 2003, EUR J ANAESTH, V20, P636, DOI 10.1097/00003643-200308000-00008; Capogna Giorgio, 2004, Paediatr Drugs, V6, P375, DOI 10.2165/00148581-200406060-00005; Caracostea G, 2007, J MATERN-FETAL NEO M, V20, P161, DOI 10.1080/14767050601134561; Evron S, 2004, INT J OBSTET ANESTH, V13, P5, DOI 10.1016/S0959-289X(03)00092-X; Gogarten W, 2004, EUR J ANAESTH, V21, P38, DOI 10.1017/S0265021504001073; GREG CM, 2000, ANESTH ANALG, V90, P1384; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Halpern SH, 2003, ANESTH ANALG, V96, P1473, DOI 10.1213/01.ANE.0000052383.01056.8F; Hamza J, 1994, Cah Anesthesiol, V42, P265; Lee BB, 2004, ANESTH ANALG, V98, P1145, DOI 10.1213/01.ANE.0000103264.71747.0F; Lieberman E, 2005, OBSTET GYNECOL, V105, P974, DOI 10.1097/01.AOG.0000158861.43593.49; Merson N, 2001, AANA J, V69, P54; MOON RE, 2000, ANESTHESIA, P2270; O'Hana HP, 2008, J MATERN-FETAL NEO M, V21, P517, DOI 10.1080/14767050802040864; POLVI HJ, 1995, OBSTET GYNECOL, V86, P795, DOI 10.1016/0029-7844(95)00260-X; Reynolds F, 1997, INT J OBSTET ANESTH, V6, P257, DOI 10.1016/S0959-289X(97)80034-9; Reynolds F, 2002, BJOG-INT J OBSTET GY, V109, P1344, DOI 10.1016/S1470-0328(02)01961-4; Senard M, 2004, ANESTH ANALG, V98, P389, DOI 10.1213/01.ANE.0000093389.80111.02; Spinillo A, 2009, ACTA OBSTET GYN SCAN, V88, P159, DOI 10.1080/00016340802632358; Tarzamni MK, 2009, ARCH IRAN MED, V12, P29; Tchirikov M, 2009, EUR J OBSTET GYN R B, V142, P129, DOI 10.1016/j.ejogrb.2008.10.015; TRUDINGER B, 1999, MED FETUS MOTHERS, P735; Xu Heng, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P2207	29	1	5	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6349	1600-0412		ACTA OBSTET GYN SCAN	Acta Obstet. Gynecol. Scand.	JUL	2010	89	7					909	915		10.3109/00016349.2010.484042			7	Obstetrics & Gynecology	Obstetrics & Gynecology	663MO	WOS:000282892200008	20583937				2020-06-30	J	Han, SS; Lee, SC; Ro, YJ; Min, SW; Huh, J				Han, S. S.; Lee, S. C.; Ro, Y. J.; Min, S. W.; Huh, J.			Warming the epidural injectate improves first sacral segment block: a randomised double-blind study	ANAESTHESIA AND INTENSIVE CARE			English	Article						epidural anaesthesia; lignocaine; pain threshold; injectate temperature	TEMPORAL SUMMATION; EXTRADURAL ANESTHESIA; SENSORY BLOCK; TEMPERATURE; LIDOCAINE; PAIN	This study investigated the effect of local anaesthetic temperature on block of the first sacral segment. Twenty-four patients undergoing lumbar epidural anaesthesia at L2-3 or L3-4 were randomly divided in double-blind fashion into two groups to receive 22 ml of lignocaine 2% with adrenaline 1:200,000, sodium bicarbonate and fentanyl, at either 21 degrees C (cold group) or 37 degrees C (warm group). The sensory block was assessed by loss of sensation to pinprick and the pain threshold after repeated electrical stimulation at L2, S1 and S3 dermatomes. Motor block was evaluated using the modified Bromage scale. Patient characteristics were comparable between the groups. Onset of block at the first sacral segment (S1) was faster in the warm group than in the cold (10 vs 17.5 minutes, P < 0.001). The pain threshold at Si was significantly higher in the warm group. We concluded that epidural lignocaine 2% with adrenaline 1:200,000, sodium bicarbonate and fentanyl injected at 37 degrees C hastens Si block within 10 minutes of administration.	[Han, S. S.; Lee, S. C.; Ro, Y. J.; Min, S. W.; Huh, J.] Seoul Natl Univ, Dept Anesthesiol & Pain Med, Boramae Metropolitan Hosp, Seoul 156707, South Korea; [Han, S. S.; Lee, S. C.] Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul Natl Univ Hosp, Seoul 156707, South Korea; [Ro, Y. J.] Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, Ulsan, South Korea	Huh, J (reprint author), Seoul Natl Univ, Dept Anesthesiol & Pain Med, Boramae Metropolitan Hosp, 425 Shindaebang Dong, Seoul 156707, South Korea.	amandla@snu.ac.kr	Lee, Sang Chul/E-4151-2012; Min, Seong Won/J-5470-2012; Huh, Jin/J-5718-2012				Arakawa M, 2003, REGION ANESTH PAIN M, V28, P208, DOI 10.1053/rapm.2003.50053; Arakawa M, 2003, BRIT J ANAESTH, V90, P173, DOI 10.1093/bja/aeg045; ARENDTNIELSEN L, 1994, EUR J APPL PHYSIOL O, V68, P266, DOI 10.1007/BF00376776; CLARK V, 1994, BRIT J ANAESTH, V72, P221, DOI 10.1093/bja/72.2.221; CURATOLO M, 1995, BRIT J ANAESTH, V75, P634, DOI 10.1093/bja/75.5.634; Curatolo M, 1998, ANESTH ANALG, V86, P341, DOI 10.1097/00000539-199802000-00024; Curatolo M, 1997, ANESTHESIOLOGY, V87, P785, DOI 10.1097/00000542-199710000-00011; DYHRE H, 1994, ACTA ANAESTH SCAND, V38, P594, DOI 10.1111/j.1399-6576.1994.tb03958.x; Eichenberger U, 2003, BRIT J ANAESTH, V90, P467, DOI 10.1093/bja/aeg100; GALINDO A, 1975, BRIT J ANAESTH, V47, P41, DOI 10.1093/bja/47.1.41; GOSTELI P, 1995, ANESTH ANALG, V81, P104, DOI 10.1097/00000539-199507000-00021; SANCHEZ V, 1987, ANESTH ANALG, V66, P159	12	1	1	0	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	JUL	2010	38	4					690	694		10.1177/0310057X1003800412			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	663DU	WOS:000282864000013	20715733	Bronze			2020-06-30	J	Dong, YX; Meng, LX; Wang, Y; Zhang, JJ; Zhao, GY; Ma, CH				Dong, Y. X.; Meng, L. X.; Wang, Y.; Zhang, J. J.; Zhao, G. Y.; Ma, C. H.			The effect of remifentanil on the incidence of agitation on emergence from sevoflurane anaesthesia in children undergoing adenotonsillectomy	ANAESTHESIA AND INTENSIVE CARE			English	Article						emergence agitation; remifentanil; sevoflurane; paediatric anaesthesia	PEDIATRIC ANESTHESIA; DELIRIUM SCALE; HALOTHANE; SURGERY; ISOFLURANE; RECOVERY; PROPOFOL	The aim of the present study was to assess the effect of remifentanil on the incidence of emergence agitation in preschool-aged children undergoing adenotonsillectomy with sevoflurane anaesthesia. Sixty children, aged three to seven years, American Society of Anesthesiologists physical status I or II, were randomised into either group S (sevoflurane alone, n=30) or group R (sevoflurane plus remifentanil, n=30). Anaesthesia was induced with an intravenous bolus injection of fentanyl 3 mu g/kg and propofol 2.5 mg/kg. Endotracheal intubation was facilitated by vecuronium 0.1 mg/kg. All patients were ventilated with 50% nitrous oxide and 1.5 to 2.5% sevoflurane in oxygen. End-tidal CO(2) was maintained at 35 +/- 4 mmHg. Group S received no other medication while group R received remifentanil 1 mu g/kg/minute intraoperatively. Mean blood pressure, heart rate, pulse oximetry, eye-opening time and extubation time were recorded in the operating room. In recovery, emergence agitation was assessed using the Pediatric Anesthesia Emergence Delirium scale with a score >= 10 taken as indicating agitation. Emergence agitation occurred in 20 of the 30 patients in group S and seven of the 30 patients in group R (P < 0.01). In preschool-aged children undergoing adenotonsillectomy with sevoflurane general anaesthesia, after propofol and fentanyl induction, intraoperative remifentanil decreased the incidence of emergence agitation.	[Dong, Y. X.; Meng, L. X.; Wang, Y.; Zhang, J. J.; Zhao, G. Y.; Ma, C. H.] China Med Univ, Dept Anesthesia, Shengjing Hosp, Shenyang 110004, Liaoning Prov, Peoples R China	Meng, LX (reprint author), China Med Univ, Dept Anesthesia, Shengjing Hosp, Shenyang 110004, Liaoning Prov, Peoples R China.			Dong, Yunxia/0000-0003-2278-4785			Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Bakhamees HS, 2009, SAUDI MED J, V30, P500; Beskow A, 1999, ACTA ANAESTH SCAND, V43, P536, DOI 10.1034/j.1399-6576.1999.430508.x; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; Bortone L, 2006, PEDIATR ANESTH, V16, P1138, DOI 10.1111/j.1460-9592.2006.01954.x; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; da Silva LM, 2008, J PEDIAT-BRAZIL, V84, P107, DOI [10.2223/JPED.1763, 10.1590/S0021-75572008000200004]; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; Meyer RR, 2007, PEDIATR ANESTH, V17, P56, DOI 10.1111/j.1460-9592.2006.01998.x; Nakayama S, 2007, J ANESTH, V21, P19, DOI 10.1007/s00540-006-0466-x; NORIFUMI K, 2008, ANESTHESIOLOGY, V109, P225; SARNER JB, 1995, ANESTHESIOLOGY, V82, P38, DOI 10.1097/00000542-199501000-00006; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Walker SM, 1997, ANAESTH INTENS CARE, V25, P643, DOI 10.1177/0310057X9702500609; Wells LT, 1999, ANESTH ANALG, V88, P1308, DOI 10.1097/00000539-199906000-00020	17	24	28	0	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUL	2010	38	4					718	722		10.1177/0310057X1003800416			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	663DU	WOS:000282864000017	20715737	Bronze			2020-06-30	J	Sindjelic, RP; Vlajkovic, GP; Davidovic, LB; Markovic, DZ; Markovic, MD				Sindjelic, Radomir P.; Vlajkovic, Gordana P.; Davidovic, Lazar B.; Markovic, Dejan Z.; Markovic, Miroslav D.			The Addition of Fentanyl to Local Anesthetics Affects the Quality and Duration of Cervical Plexus Block: A Randomized, Controlled Trial	ANESTHESIA AND ANALGESIA			English	Article							CAROTID-ENDARTERECTOMY; NERVE BLOCK; ANALGESIA; ROPIVACAINE; SUFENTANIL; PROLONGS	BACKGROUND: Cervical plexus block is frequently associated with unsatisfactory sensory blockade. In this randomized, double-blind, placebo-controlled trial, we examined whether the addition of fentanyl to local anesthetics improves the quality of cervical plexus block in patients undergoing carotid endarterectomy (CEA). METHODS: Seventy-seven consecutive adult patients scheduled for elective CEA were randomized to receive either fentanyl 1 mL (50 mu g) or saline placebo 1 mL in a mixture of 10 mL bupivacaine 0.5% and 4 mL lidocaine 2% for deep cervical plexus block. Superficial cervical plexus block was performed using a mixture of 10 mL bupivacaine 0.5% and 5 mL lidocaine 2%. Pain was assessed using the verbal rating scale (0-10; 0 = no pain, 10 = worst pain imaginable), and propofol in 20-mg IV bolus doses was given to patients reporting verbal rating scale >3 during the procedure. Rescue medication consumption during surgery and analgesia requirements over the next 24 hours, as well as onset of sensory blockade, were recorded. A P value <0.05 was regarded as statistically significant. RESULTS: Fewer patients in the fentanyl group (4 of 38, 10.5%) required propofol compared with the placebo group (26 of 39, 66.7%; P < 0.001). In comparison with the placebo group, the fentanyl group consumed less propofol (median 0 [0-60] vs 60 [0-160] mg, respectively; P < 0.001), required postoperative analgesia less frequently (22 of 38 patients, 57.9% vs 35 of 39 patients, 89.7%, respectively; P = 0.002), and requested the first analgesic after surgery later (median 5.8 [1.9-15.6] vs 3.1 [1.0-11.7] hours, respectively; P < 0.001), whereas the onset time of sensory blockade was similar in both groups (median 12 [9-18] vs 15 [9-18) minutes, respectively; P = 0.18). CONCLUSIONS: The addition of fentanyl to local anesthetics improved the quality and prolonged the duration of cervical plexus block in patients undergoing CEA. (Anesth Analg 2010;111:234-7)	[Vlajkovic, Gordana P.] Univ Belgrade, Sch Med, Clin Ctr Serbia, Inst Anesthesia & Resuscitat,Inst Cardiovasc Dis, Belgrade 11000, Serbia; [Davidovic, Lazar B.; Markovic, Miroslav D.] Univ Belgrade, Sch Med, Clin Ctr Serbia, Inst Cardiovasc Dis, Belgrade 11000, Serbia	Vlajkovic, GP (reprint author), Univ Belgrade, Sch Med, Clin Ctr Serbia, Inst Anesthesia & Resuscitat,Inst Cardiovasc Dis, Dr Koste Todorovica 8, Belgrade 11000, Serbia.	gvlajkov@eunet.rs					Bouaziz H, 2000, ANESTH ANALG, V90, P383, DOI 10.1097/00000539-200002000-00027; Burlacu CL, 2006, ANAESTHESIA, V61, P932, DOI 10.1111/j.1365-2044.2006.04793.x; Fanelli G, 2001, ACTA ANAESTH SCAND, V45, P590, DOI 10.1034/j.1399-6576.2001.045005590.x; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; Gormley WP, 1996, BRIT J ANAESTH, V76, P802; Karakaya D, 2001, REGION ANESTH PAIN M, V26, P434, DOI 10.1053/rapm.2001.24675; Krenn H, 2002, BRIT J ANAESTH, V89, P637, DOI 10.1093/bja/aef233; MAYS KS, 1987, ANESTH ANALG, V66, P417, DOI 10.1213/00000539-198705000-00008; Merle JC, 1999, ANESTH ANALG, V89, P1366, DOI 10.1097/00000539-199912000-00006; Murphy DB, 2000, ANESTH ANALG, V90, P1122, DOI 10.1097/00000539-200005000-00023; Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028; Pandit JJ, 2007, BRIT J ANAESTH, V99, P159, DOI 10.1093/bja/aem160; Pandit JJ, 2000, ANESTH ANALG, V91, P781, DOI 10.1097/00000539-200010000-00004; POWER I, 1991, REGION ANESTH, V16, P204; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Muniz MT, 2008, ANESTH ANALG, V107, P2085, DOI 10.1213/ane.0b013e318186641d; Umbrain VJ, 2004, REGION ANESTH PAIN M, V29, P312, DOI 10.1016/j.rapm.2004.04.007	18	22	22	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2010	111	1					234	237		10.1213/ANE.0b013e3181e1e9ab			4	Anesthesiology	Anesthesiology	617LF	WOS:000279281500041	20519423				2020-06-30	J	Souvatzis, X; Katonis, PG; Licoudis, SA; Marouli, DG; Askitopoulou, H				Souvatzis, Xenia; Katonis, Pavlos G.; Licoudis, Savas A.; Marouli, Diamantina G.; Askitopoulou, Helen			Subarachnoid Anesthesia for Kyphoplasty: Is Anesthesia Adequate?	ANESTHESIA AND ANALGESIA			English	Article							VERTEBRAL COMPRESSION FRACTURES; SPINAL-ANESTHESIA; PERCUTANEOUS VERTEBROPLASTY; BALLOON KYPHOPLASTY; BUPIVACAINE	We performed a prospective pilot study of subarachnoid anesthesia for kyphoplasty in 11 nonrandomized patients. Subarachnoid anesthesia was administered at the level of the best palpable intervertebral space below L3. Patients received intrathecally either hyperbaric or plain bupivacaine with or without fentanyl. Five patients experienced pain during the surgical procedure and received supplemental IV analgesia. One patient felt pain from the pressure on the ribs while in the prone position. The remaining patients were comfortable. In no patient was respiratory compromise or deep sedation observed. We conclude that subarachnoid anesthesia may be an adequate technique for kyphoplasty. (Anesth Analg 2010;111:238-40)	[Souvatzis, Xenia; Marouli, Diamantina G.; Askitopoulou, Helen] Univ Hosp Heraklion, Dept Anesthesiol, GR-71110 Iraklion, Greece; [Katonis, Pavlos G.; Licoudis, Savas A.] Univ Hosp Heraklion, Dept Orthopaed Surg & Traumatol, GR-71110 Iraklion, Greece; [Askitopoulou, Helen] Univ Crete, Fac Med, Sch Med, Dept Anesthesiol, Iraklion, Crete, Greece	Souvatzis, X (reprint author), Univ Hosp Heraklion, Dept Anesthesiol, POB 1352, GR-71110 Iraklion, Greece.	x.souvatzis@gmx.de					Burton A, 2005, NEUROSURG FOCUS, V18, pe1, DOI DOI 10.3171/FOC.2005.18.3.2; Gaitanis IN, 2005, EUR SPINE J, V14, P250, DOI 10.1007/s00586-004-0767-4; Garfin SR, 2001, SPINE, V26, P1511, DOI 10.1097/00007632-200107150-00002; Gouveia MA, 2006, ACTA ANAESTH SCAND, V50, P260, DOI 10.1111/j.1399-6576.2005.00895.x; Groen RJM, 2004, SPINE, V29, P1465, DOI 10.1097/01.BRS.0000128758.64381.75; Hadjipavlou AG, 2005, J BONE JOINT SURG BR, V87B, P1595, DOI 10.1302/0301-620X.87B12.16074; Hannallah M, 2008, ANESTH ANALG, V106, P1329, DOI 10.1213/ane.0b013e318167b2f5; Higuchi Katsura, 2002, Folia Morphol (Warsz), V61, P71; Hulme PA, 2006, SPINE, V31, P1983, DOI 10.1097/01.brs.0000229254.89952.6b; Jellish W Scott, 2003, Best Pract Res Clin Anaesthesiol, V17, P323, DOI 10.1016/S1521-6896(02)00115-5; Lieberman IH, 2001, SPINE, V26, P1631, DOI 10.1097/00007632-200107150-00026; Lovstad RZ, 2000, ACTA ANAESTH SCAND, V44, P48, DOI 10.1034/j.1399-6576.2000.440109.x; Luginbuhl M, 2008, CURR OPIN ANESTHESIO, V21, P504, DOI 10.1097/ACO.0b013e328303be62; Ohtori S, 2007, SPINE, V32, P1498, DOI 10.1097/BRS.0b013e318067dbf8; POVEY HMR, 1989, ACTA ANAESTH SCAND, V33, P295, DOI 10.1111/j.1399-6576.1989.tb02911.x; Reynolds F, 2000, ANAESTHESIA, V55, P1045, DOI 10.1046/j.1365-2044.2000.01830.x; Robinson Y, 2008, PATIENT SAF SURG, V2, P1, DOI 10.1186/1754-9493-2-2; Schofer MD, 2008, ORTHOPADE, V37, P462, DOI 10.1007/s00132-008-1220-x; TETZLAFF JE, 1995, REGION ANESTH, V20, P533	19	4	4	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2010	111	1					238	240		10.1213/ANE.0b013e3181e0574c			3	Anesthesiology	Anesthesiology	617LF	WOS:000279281500042	20457767				2020-06-30	J	Erb, TO; von Ungern-Sternberg, BS; Keller, K; Rosner, GL; Craig, D; Frei, FJ				Erb, Thomas O.; von Ungern-Sternberg, Britta S.; Keller, Kathrin; Rosner, Gary L.; Craig, Damian; Frei, Franz J.			Fentanyl Does Not Reduce the Incidence of Laryngospasm in Children Anesthetized with Sevoflurane	ANESTHESIOLOGY			English	Article							ANESTHESIA; REFLEXES; COUGH; ENFLURANE; PROPOFOL	Background: The modifying effects of fentanyl on protective airway reflexes have not been characterized in children. The aim of this study was to assess the impact of increasing doses of fentanyl on laryngeal reflex responses in children anesthetized with sevoflurane. The authors hypothesized that the incidence of laryngospasm evoked by laryngeal stimulation is reduced with increasing doses of fentanyl. Methods: Sixty-three children, aged 2-6 yr, scheduled for elective surgery, were anesthetized with sevoflurane (1 minimum alveolar concentration). By using an established technique, laryngeal and respiratory responses were elicited by spraying distilled water on the laryngeal mucosa: (1) before the administration of fentanyl, (2) after the administration of 1.5 mu g/kg fentanyl, and (3) after the administration of a second dose of 1.5 mu g/kg fentanyl. In 10 children, serving as a time control, three successive laryngeal stimulations were performed without the administration of fentanyl. The responses were assessed by a blinded reviewer. Results: The study was completed in 60 patients. The incidence of laryngospasm was not reduced when up to two successive doses of 1.5 mu g/kg fentanyl were administered. The incidence of laryngospasm lasting for more than 10 s was 26% before receiving fentanyl, 31% after recieving 1.5 mu g/kg fentanyl, and 18% after receiving a second dose of 1.5 mu g/kg fentanyl (P = 0.36 and 0.78, respectively). This response was similar to that observed in the time control group (P = 0.21). Conclusion: Two successive doses of 1.5 mu g/kg fentanyl did not effectively prevent laryngospasm in children, aged 2-6 yr, anesthetized with sevoflurane.	[Erb, Thomas O.; von Ungern-Sternberg, Britta S.; Keller, Kathrin; Rosner, Gary L.; Craig, Damian; Frei, Franz J.] Univ Childrens Hosp, Dept Anesthesia, CH-4058 Basel, Switzerland	Erb, TO (reprint author), Univ Childrens Hosp, Dept Anesthesia, 8 Roemergasse, CH-4058 Basel, Switzerland.	thomas.erb@ukbb.ch	von Ungern-Sternberg, Britta/S-5532-2019	von Ungern-Sternberg, Britta/0000-0002-8043-8541	Swiss National Science Foundation (SNSF), Bern, SwitzerlandSwiss National Science Foundation (SNSF) [3200BO-109322]; Department of Anesthesia, University Hospital Basel, Basel, Switzerland	Received from the Department of Anesthesia, University Children's Hospital, Basel, Switzerland. Submitted for publication February 20, 2009. Accepted for publication February 16, 2010. Supported by the Swiss National Science Foundation (SNSF 3200BO-109322), Bern, Switzerland, and the Department of Anesthesia, University Hospital Basel, Basel, Switzerland. Presented in part at the American Society of Anesthesiologists Annual Meeting, San Francisco, California, October 14, 2007.	Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Bhananker SM, 2007, ANESTH ANALG, V105, P344, DOI 10.1213/01.ane.0000268712.00756.dd; Bolser DC, 2002, PULM PHARMACOL THER, V15, P221, DOI 10.1006/pupt.2002.0361; Bolser DC, 2006, RESP PHYSIOL NEUROBI, V152, P349, DOI 10.1016/j.resp.2006.01.015; Bolser DC, 2006, RESP PHYSIOL NEUROBI, V152, P255, DOI 10.1016/j.resp.2006.01.008; Davidian M, 1995, NONLINEAR MODELS REP, P97; DOI M, 1993, CAN J ANAESTH, V40, P122, DOI 10.1007/BF03011308; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; FINK BR, 1956, ANESTHESIOLOGY, V17, P569, DOI 10.1097/00000542-195607000-00007; Ishikawa T, 2005, ANESTH ANALG, V101, P1615, DOI 10.1213/01.ANE.0000784134.80849.17; Kohno Tatsuro, 2008, Masui, V57, P1213; MORRAY JP, 1993, ANESTHESIOLOGY, V78, P461, DOI 10.1097/00000542-199303000-00009; NISHINO T, 1981, ANESTHESIOLOGY, V55, P286, DOI 10.1097/00000542-198109000-00018; NISHINO T, 1989, J APPL PHYSIOL, V66, P2642; Oberer C, 2005, ANESTHESIOLOGY, V103, P1142, DOI 10.1097/00000542-200512010-00007; Olofsen E, 2002, ANESTHESIOLOGY, V96, P555, DOI 10.1097/00000542-200203000-00009; OLSSON GL, 1984, ACTA ANAESTH SCAND, V28, P567, DOI 10.1111/j.1399-6576.1984.tb02121.x; ROSEN CL, 1992, AM REV RESPIR DIS, V146, P1231, DOI 10.1164/ajrccm/146.5_Pt_1.1231; ROY WL, 1988, CAN J ANAESTH, V35, P93, DOI 10.1007/BF03010554; Shannon R, 1996, PULM PHARMACOL THER, V9, P343, DOI 10.1006/pulp.1996.0045; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; Tanaka A, 2005, ANESTHESIOLOGY, V102, P20, DOI 10.1097/00000542-200501000-00007; Turnbull D, 2008, ANAESTHESIA, V63, P458, DOI 10.1111/j.1365-2044.2007.05399.x; Warner DO, 1998, ANESTHESIOLOGY, V88, P1433, DOI 10.1097/00000542-199806000-00003; WHEELER M, 2001, PRACTICE ANESTHESIA, P79	25	11	11	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	2010	113	1					41	47		10.1097/ALN.0b013e3181dcd875			7	Anesthesiology	Anesthesiology	616XM	WOS:000279244800008	20508496	Bronze			2020-06-30	J	Lu, CA; Jia, JY; Gui, YZ; Liu, GY; Shi, XJ; Li, SJ; Yu, C				Lu, Chuan; Jia, Jing-ying; Gui, Yu-zhou; Liu, Gang-yi; Shi, Xiao-jin; Li, Shui-jun; Yu, Chen			Development of a liquid chromatography-isotope dilution mass spectrometry method for quantification of fentanyl in human plasma	BIOMEDICAL CHROMATOGRAPHY			English	Article						fentanyl; LC-ID/MS; bioequivalence; human plasma	SOLID-PHASE EXTRACTION; ASSAY; PHARMACOKINETICS; NORFENTANYL; ALFENTANIL; MIDAZOLAM; SAMPLES; WATER	Fentanyl is a potent analgesic drug in relieving chronic pain in patients. In this report, we present a simple, reliable and sensitive LC-ID/MS method for the quantification of fentanyl in human plasma. LC-ID/MS analysis was carried out on a triple quadrupole mass spectrometer operated in positive electrospray ionization multiple-reaction-monitoring using the transitions m/z 337.6 -> 4 187.9 for fentanyl and m/z 342.6 -> 187.9 for the internal standard (D5-fentany1). The calibration curve covered the range 0.02-10 ng/mL. The intra- and inter-batch precision were less than 6.739 and 3.126% for fentanyl and IS, with accuracy from 94.16 to 102.0%. The lower limit of quantification was identifiable and reproducible at 0.02 ng/mL. The validated method offered increased sensitivity and wide linear concentration range. This method was successfully adopted for the evaluation of bioequivalence of two fentanyl transdermal preparations after single dose administration to 20 Chinese pain-patients. Copyright (C) 2009 John Wiley & Sons, Ltd.	[Lu, Chuan; Jia, Jing-ying; Gui, Yu-zhou; Liu, Gang-yi; Li, Shui-jun; Yu, Chen] Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai 200031, Peoples R China; [Shi, Xiao-jin] Shanghai Huashan Hosp, Shanghai 200040, Peoples R China	Yu, C (reprint author), Shanghai Xuhui Cent Hosp, Cent Lab, 966 Huaihai Middle Rd, Shanghai 200031, Peoples R China.	chen-yu@online.sh.cn		Jia, Jingying/0000-0002-2492-3219			Boleda MR, 2007, J CHROMATOGR A, V1175, P38, DOI 10.1016/j.chroma.2007.10.029; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Ebrahimzadeh H, 2008, ANAL CHIM ACTA, V626, P193, DOI 10.1016/j.aca.2008.07.047; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Lambropoulos J, 2000, J PHARMACEUT BIOMED, V23, P421, DOI 10.1016/S0731-7085(00)00312-5; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Nitsun M, 2006, CLIN PHARMACOL THER, V79, P549, DOI 10.1016/j.clpt.2006.02.010; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255	11	2	3	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-3879	1099-0801		BIOMED CHROMATOGR	Biomed. Chromatogr.	JUL	2010	24	7					711	716		10.1002/bmc.1351			6	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	618PK	WOS:000279367900005	19882744				2020-06-30	J	Veldhorst-Janssen, NML; Fiddelers, AAA; van der Kuy, PHM; Kessels, AGH; Theunissen, HMS; van der Hulst, RRWJ; Neef, C; Marcus, MAE				Veldhorst-Janssen, Nicole M. L.; Fiddelers, Audrey A. A.; van der Kuy, Paul-Hugo M.; Kessels, Alfons G. H.; Theunissen, H. Maurice S.; van der Hulst, Rene R. W. J.; Neef, Cees; Marcus, Marco A. E.			Pharmacokinetics, Analgesic Effect, and Tolerability of a Single Preprocedural Dose of Intranasal Fentanyl in Patients Undergoing Drain Removal After Breast Reduction or Augmentation Surgery: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study	CLINICAL THERAPEUTICS			English	Article						intranasal; fentanyl; postoperative pain; opioids	POSTOPERATIVE PAIN; MANAGEMENT; OPIOIDS; ADULTS	Background: Although acetaminophen is used to reduce pain after breast reduction or augmentation surgery, pain during the removal of the surgical drains is typically not specifically treated. Intranasally administered fentanyl may be suitable for pain control during removal of drains. The reported therapeutic window of fentanyl is between 0.2 and 1.2 ng/mL. Objective: The aim of this study was to evaluate the analgesic effect, tolerability, and pharmacokinetics of a single preprocedural dose of intranasal fentanyl administered before removal of surgical drains in patients who had undergone breast reduction or augmentation surgery. Methods: This was a randomized, double-blind, prospective study in healthy women (American Society of Anesthesiologists physical status I or II) between the ages of 18 and 65 years who were scheduled to undergo removal of surgical drains 1 to 4 days after breast reduction or augmentation surgery. A single dose of fentanyl nasal spray 0.05 mg/0.1 mL or placebo (preserved normal saline) 0.1 mL was administered 10 minutes before removal of drains. Because drain removal is generally carried out without specific analgesia, no rescue medication was provided. Pain intensity was measured on a visual analog scale (VAS) from 0 = no pain at all to 100 = worst pain possible. Pain intensity was evaluated immediately before administration of study medication (t = 0), at the time of drain removal (t = 10), and at 15, 20, 25, 40, and 70 minutes after administration of study medication. Safety measures included oxygen saturation, respiratory rate, heart rate, and blood pressure. Local and systemic adverse events were elicited by direct questioning throughout the study. Blood samples for pharmacokinetic analysis were collected at baseline and at 5, 10, 15, 30, 60, and 120 minutes after administration of study medication. The population pharmacokinetic parameters of fentanyl were calculated according to a 1-compartment open model with an iterative 2-stage Bayesian fitting procedure. Results: Thirty-six women were randomized to treatment, and 33 completed the study. Their mean (SD) age was 39.2 (13.0) years, and their mean weight was 68.9 (10.7) kg. Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS). Analysis of a random-effects model with mean VAS scores as a function of time as the dependent variable indicated a significant difference in mean VAS scores between the fentanyl and placebo groups (P = 0.006). The overall incidence of adverse events was 39.4% (13/33). Among the 17 patients in the fentanyl group, 8 reported >= 1 adverse event; among the 16 patients in the placebo group, 9 reported >= 1 adverse event. A mean estimated C(max) of 0.184 (0.069) ng/mL was reached at 13.76 (3.56) minutes after administration of intranasal fentanyl. The mean measured C(max) was 0.22 (0.088) ng/mL. Conclusions: In these women who had undergone breast reduction or augmentation surgery, a single preprocedural dose of intranasal fentanyl was significantly more effective than placebo in reducing pain intensity over the hour after removal of surgical drains. However, there was no significant difference in pain intensity between fentanyl at the time of drain removal and placebo. Intranasal fentanyl was generally well tolerated. At the dose used (0.05 mg), plasma fentanyl concentrations were below the reported therapeutic window. (Clin Then 2010;32:1427-1436) (C) 2010 Excerpta Medica Inc.	[Veldhorst-Janssen, Nicole M. L.; Neef, Cees] Maastricht Univ, Med Ctr, Dept Clin Pharmacol & Toxicol, NL-6202 AZ Maastricht, Netherlands; [Fiddelers, Audrey A. A.; Theunissen, H. Maurice S.; Marcus, Marco A. E.] Maastricht Univ, Med Ctr, Dept Anaesthesiol, NL-6202 AZ Maastricht, Netherlands; [van der Kuy, Paul-Hugo M.] Orbis Med Ctr, Dept Clin Pharmacol & Clin Toxicol, Sittard, Netherlands; [Kessels, Alfons G. H.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, NL-6202 AZ Maastricht, Netherlands; [van der Hulst, Rene R. W. J.] Maastricht Univ, Med Ctr, Dept Plast Surg, NL-6202 AZ Maastricht, Netherlands	Veldhorst-Janssen, NML (reprint author), Maastricht Univ, Med Ctr, Dept Clin Pharmacol & Toxicol, POB 5800, NL-6202 AZ Maastricht, Netherlands.	n.veldhorst@mumc.nl	Neef, Cees/G-3671-2010				Barnard James, 2004, Interact Cardiovasc Thorac Surg, V3, P229, DOI 10.1016/j.icvts.2003.11.004; Bonate PL, 2001, CLIN PHARMACOKINET, V40, P15, DOI 10.2165/00003088-200140010-00002; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Field A, 2009, DISCOVERING STAT USI; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Friesner SA, 2006, HEART LUNG, V35, P269, DOI 10.1016/j.hrtlng.2005.10.005; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hummel P, 2006, SEMIN FETAL NEONAT M, V11, P237, DOI 10.1016/j.siny.2006.02.004; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jelliffe RW, 1998, CLIN PHARMACOKINET, V34, P57, DOI 10.2165/00003088-199834010-00003; JELLIFFE RW, 1993, THER DRUG MONIT, V15, P380, DOI 10.1097/00007691-199310000-00005; Krueger Charlene, 2004, Biol Res Nurs, V6, P151, DOI 10.1177/1099800404267682; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; MANTHA S, 1993, ANESTH ANALG, V77, P1041; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PROOST JH, 1992, COMPUT BIOL MED, V22, P155, DOI 10.1016/0010-4825(92)90011-B; SCHOUTEN HJ, 1999, KLINISCHE STAT PRAKT; Sommer M, 2009, ARCH OTOLARYNGOL, V135, P124, DOI 10.1001/archoto.2009.3; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; Tveita T, 2008, ACTA ANAESTH SCAND, V52, P920, DOI 10.1111/j.1399-6576.2008.01608.x; Veldhorst-Janssen NML, 2009, CLIN THER, V31, P2954, DOI 10.1016/j.clinthera.2009.12.015	23	14	16	0	4	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918			CLIN THER	Clin. Ther.	JUL	2010	32	7					1427	1436		10.1016/j.clinthera.2010.07.001			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	637PF	WOS:000280829800018	20678689				2020-06-30	J	Lossignol, DA; Dumitrescu, C				Lossignol, Dominique A.; Dumitrescu, Cristina			Breakthrough pain: progress in management	CURRENT OPINION IN ONCOLOGY			English	Review						breakthrough pain; cancer; fentanyl	TRANSMUCOSAL FENTANYL CITRATE; CANCER PAIN; OPEN-LABEL; TRIAL; OTFC	Purpose of review To present recent developments in the treatment of breakthrough pain (BTP) in cancer, we reviewed the literature with a special focus on last publications using Medline. Recent findings BTP is distinguished from other pain syndromes because of its unique physiopathology, clinical and socio-economic importance and treatment considerations. Despite medical awareness, BTP remains underdiagnosed and therefore undertreated. Clinical information is essentially based on case series and expert opinion. Fentanyl, oral or nasal, remains the molecule of choice to treat BTP, but very important development is ongoing to improve tolerance, efficacy and pharmacokinetics. Summary Data from epidemiological and clinical studies show that breakthrough pain remains a challenge especially among cancer patients. An accurate diagnosis followed by a specific treatment is the key for an effective pain relief.	[Lossignol, Dominique A.] Inst Jules Bordet, Pain Clin, B-1000 Brussels, Belgium; [Dumitrescu, Cristina] Inst Jules Bordet, Oncol Clin, B-1000 Brussels, Belgium	Lossignol, DA (reprint author), Inst Jules Bordet, Pain Clin, B-1000 Brussels, Belgium.	dominique.lossignol@bordet.be			Institut Jules Bordet	The authors would like to thank their colleagues at the Institut Jules Bordet, doctors and nurses for their support. There is no conflict of interest.	BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2689; *EUR MED AG, 2009, ASS REP INST; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; RAUCK R, 2009, ANN ONCOL; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Tateishi T, 1996, ANESTH ANALG, V82, P167; WEINSTEIN SM, 2009, CANCER, V15, P3372	19	10	11	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-8746	1531-703X		CURR OPIN ONCOL	Curr. Opin. Oncol.	JUL	2010	22	4					302	306		10.1097/CCO.0b013e32833a873a			5	Oncology	Oncology	615QL	WOS:000279150200002	20489619				2020-06-30	J	Dere, K; Sucullu, I; Budak, ET; Yeyen, S; Filiz, AI; Ozkan, S; Dagli, G				Dere, Kamer; Sucullu, Ilker; Budak, Ersel Tan; Yeyen, Suleyman; Filiz, Ali Ilker; Ozkan, Sezai; Dagli, Guner			A comparison of dexmedetomidine versus midazolam for sedation, pain and hemodynamic control, during colonoscopy under conscious sedation	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						colonoscopy; dexmedetomidine; hemodynamics; midazolam; sedation	COMBINATION; ENDOSCOPY; RECOVERY; AGONISTS	Objective The intent of our study was to compare the effects of dexmedetomidine versus midazolam on perioperative hemodynamics, sedation, pain, satisfaction and recovery scores during colonoscopy. Material and methods A total of 60 ASA I-II patients, between 20 and 80 years of age were included in the study. Patients were randomly assigned to two groups. Midazolam 0.05 mg kg(-1) and fentanyl citrate 1 mu g kg(-1) were administered intravenously to cases in Group I (n=30). An initial loading dose of 1 mu g kg(-1) dexmedetomidine was administered intravenously in 10 min to cases in Group II (n=30) before the procedure and as a continuous infusion dose of 0.5 mu g kg(-1) h(-1) just before the procedure started. Also 1 mu g kg(-1) fentanyl citrate was administered intravenously immediately before the procedure. Peripheral oxygen saturation (Spo(2)), mean arterial pressure (MAP), heart rate (HR), Ramsay Sedation Scale (RSS), Numeric Rating Scale (NRS) scores and colonoscopist satisfaction scores of the cases were recorded. Results Although statistically significant values were not detected between the two groups with regard to mean arterial pressure, in Group I heart rates were higher and Spo(2) scores were lower in a statistically significant manner. When the groups were compared with regard to RSS, the RSS scores of Group I at the 10th and 15th minutes were significantly lower than Group II. There was no statistically significant difference between the two groups when compared with regard to NRS scores. Satisfaction scores were significantly lower in Group II. Conclusion Dexmedetomidine provides more efficient hemodynamic stability, higher Ramsay sedation scale scores, higher satisfaction scores and lower NRS scores in colonoscopies. According to our results we believe that dexmedetomidine can be used safely as a sedoanalgesic agent in colonoscopies. Eur J Anaesthesiol 2010;27:648-652	[Dere, Kamer] GATA Haydarpasa Training Hosp, Dept Anesthesiol, Div Algol, Istanbul, Turkey; [Sucullu, Ilker; Filiz, Ali Ilker] GATA Haydarpasa Training Hosp, Dept Gen Surg, Istanbul, Turkey	Budak, ET (reprint author), Gumussuyu Mil Hosp, Dept Anesthesiol, Istanbul, Turkey.	erselta@yahoo.com					AANTAA R, 1993, ACTA ANAESTH SCAND, V37, P1; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Demiraran Y, 2007, CAN J GASTROENTEROL, V21, P25, DOI 10.1155/2007/350279; Gan TJ, 2006, CLIN PHARMACOKINET, V45, P855, DOI 10.2165/00003088-200645090-00001; Gould D, 2001, J CLIN NURS, V10, P697, DOI 10.1046/j.1365-2702.2001.00525.x; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Ozel AM, 2008, TURK J GASTROENTEROL, V19, P8; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Robin Christian, 2002, Anesth Prog, V49, P128; Seybold JL, 2007, PEDIATR ANESTH, V17, P1212, DOI 10.1111/j.1460-9592.2007.02346.x; Taittonen MT, 1997, BRIT J ANAESTH, V78, P400; Uzumcugil F, 2008, EUR J ANAESTH, V25, P675, DOI 10.1017/S0265021508004213; Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x; Wijeysundera DN, 2003, AM J MED, V114, P742, DOI 10.1016/S0002-9343(03)00165-7; Wong RCK, 2001, GASTROINTEST ENDOSC, V54, P122, DOI 10.1067/mge.2001.116115; Zeyneloglu P, 2008, EUR J ANAESTH, V25, P961, DOI 10.1017/S0265021508004699	19	50	67	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	JUL	2010	27	7					648	652		10.1097/EJA.0b013e3283347bfe			5	Anesthesiology	Anesthesiology	607WH	WOS:000278537500013	20531094				2020-06-30	J	Panagiotou, I; Mystakidou, K				Panagiotou, Irene; Mystakidou, Kyriaki			Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications	EXPERT REVIEW OF ANTICANCER THERAPY			English	Review						acute pain; breakthrough pain; cancer; fentanyl; intranasal; postoperative pain	POSTOPERATIVE PAIN MANAGEMENT; RANDOMIZED CONTROLLED-TRIAL; BREAKTHROUGH CANCER PAIN; OPIOID-TREATED PATIENTS; ORAL MORPHINE; BUCCAL TABLET; DOUBLE-BLIND; INTRAVENOUS MORPHINE; ANALGESIA PCINA; NASAL FENTANYL	Fentanyl, a short-acting synthetic pure opiate, offers an excellent option for the treatment of cancer and chronic pain. While oral administration is not an option, its high potency and lipophilicity have made intranasal administration feasible. Intranasal fentanyl has a bioavailability of 89%, with a short onset of action (similar to 7 min) and duration times (similar to 1 h). It bypasses the oral/gastrointestinal route, delivers the analgesic dose in a volume of 150 mu l that can be adequately absorbed and, with a pH of 6.4, avoids local irritation. Intranasal fentanyl has been investigated to assess its potential as a well-tolerated acute postoperative breakthrough pain relief medication. It has been shown to be superior to oral transmucosal fentanyl for the treatment of cancer breakthrough pain. Similar analgesic effects to fentanyl or morphine intravenously and orally, with a similar safety profile, have been reported for postoperative or acute pain treatment of children and adults in the prehospital and hospital settings.	[Panagiotou, Irene; Mystakidou, Kyriaki] Univ Athens, Sch Med, Dept Radiol 1, Pain Relief & Palliat Care Unit,Arete Hosp, Athens 11526, Greece	Mystakidou, K (reprint author), Univ Athens, Sch Med, Dept Radiol 1, Pain Relief & Palliat Care Unit,Arete Hosp, 27 Korinthias Ave, Athens 11526, Greece.	mistakidou@yahoo.com					Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Christo Paul J, 2004, Adv Psychosom Med, V25, P123; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Klepstad P, 2005, PALLIATIVE MED, V19, P477, DOI 10.1191/0269216305pm1054oa; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Mystakidou K, 2004, IN VIVO, V18, P633; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; NAVE R, 2009, EFIC LISB PORT 9 12; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Ueda W, 2001, ANESTHESIOLOGY, V95, P812, DOI 10.1097/00000542-200109000-00050; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; Yost Jennifer, 2008, Evid Based Nurs, V11, P42, DOI 10.1136/ebn.11.2.42; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9; 1998, PRESCRIRE INT, V37, P137	51	28	30	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1473-7140	1744-8328		EXPERT REV ANTICANC	Expert Rev. Anticancer Ther	JUL	2010	10	7					1009	1021		10.1586/ERA.10.77			13	Oncology	Oncology	633XJ	WOS:000280540200011	20645689				2020-06-30	J	Wong, CA; McCarthy, RJ; Blouin, J; Landau, R				Wong, C. A.; McCarthy, R. J.; Blouin, J.; Landau, R.			Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						mu-opioid receptor polymorphism; Opioids; Opioid analgesia; Intrathecal analgesia; Obstetric analgesia; Labor analgesia; Cesarean delivery analgesia	SINGLE-NUCLEOTIDE POLYMORPHISM; DOSE-RESPONSE RELATIONSHIP; MORPHINE CONSUMPTION; RESPIRATORY DEPRESSION; FENTANYL ANALGESIA; PAIN; A118G; PHARMACOGENETICS; VARIABILITY; PREGNANCY	Background: The purpose of this two-part prospective observational and blinded trial was to determine whether the single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1:c.304A>G) modifies (I) the duration of intrathecal fentanyl labor analgesia and (2) supplemental analgesic requirements after intrathecal morphine analgesia following cesarean delivery. Methods: Labor analgesia was initiated with intrathecal fentanyl 25 mu g. Patients undergoing primary cesarean delivery under spinal anesthesia received intrathecal morphine 150 mu g. The primary outcome variables were duration of intrathecal fentanyl analgesia in the labor study and the requirement for supplemental systemic analgesia in the cesarean study. Outcomes were compared between 304A homozygotes (group A) and 304A>G heterozygotes and 304G homozygotes (group G). Results: The labor study included 190 participants and the post-cesarean study included 103 participants; 24% subjects carried the 304A>G allele. The median (95% CI) duration of intrathecal fentanyl analgesia was 70 min (62, 78) in group A and 63 min (50, 76) in group G (P = 0.54). There was no difference in the amount of supplemental oral morphine equivalents required to treat breakthrough pain within 72 h after intrathecal morphine between groups A and G (median [TOR] 68 mg (37, 97) and 75 mg (37, 90) respectively, P = 0.99) or in the duration of intrathecal morphine analgesia (P = 0.84). The incidence of pruritus was greater in group A. Conclusions: Using the two outcome parameters duration of analgesia and treatment for breakthrough pain, we did not find a simple association between intrathecal opioid analgesia and OPRM1 304A/G polymorphism. (C) 2009 Elsevier Ltd. All rights reserved.	[Wong, C. A.; McCarthy, R. J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Blouin, J.; Landau, R.] Univ Geneva, Geneva, Switzerland	Wong, CA (reprint author), Northwestern Univ, Feinberg Sch Med, 251 E Huron St,F5-704, Chicago, IL 60611 USA.	c-wong2@northwestern.ed	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311; Wong, Cynthia/0000-0002-7144-7008	Department of Anesthesiology, Northwestern University Feinberg School of Medicine; Department of Anesthesia, Pharmacology and Surgical Intensive Care of the University Hospital of Geneva, Switzerland [0506]	The study was funded by the Department of Anesthesiology, Northwestern University Feinberg School of Medicine, and the Fonds APSI #0506 from the Department of Anesthesia, Pharmacology and Surgical Intensive Care of the University Hospital of Geneva, Switzerland.	Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Belfer I, 2004, ANESTHESIOLOGY, V100, P1562, DOI 10.1097/00000542-200406000-00032; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; CARVALHO B, 2009, CHESTNUTS OBSTET ANE, P593; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; COGAN R, 1986, PAIN, V27, P63, DOI 10.1016/0304-3959(86)90223-X; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; DENDUNNEN J, NOMENCLATURE DESCRIP; *E ENS, ENSG00000112038; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Gaiser RR, 1998, J CLIN ANESTH, V10, P488, DOI 10.1016/S0952-8180(98)00076-2; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; Iohom G, 2004, BRIT J ANAESTH, V93, P440, DOI 10.1093/bja/aeh200; IWASAKI H, 1991, ANESTHESIOLOGY, V74, P927, DOI 10.1097/00000542-199105000-00019; Landau R, 2004, ANESTHESIOLOGY, V100, P1030, DOI 10.1097/00000542-200404000-00042; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Landau R, 2006, ANESTHESIOLOGY, V105, P235, DOI 10.1097/00000542-200608000-00003; Lotsch J, 2006, PAIN, V121, P1, DOI 10.1016/j.pain.2006.01.010; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Oertel BG, 2006, PHARMACOGENET GENOM, V16, P625, DOI 10.1097/01.fpc.0000220566.90466.a2; Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200; PALAHNIUK RJ, 1974, ANESTHESIOLOGY, V41, P82, DOI 10.1097/00000542-197407000-00021; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Palmer CM, 1999, ANESTHESIOLOGY, V91, P84, DOI 10.1097/00000542-199907000-00015; Palmer SN, 2005, ANESTHESIOLOGY, V102, P663, DOI 10.1097/00000542-200503000-00028; Romberg RR, 2005, ANESTHESIOLOGY, V102, P522, DOI 10.1097/00000542-200503000-00008; Shi JX, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9026; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Skarke C, 2003, CLIN PHARMACOL THER, V73, P107, DOI 10.1067/mcp.2003.5; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008; Viscomi CM, 1997, ANESTH ANALG, V84, P1108, DOI 10.1097/00000539-199705000-00028; WONG CA, 2009, CHESTNUTS OBSTET ANE, P593; SINGLE NUCLEOTIDE PO	40	39	43	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2010	19	3					246	253		10.1016/j.ijoa.2009.09.005			8	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	631WJ	WOS:000280381000002	20171873				2020-06-30	J	Wieczorek, PM; Guest, S; Balki, M; Shah, V; Carvalho, JCA				Wieczorek, P. M.; Guest, S.; Balki, M.; Shah, V.; Carvalho, J. C. A.			Breastfeeding success rate after vaginal delivery can be high despite the use of epidural fentanyl: an observational cohort study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Epidural opioids; Side effects; Breastfeeding	ANALGESIA; LABOR; BUPIVACAINE	Background: Epidural labor analgesia inclusive of high-dose fentanyl has been thought to affect breastfeeding in multiparous patients. In our experience, this effect is not as significant as quoted in the literature. This study was designed to evaluate breastfeeding success in women receiving epidural analgesia with fentanyl-containing solutions at our institution. Methods: Term multiparous women who received epidural analgesia for labor, had previously breastfed, and who intended to breastfeed, were recruited. Baseline demographics, as well as detailed epidural, obstetric and neonatal data, were collected. Epidural analgesia was achieved with a mixture of bupivacaine and fentanyl. Subjects were telephoned both 1 and 6 weeks after delivery, and a breastfeeding questionnaire was completed. Our primary outcome was breastfeeding cessation at 6 weeks. Results: One hundred and five women were recruited, with 18 exclusions. The median cumulative epidural fentanyl dose was 151.4 mu g (30-570 mu g). No neonates developed complications attributable to labor analgesia. Four women stopped breastfeeding because of issues related to the baby (4.6%); only one of them received a fentanyl dose >150 mu g. The breastfeeding success rate was therefore >95%. The women had a median maternity leave of 12 months, and 69% received post-partum lactation support. Conclusions: The incidence of successful breastfeeding in multiparous women who undergo vaginal delivery with epidural analgesia inclusive of fentanyl is much greater at our institution than previously reported in the literature. This may be due to favorable conditions such as time off work and post-natal support. (C) 2010 Elsevier Ltd. All rights reserved.	[Wieczorek, P. M.] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Pediat & Nursing, Toronto, ON M5G 1X5, Canada	Wieczorek, PM (reprint author), Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, 600 Univ Ave,Room 781, Toronto, ON M5G 1X5, Canada.	paul.wieczorek@gmail.com	Shah, Vibhuti/P-5853-2015; Balki, Mrinalini/A-2669-2015				Armstrong HC, 1992, TRAINING GUIDE LACTA, P1; Baumgarder DJ, 2003, J AM BOARD FAM PRACT, V16, P7, DOI 10.3122/jabfm.16.1.7; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Chang ZM, 2005, J HUM LACT, V21, P305, DOI 10.1177/0890334405277604; Gartner LM, 2005, PEDIATRICS, V115, P496, DOI [10.1542/peds.2004-2491, 10.1542/peds.2011-3552]; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x; Henderson JJ, 2003, AUST NZ J OBSTET GYN, V43, P372, DOI 10.1046/j.0004-8666.2003.t01-1-00117.x; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; Riordan J, 2001, J Hum Lact, V17, P20, DOI 10.1177/089033440101700105; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; Torvaldsen S, 2006, INT BREASTFEED J, V1, DOI 10.1186/1746-4358-1-24; Volmanen P, 2004, INT J OBSTET ANESTH, V13, P25, DOI 10.1016/S0959-289X(03)00104-3; Wiklund I, 2009, MIDWIFERY, V25, pE31, DOI 10.1016/j.midw.2007.07.005; Wilson MJA, 2010, ANAESTHESIA, V65, P145, DOI 10.1111/j.1365-2044.2009.06136.x	18	15	15	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2010	19	3					273	277		10.1016/j.ijoa.2010.02.001			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	631WJ	WOS:000280381000006	20627690				2020-06-30	J	Vasisht, N; Gever, LN; Tagarro, I; Finn, AL				Vasisht, Niraj; Gever, Larry N.; Tagarro, Ignacio; Finn, Andrew L.			Evaluation of the Single- and Multiple-Dose Pharmacokinetics of Fentanyl Buccal Soluble Film in Normal Healthy Volunteers	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Buccal; drug absorption; fentanyl; opioids; pharmacokinetics; transmucosal	BREAKTHROUGH PAIN; DELIVERY; CITRATE	Fentanyl buccal soluble film (FBSF) is a rapidly absorbed transmucosal formulation of fentanyl for the management of breakthrough pain in opioid-tolerant patients with cancer. This open-label, 3-period, sequential dose study -evaluated the dose-to-dose reproducibility of the pharmacokinetics of fentanyl following the administration of 600- or 1800-mu g doses of FBSF in 12 naltrexone-blocked, healthy adult volunteers. Subjects received 3 study treatments: single doses of 600 mu g of FBSF on day 1 and day 4 and three 600-mu g doses administered at 1-hour intervals on day 7. Plasma fentanyl concentrations were measured over a 48-hour period after each single dose of FBSF and 72 hours after the 3-dose regimen. Peak plasma concentrations (mean C-max = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >= .1, all comparisons). C-max and overall fentanyl exposure (AUC(inf)) increased approximately 3-fold with the 3-dose regimen compared with the singledose periods. Fentanyl plasma concentrations following single doses of FBSF were reproducible, and 3 doses administered 1 hour apart produced a tripling in exposure and maximal concentration compared with a single dose.	[Vasisht, Niraj; Finn, Andrew L.] BioDelivery Sci Int Inc, Raleigh, NC 27607 USA; [Gever, Larry N.] Meda Pharmaceut Inc, Somerset, NJ USA; [Tagarro, Ignacio] Meda Pharma, Madrid, Spain	Finn, AL (reprint author), BioDelivery Sci Int Inc, 801 Corp Ctr Dr,Suite 210, Raleigh, NC 27607 USA.	afinn@bdsinternational.com			Meda Pharmaceuticals (Somerset, NJ)	Funding for the design and conduct of this study and for the collection, management, and analysis of the resulting data was provided by BioDelivery Sciences International (Raleigh, NC). Funding for the preparation of this manuscript was provided by Meda Pharmaceuticals (Somerset, NJ).	*CEPH, 2007, FENT FENT BUCC TABL; *CEPH, 2007, ACT FENT CITR OR TRA; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; del Consuelo ID, 2007, J CONTROL RELEASE, V122, P135, DOI 10.1016/j.jconrel.2007.05.017; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; McCarberg BH, 2007, PAIN MED, V8, pS8; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; *METR LIF INS CO, 1999, METR HEIGHT WEIGHT T; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; *US FDA, 2001, [No title captured]; VASISHT N, 2008, 27 ANN SCI M AM PAIN; VASISHT N, 2008, PAIN MED, V9, P104; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	23	11	12	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JUL	2010	50	7					785	791		10.1177/0091270010361354			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	611OW	WOS:000278829600006	20150521				2020-06-30	J	Radtke, FM; Franck, M; Lorenz, M; Luetz, A; Heymann, A; Wernecke, KD; Spies, CD				Radtke, F. M.; Franck, M.; Lorenz, M.; Luetz, A.; Heymann, A.; Wernecke, K-D; Spies, C. D.			Remifentanil Reduces the Incidence of Post-operative Delirium	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						REMIFENTANIL; FENTANYL; OPIOIDS ANALGESIA; DELIRIUM; INTRAOPERATIVE; OUTCOME	HOSPITALIZED CANCER-PATIENTS; INTENSIVE-CARE-UNIT; PSYCHOACTIVE MEDICATIONS; PRECIPITATING FACTORS; NONCARDIAC SURGERY; ELDERLY-PATIENTS; SCREENING SCALE; RISK; SYMPTOMS; RECOVERY	A secondary exploratory analysis of data from an observational study was used to study the influence of the opioid used for intraoperative anaesthesia on the incidence of post-operative delirium. Patients who had been admitted to the recovery room following elective general anaesthesia were divided into those who had received fentanyl or remifentanil. For unbiased patient analysis, matched pairs were built with respect to gender, age, physical status, anaesthetic type and surgery duration. In 752 patients, the overall incidence of delirium was 9.9% in the recovery room and 3.8% on the first post-operative day. Compared with the remifentanil group, the fentanyl group had a significantly higher incidence of delirium in the recovery room (12.2% versus 7.7%) and on the first postoperative day (5.8% versus 1.9%). Delirium in the recovery room and on the first post-operative day were both associated with a significantly prolonged post-operative hospital stay. The choice of intraoperative opioid influences the incidence of post-operative delirium. Remifentanil was associated with a lower incidence of post-operative delirium in the early post-operative period.	[Radtke, F. M.; Franck, M.; Lorenz, M.; Luetz, A.; Heymann, A.; Spies, C. D.] Charite, Dept Anaesthesia & Intens Care, D-10117 Berlin, Germany; [Wernecke, K-D] SoStAna GmbH, Berlin, Germany	Spies, CD (reprint author), Charite, Dept Anaesthesia & Intens Care, Charitepl 1, D-10117 Berlin, Germany.	claudia.spies@charite.de		Luetz, Alawi/0000-0001-8814-1809	Charite - Universitaetsmedizin Berlin, Germany	This study was supported by grants from the Charite - Universitaetsmedizin Berlin, Germany.	[Anonymous], ASA PHYS STAT CLASS; Bickel H, 2008, DEMENT GERIATR COGN, V26, P26, DOI 10.1159/000140804; Bohner H, 2003, CHIRURG, V74, P931, DOI 10.1007/s00104-003-0677-8; Bruce AJ, 2007, INT PSYCHOGERIATR, V19, P197, DOI 10.1017/S104161020600425X; Cavaliere F, 2005, CURR DRUG TARGETS, V6, P807, DOI 10.2174/138945005774574489; Dasgupta M, 2006, J AM GERIATR SOC, V54, P1578, DOI 10.1111/j.1532-5415.2006.00893.x; de Jonghe JFM, 2007, AM J GERIAT PSYCHIAT, V15, P112, DOI 10.1097/01.JGP.0000241002.86410.c2; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Fong HK, 2006, ANESTH ANALG, V102, P1255, DOI 10.1213/01.ane.0000198602.29716.53; Gaudreau JD, 2005, J CLIN ONCOL, V23, P6712, DOI 10.1200/JCO.2005.05.140; Gaudreau JD, 2005, J PAIN SYMPTOM MANAG, V29, P368, DOI 10.1016/j.jpainsymman.2004.07.009; Gaudreau JD, 2007, CANCER, V109, P2365, DOI 10.1002/cncr.22665; Inouye SK, 1999, DEMENT GERIATR COGN, V10, P393, DOI 10.1159/000017177; Inouye SK, 2001, ARCH INTERN MED, V161, P2467, DOI 10.1001/archinte.161.20.2467; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; KOX WJ, 2005, CHECK UP ANAESTHESIO; Lutz A, 2008, ANASTH INTENSIV NOTF, V43, P98, DOI 10.1055/s-2008-1060551; MacLullich AMJ, 2008, J PSYCHOSOM RES, V65, P229, DOI 10.1016/j.jpsychores.2008.05.019; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Norkiene I, 2007, SCAND CARDIOVASC J, V41, P180, DOI 10.1080/14017430701302490; Ohki T, 2006, PSYCHIAT CLIN NEUROS, V60, P277, DOI 10.1111/j.1440-1819.2006.01502.x; Peterson JF, 2006, J AM GERIATR SOC, V54, P479, DOI 10.1111/j.1532-5415.2005.00621.x; Radtke FM, 2008, BRIT J ANAESTH, V101, P338, DOI 10.1093/bja/aen193; Radtke FM, 2010, EUR J ANAESTH, V27, P411, DOI 10.1097/EJA.0b013e3283335cee; Robinson TN, 2009, ANN SURG, V249, P173, DOI 10.1097/SLA.0b013e31818e4776; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; von Dossow V, 2008, J INT MED RES, V36, P1235, DOI 10.1177/147323000803600610; Wacker P, 2006, DEMENT GERIATR COGN, V21, P221, DOI 10.1159/000091022; Winterhalter M, 2008, EUR J ANAESTH, V25, P326, DOI 10.1017/S0265021507003043	32	17	24	0	2	FIELD HOUSE PUBLISHING LLP	WORTHING	6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND	0300-0605			J INT MED RES	J. Int. Med. Res.	JUL-AUG	2010	38	4					1225	1232		10.1177/147323001003800403			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	665HC	WOS:000283025000003	20925994				2020-06-30	J	Dixon, MJ; Taylor, PM; Slingsby, L; Hoffmann, MV; Kastner, SBR; Murrell, J				Dixon, M. J.; Taylor, P. M.; Slingsby, L.; Hoffmann, M. V.; Kaestner, S. B. R.; Murrell, J.			A small, silent, low friction, linear actuator for mechanical nociceptive testing in veterinary research	LABORATORY ANIMALS			English	Article						Nociceptive threshold testing; unrestrained; pressure actuator; analgesia; opioid	CATS; BUPRENORPHINE; THRESHOLDS; SALINE; CARPROFEN	Air pressure is commonly used to drive a mechanical stimulus for nociceptive threshold testing. This may be bulky, noisy, non-linear and suffer from friction, hence development of a better system is described. A novel, light (14 g) rolling diaphragm actuator was constructed, which supplied 20 N force via a constant actuation area irrespective of the pressure and position in the stroke. Three round-ended pins, 2.5 mm diameter, mounted in a triangle on the piston, provided the stimulus. Pressure was increased manually using a syringe with the rate of rise of force controlled at 0.8 N/s by warning lights. The pressure/force relationship was calibrated using a static force transducer and mercury column. Data were collected with the actuator attached to the antero-medial radius of 12 cats and four dogs. Mechanical threshold was recorded when the animal withdrew the limb and/or turned towards the actuator. Safety cut-off was 20 N. The pressure/force relationship was linear and independent of the start point in the actuator stroke. Baseline feline thresholds were 10.0 +/- 2.5 N (mean +/- SD), which increased significantly 30 min after butorphanol administration. Baseline canine thresholds were 5.5 +/- 1.4 N and increased significantly between 15 and 45 min after administration of fentanyl or butorphanol. The system overcame the problems of earlier devices and detected an opioid-induced increase in threshold. It has considerable advantages over previous systems for research in analgesia.	[Taylor, P. M.] Topcat Metrol, Gravel Head Farm, Nr Ely CB6 2TY, Cambs, England; [Slingsby, L.; Murrell, J.] Univ Bristol, Sch Vet Sci, Bristol BS18 7DU, Avon, England; [Hoffmann, M. V.; Kaestner, S. B. R.] Univ Vet Med, Hannover, Germany	Taylor, PM (reprint author), Topcat Metrol, Gravel Head Farm, Nr Ely CB6 2TY, Cambs, England.	polly@taylormonroe.co.uk	Taylor, Polly/M-3239-2015	Taylor, Polly/0000-0003-1322-3468			CHAMBERS JP, 1993, RES VET SCI, V54, P52, DOI 10.1016/0034-5288(93)90010-D; Dixon MJ, 2007, RES VET SCI, V82, P85, DOI 10.1016/j.rvsc.2006.03.010; Kemp MH, 2008, VET REC, V163, P175, DOI 10.1136/vr.163.6.175; Lascelles BDX, 1998, VET SURG, V27, P568, DOI 10.1111/j.1532-950X.1998.tb00533.x; Le Bars D, 2001, PHARMACOL REV, V53, P597; Millette VM, 2008, VET ANAESTH ANALG, V35, P543, DOI 10.1111/j.1467-2995.2008.00419.x; NOLAN A, 1987, BRIT J PHARMACOL, V92, P527, DOI 10.1111/j.1476-5381.1987.tb11353.x; SLINGSBY LA, 2009, P 10 WORLD C VET AN; Steagall PVM, 2006, J VET PHARMACOL THER, V29, P531, DOI 10.1111/j.1365-2885.2006.00800.x; Steagall PVM, 2008, J FELINE MED SURG, V10, P24, DOI 10.1016/j.jfms.2007.06.009; Steagall PVM, 2007, VET ANAESTH ANALG, V34, P344, DOI 10.1111/j.1467-2995.2006.00331.x; STEAGALL PV, 2008, VET J; Whay HR, 2005, VET REC, V157, P729, DOI 10.1136/vr.157.23.729	13	27	27	1	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	JUL	2010	44	3					247	253		10.1258/la.2010.009080			7	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	628RQ	WOS:000280138800013	20457825	Bronze			2020-06-30	J	Van Nimmen, NFJ; Poels, KLC; Severi, MJ; Godderis, L; Veulemans, HAF				Van Nimmen, N. F. J.; Poels, K. L. C.; Severi, M. J.; Godderis, L.; Veulemans, H. A. F.			Selecting an appropriate biomonitoring strategy to evaluate dermal exposure to opioid narcotic analgesics in pharmaceutical production workers	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							CLINICAL PHARMACOKINETICS; TRANSDERMAL FENTANYL; IDENTIFICATION; SUFENTANIL; ALFENTANIL; MODELS; URINE	Objectives In a follow-up study of previous research, in which exposure pathways for opioid narcotic analgesics were identified in pharmaceutical workers involved in drug synthesis, the current research focused on the selection of an appropriate biomonitoring strategy. Methods Six opioid narcotic production workers were intensively monitored during a (1 week) fentanyl production campaign. A systematic sampling scheme was followed that provided information about hand contamination and biomarker levels at multiple time points. Results Linear mixed-effects models, incorporating half-shift and end-of-shift hand contamination levels, showed a positive and significant correlation with fentanyl urinary excretion occurring at many of the 4 h time lags investigated (4-28 h). Optimum model characteristics, including both minimal between- and within-worker variability, were obtained at lag times of 24 h and 20 h, respectively, advocating a pre-shift urine sampling strategy on the following day. In addition, for these lag times the portion of the variability explained by the model was maximal. Furthermore, using a distributed lag model, it was demonstrated that urinary fentanyl levels were positively correlated with hand contamination levels measured at the preceding four 8 h time lags (8-32 h), although statistical significance was only shown for a lag time of 24 h. Conclusion Fentanyl levels in pre-shift urine samples reflect dermal exposure to the compound during the previous day. Thus, in the specific working environment investigated, a biological monitoring protocol evaluating pre-shift urinary fentanyl levels could provide an adequate risk estimate in individual workers.	[Van Nimmen, N. F. J.; Poels, K. L. C.; Severi, M. J.; Godderis, L.; Veulemans, H. A. F.] Katholieke Univ Leuven, Dept Occupat Environm & Insurance Med, Lab Occupat Hyg & Toxicol, B-3000 Leuven, Belgium; [Godderis, L.] IDEWE, External Serv Protect & Prevent Work, Heverlee, Belgium	Godderis, L (reprint author), Katholieke Univ Leuven, Dept Occupat Environm & Insurance Med, Lab Occupat Hyg & Toxicol, Kapucijnenvoer 35-5, B-3000 Leuven, Belgium.	lode.godderis@med.kuleuven.be	Godderis, Lode/AAE-5880-2019	Godderis, Lode/0000-0003-4764-8835			*ACGIH, 2009, 2009 TLVS BEIS THRES, P97; Binks SP, 2003, OCCUP MED-OXFORD, V53, P363, DOI 10.1093/occmed/kqg116; Burdorf A, 2005, OCCUP ENVIRON MED, V62, P344, DOI 10.1136/oem.2004.015198; Drexler H, 2003, INT ARCH OCC ENV HEA, V76, P359, DOI 10.1007/s00420-002-0423-4; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Hines CJ, 2003, ANN OCCUP HYG, V47, P503, DOI 10.1093/annhyg/meg067; Mcclean MD, 2004, ANN OCCUP HYG, V48, P565, DOI 10.1093/annhyg/meh044; MEULDERMANS W, 1993, MORPHINIQUES, P85; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Van Nimmen NFJ, 2006, ANN OCCUP HYG, V50, P665, DOI [10.1093/annhyg/mel028, 10.1093/annhyg/me1028]; Peretz C, 2002, ANN OCCUP HYG, V46, P69, DOI 10.1093/annhyg/mef009; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; VANNIMMEN NF, 2009, J CLIN PHAR IN PRESS	15	4	4	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JUL	2010	67	7					464	470		10.1136/oem.2009.050583			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	616BE	WOS:000279181900007	19914914				2020-06-30	J	Zeppetella, G; Messina, J; Xie, F; Slatkin, NE				Zeppetella, Giovambattista; Messina, John; Xie, Fang; Slatkin, Neal E.			Consistent and Clinically Relevant Effects with Fentanyl Buccal Tablet in the Treatment of Patients Receiving Maintenance Opioid Therapy and Experiencing Cancer-Related Breakthrough Pain	PAIN PRACTICE			English	Article						breakthrough pain; cancer; opioids; fentanyl buccal tablet; clinically relevant pain treatment	PREVALENCE	Fentanyl buccal tablet (FBT) has shown efficacy and tolerability in patients with cancer-related persistent pain treated with maintenance opioids. We conducted a combined analysis of two similarly designed, randomized, placebo-controlled studies to further evaluate the consistency and clinical relevance of analgesia outcomes. Of the 252 patients enrolled, 150 fulfilled the criteria for efficacy analysis and experienced 1,417 breakthrough pain episodes. A consistently greater effect was noted with FBT vs. placebo on the following measures: improvements from baseline of >= 33% and >= 50% in pain intensity (PI), a >= 2-point reduction in PI, and a score of >= 2 for pain relief. Improvements in these clinically meaningful efficacy measures were seen with FBT at 15 minutes (earliest common evaluation) and remained evident at 60 minutes (final common evaluation). They were also reflected in a more favorable global medication performance assessment for FBT over placebo. FBT was generally well tolerated; most adverse events were typical of potent opioid use in a cancer population. Application-site (buccal) abnormalities were infrequent and led to withdrawal of three patients. There were no serious adverse events or deaths attributable to FBT. This analysis suggests that FBT provides an analgesic effect that is consistent across multiple clinically relevant efficacy measures.	[Zeppetella, Giovambattista] St Clare Hosp, Hastingwood CM17 9JX, Essex, England; [Messina, John; Xie, Fang] Cephalon Inc, Frazer, PA USA; [Slatkin, Neal E.] City Hope Med Grp, Monrovia, CA USA	Zeppetella, G (reprint author), St Clare Hosp, Hastingwood Rd, Hastingwood CM17 9JX, Essex, England.	john.zeppetella@stclarehospice.org.uk			Cephalon, Inc. (Frazer, PA, USA); Cephalon, Inc.	This study was sponsored by Cephalon, Inc. (Frazer, PA, USA). Writing support for the preparation of this paper was provided by David Peters, MSc; funding for this support was provided by Cephalon, Inc.	BENNETT D, 2005, [No title captured], V30, P296; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	13	9	10	0	1	WILEY PERIODICALS, INC	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA	1530-7085			PAIN PRACT	Pain Pract.	JUL-AUG	2010	10	4					287	293		10.1111/j.1533-2500.2010.00359.x			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	840TD	WOS:000296463300005	20230447				2020-06-30	J	Batra, YK; Rakesh, SV; Panda, NB; Lokesh, VC; Subramanyam, R				Batra, Yatindra K.; Rakesh, Sondekoppam V.; Panda, Nidhi B.; Lokesh, Vanajakshi C.; Subramanyam, Rajeev			Intrathecal clonidine decreases propofol sedation requirements during spinal anesthesia in infants	PEDIATRIC ANESTHESIA			English	Article						clonidine; fentanyl; intrathecal; procedural sedation; propofol	CHILDREN; BUPIVACAINE; INDEX; DEPTH	P>Background: Propofol is a popular agent for providing procedural sedation in pediatric population during lumbar puncture and spinal anesthesia. Adjuvants like clonidine and fentanyl are administered intrathecally to prolong the duration of spinal anesthesia and to provide postoperative analgesia. We studied the propofol requirement after intrathecal administration of clonidine or fentanyl in infants undergoing lower abdominal surgeries. Methods: Sixty-five ASA I infants undergoing elective lower abdominal surgery under spinal anesthesia were assigned into four groups in this prospective randomized double-blinded study. Group B received bupivacaine based on body weight (< 5 kg = 0.5 mg center dot kg-1; 5-10 kg = 0.4 mg center dot kg-1). Group BC received 1 mu g center dot kg-1 of clonidine with bupivacaine, group BF received 1 mu g center dot kg-1 of fentanyl with bupivacaine, and patients in group BCF received 1 mu g center dot kg-1 each of clonidine and fentanyl with bupivacaine. A bolus of 2-3 mg center dot kg-1 of propofol bolus was administered for lumbar puncture. Sedation was assessed using a six-point sedation score (0-5) and a five-point reactivity score (0-4) which was based on a behavioral score. After achieving a sedation and reactivity score of 3-4, the patients were placed lateral in knee chest position and lumbar puncture performed and test drug administered. Further intraoperative sedation was maintained with an infusion of 25-50 mu g center dot kg-1 center dot min-1 of propofol infusion. Results: The mean +/- sd infusion requirement of propofol decreased from 35.5 +/- 4.5 in group B to 33.4 +/- 5.4 mu g center dot kg-1 center dot min-1 in group BF and further decreased to 16.7 +/- 6.2 mu g center dot kg-1 center dot min-1 and 14.8 +/- 4.9 mu g center dot kg-1 center dot min-1 in group BC and BCF, respectively. There were no statistically significant differences between BC and BCF groups. The mean sedation and reactivity scores were higher in groups BC and BCF when compared to groups B and BF. Conclusion: Our study show that the requirement of propofol sedation reduces with intrathecal adjuvants. The reduction was significant with the addition of clonidine and clonidine-fentanyl combination as opposed to bupivacaine alone or with fentanyl. There was no significant difference in propofol infusion requirement with the use of bupivacaine alone or with fentanyl.	[Batra, Yatindra K.; Rakesh, Sondekoppam V.; Panda, Nidhi B.; Lokesh, Vanajakshi C.; Subramanyam, Rajeev] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India	Batra, YK (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India.	ykbatra@glide.net.in					Batra YK, 2009, ACTA ANAESTH SCAND, V53, P470, DOI 10.1111/j.1399-6576.2008.01837.x; Batra YK, 2008, PEDIATR ANESTH, V18, P613, DOI 10.1111/j.1460-9592.2008.02613.x; Contreras Dominguez V, 2007, Rev Esp Anestesiol Reanim, V54, P421; CONTRERAS DV, 2008, REV ESP ANESTESIOL R, V55, P282; Davidson AJ, 2007, CURR OPIN ANESTHESIO, V20, P236, DOI 10.1097/ACO.0b013e3280c60c66; Disma N, 2009, PEDIATR ANESTH, V19, P133, DOI 10.1111/j.1460-9592.2008.02859.x; DOHI S, 1979, ANESTHESIOLOGY, V50, P319; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; Hermanns H, 2006, BRIT J ANAESTH, V97, P380, DOI 10.1093/bja/ael156; JAMES CE, 1995, ANESTHESIOLOGY, V85, P655; KATARIA BK, 1994, ANESTHESIOLOGY, V80, P104, DOI 10.1097/00000542-199401000-00018; Machata AM, 2008, BRIT J ANAESTH, V101, P239, DOI 10.1093/bja/aen153; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Ozkan-Seyhan T, 2006, BRIT J ANAESTH, V96, P645, DOI 10.1093/bja/ael055; Powers KS, 2005, PEDIATRICS, V115, P1666, DOI 10.1542/peds.2004-1979; Rochette A, 2005, PEDIATR ANESTH, V15, P1072, DOI 10.1111/j.1460-9592.2005.01664.x; Rochette A, 2004, ANESTH ANALG, V98, P56, DOI 10.1213/01.ANE.0000093229.17729.6C; Tobias JD, 2000, PAEDIATR ANAESTH, V10, P5, DOI 10.1046/j.1460-9592.2000.00460.x; Wheeler DS, 2003, PEDIATR EMERG CARE, V19, P385, DOI 10.1097/01.pec.0000101578.65509.71; Yang MK, 2007, BRIT J ANAESTH, V98, P515, DOI 10.1093/bja/aem038	21	11	11	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JUL	2010	20	7					625	632		10.1111/j.1460-9592.2010.03326.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	612UR	WOS:000278930000006	20642661				2020-06-30	J	Chung, S; Lim, R; Goldman, RD				Chung, Seen; Lim, Ruth; Goldman, Ran D.			Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography	PEDIATRIC RADIOLOGY			English	Article						Fentanyl; Pain; Children; Catheterization; Cystourethrogram	YOUNG-CHILDREN; NITROUS-OXIDE; MIDAZOLAM; SEDATION; PREMEDICATION; ANALGESIA; DISTRESS	Voiding cystourethrogram (VCUG) is a common procedure at pediatric tertiary care centres that can be painful as it involves a urinary catheter. Currently there are no widely utilized protocols for non-topical medications to decrease pain that children feel during catheterization. To determine if intranasal (IN) fentanyl is effective at decreasing pain that children feel during catheterization of VCUG when compared with sterile water. We performed a double-blind randomized controlled trial, using IN fentanyl (2 mu g/kg) compared to placebo (sterile water,) in children 4-8 years of age scheduled for elective VCUG in one urban pediatric tertiary center. Using the Face Pain Score-Revised, children receiving IN fentanyl scored 2.58 (1.93-3.25 95% CI) while those receiving sterile water scored 2.86 (2.20-3.51 95% CI) showing no statistically significant difference. There were no adverse events. Although we were unable to show a statistically significant difference between our study and control groups, we believe that this may be due to technique (positioning, delivery device) and timing of administration of IN fentanyl as well as multi-factorial causes of distress during VCUG. Future studies investigating alternative delivery techniques of IN fentanyl for analgesia during VCUG may yield more promising results.	[Goldman, Ran D.] Univ British Columbia, Child & Family Res Inst, Dept Pediat, Div Pediat Emergency Med,BC Childrens Hosp, Vancouver, BC V6H 3V4, Canada; [Lim, Ruth] Univ Toronto, Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada; [Chung, Seen] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Pediat Emergency Med, Toronto, ON M5G 1X8, Canada	Goldman, RD (reprint author), Univ British Columbia, Child & Family Res Inst, Dept Pediat, Div Pediat Emergency Med,BC Childrens Hosp, Room K4-226,Ambulatory Care Bldg,4480 Oak St, Vancouver, BC V6H 3V4, Canada.	rgoldman@cw.bc.ca					Akil I, 2005, PEDIATR NEPHROL, V20, P1106, DOI 10.1007/s00467-005-1874-0; Berde C, 2003, J PEDIATR-US, V142, P361, DOI 10.1067/mpd.2003.194; Bergman DA, 1999, PEDIATRICS, V103, P843; Beyer JE, 1984, OUCHER USERS MANUAL; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Bozkurt P, 1996, BRIT J UROL, V78, P282, DOI 10.1046/j.1464-410X.1996.04325.x; ELDER JS, 1995, AM J ROENTGENOL, V164, P1229, DOI 10.2214/ajr.164.5.7717236; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Golianu B, 2000, PEDIATR CLIN N AM, V47, P559, DOI 10.1016/S0031-3955(05)70226-1; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Kennedy RM, 1999, PEDIATR CLIN N AM, V46, P1215, DOI 10.1016/S0031-3955(05)70184-X; Kogan A, 2002, PAEDIATR ANAESTH, V12, P685, DOI 10.1046/j.1460-9592.2002.00918.x; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Merguerian PA, 2006, J UROLOGY, V176, P299, DOI 10.1016/S0022-5347(06)00584-2; MERRITT KA, 1994, PEDIATRICS, V94, P17; Sargent MA, 2000, PEDIATR RADIOL, V30, P587, DOI 10.1007/s002470000263; Shaw MN, 1998, PEDIATRICS, V102, P16; Stashinko E E, 1998, Issues Compr Pediatr Nurs, V21, P85; Stokland E, 2003, PEDIATR RADIOL, V33, P247, DOI 10.1007/s00247-003-0874-0; STREIBEL HW, 1993, ANAESTHESIA, V48, P753; STREIBEL HW, 1992, ANESTHESIOLOGY, V77, P281; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Zier JL, 2007, PEDIATR RADIOL, V37, P678, DOI 10.1007/s00247-007-0508-z; Zier JL, 2007, ANESTH ANALG, V104, P876, DOI 10.1213/01.ane.0000258763.17768.ce	24	14	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449			PEDIATR RADIOL	Pediatr. Radiol.	JUL	2010	40	7					1236	1240		10.1007/s00247-009-1521-1			5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	608KH	WOS:000278582300009	20180109				2020-06-30	J	Lynch, RE; Hack, RA				Lynch, Robert E.; Hack, Richard A.			Methadone-Induced Rigid-Chest Syndrome After Substantial Overdose	PEDIATRICS			English	Article						rigid chest; methadone; narcotic withdrawal	WALL RIGIDITY; FENTANYL; SUFENTANIL	We report here the case of an infant who developed life-threatening rigid-chest syndrome after receiving an accidental overdose of methadone. The child responded to narcotic reversal. Pediatric physicians should be aware of this possible complication. Pediatrics 2010;126:e232-e234	[Lynch, Robert E.; Hack, Richard A.] St Johns Mercy Childrens Hosp, Creve Coeur, MO 63141 USA	Lynch, RE (reprint author), St Johns Mercy Childrens Hosp, 621 S New Ballas Rd, Creve Coeur, MO 63141 USA.	robert.lynch2@mercy.net					Ackerman W E, 1990, Anesth Prog, V37, P46; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Carvalho B, 2004, INT J OBSTET ANESTH, V13, P53, DOI 10.1016/j.ijoa.2003.09.001; Corkery JM, 2004, HUM PSYCHOPHARM CLIN, V19, P565, DOI 10.1002/hup.630; Elakkumanan LB, 2008, PEDIATR ANESTH, V18, P1115, DOI 10.1111/j.1460-9592.2008.02602.x; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; GRAVLEE GP, 1988, ANESTH ANALG, V67, P39; HAMILTON WK, 1953, ANESTHESIOLOGY, V14, P550, DOI 10.1097/00000542-195311000-00002; Ito S, 2008, J PALLIAT MED, V11, P838, DOI 10.1089/jpm.2008.0040; Jansson Lauren M, 2009, J Opioid Manag, V5, P47; MacGregor DA, 1996, J CLIN ANESTH, V8, P251, DOI 10.1016/0952-8180(96)00020-7; Stockham R J, 1987, J Cardiothorac Anesth, V1, P19, DOI 10.1016/S0888-6296(87)92558-0; Vaughn R L, 1981, Anesth Prog, V28, P50	13	10	10	0	0	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2010	126	1					E232	E234		10.1542/peds.2009-3243			3	Pediatrics	Pediatrics	619LF	WOS:000279431000053	20587670				2020-06-30	J	Lugli, AK; Donatelli, F; Schricker, T; Kindler, C; Wykes, L; Carli, F				Lugli, Andrea Kopp; Donatelli, Francesco; Schricker, Thomas; Kindler, Christoph; Wykes, Linda; Carli, Franco			Protein Balance in Nondiabetic Versus Diabetic Patients Undergoing Colon Surgery Effect of Epidural Analgesia and Amino Acids	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							GLUCOSE EFFECTIVENESS; LEUCINE METABOLISM; BLOCKADE; MELLITUS; VOLUNTEERS; MANAGEMENT; ANESTHESIA; INFUSION	Background: Surgical injury provokes a stress response that is thought to be pronounced in patients with diabetes mellitus type 2 (DM2) leading to intensified catabolism. The aim of this study was to compare the effects of perioperative epidural analgesia (EDA) versus patient-controlled analgesia (PCA) and amino acid infusion on postoperative metabolism in patients with and without DM2. Methods: For this study, 12 nondiabetic patients and 12 diabetic patients undergoing colorectal surgery were randomly assigned to 4 groups (n = 6 per group) receiving either EDA (nondiabetic EDA and diabetic EDA [DEDA group]) or PCA with morphine (nondiabetic PCA and diabetic PCA) for perioperative pain control. Protein and glucose kinetics were measured on the second postoperative day using L[1-(13)C]leucine and [6,6-(2)H(2)]glucose infusion during a fasted state and a 3-hr fed state with amino acid infusion. Results: The transition from the fasted to fed state suppressed endogenous rate of appearance (Ra) of glucose (P < 0.001) with a distinct effect for the DEDA group (P < 0.001). The Ra of leucine and the endogenous rate of appearance of leucine tended to be lower in the DEDA group (P = 0.056 and P = 0.07). Leucine oxidation was more suppressed in the DEDA group (P = 0.02) and when receiving amino acids (P = 0.001). Diabetic patients achieved a higher protein balance than nondiabetic patients (P = 0.032) and when receiving EDA instead of PCA (P = 0.012) or infusion of amino acids (P = 0.014). Conclusions: A short-term infusion of amino acids reduced protein breakdown, increased protein synthesis, and rendered protein balance positive. This anabolic effect was pronounced in diabetic patients with EDA compared with nondiabetic patients or PCA, respectively, and prevented an undesirable hyperglycemia.	[Lugli, Andrea Kopp] Univ Hosp, Dept Anesthesia, CH-4031 Basel, Switzerland; [Lugli, Andrea Kopp; Donatelli, Francesco; Schricker, Thomas; Carli, Franco] McGill Univ, Dept Anesthesia, Montreal, PQ, Canada; [Lugli, Andrea Kopp; Donatelli, Francesco; Wykes, Linda] McGill Univ, Sch Dietet & Human Nutr, Montreal, PQ, Canada; [Lugli, Andrea Kopp; Kindler, Christoph] Cantonal Hosp, Dept Anesthesia & Perioperat Intens Care Med, Aarau, Switzerland	Lugli, AK (reprint author), Univ Hosp, Dept Anesthesia, CH-4031 Basel, Switzerland.	akopp@uhbs.ch			Swiss National Science Foundation, Zurich, SwitzerlandSwiss National Science Foundation (SNSF) [PBZHB-110303]; Kantonsspital Aarau, Switzerland; Fresenius Switzerland; European Society of Anesthesia [2]; McGill University Health Centre Foundation, Montreal, Canada; Canadian Institutes of Health Research, Ottawa, CanadaCanadian Institutes of Health Research (CIHR) [MOP 64456]; Fonds de la recherche en sante Quebec, CanadaFonds de la Recherche en Sante du Quebec	Andrea Kopp Lugli is recipient of a study grant (PBZHB-110303) from the Swiss National Science Foundation, Zurich, Switzerland; the Kantonsspital Aarau, Switzerland (no specific grant number); and the Fresenius Switzerland (no specific grant number). Francesco Donatelli is recipient of a study grant from the European Society of Anesthesia (ESA Research Grant 2005, no. 2) and the McGill University Health Centre Foundation Fellowship (no specific grant number), Montreal, Canada. Thomas Schricker is supported by grants from the Canadian Institutes of Health Research (MOP 64456), Ottawa, Canada, and the Fonds de la recherche en sante Quebec (no specific grant number), Canada.	Basu A, 1997, DIABETES, V46, P421, DOI 10.2337/diabetes.46.3.421; CARLI F, 1991, BRIT J ANAESTH, V67, P729, DOI 10.1093/bja/67.6.729; Carli F, 1997, ANESTHESIOLOGY, V86, P1033, DOI 10.1097/00000542-199705000-00005; CASTELLINO P, 1987, J CLIN INVEST, V80, P1784, DOI 10.1172/JCI113272; Coursin DB, 2004, CRIT CARE MED, V32, pS116, DOI 10.1097/01.CCM.0000115623.52021.C0; Donatelli F, 2006, ANESTHESIOLOGY, V105, P253, DOI 10.1097/00000542-200608000-00007; FRAYN KN, 1986, CLIN ENDOCRINOL, V24, P577, DOI 10.1111/j.1365-2265.1986.tb03288.x; Hawkins M, 2003, DIABETES, V52, P2748, DOI 10.2337/diabetes.52.11.2748; Holte K, 2002, CLIN NUTR, V21, P199, DOI 10.1054/clnu.2001.0514; KINNEY JM, 1983, NUTR SUPPORT SERIOUS, P5; Krinsley J, 2006, CURR OPIN ANESTHESIO, V19, P111, DOI 10.1097/01.aco.0000192767.12206.ec; Ljungqvist O, 2005, CURR OPIN CRIT CARE, V11, P295, DOI 10.1097/01.ccx.0000166395.65764.71; Lugli AK, 2008, ANESTHESIOLOGY, V108, P1093, DOI 10.1097/ALN.0b013e3181730239; MCCLAVE SA, 1999, CHEST, V115, P64; Romijn JA, 2000, P NUTR SOC, V59, P447, DOI 10.1017/S0029665100000616; Schricker T, 2000, AM J PHYSIOL-ENDOC M, V279, pE646; Schricker T, 2005, ANESTHESIOLOGY, V102, P320, DOI 10.1097/00000542-200502000-00013; Schricker T, 2002, ANESTHESIOLOGY, V97, P943, DOI 10.1097/00000542-200210000-00029; Schricker T, 1999, ANESTHESIOLOGY, V90, P1636, DOI 10.1097/00000542-199906000-00020; Schricker T, 1996, HEPATOLOGY, V24, P330; Schricker T, 2000, ANESTHESIOLOGY, V92, P62, DOI 10.1097/00000542-200001000-00015; Smeets HJ, 1995, NUTRITION, V11, P423; STATEN MA, 1986, DIABETES, V35, P1249, DOI 10.2337/diabetes.35.11.1249; VEDRINNE C, 1989, ANESTH ANALG, V69, P354; ZIEGLER TR, 1993, CLIN NUTRITION PAREN, P649	25	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUL-AUG	2010	35	4					355	360		10.1097/AAP.0b013e3181e66e4f			6	Anesthesiology	Anesthesiology	622EH	WOS:000279643100008	20607877				2020-06-30	J	Melief, EJ; Miyatake, M; Bruchas, MR; Chavkin, C				Melief, Erica J.; Miyatake, Mayumi; Bruchas, Michael R.; Chavkin, Charles			Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						acute analgesic tolerance; biased agonism; collateral agonist; desensitization	FUNCTIONAL SELECTIVITY; BIASED AGONISM; DESENSITIZATION; ENDOCYTOSIS; PHOSPHORYLATION; MECHANISMS; TOLERANCE	Ligand-directed signaling has been suggested as a basis for the differences in responses evoked by otherwise receptor-selective agonists. The underlying mechanisms are not understood, yet clearer definition of this concept may be helpful in the development of novel, pathway-selective therapeutic agents. We previously showed that.-opioid receptor activation of JNK by one class of ligand, but not another, caused persistent receptor inactivation. In the current study, we found that the mu-opioid receptor (MOR) could be similarly inactivated by a specific ligand class including the prototypical opioid, morphine. Acute analgesic tolerance to morphine and related opioids (morphine-6-glucuronide and buprenorphine) was blocked by JNK inhibition, but not by G protein receptor kinase 3 knockout. In contrast, a second class of mu-opioids including fentanyl, methadone, and oxycodone produced acute analgesic tolerance that was blocked by G protein receptor kinase 3 knockout, but not by JNK inhibition. Acute MOR desensitization, demonstrated by reduced D-Ala(2)-Met(5)-Glyol-enkephalin-stimulated [S-35]GTP gamma S binding to spinal cord membranes from morphine-pretreated mice, was also blocked by JNK inhibition; however, desensitization of D-Ala(2)-Met(5)-Glyol-enkephalin-stimulated [S-35]GTP gamma S binding following fentanyl pretreatment was not blocked by JNK inhibition. JNK-mediated receptor inactivation of the mu-opioid receptor was evident in both agonist-stimulated [S-35]GTP gamma S binding and opioid analgesic assays; however, gene knockout of JNK 1 selectively blocked.-receptor inactivation, whereas deletion of JNK 2 selectively blocked MOR inactivation. These findings suggest that ligand-directed activation of JNK kinases may generally provides an alternate mode of G protein-coupled receptor regulation.	[Melief, Erica J.; Miyatake, Mayumi; Bruchas, Michael R.; Chavkin, Charles] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Chavkin, C (reprint author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010; Bruchas, Michael/G-7616-2012		US Public Health ServiceUnited States Public Health Service [R37-DA11672, K99-DA025182]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [KO5 DA20570]	We thank Dr. John Pintar (University of Medicine and Dentistry of New Jersey) for the MOR (-/-) mice and Drs. Marc Caron and Robert Lefkowitz (Duke University) for the GRK3 (-/-) mice. We thank Dr. Nephi Stella for help with the [<SUP>35</SUP>S] GTP gamma S studies. Dan Messinger monitored the mouse breeding and genotyped the mice. Funding was provided by US Public Health Service Grants R37-DA11672 and K99-DA025182 and National Institute on Drug Abuse Grant KO5 DA20570.	Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berg KA, 1998, MOL PHARMACOL, V54, P94; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; Bruchas MR, 2007, J BIOL CHEM, V282, P29803, DOI 10.1074/jbc.M705540200; Chu J, 2008, CELL SIGNAL, V20, P1616, DOI 10.1016/j.cellsig.2008.05.004; Clayton CC, 2010, MOL PHARMACOL, V77, P339, DOI 10.1124/mol.109.060558; Dang VC, 2009, J NEUROSCI, V29, P3322, DOI 10.1523/JNEUROSCI.4749-08.2009; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Galandrin S, 2008, MOL PHARMACOL, V74, P162, DOI 10.1124/mol.107.043893; HORAN P, 1992, J PHARMACOL EXP THER, V260, P1237; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kam AYF, 2004, J NEUROCHEM, V89, P391, DOI 10.1111/j.1471-4159.2004.02338.x; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kenakin T, 2007, MOL PHARMACOL, V72, P1393, DOI 10.1124/mol.107.040352; Kovoor A, 1998, MOL PHARMACOL, V54, P704; LAWRENCE AJ, 1992, BIOCHEM PHARMACOL, V43, P2335, DOI 10.1016/0006-2952(92)90311-6; Lowe JD, 2002, J BIOL CHEM, V277, P15729, DOI 10.1074/jbc.M200612200; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; REISINE T, 1995, NEUROPHARMACOLOGY, V34, P463, DOI 10.1016/0028-3908(95)00025-2; Schuller AGP, 1999, NAT NEUROSCI, V2, P151; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	27	92	94	0	10	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 22	2010	107	25					11608	11613		10.1073/pnas.1000751107			6	Multidisciplinary Sciences	Science & Technology - Other Topics	614KS	WOS:000279058000081	20534436	Green Published, Bronze			2020-06-30	J	Zheng, H; Zeng, Y; Chu, J; Kam, AY; Loh, HH; Law, PY				Zheng, Hui; Zeng, Yan; Chu, Ji; Kam, Angel YuetFang; Loh, Horace H.; Law, Ping-Yee			Modulations of NeuroD Activity Contribute to the Differential Effects of Morphine and Fentanyl on Dendritic Spine Stability	JOURNAL OF NEUROSCIENCE			English	Article							MU-OPIOID-RECEPTORS; PROTEIN-KINASE-II; NUCLEUS-ACCUMBENS; OPIATE TREATMENT; RAT HIPPOCAMPUS; AGONIST; INTERNALIZATION; MORPHOLOGY; NEUROGENESIS; MECHANISMS	The cellular level of neurogenic differentiation 1 (NeuroD) is modulated differentially by mu-opioid receptor agonists; fentanyl increases NeuroD level by reducing the amount of microRNA-190 (miR-190), an inhibitor of NeuroD expression, whereas morphine does not alter NeuroD level. In the current study, NeuroD activity was demonstrated to be also under agonist-dependent regulation. After 3 d of treatment, morphine and fentanyl decreased the activity of the Ca(2+)/calmodulin-dependent protein kinase II alpha (CaMKII alpha), which phosphorylates and activates NeuroD. Because NeuroD activity is determined by both the CaMKII alpha activity and the cellular NeuroD level, the overall NeuroD activity was reduced by morphine, but maintained during fentanyl treatment. The differential effects of agonists on NeuroD activity were further confirmed by measuring the mRNA levels of four NeuroD downstream targets: doublecortin, Notch1, neurogenic differentiation 4, and Roundabout 1. Decreased dendritic spine stability and mu-opioid receptor signaling capability were also observed when NeuroD activity was attenuated by miR-190 overexpression or treatment with KN93, a CaMKII alpha inhibitor. The decrease could be rescued by NeuroD overexpression, which restored NeuroD activity to the basal level. Furthermore, elevating NeuroD activity attenuated the morphine-induced decrease in dendritic spine stability. Therefore, by regulating NeuroD activity, mu-opioid receptor agonists modulate the stability of dendritic spines.	[Zheng, Hui; Zeng, Yan; Chu, Ji; Kam, Angel YuetFang; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Zheng, H (reprint author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zhenhui2055@hotmail.com		Law, Ping-Yee/0000-0002-5364-1093; Zheng, Hui/0000-0001-6801-0529	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA007339, DA016674, DA000564, DA011806];  [K05-DA70544];  [K05-DA00513]	The research was supported by National Institutes of Health Grants DA007339, DA016674, DA000564, and DA011806. H. H. L. and P.Y.L. are recipients of Grants K05-DA70544 and K05-DA00513, respectively. We thank Dr. Liao Dezhi for advice on preparing primary cultures and Dr. David L. Turner for NeuroD cDNA.	Bao GB, 2007, NEUROPSYCHOPHARMACOL, V32, P1738, DOI 10.1038/sj.npp.1301308; Breunig JJ, 2007, P NATL ACAD SCI USA, V104, P20558, DOI 10.1073/pnas.0710156104; Chae JH, 2004, MOL CELLS, V18, P271; CHEN Y, 1993, BIOCHEM J, V295, P625, DOI 10.1042/bj2950625; Cho JH, 2004, MOL NEUROBIOL, V30, P35, DOI 10.1385/MN:30:1:035; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Diana M, 2006, ANN NY ACAD SCI, V1074, P446, DOI 10.1196/annals.1369.045; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Gaborik Z, 2001, MOL PHARMACOL, V59, P239; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Kayser MS, 2008, NEURON, V59, P56, DOI 10.1016/j.neuron.2008.05.007; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Liao D, 2007, MOL CELL NEUROSCI, V35, P456, DOI 10.1016/j.mcn.2007.04.007; Liao DZ, 2007, J NEUROPHYSIOL, V97, P1485, DOI 10.1152/jn.00790.2006; Lin H, 2009, NEUROPSYCHOPHARMACOL, V34, P2097, DOI 10.1038/npp.2009.34; Lou LG, 1999, MOL PHARMACOL, V55, P557; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; Mei B, 2009, SYNAPSE, V63, P1154, DOI 10.1002/syn.20694; Pratt KG, 2003, NEURON, V39, P269, DOI 10.1016/S0896-6273(03)00422-7; Pu L, 2002, J NEUROSCI, V22, P1914, DOI 10.1523/JNEUROSCI.22-05-01914.2002; RICALDE AA, 1990, NEUROSCI LETT, V115, P137, DOI 10.1016/0304-3940(90)90444-E; Robinson TE, 2002, SYNAPSE, V46, P271, DOI 10.1002/syn.10146; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Seo S, 2007, EMBO J, V26, P5093, DOI 10.1038/sj.emboj.7601923; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Vaillant AR, 2002, NEURON, V34, P985, DOI 10.1016/S0896-6273(02)00717-1; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wayman GA, 2008, NEURON, V59, P914, DOI 10.1016/j.neuron.2008.08.021; Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	35	42	48	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 16	2010	30	24					8102	8110		10.1523/JNEUROSCI.6069-09.2010			9	Neurosciences	Neurosciences & Neurology	611WT	WOS:000278856300006	20554861	Green Accepted, Bronze, Green Published			2020-06-30	J	Yang, QO; Xie, DR; Jiang, ZM; Ma, W; Zhang, YD; Bi, ZF; Chen, DL				Yang, Qiong; Xie, De-Rong; Jiang, Zhi-Min; Ma, Wen; Zhang, Yuan-Dong; Bi, Zhuo-Fei; Chen, Deng-Lin			Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH			English	Article							QUALITY-OF-LIFE	Background: Previous meta-analysis suggested that transdermal fentanyl was not inferior to sustained-release oral morphine in treating moderate-severe cancer pain with less adverse effects. Now, we updated the data and performed a systematic review. Methods: Updated cohort studies on transdermal fentanyl and oral morphine in the treatment of cancer pain were searched in electronic databases including CBMdisc, CNKI, VIP, Medline, EMBASE and Cochrane Library. Primary end points assessed by meta-analysis were remission rate of pain and incidence of adverse effects. Quality of life was assessed by systematic review, which was the second end point. Results: 32 cohort studies, which included 2651 patients, were included in present study. The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23]. Compared with oral morphine group, there were less adverse effects in terms of constipation [RR = 0.35, 95% CI (0.27, 0.45), P < 0.00001], nausea/vomiting [RR = 0.57, 95% CI (0.49, 0.67), P < 0.00001], and vertigo/somnolence [RR = 0.59, 95% CI (0.51, 0.68), P < 0.00001] in transdermal fentanyl group. Six of selected trials supported either transdermal fentanyl or sustained-release oral morphine improved QOL of cancer patients and one of them showed more patients got better QOL after sustained-release oral morphine transferred to transdermal fentanyl. Conclusions: Our study showed again that both transdermal fentanyl and oral morphine had the same efficacy in the treatment of moderate-severe cancer pain in Chinese population, but the former might have less adverse effects and better quality of life.	[Yang, Qiong; Xie, De-Rong; Jiang, Zhi-Min; Ma, Wen; Zhang, Yuan-Dong; Bi, Zhuo-Fei; Chen, Deng-Lin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou 510120, Guangdong, Peoples R China	Xie, DR (reprint author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, 107 W Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.	xiederong@21cn.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; AN HZ, 2004, SHI YONG ZHEN DUAN Y, V18, P400; BAI Y, 2006, XIAN DAI LIN CHUANG, V32, P34; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; CAO YK, 2005, LIN CHUANG YAN JIU, V3, P50; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; DONG HY, 2006, ZHONGGUO YI SHI ZA Z, V8, P1430; GUO JP, 2003, NANTONG YI XUE YUAN, V23, P200; GUO Y, 2006, YAO WU YU LIN CHUANG, V3, P71; JIANG B, 2002, ZHONGGUO ZHONG LIU L, V9, P116; JIN BW, 2002, CHUANG FEI KE ZA ZHI, V7, P38; JIN XJ, 2002, ZHONGGUO ZHONG LIU L, V29, P825; LAN HT, 2005, XIBU YI XUE, V17, P150; LEI W, 2003, LIN CHUANG ZHONG LIU, V8, P136; Li JB, 2008, JIANGXI YI YAO, V43, P569; LI R, 2002, ZHONGGUO ZONG HE LIN, V18, P471; LI RM, 2005, SHI YONG ZHONG LIU Z, V2, P174; LI ZB, 2003, GUANGDONG YAO XUE YU, V19, P89; LIAN ZP, 2006, XIAN DAI ZHONG LIU Y, V14, P491; LIU XF, 2006, ZHONGHUA XIAN DAI NE, V3, P773; Loosemore M, 2007, BMJ-BRIT MED J, V335, P809, DOI 10.1136/bmj.39342.690220.55; MENG LH, 2004, ZHONGHUA YI YAO ZA Z, V4, P425; PANG DM, 2001, SHI YONG ZHONG LIU X, V15, P311; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Qu YH, 2004, JINZHOU YI XUE YUAN, V25, P80; Ripamonti C, 2001, DRUGS, V61, P955, DOI 10.2165/00003495-200161070-00005; SHEN J, 2004, QILU YI XUE ZA ZHI, V19, P511; Staats PS, 2004, SOUTH MED J, V97, P129, DOI 10.1097/01.SMJ.0000109215.54052.D8; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; TANG CR, 2005, ZHONG LIU FANG ZHI Z, V12, P479; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Tassinari D, 2009, J PALLIAT CARE, V25, P172, DOI 10.1177/082585970902500304; WANG GS, 2004, ZHONGGUO ZHONG LIU, V13, P451; WANG QC, 2006, ZHONGGUO WU ZHEN XUE, V6, P3730; WANG X, 2005, TIANJIN YI KE DA XUE, V11, P586; WU B, 2008, YI XUE LI LUN YU SHI, V21, P667; WU JH, 2004, ZHONGGUO YI XUE LI L, V14, P1132; Yang HY, 2004, CONTROL ENG PRACT, V12, P563, DOI 10.1016/S0967-0661(03)00139-4; YANG Q, 2008, LIN CHUANG ZHONG LIU, V13, P109; YI JQ, 2003, XIAN DAI LIN CHUANG, V9, P332; Yu Shi-ying, 2005, Zhonghua Zhongliu Zazhi, V27, P369; ZHANG JW, 2004, LIN CHUANG HUI CUI, V19, P101; ZHANG SJ, 2004, DONGNAN DA XUE XUE B, V23, P317; ZHOU ZQ, 2006, NANFANG YI KE DA XUE, V26, P1826	44	19	21	1	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1756-9966			J EXP CLIN CANC RES	J. Exp. Clin. Cancer Res.	JUN 9	2010	29								67	10.1186/1756-9966-29-67			6	Oncology	Oncology	628DE	WOS:000280093800001	20529380	DOAJ Gold, Green Published			2020-06-30	J	Farrar, JT; Polomano, RC; Berlin, JA; Strom, BL				Farrar, John T.; Polomano, Rosemary C.; Berlin, Jesse A.; Strom, Brian L.			A Comparison of Change in the 0-10 Numeric Rating Scale to a Pain Relief Scale and Global Medication Performance Scale in a Short-term Clinical Trial of Breakthrough Pain Intensity	ANESTHESIOLOGY			English	Article							POSTOPERATIVE PAIN; SEX-DIFFERENCES; DOUBLE-BLIND; CANCER PAIN; DIABETIC-NEUROPATHY; RANDOMIZED-TRIAL; MORPHINE; OUTCOMES; PATIENT; PATCH	Background: Pain intensity is commonly reported using a 0-10 Numeric Rating Scale in pain clinical trials. Analysis of the change on the Pain Intensity Numerical Rating Scale as a proportion has most consistently correlated with clinically important differences reported on the patient's global impression of change. The correlation of data from patients with breakthrough pain with a Pain Relief Scale and a different global outcomemeasures will extend our understanding of these measures. Methods: Data were obtained from the open titration phase of a multiple crossover, randomized, double-blind clinical trial comparing oral transmucosal fentanyl citrate with immediate-release oral morphine sulfate for the treatment of cancer-related breakthrough pain. Raw and percentage changes in the pain intensity scores from 1,307 episodes of pain in 134 oral transmucosal fentanyl citrate-naive patients were correlated with the clinically relevant secondary outcomes of Pain Relief Verbal Response sponse Scale and the global medication performance scale. The changes in raw and percentage change were assessed over time and compared with the ordinal Pain Relief Verbal Response Scale and Global Medication Performance Scale. Results: The P value of the interaction between the raw pain intensity difference was significant (P = 0.034) for four 15-min time periods but not for the percentage pain intensity difference score (P = 0.26). We found similar results in comparison with the ordinal Pain Relief Verbal Response Scale (P = 0.0048 and P = 0.36 respectively) and global medication performance categories (P = 0.048 and P = 0.45, respectively). Conclusion: The change in pain intensity in breakthrough pain was more consistent over time and when compared with both the Pain Relief Verbal Response Scale and the Global Medication Performance Scale when the percentage change is used rather than raw pain intensity difference.	[Farrar, John T.; Polomano, Rosemary C.; Berlin, Jesse A.; Strom, Brian L.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	Farrar, JT (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol Primary, Blockley Hall,Room 816,423 Guardian Dr, Philadelphia, PA 19104 USA.	jfarrar@mail.med.upenn.edu	Farrar, John/A-1037-2007	Farrar, John/0000-0001-8656-5157	Cephalon Inc., West Chester, Pennsylvania; National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 CA73797]; Pfizer, Inc., New York, New YorkPfizer; Endo Pharmaceuticals, Chadds Ford, Pennsylvania; Pharmacia, Kalamazoo, Michigan; Eli Lilly, Indianapolis, IndianaEli Lilly; Glaxo Smith Kline, Research Triangle Park, North CarolinaGlaxoSmithKline	Received from the Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. Submitted for publication March 18, 2009. Accepted for publication January 8, 2010. Supported in part by grants from Cephalon Inc., West Chester, Pennsylvania, and the National Institutes of Health, Bethesda, Maryland, grant R01 CA73797. The laboratory has also received research funds from Pfizer, Inc., New York, New York; Endo Pharmaceuticals, Chadds Ford, Pennsylvania; Pharmacia, Kalamazoo, Michigan; Eli Lilly, Indianapolis, Indiana; and Glaxo Smith Kline, Research Triangle Park, North Carolina.	Aubrun F, 2005, ANESTHESIOLOGY, V103, P156, DOI 10.1097/00000542-200507000-00023; Beecher HK, 1959, MEASUREMENT SUBJECTI; BERGER VW, 2002, J MODERN APPL STAT M, V1, P74; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; BROMM B, 1984, MAN NEUROPHYSIOLOGIC, P3; Cepeda MS, 2003, PAIN, V105, P151, DOI 10.1016/S0304-3959(03)00176-3; Chapman C R, 1998, Curr Opin Anaesthesiol, V11, P533, DOI 10.1097/00001503-199810000-00015; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Donaldson G, 2008, QUAL LIFE RES, V17, P1303, DOI 10.1007/s11136-008-9408-4; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Edrington JN, 2004, J PAIN SYMPTOM MANAG, V28, P225, DOI 10.1016/j.jpainsymman.2003.12.013; Farrar JT, 2006, J PAIN SYMPTOM MANAG, V31, P369, DOI 10.1016/j.jpainsymman.2005.08.018; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; *FDA, 1999, FDA GUID IND CLIN DE; Fishbain D, 2000, ANN MED, V32, P305, DOI 10.3109/07853890008995932; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; GOLDSMITH CH, 1993, J RHEUMATOL, V20, P561; Hobara M, 2005, EUR J PAIN, V9, P389, DOI 10.1016/j.ejpain.2004.09.006; HOUDE RW, 1982, ACTA ANAESTH SCAND, V26, P25, DOI 10.1111/j.1399-6576.1982.tb01840.x; Jensen MP, 2006, CLIN J PAIN, V22, pS9, DOI 10.1097/01.ajp.0000193829.45571.4f; Jensen MP, 2005, J PAIN, V6, P400, DOI 10.1016/j.jpain.2005.01.360; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005; LASAGNA L, 1960, ANN NY ACAD SCI, V86, P28, DOI 10.1111/j.1749-6632.1960.tb42788.x; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lin PL, 2008, REGION ANESTH PAIN M, V33, P320, DOI 10.1016/j.rapm.2007.02.015; Moore A, 1996, PAIN, V66, P229, DOI 10.1016/0304-3959(96)03032-1; Moore RA, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2394; Rowbotham MC, 2005, J PAIN, V6, P741, DOI 10.1016/j.jpain.2005.07.001; Simpson DM, 2008, NEUROLOGY, V70, P2305, DOI 10.1212/01.wnl.0000314647.35825.9c; Stacey Brett R, 2006, Curr Pain Headache Rep, V10, P179, DOI 10.1007/s11916-006-0043-x; STEGMANN JU, 2008, CURR MED RES OPIN, V10, P10; Sultan A, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-29; Svensson E, 2001, J REHABIL MED, V33, P47, DOI 10.1080/165019701300006542; Tolle T, 2008, EUR J PAIN, V12, P203, DOI 10.1016/j.ejpain.2007.05.003; TURK DC, 1993, PAIN, V53, P3, DOI 10.1016/0304-3959(93)90049-U; Turk DC, 2008, PAIN, V137, P276, DOI 10.1016/j.pain.2007.09.002; Vickers A J, 2001, BMC Med Res Methodol, V1, P6, DOI 10.1186/1471-2288-1-6; Viscusi ER, 2005, ANESTHESIOLOGY, V102, P1014, DOI 10.1097/00000542-200505000-00022; Wijnhoven HAH, 2006, PAIN, V124, P158, DOI 10.1016/j.pain.2006.04.012; Wu CL, 2008, ANESTHESIOLOGY, V109, P289, DOI 10.1097/ALN.0b013e31817f4523	42	49	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUN	2010	112	6					1464	1472		10.1097/ALN.0b013e3181de0e6d			9	Anesthesiology	Anesthesiology	605HT	WOS:000278339200022	20463579	Green Accepted, Bronze			2020-06-30	J	Nejmi, H; Fath, K; Anaflous, R; Sourour, S; Samkaoui, MA				Nejmi, H.; Fath, K.; Anaflous, R.; Sourour, S.; Samkaoui, M. A.			A prospective randomized comparison of nebulized morphine versus thoracic epidural analgesia in the management of thoracic trauma	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						Post-traumatic pain; Nebulized morphine; Epidural analgesia	MULTIPLE RIB FRACTURES; CONTROLLED-TRIAL; ANESTHESIA; PHARMACOKINETICS; FENTANYL; SURGERY; DYSPNEA; OPIOIDS; PAIN	Introduction. - Successful management of pain reduces morbidity and improves patient satisfaction of patient after a chest trauma. The purpose of the study was to evaluate the efficacy of the respiratory administration of nebulized morphine in such patients. Patients and methods. - Patients were included in this prospective and randomized study patients to receive either nebulized morphine in group M or a mixture of bupivacaine-fentanyl by epidural route. In group M, patients received nebulized morphine every 30 minutes until the second hour then every 4 hours during 48 hours. In the thoracic epidural analgesia group (group P) they received a mixture of 0.125% bupivacaine and 0.115% of fentanyl continuously infused at the rate of 7 ml/h during 48 hours. The main criterion of judgment was the analgesic effects of analgesic regimen with EVA < 4. Sedation, haemodynamic and respiratory parameters were continuously recorded, as adverse side effects were they occurred. Statistical comparisons were performed with Chi(2), Fisher or Student t-test when appropriate (p < 0.05). Results. - Forty patients were randomized in two groups. Groups were not different regarding the demographic parameters. Analgesia was effective in both groups (NS). Sedation, hemodynamic and respiratory parameters were not different between groups. No side effect was noted in groups. Conclusion. - Nebulized morphine was an analgesic technique as effective as epidural bupivacaine-fentanyl in our series. This non-invasive route of administration of morphine appears to be useful to treat pain after a chest trauma. (C) 2010 Elsevier Masson SAS. All rights reserved.	[Nejmi, H.; Fath, K.] CHU Mohammed VI, Serv Accueil Urgences, Marrakech 40000, Morocco; [Anaflous, R.; Sourour, S.; Samkaoui, M. A.] CHU Mohammed VI, Serv Anesthesie Reanimat, Marrakech 40000, Morocco	Nejmi, H (reprint author), CHU Mohammed VI, Serv Accueil Urgences, Marrakech 40000, Morocco.	nejmihicham@yahoo.fr					ADNET P, 1995, MED URGENCE, P113; AVARO JP, 2006, REANIMATION, V15, P561; BAILEY PL, 1996, SEMIN ANESTH, V15, P343; Ballas SK, 2004, AM J HEMATOL, V76, P190, DOI 10.1002/ajh.20064; BOLLIGER CT, 1990, CHEST, V97, P943, DOI 10.1378/chest.97.4.943; Chrubasik J, 1987, ANESTH ANALG, V66, pS29; Dershwitz M, 2000, ANESTHESIOLOGY, V93, P619, DOI 10.1097/00000542-200009000-00009; Foral PA, 2004, CHEST, V125, P691, DOI 10.1378/chest.125.2.691; Fulda GJ, 2005, J TRAUMA, V59, P382, DOI 10.1097/01.ta.0000179452.70520.1b; Giebler RM, 1997, ANESTHESIOLOGY, V86, P55, DOI 10.1097/00000542-199701000-00009; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; HOPF HB, 1990, ANESTHESIOLOGY, V73, P882, DOI 10.1097/00000542-199011000-00015; Kindler CH, 1998, ACTA ANAESTH SCAND, V42, P614, DOI 10.1111/j.1399-6576.1998.tb05291.x; KIRNO K, 1994, ANESTH ANALG, V79, P1075; LENFANT F, 2002, MED URGENCE, P29; Magnusdottir H, 1999, ANESTHESIOLOGY, V91, P1299, DOI 10.1097/00000542-199911000-00021; MARTIN C, 1999, SEDATION ANALGESIE R, P121; Mazoit JX, 1998, ANN FR ANESTH, V17, P573, DOI 10.1016/S0750-7658(98)80041-5; Melillo E M, 1996, Monaldi Arch Chest Dis, V51, P405; Moon MR, 1999, ANN SURG, V229, P684, DOI 10.1097/00000658-199905000-00011; MOON MR, 1999, ANN SURG, V229, P691; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Sarhill N, 2000, Am J Hosp Palliat Care, V17, P389, DOI 10.1177/104990910001700609; Sharma S, 2001, J CLIN ONCOL, V19, P1839, DOI 10.1200/JCO.2001.19.6.1839; Tanaka K, 1999, JPN J CLIN ONCOL, V29, P600, DOI 10.1093/jjco/29.12.600; Thipphawong JB, 2003, ANESTHESIOLOGY, V99, P693, DOI 10.1097/00000542-200309000-00026; ULLMAN DA, 1989, REGION ANESTH, V14, P43; Ward ME, 1997, CLIN PHARMACOL THER, V62, P596, DOI 10.1016/S0009-9236(97)90079-5; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3	30	5	5	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0750-7658			ANN FR ANESTH	Ann. Fr. Anest. Reanim.	JUN	2010	29	6					415	418		10.1016/j.annfar.2010.02.026			4	Anesthesiology	Anesthesiology	635ZK	WOS:000280696800001	20537851				2020-06-30	J	Rauck, R; North, J; Gever, LN; Tagarro, I; Finn, AL				Rauck, R.; North, J.; Gever, L. N.; Tagarro, I.; Finn, A. L.			Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study	ANNALS OF ONCOLOGY			English	Article						breakthrough cancer pain; clinical study; fentanyl buccal soluble film	CITRATE; PREVALENCE; MECHANISMS; TRIAL	Background: Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer. The objective of this study was to evaluate the efficacy of FBSF at doses of 200-1200 mu g in the management of breakthrough pain in patients with cancer receiving ongoing opioid therapy. Patients and methods: This was a multicenter, randomized, double-blind, placebo-controlled, multiple-crossover study that included opioid-tolerant adult patients with chronic cancer pain who experienced one to four daily episodes of breakthrough pain. The primary efficacy assessment was the sum of pain intensity differences at 30 min (SPID30) postdose. Results: The intent-to-treat population consisted of 80 patients with 1 post-baseline efficacy assessment. The least-squares mean (LSM +/- SEM) of the SPID30 was significantly greater for FBSF-treated episodes of breakthrough pain than for placebo-treated episodes (47.9 +/- 3.9 versus 38.1 +/- 4.3; P = 0.004). There was statistical separation from placebo starting at 15 min up through 60 min (last time point assessed). There were no unexpected adverse events (AEs) or clinically significant safety findings. Conclusions: FBSF is an effective option for control of breakthrough pain in patients receiving ongoing opioid therapy. In this study, FBSF was well tolerated in the oral cavity, with no reports of treatment-related oral AEs.	[Finn, A. L.] BioDelivery Sci Int Inc, Raleigh, NC 27607 USA; [Rauck, R.; North, J.] Carolinas Pain Inst, Winston Salem, NC USA; [Gever, L. N.] Meda Pharmaceut Inc, Somerset, NJ USA; [Tagarro, I.] Meda Pharmaceut, Madrid, Spain	Finn, AL (reprint author), BioDelivery Sci Int Inc, 801 Corp Ctr Dr,Suite 210, Raleigh, NC 27607 USA.	afinn@bdsinternational.com			BioDelivery Sciences International	BioDelivery Sciences International.	*AN CORP, 2007, ACT FENT CLTR OR TRA; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Benedetti F, 2008, ANNU REV PHARMACOL, V48, P33, DOI 10.1146/annurev.pharmtox.48.113006.094711; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; *CEPH INC, 2007, FENT FENT BUCC TABL; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; DeConno F, 1996, J CLIN ONCOL, V14, P2836, DOI 10.1200/JCO.1996.14.10.2836; Enck P, 2008, NEURON, V59, P195, DOI 10.1016/j.neuron.2008.06.030; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Finniss DG, 2005, PAIN, V114, P3, DOI 10.1016/j.pain.2004.12.012; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; VASISHT N, 2008 ANN GEN M AM SO; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; WELLING PG, 1997, PHARMACOKINETICS PRO; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	18	52	54	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	JUN	2010	21	6					1308	1314		10.1093/annonc/mdp541			7	Oncology	Oncology	603QS	WOS:000278223700029	19940014	Other Gold, Green Published			2020-06-30	J	Ashley, PF; Parry, J; Parekh, S; Al-Chihabi, M; Ryan, D				Ashley, P. F.; Parry, J.; Parekh, S.; Al-Chihabi, M.; Ryan, D.			Sedation for dental treatment of children in the primary care sector (UK)	BRITISH DENTAL JOURNAL			English	Article								Objective To audit the clinical practice of a dental sedation service in the primary care sector and determine which services dentists use to manage unco-operative children. Design Retrospective analysis and prospective audit. Setting Sedation clinic in primary care, 2007, England. Subjects Children attending for dental treatment under sedation. General dental practitioners (GDPs) in the Brighton and West Sussex regions. Interventions Questionnaire. Main outcome measures Clinical service audit, patient satisfaction, referrer satisfaction. Results Four hundred children (age range 5-12 years) had been referred for caries (78%), with the remainder for orthodontic extractions. The most common treatment carried out on primary and permanent teeth was extractions followed by restorations. A combination of intravenous (IV) midazolam/ketamine/fentanyl was used in 40% of cases, and IV midazolam/ketamine was used in 34% of cases. Seventy-four percent of parents responded to the satisfaction questionnaire; of these 97% rated sedation as excellent/good and 80% would choose sedation or recommend sedation for others. Only 45% of questionnaires to referrers were returned. Fifty-six percent of dentists preferred general anaesthesia (GA) and 66% preferred IV sedation. Conclusions Dental treatment for children was provided under IV sedation with most parents satisfied with the procedure. Little difference was seen between referring dentists' perceptions of IV sedation or GA.	[Ashley, P. F.] UCL Eastman Dent Inst, Dept Paediat Dent, London WC1X 8LD, England; [Parry, J.] Haywards Heath Hlth Ctr, W Sussex Primary Care Trust, Haywards Heath RH16 3BB, England; [Al-Chihabi, M.] Ulster Hosp, Belfast BT16 1RH, Down, North Ireland; [Ryan, D.] St Faith Dent Clin, E Grinstead RH19 1PN, W Sussex, England	Ashley, PF (reprint author), UCL Eastman Dent Inst, Dept Paediat Dent, 256 Grays Inn Rd, London WC1X 8LD, England.	p.ashley@eastman.ucl.ac.uk		Ashley, Paul/0000-0003-0312-5311			Chadwick B L, 2006, Br Dent J, V201, P453, DOI 10.1038/sj.bdj.4814074; Department of Health, 2000, CONSC DEC REV US GEN; MASON C, 1995, BRIT DENT J, V179, P136, DOI 10.1038/sj.bdj.4808855; Matharu L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003877.pub3; Milnes Alan R, 2003, J Can Dent Assoc, V69, P298; Strunin L, 2007, ANAESTHESIA, V62, P645, DOI 10.1111/j.1365-2044.2007.05177.x; Wilson KE, 2003, BRIT J ANAESTH, V91, P850, DOI 10.1093/bja/aeg278	7	2	2	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0610	1476-5373		BRIT DENT J	Br. Dent. J.	JUN	2010	208	11							E21	10.1038/sj.bdj.2010.542			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	609CR	WOS:000278633200012	20543774	Bronze			2020-06-30	J	Kushikata, T; Yoshida, H; Kudo, M; Kudo, T; Hirota, K				Kushikata, T.; Yoshida, H.; Kudo, M.; Kudo, T.; Hirota, K.			Changes in plasma orexin A during propofol-fentanyl anaesthesia in patients undergoing eye surgery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia; general; monitoring; depth of anaesthesia; nerves; neurotransmitters; surgery; ophthalmological	GENERAL-ANESTHESIA; BRAIN NORADRENALINE; LOCAL-ANESTHESIA; CATARACT-SURGERY; STRESS-RESPONSE; SLEEP; RAT; RELEASE; NEURONS; SYSTEMS	Central orexinergic and noradrenergic neurones are involved in the control of sleep and wakefulness. In addition, previous reports suggest that both neurones may have an important role to play in general anaesthesia. In the present study, we have determined whether general anaesthesia would affect plasma orexin A (OXA) and norepinephrine concentrations. Twenty-two patients undergoing elective ophthalmic surgery under general anaesthesia with propofol, fentanyl, and vecuronium were studied. Arterial blood was collected before and 1 and 2 h after induction of anaesthesia and at emergence to measure plasma OXA, propofol, norepinephrine, and epinephrine concentrations. During anaesthesia, the propofol infusion rate was changed to maintain the bispectral index between 40 and 50. Plasma OXA and norepinephrine did not change during anaesthesia but significantly increased after emergence compared with pre-anaesthesia [from 19.9 (sd 3.2) to 28.3 (4.3) pM, P < 0.01, and from 1351 (146) to 1798 (251) pM, P < 0.05, respectively]. Plasma epinephrine did not change. There was a significant correlation between plasma OXA and norepinephrine (P < 0.05) and also between plasma propofol and OXA (P < 0.05) and norepinephrine (P < 0.01). We found that plasma OXA and norepinephrine significantly increased during emergence from propofol-fentanyl anaesthesia.	[Kushikata, T.; Yoshida, H.; Kudo, M.; Kudo, T.; Hirota, K.] Hirosaki Univ, Grad Sch Med, Dept Anesthesiol, Hirosaki, Aomori 0368562, Japan	Hirota, K (reprint author), Hirosaki Univ, Grad Sch Med, Dept Anesthesiol, Hirosaki, Aomori 0368562, Japan.	hirotak@cc.hirosaki-u.ac.jp	Hirota, Kazuyoshi/S-3292-2019; Hirota, Kazuyoshi/D-1758-2010	Hirota, Kazuyoshi/0000-0001-6936-0985	Ministry of Education, Science and Culture in JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17390423]	This study was funded by grant-in-aid for scientific research (no. 17390423) from the Ministry of Education, Science and Culture in Japan.	Allada R, 2008, P NATL ACAD SCI USA, V105, P2257, DOI 10.1073/pnas.0711532105; BARKER JP, 1991, ANAESTHESIA, V46, P642, DOI 10.1111/j.1365-2044.1991.tb09712.x; Bourgin P, 2008, LANCET NEUROL, V7, P649, DOI 10.1016/S1474-4422(08)70140-6; Chave S, 1996, BRAIN RES, V706, P293, DOI 10.1016/0006-8993(95)01080-7; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Dong HL, 2009, NEUROPEPTIDES, V43, P179, DOI 10.1016/j.npep.2009.04.006; Gallopin T, 2000, NATURE, V404, P992; He Y, 2007, ANESTH ANALG, V104, P338, DOI 10.1213/01.ane.0000252413.62821.2e; Higuchi S, 2002, NEUROSCI LETT, V318, P61, DOI 10.1016/S0304-3940(01)02476-4; Hirota K, 2001, BRIT J ANAESTH, V87, P811, DOI 10.1093/bja/87.6.811; Hirota K, 2008, NEUROSCI LETT, V432, P162, DOI 10.1016/j.neulet.2007.12.015; Kastin AJ, 1999, J PHARMACOL EXP THER, V289, P219; Kayama Y, 1998, EUR UROL, V33, P12, DOI 10.1159/000052235; Kelz MB, 2008, P NATL ACAD SCI USA, V105, P1309, DOI 10.1073/pnas.0707146105; Kirchgessner AL, 2002, ENDOCR REV, V23, P1, DOI 10.1210/er.23.1.1; Kiyashchenko LI, 2002, J NEUROSCI, V22, P5282; Kushikata T, 2003, NEUROSCIENCE, V121, P855, DOI 10.1016/S0306-4522(03)00554-2; Kushikata T, 2002, ANESTH ANALG, V94, P1201, DOI 10.1097/00000539-200205000-00028; MASON ST, 1983, NEUROSCIENCE, V10, P177, DOI 10.1016/0306-4522(83)90091-X; MASON ST, 1983, PSYCHOPHARMACOLOGY, V81, P73, DOI 10.1007/BF00439277; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Ouedraogo R, 2003, DIABETES, V52, P111, DOI 10.2337/diabetes.52.1.111; Sakurai S, 2005, CHEST, V127, P731, DOI 10.1378/chest.127.3.731; Schwall B, 2000, ACTA ANAESTH SCAND, V44, P343, DOI 10.1034/j.1399-6576.2000.440322.x; Spinazzi R, 2006, PHARMACOL REV, V58, P46, DOI 10.1124/pr.58.1.4; Taheri S, 1999, FEBS LETT, V457, P157, DOI 10.1016/S0014-5793(99)01030-3; Tononi G, 2007, J CLIN INVEST, V117, P3648, DOI 10.1172/JCI34250; Tose R, 2009, ANESTH ANALG, V108, P491, DOI 10.1213/ane.0b013e31819000c8; Winsky-Sommerer R, 2004, J NEUROSCI, V24, P11439, DOI 10.1523/JNEUROSCI.3459-04.2004	29	18	18	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUN	2010	104	6					723	727		10.1093/bja/aeq098			5	Anesthesiology	Anesthesiology	597BQ	WOS:000277731100009	20430767	Bronze, Green Published			2020-06-30	J	Taddio, A; Pulleyblank, R; Stephens, D; McNair, C; Shah, V				Taddio, Anna; Pulleyblank, Ryan; Stephens, Derek; McNair, Carol; Shah, Vibhuti			Canadian Neonatologist Practices Regarding Opioid Use in Ventilated and Spontaneously Breathing Infants Undergoing Medical Procedures	CLINICAL JOURNAL OF PAIN			English	Article						opioid; morphine; fentanyl; infant/newborn; pain management; pharmacotherapy; questionnaire; physician practice patterns	PAIN MANAGEMENT; MORPHINE; GUIDELINES; ANALGESIA; NEWBORN	Objectives: Opioids are indicated for the management of procedural pain in neonates. There are limited data describing factors influencing patterns of use. Patients and Methods: We conducted an online English survey of Canadian neonatologists using Survey Monkey, whereby they answered questions about the frequency and pattern of use of opioids, and specifically, of morphine and fentanyl, for ventilated and spontaneously breathing infants undergoing selected painful medical procedures. Results: Hundred and twenty nine of 225 (57%) eligible neonatologists participated. They reported that opioids were part of their practice for managing procedural pain in 100% of ventilated infants and 93% of spontaneously breathing infants. Frequency of opioid use was associated with infant ventilation status: spontaneously breathing infants were 28% less likely to receive them (P = 0.013). For morphine, the most commonly used dose was 100 mg/kg in ventilated infants and 50 mg/kg in spontaneously breathing infants. For fentanyl, 1 mg/kg was the most frequently used dose in both infant populations. Use of morphine and fentanyl were significantly associated with 2-way interactions (P < 0.0001) between infant ventilation status, gestational age, and opioid dose. Eighty-two percent of respondents cited respiratory depression as a concern for spontaneously breathing infants compared with 31% for ventilated infants (P < 0.0001). Conclusions: Neonatologists frequently report using opioids to manage procedural pain, however, spontaneously breathing infants are less likely to receive them, and their use varies according to infant and procedure characteristics. These data point to the need to further investigate, in a more controlled design, the pharmacologic effects of opioids in this population to better guide clinicians about their optimal use.	[Taddio, Anna] Univ Toronto, Leslie Dan Fac Pharm, Grad Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada; [Taddio, Anna; Pulleyblank, Ryan; McNair, Carol] Child Hlth Evaluat Sci, Toronto, ON, Canada; [Stephens, Derek] Hosp Sick Children, Dept Paediat, Toronto, ON, Canada; [Shah, Vibhuti] Mt Sinai Hosp, Dept Paediat, Toronto, ON, Canada	Taddio, A (reprint author), Univ Toronto, Leslie Dan Fac Pharm, Grad Dept Pharmaceut Sci, 144 Coll St, Toronto, ON M5S 3M2, Canada.	anna.taddio@utoronto.ca	Shah, Vibhuti/P-5853-2015		Canadian Institutes of Health Research (CIHR) (Ottawa, Ontario, Canada)Canadian Institutes of Health Research (CIHR)	This study was funded by a Canadian Institutes of Health Research (CIHR) (Ottawa, Ontario, Canada), New Investigator Award to Dr Taddio. There are no conflicts of interest.	Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Carbajal R, 2008, JAMA-J AM MED ASSOC, V300, P60, DOI 10.1001/jama.300.1.60; Debillon T, 2002, ACTA PAEDIATR, V91, P822, DOI 10.1080/08035250213224; Enders J, 2006, ACTA PAEDIATR, V95, P1087, DOI 10.1080/08035250600577871; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Klosowski S, 2003, ARCH PEDIATRIE, V10, P766, DOI 10.1016/S0929-693X(03)00397-X; Lago P, 2009, ACTA PAEDIATR, V98, P932, DOI 10.1111/j.1651-2227.2009.01291.x; Lemons JA, 2000, PEDIATRICS, V105, P454; McKechnie L, 2008, J PERINATOL, V28, P107, DOI 10.1038/sj.jp.7211822; Paediatrics & Child Health Division The Royal Australasian College of Physicians, 2006, J PAEDIATR CHILD H, V42, pS31; Prestes Ana Claudia Y., 2005, J. Pediatr. (Rio J.), V81, P405, DOI 10.1590/S0021-75572005000600012; Rohrmeister K, 2003, WIEN KLIN WOCHENSCHR, V115, P715, DOI 10.1007/BF03040888; Sarkar S, 2006, J PERINATOL, V26, P286, DOI 10.1038/sj.jp.7211499; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Taddio A, 2006, JAMA-J AM MED ASSOC, V295, P793, DOI 10.1001/jama.295.7.793; Taddio A, 2009, CLIN J PAIN, V25, P418, DOI 10.1097/AJP.0b013e31819b7a3b	18	7	7	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	JUN	2010	26	5					422	428		10.1097/AJP.0b013e3181d36da7			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	601OY	WOS:000278073100010	20473050				2020-06-30	J	Landau, R; Kraft, JC				Landau, Ruth; Kraft, John C.			Pharmacogenetics in obstetric anesthesia	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						analgesia; fentanyl; labor pain; mu-opioid receptor; opioids; pharmacogenetics; polymorphism	MU-OPIOID RECEPTOR; SINGLE-NUCLEOTIDE POLYMORPHISM; BREAST-FED NEONATE; ELECTIVE CESAREAN DELIVERY; PRESSURE PAIN SENSITIVITY; POSTOPERATIVE PAIN; PERIOPERATIVE MEDICINE; GENETIC-VARIABILITY; POSTSURGICAL PAIN; RISK-FACTORS	Purpose of review Genomic research in pain, anesthesia and analgesia generated some hope that pharmacogenetics may guide anesthesiologists to provide effective medicine in a 'tailored' manner. Within the field of obstetric anesthesia, relatively few studies have evaluated the effect of polymorphisms on the perception of labor or postcesarean pain or the response to analgesics for childbirth. Because of the multifactorial nature of labor and delivery pain and particularly challenging clinical context, many consider that 'titration of drugs to the desired effect works just fine'. With recent evidence highlighting an association between severe postdelivery pain and persistent pain, early recognition of an increased susceptibility for acute pain has become particularly relevant. Recent findings Neuraxial labor analgesia is influenced by a common polymorphism of the mu-opioid receptor gene. This polymorphism also affects the analgesic response to systemic opioids for postcesarean pain and other types of surgeries. Finally, the risk for persistent pain after cesarean deliveries may be associated with a certain genetic profile. Summary Although still premature to anticipate clinical implications and a change in practice based on these recent discoveries, genetic variability clearly appears to affect pain perception, response to analgesics and predisposition for the development of chronic pain.	[Landau, Ruth] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Med Ctr, Seattle, WA 98195 USA	Landau, R (reprint author), Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Med Ctr, 1959 NE Pacific St,Suite BB 1415B, Seattle, WA 98195 USA.	rulandau@u.washington.edu			Swiss National Foundation (SNF)Swiss National Science Foundation (SNSF) [3200B0-114129]	R.L. is the recipient of a Swiss National Foundation Research grant (SNF no. 3200B0-114129) that funded in part the OPRM1 genetic research conducted in Switzerland.	Andersen S, 2009, PHARMACOGENOMICS, V10, P669, DOI 10.2217/PGS.09.13; Berlin CM, 2009, CLIN PHARMACOL THER, V85, P20, DOI 10.1038/clpt.2008.209; Ciszkowski C, 2009, NEW ENGL J MED, V361, P827, DOI 10.1056/NEJMc0904266; Crowley JJ, 2003, PSYCHIAT GENET, V13, P169, DOI 10.1097/00041444-200309000-00006; de Leon J, 2006, MOL DIAGN THER, V10, P135, DOI 10.1007/BF03256453; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; Eisenach JC, 2008, PAIN, V140, P87, DOI 10.1016/j.pain.2008.07.011; Eisenach JH, 2009, ANESTHESIOLOGY, V110, P693, DOI 10.1097/ALN.0b013e31819b58f6; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Flockhart DA, 2009, CLIN PHARMACOL THER, V86, P109, DOI 10.1038/clpt.2009.39; Foulkes T, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000086; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gasche Y, 2004, NEW ENGL J MED, V351, P2827, DOI 10.1056/NEJMoa041888; Ginosar Y, 2009, BRIT J ANAESTH, V103, P420, DOI 10.1093/bja/aep192; Glorioso JC, 2009, GENE THER, V16, P453, DOI 10.1038/gt.2009.18; Granot M, 2009, CURR OPIN ANESTHESIO, V22, P425, DOI 10.1097/ACO.0b013e32832a40e1; Huang CJ, 2008, ANAESTHESIA, V63, P1288, DOI 10.1111/j.1365-2044.2008.05760.x; Ikediobi ON, 2009, CLIN PHARMACOL THER, V86, P28, DOI 10.1038/clpt.2009.30; Iravani M, 2009, AM J THER, V16, P313, DOI 10.1097/MJT.0b013e3181aef49d; Jensen KB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006016; Kainu JP, 2010, INT J OBSTET ANESTH, V19, P4, DOI 10.1016/j.ijoa.2009.03.013; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kim H, 2009, PHARMACOGENOMICS, V10, P171, DOI 10.2217/14622416.10.2.171; Kim H, 2009, J PAIN, V10, P663, DOI 10.1016/j.jpain.2009.04.001; Kim JH, 2008, CAN J ANAESTH, V55, P799, DOI 10.1007/BF03034050; Koren G, 2006, LANCET, V368, P704, DOI 10.1016/S0140-6736(06)69255-6; Kosarac B, 2009, CURR OPIN ANESTHESIO, V22, P476, DOI 10.1097/ACO.0b013e32832e34c9; LaCroix-Fralish ML, 2009, ANNU REV PHARMACOL, V49, P97, DOI 10.1146/annurev-pharmtox-061008-103222; Landau R, 2004, ANESTHESIOLOGY, V100, P1030, DOI 10.1097/00000542-200404000-00042; LANDAU R, 2010, BEST PRACT RES CLIN; Landau R, 2010, J VIS EXP, P1671, DOI 10.3791/1671; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Lavand'homme P, 2006, CURR OPIN ANESTHESIO, V19, P244, DOI 10.1097/01.aco.0000192815.22989.61; Lavand'homme P, 2010, INT J OBSTET ANESTH, V19, P1, DOI 10.1016/j.ijoa.2009.09.003; Lavand'homme PM, 2008, ANESTH ANALG, V107, P948, DOI 10.1213/ane.0b013e31817f1595; Lavand'homme PM, 2007, ANESTHESIOLOGY, V106, P1220, DOI 10.1097/01.anes.0000267606.17387.1d; Madadi P, 2009, CLIN PHARMACOL THER, V85, P31, DOI 10.1038/clpt.2008.157; Madadi P, 2008, PHARMACOGENOMICS, V9, P1267, DOI 10.2217/14622416.9.9.1267; Madadi P, 2007, CAN FAM PHYSICIAN, V53, P33; Mogil JS, 2009, PAIN, V146, P231, DOI 10.1016/j.pain.2009.07.023; Nielsen CS, 2009, J PAIN, V10, P231, DOI 10.1016/j.jpain.2008.09.010; Nielsen PR, 2007, ACTA ANAESTH SCAND, V51, P582, DOI 10.1111/j.1399-6576.2007.01271.x; Nikolajsen L, 2004, ACTA ANAESTH SCAND, V48, P111, DOI 10.1111/j.1399-6576.2004.00271.x; Restrepo JG, 2009, CURR DRUG METAB, V10, P236, DOI 10.2174/138920009787846305; Searle R, 2009, BRIT J ANAESTH, V103, P14, DOI 10.1093/bja/aep130; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Sng BL, 2009, ANAESTH INTENS CARE, V37, P748, DOI 10.1177/0310057X0903700513; Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008; Tan EC, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-32; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wang LW, 2008, HUM MOL GENET, V17, pR174, DOI 10.1093/hmg/ddn270; Willmann S, 2009, CLIN PHARMACOL THER, V86, P634, DOI 10.1038/clpt.2009.151; Wolfe D, 2009, PAIN MED, V10, P1325, DOI 10.1111/j.1526-4637.2009.00720.x; WONG C, 2010, INT J OBSTET ANESTH; Woodcock J, 2009, NEW ENGL J MED, V360, P811, DOI 10.1056/NEJMe0810630; Wu WD, 2009, MOL DIAGN THER, V13, P331, DOI 10.2165/11317320-000000000-00000; Yarnitsky D, 2008, PAIN, V138, P22, DOI 10.1016/j.pain.2007.10.033; Zhang YQ, 2009, SEP PURIF TECHNOL, V65, P130, DOI 10.1016/j.seppur.2008.10.049; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	59	11	13	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0952-7907			CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	JUN	2010	23	3					323	329		10.1097/ACO.0b013e328339802c			7	Anesthesiology	Anesthesiology	600RL	WOS:000278004800006	20440109				2020-06-30	J	Reich, M; Lefebvre-Kuntz, D				Reich, M.; Lefebvre-Kuntz, D.			Serotoninergic antidepressants and opiate analgesics: A sometimes-painful association. A case report	ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE			French	Article						Serotonin syndrome; Selective serotonin reuptake inhibitor antidepressants; Opiate analgesics	REUPTAKE INHIBITORS; ESCITALOPRAM; PAROXETINE; TRAMADOL; VENLAFAXINE; CITALOPRAM; MANAGEMENT; EFFICACY	Case-report. - We report a case of serotonin syndrome caused by interaction between nasal fentanyl, oxycodone and escitalopram. Due to chronic painful episodes with paroxistic level of pain, a 66-year-old patient, treated for prostate adenocarcinoma and bone metastases received an association of major opiate analgesics (oxycodone 120 mg/day for 6 months and fentanyl nasal spray four puff of 200 mu g/puff). After the addition, for mood disorders, of a small dose of escitalopram (5 mg/day), he developed severe serotoninergic features including diaphoresis, night sweating, tremor, diarrhea, visual disorders with mydriasis and weight loss of 8.8 lbs (4 kg). Discontinuation of escitalopram resulted in complete resolution of his symptoms within 48 h except for persistent blurred vision. Discussion. - The clinical manifestations of this case meet Sternbach's criteria of serotonin syndrome. Its possible etiologic factors include adverse drug reaction and pharmacodynamic interaction between selective serotonin reuptake inhibitor (SSRI) antidepressant and opioid analgesics. The Naranjo probability scale suggested a probable causality of escitalopram, oxycodone and fentanyl treatment on the serotonin syndrome. Serotonin syndrome occurrence is estimated around 0.04% in the literature with incidence rates between 14 to 16% in voluntary overdose with serotoninergic agents. It is an infrequent syndrome with, most of the time, a mild to moderate clinical expression. Nevertheless, lethal evolution might occur resulting from either monotherapy with serotoninergic agents (eg: SSRI antidepressants) or the combination of several medications that will increase serotoninergic transmission and therefore intra cerebral serotonin levels. Its physiopathology is related to a hyperstimulation of 5-HT1A receptors. Its clinical manifestations involve mental status impairment and cognitive disorders, neuromuscular disorders and neurovegetative impairment. The prescription of SSRI antidepressants among patients depressed, and in pain, exhibiting somatic diseases, and who require regimens of major opiate or related analgesics, is not without risk. Conclusion. - Clinicians and especially psychiatrists should be aware of possible interaction and the risk of serotonin syndrome when a patient receives a combination of different opioid analgesics and serotonin reuptake inhibitor antidepressants. Improved information and collaboration with somatic and pain specialists and the general practitioners could help reduce the occurrence of this syndrome which can have dreadful consequences. Patients must be informed of such complications, which means that patients should be asked for a history of such events and monitored for serotoninergic adverse events, in order to avoid delays in this diagnosis. (C) L'Encephale, Paris, 2009.	[Reich, M.] Ctr Oscar Lambret, Equipe Psychooncol, F-59020 Lille, France; [Lefebvre-Kuntz, D.] Ctr Oscar Lambret, Dept Anesthesiol, F-59020 Lille, France	Reich, M (reprint author), Ctr Oscar Lambret, Equipe Psychooncol, 3 Rue Frederic Combemale,BP 307, F-59020 Lille, France.	m-reich@o-lambret.fr		Reich, Michel/0000-0003-1590-8057			Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Anderson T, 2005, J EUR SOINS PALLIAT, V12, P97; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Carbone JR, 2000, EMERG MED CLIN N AM, V18, P317, DOI 10.1016/S0733-8627(05)70127-9; Colpaert FC, 2006, J PHARMACOL EXP THER, V316, P892, DOI 10.1124/jpet.105.095109; Demirkiran M, 1996, CLIN NEUROPHARMACOL, V19, P157, DOI 10.1097/00002826-199619020-00004; Egberts ACG, 1997, INT CLIN PSYCHOPHARM, V12, P181, DOI 10.1097/00004850-199705000-00010; Ener RA, 2003, PAIN MED, V4, P63, DOI 10.1046/j.1526-4637.2003.03005.x; Fantino B, 2007, INT CLIN PSYCHOPHARM, V22, P107, DOI 10.1097/YIC.0b013e3280128d16; FISCHER P, 1995, J CLIN PSYCHOPHARM, V15, P440, DOI 10.1097/00004714-199512000-00009; Gillman PK, 1997, J CLIN PSYCHOPHARM, V17, P128, DOI 10.1097/00004714-199704000-00017; Gnanadesigan Nallini, 2005, J Am Med Dir Assoc, V6, P265, DOI 10.1016/j.jamda.2005.04.012; Graudins A, 1998, J Emerg Med, V16, P615, DOI 10.1016/S0736-4679(98)00057-2; Hamilton S, 2000, J CLIN PSYCHOPHARM, V20, P103, DOI 10.1097/00004714-200002000-00020; Hernandez JL, 2002, ANN PHARMACOTHER, V36, P641; Houlihan DJ, 2004, ANN PHARMACOTHER, V38, P411, DOI 10.1345/aph.1D344; Huska MT, 2007, CNS SPECTRUMS, V12, P270, DOI 10.1017/S1092852900021027; Isbister GK, 2004, J TOXICOL-CLIN TOXIC, V42, P277, DOI 10.1081/CLT-120037428; Jaunay E, 2001, PRESSE MED, V30, P1695; Karki SD, 2003, ANN PHARMACOTHER, V37, P388, DOI 10.1345/aph.1C228; Karunatilake H, 2006, ANN PHARMACOTHER, V40, P155, DOI 10.1345/aph.1E671; Kennedy SH, 2006, J PSYCHIATR NEUROSCI, V31, P122; Lheureux P, 2002, Rev Med Brux, V23, P422; Llinares-Tello F, 2007, MED CLIN-BARCELONA, V128, P438, DOI 10.1016/S0025-7753(07)72615-5; Mackay FJ, 1999, BRIT J GEN PRACT, V49, P871; Mahlberg R, 2004, AM J PSYCHIAT, V161, P1129, DOI 10.1176/appi.ajp.161.6.1129; Mason BJ, 1997, ANN PHARMACOTHER, V31, P175, DOI 10.1177/106002809703100208; McDaniel WW, 2001, ANN PHARMACOTHER, V35, P870; MILLAN MJ, 1991, J PHARMACOL EXP THER, V256, P983; Murdoch D, 2005, DRUGS, V65, P2379, DOI 10.2165/00003495-200565160-00013; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Pan JJ, 2003, ANN PHARMACOTHER, V37, P209; Radomski JW, 2000, MED HYPOTHESES, V55, P218, DOI 10.1054/mehy.2000.1047; Rao N, 2007, CLIN PHARMACOKINET, V46, P281, DOI 10.2165/00003088-200746040-00002; Rosebraugh CJ, 2001, J CLIN PHARMACOL, V41, P224, DOI 10.1177/00912700122009926; Sastre-Coll A, 2002, N-S ARCH PHARMACOL, V365, P210, DOI 10.1007/s00210-001-0508-8; SATOH K, 2006, J MED, V52, P29; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705	38	6	6	0	8	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0013-7006			ENCEPHALE	Enceph.-Rev. Psychiatr. Clin. Biol. Ther.	JUN	2010	36			2			D119	D123		10.1016/j.encep.2009.03.010			5	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	635AR	WOS:000280628500014	20513454				2020-06-30	J	Kress, HG; Boss, H; Delvin, T; Lahu, G; Lophaven, S; Marx, M; Skorjanec, S; Wagner, T				Kress, Hans G.; Boss, Hildegard; Delvin, Thomas; Lahu, Gezim; Lophaven, Soren; Marx, Michael; Skorjanec, Sophie; Wagner, Thomas			Transdermal fentanyl matrix patches Matrifen (R) and Durogesic (R) DTrans (R) are bioequivalent	EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS			English	Article						Bioequivalence; Fentanyl; Healthy subjects; Pharmacokinetics; Phase I; Pain; Opioid; Safety; Matrifen (R); Durogesic (R); DTrans (R)	AVAILABLE RESERVOIR FORMULATION; CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; CANCER PAIN; DELIVERY-SYSTEM; EFFICACY; SAFETY; ADULTS	Aim: The pharmacokinetic profiles of the two commercially available transdermal fentanyl patches Matrifen (R) (100 mu g/h) and Durogesic (R) DTrans (R) (100 mu g/h), used to manage severe chronic pain, were compared regarding their systemic exposure, rate of absorption, and safety. Methods: Transdermal matrix fentanyl patches [Matrifen (R) or Durogesic (R) DTrans (R) (100 mu g/h)] were applied for 72 h to 30 healthy male subjects in a randomized, four-period (two replicated treatment sequences), crossover study; 28 subjects completed the study. The pharmacokinetic parameters of fentanyl were determined for 144 h after application using plasma samples. Safety of the patches (adverse events) and performance (adhesion, skin irritation, residual fentanyl content in the patch) were evaluated. Results: The plasma concentration-time curves of Matrifen (R) (Test) and Durogesic (R) DTrans (R) (Reference) were similar. The geometric least square means of the Test/Reference ratio (90% confidence intervals [CI]) were within the range of 80-125%, demonstrating bioequivalence of Matrifen (R) and Durogesic (R) DTrans (R): AUC(0-tlast) 92.5 (CI 88.7-96.4), AUC(0-inf) 91.7 (CI 88.0-95.7), and C-max 98.3 (CI 92.9-104.1). After 72 h application. Matrifen had a more efficient utilization of fentanyl (mean +/- SD 82.3 +/- 9.43%) than Durogesic (R) DTrans (R) (52.3 +/- 12.8%), with substantially lower residual fentanyl in patch after use. The pharmacokinetic parameters showed lower intra- and inter-subject variability for Matrifen than for Durogesic (R) DTrans (R) patch. Conclusions: Despite different technologies, the transdermal fentanyl patches Matrifen (R) and Durogesic (R) DTrans (R) are bioequivalent. Compared with Durogesic (R) DTrans (R), the Matrifen (R) patch had lower initial and lower residual fentanyl content, as well as lower intra- and inter-subject variability, allowing reproducible drug delivery and reliable analgesia. (C) 2010 Elsevier B.V. All rights reserved.	[Wagner, Thomas] Nycomed GmbH, Dept Pharmacometr, D-78467 Constance, Germany; [Kress, Hans G.] Med Univ AKH, Dept Special Anaesthesia & Pain Therapy, Vienna, Austria; [Marx, Michael] MEDA Mfg GmbH, ClinPharmCologne, Cologne, Germany; [Delvin, Thomas; Lophaven, Soren] Nycomed Grp, Roskilde, Denmark	Wagner, T (reprint author), Nycomed GmbH, Dept Pharmacometr, Byk Gulden Str 2, D-78467 Constance, Germany.	thomas.wagner@nycomed.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Cormie PJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2154; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; *FDA, 2006, DRAFT GUID LID PATCH; *FDA, 2007, INF HEALTHC PROF FEN; *FDA, 2001, GUID IND STAT APPR E; Hair PI, 2008, DRUGS, V68, P2001, DOI 10.2165/00003495-200868140-00005; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; *JANSS CIL LTD, 2008, DUR DTRANS TRANSD PA; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; *NYC, 2008, MATR TRANSD PATCH SU; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Staats PS, 2004, SOUTH MED J, V97, P129, DOI 10.1097/01.SMJ.0000109215.54052.D8; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Williams A.C., 2003, TRANSDERMAL TOPICAL	22	5	6	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0939-6411	1873-3441		EUR J PHARM BIOPHARM	Eur. J. Pharm. Biopharm.	JUN	2010	75	2					225	231		10.1016/j.ejpb.2010.02.005			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	616OB	WOS:000279217600020	20152899				2020-06-30	J	Foley, E; Mc Dermott, T; Shanahan, E; Phelan, D				Foley, E.; Mc Dermott, T. E. D.; Shanahan, E.; Phelan, D.			Transient isolated lingual nerve neuropraxia associated with general anaesthesia and laryngeal mask use: two case reports and a review of the literature	IRISH JOURNAL OF MEDICAL SCIENCE			English	Article						Lingual nerve neuropraxia; Laryngeal mask airway; General anaesthesia	TRACHEAL INTUBATION; INJURY; AIRWAY; COMPLICATION	Transient, isolated lingual nerve neuropraxia is a rare complication following general anaesthesia. Reports implicate airway manipulation and we describe two new cases associated with laryngeal mask airway (LMA) and review the related English language literature. Unilateral numbness and loss of taste on the anterior tongue were the characteristic symptoms. Collation of literature data (median and range) with that from the new cases showed: patient age was 38 (20-61) years and female to male ratio was 1.2:1. Surgery time was 62.5 (20-150) min and symptom duration was 28 (7-120) days. Lingual neuropraxias reported have been transient and patients can be advised, despite disturbing symptoms, that recovery is anticipated in about 1 month. Lingual neuropraxia reports are becoming more frequent, perhaps associated with increasing LMA use. Research is recommended as modification to LMA cuff volume, pressure and/or position within the oral cavity might ameliorate the entity.	[Foley, E.; Phelan, D.] Mater Hosp, Dept Anaesthesia & Intens Care, Dublin, Ireland; [Mc Dermott, T. E. D.] Natl Childrens Hosp, Adelaide & Meath Hosp, Dept Urol, Dublin, Ireland; [Shanahan, E.] Natl Childrens Hosp, Adelaide & Meath Hosp, Dept Anaesthesia & Intens Care, Dublin, Ireland	Foley, E (reprint author), Mater Hosp, Dept Anaesthesia & Intens Care, Dublin, Ireland.	edfoley@eircom.net					Ahmad NS, 1996, ANAESTHESIA, V51, P707, DOI 10.1111/j.1365-2044.1996.tb07865.x; BRAIN AIJ, 1983, BRIT J ANAESTH, V55, P801, DOI 10.1093/bja/55.8.801; Brimacombe J, 2005, BRIT J ANAESTH, V95, P420, DOI 10.1093/bja/aei187; BRIMACOMBE J, 1993, ANAESTH INTENS CARE, V21, P107, DOI 10.1177/0310057X9302100127; ELLIS H, 1988, ANATOMY ANAESTHETIST; Gaylard D, 1999, ANAESTH INTENS CARE, V27, P668; JONES BC, 1971, BRIT J ANAESTH, V43, P730; Kadry MA, 2001, EUR J ANAESTH, V18, P264, DOI 10.1046/j.0265-0215.2000.00838.x; Laxton CH, 1996, ANAESTHESIA, V51, P869, DOI 10.1111/j.1365-2044.1996.tb12621.x; LOUGHMAN E, 1983, ANAESTH INTENS CARE, V11, P171, DOI 10.1177/0310057X8301100216; Majumder S, 1998, ANAESTHESIA, V53, P184, DOI 10.1046/j.1365-2044.1998.00313.x; TEICHNER RL, 1971, BRIT J ANAESTH, V43, P413, DOI 10.1093/bja/43.4.413; Wang Kuo-Ching, 2006, Acta Anaesthesiol Taiwan, V44, P119	13	8	8	0	6	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0021-1265			IRISH J MED SCI	Irish J. Med. Sci.	JUN	2010	179	2					297	300		10.1007/s11845-009-0347-z			4	Medicine, General & Internal	General & Internal Medicine	608JN	WOS:000278580000026	19437092				2020-06-30	J	Coskun, D; Celebi, H; Karaca, G; Karabiyik, L				Coskun, Demet; Celebi, Hulya; Karaca, Gozde; Karabiyik, Lale			Remifentanil versus fentanyl compared in a target-controlled infusion of propofol anesthesia: quality of anesthesia and recovery profile	JOURNAL OF ANESTHESIA			English	Article						Target-controlled infusion; Propofol; Remifentanil; Fentanyl; Bispectral index	ALFENTANIL; EMERGENCE; INDEX; MULTICENTER; CRANIOTOMY	The aim of the present study was to compare the clinical properties of fentanyl versus remifentanil in a target-controlled infusion (TCI) of propofol anesthesia regimen with bispectral index (BIS) monitoring. Forty consenting patients scheduled for elective septorhinoplasty were prospectively studied as one of two groups: fentanyl (group F) or remifentanil (group R). After loading boluses of fentanyl 3 mu g kg(-1) or remifentanil 1 mu g kg(-1) were administered, the continuous infusion of fentanyl or remifentanil was started at a rate of 0.03 or 0.15 mu g kg(-1) min(-1), respectively. Propofol infusion was then commenced with a 3 mu g ml(-1) effect site concentration (Ce) by means of a TCI device. The Ce propofol was adjusted to keep BIS at 50 +/- A 10. The general mean value of propofol Ce for group F and group R was 4.0 and 3.5 mu g ml(-1), respectively. As to the recovery profile, the eye opening time (mean, 6.7 vs. 4.6 min), extubation time (mean, 7.3 vs. 4.7 min), and orientation time (mean, 7.6 vs. 4.9 min) were found to be significantly longer in group F than in group R. We concluded that in propofol-based TCI anesthesia under BIS supervision for septorhinoplasty operations, remifentanil was better than fentanyl, especially with respect to emergence from total intravenous anesthesia (TIVA). Furthermore, the durations of anesthesia and operation were rather short, which indicates that fentanyl can be safely used.	[Coskun, Demet; Celebi, Hulya; Karaca, Gozde; Karabiyik, Lale] Gazi Univ, Dept Anesthesiol & Reanimat, Fac Med, TR-06500 Ankara, Turkey	Coskun, D (reprint author), Gazi Univ, Dept Anesthesiol & Reanimat, Fac Med, TR-06500 Ankara, Turkey.	dcoskun@gazi.edu.tr		Coskun, Demet/0000-0002-5773-0624			Beers RA, 2000, ANESTH ANALG, V91, P1420, DOI 10.1097/00000539-200012000-00022; Davis PJ, 2000, ANESTH ANALG, V90, P863, DOI 10.1213/00000539-200004000-00017; Fukuda K., 2005, MILLERS ANESTHESIA, P380; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; GAUDIO AD, 2006, MINERVA ANESTESIOL, V72, P309; Guarracino F, 2005, Minerva Anestesiol, V71, P335; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Hall AP, 2000, BRIT J ANAESTH, V84, P100; Howie MB, 2001, ANESTH ANALG, V92, P1084; Inoue Yoshitaka, 2005, J Anesth, V19, P12, DOI 10.1007/s00540-004-0278-9; Joshi GP, 2002, J CLIN ANESTH, V14, P494, DOI 10.1016/S0952-8180(02)00404-X; Koitabashi T, 2002, ANESTH ANALG, V94, P1530, DOI 10.1097/00000539-200206000-00028; Kovac AL, 1997, J CLIN ANESTH, V9, P532, DOI 10.1016/S0952-8180(97)00140-2; Mackey JJ, 2000, J CLIN ANESTH, V12, P427, DOI 10.1016/S0952-8180(00)00185-9; Magni G, 2005, J NEUROSURG ANESTH, V17, P134, DOI 10.1097/01.ana.0000167447.33969.16; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Sneyd JR, 2003, BRIT J ANAESTH, V91, P771, DOI 10.1093/bja/aeg268; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; Struys M, 1998, ANAESTHESIA, V53, P4, DOI 10.1046/j.1365-2044.1998.00279.x; Suttner S, 1999, ANESTH ANALG, V88, P77, DOI 10.1097/00000539-199901000-00015; Twersky RS, 2001, J CLIN ANESTH, V13, P407, DOI 10.1016/S0952-8180(01)00292-6; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; Wuesten R, 2001, ANESTHESIOLOGY, V94, P211, DOI 10.1097/00000542-200102000-00008; YUILL G, 2002, [No title captured], V2, P24, DOI DOI 10.1093/BJACEPD/2.1.24	26	15	17	1	4	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2010	24	3					373	379		10.1007/s00540-010-0898-1			7	Anesthesiology	Anesthesiology	609UZ	WOS:000278684300005	20229001				2020-06-30	J	Nishiyama, T; Komatsu, K				Nishiyama, Tomoki; Komatsu, Kyoko			Cerebral state index versus bispectral index during propofol-fentanyl-nitrous oxide anesthesia	JOURNAL OF ANESTHESIA			English	Article						Anesthetic depth indexes; Bispectral index; Electroencephalogram; Fentanyl; Propofol	CRITICALLY-ILL PATIENTS; CONSCIOUSNESS; INDUCTION; OBSERVER; SEDATION; MONITOR	The aim of this study was to compare the cerebral state index (CSI) and bispectral index (BIS) during propofol-fentanyl-nitrous oxide anesthesia. Thirty patients scheduled for abdominal surgery, with a mean age of 30-70 years, were enrolled. Anesthesia was induced with propofol and fentanyl and was maintained with propofol, fentanyl, epidural mepivacaine, and nitrous oxide in oxygen. During surgery, the propofol infusion rate was adjusted to try to keep BIS at 40 +/- A 3 for 10 min and then decreased to keep the BIS at 60 +/- A 3 for 10 min. The BIS had a larger value for the time between switching on the apparatus and starting to measure at a signal quality index > 75%. The recovery time from disturbance by an electric cautery event was 41 +/- A 14 s for the BIS and 3 +/- A 1 s for the CSI (P < 0.05). The absolute values of the BIS and CSI were not significantly different and they showed a good correlation. The bias (mean of the differences, BIS - CSI) was negative at all measurement points, but the limits of agreement and percentage error were small. The absolute values of the BIS and CSI were not significantly different during propofol-fentanyl-nitrous oxide anesthesia. The start of the measurement was faster with the CSI than with the BIS after switch-on, and measurement was less disturbed by electric cautery with the CSI.	[Nishiyama, Tomoki] Kamagaya Gen Hosp, Dept Anesthesiol & Crit Care, Chiba 2730121, Japan; [Komatsu, Kyoko] Univ Tokyo, Dept Crit Care Med, Bunkyo Ku, Tokyo 1138655, Japan	Nishiyama, T (reprint author), 4-7-3-2015 Minamisenju,Arakawa Ku, Tokyo 1160003, Japan.	nishit-tky@umin.ac.jp					Anderson RE, 2006, EUR J ANAESTH, V23, P208, DOI 10.1017/S0265021505002206; Anderson RE, 2005, ACTA ANAESTH SCAND, V49, P750, DOI 10.1111/j.1399-6576.2005.00737.x; Barr G, 2000, ACTA ANAESTH SCAND, V44, P807, DOI 10.1034/j.1399-6576.2000.440707.x; Cortinez LI, 2007, ANESTH ANALG, V104, P605, DOI 10.1213/01.ane.0000255152.96354.17; Disma N, 2007, PEDIATR ANESTH, V17, P445, DOI 10.1111/j.1460-9592.2006.02146.x; DUTTON RC, 1995, J CLIN MONITOR, V11, P35, DOI 10.1007/BF01627418; Gajraj RJ, 1998, BRIT J ANAESTH, V80, P46; Hernandez-Gancedo C, 2006, EUR J ANAESTH, V23, P649, DOI 10.1017/S0265021506000056; Hoymork SC, 2007, ACTA ANAESTH SCAND, V51, P210, DOI 10.1111/j.1399-6576.2006.01213.x; Iselin-Chaves Irene A., 1998, Anesthesia and Analgesia, V87, P949, DOI 10.1097/00000539-199810000-00038; JANG JSR, 1993, IEEE T SYST MAN CYB, V23, P665, DOI 10.1109/21.256541; Jensen EW, 2006, ANESTHESIOLOGY, V105, P28, DOI 10.1097/00000542-200607000-00009; JENSEN EW, 1998, P EUFIT AACH, P1809; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Nishiyama T, 2009, EUR J ANAESTH, V26, P638, DOI 10.1097/EJA.0b013e328324e946; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P671, DOI 10.1097/00000542-199809000-00017; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Zhong T, 2005, BRIT J ANAESTH, V95, P798, DOI 10.1093/bja/aei253	19	5	6	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2010	24	3					380	385		10.1007/s00540-010-0906-5			6	Anesthesiology	Anesthesiology	609UZ	WOS:000278684300006	20339885				2020-06-30	J	Karamchandani, K; Rewari, V; Trikha, A; Batra, RK				Karamchandani, Kunal; Rewari, Vimi; Trikha, Anjan; Batra, Ravinder Kumar			Bispectral index correlates well with Richmond agitation sedation scale in mechanically ventilated critically ill patients	JOURNAL OF ANESTHESIA			English	Article						Sedation; Intensive care unit; Monitoring; Bispectral index; Richmond agitation sedation scale	INTENSIVE-CARE-UNIT; MONITORING SEDATION; ICU PATIENTS; ANALGESIA; RELIABILITY; ANESTHESIA; VALIDITY	The clinical sedation scores available for assessing sedation in the intensive care unit (ICU) have drawbacks and limit their usefulness in paralyzed and deeply sedated patients. An objective tool, the bispectral index (BIS), could prove beneficial in such circumstances. We evaluated the ability of BIS to assess the level of sedation and its correlation with the Richmond agitation sedation scale (RASS) in ICU. Twenty-four, mechanically ventilated, critically ill patients of either sex, 15-65 years of age, were studied over a period of 24 h. They received a standard sedation regimen consisting of a bolus dose of propofol 0.5 mg/kg and fentanyl 1 mu g/kg followed by infusions of propofol and fentanyl ranging from 1.5 to 5 mg/kg/h and 0.5 to 2.0 mu g/kg/h, respectively. Hemodynamic parameters, temperature, end-tidal carbon dioxide, BIS and RASS values were recorded. The correlation of BIS and RASS was expressed as Kendall correlation coefficients (tau). A p value of < 0.05 was considered statistically significant. A total of 414 readings was obtained. On comparing BIS values for all patients with the corresponding RASS values, there was a statistically highly significant correlation between the two. (tau = 0.56, p < 0.0001). For adequate sedation as judged by a RASS value of 0 to -3, the median BIS value was found to be 56 (range 42-89). A BIS value of 70 had a high sensitivity (85%) and specificity (80%) to differentiate adequate from inadequate sedation. Our results illustrate that BIS correlates well with RASS when assessing the level of sedation in mechanically ventilated critically ill patients. BIS reliably differentiates inadequate from adequate sedation.	[Rewari, Vimi; Trikha, Anjan; Batra, Ravinder Kumar] All India Inst Med Sci, Dept Anaesthesiol & Intens Care, New Delhi 110029, India; [Karamchandani, Kunal] Cleveland Clin Fdn, Inst Anesthesiol, Cleveland, OH 44195 USA	Rewari, V (reprint author), K-25 Jangpura Extn, New Delhi 110014, India.	vimirewari@gmail.com					Berkenbosch JW, 2002, ANESTH ANALG, V94, P506, DOI 10.1097/00000539-200203000-00006; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Dahaba AA, 2004, ANESTH ANALG, V99, P781, DOI 10.1213/01.ANE.0000132997.19872.BC; De Jonghe B, 2000, INTENS CARE MED, V26, P275, DOI 10.1007/s001340051150; Deogaonkar A, 2004, CRIT CARE MED, V32, P2403, DOI 10.1097/01.CCM.0000147442.14921.A5; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Liu SS, 2004, ANESTHESIOLOGY, V101, P311, DOI 10.1097/00000542-200408000-00010; Lu CH, 2008, ANESTH ANALG, V107, P1290, DOI 10.1213/ane.0b013e31818061ae; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Olson DM, 2007, AACN ADV CRIT CARE, V18, P380, DOI 10.1097/01.AACN.0000298630.53276.be; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; RAMSAY MAE, 2005, SEMIN ANESTH PERIO M, V24, P195, DOI DOI 10.1053/j.sane.2005.10.002; Riess ML, 2002, EUR J ANAESTH, V19, P18, DOI 10.1017/S0265021502000030; RIKER RR, 1994, CRIT CARE MED, V22, P433, DOI 10.1097/00003246-199403000-00013; Riker RR, 2001, INTENS CARE MED, V27, P853, DOI 10.1007/s001340100912; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sessler CN, 2001, SEMIN RESP CRIT CARE, V22, P211, DOI 10.1055/s-2001-13834; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6148; Tonner PH, 2005, CRIT CARE MED, V33, P580, DOI 10.1097/01.ccm.0000156291.04287.7F; Turkmen A, 2006, EUR J ANAESTH, V23, P300, DOI 10.1017/S0265021506000081; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006	22	30	36	1	8	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2010	24	3					394	398		10.1007/s00540-010-0915-4			5	Anesthesiology	Anesthesiology	609UZ	WOS:000278684300008	20225074				2020-06-30	J	Sakura, S; Hara, K; Ota, J; Tadenuma, S				Sakura, Shinichi; Hara, Kaoru; Ota, Junichi; Tadenuma, Saki			Ultrasound-guided peripheral nerve blocks for anterior cruciate ligament reconstruction: effect of obturator nerve block during and after surgery	JOURNAL OF ANESTHESIA			English	Article						Nerve block; Obturator nerve; Knee surgery; Ultrasonography	TOTAL KNEE REPLACEMENT; PSOAS COMPARTMENT BLOCK; POSTOPERATIVE ANALGESIA; REGIONAL ANESTHESIA; LUMBAR PLEXUS; POSTERIOR APPROACH	Three studies were conducted to determine whether and how the obturator nerve bears relevance to intra- and postoperative pain in patients undergoing anterior cruciate ligament (ACL) reconstruction using a hamstring autograft. Patients undergoing arthroscopic ACL reconstruction using a hamstring autograft were enrolled in three studies. In the first study, we studied the analgesic effect of combined posterior lumbar plexus (PLP) and sciatic nerve blocks as well as combined femoral, lateral femoral cutaneous, and sciatic nerve blocks during and for 24 h after surgery. The second study was conducted to compare the analgesic effect of the combination of femoral, lateral femoral cutaneous, and sciatic nerve blocks with and without an obturator nerve block. Finally, we compared a postoperative continuous femoral nerve block and PLP block both during and for 48 h after surgery. In the first study, patients receiving the PLP block required significantly less fentanyl intraoperatively than those given the femoral nerve block. In the second, significantly less fentanyl was required during surgery for patients with the obturator nerve block than for those without. Finally, the continuous postoperative PLP block showed higher visual analog pain scores than those with the continuous femoral nerve block during movement at 48 h. The present results suggest the involvement of the obturator nerve in ACL reconstruction using a hamstring autograft. However, although obturator nerve blockade is crucial for intraoperative analgesia, a continuous obturator nerve block is not necessary beyond 24 h postoperatively.	[Sakura, Shinichi] Shimane Univ, Sch Med, Univ Hosp, Surg Ctr, Izumo, Shimane 6938501, Japan; [Hara, Kaoru; Ota, Junichi; Tadenuma, Saki] Shimane Univ, Sch Med, Dept Anesthesiol, Izumo, Shimane 6938501, Japan	Sakura, S (reprint author), Shimane Univ, Sch Med, Univ Hosp, Surg Ctr, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	ssakura@med.shimane-u.ac.jp			departmental and institutional sources; SonoSite Japan. KK (Tokyo, Japan)	Funding and study equipment support were provided by departmental and institutional sources and SonoSite Japan. KK (Tokyo, Japan).	Capdevila X, 2002, ANESTH ANALG, V94, P1606, DOI 10.1097/00000539-200206000-00045; Doi K, 2010, ANAESTH INTENS CARE, V38, P213; Gray AT, 2006, ANESTHESIOLOGY, V104, P368, DOI 10.1097/00000542-200602000-00024; Gray AT, 2004, TECH REG ANESTH PAIN, V8, P155; HARA K, 2008, EUR J ANAESTH, V25; Kaloul I, 2004, CAN J ANAESTH, V51, P45, DOI 10.1007/BF03018546; Macalou D, 2004, ANESTH ANALG, V99, P251, DOI 10.1213/01.ANE.0000121350.09915.84; Marhofer P, 2005, BRIT J ANAESTH, V94, P7, DOI 10.1093/bja/aei002; Marhofer P, 2008, ULTRASOUND GUIDANCE; Marhofer P, 2007, ANESTH ANALG, V104, P1265, DOI 10.1213/01.ane.0000260614.32794.7b; McNamee DA, 2002, ACTA ANAESTH SCAND, V46, P95, DOI 10.1034/j.1399-6576.2002.460117.x; Ota J, 2009, ANESTH ANALG, V108, P660, DOI 10.1213/ane.0b013e31818fc252; Ozalp G, 2007, J ANESTH, V21, P409, DOI 10.1007/s00540-007-0515-0; ROBARDS C, 2007, TXB REGIONAL ANESTHE, P481; SAKURA S, 2009, ULTRASOUND GUIDED RE, P81; Sinha SK, 2009, REGION ANESTH PAIN M, V34, P261, DOI 10.1097/AAP.0b013e3181a32c4d; Sites BD, 2007, REGION ANESTH PAIN M, V32, P412, DOI 10.1016/j.rapm.2007.05.005	17	25	28	0	5	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	JUN	2010	24	3					411	417		10.1007/s00540-010-0916-3			7	Anesthesiology	Anesthesiology	609UZ	WOS:000278684300011	20225073				2020-06-30	J	Gan, TJ; Berry, BD; Ekman, EF; Muckerman, RC; Shore, N; Hardi, R				Gan, Tong J.; Berry, Bradley D.; Ekman, Evan F.; Muckerman, Richard C., II; Shore, Neal; Hardi, Robert			Safety evaluation of fospropofol for sedation during minor surgical procedures	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Fospropofol; Minor surgery; Moderate sedation; Patient safety	WATER-SOLUBLE PRODRUG; SEE VOL. 112; MODERATE SEDATION; DOUBLE-BLIND; NON-ANESTHESIOLOGISTS; BOLUS INJECTION; PG. 1058; COLONOSCOPY; MIDAZOLAM; PROPOFOL	Study Objective: To evaluate the safety of intravenous (IV) fospropofol when used to provide minimal to moderate sedation in patients undergoing minor surgical procedures. Design: Phase 3, open-label, single-arm study. Setting: Multi-center. Patients: 123 ASA physical status I, II, III, and IV patients, aged >= 18 years. Interventions: Patients were pretreated with fentanyl 50 mu g before receiving an initial dose of IV fospropofol 6.5 mg/kg. Patients could receive up to 5 supplemental doses of fospropofol 1.63 mg/kg to reach a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score <= 4 to allow the start of the procedure and to maintain adequate sedation levels during the procedure. Measurements: Study endpoints included measures of sedation depth, requirement for supplemental sedative doses, use of alternative sedatives, and the frequency and nature of treatment-emergent and sedative-related adverse events. Main Results: A mean of 2.4 supplemental doses of fospropofol was administered, and in 60% of patients, two or fewer supplemental doses of fospropofol were sufficient to initiate and complete the procedure. Alternative sedative medication was administered in 6 of 123 patients (4.9%). Mean (SD) MOAA/S score during the procedure was 3.8 (0.5). Sixty-one percent (61%) of patients had a MOAA/S score of 5 (fully alert) within two minutes after the end of the procedure. Few patients (7 of 123; 5.7%) had MOAA/S scores of 0 to 1 (deep sedation) during the procedure, and all 7 were either ASA physical status I (n = 1) or (n = 6). The most common treatment-related adverse events (TRAEs) were self-limited: paresthesias (62.6%) and pruritus (27.6%). Five patients experienced sedation-related adverse events, including hypotension (n = 4), bradycardia (concurrently with hypotension and managed with atropine; n = 1), or hypoxemia (less than one min and managed with chin lift and verbal stimulation; n = 1). Twenty patients with previous or existing hepatic disease (ranging from minimal to severe) and 5 patients with severe renal impairment had adverse events similar to the overall population. No deaths were reported, and no patient discontinued the study due to adverse events. Conclusion: An initial dose of IV fospropofol 6.5 mg/kg with supplemental doses was safe and well-tolerated as moderate sedation for use in minor surgical procedures. (C) 2010 Elsevier Inc. All rights reserved.	[Gan, Tong J.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Berry, Bradley D.] Int Heart Inst Montana, Missoula, MT 59802 USA; [Ekman, Evan F.] So Orthoped Sports Med, Columbia, SC 29204 USA; [Muckerman, Richard C., II] St Louis Womens Healthcare Grp, Chesterfield, MO 63017 USA; [Shore, Neal] Carolina Urol Res Ctr, Myrtle Beach, SC 29572 USA; [Hardi, Robert] Metropolitan Gastroenterol Grp, Chevy Chase, MD 20815 USA	Gan, TJ (reprint author), Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA.	gan00001@mc.duke.edu			MGI Pharma, Inc., Bloomington, MN, USA	Supported by MGI Pharma, Inc., Bloomington, MN, USA.	Cohen LB, 2008, ALIMENT PHARM THERAP, V27, P597, DOI 10.1111/j.1365-2036.2008.03598.x; Cohen LB, 2007, GASTROINTEST ENDOSC, V65, pAB367, DOI 10.1016/j.gie.2007.03.956; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Floyd MD, 2003, PHARMACOGENETICS, V13, P595, DOI 10.1097/00008571-200310000-00003; Gibiansky E, 2005, ANESTHESIOLOGY, V103, P718, DOI 10.1097/00000542-200510000-00010; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; KRONBACH T, 1989, MOL PHARMACOL, V36, P89; Levitzky Benjamin E, 2008, Ther Clin Risk Manag, V4, P733; PRATILA MG, 1993, J CLIN ANESTH, V5, P268, DOI 10.1016/0952-8180(93)90117-W; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; Rex DK, 2007, GASTROINTEST ENDOSC, V65, pAB369, DOI 10.1016/j.gie.2007.03.967; SHAH A, 2007, ANESTHESIOLOGY, V107, pA46; Silvestri GA, 2009, CHEST, V135, P41, DOI 10.1378/chest.08-0623; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Struys MMRF, 2005, ANESTHESIOLOGY, V103, P730, DOI 10.1097/00000542-200510000-00011; Vicari Joseph J, 2002, Gastrointest Endosc Clin N Am, V12, P297, DOI 10.1016/S1052-5157(01)00011-3	17	17	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	JUN	2010	22	4					260	267		10.1016/j.jclinane.2009.08.007			8	Anesthesiology	Anesthesiology	610DF	WOS:000278710100007	20522356				2020-06-30	J	Van Nimmen, NFJ; Poels, KLC; Menten, JJ; Godderis, L; Veulemans, HAF				Van Nimmen, Nadine F. J.; Poels, Katrien L. C.; Menten, Joannes J.; Godderis, Lode; Veulemans, Hendrik A. F.			Fentanyl Transdermal Absorption Linked to Pharmacokinetic Characteristics in Patients Undergoing Palliative Care	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Absorption; skin; fentanyl; monitoring; pharmacokinetics	CANCER PAIN PATIENTS; PHARMACOLOGICAL-PROPERTIES; CLINICAL PHARMACOKINETICS; THERAPEUTIC-EFFICACY; ALFENTANIL; SUFENTANIL; METABOLISM; PATCHES; OPIOIDS; URINE	Delivery rates and plasma concentrations vary among patients treated with fentanyl patches. Absorption and urinary excretion characteristics of fentanyl were studied in patients undergoing palliative care. Almost 500 patches were analyzed for residual fentanyl content. Fentanyl and norfentanyl levels were determined in the urine of 50 patients. General and mixed effects linear regression models were established for the relationship between fentanyl dose rate and urinary excretion and to incorporate influencing factors. For different patch nominal dose strengths, wide but comparable variability in estimated dose rate and delivery efficiency was observed (coefficients of variation of 15% to 17%). Fentanyl delivery efficiency was 8.5% higher for patches of 25 mu g/h as compared to 75 mu g/h and, accordingly, 7.5% for patch application on the arm as compared to the leg. Urinary fentanyl and norfentanyl concentrations varied considerably. The general linear model revealed a positive effect of the calculated transdermal dose rate on urinary fentanyl levels, explaining 34% of the variability ( P < .0001). In addition, gender ( P = .04) and type of cancer pathology ( P = .03) exerted significant effects on the linear model, explaining 40% and 64% of the variability, respectively. Delivery efficiency of fentanyl patches can vary substantially, possibly leading to either underdosing or overdosing.	[Van Nimmen, Nadine F. J.; Poels, Katrien L. C.; Godderis, Lode; Veulemans, Hendrik A. F.] Katholieke Univ Leuven, Dept Occupat Environm & Insurance Med, Lab Occupat Hyg & Toxicol, B-3000 Louvain, Belgium; [Menten, Joannes J.] Univ Hosp UZ Gasthuisberg, Dept Expt Radiotherapy, Leuven, Belgium; [Godderis, Lode] IDEWE, External Serv Protect & Prevent Work, Heverlee, Belgium	Godderis, L (reprint author), Katholieke Univ Leuven, Dept Occupat Environm & Insurance Med, Lab Occupat Hyg & Toxicol, Kapucijnenvoer 35-5, B-3000 Louvain, Belgium.	lode.godderis@med.kuleuven.be	Godderis, Lode/AAE-5880-2019	Godderis, Lode/0000-0003-4764-8835			ACGIH (American Conference of Governmental Industrial Hygienists), 2008, TLVS BEIS THRESH LIM; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; HABERER JP, 1982, BRIT J ANAESTH, V54, P1267, DOI 10.1093/bja/54.12.1267; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Karst M, 2001, PAIN MED, V2, P225, DOI 10.1046/j.1526-4637.2001.01028.x; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Meibohm B, 2002, CLIN PHARMACOKINET, V41, P329, DOI 10.2165/00003088-200241050-00002; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Rademaker M, 2001, Am J Clin Dermatol, V2, P349, DOI 10.2165/00128071-200102060-00001; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Schwartz JB, 2003, CLIN PHARMACOKINET, V42, P107, DOI 10.2165/00003088-200342020-00001; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; SOMEYA T, 1992, J CLIN PSYCHOPHARM, V12, P169; SOUTHWELL D, 1984, INT J PHARM, V18, P299, DOI 10.1016/0378-5173(84)90145-5; Tegeder I, 1999, CLIN PHARMACOKINET, V37, P17, DOI 10.2165/00003088-199937010-00002; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044	23	14	13	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2010	50	6					667	678		10.1177/0091270009347872			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	596SG	WOS:000277705100006	20097932				2020-06-30	J	Cushing, A; McClean, M				Cushing, Andrew; McClean, Modesto			USE OF THIAFENTANIL-MEDETOMIDINE FOR THE INDUCTION OF ANESTHESIA IN EMUS (DROMAIUS NOVAEHOLLANDIAE) WITHIN A WILD ANIMAL PARK	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Review						anesthesia; Dromaius novaehollandiae; emu; medetomidine; midazolam; thiafentanil	OSTRICHES STRUTHIO-CAMELUS; CHEMICAL IMMOBILIZATION; TILETAMINE-ZOLAZEPAM; EXERTIONAL MYOPATHY; DOMESTIC PIGEONS; KETAMINE; COMBINATION; XYLAZINE; RATITES; A3080	Fifteen adult emu (Dromaius novaehollandiae) anesthetic events were successfully undertaken with the use of thiafentanil oxalate (A3080) 0.175 mg/kg i.m. (SD 0.026) and medetomidine 0.092 mg/kg i.m. (SD 0.009) via remote injection. Following induction, the birds were transported to the clinic, where a venous blood gas sample was taken for analysis, which indicated a respiratory acidosis, with a mean arterial pCO(2) of 54.46 mmHg (SD 9.31) and venous pH of 7.135 (SD 0.11), most likely due to moderate bradypnoea. Atipamezole 0.2 mg/kg i.v. (SD 0.02) was administered, immediately followed by orotracheal intubation initiating 2-3% isoflurane with 2 L/min oxygen flow. Parameters evaluated during anesthesia included heart rate, respiratory rate, anesthetic depth, and electrocardiogram readings. Physical exams plus any required procedures were performed in addition to venous blood samples for biochemistry and full blood counts. The birds were then recovered in a crate padded with grass hay with administration of 8.75 mg/kg (SD 1.36) naltrexone (50 mg/mg A3080) administered in equal doses i.v. and i.m. along with 5 mg midazolam i.m. to reduce excitement. Emus were placed in a lateral position and given 4 L/min oxygen via the endotracheal tube, until movement of the head and neck necessitated extubation. Recovery was rapid and smooth in each case with a mean time of 3.1 min from antagonist administration to sternal recovery. On the basis of rapid, smooth, and successful inductions and recoveries, the described dosage of thiafentanil and medetomidine, with administration of midazolam prior to recovery, is recommended for immobilization of adult emus. Due to evidence of respiratory acidosis and bradypnoea, careful monitoring should be instituted throughout and oxygen provision recommended from initial contact.		Cushing, A (reprint author), Birch Hlth Exot Referral Clin, Birch Hlth Rd, Tarporley CW6 9UU, Cheshire, England.	a.c.cushing@hotmail.co.uk		Cushing, Andrew/0000-0002-5258-1543	Western University; Wildlife Safari	The authors thank the veterinary students and staff at Wildlife Safari, especially those of the ungulate department, for their invaluable assistance during procedures. The authors would also like to thank Western University and Wildlife Safari for helping to supply funding for the study.	Atalan G, 2002, J VET MED A, V49, P281, DOI 10.1046/j.1439-0442.2002.00451.x; Bouda J, 2009, RES VET SCI, V87, P26, DOI 10.1016/j.rvsc.2008.12.011; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; Cooper DV, 2005, J S AFR VET ASSOC, V76, P18; CORNICK JL, 1992, J AM VET MED ASSOC, V200, P1661; Cornick-Seahorn Janyce L., 1996, P79; Gilsleider EF, 1998, VET CLIN N AM-FOOD A, V14, P503, DOI 10.1016/S0749-0720(15)30233-4; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; HOCHLEITHNER M, 1994, AVIAN MED PRINCIPLES, P241; JANSSEN DL, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P340; JENSEN JM, 1994, P AM ASS ZOO VET, P117; Kreeger T. J., 2002, HDB WILDLIFE CHEM IM; Langan JN, 2000, J AVIAN MED SURG, V14, P2, DOI 10.1647/1082-6742(2000)014[0002:CASEOI]2.0.CO;2; Lewandowski AH, 2002, J ZOO WILDLIFE MED, V33, P332, DOI 10.1638/1042-7260(2002)033[0332:TZKAXA]2.0.CO;2; Lin HC, 1997, J AM VET MED ASSOC, V210, P244; MCJAMES SW, 1993, P AM ASS ZOO VET, P408; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Mouser David, 1996, P41; OSTROWSKI S, 1995, VET REC, V136, P145, DOI 10.1136/vr.136.6.145; Paul-Murphy J, 2001, INJECTABLE ANESTHESI; RAATH JP, 1992, J S AFR VET ASSOC, V63, P138; SAMOUR JH, 1990, VET REC, V127, P575; Sandmeier P, 2000, J AVIAN MED SURG, V14, P8, DOI 10.1647/1082-6742(2000)014[0008:EOMFST]2.0.CO;2; SAVOLA JM, 1986, J AUTON PHARMACOL, V6, P275, DOI 10.1111/j.1474-8673.1986.tb00654.x; Smith KM, 2005, J ZOO WILDLIFE MED, V36, P316, DOI 10.1638/04-050.1; Smith KM, 2006, J ZOO WILDLIFE MED, V37, P513, DOI 10.1638/06-027.1; STOSKOPF MJ, 1982, J ZOO ANIM MED, V13, P160, DOI 10.2307/20094611; TOFLEGAARD M, 2009, EMERG MED J, V26, P268; Tully Thomas N. Jr, 1996, Journal of Avian Medicine and Surgery, V10, P96; VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3; Westcott DA, 2002, AUST VET J, V80, P150, DOI 10.1111/j.1751-0813.2002.tb11380.x	31	8	8	0	5	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	JUN	2010	41	2					234	241		10.1638/2009-0143R1.1			8	Veterinary Sciences	Veterinary Sciences	610YK	WOS:000278776600006	20597214				2020-06-30	J	Duman, A; Apiliogullari, S; Duman, I				Duman, Ates; Apiliogullari, Seza; Duman, Ipek			Effects of intrathecal fentanyl on quality of spinal anesthesia in children undergoing inguinal hernia repair	PEDIATRIC ANESTHESIA			English	Article						pediatric; spinal anesthesia; fentanyl; hernia	NERVE BLOCK; HYPERBARIC BUPIVACAINE; PARAVERTEBRAL BLOCK; ANALGESIA; INFANTS; SURGERY; HERNIORRHAPHY; HERNIOTOMY; LIDOCAINE	Background: The effect of intrathecal fentanyl on the characteristics of spinal anesthesia has not been investigated in children undergoing inguinal hernia repair. The purpose of this study was to assess whether the incidence and severity of pain during peritoneal sac traction is decreased by addition of fentanyl to bupivacaine in children undergoing inguinal hernia repair with spinal anesthesia. Methods: Children (6-14 years) were randomized into two groups. Group F (n = 25): hyperbaric bupivacaine plus 0.2 mu g.kg(-1) of fentanyl. Group P (n = 25): hyperbaric bupivacaine plus 0.9% NaCl (placebo). The dose of bupivacaine was 0.4 mg.kg(-1). The primary variable was the incidence and severity of pain during peritoneal sac traction. Spinal block characteristics, duration of spinal anesthesia assessed by recovery of hip flexion and duration of analgesia were the secondary variables measured, and the side effects were noted. Results: There were significant differences in incidence of pain and pain scores during sac traction with lower incidence and scores in the fentanyl group (P = 0.009). Two groups were similar regarding the level of sensory block during sac traction and duration of spinal anesthesia. Duration of spinal analgesia was prolonged significantly in the fentanyl group (P = 0.025). Conclusion: Intrathecal fentanyl at a dose of 0.2 mu g.kg(-1) added to bupivacaine significantly improves the quality of intraoperative analgesia and prolongs postoperative analgesia in children undergoing inguinal hernia repair with spinal anesthesia.	[Duman, Ipek] Minist Hlth, Konya, Turkey; [Apiliogullari, Seza] Selcuk Univ, Fac Dent, Dept Anesthesiol, Konya, Turkey; [Duman, Ates] Selcuk Univ, Fac Med, Dept Anesthesia & Intens Care, Konya, Turkey	Apiliogullari, S (reprint author), Selcuk Univ, Dept Oral & Maxillofacial Surg, TR-42070 Konya, Turkey.	sapiliogullari@yahoo.com	DUMAN, IPEK/AAB-9235-2020				Apiliogullari S, 2008, PEDIATR ANESTH, V18, P1248, DOI 10.1111/j.1460-9592.2008.02751.x; Batra YK, 2008, PEDIATR ANESTH, V18, P613, DOI 10.1111/j.1460-9592.2008.02613.x; Ben-David B, 2002, ANESTH ANALG, V95, P1596, DOI 10.1097/00000539-200212000-00023; Benhamou D, 1998, ANESTH ANALG, V87, P609, DOI 10.1097/00000539-199809000-00022; DOHI S, 1979, ANESTHESIOLOGY, V50, P319; Fujiwara Y, 2009, ACTA ANAESTH SCAND, V53, P476, DOI 10.1111/j.1399-6576.2008.01800.x; Glick Philip L., 2006, PEDIAT SURG, P1172; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Klein SM, 2002, REGION ANESTH PAIN M, V27, P476, DOI 10.1053/rapm.2002.35147; Kokki H, 2000, PAEDIATR ANAESTH, V10, P413, DOI 10.1046/j.1460-9592.2000.00498.x; Kokki H, 1998, BRIT J ANAESTH, V81, P502, DOI 10.1093/bja/81.4.502; LEIGHTON BL, 1989, ANESTH ANALG, V69, P122; Lim SL, 2002, PAEDIATR ANAESTH, V12, P255, DOI 10.1046/j.1460-9592.2002.00832.x; Machotta A, 2003, PAEDIATR ANAESTH, V13, P397, DOI 10.1046/j.1460-9592.2003.01080.x; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; Naja ZM, 2006, ANAESTHESIA, V61, P1064, DOI 10.1111/j.1365-2044.2006.04833.x; Ozkan D, 2009, REGION ANESTH PAIN M, V34, P312, DOI 10.1097/AAP.0b013e3181ae1169; Pirat A, 2002, ANESTH ANALG, V95, P1207, DOI 10.1097/00000539-200211000-00017; SPLINTER WM, 1995, CAN J ANAESTH, V42, P197, DOI 10.1007/BF03010675; Tobias JD, 2000, PAEDIATR ANAESTH, V10, P367, DOI 10.1046/j.1460-9592.2000.00499.x; Tsuchiya N, 2004, PEDIATR ANESTH, V14, P468, DOI 10.1111/j.1460-9592.2004.01234.x; WEBSTER AC, 1993, CAN J ANAESTH, V40, P670, DOI 10.1007/BF03009705	22	9	9	1	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUN	2010	20	6					530	536		10.1111/j.1460-9592.2010.03315.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	600JJ	WOS:000277981700007	20456062				2020-06-30	J	Lee-Jayaram, JJ; Green, A; Siembieda, J; Gracely, EJ; Mull, CC; Quintana, E; Adirim, T				Lee-Jayaram, Jannet J.; Green, Adam; Siembieda, Joshua; Gracely, Edward J.; Mull, Colette C.; Quintana, Eileen; Adirim, Terry			Ketamine/Midazolam Versus Etomidate/Fentanyl Procedural Sedation for Pediatric Orthopedic Reductions	PEDIATRIC EMERGENCY CARE			English	Article						procedural sedation; etomidate; ketamine	RAPID-SEQUENCE INTUBATION; KETAMINE SEDATION; DOUBLE-BLIND; EMERGENCY; CHILDREN; MIDAZOLAM; INDUCTION	Background: Orthopedic reductions are commonly performed procedures requiring sedation in the pediatric emergency department (PED). Ketamine is a widely used agent for pediatric procedural sedation, but its use may present difficulties in select populations, such as those with psychiatric diagnoses. In such a case, alternative agents that are safe and effective are needed. Etomidate is a commonly used induction agent for rapid-sequence intubation in the PED. Several retrospective and few prospective studies support etomidate's safety and efficacy in pediatric procedural sedation. Objective: The objective was to compare etomidate/fentanyl (E/F) with ketamine/midazolam (K/M) for procedural sedation during orthopedic reductions in the PED. Methods: Prospective, partially blinded, randomized controlled study comparing intravenously administered K/M with intravenously administered E/F. A convenience sample of patients, aged 5 to 18 years, presenting to an urban PED with fracture requiring reduction was enrolled. Outcome measures included guardian and staff completion of visual analog scale and Likert scales for observed pain and satisfaction, blinded OSBD-r (Observational Scale of Behavioral Distress-Revised) scoring of digital recordings of reductions, and sedation and recovery times. Descriptive tracking of adverse effects, adverse events, and interventions were recorded at the sedation. Results: Twenty-three patients were enrolled, 11 in the K/M group and 12 in the E/F group. The K/M group had significantly lower mean OSBD-r scores compared with the E/F group (0.08 vs 0.89, P = 0.001). Parents rated lower visual analog scale scores with K/M than with E/F (13.7 vs 50.5, P = 0.003) and favored K/M on a 5-point satisfaction scale (P = 0.004). The E/F group had significantly shorter total sedation times (49.6 vs 77.6 minutes, P = 0.003) and recovery times (24.7 vs 61.4 minutes, P = 0.000). There were no significant differences with respect to procedural amnesia and orthopedic practitioner satisfaction. Adverse effects noted in the K/M group included dysphoric emergence reaction and vomiting. Vomiting, injection-site pain, myoclonus, airway readjustment, and supplemental oxygen use were observed in the E/F group. Conclusions: This is a small study that strongly suggests that, for pediatric orthopedic reductions, K/M is more effective at reducing observed distress than E/F, although both provide equal procedural amnesia. With its significantly shorter sedation and recovery times, E/F may be more applicable for procedural sedation for shorter, simpler procedures in the PED.	[Lee-Jayaram, Jannet J.] Kapiolani Med Ctr Women & Children, Dept Pediat, Honolulu, HI 96826 USA; [Green, Adam; Siembieda, Joshua; Gracely, Edward J.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; [Mull, Colette C.; Quintana, Eileen] Rady Childrens Hosp San Diego, San Diego, CA USA; [Adirim, Terry] Off Hlth Affairs, Dept Homeland Secur, Washington, DC USA	Lee-Jayaram, JJ (reprint author), Kapiolani Med Ctr Women & Children, Dept Pediat, 1319 Punahou St, Honolulu, HI 96826 USA.	jalee@rchsd.org		Adirim, Terry/0000-0001-6917-5683	St Christopher's Foundation	This study was supported by the Young Investigator Grant from St Christopher's Foundation for Children.	[Anonymous], 2004, ANN EMERG MED, V44, P342, DOI 10.1016/j.annemergmed.2004.04.012; Baxter AL, 2007, PEDIATR EMERG CARE, V23, P690, DOI 10.1097/PEC.0b013e3181558d5c; Di Liddo L, 2006, ANN EMERG MED, V48, P433, DOI 10.1016/j.annemergmed.2006.03.004; Dickinson R, 2001, ACAD EMERG MED, V8, P74, DOI 10.1111/j.1553-2712.2001.tb00558.x; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Guldner G, 2003, ACAD EMERG MED, V10, P134, DOI 10.1111/j.1553-2712.2003.tb00030.x; JAY SM, 1983, [No title captured], V2, P133, DOI DOI 10.1037/0278-6133.2.2.133; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kienstra AJ, 2004, PEDIATR EMERG CARE, V20, P499, DOI 10.1097/01.pec.0000136065.22328.df; MCDOWALL RH, 1995, J CLIN ANESTH, V7, P273, DOI 10.1016/0952-8180(95)00017-C; Schenarts CL, 2001, ACAD EMERG MED, V8, P1, DOI 10.1111/j.1553-2712.2001.tb00537.x; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; Sokolove PE, 2000, PEDIATR EMERG CARE, V16, P18, DOI 10.1097/00006565-200002000-00005; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Zuckerbraun NS, 2006, ACAD EMERG MED, V13, P602, DOI 10.1197/j.aem.2005.12.026	16	23	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	JUN	2010	26	6					408	412		10.1097/PEC.0b013e3181e057cd			5	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	607WG	WOS:000278537400003	20502386				2020-06-30	J	Bernet, V; Latal, B; Natalucci, G; Doell, C; Ziegler, A; Wohlrab, G				Bernet, Vera; Latal, Beatrice; Natalucci, Giancarlo; Doell, Carsten; Ziegler, Anna; Wohlrab, Gabriele			Effect of Sedation and Analgesia on Postoperative Amplitude-Integrated EEG in Newborn Cardiac Patients	PEDIATRIC RESEARCH			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; FULL-TERM INFANTS; SEVERE PERINATAL ASPHYXIA; SUFENTANIL PHARMACOKINETICS; NEONATAL ENCEPHALOPATHY; PREDICTIVE-VALUE; BIRTH ASPHYXIA; ELECTROENCEPHALOGRAPHY; MORPHINE; TRIAL	The aim of this study is to describe the effect of sedation and analgesia on postoperative amplitude-integrated EEG (aEEG) in newborns with congenital heart disease (CHD) undergoing heart surgery. This is a consecutive series of 26 newborns with CHD of which 16 patients underwent cardiopulmonary bypass (CPB) surgery and 10 patients did not. aEEG was monitored for at least 12 h preoperatively and started within the first 6 h postoperatively for 48 h. Outcome was assessed at I year of age. All 26 patients showed a normal preoperative continuous cerebral activity with sleep-wake cycles (SWC). The postoperative duration to return to normal background activity with SWC was similar for both groups. Independent of group assignment, patients requiring midazolam had a significantly later onset of a normal SWC than those without midazolam (p = 0.03). Three patients in the CPB group and two in the non-CPB group showed continuous low voltage or flat trace after administration of fentanyl. These changes did not correlate with neurodevelopmental outcome. Sedation with midazolam has a transient effect on the background activity, whereas fentanyl can induce a severe pathologic background pattern. The significance of these changes on outcome is not yet clear. Thus, more attention should be paid to these effects when interpreting aEEG in this population. (Pediatr Res 67: 650-655, 2010)	[Bernet, Vera; Doell, Carsten; Ziegler, Anna] Univ Childrens Hosp, Dept Pediat Intens Care & Neonatol, CH-8032 Zurich, Switzerland; [Latal, Beatrice; Natalucci, Giancarlo] Univ Childrens Hosp, Child Dev Ctr, CH-8032 Zurich, Switzerland; [Wohlrab, Gabriele] Univ Childrens Hosp, Dept Neurophysiol, CH-8032 Zurich, Switzerland	Bernet, V (reprint author), Univ Childrens Hosp, Dept Pediat Intens Care & Neonatol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	vera.bernet@kispi.uzh.ch		Natalucci, Giancarlo/0000-0003-0225-2431	Anna Muller Grocholski-Foundation; Foundation for Scientific Research of the University of Zurich	Supported by the Anna Muller Grocholski-Foundation and the Foundation for Scientific Research of the University of Zurich.	al Naqeeb N, 1999, PEDIATRICS, V103, P1263, DOI 10.1542/peds.103.6.1263; Azzopardi D, 1999, EARLY HUM DEV, V55, P113, DOI 10.1016/S0378-3782(99)00010-9; Bayley N, 1993, BAYLEY SCALES INFANT, P1; BELL AH, 1993, ACTA PAEDIATR, V82, P35, DOI 10.1111/j.1651-2227.1993.tb12511.x; Bellinger DC, 2003, J THORAC CARDIOV SUR, V126, P1385, DOI 10.1016/S0022-5223(03)00711-6; de Vries LS, 2006, CLIN PERINATOL, V33, P619, DOI 10.1016/j.clp.2006.06.002; EKEN P, 1995, ARCH DIS CHILD-FETAL, V73, pF75, DOI 10.1136/fn.73.2.F75; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; GREELEY WJ, 1988, ANESTH ANALG, V67, P86; GREELEY WJ, 1987, ANESTH ANALG, V66, P1067; HELLSTROMWESTAS L, 1995, ARCH DIS CHILD-FETAL, V72, pF34, DOI 10.1136/fn.72.1.F34; JacqzAigrain E, 1996, CLIN PHARMACOKINET, V31, P423, DOI 10.2165/00003088-199631060-00003; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; KUENZLE C, 1994, NEUROPEDIATRICS, V25, P191, DOI 10.1055/s-2008-1073021; MARLOW N, 1990, ARCH DIS CHILD-FETAL, V65, P349, DOI 10.1136/adc.65.4_Spec_No.349; MEISTELMAN C, 1990, ANESTHESIOLOGY, V72, P470, DOI 10.1097/00000542-199003000-00013; Niemarkt HJ, 2008, ACTA PAEDIATR, V97, P132, DOI 10.1111/j.1651-2227.2007.00583.x; Osredkar D, 2005, PEDIATRICS, V115, P327, DOI 10.1542/peds.2004-0863; Santeiro M L, 1997, J Perinatol, V17, P135; Spitzmiller RE, 2007, J CHILD NEUROL, V22, P1069, DOI 10.1177/0883073807306258; ter Horst H, 2004, PEDIATR RES, V55, P1026, DOI 10.1203/01.pdr.0000127019.52562.8c; THORNBERG E, 1994, ACTA PAEDIATR, V83, P596; Tich SNT, 2003, PEDIATRICS, V111, P123, DOI 10.1542/peds.111.1.123; Toet MC, 2002, PEDIATRICS, V109, P772, DOI 10.1542/peds.109.5.772; Toet MC, 1999, ARCH DIS CHILD-FETAL, V81, pF19, DOI 10.1136/fn.81.1.F19; Toet MC, 2005, EXP BRAIN RES, V165, P343, DOI 10.1007/s00221-005-2300-3; van Leuven K, 2004, ACTA PAEDIATR, V93, P1221, DOI 10.1080/08035250410028057; van Rooij LGM, 2005, ARCH DIS CHILD-FETAL, V90, P245, DOI 10.1136/adc.2004.064964	28	22	22	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998			PEDIATR RES	Pediatr. Res.	JUN	2010	67	6					650	655		10.1203/PDR.0b013e3181da44ba			6	Pediatrics	Pediatrics	600CS	WOS:000277962200014	20496474	Bronze			2020-06-30	J	Romero, A; Miranda, HF; Puig, MM				Romero, Asuncion; Miranda, Hugo F.; Puig, Margarita M.			Analysis of the opioid-opioid combinations according to the nociceptive stimulus in mice	PHARMACOLOGICAL RESEARCH			English	Article						Opioid-opioid interaction; Isobolographic analysis; Nociceptive stimulus	GASTROINTESTINAL TRANSIT; INTRATHECAL MORPHINE; BREAKTHROUGH PAIN; SPINAL MORPHINE; TRAMADOL; MU; RECEPTORS; AGONISTS; ANALGESIA; OXYCODONE	The purpose of the present study was to characterize the antinociceptive effects of tramadol, fentanyl and morphine, when two of them were systemically combined in a 1:1 potency ratio, in the hot plate, the acetic acid writhing, and the formalin tests in mice. Interaction indexes and isobolographic analysis were used to assess the type of interaction. Fentanyl was the most potent drug, followed by morphine and tramadol, with the exception in the phase I of formalin test. Synergistic interactions were obtained when tramadol was combined with fentanyl or with morphine in the writhing and formalin tests. But, in the hot plate only additive interactions were obtained. Changes were induced on the type of interaction depending on the level of effect of opioid-opioid combinations. Moreover, co-administration of fentanyl with morphine showed additivity, regardless of the type of stimulus. Standard rotarod test analysis confirmed intact motor coordination. The present findings suggest that the type of interaction between opioids is not only related to the nature of nociceptive stimulus but also to non-opioid analgesic pathways. (C) 2010 Elsevier Ltd. All rights reserved.	[Romero, Asuncion; Puig, Margarita M.] Univ Autonoma Barcelona, IMIM Hosp del Mar, Dept Anaesthesiol Physiopathol & Management Pain, Barcelona 08003, Spain; [Miranda, Hugo F.] Univ Chile, Dept Pharmacol, ICBM, Sch Med, Santiago, Chile	Romero, A (reprint author), Univ Autonoma Barcelona, IMIM Hosp del Mar, Dept Anaesthesiol Physiopathol & Management Pain, Dr Aiguader 88, Barcelona 08003, Spain.	mromero@imim.es; hmiranda@med.uchile.cl; MPuigR@imas.imim.es	Romero, Asuncion/L-6030-2014	Romero, Asuncion/0000-0002-5182-1672	Instituto de Salud Carlos III, Madrid, SpainInstituto de Salud Carlos III [PI 060669]; La Marato de TV3 [071110]	We are grateful to Ms. Carolina Zamora for her excellent technical help. Financial support for this study was provided by grants from Instituto de Salud Carlos III, Madrid, Spain (PI 060669), La Marato de TV3 (071110) and the Endowed Chair in Pain Management UAB-IMAS-MENARINI (MMP).	ADAM F, 2009, ANESTH REANIM, V28, pPE61; Aldenkamp AP, 2000, EPILEPSIA, V41, P1167, DOI 10.1111/j.1528-1157.2000.tb00322.x; AURILIO C, 2009, EXP CLIN CANC RES, V7, P28; Barrera NP, 2005, TRENDS PHARMACOL SCI, V26, P526, DOI 10.1016/j.tips.2005.08.003; Bobo WV, 2009, NEUROPSYCH DIS TREAT, V5, P369; Bolan EA, 2002, J PHARMACOL EXP THER, V303, P557, DOI 10.1124/jpet.102.035881; Castane A, 2006, NEUROPHARMACOLOGY, V51, P631, DOI 10.1016/j.neuropharm.2006.05.005; Cristiano M. P., 2008, Autonomic & Autacoid Pharmacology, V28, P103, DOI 10.1111/j.1474-8673.2008.00423.x; Dietis N, 2009, BRIT J ANAESTH, V103, P38, DOI 10.1093/bja/aep129; Dursteler C, 2006, EUR J PAIN, V10, P629, DOI 10.1016/j.ejpain.2005.10.002; Friedman Zeev, 2008, Pain Pract, V8, P248, DOI 10.1111/j.1533-2500.2008.00212.x; Gallantine EL, 2008, BASIC CLIN PHARMACOL, V103, P419, DOI 10.1111/j.1742-7843.2008.00306.x; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088-200443130-00004; GUTTMAN R, 1997, EUR J PAIN, V4, P293; Ide S, 2006, NEUROPHARMACOLOGY, V51, P651, DOI 10.1016/j.neuropharm.2006.05.008; Jones CK, 2005, J PHARMACOL EXP THER, V312, P726, DOI 10.1124/jpet.104.075960; KLAASSEN CD, 2001, PHARMACOL BASIS THER, P67; Lauretti GR, 2003, BRIT J CANCER, V89, P2027, DOI 10.1038/sj.bjc.6601365; Le Bars D, 2001, PHARMACOL REV, V53, P597; LOOMIS CW, 1989, ANESTHESIOLOGY, V71, P704, DOI 10.1097/00000542-198911000-00013; Marcou TA, 2005, ANESTH ANALG, V100, P469, DOI 10.1213/01.ANE.0000142121.24052.25; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Mercadante S, 2004, SUPPORT CARE CANCER, V12, P762, DOI 10.1007/s00520-004-0650-1; MIASKOWSKI C, 1992, BRAIN RES, V595, P32, DOI 10.1016/0006-8993(92)91449-O; Minami K, 2007, J PHARMACOL SCI, V103, P253, DOI 10.1254/jphs.CR0060032; Miranda H F, 2001, Pain Res Manag, V6, P190; Miranda HF, 2009, FUND CLIN PHARMACOL, V23, P81, DOI 10.1111/j.1472-8206.2008.00636.x; Nemirovsky A, 2001, ANESTH ANALG, V93, P197; Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022; Niv D, 1998, ANESTH ANALG, V87, P583, DOI 10.1097/00000539-199809000-00016; OSSIPOV MH, 1989, ANESTH ANALG, V68, P194; Ozdogan UK, 2006, EUR J PHARMACOL, V529, P105, DOI 10.1016/j.ejphar.2005.10.029; Pasternak GW, 2005, J PAIN SYMPTOM MANAG, V29, pS2, DOI 10.1016/j.jpainsymman.2005.01.011; PICK CG, 1992, EUR J PHARMACOL, V220, P275, DOI 10.1016/0014-2999(92)90761-R; Poveda R, 2003, EUR J PAIN, V7, P439, DOI 10.1016/S1090-3801(03)00003-X; Puig MM, 2000, ANESTHESIOLOGY, V93, P219, DOI 10.1097/00000542-200007000-00033; ROSLAND JH, 1990, PAIN, V42, P235, DOI 10.1016/0304-3959(90)91167-H; Ross FB, 2000, PAIN, V84, P421, DOI 10.1016/S0304-3959(99)00230-4; Scherrer G, 2004, EUR J NEUROSCI, V19, P2239, DOI 10.1111/j.0953-816X.2004.03339.x; Smith MT, 2008, CURR OPIN ANESTHESIO, V21, P596, DOI 10.1097/ACO.0b013e32830a4c4a; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; SUTTERS KA, 1990, BRAIN RES, V530, P290, DOI 10.1016/0006-8993(90)91297-T; TALLARIDA R, 2000, DRUG SYNERGISM DOSE; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Vasudevan A, 2007, BRIT J ANAESTH, V98, P241, DOI 10.1093/bja/ael346; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Webb AR, 2002, ANESTH ANALG, V95, P1713, DOI 10.1097/00000539-200212000-00045; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	50	21	22	0	2	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	JUN	2010	61	6					511	518		10.1016/j.phrs.2010.02.011			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	599AV	WOS:000277883200006	20206265				2020-06-30	J	Hoya, Y; Okamoto, T; Yanaga, K				Hoya, Yoshiyuki; Okamoto, Tomoyoshi; Yanaga, Katsuhiko			Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line	SUPPORTIVE CARE IN CANCER			English	Article						Analgesic effect; Fentanyl; Transdermal patch; Cancer pain	RELEASE ORAL MORPHINE; NARCOTIC ANALGESICS; MANAGEMENT; DELIVERY	Initial treatment with morphine followed by fentanyl transdermal patch is the standard in Japan, since even the smallest patch (2.5 mg) could deliver too high an initial dose for Japanese patients. We evaluated the analgesic effect and safety of using the fentanyl transdermal patch as a first-line strong opioid for cancer pain that is resistant to nonsteroidal anti-inflammatory drugs (NSAIDs). For 20 hospitalized patients with cancer pain that could not be controlled by NSAIDs, the fentanyl transdermal patch (1.25 mg; half of a 2.5-mg patch) was administered as a first-line strong opioid. We used rescue medications depending on the degree of pain, and the dose of fentanyl transdermal patch was adjusted every 3 days. To evaluate analgesic efficacy of the patch, the degree of pain was assessed twice a day, in the morning and at night, using a face rating scale. The formulation and dose of morphine used during observation period were recorded. The safety of treatment was evaluated by measuring vital signs once a day, and the severity of side effects were evaluated. Any abnormal findings in blood and urine test were recorded. The median pain score before administration of fentanyl transdermal patch was 3 +/- 0.58 and was decreased to 2 +/- 0.71 on day 9 of administration. The mean dose of fentanyl transdermal patch on day 9 of administration was 2.31 +/- 1.34 mg, and the mean dose of morphine as rescue therapy was 4.62 +/- 7.76 mg. No clinically significant changes in vital signs were observed. No severe adverse events were present when the dose of the fentanyl transdermal patch was 1.25 mg, but two patients experienced dizziness when the dose was increased from 2.5 to 5 mg. No abnormal laboratory data appeared during the administration. The use of 1.25-mg fentanyl transdermal patch (50% of a 2.5-mg patch) seems to be safe and efficient as a first-line strong opioid. The use of 3.75-mg fentanyl transdermal patch may be necessary since adverse events including nausea and sleepiness are likely to occur by increasing from 2.5 to 5 mg.	[Hoya, Yoshiyuki; Okamoto, Tomoyoshi] Jikei Univ, Sch Med, Dept Surg, Daisan Hosp, Tokyo 2018601, Japan; [Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Minato Ku, Tokyo 1058461, Japan	Hoya, Y (reprint author), Jikei Univ, Sch Med, Dept Surg, Daisan Hosp, 4-11-1 Izumihon Cho, Tokyo 2018601, Japan.	hoya@jikei.ac.jp	Yanaga, Katsuhiko/Y-6290-2019	Yanaga, Katsuhiko/0000-0001-8918-4720			AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; GARDOCKI JF, 1964, TOXICOL APPL PHARM, V6, P48, DOI 10.1016/0041-008X(64)90021-3; HIRAGA K, 1999, PALLIAT CARE, V1, P134; HIRAGA K, 1999, PAIN CLINIC, V20, P479; Kongsgaard UE, 1998, EUR J PAIN-LONDON, V2, P53, DOI 10.1016/S1090-3801(98)90046-5; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; *MIN HLTH WELF DIV, 1993, OUTL DRUG STIM ADM 1; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; TAKEDA F, 1996, OPENING PAIN CANC WH; Tan M, 2004, CURR MED RES OPIN, V20, P879, DOI 10.1185/030079904125003728; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045	18	5	5	2	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	JUN	2010	18	6					761	764		10.1007/s00520-010-0869-y			4	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	599VV	WOS:000277942800014	20354734				2020-06-30	J	Saadawy, IM; Kaki, AM; Abd El Latif, AA; Abd-Elmaksoud, AM; Tolba, OM				Saadawy, I. M.; Kaki, A. M.; Abd El Latif, A. A.; Abd-Elmaksoud, A. M.; Tolba, O. M.			Lidocaine vs. magnesium: effect on analgesia after a laparoscopic cholecystectomy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							ASPARTATE NMDA RECEPTORS; POSTOPERATIVE PAIN; INTRAVENOUS LIDOCAINE; AMBULATORY SURGERY; LOCAL-ANESTHETICS; INFUSION; SULFATE; SENSITIZATION; REQUIREMENTS; INHIBITION	Background This double-blinded study aimed at evaluating and comparing the effects of magnesium and lidocaine on pain, analgesic requirements, bowel function, and quality of sleep in patients undergoing a laparoscopic cholecystectomy (LC). Methods Patients were randomized into three groups (n=40 each). Group M received magnesium sulfate 50 mg/kg intravenously (i.v.), followed by 25 mg/kg/h i.v., group L received lidocaine 2 mg/kg i.v., followed by 2 mg/kg/h i.v., and group P received saline i.v. Bolus doses were given over 15 min before induction of anesthesia, followed by an i.v. infusion through the end of surgery. Intraoperative fentanyl consumption and averaged end-tidal sevoflurane concentration were recorded. Abdominal and shoulder pain were evaluated up to 24 h using a visual analog scale (VAS). Morphine consumption was recorded at 2 and 24 h, together with quality of sleep and time of first flatus. Results Lidocaine or magnesium reduced anesthetic requirements (P < 0.01), pain scores (P < 0.05), and morphine consumption (P < 0.001) relative to the control group. Lidocaine resulted in lower morphine consumption at 2 h [4.9 +/- 2.3 vs. 6.8 +/- 2.8 (P < 0.05)] and lower abdominal VAS scores compared with magnesium (1.8 +/- 0.8 vs. 3.2 +/- 0.9, 2.2 +/- 1 vs. 3.6 +/- 1.6, and 2.1 +/- 1.4 vs. 3.3 +/- 1.9) at 2, 6, and 12 h, respectively (P < 0.05). Lidocaine was associated with earlier return of bowel function and magnesium was associated with better sleep quality (P < 0.05). Conclusion I.v. lidocaine and magnesium improved post-operative analgesia and reduced intraoperative and post-operative opioid requirements in patients undergoing LC. The improvement of quality of recovery might facilitate rapid hospital discharge.	[Saadawy, I. M.; Kaki, A. M.; Abd El Latif, A. A.; Abd-Elmaksoud, A. M.; Tolba, O. M.] King Abdulaziz Univ, Dept Anaesthesia, Jeddah 21413, Saudi Arabia; [Saadawy, I. M.] Cairo Univ, Dept Anesthesiol, Cairo, Egypt	Saadawy, IM (reprint author), King Abdulaziz Univ, Dept Anaesthesia, Jeddah 21413, Saudi Arabia.	ninaeg2001@yahoo.com		Abd Elmaksoud Abd Elbary, Ahmed/0000-0001-8925-7432			Beaulieu P, 2007, CAN J ANAESTH, V54, P481, DOI 10.1007/BF03022036; Bhatia A, 2004, J CLIN ANESTH, V16, P262, DOI 10.1016/j.jclinane.2003.08.012; CASSUTO J, 1985, ANESTH ANALG, V64, P971; Cepeda MS, 1996, ANESTH ANALG, V83, P102, DOI 10.1097/00000539-199607000-00018; Dirks J, 2000, ANESTH ANALG, V91, P967, DOI 10.1097/00000539-200010000-00037; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; INSLER SR, 1995, J CARDIOTHOR VASC AN, V9, P541, DOI 10.1016/S1053-0770(05)80138-7; Jin FL, 1998, CAN J ANAESTH, V45, P293, DOI 10.1007/BF03012017; Kaba A, 2007, ANESTHESIOLOGY, V106, P11, DOI 10.1097/00000542-200701000-00007; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Koppert W, 2004, ANESTH ANALG, V98, P1050, DOI 10.1213/01.ANE.0000104582.71710.EE; Kuo CP, 2006, BRIT J ANAESTH, V97, P640, DOI 10.1093/bja/ael217; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; Lahav M, 2002, CLIN EXP IMMUNOL, V127, P226, DOI 10.1046/j.1365-2249.2002.01747.x; Lauwick S, 2008, CAN J ANAESTH, V55, P754, DOI 10.1007/BF03016348; Levaux C, 2003, ANAESTHESIA, V58, P131, DOI 10.1046/j.1365-2044.2003.02999.x; Lysakowski C, 2007, ANESTH ANALG, V104, P1532, DOI 10.1213/01.ane.0000261250.59984.cd; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; Mentes O, 2008, ACTA ANAESTH SCAND, V52, P1353, DOI 10.1111/j.1399-6576.2008.01816.x; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; Poleszak E, 2008, PHARMACOL REP, V60, P483; RIMBACK G, 1990, ANESTH ANALG, V70, P414; Ryu JH, 2008, BRIT J ANAESTH, V100, P397, DOI 10.1093/bja/aem407; Schulz-Stubner S, 2001, EUR J ANAESTH, V18, P723, DOI 10.1046/j.1365-2346.2001.00921.x; Sugimoto M, 2003, BRIT J PHARMACOL, V138, P876, DOI 10.1038/sj.bjp.0705107; Tramer MR, 2007, ANESTH ANALG, V104, P1374, DOI 10.1213/01.ane.0000263416.14948.dc; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019; WilderSmith CH, 1997, ACTA ANAESTH SCAND, V41, P1023, DOI 10.1111/j.1399-6576.1997.tb04830.x; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	32	50	52	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2010	54	5					549	556		10.1111/j.1399-6576.2009.02165.x			8	Anesthesiology	Anesthesiology	577SQ	WOS:000276244700004	19919581				2020-06-30	J	Cesur, M; Yapanoglu, T; Erdem, AF; Ozbey, I; Alici, HA; Aksoy, Y				Cesur, M.; Yapanoglu, T.; Erdem, A. F.; Ozbey, I.; Alici, H. A.; Aksoy, Y.			Caudal analgesia for prostate biopsy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							PROSPECTIVE RANDOMIZED-TRIAL; PERIPROSTATIC LIDOCAINE INJECTION; COMPARING 2 METHODS; INTRARECTAL LIDOCAINE; LOCAL-ANESTHESIA; PAIN-CONTROL; NERVE BLOCK; GUIDED BIOPSY; TOLERANCE; CANCER	Background Although various local anesthesia techniques have been suggested to decrease pain and discomfort during a transrectal ultrasound (TRUS)-guided prostate biopsy, the best method has not yet been defined. The present prospective, double-blind, randomized study aims to investigate the clinical efficacy of 'walking' caudal block compared with an intrarectal lidocaine gel for this procedure. Methods One hundred patients were randomly assigned to two groups. In the lidocaine gel group, 10 ml of gel containing 2% lidocaine was given intrarectally. In the caudal group, 20 ml 0.1% bupivacaine with 75 mu g fentanyl was injected. Pain scores, anal sphincter tone and patient satisfaction were evaluated. Results The pain scores were significantly lower in the caudal group at all stages. Verbal rating scores (scale 1-4) during probe insertion, probe maneuver and biopsies were 1 (0-2), 1 (0-2) and 1 (0-2) vs. 3 (0-5), 2 (1-3) and 4 (2-6), respectively (P value < 0.0001 at all stages). The anal sphincter was more relaxed in the caudal group than in the gel group (P value < 0.0001 in all categories). Highly satisfied patients were more frequently encountered in the caudal group, 34 (68%) vs. 8 (16%), P < 0.0001, and unsatisfied patients were more frequently found in the gel group 1 (2%) vs. 12 (24%); P < 0.001. All patients were able to walk without any assistance immediately after the procedures. Conclusion 'Walking' caudal analgesia is an efficacious method for relieving the pain during TRUS-guided prostate biopsies in ambulatory practice.	[Cesur, M.; Erdem, A. F.; Alici, H. A.] Ataturk Univ, Fac Med, Dept Anesthesiol & Reanimat, Erzurum, Turkey; [Yapanoglu, T.; Ozbey, I.; Aksoy, Y.] Ataturk Univ, Dept Urol, Erzurum, Turkey	Cesur, M (reprint author), Ataturk Mah 1,Cadde Nergis Konutlari,A Blok 6, Gaziantep, Turkey.	mcesur68@gmail.com	CESUR, MEHMET/AAL-5471-2020	CESUR, MEHMET/0000-0003-1077-4715	Ataturk UniversityAtaturk University	Funding sources. Ataturk University.	Adebamowo C A, 2000, Afr J Med Med Sci, V29, P133; Alavi AS, 2001, J UROLOGY, V166, P1343, DOI 10.1016/S0022-5347(05)65765-5; Aus G, 2005, SCAND J UROL NEPHROL, V39, P124, DOI 10.1080/00365590510007784; Brown DL, 1997, MAYO CLIN PROC, V72, P20, DOI 10.4065/72.1.20; Cevik I, 2002, EUR UROL, V42, P217, DOI 10.1016/S0302-2838(02)00275-0; Chang SS, 2001, J UROLOGY, V166, P2178, DOI 10.1016/S0022-5347(05)65529-2; CLEMENTS R, 1993, CLIN RADIOL, V47, P125, DOI 10.1016/S0009-9260(05)81188-2; COLLINS GN, 1993, BRIT J UROL, V71, P460, DOI 10.1111/j.1464-410X.1993.tb15993.x; Desgrandchamps F, 1999, BJU INT, V83, P1007; Emiliozzi P, 2004, J UROLOGY, V171, P197, DOI 10.1097/01.ju.0000099824.73886.f3; Horinaga M, 2006, UROLOGY, V68, P348, DOI 10.1016/j.urology.2006.02.025; Ikuerowo SO, 2010, INT UROL NEPHROL, V42, P19, DOI 10.1007/s11255-006-9095-4; Irani J, 1997, BRIT J UROL, V79, P608, DOI 10.1046/j.1464-410X.1997.00120.x; Issa MM, 2000, J UROLOGY, V164, P397, DOI 10.1016/S0022-5347(05)67369-7; Leibovici D, 2002, J UROLOGY, V167, P563, DOI 10.1016/S0022-5347(01)69086-4; Lynn NNK, 2002, BJU INT, V90, P424, DOI 10.1046/j.1464-410X.2002.02902.x; Mulroy M. F., 1996, REGIONAL ANESTHESIA, V125; Obek C, 2004, J UROLOGY, V172, P502, DOI 10.1097/01.ju.0000131601.06286.26; Okeke L I, 2002, West Afr J Med, V21, P280; Ozveri H, 2003, PROSTATE CANCER P D, V6, P311, DOI 10.1038/sj.pcan.4500669; Rodriguez A, 2003, EUR UROL, V44, P195, DOI 10.1016/S0302-2838(03)00188-X; Schostak M, 2002, UROLOGY, V60, P253, DOI 10.1016/S0090-4295(02)01730-2; Scott D. B., 1995, TECHNIQUES REGIONAL, V184; Takenaka A, 2006, INT J UROL, V13, P10, DOI 10.1111/j.1442-2042.2006.01221.x; von Knobloch R, 2002, EUR UROL, V41, P508, DOI 10.1016/S0302-2838(02)00072-6; Willis RJ, 1998, NEURAL BLOCKADE CLIN, P323	26	11	11	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2010	54	5					557	561		10.1111/j.1399-6576.2009.02168.x			5	Anesthesiology	Anesthesiology	577SQ	WOS:000276244700005	19919580				2020-06-30	J	George, AV; Lu, JJ; Pisano, MV; Metz, J; Erickson, TB				George, Antony V.; Lu, Jenny J.; Pisano, Matthew V.; Metz, Jessica; Erickson, Timothy B.			Carfentanil-an ultra potent opioid	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter									[George, Antony V.; Lu, Jenny J.] Cook Cty Stroger Hosp, Dept Emergency Med, Chicago, IL USA; [Lu, Jenny J.; Erickson, Timothy B.] Toxikon Consortium, Chicago, IL 60612 USA; [Pisano, Matthew V.] Elmhurst Mem Hosp, Elmhurst, NY USA; [Metz, Jessica] Illinois Poison Ctr, Chicago, IL USA; [Erickson, Timothy B.] Univ Illinois, Dept Emergency Med, Chicago, IL USA	George, AV (reprint author), Cook Cty Stroger Hosp, Dept Emergency Med, Chicago, IL USA.	jlu@ccbh.org					LUST EB, 2009, J EMERG MED; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; *ZOOPHARM, DRUG INF SHEET CARF	4	47	47	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAY	2010	28	4					530	532		10.1016/j.ajem.2010.03.003			3	Emergency Medicine	Emergency Medicine	600KN	WOS:000277984800035	20466249				2020-06-30	J	Elcock, DH				Elcock, D. H.			Fentanyl-induced cough	ANAESTHESIA			English	Letter											david.elcock@sath.nhs.uk					Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Ambesh SP, 2009, INTERNET J ANESTHESI, V20, P1; Anderson L, 1998, ANAESTHESIA, V53, P1117, DOI 10.1046/j.1365-2044.1998.00560.x; CHIN SL, 2004, CANADIAN J ANESTHESI, V51, P654; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021	10	2	6	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAY	2010	65	5					536	537		10.1111/j.1365-2044.2010.06321.x			2	Anesthesiology	Anesthesiology	582MI	WOS:000276601300028	20522043				2020-06-30	J	Schmutz, JL; Barbaud, A; Trechot, P				Schmutz, J. -L.; Barbaud, A.; Trechot, P.			Codeine and cutaneous drug reactions: Absence of cross-allergy with tramadol and fentanyl	ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE			French	Editorial Material									[Schmutz, J. -L.; Barbaud, A.] Hop Fournier, Serv Dermatol, F-54000 Nancy, France; [Trechot, P.] Hop Cent, F-54000 Nancy, France	Schmutz, JL (reprint author), Hop Fournier, Serv Dermatol, 36 Quai de la Bataille, F-54000 Nancy, France.	jl.schmutz@chu-nancy.fr					Kalkan IK, 2009, ALLERGY, V64, P1692, DOI [10.1111/j.1398-9995.2009.02113.x, 10.1111/j.1398-9995.2009.02114.x]	1	2	2	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0151-9638	2214-5451		ANN DERMATOL VENER	Ann. Dermatol. Venereol.	MAY	2010	137	5					429	429		10.1016/j.annder.2010.02.014			1	Dermatology	Dermatology	611YW	WOS:000278862400021	20470933				2020-06-30	J	Colvin, LA; Fallon, MT				Colvin, L. A.; Fallon, M. T.			Oxygen saturation decreases acutely when opioids are given during anaesthesia	BRITISH JOURNAL OF ANAESTHESIA			English	Letter							INDUCED HYPERALGESIA; DOSE KETAMINE; PAIN				lesley.colvin@ed.ac.uk		Fallon, Marie/0000-0001-9214-0091			BELL RF, 2006, PERIOPERATIVE KETAMI; Berti M, 2009, CURR DRUG TARGETS, V10, P707, DOI 10.2174/138945009788982496; Colvin LA, 2010, BRIT J ANAESTH, V104, P125, DOI 10.1093/bja/aep392; Menigaux C, 2000, ANESTH ANALG, V90, P129, DOI 10.1097/00000539-200001000-00029; Minville V, 2010, BRIT J ANAESTH, V104, P231, DOI 10.1093/bja/aep363; Rogers R, 2004, ANESTHESIOLOGY, V100, P292, DOI 10.1097/00000542-200402000-00018; SEGERDAHL M, 1994, ANESTH ANALG, V79, P787; Sprenger T, 2006, ANESTH ANALG, V103, P729, DOI 10.1213/01.ane.0000231635.14872.40	8	6	6	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	MAY	2010	104	5					661	661		10.1093/bja/aeq076			1	Anesthesiology	Anesthesiology	584FP	WOS:000276736800026	20400616	Bronze			2020-06-30	J	Vissers, D; Stam, W; Nolte, T; Lenre, M; Jansen, J				Vissers, Debby; Stam, Wiro; Nolte, Thomas; Lenre, Malin; Jansen, Jeroen			Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Cancer breakthrough pain; Fentanyl buccal tablet; Indirect comparison; Intranasal fentanyl spray; Meta-analysis; Opioids; Oral transmucosal fentanyl citrate		Objective: To compare the efficacy of intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC), fentanyl buccal tablet (FBT) and oral morphine (OM) for the treatment of breakthrough cancer pain (BTCP). Methods: A systematic literature review (Medline, EMBASE, BIOSIS; 1996-2007) identified six randomised controlled trials (RCTs) investigating the effects of INFS, OTFC, FBT and OM for the treatment of BTCP. The endpoint of interest was pain intensity difference (PID, reported on a 0-10 numeric rating scale [NRS]) up to 60 minutes after intake. Results of all trials were analysed simultaneously with a mixed treatment comparison (extended meta-analysis). MTC can be considered a valid method when included studies are comparable regarding effect modifying baseline patient and study characteristics. Results: INFS provided the greatest reduction in pain relative to placebo: PID 1.7 points (95% CrI: 1.4; 1.9) at 15 minutes, 2.0 (1.6; 2.3) at 30 minutes, 2.0 (1.5; 2.4) at 45 minutes and 1.9 (1.5; 2.4) at 60 minutes. PID for OTFC and FBT relative to placebo were 0.4 (0.0; 0.8) and 0.5 (0.3; 0.7) at 15 minutes. Both treatments provided a reduction in pain superior to placebo at other time points. INFS displayed a more than 99% probability of providing the greatest pain reduction out of all interventions compared at 15 minutes after intake. This was maintained for any measured time point before 45 minutes when compared to FBT and for any measured time point before 60 minutes when compared to OTFC. Only from 45 minutes onwards did OM show a greater pain reduction than placebo. Conclusion: Based on currently available evidence, INFS is expected to provide the greatest improvement in the treatment of BTCP. Due to its slow onset to effect OM cannot be considered an efficacious treatment for BTCP.	[Vissers, Debby; Stam, Wiro] Mapi Values, Utrecht, Netherlands; [Nolte, Thomas] Schmerz & Palliat Zentrum, Wiesbaden, Germany; [Lenre, Malin] NYCOMED AS, Taastrup, Denmark; [Jansen, Jeroen] Mapi Values, Boston, MA USA	Vissers, D (reprint author), Mapi Values Netherlands BV, De Molen 84, NL-3995 AX Houten, Netherlands.	debby.vissers@mapivalues.com			Nycomed	This study was funded by Nycomed.	BENNETT D, 2005, PHARMACOL THERAPEUT, V6, P354; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; *CEPH UK LTD, SUMM PROD CHAR EFF; *CEPH UK LTD, SUMM PROD CHAR ACT; CHAUSHU G, 2000, CANCER, V5, P984; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Edwards SJ, 2009, CURR MED RES OPIN, V25, P251, DOI 10.1185/03007990802633160 ; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fitzgibbon D, 2003, PAIN, V106, P309, DOI 10.1016/S0304-3959(03)00318-X; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Fryback DG, 2001, INT J TECHNOL ASSESS, V17, P98, DOI 10.1017/S0266462301104095; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Jansen JP, 2008, VALUE HEALTH, V11, P956, DOI 10.1111/j.1524-4733.2008.00347.x; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; MERCADANTE S, 2002, CANCER, V3, P832; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; *NYC UK LTD, SUMM PROD CHAR INST; Pavis H, 2002, J PAIN SYMPTOM MANAG, V24, P598, DOI 10.1016/S0885-3924(02)00522-5; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Sweeney MP, 1998, ORAL ONCOL, V34, P123, DOI 10.1016/S1368-8375(97)00076-6; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304; Zeppetella G., 2006, COCHRANE DB SYST REV, V1, pCD004311	40	43	45	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	MAY	2010	26	5					1037	1045		10.1185/03007991003694340			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	583MO	WOS:000276680900004	20199140				2020-06-30	J	Mattia, C; Coluzzi, F; Sonnino, D; Anker-Moller, E				Mattia, Consalvo; Coluzzi, Flaminia; Sonnino, Davide; Anker-Moller, Erling			Efficacy and safety of fentanyl HCl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management for patient subgroups	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						administration; analgesia; cutaneous; fentanyl; infusion pumps; intravenous drug delivery systems; iontophoresis; patient-controlled; postoperative pain; transdermal administration	PLACEBO-CONTROLLED TRIAL; MULTICENTER; DELIVERY; SURGERY; PUMP	Background and objective Inadequate postoperative pain control remains a problem for many patients undergoing surgery. This study presents subgroup analyses from a large, randomized, multicentre, European study comparing the efficacy and safety of the fentanyl HCl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia for postoperative pain management. Methods The efficacy and safety of the fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia were evaluated for patients divided by surgery type, sex, American Society of Anesthesiologists physical status and type of anaesthesia used during surgery. Efficacy measures included a patient global assessment of the method of pain control (a rating of 'good' or 'excellent' was considered as a success rating) and mean last pain intensity scores in the first 24 h. Discontinuation rates and the incidence of adverse events were also evaluated. Results Numerically similar percentages of patients in most subgroups reported success on the last patient global assessment in the first 24 h for both the fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia. Similar percentages of investigators reported success ratings on the investigator global assessment at the last assessment for both treatment groups regardless of surgery type, except for the knee surgery subgroup (fentanyl iontophoretic transdermal system, 75%; morphine intravenous patient-controlled analgesia, 95%). Mean last pain intensity scores in the first 24 h after surgery were similar in all subgroups. Rates of patient withdrawals and the incidence of adverse events were generally similar between treatment groups in the patient subgroups. Conclusion The fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia are comparably well tolerated and effective methods of pain control, regardless of sex, American Society of Anesthesiologists physical status or the type of anaesthesia used for surgery, and following most surgery types. Eur J Anaesthesiol 2010;27:433-440	[Mattia, Consalvo; Coluzzi, Flaminia] Univ Roma La Sapienza, Dept Anaesthesiol Intens Care Med & Pain Therapy, ICOT Polo Pontino, I-00161 Rome, Italy; [Sonnino, Davide] Janssen Cilag SpA, Dept Med, Milan, Italy; [Anker-Moller, Erling] Arhus Univ Hosp, Aarhus C, Denmark	Mattia, C (reprint author), Univ Roma La Sapienza, Dept Anaesthesiol Intens Care Med & Pain Therapy, ICOT Polo Pontino, Viale Policlin 155, I-00161 Rome, Italy.	consalvo.mattia@uniroma1.it			Janssen-Cilag NV	Janssen-Cilag NV funded these analyses.	Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; Brown Amanda K, 2004, Best Pract Res Clin Anaesthesiol, V18, P703, DOI 10.1016/j.bpa.2004.05.004; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hicks RW, 2008, AM J HEALTH-SYST PH, V65, P429, DOI 10.2146/ajhp070194; HUTCHISON RW, 2007, HOSP PHARM, V42, P1036; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Macintyre PE, 2005, ACUTE PAIN MANAGEMEN; Miaskowski Christine, 2005, J Perianesth Nurs, V20, P255, DOI 10.1016/j.jopan.2005.05.005; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Sinatra R, 2005, CLIN PHARMACOKINET, V44, P1; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	17	8	8	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	MAY	2010	27	5					433	440		10.1097/EJA.0b013e3283349d82			8	Anesthesiology	Anesthesiology	581VL	WOS:000276552900007	20186064				2020-06-30	J	Bhambhani, Y; Gross, DP; Haykowsky, M; Rashiq, S				Bhambhani, Yagesh; Gross, Douglas P.; Haykowsky, Mark; Rashiq, Saifudin			Effect of opioid administration on cardiorespiratory and muscle oxygenation during lifting in chronic back pain patients	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY			English	Article						Repetitive lifting; Fentanyl; Oxygen consumption; Heart rate; Erector spinae oxygenation	NEAR-INFRARED SPECTROSCOPY; PERCEIVED EXERTION; STROKE VOLUME; BLOOD-VOLUME; EXERCISE; RESPONSES; RELIABILITY; PERFORMANCE; CAPACITY; PULSE	The objectives of this study were to examine the effects of opioid administration on the acute cardiorespiratory and muscle oxygenation responses during a repetitive lifting and lowering test (RLL) to voluntary fatigue in participants with chronic low back pain (LBP). Written informed consent was obtained from 27 LBP participants (mean age 50.9 +/- 16.4 years) who completed one testing session during which they were administered a saline placebo and opioid (1 mu g/kg of fentanyl intravenously) in random order. The participants performed the RLL at a rate that they felt that they could sustain for an 8-h working day. Acute opioid administration increased the total lifting time and total work done during RLL by 35 and 48%, respectively (p < 0.05). However, the increased work capacity was accompanied by a significant (p < 0.05) increase in oxygen cost of 22% per unit amount of work done and significant (p < 0.05) increases in heart rate (7%) and ventilation rate (10%). Near infrared spectroscopic analysis of erector spinae oxygenation and blood volume responses during RLL indicated no significant (p > 0.05) differences between the opioid and placebo phases. These findings suggest that the increased energy cost of lifting as a result of opioid administration was due to enhanced central oxygen transport and not peripheral muscle oxygen extraction.	[Bhambhani, Yagesh] Univ Alberta, Dept Occupat Therapy, Edmonton, AB T6G 2G4, Canada; [Gross, Douglas P.; Haykowsky, Mark] Univ Alberta, Dept Phys Therapy, Edmonton, AB T6G 2G4, Canada; [Gross, Douglas P.] Workers Compensat Board Alberta Millard Hlth, Edmonton, AB, Canada; [Rashiq, Saifudin] Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB T6G 2G4, Canada	Bhambhani, Y (reprint author), Univ Alberta, Dept Occupat Therapy, Room 3-73,Corbett Hall, Edmonton, AB T6G 2G4, Canada.	yagesh.bhambhani@ualberta.ca	Gross, Douglas P./AAF-6997-2020	Gross, Douglas P./0000-0002-2427-6277	Department of Physical Therapy, University of AlbertaUniversity of Alberta	The authors would like to thank the individuals with LBP for participating in this study; Ms. Kathryn Jamieson-Lega for her assistance in organizing this study; and Derrick von Os and Nick Jendzjowsky for their technical assistance during data collection. This research was funded by a grant from the Department of Physical Therapy, University of Alberta.	Alpert J, 1991, J Occup Rehabil, V1, P13, DOI 10.1007/BF01073277; Bhambhani Y, 1985, Can J Appl Sport Sci, V10, P44; BHAMBHANI Y, 1994, CAN J APPL PHYSIOL, V19, P49, DOI 10.1139/h94-003; Bhambhani YN, 2004, CAN J APPL PHYSIOL, V29, P504, DOI 10.1139/h04-033; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Chaloupka EC, 2000, J ORTHOP SPORT PHYS, V30, P249, DOI 10.2519/jospt.2000.30.5.249; Davis JA, 2006, CLIN PHYSIOL FUNCT I, V26, P191, DOI 10.1111/j.1475-097X.2006.00674.x; FINCH E, 2002, PHYS REHABILITATION; Gross DP, 2008, J PAIN, V9, P856, DOI 10.1016/j.jpain.2008.04.006; Gross Douglas P, 2006, Curr Pain Headache Rep, V10, P107, DOI 10.1007/s11916-006-0021-3; Hamaoka T, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2805437; Kell RT, 2006, SPINE, V31, P2630, DOI 10.1097/01.brs.0000240647.57959.72; Kell RT, 2004, EUR J APPL PHYSIOL, V91, P499, DOI 10.1007/s00421-003-1014-0; MacLaren JE, 2006, CLIN J PAIN, V22, P392, DOI 10.1097/01.ajp.0000208250.15572.01; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; McCully K K, 2000, Exerc Sport Sci Rev, V28, P123; Okamoto T, 2009, CLIN PHYSIOL FUNCT I, V29, P32, DOI 10.1111/j.1475-097X.2008.00829.x; Paquette S, 2008, WORK, V31, P63; Rashiq S, 2003, PAIN, V106, P119, DOI 10.1016/S0304-3959(03)00299-9; Sgherza AL, 2002, J APPL PHYSIOL, V93, P2023, DOI 10.1152/japplphysiol.00521.2002; Staal JB, 2003, OCCUP ENVIRON MED, V60, P618, DOI 10.1136/oem.60.9.618; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; TROUP JDG, 1987, SPINE, V12, P645, DOI 10.1097/00007632-198709000-00003; *US DEP HHS, 1981, PUBL US DEP HLTH HUM; van Beekvelt MCP, 2001, CLIN SCI, V101, P21, DOI 10.1042/CS20000247; Volinn E, 2009, PAIN, V142, P194, DOI 10.1016/j.pain.2008.12.017; Whipp BJ, 1996, J APPL PHYSIOL, V81, P2674	27	6	6	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-6319	1439-6327		EUR J APPL PHYSIOL	Eur. J. Appl. Physiol.	MAY	2010	109	2					241	250		10.1007/s00421-009-1332-y			10	Physiology; Sport Sciences	Physiology; Sport Sciences	589TO	WOS:000277177000010	20063106				2020-06-30	J	Davis, MP				Davis, Mellar P.			Recent development in therapeutics for breakthrough pain	EXPERT REVIEW OF NEUROTHERAPEUTICS			English	Review						breakthrough; incident pain; intranasal; oral; pain; pharmacokinetic; spinal; sublingual	ORAL TRANSMUCOSAL FENTANYL; CONTROLLED INTRANASAL ANALGESIA; OPIOID-TREATED PATIENTS; DRY POWDER INHALER; 400 MU-G; CANCER PAIN; BUCCAL TABLET; INTRAVENOUS MORPHINE; HEALTHY-VOLUNTEERS; INCIDENT PAIN	Breakthrough pain is defined as transitory flares of pain. Breakthrough pain is caused by cancer, cancer complications, treatment or comorbidities. The usual onset to maximum breakthrough pain intensity time is 3 min and duration is 30 min; therefore, the assessment for response needs to be at short intervals. The rapid onset and offset of pain results in inadequate responses when oral opioids are used to manage pain flares. Several strategies have been used to manage breakthrough pain: titration of the chronic opioid, independent titration of rescue opioids and alternative routes. Buccal fentanyl has a rapid onset to analgesia and appears to be superior to oral morphine. Newer fentanyl preparations have been released to manage breakthrough pain in the opioid-tolerant individual. Other routes of administration that have a rapid onset to analgesia include intranasal hydrophilic and lipophilic opioids, inhaled opioids delivered by special delivery devices and parenteral morphine. In a small series of patients experiencing severe flares of pain with spinal opioids unrelieved by parenteral opioids, sublingual ketamine and bolus doses of intrathecal local anesthetics have been effective. Nonpharmacological approaches to managing activity-related pain include radiation therapy, surgical correction of impending fractures, kyphoplasty and radioisotopes.	[Davis, Mellar P.] Case Western Reserve Univ, Cleveland Clin, Lerner Sch Med, Cleveland, OH 44195 USA; [Davis, Mellar P.] Cleveland Clin, Harry R Horvitz Ctr Palliat Med, Taussig Canc Inst, Cleveland, OH 44195 USA	Davis, MP (reprint author), Case Western Reserve Univ, Cleveland Clin, Lerner Sch Med, 9500 Euclid Ave,R35, Cleveland, OH 44195 USA.	davism6@ccf.org					Al-Ghananeem AM, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070123; Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; BELL MDD, 1985, LANCET, V1, P71; Beyssac E, 1998, BIOPHARM DRUG DISPOS, V19, P401, DOI 10.1002/(SICI)1099-081X(199809)19:6<401::AID-BDD116>3.0.CO;2-U; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; BOUNES V, 2009, J OPIOID MANAGE, V6, P23; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; BURTON A, 2009, AM PAIN SOC 28 ANN S; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Carr DB, 2004, PAIN, V108, P17, DOI 10.1016/j.pain.2003.07.001; Carr DB, 2004, PAIN, V110, P762, DOI 10.1016/j.pain.2004.04.014; CHANG SF, 1988, PHARMACEUT RES, V5, P718, DOI 10.1023/A:1015959912021; CHERNY NI, 1993, CANCER-AM CANCER SOC, V72, P3393, DOI 10.1002/1097-0142(19931201)72:11+<3393::AID-CNCR2820721606>3.0.CO;2-O; Chong C, 2009, CLIN DRUG INVEST, V29, P317, DOI 10.2165/00044011-200929050-00004; Christensen KS, 2008, ANESTH ANALG, V107, P2018, DOI 10.1213/ane.0b013e318187b952; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; Coda BA, 2003, ANESTH ANALG, V97, P117, DOI 10.1213/01.ANE.0000066311.40978.4F; Coluzzi PH, 1998, J PAIN SYMPTOM MANAG, V16, P184, DOI 10.1016/S0885-3924(98)00046-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Cormie PJ, 2008, BMJ-BRIT MED J, V337, P1106; Dale O, 2002, CLIN PHARMACOL THER, V72, P536, DOI 10.1067/mcp.2002.128386; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis T, 1993, Hosp J, V9, P85, DOI 10.1300/J011v09n01_07; Dershwitz M, 2000, ANESTHESIOLOGY, V93, P619, DOI 10.1097/00000542-200009000-00009; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Enting RH, 2005, J PAIN SYMPTOM MANAG, V29, P213, DOI 10.1016/j.jpainsymman.2004.05.010; Farr SJ, 2006, ADV DRUG DELIVER REV, V58, P1076, DOI 10.1016/j.addr.2006.07.013; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Goncalves JAF, 2008, PALLIATIVE MED, V22, P195, DOI 10.1177/0269216307087141; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Fisher K, 2004, J PAIN SYMPTOM MANAG, V28, P619, DOI 10.1016/j.jpainsymman.2004.03.003; Fitzgibbon D, 2003, PAIN, V106, P309, DOI 10.1016/S0304-3959(03)00318-X; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Freye Enno, 2007, Pain Pract, V7, P324, DOI 10.1111/j.1533-2500.2007.00157.x; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; Gonda I, 2006, J AEROSOL MED, V19, P47, DOI 10.1089/jam.2006.19.47; GONDA I, 1999, J AEROSOL MED, V12, P114; Good P, 2009, PALLIATIVE MED, V23, P54, DOI 10.1177/0269216308100249; GOURLAY GK, 1986, PAIN, V25, P297, DOI 10.1016/0304-3959(86)90234-4; Grossman SA, 2000, ONCOLOGY-NY, V14, P135; Hagen NA, 2008, J PAIN SYMPTOM MANAG, V35, P136, DOI 10.1016/j.jpainsymman.2007.03.016; Hagen NA, 2007, J PALLIAT MED, V10, P331, DOI 10.1089/jpm.2006.0163; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Heit HA, 2008, CLIN J PAIN, V24, P93, DOI 10.1097/AJP.0b013e31815ca2b4; HELMERS JHJH, 1989, CAN J ANAESTH, V36, P494, DOI 10.1007/BF03005373; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; INTURRISI CE, 1987, CLIN PHARMACOL THER, V41, P392, DOI 10.1038/clpt.1987.47; Jogani Viral, 2008, Recent Pat Drug Deliv Formul, V2, P25; Kendall JM, 2003, CLIN PHARMACOKINET, V42, P501, DOI 10.2165/00003088-200342060-00001; Kokki H, 2004, CLIN PHARMACOKINET, V43, P613, DOI 10.2165/00003088-200443090-00004; Kokki H, 2006, CLIN PHARMACOKINET, V45, P745, DOI 10.2165/00003088-200645070-00009; KROENENBERG RH, 2002, J PAIN PALLIAT CARE, V16, P27; Kuhlman JJ, 1996, J ANAL TOXICOL, V20, P369, DOI 10.1093/jat/20.6.369; KUNZ KM, 1993, J PAIN SYMPTOM MANAG, V8, P189, DOI 10.1016/0885-3924(93)90125-F; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; LIU K, 1999, AM ASS PHARM SCI ANN; Masood AR, 1996, BRIT J CLIN PHARMACO, V41, P250, DOI 10.1111/j.1365-2125.1996.tb00192.x; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Mathieu N, 2006, CAN J ANAESTH, V53, P60, DOI 10.1007/BF03021528; MCQUAY HJ, 1986, ADV PAIN RES THER, P407; Mendelson J, 1997, J CLIN PHARMACOL, V37, P31, DOI 10.1177/009127009703700106; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2005, J PAIN SYMPTOM MANAG, V30, P485, DOI 10.1016/j.jpainsymman.2005.04.014; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P505, DOI 10.1016/j.jpainsymman.2004.02.024; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2003, J PAIN SYMPTOM MANAG, V25, P302, DOI 10.1016/S0885-3924(03)00047-2; MERCADANTE S, 1995, REGION ANESTH, V20, P343; MERCADANTE S, 2009, 6 C EUR FED INT ASS; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Miszczyk L, 2008, TUMORI J, V94, P813; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Montague L, 2009, PAIN MED, V10, P549, DOI 10.1111/j.1526-4637.2009.00564.x; Oertel BG, 2008, CLIN PHARMACOL THER, V83, P577, DOI 10.1038/sj.clpt.6100441; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; Otulana B, 2004, INT J CLIN PHARM TH, V42, P456; Overhoff KA, 2008, DRUG DEV IND PHARM, V34, P960, DOI [10.1080/03639040802154897, 10.1080/03639040802154897 ]; PANNUTI F, 1982, PHARMACOL RES COMMUN, V14, P369, DOI 10.1016/S0031-6989(82)80107-0; Pavis H, 2002, J PAIN SYMPTOM MANAG, V24, P598, DOI 10.1016/S0885-3924(02)00522-5; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Penson RT, 2002, BRIT J CLIN PHARMACO, V53, P347, DOI 10.1046/j.1365-2125.2002.01554.x; Pitcairn GR, 2000, J AEROSOL MED, V13, P97, DOI 10.1089/089426800418622; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; PORTENOY RK, 1990, PAIN, V45, P273; Portenoy RK, 2004, OXFORD TXB PALLIATIV, P438; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; RALLEY FE, 1989, CAN J ANAESTH, V36, P491, DOI 10.1007/BF03005372; Reisfield GM, 2007, J PALLIAT MED, V10, P465, DOI 10.1089/jpm.2006.0150; Ripamonti C, 2007, SUPPORT CARE CANCER, V15, P339, DOI 10.1007/s00520-006-0131-9; ROBBIE DS, 1979, BRIT J CLIN PHARMACO, V7, pS315, DOI 10.1111/j.1365-2125.1979.tb04706.x; Schuh KJ, 1996, J PHARMACOL EXP THER, V278, P836; SCHWAGMEIER R, 1995, J CLIN ANESTH, V7, P109, DOI 10.1016/0952-8180(94)00023-W; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stoker DG, 2008, PAIN MED, V9, P3, DOI 10.1111/j.1526-4637.2007.00300.x; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; Takala A, 1997, ACTA ANAESTH SCAND, V41, P309, DOI 10.1111/j.1399-6576.1997.tb04684.x; Thipphawong JB, 2003, ANESTHESIOLOGY, V99, P693, DOI 10.1097/00000542-200309000-00026; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; WALLACE M, 2009, AM PAIN SOC 28 ANN S; Ward ME, 1997, CLIN PHARMACOL THER, V62, P596, DOI 10.1016/S0009-9236(97)90079-5; Wardlaw D, 2009, LANCET, V373, P1016, DOI 10.1016/S0140-6736(09)60010-6; Washington SJ, 2009, ANAESTHESIA, V64, P457, DOI [10.1111/j.1365-2044.2009.05911.x, 10.1111/j.1365-2044.2009.05910.x]; Watson NW, 1996, J PHARM PHARMACOL, V48, P1256, DOI 10.1111/j.2042-7158.1996.tb03932.x; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Weber F, 2004, PEDIATR ANESTH, V14, P983, DOI 10.1111/j.1460-9592.2004.01358.x; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Wu HB, 2008, EXPERT OPIN DRUG DEL, V5, P1159, DOI 10.1517/17425247.5.10.1159 ; Wu HY, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-33; Yanagihara Y, 2003, BIOPHARM DRUG DISPOS, V24, P37, DOI 10.1002/bdd.336; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9; Zeppetella G., 2006, COCHRANE DB SYST REV, V1, pCD004311; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003; Zhao Y, 2008, J PHARM PHARMACOL, V60, P1149, DOI 10.1211/jpp.60.9.0005	135	11	13	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1473-7175	1744-8360		EXPERT REV NEUROTHER	Expert Rev. Neurother.	MAY	2010	10	5					757	773		10.1586/ERN.10.41			17	Clinical Neurology; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	595EH	WOS:000277593000016	20420495				2020-06-30	J	Cohen, LB; Cattau, E; Goetsch, A; Shah, A; Weber, JR; Rex, DK; Kline, JM				Cohen, Lawrence B.; Cattau, Edward; Goetsch, Allen; Shah, Atul; Weber, John R.; Rex, Douglas K.; Kline, Jacqueline M.			A Randomized, Double-blind, Phase 3 Study of Fospropofol Disodium for Sedation During Colonoscopy	JOURNAL OF CLINICAL GASTROENTEROLOGY			English	Article						colonoscopy; fospropofol disodium; moderate sedation; randomized clinical trial	MODERATE SEDATION; ENDOSCOPY; PROPOFOL; PATTERNS	Goals: This double-blind, multicenter study evaluated the safety and efficacy of intravenous fospropofol (6.5 mg/kg vs. 2 mg/kg) for moderate sedation in patients undergoing colonoscopy. Methods: In all, 314 patients >= 18 years (American Society of Anesthesiologists PS1 to PS3) were randomized to receive fospropofol 2 mg/kg, fospropofol 6.5-mg/kg, or midazolam 0.02 mg/kg, after pretreatment with intravenous fentanyl 50 mcg. Supplemental doses of study medication were permitted to achieve a Modified Observer's Assessment of Alertness/Sedation scale score <= 4 and to enable the investigator to begin a procedure. The study end points included sedation success, recovery, memory retention, physician satisfaction, and safety. Results: Sedation success was higher in the fospropofol 6.5 mg/kg versus 2 mg/kg group (87% vs. 26%; P<0.001) and was 69% in the midazolam group. Patients in the 6.5-mg/kg group were significantly less likely to remember being awake during the procedure (51% vs. 100% in the 2-mg/kg group, P<0.001; 60% for the midazolam group). Patients in the fospropofol groups had similar memory retention (70% and 82% for the 6.5 mg/kg and 2 mg/kg groups, respectively) compared with 41% for the midazolam group. Mean physician satisfaction scores were higher in the fospropofol 6.5-mg/kg group (7.7) than the 2-mg/kg group (4.5), P<0.001. Most adverse events were mild to moderate in intensity; the most common treatment-related adverse events were paresthesias (68% vs. 60%) and pruritus (16% vs. 26%) in the fospropofol 6.5 and 2 mg/kg groups, respectively. Conclusions: The fospropofol 6.5-mg/kg dosing regimen was well tolerated and effective for sedation during colonoscopy and was associated with higher rates of sedation success, memory retention, and physician satisfaction than the fospropofol 2-mg/kg dose.	[Cohen, Lawrence B.] Mt Sinai Hosp, Dept Med Gastroenterol, New York, NY 10021 USA; [Cattau, Edward] PC Summit Res Solut, Memphis Gastroenterol Grp, Germantown, TN USA; [Goetsch, Allen] Clin Res Associates, Huntsville, AL USA; [Shah, Atul] Shah Associates, Prince Frederick, MD USA; [Weber, John R.] Ctr Digest Hlth, Troy, MI USA; [Rex, Douglas K.] Indiana Univ, Med Ctr, Dept Med, Indianapolis, IN USA; [Kline, Jacqueline M.] Eisai Inc, Woodcliff Lake, NJ USA	Cohen, LB (reprint author), Mt Sinai Hosp, Dept Med Gastroenterol, 311 E 79th St,Suite 2A, New York, NY 10021 USA.	lawrence.cohen@nyga.md			MGI/Eisai Corp	Funding Declaration: This study was funded, designed, conducted, and supervised in full by the sponsor, MGI/Eisai Corp. MGI analyzed and interpreted the study data and oversaw the writing of the study reports. Dr Lawrence B. Cohen and coinvestigators were responsible for analysis and interpretation of the data and are the guarantors of the manuscript and its content. The writing of this manuscript and editorial assistance was supported by MGI/Eisai Corp.	*AM PHARM PARTN, 2004, DEX PACK INS; *BEDF LAB, 2001, MID PACK INS; Cohen LB, 2008, ALIMENT PHARM THERAP, V27, P597, DOI 10.1111/j.1365-2036.2008.03598.x; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; Fechner J, 2003, ANESTHESIOLOGY, V99, P303, DOI 10.1097/00000542-200308000-00012; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; Horn Ed, 2004, Gastrointest Endosc Clin N Am, V14, P247, DOI 10.1016/j.giec.2004.01.001; Luer MS, 1998, NEUROL RES, V20, P178; Perron G, 2003, CAN J ANAESTH, V50, P749, DOI 10.1007/BF03018722; *PFIZ INC PARK DAV, 2002, CER PACK INS; RASCHE H, 1986, DEUT MED WOCHENSCHR, V111, P1406, DOI 10.1055/s-2008-1068642; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; SHAH A, 2007, ANESTHESIOLOGY, V107, pA46; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith I, 1997, J CLIN ANESTH, V9, P148, DOI 10.1016/S0952-8180(96)00240-1; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4	17	30	33	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0192-0790			J CLIN GASTROENTEROL	J. Clin. Gastroenterol.	MAY-JUN	2010	44	5					345	353		10.1097/MCG.0b013e3181c2987e			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	588VK	WOS:000277102300009	19996984				2020-06-30	J	Kirschner, R; Donovan, JW				Kirschner, Ron; Donovan, J. Ward			SEROTONIN SYNDROME PRECIPITATED BY FENTANYL DURING PROCEDURAL SEDATION	JOURNAL OF EMERGENCY MEDICINE			English	Article						serotonin syndrome; serotonin toxicity; fentanyl; drug interaction; procedural sedation	TOXICITY; RIGIDITY; VOLUNTEERS; DIAGNOSIS	Fentanyl is frequently used for analgesia during emergency procedures. We present the cases of 2 patients who developed agitation and delirium after intravenous fentanyl administration. These patients were chronically taking selective serotonin reuptake inhibitors (SSRIs). Both developed neuromuscular examinations consistent with serotonin syndrome, a diagnosis that must be established on the basis of clinical criteria. Although they required aggressive supportive care, including mechanical ventilation, both patients made a full recovery. Use of fentanyl for procedural sedation may precipitate serotonin syndrome in patients taking SSRIs or other serotonergic drugs. (C) 2010 Elsevier Inc.	[Kirschner, Ron; Donovan, J. Ward] Penn State Univ Toxicol Fellowship, PinnacleHlth Toxicol Ctr, Harrisburg, PA USA	Kirschner, R (reprint author), Scott & White Mem Hosp & Clin, Cent Texas Poison Ctr, 2401 S 31 St, Temple, TX 76508 USA.						Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Bpharm SR, 2003, CAN J ANAESTH, V50, P32, DOI 10.1007/BF03020183; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Giese SY, 2001, PLAST RECONSTR SURG, V107, P293, DOI 10.1097/00006534-200101000-00069; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Isbister GK, 2007, MED J AUSTRALIA, V187, P361, DOI 10.5694/j.1326-5377.2007.tb01282.x; Isbister GK, 2005, CLIN NEUROPHARMACOL, V28, P205, DOI 10.1097/01.wnf.0000177642.89888.85; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; MILLS K, 2005, CRITICAL CARE TOXICO, P281; Murphy GM, 2003, AM J PSYCHIAT, V160, P1830, DOI 10.1176/appi.ajp.160.10.1830; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; Stuerenburg HJ, 2000, J NEUROL NEUROSUR PS, V69, P281, DOI 10.1136/jnnp.69.2.281; Tao R, 2003, BRIT J PHARMACOL, V139, P1498, DOI 10.1038/sj.bjp.0705378; WEINGER MB, 1987, ANESTHESIOLOGY, V67, P348, DOI 10.1097/00000542-198709000-00012	19	23	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	MAY	2010	38	4					477	480		10.1016/j.jemermed.2008.01.003			4	Emergency Medicine	Emergency Medicine	597ZZ	WOS:000277802600013	18757161				2020-06-30	J	Vey, EL; Kovelman, I				Vey, Eric L.; Kovelman, Inna			Adverse events, toxicity and post-mortem data on duloxetine: Case reports and literature survey	JOURNAL OF FORENSIC AND LEGAL MEDICINE			English	Review						Duloxetine; Toxicity; Post-mortem; Autopsy; Suicide; Overdose	DATA-SYSTEM NPDS; AMERICAN-ASSOCIATION; DOUBLE-BLIND; ANTIDEPRESSANT DRUG; BACLOFEN OVERDOSE; NEUROPATHIC PAIN; HEALTHY-SUBJECTS; PHARMACOKINETICS; INHIBITOR; SEROTONIN	Duloxetine, a dual acting norepinephrine serotonin reuptake inhibitor, is a relatively new pharmacologic agent utilized in the treatment of depression, as well as diabetic neuropathic pain, fibromyalgia, and female stress urinary incontinence. This expanding scope of usage will inevitably lead to its eventual appearance during routine post-mortem toxicologic assays. Currently there is a paucity of post-mortem toxicologic data concerning duloxetine. The current report provides six additional case reports of postmortem duloxetine levels, along with a review of duloxetine's pharmacokinetics, and the toxicologic manifestations which have been reported in the literature. The post-mortem levels reported, including the highest level recorded to date, are integrated with previously published reports to generate a foundation for a nascent guide to the interpretation of post-mortem duloxetine levels that could be encountered during routine post-mortem toxicologic analyses, and establish a basis upon which the establishment of toxic and lethal thresholds for this compound can be further elucidated with greater clarity. (C) 2010 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.	[Vey, Eric L.] Erie Cty Coroners Off, Erie, PA 16501 USA; [Kovelman, Inna] Lehigh Valley Med Ctr, Lehigh, PA USA	Vey, EL (reprint author), Erie Cty Coroners Off, 140 W 6th St, Erie, PA 16501 USA.	padrdeat@velocity.net					Anderson D, 2006, J ANAL TOXICOL, V30, P576, DOI 10.1093/jat/30.8.576; Arnold LM, 2005, PAIN, V119, P5, DOI 10.1016/j.pain.2005.06.031; Balhara YPS, 2007, J POSTGRAD MED, V53, P44, DOI 10.4103/0022-3859.30328; BASELT RC, 2008, DISPOSITION TOXIC DR, P617; BASELT RC, 2008, DISPOSITION TOXIC CH, P134; Bergman BR, 2008, ANN INTERN MED, V149, P218, DOI 10.7326/0003-4819-149-3-200808050-00021; Bronstein AC, 2007, CLIN TOXICOL, V45, P815, DOI 10.1080/15563650701754763; Bronstein AC, 2008, CLIN TOXICOL, V46, P927, DOI 10.1080/15563650802559632; Bymaster FP, 2005, CURR PHARM DESIGN, V11, P1475, DOI 10.2174/1381612053764805; Chalon SA, 2003, NEUROPSYCHOPHARMACOL, V28, P1685, DOI 10.1038/sj.npp.1300209; Chan C, 2007, BRIT J CLIN PHARMACO, V63, P310, DOI 10.1111/j.1365-2125.2006.02770.x; Chong CF, 2005, EMERG MED J, V22, P673, DOI 10.1136/emj.2003.011908; *CIPL LTD, 2008, PROD INF CIPL THER I; Cook DS, 2000, J CLIN PATHOL, V53, P282, DOI 10.1136/jcp.53.4.282; CRUZ MP, 2006, P & T, V31, P84; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; Cuevas CD, 2007, J CLIN PSYCHOPHARM, V27, P106; Deuschle M, 2006, PHARMACOPSYCHIATRY, V39, P237, DOI 10.1055/s-2006-951608; *E LILL CO, 2004, PRESCR INF CYMB DUL; *E LILL CO, 2005, CYMBALTA DUL HYDR DE; EISENBERG P, 2005, SAFETY DATA CYMBALTA; Espeleta VJ, 2007, CHEST, V131, P901, DOI 10.1378/chest.06-1659; Ezzo DC, 2007, AM J HEALTH-SYST PH, V64, P495, DOI 10.2146/ajhp060069; FULLER RW, 1994, J PHARMACOL EXP THER, V269, P132; HARIJE AJ, 2006, CLIN GASTROENTEROL H, V4, P912; Kajdasz DK, 2007, CLIN THER, V29, P2536, DOI 10.1016/j.clinthera.2007.12.002; KAVANAGH RE, 2002, 21427 FOOD DRUG ADM; Lai MW, 2006, CLIN TOXICOL, V44, P803, DOI 10.1080/15563650600907165; Lantz RJ, 2003, DRUG METAB DISPOS, V31, P1142, DOI 10.1124/dmd.31.9.1142; Loper T, 2007, PSYCHOSOMATICS, V48, P179, DOI 10.1176/appi.psy.48.2.179; Lott RS, 2003, ADV PHARMACOL, V1, P228; Ma N, 2007, CLIN CHIM ACTA, V380, P100, DOI 10.1016/j.cca.2007.01.018; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319; MENCHETTI M, WORLD J BIOL PSYCHAI, P1; MINYARD AN, 1999, 51 ANN M AM AC FOR S; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; OGDEN CL, 2004, [No title captured], V347, P1, DOI DOI 10.1377/HLTHAFF.28.5.W822; Oulis P, 2008, J CLIN PSYCHOPHARM, V28, P104, DOI 10.1097/jcp.0b013e318160863e; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; Preskorn Sheldon H, 2004, J Psychiatr Pract, V10, P375; Schulz M, 2003, PHARMAZIE, V58, P447; Sharma A, 2000, J CLIN PHARMACOL, V40, P161, DOI 10.1177/00912700022008810; Skinner MH, 2004, BRIT J CLIN PHARMACO, V57, P54, DOI 10.1046/j.1365-2125.2003.01963.x; Suri A, 2005, INT J CLIN PHARM TH, V43, P78; SUSSMAN N, 2003, [No title captured], V5, P19; Wall GC, 2006, AM J CRIT CARE, V15, P611; Watson WA, 2005, AM J EMERG MED, V23, P589, DOI 10.1016/j.ajem.2005.05.001; WONG DT, 1988, LIFE SCI, V43, P2049, DOI 10.1016/0024-3205(88)90579-6; Yang J, 2007, CHROMATOGRAPHIA, V66, P389, DOI 10.1365/s10337-007-0337-0	49	12	13	2	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1752-928X	1532-2009		J FORENSIC LEG MED	J. Forensic Leg. Med.	MAY	2010	17	4					175	185		10.1016/j.jflm.2010.02.002			11	Medicine, Legal	Legal Medicine	731WJ	WOS:000288140400001	20382351				2020-06-30	J	Tang, YY; Lin, XM; Huang, W; Jiang, XQ				Tang, Yu-Ying; Lin, Xue-Mei; Huang, Wei; Jiang, Xiao-Qing			Addition of Low-Dose Ketamine to Propofol-Fentanyl Sedation for Gynecologic Diagnostic Laparoscopy: Randomized Controlled Trial	JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY			English	Article						Fentanyl; Gynecologic diagnostic laparoscopy; Ketamine; Propofol	POSTOPERATIVE NAUSEA; SUPPLEMENT PROPOFOL; ANESTHESIA; CHILDREN; PAIN; COMBINATION; RESPIRATION; INJECTION; QUALITY; SOCIETY	Study Objective: To assess the feasibility of propofol-fentanyl sedation protocol with ketamine for gynecologic diagnostic laparoscopy. Design: Prospective, double-blind, randomized study (Canadian Task Force classification I). Setting: Outpatient operating unit in a university hospital specializing in obstetrics and gynecology. Patients: Eighty women who underwent outpatient gynecologic diagnostic laparoscopy. Interventions: Patients were randomly assigned to receive fentanyl. 1 mu g/kg, and normal saline solution (group F, n = 40), or fentanyl, 1 mu g/kg, and ketamine, 0.5 mg/kg (group FK, n = 40), followed by propofol, 2.0 mg/kg, for sedation induction. During surgery, propofol was supplemented to achieve a target Ramsey score of 6, and cardiopulmonary support was required to maintain stable vital signs. Measurements and Main Results: Five of 40 patients (12.5%) in group FK reported pain associated with propofol injection compared with 33 of 40 patients (82.5%) in group F. During surgery, 7 patients (17.5%) in group FK required rescue propofol compared with 32 patients (80.0%) in group F (p < .001). The mean (SD) rescue dose of propofol was 0.4 (0.5) mg/kg in group FK compared with 1.6 (0.6) mg/kg in group F (p < .001). In group F, 17 patients (42.5%) required assisted mask ventilation because of respiratory depression, and in 21 patients (52.5%), atropine therapy was necessary to treat bradycardia, compared with 6 patients (15.0%) and 11 patients (27.5%), respectively, in group FK (p < .05). The mean arterial blood pressure at the end of induction, pneumoperitoneum inflation, and trocar insertion was significantly decreased in group F compared with group FK (p < .05). No differences were observed between the 2 groups insofar as operation duration, recovery time, discharge time, intraoperative awareness, incidence of postoperative nausea and vomiting, and postoperative pain. Although patient satisfaction scores were comparable, a higher degree of gynecologist satisfaction was observed in group FK compared with group F (p < .001). Conclusion: Addition of low-dose ketamine to propofol-fentanyl sedation can provide more stable and satisfactory operation conditions in gynecologic diagnostic laparoscopy. journal of Minimally Invasive Gynecology (2010) 17, 325-330 (C) 2010 AAGL. All rights reserved.	[Tang, Yu-Ying; Lin, Xue-Mei; Huang, Wei; Jiang, Xiao-Qing] Sichuan Univ, W China Hosp 2, Dept Anesthesiol, Chengdu 610064, Peoples R China	Tang, YY (reprint author), 20,Sect 3,S Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.	yuyingtang@sohu.com					Badrinath S, 2000, ANESTH ANALG, V90, P858, DOI 10.1213/00000539-200004000-00016; Bosteels J, 2007, HUM REPROD UPDATE, V13, P477, DOI 10.1093/humupd/dmm014; BRAD DV, 2007, J BRONCHOL, V14, P173; BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Erden IA, 2009, PEDIATR ANESTH, V19, P500, DOI 10.1111/j.1460-9592.2009.02971.x; Frey K, 1999, ANESTH ANALG, V89, P317, DOI 10.1097/00000539-199908000-00013; Gan TJ, 2007, ANESTH ANALG, V105, P1615, DOI 10.1213/01.ane.0000295230.55439.f4; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; Gerges FJ, 2006, J CLIN ANESTH, V18, P67, DOI 10.1016/j.jclinane.2005.01.013; Guzick DS, 1997, FERTIL STERIL, V67, P822, DOI 10.1016/S0015-0282(97)81392-1; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; Hollman GA, 2008, PEDIATR CRIT CARE ME, V9, P616, DOI 10.1097/PCC.0b013e31818e3ad3; Horn Ed, 2004, Gastrointest Endosc Clin N Am, V14, P247, DOI 10.1016/j.giec.2004.01.001; HUI TW, 1995, ANESTHESIOLOGY, V82, P641, DOI 10.1097/00000542-199503000-00005; KANTO J, 1989, CLIN PHARMACOKINET, V17, P308, DOI 10.2165/00003088-198917050-00002; KESTIN IG, 1989, ANAESTHESIA, V44, P994, DOI 10.1111/j.1365-2044.1989.tb09207.x; Koo SW, 2006, ANESTH ANALG, V103, P1444, DOI 10.1213/01.ane.0000243334.83816.53; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; LERMAN J, 1992, [No title captured], V69, P24; Leslie K, 2005, CURR OPIN ANESTHESIO, V18, P431, DOI 10.1097/01.aco.0000168328.02444.3c; Lichtenbelt BJ, 2004, CLIN PHARMACOKINET, V43, P577, DOI 10.2165/00003088-200443090-00002; MCCRIRRICK A, 1990, ANAESTHESIA, V45, P443, DOI 10.1111/j.1365-2044.1990.tb14329.x; Moerman AT, 2004, J CLIN ANESTH, V16, P237, DOI 10.1016/j.jclinane.2003.08.005; Mortero RF, 2001, ANESTH ANALG, V92, P1465; ROWE PJ, 1993, WHO MANUAL STANDARDI, P64; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Visser K, 2001, ANESTHESIOLOGY, V95, P616, DOI 10.1097/00000542-200109000-00012; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	30	8	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1553-4650			J MINIM INVAS GYN	J. Mimim. Invasive Gynecol.	MAY-JUN	2010	17	3					325	330		10.1016/j.jmig.2010.01.017			6	Obstetrics & Gynecology	Obstetrics & Gynecology	597US	WOS:000277788200010	20417423				2020-06-30	J	Prodduturi, S; Sadrieh, N; Wokovich, AM; Doub, WH; Westenberger, BJ; Buhse, L				Prodduturi, Suneela; Sadrieh, Nakissa; Wokovich, Anna M.; Doub, William H.; Westenberger, Benjamin J.; Buhse, Lucinda			Transdermal Delivery of Fentanyl from Matrix and Reservoir Systems: Effect of Heat and Compromised Skin	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						fentanyl; transdermal drug delivery systems; matrix; reservoir; compromised skin; skin permeation		The United States Food and Drug Administration (FDA) has received numerous reports of serious adverse events, including death, in patients using fentanyl transdermal systems (FTS). To gain a better understanding of these problems, the current research focuses on the in vitro characterization of fentanyl reservoir (Duragesic (R)) and matrix (Mylan) systems with respect to drug release and skin permeation under conditions of elevated temperature and compromised skin. In addition, different synthetic membrane barriers were evaluated to identify the one that best simulates fentanyl skin transport, and thus may be useful as a model for these systems in future studies. The results indicate that reservoir and matrix FTS are comparable when applied to intact skin at normal skin temperature but the kinetics of drug delivery are different in the two systems. At 40 degrees C, the permeation rate of fentanyl was twice that seen at 32 degrees C over the first 24h in both systems; however, the total drug permeation in 72 h is significantly higher in the reservoir FTS. When applied to partially compromised skin, matrix FTS has a greater permeation enhancement effect than reservoir FTS. The intrinsic rate limiting membrane of the reservoir system served to limit drug permeation when the skin (barrier) permeability was compromised. Different ethylene vinyl acetate membranes were shown to have fentanyl permeability values encompassing the variability in human skin. Results using the in vitro model developed using synthetic membranes suggest that they mimic the effect of compromised skin on fentanyl permeability. Especially for highly potent drugs such as fentanyl, it is important that patients follow instructions regarding application of heat and use of the product on compromised skin. (C) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:2357-2366, 2010	[Sadrieh, Nakissa; Wokovich, Anna M.; Doub, William H.; Westenberger, Benjamin J.; Buhse, Lucinda] US FDA, Div Pharmaceut Anal, St Louis, MO 63101 USA; [Prodduturi, Suneela] Aizant Drug Res Solut Private Ltd, Hyderabad 50014, Andhra Pradesh, India	Doub, WH (reprint author), US FDA, Div Pharmaceut Anal, 1114 Market St Room 1002, St Louis, MO 63101 USA.	william.doub@fda.hhs.gov					[Anonymous], 2008, PRIC REC 25 MCG HR D; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Bashir SJ, 2001, SKIN RES TECHNOL, V7, P40, DOI 10.1034/j.1600-0846.2001.007001040.x; BRONAUGH RL, 1985, J PHARM SCI, V74, P1062, DOI 10.1002/jps.2600741008; *FDA, 2007, FDA ISS PUBL HLTH AD; *FDA, 2008, ACT REC CERT FENT PA; *FDA, 2008, SAF AL FENT TRANSD S; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018; HULL W, 2002, J APPL RES CLIN EXP, V2, P69; *JANSS PHARM PROD, 2007, DUR FENT TRANSD SYST; Mehdizadeh Amir, 2004, Acta Pharmaceutica (Zagreb), V54, P301; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; *MYL TECHN I, 2007, FENT TRANSD SYST FEN; NANGIA A, 2009, PERCUTANEOUS ABSORPT, P587; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; Schaefer U, 1996, PHARMACOL RES S, V13, P366; *SCHWARZ PHARM, 2008, PRESCR PATCH NEUPR R; SHAW JE, 1979, DRUG ABSORPTION, P186; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; Wagner H, 2000, PHARM RES-DORDR, V17, P1475, DOI 10.1023/A:1007648807195	21	42	43	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	MAY	2010	99	5					2357	2366		10.1002/jps.22004			10	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	589FO	WOS:000277132500013	19967778				2020-06-30	J	Carson, HJ; Knight, LD; Dudley, MH; Garg, U				Carson, Henry J.; Knight, Laura D.; Dudley, Mary H.; Garg, Uttam			A fatality involving an unusual route of fentanyl delivery: Chewing and aspirating the transdermal patch	LEGAL MEDICINE			English	Article						Fentanyl; Transdermal patch; Drug abuse; Methamphetamine	DEATHS; ABUSE; PAIN	We recently encountered a subject who died from an uncommon misuse of a fentanyl transdermal patch, chewing, followed by complications of aspiration of the patch. We report this case to alert medical examiners to the troubling trend of increased fentanyl patch abuse and its expanding range of misuses and associated morbidities. The decedent was a 28-year-old white male with a past medical history of prescription drug abuse who was pronounced dead in the emergency department shortly after arrival. An autopsy was completed and a tough but stretchy beige foreign body was identified lodged in a mainstem bronchus. Toxicological analysis of femoral blood showed methamphetamine, fentanyl and norfentanyl concentrations of 1456, 8.6 and 1.4 ng/mL, respectively. Individuals who abuse prescription medications often modify the route of administration of the drug from the intended method. As this case demonstrates, this choice can be fatal. The novel findings include a chewed patch, aspiration of a drug patch, and combination with an illicit drug at potentially lethal blood levels for both methamphetamine and fentanyl in a novice user. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Carson, Henry J.; Dudley, Mary H.] Off Jackson Cty Med Examiner, Kansas City, MO 64108 USA; [Knight, Laura D.] Med Examiners Off, Onondaga Cty Dept Hlth, Syracuse, NY USA; [Knight, Laura D.] SUNY Syracuse, Sch Med, Syracuse, NY USA; [Garg, Uttam] Univ Missouri, Sch Med, Dept Pathol & Lab Med, Childrens Mercy Hosp & Clin, Kansas City, MO 64108 USA	Carson, HJ (reprint author), Off Jackson Cty Med Examiner, 660 E 24th St, Kansas City, MO 64108 USA.	hjcmd@earthlink.net					Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Degenhardt Louisa, 2005, J Clin Forensic Med, V12, P187, DOI 10.1016/j.jcfm.2004.11.003; Karch SB, 1999, J FORENSIC SCI, V44, P359; KARCH SB, 2009, KARCHS PATHOLOGY DRU, P261; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Molina DK, 2010, HDB FORENSIC TOXICOL; Otis J, 2006, CURR MED RES OPIN, V22, P1493, DOI 10.1185/030079906X115540; Oxford University The Physical and Theoretical Chemistry Laboratory, 2009, CHEM OTH SAF INF; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Scott G, 2007, J URBAN HEALTH, V84, P292, DOI 10.1007/s11524-007-9157-7; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thomas S, 2008, AM J FOREN MED PATH, V29, P162, DOI 10.1097/PAF.0b013e3181651b66; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; 2007, DAILY MED        APR	19	23	23	1	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED	Leg. Med.	MAY	2010	12	3					157	159		10.1016/j.legalmed.2010.03.001			3	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	587TZ	WOS:000277017500011	20362485				2020-06-30	J	Bourne, MH; Chelly, JE; Damaraju, CV; Nelson, WW; Schein, JR; Hewitt, DJ				Bourne, Michael H.; Chelly, Jacques E.; Damaraju, C. V.; Nelson, Winnie W.; Schein, Jeff R.; Hewitt, David J.			Physical Therapists' Perceptions of Ease of Care in Patients Receiving 2 Forms of Analgesia After Total Hip Arthroplasty	PHYSICAL THERAPY			English	Article							IONTOPHORETIC TRANSDERMAL SYSTEM; POSTOPERATIVE PAIN MANAGEMENT; PLACEBO-CONTROLLED TRIAL; MORPHINE; EFFICACY; SAFETY; REHABILITATION; MULTICENTER; SURGERY; PERIOD	Background. Pain management modalities that facilitate patient mobility may contribute to recovery after total hip replacement (THR) surgery. Objective. The aim of this study was to evaluate the impact of morphine intravenous (IV) patient-controlled analgesia (PCA) and the fentanyl iontophoretic transdermal system (fentanyl ITS) on physical therapists' ability to complete care tasks for patients after THR. Design. The data were from an open-label, randomized, multicenter, active-control phase IIIb clinical trial. Methods. The settings were 52 US-based teaching and community hospitals. The patients were >= 18 years of age (mean [SEM]: 62.8 [0.6] years in the fentanyl ITS group and 62.9 [0.6] years in the morphine IV PCA group); had an American Society of Anesthesiologists physical status of I, II, or III; and were scheduled to undergo primary unilateral THR surgery. The patients were randomized to receive analgesia for up to 72 hours via the fentanyl ITS (40 mu g of fentanyl over 10 minutes for up to 6 doses per hour for 24 hours or 80 closes per system, whichever occurred first) or morphine IV PCA (1-mg bolus closes [with a 5-minute lockout interval between doses] for up to 10 closes per hour for 24 hours). All patients received the usual treatment administered by physical therapists. After each therapy session, physical therapists completed a validated Physical Therapist Ease-of-Care Questionnaire, which included time efficiency and convenience subscales (lower scores indicated more positive responses) and a satisfaction subscale (a higher score indicated a more positive response). Therapists whose average scores were on all items of the time efficiency and convenience subscales or on both items of the satisfaction subscale were considered responders. Results. Higher percentages of physical therapists were responders for the fentanyl ITS than for morphine IV PCA on the subscales that assessed time efficiency (84.9% and 59.1%, respectively), convenience (86.6% and 71.2%, respectively), and satisfaction (54.3% and 30.5%, respectively). Higher percentages of physical therapists favored the fentanyl ITS than favored morphine IV PCA. Limitations. The trial was limited by its open-label design, and physical therapists were more familiar with TV PCA than with the fentanyl ITS. Conclusions. The findings demonstrate benefits to physical therapists of using the fentanyl ITS over morphine IV PGA in terms of time efficiency, convenience, and satisfaction.	[Bourne, Michael H.] St Marks Hosp, Div Orthopaed Surg, Salt Lake Orthopaed Clin, Salt Lake City, UT 84124 USA; [Chelly, Jacques E.] Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Div Acute Intervent Perioperat Pain & Reg Anesthe, Pittsburgh, PA 15260 USA; [Chelly, Jacques E.] UPMC, Shadyside Hosp, Pittsburgh, PA USA; [Chelly, Jacques E.] UPMC, Presbyterian Shadyside Hosp, Pittsburgh, PA USA; [Damaraju, C. V.] Ortho McNeil Janssen Sci Affairs LLC, Biostat, Raritan, NJ USA; [Nelson, Winnie W.; Schein, Jeff R.] Ortho McNeil Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res, Raritan, NJ USA; [Hewitt, David J.] Merck & Co Inc, Merck Res Labs, Clin Neurosci, N Wales, PA USA	Bourne, MH (reprint author), St Marks Hosp, Div Orthopaed Surg, Salt Lake Orthopaed Clin, 1160 E 3900 S,Suite 5000, Salt Lake City, UT 84124 USA.	mhbourne@msn.com			Johnson & Johnson Pharmaceutical Services, LLCJohnson & Johnson USA; Ortho-McNeil Inc	The authors thank the following physical therapists for their help in conducting this study and for providing editorial assistance: Gina Rose, Jim Swinyard, Marcus Schellenburg, and Garth Dunford. Editorial assistance was provided by Ashley O'Dunne, PhD, of MedErgy and was funded by Johnson & Johnson Pharmaceutical Services, LLC. The authors were not compensated and retained full editorial control over the content of the article.; Ortho-McNeil Inc was the sponsor of the original clinical trial from which data for the present analysis were obtained.	Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Carr DB, 2005, REGION ANESTH PAIN M, V30, P286, DOI 10.1016/j.rapm.2004.10.009; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Chumbley GM, 1999, ANAESTHESIA, V54, P386, DOI 10.1046/j.1365-2044.1999.00836.x; DEFRANCES CJ, 2006, ADV DATA VITAL HLTH, V371; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Harding G, 2004, VALUE HEALTH, V7, P728; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; Nixon J, 2000, INT J NURS STUD, V37, P279, DOI 10.1016/S0020-7489(99)00059-0; PHILLIPS S, 2005, REG ANESTH PAIN MED, V30; Ramzi DW, 2004, AM FAM PHYSICIAN, V69, P2829; Roos EM, 2003, CURR OPIN RHEUMATOL, V15, P160, DOI 10.1097/00002281-200303000-00014; Rothman M, 2009, CURR MED RES OPIN, V25, P1433, DOI 10.1185/03007990902862032; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; The American Society of Anesthesiologists, ASA PHYS STAT CLASS; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Weill-Engerer S, 2004, J AM GERIATR SOC, V52, P1299, DOI 10.1111/j.1532-5415.2004.52359.x	27	6	6	0	6	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	0031-9023			PHYS THER	Phys. Ther.	MAY	2010	90	5					707	713		10.2522/ptj.20080323			7	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	592TA	WOS:000277402000007	20299408	Bronze			2020-06-30	J	Nguyen, M; Vandenbroucke, F; Roy, JD; Beaulieu, D; Seal, RF; Lapointe, R; Dagenais, M; Roy, A; Massicotte, L				Nguyen, Micheline; Vandenbroucke, Franck; Roy, Jean-Denis; Beaulieu, Danielle; Seal, Robert F.; Lapointe, Real; Dagenais, Michel; Roy, Andre; Massicotte, Luc			Evaluation of the Addition of Bupivacaine to Intrathecal Morphine and Fentanyl for Postoperative Pain Management in Laparascopic Liver Resection	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							INCREASED PROTHROMBIN TIME; DONOR RIGHT HEPATECTOMY; LAPAROSCOPIC CHOLECYSTECTOMY; PREEMPTIVE ANALGESIA; EPIDURAL ANALGESIA; CENTRAL SENSITIZATION; INJURY DISCHARGE; ANESTHESIA; SURGERY; RELIEF	Background: Optimal modality of pain management after liver resection has been controversial. Epidural analgesia is often avoided because of transient coagulopathy and the associated risk of epidural hematoma. Single-dose intrathecal morphine has been shown to be an effective alternative in open liver resection. The purpose of this trial was to compare the analgesic efficacy of intrathecal morphine and fentanyl versus intrathecal bupivacaine 0.5%, morphine, and fentanyl for patients undergoing laparoscopic liver resection. Methods: This prospective randomized controlled double-blind trial compared morphine consumption between control (CTRL) group receiving a spinal injection of fentanyl 15 mu g and morphine 0.4 mg and bupivacaine (BUPI) group receiving the same medications in addition to bupivacaine 0.5% (15 mg). Forty patients scheduled for laparoscopic liver resection were enrolled. Primary outcome was intravenous patient-controlled analgesia morphine consumption measured at 6, 9, 12, 18, 24, 36, and 48 hrs after spinal injection. Secondary outcomes were pain scores at rest and with movement, sedation, nausea, pruritus, and respiratory rate. Results: Cumulative doses of morphine were significantly lower for all time intervals in the BUPI group: 54 (30) versus 94 (47) mg (P = 0.01) at 48 hrs. Morphine consumption was significantly lower for each time interval up to 18 hrs. Pain scores with movement were significantly lower ill the BUPI group up to 24 hrs after injection. Pain score at rest was significantly lower in the BUPI group 9 hrs after injection. There were no differences in adverse effects. Conclusions: The addition of bupivacaine to intrathecal morphine and fentanyl significantly reduced intravenous morphine consumption after laparoscopic liver resection.	[Nguyen, Micheline; Roy, Jean-Denis; Beaulieu, Danielle; Massicotte, Luc] Univ Montreal, Ctr Hosp, Hop St Luc, Dept Anesthesiol, Montreal, PQ H2X 3J4, Canada; [Vandenbroucke, Franck; Lapointe, Real; Dagenais, Michel; Roy, Andre] Univ Montreal, Ctr Hosp, Hop St Luc, Dept Surg,Hepatobiliary Serv, Montreal, PQ H2X 3J4, Canada; [Seal, Robert F.] Univ Alberta, Dept Anesthesiol, Edmonton, AB, Canada	Massicotte, L (reprint author), Univ Montreal, Ctr Hosp, Hop St Luc, Dept Anesthesiol, 1058 St Denis, Montreal, PQ H2X 3J4, Canada.	luc.massicotte@umontreal.ca					Belli G, 2007, SURG ENDOSC, V21, P2004, DOI 10.1007/s00464-007-9503-6; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Borromeo CJ, 2000, ANESTH ANALG, V91, P1139, DOI 10.1097/00000539-200011000-00018; Choiniere M, 1996, J PAIN SYMPTOM MANAG, V11, P299, DOI 10.1016/0885-3924(95)00204-9; Dahl JB, 2004, BRIT MED BULL, V71, P13, DOI 10.1093/bmb/ldh030; De Pietri L, 2006, ANESTH ANALG, V102, P1157, DOI 10.1213/01.ane.0000198567.85040.ce; Erol DD, 2008, ADV THER, V25, P45, DOI 10.1007/s12325-008-0005-2; Heitmiller E, 2007, ANESTHESIOLOGY, V106, P654, DOI 10.1097/01.anes.0000264753.39511.4c; Ho AMH, 2007, HEPATO-GASTROENTEROL, V54, P1494; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Katz J, 2003, ANESTHESIOLOGY, V98, P1449, DOI 10.1097/00000542-200306000-00023; Koffron AJ, 2007, ANN SURG, V246, P385, DOI 10.1097/SLA.0b013e318146996c; Kong SK, 2002, ANAESTHESIA, V57, P1168, DOI 10.1046/j.1365-2044.2002.02873.x; LASCELLES BDX, 1995, PAIN, V62, P201, DOI 10.1016/0304-3959(94)00266-H; Malinovsky JM, 1999, ANESTHESIOLOGY, V91, P1260, DOI 10.1097/00000542-199911000-00016; Massicotte L, 2006, LIVER TRANSPLANT, V12, P117, DOI 10.1002/lt.20559; Massicotte L, 2009, ACTA ANAESTH SCAND, V53, P641, DOI 10.1111/j.1399-6576.2009.01930.x; Matot I, 2002, ANESTH ANALG, V95, P1179, DOI 10.1097/00000539-200211000-00009; Melzack R, 1989, J Pain Symptom Manage, V4, P157, DOI 10.1016/0885-3924(89)90010-9; Meylan N, 2009, BRIT J ANAESTH, V102, P156, DOI 10.1093/bja/aen368; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; Mondor ME, 2010, REGION ANESTH PAIN M, V35, P51, DOI 10.1097/AAP.0b013e3181c6f8f2; Motamed C, 2000, ANAESTHESIA, V55, P118, DOI 10.1046/j.1365-2044.2000.055002118.x; Parlow JL, 2004, ANESTH ANALG, V98, P1072, DOI 10.1213/01.ANE.0000105880.59649.5C; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; Roy JD, 2006, ANESTH ANALG, V103, P990, DOI 10.1213/01.ane.0000238040.41872.7e; Schumann R, 2004, LIVER TRANSPLANT, V10, P363, DOI 10.1002/lt.20059; SELTZER Z, 1991, PAIN, V46, P327, DOI 10.1016/0304-3959(91)90115-E; Siniscalchi A, 2004, LIVER TRANSPLANT, V10, P1144, DOI 10.1002/lt.20235; WELSH EM, 1995, PAIN, V60, P159, DOI 10.1016/0304-3959(94)00110-Z; Wills VL, 2000, BRIT J SURG, V87, P273, DOI 10.1046/j.1365-2168.2000.01374.x; YAMAMOTO T, 1993, ANESTHESIOLOGY, V79, P993, DOI 10.1097/00000542-199311000-00018	33	4	4	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAY-JUN	2010	35	3					261	266		10.1097/AAP.0b013e3181de12e4			6	Anesthesiology	Anesthesiology	598EK	WOS:000277815800007	20921837				2020-06-30	J	Tang, QF; Qian, YN; Zhang, QW; Yang, JJ; Wang, ZY				Tang, Qifeng; Qian, Yanning; Zhang, Qingwei; Yang, Jianjun; Wang, Zhongyun			Effects of different priming doses of propofol on fentanyl-induced cough during anesthesia induction: A preliminary randomized controlled study	UPSALA JOURNAL OF MEDICAL SCIENCES			English	Article							SMOOTH-MUSCLE; ASTHMA; BOLUS	Fentanyl-induced cough is not an uncommon condition during the induction of general anesthesia. A preliminary randomized controlled study was designed to observe the effects of different priming doses of propofol on fentanyl-induced cough during anesthesia induction. A total of 120 patients were randomized into 4 groups (n = 30) to receive the intravenous injection of intralipid (group I), propofol 1 mg center dot kg<SU-1</SU (group II), propofol 1.5 mg center dot kg<SU-1</SU (group III), or propofol 2 mg center dot kg<SU-1</SU (group IV) 1 minute before a bolus of fentanyl 2.5 mu g center dot kg<SU-1</SU. The occurrence and severity of cough were recorded for 2 minutes after fentanyl bolus. The severity of cough was graded as none (grade 0), mild (grade 1-2), moderate (grade 3-4), or severe (grade 5 or more). The average bolus time of fentanyl was 1.5 +/- 0.3 seconds in the present study. The incidence of fentanyl-induced cough was 80.0% in group I, 40.0% in group II, 6.7% in group III, and 3.3% in group IV, respectively. Groups II, III, and IV had a lower incidence and less severity of cough than group I (P < 0.05). Groups III and IV had a lower incidence and less severity of cough than group II (P < 0.05). In summary, a priming dose of more than 1 mg center dot kg<SU-1</SU of propofol is effective to suppress fentanyl-induced cough in a dose-dependent manner. We suggest using a priming dose of propofol 1.5 mg center dot kg<SU-1</SU to suppress cough during the anesthesia induction with propofol and fentanyl in clinical practice.	[Qian, Yanning; Wang, Zhongyun] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing 210029, Peoples R China; [Tang, Qifeng] Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Anesthesiol, Suzhou, Peoples R China; [Zhang, Qingwei; Yang, Jianjun] Nanjing Univ, Jinling Hosp, Dept Anesthesiol, Nanjing 210008, Peoples R China	Wang, ZY (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou Rd 300, Nanjing 210029, Peoples R China.	WXCXP@yahoo.com.cn					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Burburan SM, 2007, MINERVA ANESTESIOL, V73, P357; Cheng EY, 1996, ANESTH ANALG, V83, P162, DOI 10.1097/00000539-199607000-00028; Fakuda K., 2005, MILLERS ANESTHESIA, P379; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lin JA, 2007, J FORMOS MED ASSOC, V106, P649, DOI 10.1016/S0929-6646(08)60022-4; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; PIZOV R, 1995, ANESTHESIOLOGY, V82, P1111, DOI 10.1097/00000542-199505000-00004; Schapermeier U, 2008, ACTA ANAESTH SCAND, V52, P1071, DOI 10.1111/j.1399-6576.2008.01721.x; Shen JC, 2008, CURR THER RES CLIN E, V69, P480, DOI 10.1016/j.curtheres.2008.12.002; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; Yamaguchi M, 2006, ANESTH ANALG, V103, P594, DOI 10.1213/01.ane.0000229853.01875.60; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021	18	19	26	0	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-9734			UPSALA J MED SCI	Ups. J. Med. Sci.	MAY	2010	115	2					121	124		10.3109/03009730903291034			4	Medicine, General & Internal	General & Internal Medicine	579IF	WOS:000276361900007	19824805	DOAJ Gold, Green Published			2020-06-30	J	Huncke, TK; Adelman, M; Jacobowitz, G; Maldonado, T; Bekker, A				Huncke, Tessa Kate; Adelman, Mark; Jacobowitz, Glenn; Maldonado, Thomas; Bekker, Alex			A Prospective, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Dexmedetomidine for Sedation During Vascular Procedures	VASCULAR AND ENDOVASCULAR SURGERY			English	Article						anesthesia; endovascular; dexmedetomidine	MONITORED ANESTHESIA CARE; FIBEROPTIC INTUBATION; CAROTID-ENDARTERECTOMY; NONCARDIAC SURGERY; DOUBLE-BLIND; ANALGESIA; MIDAZOLAM; PATIENT; PROPOFOL; INFUSION	Objective: To examine the efficacy of dexmedetomidine (DEX) as a primary sedative during vascular procedures performed under monitored anesthesia care (MAC). A total of 55 patients were randomized in a 2:2:1 ratio to receive either DEX 1.0 mu g/kg load or DEX 0.5 mu g/kg load versus midazolam (MDZ) boluses, the current standard of care. This was followed by a maintenance infusion of DEX versus a normal saline infusion for the control group. Midazolam was given in 0.5 mg increments to maintain an equivalent target level of sedation among the 3 study groups. Fentanyl was given in 25 mu g increments to treat pain as needed. The percentage of DEX patients not requiring MDZ and the total dose of MDZ and fentanyl were compared to the control. Dexmedetomidine was efficacious as a sole sedative for 50% of patients. The total dose of MDZ and fentanyl was significantly less during the DEX infusions. Patient satisfaction was superior with DEX.	[Huncke, Tessa Kate; Bekker, Alex] NYU, Sch Med, Dept Anesthesiol, New York, NY 10016 USA; [Adelman, Mark; Jacobowitz, Glenn; Maldonado, Thomas] NYU, Dept Surg, Div Vasc Surg, Med Ctr, New York, NY 10016 USA	Huncke, TK (reprint author), NYU, Sch Med, Dept Anesthesiol, 550 1st Ave,IRM 605, New York, NY 10016 USA.	tessa.huncke@nyumc.org		Jacobowitz, Glenn/0000-0002-8136-2518; Adelman, Mark/0000-0001-9276-6131	Hospira	The authors disclosed receipt of the following financial support for the research and/or authorship of this article: This study was funded by a grant from Hospira.	Abdalla Mahmoud I M, 2006, J Anesth, V20, P54, DOI 10.1007/s00540-005-0351-z; AHO M, 1992, ANESTH ANALG, V75, P940; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; Alhashemi JA, 2004, CAN J ANAESTH, V51, P342, DOI 10.1007/BF03018237; Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bekker AY, 2004, J NEUROSURG ANESTH, V16, P126, DOI 10.1097/00008506-200404000-00004; Bergese SD, 2007, J CLIN ANESTH, V19, P141, DOI 10.1016/j.jclinane.2006.07.005; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; Biccard BM, 2008, ANAESTHESIA, V63, P4, DOI 10.1111/j.1365-2044.2007.05306.x; Candiotti KA, 2010, ANESTH ANALG, V110, P47, DOI 10.1213/ane.0b013e3181ae0856; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Dexter F, 1997, ANESTHESIOLOGY, V87, P865, DOI 10.1097/00000542-199710000-00021; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Grant SA, 2004, J CLIN ANESTH, V16, P124, DOI 10.1016/j.jclinane.2003.05.010; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1016/S1053-0770(03)00200-3; Hofer RE, 2005, CAN J ANAESTH, V52, P176, DOI 10.1007/BF03027725; Jalonen J, 1997, ANESTHESIOLOGY, V86, P331; Jorden VSB, 2004, ANN PHARMACOTHER, V38, P803, DOI 10.1345/aph.1D376; Koroglu A, 2006, ANESTH ANALG, V103, P63, DOI 10.1213/01.ane.0000219592.82598.AA; McCutcheon CA, 2006, ANESTH ANALG, V102, P668, DOI 10.1213/01.ane.0000197777.62397.d5; Oliver MF, 1999, ANESTHESIOLOGY, V91, P951, DOI 10.1097/00000542-199910000-00014; Ramsay MAE, 2004, ANESTHESIOLOGY, V101, P787; Stamenkovic DM, 2006, ACTA ANAESTH SCAND, V50, P1314, DOI 10.1111/j.1399-6576.2006.01157.x; Taghinia AH, 2008, PLAST RECONSTR SURG, V121, P269, DOI 10.1097/01.prs.0000293867.05857.90; TALKE P, 1995, ANESTHESIOLOGY, V82, P620, DOI 10.1097/00000542-199503000-00003; Unlugenc H, 2005, EUR J ANAESTH, V22, P386, DOI 10.1017/S0265021505000669; Ustun Y, 2006, J ORAL MAXIL SURG, V64, P1353, DOI 10.1016/j.joms.2006.05.020; Wahlander S, 2005, J CARDIOTHOR VASC AN, V19, P630, DOI 10.1053/j.jvca.2005.07.006	33	10	13	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1538-5744			VASC ENDOVASC SURG	Vasc. Endovasc. Surg.	MAY	2010	44	4					257	261		10.1177/1538574410363621			5	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	585DC	WOS:000276803500003	20308169				2020-06-30	J	Weltrowska, G; Chung, NN; Lemieux, C; Guo, JX; Lu, YX; Wilkes, BC; Schiller, PW				Weltrowska, Grazyna; Chung, Nga N.; Lemieux, Carole; Guo, Jianxin; Lu, Yixin; Wilkes, Brian C.; Schiller, Peter W.			"Carba"-Analogues of Fentanyl are Opioid Receptor Agonists	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							PEPTIDE AGONISTS; OPIATE RECEPTOR; ANTAGONISTS; CONSTRAINTS; ENKEPHALIN; MORPHINE; LIGANDS; RECOGNITION; LACKING; POTENT	There is evidence to indicate that the Asp residue in the third transmembrane helix (TMH) of opioid receptors forms a salt bridge with the positively charged nitrogen of endogenous and exogenous opioid ligands. To further examine the role of this electrostatic interaction in receptor binding and activation, we synthesized "carba"-analogues of a published fentanyl analogue containing a 3-(guanidinomethyl)-benzyl group in place of the phenyl moiety attached to the ethylamido group (C. Dardonville et al., Bioorg. Med. Chem. 2006, 14, 6570-6580 (1)), in which the piperidine ring nitrogen was replaced with a carbon. As expected, the resulting cis and trans isomers (8a and 8b) showed reduced mu and kappa opioid receptor binding affinities as compared to 1 but, surprisingly, retained opioid full agonist activity with about half the potency of leucine-enkephalin in the guinea pia ileum assay. In conjunction with performed receptor docking studies, these results indicate that the electrostatic interaction of the protonated nitrogen in the piperidine ring of fentanyl analogues with the Asp residue in the third TMH is not a conditio sine qua non for opioid receptor activation.	[Lu, Yixin] Natl Univ Singapore, Dept Chem, Singapore, Singapore; [Lu, Yixin] Natl Univ Singapore, Med Chem Program, Off Life Sci, Singapore, Singapore; [Weltrowska, Grazyna; Chung, Nga N.; Lemieux, Carole; Wilkes, Brian C.; Schiller, Peter W.] Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ H2W 1R7, Canada; [Schiller, Peter W.] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; [Guo, Jianxin] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA	Lu, YX (reprint author), Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore, Singapore.	chmlyx@nus.edu.sg; schillp@ircm.qc.ca			U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA-004443]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-89716]	This work was financially supported by the U.S. National Institutes of Health (Grant DA-004443) and the Canadian Institutes of Health Research (Grant MOP-89716).	Berezowska I, 2009, CHEM BIOL DRUG DES, V74, P329, DOI 10.1111/j.1747-0285.2009.00867.x; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dardonville C, 2006, BIOORGAN MED CHEM, V14, P6570, DOI 10.1016/j.bmc.2006.06.007; DIMAIO J, 1982, J MED CHEM, V25, P1432, DOI 10.1021/jm00354a008; ESSAWI MYH, 1983, J MED CHEM, V26, P348, DOI 10.1021/jm00357a007; Fowler CB, 2004, BIOCHEMISTRY-US, V43, P15796, DOI 10.1021/bi048413q; Harding WW, 2005, J MED CHEM, V48, P4765, DOI 10.1021/jm048963m; HENDERSON G, 1972, BRIT J PHARMACOL, V46, P764, DOI 10.1111/j.1476-5381.1972.tb06901.x; Jagerovic N, 2002, BIOORGAN MED CHEM, V10, P817, DOI 10.1016/S0968-0896(01)00345-5; Kane BE, 2006, AAPS J, V8, pE126, DOI 10.1208/aapsj080115; Kane BE, 2008, J MED CHEM, V51, P1824, DOI 10.1021/jm701040v; KOSTERLITZ HW, 1968, BRIT J PHARMACOL, V33, P266, DOI 10.1111/j.1476-5381.1968.tb00988.x; Li JG, 1999, LIFE SCI, V65, P175, DOI 10.1016/S0024-3205(99)00234-9; Lu YX, 2001, J MED CHEM, V44, P3048, DOI 10.1021/jm0101186; PATON WDM, 1957, BRIT J PHARM CHEMOTH, V12, P119, DOI 10.1111/j.1476-5381.1957.tb01373.x; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; REES DC, 1990, COMPREHENSIVE MED CH, P805; Rosowsky A, 1999, J MED CHEM, V42, P1007, DOI 10.1021/jm980572i; Schiller PW, 2000, J MED CHEM, V43, P551, DOI 10.1021/jm990461z; Schiller PW, 2003, LIFE SCI, V73, P691, DOI 10.1016/S0024-3205(03)00389-8; SCHILLER PW, 1978, BIOCHEM BIOPH RES CO, V85, P1332, DOI 10.1016/0006-291X(78)91149-X; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; WATERFIELD AA, 1979, EUR J PHARMACOL, V58, P11, DOI 10.1016/0014-2999(79)90334-0; Weltrowska G, 2004, BIOORG MED CHEM LETT, V14, P4731, DOI 10.1016/j.bmcl.2004.06.077; WILKES BC, 1990, BIOPOLYMERS, V29, P89, DOI 10.1002/bip.360290113	27	18	18	0	8	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	APR 8	2010	53	7					2875	2881		10.1021/jm9019068			7	Chemistry, Medicinal	Pharmacology & Pharmacy	575VC	WOS:000276096300016	20218625	Green Accepted			2020-06-30	J	Wang, YH; Sun, JF; Tao, YM; Xu, XJ; Chi, ZQ; Liu, JG				Wang, Yu-hua; Sun, Jian-feng; Tao, Yi-min; Xu, Xue-jun; Chi, Zhi-qiang; Liu, Jing-gen			Paradoxical relationship between RAVE (relative activity versus endocytosis) values of several opioid receptor agonists and their liability to cause dependence	ACTA PHARMACOLOGICA SINICA			English	Article						RAVE; mu-opioid receptor; cyclic AMP; endocytosis; physical dependence; psychological dependence	MORPHINE-TOLERANCE; OHMEFENTANYL STEREOISOMERS; PLACE PREFERENCE; OPIATE DRUGS; CYCLIC-AMP; G-PROTEIN; IN-VIVO; MICE; INTERNALIZATION; DIHYDROETORPHINE	Aim: To examine the relationship between the RAVE (relative activity versus endocytosis) values of opiate agonists and their dependence liability by studying several potent analgesics with special profiles in the development of physical and psychological dependence. Methods: The effects of (-)-cis-(3R, 4S, 2'R) ohmefentanyl (F9202), (+)-cis-(3R, 4S, 2'S) ohmefentanyl (F9204), dihydroetorphine (DHE) and morphine on [S-35] GTP gamma S binding, forskolin-stimulated cAMP accumulation, and receptor internalization were studied in CHO cells stably expressing HA-tagged mu-opioid receptors (CHO-HA-MOR). cAMP overshoot in response to the withdrawal of these compound treatments was also tested. Results: All four agonists exhibited the same rank order of activity in stimulation of [S-35]GTP gamma S binding, inhibition of adenylyl cyclase (AC) and induction of receptor internalization: DHE>F9204>F9202> morphine. Based on these findings and the previous in vivo analgesic data obtained from our and other laboratories, the RAVE values of the four agonists were calculated. The rank order of RAVE values was morphine>F9202>F9204>DHE. For the induction of cAMP overshoot, the rank order was F9202 >= morphine>F9204 >= DHE. Conclusion: Taken in combination with previous findings of these compounds' liability to develop dependence, the present study suggests that the agonist with the highest RAVE value seems to have a relatively greater liability to develop psychological dependence relative to the agonist with the lowest RAVE value. However, the RAVE values of these agonists are not correlated with their probability of developing physical dependence or inducing cAMP overshoot, a cellular hallmark of dependence.	[Wang, Yu-hua; Sun, Jian-feng; Tao, Yi-min; Xu, Xue-jun; Chi, Zhi-qiang; Liu, Jing-gen] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China; [Wang, Yu-hua] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Peoples R China; [Wang, Yu-hua] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210046, Peoples R China	Liu, JG (reprint author), Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China.	jgliu@mail.shcnc.ac.cn					Alt A, 2001, J PHARMACOL EXP THER, V298, P116; Alvarez V, 2001, NEURON, V32, P761, DOI 10.1016/S0896-6273(01)00530-X; Berrendero F, 2002, J NEUROSCI, V22, P10935; CAO GH, 1990, ZHONGGUO LIN CHUANG, V6, P54; COLLIER HOJ, 1975, NATURE, V255, P159, DOI 10.1038/255159b0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Grecksch G, 2006, PSYCHOPHARMACOLOGY, V186, P177, DOI 10.1007/s00213-006-0365-8; Guo GW, 2000, LIFE SCI, V67, P113, DOI 10.1016/S0024-3205(00)00617-2; Guo GW, 2001, LIFE SCI, V68, P2383, DOI 10.1016/S0024-3205(01)01030-X; He L, 2005, CURR BIOL, V15, P1028, DOI 10.1016/j.cub.2005.04.052; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hiebel AC, 2007, J MED CHEM, V50, P3765, DOI 10.1021/jm061325e; Hong MH, 2009, J NEUROCHEM, V108, P102, DOI 10.1111/j.1471-4159.2008.05740.x; Huang M, 1982, Zhongguo Yao Li Xue Bao, V3, P9; HUANG M, 1994, REGUL PEPTIDES, V53, pS81; Jin WQ, 1996, ACTA PHARM SINIC, V17, P421; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kim IH, 2008, J MICROBIOL BIOTECHN, V18, P35; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Liu JG, 2002, J PHARMACOL EXP THER, V302, P1070, DOI 10.1124/jpet.102.035964; Liu JG, 1999, ACTA PHARMACOL SIN, V20, P452; Liu ZH, 2004, LIFE SCI, V74, P3001, DOI 10.1016/j.lfs.2003.10.027; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; Ohmori S, 2002, CNS DRUG REV, V8, P391; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Roth BL, 1999, NEURON, V23, P629, DOI 10.1016/S0896-6273(02)23443-1; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Tokuyama S, 1996, JPN J PHARMACOL, V71, P357, DOI 10.1254/jjp.71.357; TOKUYAMA S, 1993, BIOL PHARM BULL, V16, P774; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; WANG DX, 1995, J PHARM PHARMACOL, V47, P669, DOI 10.1111/j.2042-7158.1995.tb05857.x; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Yang Z, 2008, ACTA PHARMACOL SIN, V29, P781, DOI 10.1111/j.1745-7254.2008.00817.x; Zhang JL, 2009, ACTA PHARMACOL SIN, V30, P559, DOI 10.1038/aps.2009.43	44	3	5	0	3	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	APR	2010	31	4					393	398		10.1038/aps.2010.19			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	585OC	WOS:000276834300002	20228826	Bronze, Green Published			2020-06-30	J	Taha, SK; El-Khatib, MF; Baraka, AS; Haidar, YA; Abdallah, FW; Zbeidy, RA; Siddik-Sayyid, SM				Taha, S. K.; El-Khatib, M. F.; Baraka, A. S.; Haidar, Y. A.; Abdallah, F. W.; Zbeidy, R. A.; Siddik-Sayyid, S. M.			Effect of suxamethonium vs rocuronium on onset of oxygen desaturation during apnoea following rapid sequence induction	ANAESTHESIA			English	Article							SUCCINYLCHOLINE; CONSUMPTION; MUSCLE; CHILDREN; FASCICULATION; ANESTHESIA; LIDOCAINE	This study investigates the effect of suxamethonium vs rocuronium on the onset of haemoglobin desaturation during apnoea, following rapid sequence induction of anaesthesia. Sixty patients were randomly allocated to one of three groups. Anaesthesia was induced with lidocaine 1.5 mg. kg(-1), fentanyl 2 mu g.kg(-1) and propofol 2 mg.kg(-1), followed by either rocuronium 1 mg.kg(-1) (Group R) or suxamethonium 1.5 mg.kg(-1) (Group S). The third group received propofol 2 mg.kg(-1) and suxamethonium 1.5 mg.kg(-1) only (Group SO). The median (IQR [range]) time to reach SpO2 of 95% was significantly shorter in Group S (358 (311-373 [215-430]) s) than in Group R (378 (370-393 [366-420]) s; p=0.003), and shorter in Group SO (242 (225-258 [189-370]) s) than in both Group R (p<0.001) and Group S (p<0.001). When suxamethonium is administered for rapid sequence induction of anaesthesia, a faster onset of oxygen desaturation is observed during the subsequent apnoea compared with rocuronium. However, time to desaturation is prolonged whenever lidocaine and fentanyl precede suxamethonium.	[Taha, S. K.; El-Khatib, M. F.; Baraka, A. S.; Haidar, Y. A.; Zbeidy, R. A.; Siddik-Sayyid, S. M.] Amer Univ Beirut, Dept Anesthesiol, Beirut, Lebanon	Siddik-Sayyid, SM (reprint author), Amer Univ Beirut, Dept Anesthesiol, Beirut, Lebanon.	ss01@aub.edu.lb		Zbeidy, Reine/0000-0002-6963-885X; Abdallah, Faraj W./0000-0003-2435-6186			DUKE PC, 1979, CAN ANAESTH SOC J, V26, P201, DOI 10.1007/BF03006982; ERBGUTH PH, 1973, ANESTHESIOLOGY, V39, P447, DOI 10.1097/00000542-197310000-00023; FUKUDA S, 1987, ANESTH ANALG, V66, P325; Hardman JG, 2000, ANESTH ANALG, V90, P619, DOI 10.1097/00000539-200003000-00022; Hassani Mansour, 2006, Middle East Journal of Anesthesiology, V18, P929; Hausmann D, 1992, Anasthesiol Intensivmed Notfallmed Schmerzther, V27, P469, DOI 10.1055/s-2007-1000340; LINDGREN L, 1983, BRIT J ANAESTH, V55, P747, DOI 10.1093/bja/55.8.747; McCourt KC, 1998, ANAESTHESIA, V53, P867, DOI 10.1046/j.1365-2044.1998.00342.x; MINGUS ML, 1990, ANAESTHESIA, V45, P834, DOI 10.1111/j.1365-2044.1990.tb14565.x; MULDOON SM, 1969, ANESTHESIOLOGY, V31, P437, DOI 10.1097/00000542-196911000-00014; PALMISANO BW, 1984, ANESTHESIOLOGY, V61, P518, DOI 10.1097/00000542-198411000-00007; Rasmussen LS, 2007, ACTA ANAESTH SCAND, V51, P787, DOI 10.1111/j.1399-6576.2007.01385.x; STANDAERT FG, 1965, J PHARMACOL EXP THER, V149, P113; THEYE RA, 1971, ANESTHESIOLOGY, V35, P304, DOI 10.1097/00000542-197109000-00014; USUBIAGA JE, 1968, J PHAM EXPT THERAPEU, V159, P349; WIKINSKI R, 1965, ANESTHESIOLOGY, V26, P3; YLIHANKALA A, 1992, ACTA ANAESTH SCAND, V36, P588, DOI 10.1111/j.1399-6576.1992.tb03524.x	17	41	43	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	APR	2010	65	4					358	361		10.1111/j.1365-2044.2010.06243.x			4	Anesthesiology	Anesthesiology	571BV	WOS:000275725200008	20402874				2020-06-30	J	Stammschulte, T; Brune, K				Stammschulte, T.; Brune, K.			Drug safety problems in association with the use of opioid containing patches for the management of pain	DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT			German	Editorial Material						fentanyl; transdermal; adverse drugs reactions; incorrect use	TRANSDERMAL FENTANYL PATCH; EAPC RECOMMENDATIONS; CHILD		[Stammschulte, T.] AkdA, D-10623 Berlin, Germany; [Brune, K.] Univ Erlangen Nurnberg, Inst Expt & Klin Pharmakol & Toxikol, D-8520 Erlangen, Germany	Stammschulte, T (reprint author), AkdA, Herbert Lewin Pl 1, D-10623 Berlin, Germany.	thomas.stammschulte@akdae.de					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; *ARZN DTSCH ARZT, 2007, EMPF THER TUM, V34; *FDA, 2007, PUBL HLTH ADV IMP IN; GRISSINGER M, 2009, P & T, V34, P343; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; *JANSS GMBH, 2008, FACH DUR SMAT; JANSSEN LP, 2005, IMPORTANT DRUG WARNI; LONGO M, 2009, CANADIAN ADVERSE REA, V19, P3; MCMORRAN M, 2009, CANADIAN ADVERSE REA, V18, P1; Medicines and Healthcare Products Regulatory Agency, 2008, DRUG SAFETY UPDATE, V2, P2; Mitra Sukanya, 2008, J Opioid Manag, V4, P123; *ORTH PHARM INC, 2009, DUR FENT TRANSD SYST; Ripamonti C, 2006, SUPPORT CARE CANCER, V14, P400, DOI 10.1007/s00520-005-0918-0; Schwabe U, 2009, ARZNEIVERORDNUNGS RE; SCHWABE U, 2005, ARZNEIVERORDNUNGS RE; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3	17	3	3	0	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0012-0472			DEUT MED WOCHENSCHR	Dtsch. Med. Wochenschr.	APR	2010	135	17					870	873		10.1055/s-0030-1253672			4	Medicine, General & Internal	General & Internal Medicine	585WA	WOS:000276859700007	20408108				2020-06-30	J	Finn, M; Harris, D				Finn, Maria; Harris, Dan			Intranasal fentanyl for analgesia in the paediatric emergency department	EMERGENCY MEDICINE JOURNAL			English	Article							MORPHINE; CHILDREN; PAIN	Intranasal opiate analgesia is the first choice in children presenting to paediatric emergency departments with severe pain. A prospective observational study was performed which showed that intranasal fentanyl is a safe effective alternative to diamorphine.	[Harris, Dan] Kingston Hosp NHS Trust, Dept Emergency Med, Kingston Upon Thames KT2 7QB, England	Harris, D (reprint author), Kingston Hosp NHS Trust, Dept Emergency Med, Galsworthy Rd, Kingston Upon Thames KT2 7QB, England.	drdanharris@msn.com					Babl FE, 2008, EMERG MED J, V25, P717, DOI 10.1136/emj.2007.053751; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Chen Z.H., 2008, J DATA SCI, V6, P261; *COLL EM MED CLIN, GUID MAN PAIN CHILDR; College of Emergency Medicine, 2008, CLIN STAND EM DEP; Downing A, 2006, EMERG MED J, V23, P391, DOI 10.1136/emj.2005.025411; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Maurice SC, 2002, EMERG MED J, V19, P101, DOI 10.1136/emj.19.2.101; Ugwoke MI, 2001, J PHARM PHARMACOL, V53, P3, DOI 10.1211/0022357011775145; Younge P, 1999, EMERGEN MED, V11, P90	12	30	30	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	APR	2010	27	4					300	301		10.1136/emj.2008.070474			2	Emergency Medicine	Emergency Medicine	581IA	WOS:000276514400014	20385685				2020-06-30	J	Chang, JTC; Lin, CY; Lin, JC; Lee, MS; Chen, YJ; Wang, HM				Chang, Joseph Tung-Chieh; Lin, Chien Yu; Lin, Jin-Ching; Lee, Moon-Sing; Chen, Yu-Jen; Wang, Hung-Ming			Transdermal Fentanyl for Pain Caused by Radiotherapy in Head and Neck Cancer Patients Treated in an Outpatient Setting: A Multicenter Trial in Taiwan	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						transdermal fentanyl; head and neck cancer; radiotherapy	QUALITY-OF-LIFE; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; CONCOMITANT CHEMOTHERAPY; NASOPHARYNGEAL CARCINOMA; MANAGEMENT; EFFICACY; SAFETY; NAIVE	This study evaluated the efficacy and safety of transdermal fentanyl in the outpatient treatment of head and neck cancer patients with pain caused by radiotherapy. Patients with a visual analogue scale score >= 4 were invited to participate in the study. The following variables were collected: visual analogue scale, the Brief Pain Inventory, concomitant pain medications and adverse effects. A total of 163 head and neck cancer patients were enrolled (148 males and 15 females; median age, 53 years; age range, 21-72 years). Seventy-two (44%) patients had a visual analogue scale score > 6 at enrollment, despite the use of non-steroidal anti-inflammatory drugs or weak opioids. Ninety-four (57.7%) patients received concurrent chemotherapy. A total of 88 patients completed the study, whereas 55 underwent a drop-out by side effects. The most frequently reported adverse events were vomiting (23.9%) and nausea (16.6%). Treatment with transdermal fentanyl resulted in a significant decrease in visual analogue scale and Brief Pain Inventory scores that persisted during treatment. In the overall efficacy evaluation, the pain-alleviating effect, the easiness of application and the overall impression of transdermal fentanyl were rated as good by 54.5%, 65.9% and 59.1% of the completers, respectively. Effects of transdermal fentanyl were rated as good by 64.8% of the investigators. Our data provide evidence that transdermal fentanyl is effective and relatively easy to use for outpatient treatment of pain control in head and neck cancer patients following radiotherapy in selected patients. Reduction of side effects and effective pain management need to be paramount in the management of head and neck cancer patients undergoing radiotherapy.	[Chang, Joseph Tung-Chieh; Wang, Hung-Ming] Chang Gung Univ, Dept Med, Tao Yuan 33333, Taiwan; [Chang, Joseph Tung-Chieh; Lin, Chien Yu] Chang Gung Mem Hosp, Dept Radiat Oncol, Linkou Med Ctr, Linkou, Taiwan; [Chang, Joseph Tung-Chieh; Lin, Chien Yu; Wang, Hung-Ming] Chang Gung Mem Hosp, Taipei Chang Gung Head & Neck Oncol Grp, Linkou Med Ctr, Tao Yuan, Taiwan; [Lin, Chien Yu] Chang Gung Univ, Grad Inst Clin Med Sci, Tao Yuan, Taiwan; [Lin, Jin-Ching] Taichung Vet Gen Hosp, Dept Radiat Oncol, Taichung, Taiwan; [Lee, Moon-Sing] Dalin Tzu Chi Gen Hosp, Dept Radiat Oncol, Dalin, Taiwan; [Chen, Yu-Jen] Mackay Mem Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Wang, Hung-Ming] Chang Gung Mem Hosp, Div Hematol Oncol, Dept Internal Med, Linkou Med Ctr, Linkou, Taiwan	Wang, HM (reprint author), Chang Gung Univ, Dept Med, 5 Fu Shin Rd, Tao Yuan 33333, Taiwan.	cgmhnog@yahoo.com			Janssen-Cilag, TaiwanJohnson & Johnson USAJanssen Biotech Inc [DUR-TWN-MA6]	This study was funded by Janssen-Cilag, Taiwan (protocol number DUR-TWN-MA6).	Bartelink H, 2002, EUR J CANCER, V38, P216, DOI 10.1016/S0959-8049(01)00363-X; Brizel DM, 1998, SEMIN RADIAT ONCOL, V8, P237, DOI 10.1016/S1053-4296(98)80021-0; BROWMAN GP, 1993, J CLIN ONCOL, V11, P863, DOI 10.1200/JCO.1993.11.5.863; Browman GP, 2001, HEAD NECK-J SCI SPEC, V23, P579, DOI 10.1002/hed.1081; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Fu KK, 1998, SEMIN RADIAT ONCOL, V8, P247, DOI 10.1016/S1053-4296(98)80022-2; Ger LP, 2000, J PAIN SYMPTOM MANAG, V20, P335, DOI 10.1016/S0885-3924(00)00207-4; Hsu TH, 2003, J PAIN SYMPTOM MANAG, V26, P835, DOI 10.1016/S0885-3924(03)00257-4; Huang HY, 2000, CANCER PRACT, V8, P274, DOI 10.1046/j.1523-5394.2000.86007.x; Huang HY, 2003, J PAIN SYMPTOM MANAG, V25, P247, DOI 10.1016/S0885-3924(02)00678-4; Komurcu S, 2007, EUR J CANCER CARE, V16, P67, DOI 10.1111/j.1365-2354.2006.00707.x; Lazarus CL, 1996, LARYNGOSCOPE, V106, P1157, DOI 10.1097/00005537-199609000-00021; List MA, 1997, QUAL LIFE RES, V6, P274; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Ohrn KEO, 2001, SUPPORT CARE CANCER, V9, P247, DOI 10.1007/s005200000214; Plevova P, 1999, ORAL ONCOL, V35, P453, DOI 10.1016/S1368-8375(99)00033-0; Ressel A, 2002, EUR J CANCER, V38, P594, DOI 10.1016/S0959-8049(01)00411-7; Thienthong Somboon, 2006, Journal of the Medical Association of Thailand, V89, P1120; VOKES EE, 1991, HEMATOL ONCOL CLIN N, V5, P753; WILSON PR, 1991, CANCER NURS, V14, P98	21	10	10	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	APR	2010	40	4					307	312		10.1093/jjco/hyp166			6	Oncology	Oncology	578OY	WOS:000276304300005	20042478	Bronze			2020-06-30	J	Borazan, H; Tuncer, S; Yalcin, N; Erol, A; Otelcioglu, S				Borazan, Hale; Tuncer, Sema; Yalcin, Naime; Erol, Atilla; Otelcioglu, Seref			Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial	JOURNAL OF ANESTHESIA			English	Article						Melatonin; Postoperative analgesia; Sedation; Tramadol; General anesthesia	RECEPTORS; SURGERY; TIME; PAIN; PREMEDICATION; ISOFLURANE; ANESTHESIA; MIDAZOLAM	Our intention was to assess the effectiveness of preoperative oral melatonin medication on sedation, sleep quality, and postoperative analgesia in patients undergoing elective prostatectomy. Fifty-two ASA I-II patients undergoing elective prostatectomy were included in this study, randomly divided into two groups. Patients received an oral placebo (n = 26) or 6 mg melatonin (n = 26) the night before and 1 h before surgery. All patients received a standard anesthetic protocol. At the end of surgery, all patients received tramadol i.v. via a PCA device. Extubation time, intraoperative fentanyl consumption, and recovery time were assessed at the end of the operation. Pain scores, tramadol consumption, and sedation scores were assessed at 1, 2, 4, 6, 12, 18, and 24 h postoperatively, and sleep quality and subjective analgesic efficacy were assessed at 24 h after surgery. There were no significant differences in demographic data between the groups. Extubation time and recovery time from anesthesia were significantly longer in the melatonin group (P < 0.05). Intraoperative fentanyl usage, pain scores, and tramadol consumption were significantly lower in the melatonin group (P < 0.05). The postoperative sleep quality of patients was significantly better in the melatonin group than in the control group (P < 0.05). Postoperative VAS of pain was significantly lower in the melatonin group compared with the control group at 1, 2, 4, 6, 12, 18, and 24 h postoperatively (P < 0.05). Subjective analgesic efficacy of patients was significantly different between groups (P < 0.05). The sedation scores were significantly higher in the melatonin group than in the control group at 1 h and 2 h after surgery (P < 0.05). Preoperative oral melatonin administration decreased pain scores and tramadol consumption and enhanced sleep quality, sedation scores, and subjective analgesic efficacy during the postoperative period.	[Borazan, Hale] Selcuk Univ, Meram Tip Fak, Anesteziyoloji & Reanimasyon AD, Meram, Konya, Turkey; [Borazan, Hale; Tuncer, Sema; Yalcin, Naime; Erol, Atilla; Otelcioglu, Seref] Selcuk Univ, Sch Med, Dept Anesthesiol & Reanimat, Konya, Turkey	Borazan, H (reprint author), Selcuk Univ, Meram Tip Fak, Anesteziyoloji & Reanimasyon AD, Meram, Konya, Turkey.	hborazan@hotmail.com					BASKETT JJ, 1991, AGE AGEING, V20, P430, DOI 10.1093/ageing/20.6.430; Caumo W, 2007, ANESTH ANALG, V105, P1263, DOI 10.1213/01.ane.0000282834.78456.90; Chassard D, 2007, CAN J ANAESTH, V54, P685, DOI 10.1007/BF03026864; CLOSS SJ, 1992, INT J NURS STUD, V29, P381, DOI 10.1016/0020-7489(92)90016-A; Ebadi M, 1998, J PINEAL RES, V24, P193, DOI 10.1111/j.1600-079X.1998.tb00532.x; FRINK EJ, 1992, ANESTH ANALG, V74, P241, DOI 10.1213/00000539-199202000-00012; Gogenur I, 2006, SLEEP: A COMPREHENSIVE HANDBOOK, P913; GOLOMBEK DA, 1991, EUR J PHARMACOL, V194, P25, DOI 10.1016/0014-2999(91)90119-B; Hanania M, 2002, ANESTH ANALG, V94, P338, DOI 10.1097/00000539-200202000-00019; Karkela J, 2002, ACTA ANAESTH SCAND, V46, P30, DOI 10.1034/j.1399-6576.2002.460106.x; Naguib M, 1999, BRIT J ANAESTH, V82, P875; Naguib M, 2000, ANESTH ANALG, V91, P473, DOI 10.1097/00000539-200008000-00046; Pacchierotti C, 2001, FRONT NEUROENDOCRIN, V22, P18, DOI 10.1006/frne.2000.0202; PHILLIPS GD, 1986, NEUROLOGICAL MECH PA, P21; RAWAL N, 1994, PAIN, V57, P117, DOI 10.1016/0304-3959(94)90115-5; Reiter RJ, 2000, ANN NY ACAD SCI, V917, P376; Shavali S, 2005, BRAIN RES BULL, V64, P471, DOI 10.1016/j.brainresbull.2004.09.008; Soppitt AJ, 1999, J CLIN ANESTH, V11, P652, DOI 10.1016/S0952-8180(99)00118-X; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; TZISCHINSKY O, 1994, SLEEP, V17, P638, DOI 10.1093/sleep/17.7.638; Wan Q, 1999, NAT NEUROSCI, V2, P401; WEAVER DR, 1993, J CLIN ENDOCR METAB, V76, P295, DOI 10.1210/jc.76.2.295; Webb AR, 2002, ANESTH ANALG, V95, P1713, DOI 10.1097/00000539-200212000-00045; WURTMAN RJ, 1995, LANCET, V346, P1491, DOI 10.1016/S0140-6736(95)92509-0; Yu CX, 2000, EUR J PHARMACOL, V403, P49, DOI 10.1016/S0014-2999(00)00421-0	25	37	42	0	3	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	APR	2010	24	2					155	160		10.1007/s00540-010-0891-8			6	Anesthesiology	Anesthesiology	583GC	WOS:000276660500001	20186437				2020-06-30	J	Kitajima, O; Suzuki, T; Watanabe, N; Maeda, T; Noda, Y; Saeki, S; Ogawa, S				Kitajima, Osamu; Suzuki, Takahiro; Watanabe, Naoto; Maeda, Takeshi; Noda, Yoshikazu; Saeki, Shigeru; Ogawa, Setsuro			Monitoring masseter muscle evoked responses enables faster tracheal intubation	JOURNAL OF ANESTHESIA			English	Article						Neuromuscular block; Masseter muscle; Adductor pollicis muscle; Vecuronium	ADDUCTOR POLLICIS MUSCLES; NEUROMUSCULAR BLOCKADE; BLOOD-FLOW; ROCURONIUM; HUMANS; DIAPHRAGM; PANCURONIUM; VECURONIUM; LARYNX	The aim of this study was to investigate whether monitoring neuromuscular block at the masseter muscle (MM) would allow faster tracheal intubation when compared with that at the adductor pollicis muscle (APM). Twenty female patients undergoing gynecological surgery were enrolled into this study. Immediately after inducing anesthesia with fentanyl and propofol, both the left masseter and ulnar nerves were stimulated in a 2 Hz train-of-four (TOF) mode using peripheral nerve stimulators. Contractions of the MM were felt with the anesthesiologist's left hand lifting the patient's jaw and holding an anesthesia facemask, while those of the APM were visually observed. Immediately after the contracting responses of the muscles were confirmed, all of the patients received an iv bolus of vecuronium 0.1 mg kg(-1). Onset times after vecuronium were defined as the duration until the contractions became impalpable at the MM or invisible at the APM. When the contraction of the MM could no longer be felt, the conditions for laryngoscopy and tracheal intubation were assessed. Onset time evaluated tactually at the MM (mean +/- A SD, 108.4 +/- A 27.7 s) was significantly shorter than that evaluated visually at the APM (181.2 +/- A 32.1 s, P < 0.0001). The intubating conditions for all patients were graded as either excellent or good. Tactual evaluation of muscle paralysis of the MM during induction of anesthesia is clinically useful since it leads to faster tracheal intubation.	[Suzuki, Takahiro; Saeki, Shigeru; Ogawa, Setsuro] Surugadai Nihon Univ Hosp, Dept Anesthesiol, Chiyoda Ku, Tokyo 1018309, Japan; [Kitajima, Osamu; Watanabe, Naoto; Maeda, Takeshi; Noda, Yoshikazu] Social Insurance Sagamino Hosp, Dept Anesthesia, Kanagawa 2290006, Japan	Suzuki, T (reprint author), Surugadai Nihon Univ Hosp, Dept Anesthesiol, Chiyoda Ku, 1-8-13 Kanda Surugadai, Tokyo 1018309, Japan.	suzukit@cd5.so-net.ne.jp					Abdulatif M, 1997, BRIT J ANAESTH, V79, P24; CANTINEAU JP, 1994, ANESTHESIOLOGY, V81, P585, DOI 10.1097/00000542-199409000-00010; CHAUVIN M, 1987, ANESTH ANALG, V66, P117; CHOI WW, 1984, ACTA ANAESTH SCAND, V28, P608, DOI 10.1111/j.1399-6576.1984.tb02130.x; de Rossi L, 1999, CAN J ANAESTH, V46, P1133, DOI 10.1007/BF03015521; Fuchs-Buder T, 2007, ACTA ANAESTH SCAND, V51, P789, DOI 10.1111/j.1399-6576.2007.01352.x; HELBOHANSEN HS, 1992, ANESTHESIOLOGY, V76, P199, DOI 10.1097/00000542-199202000-00007; Hemmerling TM, 2003, CAN J ANAESTH, V50, P779, DOI 10.1007/BF03019373; Ibebunjo C, 1999, BRIT J ANAESTH, V83, P284, DOI 10.1093/bja/83.2.284; MEISTELMAN C, 1992, CAN J ANAESTH, V39, P665, DOI 10.1007/BF03008227; Mey JC, 1999, EUR J ANAESTH, V16, P387, DOI 10.1046/j.1365-2346.1999.00503.x; Nakamura Y, 2005, J ORAL REHABIL, V32, P545, DOI 10.1111/j.1365-2842.2005.01461.x; PLAUD B, 1995, CLIN PHARMACOL THER, V58, P185, DOI 10.1016/0009-9236(95)90196-5; Rowlerson A, 2005, AM J ORTHOD DENTOFAC, V127, P37, DOI 10.1016/j.ajodo.2004.03.025; SMITH CE, 1989, ANESTHESIOLOGY, V71, P57, DOI 10.1097/00000542-198907000-00011	15	5	5	0	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2010	24	2					173	176		10.1007/s00540-009-0848-y			4	Anesthesiology	Anesthesiology	583GC	WOS:000276660500004	20091062				2020-06-30	J	Izumi, Y; Amaya, F; Hosokawa, K; Ueno, H; Hosokawa, T; Hashimoto, S; Tanaka, Y				Izumi, Yuta; Amaya, Fumimasa; Hosokawa, Koji; Ueno, Hiroshi; Hosokawa, Toyoshi; Hashimoto, Satoru; Tanaka, Yoshifumi			Five-day pain management regimen using patient-controlled analgesia facilitates early ambulation after cardiac surgery	JOURNAL OF ANESTHESIA			English	Article						Postoperative pain; Cardiac surgery; PCA; Ambulation	ARTERY-BYPASS-SURGERY; RECOVERY; QUALITY; PCA; IV	Excessive pain may interrupt early rehabilitation after cardiac surgery. The purpose of this study was to evaluate the efficacy of a longer patient-controlled analgesia (PCA) regimen for early ambulation after cardiac surgery. This study was designed to be a retrospective, single-institutional (focusing on an urban, university-affiliated hospital), pre-post intervention survey. Fifty-nine patients undergoing elective cardiac surgery were included. A long pain management regimen (subcutaneous fentanyl PCA for up to 120 h) protocol was implemented for the postoperative care for adult cardiac surgery patients. Before implementing this extended protocol, the same PCA regimen was used for up to 40 h. Perioperative and postoperative management was similar for all patients. The number of days required to walk more than 100 m without assistance was recorded. Additional usage of analgesic drugs and pain intensity on movement were documented up to POD 5. Time required to walk more than 100 m without assistance was significantly shorter in the 120 h PCA group. Need for another analgesic regimen and pain score during the ambulation phase were significantly lower in the 120 h PCA than in the 40 h PCA group. Frequency of side effects was similar for both groups. Pain management using a PCA system can be recommended for patients during the ambulation period after cardiac surgery. Subcutaneous PCA with fentanyl is a safe and effective analgesic regimen for this purpose.	[Amaya, Fumimasa] Kyoto Prefectural Univ Med, Dept Anesthesia & Intens Care, Kamigyo Ku, Kyoto 6028566, Japan; [Ueno, Hiroshi; Hosokawa, Toyoshi] Kyoto Prefectural Univ Med, Dept Pain Treatment & Palliat Med, Kyoto 6028566, Japan; [Amaya, Fumimasa; Hosokawa, Koji; Hashimoto, Satoru] Kyoto Prefectural Univ Med, Div Intens Care Med, Kyoto 6028566, Japan; [Izumi, Yuta; Amaya, Fumimasa; Hosokawa, Koji; Ueno, Hiroshi; Hosokawa, Toyoshi; Hashimoto, Satoru; Tanaka, Yoshifumi] Kyoto Prefectural Univ Med, Dept Anesthesiol, Kyoto 6028566, Japan	Amaya, F (reprint author), Kyoto Prefectural Univ Med, Dept Anesthesia & Intens Care, Kamigyo Ku, Kajii Cho 465, Kyoto 6028566, Japan.	ama@koto.kpu-m.ac.jp	amaya, fumimasa/AAD-7176-2020	amaya, fumimasa/0000-0003-2934-0845	JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [J092004093]	The authors did not have any conflicts of interest during this study. FA was supported by JSPS Grant-in-Aid for Scientific Research (J092004093). We thank Ayako Noguchi, RN, Momoe Matsuoka, RN and Kimiko Otsubo, RN for data management.	Bainbridge D, 2006, CAN J ANAESTH, V53, P492, DOI 10.1007/BF03022623; BARDRAM L, 1995, LANCET, V345, P763, DOI 10.1016/S0140-6736(95)90643-6; Dawson L, 1999, J ADV NURS, V30, P875, DOI 10.1046/j.1365-2648.1999.01161.x; DOYLE E, 1994, BRIT J ANAESTH, V72, P533, DOI 10.1093/bja/72.5.533; Gust R, 1999, CRIT CARE MED, V27, P2218, DOI 10.1097/00003246-199910000-00025; Hansdottir V, 2006, ANESTHESIOLOGY, V104, P142, DOI 10.1097/00000542-200601000-00020; Mueller XM, 2000, CHEST, V118, P391, DOI 10.1378/chest.118.2.391; Munro AJ, 1998, ANESTH ANALG, V87, P11, DOI 10.1097/00000539-199807000-00004; Myles PS, 2001, ANESTHESIOLOGY, V95, P862, DOI 10.1097/00000542-200110000-00013; O'Halloran P, 1997, Intensive Crit Care Nurs, V13, P126, DOI 10.1016/S0964-3397(97)80825-7; Pettersson PH, 2000, ACTA ANAESTH SCAND, V44, P43, DOI 10.1034/j.1399-6576.2000.440108.x; Raad I, 2007, LANCET INFECT DIS, V7, P645, DOI 10.1016/S1473-3099(07)70235-9; Raue W, 2004, SURG ENDOSC, V18, P1463, DOI 10.1007/s00464-003-9238-y; Roediger L, 2006, EUR J ANAESTH, V23, P539, DOI 10.1017/S0265021506000548; SEARLE NR, 1994, CAN J ANAESTH, V41, P198, DOI 10.1007/BF03009831; Tsang J, 1999, ANAESTH INTENS CARE, V27, P464, DOI 10.1177/0310057X9902700505; WHITE PF, 1990, CLIN J PAIN, V6, P297, DOI 10.1097/00002508-199012000-00007	17	2	2	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2010	24	2					187	191		10.1007/s00540-010-0878-5			5	Anesthesiology	Anesthesiology	583GC	WOS:000276660500007	20195649				2020-06-30	J	Kiribayashi, M; Inagaki, Y; Nishimura, Y; Yamasaki, K; Takahashi, S; Ueda, K				Kiribayashi, Masumi; Inagaki, Yoshimi; Nishimura, Yukiko; Yamasaki, Kazumasa; Takahashi, Shunsaku; Ueda, Keiichiro			Caudal blockade shortens the time to walking exercise in elderly patients following low back surgery	JOURNAL OF ANESTHESIA			English	Article						Caudal block; Preemptive analgesia; Cognitive function; Rehabilitation	PREEMPTIVE ANALGESIA; POSTOPERATIVE PAIN; SEVOFLURANE	We conducted a randomized, double-blinded study to test our hypothesis that caudal blockade as preemptive analgesia for low back surgery might accelerate time to walking exercise following surgery and reduce postoperative analgesics, thereby attaining faster recovery of cognitive function. Our study included 51 elderly patients > 70 years with American Society of Anesthesiologists (ASA) physical status 1-3, who underwent lumbosacral surgery under general anesthesia. After anesthetic induction and tracheal intubation, patients in the study group (group B) were injected with simple 0.5% bupivacaine [10 ml x height (m)] as a caudal block 15 min before surgical incision, whereas patients in the control group (group C) received normal saline. After surgery, patients had access to intravenous patient-administered analgesia (IV PCA), fentanyl, for postoperative pain relief. We assessed Mini-Mental State Examination (MMSE) scores before and after the surgery, values of visual analog scale (VAS) for postoperative analgesic status, fentanyl consumption during and for 3 days after surgery, and time to begin walking exercise after surgery. VAS value of group B patients was significantly lower than those in group C throughout the postoperative 48-h period (p < 0.005), and group B patients began walking exercise significantly earlier than those in group C [mean +/- A standard deviation (SD) 70.2 (14.3) in group C, and 61.9 (7.6) in group B; p = 0.0133]. Cognitive function level was higher in group B than in group C patients 24 h after operation. Caudal blockade as preemptive analgesia shortened the time to start walking exercise after surgery and accelerated recovery of postoperative cognitive function.	[Kiribayashi, Masumi] Tottori Univ, Fac Med, Dept Anesthesiol, Tottori 6838504, Japan; [Inagaki, Yoshimi] Tottori Univ, Fac Med, Dept Anesthesiol & Crit Care Med, Tottori 6838504, Japan; [Ueda, Keiichiro] Hakuai Hosp, Dept Anesthesiol, Tottori, Japan; [Kiribayashi, Masumi; Nishimura, Yukiko; Yamasaki, Kazumasa; Takahashi, Shunsaku] Tottori Univ Hosp, Div Operating Theatre, Tottori, Japan	Kiribayashi, M (reprint author), Tottori Univ, Fac Med, Dept Anesthesiol, Nishicho 36-1, Tottori 6838504, Japan.	masui@med.tottori-u.ac.jp					Beilin B, 2003, ANESTHESIOLOGY, V98, P151, DOI 10.1097/00000542-200301000-00024; BURN JM, 1973, BRIT J ANAESTH, V45, P338, DOI 10.1093/bja/45.4.338; DUGGLEBY W, 1994, J PAIN SYMPTOM MANAG, V9, P19, DOI 10.1016/0885-3924(94)90142-2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fong HK, 2006, ANESTH ANALG, V102, P1255, DOI 10.1213/01.ane.0000198602.29716.53; Fragen RJ, 1996, J CLIN ANESTH, V8, P352, DOI 10.1016/0952-8180(96)00082-7; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Hong JY, 2008, REGION ANESTH PAIN M, V33, P44, DOI 10.1016/j.rapm.2007.07.010; Ishiyama T, 2005, ANESTH ANALG, V100, P728, DOI 10.1213/01.ANE.0000159868.06847.47; Kakiuchi M, 1997, INT ORTHOP, V21, P62, DOI 10.1007/s002640050121; Kundra P, 1997, ANESTH ANALG, V85, P135, DOI 10.1097/00000539-199707000-00024; Sekar C, 2004, Spine J, V4, P261; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Yokoyama M, 2004, ANESTHESIOLOGY, V100, P1504, DOI 10.1097/00000542-200406000-00024	14	2	4	0	1	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2010	24	2					192	196		10.1007/s00540-009-0840-6			5	Anesthesiology	Anesthesiology	583GC	WOS:000276660500008	20084409				2020-06-30	J	Zanette, G; Micaglio, M; Zanette, L; Manani, G; Facco, E				Zanette, Gastone; Micaglio, Massimo; Zanette, Lorenzo; Manani, Giovanni; Facco, Enrico			Comparison between ketamine and fentanyl-droperidol for rectal premedication in children: a randomized placebo controlled trial	JOURNAL OF ANESTHESIA			English	Article						Rectal premedication; Ketamine; Fentanyl; Droperidol; Pediatric outpatients	ORAL PREMEDICATION; PEDIATRIC-PATIENTS; MIDAZOLAM; ANESTHESIA; PREINDUCTION; AGITATION; INDUCTION; DIAZEPAM; NASAL	A common concern of anesthesiologists is the management of children involved in stressful scenarios, and premedication is considered, in most situations, as useful to reduce the stress responses. This randomized placebo-controlled study was designed to evaluate two premedicants, ketamine versus a combination of fentanyl-droperidol, rectally administered, in pediatric surgical outpatients. We randomly assigned 120 children to three equal groups to be rectally premedicated with ketamine 10 mg kg(-1) (group K), fentanyl 5 mu g kg(-1) + droperidol 100 mu g kg(-1) (group F), or saline 0.2 ml kg(-1) (group P). A blinded observer scored the children's behavior, according to a four-category behavioral scale, before premedication (time A), 45 min after premedication (time B), immediately before venipuncture (time C), and during the venipuncture (time D). Features of the premedication technique, complications, parents' opinions, and contraindications to hospital discharge were recorded. Patient discharge was delayed because of anesthesia side effects in 7 cases (5.8%) and surgical problems in 9 (7.5%). Group F showed a higher rate of postoperative nausea and vomiting (PONV) than group K, whereas the latter had a higher rate of behavioral disturbances. The data showed a significant difference in the behavioral score between groups F and P, groups K and P, and groups F and K at time B, and between groups K and P at time C. The reaction score at venipuncture shows a significant difference between groups K and P only. In this study, premedication with rectal ketamine showed significantly better overall results in the preoperative period than premedication with either fentanyl-droperidol or placebo.	[Zanette, Gastone; Manani, Giovanni; Facco, Enrico] Univ Padua, Dept Med Surg Specialties, Chair Gen & Dent Anaesthesiol, I-35100 Padua, Italy; [Micaglio, Massimo] Univ Padua, Dept Anaesthesia & Intens Care, I-35100 Padua, Italy; [Zanette, Lorenzo] Azienda Serv Sanit 3, Dept Mental Hlth, I-33013 Gemona Del Friuli, Italy	Zanette, G (reprint author), Univ Padua, Dept Med Surg Specialties, Chair Gen & Dent Anaesthesiol, Via Giustiniani 2, I-35100 Padua, Italy.	gastone.zanette@unipd.it	Boerm, Emma/A-9475-2012	FACCO, ENRICO/0000-0001-8780-3620			Astuto M, 2002, Minerva Anestesiol, V68, P593; Bailey P, 2002, ANESTHESIOLOGY, V97, P288, DOI 10.1097/00000542-200207000-00061; Barbi E, 2003, PAEDIATR ANAESTH, V13, P764, DOI 10.1046/j.1460-9592.2003.01150.x; Berry FA, 2004, PEDIATR ANESTH, V14, P807, DOI 10.1111/j.1460-9592.2004.01412.x; Bessard G, 1997, FUNDAM CLIN PHARM, V11, P133, DOI 10.1111/j.1472-8206.1997.tb00180.x; Binstock W, 2004, PEDIATR ANESTH, V14, P759, DOI 10.1111/j.1460-9592.2004.01296.x; Chang N, 2003, ANESTH ANALG, V97, P1542; DAVIES DR, 1971, BRIT J ANAESTH, V43, P65, DOI 10.1093/bja/43.1.65; Diaz JH, 1997, PAEDIATR ANAESTH, V7, P273, DOI 10.1046/j.1460-9592.1997.d01-93.x; DUPRE LJ, 1980, BRIT J ANAESTH, V52, P831; Epstein RH, 1996, ANESTH ANALG, V83, P1200, DOI 10.1097/00000539-199612000-00012; Geldner G, 1997, PAEDIATR ANAESTH, V7, P103, DOI 10.1046/j.1460-9592.1997.d01-57.x; Golparvar M, 2004, PEDIATR ANESTH, V14, P924, DOI 10.1111/j.1460-9592.2004.01349.x; Habib AS, 2003, ANESTH ANALG, V96, P1377; Kain ZN, 1998, ANESTHESIOLOGY, V89, P1147, DOI 10.1097/00000542-199811000-00015; Kararmaz A, 2004, PEDIATR ANESTH, V14, P477, DOI 10.1111/j.1460-9592.2004.01224.x; KARL HW, 1993, ANESTHESIOLOGY, V78, P885, DOI 10.1097/00000542-199305000-00013; Lin C, 2005, PEDIATR ANESTH, V15, P91, DOI 10.1111/j.1460-9592.2005.01475.x; Lonnqvist PA, 2005, PEDIATR ANESTH, V15, P263, DOI 10.1111/j.1460-9592.2005.01600.x; Malmgren W, 2004, ACTA ANAESTH SCAND, V48, P1277, DOI 10.1111/j.1399-6576.2004.00528.x; MORGANHUGHES JO, 1990, ANAESTHESIA, V45, P427, DOI 10.1111/j.1365-2044.1990.tb14326.x; Patel D, 1997, PAEDIATR ANAESTH, V7, P287, DOI 10.1046/j.1460-9592.1997.d01-88.x; Rautakorpi P, 1999, PAEDIATR ANAESTH, V9, P387, DOI 10.1046/j.1460-9592.1999.00369.x; Rosenbaum A, 2009, PEDIATR ANESTH, V19, P817, DOI 10.1111/j.1460-9592.2009.03114.x; Scuderi PE, 2005, ANESTHESIOLOGY, V102, P1081, DOI 10.1097/00000542-200506000-00003; SIGURDSSON G, 1982, BRIT J ANAESTH, V54, P1075, DOI 10.1093/bja/54.10.1075; Stuth EAE, 2004, PEDIATR ANESTH, V14, P831, DOI 10.1111/j.1460-9592.2004.01472.x; Tamura M, 2003, EUR J ANAESTH, V20, P482, DOI 10.1097/00003643-200306000-00011; Tanaka M, 2000, ANESTHESIOLOGY, V93, P1217, DOI 10.1097/00000542-200011000-00014; Thomas J, 2005, PEDIATR ANESTH, V15, P355, DOI 10.1111/j.1460-9592.2005.01626.x; VANDERWALT JH, 1987, ANAESTH INTENS CARE, V15, P151, DOI 10.1177/0310057X8701500206; VANDERWALT JH, 1990, ANAESTH INTENS CARE, V18, P5, DOI 10.1177/0310057X9001800102; VETTER TR, 1993, J CLIN ANESTH, V5, P58, DOI 10.1016/0952-8180(93)90090-2; Weber F, 2003, CAN J ANAESTH, V50, P470, DOI 10.1007/BF03021058	34	7	7	0	2	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2010	24	2					197	203		10.1007/s00540-010-0884-7			7	Anesthesiology	Anesthesiology	583GC	WOS:000276660500009	20157833				2020-06-30	J	Post, ZD; Restrepo, C; Kahl, LK; van de Leur, T; Purtill, JJ; Hozack, WJ				Post, Zachary D.; Restrepo, Camilo; Kahl, Lauren K.; van de Leur, Tim; Purtill, James J.; Hozack, William J.			A Prospective Evaluation of 2 Different Pain Management Protocols for Total Hip Arthroplasty	JOURNAL OF ARTHROPLASTY			English	Article						pain management; total hip arthroplasty; narcotic consumption; adverse effects; satisfaction	REHABILITATION; ANALGESIA; MORPHINE	Pain management after total hip arthroplasty has improved dramatically in the past decade. However, most protocols use opioid medications for pain control. In the current study, 100 patients were prospectively selected to receive a traditional narcotic-based patient-controlled analgesia protocol or a nonnarcotic oral protocol for pain management after primary total hip arthroplasty. Therapy programs were similar for both groups. Postoperatively, patients were followed daily for opioid use, medication adverse effects, pain control, and overall satisfaction. The nonnarcotic oral group showed lower mean pain scores during the first 24 hours after surgery. The satisfaction rate was high in both groups. Both protocols provided adequate pain control after total hip arthroplasty; the nonnarcotic pain management protocol resulted in significantly decreased opioid consumption and fewer adverse effects.	[Post, Zachary D.; Restrepo, Camilo; Kahl, Lauren K.; van de Leur, Tim; Purtill, James J.; Hozack, William J.] Thomas Jefferson Univ Hosp, Rothman Inst Orthopaed, Philadelphia, PA 19107 USA	Hozack, WJ (reprint author), Chestnut St,5th Floor, Philadelphia, PA 19107 USA.						Chung SA, 2008, ANESTH ANALG, V107, P1543, DOI 10.1213/ane.0b013e318187c83a; DeLoach LJ, 1998, ANESTH ANALG, V86, P102, DOI 10.1097/00000539-199801000-00020; Gehling M, 2008, ANAESTHESIST, V57, P347, DOI 10.1007/s00101-008-1341-y; Hungerford DS, 2000, ORTHOPEDICS, V23, P422; Kaye AD, 2008, CURR OPIN ANESTHESIO, V21, P439, DOI 10.1097/ACO.0b013e3283007e8d; Levine WC, 2006, CURR OPIN ANESTHESIO, V19, P320, DOI 10.1097/01.aco.0000192807.63785.59; McAuley D., 2008, NARCOTIC ANALGESIC C; Meneghini RM, 2006, CLIN ORTHOP RELAT R, P293, DOI 10.1097/01.blo.0000238859.46615.34; Peters CL, 2006, J ARTHROPLASTY, V21, P132, DOI 10.1016/j.arth.2006.04.017; Rachbauer F, 2006, ORTHOPADE, V35, P723, DOI 10.1007/s00132-006-0964-4; Singelyn FJ, 2005, REGION ANESTH PAIN M, V30, P452, DOI 10.1016/j.rapm.2005.05.008; Sloan Paul Alexander, 2008, J Opioid Manag, V4, P131	12	22	23	0	0	CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS	PHILADELPHIA	CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA	0883-5403	1532-8406		J ARTHROPLASTY	J. Arthroplast.	APR	2010	25	3					410	415		10.1016/j.arth.2010.01.003			6	Orthopedics	Orthopedics	585WY	WOS:000276862300013	20149582				2020-06-30	J	Jarmoc, M; Shastri, K; Davis, F				Jarmoc, Marcin; Shastri, Kalpakam; Davis, Fred			Anisocoria After Open Reduction and Internal Fixation of a Mandible Fracture Under General Anesthesia: A Case Report	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							UNILATERAL MYDRIASIS; POSTOPERATIVE ANISOCORIA; DIAGNOSTIC-TEST; TONIC PUPIL; PHENYLEPHRINE; PILOCARPINE; SCOPOLAMINE		[Jarmoc, Marcin; Shastri, Kalpakam] Tufts Univ, Dept Oral & Maxillofacial Surg, Sch Dent Med, Boston, MA 02111 USA; [Davis, Fred] Tufts Med Ctr, Boston, MA USA	Jarmoc, M (reprint author), Tufts Univ, Dept Oral & Maxillofacial Surg, Sch Dent Med, 1 Kneeland St,5th Floor, Boston, MA 02111 USA.	marcin.jarmoc@tufts.edu					Banerjee S, 2005, ANAEST INTENS CARE M, V6, P167, DOI 10.1383/anes.6.5.167.65036; Czerwinski M, 2008, J ORAL MAXIL SURG, V66, P2093, DOI 10.1016/j.joms.2008.04.011; GIBSON BE, 1987, ANESTH ANALG, V66, P197; HOLMGREEN WC, 1979, J ORAL SURG, V37, P740; Kobayashi M, 2008, CAN J ANAESTH, V55, P130, DOI 10.1007/BF03016329; LAM BL, 1987, AM J OPHTHALMOL, V104, P69, DOI 10.1016/0002-9394(87)90296-0; Leavitt JA, 2002, AM J OPHTHALMOL, V133, P333, DOI 10.1016/S0002-9394(01)01420-9; LEPORE FE, 1982, NEW ENGL J MED, V307, P824; LOEWENFELD IE, 1981, ANN NEUROL, V10, P275, DOI 10.1002/ana.410100316; MOORE KL, 1999, CLIN ORIENTED ANATOM, P911; PRIELIPP RC, 1994, CAN J ANAESTH, V41, P140, DOI 10.1007/BF03009808; Rempf C, 2008, ACTA ANAESTH SCAND, V52, P307, DOI 10.1111/j.1399-6576.2007.01505.x; Roos J, 2008, OPHTHALMOLOGY, V115, P1262, DOI 10.1016/j.ophtha.2008.02.018; ROSENBERG M, 1987, ANESTH ANALG, V66, P693, DOI 10.1213/00000539-198707000-00025; RUBIN MM, 1990, J ORAL MAXIL SURG, V48, P621, DOI 10.1016/S0278-2391(10)80478-1; Sitzman BT, 1996, ANESTH ANALG, V83, P633, DOI 10.1097/00000539-199609000-00035; SOBEL AM, 1965, ANESTH ANAL CURR RES, V44, P522; Sternberg TL, 1997, ANESTH ANALG, V84, P939, DOI 10.1097/00000539-199704000-00050; STIRT JA, 1985, CAN ANAESTH SOC J, V32, P422, DOI 10.1007/BF03011355; Thompson H S, 1977, Trans Am Ophthalmol Soc, V75, P587; THOMPSON H S, 1976, Survey of Ophthalmology, V21, P45, DOI 10.1016/0039-6257(76)90047-3; THOMPSON HS, 1971, ARCH OPHTHALMOL-CHIC, V86, P21, DOI 10.1001/archopht.1971.01000010023006; WEINTRAUB MI, 1970, NEW ENGL J MED, V283, P878	23	5	5	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	APR	2010	68	4					898	901		10.1016/j.joms.2009.02.010			4	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	582EO	WOS:000276579200030	20022156				2020-06-30	J	Hong, JY; Han, SW; Kim, WO; Kil, HK				Hong, Jeong-Yeon; Han, Sang Won; Kim, Won Oak; Kil, Hae Keum			Fentanyl Sparing Effects of Combined Ketorolac and Acetaminophen for Outpatient Inguinal Hernia Repair in Children	JOURNAL OF UROLOGY			English	Article						acetaminophen; analgesia; ketorolac; pain, postoperative; pediatrics	PATIENT-CONTROLLED ANALGESIA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POSTOPERATIVE PAIN MANAGEMENT; RANDOMIZED CONTROLLED-TRIALS; DOUBLE-BLIND; MORPHINE; SURGERY; PARACETAMOL; COMBINATION; EFFICACY	Purpose: In this prospective, randomized, double-blinded study we sought to evaluate the efficacy and safety of combined use of intravenous ketorolac and acetaminophen in small children undergoing outpatient inguinal hernia repair. Materials and Methods: We studied 55 children 1 to 5 years old who were undergoing elective repair of unilateral inguinal hernia. After induction of general anesthesia children in the experimental group (28 patients) received 1 mg/kg ketorolac and 20 mg/kg acetaminophen intravenously. In the control group (27 patients) the same volume of saline was administered. All patients received 1 mu g/kg fentanyl intravenously before incision. We also evaluated the number of patients requiring postoperative rescue fentanyl, total fentanyl consumption, pain scores and side effects. Results: Significantly fewer patients receiving ketorolac-acetaminophen received postoperative rescue fentanyl compared to controls (28.6% vs 81.5%). A significantly lower total dose of fentanyl was administered to patients receiving ketorolac-acetaminophen compared to controls (0.54 vs 1.37 mu g/kg). Pain scores were significantly higher in the control group immediately postoperatively but eventually decreased. The incidences of sedation use (55.6% vs 25.0%) and vomiting (33.3% vs 10.7%) were significantly higher in controls. Conclusions: Preoperative intravenous coadministration of ketorolac and acetaminophen is a simple, safe and effective method for relieving postoperative pain, and demonstrates highly significant fentanyl sparing effects in small children after outpatient inguinal hernia repair.	Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Han, Sang Won] Yonsei Univ, Coll Med, Dept Urol, Seoul, South Korea; [Han, Sang Won] Yonsei Univ, Coll Med, Urol Sci Inst, Seoul, South Korea	Kil, HK (reprint author), Severance Hosp, Dept Anesthesiol & Pain Med, 134 Sinchon Dong, Seoul 120752, South Korea.	jenyhongg@yuhs.ac; hkkil@yuhs.ac		Han, Sang Won/0000-0003-0941-1300			Agrawal D, 2004, ANN EMERG MED, V43, P247, DOI 10.1016/S0196-0644(03)00721-2; BeanLijewski JD, 1996, J CLIN ANESTH, V8, P25, DOI 10.1016/0952-8180(95)00168-9; Carney DE, 2001, J PEDIATR SURG, V36, P76, DOI 10.1053/jpsu.2001.20011; DiTomasso R A, 1991, Fam Med, V23, P127; Forrest JB, 1997, DRUG SAFETY, V16, P309, DOI 10.2165/00002018-199716050-00003; Gibb IA, 2008, ARCH DIS CHILD, V93, P241, DOI 10.1136/adc.2007.126896; Hiller A, 2006, ANESTH ANALG, V102, P1365, DOI 10.1213/01.ane.0000204278.71548.bf; Hyllested M, 2002, BRIT J ANAESTH, V88, P199, DOI 10.1093/bja/88.2.199; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Lynch EP, 1998, ANESTH ANALG, V86, P781; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; MCCORMACK K, 1994, PAIN, V59, P9, DOI 10.1016/0304-3959(94)90045-0; Morton NS, 1999, BRIT J ANAESTH, V82, P715; MUNRO HM, 1994, BRIT J ANAESTH, V72, P624, DOI 10.1093/bja/72.6.624; MURRAY MD, 1993, ANNU REV PHARMACOL, V33, P434; Pickering AE, 2002, BRIT J ANAESTH, V88, P72, DOI 10.1093/bja/88.1.72; Prins SA, 2008, PEDIATR ANESTH, V18, P582, DOI 10.1111/j.1460-9592.2008.02619.x; REINHART DJ, 1993, J CLIN ANESTH, V5, P216, DOI 10.1016/0952-8180(93)90018-A; Remy C, 2005, BRIT J ANAESTH, V94, P505, DOI 10.1093/bja/aei085; Romsing J, 2002, BRIT J ANAESTH, V88, P215, DOI 10.1093/bja/88.2.215; RUSY LM, 1995, ANESTH ANALG, V80, P226, DOI 10.1097/00000539-199502000-00004; Siddiqui ZI, 2007, J CLIN ANESTH, V19, P269, DOI 10.1016/j.jclinane.2006.12.004; Sutters K A, 1999, Am J Orthop (Belle Mead NJ), V28, P351; Symons JA, 2008, CLIN J PAIN, V24, P647, DOI 10.1097/AJP.0b013e3181706ca2; Tighe KE, 1999, ANESTH ANALG, V88, P1137, DOI 10.1097/00000539-199905000-00032; VETTER TR, 1994, J CLIN ANESTH, V6, P110, DOI 10.1016/0952-8180(94)90006-X; Viitanen H, 2003, BRIT J ANAESTH, V91, P363, DOI 10.1093/bja/aeg196; WATCHA MF, 1992, ANESTHESIOLOGY, V76, P368, DOI 10.1097/00000542-199203000-00008; Wong D L, 1988, Pediatr Nurs, V14, P9; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	30	27	28	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5347	1527-3792		J UROLOGY	J. Urol.	APR	2010	183	4					1551	1555		10.1016/j.juro.2009.12.043			5	Urology & Nephrology	Urology & Nephrology	574DG	WOS:000275968200115	20172547				2020-06-30	J	Lennernas, B; Frank-Lissbrant, I; Lennernas, H; Kalkner, KM; Derrick, R; Howell, J				Lennernas, Bo; Frank-Lissbrant, Ingela; Lennernas, Hans; Kalkner, Karl Mikael; Derrick, Rob; Howell, Julian			Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study	PALLIATIVE MEDICINE			English	Article						cancer; fentanyl; opioid; pain; sublingual	PHARMACOKINETICS; VARIABILITY; PREVALENCE; CITRATE; TABLET	In this study we evaluated the efficacy and tolerability of sublingual fentanyl (SLF) for breakthrough pain (BTP) in adult opioid-tolerant cancer patients. Patients received one dose of placebo, SLF 100, 200 and 400 mu g in random order at four pain episodes. The primary efficacy endpoint was pain intensity difference (PID) from baseline. Twenty-seven patients received study medication. Overall PID increased significantly with SLF 400 mu g versus placebo (8.57 mm, p < 0.0001). Improvements were statistically different from placebo at 15 min (p = 0.005). SLF 100 and 200 mu g showed a numerical trend towards improved pain relief. A dose that gave a clinically important reduction in pain (PID > 20 mm) was identified by 95% of patients. Reduced use of rescue medication (p < 0.001, SLF 400 mu g) and improved global assessment of treatment (p = 0.0146, SLF 400 mu g) confirmed these differences as clinically important. Nausea and dizziness were the most common treatment-related adverse effects. SLF appears to be a fast, effective and well-tolerated treatment for BTP.	[Derrick, Rob; Howell, Julian] ProStrakan Grp Plc, Galashiels TD1 1QH, Scotland; [Lennernas, Bo; Frank-Lissbrant, Ingela] Univ Gothenburg, Sahlgrenska Akad, Gothenburg, Sweden; [Kalkner, Karl Mikael] Karolinska Hosp, Radiumhemmet, S-10401 Stockholm, Sweden	Derrick, R (reprint author), ProStrakan Grp Plc, Galabank Business Pk, Galashiels TD1 1QH, Scotland.	rob.derrick@prostrakan.com; julian.howell@prostrakan.com			Orexo AB; ProStrakan	The authors would like to thank the members of the SuF-002 study team for their contribution to this study. Statistical analysis of the data and preparation of this article were supported by ProStrakan Group plc. The clinical study was sponsored by Orexo AB. Assistance with writing and preparation of this article was provided by Acumen Healthcare Communications Ltd. BL and HL have acted as consultants for Orexo, and the authors received research funding from Orexo and ProStrakan for this study. RD and JH are employees of ProStrakan. The authors declare they have no further competing interests.	Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2006, BRIT J HOSP MED, V67, P414, DOI 10.12968/hmed.2006.67.8.21960; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Portenoy R K, 1989, Oncology (Williston Park), V3, P25; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; *PSI PROF STAND WO, 2000, GUID STAND OP PROC G; Rhiner Michelle, 2004, Clin J Oncol Nurs, V8, P507, DOI 10.1188/04.CJON.507-512; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	17	41	47	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.	APR	2010	24	3					286	293		10.1177/0269216309356138			8	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	579OU	WOS:000276382100004	20015921				2020-06-30	J	Zachariah, SK; Rai, E; Ninan, S				Zachariah, Sunitha K.; Rai, Ekta; Ninan, Sarah			Anesthesia in a child with otopalatodigital syndrome	PEDIATRIC ANESTHESIA			English	Letter							SYNDROME TYPE-II		[Zachariah, Sunitha K.; Rai, Ekta; Ninan, Sarah] Christian Med Coll & Hosp, Dept Anaesthesia, Vellore, Tamil Nadu, India	Zachariah, SK (reprint author), Christian Med Coll & Hosp, Dept Anaesthesia, Vellore, Tamil Nadu, India.	sunulg97@yahoo.co.in					Butler MG, 2000, ANESTH ANALG, V91, P837, DOI 10.1097/00000539-200010000-00014; CLARK JR, 1995, ANAESTHESIA, V50, P583; Hung PC, 1999, BRAIN DEV-JPN, V21, P488, DOI 10.1016/S0387-7604(99)00044-3; ROSENBAUM S, 1986, REV BRAS GENET, V2, P341; STRATTON RF, 1991, AM J MED GENET, V41, P169, DOI 10.1002/ajmg.1320410206	5	0	0	0	0	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2010	20	4					367	368		10.1111/j.1460-9592.2010.03266.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	565ZO	WOS:000275339300012	20470342				2020-06-30	J	Steinmann, D; Knab, J; Priebe, HJ				Steinmann, Daniel; Knab, Jana; Priebe, Hans-Joachim			Perioperative management of a child with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency	PEDIATRIC ANESTHESIA			English	Letter									[Steinmann, Daniel; Knab, Jana; Priebe, Hans-Joachim] Univ Med Ctr Freiburg, Dept Anaesthesia & Crit Care Med, D-79106 Freiburg, Germany	Steinmann, D (reprint author), Univ Med Ctr Freiburg, Dept Anaesthesia & Crit Care Med, Hugstetter Str 55, D-79106 Freiburg, Germany.	daniel.steinmann@uniklinik-freiburg.de					Blake F, 2007, INT J PAEDIATR DENT, V17, P72, DOI 10.1111/j.1365-263X.2006.00763.x; den Boer MEJ, 2002, PEDIATRICS, V109, P99, DOI 10.1542/peds.109.1.99; Justiz AC, 2006, PEDIATR ANESTH, V16, P1293, DOI 10.1111/j.1460-9592.2006.02003.x; Turpin B, 2005, PEDIATR ANESTH, V15, P771, DOI 10.1111/j.1460-9592.2005.01507.x; Tyni T, 1999, ACTA PAEDIATR, V88, P237, DOI 10.1080/08035259950169954	5	2	2	0	0	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2010	20	4					371	373		10.1111/j.1460-9592.2010.03274.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	565ZO	WOS:000275339300016	20470346				2020-06-30	J	Fleischman, RJ; Frazer, DG; Daya, M; Jui, J; Newgard, CD				Fleischman, Ross J.; Frazer, David G.; Daya, Mohamud; Jui, Jonathan; Newgard, Craig D.			Effectiveness and Safety of Fentanyl Compared with Morphine for Out-of-Hospital Analgesia	PREHOSPITAL EMERGENCY CARE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 13-17, 2009	New Orleans, LA	Soc Acad Emergency Med		analgesia; fentanyl; morphine; analgesics; opioid; prehospital emergency care; emergency medical services	EMERGENCY-DEPARTMENT; MULTIPLE IMPUTATION; PROCEDURAL SEDATION; ADVANCED STATISTICS; CLINICAL-RESEARCH; MISSING DATA; ACUTE PAIN; REGISTRY	Background. Fentanyl has several potential advantages for out-of-hospital analgesia, including rapid onset, short duration, and less histamine release. Objective. To compare the effectiveness and safety of fentanyl with that of morphine. Methods. This was a retrospective before-and-after study of a protocol change from morphine to fentanyl in an advanced life support emergency medical services system in January 2007. Charts from nine months prior to the change and for nine months afterward were abstracted by two reviewers using a standardized instrument. The first three months after the change were excluded. Effectiveness was measured by change in pain scores on a 0-10 scale. A priori-defined adverse events included out-of-hospital events: respiratory rate < 12 breaths/min, pulse oximetry < 92%, systolic blood pressure < 90 mmHg, any fall in Glasgow Coma Scale score, nausea or vomiting, intubation, and use of antiemetic agents or naloxone. Emergency department charts were reviewed for initial pain scores and the same adverse events during the first two hours. Events clearly not attributable to the opioid were discounted. The changes in pain scores were also compared adjusting for confounders by multivariable linear regression. Results. Three hundred fifty-five patients aged 13 to 99 years received morphine during the nine months before the protocol change and 363 received fentanyl following the washout period. Initial pain scores for morphine (8.1) and fentanyl (8.3) were comparable (95% confidence interval [CI] for difference -1.1 to 0.3). Fentanyl patients received a higher equivalent dose of opioid (7.7 mg morphine equivalents for morphine, 9.2 mg for fentanyl, CI for the difference 0.9 to 2.3). The mean decreases in pain score were similar between the drugs (2.9 for morphine, 3.1 for fentanyl, CI for the difference -0.3 to 0.7). With regard to adverse events, 9.9% of the morphine patients and 6.6% of the fentanyl patients experienced an adverse event in the field (CI for the difference -0.8 to 7.3%). The most common event was nausea, with a rate of 7.0% for morphine vs. 3.8% for fentanyl (CI for the difference -0.1% to 6.5%). Conclusion. Morphine and fentanyl provide similar degrees of out-of-hospital analgesia, although this was achieved with a higher dose of fentanyl. Both medications had low rates of adverse events, which were easily controlled.	[Fleischman, Ross J.; Frazer, David G.; Daya, Mohamud; Jui, Jonathan; Newgard, Craig D.] Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, Portland, OR 97239 USA	Fleischman, RJ (reprint author), Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, 3181 SW Sam Jackson Pk Rd,Mail Code CR114, Portland, OR 97239 USA.	fleischr@ohsu.edu	Daya, Mohamud R/A-9322-2012		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024140, UL1 RR024140-05]		Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Berthier F, 1998, AM J EMERG MED, V16, P132, DOI 10.1016/S0735-6757(98)90029-8; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; BIJUR PE, 2009, ACAD EMERG MED S, V16, pS33; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; Dailey MV, 2009, ACAD EMERG MED S, V16, pS197; Deitch K, 2008, ANN EMERG MED, V52, P1, DOI 10.1016/j.annemergmed.2007.11.040; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Haukoos JS, 2007, ACAD EMERG MED, V14, P662, DOI 10.1197/j.aem.2006.11.037; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Little R, 2002, STAT ANAL MISSING DA; McLean Samuel A, 2004, Prehosp Emerg Care, V8, P155, DOI 10.1016/j.prehos.2003.12.006; *MD CONS, MD CONS DRUG MON FEN; Newgard CD, 2006, ACAD EMERG MED, V13, P314, DOI 10.1197/j.aem.2005.09.011; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; NIELSEN ND, 2007, J EMERGENCY MED, V33, P335; Raghunathan T, 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Sacchetti A, 2007, ACAD EMERG MED, V14, P41, DOI 10.1197/j.aem.2006.05.023; SILVFAST T, 2001, EUR J EMERG MED, V8, P275; *THOM HEALTHC, 2008, RED BOOK PHARM FUND, P437; *THOM MICR HEALTHC, 2009, DRUGDEX EV FENT; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; WELDON E, 2008, PREHOSP EMERG CARE, V12, P95; *WHO COLL CTR DRUG, 2009, ATC DDD SYST	28	24	24	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	APR-JUN	2010	14	2					167	175		10.3109/10903120903572301			9	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	563SW	WOS:000275155100006	20199230	Green Accepted			2020-06-30	J	Park, YM; Cho, JH; Lim, YS; Lee, HJ; Kang, SG; Kim, L				Park, Young-Min; Cho, Jae-Hyuck; Lim, Yong-Soo; Lee, Heon-Jeong; Kang, Seung-Gul; Kim, Leen			The withdrawal from TDF therapy could induce transient RLS	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Letter							RESTLESS LEGS SYNDROME; TRANSDERMAL FENTANYL; METHADONE; TRAMADOL; PAIN		[Park, Young-Min; Cho, Jae-Hyuck; Lim, Yong-Soo] Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Neuropsychiat, Goyang 411706, South Korea; [Lee, Heon-Jeong; Kang, Seung-Gul; Kim, Leen] Korea Univ, Coll Med, Dept Psychiat, Seoul 136705, South Korea	Park, YM (reprint author), Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Neuropsychiat, 2240 Daehwa Dong, Goyang 411706, South Korea.	medipark@hanmail.net	; Lee, Heon-Jeong/K-5871-2015	Kang, Seung-Gul/0000-0003-4933-0433; Lee, Heon-Jeong/0000-0002-9560-2383			Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Bonnet U, 1998, PHARMACOPSYCHIATRY, V31, P143, DOI 10.1055/s-2007-979316; Freye E, 2000, EUR J PAIN, V4, P307, DOI 10.1053/eujp.2000.0187; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; Hogl B, 2002, NEUROLOGY, V59, P1705, DOI 10.1212/01.WNL.0000036606.56405.3D; Hunt A, 2001, PALLIATIVE MED, V15, P405, DOI 10.1191/026921601680419456; Ishihara C, 2005, PHARM WORLD SCI, V27, P13, DOI 10.1007/s11096-004-2271-7; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Lauerma H, 1999, J CLIN PSYCHIAT, V60, P241, DOI 10.4088/JCP.v60n0407; Ondo WG, 2005, MOVEMENT DISORD, V20, P345, DOI 10.1002/mds.20359; Scherbaum N, 2003, PHARMACOPSYCHIATRY, V36, P70, DOI 10.1055/s-2003-39047; von Spiczak S, 2005, BRAIN, V128, P906, DOI 10.1093/brain/awh441; WALKER JM, 1987, EUR J PHARMACOL, V134, P53, DOI 10.1016/0014-2999(87)90130-0; Walters AS, 2003, SLEEP MED, V4, P121, DOI 10.1016/S1389-9457(02)00258-7; ZENZ M, 1994, J PAIN SYMPTOM MANAG, V9, P54, DOI 10.1016/0885-3924(94)90149-X	15	3	3	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846			PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	MAR 17	2010	34	2					419	420		10.1016/j.pnpbp.2009.12.006			2	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	571XU	WOS:000275790500029	20005913				2020-06-30	J	Negus, SS; Banks, ML; Folk, JE; Rice, KC				Negus, S. S.; Banks, M. L.; Folk, J. E.; Rice, K. C.			Modulation of delta opioid agonist-induced antinociception by repeated morphine pretreatment in rhesus monkeys	LIFE SCIENCES			English	Article						Delta opioid agonist; Delta opioid receptor; Antinociception; SNC80; Morphine; Monkey	DORSAL-ROOT GANGLIA; CHRONIC INFLAMMATION; THERMAL NOCICEPTION; MU; RECEPTORS; SNC80; RAT; TRAFFICKING; PAIN; HYPERALGESIA	Aims: Repeated treatment with morphine increases antinociceptive effects of delta opioid agonists in rodents by a mechanism that may involve increased cell-surface expression of delta receptors. The present study evaluated effects of repeated morphine treatment on behavioral effects of the delta agonist SNC80 and the mu agonist fentanyl in rhesus monkeys. Main methods: In an assay of schedule-controlled responding, three monkeys responded for food reinforcement under a fixed-ratio 30 schedule. In an assay of thermal nociception, tail-withdrawal latencies were evaluated in three monkeys using thermal stimulus intensities of 48 and 54 degrees C. In both assays, the effects of SNC80 (0.032-3.2 mg/kg) and fentanyl (0.001-0.056 mg/kg) were evaluated after repeated treatment with saline or a regimen of morphine doses modeled on the regimen that enhanced delta agonist antinociception and apparent delta receptor availability in previous rodent studies. Key findings: Both SNC80 and fentanyl dose-dependently decreased rates of schedule-controlled responding, and repeated morphine treatment did not significantly alter these effects. In the assay of thermal nociception, SNC80 had little effect on tail-withdrawal latencies from water heated to 48 or 54 degrees C, whereas fentanyl increased tail-withdrawal latencies at both temperatures. Repeated morphine tended to increase the antinociceptive effects of SNC80 and to decrease the antinociceptive effects of fentanyl, but these effects of repeated morphine were small and were significant only at the higher stimulus intensity (54 degrees C). Significance: These results provide limited support for the proposition that prior stimulation of mu receptors selectively increases the antinociceptive effects of delta agonists in rhesus monkeys. (C) 2010 Elsevier Inc. All rights reserved.	[Negus, S. S.; Banks, M. L.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23220 USA; [Folk, J. E.; Rice, K. C.] NIDA, Chem Biol Res Branch, Rockville, MD 20852 USA; [Folk, J. E.; Rice, K. C.] NIAAA, NIH, Rockville, MD 20852 USA	Negus, SS (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, 410 N 12th St,POB 980613, Richmond, VA 23298 USA.	ssnegus@vcu.edu; mbanks3@vcu.edu; kennerr@mail.nih.gov	Banks, Matthew L/K-4429-2014	Banks, Matthew L/0000-0003-4949-5246	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01-DA11460]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	This work was supported by Grant R01-DA11460 from the National Institute on Drug Abuse, National Institutes of Health. A portion of this work was also supported by the Intramural Research Programs of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism. These funding sources had no involvement in any aspect of the study. The authors would like to thank Katrina Schrode and Ember Morrissey for expert technical assistance.	Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939; BUTELMAN ER, 1995, EUR J PHARMACOL, V277, P285, DOI 10.1016/0014-2999(95)00134-7; Cahill CM, 2007, TRENDS PHARMACOL SCI, V28, P23, DOI 10.1016/j.tips.2006.11.003; Cahill CM, 2003, PAIN, V101, P199, DOI 10.1016/S0304-3959(02)00333-0; Cahill CM, 2001, J NEUROSCI, V21, P7598; Danielsson I, 2006, PHARMACOL BIOCHEM BE, V85, P428, DOI 10.1016/j.pbb.2006.09.012; Do Carmo GP, 2008, J PHARMACOL EXP THER, V326, P939, DOI 10.1124/jpet.108.138180; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Fraser GL, 2000, BRIT J PHARMACOL, V129, P1668, DOI 10.1038/sj.bjp.0703248; Gallantine EL, 2005, BASIC CLIN PHARMACOL, V97, P39, DOI 10.1111/j.1742-7843.2005.pto_97107.x; Gatch MB, 1995, J PHARMACOL EXP THER, V275, P1346; Gendron L, 2007, NEUROSCIENCE, V150, P807, DOI 10.1016/j.neuroscience.2007.09.060; Gendron L, 2007, NEUROSCIENCE, V144, P263, DOI 10.1016/j.neuroscience.2006.08.077; Gendron L, 2006, J NEUROSCI, V26, P953, DOI 10.1523/JNEUROSCI.3598-05.2006; Hack SP, 2005, J NEUROSCI, V25, P3192, DOI 10.1523/JNEUROSCI.4585-04.2005; Jutkiewicz EM, 2004, DELTA RECEPTOR, P355; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mennicken F, 2003, J COMP NEUROL, V465, P349, DOI 10.1002/cne.10839; Morgan MM, 2009, NEURAL PLAST, V2009, DOI 10.1155/2009/516328; Morinville A, 2003, J NEUROSCI, V23, P4888; Negus SS, 2008, EXP CLIN PSYCHOPHARM, V16, P386, DOI 10.1037/a0013088; Negus SS, 2009, EUR J PHARMACOL, V602, P92, DOI 10.1016/j.ejphar.2008.11.004; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 1999, J PHARMACOL EXP THER, V290, P1132; Negus SS, 2002, J PAIN, V3, P218, DOI 10.1054/jpai.2002.124734; Negus SS, 1998, J PHARMACOL EXP THER, V286, P362; NEGUS SS, 1994, J PHARMACOL EXP THER, V270, P1025; NEGUS SS, 1993, J PHARMACOL EXP THER, V266, P1355; NEGUS SS, 2004, [No title captured], P401; OSSIPOV MH, 2004, DELTA RECEPTOR, P297; Rowan MP, 2009, EUR J PHARMACOL, V602, P283, DOI 10.1016/j.ejphar.2008.11.028; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Stevenson GW, 2005, J PHARMACOL EXP THER, V314, P221, DOI 10.1124/jpet.104.082685; Stevenson GW, 2004, EUR J PHARMACOL, V506, P133, DOI 10.1016/j.ejphar.2004.10.051; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; STEWART PE, 1994, J PHARMACOL EXP THER, V268, P701; WALKER EA, 1993, J PHARMACOL EXP THER, V267, P280	37	4	4	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	MAR 13	2010	86	11-12					385	392		10.1016/j.lfs.2010.01.006			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	567ZP	WOS:000275489900002	20096291	Green Accepted			2020-06-30	J	Taghizadeh, SM; Soroushnia, A; Mohamadnia, F				Taghizadeh, Seyed Mojtaba; Soroushnia, Arezou; Mohamadnia, Fatemeh			Preparation and In Vitro Evaluation of a New Fentanyl Patch Based on Functional and Non-functional Pressure Sensitive Adhesives	AAPS PHARMSCITECH			English	Article						adhesion properties; fentanyl; peel strength; pressure-sensitive adhesive; skin permeation; tack; transdermal drug delivery system	TRANSDERMAL DELIVERY; PERMEABILITY; PERMEATION; SKIN	In this study, some single-layer and double-layer transdermal drug delivery systems (TDDSs) with different functional and non-functional acrylic pressure-sensitive adhesives (PSAs) were prepared. For this purpose, fentanyl as a drug was used. The effects of PSAs type, single-layer and double-layer TDDSs on skin permeation and in vitro drug release from devices were evaluated using a hydrodynamically well-characterized Chien permeation system fitted with excised rat abdominal skin. The adhesion properties of devices such as peel strength and tack values were obtained as well. It was found that TDDS with -COOH functional PSA showed the lowest steady-state flux. Double-layer TDDS displayed a constant flux up to 72 h. In double-and single-layer devices after 1 and 3 h, respectively, drug release followed Higuchi's kinetic model. Formulations with the highest percentage of -COOH functional PSA have displayed the lowest flux. The double-layer TDDSs with non-functional PSA demonstrated the suitable skin permeation rate close to Duragesic (R) TDDS and suitable adhesion properties.	[Taghizadeh, Seyed Mojtaba; Soroushnia, Arezou; Mohamadnia, Fatemeh] Iran Polymer & Petrochem Inst, Polymer Sci Fac, Novel Drug Delivery Syst Dept, Tehran, Iran	Taghizadeh, SM (reprint author), Iran Polymer & Petrochem Inst, Polymer Sci Fac, Novel Drug Delivery Syst Dept, POB 14965-115, Tehran, Iran.	s.m.taghizadeh@ippi.ac.ir			Iran Polymer and Petrochemical Institute	Support of this work from Iran Polymer and Petrochemical Institute is appreciated, and thanks are due to Ms. Houri Mivehchi for editing the manuscript.	Boucaud A, 2001, INT J PHARMACEUT, V228, P69, DOI 10.1016/S0378-5173(01)00820-1; Cichewicz DL, 2005, EUR J PHARMACOL, V525, P74, DOI 10.1016/j.ejphar.2005.09.039; Collaud S, 2007, J CONTROL RELEASE, V123, P203, DOI 10.1016/j.jconrel.2007.08.015; del Consuelo ID, 2007, J CONTROL RELEASE, V122, P135, DOI 10.1016/j.jconrel.2007.05.017; Fan QX, 2004, J CONTROL RELEASE, V98, P355, DOI 10.1016/j.jconrel.2004.05.005; Goicoechea C, 2008, EUR J PHARMACOL, V595, P22, DOI 10.1016/j.ejphar.2008.07.052; Kalia YN, 2001, ADV DRUG DELIVER REV, V48, P159, DOI 10.1016/S0169-409X(01)00113-2; Marinangeli Franco, 2007, Pain Pract, V7, P307, DOI 10.1111/j.1533-2500.2007.00155.x; Mehdizadeh Amir, 2006, Acta Pharmaceutica (Zagreb), V56, P219; Mehdizadeh Amir, 2004, Acta Pharmaceutica (Zagreb), V54, P301; Panchagnula Ramesh, 1997, Indian Journal of Pharmacology, V29, P140; Papadokostaki KG, 1998, J CONTROL RELEASE, V54, P251, DOI 10.1016/S0168-3659(97)00158-2; ROY SD, 1994, J PHARM SCI, V83, P1723, DOI 10.1002/jps.2600831215; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; STEFANO FJE, 2005, Patent No. 20050208116; STEFANO FJE, 2003, Patent No. 03097008; Taghizadeh SM, 2009, DRUG DEV IND PHARM, V35, P487, DOI 10.1080/03639040802448638 ; URQUHART J, 1977, Patent No. 4060084; URQUHART J, 1976, Patent No. 4031894; URQUHART J, 1981, Patent No. 4262003; Valenta C, 2005, J CONTROL RELEASE, V107, P495, DOI 10.1016/j.jconrel.2005.07.006	21	6	7	0	9	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1530-9932			AAPS PHARMSCITECH	AAPS PharmSciTech	MAR	2010	11	1					278	284		10.1208/s12249-009-9366-3			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	612SC	WOS:000278921800034	20182829	Green Published			2020-06-30	J	Olson, KN; Luckenbill, K; Thompson, J; Middleton, O; Geiselhart, R; Mills, KM; Kloss, J; Apple, FS				Olson, Kalen N.; Luckenbill, Kristin; Thompson, Jonathan; Middleton, Owen; Geiselhart, Roberta; Mills, Kelly M.; Kloss, Julie; Apple, Fred S.			Postmortem Redistribution of Fentanyl in Blood	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Fentanyl; Postmortem redistribution; Forensic; Toxicology	TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS; DRUG REDISTRIBUTION; CARDIAC BLOOD; DURAGESIC(R); ABUSE; LIVER	Fentanyl concentrations were measured in postmortem specimens collected in 20 medical examiner cases from femoral blood (FB), heart blood (HB), heart tissue, liver tissue, and skeletal muscle. Unique was a subset of 7 cases in which FB was obtained at 2 postmortem intervals, shortly after death (FB1) and at autopsy (FB2). The mean collection times of FB1 and FB2 after death were 4.0 and 21.6 hours, respectively. Fentanyl concentrations for FB1 and FB2 ranged from undetectable to 14.6 mu g/L (mean, 4.6 mu g/L) and 2.0 to 52.5 mu g/L (mean, 17.3 mu g/L), respectively. Corresponding mean HB, liver tissue, and heart tissue fentanyl concentrations were 29.8 mu g/L, 109.7 mg/kg, and 103.4 mg/kg, respectively. The fentanyl HB/FBl ratio (mean, 8.39) was higher compared with the corresponding HB/FB2 ratio (mean, 3.48). These results suggest that postmortem redistribution of fentanyl can occur in FB.	[Olson, Kalen N.; Luckenbill, Kristin; Kloss, Julie; Apple, Fred S.] Univ Minnesota, Med Ctr, Clin Lab, Minneapolis, MN 55455 USA; [Thompson, Jonathan; Middleton, Owen; Geiselhart, Roberta] Univ Minnesota, Med Ctr, Med Examiners Off, Minneapolis, MN 55455 USA; [Mills, Kelly M.] Univ Minnesota, Med Ctr, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Apple, Fred S.] Ramsey Cty Med Examiners Off, St Paul, MN USA	Apple, FS (reprint author), Hennepin Cty Med Ctr, 701 Pk Ave,Clin Labs P4, Minneapolis, MN 55415 USA.						Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; APPLE FS, 1988, AM J CLIN PATHOL, V89, P794, DOI 10.1093/ajcp/89.6.794; APPLE FS, 1989, J ANAL TOXICOL, V13, P197, DOI 10.1093/jat/13.4.197; Baselt RC, 2008, DISPOSITION TOXIC DR; Hilberg T, 1999, J FORENSIC SCI, V44, P3; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; ISENSCHMID DS, 2007, ANN M AM AC FOR SCI; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Logan BK, 1996, J FORENSIC SCI, V41, P221; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Moriya F, 1999, J FORENSIC SCI, V44, P10; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; PROUTY RW, 1990, J FORENSIC SCI, V35, P243; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Yarema MC, 2005, CLIN TOXICOL, V43, P235, DOI 10.1081/CLT-200058950; Yoshitome K, 2008, J ANAL TOXICOL, V32, P451, DOI 10.1093/jat/32.6.451	18	33	33	0	18	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2010	133	3					447	453		10.1309/AJCP4X5VHFSOERFT			7	Pathology	Pathology	557RM	WOS:000274687800012	20154283	Bronze			2020-06-30	J	Jumbelic, MI				Jumbelic, Mary I.			Deaths With Transdermal Fentanyl Patches	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article							CIRCUMSTANCES	Fentanyl is a potent Schedule II narcotic analgesic recommended for use in the management of unremitting pain not controlled by morphine or other opiate/opioid drugs. The danger inherent to fentanyl is its potency (greater than 50-100 times that of morphine) and rapidity of action, causing respiratory depression within minutes of administration. Advisories have been issued on a state and national level to health care providers and through manufacturers' package inserts for patients. Still, as will be demonstrated in this case review, the use of only a single transdermal patch taken as prescribed for the first time can prove fatal. A drug that requires such extensive warnings-that if unheeded lead to death because of its narrow therapeutic/toxic window, should have strict criteria and limited outpatient use. Initial medical observation and documentation for determining tolerance might be required before issuing a prescription. There has been a rise in the popularity of this drug evidenced by increased deaths among drug abusers and more prescriptions written. In the year 2006, the Center for Forensic Sciences in Onondaga County had 8 cases where fentanyl was considered the cause of death, often with other drugs detected in therapeutic concentrations. This number was a marked increase from the 1 to 2 cases occurring annually from 2002 to 2005. All of these 2006 overdoses because of fentanyl involved the transdermal formulation. The investigative data, blood and liver fentanyl levels, and autopsy findings will be presented.	SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY USA	Jumbelic, MI (reprint author), SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY USA.	mjumbelic@gmail.com					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; COOKLOCK K, 1996, AM ASS PHARM SCI 3M; DENTON J, 2007, P AM AC FOR SCI ANN; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; *FDA PUBL HLTH ADV, [No title captured]; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; *JANSS PHARM PROD, 2003, PAT INF DUR FENT TRA; LAGOW B, 2007, PHYS DESK REFERENCE, P2373; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; *NAT AC SCI I MED, 2006, FUT DRUG SAF PROM PR; RIPPLE M, 2007, P AM AC FOR SCI ANN; *SAMHSA DRUG INF, FENT; THORPE L, 2006, NYC DOHMH HLTH ALERT; PHARM FACTS FIGURES; FENTANYL BRIEFS BACK; DURGS SUPPLEMENTS FE; PRODUCT RECALLS AUST; 2001, CANADIAN ADVERSE REA, P14; DURAGESIC FENTANYL T	19	47	47	2	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	MAR	2010	31	1					18	21		10.1097/PAF.0b013e31818738b8			4	Medicine, Legal; Pathology	Legal Medicine; Pathology	564XD	WOS:000275250900005	19918162				2020-06-30	J	Ghali, AM; El Btarny, AM				Ghali, A. M.; El Btarny, A. M.			The effect on outcome of peribulbar anaesthesia in conjunction with general anesthesia for vitreoretinal surgery	ANAESTHESIA			English	Article							RETINAL-DETACHMENT SURGERY; OCULOCARDIAC REFLEX; STRABISMUS SURGERY; BLOCK; INJECTION; BUPIVACAINE; CHILDREN	The purpose of this study was to evaluate peri-operative outcome after vitreoretinal surgery when peribulbar anaesthesia is combined with general anaesthesia. Sixty adult patients undergoing elective primary retinal detachment surgery with scleral buckling or an encircling procedure received either peribulbar anaesthesia in conjunction with general anaesthesia or general anaesthesia alone. For peribulbar anaesthesia a single percutaneous injection of 5-7 ml of local anaesthetic solution (0.75% ropivacaine with hyaluronidase 15 iu.ml(-1)) was used. The incidence of intraoperative oculocardiac reflex and surgical bleeding interfering with the surgical field, postoperative pain and analgesia requirements, and postoperative nausea and vomiting were recorded. In the block group there was a lower incidence of oculocardiac reflex and surgical bleeding intraoperatively. Patients in the block group also had better postoperative analgesia and a lower incidence of postoperative nausea and vomiting compared with the group without a block. The use of peribulbar anaesthesia in conjunction with general anesthesia was superior to general anaesthesia alone for vitreoretinal surgery with scleral buckling.	[Ghali, A. M.] Magrabi Eye & Ear Hosp, Dept Anesthesiol, Muscat, Oman; [El Btarny, A. M.] Magrabi Eye & Ear Hosp, Dept Ophthalmol, Muscat, Oman	Ghali, AM (reprint author), Magrabi Eye & Ear Hosp, Dept Anesthesiol, Muscat, Oman.	ashrafghali@hotmail.com					Allen LE, 1998, EYE, V12, P193, DOI 10.1038/eye.1998.46; Allison CE, 2000, ANESTH ANALG, V90, P306, DOI 10.1097/00000539-200002000-00012; Calenda E, 2004, CLIN EXP OPHTHALMOL, V32, P154, DOI 10.1111/j.1442-9071.2004.00793.x; Calenda E, 2000, ACTA OPHTHALMOL SCAN, V78, P196, DOI 10.1034/j.1600-0420.2000.078002196.x; Frow MW, 2000, ANAESTHESIA, V55, P750, DOI 10.1046/j.1365-2044.2000.01530.x; Grover VK, 1998, OPHTHALMIC SURG LAS, V29, P207; Kehlet H., 1999, PAIN 1999 UPDATED RE, P459; Mahfouz AKM, 2002, RETINA-J RET VIT DIS, V22, P602, DOI 10.1097/00006982-200210000-00011; Morel J, 2006, ANESTH ANALG, V102, P1082, DOI 10.1213/01.ane.0000198638.93784.42; Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P225, DOI 10.1136/bjo.85.2.225; Nociti JR, 2001, ACTA ANAESTH SCAND, V45, P600, DOI 10.1034/j.1399-6576.2001.045005600.x; Rizzo L, 2005, ANESTH ANALG, V100, P94, DOI 10.1213/01.ANE.0000140951.65240.94; Shende D, 2000, ANAESTHESIA, V55, P970, DOI 10.1046/j.1365-2044.2000.01535.x; Subramaniam R, 2003, REGION ANESTH PAIN M, V28, P43, DOI 10.1053/rapm.2003.50032; VANDENBERG AA, 1989, ANAESTHESIA, V44, P110; Williams GA, 1994, RETINA, V3, P1979	16	14	14	2	3	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0003-2409			ANAESTHESIA	Anaesthesia	MAR	2010	65	3					249	253		10.1111/j.1365-2044.2009.06191.x			5	Anesthesiology	Anesthesiology	552PR	WOS:000274306200005	20039868				2020-06-30	J	Desai, S; Lim, Y; Tan, CH; Sia, ATH				Desai, S.; Lim, Y.; Tan, C. H.; Sia, A. T. H.			A randomised controlled trial of hyperbaric bupivacaine with opioids, injected as either a mixture or sequentially, for spinal anaesthesia for caesarean section	ANAESTHESIA AND INTENSIVE CARE			English	Article						spinal anaesthesia; caesarean section; opioid; local anaesthetic; mixture; sequential	INTRATHECAL MORPHINE; DENSITY DETERMINATION; SPREAD; DELIVERY; PAIN	It is common practice to mix opioids with hyperbaric bupivacaine in a single syringe before intrathecal injection of the mixture. Mixing these drugs may alter the density of the hyperbaric solution, affecting the spread of local anaesthetic and opioid. Forty-eight women having elective caesarean section under spinal anaesthesia were recruited to this double-blind, randomised trial. Group M (n=24) received 2 ml of 0.5% hyperbaric bupivacaine plus morphine 100 mu g plus fentanyl 15 mg, mixed in a syringe prior to administration. Group S (n=24) received 2 ml of 0.5% bupivacaine through one syringe, followed by morphine 100 mu g plus fentanyl 15 mu g through a separate syringe. All patients received patient-controlled intravenous morphine for 24 hours postoperatively. Block characteristics, postoperative pain scores and morphine use were noted. The patients in Group M had higher levels of sensory block to cold than those in Group S (median T2 vs T3)(P=0.003). Five patients in Group M and none in Group S had a block to cold >= T1 (P=0.02). There was no difference between groups in the incidence of hypotension, need for vasopressor or side-effects. Morphine consumption was significantly higher in group M (13.3 +/- 11.2 vs 6.2 +/- 7.2 mg, P=0.015). Mixing of fentanyl and morphine with hyperbaric bupivacaine results in a higher level of sensory block than sequential administration of bupivacaine then opioid and may be associated with higher postoperative opioid requirement.	[Desai, S.; Lim, Y.; Tan, C. H.; Sia, A. T. H.] KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore 229899, Singapore	Desai, S (reprint author), KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Bukit Timah Rd, Singapore 229899, Singapore.						Arai YCP, 2006, ANESTH ANALG, V102, P272, DOI 10.1213/01.ane.0000184252.16045.0E; Goodchild CS, 2004, EUR J ANAESTH, V21, P179, DOI 10.1017/S0265021504003035; GRAY JR, 1986, ANESTH ANALG, V65, P873; Hallworth SP, 2005, ANESTH ANALG, V100, P1159, DOI 10.1213/01.ANE.0000149548.88029.A2; Hare GMT, 1998, CAN J ANAESTH, V45, P341, DOI 10.1007/BF03012026; Hoppe J, 2007, INT J OBSTET ANESTH, V16, P250, DOI 10.1016/j.ijoa.2006.12.005; Kampe S, 2003, ANESTH ANALG, V96, P1234, DOI 10.1213/01.ANE.0000044046.61979.E6; Parlow JL, 1999, CAN J ANAESTH, V46, P66, DOI 10.1007/BF03012518; Richardson MG, 1996, ANESTHESIOLOGY, V85, P326, DOI 10.1097/00000542-199608000-00014; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; STEINSTRA R, 1990, REGIONAL ANESTHESIA, V15, P6; Swart M, 1997, ANAESTHESIA, V52, P373, DOI 10.1111/j.1365-2044.1997.az0083c.x; Yang T, 1999, CAN J ANAESTH, V46, P856, DOI 10.1007/BF03012975	13	5	5	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	MAR	2010	38	2					280	284		10.1177/0310057X1003800209			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	575GK	WOS:000276054800009	20369760	Bronze			2020-06-30	J	Garg, A; Ahmed, F; Khandelwal, M; Chawla, V; Verma, AP				Garg, A.; Ahmed, F.; Khandelwal, M.; Chawla, V.; Verma, A. P.			The effect of transdermal nitroglycerine on intrathecal fentanyl with bupivacaine for postoperative analgesia following gynaecological surgery	ANAESTHESIA AND INTENSIVE CARE			English	Article						postoperative analgesia; gynaecological surgery; nitorglycerine; fentabyl; bupivaciane; transdermal	NITRIC-OXIDE SYNTHASE; RAT SPINAL-CORD; MOLECULAR-MECHANISM; CGMP PATHWAY; MORPHINE; SENSITIZATION; RELEASE; INHIBITION; TOLERANCE; NEURONS	Fentanyl is a short-acting synthetic opioid with spinal analgesic properties and dose-dependent side-effects. The analgesic effect of opioids is mediated in part through activation of inhibitory descending pain pathways involving nitric oxide (as a central neurotransmitter) through the NO-cGMP system. This NO-cGMP pathway plays an important role in spinal nociception. The aim of the study was to evaluate the effect of transdermal nitroglycerine on the analgesic action of intrathecal fentanyl in patients undergoing abdominal hysterectomy. Patients (n=120) were randomised into one of four groups. All received 3 ml bupivacaine 0.5% plus 0.5 ml of an intrathecal test drug. Twenty minutes after lumbar puncture, a transdermal patch of either nitroglycerine or placebo was applied. Group B received spinal bupivacaine plus saline 0.5 ml and a placebo patch. Group B-N received bupivacaine plus saline 0.5 ml and a nitroglycerine patch. Group F received bupivacaine plus fentanyl 25 mu g and a placebo patch. Group F-N received bupivacaine plus fentanyl 25 mu g and a nitroglycerine patch. The duration of effective analgesia was longer in group FN (363.53 +/- 34.09 min) compared from the other groups (P<0.001). The times to two-segment regression in group F-N and group F were 132.87 +/- 31.2 mm and 126.40 +/- 26.81 mm respectively. The visual analog scale pain score at the time of the first rescue analgesic was similar in all groups. We conclude that nitroglycerine does not result in postoperative analgesia but enhances the analgesic effect of intrathecal fentanyl.	[Garg, A.; Ahmed, F.; Khandelwal, M.; Chawla, V.; Verma, A. P.] Sawai Man Singh Med Coll & Hosp, Dept Anaesthesia & Crit Care, Jaipur, Rajasthan, India	Garg, A (reprint author), 699 Frontier Colony,Adarsh Nagar, Jaipur 4, Rajasthan, India.						BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Biswas BN, 2002, INDIAN J ANAESTH, V46, P469; Bouaziz H, 1996, ANESTHESIOLOGY, V84, P143, DOI 10.1097/00000542-199601000-00017; BOUAZIZ H, 1995, REGION ANESTH, V20, P121; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DETWEILER DJ, 1993, J PHARMACOL EXP THER, V265, P536; DUARTE IDG, 1992, EUR J PHARMACOL, V221, P171, DOI 10.1016/0014-2999(92)90789-7; DUARTE IDG, 1990, EUR J PHARMACOL, V186, P289, DOI 10.1016/0014-2999(90)90446-D; DUARTE IDG, 1992, EUR J PHARMACOL, V217, P225, DOI 10.1016/0014-2999(92)90881-4; FERREIRA SH, 1991, EUR J PHARMACOL, V201, P121, DOI 10.1016/0014-2999(91)90333-L; Kaur G, 2007, J ANESTH CLIN PHARM, V23, P159; Khanna MS, 2002, INDIAN J ANAESTH, V46, P199; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P734, DOI 10.1097/00000542-199903000-00015; Lauretti GR, 2000, ANESTHESIOLOGY, V93, P943, DOI 10.1097/00000542-200010000-00011; Lin Q, 1997, J NEUROSCI, V17, P3293; MAJEED NH, 1994, NEUROPHARMACOLOGY, V33, P189, DOI 10.1016/0028-3908(94)90006-X; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; MINNEMAN KP, 1976, NATURE, V262, P313, DOI 10.1038/262313a0; MONCADA S, 1991, PHARMACOL REV, V43, P109; NISHIO Y, 1989, ANESTH ANALG, V69, P323; PASTERNAK GW, 1995, NEUROPSYCHOPHARMACOL, V13, P309, DOI 10.1016/0893-133X(95)00084-Q; RONAI AZ, 1982, OPIATE PEPTIDE, P1; SAITO S, 1994, NEUROSCIENCE, V59, P447, DOI 10.1016/0306-4522(94)90608-4; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; VAUPEL DB, 1995, NEUROPSYCHOPHARMACOL, V13, P315, DOI 10.1016/0893-133X(95)00138-4; Xu ZM, 1996, ANESTHESIOLOGY, V85, P107, DOI 10.1097/00000542-199607000-00015; Yamaguchi H, 1996, CAN J ANAESTH, V43, P975, DOI 10.1007/BF03011815; YAMAMOTO T, 1993, ANESTH ANALG, V77, P886; ZHUO M, 1993, PAIN, V54, P71, DOI 10.1016/0304-3959(93)90101-T	30	8	9	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	MAR	2010	38	2					285	290		10.1177/0310057X1003800210			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	575GK	WOS:000276054800010	20369761	Bronze			2020-06-30	J	Schafer, M; Keilig, S; Brack, A; Kranke, P				Schaefer, Michael; Keilig, Susanne; Brack, Alexander; Kranke, Peter			Opioid induced cough: Do we know its pathophysiology and can it be eliminated?	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article							FENTANYL BOLUS; SUFENTANIL; RECEPTORS; INJECTION; NUCLEUS		[Schaefer, Michael] Charite Univ Med Berlin, Campus Virchow Klinikum, Klin Anasthesiol Schwerpunkt Operat Intens Med, Berlin, Germany; [Keilig, Susanne; Brack, Alexander; Kranke, Peter] Univ Klinikum Wurzburg, Klin & Poliklin Anasthesiol, Wurzburg, Germany	Schafer, M (reprint author), Charite Univ Med Berlin, Campus Virchow Klinikum, Klin Anasthesiol Schwerpunkt Operat Intens Med, Berlin, Germany.		Schafer, Michael/AAB-1395-2020				Agarwal A, 2007, ANAESTHESIA, V62, P1230, DOI 10.1111/j.1365-2044.2007.05249.x; Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Auberson S, 1998, J PHARM PHARMACOL, V50, P899, DOI 10.1111/j.2042-7158.1998.tb04006.x; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Gestreau C, 1997, J NEUROSCI, V17, P9340; INOUE K, 1980, N-S ARCH PHARMACOL, V312, P57, DOI 10.1007/BF00502575; KRAJNIK M, 2009, HUM PATHOL IN PRESS; Mutolo D, 2008, AM J PHYSIOL-REG I, V295, pR243, DOI 10.1152/ajpregu.00184.2008; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Poole SL, 2007, J NEUROPHYSIOL, V98, P3060, DOI 10.1152/jn.00755.2007; Reynolds SM, 2004, TRENDS PHARMACOL SCI, V25, P569, DOI 10.1016/j.tips.2004.09.009; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Yemen TA, 1998, ANESTHESIOLOGY, V89, P271, DOI 10.1097/00000542-199807000-00043; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	15	1	1	0	5	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661			ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	MAR	2010	45	3					170	173		10.1055/s-0030-1249398			4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	569MH	WOS:000275600700004	20232272				2020-06-30	J	Reza, FM; Zahra, F; Esmaeel, F; Hossein, A				Reza, Fazel Mohammad; Zahra, Forghani; Esmaeel, Fakharian; Hossein, Akbari			Preemptive Analgesic Effect of Ketamine in Patients Undergoing Elective Cesarean Section	CLINICAL JOURNAL OF PAIN			English	Article						cesarean section; ketamine; preemptive analgesia	SMALL-DOSE KETAMINE; POSTOPERATIVE PAIN; ABDOMINAL-SURGERY; DOUBLE-BLIND; MORPHINE; HYPERALGESIA; ANTAGONIST; ANESTHESIA; RECEPTOR; PLACEBO	Objectives: In this study, the preemptive effect of a small dose of ketamine on postoperative wound pain and morphine consumption in patients undergoing elective cesarean section was evaluated. Methods: In a randomized, double-blind clinical trial, 60 women with American Society of Anesthesiologists class I and II identification undergoing elective cesarean section were enrolled. In the case group, the patients received 0.5 mg/kg ketamine, and in the control group, they received isotonic saline, 5 minutes before the induction of anesthesia. Anesthesia was induced with 4 mg/kg thiopental followed by 1.5 mg/kg succinylcholine. A further neuromuscular block was achieved by using 0.2 mg/kg of atracurium. Anesthesia was maintained with nitrous oxide 50% and halothane in oxygen. The lungs were mechanically ventilated. After fetus delivery, fentanyl (2 mu g/kg) and morphine (0.15 mg/kg) were given intravenously. In the postanesthesia care unit and in the ward, all patients received morphine. Pain was assessed by the Visual Analog Scales at 2, 6, 12, and 24 hours postoperatively; the amount of morphine used and side effects were recorded. Results: There was no significant difference between the patients considering their operative details, homodynamic variables, side effects, and Apgar scores of their babies at first and fifth minutes. Significantly, lower amounts of morphine were used in the case group (4.8 mg +/- 2.5 mg vs. 8.1 mg +/- 4.2 mg) during the first 2 hours after surgery (P = 0.01), but the difference was not significant during 2 to 24 hours (3.2 +/- 2.2 vs. 3.1 +/- 2.3). There were no statistical differences between the groups in pain 2, 6, 12, and 24 hours postoperatively. Discussion: Intraoperative low-dose ketamine had no effect on morphine consumption during 2 to 24 hours after surgery. No significant differences were seen in the pain scores of the 2 groups during the study period. The preoperative administration of 0.5 mg/kg ketamine in patients undergoing cesarean section did not elicit a preemptive analgesic effect.	[Reza, Fazel Mohammad; Zahra, Forghani] Kashan Univ Med Sci, Dept Anesthesiol, Kashan, Iran; [Esmaeel, Fakharian] Kashan Univ Med Sci, Dept Surg, Sch Med, Kashan, Iran; [Hossein, Akbari] Kashan Univ Med Sci, Dept Publ Hlth, Sch Hyg, Kashan, Iran	Reza, FM (reprint author), Matini Hosp, Dept Anesthesiol, Sch Med, Amirkabir Ave, Kashan, Iran.	drmfazel@yahoo.com	Fazel, Mohammad Reza/N-6006-2017	Fazel, Mohammad Reza/0000-0001-5944-9230			Adam F, 1999, ANESTH ANALG, V89, P444, DOI 10.1097/00000539-199908000-00036; ARENDTNIELSEN L, 1995, ANESTH ANALG, V81, P63, DOI 10.1097/00000539-199507000-00013; Argiriadou H, 2004, ANESTH ANALG, V98, P1413, DOI 10.1213/01.ANE.0000111204.31815.2D; AUBRUN F, 2007, EUR J ANAESTH, V26, P1; Becke K, 2005, PEDIATR ANESTH, V15, P484, DOI 10.1111/j.1460-9592.2005.01476.x; CLEMENTS JA, 1981, BRIT J ANAESTH, V53, P27, DOI 10.1093/bja/53.1.27; DAHL JB, 1993, BRIT J ANAESTH, V70, P434, DOI 10.1093/bja/70.4.434; Dahl V, 2000, ANESTH ANALG, V90, P1419, DOI 10.1097/00000539-200006000-00031; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; DICKENSON AH, 1987, PAIN, V30, P349, DOI 10.1016/0304-3959(87)90023-6; EJLERSEN E, 1992, ANESTH ANALG, V74, P495; FLETCHER D, 1995, PAIN, V61, P291, DOI 10.1016/0304-3959(94)00184-G; Fu ES, 1997, ANESTH ANALG, V84, P1086, DOI 10.1097/00000539-199705000-00024; GOTO T, 1994, ANESTHESIOLOGY, V80, P409, DOI 10.1097/00000542-199402000-00021; Heinke W, 1999, Anaesthesiol Reanim, V24, P60; Kwok RFK, 2004, ANESTH ANALG, V98, P1044, DOI 10.1213/01.ANE.0000105911.66089.59; Launo C, 2004, Minerva Anestesiol, V70, P727; Lehmann KA, 2001, SCHMERZ, V15, P248, DOI 10.1007/s004820100059; Mathisen LC, 1999, ACTA ANAESTH SCAND, V43, P220, DOI 10.1034/j.1399-6576.1999.430218.x; MCQUAY HJ, 1992, BRIT J ANAESTH, V69, P1, DOI 10.1093/bja/69.1.1; Menigaux C, 2001, ANESTH ANALG, V93, P606, DOI 10.1097/00000539-200109000-00016; NGAN KWD, 1997, ANESTH ANALG, V85, P1294; PEKOE GM, 1982, PAIN, V12, P57, DOI 10.1016/0304-3959(82)90170-1; RICHMOND CE, 1993, LANCET, V342, P73, DOI 10.1016/0140-6736(93)91284-S; RINGROSE NH, 1984, AM J SPORT MED, V12, P398, DOI 10.1177/036354658401200512; ROYTBLAT L, 1993, ANESTH ANALG, V77, P1161; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Suzuki M, 1999, ANESTH ANALG, V89, P98, DOI 10.1097/00000539-199907000-00017; Vatine JJ, 1998, NEUROSCI LETT, V246, P125, DOI 10.1016/S0304-3940(98)00217-1; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2; Warncke T, 1997, PAIN, V72, P99, DOI 10.1016/S0304-3959(97)00006-7; WHITE PF, 1985, BRIT J ANAESTH, V57, P197, DOI 10.1093/bja/57.2.197; WILSON RJT, 1994, ANAESTHESIA, V49, P591; YAMAMURA T, 1990, ANESTHESIOLOGY, V72, P704, DOI 10.1097/00000542-199004000-00021	34	32	33	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	MAR-APR	2010	26	3					223	226		10.1097/AJP.0b013e3181bff86d			4	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	563UH	WOS:000275159900008	20173436				2020-06-30	J	Forget, P; Collet, V; Lavand'homme, P; De Kock, M				Forget, Patrice; Collet, Valerie; Lavand'homme, Patricia; De Kock, Marc			Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						age factors; analgesia; immune response; natural killer cells; surgery	PULMONARY-NK ACTIVITY; CELL ACTIVITY; METASTATIC COLONIZATION; TUMOR-METASTASIS; PROPHYLACTIC MEASURES; INDUCED SUPPRESSION; RATS; MORPHINE; STRESS; PAIN	Background and objective Cellular immunity varies in the perioperative period. We evaluated the effects of fentanyl, clonidine and ketamine at different time points after surgery and in animals in different conditions ( young vs. old). Materials and methods Rats undergoing laparotomy under sevoflurane anaesthesia were assigned to receive saline, fentanyl (40 mu g kg(-1)), clonidine (10 mu g kg(-1)) or ketamine (10 mu g kg(-)1) 1 h before surgery. Natural killer (NK) activity was quantified at different time points ( immediately or after 18, 24, 48, 72 h and 8 days) in vitro by the lysis of YAC-1 cells. In-vivo assessment included counting the number of lung metastases induced by the MADB-106 cells. Results During the first 24 h after surgery, a rapid increase in NK activity was noted, followed by a significant depression returning to baseline at 8 days. Analgesics show specific effects: fentanyl depressed NK activity with or without surgery. Clonidine depressed NK activity in nonoperated animals and during the first 24 h after surgery. Ketamine depressed NK activity in nonoperated animals but, after surgery, this activity varied with the same time course as saline. Ketamine and clonidine significantly reduced the number of lung metastases in operated animals. Ketamine significantly reduced the number of metastases in old nonoperated animals. Finally, ageing has a significant negative influence. Conclusion Surgery, analgesics and co-existing conditions significantly influence cellular immunity. The importance of these changes varies with time. Fentanyl had a worse influence than clonidine and ketamine, but seemed equally protective against the development of metastases. Eur J Anaesthesiol 2010; 27:233-240	[Forget, Patrice; Collet, Valerie; Lavand'homme, Patricia; De Kock, Marc] Univ Catholique Louvain, Dept Anesthesiol, Hop St Luc, B-1200 Brussels, Belgium	Forget, P (reprint author), Univ Catholique Louvain, Dept Anesthesiol, Hop St Luc, Av Hippocrate 10-1821, B-1200 Brussels, Belgium.	forgetpatrice@yahoo.fr	Forget, Patrice/AAO-6918-2020	Forget, Patrice/0000-0001-5772-8439			Alam S, 1996, CAN J ANAESTH, V43, P408, DOI 10.1007/BF03011723; ALBRIGHT JW, 1983, P NATL ACAD SCI-BIOL, V80, P6371, DOI 10.1073/pnas.80.20.6371; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; BARLOZZARI T, 1985, J IMMUNOL, V134, P2783; BEILIN B, 1992, CLIN IMMUNOL IMMUNOP, V64, P173, DOI 10.1016/0090-1229(92)90196-U; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Ben-Eliyahu S, 2007, BRAIN BEHAV IMMUN, V21, P881, DOI 10.1016/j.bbi.2007.06.008; BENELIYAHU S, 2000, PSYCHONEUROIMMUNOLOG, P2545; Bentley Michael W, 2005, AANA J, V73, P427; COLACCHIO TA, 1994, AM J SURG, V167, P171; DeKock M, 1997, PHARMACOL BIOCHEM BE, V58, P109, DOI 10.1016/S0091-3057(96)00462-5; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Docquier MA, 2004, BRIT J ANAESTH, V93, P408, DOI 10.1093/bja/aeh216; Docquier MA, 2003, ANESTH ANALG, V97, P1033, DOI 10.1213/01.ANE.0000078587.51622.D0; ELENKOV IJ, 2000, PHARMACOL REV, V52, P592; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Franchi S, 2007, BRAIN BEHAV IMMUN, V21, P767, DOI 10.1016/j.bbi.2007.01.001; Galley HF, 2000, INTENS CARE MED, V26, P267, DOI 10.1007/s001340051149; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; Greisen J, 1999, BRIT J ANAESTH, V83, P235, DOI 10.1093/bja/83.2.235; Juge M, 1997, PHARMACOL RES, V36, P179, DOI 10.1006/phrs.1997.0207; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; KUROSAWA S, 1993, EUR J IMMUNOL, V23, P1029, DOI 10.1002/eji.1830230507; Liljefors M, 2003, INT J CANCER, V105, P717, DOI 10.1002/ijc.11139; Mariani E, 1998, INT IMMUNOL, V10, P981, DOI 10.1093/intimm/10.7.981; Melamed R, 2005, BRAIN BEHAV IMMUN, V19, P114, DOI 10.1016/j.bbi.2004.07.004; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Mocchegiani E, 2004, AGING CELL, V3, P177, DOI 10.1111/j.1474-9728.2004.00107.x; Nelson CJ, 1997, ANESTH ANALG, V85, P620, DOI 10.1097/00000539-199709000-00024; Ogata K, 1997, CLIN IMMUNOL IMMUNOP, V84, P269, DOI 10.1006/clin.1997.4401; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Page GG, 2005, J PAIN SYMPTOM MANAG, V29, pS25, DOI 10.1016/j.jpainsymman.2005.01.006; PAGE GG, 1994, BRAIN BEHAV IMMUN, V8, P241, DOI 10.1006/brbi.1994.1022; PAGE GG, 1993, PAIN, V54, P21, DOI 10.1016/0304-3959(93)90095-7; Page GG, 1998, BRIT J ANAESTH, V81, P216; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; Plackett TP, 2004, J LEUKOCYTE BIOL, V76, P291, DOI 10.1189/jlb.1103592; Romero-Sandoval A, 2007, BRAIN BEHAV IMMUN, V21, P569, DOI 10.1016/j.bbi.2006.09.001; Romero-Sandoval EA, 2005, J NEUROSCI, V25, P8988, DOI 10.1523/JNEUROSCI.2995-05.2005; Saurer TB, 2006, J NEUROIMMUNOL, V177, P18, DOI 10.1016/j.jneuroim.2006.05.002; Shakhar G, 1998, J IMMUNOL, V160, P3251; Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007; Shakhar G, 2007, ANN SURG ONCOL, V14, P841, DOI 10.1245/s10434-006-9078-9; SHAPIRO J, 1981, J CLIN INVEST, V68, P678, DOI 10.1172/JCI110303; SHAVIT Y, 1984, SCIENCE, V223, P188, DOI 10.1126/science.6691146; Tsai YC, 2000, PAIN, V88, P155, DOI 10.1016/S0304-3959(00)00323-7; Viswanathan K, 2005, INT IMMUNOL, V17, P1059, DOI 10.1093/intimm/dxh286; WHITESIDE TL, 1989, CLIN IMMUNOL IMMUNOP, V53, P1, DOI 10.1016/0090-1229(89)90096-2; WHITESIDE TL, 1994, CLIN DIAGN LAB IMMUN, V1, P125, DOI 10.1128/CDLI.1.2.125-133.1994; Wrona D, 2006, J NEUROIMMUNOL, V172, P38, DOI 10.1016/j.jneuroim.2005.10.017	51	56	65	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	MAR	2010	27	3					233	240		10.1097/EJA.0b013e32832d540e			8	Anesthesiology	Anesthesiology	562NG	WOS:000275058000003	19487949				2020-06-30	J	Capper, SJ; Loo, S; Geue, JP; Upton, RN; Ong, J; Macintyre, PE; Ludbrook, GL				Capper, Sarah J.; Loo, Susan; Geue, Jason P.; Upton, Richard N.; Ong, Jennifer; Macintyre, Pamela E.; Ludbrook, Guy L.			Pharmacokinetics of fentanyl after subcutaneous administration in volunteers	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						C-max; healthy volunteers; opioids; pharmacokinetics; subcutaneous fentanyl; t(max)	POSTOPERATIVE PAIN; MANAGEMENT; MORPHINE; ANALGESIA; INFUSION; SURGERY; SYSTEM	Background and objective Pain relief using intermittent subcutaneous injections of an opioid (e.g. morphine) avoids the need for venous access and does not require complex or expensive pumps and devices. Although data on the pharmacokinetics of subcutaneous morphine exist, there are no comparable data for fentanyl in healthy volunteers. Therefore, the aim of this study was to characterize the pharmacokinetics of 200 mu g fentanyl administered as a single bolus dose via the subcutaneous route in healthy opioid-naive volunteers. Methods Nine healthy male volunteers were given 200 mu g of subcutaneous fentanyl for more than 30 s. Opioid effects were blocked by administration of naltrexone. Venous blood samples taken at intervals from 5 min to 10 h after the dose were assayed using a liquid chromatography-mass spectrometry method. Pharmacokinetic data were analysed using a noncompartmental analysis approach. Results After subcutaneous bolus dose administration, the median maximum concentration of fentanyl was 0.55 ng ml(-1) ( range 0.28-0.87 ng ml(-1)), reached at a median time of 15 min ( range 10-30 min). The terminal half-life was 10.00 h ( range 5.48-16.37 h). Conclusion Absorption of subcutaneous fentanyl was relatively rapid and similar to the rate of absorption previously reported for subcutaneous morphine; the terminal half-life for fentanyl was substantially longer ( 10 h) than that of morphine (2.1 h), and blood concentrations were no more variable than that after administration by other nonintravenous routes. Eur J Anaesthesiol 2010; 27:241-246	[Ong, Jennifer] Univ Adelaide, Royal Adelaide Hosp, Discipline Anaesthesia & Intens Care, Dept Anaesthesia & Intens Care, Adelaide, SA 5005, Australia; [Geue, Jason P.] Univ Queensland, Royal Brisbane & Womens Hosp, CIPDD TetraQ, Brisbane, Qld, Australia	Ong, J (reprint author), Univ Adelaide, Royal Adelaide Hosp, Discipline Anaesthesia & Intens Care, Dept Anaesthesia & Intens Care, Adelaide, SA 5005, Australia.	jennifer.ong@adelaide.edu.au	Upton, Richard N/G-4727-2011	Upton, Richard N/0000-0001-9996-4886	Department of Anaesthesia, Pain Medicine and Hyperbaric Medicine, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia	This work was supported by the Department of Anaesthesia, Pain Medicine and Hyperbaric Medicine, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia.	*ANZCA FPM, 2005, AC PAIN MAN SCI EV; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; GRABINSKI PY, 1983, J CLIN PHARMACOL, V23, P48, DOI 10.1002/j.1552-4604.1983.tb02704.x; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Macintyre PE, 2007, ACUTE PAIN MANAGEMEN; McCormack JG, 2008, ANAESTHESIA, V63, P814, DOI 10.1111/j.1365-2044.2008.05487.x; Miller RS, 1995, BRIT J CLIN PHARMACO, V40, P553; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; R Development Core Team, 2005, R LANG ENV STAT COMP; Semple TJ, 1997, ANAESTHESIA, V52, P318, DOI 10.1111/j.1365-2044.1997.83-az0081.x; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Stuart-Harris R, 2000, BRIT J CLIN PHARMACO, V49, P207, DOI 10.1046/j.1365-2125.2000.00141.x; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77	17	13	13	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAR	2010	27	3					241	246		10.1097/EJA.0b013e328331a361			6	Anesthesiology	Anesthesiology	562NG	WOS:000275058000004	19918182				2020-06-30	J	Mirilas, P; Mentessidou, A; Kontis, E; Antypa, E; Makedou, A; Petropoulos, AS				Mirilas, P.; Mentessidou, A.; Kontis, E.; Antypa, E.; Makedou, A.; Petropoulos, A. S.			Serum Beta-Endorphin Response to Stress Before and After Operation Under Fentanyl Anesthesia in Neonates, Infants and Preschool Children	EUROPEAN JOURNAL OF PEDIATRIC SURGERY			English	Article						fentanyl; beta-endorphin; surgical stress; children; infants; neonates	SURGICAL STRESS; IMMUNOREACTIVE MATERIAL; CEREBROSPINAL-FLUID; POSTOPERATIVE PAIN; LIPOTROPIN; SURGERY; BLOOD	Introduction: The endogenous opioid beta-endorphin is a known indicator of stress and pain. Opioid anesthesia during operation may prevent postoperative beta-endorphin hypersecretion. We examine the effect on serum beta-endorphin of both preoperative stress and stress of operation under opioids in neonates, infants and preschool children. In order to eliminate the effect of hospitalization anxiety we compared with inpatients of similar age with non-surgical disease. Material and Methods: We included 74 surgical patients (25 neonates, 24 infants, 25 preschool children), and 44 non-surgical inpatients (14 neonates, 12 infants, 18 preschool children). Anesthesia comprised propofol and fentanyl. In presence of pain after extubation, supplementary morphine was administered. Sera were taken preoperatively and 2 h postoperatively in surgical patients, and once in non-surgical patients. Beta-endorphin was tested using ELISA (ng/ml). Results: In all surgical patients beta-endorphin did not increase significantly after surgery. Neonates showed significantly elevated beta-endorphin preoperatively (mean +/- SD: 2.02 +/- 0.76) and postoperatively (2.07 +/- 0.90) compared to neonates with a non-surgical disease (1.05 +/- 0.34; p < 0.005). In contrast, infants (preoperative values: 1.75 +/- 1.32, postoperative values: 2.00 +/- 1.83) did not differ from respective non-surgical inpatients (1.49 +/- 0.70). Before and after surgery, beta-endorphin was significantly elevated in preschool children (7.19 +/- 1.85, 6.42 +/- 1.31), as compared with neonates and infants (p < 0.0005), and with preschool children with non-surgical disease (1.01 +/- 0.27; p < 0.0005). Conclusions: Fentanyl/propofol anesthesia, supplemented by postoperative morphine where necessary, protects from surgical stress and postoperative pain, as denoted by no postoperative increase of beta-endorphin in all age groups. Preschool children, who exhibit increased emotional perception, have explicitly high serum beta-endorphin before and after surgery. Preoperative preparation programs might be worthy in this age group. Neonates show a moderate but still significantly high response of beta-endorphin to stress, retained after operation. In contrast, infants tolerated stress better (not increased beta-endorphin pre- and post-operatively).	[Mirilas, P.; Mentessidou, A.; Kontis, E.; Antypa, E.; Petropoulos, A. S.] Aristotle Univ Thessaloniki, Sch Med, Dept Pediat Surg 2, Thessaloniki 56429, Greece; [Makedou, A.] Aristotle Univ Thessaloniki, Sch Med, Dept Pediat 2, Thessaloniki 56429, Greece	Mirilas, P (reprint author), Aristotle Univ Thessaloniki, Sch Med, Dept Pediat Surg 2, Papageorgiou Gen Hosp, Thessaloniki 56429, Greece.	pmirilas@gmail.com	Mirilas, Petros/H-3464-2019; Boerm, Emma/A-9475-2012	Mirilas, Petros/0000-0001-7420-1233; Kontis, Elissaios/0000-0002-2619-1058			ANAND KJ, 1992, NEW ENGL J MED, V236, P1; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; ANAND KJS, 1987, NEW ENGL J MED, V21, P1321; Berg Simon, 2006, OXFORD HDB ANAESTHES, P757; Castejon-Casado J, 2001, EUR J PEDIATR SURG, V11, P44, DOI 10.1055/s-2001-12195; CORC RC, 1985, ANESTH ANALG, V64, P677; DUBOIS M, 1981, LIFE SCI, V29, P1249, DOI 10.1016/0024-3205(81)90230-7; Ivani G, 1996, Cah Anesthesiol, V44, P297; Kain ZN, 2000, J CLIN ANESTH, V12, P549, DOI 10.1016/S0952-8180(00)00214-2; LEBLANCLOUVRY I, 2000, DIGEST DIS SCI, V45, P710; LEUSCHEN MP, 1991, J CLIN ENDOCR METAB, V73, P1062, DOI 10.1210/jcem-73-5-1062; Matejec R, 2006, NEUROPEPTIDES, V40, P11, DOI 10.1016/j.npep.2005.10.001; Matejec R, 2003, ANESTH ANALG, V96, P481, DOI 10.1097/00000539-200302000-00034; McCann ME, 2001, ANESTH ANALG, V93, P98; Merli C, 1984, Minerva Anestesiol, V50, P539; PETRAGLIA F, 1983, HORM RES, V17, P147, DOI 10.1159/000179690; RAMANATHAN S, 1989, BIOL NEONATE, V56, P117; ROSENDAHL W, 1995, J PEDIATR ENDOCR MET, V8, P187; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; SPSS, 2006, SPSS BAS 15 0 US GUI; WARDLAW SL, 1979, J CLIN ENDOCR METAB, V49, P888, DOI 10.1210/jcem-49-6-888; Willis RJ, 1998, NEURAL BLOCKADE CLIN, P323	22	8	9	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-7248			EUR J PEDIATR SURG	Eur. J. Pediatr. Surg.	MAR	2010	20	2					106	110		10.1055/s-0029-1243620			5	Pediatrics; Surgery	Pediatrics; Surgery	584CF	WOS:000276726900009	20084599				2020-06-30	J	Neustein, SM; Taitt-Wynter, LM; Rosenblatt, MA				Neustein, Steven M.; Taitt-Wynter, Lisa M.; Rosenblatt, Meg A.			Treating stridor with opioids: a challenging case of paradoxical vocal cord movement	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Fiberoptic laryngoscopy; Opioids; Paradoxical vocal cord movement; Stridor	MOTION; DISORDER	A 61 year-old patient with a history of anxiety disorder presented with stridor after an uneventful laparotomy with a general anesthetic. Postoperative analgesia was withheld secondary to intermittent oxygen desaturation. She was unresponsive to standard therapies, including racemic epinephrine and albuterol nebulizers. An otolaryngology consultant performed fiberoptic laryngoscopy and paradoxical vocal cord movement was diagnosed. When fentanyl was subsequently administered to treat her pain, the stridor resolved. (C) 2010 Elsevier Inc. All rights reserved.	[Neustein, Steven M.; Taitt-Wynter, Lisa M.; Rosenblatt, Meg A.] Mt Sinai Med Ctr, Dept Anesthesiol, New York, NY 10029 USA	Neustein, SM (reprint author), Mt Sinai Med Ctr, Dept Anesthesiol, Box 1010, New York, NY 10029 USA.	steve.neustein@mountsinai.org					APPELBLATT NH, 1981, ARCH OTOLARYNGOL, V107, P305; Arndt GA, 1996, CAN J ANAESTH, V43, P1249, DOI 10.1007/BF03013434; Baldwin MK, 2007, ANESTHESIOLOGY, V107, P359, DOI 10.1097/01.anes.0000271874.60191.ed; Ibrahim WH, 2007, POSTGRAD MED J, V83, P164, DOI 10.1136/pgmj.2006.052522; Larsen B, 2004, J CLIN ANESTH, V16, P230, DOI 10.1016/j.jclinane.2003.08.010; Rewari V, 2006, ACTA ANAESTH SCAND, V50, P900, DOI 10.1111/j.1399-6576.2006.01055.x; Roberts KW, 1998, ANESTHESIOLOGY, V89, P517, DOI 10.1097/00000542-199808000-00030; ROGERS JH, 1978, J LARYNGOL OTOL, V92, P157, DOI 10.1017/S0022215100085169	8	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAR	2010	22	2					130	131		10.1016/j.jclinane.2009.02.009			2	Anesthesiology	Anesthesiology	580JM	WOS:000276444300011	20304356				2020-06-30	J	Connelly, NR; Raghunathan, K				Connelly, Neil Roy; Raghunathan, Karthik			The value of the P-value	JOURNAL OF CLINICAL ANESTHESIA			English	Letter							EPIDURAL ANALGESIA; FENTANYL; BUPIVACAINE; INFUSION; LABOR		[Connelly, Neil Roy] Baystate Med Ctr, Dept Anesthesiol, Springfield, MA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Connelly, NR (reprint author), Baystate Med Ctr, Dept Anesthesiol, Springfield, MA USA.	neil.roy.Connelly@bhs.org					BADER AM, 1995, ANESTH ANALG, V81, P829, DOI 10.1097/00000539-199510000-00029; ELLIOTT RD, 1991, CAN J ANAESTH, V38, P303, DOI 10.1007/BF03007619; Grunkemeier GL, 2009, ANN THORAC SURG, V87, P1337, DOI 10.1016/j.athoracsur.2009.03.027; Hopewell S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000006.pub3; Kain ZN, 2005, ANESTH ANALG, V101, P1454, DOI 10.1213/01.ANE.0000181331.59738.66; Lilker S, 2009, J CLIN ANESTH, V21, P108, DOI 10.1016/j.jclinane.2008.06.027; Porter J, 1998, ANESTHESIOLOGY, V89, P79, DOI 10.1097/00000542-199807000-00014	7	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAR	2010	22	2					154	155		10.1016/j.jclinane.2009.07.005			2	Anesthesiology	Anesthesiology	580JM	WOS:000276444300020	20304365				2020-06-30	J	Vadivelu, N; Gesquire, M; Mitra, S; Shelley, K; Kodumudi, G; Xia, Y; Blume, P				Vadivelu, Nalini; Gesquire, Michael; Mitra, Sukanya; Shelley, Kirk; Kodumudi, Gopal; Xia, Yu; Blume, Peter			Safety of Local Anesthesia Combined with Monitored Intravenous Sedation for American Society of Anesthesiologists 3 and 4 Patients Undergoing Lower Limb-preservation Procedures	JOURNAL OF FOOT & ANKLE SURGERY			English	Article						bupivacaine; diabetic foot infection; limb salvage; nerve block; physical status; surgical complication	VASCULAR-SURGERY; SCORE	The aim of this retrospective study is to evaluate the prognostic value of American Society of Anesthesiologists (ASA) classification with regard to perioperative variables of cardiac complications, pulmonary complications, and mortality in patients undergoing limb salvage procedures with monitored intravenous sedation and foot and ankle blocks. None of the ASA 3 or 4 patients experienced any pulmonary or cardiac complication; no patient required invasive monitoring or postoperative cardiac care unit admission. We suggest that the performance of peripheral foot and ankle blocks with monitored intravenous sedation appears to be a safe and useful option for ASA 3 and 4 patients undergoing limb-preservation surgery. (C) 2010 by the American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.	[Vadivelu, Nalini; Gesquire, Michael; Shelley, Kirk; Kodumudi, Gopal] Yale Univ, Dept Anesthesiol, New Haven, CT 06520 USA; [Mitra, Sukanya] Govt Med Coll & Hosp, Chandigarh, India; [Xia, Yu] Yale Univ, Yale Coll, New Haven, CT 06520 USA; [Blume, Peter] Yale Univ, Dept Podiatry & Orthoped, New Haven, CT 06520 USA	Vadivelu, N (reprint author), Yale Univ, Dept Anesthesiol, New Haven, CT 06520 USA.	Nalini.Vadivelu@yale.edu	Shelley, Kirk/E-4435-2010	Shelley, Kirk/0000-0002-7344-0897			Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; BRESLOW MJ, 1993, ANESTHESIOLOGY, V79, P1202, DOI 10.1097/00000542-199312000-00010; Chelly Jacques E, 2002, Best Pract Res Clin Anaesthesiol, V16, P311, DOI 10.1053/bean.2002.0240; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; COHEN MM, 1988, J CLIN EPIDEMIOL, V41, P83, DOI 10.1016/0895-4356(88)90012-1; FEIGAL DW, 1979, MED CLIN N AM, V63, P1131, DOI 10.1016/S0025-7125(16)31631-5; Michel JP, 2002, AGING CLIN EXP RES, V14, P389; Ptaszek AJ, 1999, FOOT ANKLE INT, V20, P583, DOI 10.1177/107110079902000908; Ragheb J, 2006, PEDIATR ANESTH, V16, P928, DOI 10.1111/j.1460-9592.2006.01911.x; REILLEY TE, 2002, CLIN PODIATR MED SUR, V19, pR7; Reilley Thomas E, 2002, Clin Podiatr Med Surg, V19, P125, DOI 10.1016/S0891-8422(03)00084-3; TIRET L, 1988, STAT MED, V7, P947, DOI 10.1002/sim.4780070906; Wolters U, 1996, BRIT J ANAESTH, V77, P217, DOI 10.1093/bja/77.2.217	13	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1067-2516	1542-2224		J FOOT ANKLE SURG	J. Foot Ankle Surg.	MAR-APR	2010	49	2					152	154		10.1053/j.jfas.2009.09.006			3	Orthopedics; Surgery	Orthopedics; Surgery	561EH	WOS:000274958100011	20137984				2020-06-30	J	Hull, LC; Llorente, J; Gabra, BH; Smith, FL; Kelly, E; Bailey, C; Henderson, G; Dewey, WL				Hull, L. C.; Llorente, J.; Gabra, B. H.; Smith, F. L.; Kelly, E.; Bailey, C.; Henderson, G.; Dewey, W. L.			The Effect of Protein Kinase C and G Protein-Coupled Receptor Kinase Inhibition on Tolerance Induced by mu-Opioid Agonists of Different Efficacy	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							MORPHINE-TOLERANCE; FUNCTIONAL SELECTIVITY; RAT THALAMUS; DESENSITIZATION; MICE; PKC; INTERNALIZATION; INVOLVEMENT; ACTIVATION; MECHANISMS	Differences in the mechanisms underlying tolerance and mu-opioid receptor desensitization resulting from exposure to opioid agonists of different efficacy have been suggested previously. The objective of this study was to determine the effects of protein kinase C (PKC) and G protein-coupled receptor kinase (GRK) inhibition on antinociceptive tolerance in vivo to opioid agonists of different efficacy. A rapid (8-h) tolerance-induction model was used where each opioid was repeatedly administered to naive mice. Animals were then challenged with the opioid after injection of a kinase inhibitor to determine its effects on the level of tolerance. Tolerance to meperidine, morphine, or fentanyl was fully reversed by the PKC inhibitor 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole (Go6976). However, in vivo tolerance to [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO) was not reversed by PKC inhibition. The novel small-molecule GRK inhibitors beta-adrenergic receptor kinase 1 inhibitor and 2-(8-[(dimethylamino) methyl]-6,7,8,9-tetrahydropyridol[1,2-a]indol-3-yl)-3-(1-methylindol-3-yl)maleimide (Ro 32-0432) did not reverse the tolerance to meperidine, fentanyl, or morphine but did reverse the tolerance to DAMGO. To correlate GRK-dependent DAMGO-induced tolerance with mu-opioid receptor desensitization, we used in vitro whole-cell patch-clamp recording from mouse locus coeruleus neurons and observed that the GRK inhibitors reduced DAMGO-induced desensitization of mu-opioid receptors, whereas the PKC inhibitor had no effect. These results suggest that tolerance induced by low- and moderate-efficacy mu-opioid receptor agonists is dependent on PKC, whereas tolerance induced by the high-efficacy agonist DAMGO is dependent on GRK.	[Hull, L. C.; Gabra, B. H.; Dewey, W. L.] Virginia Commonwealth Univ, Med Ctr, Dept Pharmacol & Toxicol, Richmond, VA USA; [Smith, F. L.] Harding Univ, Coll Pharm, Dept Pharmaceut Sci, Searcy, AR USA; [Bailey, C.] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; [Llorente, J.; Kelly, E.; Henderson, G.] Univ Bristol, Dept Physiol & Pharmacol, Bristol, Avon, England	Dewey, WL (reprint author), 1112 E Clay St,POB 980613, Richmond, VA 23298 USA.	wdewey@vcu.edu	Llorente, Javier/J-8986-2012	Llorente, Javier/0000-0003-3879-9738; Bailey, Chris/0000-0003-0781-8887	National Institutes of Health National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA020836, K05-DA480, DA07027]	This work was supported in part by the National Institutes of Health National Institute of Drug Abuse [Grants DA020836, K05-DA480, DA07027].	Aiyar N, 2000, EUR J PHARMACOL, V403, P1, DOI 10.1016/S0014-2999(00)00419-2; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Bailey CP, 2009, BRIT J PHARMACOL, V158, P157, DOI 10.1111/j.1476-5381.2009.00140.x; Bailey CP, 2006, TRENDS PHARMACOL SCI, V27, P558, DOI 10.1016/j.tips.2006.09.006; Bailey CP, 2004, MOL PHARMACOL, V66, P1592, DOI 10.1124/mol.104.004747; Bailey CP, 2003, J NEUROSCI, V23, P10515; Bliss C., 1967, STAT BIOL; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; CODERRE TJ, 1983, LIFE SCI, V32, P2139, DOI 10.1016/0024-3205(83)90103-0; Colquhoun D., 1971, LECT BIOSTATISTICS I; Granados-Soto V, 2000, PAIN, V85, P395, DOI 10.1016/S0304-3959(99)00281-X; HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141; Iino M, 2002, J MED CHEM, V45, P2150, DOI 10.1021/jm010093a; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604; Madia PA, 2009, PSYCHOPHARMACOLOGY, V207, P413, DOI 10.1007/s00213-009-1673-6; Mailman RB, 2007, TRENDS PHARMACOL SCI, V28, P390, DOI 10.1016/j.tips.2007.06.002; PEDIGO NW, 1975, J PHARMACOL EXP THER, V193, P845; Saidak Z, 2006, BRIT J PHARMACOL, V147, P671, DOI 10.1038/sj.bjp.0706661; Selley DE, 1997, MOL PHARMACOL, V51, P87; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Smith FL, 1999, PHARMACOL BIOCHEM BE, V62, P381, DOI 10.1016/S0091-3057(98)00168-3; Smith FL, 2002, BRAIN RES, V958, P28, DOI 10.1016/S0006-8993(02)03394-2; Smith FL, 2003, BRAIN RES, V985, P78, DOI 10.1016/S0006-8993(03)03170-6; Smith FL, 2007, PAIN, V127, P129, DOI 10.1016/j.pain.2006.08.009; Smith FL, 2006, PHARMACOL RES, V54, P474, DOI 10.1016/j.phrs.2006.09.007; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Yabaluri N, 1997, MOL PHARMACOL, V52, P896, DOI 10.1124/mol.52.5.896; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zeitz KP, 2001, PAIN, V94, P245, DOI 10.1016/S0304-3959(01)00353-0; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	35	45	45	0	7	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAR	2010	332	3					1127	1135		10.1124/jpet.109.161455			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	559DF	WOS:000274800200048	20008489	Green Published			2020-06-30	J	Schmidt, B; Adelmann, C; Stutzer, H; Welzing, L; Hunseler, C; Kribs, A; Roth, B				Schmidt, B.; Adelmann, C.; Stuetzer, H.; Welzing, L.; Huenseler, C.; Kribs, A.; Roth, B.			Comparison of Sufentanil versus Fentanyl in Ventilated Term Neonates	KLINISCHE PADIATRIE			English	Article						opioid; pain; newborn; analgesia; sedation; clinical pharmacology	PRETERM INFANTS; HUMAN-FETAL; ANALGESIA; PHARMACOKINETICS; SEDATION; PAIN; MORPHINE; NEWBORNS; THERAPY; VALUES	Background: Increasingly frequent applications of opioid analgesics in neonatal intensive care require the evaluation of efficacy and side effects. Patients: Mechanically ventilated term neonates were consecutively enrolled. Methods: In a double-blind randomized trial 20 newborns received a continuous intravenous infusion of fentanyl (n = 10) or sufentanil (n = 10) in an assumed equipotent dose of 7:1. The analgesic dose was individually adjusted according to sedation scores. The period between cessation of analgesic medication and successful extubation (weaning time), adverse drug effects and urinary cortisol concentrations were evaluated. Results: No significant difference of weaning time was seen between fentanyl and sufentanil group (mean weaning time (+/-SD) of fentanyl group 520 +/- 381 min, median 380 min; sufentanil group 585 +/- 531 min, median 405 min, p = 0.78, 2-tailed U-Test, Mann and Whitney). The mean opioid dose resulted in a 10: 1 ratio (fentanyl 4.11 mu g/(kg x h) vs sufentanil 0.41 mu g/(kg x h)). We found no marked differences in sedation levels, blood pressure, heart rate, oxygenation index, co-medication or urinary cortisol levels. In both groups similar adverse effects were assessed including respiratory depression, mild withdrawal symptoms or decrease of gastrointestinal motility. Conclusion: In our study sufentanil did not reduce the weaning period in ventilated term neonates when compared to fentanyl. The equipotent dose ratio for fentanyl/sufentanil was 10: 1. According to sedation scores both substances provided effective pain and stress protection.	[Schmidt, B.; Adelmann, C.; Welzing, L.; Huenseler, C.; Kribs, A.; Roth, B.] Univ Cologne, Childrens Hosp, Dept Neonatol & Pediat Intens Care Med, D-50937 Cologne, Germany; [Stuetzer, H.] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50937 Cologne, Germany	Roth, B (reprint author), Univ Cologne, Childrens Hosp, Dept Neonatol & Pediat Intens Care Med, Kerpenerstr 62, D-50937 Cologne, Germany.	bernhard.roth@uk-koeln.de			Department of Anaesthesiology; Department of Pharmacology, University of Cologne	We thank Professor Dr. med. Dr. rer. nat. K. A. Lehmann, Department of Anaesthesiology and Dr. Martin Theisohn, Department of Pharmacology, University of Cologne for their constant support throughout the study.	Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Angeles DM, 2005, PEDIATR RES, V57, P873, DOI 10.1203/01.PDR.0000157676.45088.8C; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Aretz S, 2004, BIOL NEONATE, V85, P243, DOI 10.1159/000076238; BAILEY PL, 1990, ANESTH ANALG, V70, P8; BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441; Bhandari V, 2005, PEDIATRICS, V116, P352, DOI 10.1542/peds.2004-2123; COLLINS C, 1985, ANESTH ANALG, V64, P1078; ESCOBAR GJ, 1995, PEDIATRICS, V96, P918; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Franck LS, 1997, J PAIN SYMPTOM MANAG, V14, P343, DOI 10.1016/S0885-3924(97)00222-4; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; GRAY JE, 1992, PEDIATRICS, V90, P561; GREELEY WJ, 1988, ANESTH ANALG, V67, P86; Grunau RE, 2006, SEMIN FETAL NEONAT M, V11, P268, DOI 10.1016/j.siny.2006.02.007; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; HOWIE MB, 1985, ANESTH ANALG, V64, P877; Hunseler C, 2008, KLIN PADIATR, V220, P224, DOI 10.1055/s-2007-984376; HUNSELER C, 2006, Z GEBURTSH NEONATAL, V210, DOI DOI 10.1055/S-2006-946245; KINNEY HC, 1990, J COMP NEUROL, V291, P55, DOI 10.1002/cne.902910106; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; LESLIE FM, 1982, LIFE SCI, V31, P1393, DOI 10.1016/0024-3205(82)90389-7; LEVINE A, 1994, J PEDIATR-US, V125, P853, DOI 10.1016/S0022-3476(05)81998-5; Lindner U, 2008, KLIN PADIATR, V220, P238, DOI 10.1055/s-2008-1046786; MAGNAN J, 1989, DEV BRAIN RES, V45, P275, DOI 10.1016/0165-3806(89)90045-X; Menon G, 1998, SEMIN PERINATOL, V22, P417, DOI 10.1016/S0146-0005(98)80057-8; ROTH B, 1991, DEV PHARMACOL THERAP, V17, P121, DOI 10.1159/000457510; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; SANFORD TJ, 1986, ANESTH ANALG, V65, P259; Santeiro M L, 1997, J Perinatol, V17, P135; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Seguin J H, 1994, Neonatal Netw, V13, P37; SIAMOPOULOUMAVRIDOU A, 1986, ACTA PAEDIATR SCAND, V75, P919, DOI 10.1111/j.1651-2227.1986.tb10317.x; Simons SHP, 2006, SEMIN FETAL NEONAT M, V11, P227, DOI 10.1016/j.siny.2006.02.010; Stanley T H, 1988, J Cardiothorac Anesth, V2, P6, DOI 10.1016/0888-6296(88)90140-8; Zadik Z, 1999, J PEDIATR ENDOCR MET, V12, P543	39	16	19	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0300-8630	1439-3824		KLIN PADIATR	Klinische Padiatr.	MAR	2010	222	2					62	66		10.1055/s-0029-1225348			5	Pediatrics	Pediatrics	573HS	WOS:000275900900003	19731193				2020-06-30	J	Mulroy, MF; Hejtmanek, MR				Mulroy, Michael F.; Hejtmanek, Michael R.			Prevention of Local Anesthetic Systemic Toxicity	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Review							BRACHIAL-PLEXUS BLOCK; INTRAVASCULAR INJECTION; REGIONAL ANESTHESIA; HEMODYNAMIC-RESPONSES; EPIDURAL-ANESTHESIA; GENERAL-ANESTHESIA; SEDATED PATIENTS; ROPIVACAINE; COMPLICATIONS; ANALGESIA	Although new drugs and techniques may improve outcomes when unintended high blood levels of local anesthetics occur, the primary focus of daily practice should remain the prevention of such events. Although adoption of no single "safety step" will reliably prevent systemic toxicity, the combination of several procedures seems to have reduced the frequency of systemic toxicity since 1981. These include the use of minimum effective doses, careful aspiration, and incremental injection, coupled with the use of intravascular markers when large doses are used. Epinephrine remains the most widely used and Studied marker, but its reliability is impaired in the face of P-blockade, anesthesia, advanced age, and active labor. As an alternative, the use of subtoxic doses of local anesthetics themselves can produce subjective symptoms in unpremedicated patients. Fentanyl has also been confirmed to produce sedation in pregnant women when used as an alternative. The use of ultrasound observation of needle placement and injection may be useful, but has also been reported as not completely reliable. Constant vigilance and suspicion are still needed along with a combination of as many of these safety steps as practical.	[Mulroy, Michael F.] Virginia Mason Med Ctr, Fac Anesthesiologists, Dept Anesthesiol, Seattle, WA 98101 USA	Mulroy, MF (reprint author), Virginia Mason Med Ctr, Fac Anesthesiologists, Dept Anesthesiol, 1100 9th Ave, Seattle, WA 98101 USA.	Michael.Mulroy@vmmc.org					Ala-Kokko TI, 2000, ACTA ANAESTH SCAND, V44, P623, DOI 10.1034/j.1399-6576.2000.00522.x; Auroy Y, 2002, ANESTHESIOLOGY, V97, P1274, DOI 10.1097/00000542-200211000-00034; Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; Bell DN, 2007, ANAESTH INTENS CARE, V35, P335, DOI 10.1177/0310057X0703500303; Bernards CM, 2008, REGION ANESTH PAIN M, V33, P449, DOI 10.1016/j.rapm.2008.07.529; BROWN DL, 1995, ANESTH ANALG, V81, P321, DOI 10.1097/00000539-199508000-00020; Guay J, 2006, ANESTH ANALG, V102, P921, DOI 10.1213/01.ane.0000196687.88590.6b; GUINARD JP, 1995, REGION ANESTH, V20, P193; GUINARD JP, 1990, ANESTHESIOLOGY, V73, P386, DOI 10.1097/00000542-199009000-00004; JAMES FM, 1970, ANESTHESIOLOGY, V33, P25, DOI 10.1097/00000542-197007000-00010; KENEPP NB, 1981, ANESTHESIOLOGY, V54, P172; Khoo LPY, 2006, ANAESTH INTENS CARE, V34, P804, DOI 10.1177/0310057X0603400617; LEIGHTON BL, 1989, ANESTHESIOLOGY, V71, P848, DOI 10.1097/00000542-198912000-00007; Liu SS, 1996, ANESTH ANALG, V83, P97, DOI 10.1097/00000539-199607000-00017; Liu SS, 1996, ANESTHESIOLOGY, V84, P81, DOI 10.1097/00000542-199601000-00010; Loubert C, 2008, ANESTHESIOLOGY, V108, P759, DOI 10.1097/ALN.0b013e3181684bfd; Mather LE, 2001, DRUGS, V61, P333, DOI 10.2165/00003495-200161030-00002; McCartney CJL, 2003, CAN J ANAESTH, V50, P795, DOI 10.1007/BF03019374; MOORE DC, 1981, ANESTHESIOLOGY, V55, P693, DOI 10.1097/00000542-198155060-00018; Mulroy M, 1998, ANESTH ANALG, V86, P923, DOI 10.1097/00000539-199805000-00001; Mulroy MF, 1997, ANESTH ANALG, V85, P1346, DOI 10.1097/00000539-199712000-00030; Mulroy MF, 2002, REGION ANESTH PAIN M, V27, P556, DOI 10.1053/rapm.2002.37127; Norris MC, 1999, ANESTH ANALG, V88, P1073, DOI 10.1097/00000539-199905000-00019; Owen MD, 2004, ANESTHESIOLOGY, V100, P922, DOI 10.1097/00000542-200404000-00023; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Plowman AN, 1998, ANAESTH INTENS CARE, V26, P204, DOI 10.1177/0310057X9802600214; Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003; SCOTT DB, 1989, ANESTH ANALG, V69, P563, DOI 10.1213/00000539-198911000-00003; Skinner AV, 2007, PEDIATR ANESTH, V17, P387, DOI 10.1111/j.1460-9592.2006.02138.x; Takahashi S, 2002, ANESTH ANALG, V94, P717, DOI 10.1097/00000539-200203000-00044; TANAKA K, 1993, REGION ANESTH, V18, P34; Tanaka M, 2001, ANESTH ANALG, V93, P1612, DOI 10.1097/00000539-200112000-00059; VadeBoncouer TR, 2008, REGION ANESTH PAIN M, V33, P278, DOI 10.1016/j.rapm.2007.12.012; Zetlaoui PJ, 2008, ANESTHESIOLOGY, V108, P761, DOI 10.1097/ALN.0b013e3181684c0f	34	27	30	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAR-APR	2010	35	2					177	180		10.1097/AAP.0b013e3181d26068			4	Anesthesiology	Anesthesiology	566PK	WOS:000275384800010	20216035				2020-06-30	J	Mosing, M; Reich, H; Moens, Y				Mosing, Martina; Reich, Heidi; Moens, Yves			Clinical evaluation of the anaesthetic sparing effect of brachial plexus block in cats	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						brachial plexus block; cat; isoflurane sparing effect	LIDOCAINE; PROVIDE	Objective To evaluate the isoflurane sparing effect and the post-surgical analgesia provided by a brachial plexus block (BPB) in cats undergoing distal thoracic limb surgery. Study design Prospective randomized blinded clinical study. Animals Twenty client-owned cats. Methods Cats were assigned to receive either no BPB ( group NB) or a nerve stimulator guided BPB (group BPB) using lidocaine (3.6 mg kg(-1)) and bupivacaine (1.2 mg kg(-1)). Pre-medication consisted of midazolam and ketamine intravenously (IV). Anaesthesia was induced with propofol IV to effect and maintained with isoflurane delivered in oxygen and a continuous rate infusion of fentanyl (2 mu g kg(-1) hour(-1)). End-tidal isoflurane concentration (FE'ISO) was adjusted every 3 minutes guided by changes in cardiorespiratory parameters and reflexes present, to maintain a stable depth of anaesthesia. Five time points were chosen to record all parameters and compare values between groups. Recovery and post-operative pain assessment were performed using a visual analogue scale (VAS) at 15 and 45 minutes after extubation and thereafter at hourly intervals until 5 hours after placement of the BPB. Results No clinically significant differences were seen for heart rate, respiratory rate and noninvasive blood pressure between groups. Mean FE'ISO was significantly lower in group BPB compared with group NB at all time points. In group NB, all intraoperative measurements of FE'ISO were significantly higher compared with baseline ( 3 minutes before start of surgery) measurements. During recovery, VAS scores for group BPB were significantly lower than for group NB. Additional analgesics were needed in all cats within the study period. Conclusion and Clinical relevance In cats undergoing orthopaedic surgery of the thoracic limb, BPB reduced intra-operative isoflurane requirement and pain during the early post-operative period when compared with procedures without a BPB. BPB is a useful adjunct to anaesthesia in such cases.	[Mosing, Martina; Reich, Heidi; Moens, Yves] Univ Vet Med, Clin Anaesthesia & Perioperat Intens Care, Vienna, Austria	Mosing, M (reprint author), Univ Liverpool, Fac Vet Sci, Chester High Rd, Neston CH64 7TE, England.	mmosing@liverpool.ac.uk		Mosing, Martina/0000-0002-6190-5642			CHADWICK HS, 1985, ANESTHESIOLOGY, V63, P385, DOI 10.1097/00000542-198510000-00007; De Tran QH, 2007, CAN J ANAESTH, V54, P662; Freitas P. M. C., 2002, Ars Veterinaria, V18, P218; Futema F, 2002, VET ANAESTH ANALG, V29, P133, DOI 10.1046/j.1467-2995.2002.00082.x; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; Mahler SP, 2008, VET ANAESTH ANALG, V35, P80, DOI 10.1111/j.1467-2995.2007.00356.x; Moens NMM, 2000, CAN VET J, V41, P685; Neal JM, 2002, REGION ANESTH PAIN M, V27, P402, DOI 10.1053/rapm.2002.34377; Otto K, 1993, Tierarztl Prax, V21, P536; Pypendop BH, 2005, AM J VET RES, V66, P661, DOI 10.2460/ajvr.2005.66.661; Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003; Skarda RT, 2007, LUMB JONES VET ANEST, P595; STEFFEY EP, 1977, AM J VET RES, V38, P1833; Steffey EP, 2007, LUMB JONES VET ANEST, P355; Wenger S, 2005, VET REC, V156, P639, DOI 10.1136/vr.156.20.639; Wenger S, 2004, VET ANAESTH ANALG, V31, P272, DOI 10.1111/j.1467-2995.2004.00167.x	16	33	33	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAR	2010	37	2					154	161		10.1111/j.1467-2995.2009.00509.x			8	Veterinary Sciences	Veterinary Sciences	553AJ	WOS:000274336500009	20230566				2020-06-30	J	Sato, S; Suzuki, S; Lee, XP; Sato, K				Sato, Shinichi; Suzuki, Shinichi; Lee, Xiao-Pen; Sato, Keizo			Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and related compounds VII. Quantification of alpha-methylfentanyl metabolites excreted in rat urine	FORENSIC SCIENCE INTERNATIONAL			English	Article						Forensic toxicology; Fentanyl; 1-(2-Phenethyl)-4-(N-propionylanilino)piperidine analogue; alpha-Methylfentanyl; Metabolites; Designer drug	CHROMATOGRAPHY-MASS-SPECTROMETRY; ANALOGS; IDENTIFICATION; DISCRIMINATION; DERIVATIVES; ANALGESICS; DRUGS	The use of chemically modified controlled drugs, called designer drugs, is widespread internationally. In the 1980s, the dominant drugs of abuse were modifications of fentanyl formed by methylation of both the alpha-position of its phenethyl group (alpha-methylfentanyl) and the 3-position of its piperidine ring (3-methylfentanyl). Numerous analytical methods for fentanyl and its analogues, and many studies of its metabolism and major metabolites, have been reported. However, minor metabolites that reflected injection of the original compound were not included in these studies. Recently, structures of four novel and minor metabolites that reflect alpha-methylfentanyl have been reported. This study reports excretion amounts of these compounds for 96 h following peroral injection to rats of 3 mg/day and urine collection every 24 h. Major metabolites were the same as for fentanyl, with approximately 24% of alpha-methylfentanyl excreted as nor-fentanyl and 15% as omega, omega-1 hydroxypropiony nor-fentanyl up to 72 h post-injection. The novel metabolites were completely excreted within 48 h of injection and composed 2-3% of the total metabolite pool. The major metabolite nor-fentanyl was detected up to 72 h after injection. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Suzuki, Shinichi] Natl Res Inst Police Sci, Dept Forens Sci 3, Kashiwa, Chiba 2770882, Japan; [Sato, Shinichi; Lee, Xiao-Pen; Sato, Keizo] Showa Univ, Sch Med, Dept Legal Med, Shinagawa Ku, Tokyo 1428555, Japan	Suzuki, S (reprint author), Natl Res Inst Police Sci, Dept Forens Sci 3, 6-3-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan.	suzukis@nrips.go.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [21590744]	This work was supported in part by Grant-in-Aid for Scientific Research (No. 21590744) from the Ministry of Education, Science, Sports and Culture of Japan.	BAUM RM, 1985, CHEM ENG NEWS, V63, P7, DOI 10.1021/cen-v063n036.p007; BERGER JG, 1977, J MED CHEM, V20, P600, DOI 10.1021/jm00214a035; BLAKESLEE S, 1985, NY TIMES         MAR, P24; BORNE RF, 1984, J MED CHEM, V27, P1271, DOI 10.1021/jm00376a007; CASY AF, 1982, J PHARM PHARMACOL, V34, P210, DOI 10.1111/j.2042-7158.1982.tb04229.x; COOPER D, 1986, J FORENSIC SCI, V31, P511; ESSAWI MYH, 1983, J MED CHEM, V26, P348, DOI 10.1021/jm00357a007; GOROMARU T, 1982, DRUG METAB DISPOS, V10, P542; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; GOROMARU T, 1981, Anesthesiology (Hagerstown), V55, pA173; GOROMARU T, 1985, CHEM PHARM BULL, V61, P73; GROSSMANN S, 1978, ARCH PHARM, V311, P1010, DOI 10.1002/ardp.19783111206; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Higashikawa Y, 2008, J HEALTH SCI, V54, P629, DOI 10.1248/jhs.54.629; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; SHAFER J, 1985, SCIENCE 85, V6, P60; STINSON S, 1981, CHEM ENG NEWS, V59, P71, DOI 10.1021/cen-v059n003.p071; SUZUKI S, 1986, CHEM PHARM BULL, V34, P1340; SUZUKI S, 1989, FORENSIC SCI INT, V43, P15, DOI 10.1016/0379-0738(89)90117-5; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; VANWIJNGAARDEN I, 1968, LIFE SCI PT 1 PHYSI, V7, P1239, DOI 10.1016/0024-3205(68)90236-1	25	12	13	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	FEB 25	2010	195	1-3					68	72		10.1016/j.forsciint.2009.11.014			5	Medicine, Legal	Legal Medicine	548SH	WOS:000273986100011	20005651				2020-06-30	J	Yamamoto, A; Kuyama, S; Kamei, C; Sugimoto, Y				Yamamoto, Atsuki; Kuyama, Shoji; Kamei, Chiaki; Sugimoto, Yukio			Characterization of scratching behavior induced by intradermal administration of morphine and fentanyl in mice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Scratching behavior; Morphine; Fentanyl; Naloxone methiodide; Peripheral opioid receptor; Itch	MU-OPIOID RECEPTORS; ITCH-ASSOCIATED RESPONSES; OPIATE RECEPTOR; INTRAVENOUS MORPHINE; INDUCED PRURITUS; NERVE-ENDINGS; HUMAN SKIN; ANTAGONIST; NALTREXONE; EXPRESSION	Itching is known as a commonly side effect of opioid administration. However, the relationship of opioid receptors to itching is unclear. In this study, we examined the effect of intradermal injection of morphine and fentanyl on the itching sensation. When injected intradermally into the rostral back of mice, morphine and fentanyl elicited scratching behavior. in addition, an opioid receptor antagonist, naloxone, and a peripherally restricted opioid receptor antagonist, naloxone methiodide, significantly suppressed morphine- and fentanyl-induced scratching behavior. Moreover, the morphine-induced scratching behavior was suppressed by histamine H-1 receptor antagonists, such as diphenhydramine, chlorpheniramine, epinastine and cetirizine. On the other hand, fentanyl-induced scratching behavior was not suppressed by histamine H-1 receptor antagonists. Additionally, scratching behavior induced by morphine and fentanyl were not suppressed by glucocorticoids (predonisolone and dexamethasone). In conclusion, opioid-induced itching may involve in peripheral opioid receptors. Moreover, histamine and arachidonic acid metabolites played no main role in opioid-induced scratching behavior. (C) 2009 Elsevier B.V. All rights reserved.	[Yamamoto, Atsuki; Kuyama, Shoji; Kamei, Chiaki; Sugimoto, Yukio] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med Pharmacol, Okayama 7008530, Japan	Sugimoto, Y (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med Pharmacol, Tsushima Naka 1-1-1, Okayama 7008530, Japan.	sugimoto@pheasant.pharm.okayama-u.ac.jp					Bigliardi PL, 2007, J AM ACAD DERMATOL, V56, P979, DOI 10.1016/j.jaad.2007.01.007; Bigliardi PL, 2009, EXP DERMATOL, V18, P424, DOI 10.1111/j.1600-0625.2009.00844.x; Bigliardi-Qi M, 2005, DERMATOLOGY, V210, P91, DOI 10.1159/000082563; Bigliardi-Qi M, 2004, DERMATOLOGY, V209, P183, DOI 10.1159/000079887; Blunk JA, 2004, ANESTH ANALG, V98, P364, DOI 10.1213/01.ANE.0000097168.32472.0D; Brune A, 2004, HAUTARZT, V55, P1130, DOI 10.1007/s00105-004-0802-8; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Dawn AG, 2006, J AM ACAD DERMATOL, V54, P527, DOI 10.1016/j.jaad.2005.12.010; DOENICKE A, 1995, CLIN PHARMACOL THER, V58, P81, DOI 10.1016/0009-9236(95)90075-6; Jones EA, 2002, QJM-INT J MED, V95, P547, DOI 10.1093/qjmed/95.8.547; Ko MCH, 2004, J PHARMACOL EXP THER, V310, P169, DOI 10.1124/jpet.103.061101; Kostopanagiotou G, 2006, EUR J ANAESTH, V23, P418, DOI 10.1017/S0265021505001912; Kuraishi Y, 2000, J BIOMED SCI, V7, P248, DOI 10.1159/000025455; Kyriakides K, 1999, BRIT J ANAESTH, V82, P439, DOI 10.1093/bja/82.3.439; LEVY JH, 1989, ANESTHESIOLOGY, V70, P756, DOI 10.1097/00000542-198905000-00008; Maekawa T, 2000, JPN J PHARMACOL, V84, P462, DOI 10.1254/jjp.84.462; Mansour-Ghanaei F, 2006, WORLD J GASTROENTERO, V12, P1125, DOI 10.3748/wjg.v12.i7.1125; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Morita T, 2006, J PAIN SYMPTOM MANAG, V32, P100, DOI 10.1016/j.jpainsymman.2006.04.002; Murphy DB, 1997, ANESTHESIOLOGY, V87, P765, DOI 10.1097/00000542-199710000-00008; Sartain JB, 2003, ANESTHESIOLOGY, V99, P148, DOI 10.1097/00000542-200307000-00024; SUGIMOTO Y, 1998, EUR J PHARMACOL, V12, P1; THOMAS DA, 1992, BRAIN RES, V585, P315, DOI 10.1016/0006-8993(92)91227-6; Ueda Y, 2006, INT IMMUNOPHARMACOL, V6, P1609, DOI 10.1016/j.intimp.2006.06.002; Wells J, 2004, INT J OBSTET ANESTH, V13, P35, DOI 10.1016/j.ijoa.2003.07.001; Yamaguchi T, 2001, J DERMATOL SCI, V25, P20, DOI 10.1016/S0923-1811(00)00099-2; Yuan CS, 1998, DRUG ALCOHOL DEPEN, V52, P161, DOI 10.1016/S0376-8716(98)00087-8	28	13	14	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	FEB 10	2010	627	1-3					162	166		10.1016/j.ejphar.2009.10.066			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	549ZD	WOS:000274093800024	19900440				2020-06-30	J	Holdgate, A; Cao, A; Lo, KM				Holdgate, Anna; Cao, Anthony; Lo, Ka Mei			The Implementation of Intranasal Fentanyl for Children in a Mixed Adult and Pediatric Emergency Department Reduces Time to Analgesic Administration	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Winter Symposium of the Australasian-College-for-Emergency-Medicine	JUL, 2009	Darwin, AUSTRALIA	Australasian Coll Emergency Med		analgesia; administration; intranasal; fentanyl	RANDOMIZED CONTROLLED-TRIAL; MORPHINE; PAIN	Objectives: The objective was to determine whether the introduction of intranasal (IN) fentanyl for children with acute pain would reduce the time to analgesic administration in a mixed adult and pediatric emergency department (ED). Methods: A protocol for IN fentanyl (1.5 mu g/kg) for children age 1-15 years presenting with acute pain was introduced to the department. All children who received intravenous (IV) morphine in the 7 months prior to the introduction of the protocol and either IV morphine or IN fentanyl in the 7 months after the introduction of the protocol were identified from drug registers. Time to analgesic administration, time to see a doctor, and the ages of patients were compared between the periods before and after the introduction of IN fentanyl. Results: Following implementation, 81 patients received IN fentanyl and 37 received IV morphine, compared to 63 patients receiving morphine in the previous 7 months. The median time to analgesic administration for IN fentanyl was significantly shorter than for morphine (32 minutes vs. 63 minutes, p = 0.001). Children receiving fentanyl were significantly younger than those receiving morphine (median = 8.5 years vs. 12 years, p < 0.001). Conclusions: This study demonstrates that children treated with IN fentanyl received analgesic medication faster than those treated with IV morphine in a mixed ED. Younger children were more likely to receive opioid analgesia following the introduction of fentanyl.	[Holdgate, Anna; Lo, Ka Mei] Liverpool Hosp, Dept Emergency Med, Sydney, NSW, Australia; [Holdgate, Anna; Cao, Anthony] Univ NSW, Sydney, NSW, Australia	Holdgate, A (reprint author), Liverpool Hosp, Dept Emergency Med, Sydney, NSW, Australia.	anna.holdgate@swsahs.nsw.gov.au					Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; LEWIS LM, 1994, SOUTH MED J, V87, P7, DOI 10.1097/00007611-199401000-00002; Maurice SC, 2002, EMERG MED J, V19, P4, DOI 10.1136/emj.19.1.4; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Rodriguez E, 2002, EMERG MED CLIN N AM, V20, P199, DOI 10.1016/S0733-8627(03)00058-0; Wolfe Timothy R, 2004, J Emerg Nurs, V30, P141, DOI 10.1016/j.jen.2004.01.006	10	32	32	0	0	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	FEB	2010	17	2					214	217		10.1111/j.1553-2712.2009.00636.x			4	Emergency Medicine	Emergency Medicine	550QU	WOS:000274144000018	20070272				2020-06-30	J	Johnston, KD				Johnston, Kevin D.			The potential for mu-opioid receptor agonists to be anti-emetic in humans: a review of clinical data	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Review							TOTAL INTRAVENOUS ANESTHESIA; POSTOPERATIVE PAIN-CONTROL; INDUCED EMESIS; RISK SCORE; CONTROLLED TRIAL; DOUBLE-BLIND; FENTANYL; REMIFENTANIL; MORPHINE; NAUSEA	In animal models of vomiting, mu-opioid (MOP, OP3) receptors mediate both emesis and anti-emesis. mu-receptors within the blood-brain barrier, mediating anti-emesis, are more rapidly accessible to lipid-soluble mu-opioid receptor agonists such as fentanyl than to morphine, and fentanyl has broad-spectrum anti-emetic effects in a number of species. Whether a similar situation exists in humans is not known. A search was performed for clinical studies comparing the emetic side effects of opioids administered peri-operatively in an attempt to identify differences between morphine and more lipid-soluble mu-receptor-selective agonists such as fentanyl. Overall, the evidence appears to suggest that fentanyl and other phenylpiperidines are associated with less nausea and vomiting than morphine, but not all studies support this, and fentanyl-like drugs are associated with nausea and vomiting per se. Good evidence, however, exists to show that fentanyl and alfentanil do not cause more nausea and vomiting than the ultra fast-acting remifentanil. Because remifentanil is cleared rapidly post-operatively, such trials suggest that the emetic side effects of fentanyl and alfentanil are minimal. The clinical evidence, although limited, is at least consistent with the possibility that central mu-opioid receptors may mediate anti-emesis in humans. It is possible that the role of mu-opioid agonists in anti-emesis may become clearer in the future as a result of the use of peripheral mu-opioid receptor antagonists.	John Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 9DU, England	Johnston, KD (reprint author), John Radcliffe Hosp, Nuffield Dept Anaesthet, Headley Way, Oxford OX3 9DU, England.	kevin.johnston@vodafone.net					Agnew NM, 2003, J CARDIOTHOR VASC AN, V17, P336, DOI 10.1016/S1053-0770(03)00049-1; Alexander SPH, 2008, BRIT J PHARMACOL, V153, pS1, DOI 10.1038/sj.bjp.0707746; Apfel CC, 1998, ACTA ANAESTH SCAND, V42, P502, DOI 10.1111/j.1399-6576.1998.tb05158.x; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Apfel CC, 1998, ACTA ANAESTH SCAND, V42, P495, DOI 10.1111/j.1399-6576.1998.tb05157.x; BARNES NM, 1991, NEUROPHARMACOLOGY, V30, P1073, DOI 10.1016/0028-3908(91)90136-Y; Bates JJ, 2004, ANESTH ANALG, V98, P116, DOI 10.1213/01.ANE.0000090147.97636.77; BHANDARI P, 1992, NEUROPHARMACOLOGY, V31, P735, DOI 10.1016/0028-3908(92)90034-M; BHARGAVA KP, 1981, BRIT J PHARMACOL, V72, P471, DOI 10.1111/j.1476-5381.1981.tb10998.x; Breitfeld C, 2003, BRIT J ANAESTH, V91, P218, DOI 10.1093/bja/aeg165; BROWN EM, 1984, CAN ANAESTH SOC J, V31, P251, DOI 10.1007/BF03007884; Chhabra A, 2005, REGION ANESTH PAIN M, V30, P43, DOI 10.1016/j.rapm.2004.08.023; Choi SH, 2008, YONSEI MED J, V49, P204, DOI 10.3349/ymj.2008.49.2.204; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; Delaney CP, 2005, DIS COLON RECTUM, V48, P1114, DOI 10.1007/s10350-005-0035-7; Dershwitz M, 2002, J CLIN ANESTH, V14, P275, DOI 10.1016/S0952-8180(02)00353-7; Diemunsch P, 2000, DRUGS, V60, P533, DOI 10.2165/00003495-200060030-00002; Djian MC, 2006, CLIN THER, V28, P560, DOI 10.1016/j.clinthera.2006.04.001; Eberhart LHJ, 2000, ACTA ANAESTH SCAND, V44, P480, DOI 10.1034/j.1399-6576.2000.440422.x; Eltzschig HK, 2002, ANESTH ANALG, V94, P1173, DOI 10.1097/00000539-200205000-00022; Fichna J, 2007, PHARMACOL REV, V59, P88, DOI 10.1124/pr.59.1.3; FOSS JF, 1993, J CLIN PHARMACOL, V33, P747, DOI 10.1002/j.1552-4604.1993.tb05618.x; Foss JF, 1998, CANCER CHEMOTH PHARM, V42, P287, DOI 10.1007/s002800050819; Friesen RH, 2003, PAEDIATR ANAESTH, V13, P122, DOI 10.1046/j.1460-9592.2003.00978.x; Gaszynski TM, 2004, OBES SURG, V14, P498, DOI 10.1381/096089204323013488; Gerlach K, 2003, EUR J ANAESTH, V20, P813, DOI 10.1097/00003643-200310000-00007; GUPTA YK, 1989, INDIAN J EXP BIOL, V27, P52; HAIGH CG, 1993, BRIT J ANAESTH, V71, P517, DOI 10.1093/bja/71.4.517; Hung WT, 2005, J CLIN ANESTH, V17, P494, DOI 10.1016/j.jclinane.2004.09.014; Javid FA, 2001, PHARMACOL BIOCHEM BE, V68, P761, DOI 10.1016/S0091-3057(01)00470-1; Kakimoto S, 1997, BIOL PHARM BULL, V20, P739; KOBRINSKY NL, 1988, AM J PEDIAT HEMATOL, V10, P206; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Langevin S, 1999, ANESTHESIOLOGY, V91, P1666, DOI 10.1097/00000542-199912000-00019; LEJUS C, 1994, BRIT J ANAESTH, V72, P156, DOI 10.1093/bja/72.2.156; MILLER AD, 1987, J NEUROPHYSIOL, V57, P1854; MOSKOWITZ AS, 1985, BRAIN RES, V360, P117, DOI 10.1016/0006-8993(85)91227-2; Mukherjee K, 2001, ANAESTHESIA, V56, P1193; NIEMI L, 1993, ANESTH ANALG, V77, P126; Nonaka Akihiko, 2007, Masui, V56, P1343; Ozkose Z, 2002, J CLIN ANESTH, V14, P161, DOI 10.1016/S0952-8180(01)00368-3; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; PAUL D, 1988, EUR J PHARMACOL, V149, P403, DOI 10.1016/0014-2999(88)90680-2; PECK TE, 2008, PHARM ANAESTHESIA IN, P135; Rama-Maceiras P, 2005, ACTA ANAESTH SCAND, V49, P305, DOI 10.1111/j.1399-6576.2005.00650.x; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; ROWBOTHAM MC, 1983, PSYCHONEUROENDOCRINO, V8, P95, DOI 10.1016/0306-4530(83)90045-8; Rudd JA, 1999, EUR J PHARMACOL, V374, P77, DOI 10.1016/S0014-2999(99)00285-X; RUDD JA, 1995, [No title captured], P208; RUDRA P, 2004, [No title captured], V48, P461; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Shirakami Gotaro, 2006, J Anesth, V20, P188, DOI 10.1007/s00540-006-0413-x; Smith I, 2008, EUR J ANAESTH, V25, P790, DOI 10.1017/S026502150800464X; Tamura M, 2003, EUR J ANAESTH, V20, P482, DOI 10.1097/00003643-200306000-00011; Teng Yun-Hui, 2004, Chang Gung Med J, V27, P877; THOMPSON PI, 1992, BRIT J PHARMACOL, V106, P3, DOI 10.1111/j.1476-5381.1992.tb14284.x; Valairucha Songyos, 2005, Journal of the Medical Association of Thailand, V88, P921; VANDENBERG AA, 1994, BRIT J CLIN PHARMACO, V38, P533; Wong J, 2000, CAN J ANAESTH, V47, P1090, DOI 10.1007/BF03027960; Zhang YH, 2006, BRAIN RES, V1099, P33, DOI 10.1016/j.brainres.2006.04.133	63	16	19	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2010	54	2					132	140		10.1111/j.1399-6576.2009.02115.x			9	Anesthesiology	Anesthesiology	541VI	WOS:000273448700003	19817719				2020-06-30	J	Jaensson, M; Olowsson, LL; Nilsson, U				Jaensson, M.; Olowsson, L. L.; Nilsson, U.			Endotracheal tube size and sore throat following surgery: a randomized-controlled study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							TRACHEAL INTUBATION; COMPLICATIONS; ANESTHESIA; COMPLAINTS; MORBIDITY	Background Sore throat following endotracheal intubation is a common problem following surgery and one of the factors that affects the quality of recovery. This study was carried out with the primary aim of assessing whether the size of the endotracheal tube (ETT) affects the risk of sore throat in women following anaesthesia. Methods One hundred healthy adult women undergoing elective surgery were randomly allocated to oral intubation with either ETT size 6.0 or 7.0. Anaesthesia was based on either inhalation or total intravenous anaesthesia according to standardized routines. Pre- and post-operatively, sore throat and discomfort were assessed on a four-graded scale and for hoarseness on a binary scale (yes or no). Post-operatively, the assessments were performed after 1-2 and 24 h, and if there was discomfort at 24 h, a follow-up call was made at 72 and 96 h. Results After 1-2 h post-operatively, there were a higher proportion of patients with sore throat in ETT 7.0 vs. ETT 6.0 (51.1% vs. 27.1%), P=0.006. This difference between the groups was also evident, P=0.002, when comparing changes between the pre- and the post-operative values. The severity of discomfort from sore throat was also higher in ETT 7.0 (38.8%) compared with ETT 6.0 (18.8%), P=0.02. No differences were found in the incidence of hoarseness between the groups. The remaining symptoms lasted up to 96 h post-operatively in 11%, irrespective of the tube size. Conclusion Use of a smaller-sized ETT can alleviate sore throat and discomfort in women at the post-anaesthesia care unit.	[Jaensson, M.; Olowsson, L. L.; Nilsson, U.] Orebro Univ Hosp, Dept Anaesthesiol & Intens Care, SE-70185 Orebro, Sweden; [Nilsson, U.] Orebro Univ Hosp, Ctr Hlth Care Sci, Orebro, Sweden; [Nilsson, U.] Sch Med & Hlth Sci, Orebro, Sweden	Jaensson, M (reprint author), Orebro Univ Hosp, Dept Anaesthesiol & Intens Care, SE-70185 Orebro, Sweden.	maria.jaensson@orebroll.se	Nilsson, Ulrica/R-8586-2017	Nilsson, Ulrica/0000-0001-5403-4183	Centre for Health Care Sciences, Orebro County Council	The investigators thank Anna-Maria Kling for the statistical advice and Anil Gupta, MD, FRCA, PhD, for his support and linguistic assistance. This study was supported by grants from the Centre for Health Care Sciences, Orebro County Council.	Al-Qahtani Ali S., 2005, Middle East Journal of Anesthesiology, V18, P179; BEEBE DS, 2001, SEMIN ANESTH PERIO M, V20, P166; Biro P, 2005, EUR J ANAESTH, V22, P307, DOI 10.1017/S0265021505000529; Chen Kuan-Ting, 2004, Acta Anaesthesiol Taiwan, V42, P3; CHRISTENSEN AM, 1994, BRIT J ANAESTH, V73, P786, DOI 10.1093/bja/73.6.786; Combes X, 2007, BRIT J ANAESTH, V99, P276, DOI 10.1093/bja/aem147; Combes X, 2001, ANESTHESIOLOGY, V95, P1120, DOI 10.1097/00000542-200111000-00015; Higgins PP, 2002, BRIT J ANAESTH, V88, P582, DOI 10.1093/bja/88.4.582; Hisham AN, 2001, ANZ J SURG, V71, P669, DOI 10.1046/j.1445-1433.2001.02230.x; Kloub Rula, 2001, Middle East Journal of Anesthesiology, V16, P29; Mencke T, 2003, ANESTHESIOLOGY, V98, P1049, DOI 10.1097/00000542-200305000-00005; MILLER RD, 2005, ANAESTHESIA, P1650; Myles PS, 1997, ANAESTHESIA, V52, P300, DOI 10.1111/j.1365-2044.1997.89-az0091.x; Randestad A, 2000, LARYNGOSCOPE, V110, P1957; STEWART SL, 2003, AM ASS NURSE ANESTH, V6, P443; STOUT DM, 1987, ANESTHESIOLOGY, V67, P419, DOI 10.1097/00000542-198709000-00025; Takekawa Kimiko, 2006, J Anesth, V20, P44, DOI 10.1007/s00540-005-0363-8	17	40	46	0	3	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2010	54	2					147	153		10.1111/j.1399-6576.2009.02166.x			7	Anesthesiology	Anesthesiology	541VI	WOS:000273448700005	19930246				2020-06-30	J	Galvin, E; Boesjes, H; Hol, J; Ubben, JF; Klein, J; Verbrugge, SJC				Galvin, E.; Boesjes, H.; Hol, J.; Ubben, J. F.; Klein, J.; Verbrugge, S. J. C.			Modafinil reduces patient-reported tiredness after sedation/analgesia but does not improve patient psychomotor skills	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							WORK SLEEP DISORDER; SEDATION; RECOVERY; ANESTHESIA; MIDAZOLAM; VIGILANCE; ALERTNESS; DOPAMINE; PLACEBO; DRUG	Background Early recovery of patients following sedation/analgesia and anesthesia is important in ambulatory practice. The aim of this study was to assess whether modafinil, used for the treatment of narcolepsy, improves recovery following sedation/analgesia. Methods Patients scheduled for extracorporeal shock wave lithotripsy were randomly assigned to one of four groups. Two groups received a combination of fentanyl/midazolam with either modafinil or placebo. The remaining groups received remifentanil/propofol with either modafinil or placebo. Modafinil 200 mg was administered to the treatment group patients 1 h before sedation/analgesia. Groups were compared using the digital symbol substitution test (DSST), trail making test (TMT), observer scale of sedation and analgesia (OAA/S) and Aldrete score. Verbal rating scale (VRS) scores for secondary outcome variables e.g. energy, tiredness and dizziness were also recorded before and after treatment. Results Sixty-seven patients successfully completed the study. Groups received similar doses of sedation and analgesic drugs. No statistically significant difference was found for DSST between groups. No significant adverse effects occurred in relation to modafinil. No statistically significant difference between groups was identified for TMT, OAA/S and Aldrete scores. The mean VRS score for tiredness was lesser in the modafinil/fentanyl/midazolam group [1.3 (2.0)] compared with the placebo group [3.8 (2.5)], P=0.02. Such a difference was not found between the remifentanil/propofol groups [placebo 2.6 (2.2) vs. modafinil 3.1(2.7)], p > 0.05. Dizziness was greater in the modafinil/remifentanil/propofol group 1.7 (2.0) vs. placebo 0.0 (0.5), p < 0.05. Conclusion Modafinil reduces patient-reported tiredness after sedation/analgesia but does not improve recovery in terms of objective measures of patient psychomotor skills.	[Galvin, E.; Boesjes, H.; Hol, J.; Ubben, J. F.; Klein, J.] Erasmus Univ, Med Ctr Rotterdam, Dept Anesthesiol, NL-3015 GD Rotterdam, Netherlands; [Verbrugge, S. J. C.] St Franciscus Hosp, Dept Anesthesiol, Rotterdam, Netherlands	Galvin, E (reprint author), Erasmus Univ, Med Ctr Rotterdam, Dept Anesthesiol, POB 2040f, NL-3015 GD Rotterdam, Netherlands.	eilishgalvin@hotmail.com	Galvin, Eilish/M-9552-2019		Department of Anesthesiology, Erasmus University Medical Center, Rotterdam, the NetherlandsNetherlands Government	The study was financially supported by the Department of Anesthesiology, Erasmus University Medical Center, Rotterdam, the Netherlands.	Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406; Buguet A, 1995, J SLEEP RES, V4, P229, DOI 10.1111/j.1365-2869.1995.tb00173.x; *CEPH INC, 2004, PROV DRUG INF SHEET; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; Dackis CA, 2005, NEUROPSYCHOPHARMACOL, V30, P205, DOI 10.1038/sj.npp.1300600; Ferraro L, 1996, EUR J PHARMACOL, V306, P33, DOI 10.1016/0014-2999(96)00182-3; Ibrahim AE, 2001, ANESTHESIOLOGY, V94, P87, DOI 10.1097/00000542-200101000-00018; Keating GM, 2005, CNS DRUGS, V19, P785, DOI 10.2165/00023210-200519090-00005; Larijani GE, 2004, ANESTH ANALG, V98, P976, DOI 10.1213/01.ANE.0000108485.29288.B4; LEZAK MD, 1995, NEUROPSCHOLOGICAL AS; Lichtor JL, 2002, ANESTHESIOLOGY, V96, P878, DOI 10.1097/00000542-200204000-00015; Madras BK, 2006, J PHARMACOL EXP THER, V319, P561, DOI 10.1124/jpet.106.106583; Medina HJ, 2005, ANESTH ANALG, V101, P365, DOI 10.1213/01.ANE.0000159379.54705.84; Mondello Epifanio, 2002, J Clin Monit Comput, V17, P271, DOI 10.1023/A:1021250320103; NEWSON C, 1995, ANESTH ANALG, V81, P486, DOI 10.1097/00000539-199509000-00010; Orr K, 2007, CNS DRUGS, V21, P239, DOI 10.2165/00023210-200721030-00004; Parmentier R, 2007, BIOCHEM PHARMACOL, V73, P1157, DOI 10.1016/j.bcp.2007.01.002; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Randall DC, 2005, J CLIN PSYCHOPHARM, V25, P175, DOI 10.1097/01.jcp.0000155816.21467.25; Sauter C, 2000, J SLEEP RES, V9, P293; Scammell T E, 1998, Expert Opin Investig Drugs, V7, P99, DOI 10.1517/13543784.7.1.99; Taittonen MT, 1998, ANESTH ANALG, V87, P161, DOI 10.1097/00000539-199807000-00034; Thomas RJ, 2006, SLEEP, V29, P1471, DOI 10.1093/sleep/29.11.1471; Walsh JK, 2004, SLEEP, V27, P434, DOI 10.1093/sleep/27.3.434; Webster L, 2003, PAIN MED, V4, P135, DOI 10.1046/j.1526-4637.2003.03014.x; WESCHLER DA, 1981, REVISED WECHSLER ADU	27	6	6	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2010	54	2					154	161		10.1111/j.1399-6576.2009.02093.x			8	Anesthesiology	Anesthesiology	541VI	WOS:000273448700006	19719817				2020-06-30	J	Choi, SJ; Ahn, HJ; Yang, MK; Kim, CS; Sim, WS; Kim, JA; Kang, JG; Kim, JK; Kang, JY				Choi, S. J.; Ahn, H. J.; Yang, M. K.; Kim, C. S.; Sim, W. S.; Kim, J. A.; Kang, J. G.; Kim, J. K.; Kang, J. Y.			Comparison of desaturation and resaturation response times between transmission and reflectance pulse oximeters	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							PERIPHERAL PERFUSION; FOREHEAD; SENSOR	Background In general, there is a response time between actual arterial hypoxemia and its detection by pulse oximeters. We compared the desaturation and resaturation response times between two types of pulse oximeters, transmission and reflectance pulse oximeters, to find out which oximeter has a more rapid response time. Methods Thirty-three ASA 1 or 2 patients were enrolled in this study. A transmission pulse oximeter was placed on the index finger and a reflectance pulse oximeter was placed on the forehead and monitored simultaneously. After the induction of general anesthesia without pre-oxygenation, we waited until the oxygen saturation value of any of two pulse oximeters declined to 90%, and then mask ventilation was started with 100% oxygen. Oxygen saturation was recorded at an interval of 2 s during this time. Results The desaturation response time of SpO(2) to 95% after apnea was 82.0 s (interquartile range: 67.0-98.5 s) vs. 94.0 s (interquartile range: 84.0-106.5 s) (P < 0.001) and SpO(2) to 90% was 94.0 s (interquartile range: 75.5-109.5 s) vs. 100.0 s (interquartile range: 84.5-114.5 s) (P < 0.001) in the reflectance and transmission oximeters, respectively. The resaturation response time from mask ventilation to 100% SpO(2) was 23.2 +/- 5.6 vs. 28.9 +/- 7.6 s (P < 0.001) in the reflectance and transmission oximeters, respectively. Conclusion In clinical situations in which rapid changes in oxygen saturation are expected, we recommend the forehead reflectance pulse oximeter because it responds more quickly in detecting oxygen desaturation and resaturation compared with the transmission pulse oximeter.	[Choi, S. J.; Ahn, H. J.; Yang, M. K.; Kim, C. S.; Sim, W. S.; Kim, J. A.; Kang, J. G.; Kim, J. K.; Kang, J. Y.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea	Ahn, HJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, 135-710 50 Ilwon Dong, Seoul, South Korea.	hyunjooahn@skku.edu					ABUYOUSEF MM, 1992, J ULTRAS MED, V11, P263, DOI 10.7863/jum.1992.11.6.263; Berkenbosch JW, 2006, RESPIR CARE, V51, P726; BRANSON RD, 2004, RESP CARE CLIN N AM, V10, pR6; Branson Richard D, 2004, Respir Care Clin N Am, V10, P359, DOI 10.1016/j.rcc.2004.04.003; Dassel ACM, 1997, BRIT J OBSTET GYNAEC, V104, P910, DOI 10.1111/j.1471-0528.1997.tb14350.x; Hamber EA, 1999, J CLIN ANESTH, V11, P113, DOI 10.1016/S0952-8180(99)00010-0; Jopling MW, 2002, ANESTH ANALG, V94, pS62; JORGENSEN JS, 1995, J CLIN MONITOR, V11, P253, DOI 10.1007/BF01617520; MacLeod DB, 2005, ANAESTHESIA, V60, P65, DOI 10.1111/j.1365-2044.2004.04033.x; Neustein SM, 2009, ACTA ANAESTH SCAND, V53, P415, DOI 10.1111/j.1399-6576.2008.01871.x; Nilsson L, 2007, ACTA ANAESTH SCAND, V51, P1250, DOI 10.1111/j.1399-6576.2007.01375.x; Nilsson Lena, 2006, J Clin Monit Comput, V20, P431, DOI 10.1007/s10877-006-9050-z; Schallom L, 2007, HEART LUNG, V36, P188, DOI 10.1016/j.hrtlng.2006.07.007; SEVERINGHAUS JW, 1992, ANESTHESIOLOGY, V76, P1018; Yamaura Ken, 2007, J Clin Monit Comput, V21, P249, DOI 10.1007/s10877-007-9081-0; Yamaya Y, 2002, J APPL PHYSIOL, V92, P162, DOI 10.1152/japplphysiol.00409.2001	16	19	19	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2010	54	2					212	217		10.1111/j.1399-6576.2009.02101.x			6	Anesthesiology	Anesthesiology	541VI	WOS:000273448700014	19719816				2020-06-30	J	Chiou, TJ; Liu, CY; Tzeng, WF; Su, YC; Weng, YC; Hung, CJ; Tang, Y; Chen, YJ				Chiou, Tzeon-Jye; Liu, Chun-Yu; Tzeng, Woan-Fang; Su, Yu-Chieh; Weng, Yih-Chyang; Hung, Chih-Jen; Tang, Yeh; Chen, Yu-Jen		Taiwan Canc Pain Study Grp	The Use of Transdermal Fentanyl in Cancer Pain-A Compliance Study of Outpatients in Taiwan	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						cancer patients; transdermal fentanyl; opioids analgesics; cohort study; compliance; side effects	EFFICACY CLINICAL-TRIAL; RELEASE ORAL MORPHINE; QUALITY-OF-LIFE; TTS-FENTANYL; MANAGEMENT; OPIOIDS; PHARMACOKINETICS; CODEINE; SAFETY; NAIVE	The aim of this study is to investigate cancer patients' response and side effects associated with transdermal therapeutic fentanyl (TTS-F), whose pain was hardly controlled by nonweak/weak opioids in Taiwan. From 2005 to 2006, 822 outpatients received TTS-F to collect pain assessment forms and diaries for 4 weeks. Most (78.7%) patients were initially prescribed 25 mu g/h TTS-F. Doses were adjusted weekly at clinicians' discretion, according to pain assessment and side effects. Patients receiving 50 mu g/h, 75 mu g/h, and > 75 mu g/h TTS-F had increased from 17.5% to 32.1%, 1.8% to 3.4%, and 1.9% to 2.2%, respectively, by week 2; further small increases were found in weeks 3 and 4. Pain palliation improved from 60.6% during week 1 to 78.6% at week 4. The common adverse effects were nausea/vomiting. Patient's compliance was > 90%. This study found that the TTS-F is effective and well tolerated..	[Chiou, Tzeon-Jye] Taipei Vet Gen Hosp, Div Transfus Med, Dept Med, Taipei 112, Taiwan; [Liu, Chun-Yu] Taipei Vet Gen Hosp, Div Hematol & Oncol, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Tzeng, Woan-Fang] Fu Jen Catholic Univ, Dept Life Sci, Taipei, Taiwan; [Su, Yu-Chieh] Buddhist Dalin Tzu Chi Gen Hosp, Dept Hematol & Oncol, Chiayi, Taiwan; [Weng, Yih-Chyang] Taichung Vet Gen Hosp, Dept Radiat Oncol, Taichung, Taiwan; [Hung, Chih-Jen] China Med Univ Hosp, Dept Anesthesiol, Pain Clin, Taichung, Taiwan; [Tang, Yeh] Kaohsiung Chang Gung Mem Hosp, Dept Med, Div Hematol & Oncol, Kaohsiung, Taiwan; [Chen, Yu-Jen] Mackay Mem Hosp, Dept Radiat Oncol, Taipei, Taiwan	Chiou, TJ (reprint author), Taipei Vet Gen Hosp, Div Transfus Med, Dept Med, Taipei 112, Taiwan.	tjchiou@vghtpe.gov.tw	Liu, Chun-Yu/I-4358-2015; Su, Yu-Chieh/M-7867-2013	Liu, Chun-Yu/0000-0003-2336-4731; Su, Yu-Chieh/0000-0002-1771-9017	Taiwan Clinical Cancer Foundations; Veterans General HospitalTaipei Veterans General Hospital	The authors thank all the participants and patients in the following lists to put their efforts into this study. This study got partial grant support from Taiwan Clinical Cancer Foundations and Taipei Veterans General Hospital.	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hammack JE, 1996, J PAIN SYMPTOM MANAG, V12, P234, DOI 10.1016/0885-3924(96)00191-1; Jarlbaek L, 2006, SUPPORT CARE CANCER, V14, P340, DOI 10.1007/s00520-005-0890-8; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; Payne R, 1998, SEMIN ONCOL, V25, P47; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; *WHO, 1990, [No title captured], V804, P1; World Health Organization, 1996, CANC PAIN REL GUID O	22	4	5	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091			AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	FEB-MAR	2010	27	1					31	37		10.1177/1049909109346427			7	Health Care Sciences & Services	Health Care Sciences & Services	551GA	WOS:000274193800005	19801533				2020-06-30	J	Zhang, W; Chang, YZ; Kan, QC; Zhang, LR; Lu, H; Chu, QJ; Wang, ZY; Li, ZS; Zhang, J				Zhang, W.; Chang, Y. Z.; Kan, Q. C.; Zhang, L. R.; Lu, H.; Chu, Q. J.; Wang, Z. Y.; Li, Z. S.; Zhang, J.			Association of human mu-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients	ANAESTHESIA			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISM; POSTOPERATIVE PAIN; MORPHINE REQUIREMENTS; CANCER PAIN; OPRM1; PREDICTION; SENSITIVITY; EXPERIENCE; BINDING	One hundred and seventy-four Chinese gynaecology patients were studied for the impact of A118G polymorphism in the mu-opioid receptor gene (OPRM1) on pain sensitivity and postoperative fentanyl consumption. Pre-operatively, the pain threshold and pain tolerance threshold were measured using electrical stimulation. A118G polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism method. Intravenous fentanyl patient-controlled analgesia provided postoperative pain management, assessed using a visual analogue scale and fentanyl consumed in the first 24 h after surgery was noted. We found the prevalence of G118 allele was 31.3%. The A118G polymorphism had a gene-dose-dependent effect on electrical pain tolerance threshold. Fentanyl consumption was also significantly different in patients with different OPRM1 genotypes (homozygotes for 118G consumed more than did heterozygotes or homozygotes for 118A). Fentanyl consumption increased in accordance with the number of 118G alleles. We conclude that OPRM1 gene analysis may help predict individual opioid sensitivity and so optimise postoperative pain control.	[Zhang, W.; Chang, Y. Z.; Kan, Q. C.; Zhang, L. R.; Lu, H.] Zhengzhou Univ, Affiliated Hosp 1, Dept Anaesthesiol, Zhengzhou, Peoples R China; [Chu, Q. J.; Wang, Z. Y.; Li, Z. S.; Zhang, J.] Zhengzhou Univ, Sch Med, Dept Pharmacol, Zhengzhou, Peoples R China	Kan, QC (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Anaesthesiol, Zhengzhou, Peoples R China.	kanquancheng2008@163.com			Medical Science and Technology Research Projects of Henan Province [200703018]	This work was supported by grants from Medical Science and Technology Research Projects of Henan Province (No. 200703018). We thank Doctor W. J. Zhang for critical review of the manuscript.	Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; BRENNUM J, 1992, PAIN, V51, P27, DOI 10.1016/0304-3959(92)90005-V; Campa D, 2008, CLIN PHARMACOL THER, V83, P559, DOI 10.1038/sj.clpt.6100385; Cepeda MS, 2003, ANESTH ANALG, V97, P1464, DOI 10.1213/01.ANE.0000080153.36643.83; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Golembiewski J, 2005, AM J HEALTH-SYST PH, V62, P1247, DOI 10.1093/ajhp/62.12.1247; GRACELY RH, 1999, TXB PAIN; Granot M, 2003, ANESTHESIOLOGY, V98, P1422, DOI 10.1097/00000542-200306000-00018; Huang CJ, 2008, ANAESTHESIA, V63, P1288, DOI 10.1111/j.1365-2044.2008.05760.x; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Lotsch J, 2005, TRENDS MOL MED, V11, P82, DOI 10.1016/j.molmed.2004.12.006; Nagashima Makoto, 2007, Curr Pain Headache Rep, V11, P115, DOI 10.1007/s11916-007-0008-8; Nielsen PR, 2007, ACTA ANAESTH SCAND, V51, P582, DOI 10.1111/j.1399-6576.2007.01271.x; Pandit JJ, 2008, ANAESTHESIA, V63, P1284, DOI 10.1111/j.1365-2044.2008.05736.x; Rakvag TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008; Tan EC, 2008, J PAIN, V9, P849, DOI 10.1016/j.jpain.2008.04.004; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Werner MU, 2004, ANESTHESIOLOGY, V100, P115, DOI 10.1097/00000542-200401000-00020; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7; Xin Lili, 2002, AAPS PharmSci, V4, pE23; Zhang HP, 2006, HUM MOL GENET, V15, P807, DOI 10.1093/hmg/ddl024; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	32	47	56	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	FEB	2010	65	2					130	135		10.1111/j.1365-2044.2009.06193.x			6	Anesthesiology	Anesthesiology	535TT	WOS:000272994900004	20003118				2020-06-30	J	Wilson, MJA; MacArthur, C; Cooper, GM; Bick, D; Moore, PAS; Shennan, A				Wilson, M. J. A.; MacArthur, C.; Cooper, G. M.; Bick, D.; Moore, P. A. S.; Shennan, A.		COMET Study Grp UK	Epidural analgesia and breastfeeding: a randomised controlled trial of epidural techniques with and without fentanyl and a non-epidural comparison group	ANAESTHESIA			English	Article							LABOR ANALGESIA; ANESTHESIA; DELIVERY; IMPACT	We compared breastfeeding initiation and duration in 1054 nulliaparae randomised to bupivacaine Control epidural, Combined Spinal Epidural or Low Dose Infusion and 351 matched non-epidural comparisons. Women were interviewed after delivery and completed a postal questionnaire at 12 months. Regression analysis determined factors which independently predicted breastfeeding initiation. Breastfeeding duration was subjected to Kaplan-Meier analysis. A similar proportion of women in each epidural group initiated breastfeeding. Women with no epidural did not report a higher initiation rate relative to epidural groups and those who received pethidine reported a lower initiation rate than control epidural (p = 0.002). Older age groups (p < 0.001) and non-white ethnicity (p < 0.026) were predictive of breastfeeding. Epidural fentanyl dose, delivery mode and trial group were not predictive. Mean duration for breastfeeding was similar across epidural groups (Control 13.3, Combined Spinal Epidural 15.5, Low Dose Infusion 15.0 weeks). Our data do not support an effect of epidural fentanyl on breastfeeding initiation.	[Wilson, M. J. A.] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; [MacArthur, C.; Cooper, G. M.] Univ Birmingham, Birmingham, W Midlands, England; [Bick, D.] Univ London, Univ London Kings Coll, London SW3 6LX, England; [Moore, P. A. S.] Womens Hosp Birmingham, Birmingham, W Midlands, England; [Shennan, A.] Kings & St Thomas Sch Med, London, England	Wilson, MJA (reprint author), Royal Hallamshire Hosp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	Matthew.Wilson@sth.nhs.uk	Bick, Debra/P-9575-2018	Bick, Debra/0000-0002-8557-7276; Gold, Lisa/0000-0002-2733-900X			AMISOMUAH M, 2005, COCHRANE DB SYST REV; [Anonymous], 2007, FOOD NUTR PHYS ACT P; BADER AM, 1995, ANESTH ANALG, V81, P829, DOI 10.1097/00000539-199510000-00029; Baumgarder DJ, 2003, J AM BOARD FAM PRACT, V16, P7, DOI 10.3122/jabfm.16.1.7; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Camann W, 2007, INT J OBSTET ANESTH, V16, P199, DOI 10.1016/j.ijoa.2007.03.008; Chang ZM, 2005, J HUM LACT, V21, P305, DOI 10.1177/0890334405277604; Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x; Henderson JJ, 2003, AUST NZ J OBSTET GYN, V43, P372, DOI 10.1046/j.0004-8666.2003.t01-1-00117.x; Horta BL, 2007, EVIDENCE LONGTERM EF; Jordan S, 2005, BJOG-INT J OBSTET GY, V112, P927, DOI 10.1111/j.1471-0528.2005.00548.x; Jordan S, 2006, INT BREASTFEED J, V1, DOI 10.1186/1746-4358-1-25; Khor L, 2000, ANAESTHESIA, V55, P1; MacArthur C, 2002, ANESTHESIOLOGY, V97, P1567; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; *NIH CLIN EXC, 2007, INTR CAR MAN DEL CAR, pCG55; *NOAD, NAT OBST AN DAT NOAD; Quigley MA, 2007, PEDIATRICS, V119, pE837, DOI 10.1542/peds.2006-2256; Radzyminski S, 2003, JOGNN, V32, P322, DOI 10.1177/0884217503253440; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; SACN, 2008, INF FEED SURV 2005 C; Thornton JG, 2001, LANCET, V358, P2, DOI 10.1016/S0140-6736(00)05295-8; Torvaldsen S, 2006, INT BREASTFEED J, V1, DOI 10.1186/1746-4358-1-24; Wiklund I, 2009, MIDWIFERY, V25, pE31, DOI 10.1016/j.midw.2007.07.005; Wittels B, 1997, ANESTH ANALG, V85, P600, DOI 10.1097/00000539-199709000-00021	26	46	46	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	FEB	2010	65	2					145	153		10.1111/j.1365-2044.2009.06136.x			9	Anesthesiology	Anesthesiology	535TT	WOS:000272994900006	19912160				2020-06-30	J	Levine, AI; Bryson, EO				Levine, Adam I.; Bryson, Ethan O.			Intranasal Self-Administration of Remifentanil as the Foray into Opioid Abuse by an Anesthesia Resident	ANESTHESIA AND ANALGESIA			English	Article							PHARMACOKINETICS; ADDICTION; MONKEYS; COCAINE	Remifentanil is a potent mu-opioid receptor agonist that produces intense analgesia. This anilidopiperidine analog of fentanyl was approved by the United States Food and Drug Administration and became commercially available in the United States in 1997. Because of its unique chemical structure, remifentanil must be reconstituted; it has a rapid onset, and because of ester hydrolysis, it has a rapid rate of degradation. Although remifentanil's package insert warns against the potential for addiction, because of its rapid rate of degradation there was little concern that health care workers would abuse this drug. Herein, we report a case of intranasal remifentanil abuse by an anesthesiology resident. (Anesth Analg 2010;110:524-5)	[Levine, Adam I.; Bryson, Ethan O.] Mt Sinai Hosp, Dept Anesthesiol, New York, NY 10029 USA	Bryson, EO (reprint author), Mt Sinai Hosp, Dept Anesthesiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	ethan.bryson@mountsinai.org			institutional and departmental sources	Supported by institutional and departmental sources.	Baylon GJ, 2000, J CLIN PSYCHOPHARM, V20, P597, DOI 10.1097/00004714-200012000-00002; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; Crespo JA, 2006, ANN NY ACAD SCI, V1074, P497, DOI 10.1196/annals.1369.050; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; SKULSKA A, 2007, Z ZAGADNIEN NAUK SAD, V71, P303; Verghese ST, 2008, ANESTH ANALG, V107, P1176, DOI 10.1213/ane.0b013e3181838e95; Wade-Galuska T, 2007, PSYCHOPHARMACOLOGY, V194, P563, DOI 10.1007/s00213-007-0858-0; WHO, 1997, WORLD HLTH REP 1997, P15; Woolverton WL, 2008, PSYCHOPHARMACOLOGY, V198, P387, DOI 10.1007/s00213-008-1152-5	11	8	8	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2010	110	2					524	525		10.1213/ANE.0b013e3181c5f069			2	Anesthesiology	Anesthesiology	547XC	WOS:000273922100042	19917624				2020-06-30	J	Amr, YM; Yousef, AA; Alzeftawy, AE; Messbah, WI; Saber, AM				Amr, Yasser Mohamed; Yousef, Ayman Abd Al-Maksoud; Alzeftawy, Ashraf E.; Messbah, Wail I.; Saber, Ahmed Mohamed			Effect of Preincisional Epidural Fentanyl and Bupivacaine on Postthoracotomy Pain and Pulmonary Function	ANNALS OF THORACIC SURGERY			English	Article							INTERCOSTAL NERVE BLOCK; PREEMPTIVE ANALGESIA; ABDOMINAL-SURGERY; THORACIC-SURGERY; THORACOTOMY; MORPHINE; RECOVERY; RELIEF	Background. This study attempts to determine whether preemptive thoracic epidural analgesia ( TEA) initiated before surgical incision would reduce the severity of acute post-thoracotomy pain, its effects on pulmonary function and stress response. Methods. Forty patients undergoing posterolateral thoracotomy received TEA either before (preoperative-TEA group) or after (postoperative-TEA group) surgery. Postoperative analgesia was maintained with epidural infusion of bupivacaine and fentanyl. Pain scores, pulmonary functions, arterial blood gases, plasma glucose, cortisol levels and epidural fentanyl consumption were compared for 48 hours after surgery. Results. The preoperative-TEA group demonstrated significantly reduced pain scores at 2, 4, 8, 12, 24, and 48 hours at rest (p = 0.001, p = 0.002, p = 0.004, p = < 0.001, p = 0.006, and p = 0.001, respectively) and at 4, 8, 12, 24, 48 hours on coughing (p = 0.001, p = 0.001, p = 0.001, p = 0.001, p = 0.004, respectively), and a significant reduction in epidural fentanyl consumption (208.6 +/- 49.3 mL, versus 260 +/- 28.8 mL, p = 0.001). The preoperative-TEA group showed significant improvement in pulmonary functions as compared with the postoperative-TEA group (p < 0.05), except forced expiratory volume in one second at 24 hours (p = 0.061) and peak expiratory flow rate at 48 hours (p = 0.188). The postoperative-TEA treated patients were more likely to have a higher arterial carbon dioxide pressure at 4, 8, 12, and 24 hours (p = 0.017, p = 0.001, p = 0.003, p = 0.001), respectively. However, we could not demonstrate a statistical difference in oxygenation, cortisol, or glucose level. Conclusions. Though preemptive TEA appeared to reduce the severity of acute pain, preserve pulmonary function, and reduce analgesic requirements, these statistically significant differences were not enough to conclude a clinical significant difference between groups. (Ann Thorac Surg 2010;89:381-6) (C) 2010 by The Society of Thoracic Surgeons	[Amr, Yasser Mohamed; Yousef, Ayman Abd Al-Maksoud; Alzeftawy, Ashraf E.; Messbah, Wail I.; Saber, Ahmed Mohamed] Tanta Univ Hosp, Dept Anesthesiol, Fac Med, Tanta 31527, Egypt	Amr, YM (reprint author), Tanta Univ Hosp, Dept Anesthesiol, Fac Med, Tanta 31527, Egypt.	yasser.amr@gmail.com					Aguilar J. L., 1994, Regional Anesthesia, V19, P72; Aguilar JL, 1996, BRIT J ANAESTH, V76, P72; Akural EI, 2002, BRIT J ANAESTH, V88, P803, DOI 10.1093/bja/88.6.803; Amr YM, 2010, ANN THORAC SURG, V89, P381, DOI 10.1016/j.athoracsur.2009.10.060; Cliff K, 2005, ANESTH ANALG, V100, P757; DAHL JB, 1992, BRIT J ANAESTH, V69, P4, DOI 10.1093/bja/69.1.4; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; Hughes R, 2005, BJA EDUC, V5, P56, DOI 10.1093/bjaceaccp/mki014; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Kotze A, 2007, BRIT J ANAESTH, V98, P662, DOI 10.1093/bja/aem065; LUBENOW TR, 2000, CLIN ANESTH, P1403; Ng A, 2007, BRIT J ANAESTH, V98, P159, DOI 10.1093/bja/ael360; Obata H, 1999, CAN J ANAESTH, V46, P1127, DOI 10.1007/BF03015520; Ochroch EA, 2002, ANESTHESIOLOGY, V97, P1234, DOI 10.1097/00000542-200211000-00029; SABANATHAN S, 1988, ANN THORAC SURG, V46, P425, DOI 10.1016/S0003-4975(10)64657-7; SABANATHAN S, 1993, BRIT J HOSP MED, V50, P114; Senturk M, 2002, ANESTH ANALG, V94, P11; SULLIVAN E, 1995, CHEST, V108, P1718, DOI 10.1378/chest.108.6.1718; Warner DO, 2000, ANESTHESIOLOGY, V92, P1467, DOI 10.1097/00000542-200005000-00037; Wilder-Smith O H, 2000, Prog Brain Res, V129, P505; WOOLF CJ, 1986, NEUROSCI LETT, V64, P221, DOI 10.1016/0304-3940(86)90104-7; Wu CT, 2000, ACTA ANAESTH SCAND, V44, P63, DOI 10.1034/j.1399-6576.2000.440112.x	22	24	26	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	FEB	2010	89	2					381	386		10.1016/j.athoracsur.2009.10.060			6	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	547BV	WOS:000273861100007	20103303				2020-06-30	J	Douma, MR; Verwey, RA; Kam-Endtz, CE; van der Linden, PD; Stienstra, R				Douma, M. R.; Verwey, R. A.; Kam-Endtz, C. E.; van der Linden, P. D.; Stienstra, R.			Obstetric analgesia: a comparison of patient-controlled meperidine, remifentanil, and fentanyl in labour	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia; obstetric; analgesia; patient-controlled; analgesics opioid; fentanyl; analgesics opioid; meperidine; analgesics opioid; remifentanil	PARTURIENT; PAIN; PETHIDINE; PHARMACOKINETICS; PCA	To compare the analgesic efficacy of remifentanil with meperidine and fentanyl in a patient-controlled setting (patient-controlled analgesia, PCA). Parturients (n=159) were randomly assigned to receive remifentanil (n=52), meperidine (n=53), or fentanyl (n=54). Pain scores and an observer sedation scores were assessed hourly. Fetal outcome was evaluated with Apgar score, cord blood gas analysis and the Neurologic and Adaptive Capacity Score. Pain scores decreased in all groups, the decrease varying from mild to moderate, average pain scores remaining above 4.5 cm in all groups. Remifentanil PCA was associated with the greatest decrease in pain scores, but the difference was significant only at 1 h. Pain scores returned towards baseline over time; 3 h after the initiation of treatment, pain scores no longer differed significantly from baseline values in any of the groups. Significantly more parturients receiving meperidine crossed over to epidural analgesia. Overall satisfaction scores were higher with remifentanil, but remifentanil produced more sedation and itching. More periods of desaturation (Sa(o2) < 95%) were observed during administration of remifentanil and fentanyl. There were no significant differences in fetal outcome between the three groups. The efficacy of meperidine, fentanyl, and remifentanil PCA for labour analgesia varied from mild to moderate. Remifentanil PCA provided better analgesia than meperidine and fentanyl PCA, but only during the first hour of treatment. In all groups, pain scores returned to pre-treatment values within 3 h after the initiation of treatment.	[Douma, M. R.] HagaZiekenhuis Locat Red Cross, Dept Obstet & Gynaecol, NL-2506 LP The Hague, Netherlands; [Verwey, R. A.] Bronovo Hosp, Dept Obstet & Gynaecol, NL-2509 JH The Hague, Netherlands; [Kam-Endtz, C. E.] Bronovo Hosp, Dept Anaesthesia, NL-2509 JH The Hague, Netherlands; [van der Linden, P. D.] Tergooiziekenhuizen, Dept Clin Pharm, NL-1201 DA Hilversum, Netherlands; [Stienstra, R.] Sint Maartensklin, Dept Anaesthesia, NL-6500 GM Nijmegen, Netherlands	Douma, MR (reprint author), HagaZiekenhuis Locat Red Cross, Dept Obstet & Gynaecol, POB 60605, NL-2506 LP The Hague, Netherlands.	maritdouma@hotmail.com	Stienstra, Rudolf/A-2380-2016	Stienstra, Rudolf/0000-0002-0523-4530	Bronovo Research Fund	This work was supported by the Bronovo Research Fund.	Aly EE, 2000, ANAESTHESIA, V55, P419, DOI 10.1046/j.1365-2044.2000.01477.x; AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P340, DOI 10.1097/00000542-198205000-00003; Balki M, 2007, CAN J ANAESTH, V54, P626, DOI 10.1007/BF03022956; Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Blair JM, 2001, BRIT J ANAESTH, V87, P415, DOI 10.1093/bja/87.3.415; Conell-Price J, 2008, ANESTH ANALG, V106, P1509, DOI 10.1213/ane.0b013e31816d14f3; Evron S, 2005, ANESTH ANALG, V100, P233, DOI 10.1213/01.ANE.0000143351.64538.BC; Jones R, 1999, ANAESTHESIA, V54, P461, DOI 10.1046/j.1365-2044.1999.00857.x; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; KLEIMAN SJ, 1991, CAN J ANAESTH, V38, P489, DOI 10.1007/BF03007585; Lavand'homme P, 2009, ACTA ANAESTH BELG, V60, P75; McCarroll CP, 2001, BRIT J ANAESTH, V86, P135, DOI 10.1093/bja/86.1.135; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Reynolds F, 1997, LANCET, V349, P4, DOI 10.1016/S0140-6736(05)62156-3; Roelants F, 2001, CAN J ANAESTH, V48, P175, DOI 10.1007/BF03019731; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; Thurlow JA, 2000, BRIT J ANAESTH, V84, P411; Thurlow JA, 2002, BRIT J ANAESTH, V88, P374, DOI 10.1093/bja/88.3.374; Volikas I, 2005, BRIT J ANAESTH, V95, P504, DOI 10.1093/bja/aei219; Volikas I, 2001, INT J OBSTET ANESTH, V10, P86, DOI 10.1054/ijoa.2000.0831; Volmanen P, 2005, ACTA ANAESTH SCAND, V49, P453, DOI 10.1111/j.1399-6576.2005.00639.x; Volmanen P, 2002, ANESTH ANALG, V94, P913, DOI 10.1097/00000539-200204000-00026; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	26	68	75	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2010	104	2					209	215		10.1093/bja/aep359			7	Anesthesiology	Anesthesiology	547EA	WOS:000273867400011	20008859	Bronze, Green Published			2020-06-30	J	Dahmani, S; Stany, I; Brasher, C; Lejeune, C; Bruneau, B; Wood, C; Nivoche, Y; Constant, I; Murat, I				Dahmani, S.; Stany, I.; Brasher, C.; Lejeune, C.; Bruneau, B.; Wood, C.; Nivoche, Y.; Constant, I.; Murat, I.			Pharmacological prevention of sevoflurane- and desflurane-related emergence agitation in children: a meta-analysis of published studies	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques; regional; caudal; anaesthetics i; v; clonidine; anaesthetics i; v; fentanyl; anaesthetics i; v; propofol; emergence agitation	DEXMEDETOMIDINE REDUCES AGITATION; PRESCHOOL-AGED CHILDREN; PEDIATRIC-PATIENTS; GENERAL-ANESTHESIA; RECOVERY CHARACTERISTICS; BILATERAL MYRINGOTOMY; INTRANASAL FENTANYL; DELAYS RECOVERY; TUBE PLACEMENT; CAUDAL BLOCK	Emergence agitation (EA) in children is increased after sevoflurane anaesthesia. The efficacy of prophylactic treatment is controversial. The aim of this study was to provide a meta-analysis of the studies of the pharmacological prevention of EA in children. A comprehensive literature search was conducted to identify clinical trials that focused on the prevention of EA in children anaesthetized with sevoflurane, desflurane, or both. The data from each trial were combined using the Mantel-Haenszel model to calculate the pooled odds ratio (OR) and 95% confidence interval. I-2 statistics were used to assess statistics heterogeneity and the funnel plot and the Begg-Mazumdar test to assess bias. Thirty-seven articles were found which included a total of 1695 patients in the intervention groups and 1477 in the control ones. Midazolam and 5HT(3) inhibitors were not found to have a protective effect against EA [OR=0.88 (0.44, 1.76); OR=0.39 (0.12, 1.31), respectively], whereas propofol [OR=0.21 (0.16, 0.28)], ketamine [OR=0.28 (0.13, 0.60)], alpha(2)-adrenoceptors [OR=0.23 (0.17, 0.33)], fentanyl [OR=0.31 (0.18, 0.56)], and peroperative analgesia [OR=0.15 (0.07, 0.34)] were all found to have a preventive effect. Subgroup analysis according to the peroperative analgesia given does not affect the results. This meta-analysis found that propofol, ketamine, fentanyl, and preoperative analgesia had a prophylactic effect in preventing EA. The analgesic properties of these drugs do not seem to have a role in this effect.	[Dahmani, S.; Stany, I.; Brasher, C.; Lejeune, C.; Bruneau, B.; Wood, C.; Nivoche, Y.] Robert Debre Univ Hosp, AP HP, Dept Anesthesiol, F-75019 Paris, France; [Constant, I.; Murat, I.] Trousseau Univ Hosp, AP HP, Dept Anesthesiol, Paris, France	Dahmani, S (reprint author), Robert Debre Univ Hosp, AP HP, Dept Anesthesiol, 48 Bd Serurier, F-75019 Paris, France.	souhayl.dahmani@rdb.aphp.fr	Brasher, Christopher/Y-4488-2019	Brasher, Christopher/0000-0003-1037-3604; dahmani, Souhayl/0000-0002-1577-1030			Abu-Shahwan I, 2008, PEDIATR ANESTH, V18, P55, DOI 10.1111/j.1460-9592.2007.02376.x; Abu-Shahwan I, 2007, PEDIATR ANESTH, V17, P846, DOI 10.1111/j.1460-9592.2007.02298.x; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Arai YCP, 2007, ACTA ANAESTH SCAND, V51, P858, DOI 10.1111/j.1399-6576.2007.01339.x; Araki Hiromi, 2005, J Anesth, V19, P204, DOI 10.1007/s00540-005-0314-4; Binstock W, 2004, PEDIATR ANESTH, V14, P759, DOI 10.1111/j.1460-9592.2004.01296.x; Bock M, 2002, BRIT J ANAESTH, V88, P790, DOI 10.1093/bja/88.6.790; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Cohen IT, 2003, PAEDIATR ANAESTH, V13, P63, DOI 10.1046/j.1460-9592.2003.00948.x; Cohen IT, 2005, ANESTH ANALG, V101, P59, DOI 10.1213/01.ANE.0000154186.03161.35; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Da Conceicao MJ, 2006, PEDIATR ANESTH, V16, P962, DOI 10.1111/j.1460-9592.2006.01893.x; da Silva LM, 2008, J PEDIAT-BRAZIL, V84, P107, DOI [10.2223/JPED.1763, 10.1590/S0021-75572008000200004]; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; Erhan OL, 2007, INT J PEDIATR OTORHI, V71, P735, DOI 10.1016/j.ijporl.2007.01.008; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Funk W, 2008, EUR J ANAESTH, V25, P37, DOI 10.1017/S0265021507001159; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gil ML, 1999, PAEDIATR ANAESTH, V9, P485, DOI 10.1046/j.1460-9592.1999.00404.x; Goa K L, 1999, Paediatr Drugs, V1, P127, DOI 10.2165/00128072-199901020-00005; Gouda N., 2004, EGYPT J ANAESTH, V20, P63; Grundman U, 1998, ACTA ANAESTH SCAND, V42, P845, DOI 10.1111/j.1399-6576.1998.tb05332.x; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Johr M, 2002, PAEDIATR ANAESTH, V12, P293, DOI 10.1046/j.1460-9592.2002.00799.x; Johr M, 2005, BEST PRACT RES-CLIN, V19, P501, DOI 10.1016/j.bpa.2005.01.001; Kain ZN, 2007, ANESTHESIOLOGY, V106, P65, DOI 10.1097/00000542-200701000-00013; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kararmaz A, 2004, PEDIATR ANESTH, V14, P477, DOI 10.1111/j.1460-9592.2004.01224.x; Kol IO, 2008, CLIN THER, V30, P175, DOI 10.1016/j.clinthera.2008.01.008; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Lankinen U, 2006, ANESTH ANALG, V102, P1383, DOI 10.1213/01.ane.0000205745.84044.31; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Malviya S, 2006, PEDIATR ANESTH, V16, P554, DOI 10.1111/j.1460-9592.2006.01818.x; Mayer J, 2006, ANESTH ANALG, V102, P400, DOI 10.1213/01.ane.0000189561.44016.99; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nakayama S, 2007, J ANESTH, V21, P19, DOI 10.1007/s00540-006-0466-x; Nishina Kahoru, 2002, Curr Opin Anaesthesiol, V15, P309, DOI 10.1097/00001503-200206000-00006; Oh AY, 2005, ACTA ANAESTH SCAND, V49, P297, DOI 10.1111/j.1399-6576.2005.00687.x; Picard V, 2000, ACTA ANAESTH SCAND, V44, P307, DOI 10.1034/j.1399-6576.2000.440315.x; Reimer EJ, 1998, CAN J ANAESTH, V45, P1162, DOI 10.1007/BF03012457; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Shibata Shigehiro, 2005, J Anesth, V19, P160, DOI 10.1007/s00540-004-0294-9; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Steinmetz J, 2007, PEDIATR ANESTH, V17, P32, DOI 10.1111/j.1460-9592.2006.01999.x; Tesoro S, 2005, ANESTH ANALG, V101, P1619, DOI 10.1213/01.ANE.0000184204.81877.53; Tripi PA, 2005, J UROLOGY, V174, P1081, DOI 10.1097/01.ju.0000169138.90628.b9; Tsai PS, 2008, PEDIATR ANESTH, V18, P1114, DOI 10.1111/j.1460-9592.2008.02593.x; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; Veyckemans F, 2002, Minerva Anestesiol, V68, P402; Veyckemans F, 2001, Curr Opin Anaesthesiol, V14, P339, DOI 10.1097/00001503-200106000-00010; Viitanen H, 1999, CAN J ANAESTH, V46, P21, DOI 10.1007/BF03012509; Viitanen H, 1999, CAN J ANAESTH, V46, P766, DOI 10.1007/BF03013912; Viitanen H, 1999, ANESTH ANALG, V89, P75, DOI 10.1097/00000539-199907000-00014; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Yamashita M, 2003, PAEDIATR ANAESTH, V13, P641, DOI 10.1046/j.1460-9592.2003.00986_2.x	62	154	171	1	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2010	104	2					216	223		10.1093/bja/aep376			8	Anesthesiology	Anesthesiology	547EA	WOS:000273867400012	20047899	Bronze			2020-06-30	J	Ho, AL; Zakrzewski, PA; Braga-Mele, R				Ho, Adelyn L.; Zakrzewski, Peter A.; Braga-Mele, Rosa			The effect of combined topical-intracameral anaesthesia on neuroleptic requirements during cataract surgery	CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE			English	Article						phacoemulsification; cataract extraction; intraocular lens implantation	RETROBULBAR ANESTHESIA; LIDOCAINE; PHACOEMULSIFICATION; MIDAZOLAM; SEDATION; FENTANYL; TRIAL; PAIN	Objective: To evaluate whether the addition of intracameral lidocaine to topical anaesthesia during cataract surgery leads to a decrease in the administration of intraoperative midazolam and fentanyl. Design: Retrospective case-control study. Participants: The eyes of 124 patients undergoing phacoemulsification were included in the study, with 62 in the intracameral group and 62 in the control group. Methods: A single-centre, retrospective chart review of cases between April and October 2007 in which patients had undergone small-incision phacoemulsification with foldable intraocular lens insertion and received preoperatively either topical tetracaine 0.5% with unpreserved intracameral lidocaine 1% (intracameral group) or topical tetracaine 0.5% alone (control group). Intraoperatively, midazolam and fentanyl were administered as needed based on pain and anxiety. Results: A total of 124 eyes (124 patients) were included. There was no statistically significant difference between the mean intraoperative midazolam doses given for the 2 groups (p = 0.08). The mean intraoperative dose of fentanyl was lower in the intracameral than in the control group (p < 0.0001). A comparison of intraoperative fentanyl requirements between groups using a multivariate regression analysis for age, gender, surgical time, and preoperative fentanyl levels confirmed the lower need for intraoperative fentanyl in the intracameral compared with the control group (p = 0.0037). There were no anaesthetic complications among any of the study patients. Conclusions: Patients receiving topical tetracaine 0.5% with unpreserved intracameral lidocaine 1% during cataract surgery demonstrated a reduction in intraoperative fentanyl requirements. Surgeons performing cataract surgery under topical anaesthesia should consider the addition of intracameral lidocaine 1% to decrease fentanyl requirements and improve patient safety and comfort.	[Ho, Adelyn L.] Univ British Columbia, Sch Med, Vancouver, BC V5Z 1M9, Canada; [Zakrzewski, Peter A.] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada; [Braga-Mele, Rosa] Univ Toronto, Dept Ophthalmol, Kensington Eye Inst, Toronto, ON M5S 1A1, Canada	Braga-Mele, R (reprint author), 200-245 Danforth Ave, Toronto, ON M4K 1N2, Canada.	rbragamele@rogers.com			Kensington Research Institute for Statistical Analysis	This Study was supported by the Kensington Research Institute for Statistical Analysis.	Akgul A, 2007, AGRI, V19, P39; Anders N, 1999, OPHTHALMOLOGY, V106, P1863, DOI 10.1016/S0161-6420(99)90394-9; Aydin ON, 2004, J CLIN ANESTH, V16, P98, DOI 10.1016/j.jclinane.2003.05.008; Aydin ON, 2002, J CATARACT REFR SURG, V28, P1968, DOI 10.1016/S0886-3350(02)01429-3; Bardocci A, 2003, OPHTHALMOLOGY, V110, P144, DOI 10.1016/S0161-6420(02)01562-2; Biswas S, 1999, EYE, V13, P537, DOI 10.1038/eye.1999.133; Boulton JE, 2000, OPHTHALMOLOGY, V107, P68, DOI 10.1016/S0161-6420(99)00016-0; Carino NS, 1998, J CATARACT REFR SURG, V24, P1602, DOI 10.1016/S0886-3350(98)80350-7; CHERNY NI, 1994, TXB PAIN, P1437; Crandall AS, 1999, OPHTHALMOLOGY, V106, P60, DOI 10.1016/S0161-6420(99)90007-6; DAVIS DB, 1994, J CATARACT REFR SURG, V20, P327, DOI 10.1016/S0886-3350(13)80586-X; Dinsmore SC, 1996, OPHTHALMIC SURG LAS, V27, P935; DUNDEE JW, 1984, DRUGS, V28, P519, DOI 10.2165/00003495-198428060-00002; EDMONDSSEAL J, 1988, ANAESTHESIA, V43, P603, DOI 10.1111/j.1365-2044.1988.tb06707.x; Ezra DG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005276.pub2; FICHMAN RA, 1992, OCULAR SURG NEWS, V3, P20; FITZGIBBON DR, 2001, BONICAS MANAGEMENT P, P623; FUKASAKU H, 1994, J CATARACT REFR SURG, V20, P468, DOI 10.1016/S0886-3350(13)80186-1; Habib NE, 2004, J CATARACT REFR SURG, V30, P437, DOI 10.1016/S0886-3350(03)00557-1; Harman DM, 2000, J CATARACT REFR SURG, V26, P109, DOI 10.1016/S0886-3350(99)00330-2; Hasan SA, 2001, SURV OPHTHALMOL, V46, P178, DOI 10.1016/S0039-6257(01)00248-X; Inan UU, 2003, J CATARACT REFR SURG, V29, P1137, DOI 10.1016/S0886-3350(02)02053-9; Karp CL, 2001, OPHTHALMOLOGY, V108, P1704, DOI 10.1016/S0161-6420(01)00793-X; KLEINMAN RE, 2008, WALKERS PEDIAT GASTR, P1263; Leaming DV, 2000, J CATARACT REFR SURG, V26, P913, DOI 10.1016/S0886-3350(00)00469-7; MURPHY MR, 1989, CLIN ANESTH, P255; Nielsen PJ, 1998, J CATARACT REFR SURG, V24, P1136, DOI 10.1016/S0886-3350(98)80110-7; Pandey SK, 2001, J CATARACT REFR SURG, V27, P1643, DOI 10.1016/S0886-3350(01)00793-3; Patel BCK, 1998, J CATARACT REFR SURG, V24, P853, DOI 10.1016/S0886-3350(98)80143-0; Patel BCK, 1996, OPHTHALMOLOGY, V103, P1196, DOI 10.1016/S0161-6420(96)30522-8; SIMON IB, 1991, AM SURGEON, V57, P219; Tseng SH, 1998, OPHTHALMOLOGY, V105, P2007, DOI 10.1016/S0161-6420(98)91116-2; WINE NA, 1966, AM J OPHTHALMOL, V61, P456, DOI 10.1016/0002-9394(66)91051-8; WONG DHW, 1993, CAN J ANAESTH, V40, P635, DOI 10.1007/BF03009701	34	8	8	0	0	CANADIAN OPHTHAL SOC	OTTAWA	1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA	0008-4182	1715-3360		CAN J OPHTHALMOL	Can. J. Opthalmol.-J. Can. Opthalmol.	FEB	2010	45	1					52	57		10.3129/i09-204			6	Ophthalmology	Ophthalmology	558YD	WOS:000274783900010	20130711				2020-06-30	J	Basagan-Mogol, E; Goren, S; Korfali, G; Turker, G; Kaya, FN				Basagan-Mogol, Elif; Goren, Suna; Korfali, Gulsen; Turker, Gurkan; Kaya, Fatma Nur			INDUCTION OF ANESTHESIA IN CORONARY ARTERY BYPASS GRAFT SURGERY: THE HEMODYNAMIC AND ANALGESIC EFFECTS OF KETAMINE	CLINICS			English	Article						Coronary artery bypass grafting; Ketamine; Propofol; Fentanyl; Midazolam	CARDIAC SURGICAL PATIENTS; PROPOFOL; MIDAZOLAM; DIAZEPAM	OBJECTIVE: The aim of this prospective, randomized study was to evaluate the hemodynamic and analgesic effects of ketamine by comparing it with propofol starting at the induction of anesthesia until the end of sternotomy in patients undergoing coronary artery bypass grafting surgery. INTRODUCTION: Anesthetic induction and maintenance may induce myocardial ischemia in patients with coronary artery disease. A primary goal in the anesthesia of patients undergoing coronary artery bypass grafting surgery is both the attenuation of sympathetic responses to noxious stimuli and the prevention of hypotension. METHODS: Thirty patients undergoing coronary artery bypass grafting surgery were randomized to receive either ketamine 2 mg.kg(-1) (Group K) or propofol 0.5 mg.kg(-1) (Group P) during induction of anesthesia. Patients also received standardized doses of midazolam, fentanyl, and rocuronium in the induction sequence. The duration of anesthesia from induction to skin incision and sternotomy, as well as the supplemental doses of fentanyl and sevoflurane, were recorded. Heart rate, mean arterial pressure, central venous pressure, pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac index, systemic and pulmonary vascular resistance indices, stroke work index, and left and right ventricular stroke work indices were obtained before induction of anesthesia; one minute after induction; one, three, five, and ten minutes after intubation; one minute after skin incision; and at one minute after sternotomy. RESULTS: There were significant changes in the measured and calculated hemodynamic variables when compared to their values before induction. One minute after induction, mean arterial pressure and the systemic vascular resistance index decreased significantly in group P (p<0.01). CONCLUSION: There were no differences between groups in the consumption of sevoflurane or in the use of additional fentanyl. The combination of ketamine, midazolam, and fentanyl for the induction of anesthesia provided better hemodynamic stability during induction and until the end of sternotomy in patients undergoing coronary artery bypass grafting surgery.	[Basagan-Mogol, Elif; Goren, Suna; Korfali, Gulsen; Turker, Gurkan; Kaya, Fatma Nur] Uludag Univ, Sch Med, Dept Anesthesiol & Reanimat, Bursa, Turkey	Basagan-Mogol, E (reprint author), Uludag Univ, Sch Med, Dept Anesthesiol & Reanimat, Bursa, Turkey.	basagan@uludag.edu.tr		TURKER, YUNUS GURKAN/0000-0002-3019-581X			Basar H, 2003, EUR J ANAESTH, V20, P396; Bazaral M G, 1992, J Cardiothorac Vasc Anesth, V6, P248, DOI 10.1016/1053-0770(92)90209-P; BELL J, 1994, BRIT J ANAESTH, V73, P162, DOI 10.1093/bja/73.2.162; BONDY RJ, 1994, CARDIAC ANESTHESIA P, P221; Gomez M N, 1992, J Cardiothorac Vasc Anesth, V6, P245, DOI 10.1016/1053-0770(92)90208-O; GORDON AR, 1990, CAN J ANAESTH, V37, P43; Gordon P C, 1994, J Cardiothorac Vasc Anesth, V8, P284, DOI 10.1016/1053-0770(94)90239-9; JACKSON APF, 1978, BRIT J ANAESTH, V50, P375, DOI 10.1093/bja/50.4.375; KUMAR SM, 1980, CLIN THER, V3, P43; Lehmann A, 2000, J CARDIOTHOR VASC AN, V14, P416, DOI 10.1053/jcan.2000.7945; MANARA AR, 1991, BRIT J ANAESTH, V66, P716, DOI 10.1093/bja/66.6.716; MARLOW R, 1991, CAN J ANAESTH, V38, P844, DOI 10.1007/BF03036958; MOFFITT EA, 1968, ANESTHESIOLOGY, V29, P1181, DOI 10.1097/00000542-196811000-00016; Pavlin DJ, 2001, ANESTH ANALG, V93, P613, DOI 10.1097/00000539-200109000-00017; RAZA SMA, 1989, CAN J ANAESTH, V36, P617, DOI 10.1007/BF03005410; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; REVES J.G., 2000, ANESTHESIA, P228; SCHULTESASSE U, 1982, ANASTH INTENSIV NOTF, V17, P195, DOI 10.1055/s-2007-1003878; SPOTOFT H, 1979, CAN ANAESTH SOC J, V26, P463, DOI 10.1007/BF03006157	19	13	14	0	0	HOSPITAL CLINICAS, UNIV SAO PAULO	SAO PAULO	FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL	1807-5932			CLINICS	Clinics	FEB	2010	65	2					133	138		10.1590/S1807-59322010000200003			6	Medicine, General & Internal	General & Internal Medicine	567CX	WOS:000275421000003	20186295	DOAJ Gold, Green Published			2020-06-30	J	Crellin, D; Ling, RX; Babl, FE				Crellin, Dianne; Ling, Rong Xiu; Babl, Franz E.			Does the standard intravenous solution of fentanyl (50 mu g/mL) administered intranasally have analgesic efficacy?	EMERGENCY MEDICINE AUSTRALASIA			English	Article						analgesia; child; emergency department; fentanyl; intranasal; pain	EMERGENCY-DEPARTMENT; PAIN; MORPHINE; CHILDREN; SEVERITY; TRIAL	Background: Intranasal (IN) fentanyl provides rapid and powerful non-parenteral analgesia in the ED. A concentrated solution of fentanyl (300 mu g/mL) has been used in prior trials, yet many ED use the standard solution at a concentration of 50 mu g/mL, which is widely available and of low cost. We set out to determine if this lower concentration of fentanyl is also efficacious. Methods: Prospective audit in children aged 5-18 years presenting with upper limb injuries. Patients received IN fentanyl (50 mu g/mL) at 1.5 mu g/kg. Patient assessed pain scores were collected 5, 10, 20, 30 and 60 min following IN fentanyl administration using a visual analogue scale or Bieri Faces - Revised scale. Parental scores were used if patients were unable to provide a score. Results: Of the 59 eligible patients, 36 were enrolled; median age was 6.8 years (range 5-15 years), and 89% (32/36) ultimately required fracture reduction. Median first dose of IN fentanyl was 1.4 mu g/kg. Median pain scores dropped from 7 (interquartile range 5-10) pre-fentanyl to 5 (interquartile range 4-8) at 5 min and 2 (interquartile range 1-4) at 30 and 60 min. A total of 21 (58%) children did not require further analgesia in the ED. There were no adverse events. Conclusions: Standard i.v. concentration IN fentanyl (50 mu g/mL) appears to have analgesic efficacy in children with upper limb injuries.	[Crellin, Dianne] Univ Melbourne, Emergency Dept, Royal Childrens Hosp, Parkville, Vic 3055, Australia; [Crellin, Dianne; Babl, Franz E.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Crellin, D (reprint author), Univ Melbourne, Emergency Dept, Royal Childrens Hosp, Parkville, Vic 3055, Australia.	dianne.crellin@rch.org.au					BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; Bolt P, 2008, ARCH DIS CHILD, V93, P40, DOI 10.1136/adc.2006.110429; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Chambers CT, 1998, CLIN J PAIN, V14, P336, DOI 10.1097/00002508-199812000-00011; Herd D, 2009, EMERG MED AUSTRALAS, V21, P335, DOI 10.1111/j.1742-6723.2009.01207.x; LIM S, 2003, J PHARM PRACT RES, V59; Maciocia PM, 2003, EUR J EMERG MED, V10, P264, DOI 10.1097/00063110-200312000-00004; Powell CV, 2001, ANN EMERG MED, V37, P28; Singer AJ, 2002, ACAD EMERG MED, V9, P609, DOI 10.1111/j.1553-2712.2002.tb02298.x	12	42	42	1	4	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1742-6731			EMERG MED AUSTRALAS	Emerg. Med. Australas.	FEB	2010	22	1					62	67		10.1111/j.1742-6723.2010.01257.x			6	Emergency Medicine	Emergency Medicine	554BA	WOS:000274409300009	20152004				2020-06-30	J	Thangaswamy, CR; Rewari, V; Trikha, A; Dehran, M; Chandralekha				Thangaswamy, Chitra Rajeswari; Rewari, Vimi; Trikha, Anjan; Dehran, Maya; Chandralekha			Dexamethasone before total laparoscopic hysterectomy: a randomized controlled dose-response study	JOURNAL OF ANESTHESIA			English	Article						Dexamethasone; Analgesia, postoperative; Hysterectomy, laparoscopic	POSTOPERATIVE NAUSEA; ANALGESIC REQUIREMENTS; ANTIEMETIC EFFICACY; PAIN; REDUCTION; SURGERY; METHYLPREDNISOLONE; ONDANSETRON; CHOLECYSTECTOMY; DISCHARGE	A prospective, randomized, double blind, placebo-controlled study was undertaken to evaluate the efficacy of a single preoperative dose of dexamethasone, in different dosages, in providing postoperative analgesia in patients undergoing total laparoscopic hysterectomy (TLH). The study included 55 patients randomly divided into three groups. Patients in Groups P, D4, and D8 received saline, 4, and 8 mg dexamethasone, respectively, intravenously, 2 h before induction. The time to first analgesic requirement was significantly delayed in patients in the D8 group compared with the D4 group (P = 0.01) and placebo (P = 0.01). Total postoperative fentanyl consumption was significantly less in patients in the D8 group compared with the D4 group (P = 0.01) and placebo (P = 0.01). Use of 8 mg dexamethasone resulted in a 99.3 mcg decrease in total 24-h fentanyl consumption. Postoperative nausea and vomiting (PONV) was significantly less in the D8 group with a complete response rate (no emetic episodes and no rescue medication for 24 h) of 36.8% compared with the placebo group in which all the patients had PONV. No adverse effects were observed in any group. Dexamethasone at a dose of 8 mg given intravenously 2 h before induction, delays patient request for analgesia and reduces total fentanyl consumption and PONV in patients undergoing TLH.	[Thangaswamy, Chitra Rajeswari; Rewari, Vimi; Trikha, Anjan; Dehran, Maya; Chandralekha] All India Inst Med Sci, Dept Anaesthesiol & Intens Care, New Delhi 110029, India	Rewari, V (reprint author), K-25,Jangpura Extn, New Delhi 110014, India.	vimirewari@gmail.com			institutional sources	This work was supported by institutional sources only.	Afman CE, 2006, OTOLARYNG HEAD NECK, V134, P181, DOI 10.1016/j.otohns.2005.11.010; AHO MS, 1991, ANESTH ANALG, V73, P112; Alexander JI, 1997, BRIT J ANAESTH, V79, P369, DOI 10.1093/bja/79.3.369; Aminmansour B, 2006, SPINE, V31, P2415, DOI 10.1097/01.brs.0000238668.49035.19; Bisgaard T, 2003, ANN SURG, V238, P651, DOI 10.1097/01.sla.0000094390.82352.cb; BODNER M, 1991, ANESTH ANALG, V73, P250; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; Callery MP, 2003, ANN SURG, V238, P661, DOI 10.1097/01.sla.0000094391.39418.8e; Coloma M, 2001, ANESTH ANALG, V92, P85; de Lapasse C, 2008, J MINIM INVAS GYN, V15, P20, DOI 10.1016/j.jmig.2007.08.608; DING YF, 1992, ANESTH ANALG, V75, P566; Elhakim M, 2003, CAN J ANAESTH, V50, P392, DOI 10.1007/BF03021038; Ferreira SH, 1997, BRIT J PHARMACOL, V121, P883, DOI 10.1038/sj.bjp.0701211; Fujii Y, 2008, INT J GYNECOL OBSTET, V100, P27, DOI 10.1016/j.ijgo.2007.07.017; Fujii Y, 2007, OTOLARYNG HEAD NECK, V136, P274, DOI 10.1016/j.otohns.2006.09.013; HARGREAVES KM, 1990, CLIN PHARMACOL THER, V48, P168, DOI 10.1038/clpt.1990.132; HAYNES R, 2001, GOODMAN GILMANS PHAR, P1466; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6; HONG D, 1993, PAIN, V55, P171, DOI 10.1016/0304-3959(93)90146-G; Huang JC, 2001, CAN J ANAESTH, V48, P973, DOI 10.1007/BF03016586; KAHN BS, 2008, J MINIM INVAS GYN, V15, pS21; Karanicolas PJ, 2008, ANN SURG, V248, P751, DOI 10.1097/SLA.0b013e3181856024; Kluivers KB, 2008, EUR J OBSTET GYN R B, V136, P3, DOI 10.1016/j.ejogrb.2007.06.004; Li HQ, 2007, ANESTHESIOLOGY, V107, P469, DOI 10.1097/01.anes.0000278907.37774.8d; Numazaki M, 2005, J CLIN ANESTH, V17, P182, DOI 10.1016/j.jclinane.2004.06.018; Pace MC, 2008, ANN NY ACAD SCI, V1127, P147, DOI 10.1196/annals.1434.019; RAPHAEL JH, 1993, BRIT J ANAESTH, V71, P845, DOI 10.1093/bja/71.6.845; Romundstad L, 2006, ANESTH ANALG, V102, P418, DOI 10.1213/01.ane.0000194358.46119.e1; Romundstad L, 2004, ACTA ANAESTH SCAND, V48, P1223, DOI 10.1111/j.1399-6576.2004.00480.x; Sauerland S, 2000, DRUG SAFETY, V23, P449, DOI 10.2165/00002018-200023050-00007; SKJELBRED P, 1982, EUR J CLIN PHARMACOL, V21, P391, DOI 10.1007/BF00542325; Sniadach MS, 1997, ANESTH ANALG, V85, P797, DOI 10.1097/00000539-199710000-00015; Thiel J, 2003, J AM ASSOC GYN LAP, V10, P481, DOI 10.1016/S1074-3804(05)60149-1; Wang JJ, 2000, BRIT J ANAESTH, V84, P459; WHEATLEY SA, 1994, BRIT J OBSTET GYNAEC, V101, P443, DOI 10.1111/j.1471-0528.1994.tb11920.x	36	33	34	1	5	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2010	24	1					24	30		10.1007/s00540-009-0830-8			7	Anesthesiology	Anesthesiology	552YW	WOS:000274332200005	20052502				2020-06-30	J	Perrey, S				Perrey, Stephane			PREDOMINANCE OF CENTRAL MOTOR COMMAND IN THE REGULATION OF EXERCISE	JOURNAL OF APPLIED PHYSIOLOGY			English	Letter									Univ Montpellier 1, F-34006 Montpellier, France	Perrey, S (reprint author), Univ Montpellier 1, F-34006 Montpellier, France.		perrey, stephane/B-7483-2008; , Home/X-9826-2019; Gandevia, Simon C/D-5009-2011; Taylor, Janet L/C-9667-2011; Smirmaul, Bruno P/H-3905-2012; Noakes, Tim/AAD-3162-2020; Millet, Gregoire/M-3220-2019; perrey, stephane/J-6744-2019; Kayser, Bengt/M-8643-2013	, Home/0000-0002-6956-9188; Gandevia, Simon C/0000-0002-1345-3821; Taylor, Janet L/0000-0001-8976-5162; Smirmaul, Bruno P/0000-0001-7612-3099; Noakes, Tim/0000-0001-7244-2375; Millet, Gregoire/0000-0001-8081-4423; perrey, stephane/0000-0002-8741-629X; Kayser, Bengt/0000-0002-9776-7501			Amann M, 2010, J APPL PHYSIOL, V108, P452, DOI 10.1152/japplphysiol.00976.2009; GANDEVIA SC, 1978, J PHYSIOL-LONDON, V283, P493; Lafargue G, 2003, EUR J NEUROSCI, V17, P2741, DOI 10.1046/j.1460-9568.2003.02700.x; Marcora S, 2010, J APPL PHYSIOL, V108, P454, DOI 10.1152/japplphysiol.00976.2009a; Sarter M, 2006, BRAIN RES REV, V51, P145, DOI 10.1016/j.brainresrev.2005.11.002; Todd G, 2005, J PHYSIOL-LONDON, V563, P621, DOI 10.1113/jphysiol.2004.077115	6	9	9	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	FEB	2010	108	2					458	458		10.1152/japplphysiol.01388.2009			1	Physiology; Sport Sciences	Physiology; Sport Sciences	550VI	WOS:000274158300033	20118350				2020-06-30	J	Han, JI; Lee, H; Kim, CH; Lee, GY				Han, Jong In; Lee, Heeseung; Kim, Chi Hyo; Lee, Guie Yong			The frequency of fentanyl-induced cough in children and its effects on tracheal intubation	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Anesthesia, pediatric; Coughing; Fentanyl; Intubation, intratracheal; Pediatrics	PROLONGED INJECTION TIME; INTRAVENOUS LIDOCAINE; HEMODYNAMIC-RESPONSE; DOSE FENTANYL; BOLUS	Study Objective: To determine if fentanyl-induced cough was dose-dependent in children and whether it could affect tracheal intubation. Design: Prospective, randomized, double-blinded study. Setting: Operating room of a university-affiliated hospital. Patients: 160 ASA physical status I pediatric patients, aged two to 14 years, scheduled for elective surgery during general anesthesia and requiring orotracheal intubation. Interventions: Patients were divided into two groups. Group 1 patients were given fentanyl at a dosage of one mu g/kg; Group 2 patients received two mu g/kg of fentanyl. Induction of anesthesia was conducted immediately following cough cessation or one minute after the end of injection with propofol 2.5 mg/kg. At loss of eyelash reflex, rocuronium 0.6 mg/kg was given intravenously (IV). Two minutes later, tracheal intubation was started. Measurements: Onset and degree of cough and intubating conditions were observed and recorded. Main Results: No statistically significant differences in frequency of coughing or in intubating conditions between the two groups were noted. Cough severity in Group 1 was statistically lower than that of Group 2 (P < 0.05). Onset of cough in Group 2 (12.2 +/- 3.4 sec) was statistically shorter than in Group 1 (16.9 +/- 7.6 sec, P < 0.05). Conclusion: Fentanyl at doses of one and two mu g/kg may induce coughing in pediatric patients. (C) 2010 Elsevier Inc. All rights reserved.	[Han, Jong In; Lee, Heeseung; Kim, Chi Hyo; Lee, Guie Yong] Ewha Womans Univ, Dept Anesthesiol & Pain Med, Sch Med, Seoul 158710, South Korea	Han, JI (reprint author), Ewha Womans Univ, Dept Anesthesiol & Pain Med, Mokdong Hosp, Seoul 158710, South Korea.	hanji@ewha.ac.kr					Adachi YU, 2002, ANESTH ANALG, V95, P233, DOI 10.1097/00000539-200207000-00043; Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; CHUNG F, 1985, CAN ANAESTH SOC J, V32, P622, DOI 10.1007/BF03011409; Han JI, 1996, KOREAN J ANESTHESIOL, V31, P462; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; REITAN JA, 1978, ANESTH ANALG, V57, P31; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	17	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	FEB	2010	22	1					3	6		10.1016/j.jclinane.2009.01.019			4	Anesthesiology	Anesthesiology	584WH	WOS:000276783800002	20206844				2020-06-30	J	Hong, JY; Jee, YS; Jeong, HJ; Song, Y; Kil, HK				Hong, Jeong-Yeon; Jee, Young Seok; Jeong, Hyeong Jun; Song, Young; Kil, Hae Keum			Effects of Epidural Fentanyl on Speed and Quality of Block for Emergency Cesarean Section in Extending Continuous Epidural Labor Analgesia Using Ropivacaine and Fentanyl	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						Cesarean Section; Epidural Fentanyl; Labor Analgesia	TOUCH SENSATION; SENSORY BLOCK; ANESTHESIA; BUPIVACAINE; LIDOCAINE; MORPHINE; RAT	We performed a prospective, randomized, and double-blind study comparing the top-up effects of 2% lidocaine/100 mu g fentanyl/epinephrine (n=31) and 2% lidocaine/saline/epinephrine (n=30) when extending an epidural labor analgesia using low-dose ropivacaine and fentanyl. Survival analysis for the sensory blocks to the T4 level showed no statistically significant differences in onset time to T4 between the 2 groups. Onset times (min) to T4-sensory blocks for cold and pinprick were not different between the two groups. However, median maximum sensory level in the lidocaine-fentanyl group (T1 for cold and T2 for pinprick) was significantly higher than that in the lidocaine-saline group (T3 and T4, respectively). The lidocaine-fentanyl group exhibited less visceral pain (6.5% vs. 36.7%), less supplementation of lidocaine (6.5% vs. 43.3%), and less nausea (6.5% vs. 26.7%) compared with the lidocaine-saline group during the intraoperative period. It is concluded that adding fentanyl to 2% lidocaine does not speed up the onset of the block when the onset is tested with cold or sharp pinprick but improves the quality of analgesia with fewer side effects in emergency top-up for cesarean section.	[Hong, Jeong-Yeon; Jeong, Hyeong Jun; Song, Young; Kil, Hae Keum] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea; [Jee, Young Seok] Kwangdong Univ, Coll Med, Dept Anesthesiol & Pain Med, Cheil Gen Hosp,Womens Hlth Care Ctr, Seoul, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Severance Hosp, 262 Seongsan Ro, Seoul 120752, South Korea.	jenyhongg@hanmail.net					Balaji P, 2009, INT J OBSTET ANESTH, V18, P335, DOI 10.1016/j.ijoa.2009.03.011; Camorcia M, 2006, EUR J ANAESTH, V23, P611, DOI 10.1017/S0265021506000421; Cherng CH, 2001, REGION ANESTH PAIN M, V26, P523, DOI 10.1053/rapm.2001.27852; Collier C, 2005, INT J OBSTET ANESTH, V14, P82, DOI 10.1016/j.ijoa.2004.09.005; CURATOLO M, 1994, ACTA ANAESTH SCAND, V38, P646, DOI 10.1111/j.1399-6576.1994.tb03971.x; Dahlgren G, 2006, INT J OBSTET ANESTH, V15, P298, DOI 10.1016/j.ijoa.2006.06.007; Dallel R, 1998, J NEUROSCI, V18, P3529; Dhileepan S, 2007, INT J OBSTET ANESTH, V16, P192, DOI 10.1016/j.ijoa.2006.11.011; Gaiser R R, 1994, Int J Obstet Anesth, V3, P208, DOI 10.1016/0959-289X(94)90070-1; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; Goring-Morris J, 2006, INT J OBSTET ANESTH, V15, P109, DOI 10.1016/j.ijoa.2005.11.005; HARADA Y, 1995, ANESTHESIOLOGY, V83, P336, DOI 10.1097/00000542-199508000-00014; HIRABAYASHI Y, 1995, BRIT J ANAESTH, V75, P266, DOI 10.1093/bja/75.3.266; HOLDCROFT A, 2000, PRINCIPLES PRACTICE, V261; LAISHLEY RS, 1988, BRIT J ANAESTH, V60, P180, DOI 10.1093/bja/60.2.180; Lam DTC, 2001, ANAESTHESIA, V56, P790; Levy DM, 2006, ANAESTHESIA, V61, P786, DOI 10.1111/j.1365-2044.2006.04711.x; Lucas DN, 2000, J ROY SOC MED, V93, P346, DOI 10.1177/014107680009300703; Ma DQ, 1998, ANESTH ANALG, V87, P211, DOI 10.1097/00000539-199807000-00043; Malhotra S, 2007, ANAESTHESIA, V62, P667, DOI 10.1111/j.1365-2044.2007.05096.x; MCFADZEAN I, 1988, NEUROPEPTIDES, V11, P173, DOI 10.1016/0143-4179(88)90072-8; MORGAN B, 1990, ANAESTHESIA, V45, P148, DOI 10.1111/j.1365-2044.1990.tb14284.x; NORTH RA, 1985, J PHYSIOL-LONDON, V364, P265, DOI 10.1113/jphysiol.1985.sp015743; POWER I, 1991, REGION ANESTH, V16, P204; Price M L, 1991, Int J Obstet Anesth, V1, P13, DOI 10.1016/0959-289X(91)90024-K; REYNOLDS F, 1990, ANAESTHESIA, V45, P120, DOI 10.1111/j.1365-2044.1990.tb14275.x; Tortosa JC, 2003, BRIT J ANAESTH, V91, P532, DOI 10.1093/bja/aeg214; Wee MYK, 2005, INT J OBSTET ANESTH, V14, P147, DOI 10.1016/j.ijoa.2004.09.008; Yentis SM, 2003, INT J OBSTET ANESTH, V12, P246, DOI 10.1016/S0959-289X(03)00009-8; YENTIS SM, 2001, ANALGESIA ANAESTHESI, V92	30	8	9	0	2	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	FEB	2010	25	2					287	292		10.3346/jkms.2010.25.2.287			6	Medicine, General & Internal	General & Internal Medicine	554CP	WOS:000274413400016	20119585	DOAJ Gold, Green Published			2020-06-30	J	Eventov-Friedman, S; Rozin, I; Shinwell, ES				Eventov-Friedman, S.; Rozin, I.; Shinwell, E. S.			Case of chest-wall rigidity in a preterm infant caused by prenatal fentanyl administration	JOURNAL OF PERINATOLOGY			English	Article						fentanyl; placental transfer; chest-wall rigidity; preterm infant; lung compliance	MUSCLE RIGIDITY; PHARMACOKINETICS; AGE	The inability to appropriately ventilate neonates shortly after their birth could be related in rare cases to chest-wall rigidity caused by the placental transfer of fentanyl. Although this adverse effect is recognized when fentanyl is administered to neonates after their birth, the prenatal phenomenon is less known. Treatment with either naloxone or muscle relaxants reverses the fentanyl effect and may prevent unnecessary excessive ventilatory settings. Journal of Perinatology (2010) 30, 149-150; doi: 10.1038/jp.2009.66	[Eventov-Friedman, S.; Rozin, I.; Shinwell, E. S.] Kaplan Med Ctr, Dept Neonatol, IL-76100 Rehovot, Israel; [Eventov-Friedman, S.; Rozin, I.; Shinwell, E. S.] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel	Shinwell, ES (reprint author), Kaplan Med Ctr, Dept Neonatol, POB 1, IL-76100 Rehovot, Israel.	eric_s@clalit.org.il					Bolisetty S, 1999, INTENS CARE MED, V25, P1337, DOI 10.1007/s001340051074; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; Giroux M, 1997, BIOL NEONATE, V72, P133; Lindemann R, 1998, EUR J PEDIATR, V157, P1012, DOI 10.1007/s004310050988; Moises ECD, 2005, EUR J CLIN PHARMACOL, V61, P517, DOI 10.1007/s00228-005-0967-9; Nikkola E M, 2000, J Clin Monit Comput, V16, P597, DOI 10.1023/A:1012268617009; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; TURSKI L, 1982, LIFE SCI, V31, P2327, DOI 10.1016/0024-3205(82)90148-5	9	5	5	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	FEB	2010	30	2					149	150		10.1038/jp.2009.66			2	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	549VT	WOS:000274083100014	20118943	Green Published, Other Gold			2020-06-30	J	KuKanich, B; Hubin, M				KuKanich, B.; Hubin, M.			The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							P-GLYCOPROTEIN; BEAGLE DOGS; GREYHOUNDS; PHARMACODYNAMICS; INHIBITION; ENFLURANE; TRANSPORT; INFUSION; DISEASES; UPDATE	Ketoconazole inhibits the Cytochrome P450 3A12 (CYP3A12) metabolizing enzyme as well as the p-glycoprotein efflux pump. The extent and clinical consequence of these effects are poorly understood in dogs. The objective was to assess the pharmacokinetics of ketoconazole after single and multiple doses and the effect of multiple doses of ketoconazole on midazolam (a known CYP3A12 substrate) and the opioid fentanyl. Six greyhound dogs were studied. The study consisted of three phases. Phase 1 consisted of i.v. midazolam (0.23 mg/kg base) and fentanyl (15.71 mu g/kg base). Phase 2 consisted of a single oral dose of ketoconazole (mean dose 12.34 mg/kg). Phase 3 consisted of i.v. midazolam (0.23 mg/kg) and fentanyl (10 mu g/kg) after 5 days of oral ketoconazole (12.25 mg/kg/day). Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3. Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h. The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h. The MRT was the most robust estimate of decreased drug elimination.	[KuKanich, B.; Hubin, M.] Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA	KuKanich, B (reprint author), Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, 228 Coles Hall, Manhattan, KS 66506 USA.	kukanich@ksu.edu	KuKanich, Butch/A-7911-2008		Kansas State University; College of Veterinary Medicine at Kansas State University; Department of Anatomy and Physiology at Kansas State University; Analytical Pharmacology Laboratory at Kansas State University; Developing Scholars Program at Kansas State University	The authors would like to thank Bryan Meyer and the Department of Animal Resources for their assistance with the study. The authors would also like to thank Kansas State University, the College of Veterinary Medicine at Kansas State University, the Department of Anatomy and Physiology at Kansas State University, the Analytical Pharmacology Laboratory at Kansas State University, and the Developing Scholars Program at Kansas State University for their financial support of the study.	BAXTER JG, 1986, J PHARM SCI, V75, P443, DOI 10.1002/jps.2600750504; BROWN SA, 1993, J VET PHARMACOL THER, V16, P419, DOI 10.1111/j.1365-2885.1993.tb00207.x; COURT MH, 1992, J VET PHARMACOL THER, V15, P343, DOI 10.1111/j.1365-2885.1992.tb01026.x; DANESHMEND TK, 1983, J ANTIMICROB CHEMOTH, V12, P185, DOI 10.1093/jac/12.2.185; DMELLO A, 1989, RES COMMUN CHEM PATH, V64, P441; Fan Y, 2008, XENOBIOTICA, V38, P107, DOI 10.1080/00498250701744625 ; Grooters AM, 2003, VET CLIN N AM-SMALL, V33, P749, DOI 10.1016/S0195-5616(03)00038-X; HALL RI, 1988, J PHARMACOKINET BIOP, V16, P251, DOI 10.1007/BF01062136; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; Hugnet C, 2007, J PHARM PHARM SCI, V10, P311; Kerl ME, 2003, VET CLIN N AM-SMALL, V33, P721, DOI 10.1016/S0195-5616(03)00035-4; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; KuKanich B, 2005, J VET PHARMACOL THER, V28, P461, DOI 10.1111/j.1365-2885.2005.00681.x; KuKanich B, 2008, AM J VET RES, V69, P664, DOI 10.2460/ajvr.69.5.664; Kuroha M, 2004, J VET PHARMACOL THER, V27, P355, DOI 10.1111/j.1365-2885.2004.00610.x; Kuroha M, 2002, J PHARM SCI, V91, P868, DOI 10.1002/jps.10086; Kuroha M, 2002, DRUG METAB DISPOS, V30, P63, DOI 10.1124/dmd.30.1.63; Lu P, 2005, J PHARMACOL EXP THER, V313, P518, DOI 10.1124/jpet.104.077651; Mealey KL, 2004, J VET PHARMACOL THER, V27, P257, DOI 10.1111/j.1365-2885.2004.00607.x; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; MYRE SA, 1991, PHARMACOLOGY, V43, P233, DOI 10.1159/000138850; Negre A, 2009, VET DERMATOL, V20, P1, DOI 10.1111/j.1365-3164.2008.00721.x; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Peano A., 2008, Parassitologia (Rome), V50, P85; Riviere J. E., 2009, VET PHARM THERAPEUTI, P47; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; SAMS RA, 1985, AM J VET RES, V46, P1677; SAMS RA, 1988, AM J VET RES, V49, P245; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Taub ME, 2005, DRUG METAB DISPOS, V33, P1679, DOI 10.1124/dmd.105.005421; Vertzoni MV, 2006, J CHROMATOGR B, V839, P62, DOI 10.1016/j.jchromb.2006.03.010	32	7	7	0	4	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	FEB	2010	33	1					42	49		10.1111/j.1365-2885.2009.01105.x			8	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	543RK	WOS:000273595800007	20444024				2020-06-30	J	Burne, THJ; Johnston, ANB; Wilkinson, LS; Kendrick, KM				Burne, T. H. J.; Johnston, A. N. B.; Wilkinson, L. S.; Kendrick, K. M.			Effects of anesthetic agents on socially transmitted olfactory memories in mice	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Olfactory learning; Food neophobia; Non-spatial relational memory	RATS RATTUS-NORVEGICUS; FOOD PREFERENCE; RECEPTOR; AVERSION; TRANSMISSION; ODOR; TASK; FEAR; SYSTEM; IMPAIR	Mice can learn a food preference from odor cues transmitted on the breath of a conspecific, even if the "demonstrator" is anesthetized. To our knowledge there are no studies examining the effect of anesthetizing the "observer" on development of memory for socially transmitted food preferences (STFP). In Experiment 1 we found that 2-4 month-old F2 C57Bl/6x129sv male and female mice demonstrated a STFP after a 5 min exposure to an anesthetized demonstrator mouse when tested 24 h later. In Experiment 2, observer mice anesthetized with Sagatal (60 mg/kg) prior to the "social interaction" preferentially avoided the cued food when tested 24 h later. This aversion was not due to any overt aversive effects of this dose of Sagatal because mice that ate the food and were then anesthetized, or could only smell the food for 5 min while anesthetized, showed no preference or aversion. In a third experiment we found that the Sagatal-induced aversion was not a general property of anesthesia because there were varied results produced by observer mice treated with anesthetic drugs with different mechanisms of action. Vetalar (200 mg/kg) and Rompun (10 mg/kg) treated animals ate similar amounts of cued and non-cued food at test, indicating an absence of learning. Hypnorm (0.5 ml/kg) treated animals showed a preference for the cued food whereas those treated with Hypnovel (2.5 ml/kg) showed an aversion to the cued food. These results show that the food aversion observed with Sagatal is not a general property of anesthetic agents, but appears to be restricted to those acting primarily on the GABAergic system. Thus, we have shown that under certain conditions it is possible for an anesthetized observer mouse to learn a preference or aversion of a socially-linked olfactory cue. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.	[Burne, T. H. J.; Wilkinson, L. S.; Kendrick, K. M.] Babraham Inst, Cambridge CB22 3AQ, England; [Burne, T. H. J.; Johnston, A. N. B.] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Nathan, Qld 4111, Australia	Burne, THJ (reprint author), Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.	t.burne@uq.edu.au	Burne, Thomas/C-5656-2009; Johnston, Amy N.B./B-2931-2010	Burne, Thomas/0000-0003-3502-9789; Johnston, Amy N.B./0000-0002-9979-997X; Kendrick, Keith/0000-0002-0371-5904	Biotechnology and Biological Sciences Research Council (BBSRC)Biotechnology and Biological Sciences Research Council (BBSRC); Medical Research CouncilMedical Research Council UK (MRC) [G0801418B]	This work was funded by a Biotechnology and Biological Sciences Research Council (BBSRC) GAIN initiative grant (to KMK and LSW).	AGUADO L, 1994, BEHAV NEURAL BIOL, V61, P271, DOI 10.1016/S0163-1047(05)80010-X; Albrecht E, 1997, PHARMACOL BIOCHEM BE, V58, P189, DOI 10.1016/S0091-3057(96)00480-7; Alvarez P, 2002, NEUROBIOL LEARN MEM, V78, P470, DOI 10.1006/nlme.2002.4068; Archer DP, 2007, ANESTH ANALG, V104, P840, DOI 10.1213/01.ane.0000256874.33810.3a; Ardayfio P, 2008, NEUROBIOL DIS, V31, P406, DOI 10.1016/j.nbd.2008.05.017; Best AR, 2004, J NEUROSCI, V24, P652, DOI 10.1523/JNEUROSCI.4220-03.2004; Boix-Trelis N, 2007, NEUROBIOL LEARN MEM, V87, P659, DOI 10.1016/j.nlm.2006.12.003; Burton S, 2000, J NEUROSCI, V20, P5468, DOI 10.1523/JNEUROSCI.20-14-05468.2000; CARBALLOMARQUEZ A, 2008, NEUROBIOLOGY LEARNIN; Choleris E, 1998, PHARMACOL BIOCHEM BE, V60, P575, DOI 10.1016/S0091-3057(98)00005-7; DIXON AK, 1982, PSYCHOPHARMACOLOGY, V77, P246, DOI 10.1007/BF00464575; Dutton RC, 2002, ANESTHESIOLOGY, V96, P1223, DOI 10.1097/00000542-200205000-00027; El Hassani AK, 2008, NEUROBIOL LEARN MEM, V90, P589, DOI 10.1016/j.nlm.2008.07.018; GALEF BG, 1988, PHYSIOL BEHAV, V42, P119, DOI 10.1016/0031-9384(88)90285-5; GALEF BG, 1986, J COMP PSYCHOL, V100, P432, DOI 10.1037/0735-7036.100.4.432; GALEF BG, 1994, J COMP PSYCHOL, V108, P266; GALEF BG, 1985, ANN NY ACAD SCI, V443, P203, DOI 10.1111/j.1749-6632.1985.tb27074.x; Galef BG, 2000, PSYCHON B REV, V7, P631, DOI 10.3758/BF03213000; GALEF BG, 1983, J COMP PSYCHOL, V97, P358, DOI 10.1037/0735-7036.97.4.358; Galef Jr B. G., 2003, CURRENT PROTOCOLS NE; Harley CW, 2006, LEARN MEMORY, V13, P8, DOI 10.1101/lm.62006; HEYES CM, 1994, BIOL REV, V69, P207, DOI 10.1111/j.1469-185X.1994.tb01506.x; HIKAMI K, 1990, J COMP PSYCHOL, V104, P233, DOI 10.1037/0735-7036.104.3.233; Hines RM, 2008, J NEUROSCI, V28, P6055, DOI 10.1523/JNEUROSCI.0032-08.2008; Johnston ANB, 1998, ANIM BEHAV, V56, P1347, DOI 10.1006/anbe.1998.0901; Kavaliers M, 2004, HORM BEHAV, V46, P272, DOI 10.1016/j.yhbeh.2004.03.005; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; LIU X, 2008, NATURE NEUROSCIENCE; Lupfer-Johnson G, 2007, BEHAV PROCESS, V74, P104, DOI 10.1016/j.beproc.2006.09.006; Moles A, 1999, BEHAV PROCESS, V44, P277, DOI 10.1016/S0376-6357(98)00031-X; Moreira EG, 2000, PHARMACOL BIOCHEM BE, V65, P7, DOI 10.1016/S0091-3057(99)00177-X; MOULY AM, 1995, BRAIN RES, V681, P47, DOI 10.1016/0006-8993(95)00280-4; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; Pang R, 1996, PHYSIOL BEHAV, V59, P873, DOI 10.1016/0031-9384(95)02137-X; Prescott MJ, 2005, AM J PRIMATOL, V65, P313, DOI 10.1002/ajp.20118; Roberts M, 2002, BEHAV NEUROSCI, V116, P1059, DOI 10.1037//0735-7044.116.6.1059; Ryan BC, 2008, BEHAV BRAIN RES, V193, P235, DOI 10.1016/j.bbr.2008.06.002; Sanchez-Andrade G, 2005, J REPROD DEVELOP, V51, P547, DOI 10.1262/jrd.17031; Sanchez-Andrade G, 2009, BEHAV BRAIN RES, V200, P323, DOI 10.1016/j.bbr.2008.12.021; Sokolic L, 2007, BEHAV NEUROSCI, V121, P527, DOI 10.1037/0735-7044.121.3.527; Sonner JM, 2005, ANESTH ANALG, V100, P1333, DOI 10.1213/01.ANE.0000148619.77117.C7; TICKU MK, 1992, EPILEPSY RES, P57; Valsecchi P, 1989, INT J COMP PSYCHOL, V2, P245; Veyrac A, 2007, LEARN MEMORY, V14, P847, DOI 10.1101/lm.708807; WEINBERGER NM, 1984, SCIENCE, V223, P605, DOI 10.1126/science.6695173; White TL, 2004, BRAIN RES, V1021, P1, DOI 10.1016/j.brainres.2004.05.114; Whitwam JG, 1995, ACTA ANAESTH SCAND, V39, P15, DOI 10.1111/j.1399-6576.1995.tb04375.x; Yamada K, 2000, BRAIN RES, V870, P20, DOI 10.1016/S0006-8993(00)02395-7; ZAHABY EM, 1994, ANESTHESIOLOGY, V81, P229; ZANGROSSI H, 1992, PHARMACOL BIOCHEM BE, V43, P1195, DOI 10.1016/0091-3057(92)90502-7	50	8	8	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	FEB	2010	93	2					268	274		10.1016/j.nlm.2009.10.007			7	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Behavioral Sciences; Neurosciences & Neurology; Psychology	565RO	WOS:000275312200016	19879368				2020-06-30	J	Nissen, P; Brassard, P; Jorgensen, TB; Secher, NH				Nissen, Peter; Brassard, Patrice; Jorgensen, Thomas B.; Secher, Niels H.			Phenylephrine but not Ephedrine Reduces Frontal Lobe Oxygenation Following Anesthesia-Induced Hypotension	NEUROCRITICAL CARE			English	Article						Cerebral autoregulation; Cardiac output; Arterial pressure; Near infrared spectroscopy; Drug effect	CEREBRAL-BLOOD-FLOW; NEAR-INFRARED SPECTROSCOPY; HYPOTHERMIC CARDIOPULMONARY BYPASS; ORTHOTOPIC LIVER-TRANSPLANTATION; CARDIAC-OUTPUT; ARTERIAL-PRESSURE; HUMANS; EXERCISE; BRAIN; AUTOREGULATION	Background Vasopressor agents are used to correct anesthesia-induced hypotension. We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (ScO2) following anesthesia-induced hypotension. Methods Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (ScO2) were registered. Results Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in ScO2. After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD). However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in ScO2 (P < 0.05) followed with no change in ;CO (3.7 +/- 1.1 to 3.4 +/- 0.9 1 min(-1)). The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 1 min(-1)), and preserved ScO2. Conclusions The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on ScO2 while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.	[Nissen, Peter; Brassard, Patrice; Jorgensen, Thomas B.; Secher, Niels H.] Univ Copenhagen, Rigshosp 2041, Dept Anesthesia, DK-2100 Copenhagen O, Denmark	Nissen, P (reprint author), Univ Copenhagen, Rigshosp 2041, Dept Anesthesia, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	p.nissen@rh.regionh.dk	Brassard, Patrice/H-6115-2019				Bogert LWJ, 2005, EXP PHYSIOL, V90, P437, DOI 10.1113/expphysiol.2005.030262; Brassard P, 2009, BRIT J ANAESTH, V102, P800, DOI 10.1093/bja/aep065; Dinenno FA, 2002, J PHYSIOL-LONDON, V540, P1103, DOI 10.1113/jphysiol.2001.015297; Dunaway S, 2007, PERFUSION-UK, V22, P289, DOI 10.1177/0267659107084145; Erkinaro T, 2007, ACTA ANAESTH SCAND, V51, P922, DOI 10.1111/j.1399-6576.2007.01327.x; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; Grubhofer G, 1997, ANAESTHESIA, V52, P116, DOI 10.1111/j.1365-2044.1997.20-az020.x; Harms MPM, 1999, CLIN SCI, V97, P291, DOI 10.1042/CS19990061; Harms MPM, 2000, STROKE, V31, P1608, DOI 10.1161/01.STR.31.7.1608; Hunt K, 2006, PHYSIOL MEAS, V27, P777, DOI 10.1088/0967-3334/27/9/002; Ide K, 1999, CLIN PHYSIOL, V19, P284; Ide K, 1999, J APPL PHYSIOL, V87, P1604; Jansen JRC, 2001, BRIT J ANAESTH, V87, P212, DOI 10.1093/bja/87.2.212; JENSTRUP M, 1995, ACTA ANAESTH SCAND, V39, P29, DOI 10.1111/j.1399-6576.1995.tb04326.x; Kadoi Y, 2001, J AM COLL CARDIOL, V38, P1450, DOI 10.1016/S0735-1097(01)01584-4; Kurihara K, 2007, J APPL PHYSIOL, V103, P1326, DOI 10.1152/japplphysiol.01191.2006; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Lavi S, 2003, CIRCULATION, V107, P1901, DOI 10.1161/01.CIR.0000057973.99140.5A; Madsen P, 1998, ACTA PHYSIOL SCAND, V162, P501; Madsen PL, 1999, PROG NEUROBIOL, V58, P541, DOI 10.1016/S0301-0082(98)00093-8; Madsen PL, 2000, ANESTH ANALG, V90, P489, DOI 10.1097/00000539-200002000-00046; Mitchell DA, 2009, J PHYSIOL-LONDON, V587, P2589, DOI 10.1113/jphysiol.2008.167999; Nissen Peter, 2009, AANA J, V77, P271; Nissen P, 2009, NEUROCRIT CARE, V11, P235, DOI 10.1007/s12028-009-9226-8; Nissen P, 2009, LIVER TRANSPLANT, V15, P287, DOI 10.1002/lt.21689; NJEMANZE PC, 1992, STROKE, V23, P1743, DOI 10.1161/01.STR.23.12.1743; Ogoh S, 2005, J PHYSIOL-LONDON, V569, P697, DOI 10.1113/jphysiol.2005.095836; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PAWELCZYK JA, 1992, J APPL PHYSIOL, V73, P1838; Pfister D, 2008, EUR J ANAESTH, V25, P98, DOI 10.1017/S0265021507003407; Plachky J, 2004, ANESTH ANALG, V99, P344; ROGERS AT, 1988, ANESTHESIOLOGY, V69, P547, DOI 10.1097/00000542-198810000-00015; Schaller B, 2004, BRAIN RES REV, V46, P243, DOI 10.1016/j.brainresrev.2004.04.005; SCHLEIEN CL, 1989, CIRCULATION, V79, P1332, DOI 10.1161/01.CIR.79.6.1332; Schwartz AE, 1996, ANESTHESIOLOGY, V85, P380, DOI 10.1097/00000542-199608000-00020; Secher NH, 2008, J APPL PHYSIOL, V104, P306, DOI 10.1152/japplphysiol.00853.2007; Skak C, 1997, ANESTH ANALG, V84, P730, DOI 10.1097/00000539-199704000-00005; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; Suzuki K, 2008, INTERNAL MED, V47, P1681, DOI 10.2169/internalmedicine.47.1094; VATNER SF, 1975, NEW ENGL J MED, V293, P970, DOI 10.1056/NEJM197511062931906; WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566; Yao FSF, 2004, J CARDIOTHOR VASC AN, V18, P552, DOI 10.1053/j.jvca.2004.07.007	43	64	67	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2010	12	1					17	23		10.1007/s12028-009-9313-x			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	571HL	WOS:000275742800004	19957053				2020-06-30	J	Kocum, A; Sener, M; Caliskan, E; Aribogan, A				Kocum, Aysu; Sener, Mesut; Caliskan, Esra; Aribogan, Anis			Anesthetic management for a child with unknown type of limb-girdle muscular dystrophy	PEDIATRICS INTERNATIONAL			English	Article						limb-girdle muscular dystrophy; pediatric anesthesia; propofol	MYOPATHY		[Kocum, Aysu; Sener, Mesut; Caliskan, Esra; Aribogan, Anis] Baskent Univ, Dept Anesthesiol & Reanimat, Fac Med, TR-06490 Ankara, Turkey	Kocum, A (reprint author), Baskent Univ Adana Seyhan Hastanesi, Anesteziyol & Reanimasyon AD, Baraj Yolu 1 Durak 37, TR-01140 Seyhan Adana, Turkey.	aysukocum@yahoo.com.tr	sener, mesut/A-7031-2012	Caliskan, Esra/0000-0001-6497-0610			Birnkrant DJ, 2007, CHEST, V132, P1977, DOI 10.1378/chest.07-0458; CORNELIO F, 1980, ITAL J NEUROL SCI, V1, P95; Frosk P, 2005, HUM MUTAT, V25, P38, DOI 10.1002/humu.20110; FRUEN BR, 1995, ANESTHESIOLOGY, V82, P1274, DOI 10.1097/00000542-199505000-00023; Hayes J, 2008, PEDIATR ANESTH, V18, P100, DOI 10.1111/j.1460-9592.2007.02302.x; Straub Volker, 2006, Semin Pediatr Neurol, V13, P104, DOI 10.1016/j.spen.2006.06.006; TEIN I, 1995, PEDIATR NEUROL, V12, P68, DOI 10.1016/0887-8994(94)00109-F	7	3	4	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1328-8067			PEDIATR INT	Pediatr. Int.	FEB	2010	52	1					E37	E38		10.1111/j.1442-200X.2009.02984.x			2	Pediatrics	Pediatrics	548VU	WOS:000273998000020	20158645				2020-06-30	J	Lafreniere, NM; Watterson, JH				Lafreniere, Nelson M.; Watterson, James H.			Detection of acute fentanyl exposure in fresh and decomposed skeletal tissues part II: The effect of dose-death interval	FORENSIC SCIENCE INTERNATIONAL			English	Article						Forensic toxicology; Bone; Fentanyl; Drug; ELISA	MASS-SPECTROMETRY CONFIRMATION; BONE-MARROW; KETAMINE EXPOSURE; ELISA ASSAY; DRUGS; BLOOD	The effects of dose-death interval on the detection of acute fentanyl exposure in fresh and decomposed skeletal tissues (marrow and bone), by automated enzyme-linked immunosorbent assay (ELISA) are described. Rats (n = 14) were administered fentanyl acutely at a dose of 0 (n = 2) or 60 mu g/kg (n = 12) by intraperitoneal injection, and euthanized within 20, 45, 135, or 225 min. Femora and tibiae were extracted from the fresh corpses and marrow was isolated from the femoral and tibial medullary cavities. The remains were then allowed to decompose outdoors to the point of complete skeletonization, and vertebrae, pelvi and miscellaneous (humeri and scapulae) were recovered for analysis. In all cases, bones were cleaned in alkaline solution and then ground into a fine powder. Marrow was homogenized in alkaline solution. Fentanyl was extracted from ground bone by methanolic extraction. Extracts were adjusted to pH 6 and analyzed by ELISA. Perimortem heart blood was also collected and diluted in phosphate buffer prior to screening by ELISA. The effect of tissue type on ELISA response was examined through determination of binary classification test sensitivity and the relative decrease in absorbance (%DA, drug-positive tissues vs. drug-free controls) in each tissue type. Overall, the %DA varied significantly between extracts from different skeletal tissues at a given dose-death interval, according to the general order of marrow > decomposed bone > fresh bone. Binary classification test sensitivity values for fentanyl in marrow, fresh epiphyseal (femoral and tibial) bone, fresh diaphyseal (femoral and tibial) bone, decomposed vertebrae, decomposed pelvic bone, and decomposed miscellaneous bone were 67-100%, 0-33%, 0-33%, 0-67%, 0-67% and 0-33%, respectively, over all dose-death intervals. Although group mean %DA values showed a strong negative correlation with dose-death interval in marrow, fresh epiphyseal bone, decomposed vertebrae, pelvic and miscellaneous bone (r = -0.989, -0.930, -0.955, -0.903, and -0.974, respectively), the high variability in both fresh and decomposed bone precluded differentiation of the dose-death intervals based on %DA value alone. Overall, the results suggested that the type of skeletal tissue sampled may not be as important as the amount of residual marrow remaining in skeletonized remains. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Lafreniere, Nelson M.; Watterson, James H.] Laurentian Univ, Dept Forens Sci, Forens Toxicol Res Lab, Sudbury, ON P3E 2C6, Canada	Watterson, JH (reprint author), Laurentian Univ, Dept Forens Sci, Forens Toxicol Res Lab, 935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.	jwatterson@laurentian.ca	Watterson, James/F-7168-2013				CLARK MA, 1997, FORENSIC TAPHONOMY P; Drummer Olaf H., 2008, P131, DOI 10.1007/978-1-59745-318-9_8; Gorczynski LY, 2001, J FORENSIC SCI, V46, P916; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; JENKINS AK, 2008, P INT LAB P C U COLL, P1; KERRIGAN S, 2006, PRINCIPLES FORENSIC, P230; Kupiec T, 2002, J ANAL TOXICOL, V26, P513, DOI 10.1093/jat/26.7.513; Lafreniere NM, 2009, FORENSIC SCI INT, V185, P100, DOI 10.1016/j.forsciint.2008.12.019; LYMAN RL, 1997, FORENSIC TAPHONOMY P; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McGrath KK, 2009, AM J FOREN MED PATH, V30, P40, DOI 10.1097/PAF.0b013e31818738c9; McIntyre IM, 2000, THER DRUG MONIT, V22, P79, DOI 10.1097/00007691-200002000-00017; Moore C, 2008, FORENSIC SCI INT, V176, P47, DOI 10.1016/j.forsciint.2007.06.027; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; RAIKOS N, 2006, FORENSIC SCI INT, V13, P140; VandenBoer TC, 2008, J FORENSIC SCI, V53, P1474, DOI 10.1111/j.1556-4029.2008.00866.x; Watterson J, 2006, ANALYST, V131, P961, DOI 10.1039/b609130j; Watterson JH, 2008, J ANAL TOXICOL, V32, P631, DOI 10.1093/jat/32.8.631; Watterson JH, 2009, J FORENSIC SCI, V54, P708, DOI 10.1111/j.1556-4029.2009.00998.x; WINEK CL, 1983, FORENSIC SCI INT, V22, P151, DOI 10.1016/0379-0738(83)90008-7; WINEK CL, 1990, FORENSIC SCI INT, V48, P49, DOI 10.1016/0379-0738(90)90271-Y; WINEK CL, 1993, J ANAL TOXICOL, V17, P93, DOI 10.1093/jat/17.2.93	22	19	19	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JAN 30	2010	194	1-3					60	66		10.1016/j.forsciint.2009.10.008			7	Medicine, Legal	Legal Medicine	548SF	WOS:000273985900010	19963329				2020-06-30	J	Kerker, A; Hardt, C; Schlief, HE; Dumoulin, FL				Kerker, Astrid; Hardt, Christian; Schlief, Hans-Eugen; Dumoulin, Franz Ludwig			Combined sedation with midazolam/propofol for gastrointestinal endoscopy in elderly patients	BMC GASTROENTEROLOGY			English	Article							HIGH-RISK OCTOGENARIANS; DEEP SEDATION; CONSCIOUS SEDATION; MODERATE SEDATION; PROPOFOL; ANESTHESIA; COLONOSCOPY; METAANALYSIS; COMBINATION	Background: Although gastrointestinal endoscopy with sedation is increasingly performed in elderly patients, data on combined sedation with midazolam/propofol are very limited for this age group. Methods: We retrospectively analyzed 454 endoscopic procedures in 347 hospitalized patients >= 70 years who had received combined sedation with midazolam/propofol. 513 endoscopic procedures in 397 hospitalized patients < 70 years during the observation period served as controls. Characteristics of endoscopic procedures, co-morbidity, complications and mortality were compared. Results: Elderly patients had a higher level of co-morbidity and needed lower mean propofol doses for sedation. We observed no major complication and no difference in the number of minor complications. The procedure-associated mortality was 0%; the 28-day mortality was significantly higher in the elderly (2.9% vs. 1.0%). Conclusions: In this study on elderly patients with high level co-morbidity, a favourable safety profile was observed for a combined sedation with midazolam/propofol with a higher sensitivity to propofol in the elderly.	[Kerker, Astrid; Hardt, Christian; Dumoulin, Franz Ludwig] Gemeinschaftskrankenhaus Bonn, Dept Med, D-53113 Bonn, Germany; [Schlief, Hans-Eugen] St Agnes Hosp Bocholt, Dept Med Gastroenterol & Oncol 2, D-46399 Bocholt, Germany	Dumoulin, FL (reprint author), Gemeinschaftskrankenhaus Bonn, Dept Med, Bonner Talweg 4-6, D-53113 Bonn, Germany.	f.dumoulin@gk-bonn.de	Dumoulin, Franz Ludwig/AAJ-1540-2020	Dumoulin, Franz Ludwig/0000-0002-1058-7867			Adachi YU, 2001, J CLIN ANESTH, V13, P277, DOI 10.1016/S0952-8180(01)00265-3; CARLSSON U, 1995, ENDOSCOPY, V27, P240, DOI 10.1055/s-2007-1005678; Cillo JE, 2006, J ORAL MAXIL SURG, V64, P1338, DOI 10.1016/j.joms.2006.05.018; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cordruwisch W, 2000, DEUT MED WOCHENSCHR, V125, P619, DOI 10.1055/s-2007-1024386; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; Gill PS, 2001, EUR J ANAESTH, V18, P166, DOI 10.1046/j.0265-0215.2000.00805.x; Hansen JJ, 2004, AM J GASTROENTEROL, V99, P52, DOI 10.1046/j.1572-0241.2003.04022.x; Heuss LT, 2003, ALIMENT PHARM THER, V17, P1493, DOI 10.1046/j.1365-2036.2003.01608.x; Ladas SD, 2006, DIGESTION, V74, P69, DOI 10.1159/000097466; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Meining A, 2007, ENDOSCOPY, V39, P345, DOI 10.1055/s-2006-945195; Oei-Lim VLB, 1998, EUR J ANAESTH, V15, P535, DOI 10.1046/j.1365-2346.1998.00349.x; Paspatis GA, 2008, ENDOSCOPY, V40, P308, DOI 10.1055/s-2007-995346; Paspatis GA, 2002, AM J GASTROENTEROL, V97, P1963; Qadeer MA, 2005, CLIN GASTROENTEROL H, V3, P1049, DOI 10.1016/S1542-3565(05)00742-1; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Riphaus A, 2005, AM J GASTROENTEROL, V100, P1957, DOI 10.1111/j.1572-0241.2005.41672.x; Rudner R, 2003, GASTROINTEST ENDOSC, V57, P657, DOI 10.1067/mge.2003.207; Schilling D, 2009, ENDOSCOPY, V41, P295, DOI 10.1055/s-0028-1119671; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x	23	23	24	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-230X			BMC GASTROENTEROL	BMC Gastroenterol.	JAN 27	2010	10								11	10.1186/1471-230X-10-11			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	556WW	WOS:000274625000001	20105314	DOAJ Gold, Green Published			2020-06-30	J	Peng, YZ; Li, XX; Wang, YW				Peng, Yuan-Zhi; Li, Xiao-Xi; Wang, Ying-Wei			Effects of Parecoxib and Fentanyl on nociception-induced cortical activity	MOLECULAR PAIN			English	Article							ANTERIOR CINGULATE CORTEX; LONG-TERM-POTENTIATION; SPINAL DORSAL-HORN; NEURONS IN-VIVO; POSTOPERATIVE PAIN; NEOCORTICAL NEURONS; INFLAMMATORY PAIN; NEUROPATHIC PAIN; UP-REGULATION; FEAR MEMORY	Background: Analgesics, including opioids and non-steroid anti-inflammatory drugs reduce postoperative pain. However, little is known about the quantitative effects of these drugs on cortical activity induced by nociceptive stimulation. The aim of the present study was to determine the neural activity in response to a nociceptive stimulus and to investigate the effects of fentanyl (an opioid agonist) and parecoxib (a selective cyclooxygenase-2 inhibitor) on this nociception-induced cortical activity evoked by tail pinch. Extracellular recordings (electroencephalogram and multi-unit signals) were performed in the area of the anterior cingulate cortex while intracellular recordings were made in the primary somatosensory cortex. The effects of parecoxib and fentanyl on induced cortical activity were compared. Results: Peripheral nociceptive stimulation in anesthetized rats produced an immediate electroencephalogram (EEG) desynchronization resembling the cortical arousal (low-amplitude, fast-wave activity), while the membrane potential switched into a persistent depolarization state. The induced cortical activity was abolished by fentanyl, and the fentanyl's effect was reversed by the opioid receptor antagonist, naloxone. Parecoxib, on the other hand, did not significantly affect the neural activity. Conclusion: Cortical activity was modulated by nociceptive stimulation in anesthetized rats. Fentanyl showed a strong inhibitory effect on the nociceptive-stimulus induced cortical activity while parecoxib had no significant effect.	[Peng, Yuan-Zhi; Li, Xiao-Xi; Wang, Ying-Wei] Shanghai Jiao Tong Univ, Dept Anesthesiol, Xinhua Hosp, Sch Med, Shanghai 200092, Peoples R China	Wang, YW (reprint author), Shanghai Jiao Tong Univ, Dept Anesthesiol, Xinhua Hosp, Sch Med, Shanghai 200092, Peoples R China.	wangyingwei@yahoo.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30872443]; Shanghai Municipal Education of Commission [08SG18]; Rising Star Program of Shanghai [09QH1401800]	This work was supported by grants from the National Natural Science Foundation of China(No. 30872443), Shuguang Program (08SG18) of Shanghai Municipal Education of Commission and Rising Star Program of Shanghai(No. 09QH1401800). Thanks for Dr. Min Zhuo's suggestions on revising the manuscript ( Professor of Physiology, University of Toronto, Canada).	Antognini JF, 2000, ANESTHESIOLOGY, V92, P559, DOI 10.1097/00000542-200002000-00040; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Barton SF, 2002, ANESTHESIOLOGY, V97, P306, DOI 10.1097/00000542-200208000-00004; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; Benrath J, 2004, ANESTHESIOLOGY, V100, P1545, DOI 10.1097/00000542-200406000-00030; Bischoff P, 1996, J CLIN ANESTH, V8, P36, DOI 10.1016/0952-8180(95)00170-0; Chen YP, 2005, J PHARMACOL EXP THER, V315, P696, DOI 10.1124/jpet.105.091314; Desjardins PJ, 2001, ANESTH ANALG, V93, P721, DOI 10.1097/00000539-200109000-00036; Deyama S, 2007, NEUROSCI RES, V59, P199, DOI 10.1016/j.neures.2007.06.1473; Gajraj NM, 2003, ANESTH ANALG, V96, P1720, DOI 10.1213/01.ANE.0000061461.55712.C5; Gilron I, 2003, ANESTHESIOLOGY, V99, P1198, DOI 10.1097/00000542-200311000-00029; Grundmann U, 2006, ANESTH ANALG, V103, P217, DOI 10.1213/01.ane.0000221438.08990.06; Ikeda H, 2006, SCIENCE, V312, P1659, DOI 10.1126/science.1127233; Ingram S L, 2000, Prog Brain Res, V129, P483; John ER, 2002, BRAIN RES REV, V39, P1, DOI 10.1016/S0165-0173(02)00142-X; Ko SW, 2005, J PAIN, V6, P12, DOI 10.1016/j.jpain.2004.10.001; Kuo CC, 2009, J NEUROPHYSIOL, V101, P1201, DOI 10.1152/jn.90347.2008; Liauw J, 2005, J NEUROPHYSIOL, V94, P878, DOI 10.1152/jn.01205.2004; Maihofner C, 2007, EUR J NEUROSCI, V26, P1344, DOI 10.1111/j.1460-9568.2007.05733.x; Nagata T, 2003, EXP BRAIN RES, V149, P505, DOI 10.1007/s00221-003-1381-0; Ohara PT, 2005, CELL MOL LIFE SCI, V62, P44, DOI 10.1007/s00018-004-4283-9; Padi SSV, 2004, EUR J PHARMACOL, V491, P69, DOI 10.1016/j.ejphar.2004.03.013; Paxinos G., 1998, RAT BRAIN STEREOTAXI; Puolakka PAE, 2006, ACTA ANAESTH SCAND, V50, P1027, DOI 10.1111/j.1399-6576.2006.01116.x; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Reeve AJ, 1998, J NEUROPHYSIOL, V79, P1494; Riest G, 2008, BRIT J ANAESTH, V100, P256, DOI 10.1093/bja/aem345; Romsing J, 2004, ACTA ANAESTH SCAND, V48, P525, DOI 10.1111/j.0001-5172.2004.00379.x; Rudolph M, 2005, J NEUROPHYSIOL, V94, P2805, DOI 10.1152/jn.01313.2004; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027; Shyu BC, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-51; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Tang JR, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-6; Wei F, 2001, NAT NEUROSCI, V4, P164, DOI 10.1038/83993; Wei F, 2006, J NEUROSCI, V26, P851, DOI 10.1523/JNEUROSCI.3292-05.2006; Wei F, 1999, J NEUROSCI, V19, P9346; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652; Wu LJ, 2005, J NEUROSCI, V25, P11107, DOI 10.1523/JNEUROSCI.1678-05.2005; Wu LJ, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-11; Wu MF, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-23; Wu ZZ, 2004, J PHARMACOL EXP THER, V311, P939, DOI 10.1124/jpet.104.073429; Xu H, 2008, J NEUROSCI, V28, P7445, DOI 10.1523/JNEUROSCI.1812-08.2008; Zhao MG, 2005, NEURON, V47, P859, DOI 10.1016/j.neuron.2005.08.014; Zhuo M, 2008, TRENDS NEUROSCI, V31, P199, DOI 10.1016/j.tins.2008.01.003; Zhuo M, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-14	48	12	13	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1744-8069			MOL PAIN	Mol. Pain	JAN 21	2010	6								3	10.1186/1744-8069-6-3			12	Neurosciences	Neurosciences & Neurology	553YC	WOS:000274401700001	20089200	DOAJ Gold, Green Published			2020-06-30	J	Privado, MS; Issy, AM; Lanchote, VL; Garcia, JBS; Sakata, RK				Privado, Marcelo Soares; Issy, Adriana Machado; Lanchote, Vera Lucia; Santos Garcia, Joao Batista; Sakata, Rioko Kimiko			Epidural versus intravenous fentanyl for postoperative analgesia following orthopedic surgery: randomized controlled trial	SAO PAULO MEDICAL JOURNAL			English	Article						Analgesia; Analgesia, epidural; Fentanyl; Pharmacology; Orthopedics	PLASMA-CONCENTRATIONS; POSTTHORACOTOMY PAIN; EXTRADURAL FENTANYL; INFUSION; LUMBAR; THORACOTOMY; LABOR; VOLUNTEERS; MORPHINE; THERAPY	CONTEXT AND OBJECTIVE: Controversy exists regarding the site of action of fentanyl after epidural injection. The objective of this investigation was to compare the efficacy of epidural and intravenous fentanyl for orthopedic surgery. DESIGN AND SETTING: A randomized double-blind study was performed in Hospital Sao Paulo. METHODS: During the postoperative period, in the presence of pain. 29 patients were divided into two groups: group 1 (n = 14) received 100 mu g of fentanyl epidurally and 2 ml of saline intravenously; group 2 (n = 15) received 5 ml of saline epidurally and 100 mu g of fentanyl intravenously. The analgesic supplementation consisted of 40 mg of tenoxicam intravenously and, if necessary, 5 ml of 0.25% bupivacaine epidurally. Pain intensity was evaluated on a numerical scale and plasma concentrations of fentanyl were measured simultaneously. RESULTS: The percentage of patients who required supplementary analgesia with tenoxicam was lower in group 1(71.4%) than in group 2 (100%): 95% confidence interval (CI) = 0.001-0.4360 (P = 0.001, Fisher's exact test; relative risk, RR = 0.07). Epidural bupivacaine supplementation was also lower in group 1(14.3%) than in group 2(53.3%): 95% CI = 0.06-1.05 (P = 0.03, Fisher's exact test; RR = 0.26). There was no difference in pain intensity on the numerical scale. Mean fentanyl plasma concentrations were similar in the two groups. CONCLUSION: Intravenous and epidural fentanyl appear to have similar efficacy for reducing pain according to the numerical scale, but supplementary analgesia was needed less frequently when epidural fentanyl was used.	[Sakata, Rioko Kimiko] Univ Fed Sao Paulo, EPM, Dept Anesthesia, Pain Clin, Sao Paulo, Brazil; [Privado, Marcelo Soares; Santos Garcia, Joao Batista] Univ Fed Maranhao, Dept Anesthesia, Sao Luis, Maranhao, Brazil; [Lanchote, Vera Lucia] Univ Sao Paulo, Dept Toxicol, Sao Paulo, Brazil	Issy, AM (reprint author), Rua Nova York,539 Apto 81, BR-04560001 Brooklin Sao Paulo, SP, Brazil.	issyam.dcir@epm.br	Lanchote, Vera Lucia/P-5925-2016; Lanchote, Vera/C-1987-2012; Sakata, Rioko K/O-3688-2015	Lanchote, Vera Lucia/0000-0002-0074-4953; Sakata, Rioko/0000-0001-6159-1746			AUSTIN KL, 1980, ANESTHESIOLOGY, V53, P460, DOI 10.1097/00000542-198012000-00005; BAXTER AD, 1994, CAN J ANAESTH, V41, P184, DOI 10.1007/BF03009829; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; COOPER DW, 1995, BRIT J ANAESTH, V74, P184, DOI 10.1093/bja/74.2.184; D'Angelo R, 1998, ANESTHESIOLOGY, V88, P1519, DOI 10.1097/00000542-199806000-00016; DAHLSTROM B, 1982, CLIN PHARMACOKINET, V7, P266, DOI 10.2165/00003088-198207030-00006; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P981, DOI 10.1097/00000542-199006000-00006; GLASS PSA, 1992, ANESTH ANALG, V74, P345; GRANT RP, 1992, CAN J ANAESTH, V39, P214, DOI 10.1007/BF03008779; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; LOPER KA, 1990, ANESTH ANALG, V70, P72; Mularski RA, 2006, J GEN INTERN MED, V21, P607, DOI 10.1111/j.1525-1497.2006.00415.x; Panos L, 1990, Can J Anaesth, V37, pS66; RENAUD B, 1988, ANESTH ANALG, V67, P971; REYNOLDS F, 1989, ANAESTHESIA, V44, P341, DOI 10.1111/j.1365-2044.1989.tb11292.x; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003; TAMSEN A, 1982, CLIN PHARMACOKINET, V7, P164, DOI 10.2165/00003088-198207020-00005; THOMSON CA, 1995, ANESTH ANALG, V81, P973, DOI 10.1097/00000539-199511000-00014; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013; WELCHEW EA, 1991, ANAESTHESIA, V46, P438, DOI 10.1111/j.1365-2044.1991.tb11678.x	24	3	4	0	1	ASSOCIACAO PAULISTA MEDICINA	SAO PAULO	AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL	1516-3180			SAO PAULO MED J	Sao Paulo Med. J.	JAN 7	2010	128	1					5	9		10.1590/S1516-31802010000100002			5	Medicine, General & Internal	General & Internal Medicine	599PB	WOS:000277924500002	20512273	DOAJ Gold, Green Published			2020-06-30	J	Hung, KC; Chen, CW; Lin, VCH; Weng, HC; Hsieh, SW				Hung, K. -C.; Chen, C. -W.; Lin, V. C. -H.; Weng, H. -C.; Hsieh, S. -W.			The effect of pre-emptive use of minimal dose fentanyl on fentanyl-induced coughing	ANAESTHESIA			English	Article							BOLUS; ALFENTANIL; INJECTION	We performed a randomised, double-blind study to evaluate the effect of the pre-emptive use of minimal dose intravenous fentanyl (25 mu g) on the incidence of cough caused by a larger bolus of intravenous fentanyl. Six hundred patients were randomly assigned to one of three groups to receive either 0.5 ml saline 0.9% 1 min before administration of fentanyl 150 mu g (3 ml), or pre-emptive fentanyl 25 mu g (0.5 ml) 1 min before administration of fentanyl 125 mu g or 150 mu g. The incidence of fentanyl-induced cough was significantly lower in both pre-emptive groups (7 (3.5%) for 125 mu g fentanyl and 15 (7.5%) for 150 mu g fentanyl) than in the saline group (37 (18.5%); p = 0.001). We conclude that pre-emptive use of fentanyl 25 mu g, administered 1 min before bolus injection of fentanyl (125 or 150 mu g), can effectively suppress fentanyl-induced cough.	[Hung, K. -C.; Hsieh, S. -W.] E DA Hosp, Dept Anesthesiol, Kaohsiung Cty, Taiwan; [Lin, V. C. -H.] E DA Hosp, Dept Urol, Kaohsiung Cty, Taiwan; [Weng, H. -C.] I Shou Univ, Dept Hlth Management, Kaohsiung Cty, Taiwan; [Lin, V. C. -H.] I Shou Univ, Dept Nursing, Kaohsiung Cty, Taiwan; [Chen, C. -W.] Kaohsiung Med Univ, Coll Med, Dept Physiol, Kaohsiung Cty, Taiwan; [Chen, C. -W.] Kaohsiung Med Univ, Coll Med, Masters Program, Kaohsiung Cty, Taiwan	Hsieh, SW (reprint author), E DA Hosp, Dept Anesthesiol, Kaohsiung Cty, Taiwan.	billwintw@yahoo.com.tw	Hung, Kuo-chuan/K-8345-2019	Hung, Kuo-chuan/0000-0002-4507-8085			Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; KNOLL J, 1977, POL J PHARMACOL PHAR, V29, P165; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Metz C, 2000, ANESTHESIOLOGY, V92, P1559, DOI 10.1097/00000542-200006000-00012; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021	14	17	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JAN	2010	65	1					4	7		10.1111/j.1365-2044.2009.06109.x			4	Anesthesiology	Anesthesiology	528IJ	WOS:000272437000003	19889113				2020-06-30	J	Wong, THK; Critchley, LAH; Lee, A; Khaw, KS; Ngan Kee, WD; Gin, T				Wong, T. H. K.; Critchley, L. A. H.; Lee, A.; Khaw, K. S.; Ngan Kee, W. D.; Gin, T.			Fentanyl dosage and timing when inserting the Laryngeal Mask Airway	ANAESTHESIA AND INTENSIVE CARE			English	Article						laryngeal mask airway; propofol; fentanyl; dose-response	TRACHEAL INTUBATION; PROPOFOL; ALFENTANIL; THIOPENTONE; INDUCTION; REMIFENTANIL; FACILITATE; ANESTHESIA; MIDAZOLAM	The study objective was to show that fentanyl given five minutes prior to induction improved insertion conditions for tire Classic Laryngeal Mask Airway. Previous work had shown fentanyl at 90 seconds to be unpredictable. A probit analysis design was used in which success/failure rates of different doses of fentanyl were measured and dose-response curves drawn from which the ED50 and ED95 with 95% confidence intervals were determined. Adult Chinese patients with American Society of Anesthesiologists physical status classification I or II and requiring anaesthesia for minor surgery with a laryngeal mask were recruited. They were randomly assigned to one of six dosage groups: 0.25, 0.5, 7.0, 1.5, 2.0 and 3.0 mu g.kg(-1). Fentanyl was given prior to propofol 2.5 mg.kg(-1), and insertion was assessed 90 seconds later using six categories of patient response. Ninety-six patients, aged 18 to 63 years, were studied. The six dosage groups were similar. As the fentanyl dose increased, fewer patients responded to insertion (P < 0.01). Dose-responses could be predicted for all categories, except resistance to insertion and laryngospasm. Probit analysis predicted an ED50 of 0.5 mu g.kg(-1) and ED95 of 7.5 mu g.kg(-1) for ideal insertion conditions (i.e. no swallowing, gagging, body movement or laryngospasm). Commonly used fentanyl doses of 1 to 2 mu g.kg(-1) only prevented patients responding to insertion in 70 to 80% of cases. When using propofol 2.5 mg.kg(-1), administering fentanyl five minutes before laryngeal mask insertion does not provide ideal insertion conditions in 95% of cases unless excessively large doses are used. An ideal dose of fentanyl that produces optimum insertion conditions could not be determined.	[Wong, T. H. K.; Critchley, L. A. H.; Lee, A.; Khaw, K. S.; Ngan Kee, W. D.; Gin, T.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anesthesia & Intens Care, Shatin, Hong Kong, Peoples R China	Critchley, LAH (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anesthesia & Intens Care, Shatin, Hong Kong, Peoples R China.		Ngan Kee, Warwick/J-8817-2013; Khaw, K/J-9469-2013; GIN, Tony/J-2521-2013; Lee, Anna/B-2773-2009; Critchley, Lester A H/J-9420-2013	Ngan Kee, Warwick/0000-0003-1000-7735; Khaw, K/0000-0002-5950-0275; GIN, Tony/0000-0001-7283-6761; Lee, Anna/0000-0003-2864-0045; 	Chinese University of Hong KongChinese University of Hong Kong	This project was funded by our department and The Chinese University of Hong Kong.	Bapat P, 1996, CAN J ANAESTH, V43, P564, DOI 10.1007/BF03011767; BRAIN AIJ, 1985, ANAESTHESIA, V40, P356; BROWN GW, 1991, ANAESTHESIA, V46, P771, DOI 10.1111/j.1365-2044.1991.tb09776.x; CHUI PT, 1998, ANAESTHESIA, V53, P486; Gill PS, 2001, EUR J ANAESTH, V18, P166, DOI 10.1046/j.0265-0215.2000.00805.x; Hui JKL, 2002, CAN J ANAESTH, V49, P508, DOI 10.1007/BF03017932; Kim MK, 2009, ANAESTHESIA, V64, P136, DOI 10.1111/j.1365-2044.2008.05707.x; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Lee MPL, 2001, ANESTH ANALG, V93, P359, DOI 10.1097/00000539-200108000-00025; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; SCANLON P, 1993, CAN J ANAESTH, V40, P816, DOI 10.1007/BF03009250; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Sivalingam P, 1999, ANAESTHESIA, V54, P271, DOI 10.1046/j.1365-2044.1999.00663.x; Soares LGL, 2003, J PAIN SYMPTOM MANAG, V26, P876, DOI 10.1016/S0885-3924(03)00314-2; Stanski D R, 1987, Eur J Anaesthesiol Suppl, V1, P3; STONEHAM MD, 1995, ANAESTHESIA, V50, P464, DOI 10.1111/j.1365-2044.1995.tb06007.x; Tallarida R. J., 2000, DRUG SYNERGISM DOSE, P91; TALLARIDA RJ, 2000, DRUG SYNERGISM DOSE, P41; Wong CM, 2007, ANAESTHESIA, V62, P654, DOI 10.1111/j.1365-2044.2007.05057.x; Yu ALY, 2006, ANESTHESIOLOGY, V105, P684, DOI 10.1097/00000542-200610000-00012	20	1	1	0	4	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	JAN	2010	38	1					55	64		10.1177/0310057X1003800111			10	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	555KN	WOS:000274509800011	20191778	Bronze			2020-06-30	J	Tan, ASB; Wang, CY				Tan, A. S. B.; Wang, C. Y.			Fentanyl dose for the insertion of Classic (TM) Laryngeal Mask Airways in non-paralysed patients induced with propofol 2.5 mg/kg	ANAESTHESIA AND INTENSIVE CARE			English	Article						LMA; insertion; fentanyl; dose	ALFENTANIL; PHARMACODYNAMICS; REQUIREMENT; THIOPENTONE; MANAGEMENT	The aim of this randomised, controlled trial was to determine the optimum dose of fentanyl in combination with propofol 2.5 mg.kg(-1) when inserting the Classic (TM) Laryngeal Mask Airway. Seventy-five ASA I or II patients were randomly assigned to five groups of fentanyl dosage: 0 mu g.kg(-1) (placebo), 0.5 mu g.kg(-1), 1.0 mu g.kg(-1), 1.5 mu g.kg(-1) and 2.0 mu g.kg(-1). Anaesthesia was induced by first injecting the study drug over 10 seconds. Three minutes after the study drug was injected, propofol (2.5 mg.kg(-1)) was injected over 10 seconds. The Classic (TM) Laryngeal Mask Airway was inserted four minutes and 30 seconds after injection of the study drug. Insertion conditions were evaluated using a four-category score. Thirty-nine males and 36 females aged 19 to 59 years were studied. The incidence of prolonged apnoea increased as fentanyl dose increased. We found that there was a high rate of successful first attempt at insertion with 1 mu g.kg(-1) and 1.5 mu g.kg(-1), 93% and 87% respectively; compared to 87% in the 2.0 mu g.kg(-1) group. The 1.0 mu g.kg(-1) group also achieved an 80% optimal insertion conditions score of 4, compared to 73% in the 1.5 mu g.kg(-1) group and 80% in the 2 mu g.kg(-1) group. Therefore we recommend 1.0 mu g.kg(-1) as the optimal dose of fentanyl when used in addition to propofol 2.5 mg/kg for the insertion of the Classic (TM) Latyngeal Mask Airway.	[Tan, A. S. B.; Wang, C. Y.] Univ Malaya, Dept Anaesthesiol, Fac Med, Kuala Lumpur 59100, Malaysia	Wang, CY (reprint author), Univ Malaya, Dept Anaesthesiol, Fac Med, Kuala Lumpur 59100, Malaysia.	wangcy1836@gmail.com	WANG, CHEW YIN/B-7534-2010; Wang, Chew Yin/F-7573-2010				BRAIN AIJ, 1983, BRIT J ANAESTH, V55, P801, DOI 10.1093/bja/55.8.801; BROWN GW, 1991, ANAESTHESIA, V46, P771, DOI 10.1111/j.1365-2044.1991.tb09776.x; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; CHUI PT, 1998, ANAESTHESIA, V53, P486; Goyagi T, 2003, ACTA ANAESTH SCAND, V47, P771, DOI 10.1034/j.1399-6576.2003.00123.x; Hui JKL, 2002, CAN J ANAESTH, V49, P508, DOI 10.1007/BF03017932; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Kodaka M, 2004, BRIT J ANAESTH, V92, P238, DOI 10.1093/bja/aeh033; OMEARA ME, 1993, BMJ-BRIT MED J, V306, P224, DOI 10.1136/bmj.306.6872.224; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; SCANLON P, 1993, CAN J ANAESTH, V40, P816, DOI 10.1007/BF03009250; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Sivalingam P, 1999, ANAESTHESIA, V54, P271, DOI 10.1046/j.1365-2044.1999.00663.x; Tanaka M, 2003, BRIT J ANAESTH, V90, P14, DOI 10.1093/bja/aeg018; Wong CM, 2007, ANAESTHESIA, V62, P654, DOI 10.1111/j.1365-2044.2007.05057.x; Yu ALY, 2006, ANESTHESIOLOGY, V105, P684, DOI 10.1097/00000542-200610000-00012	17	6	6	0	1	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	JAN	2010	38	1					65	69		10.1177/0310057X1003800112			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	555KN	WOS:000274509800012	20191779	Bronze			2020-06-30	J	MacKay, EC; Sleigh, JW; Voss, LJ; Barnard, JP				MacKay, E. C.; Sleigh, J. W.; Voss, L. J.; Barnard, J. P.			Episodic waveforms in the electroencephalogram during general anaesthesia: a study of patterns of response to noxious stimuli	ANAESTHESIA AND INTENSIVE CARE			English	Article						electroencephalography; opioid; anaesthesia; spindles; slow oscillation	SEVOFLURANE ANESTHESIA; THALAMOCORTICAL NEURONS; NEOCORTICAL NEURONS; TRACHEAL INTUBATION; NITROUS-OXIDE; IN-VITRO; SLEEP; FENTANYL; PHARMACOKINETICS; PHARMACODYNAMICS	Previous studies of the electroencephalogram (EEG) during anaesthesia have identified two distinct patterns of change in response to a noxious stimulus, a classical arousal pattern and a paradoxical arousal pattern. We developed methods of EEG analysis to quantify episodic EEG patterns - namely sleep spindle-like ('10 Hz-score') and burst-suppression-like fluctuations in high frequencies ('high frequency variation index') - and used traditional power spectral quantification of non-episodic delta waves. We studied 30 healthy adult patients undergoing elective surgery under general anaesthesia with propofol, fentanyl (1.0, 2.5 or 4.0 mu g/kg, n=10 for each group), muscle relaxant and sevoflurane. Prefrontal EEG data were recorded during the operation and analysed for changes in episodic patterns before and after noxious stimuli (intubation and incision). Before noxious stimuli, the EEG patterns varied markedly between patients and were not strongly correlated to calculated effect-site concentrations of fentanyl, propofol or sevoflurane. Noxious stimuli reduced the 10 Hz-score from 0.25 to 0.20 (P=0.01) after intubation and from 0.33 to 0.27 (P=0.01) after incision; and high frequency variation index from 2.8 to 2.0 (P=0.02) after incision - the classical arousal pattern. The nociception-induced reduction in spindles was greater in the low-dose fentanyl group (P=0.01). There was less tachycardia in the high-dose fentanyl group (P=0.002). It is possible to quantify such episodic EEG patterns during general anaesthesia and in this study noxious stimulation tended to reduce the prevalence of these patterns.	[Sleigh, J. W.] Waikato Hosp, Waikato Clin Sch, Dept Anaesthesia, Hamilton 3240, New Zealand	Sleigh, JW (reprint author), Waikato Hosp, Waikato Clin Sch, Dept Anaesthesia, Private Bag 3200, Hamilton 3240, New Zealand.				Waikato Medical Research Foundation; Braemar Charitable Trust	This work was funded by the Waikato Medical Research Foundation and the Braemar Charitable Trust.	Bischoff P, 1996, J CLIN ANESTH, V8, P36, DOI 10.1016/0952-8180(95)00170-0; Chen XD, 2005, J NEUROSCI, V25, P5803, DOI 10.1523/JNEUROSCI.1153-05.2005; Crunelli V, 2006, CELL CALCIUM, V40, P175, DOI 10.1016/j.ceca.2006.04.022; De Gennaro L, 2003, SLEEP MED REV, V7, P423, DOI 10.1053/smrv.2002.0252; Hagihira S, 2004, ANESTHESIOLOGY, V100, P818, DOI 10.1097/00000542-200404000-00011; Hayashi K, 2008, ANESTHESIOLOGY, V108, P841, DOI 10.1097/ALN.0b013e31816bbd9b; Hobson JA, 2000, BEHAV BRAIN SCI, V23, P793, DOI 10.1017/S0140525X00003976; Hughes SW, 2002, NEURON, V33, P947, DOI 10.1016/S0896-6273(02)00623-2; Kox WJ, 2006, ANESTH ANALG, V102, P825, DOI 10.1213/01.ane.0000197776.26307.fa; Kroeger D, 2007, J NEUROSCI, V27, P10597, DOI 10.1523/JNEUROSCI.3440-07.2007; Lee KH, 1997, NEUROSCIENCE, V77, P335, DOI 10.1016/S0306-4522(96)00481-2; Luthi A, 1999, NAT NEUROSCI, V2, P634, DOI 10.1038/10189; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P319, DOI 10.1113/jphysiol.1990.sp018332; McKay IDH, 2006, ANESTH ANALG, V102, P91, DOI 10.1213/01.ane.0000184825.65124.24; Molle M, 2002, J NEUROSCI, V22, P10941; Morimoto Y, 2005, ANESTH ANALG, V100, P1370, DOI 10.1213/01.ANE.0000148124.02288.D1; Morimoto Y, 2006, ANESTH ANALG, V103, P641, DOI 10.1213/01.ane.0000229699.99371.3c; Mukovski M, 2007, CEREB CORTEX, V17, P400, DOI 10.1093/cercor/bhj157; Muthuswamy J, 1998, J NEUROSCI METH, V83, P1, DOI 10.1016/S0165-0270(98)00065-X; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Rundshagen I, 2004, BRIT J ANAESTH, V92, P33, DOI 10.1093/bja/aeh020; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; SHAFER SL, 1993, J CLIN ANESTH, V5, pS14; Steriade M, 2006, NEUROSCIENCE, V137, P1087, DOI 10.1016/j.neuroscience.2005.10.029; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; White M, 1999, BRIT J ANAESTH, V82, P333, DOI 10.1093/bja/82.3.333; WILLENS JS, 1993, HEART LUNG, V22, P239; Ying SW, 2006, EUR J NEUROSCI, V23, P465, DOI 10.1111/j.1460-9568.2005.04587.x	29	18	18	0	1	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	JAN	2010	38	1					102	112		10.1177/0310057X1003800118			11	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	555KN	WOS:000274509800018	20191785	Bronze			2020-06-30	J	Candiotti, KA; Bergese, SD; Bokesch, PM; Feldman, MA; Wisemandle, W; Bekker, AY				Candiotti, Keith A.; Bergese, Sergio D.; Bokesch, Paula M.; Feldman, Marc A.; Wisemandle, Wayne; Bekker, Alex Y.		MAC Study Grp	Monitored Anesthesia Care with Dexmedetomidine: A Prospective, Randomized, Double-Blind, Multicenter Trial	ANESTHESIA AND ANALGESIA			English	Article							CATARACT-SURGERY; INTENSIVE-CARE; SEDATION; MIDAZOLAM; RECOVERY; PROPOFOL; PATIENT; EFFICACY; SCALE	BACKGROUND: Dexmedetomidine (DEX) is increasingly being used as a sedative for monitored anesthesia care (MAC) because of its analgesic properties, "cooperative sedation," and lack of respiratory depression. In this randomized, multicenter, double-blind, Phase III Food and Drug Administration Study, we evaluated the safety and efficacy of two doses of DEX for sedation of patients undergoing a broad range Of Surgical or diagnostic procedures requiring MAC. METHODS: Three hundred twenty-six patients were randomized 2:2:1 to DEX 0.5 mu g/kg, DEX 1 mu g/kg, or saline placebo initial loading dose, followed by a maintenance infusion of 0.2-1.0 mu g . kg(-1) . h(-1) of DEX (or equivalent volume of saline) titrated to a targeted level of sedation (:54 on the Observer's Assessment of Alertness/Sedation Scale [OAA/S]). Study drug was started at least 15 min before placement of regional or local anesthetic block. Midazolam was given for OAA/S >4 and fentanyl for pain. The primary end-point was the percentage of patients not requiring rescue midazolam. RESULTS: Significantly fewer patients in the 0.5- and 1-mu g/kg DEX groups required supplemental midazolam compared with placebo (59.7% [80/134], 45.7% [59/129] vs 96.8% [61/63], respectively; P < 0.001) and at lower doses to achieve an OAA/S <= 4 before and during surgery compared with the saline group (1.4 and 0.9 mg vs; 4.1 mg, respectively; P < 0.001, each group compared with placebo). Both DEX groups required significantly less fentanyl (84.8 and 83.6 mu g vs 1.44.4 mu g, respectively; P < 0.001, for both DEX groups versus placebo) for all surgical subtypes. Anesthesiologists indicated significantly increased ease of achieving and maintaining targeted sedation in both DEX groups compared with placebo with midazolam (P < 0.001). Patient satisfaction was significantly higher with DEX (P <= 0.009, both groups versus placebo). Common adverse events with DEX were protocol-defined bradycardia and hypotension that were predominately mild to moderate in severity. The incidence of clinically significant respiratory depression (defined as a respiratory rate of <8 or M oxygen saturation of <90%) was lower in DEX-treated patients (P = 0.018, for both groups versus placebo). CONCLUSIONS: DEX is an effective baseline sedative for patients undergoing MAC for a broad range of surgical procedures providing better patient satisfaction, less opioid requirements, and less respiratory depression than placebo rescued with midazolam and fentanyl. (Anesth Analg 2010;110:47-56)	[Candiotti, Keith A.] Univ Miami, Dept Anesthesiol Perioperat Med & Pain Management, Div Perioperat Med, Miami, FL 33101 USA; [Bergese, Sergio D.] Ohio State Univ, Dept Anesthesiol, Columbus, OH 43210 USA; [Bergese, Sergio D.] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Bokesch, Paula M.; Wisemandle, Wayne] Hospira Inc, Lake Forest, IL USA; [Feldman, Marc A.] Cleveland Clin, Sect Anesthesia, Cole Eye Inst, Cleveland, OH 44106 USA; [Bekker, Alex Y.] NYU, Dept Anesthesiol, Med Ctr, New York, NY 10016 USA	Candiotti, KA (reprint author), Univ Miami, Dept Anesthesiol Perioperat Med & Pain Management, Div Perioperat Med, POB 016370, Miami, FL 33101 USA.	kcandiot@med.miami.edu		Bergese, Sergio/0000-0001-5641-5908	Hospira, Inc., Lake Forest, IL	Supported by Hospira, Inc., Lake Forest, IL.	Abdalla Mahmoud I M, 2006, J Anesth, V20, P54, DOI 10.1007/s00540-005-0351-z; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; Arain SR, 2002, ANESTH ANALG, V95, P461, DOI 10.1097/00000539-200208000-00042; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cooper L, 2007, ANESTH ANALG, V104, pS41; Demiraran Y, 2007, CAN J GASTROENTEROL, V21, P25, DOI 10.1155/2007/350279; Dexter F, 1997, ANESTHESIOLOGY, V87, P865, DOI 10.1097/00000542-199710000-00021; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Elbaradie Samia, 2004, J Egypt Natl Canc Inst, V16, P153; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1016/S1053-0770(03)00200-3; Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009; McCutcheon CA, 2006, ANESTH ANALG, V102, P668, DOI 10.1213/01.ane.0000197777.62397.d5; Muttu S, 2005, J CATARACT REFR SURG, V31, P1845, DOI 10.1016/j.jcrs.2005.09.019; Reich DL, 2002, ANESTH ANALG, V95, P273, DOI 10.1097/00000539-200208000-00003; Smith H, 2001, Curr Opin Anaesthesiol, V14, P513, DOI 10.1097/00001503-200110000-00009; Taghinia AH, 2008, PLAST RECONSTR SURG, V121, P269, DOI 10.1097/01.prs.0000293867.05857.90; Ustun Y, 2006, J ORAL MAXIL SURG, V64, P1353, DOI 10.1016/j.joms.2006.05.020; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Wijeysundera DN, 2003, AM J MED, V114, P742, DOI 10.1016/S0002-9343(03)00165-7; Zeyneloglu P, 2008, EUR J ANAESTH, V25, P961, DOI 10.1017/S0265021508004699	26	116	136	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2010	110	1					47	56		10.1213/ane.0b013e3181ae0856			10	Anesthesiology	Anesthesiology	538OL	WOS:000273193700010	19713256				2020-06-30	J	Dabu-Bondoc, S; Vadivelu, N; Benson, J; Perret, D; Kain, ZN				Dabu-Bondoc, Susan; Vadivelu, Nalini; Benson, Judy; Perret, Danielle; Kain, Zeev N.			Hemispheric Synchronized Sounds and Perioperative Analgesic Requirements	ANESTHESIA AND ANALGESIA			English	Article								BACKGROUND: Data on the effect of Hemisync (R) sounds on perioperative analgesic requirements are scant. METHODS: We randomized surgical outpatients into a treatment group that received Hemisync Sounds (n = 20), a music group that received music (n = 20), and a control group that had a blank cassette tape (n 20). All subjects underwent a controlled standardized propofol-nitrous-vecuronium and fentayl general anesthesia. RESULTS:The treatment group had significantly reduced intraoperative fentanyl consumption (P < 0.05). Postoperatively, pain visual analog scale scores were significantly lower in the Hemisync group at 1 h (P = 0.02) and 24 h (P = 0.005). Subjects in the Hemisync group were also discharged earlier (P = 0.048). CONCLUSION: The use of Hemisync sounds before and during general anesthesia reduces intraoperative analgesic requirements, postoperative pain scores, and discharge time. (Anesth Analg 2010;110:208-10)	[Benson, Judy; Perret, Danielle; Kain, Zeev N.] Univ Calif Irvine, Dept Anesthesiol, Irvine, CA 92717 USA; [Benson, Judy; Kain, Zeev N.] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA; [Benson, Judy; Kain, Zeev N.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA; [Dabu-Bondoc, Susan; Vadivelu, Nalini; Benson, Judy] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA	Kain, ZN (reprint author), Univ Calif Irvine, Dept Anesthesiol, Irvine, CA 92717 USA.	zkain@uci.edu			National Institutes of Health, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD37007-02]	Supported by the National Institutes of Health (R01HD37007-02), Bethesda, MD (to ZN-K).	Atwater F.H., 1997, HEMI SYNC PROCESS; Dabu-Bondoc S, 2003, ANESTH ANALG, V97, P772, DOI 10.1213/01.ANE.0000076145.83783.E7; Kliempt P, 1999, ANAESTHESIA, V54, P769, DOI 10.1046/j.1365-2044.1999.00958.x; Lewis AK, 2004, ANESTH ANALG, V98, P533, DOI 10.1213/01.ANE.0000096181.89116.D2; SMITH JC, 1975, ELECTROEN CLIN NEURO, V39, P465, DOI 10.1016/0013-4694(75)90047-4; Spielberger C., 1983, MANUAL STATE TRAIT A	6	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2010	110	1					208	210		10.1213/ANE.0b013e3181bea424			3	Anesthesiology	Anesthesiology	538OL	WOS:000273193700034	19861358				2020-06-30	J	Nelson, KE; Houle, TT; Eisenach, JC				Nelson, Kenneth E.; Houle, Timothy T.; Eisenach, James C.			Blood Pressure, but Not Cerebrospinal Fluid Fentanyl Concentration, Predicts Duration of Labor Analgesia from Spinal Fentanyl	ANESTHESIOLOGY			English	Article							INTRATHECAL FENTANYL; SUFENTANIL; BUPIVACAINE; PULSATIONS; VELOCITY; VOLUME; EXTENT; FLOW	Background: There is a wide variability in dilution of drugs in cerebrospinal fluid after spinal injection, as measured near the site of injection. With local anesthetics, there is a wide variability in speed of onset, which correlates with block duration. The authors tested whether local cerebrospinal fluid drug concentrations and onset time would predict duration of analgesia from spinal fentanyl in laboring women. Methods: After written informed consent, fentanyl (50 mu g) was injected using the combined spinal epidural method in 56 women requesting analgesia for labor, The stylet was reinserted in the spinal needle, and 60 s later, the cerebrospinal fluid was aspirated for fentanyl assay. Time to analgesia and duration of analgesia were recorded, and data were analyzed by linear regression. Results: Fifty-two women were included for data analysis. The cerebrospinal fluid fentanyl concentrations were 3.1 +/- 5.9 mu g/ml, with a 7-fold range (0,9-5.9 mu g/ml). Fentanyl concentration did not correlate with onset, initial sensory level at 5 and 10 min, or duration of analgesia. Decreased diastolic and increased systolic blood pressure and lower parity, but not fentanyl concentrations, correlated with longer labor analgesia. The resultant model was predictive when applied to data from four previous studies of spinal opioid analgesia duration. Conclusions: Contrary to our hypothesis, the local concentration of fentanyl in the cerebrospinal fluid 1 min after injection was not correlated with onset or duration of labor analgesia. The unexpected but consistent relationship between blood pressure and combined spinal epidural analgesia duration suggests that resting hemodynamic state affects the distribution and/or clearance of intrathecally administered opioids.	[Nelson, Kenneth E.; Houle, Timothy T.] Wake Forest Univ, Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA; [Eisenach, James C.] Wake Forest Univ, Sch Med, Dept Anesthesiol & Physiol & Pharmacol, Winston Salem, NC 27157 USA	Eisenach, JC (reprint author), Wake Forest Univ, Sch Med, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	eisenach@wfubmc.edu	Houle, Timothy T/I-7649-2019	Houle, Timothy/0000-0001-9584-5580	National Institute of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM148805]	Received from Department of Anesthesiology. Wake Forest University School of Medicine. Winston Salem, North Carolina. Submitted for Publication June 24, 2009. Accepted for Publication September 23, 2009. Supported in part by a grant GM148805 from the National Institute of Health, Bethesda, Maryland.	Baledent O, 2001, INVEST RADIOL, V36, P368, DOI 10.1097/00004424-200107000-00003; Bhadelia RA, 1997, NEURORADIOLOGY, V39, P258, DOI 10.1007/s002340050404; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; D'Angelo R, 1999, ANESTH ANALG, V88, P573, DOI 10.1097/00000539-199903000-00020; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; Gage JC, 1997, ANESTH ANALG, V85, P826, DOI 10.1097/00000539-199710000-00020; Harrell F, 2001, REGRESSION MODELING, p[2001, 247], DOI DOI 10.1007/978-3-319-19425-7; Henry-Feugeas MC, 2000, MAGN RESON IMAGING, V18, P387, DOI 10.1016/S0730-725X(99)00142-3; Higuchi H, 2004, ANESTHESIOLOGY, V100, P106, DOI 10.1097/00000542-200401000-00019; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Nelson KE, 1999, ANESTHESIOLOGY, V91, P1293, DOI 10.1097/00000542-199911000-00020; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; NORRIS MC, 1988, ANESTH ANALG, V67, P555; Pan PH, 2005, ANESTHESIOLOGY, V103, P595, DOI 10.1097/00000542-200509000-00023; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Tanaka H, 1998, INVEST RADIOL, V33, P141, DOI 10.1097/00004424-199803000-00003; Viscomi CM, 1997, ANESTH ANALG, V84, P1108, DOI 10.1097/00000539-199705000-00028	17	2	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JAN	2010	112	1					174	180		10.1097/ALN.0b013e3181c38c0b			7	Anesthesiology	Anesthesiology	540EP	WOS:000273314200025	19996953	Bronze			2020-06-30	J	Egan, JA; Nugent, RP; Filer, CN				Egan, Judith A.; Nugent, Richard P.; Filer, Crist N.			Mirfentanil and A-4334: Tritiation at high specific activity	APPLIED RADIATION AND ISOTOPES			English	Article						A-4334; Mirfentanil; Tritium; Tritium NMR	RECEPTORS	Methods are presented to synthesize and characterize [H-3] mirfentanil and [H-3] A-4334. (C) 2009 Elsevier Ltd. All rights reserved.	[Egan, Judith A.; Nugent, Richard P.; Filer, Crist N.] PerkinElmer Hlth Sci Inc, Waltham, MA 02451 USA	Filer, CN (reprint author), PerkinElmer Hlth Sci Inc, 940 Winter St, Waltham, MA 02451 USA.	crist.filer@perkinelmer.com					BAGLEY JR, 1991, MED RES REV, V11, P403, DOI 10.1002/med.2610110404; FILER CN, 1981, J ORG CHEM, V46, P4968, DOI 10.1021/jo00337a029; FOWLER CJ, 1994, NEUROCHEM INT, V24, P401, DOI 10.1016/0197-0186(94)90089-2; KVALO LT, 1991, J CHROMATOGR-BIOMED, V565, P391, DOI 10.1016/0378-4347(91)80400-7; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; Snyder SH, 2003, TRENDS PHARMACOL SCI, V24, P198, DOI 10.1016/S0165-6147(03)00066-X	6	3	3	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0969-8043			APPL RADIAT ISOTOPES	Appl. Radiat. Isot.	JAN	2010	68	1					120	121		10.1016/j.apradiso.2009.10.002			2	Chemistry, Inorganic & Nuclear; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Chemistry; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	580BQ	WOS:000276422300022	19875301				2020-06-30	J	Ambesh, SP; Singh, N; Gupta, D; Singh, PK; Singh, U				Ambesh, S. P.; Singh, N.; Gupta, D.; Singh, P. K.; Singh, U.			A huffing manoeuvre, immediately before induction of anaesthesia, prevents fentanyl-induced coughing: a prospective, randomized, and controlled study	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesics opioid; fentanyl; cough; huffing manoeuvre; receptors; stretch receptors	INTRAVENOUS LIDOCAINE; RECEPTORS	Preinduction i.v. fentanyl bolus is associated with coughing in 28-65% of patients. Fentanyl-induced coughing (FIC) is not always benign and can be remarkably troublesome at the most critical moment of induction of anaesthesia when airway reflex is lost. We postulated that the huffing manoeuvre, a forced expiration against open glottis, just before i.v. fentanyl, may suppress this undesirable spasmodic cough. Three hundred patients of ASA I and II, aged 18-60 yr, undergoing elective surgical procedures were randomly allocated into two groups consisting of 150 patients. Both groups received i.v. fentanyl (2.5 mu g kg(-1)). Group 1 patients breathed normally whereas Group 2 patients were asked to perform huffing manoeuvre just before the fentanyl injection. The incidence of cough was recorded for 1 min before the induction of anaesthesia, and graded as mild (1-2 cough), moderate (3-5 cough), and severe (> 5 cough). The incidence of FIC was analysed with Fisher's exact test and severity was analysed with the Mann-Whitney U-test. A P-value of < 0.05 was considered significant. The incidence of cough was 32% in the control group and 4% in the huffing manoeuvre group (P < 0.00). In the control group, 12% of FIC cases were moderate to severe in nature whereas no patient suffered severe coughing in the huffing manoeuvre group (P=0.049). A huffing manoeuvre performed just before i.v. fentanyl (2.5 mu g kg(-1)) significantly reduces the incidence and severity of FIC in the majority of the patients.	[Ambesh, S. P.; Singh, N.; Gupta, D.; Singh, P. K.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India; [Singh, U.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Ambesh, SP (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Type V-7,New Campus, Lucknow 226014, Uttar Pradesh, India.	ambeshsp@hotmail.com			Department of Anaesthesiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India	Support was provided solely from the Department of Anaesthesiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.	Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; AMBESH SP, 2009, INT J ANESTHESIOL, V20; AMBROGIO FBS, 1982, RESP PHYSL, V49, P49; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; DAYMAN HG, 1957, ANN INTERN MED, V47, P460, DOI 10.7326/0003-4819-47-3-460; HARRIS RS, 1968, CLIN SCI, V34, P569; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; McCool FD, 2006, CHEST, V129, p250S, DOI 10.1378/chest.129.1_suppl.250S; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; PAINTAL AS, 1969, J PHYSIOL-LONDON, V203, P511, DOI 10.1113/jphysiol.1969.sp008877; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; Pavia D, 1987, Eur J Respir Dis Suppl, V153, P123; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; PRYOR JA, 1979, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.6187.417; SANTAMBROGIO G, 1978, RESP PHYSIOL, V33, P359, DOI 10.1016/0034-5687(78)90062-2; Schlimp CJ, 2005, CAN J ANAESTH, V52, P207, DOI 10.1007/BF03027731; Tanaka M, 2005, J PHARMACOL SCI, V99, P77, DOI 10.1254/jphs.FPJ05014X; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012	23	24	30	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JAN	2010	104	1					40	43		10.1093/bja/aep333			4	Anesthesiology	Anesthesiology	531RC	WOS:000272684500007	19933512	Bronze			2020-06-30	J	O'Donnell, D; Manickam, B; Perlas, A; Karkhanis, R; Chan, VWS; Syed, K; Brull, R				O'Donnell, Dermot; Manickam, Baskar; Perlas, Anahi; Karkhanis, Reena; Chan, Vincent W. S.; Syed, Khalid; Brull, Richard			Spinal mepivacaine with fentanyl for outpatient knee arthroscopy surgery: a randomized controlled trial	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							TRANSIENT NEUROLOGIC SYMPTOMS; CHLOROPROCAINE NEUROTOXICITY; 0.5-PERCENT BUPIVACAINE; INTRATHECAL FENTANYL; EPIDURAL-ANESTHESIA; PROLONGING RECOVERY; AMBULATORY SURGERY; LIDOCAINE; 2-CHLOROPROCAINE; DISCHARGE	The foremost limitation of local anesthetic solutions for spinal anesthesia in the outpatient setting is prolonged motor blockade and delayed ambulation. The purpose of this study was to determine if the addition of intrathecal fentanyl to low-dose spinal mepivacaine provides adequate anesthesia with shorter duration of functional motor blockade for ambulatory knee surgery compared with spinal mepivacaine alone. Following institutional review board approval and informed consent, 34 patients undergoing unilateral knee arthroscopy were enrolled in this study. The patients were randomly assigned to receive either 30 mg of isobaric mepivacaine 1.5% plus fentanyl 10 mu g (M + F group) or 45 mg of isobaric mepivacaine 1.5% alone (M group) intrathecally. Postoperatively, the times to achieve sensory block regression to the S1 dermatome and to attain functional motor block recovery enabling ambulation were recorded. All assessments were blinded. The time to completion of Phase I recovery was shorter in the M + F group (104.6 +/- A 28.4 min) than in the M group (129.1 +/- A 30.4 min; P = 0.023). Regression of sensory blockade to S1 was earlier in the M + F group (118.4 +/- A 53.5 min) than in the M group (169.7 +/- A 38.9 min; P = 0.003). Patients in the M + F group (176.4 +/- A 40.3 min) were able to ambulate significantly earlier than those in the M group (205.6 +/- A 31.4 min; P = 0.025). No cases of transient or persistent neurological dysfunction were noted. When compared with 45 mg isobaric mepivacaine 1.5%, an intrathecal dose of 30 mg isobaric mepivacaine 1.5% plus 10 mu g fentanyl produces reliable anesthesia, hastens block regression, shortens stay in Phase I recovery, and enables earlier ambulation for patients undergoing unilateral knee arthroscopy (Registration no. NCT00803725).	[O'Donnell, Dermot; Manickam, Baskar; Perlas, Anahi; Karkhanis, Reena; Chan, Vincent W. S.; Brull, Richard] Univ Hlth Network, Toronto Western Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5T 2S8, Canada; [Syed, Khalid] Univ Hlth Network, Toronto Western Hosp, Dept Orthoped Surg, Toronto, ON M5T 2S8, Canada	Brull, R (reprint author), Univ Hlth Network, Toronto Western Hosp, Dept Anesthesia & Pain Management, Mc Laughlin Pavil 2-405,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	richard.brull@uhn.on.ca					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Axelrod EH, 1998, ANESTHESIOLOGY, V89, pU136, DOI 10.1097/00000542-199809010-00047; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; Borghi B, 2003, J CLIN ANESTH, V15, P351, DOI 10.1016/S0952-8180(03)00078-3; Casati A, 2007, ANESTH ANALG, V104, P959, DOI 10.1213/01.ane.0000258766.73612.d8; Casati Andrea, 2002, Curr Opin Anaesthesiol, V15, P543, DOI 10.1097/00001503-200210000-00012; CHUNG F, 1995, CAN J ANAESTH, V42, P1056, DOI 10.1007/BF03011083; Fanelli G, 2000, CAN J ANAESTH, V47, P746, DOI 10.1007/BF03019476; Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012; Hiller A, 1997, BRIT J ANAESTH, V79, P301, DOI 10.1093/bja/79.3.301; Imarengiaye CO, 2003, ANESTHESIOLOGY, V98, P511, DOI 10.1097/00000542-200302000-00033; Korhonen AM, 2004, ANESTH ANALG, V99, P1668, DOI 10.1213/01.ANE.0000139351.40608.05; KUHNERT BR, 1980, ANESTHESIOLOGY, V53, P21, DOI 10.1097/00000542-198007000-00005; Liguori GA, 1998, ANESTHESIOLOGY, V88, P619, DOI 10.1097/00000542-199803000-00010; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Liu SS, 1996, ANESTHESIOLOGY, V85, P729, DOI 10.1097/00000542-199610000-00007; MOORE DC, 1982, ANESTH ANALG, V61, P155; Mulroy MF, 2002, ANESTHESIOLOGY, V97, P315, DOI 10.1097/00000542-200208000-00005; OBRIEN JE, 1979, J PHARM SCI, V68, P75, DOI 10.1002/jps.2600680123; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; Pawlowski J, 2000, ANESTH ANALG, V91, P580, DOI 10.1213/00000539-200009000-00015; Pollock JE, 1996, ANESTHESIOLOGY, V84, P1361, DOI 10.1097/00000542-199606000-00012; RAVINDRAN RS, 1980, ANESTH ANALG, V59, P447; REISNER LS, 1980, ANESTH ANALG, V59, P452; Salazar F, 2001, ACTA ANAESTH SCAND, V45, P240, DOI 10.1034/j.1399-6576.2001.450216.x; SCHREINER MS, 1992, ANESTHESIOLOGY, V76, P528, DOI 10.1097/00000542-199204000-00007; Sime A C, 2000, AANA J, V68, P163; SINGH H, 1995, CAN J ANAESTH, V42, P987, DOI 10.1007/BF03011070; Taniguchi M, 2004, ANESTHESIOLOGY, V100, P85, DOI 10.1097/00000542-200401000-00016; Tarkkila P, 1997, ANAESTHESIA, V52, P1157, DOI 10.1111/j.1365-2044.1997.223-az0358.x; Urmey William F, 2003, Best Pract Res Clin Anaesthesiol, V17, P335, DOI 10.1016/S1521-6896(03)00015-6; Wong J, 2001, CAN J ANAESTH, V48, P369, DOI 10.1007/BF03014965; YaDeau JT, 2005, ANESTH ANALG, V101, P661, DOI 10.1213/01.ane.0000167636.94707.d3; Zaric D, 2005, ANESTH ANALG, V100, P1811, DOI 10.1213/01.ANE.0000136844.87857.78; Zayas VM, 1999, ANESTH ANALG, V89, P1167, DOI 10.1213/00000539-199911000-00015	36	19	20	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JAN	2010	57	1					32	38		10.1007/s12630-009-9207-6			7	Anesthesiology	Anesthesiology	541FG	WOS:000273399600005	19856040	Bronze			2020-06-30	J	Vieira, WS; Hidalgo, MPL; Torres, IDL; Caumo, W				Vieira, Waleska Schneider; Loayza Hidalgo, Maria Paz; Lucena Torres, Iraci da Silva; Caumo, Wolnei			BIOLOGICAL RHYTHMS OF SPINAL-EPIDURAL LABOR ANALGESIA	CHRONOBIOLOGY INTERNATIONAL			English	Article						Analgesia; Chronobiology; Labor; Pain; PCA	INTRATHECAL FENTANYL; PAIN PERCEPTION; CHRONOBIOLOGY; MELATONIN; DURATION; MORPHINE; HOUR; SUFENTANIL; CLONIDINE; TOXICITY	Pain exhibits temporal variations in intensity due to multiple factors, including endogenous neuroendocrine and various external influences that vary over the 24 h. Also, medications can vary in potency and/or toxicity according to the time when they are administered. However, there is no consensus among studies regarding the 24-h pattern of analgesia during labor. Taking into account the time-of-day when labor analgesia is administered, this study aimed to answer two questions: (i) Is there diurnal variation in visual analogue scale (VAS)-rated pain relief and duration of intrathecal analgesia in patients undergoing labor analgesia? (ii) If there is, what is the influence of the duration of labor on the diurnal variation of the level of pain relief and duration of intrathecal analgesia? This prospective cohort included 41 healthy, nulliparous women in the first stage of labor undergoing spinal-epidural (CSE) analgesia using fentanyl combined with bupivacaine. Subjects had an epidural catheter fitted for additional, patient-controlled analgesia (PCA) if their pain relief was unsatisfactory. The number of VAS assessments (n = 558) was divided into six time periods of the 24 h. The adjusted coefficient of determination (r(2)), the proportion of the variance explained by the association between the duration of labor and the temporal pattern of the outcomes variable, was 58% (r(2) = 0.58) for pain relief and 44% (r(2) = 0.44) for duration of intrathecal analgesia. The peak effect of labor analgesia occurred between 02: 00 and 05: 59 h. However, the duration of intrathecal analgesia showed two peaks, i. e., at similar to 00:00 and similar to 12:00 h. These results demonstrate that labor analgesia achieved by fentanyl combined with bupivacaine shows a diurnal pattern in pain relief and duration of spinal analgesia. However, part of these temporal patterns was explained by the association with duration of labor. (Author correspondence: caumo@cpovo.net)	[Caumo, Wolnei] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Chronopharmacol & Pain Div, Pain & Palliat Care Serv,Lab Chronobiol, BR-90035003 Porto Alegre, RS, Brazil; [Vieira, Waleska Schneider; Loayza Hidalgo, Maria Paz; Lucena Torres, Iraci da Silva; Caumo, Wolnei] Univ Fed Rio Grande do Sul, Postgrad Program Med Sci, Sch Med, BR-90035003 Porto Alegre, RS, Brazil; [Lucena Torres, Iraci da Silva; Caumo, Wolnei] Univ Fed Rio Grande do Sul, Dept Pharmacol Dept, Inst Ciencias Basicas Saude, BR-90035003 Porto Alegre, RS, Brazil; [Loayza Hidalgo, Maria Paz] Univ Fed Rio Grande do Sul, HCPA, Dept Psychiat, Sch Med,Psychiat Serv, BR-90035003 Porto Alegre, RS, Brazil	Caumo, W (reprint author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Chronopharmacol & Pain Div, Pain & Palliat Care Serv,Lab Chronobiol, Rua Ramiro Barcelos 2350, BR-90035003 Porto Alegre, RS, Brazil.	caumo@cpovo.net	Hidalgo, Maria Paz Loayza/V-5612-2019; Torres, Iraci L. S./G-6693-2012; caumo, wolnei/Q-8728-2016; Stevens, David/F-4683-2015	Hidalgo, Maria Paz Loayza/0000-0002-7886-770X; Torres, Iraci L. S./0000-0002-3081-115X; Stevens, David/0000-0002-8412-2202; Caumo, Wolnei/0000-0002-5083-4658	Postgraduate Research Group at Hospital de Clinicas de Porto Alegre, Brazil; Medical Science, School of Medicine, and Federal University of Rio Grande do Sul	This research was supported by the Postgraduate Research Group at Hospital de Clinicas de Porto Alegre, Brazil, and the Postgraduate Program in Medical Science, School of Medicine, and Federal University of Rio Grande do Sul.	Aya AGM, 2004, BRIT J ANAESTH, V93, P451, DOI 10.1093/bja/aeh223; Ayar A, 2001, NEUROSCI LETT, V313, P73, DOI 10.1016/S0304-3940(01)02188-7; BACHE B, 1991, ACTA OBSTET GYNECOL, V70, P645; BELLAMY N, 1990, J RHEUMATOL, V17, P364; Bewick V, 2003, CRIT CARE, V7, P451, DOI 10.1186/cc2401; BRUGUEROLLE B, 1988, J PHARM PHARMACOL, V40, P592, DOI 10.1111/j.2042-7158.1988.tb05314.x; Cadeddu M, 2008, CAN J SURG, V51, P476; Caumo W, 2007, ANESTH ANALG, V105, P1263, DOI 10.1213/01.ane.0000282834.78456.90; Caumo W, 2009, J PAIN, V10, P100, DOI 10.1016/j.jpain.2008.08.007; Charles E, 1953, BRIT J PREV SOC MED, V7, P43; Chassard D, 2007, CURR OPIN ANESTHESIO, V20, P186, DOI 10.1097/ACO.0b013e328136c55e; Cohen J, 1997, J COMPUT BIOL, V4, P547, DOI 10.1089/cmb.1997.4.547; DAVIS GC, 1978, LIFE SCI, V23, P1449, DOI 10.1016/0024-3205(78)90126-1; Debon R, 2004, ANESTHESIOLOGY, V101, P978, DOI 10.1097/00000542-200410000-00024; Debon R, 2002, ANESTHESIOLOGY, V96, P542, DOI 10.1097/00000542-200203000-00006; Desai S, 2009, INT J OBSTET ANESTH, V18, P43, DOI 10.1016/j.ijoa.2008.07.012; Duguay D, 2009, CHRONOBIOL INT, V26, P1479, DOI 10.3109/07420520903497575; Goldbeter A, 2008, CURR BIOL, V18, pR751, DOI 10.1016/j.cub.2008.06.044; Heres MHG, 2000, MIDWIFERY, V16, P173, DOI 10.1054/midw.1999.0210; Hidalgo MPL, 2005, ANESTH ANALG, V100, P795, DOI 10.1213/01.ANE.0000143568.59766.B2; Kain ZN, 2000, ANESTHESIOLOGY, V93, P141, DOI 10.1097/00000542-200007000-00024; Karakucuk EH, 2006, CHRONOBIOL INT, V23, P675, DOI 10.1080/07420520600650745; KAVALIERS M, 1983, BRAIN RES, V279, P387, DOI 10.1016/0006-8993(83)90216-0; KING PD, 1956, SCIENCE, V123, P985, DOI 10.1126/science.123.3205.985; KOWANKO IC, 1982, ANN RHEUM DIS, V41, P453, DOI 10.1136/ard.41.5.453; LABRECQUE G, 1995, PHARMACOL THERAPEUT, V68, P129, DOI 10.1016/0163-7258(95)02003-9; Lindow SW, 1996, CLIN ENDOCRINOL, V45, P443, DOI 10.1046/j.1365-2265.1996.8290840.x; MALEK J, 1952, Gynaecologia, V133, P365; Moldofsky H, 2001, SLEEP MED REV, V5, P387, DOI 10.1053/smrv.2001.0179; Naaktgeboren Cornelius, 1989, EFFECTIVE CARE PREGN, P795; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Ohdo S, 2003, DRUG SAFETY, V26, P999, DOI 10.2165/00002018-200326140-00002; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Pan PH, 2005, ANESTHESIOLOGY, V103, P595, DOI 10.1097/00000542-200509000-00023; PANDUROBARON G, 1994, INT J GYNECOL OBSTET, V45, P283, DOI 10.1016/0020-7292(94)90257-7; Pang CS, 2001, LIFE SCI, V68, P943, DOI 10.1016/S0024-3205(00)00996-6; Peugh JL, 2005, EDUC PSYCHOL MEAS, V65, P811, DOI 10.1177/0013164405278558; Portaluppi F, 2008, CHRONOBIOL INT, V25, P999, DOI 10.1080/07420520802544530; REINBERG A, 1977, N-S ARCH PHARMACOL, V297, P149, DOI 10.1007/BF00499924; RIGAS B, 1990, J CLIN GASTROENTEROL, V12, P409, DOI 10.1097/00004836-199008000-00011; Roenneberg T, 2003, J BIOL RHYTHM, V18, P80, DOI 10.1177/0748730402239679; Smolensky M., 1972, ADV CLIMATIC PHYSL, P281; Teoh WHL, 2003, ANESTH ANALG, V97, P873, DOI 10.1213/01.ANE.0000076388.17223.37; TOKUTOMI T, 2009, ARCH GYNECOL OBSTET, V279, P329; YERUSHALMY J, 1983, AM J HYG, V28, P244; Zar J. H., 1999, BIOSTAT ANAL, P377	46	4	5	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0742-0528	1525-6073		CHRONOBIOL INT	Chronobiol. Int.		2010	27	4					865	878		10.3109/07420521003721914			14	Biology; Physiology	Life Sciences & Biomedicine - Other Topics; Physiology	652RJ	WOS:000282027300011	20560716				2020-06-30	J	Darwish, M; Kirby, M; Robertson, P; Tracewell, W; Xie, F				Darwish, Mona; Kirby, Mary; Robertson, Philmore, Jr.; Tracewell, William; Xie, Fang			Dose Proportionality of Fentanyl Buccal Tablet in Doses Ranging from 600 to 1300 mu g in Healthy Adult Subjects A Randomized, Open-Label, Four-Period, Crossover, Single-Centre Study	CLINICAL DRUG INVESTIGATION			English	Article							BREAKTHROUGH PAIN; RELATIVE BIOAVAILABILITY; VOLUNTEERS; PHARMACOKINETICS; PREVALENCE; CITRATE	Background: Fentanyl buccal tablet (FBT) is indicated for the treatment of breakthrough pain in patients who are already receiving, and who are tolerant to, opioid therapy for underlying, persistent cancer pain. Breakthrough pain may be severe or excruciating, and some patients may require high doses of rapid-onset opioids to obtain adequate analgesia. Objective: The objective of this study was to assess the dose proportionality of FBT over a range of 600-1300 mu g in healthy subjects. Methods: This was a randomized, open-label, four-period, crossover, single-centre study of FBT (Fentora (R)) conducted in healthy adult subjects who were not tolerant to opioids. The study included 120 men and women aged 18-45 years with a body mass index of 20-30 kg/m(2) who had no clinically significant findings on medical and psychiatric histories, physical examination, ECG or standard clinical laboratory tests, and who had a negative urine screen for drugs and alcohol. Eligible subjects were randomized to one of four dose sequences: ABDC, BCAD, CDBA and DACB, where A, B, C and D were FBT doses from lowest to highest (600, 1000, 1200 and 1300 mu g). Each dose of FBT was separated by a minimum of 7 days. Naltrexone 50 mg was administered to block the opioid receptor-mediated effects of fentanyl. Plasma fentanyl concentration was measured through 72 hours after placement of FBT. The main outcome measures, maximum plasma fentanyl concentration (C-max) and area under the plasma drug concentration versus time curve from time zero to infinity (AUC(infinity)), were analysed to determine dose proportionality. Other pharmacokinetic parameters were also evaluated. Dose proportionality was concluded if the two-sided 90% confidence intervals (CIs) for the slopes of the C-max versus dose and AUC(infinity) versus dose curves were completely contained within the range of 0.711-1.289. The safety and tolerability of FBT were assessed throughout the study. Results: The slope for C-max versus dose was 0.8627 (90% CI 0.7730, 0.9525), and the slope for AUC(infinity) versus dose was 0.9330 (90% CI 0.8738, 0.9922). Given that the CIs for C-max and AUC(infinity) were within the predefined range of 0.711-1.289, dose proportionality was concluded over the 600-1300 mu g range. The mean dose-normalized plasma fentanyl concentration reached 80% of C-max within 25 minutes; plasma fentanyl concentration was maintained at this level for 3 hours after dose. No unexpected safety or tolerability concerns were noted in the naltrexone-blocked healthy subjects. Seventy-four subjects (68%) experienced adverse events (AEs); all were mild (56 [51%]) or moderate (18 [17%]). The most common AEs were nausea, dizziness and headache. No serious AEs were reported. Conclusion: The dose proportionality of FBT from 600-1300 mu g was shown in healthy subjects. Based on the data, when FBT is titrated up to 1300 mu g, a predictable and linear increase in systemic exposure can be expected. Currently, FBT is approved up to 800 mu g. This study provides pharmacokinetic data to support a potential, expanded therapeutic dose range of FBT.	[Darwish, Mona] Cephalon Inc, Clin Pharmacol, Clin Res, Frazer, PA 19355 USA; [Robertson, Philmore, Jr.; Tracewell, William] Cephalon Inc, Drug Safety & Disposit, Frazer, PA 19355 USA	Darwish, M (reprint author), Cephalon Inc, Clin Pharmacol, Clin Res, 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com			Cephalon, Inc. (Frazer, PA, USA)	This study was sponsored by Cephalon, Inc. (Frazer, PA, USA). The authors acknowledge the medical review by Arvind Narayana, MD, MBA (Cephalon, Inc.). Writing support was provided by Pelo ton Advantage, LLC, funded by Cephalon, Inc. The authors are employees of Cephalon, Inc.	BOWER S, 1982, J PHARM PHARMACOL, V34, P181, DOI 10.1111/j.2042-7158.1982.tb04217.x; *CEPH INC, 2009, FENT PACK INS; *CEPH INC, 2006, DAT FIL; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; International Conference on Harmonisation Working Group, 1996, ICH HARM TRIP GUID G; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279	18	8	8	0	2	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.		2010	30	6					365	373		10.1007/BF03256906			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	610EF	WOS:000278713300002	20441245				2020-06-30	J	Alkhatib, AA; Peterson, KA; Tuteja, AK				Alkhatib, Amer A.; Peterson, Kathryn A.; Tuteja, Ashok K.			Serotonin Syndrome as a Complication of Fentanyl Sedation During Esophagogastroduodenoscopy	DIGESTIVE DISEASES AND SCIENCES			English	Letter									[Alkhatib, Amer A.; Peterson, Kathryn A.; Tuteja, Ashok K.] Univ Utah, Dept Internal Med, Div Gastroenterol, Salt Lake City, UT 84112 USA; [Alkhatib, Amer A.] Washington State Univ, Coll Pharm, Dept Pharmacotherapy, Spokane, WA USA	Alkhatib, AA (reprint author), Univ Utah, Dept Internal Med, Div Gastroenterol, Salt Lake City, UT 84112 USA.	khatibamer@yahoo.com					Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Mason PJ, 2000, MEDICINE, V79, P201, DOI 10.1097/00005792-200007000-00001	3	13	13	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116			DIGEST DIS SCI	Dig. Dis. Sci.	JAN	2010	55	1					215	216		10.1007/s10620-009-0711-x			2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	542TZ	WOS:000273520500035	19165596				2020-06-30	J	Grape, S; Schug, SA; Lauer, S; Schug, BS				Grape, Sina; Schug, Stephan A.; Lauer, Stefan; Schug, Barbara S.			Formulations of Fentanyl for the Management of Pain	DRUGS			English	Review							PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; CONTROLLED INTRANASAL ANALGESIA; CONTROLLED TRANSDERMAL SYSTEM; PATIENT-CONTROLLED ANALGESIA; EFFERVESCENT BUCCAL TABLETS; RANDOMIZED CONTROLLED-TRIAL; BREAKTHROUGH CANCER PAIN; HEALTHY ADULT VOLUNTEERS; RELEASE ORAL MORPHINE	Fentanyl is an opioid initially developed for parenteral administration. While oral administration is not an option due to a high first-pass metabolism, its high potency and lipophilicity have made a number of new routes of administration feasible. The transdermal therapeutic system offers an excellent option for long-term treatment of cancer and chronic pain, achieving stable plasma concentrations over the treatment period. The recent change from reservoir to matrix systems has made these systems more convenient to wear and safer to use, while being bioequivalent. In contrast, the patient-controlled iontophoretic transdermal system has been developed to enable on-demand delivery of transdermal bolus doses of fentanyl to treat postoperative pain. It offers a needle-free system to provide patient-con trolled analgesia otherwise offered by intravenous pumps. However, due to technical difficulties the system is currently not clinically available. Oral transmucosal fentanyl utilizes the rapid uptake through the buccal mucosa to achieve high plasma concentrations rapidly and is indicated to treat breakthrough pain in patients who are not opioid-naive. The recently introduced fentanyl buccal tablets offer slightly better pharmacokinetics for the same indication. The intranasal route is another option to achieve rapid uptake of fentanyl, and is currently being investigated to provide acute and breakthrough pain relief. Transpulmonary administration of fentanyl remains experimental and this route of administration is not yet in clinical use. Overall, the specific pharmacological and physicochemical properties of fentanyl have made this compound highly suitable for novel routes of administration in a range of clinical indications.	[Grape, Sina; Schug, Stephan A.] Royal Perth Hosp, UWA Anaesthesia, Dept Anaesthesia & Pain Med, Perth, WA 6847, Australia; [Schug, Stephan A.] Univ Western Australia, Pharmacol & Anaesthesiol Unit, Perth, WA 6009, Australia; [Schug, Stephan A.; Lauer, Stefan] Univ Munster, Dept Anaesthesiol & Intens Care Med, Munster, Germany; [Schug, Barbara S.] SocraTec R&D GmbH, Oberursel, Germany	Schug, SA (reprint author), Royal Perth Hosp, UWA Anaesthesia, Dept Anaesthesia & Pain Med, Level 2,MRF Bldg G Block,GPO Box X2213, Perth, WA 6847, Australia.	stephan.schug@uwa.edu.au	Schug, Stephan/G-1432-2010	Schug, Stephan/0000-0002-0302-2315	Janssen PharmaceuticalsJohnson & Johnson USAJanssen Biotech Inc	The department of Dr Stephan Schug receives research and consultancy funding from Janssen Pharmaceuticals, which manufacture some of the products mentioned in the review. The company of Dr Barbara Schug, Socratec R&D GmbH, has performed several bioavailability and bioequivalence studies of fentanyl preparations for Ratiopharm, Spirit and Haupt, and has acted as consultants for these companies as well as for Stada. Drs Grape and Lauer have no conflicts that are directly relevant to the content of this review.	Agarwal S, 2007, PAIN MED, V8, P554, DOI 10.1111/j.1526-4637.2006.00246.x; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Berliner MN, 2007, CLIN J PAIN, V23, P530, DOI 10.1097/AJP.0b013e318074c9b1; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Catterall RA, 1997, PALLIATIVE MED, V11, P169; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; del Consuelo ID, 2007, J CONTROL RELEASE, V122, P135, DOI 10.1016/j.jconrel.2007.05.017; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; European Medicines Agency, EUR MED AG REC SUSP; *FDA, IMP SAF INF FENT; Fine PG, 2000, REGION ANESTH PAIN M, V25, P1, DOI 10.1016/S1098-7339(00)80002-4; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; GUPTA SK, 1995, J CLIN PHARMACOL, V35, P159, DOI 10.1002/j.1552-4604.1995.tb05005.x; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; HANKS GW, 1995, J PAIN SYMPTOM MANAG, V10, P87, DOI 10.1016/S0885-3924(08)80004-8; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HOLDSWORTH MT, 1994, GERONTOLOGY, V40, P32; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Landy SH, 2004, HEADACHE, V44, P762, DOI 10.1111/j.1526-4610.2004.04142.x; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Manjushree R, 2002, CAN J ANAESTH, V49, P190; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Neighbors DM, 2001, J PAIN SYMPTOM MANAG, V21, P129, DOI 10.1016/S0885-3924(00)00247-5; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; SANDLER A, 1992, J PAIN SYMPTOM MANAG, V7, pS27, DOI 10.1016/0885-3924(92)90050-R; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; SANDLER AN, 1994, ANESTHESIOLOGY, V81, pA1126; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Shaiova L, 2004, J NATL MED ASSOC, V96, P984; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Skaer TL, 2004, DRUGS, V64, P2629, DOI 10.2165/00003495-200464230-00002; Slatkin Neal E, 2007, J Support Oncol, V5, P327; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Striebel H W, 1993, Schmerz, V7, P174, DOI 10.1007/BF02530425; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Tennant Forest, 2002, J Pain Palliat Care Pharmacother, V16, P37; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	99	64	66	0	14	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs		2010	70	1					57	72		10.2165/11531740-000000000-00000			16	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	547LA	WOS:000273888100004	20030425				2020-06-30	J	Chwieduk, CM; McKeage, K				Chwieduk, Claudine M.; McKeage, Kate			Fentanyl Sublingual In Breakthrough Pain in Opioid-Tolerant Adults with Cancer	DRUGS			English	Article							PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; TRANSDERMAL FENTANYL; MANAGEMENT; MORPHINE; TABLET; RECOMMENDATIONS; RECEPTORS; CITRATE	Fentanyl is a potent opioid with a short duration of action Fentanyl sublingual has been formulated as a rapidly disintegrating tablet that is quickly absorbed, producing a fast onset of analgesia In two randomized, double-blind clinical trials, fentanyl sublingual as single fixed or titrated doses reduced pain intensity during breakthrough pain episodes to a significantly greater extent than placebo in opioid-tolerant cancer patients In a fixed-dose phase II trial and a titrated-dose phase III trial, fentanyl sublingual (as a single 400 mu g dose and as titrated doses) reduced mean pain intensity difference (PID) to a significantly greater extent than placebo over the entire treatment period (up to 60 minutes), reaching statistical significance 15 minutes post-dose In the titrated-dose study, the mean sum of PID (area under the PID vs time curve) at 30 minutes post-dose was significantly greater with fentanyl sublingual than placebo, with significant improvements in PID seen at 10 minutes maintained at 60 minutes post-dose In the phase III study, patients receiving fentanyl sublingual were more satisfied with their treatment than patients receiving placebo (measured using the Patient Global Evaluation of Medication score), and almost half of all fentanyl sublingual recipients were satisfied or very satisfied with their treatment Fentanyl sublingual was generally well tolerated in the two trials and most adverse events were mild to moderate in intensity	[Chwieduk, Claudine M.; McKeage, Kate] Adis, Auckland 0754, New Zealand	Chwieduk, CM (reprint author), Adis, 41 Centorian Dr,Private Bag 65901, Auckland 0754, New Zealand.						[Anonymous], ABSTR SUBL TABL SUMM; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; BOVILL JG, 1987, DRUGS, V33, P520, DOI 10.2165/00003495-198733050-00006; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Christrup LL, 2009, THERAPY, V6, P695; DANJOUX C, 2004, CURR ONCOL, V11, P3; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fine PG, 2000, CNS DRUGS, V13, P313, DOI 10.2165/00023210-200013050-00002; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hair PI, 2008, DRUGS, V68, P2001, DOI 10.2165/00003495-200868140-00005; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Lorch U, 2008, PROCEEDINGS OF THE 13TH INTERNATIONAL PAIN CLINIC CONGRESS: WORLD SOCIETY OF PAIN CLINICIANS, P131; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Mercadante S, 2005, ANN ONCOL, V16, P132, DOI 10.1093/annonc/mdi922; MIASKOWSKI C, AM PAIN SOC GUIDELIN; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; NALAMACHU S, 2009, AM ACAD PAIN MED 25; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; *SCOTT INT GUID NE, CONTR PAIN AD CANC; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003; WILLIAMS DA, 2002, [No title captured]; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304	31	14	15	1	2	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	0012-6667			DRUGS	Drugs		2010	70	17					2281	2288		10.2165/11200910-000000000-00000			8	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	693MO	WOS:000285228400007	21080744				2020-06-30	J	Chu, KS; Wang, FY; Hsu, HT; Lu, IC; Wang, HM; Tsai, CJ				Chu, Koung-Shing; Wang, Fu-Yuan; Hsu, Hung-Te; Lu, I-Cheng; Wang, Hsun-Mo; Tsai, Cheng-Jing			The effectiveness of dexmedetomidine infusion for sedating oral cancer patients undergoing awake fibreoptic nasal intubation	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						dexmedetomidine; fibreoptic nasal intubation; oral cancer	TARGET-CONTROLLED INFUSION; CONSCIOUS SEDATION; ANESTHETIC REQUIREMENTS; HEMODYNAMIC STABILITY; REMIFENTANIL; PROPOFOL; SURGERY; HUMANS	Background and objective Dexmedetomidine is characterized with effects of sedation, analgesia, amnesia and lack of respiratory depression. Hence, it should be suitable for awake fibreoptic intubation (AFOI). Methods We enrolled 30 oral cancer patients with limited mouth openings who were undergoing AFOI for elective surgery. Patients were randomly allocated into two groups; the Dex group (n = 16) that received dexmedetomidine (1.0 mu g kg(-1)) infusion and the Control group (n = 14) that received fentanyl (1.0 mu g kg(-1)) infusion. Main outcomes were evaluated by grading scores presenting conditions for nasal intubation and postintubation. Other analysed parameters included airway obstruction, haemodynamic changes, consumption time for intubation, amnesia level and satisfaction. Results Intubation score (1-5) representing condition for nasal intubation was significantly better in the Dex group [2(1-3)] than in the Control group [3(2-5)] (P=0.001). Postintubation score (1-3) representing tolerance to intubation also showed more favourable results in the Dex group[1(1-3)]than in the Control group[2(2-3)] (P=0.002). The Dex group showed significantly reduced haemodynamic response to intubation than the Control group. Incidence requiring temporary haemodynamic support was higher in the Dex group but not of significance. Both levels of amnesia and satisfaction score were significant in the Dex group. Other analysed parameters such as consumption time for intubation, airway obstruction score and postoperative adverse events did not differ significantly. Conclusion Combination of dexmedetomidine loading with topical anaesthesia provides significant benefit for AFOI in intubation condition, patient tolerance, haemodynamic response, amnesia and satisfaction. Dexmedetomidine is effective for AFOI in anticipated difficult airway with only minor and temporary haemodynamic adverse effects. Eur J Anaesthesiol 27:36-40 (C) 2010 European Society of Anaesthesiology.	[Chu, Koung-Shing; Wang, Fu-Yuan; Hsu, Hung-Te; Lu, I-Cheng; Tsai, Cheng-Jing] Kaohsiung Med Univ, Dept Anesthesiol, Kaohsiung Med Univ Hosp, Kaohsiung 807, Taiwan; [Chu, Koung-Shing; Lu, I-Cheng] Kaohsiung Med Univ, Dept Anesthesiol, Kaohsiung Med Univ Hosp, Grad Inst Med, Kaohsiung 807, Taiwan; [Chu, Koung-Shing] Kaohsiung Med Univ, Dept Anesthesiol, Kaohsiung Med Univ Hosp, Fac Med,Coll Med, Kaohsiung 807, Taiwan; [Wang, Hsun-Mo] Kaohsiung Med Univ, Dept Otorhinolaryngol, Kaohsiung Med Univ Hosp, Kaohsiung 807, Taiwan	Tsai, CJ (reprint author), Kaohsiung Med Univ, Dept Anesthesiol, Kaohsiung Med Univ Hosp, 100 Tzyou 1st Rd, Kaohsiung 807, Taiwan.	t8501107@yahoo.com.tw		Hsu, Hung-Te/0000-0002-2140-3146	Kaohsiung Medical University Hospital [KMUH97-7G21]	This Study was supported by a grant from the Kaohsiung Medical University Hospital (Grant KMUH97-7G21).	AANTAA R, 1990, ANESTHESIOLOGY, V73, P230, DOI 10.1097/00000542-199008000-00007; Abdelmalak B, 2007, J CLIN ANESTH, V19, P370, DOI 10.1016/j.jclinane.2006.09.006; Avitsian R, 2005, J NEUROSURG ANESTH, V17, P97, DOI 10.1097/01.ana.0000161268.01279.ba; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; Bergese SD, 2007, J CLIN ANESTH, V19, P141, DOI 10.1016/j.jclinane.2006.07.005; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Grant SA, 2004, J CLIN ANESTH, V16, P124, DOI 10.1016/j.jclinane.2003.05.010; JAAKOLA ML, 1992, BRIT J ANAESTH, V68, P570, DOI 10.1093/bja/68.6.570; Jooste EH, 2005, ANESTH ANALG, V101, P1248, DOI 10.1213/01.ANE.0000173765.94392.80; Knolle E, 2003, EUR J ANAESTH, V20, P565, DOI 10.1097/00003643-200307000-00009; Lallo A, 2009, ANESTH ANALG, V108, P852, DOI 10.1213/ane.0b013e318184eb31; Lawrence CJ, 1997, ANAESTHESIA, V52, P736, DOI 10.1111/j.1365-2044.1997.169-az0303.x; Machata AM, 2003, ANESTH ANALG, V97, P904, DOI 10.1213/01.ANE.0000074089.39416.F1; Maroof M, 2005, CAN J ANAESTH, V52, P776, DOI 10.1007/BF03016576; Puchner W, 2002, ACTA ANAESTH SCAND, V46, P350, DOI 10.1034/j.1399-6576.2002.460403.x; Rai MR, 2008, BRIT J ANAESTH, V100, P125, DOI 10.1093/bja/aem279; Scher CS, 2003, CAN J ANAESTH, V50, P607, DOI 10.1007/BF03018650; Stamenkovic DM, 2006, ACTA ANAESTH SCAND, V50, P1314, DOI 10.1111/j.1399-6576.2006.01157.x; Stricker P, 2008, ACTA ANAESTH SCAND, V52, P866, DOI 10.1111/j.1399-6576.2008.01631.x; Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x	20	29	57	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JAN	2010	27	1					36	40		10.1097/EJA.0b013e32832e0d2b			5	Anesthesiology	Anesthesiology	542MA	WOS:000273496300009	19550337				2020-06-30	J	Zhang, W; Chang, YZ; Kan, QC; Zhang, LR; Li, ZS; Lu, H; Wang, ZY; Chu, QJ; Zhang, J				Zhang, Wei; Chang, Yan-Zi; Kan, Quan-Cheng; Zhang, Li-Rong; Li, Zhi-Song; Lu, Hui; Wang, Zhong-Yu; Chu, Qin-Jun; Zhang, Jie			CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						CYP3A; Phenotype; Polymorphisms; Fentanyl; Analgesia	DRUG; VARIABILITY; DISPOSITION; MIDAZOLAM; 3A4; PHARMACOGENOMICS; CYCLOSPORINE; EFFICACY; PROBE	Purpose To investigate whether the CYP3A4*1G genetic polymorphism contributes to the variability in CYP3A activity and response to fentanyl. Methods One hundred and forty-three gynecologic patients who were scheduled to undergo abdominal total hysterectomy or myomectomy with general anesthesia were enrolled in this study. Intravenous fentanyl patient-controlled analgesia was provided postoperatively for satisfactory analgesia. The degrees of pain at rest during PCA treatment were assessed with visual analog scale. The fentanyl consumption and occurrence of any adverse effects were recorded in the first 24 h postoperatively. CYP3A activity was measured by plasma 1'-hydroxymidazolam-to-midazolam ratio 1 h after intravenous administration of 0.1 mg/kg midazolam. CYP3A4*1G variant allele was genotyped using the polymerase chain reaction-restriction fragment length polymorphism method. Results The frequency of the CYP3A4*1G variant allele was 0.269 in 143 Chinese gynecologic patients. The activity of CYP3A4 in patients homozygous for the *1G/*1G variant (0.34 +/- 0.15) was significantly lower than that in patients bearing the wild-type allele (*1/*1) (0.46 +/- 0.14) or in patients heterozygous for the *1/*1G variant (0.46 +/- 0.12) (P<0.05). The patients with the CYP3A4*1G/*1G genotype needed less fentanyl (227.8 +/- 55.2 mu g) to achieve pain control than patients carrying the CYP3A4*1/*1 (381.6 +/- 163.6 mu g) and CYP3A4*1/*1G (371.9 +/- 180.1 mu g) genotypes (P<0.05) during the first 24 h postoperatively. There was no significant difference in incidence of adverse events among the different genotype groups (P>0.05). Conclusions CYP3A4*1G genetic polymorphism decreases CYP3A activity and fentanyl consumption for postoperative pain control.	[Zhang, Wei; Chang, Yan-Zi; Kan, Quan-Cheng; Li, Zhi-Song; Lu, Hui; Wang, Zhong-Yu; Chu, Qin-Jun; Zhang, Jie] Zhengzhou Univ, Dept Anesthesiol, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China; [Zhang, Li-Rong] Zhengzhou Univ, Dept Pharmacol, Sch Med, Zhengzhou 450052, Henan, Peoples R China	Kan, QC (reprint author), Zhengzhou Univ, Dept Anesthesiol, Affiliated Hosp 1, 1 E JianShe Rd, Zhengzhou 450052, Peoples R China.	kanquancheng2008@163.com			Medical Science and Technology Research Projects of Henan Province [200703018]	This work was supported by grants from Medical Science and Technology Research Projects of Henan Province (No. 200703018). The authors acknowledge the technical assistance of Shu-Sheng Zhang (Department of Chemistry, Zhengzhou University) in carrying out the LC-MS analysis.	Du J, 2010, J PSYCHOPHARMACOL, V24, P1115, DOI 10.1177/0269881109104932; Du J, 2007, CLIN CHIM ACTA, V383, P172, DOI 10.1016/j.cca.2007.04.027; Du J, 2006, PHARMACOGENOMICS, V7, P831, DOI 10.2217/14622416.7.6.831; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Fukushima-Uesaka Hiromi, 2004, Hum Mutat, V23, P100, DOI 10.1002/humu.9210; Gao Y, 2008, EUR J CLIN PHARMACOL, V64, P877, DOI 10.1007/s00228-008-0502-x; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Hu YF, 2007, XENOBIOTICA, V37, P315, DOI 10.1080/00498250601149206; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Kanazawa H, 2004, J CHROMATOGR A, V1031, P213, DOI 10.1016/j.chroma.2003.12.039; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Streetman DS, 2000, PHARMACOGENETICS, V10, P187, DOI 10.1097/00008571-200004000-00001; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; THUMMEL KE, 1994, J PHARMACOL EXP THER, V271, P557; Villeneuve JP, 2000, CLIN PHARMACOL THER, V67, P242, DOI 10.1067/mcp.2000.104642; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7; Zhu B, 2003, BRIT J CLIN PHARMACO, V55, P264, DOI 10.1046/j.1365-2125.2003.01728.x	21	59	71	0	17	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	JAN	2010	66	1					61	66		10.1007/s00228-009-0726-4			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	549DH	WOS:000274022100006	19784640				2020-06-30	J	Chapa, HO; Venegas, G; VanDuyne, CP; Suvunrungsi, L; Antonetti, AG; Sandate, J				Chapa, Hector O.; Venegas, Gonzalo; VanDuyne, Charles P.; Suvunrungsi, Luke; Antonetti, Alfred G.; Sandate, Jeffrey			In-Office Thermachoice III Ablation: A Comparison of Two Anesthetic Techniques	GYNECOLOGIC AND OBSTETRIC INVESTIGATION			English	Article						In-office ablations; Local anesthesia; Transdermal anesthesia	POSTOPERATIVE PAIN MANAGEMENT; TRANSDERMAL FENTANYL; ENDOMETRIAL ABLATION; CONTROLLED-TRIAL; DOUBLE-BLIND; OUTPATIENT; SEDATION; EFFICACY; PLACEBO; BIOPSY	Background: Patient comfort and safety are prerequisites for office procedures. Study objective: comparison of the fentanyl transdermal patch with injection of local anesthesia for intraoperative/postoperative pain from in-office Thermachoice III ablations. Methods: Single-center prospective randomized (1: 1) cohort study. Primary endpoint: intraoperative and postoperative VAS pain scores (0 as no pain, 10 as extreme pain). Secondary endpoints: patient satisfaction between cohorts and adverse events. Results: 41 patients were randomized [ 21 patch protocol (FP), 20 injection protocol (IP)]. For patch users, the median VAS scores were 2.60 (range 1-4) intraoperatively and 3.30 (range 2-5) postoperatively (p = 0.09, CI = -0.8 to 0.4), with the most common adverse events being nausea (62%) and vomiting (38%). Compared to injection, there was no significant difference in intraoperative VAS score (FP median VAS = 2.60, IP median VAS = 2.59; p = 0.15, CI = -0.05 to 0.48), but a significant difference postoperatively (FP median VAS = 3.30, IP median VAS = 6.0; p = 0.01, CI = -2.6 to -1.4). Less NSAIDs were used postoperatively with the FP. At 24 h, more FP patients were 'very satisfied' or 'satisfied' than IP patients. Conclusion: Patch intraoperative VAS pain scores are comparable to uterine block scores; postoperative VAS pain scores were statistically lower with the FP. FP resulted in more favorable 'satisfaction' rates compared to IP. Copyright (C) 2009 S. Karger AG, Basel	[Chapa, Hector O.; Venegas, Gonzalo; VanDuyne, Charles P.; Suvunrungsi, Luke; Antonetti, Alfred G.; Sandate, Jeffrey] Womens Specialty Ctr, Dallas, TX 75208 USA	Chapa, HO (reprint author), Womens Specialty Ctr, 1135 N Bishop Ave, Dallas, TX 75208 USA.	ChapaMD@aol.com					Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Ball AM, 2006, ORTHOPEDICS, V29, P217, DOI 10.3928/01477447-20060301-13; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Chan Y. H., 2003, SMJ Singapore Medical Journal, V44, P172; Chapa HO, 2009, J REPROD MED, V54, P232; Chapa HO, 2008, J REPROD MED, V53, P829; Department of Health and Human Services (HHS), 2007, GUID REV REP UN PROB; *FENT TRANSD SYST, 2008, PHYS DESK REF, P2352; Glantz JC, 2001, INT J GYNECOL OBSTET, V72, P171, DOI 10.1016/S0020-7292(00)00292-7; GLICK E, 1987, 11 ANN C NAT AB FED; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Lehmann LJ, 1997, REGION ANESTH, V22, P24, DOI 10.1016/S1098-7339(06)80052-0; Lok IH, 2002, J AM ASSOC GYN LAP, V9, P436, DOI 10.1016/S1074-3804(05)60515-4; Marsh F, 2005, FERTIL STERIL, V83, P715, DOI 10.1016/j.fertnstert.2004.08.030; Marsh F, 2007, FERTIL STERIL, V87, P642, DOI 10.1016/j.fertnstert.2006.07.1502; Rattanachaiyanont M, 2005, OBSTET GYNECOL, V106, P533, DOI 10.1097/01.AOG.0000172424.09992.3e; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; SANDLER AN, 1994, ANESTHESIOLOGY, V81, pA26; Sevarino FB, 1997, J CLIN ANESTH, V9, P173, DOI 10.1016/S0952-8180(97)00043-3; STUBBLEFIELD PG, 1989, INT J GYNECOL OBSTET, P131; Trolice MP, 2000, OBSTET GYNECOL, V95, P345, DOI 10.1016/S0029-7844(99)00557-8; WAKNINE Y, 2007, [No title captured]; ZUPI E, 1995, FERTIL STERIL, V63, P414	23	3	3	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-7346	1423-002X		GYNECOL OBSTET INVES	Gynecol.Obstet.Invest.		2010	69	2					140	144		10.1159/000267323			5	Obstetrics & Gynecology	Obstetrics & Gynecology	534MC	WOS:000272900300015	20029223				2020-06-30	J	Talu, A; Rajaleid, K; Abel-Ollo, K; Ruutel, K; Rahu, M; Rhodes, T; Platt, L; Bobrova, N; Uuskula, A				Talu, Ave; Rajaleid, Kristiina; Abel-Ollo, Katri; Rueuetel, Kristi; Rahu, Mati; Rhodes, Tim; Platt, Lucy; Bobrova, Natalia; Uuskuela, Anneli			HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: Implications for intervention	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Injecting drug use; HIV; Fentanyl; Amphetamine; 3-Methylfentanyl; Risk behaviour	DRUG-USERS; HIGH-PREVALENCE; TOGLIATTI CITY; METHAMPHETAMINE USE; RUSSIAN-FEDERATION; SYRINGE EXCHANGE; ILLICIT FENTANYL; UNITED-STATES; COCAINE USE; EPIDEMIC	Background: Following a heroin shortage, fentanyl and 3-methylfentanyl, known as "China White" and "White Persian", have become the most widely used drugs, along with amphetamine, among injecting drug users (IDUs) in Tallinn, Estonia. Methods: In order to assess the relationships between the injection of fentanyl and amphetamine, and levels of HIV prevalence and risk behaviour, 350 current IDUs were recruited using respondent-driven sampling for an interviewer-administered unlinked cross-sectional survey and HIV testing. IDUs were categorised into groups based on self-report of the main drug used within the last 28 days. Results: 77% (256/331) of participants reported fentanyl and 23% (75/331) amphetamine as their main drug of injection. HIV prevalence was 27% (95% confidence interval [CI]: 18.45-35.51) and 62% (95% CI: 56.97-67.03) among amphetamine and fentanyl injectors, respectively. After adjustment, fentanyl injectors had three times the odds of being HIV positive (adjusted odds ratio [AOR] = 2.89; 95% CI: 1.55-5.39). They also had higher odds for injecting in the street with a previously used needle/syringe (AOR = 2.39; 95% CI: 1.14-5.04) and sharing a needle/syringe with somebody known to have HIV (AOR = 3.00, 95% CI: 1.33-6.79). Fentanyl injectors also had higher odds for lifetime overdose (AOR= 3.02, 95% CI: 1.65-5.54). Conclusion: The injection of fentanyl is associated with elevated injecting risk behaviour derived from injection practice and situational risk factors, and needs urgently targeted interventions. Crown Copyright (C) 2009 Published by Elsevier B.V. All rights reserved.	[Talu, Ave; Abel-Ollo, Katri] Natl Inst Hlth Dev, Estonian Drug Monitoring Ctr, EE-11619 Tallinn, Estonia; [Talu, Ave; Rueuetel, Kristi; Uuskuela, Anneli] Univ Tartu, Dept Publ Hlth, EE-50411 Tartu, Estonia; [Rajaleid, Kristiina] Stockholm Univ, Karolinska Inst, Ctr Hlth Equ Studies, SE-10691 Stockholm, Sweden; [Rueuetel, Kristi] Natl Inst Hlth Dev, Dept Infect Dis & Drug Prevent, EE-11619 Tallinn, Estonia; [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, EE-11619 Tallinn, Estonia; [Rahu, Mati; Uuskuela, Anneli] Estonian Ctr Behav & Hlth Sci, Tartu, Estonia; [Rhodes, Tim; Platt, Lucy] London Sch Hyg & Trop Med, Ctr Res Drugs & Hlth Behav, London WC1E 7HT, England; [Bobrova, Natalia] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	Talu, A (reprint author), Natl Inst Hlth Dev, Estonian Drug Monitoring Ctr, Hiiu 42, EE-11619 Tallinn, Estonia.	ave.talu@tai.ee	Uuskula, Anneli/H-3303-2015; Rahu, Mati/A-9981-2008; Rajaleid, Kristiina/AAI-3452-2020	Uuskula, Anneli/0000-0002-4036-3856; Rhodes, Tim/0000-0003-2400-9838	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW000233, R01 TW006990]		ABEL K, 2005, ESTONIA DRUG SITUATI; ABEL K, 2004, ESTONIA DRUG SITUATI; ABELOLLO K, 2007, NATL REPORT 2006 DAT; Atlani L, 2000, SOC SCI MED, V50, P1547, DOI 10.1016/S0277-9536(99)00464-5; Ball AL, 2007, ADDICTION, V102, P684, DOI 10.1111/j.1360-0443.2007.01761.x; Berens AIL, 1996, LANCET, V347, P1334, DOI 10.1016/S0140-6736(96)90981-2; Booth RE, 2008, AIDS BEHAV, V12, P652, DOI 10.1007/s10461-008-9359-3; Braine N, 2005, AIDS EDUC PREV, V17, P515, DOI 10.1521/aeap.2005.17.6.515; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Colfax Grant, 2005, Curr HIV/AIDS Rep, V2, P194, DOI 10.1007/s11904-005-0016-4; CONNELL JA, 1993, J MED VIROL, V41, P159, DOI 10.1002/jmv.1890410212; Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3; Dehne KL, 1999, AIDS, V13, P741, DOI 10.1097/00002030-199905070-00002; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Des Jarlais Don C., 1994, P65; *EUR CTR EP MON HI, 2007, HIV AIDS SURV EUR EN; *EUR MON CTR DRUGS, 2006, [No title captured]; *EUR MON CTR DRUGS, 2004, [No title captured]; Fuller CM, 2003, JAIDS, V32, P86, DOI 10.1097/00126334-200301010-00013; Hagan H, 2000, MT SINAI J MED, V67, P423; Hagan H, 2005, AIDS, V19, pS199, DOI 10.1097/01.aids.0000192066.86410.8c; Hamers FF, 2003, LANCET, V361, P1035, DOI 10.1016/S0140-6736(03)12831-0; Heckathorn DD, 2002, SOC PROBL, V49, P11, DOI 10.1525/sp.2002.49.1.11; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m; HECKATHORN DD, 2006, RDSAT VERSION 5 6; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hien NT, 2001, J SUBST ABUSE, V13, P45, DOI 10.1016/S0899-3289(01)00059-1; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Jonsson AK, 2007, FORENSIC SCI INT, V169, P101, DOI 10.1016/j.forsciint.2006.08.002; Kelly JA, 2003, INT J STD AIDS, V14, P361, DOI 10.1258/095646203765371231; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; LOHMUS L, 2007, SUSTL KUL HIV AIDS I; Magis-Rodriguez C, 2005, J PSYCHOACTIVE DRUGS, V37, P333, DOI 10.1080/02791072.2005.10400528; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Molitor F, 1999, AM J DRUG ALCOHOL AB, V25, P475, DOI 10.1081/ADA-100101874; Molitor F, 1998, WESTERN J MED, V168, P93; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; OOLE K, 2006, NATL REPORT 2005 DAT; PARRY JV, 1995, J MED VIROL, V45, P10, DOI 10.1002/jmv.1890450103; Platt L, 2006, AIDS, V20, P2120, DOI 10.1097/01.aids.0000247586.23696.20; *POL, 2005, NARK NEND MOJ KUR EE; Pollini RA, 2008, ADDICTION, V103, P101, DOI 10.1111/j.1360-0443.2007.02051.x; Rhodes T, 2005, SOC SCI MED, V61, P1026, DOI 10.1016/j.socscimed.2004.12.024; Rhodes T, 2004, JAIDS-J ACQ IMM DEF, V35, P293, DOI 10.1097/00126334-200403010-00011; Rhodes T, 2003, SOC SCI MED, V57, P39, DOI 10.1016/S0277-9536(02)00521-X; Rhodes T, 2002, AIDS, V16, pF25, DOI 10.1097/00002030-200209060-00002; *RIIKL TERV, 2005, RIIGI TEATAJA, V117, P1856; Rosenblum A, 2007, DRUG ALCOHOL DEPEN, V90, P64, DOI 10.1016/j.drugalcdep.2007.02.012; TALU A, 2003, ESTONIA DRUG SITUATI; TALU A, 2008, 2008 NATL REPORT 200; Tyndall MW, 2003, AIDS, V17, P887, DOI 10.1097/00002030-200304110-00014; *UNAIDS WHO, 2006, AIDS EP UPD DEC 2006; United Nations Office on Drugs and Crime (UNODC), 2005, WORLD DRUG REP; Uuskula A, 2006, J INFECT DIS, V193, P455, DOI 10.1086/499436; Uuskula A, 2008, J PUBLIC HEALTH-UK, V30, P119, DOI 10.1093/pubmed/fdn014; Uuskula A, 2007, ADDICT RES THEORY, V15, P411, DOI 10.1080/16066350701417533; Uuskula A, 2007, INT J STD AIDS, V18, P41, DOI 10.1258/095646207779949907; Vallejo Ricardo, 2004, Am J Ther, V11, P354, DOI 10.1097/01.mjt.0000132250.95650.85; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; Wang JC, 2005, DRUG ALCOHOL DEPEN, V78, P147, DOI 10.1016/j.drugalcdep.2004.10.011; Wei G, 2003, BIOCHEM PHARMACOL, V65, P1761, DOI 10.1016/S0006-2952(03)00085-6; Werb D, 2008, J PUBLIC HEALTH-UK, V30, P126, DOI 10.1093/pubmed/fdn021; Wilson TE, 2007, INT J STD AIDS, V18, P389, DOI 10.1258/095646207781024900; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x; Wood E, 2005, PUBLIC HEALTH REP, V120, P150, DOI 10.1177/003335490512000208	67	31	32	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	JAN	2010	21	1					56	63		10.1016/j.drugpo.2009.02.007			8	Substance Abuse	Substance Abuse	547RX	WOS:000273908000009	19395249				2020-06-30	J	Carvalho, B; Coleman, L; Saxena, A; Fuller, AJ; Riley, ET				Carvalho, B.; Coleman, L.; Saxena, A.; Fuller, A. J.; Riley, E. T.			Analgesic requirements and postoperative recovery after scheduled compared to unplanned cesarean delivery: a retrospective chart review	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Review						Postoperative analgesia; Epidural; Spinal; Cesarean delivery; Recovery	RELEASE EPIDURAL MORPHINE; POSTPARTUM TUBAL-LIGATION; INTRATHECAL MORPHINE; SPINAL-ANESTHESIA; CONTROLLED-TRIAL; DOSE-RESPONSE; PAIN; SECTION; MANAGEMENT; PLACEBO	Background: Studies examining the effects of various analgesics and anesthetics on postoperative pain following cesarean delivery conventionally use the scheduled cesarean population. This study compares postoperative analgesic requirements and recovery profiles in women undergoing scheduled cesarean compared to unplanned cesarean delivery following labor. We postulated that unplanned cesarean deliveries may increase postoperative analgesic requirements. Methods: We conducted a retrospective chart review of 200 cesarean deliveries at Lucile Packard Children's Hospital, California. We examined the records of 100 patients who underwent scheduled cesarean delivery under spinal anesthesia (hyperbaric bupivacaine 12 mg with intrathecal fentanyl 10 mu g and morphine 200 mu g) and 100 patients that following a trail of labor required unplanned cesarean under epidural anesthesia (10-25 mL 2% lidocaine top-Lip with epidural morphine 4 mg after clamping of the umbilical cord). We recorded pain scores, analgesic consumption, time to first analgesic request, side effects, and length of hospital stay. Results: We found no differences in postoperative pain scores and analgesic consumption between scheduled and unplanned cesarean deliveries for up to five days postoperatively. There were no differences in treatment of side effects such as nausea, vomiting, or pruritus (P > 0.05). Conclusion: The results indicate that women experience similar pain and analgesic requirements after scheduled compared to unplanned cesarean delivery. This suggests that the non-scheduled cesarean population may be a suitable pain model to study pain management strategies; and that alterations in pain management are not necessary for the unplanned cesarean delivery population. (C) 2009 Elsevier Ltd. All rights reserved.	[Carvalho, B.; Coleman, L.; Saxena, A.; Fuller, A. J.; Riley, E. T.] Stanford Univ, Dept Anesthesia, Sch Med, Stanford, CA 94305 USA	Carvalho, B (reprint author), Stanford Univ, Dept Anesthesia, Sch Med, Stanford, CA 94305 USA.	bcarvalho@stanford.edu					Angle PJ, 2002, ANESTH ANALG, V95, P741, DOI 10.1097/00000539-200209000-00038; Bucklin BA, 2003, CLIN OBSTET GYNECOL, V46, P657, DOI 10.1097/00003081-200309000-00018; Campbell DC, 2001, ANESTH ANALG, V93, P1006, DOI 10.1097/00000539-200110000-00042; Carvalho B, 2005, ANESTH ANALG, V100, P1150, DOI 10.1213/01.ANE.0000149544.58230.FF; Carvalho B, 2007, ANESTH ANALG, V105, P176, DOI 10.1213/01.ane.0000265533.13477.26; Carvalho B, 2006, ANESTH ANALG, V103, P664, DOI 10.1213/01.ane.0000229702.42426.a6; Chumpathong Saowapark, 2002, Journal of the Medical Association of Thailand, V85, pS956; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Duale C, 2003, BRIT J ANAESTH, V91, P690, DOI 10.1093/bja/aeg249; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Kulmatycki KM, 2007, J PHARM PHARM SCI, V10, P554; Lowder JL, 2003, AM J OBSTET GYNECOL, V189, P1559, DOI 10.1016/j.ajog.2003.08.014; Ogun CO, 2003, REGION ANESTH PAIN M, V28, P253, DOI 10.1053/rapm.2003.50054; PALMER CM, 1995, REGION ANESTH, V20, P389; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Palmer CM, 2000, ANESTH ANALG, V90, P887, DOI 10.1213/00000539-200004000-00021; Qazi GR, 2007, JCPSP-J COLL PHYSICI, V17, P611; Rastogi S, 2008, INT J OBSTET ANESTH, V17, P82, DOI 10.1016/j.ijoa.2007.03.007; Saravanakumar K, 2006, ANAESTHESIA, V61, P36, DOI 10.1111/j.1365-2044.2005.04433.x; Sarvela J, 2002, ANESTH ANALG, V95, P436, DOI 10.1097/00000539-200208000-00037; SUNSHINE A, 1993, CLIN PHARMACOL THER, V54, P546, DOI 10.1038/clpt.1993.187; Terajima Katsuyuki, 2003, Journal of Nippon Medical School, V70, P327	22	16	16	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2010	19	1					10	15		10.1016/j.ijoa.2009.02.012			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	546WO	WOS:000273845400004	19954964				2020-06-30	J	Milic, M; Goranovic, T; Knezevic, P				Milic, M.; Goranovic, T.; Knezevic, P.			Complications of sevoflurane-fentanyl versus midazolam-fentanyl anesthesia in pediatric cleft lip and palate surgery: a randomized comparison study	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						anesthesia; general; anesthesia; recovery period; cleft palate; emergence agitation; midazolam; sevoflurane; postoperative nausea and vomiting	INHALATIONAL INDUCTION; EMERGENCE AGITATION; CHILDREN; MANAGEMENT; DELIRIUM	Careful choice of anesthetic agents in pediatric patients reduces the frequency of anesthesia-related complications. The frequency and type of intraoperative and postoperative complications of sevofluranc-fentanyl versus midazolam-fentanyl anesthesia were compared in, 140 Consecutive Children (aged 3 months to 10 years) undergoing cleft lip and palate repair. Midazolam-fentanyl anesthesia was induced with midazolam (0.05 mg/kg), fentanyl (0.005 mg/kg) and vecuronium (0.1 mg/kg), and maintained with the same agents according to the defined parametars. Sevoflurane-fentanyl anesthesia was induced and maintained with sevoflurane (5-8 vol% and 0.8-1 vol%, respectively) in ail oxygen/air mixture and supplemented with fentallyl (0.005 mg/kg). Both groups were comparable in basic demographic data, hemodynamic and respiratory parameters. Difficult intubation occurred ill 6 of 76 children (midazolam-fentanyl group) and 4 of 64 children (sevoflurane-fentanyl group) (P=0.754). Ventricular extrasystole and bronchospasm occurred ill one patient each in the sevoflurane-fentanyl,group. Postoperatively, emergence agitation was observed in the sevoflurane-fentanyl group (17 cases; P < 0.001); postoperative nausea and vomiting Occurred in 2 children (midazolan-fentanyl group) and 3 children (sevofluranc-fentanyl group) (P = 0.660). Midazolam-based anesthesia ill children is safer than sevoflurane-based anesthesia regarding occurrence of emergence agitation.	[Milic, M.] Univ Zagreb, Dubrava Univ Hosp, Dept Anesthesiol Reanimatol & Intens Care Med, Zagreb, Croatia; [Goranovic, T.] Univ Zagreb, Holy Ghost Gen Hosp, Dept Anesthesia & Intens Care Unit, Zagreb, Croatia; [Knezevic, P.] Univ Zagreb, Dubrava Univ Hosp, Dept Oral & Maxillofacial Surg, Zagreb, Croatia	Goranovic, T (reprint author), Univ Zagreb, Gen Hosp Sveti Duh, Dept Anesthesia & Intens Care Unit, Sveti Duh 64, Zagreb 10000, Croatia.	tanjagoranovic@hotmail.com	Ziegler, Michael/L-4728-2019				Afonin D. V., 2007, Anesteziologiya i Reanimatologiya, P7; Breschan C, 2007, PEDIATR ANESTH, V17, P347, DOI 10.1111/j.1460-9592.2006.02101.x; Chawathe M, 2005, PEDIATR ANESTH, V15, P470, DOI 10.1111/j.1460-9592.2005.01478.x; Constant I, 2005, PEDIATR ANESTH, V15, P266, DOI 10.1111/j.1460-9592.2004.01538.x; Constant I, 2005, CURR OPIN ANESTHESIO, V18, P277, DOI 10.1097/01.aco.0000169235.83561.3a; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dell'Oste C, 2004, ACTA ANAESTH SCAND, V48, P787, DOI 10.1111/j.0001-5172.2004.00407.x; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; Funk W, 1996, ANAESTHESIST, V45, P22, DOI 10.1007/s001010050236; Gunawardana RH, 1996, BRIT J ANAESTH, V76, P757; Hallen J, 2001, J CLIN ANESTH, V13, P161, DOI 10.1016/S0952-8180(01)00236-7; Klingmann A, 2006, ANAESTHESIST, V55, P93, DOI 10.1007/s00101-005-0954-7; Lodes U, 1999, Anaesthesiol Reanim, V24, P13; Machotta A, 2005, ANAESTHESIST, V54, P455, DOI 10.1007/s00101-005-0823-4; Malmgren W, 2004, ACTA ANAESTH SCAND, V48, P1277, DOI 10.1111/j.1399-6576.2004.00528.x; Roulleau P, 2003, PAEDIATR ANAESTH, V13, P701, DOI 10.1046/j.1460-9592.2003.01102.x; Tazeroualti N, 2007, BRIT J ANAESTH, V98, P667, DOI 10.1093/bja/aem071; Veyckemans F, 2002, Minerva Anestesiol, V68, P402; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Wang X, 1999, Hua Xi Kou Qiang Yi Xue Za Zhi, V17, P239; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08	21	14	19	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027	1399-0020		INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	JAN	2010	39	1					5	9		10.1016/j.ijom.2009.09.007			5	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	559QX	WOS:000274842400002	19854614				2020-06-30	J	Law, BF; Hettick, JM; Hornsby-Myers, J; Siegel, PD				Law, Brandon F.; Hettick, Justin M.; Hornsby-Myers, Jennifer; Siegel, Paul D.			Analytical Methodology and Assessment of Potential Second-Hand Exposure to Fentanyl in the Hospital Surgical Setting	JOURNAL OF ADDICTIVE DISEASES			English	Article						Fentanyl; second-hand; air sampling; surgical	SUBSTANCE MISUSE; ANESTHETISTS; PHYSICIANS; ADDICTION	Second-hand exposure to aerosols containing fentanyl and other opiates during surgical procedures has been implicated as possibly contributing to maintenance of addiction among medical professionals, specifically anesthesiologists. This article outlines a pilot study that was conducted to verify a reported finding fentanyl in the air of operating suites. Environmental fentanyl air sampling and analysis methods were developed and evaluated for this study. Multiple sampling media and extraction solvents were evaluated for trace fentanyl air sampling. Non-specific binding losses were reduced by using silanized binder-free glass fiber sampling media with subsequent methanol extraction. Filtration air samples were then collected in surgical suites during the entire operation time from two cardiovascular surgical procedures. Both surgical procedures were conducted at the same hospital but on different days. Samples were extracted and analyzed by high-performance liquid chromatography/tandem mass spectrometry using a capillary high-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. The total air volume collected per surgery was 290 to 300 L at a rate of 1 LPM giving an limit of quantification for fentanyl of 57 pg/m(3) air (17 pg/filter). No fentanyl was detected in the air during cardiovascular surgical operations from either surgical suite.	[Law, Brandon F.; Hettick, Justin M.; Siegel, Paul D.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; [Hornsby-Myers, Jennifer] NIOSH, Off Director, Morgantown, WV 26505 USA	Law, BF (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, 1095 Willowdale Rd,MS 4020, Morgantown, WV 26505 USA.	bh17@cdc.gov	Hettick, Justin/E-9955-2010				*AC ARCH HLTH AM I, 1996, GUID DES CONSTR HOSP; Baird WLM, 2000, ANAESTHESIA, V55, P943, DOI 10.1046/j.1365-2044.2000.01765.x; Berry CB, 2000, ANAESTHESIA, V55, P946, DOI 10.1046/j.1365-2044.2000.01758.x; Cohen PJ, 2006, J ADDICT DIS, V25, P135, DOI 10.1300/J069v25n04_14; Denisco RA, 2006, J ADDICT DIS, V25, P137, DOI 10.1300/J069v25n04_15; Gold MS, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n01_04; Gold MS, 2004, PSYCHIAT CLIN N AM, V27, P745, DOI 10.1016/j.psc.2004.07.006; Gorman E, 2006, J ADDICT DIS, V25, P139, DOI 10.1300/J069v25n04_16; Gupta PK, 2008, J CHEM ENG DATA, V53, P841, DOI 10.1021/je7005067; Hughes PH, 1999, J ADDICT DIS, V18, P23, DOI 10.1300/J069v18n02_03; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; NADINE FJ, 2004, J CHROMATOGR A, V1035, P249; Verghese A, 2002, NEW ENGL J MED, V346, P1510, DOI 10.1056/NEJM200205163462002	14	5	5	0	5	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	1055-0887			J ADDICT DIS	J. Addict. Dis.		2010	29	1					51	58		10.1080/10550880903438933			8	Substance Abuse	Substance Abuse	559BU	WOS:000274795600005	20390698				2020-06-30	J	Stimmel, B				Stimmel, Barry			Anesthesiologists and Fentanyl: Fact or Fancy?	JOURNAL OF ADDICTIVE DISEASES			English	Editorial Material							2ND-HAND EXPOSURE		Mt Sinai Sch Med, New York, NY 10029 USA	Stimmel, B (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA.	barry.stimmel@mssm.edu					Gold MS, 2004, PSYCHIAT CLIN N AM, V27, P745, DOI 10.1016/j.psc.2004.07.006; Law BF, 2010, J ADDICT DIS, V29, P51, DOI 10.1080/10550880903438933; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030	3	1	1	0	1	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	1055-0887			J ADDICT DIS	J. Addict. Dis.		2010	29	3					279	279	PII 924396976	10.1080/10550887.2010.490465			1	Substance Abuse	Substance Abuse	626JY	WOS:000279963500001	20635275				2020-06-30	J	Gold, MS; Graham, NA; Goldberger, BA				Gold, Mark S.; Graham, Noni A.; Goldberger, Bruce A.			Second-Hand and Third-Hand Drug Exposures in the Operating Room: A Factor in Anesthesiologists' Dependency on Fentanyl	JOURNAL OF ADDICTIVE DISEASES			English	Article							PROPOFOL CONCENTRATIONS; SPECTROMETRY; BREATH		[Gold, Mark S.; Graham, Noni A.; Goldberger, Bruce A.] Univ Florida, Dept Psychiat, Coll Med, Gainesville, FL 32610 USA; [Goldberger, Bruce A.] Univ Florida, Dept Pathol Immunol & Loboratory Med, Coll Med, Gainesville, FL 32610 USA	Gold, MS (reprint author), Univ Florida, Dept Psychiat, Coll Med, Gainesville, FL 32610 USA.	msgold@ufl.edu					Gong Y, 2009, J INT MED RES, V37, P1465, DOI 10.1177/147323000903700522; Grossherr M, 2009, BRIT J ANAESTH, V102, P608, DOI 10.1093/bja/aep053; Law BF, 2010, J ADDICT DIS, V29, P51, DOI 10.1080/10550880903438933; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030; Merlo LJ, 2008, HARVARD REV PSYCHIAT, V16, P181, DOI 10.1080/10673220802160316; MERLO LJ, 2010, AM SOC ADD MED 41 AN; Perl T, 2009, BRIT J ANAESTH, V103, P822, DOI 10.1093/bja/aep312; SCHEBESTA K, 2010, ACTA ANAESTHESI 0106	8	4	4	0	0	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	1055-0887			J ADDICT DIS	J. Addict. Dis.		2010	29	3					280	281	PII 924376286	10.1080/10550887.2010.490466			2	Substance Abuse	Substance Abuse	626JY	WOS:000279963500002	20635276				2020-06-30	J	Law, BF; Hettick, JM; Hornsby-Myers, J; Siegel, PD				Law, Brandon F.; Hettick, Justin M.; Hornsby-Myers, Jennifer; Siegel, Paul D.			Reservations Concerning Second-Hand Fentanyl Exposure in the Operating Room	JOURNAL OF ADDICTIVE DISEASES			English	Article									[Law, Brandon F.; Hettick, Justin M.; Hornsby-Myers, Jennifer; Siegel, Paul D.] Ctr Dis Control, NIOSH, Morgantown, WV 26505 USA	Law, BF (reprint author), Ctr Dis Control, NIOSH, 944 Chestnut Ridge Rd, Morgantown, WV 26505 USA.	bhl7@cdc.gov	Hettick, Justin/E-9955-2010				Cohen PJ, 2006, J ADDICT DIS, V25, P135, DOI 10.1300/J069v25n04_14; Denisco RA, 2006, J ADDICT DIS, V25, P137, DOI 10.1300/J069v25n04_15; Gorman E, 2006, J ADDICT DIS, V25, P139, DOI 10.1300/J069v25n04_16; Law BF, 2010, J ADDICT DIS, V29, P51, DOI 10.1080/10550880903438933; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030; NADINE FJ, 2004, J CHROMATOGR A, V1035, P249; POLK SL, ASA NEWSLETTER	7	0	0	0	1	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	1055-0887			J ADDICT DIS	J. Addict. Dis.		2010	29	3					282	283	PII 924374660	10.1080/10550887.2010.490467			2	Substance Abuse	Substance Abuse	626JY	WOS:000279963500003	20635277				2020-06-30	J	Yamamoto, Y; Kawaguchi, M; Hayashi, H; Abe, R; Inoue, S; Nakase, H; Sakaki, T; Furuya, H				Yamamoto, Yuri; Kawaguchi, Masahiko; Hayashi, Hironobu; Abe, Ryuichi; Inoue, Satoki; Nakase, Hiroyuki; Sakaki, Toshisuke; Furuya, Hitoshi			Evaluation of Posttetanic Motor Evoked Potentials-The Influences of Repetitive Use, the Residual Effects of Tetanic Stimulation to Peripheral Nerve, and the Variability	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						posttetanic motor evoked potentials; posttetanic potentiation; fatigue; variability	TRANSCRANIAL ELECTRICAL-STIMULATION; NEUROMUSCULAR BLOCKADE; GENERAL-ANESTHESIA; ISOMETRIC TWITCH; SKELETAL MUSCLE; SPINAL-CORD; PROPOFOL; SINGLE; ISOFLURANE; AMPLITUDES	Background: Recently, we developed a new technique to augment myogenic motor evoked potentials (MEPs), called as posttetanic MEPs (p-MEPs), in which tetanic stimulation is applied to peripheral nerve before transcranial stimulation. However, the data on p-MEPs are limited. This study was conducted; (1) to evaluate the influences of repetitive use of p-MEPs on p-MEP amplitudes, (2) to evaluate the residual effects of use of p-MEPs on subsequent conventional MEPs (c-MEPs),. and (3) to compare the variability of p-MEPs with that of c-MEPs. Methods: Sixty patients under propofol/fentanyl anesthesia with partial neuromuscular blockade were enrolled. For p-MEP measurements, tetanic stimulation was applied to posterior tibial nerve I second before transcranial stimulation. In study 1, p-MEPs were repetitively recorded with intervals of 10 or 60 seconds. In study 2, the amplitudes of c-MEPs recorded 15, 30, 60, and 120 seconds after p-MEP recordings were compared with those of control. In study 3, the coefficients of variation of c-MEP and p-MEP responses were compared. Results: The repetitive use of p-MEP with an interval of 10 seconds, but not 60 seconds, induced a significant reduction of p-MEP amplitude. Amplitudes of c-MEP were significantly increased when applied within 60 seconds after p-MEP recordings. The coefficient of variations of p-M Us was similar to those of c-MEPs. Conclusions: The results indicated that the amplitudes of p-MEP and c-MEP might be affected when applied with a short interval after p-MEP recording. I	[Yamamoto, Yuri; Kawaguchi, Masahiko; Hayashi, Hironobu; Abe, Ryuichi; Inoue, Satoki; Furuya, Hitoshi] Nara Med Univ, Dept Anesthesiol, Nara 6348522, Japan; [Nakase, Hiroyuki; Sakaki, Toshisuke] Nara Med Univ, Dept Neurosurg, Nara 6348522, Japan	Kawaguchi, M (reprint author), Nara Med Univ, Dept Anesthesiol, Shijo Cho 840, Nara 6348522, Japan.	drjkawa@naramed-u.ac.jp		Hayashi, Hironobu/0000-0002-4352-0423			CLOSE R, 1968, J PHYSIOL-LONDON, V197, P461, DOI 10.1113/jphysiol.1968.sp008570; CONNOLLY R, 1971, J GEN PHYSIOL, V57, P697; CUPIDO CM, 1992, EUR J APPL PHYSIOL, V65, P567, DOI 10.1007/BF00602367; Hayashi H, 2008, SPINE, V33, pE994, DOI 10.1097/BRS.0b013e318188adfc; Kakimoto M, 2005, ANESTHESIOLOGY, V102, P733, DOI 10.1097/00000542-200504000-00007; KALKMAN CJ, 1993, ACTA ORTHOP SCAND, V64, P114, DOI 10.3109/17453679308994549; Kawaguchi M, 2000, SPINE, V25, P974, DOI 10.1097/00007632-200004150-00013; Kawaguchi M, 1998, J NEUROSURG ANESTH, V10, P131, DOI 10.1097/00008506-199807000-00001; KAWAGUCHI M, 1996, ANESTHESIOLOGY, V85, P176; Kawaguchi Masahiko, 2004, J Anesth, V18, P18, DOI 10.1007/s00540-003-0201-9; Lotto ML, 2004, J NEUROSURG ANESTH, V16, P32, DOI 10.1097/00008506-200401000-00008; MacDonald DB, 2002, J CLIN NEUROPHYSIOL, V19, P416, DOI 10.1097/00004691-200210000-00005; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; Ubags LH, 1998, NEUROSURGERY, V43, P90, DOI 10.1097/00006123-199807000-00058; van Dongen EP, 1999, ANESTH ANALG, V88, P22, DOI 10.1097/00000539-199901000-00005; VERGARA JL, 1977, AM J PHYSIOL, V232, pC185; Wu LG, 1998, BIOPHYS J, V74, P3003, DOI 10.1016/S0006-3495(98)78007-5; Yamamoto Y, 2008, ANESTH ANALG, V106, P930, DOI 10.1213/ane.0b013e3181617508; Yamamoto Y, 2007, ANESTH ANALG, V104, P1488, DOI 10.1213/01.ane.0000261518.62873.91; Yamamoto Y, 2006, ANESTH ANALG, V102, P1715, DOI 10.1213/01.ane.0000208992.83093.5c	20	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2010	22	1					6	10		10.1097/ANA.0b013e3181b9dd3a			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	540FH	WOS:000273316200002	19779367				2020-06-30	J	Forsgren, J; Jamstorp, E; Bredenberg, S; Engqvist, H; Stromme, M				Forsgren, Johan; Jamstorp, Erik; Bredenberg, Susanne; Engqvist, Hakan; Stromme, Maria			A Ceramic Drug Delivery Vehicle for Oral Administration of Highly Potent Opioids	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						sustained release; ceramic drug carrier; opioids; potent drugs; oral administration	WEIBULL FUNCTION; RELEASE; HALLOYSITE; PREVALENCE; MANAGEMENT; SIMULATION; MATRICES	Pellets composed of the ceramic material Halloysite and microcrystalline cellulose were synthesized with the aim of producing a drug delivery vehicle for sustained release of the opioid Fentanyl with low risk for dose dumping at oral intake of the highly potent drug. Drug release profiles of intact and crushed pellets, to simulate swallowing without or with chewing, in pH 6.8, pH 1, and in 48% ethanol were recorded in order to replicate the conditions in the small intestines, in the stomach, as well as cointake of the drug with alcohol. The drug release was analyzed by employing the Weibull equation, which showed that the release profiles were either governed by fickian diffusion (intact pellets in pH 6.8 and in ethanol) or by diffusion in a fractal or disordered pore network (intact pellets in pH 1 and crushed pellets in all solutions). A sustained release for similar to 3-4h was obtained in all studied solutions from intact pellets, whereas crushed pellets released the drug content during similar to 2-3 h. The finding that a sustained release profile could be obtained both in alcohol and after crushing of the pellets, shows that the ceramic carrier under investigation, at least to some extent, hampers dose dumping, and may thus be a promising material in future developments of new opioid containing oral dosage forms. (C) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:219-226, 2010	[Engqvist, Hakan] Uppsala Univ, Div Mat Sci, Dept Engn Sci, Angstrom Lab, SE-75121 Uppsala, Sweden; [Forsgren, Johan; Jamstorp, Erik; Stromme, Maria] Uppsala Univ, Div Nanotechnol & Funct Mat, Dept Engn Sci, Angstrom Lab, SE-75121 Uppsala, Sweden; [Bredenberg, Susanne] Orexo AB, SE-75105 Uppsala, Sweden	Engqvist, H (reprint author), Uppsala Univ, Div Mat Sci, Dept Engn Sci, Angstrom Lab, POB 534, SE-75121 Uppsala, Sweden.	hakan.engqvist@angstrom.uu.se; maria.stromme@angstrom.uu.se	Berg, Erik J./AAG-9424-2020; J. Berg, Erik/G-4999-2017; Forsgren, Johan/D-3627-2009	Berg, Erik J./0000-0001-5653-0383; J. Berg, Erik/0000-0001-5653-0383; Engqvist, Hakan/0000-0001-9529-650X	VinnovaVinnova; Uppsala BIO-X; Orexo AB	The Swedish funding agency Vinnova, Uppsala BIO-X and Orexo AB are greatly acknowledged for financial support of this project. Anna Dahlgren and Maria Nystrom, Orexo AB, are acknowledged for their assistance during sample preparation, particle size distribution measurements and drug release analysis.	BARRET EP, 1951, J AM CHEM SOC, V73, P380; Bolen J, 2002, JAMA-J AM MED ASSOC, V288, P3103; Bonica J. J., 1987, CHRONIC NONCANCER PA, P13; Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; Byrne RS, 2005, J MICROENCAPSUL, V22, P423, DOI 10.1080/02652040500100196; CHURCHMAN GJ, 1995, CLAY MINER, V30, P89, DOI 10.1180/claymin.1995.030.2.01; Davis JJ, 2003, ANESTH ANALG, V97, P1661, DOI 10.1213/01.ANE.0000090151.13573.42; DIXON JB, 1974, CLAY CLAY MINER, V22, P127, DOI 10.1346/CCMN.1974.0220118; Dollery C.S., 1991, THERAPEUTIC DRUGS; FDA, 2005, FDA AL HEALTHC PROF; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011; Harrison J.L., 1962, CLAY MINER, V9, P374; HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018; Joussein E, 2005, CLAY MINER, V40, P383, DOI 10.1180/0009855054040180; Kosmidis K, 2003, PHARM RES-DORDR, V20, P988, DOI 10.1023/A:1024497920145; Lasserre A, 1998, CRIT REV THER DRUG, V15, P1; Levis SR, 2003, INT J PHARM, V253, P145, DOI 10.1016/S0378-5173(02)00702-0; Levis SR, 2002, INT J PHARM, V243, P125, DOI 10.1016/S0378-5173(02)00274-0; MARTIN D, 2000, 2000 NZ MINERALS MIN; Papadopoulou V, 2006, INT J PHARMACEUT, V309, P44, DOI 10.1016/j.ijpharm.2005.10.044; Paul W, 2003, J BIOMATER APPL, V17, P253, DOI 10.1177/0885328203017004001; PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110; Price RR, 2001, J MICROENCAPSUL, V18, P713; Sloan Paul, 2006, Expert Opin Drug Deliv, V3, P489, DOI 10.1517/17425247.3.4.489; Tari G, 1999, J COLLOID INTERF SCI, V210, P360, DOI 10.1006/jcis.1998.5917; Thurlkill RL, 2005, J CARDIOTHOR VASC AN, V19, P759, DOI 10.1053/j.jvca.2004.11.039; Vallet-Regi M, 2006, DALTON T, P5211, DOI 10.1039/b610219k; Villalobos R, 2006, J SOL-GEL SCI TECHN, V37, P195, DOI 10.1007/s10971-005-6628-8	29	50	52	1	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	JAN	2010	99	1					219	226		10.1002/jps.21814			8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	537YV	WOS:000273151500016	19492338				2020-06-30	J	Erturk, E; Tutuncu, C; Eroglu, A; Gokben, M				Erturk, Engin; Tutuncu, Cigdem; Eroglu, Ahmet; Gokben, Merih			Clinical Comparison of 12 mg Ropivacaine and 8 mg Bupivacaine, Both with 20 mu g Fentanyl, in Spinal Anaesthesia for Major Orthopaedic Surgery in Geriatric Patients	MEDICAL PRINCIPLES AND PRACTICE			English	Article						Ropivacaine; Bupivacaine; Fentanyl; Spinal anaesthesia; Geriatric patients	INTRATHECAL ROPIVACAINE; HYPERBARIC SOLUTIONS; ELECTIVE SURGERY; CESAREAN-SECTION; PLAIN; LEVOBUPIVACAINE; 0.5-PERCENT; SPREAD; ML(-1)	Objective: The aim of this study was to compare the haemodynamic and anaesthetic effects of 12 mg ropivacaine and 8 mg bupivacaine, both with 20 mu g fentanyl, in spinal anaesthesia for major orthopaedic surgery in geriatric patients. Subjects and Methods: Sixty American Society of Anesthesiologists (ASA) II-III patients scheduled for hip arthroplasty were randomly assigned to receive an intrathecal injection of either 12 mg ropivacaine with 20 mu g fentanyl (group R, aged 70 8 7 years, range 67-89) or 8 mg hyperbaric bupivacaine with 20 mu g fentanyl (group B, aged 69 +/- 6 years, range 66-92). Motor and sensory block, haemodynamics and side effects were recorded. Results: Mean levels of sensory block were similar, but the onset time of sensory block in group B (2.52 +/- 0.69 min) was shorter than that in group R (3.17-0.72 min); the difference was statistically significant (p < 0.01), and the number of patients who had motor Bromage scale 3 in group B (24) was greater than in group R (16). The difference was also statistically significant (p < 0.05). Systolic and diastolic arterial pressures (SAP, DAP) and heart rate (HR) decreased after the block in both groups. SAP (after the 60th and 120th min of block), DAP (all measurement times), and HR (after the 20th, 25th and 30th min of block) were lower in group B than in group R. Conclusions: The data showed that 12 mg of ropivacaine and 8 mg of bupivacaine with 20 mu g fentanyl in spinal anaesthesia can provide sufficient motor and sensory block for major orthopaedic surgery in geriatric patients. However, ropivacaine caused less motor block and haemodynamic side effects than bupivacaine during the procedure. Copyright (C) 2010 S. Karger AG, Basel	[Erturk, Engin; Eroglu, Ahmet] Karadeniz Tech Univ, Fac Med, Dept Anaesthesiol & Intens Care, TR-61080 Trabzon, Turkey; [Tutuncu, Cigdem; Gokben, Merih] Gulhane Mil Med Acad, Dept Anaesthesiol, Haydarpasa Educ Hosp, Istanbul, Turkey	Erturk, E (reprint author), Karadeniz Tech Univ, Fac Med, Dept Anaesthesiol & Intens Care, TR-61080 Trabzon, Turkey.	engin_md@yahoo.com	Eroglu, Ahmet/B-1414-2012; Tutuncu, Cigdem/V-1187-2017	Eroglu, Ahmet/0000-0002-0396-1582; Tutuncu, Cigdem/0000-0003-2608-4778; Erturk, Engin/0000-0002-5864-1754			BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Boztug N, 2006, J CLIN ANESTH, V18, P521, DOI 10.1016/j.jclinane.2006.03.006; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; Fettes PDW, 2005, BRIT J ANAESTH, V94, P107, DOI 10.1093/bja/aei008; Gautier P, 2003, BRIT J ANAESTH, V91, P684, DOI 10.1093/bja/aeg251; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; Hocking G, 2004, BRIT J ANAESTH, V93, P568, DOI 10.1093/bja/aeh204; Kallio H, 2005, REGION ANESTH PAIN M, V30, P48, DOI 10.1016/j.rapm.2004.11.002; Kallio H, 2004, BRIT J ANAESTH, V93, P664, DOI 10.1093/bja/aeh257; Lee YY, 2005, ACTA ANAESTH SCAND, V49, P1477, DOI 10.1111/j.1399-6576.2005.00864.x; Luck JF, 2008, BRIT J ANAESTH, V101, P705, DOI 10.1093/bja/aen250; Malinovsky JM, 2000, ANESTH ANALG, V91, P1457, DOI 10.1097/00000539-200012000-00030; McNamee DA, 2002, BRIT J ANAESTH, V89, P702, DOI 10.1093/bja/aef259; McNamee DA, 2001, BRIT J ANAESTH, V87, P743, DOI 10.1093/bja/87.5.743; Veering BT, 1996, BRIT J ANAESTH, V77, P343; Wahedi W, 1996, ANAESTHESIST, V45, P737, DOI 10.1007/s001010050306; Whiteside JB, 2003, BRIT J ANAESTH, V90, P304, DOI 10.1093/bja/aeg077	17	7	8	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1011-7571			MED PRIN PRACT	Med. Princ. Pract.		2010	19	2					142	147		10.1159/000249581			6	Medicine, General & Internal	General & Internal Medicine	552TE	WOS:000274315700009	20134178	Bronze			2020-06-30	J	Zheng, H; Zeng, Y; Zhang, XX; Chu, J; Loh, HH; Law, PY				Zheng, Hui; Zeng, Yan; Zhang, Xiaoxiao; Chu, Ji; Loh, Horace H.; Law, Ping-Yee			mu-Opioid Receptor Agonists Differentially Regulate the Expression of miR-190 and NeuroD	MOLECULAR PHARMACOLOGY			English	Article							ERK1/2 ACTIVATION; BETA-ARRESTINS; TOLERANCE; SYSTEM; KINASE; INTERNALIZATION; DESENSITIZATION; INHIBITOR; MICRORNAS; BRAIN	The agonists of mu-opioid receptor (OPRM1) induce extracellular signal-regulated kinase (ERK) phosphorylation through different pathways: morphine uses the protein kinase C (PKC)-pathway, whereas fentanyl functions in a beta-arrestin2-dependent manner. In addition, the two pathways result in the different cellular location of phosphorylated ERK and the activation of different sets of transcriptional factors. In the current study, the influence of the two pathways on the expression of microRNAs (miRNAs) was investigated. After treating the primary culture of rat hippocampal neurons and the mouse hippocampi with morphine or fentanyl for 3 days, seven miRNAs regulated by one or two of the agonists were identified. One of the identified miRNAs, miR-190, was down-regulated by fentanyl but not by morphine. This down-regulation was attenuated by 1,4-diamino-2,3-di-cyano-1,4-bis(methylthio) butadiene (U0126), which blocks the phosphorylation of ERK. When fentanyl-induced but not morphine-induced ERK phosphorylation was blocked in the primary cultures from beta-arrestin2(-/-) mouse, fentanyl did not decrease the expression of miR-190. However, a PKC inhibitor that blocked morphine-induced ERK phosphorylation specifically had no effect on the miR-190 down-regulation. Therefore the decrease in miR-190 expression resulted from the agonist-selective ERK phosphorylation. In addition, the expressional changes in one of the miR-190 targets, neurogenic differentiation 1 (NeuroD), correlated with those in miR-190 expression, suggesting the OPRM1 could regulate the NeuroD pathways via the control of miR-190 expression.	[Zheng, Hui; Zeng, Yan; Zhang, Xiaoxiao; Chu, Ji; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Zheng, H (reprint author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zhen0091@umn.edu		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA007339, DA016674, DA000564, DA011806, K05-DA70544, K05-DA00513]	This research was supported by the National Institutes of Health National Institute on Drug Abuse [Grants DA007339, DA016674, DA000564, DA011806, K05-DA70544, K05-DA00513].	ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Borgland S, 2001, CLIN EXP PHARMACOL P, V28, P147, DOI 10.1046/j.1440-1681.2001.03418.x; Cho JH, 2004, MOL NEUROBIOL, V30, P35, DOI 10.1385/MN:30:1:035; Chu J, 2008, CELL SIGNAL, V20, P1616, DOI 10.1016/j.cellsig.2008.05.004; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; JIN WZ, 1994, BRAIN RES, V642, P237, DOI 10.1016/0006-8993(94)90927-X; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kalscheuer S, 2008, CARCINOGENESIS, V29, P2394, DOI 10.1093/carcin/bgn209; Keith DE, 1998, MOL PHARMACOL, V53, P377; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Liao D, 2007, MOL CELL NEUROSCI, V35, P456, DOI 10.1016/j.mcn.2007.04.007; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Nam S, 2008, NUCLEIC ACIDS RES, V36, pD159, DOI 10.1093/nar/gkm829; Narita M, 2006, NEUROSCIENCE, V138, P609, DOI 10.1016/j.neuroscience.2005.11.046; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Seo S, 2007, EMBO J, V26, P5093, DOI 10.1038/sj.emboj.7601923; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842	32	65	77	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X			MOL PHARMACOL	Mol. Pharmacol.	JAN	2010	77	1					102	109		10.1124/mol.109.060848			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	533CY	WOS:000272801300012	19854889	Green Published			2020-06-30	J	Vasisht, N; Gever, LN; Tagarro, I; Finn, AL				Vasisht, Niraj; Gever, Larry N.; Tagarro, Ignacio; Finn, Andrew L.			Single-Dose Pharmacokinetics of Fentanyl Buccal Soluble Film	PAIN MEDICINE			English	Article						Breakthrough Pain; Buccal Absorption; Buccal Soluble Film; Drug Absorption; Fentanyl; Pharmacokinetics	BREAKTHROUGH PAIN; CANCER PAIN; CITRATE; BIOAVAILABILITY; TABLETS	Objective. The objectives of the study were to determine the absolute bioavailability of fentanyl from fentanyl buccal soluble film, estimate the percentage of a fentanyl dose absorbed through the buccal mucosa, and compare the bioavailability of equivalent doses administered either as single or multiple dose units. Design. Open-label, randomized, four-period, Latin-square crossover pharmacokinetic study. Setting. Inpatient phase 1 unit. Patients. Twelve healthy volunteers. Interventions. Injectable fentanyl citrate (200 mu g) administered by intravenous infusion, injectable fentanyl citrate (800 mu g/16 mL) administered orally, and fentanyl buccal soluble film (800 mu g) administered as a single film and as four separate 200 mu g films simultaneously. Outcome Measures. Plasma concentrations after fentanyl dosing; pharmacokinetic parameters. Results. The two buccal film treatments were bioequivalent and both had an absolute bioavailability of 71%. The percentage of an administered dose absorbed through the buccal mucosa was calculated to be 51%. Conclusions. Fentanyl buccal soluble film effectively delivers a high percentage of the administered fentanyl dose and nearly identical plasma profiles are obtained when equivalent doses are delivered by single or multiple dosage units.	[Vasisht, Niraj; Finn, Andrew L.] BioDelivery Sci Int Inc, Raleigh, NC 27607 USA; [Gever, Larry N.] Meda Pharmaceut Inc, Somerset, NJ USA; [Tagarro, Ignacio] Meda Pharma SAU, Madrid, Spain	Finn, AL (reprint author), BioDelivery Sci Int Inc, 801 Corp Ctr Dr,Suite 210, Raleigh, NC 27607 USA.	afinn@bdsinternational.com			BioDelivery Sciences International, Inc.	This study was funded by BioDelivery Sciences International, Inc. Editorial assistance was provided by Blair J. Jarvis and Carol A. Lewis, PhD.	Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Food and Drug Administration, 2001, GUID IND STAT APPR E; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	11	31	32	1	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.		2010	11	7					1017	1023		10.1111/j.1526-4637.2010.00875.x			7	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	615HI	WOS:000279125000006	20492573	Green Published, Bronze			2020-06-30	J	Fine, PG; Narayana, A; Passik, SD				Fine, Perry G.; Narayana, Arvind; Passik, Steven D.			Treatment of Breakthrough Pain with Fentanyl Buccal Tablet in Opioid-Tolerant Patients with Chronic Pain: Appropriate Patient Selection and Management	PAIN MEDICINE			English	Review						Appropriate Patient Selection; Breakthrough Pain; Chronic Pain; Fentanyl; Opioid Analgesics; Pain	CHRONIC NONCANCER PAIN; LONG-TERM USE; CANCER-PATIENTS; TREATED PATIENTS; DOSE-TITRATION; CITRATE OTFC(R); PREVALENCE; VALIDATION; THERAPY; OUTCOMES	Background. Opioids can be a safe and effective option for carefully selected patients with a structured treatment program that includes consistent monitoring. However, the benefits and risks of opioid therapy for patients with chronic pain, and society as a whole, have been sharply debated. A key component of this debate has involved the administration of rapid-onset opioids for the management of breakthrough pain. Objective. Review key aspects of breakthrough pain management with fentanyl buccal tablet, with a focus on minimizing risk to optimize therapeutic outcomes. Recommendations that apply broadly to all rapid-onset opioids are also discussed. Design. Available fentanyl buccal tablet clinical and post-marketing data were reviewed. Results. Like other schedule II controlled substances, and because fentanyl buccal tablet is a highly potent opioid, its use is associated with risk of overdose, misuse, and diversion. As with all rapid-onset opioids, particular attention to patient selection and risk assessment is warranted. The inclusion and exclusion criteria in fentanyl buccal tablet clinical studies represent patient selection standards that should be translated to clinical practice, most importantly, that patients are opioid-tolerant before fentanyl buccal tablet initiation. Titration of fentanyl buccal tablet from a low starting dose to a successful dose allows the safe identification of a dose that provides the greatest pain relief without unacceptable adverse events. After initiating fentanyl buccal tablet therapy, all patients should continue to be regularly monitored for response, including analgesia, functioning, tolerability, and aberrant behavior. Conclusions. Fentanyl buccal tablet can be an effective and generally safe treatment for breakthrough pain when appropriate patient selection, administration, dosing, and monitoring are applied.	[Fine, Perry G.] Univ Utah, Pain Res Ctr, Dept Anesthesiol, Salt Lake City, UT 84109 USA; [Narayana, Arvind] Cephalon Inc, Frazer, PA USA; [Passik, Steven D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Fine, PG (reprint author), Univ Utah, Pain Res Ctr, Dept Anesthesiol, Ste 200,615 Arapeen Dr, Salt Lake City, UT 84109 USA.	perry.fine@hsc.utah.edu					Belgrade MJ, 2006, J PAIN, V7, P671, DOI 10.1016/j.jpain.2006.03.001; BENNETT D, 2005, [No title captured], V30, P354; Butler SF, 2004, PAIN, V112, P65, DOI 10.1016/j.pain.2004.07.026; Butler SF, 2008, J PAIN, V9, P360, DOI 10.1016/j.jpain.2007.11.014; Butler SF, 2007, PAIN, V130, P144, DOI 10.1016/j.pain.2007.01.014; *CEPH INC, 2009, ACTIQ FENT CITR OR T; *CEPH INC, 2008, US FOOD DRUG ADM JOI; *CEPH INC, 2009, FENTORA FENT BUCC TA; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Cicero T. J, 2008, ADV PAIN MANAGE, V2, P17; Cicero TJ, 2009, PAIN, V144, P20, DOI 10.1016/j.pain.2009.01.026; *COL U NAT CTR ADD, 2005, COUNT DIV AB CONTR P; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Edlund MJ, 2007, PAIN, V129, P355, DOI 10.1016/j.pain.2007.02.014; Edwards JE, 2002, J PAIN SYMPTOM MANAG, V23, P121, DOI 10.1016/S0885-3924(01)00404-3; European Medicines Agency, 2010, EUR PUBL ASS REP EPA; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2008, PAIN MED, V9, P102; Fine PG, 2008, DIAGNOSIS TREATMENT; FINE PG, 2010, J PAIN SYMP IN PRESS; Fishbain David A, 2008, Am J Manag Care, V14, pS123; Fleming MF, 2007, J PAIN, V8, P573, DOI 10.1016/j.jpain.2007.02.432; Gourlay DL, 2005, PAIN MED, V6, P107, DOI 10.1111/j.1526-4637.2005.05031.x; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Heit HA, 2004, J PAIN SYMPTOM MANAG, V27, P260, DOI 10.1016/j.jpainsymman.2003.07.008; Heit Howard A, 2003, J Pain Palliat Care Pharmacother, V17, P15; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1213, DOI 10.1001/jama.2009.367; LANGER G, AM SEARCHING PAIN RE; Markman JD, 2008, PAIN, V136, P227, DOI 10.1016/j.pain.2008.03.011; Marsch LA, 2001, J PHARMACOL EXP THER, V299, P1056; *MED PHARM, 2009, ONS FENT BUCC SOL FI; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI 10.1016/j.jpainsymman.2004.04.007; Michna E, 2007, CLIN J PAIN, V23, P173, DOI 10.1097/AJP.0b013e31802b4f95; NARAYANA A, 2009, PAIN MED, V10, P278; Olsen Y, 2006, J PAIN, V7, P225, DOI 10.1016/j.jpain.2005.11.006; Passik SD, 2004, CLIN THER, V26, P552, DOI 10.1016/S0149-2918(04)90057-4; PASSIK SD, 2010, J PAIN SYMP IN PRESS; Passik SD, 2008, PAIN MED, V9, pS145, DOI 10.1111/j.1526-4637.2008.00486.x; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Payne R, 2007, PAIN MED, V8, pS3; Portenoy R K, 1997, Semin Oncol, V24, pS16; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2007, CLIN J PAIN, V23, P287, DOI 10.1097/AJP.0b013e31802b582f; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7; Shi QL, 2007, J PAIN, V8, P624, DOI 10.1016/j.jpain.2007.03.006; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Substance Abuse and Mental Health Services Administration, 2007, RES 2007 NAT SURV DR; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Tfelt-Hansen P, 2002, CEPHALALGIA, V22, P664, DOI 10.1046/j.1468-2982.2002.00402.x; Trescot Andrea M, 2006, Pain Physician, V9, P1; *US FDA, 2009, IND M RISK EV MIT ST; *US FDA, 2007, IMP INF SAF US FENT; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x; WEBSTER LR, 2005, AM J MANAG CARE S, V14, pS116; Webster LR, 2006, EXPERT OPIN INV DRUG, V15, P1469, DOI 10.1517/13543784.15.11.1469; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Wu SM, 2006, J PAIN SYMPTOM MANAG, V32, P342, DOI 10.1016/j.jpainsymman.2006.05.010; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G., 2006, COCHRANE DB SYST REV, V1, pCD004311	80	16	16	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.		2010	11	7					1024	1036		10.1111/j.1526-4637.2010.00891.x			13	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	615HI	WOS:000279125000007	20642730	Bronze			2020-06-30	J	Farrar, JT; Messina, J; Xie, F; Portenoy, RK				Farrar, John T.; Messina, John; Xie, Fang; Portenoy, Russell K.			A Novel 12-Week Study, with Three Randomized, Double-Blind Placebo-Controlled Periods to Evaluate Fentanyl Buccal Tablets for the Relief of Breakthrough Pain in Opioid-Tolerant Patients with Noncancer-Related Chronic Pain	PAIN MEDICINE			English	Article						Fentanyl Buccal Tablet; Breakthrough Pain; Opioid-Tolerant; Noncancer-Related Chronic Pain; Multi-Period Crossover Design; Randomized, Blinded, Placebo-Controlled, Clinical Trial	OXYMORPHONE EXTENDED-RELEASE; TREATED PATIENTS; CONTROLLED TRIAL; CANCER-PATIENTS; MULTICENTER; PREVALENCE; EFFICACY; CITRATE; SAFETY; SF-36	Objective. To evaluate the time of onset, overall efficacy, and safety of fentanyl buccal tablet (FBT) for noncancer-related breakthrough pain (BTP) in opioid-tolerant adults over 12 weeks. Design. A novel 12-week study that mimicked clinical practice with dose titration to effective dose, open-label treatment, and three randomized, double-blind, placebo-controlled, multiple-crossover periods at weeks 4, 8, and 12. For each double-blind period, study patients received nine doses (FBT = 6, placebo = 3) in a randomized sequence. Setting. Twenty-one study centers in the United States. Population. Opioid-tolerant adults with noncancer-related chronic pain and BTP. Outcome Measures. The primary outcome was the sum of the pain intensity differences (PID) 5-60 minutes post dose (SPID60) during the final double-blind period. Secondary outcomes included pain relief (PR), meaningful PR, and proportion of episodes with a PID of >= 33% and >= 50%. Results. Of 148 patients who entered the titration phase, 105 (71%) achieved a successful dose and 81 (55%) participated in all three assessment periods in the study. The final RCT assessment period results demonstrated continued efficacy of FBT vs placebo (P < 0.05) for SPID60 (mean [SD]: 7.7 [6.2] vs 4.6 [4.7]). The average onset of PR began at 5 minutes, with meaningful PR by <= 10 minutes. The proportion of episodes with >= 33% improvement in PI was 7% with FBT vs 3% with placebo at 5 minutes and with >= 50% was 17% vs 10% at 15 minutes. All periods showed similar results. Adverse events and patient discontinuations were generally typical of clinical opioid use. Conclusions. FBT showed continued clinically important analgesic effects and was generally well tolerated over 12 weeks of treatment.	[Farrar, John T.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostatist, Philadelphia, PA 19104 USA; [Messina, John; Xie, Fang] Cephalon Inc, Frazer, PA USA; [Portenoy, Russell K.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA	Farrar, JT (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostatist, 423 Guardian Dr,Room 816,Blockley Hall, Philadelphia, PA 19104 USA.	jfarrar@mail.med.upenn.edu	Farrar, John/A-1037-2007	Farrar, John/0000-0001-8656-5157	Cephalon, Inc.	This study was sponsored by Cephalon, Inc. Preliminary writing assistance was provided by Ogilvy Healthworld, funded by Cephalon, Inc.	Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; BENNETT D, 2005, [No title captured], V30, P296; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Good P, 2008, CONTEMP CLIN TRIALS, V29, P565, DOI 10.1016/j.cct.2008.01.006; Hale ME, 2007, J PAIN, V8, P175, DOI 10.1016/j.jpain.2006.09.011; International Conference on Harmonisation Working Group, 1996, INT C HARM TECHN REQ; Katz N, 2007, CURR MED RES OPIN, V23, P117, DOI 10.1185/030079906X162692; McNair D, 1992, POMS MANUAL PROFILE; MERCADANTE S, 1992, PAIN, V50, P151, DOI 10.1016/0304-3959(92)90155-5; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2007, CLIN J PAIN, V23, P287, DOI 10.1097/AJP.0b013e31802b582f; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Rauck Richard L, 2006, J Opioid Manag, V2, P155; Rauck RL, 2006, J PAIN SYMPTOM MANAG, V31, P393, DOI 10.1016/j.jpainsymman.2005.10.003; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Swarm Robert, 2007, J Natl Compr Canc Netw, V5, P726; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279	34	19	21	1	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.		2010	11	9					1313	1327		10.1111/j.1526-4637.2010.00939.x			15	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	647SA	WOS:000281638100002	20807345	Bronze			2020-06-30	J	Li, N; Tieng, A; Novak, S; Fernandes, A; Jalal, PK; Akerman, M; Sideridis, K; Bank, S				Li, N.; Tieng, A.; Novak, S.; Fernandes, A.; Jalal, P. K.; Akerman, M.; Sideridis, K.; Bank, S.			Effects of Medications on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis	PANCREATOLOGY			English	Article						Angiotensin receptor blocker; Endoscopic retrograde cholangiopancreatography; Pancreatitis; Propofol; Smoking	ERCP PANCREATITIS; RISK-FACTORS; PROSPECTIVE MULTICENTER; PROPOFOL; COMPLICATIONS; RECHALLENGE; HYPERTRIGLYCERIDEMIA; PREVENTION; RECURRENCE; THERAPY	Background and Aims: Drug-induced pancreatitis accounts for about 2% of acute pancreatitis. The aim of this study is to determine whether propofol and other medications are associated with increased risk for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Methods: A retrospective study was conducted at a single tertiary care hospital. All patients who underwent ERCP from 2001 to 2004 were included. Diagnosis of acute post-ERCP pancreatitis was based on a consensus definition. Results: A total of 506 patients underwent ERCP. The total incidence of post-ERCP pancreatitis was 7.1%. There was no significant difference in post-ERCP pancreatitis between patients who received propofol compared to patients who received midazolam and fentanyl (9.0 vs. 5.9%, p = 0.18). Patients receiving an angiotensin receptor blocker were approximately 4 times more likely to develop post-ERCP pancreatitis (OR = 4.1, 95% CI 1.6-10.9). Patients younger than 65 years and smokers also had higher risk of developing acute post-ERCP pancreatitis than those who were older than 65 years (OR = 3.9, 95% CI 1.7-9.1) and non-smokers (OR = 2.8, 95% CI 1.3-6.2). Conclusions: Propofol is a safe sedative drug for ERCP without additional risk of developing acute post-ERCP pancreatitis. Use of angiotensin receptor blockers, smoking and younger age are independent risk factors for post-ERCP pancreatitis. Copyright (C) 2010 S. Karger AG, Basel and IAP	[Li, N.; Novak, S.] Long Isl Jewish Med Ctr, Dept Med, New Hyde Pk, NY 11040 USA; [Tieng, A.; Fernandes, A.; Jalal, P. K.; Sideridis, K.; Bank, S.] Long Isl Jewish Med Ctr, Dept Gastroenterol, New Hyde Pk, NY 11040 USA; [Akerman, M.] Feinstein Inst Med Res, Biostat Unit, Manhasset, NY USA	Li, N (reprint author), Long Isl Jewish Med Ctr, Dept Med, 270-05 76th Ave, New Hyde Pk, NY 11040 USA.	lina.liukai@gmail.com					Bedrossian S, 2007, DIGEST DIS SCI, V52, P558, DOI 10.1007/s10620-006-9220-3; Birck R, 1998, LANCET, V351, P1178, DOI 10.1016/S0140-6736(05)79122-4; Blomgren KB, 2002, DIABETES CARE, V25, P298, DOI 10.2337/diacare.25.2.298; Cheng CL, 2006, AM J GASTROENTEROL, V101, P139, DOI 10.1111/j.1572-0241.2006.00380.x; Cheng RMS, 2003, ANN PHARMACOTHER, V37, P994, DOI 10.1345/aph.1C270; Christensen M, 2004, GASTROINTEST ENDOSC, V60, P721, DOI 10.1016/S0016-5107(04)02169-8; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; Devlin JW, 2005, PHARMACOTHERAPY, V25, P1348, DOI 10.1592/phco.2005.25.10.1348; Elmunzer BJ, 2008, GUT, V57, P1262, DOI 10.1136/gut.2007.140756; FARMER RG, 1973, AM J MED, V54, P161, DOI 10.1016/0002-9343(73)90219-2; Fimognari FL, 2006, DIABETES CARE, V29, P1183, DOI 10.2337/dc06-0338; Fisher AA, 2002, ANN PHARMACOTHER, V36, P1883, DOI 10.1345/aph.1C099; Gershon T, 1998, AM J EMERG MED, V16, P523, DOI 10.1016/S0735-6757(98)90009-2; Gottschling S, 2005, PEDIATR ANESTH, V15, P1006, DOI 10.1111/j.1460-9592.2004.01562.x; Gottschling S, 2005, ANAESTHESIA, V60, P660, DOI 10.1111/j.1365-2044.2005.04231.x; Jawaid Q, 2002, DIGEST DIS SCI, V47, P614, DOI 10.1023/A:1017932522875; Kumar AN, 1999, CHEST, V115, P1198, DOI 10.1378/chest.115.4.1198; Lankisch PG, 2008, AM J GASTROENTEROL, V103, P244, DOI 10.1111/j.1572-0241.2007.01562_5.x; Loperfido S, 1998, GASTROINTEST ENDOSC, V48, P1, DOI 10.1016/S0016-5107(98)70121-X; Marik PE, 2004, CURR PHARM DESIGN, V10, P3639, DOI 10.2174/1381612043382846; Maringhini A, 1997, AM J GASTROENTEROL, V92, P166; Piper SN, 2001, ANAESTHESIA, V56, P836, DOI 10.1046/j.1365-2044.2001.02175.x; Prat F, 2002, GASTROINTEST ENDOSC, V56, P202, DOI 10.1067/mge.2002.126065; TOSKES PP, 1994, GASTROENTEROLOGY, V106, P810, DOI 10.1016/0016-5085(94)90720-X; Trivedi CD, 2005, J CLIN GASTROENTEROL, V39, P709, DOI 10.1097/01.mcg.0000173929.60115.b4; Yamada T, 2005, J PHARMACOL EXP THER, V313, P36, DOI 10.1124/jpet.104.077883; Yamada T, 2003, J PHARMACOL EXP THER, V307, P17, DOI 10.1124/jpet.103.053322	27	11	11	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1424-3903			PANCREATOLOGY	Pancreatology		2010	10	2-3					238	242		10.1159/000279306			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	621MO	WOS:000279583200019	20484961				2020-06-30	J	Jus, A; Bujalska, M; Makulska-Nowak, HE				Jus, Anna; Bujalska, Magdalena; Makulska-Nowak, Helena E.			Modification of Fentanyl Analgesia by Antidepressants	PHARMACOLOGY			English	Article						Fentanyl; Antidepressants; Acute and chronic pretreatment; Pain; Rats	MU-OPIOID RECEPTOR; RAT-BRAIN; MORPHINE ANALGESIA; TRICYCLIC ANTIDEPRESSANTS; FORMALIN TEST; BEHAVIORAL-RESPONSE; CHRONIC IMIPRAMINE; ARTHRITIC RATS; BINDING-SITES; FLUOXETINE	Clinical practice often requires simultaneous administration of antidepressants with opioids (oncology, rheumatology). Coadministration may either attenuate or potentiate opioid analgesia. The purpose of this paper was to verify how the analgesic action of fentanyl (0.05 mg/kg) is affected by single administration as well as 4- or 21-day premedication with antidepressants characterized by various mechanisms of action. The effects of amitriptyline 3 mg/kg, moclobemide 5 mg/kg, fluoxetine 5 mg/kg and reboxetine 0.08 mg/kg were investigated. Experiments were conducted on normotensive Wistar Kyoto rats. The pain threshold was measured using an analgesimeter. It was concluded that the single administration of an antidepressant increases the analgesic action of fentanyl. Four-day premedication with fluoxetine and reboxetine significantly attenuated the antinociceptive action of fentanyl, whereas 21-day premedication with all antidepressants investigated (fluoxetine, amitriptyline, moclobemide, reboxetine) markedly decreased it. The potential clinical importance of this observation is discussed. Copyright (C) 2009 S. Karger AG, Basel	[Jus, Anna; Bujalska, Magdalena; Makulska-Nowak, Helena E.] Med Univ Warsaw, Dept Pharmacodynam, PL-00927 Warsaw 64, Poland	Jus, A (reprint author), Med Univ Warsaw, Dept Pharmacodynam, Krakowskie Przedmiescie Str 26-28,POB 3, PL-00927 Warsaw 64, Poland.	aniajus1@wp.pl		Bujalska-Zadrozny, Magdalena/0000-0002-4270-6373			ABBOTT FV, 1988, PHARMACOL BIOCHEM BE, V31, P855, DOI 10.1016/0091-3057(88)90395-4; Acebes I, 2000, REV NEUROLOGIA, V31, P919, DOI 10.33588/rn.3110.2000354; BENKELFAT C, 1989, J PHARM PHARMACOL, V41, P865, DOI 10.1111/j.2042-7158.1989.tb06390.x; BUTLER SH, 1985, PAIN, V23, P159, DOI 10.1016/0304-3959(85)90057-0; Canciani L, 2006, EUR J PHARMACOL, V553, P269, DOI 10.1016/j.ejphar.2006.09.025; Chen F, 2004, J PHARMACOL EXP THER, V310, P1020, DOI 10.1124/jpet.104.068692; Churruca I, 2006, INT J NEUROSCI, V116, P289, DOI 10.1080/00207450500403231; de Gandarias JM, 1999, BRAIN RES, V817, P236, DOI 10.1016/S0006-8993(98)01256-6; DEFELIPE MC, 1985, EUR J PHARMACOL, V112, P119, DOI 10.1016/0014-2999(85)90247-X; Erjavec MK, 2000, J CLIN PHARMACOL, V40, P1286; GODEFROY F, 1986, PAIN, V25, P233, DOI 10.1016/0304-3959(86)90099-0; GOLDSTEIN FJ, 1990, PAIN, V42, P331, DOI 10.1016/0304-3959(90)91146-A; GORDON NC, 1994, PAIN, V58, P85, DOI 10.1016/0304-3959(94)90187-2; Gould GG, 2003, NEUROPSYCHOPHARMACOL, V28, P1633, DOI 10.1038/sj.npp.1300236; Gutierrez M, 2003, NEUROSCI LETT, V352, P37, DOI 10.1016/j.neulet.2003.08.020; Holland JC, 1998, PSYCHO-ONCOL, V7, P291, DOI 10.1002/(SICI)1099-1611(199807/08)7:4<291::AID-PON361>3.3.CO;2-L; KELLSTEIN DE, 1988, NEUROPHARMACOLOGY, V27, P1, DOI 10.1016/0028-3908(88)90194-3; KELLSTEIN DE, 1984, PAIN, V20, P323, DOI 10.1016/0304-3959(84)90110-6; Khoromi S, 2007, PAIN, V130, P66, DOI 10.1016/j.pain.2006.10.029; Kurlekar P. N., 2004, Indian Journal of Pharmacology, V36, P369; KURUMAJI A, 1988, PSYCHOPHARMACOLOGY, V94, P188; LARSON AA, 1977, LIFE SCI, V21, P1807, DOI 10.1016/0024-3205(77)90162-X; LESCH KP, 1991, PSYCHOPHARMACOLOGY, V105, P415, DOI 10.1007/BF02244438; LUND A, 1991, NEUROPHARMACOLOGY, V30, P481, DOI 10.1016/0028-3908(91)90010-9; Matoba M, 2001, EUR J PAIN-LONDON, V5, P59, DOI 10.1053/eujp.2001.0281; Mico JA, 2006, TRENDS PHARMACOL SCI, V27, P348, DOI 10.1016/j.tips.2006.05.004; Nayebi ARM, 2001, J PHARM PHARMACOL, V53, P219, DOI 10.1211/0022357011775235; Nicholson B, 2003, DRUGS, V63, P17, DOI 10.2165/00003495-200363010-00002; Nozaki C, 2006, EUR J PHARMACOL, V552, P99, DOI 10.1016/j.ejphar.2006.09.029; ONEILL KA, 1986, PHARMACOL BIOCHEM BE, V24, P155, DOI 10.1016/0091-3057(86)90061-4; Ortega-Alvaro A, 2004, PSYCHOPHARMACOLOGY, V176, P305, DOI 10.1007/s00213-004-1894-7; Pakulska W, 2002, PHARMACOL RES, V46, P415, DOI 10.1016/S1043661802001299; Pakulska Wanda, 2004, Acta Pol Pharm, V61, P157; Przewlocki R, 1997, POL J PHARMACOL, V49, P351; Raap DK, 1999, J PHARMACOL EXP THER, V288, P98; REISINE T, 1982, EUR J PHARMACOL, V77, P39, DOI 10.1016/0014-2999(82)90532-5; SHIRAYAMA Y, 1993, EUR J PHARMACOL, V237, P117, DOI 10.1016/0014-2999(93)90100-V; Singh VP, 2001, BRAIN RES, V915, P218, DOI 10.1016/S0006-8993(01)02854-2; STENGAARDPEDERSEN K, 1985, ACTA PHARMACOL TOX, V56, P170; Vilpoux C, 2002, EUR J PHARMACOL, V443, P85, DOI 10.1016/S0014-2999(02)01585-6; WAHLSTROM A, 1994, PHARMACOL TOXICOL, V75, P23, DOI 10.1111/j.1600-0773.1994.tb00319.x; Yasuda T, 2005, PAIN, V115, P161, DOI 10.1016/j.pain.2005.02.026	42	6	6	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012			PHARMACOLOGY	Pharmacology		2010	85	1					48	53		10.1159/000268105			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	536NU	WOS:000273051900006	20029244				2020-06-30	J	Chi, OZ; Hunter, C; Liu, X; Chokshi, SK; Weiss, HR				Chi, Oak Z.; Hunter, Christine; Liu, Xia; Chokshi, Sagar K.; Weiss, Harvey R.			Effects of Fentanyl Pretreatment on Regional Cerebral Blood Flow in Focal Cerebral Ischemia in Rats	PHARMACOLOGY			English	Article						Fentanyl preconditioning; Regional cerebral blood flow; Focal cerebral ischemia	OPIOID RECEPTORS; NEUROPROTECTION; MORPHINE; STIMULATION; ANTAGONISTS; ACTIVATION; TOLERANCE; BRAIN	Background: There are reports that opioid preconditioning induces opioid-receptor-dependent neuroprotection against cerebral ischemia. This experiment was performed to test whether pretreatment with fentanyl, a synthetic primary mu-opioid receptor agonist, would affect the regional cerebral blood flow (rCBF) in focal cerebral ischemia in rats. Methods: Twenty-four hours before permanent and unilateral middle cerebral artery (MCA) occlusion, rats were pretreated with normal saline, 200 mu g/kg of fentanyl i.p. or 500 mu g/kg of fentanyl i.p. The rats were anesthetized with isoflurane and were mechanically ventilated to cannulate the vessels and to occlude MCA. One hour after MCA occlusion, the rCBF was measured using C-14-iodoantipyrine. Results: The cortical rCBF decreased 1 h after MCA occlusion in all the experimental groups. In the ischemic cortex, the rCBF of the rats treated with 500 mu g/kg of fentanyl was significantly greater (+ 80%, p < 0.05) than that of the control animals. The rCBF of the ischemic cortex of the rats treated with fentanyl 200 mu g/kg seemed higher than in the control animals, but the difference was not statistically significant. The rCBF was similar in the nonischemic brain regions such as the contralateral cortex or pons among the experimental groups. Conclusion: Our data demonstrated that pretreatment with fentanyl improved the rCBF in the focal ischemic area without change in rCBF in the nonischemic cortex. Our data suggest that fentanyl could be effective in improving the rCBF in the focal ischemic area when used as a preconditioning agent and that improvement of rCBF could be one of the contributing factors of neuroprotection by opioid preconditioning. Copyright (C) 2010 S. Karger AG, Basel	[Chi, Oak Z.; Hunter, Christine; Liu, Xia] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, New Brunswick, NJ 08901 USA; [Chokshi, Sagar K.] Rutgers State Univ, Dept Cell Biol & Neurosci, New Brunswick, NJ 08903 USA; [Weiss, Harvey R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Chi, OZ (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, 125 Paterson St,Suite 3100, New Brunswick, NJ 08901 USA.	chi@umdnj.edu					Ammon-Treiber S, 2005, NEUROPHARMACOLOGY, V49, P1160, DOI 10.1016/j.neuropharm.2005.06.016; Barry U, 2005, CURR PHARM DESIGN, V11, P1343, DOI 10.2174/1381612053507459; Berrios I, 2008, P R HEALTH SCI J, V27, P119; Chi OZ, 1999, NEUROL RES, V21, P299, DOI 10.1080/01616412.1999.11740935; CHI OZ, 2009, AM SOC AN ANN M, pA408; Dershwitz M, 2002, CLIN ANESTHESIA PROC, P156; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Iwata M, 2007, NEUROSCI LETT, V414, P242, DOI 10.1016/j.neulet.2006.12.021; Lim YJ, 2004, ANESTHESIOLOGY, V100, P562, DOI 10.1097/00000542-200403000-00015; Liu X, 2003, NEUROCHEM RES, V28, P1799, DOI 10.1023/A:1026159422237; Liu YH, 2006, CAN J ANAESTH, V53, P194, DOI 10.1007/BF03021827; Meng FJ, 2006, J NEUROSURG ANESTH, V18, P119, DOI 10.1097/00008506-200604000-00005; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; Rehni AK, 2008, PHARMACOL REP, V60, P904; Rubaj A, 2000, PHARMACOL BIOCHEM BE, V67, P65, DOI 10.1016/S0091-3057(00)00294-X; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047; Zhang JH, 2002, AM J PHYSIOL-CELL PH, V282, pC1225, DOI 10.1152/ajpcell.00226.2001; Zhang JH, 2000, BRAIN RES, V885, P143, DOI 10.1016/S0006-8993(00)02906-1; Zhao P, 2004, ANESTHESIOLOGY, V101, P695, DOI 10.1097/00000542-200409000-00018; Zhao P, 2006, J NEUROPATH EXP NEUR, V65, P945, DOI 10.1097/01.jnen.0000235123.05677.4b	21	10	13	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012	1423-0313		PHARMACOLOGY	Pharmacology		2010	85	3					153	157		10.1159/000269811			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	566JN	WOS:000275366000004	20150753				2020-06-30	J	Sia, S; Lepri, A; Marchi, M				Sia, Salvatore; Lepri, Antonella; Marchi, Marco			Axillary Block by "Selective" Injections at the Nerves Involved in Surgery Using a Peripheral Nerve Stimulator A Comparison With a "Standard" Triple-Injection Technique	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							BRACHIAL-PLEXUS BLOCK; LOCALIZATION; SINGLE; ULNAR	Background and Objectives: A triple-injection technique (injections at the median, musculocutaneous, and radial nerves) for axillary block affords a high incidence of complete block (all the nerves below the elbow). However, in certain surgeries, only I or 2 nerves are involved in the surgical field. The aim of this prospective randomized study was to test the effectiveness of surgical anesthesia of a "selective" approach in which only the nerves involved in surgery were electrically located and injected. Methods: Three types of surgery were selected. Type 1 included surgery on the fifth finger, type 2 included superficial surgery (without bone involvement) on the palm or on the dorsum of the hand, and type 3 included any surgery on the first 3 fingers. For each type, 138 patients were enrolled and divided into 2 groups: group SEL in which only the nerves involved in the surgical field (1 or 2) were located and injected and group TNS in which a standard triple-nerve stimulation technique was used. Results: A lower rate of surgical anesthesia (84% vs 92%; P < 0.05) was recorded in group SEL considered as a whole: this was mainly due to the significant difference recorded in type 2 surgery (75% vs 93%; P < 0.05). More patients needed intravenous administration of fentanyl for tourniquet pain (18% vs 8%; P < 0.005) and of midazolam for intraoperative anxiety (20% vs 8%; P < 0.005) in group SEL considered as a whole. In type 1, improved patient comfort at block performance (P < 0.05), a 7-min saving on total anesthetic time (P < 0.001), and a higher need for midazolam administration (P < 0.05) were recorded in group SEL. In type 2, a higher need for midazolam administration (P < 0.05) was recorded in group SEL. In type 3, no clinically significant differences between the groups were recorded. Conclusions: A standard triple-nerve stimulation technique seems to be preferable to the selective approach even when a limited number of nerves are involved in the surgical field.	[Sia, Salvatore; Lepri, Antonella] Azienda Osped Careggi, Dept Anesthesiol, Ctr Traumatol Ortoped, Florence, Italy; [Marchi, Marco] Univ Florence, Dept Stat, I-50121 Florence, Italy	Sia, S (reprint author), Via Santelli 41, I-50134 Florence, Italy.	sia3@interfree.it					Casati A, 2007, ANESTHESIOLOGY, V106, P992, DOI 10.1097/01.anes.0000265159.55179.e1; Coventry DM, 2001, BRIT J ANAESTH, V86, P80, DOI 10.1093/bja/86.1.80; Curatolo M, 2000, ANESTHESIOLOGY, V93, P1517, DOI 10.1097/00000542-200012000-00025; Deleuze A, 2003, REGION ANESTH PAIN M, V28, P89, DOI 10.1053/rapm.2003.50038; Doyle J, 2003, SURG ANATOMY HAND UP; Galvin EM, 2006, ANESTH ANALG, V102, P598, DOI 10.1213/01.ane.0000189556.49429.16; HANDOLL HH, 2006, [No title captured], V1; Koscielniak-Nielsen ZJ, 2004, REGION ANESTH PAIN M, V29, P328, DOI 10.1016/j.rapm.2004.04.004; Koscielniak-Nielsen ZJ, 1998, ACTA ANAESTH SCAND, V42, P570, DOI 10.1111/j.1399-6576.1998.tb05168.x; Koscielniak-Nielsen ZJ, 1999, CAN J ANAESTH, V46, P658, DOI 10.1007/BF03013954; KoscielniakNielsen ZJ, 1997, EUR J ANAESTH, V14, P164, DOI 10.1046/j.1365-2346.1997.00093.x; Paqueron X, 2004, ANESTHESIOLOGY, V101, P162, DOI 10.1097/00000542-200407000-00025; Sia S, 2001, REGION ANESTH PAIN M, V26, P12, DOI 10.1053/rapm.2001.19638; Sia S, 2001, REGION ANESTH PAIN M, V26, P499, DOI 10.1053/rapm.2001.25896; Sia S, 2000, ANESTH ANALG, V91, P647; Sia S, 2006, REGION ANESTH PAIN M, V31, P514, DOI 10.1016/j.rapm.2006.06.252; Spinner M, 1978, INJURIES MAJOR BRANC; Tountas CP, 1993, ANATOMIC VARIATIONS; von Lanz T, 1972, PRAKTISCHE ANATOMIE	19	7	7	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JAN-FEB	2010	35	1					22	27		10.1097/AAP.0b013e3181c6f395			6	Anesthesiology	Anesthesiology	545EY	WOS:000273716500006	20052813				2020-06-30	J	Murrell, JC; Mitchinson, SL; Lesperance, L; Sivakumaran, S; Johnson, CB				Murrell, Joanna C.; Mitchinson, Sheryl L.; Lesperance, Lucy; Sivakumaran, Subathira; Johnson, Craig B.			Electroencephalography during ovariohysterectomy in rats anaesthetized with halothane	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						electroencephalogram; nociception; ovariohysterectomy; rats	TOTAL INTRAVENOUS ANESTHESIA; NOXIOUS-STIMULATION; SENSORY INNERVATION; ORTHOPEDIC-SURGERY; GENERAL-ANESTHESIA; ANTLER REMOVAL; SPECTRAL EDGE; FEMALE RAT; RESPONSES; EEG	Objective To evaluate electroencephalographic (EEG) changes during ovariohysterectomy (OVH) in rats anaesthetized with halothane, and modification of the EEG changes by the co-administration of fentanyl, ketamine or thiopental. Study design Prospective, randomized, blinded controlled study. Animals Sixty adult female Sprague-Dawley rats. Methods Anaesthesia was induced and maintained with halothane [Fe'HAL 0.95 +/- 0.05%]. The electroencephalogram was recorded continuously from the left and right primary somatosensory cortices. Rats were randomly divided into four groups and a rapid IV infusion of physiological saline, thiopental, ketamine or fentanyl was administered. OVH started 10 minutes after drug administration. Blood samples, for assay of plasma drug concentrations, were collected 5 minutes after administration and at the end of surgery. Electroencephalograph descriptors median frequency (F50), spectral edge frequency 95% (F95) and total power (P-tot), recorded during non-surgical baseline periods, were compared with those recorded during defined surgical periods; skin incision, right and left ovarian pedicle ligation; cervical ligation. Plasma drug concentrations were measured using high performance lipid chromatography. Results Although a large number of statistical differences in EEG data were observed, these generally represented a reduction in F50 or F95 throughout the experimental recording period and were similar between groups. A significant reduction in P-tot occurred during ligation of the ovaries and cervix in the control group compared with other recording periods. The co-administration of ketamine, fentanyl and thiopental obtunded the reduction in P-tot. Conclusions and clinical relevance Electroencephalographic changes, in the control group, mimicked changes reported in other studies using the minimal anaesthesia model. However, the stability in F50 during the surgical period compared with the baseline period indicated that OVH is an unsuitable surgical stimulus to investigate EEG changes with noxious stimulation. This may be attributed to the relatively prolonged duration of this surgical procedure and the primarily visceral afferent sensory innervation of the genital tract.	[Murrell, Joanna C.; Mitchinson, Sheryl L.; Johnson, Craig B.] Massey Univ, IVABS, Palmerston North, New Zealand; [Lesperance, Lucy] Food Ind Sci Ctr, Palmerston North, New Zealand; [Sivakumaran, Subathira] AgResearch, Food & Hlth Grp, Grasslands Res Ctr, Palmerston North, New Zealand	Murrell, JC (reprint author), Univ Bristol, Dept Vet Clin Sci, Langford House, Langford BS40 5DU, North Somerset, England.	jo.murrell@bristol.ac.uk	Johnson, Craig/B-5559-2014				Antognini JF, 2000, ANESTH ANALG, V91, P1282, DOI 10.1097/00000539-200011000-00043; Antunes LM, 2003, EUR J ANAESTH, V20, P800, DOI 10.1097/00003643-200310000-00005; ARCHER DP, 1994, ANESTHESIOLOGY, V80, P168, DOI 10.1097/00000542-199401000-00024; ARENDTNIELSEN L, 1995, ANESTH ANALG, V81, P63, DOI 10.1097/00000539-199507000-00013; BALJET B, 1980, ACTA ANAT, V107, P241; Bell RF, 2005, ACTA ANAESTH SCAND, V49, P1405, DOI 10.1111/j.1399-6576.2005.00814.x; BERKLEY KJ, 1993, J NEUROPHYSIOL, V69, P533; BROMM B, 1985, METHOD FIND EXP CLIN, V7, P161; BURDEN HW, 1983, ANAT REC, V207, P623, DOI 10.1002/ar.1092070410; Chang PF, 2001, EXP BRAIN RES, V141, P195, DOI 10.1007/s002210100864; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; DeBeer NAM, 1996, BRIT J ANAESTH, V76, P685; DRUMMOND JC, 1991, ACTA ANAESTH SCAND, V35, P693, DOI 10.1111/j.1399-6576.1991.tb03374.x; DWYER RC, 1994, ANESTHESIOLOGY, V81, P403, DOI 10.1097/00000542-199408000-00019; Edwards SR, 2002, BRIT J ANAESTH, V88, P94, DOI 10.1093/bja/88.1.94; Gibson TJ, 2007, NEW ZEAL VET J, V55, P152, DOI 10.1080/00480169.2007.36760; Gonzalez MI, 2000, PAIN, V88, P79, DOI 10.1016/S0304-3959(00)00309-2; GRANT IS, 1981, BRIT J ANAESTH, V53, P805, DOI 10.1093/bja/53.8.805; GUSTAFSSON LL, 1992, PHARMACEUT RES, V9, P800, DOI 10.1023/A:1015863824277; Haga HA, 2005, VET ANAESTH ANALG, V32, P1, DOI 10.1111/j.1467-2995.2004.00225.x; HODSON N, 1970, TESTIS, V1, P47; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Ichinose F, 1999, PAIN, V80, P251, DOI 10.1016/S0304-3959(98)00213-9; Johnson CB, 2005, NEW ZEAL VET J, V53, P433, DOI 10.1080/00480169.2005.36589; Johnson CB, 2005, VET ANAESTH ANALG, V32, P61, DOI 10.1111/j.1467-2995.2005.00228.x; Kiyama S, 1997, BRIT J ANAESTH, V79, P750; Kiyama S, 1997, BRIT J ANAESTH, V78, P751, DOI 10.1093/bja/78.6.751; KOCHS E, 1994, ANESTHESIOLOGY, V80, P1026, DOI 10.1097/00000542-199405000-00012; LONG CW, 1989, ANESTH ANALG, V69, P169; Mather LE, 2000, LIFE SCI, V66, P105; Morris JP, 1997, AUST VET J, V75, P883, DOI 10.1111/j.1751-0813.1997.tb11258.x; MURRELL J, 2000, VET ANAESTH ANALG, V27, P116; MURRELL J, 2001, SPONTANEOUS EEG CHAN; Murrell JC, 2006, J VET PHARMACOL THER, V29, P325, DOI 10.1111/j.1365-2885.2006.00758.x; Murrell JC, 2005, VET ANAESTH ANALG, V32, P212, DOI 10.1111/j.1467-2995.2005.00201.x; Murrell JC, 2003, VET ANAESTH ANALG, V30, P138, DOI 10.1046/j.1467-2995.2003.00138.x; Orth M, 2005, BRIT J ANAESTH, V95, P477, DOI 10.1093/bja/aei208; Otto KA, 2003, RES VET SCI, V75, P103, DOI 10.1016/S0034-5288(03)00077-8; PETERS LC, 1987, BRAIN RES, V408, P199, DOI 10.1016/0006-8993(87)90372-6; RAJA SN, 1988, ANESTHESIOLOGY, V68, P571, DOI 10.1097/00000542-198804000-00016; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Schraag S, 1998, ANAESTHESIA, V53, P320, DOI 10.1046/j.1365-2044.1998.00311.x; Stafford KJ, 2005, VET J, V169, P337, DOI 10.1016/j.tvjl.2004.02.005; Tatsuo MAKF, 1997, BRAZ J MED BIOL RES, V30, P251, DOI 10.1590/S0100-879X1997000200015; Temple JL, 1999, PAIN, pS13; THEILEN A, 2002, CRIT CARE MED, V30, P1919; TRAAST HS, 1995, ANESTH ANALG, V81, P366, DOI 10.1097/00000539-199508000-00027; WHITE PF, 1989, ANESTH ANALG, V68, P177, DOI 10.1213/00000539-198902000-00020; Wilson PR, 2002, NEW ZEAL VET J, V50, P221, DOI 10.1080/00480169.2002.36317	51	7	7	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2010	37	1					14	24		10.1111/j.1467-2995.2009.00504.x			11	Veterinary Sciences	Veterinary Sciences	531JX	WOS:000272663000003	20017815				2020-06-30	J	Gatineau, M; Dupuis, J				Gatineau, M.; Dupuis, J.			Longitudinal tendon tear concurrent with bilateral medial luxation of the superficial digital flexor muscle tendon in a dog	VETERINARY AND COMPARATIVE ORTHOPAEDICS AND TRAUMATOLOGY			English	Article						Tear; superficial flexor tendon; luxation; dog		Luxation of the superficial digital flexor muscle tendon (SDFMT) is a rarely reported condition in dogs, and tendon tear concurrent with SDFMT luxation had never been reported. Abnormal conformation of both calcanei and strenuous activity were suspected as contributing factors in this case. Bilateral medial SDFMT luxation was surgically treated with bursa medial incision release, redundant lateral bursa excision and apposition to the edge of the SDFMT with non-absorbable sutures. The unilateral longitudinal tendon tear of the SDFMT associated with medial SDFMT luxation was successfully treated with horizontal mattress sutures, and a good outcome was reported for both hindlimbs.	[Gatineau, M.; Dupuis, J.] Ctr Vet, Montreal, PQ, Canada	Gatineau, M (reprint author), Ctr Vet DMV, Montreal, PQ H8T 3R2, Canada.	gatineaumatthieu@hotmail.com					BERNARD MA, 1977, CAN VET J, V18, P105; EVANS HE, 1993, MILLERS ANATOMY DOG, P369; HOSCHEIT LP, 1994, CAN VET J, V35, P120; HOULTON JEF, 1993, VET COMP ORTHO TRAUM, P129; Lamb CR, 2005, VET RADIOL ULTRASOUN, V46, P326, DOI 10.1111/j.1740-8261.2005.00061.x; MAUTERER JV, 1993, J AM VET MED ASSOC, V203, P1162; Piermattei DL, 2006, HDB SMALL ANIMAL ORT, P661; REINKE JD, 1993, J AM ANIM HOSP ASSOC, V29, P303; ROE S.C., 1998, CANINE SPORTS MED SU, P92; Solanti Sari, 2002, Vet Ther, V3, P97	10	0	0	2	10	SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN	STUTTGART	HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY	0932-0814			VET COMP ORTHOPAED	Vet. Comp. Orthop. Traumatol.		2010	23	4					289	293		10.3415/VCOT-09-05-0059			5	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	638OQ	WOS:000280904600014	20585712				2020-06-30	J	Fukuda, K; Hayashida, M; Ide, S; Saita, N; Kokita, Y; Kasai, S; Nishizawa, D; Ogai, Y; Hasegawa, J; Nagashima, M; Tagami, M; Komatsu, H; Sora, I; Koga, H; Kaneko, Y; Ikeda, K				Fukuda, Kenichi; Hayashida, Masakazu; Ide, Soichiro; Saita, Naoko; Kokita, Yoshihiko; Kasai, Shinya; Nishizawa, Daisuke; Ogai, Yasukazu; Hasegawa, Junko; Nagashima, Makoto; Tagami, Megumi; Komatsu, Hiroshi; Sora, Ichiro; Koga, Hisashi; Kaneko, Yuzuru; Ikeda, Kazutaka			Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery	PAIN			English	Article						mu-Opioid receptor; Association study; Single nucleotide polymorphism; Pain; Fentanyl; Perioperative analgesia	MU-OPIOID-RECEPTOR; SINGLE-NUCLEOTIDE POLYMORPHISM; MORPHINE CONSUMPTION; A118G POLYMORPHISM; SEX-DIFFERENCES; ANALGESIA; REQUIREMENTS; REGION; MICE; KNOCKOUT	Individual differences in sensitivity to fentanyl, a widely used opioid analgesic, can hamper effective pain treatment. Still controversial is whether the single nucleotide polymorphisms (SNPs) of the human OPRM1 gene encoding the l-opioid receptor influence the analgesic effects of opioids. We examined associations between fentanyl sensitivity and the two SNPs, A118G and IVS3+A8449G, in the human OPRM1 gene in 280 Japanese patients undergoing painful orofacial cosmetic surgery, including bone dissection. Regarding the A118G SNP in exon 1, in a cold pressor-induced pain test before surgery, less analgesic effects of fentanyl were shown in subjects carrying the minor G allele of the A118G SNP (median of difference between pain perception latencies before and after fentanyl injection [PPLpost-PPLpre]: 12 s) compared with subjects not carrying this allele (PPLpost-PPLpre: 15 s, p = 0.046). Furthermore, the IVS3+A8449G SNP in intron 3, which represents a complete linkage disequilibrium block with more than 30 SNPs from intron 3 to the 3' untranslated region, was associated with 24-h postoperative fentanyl requirements. Subjects carrying the minor G allele of the IVS3+A8449G SNP required significantly less fentanyl for 24-h postoperative pain control (median: 1.5 mu g/kg) compared with subjects not carrying this allele (median: 2.5 mu g/kg, p = 0.010). Although further validation is needed, the present findings shed light on the involvement of OPRM1 3' untranslated region polymorphisms in fentanyl sensitivity in addition to the A118G SNP and open new avenues for personalized pain treatment with fentanyl. (C) 2009 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.	[Ide, Soichiro; Kasai, Shinya; Nishizawa, Daisuke; Ogai, Yasukazu; Hasegawa, Junko; Ikeda, Kazutaka] Tokyo Inst Psychiat, Div Psychobiol, Setagaya Ku, Tokyo 1568585, Japan; [Fukuda, Kenichi; Saita, Naoko; Kokita, Yoshihiko] Suidoubashi Hosp, Div Dent Anesthesiol, Orofacial Pain Ctr, Tokyo Dent Coll,Dept Oral Hlth & Clin Sci,Chiyoda, Tokyo 1010061, Japan; [Hayashida, Masakazu] Saitama Med Univ, Int Med Ctr, Dept Anesthesiol, Hidaka, Saitama 3501298, Japan; [Ide, Soichiro] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Nagashima, Makoto] Toho Univ, Sakura Med Ctr, Dept Surg, Sakura, Chiba 2858741, Japan; [Tagami, Megumi] Toho Univ, Sakura Med Ctr, Dept Anesthesiol, Sakura, Chiba 2858741, Japan; [Komatsu, Hiroshi; Sora, Ichiro] Tohoku Univ, Grad Sch Med, Dept Neurosci, Div Psychobiol, Sendai, Miyagi 9808574, Japan; [Koga, Hisashi] Kazusa DNA Res Inst, Dept Human Genome Technol, Lab Med Genom, Kisarazu, Chiba 2920818, Japan; [Kaneko, Yuzuru] Tokyo Dent Coll, Dept Dent Anesthesiol, Mihama Ku, Chiba 2618502, Japan	Ikeda, K (reprint author), Tokyo Inst Psychiat, Div Psychobiol, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 1568585, Japan.	ikedak@prit.go.jp	Ikeda, Kazutaka/I-4694-2013; Nishizawa, Daisuke/G-6933-2013; Ide, Soichiro/D-5472-2012	Ikeda, Kazutaka/0000-0001-8342-0278; 	Ministry of Health, Labour and Welfare of JapanMinistry of Health, Labour and Welfare, Japan [H17-Pharmaco-001, H19-Iyaku-023]; Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20602020, 19659405, 20390162]	We acknowledge Mr. Michael Arends for his assistance with editing the manuscript. We are grateful to the volunteers for their participation in this study and the anesthesiologists and surgeons at Tokyo Dental College Suidoubashi Hospital for collecting clinical data. This work was supported by grants from the Ministry of Health, Labour and Welfare of Japan (H17-Pharmaco-001, H19-Iyaku-023) and the Ministry of Education, Culture, Sports, Science and Technology of Japan(20602020, 19659405, 20390162). The authors declare no conflict of interest.	Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; BURNS JW, 1989, ANAESTHESIA, V44, P2, DOI 10.1111/j.1365-2044.1989.tb11086.x; Cepeda MS, 2003, ANESTH ANALG, V97, P1464, DOI 10.1213/01.ANE.0000080153.36643.83; Chia YY, 2002, CAN J ANAESTH, V49, P249, DOI 10.1007/BF03020523; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Cicero TJ, 1997, J PHARMACOL EXP THER, V282, P939; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Gear RW, 1996, NAT MED, V2, P1248, DOI 10.1038/nm1196-1248; GORDON NC, 1995, NEUROSCIENCE, V69, P345, DOI 10.1016/0306-4522(95)00335-G; Han WH, 2006, PHARMACOGENET GENOM, V16, P451, DOI 10.1097/01.fpc.0000215072.36965.8d; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; Huang CJ, 2008, ANAESTHESIA, V63, P1288, DOI 10.1111/j.1365-2044.2008.05760.x; Ide S, 2005, GENE, V364, P139, DOI 10.1016/j.gene.2005.05.040; Ide S, 2006, PHARMACOGENOMICS J, V6, P179, DOI 10.1038/sj.tpj.6500355; Ide S, 2004, ANN NY ACAD SCI, V1025, P316, DOI 10.1196/annals.1316.039; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Ikeda K, 2001, J NEUROSCI, V21, P1334; Imai K, 2007, MOL BIOSYST, V3, P547, DOI 10.1039/b701645j; Janicki PK, 2006, ANESTH ANALG, V103, P1011, DOI 10.1213/01.ane.0000231634.20341.88; Kasai S, 2006, PSYCHIAT CLIN NEUROS, V60, pS11, DOI 10.1111/j.1440-1819.2006.01523.x-i1; KEPLER KL, 1991, PAIN, V45, P87, DOI 10.1016/0304-3959(91)90168-W; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x; Lotsch J, 2006, BEHAV NEUROSCI, V120, P1218, DOI 10.1037/0735-7044.120.6.1218; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Martikainen IK, 2004, NEUROSCI LETT, V361, P140, DOI 10.1016/j.neulet.2003.12.060; Miller PL, 2004, SOUTH MED J, V97, P35, DOI 10.1097/01.SMJ.0000085743.68121.A9; Olofsen E, 2005, ANESTHESIOLOGY, V103, P130, DOI 10.1097/00000542-200507000-00020; Risch N, 2000, J CLIN INVEST, V105, P1503, DOI 10.1172/JCI10266; Romberg R, 2004, ANESTHESIOLOGY, V100, P120, DOI 10.1097/00000542-200401000-00021; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Sora I, 2001, NEUROPSYCHOPHARMACOL, V25, P41, DOI 10.1016/S0893-133X(00)00252-9; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	39	80	87	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	DEC 15	2009	147	1-3					194	201		10.1016/j.pain.2009.09.004			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	530SN	WOS:000272612700032	19783098				2020-06-30	J	Chevillard, L; Megarbane, B; Risede, P; Baud, FJ				Chevillard, Lucie; Megarbane, Bruno; Risede, Patricia; Baud, Frederic J.			Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats	TOXICOLOGY LETTERS			English	Article						Buprenorphine; Fentanyl; Methadone; Morphine; Plethysmography; Respiratory depression	MU-OPIOID RECEPTORS; BLOOD-GAS CONCENTRATIONS; CENTRAL-NERVOUS-SYSTEM; ANESTHETIZED RATS; BETA-FUNALTREXAMINE; OPIATE RECEPTORS; SPINAL-CORD; PHARMACOLOGICAL CHARACTERIZATION; VENTILATORY DEPRESSION; MUSCLE RIGIDITY	Opioids are known to induce respiratory depression. We aimed to characterize in rats the effects of four opioids on arterial blood gases and plethysmography after intraperitoneal administration at 80% of their LD50 in order to identify opioid molecule-specific patterns and classify response severity. Opioid-receptor (OR) antagonists, including intravenous 10 mg kg(-1)-naloxonazine at 5 min [mu-OR antagonist], subcutaneous 30 mg kg(-1)-naloxonazine at 24 h [mu1-OR antagonist], subcutaneous 3 mg kg(-1)-naltrindole at 45 min [delta-OR antagonist], and subcutaneous 5 mg kg(-1)-Nor-binaltorphimine at 6 h [kappa-OR antagonist] were pre-administered to test the role of each OR. Methadone. morphine, and fentanyl significantly decreased PaO2 (P<0.001) and increased PaCO2 (P<0.05). while buprenorphine only decreased PaO2 (P<0.05) While all opioids significantly increased inspiratory time (T-1, P < 0.001), methadone and fentanyl also increased expiratory time (T-E, P < 0.05). Intravenous 10 mg kg(-1)-naloxonazine at 5 min completely reversed opioid-related effects on PaO2 (P < 0.05). PaCO2 (P < 0001). T-1 (P < 0.05) and T-E (P < 0.01) except in buprenorphine. Subcutaneous 30 mg kg(-1)-naloxonazine at 24 h completely reversed effects on PaCO2 (P < 001) and T-E (P < 0001), partially reversed effects on T-1 (P < 0.001), and did not reverse effects on PaO2. Naltrindole reversed methadone-induced T-E increases (P < 0.01) but worsened fentanyl's effect on PaCO2 (P < 0.05) and T-1 (P < 0 05) Nor-binaltorphimine reversed morphine- and buprenorphine-induced T-1 increases (P < 0.001) but worsened methadone's effect on PaO2 (P < 0 05) and morphine (P < 0 001) and buprenorphine's (P < 0 01) effects on pH. In conclusion, opioid-related respiratory patterns are not uniform. Opioid-induced hypoxemia as well as increases in T-1 and T-E are caused by mu-OR, while delta and kappa-OR roles appear limited, depending on the specific opioid. Regarding severity of opioid-incluced respiratory effects at 80% of their LD50, all drugs increased T-1. Methadone and fentanyl induced hypoxemia, hypercapnia, and T-E increases. morphine caused both hypoxemia and hypercapnia while buprenorphine caused only hypoxemia (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Megarbane, Bruno; Baud, Frederic J.] Univ Paris Diderot, Hop Lariboisiere, AP HP, F-75010 Paris, France; [Chevillard, Lucie; Megarbane, Bruno; Risede, Patricia; Baud, Frederic J.] INSERM, U705, Paris, France; [Chevillard, Lucie; Megarbane, Bruno; Risede, Patricia; Baud, Frederic J.] Univ Paris 05, CNRS, UMR7157, Fac Pharm, F-75010 Paris, France; [Chevillard, Lucie; Megarbane, Bruno; Risede, Patricia; Baud, Frederic J.] Univ Paris Diderot, F-75010 Paris, France; Hop Fernand Widal, F-75010 Paris, France	Megarbane, B (reprint author), Univ Paris Diderot, Hop Lariboisiere, AP HP, 2 Rue Ambroise Pare, F-75010 Paris, France.		Chevillard, Lucie M/S-5942-2016	Chevillard, Lucie M/0000-0003-2910-9117; Megarbane, Bruno/0000-0002-2522-2764			ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Bailey PL, 2000, NEW ENGL J MED, V343, P1228, DOI 10.1056/NEJM200010263431705; BARTLETT D, 1970, RESP PHYSIOL, V10, P384, DOI 10.1016/0034-5687(70)90056-3; BESSE D, 1991, BRAIN RES, V548, P287, DOI 10.1016/0006-8993(91)91134-M; Bonora M, 2004, PEDIATR RES, V55, P738, DOI 10.1203/01.PDR.0000117841.81730.2B; Bronstein AC, 2008, CLIN TOXICOL, V46, P927, DOI 10.1080/15563650802559632; BUTELMAN ER, 1993, J PHARMACOL EXP THER, V264, P145; CAMPBELL C, 1995, RESP PHYSIOL, V100, P107, DOI 10.1016/0034-5687(94)00119-K; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Chen SW, 1996, EUR J PHARMACOL, V312, P241, DOI 10.1016/0014-2999(96)00571-7; Cheng PY, 1996, BRAIN RES, V731, P141, DOI 10.1016/S0006-8993(96)00492-1; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; Dahan A, 2001, ANESTHESIOLOGY, V94, P824, DOI 10.1097/00000542-200105000-00021; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dart RC, 2005, ANN INTERN MED, V143, P620, DOI 10.7326/0003-4819-143-8-200510180-00028; Ding YQ, 1998, BRAIN RES, V792, P149, DOI 10.1016/S0006-8993(98)00205-4; DOSAKAAKITA K, 1993, J PHARMACOL EXP THER, V264, P631; Endoh H, 2001, CRIT CARE MED, V29, P623, DOI 10.1097/00003246-200103000-00027; FADEN AI, 1983, BRIT J PHARMACOL, V79, P997, DOI 10.1111/j.1476-5381.1983.tb10547.x; FONE KCF, 1986, BRIT J PHARMACOL, V89, P67, DOI 10.1111/j.1476-5381.1986.tb11121.x; Fugelstad A, 2007, ADDICTION, V102, P406, DOI 10.1111/j.1360-0443.2006.01714.x; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; Guenther U, 2009, ANESTH ANALG, V108, P1169, DOI 10.1213/ane.0b013e318198f828; Gueye PN, 2002, TOXICOL SCI, V65, P107, DOI 10.1093/toxsci/65.1.107; Gueye PN, 2001, TOXICOL SCI, V62, P148, DOI 10.1093/toxsci/62.1.148; HASSEN AH, 1984, NEUROPHARMACOLOGY, V23, P407, DOI 10.1016/0028-3908(84)90248-X; HOFFMAN JR, 1991, ANN EMERG MED, V20, P246, DOI 10.1016/S0196-0644(05)80933-3; HOLADAY JW, 1983, NEUROSCI LETT, V37, P199, DOI 10.1016/0304-3940(83)90153-2; Hreiche R, 2006, TOXICOL APPL PHARM, V217, P352, DOI 10.1016/j.taap.2006.09.011; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Janczewski WA, 2006, J PHYSIOL-LONDON, V570, P407, DOI 10.1113/jphysiol.2005.098848; Kaczynska K, 2005, J PHYSIOL PHARMACOL, V56, P195; Kasaba T, 1998, Masui, V47, P414; Kasaba T, 1997, Masui, V46, P1570; Kintz P, 2001, FORENSIC SCI INT, V121, P65, DOI 10.1016/S0379-0738(01)00454-6; KIRITSYROY JA, 1989, J PHARMACOL EXP THER, V251, P1096; Latasch L, 2002, ARZNEIMITTEL-FORSCH, V52, P870; LING GSF, 1985, J PHARMACOL EXP THER, V232, P149; LING GSF, 1986, EUR J PHARMACOL, V129, P33, DOI 10.1016/0014-2999(86)90333-X; LUI PW, 1989, ANESTHESIOLOGY, V70, P984, DOI 10.1097/00000542-198906000-00017; LYNCH TA, 1958, J AM PHARM ASSOC, V47, P323, DOI 10.1002/jps.3030470507; MAY CN, 1989, BRIT J PHARMACOL, V98, P903, DOI 10.1111/j.1476-5381.1989.tb14620.x; MCCORMICK GY, 1984, J PHARMACOL EXP THER, V230, P353; Megarbane B, 2005, TOXICOL LETT, V157, P211, DOI 10.1016/j.toxlet.2005.02.002; MORINSURUN MP, 1984, EUR J PHARMACOL, V98, P241, DOI 10.1016/0014-2999(84)90595-8; NEGUS SS, 1993, J PHARMACOL EXP THER, V264, P739; Nielsen S, 2005, DRUG ALCOHOL DEPEN, V79, P95, DOI 10.1016/j.drugalcdep.2005.01.004; Ohtani M, 1997, J PHARMACOL EXP THER, V281, P428; Onimaru H, 2003, J NEUROSCI, V23, P1478; PASTERNAK GW, 1983, LIFE SCI, V33, P167, DOI 10.1016/0024-3205(83)90470-8; PASTERNAK GW, 1980, J PHARMACOL EXP THER, V214, P455; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; PAZOS A, 1984, EUR J PHARMACOL, V99, P15, DOI 10.1016/0014-2999(84)90427-8; PFEIFFER A, 1983, J PHARMACOL EXP THER, V225, P735; PICK CG, 1991, LIFE SCI, V48, P2005, DOI 10.1016/0024-3205(91)90155-5; Pirnay SO, 2008, BASIC CLIN PHARMACOL, V103, P228, DOI 10.1111/j.1742-7843.2008.00273.x; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1996, [No title captured], P521; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Smith MY, 2007, CLIN TOXICOL, V45, P23, DOI 10.1080/15563650600956170; Su YF, 1998, J PHARMACOL EXP THER, V287, P815; Szeto HH, 1999, PEPTIDES, V20, P101, DOI 10.1016/S0196-9781(98)00141-7; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Tallarida RJ, 1981, MANUAL PHARM CALCULA, P47; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; VANDENHOOGEN RHWM, 1986, J PHARMACOL EXP THER, V237, P252; Verborgh C, 1999, PHARMACOL BIOCHEM BE, V63, P175, DOI 10.1016/S0091-3057(98)00238-X; VERBORGH C, 1999, PAIN, V1983, P17; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; WARD SJ, 1982, J PHARMACOL EXP THER, V220, P494; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; WHITE WJ, 1979, J PHARMACOL EXP THER, V209, P451; Wojciechowski P, 2007, EUR J PHARMACOL, V563, P209, DOI 10.1016/j.ejphar.2007.02.012; WOLOZIN BL, 1981, P NATL ACAD SCI-BIOL, V78, P6181, DOI 10.1073/pnas.78.10.6181; YEADON M, 1990, GEN PHARMACOL, V21, P655, DOI 10.1016/0306-3623(90)91013-H; 2009, YAKUDS GEKKAN YAKUJI	81	23	23	1	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	DEC 15	2009	191	2-3					327	340		10.1016/j.toxlet.2009.09.017			14	Toxicology	Toxicology	532OV	WOS:000272760200032	19819313				2020-06-30	J	Gillman, AG; Leffel, JK; Kosobud, AEK; Timberlake, W				Gillman, Andrea G.; Leffel, Joseph K., II; Kosobud, Ann E. K.; Timberlake, William			Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24-and 31-h intervals	BEHAVIOURAL BRAIN RESEARCH			English	Article						Fentanyl; Haloperidol; Drug addiction; Drug abuse; Circadian rhythms; Locomotor entrainment; Drug anticipation; Ensuing activity; Wheel running	DORSOMEDIAL HYPOTHALAMIC NUCLEUS; FOOD-ANTICIPATORY ACTIVITY; DRUG-ADDICTION; MOTOR-ACTIVITY; COCAINE SENSITIZATION; LOCOMOTOR-ACTIVITY; DIURNAL-VARIATIONS; RUNNING ACTIVITY; HEART-RATE; SLEEP	Administration of several drugs of abuse on a 24-h schedule has been shown to entrain both pre-drug (anticipatory) and post-drug (evoked) circadian activity episodes that persist for several days when the drug is withheld. The present study tested the entrainment effects of fentanyl, an opioid agonist with a noted abuse liability, and haloperidol, an anti-psychotic dopamine antagonist without apparent abuse liability. Adult female Sprague-Dawley rats housed under constant light in cages with attached running wheels received repeated low, medium, or high doses of either fentanyl or haloperidol on a 24-h administration schedule followed by a 31-h schedule (Experiment 1) or solely on a 31-h schedule (Experiment 2). The results showed that all three doses of fentanyl entrained both pre-drug and post-drug episodes of wheel running when administered every 24 h, and the combined pre- and post-fentanyl activity episodes persisted for at least 3 days when the drug was withheld during test days. On the 31-h schedule, fentanyl produced an "ensuing" activity episode approximately 24 h post-administration, but failed to produce an anticipatory episode 29-31 h post-administration. In contrast, haloperidol injections failed to produce both pre-drug episodes on the 24-h schedule and circadian ensuing episodes on the 31-h schedule, and post-haloperidol suppression of activity appeared to mask the free-running activity rhythm. Taken together, these results provide additional evidence that drugs of abuse share a common ability to entrain circadian activity episodes. (C) 2009 Elsevier B.V. All rights reserved.	[Gillman, Andrea G.; Leffel, Joseph K., II; Timberlake, William] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA	Gillman, AG (reprint author), Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.	aggillma@indiana.edu			NIH/NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA017692]	This research was supported by NIH/NIDA R01DA017692. The authors would like to thank Doug Toms, Mike Bailey, George Rebec, and Scott Bar-ton for technical assistance and two anonymous reviewers for their comments on a previous version of this manuscript.	Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; Adan A, 1995, INT J PSYCHOPHYSIOL, V20, P189, DOI 10.1016/0167-8760(95)00037-2; Akhisaroglu M, 2004, PHARMACOL BIOCHEM BE, V79, P37, DOI 10.1016/j.pbb.2004.06.014; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Angeles-Castellanos M, 2008, NEUROSCIENCE, V155, P297, DOI 10.1016/j.neuroscience.2008.06.001; Balogh B, 2004, PSYCHOPHARMACOLOGY, V173, P296, DOI 10.1007/s00213-004-1787-9; Baylon GJ, 2000, J CLIN PSYCHOPHARM, V20, P597, DOI 10.1097/00004714-200012000-00002; Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121; Brower KJ, 2001, ALCOHOL RES HEALTH, V25, P110; CAMPBELL A, 1982, PSYCHOPHARMACOLOGY, V77, P150, DOI 10.1007/BF00431938; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Danel T, 2003, CHRONOBIOL INT, V20, P1093, DOI 10.1081/CBI-120025533; Davidson AJ, 2006, AM J PHYSIOL-REG I, V290, pR1524, DOI 10.1152/ajpregu.00073.2006; Davidson AJ, 2003, GENES BRAIN BEHAV, V2, P32, DOI 10.1034/j.1601-183X.2003.00005.x; Davidson AJ, 2000, AM J PHYSIOL-REG I, V278, pR1296; Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032; EASTMAN C, 1983, PHYSIOL BEHAV, V31, P417, DOI 10.1016/0031-9384(83)90061-6; EDMONDS SC, 1977, PHYSIOL BEHAV, V18, P915, DOI 10.1016/0031-9384(77)90201-3; EDMONDS SC, 1977, PHYSIOL BEHAV, V18, P921, DOI 10.1016/0031-9384(77)90202-5; Erickson TB, 1998, AM J EMERG MED, V16, P568, DOI 10.1016/S0735-6757(98)90220-0; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Fowler SC, 1998, PSYCHOPHARMACOLOGY, V137, P50, DOI 10.1007/s002130050592; Gillman AG, 2008, PHYSIOL BEHAV, V93, P337, DOI 10.1016/j.physbeh.2007.09.013; Gooley JJ, 2006, NAT NEUROSCI, V9, P398, DOI 10.1038/nn1651; GURTU S, 1990, LIFE SCI, V46, P1539, DOI 10.1016/0024-3205(90)90427-S; Halliburton J R, 1988, AANA J, V56, P229; HARDY DF, 1970, PHYSIOL BEHAV, V5, P421, DOI 10.1016/0031-9384(70)90246-5; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Irving CB, 2006, COCHRANE DATABASE SY; JACOBER A, 1994, CHRONOBIOL INT, V11, P320, DOI 10.3109/07420529409057248; JARVIK M, 1993, J BEHAV MED, V16, P413, DOI 10.1007/BF00844781; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; KAY DC, 1975, PSYCHOPHARMACOLOGIA, V44, P117, DOI 10.1007/BF00420997; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Kosobud AEK, 1998, NEUROSCI LETT, V250, P99, DOI 10.1016/S0304-3940(98)00439-X; Kosobud Ann E K, 2007, ScientificWorldJournal, V7, P203; Kudo S, 1999, CLIN PHARMACOKINET, V37, P435, DOI 10.2165/00003088-199937060-00001; LAHOSTE GJ, 1992, SYNAPSE, V12, P14, DOI 10.1002/syn.890120103; Landry GJ, 2007, BRAIN RES, V1141, P108, DOI 10.1016/j.brainres.2007.01.032; Landry GJ, 2006, AM J PHYSIOL-REG I, V290, pR1527, DOI 10.1152/ajpregu.00874.2005; Landry GJ, 2007, J BIOL RHYTHM, V22, P467, DOI 10.1177/0748730407307804; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; Liu J, 2008, NEUROPHARMACOLOGY, V55, P812, DOI 10.1016/j.neuropharm.2008.06.034; McClung CA, 2005, P NATL ACAD SCI USA, V102, P9377, DOI 10.1073/pnas.0503584102; Mieda M, 2006, P NATL ACAD SCI USA, V103, P12150, DOI 10.1073/pnas.0604189103; Mistlberger RE, 2005, BRAIN RES REV, V49, P429, DOI 10.1016/j.brainresrev.2005.01.005; MISTLBERGER RE, 1994, NEUROSCI BIOBEHAV R, V18, P171, DOI 10.1016/0149-7634(94)90023-X; MOOREEDE MC, 1986, AM J PHYSIOL, V250, pR737; Moriya T, 1996, NEUROSCI LETT, V208, P129, DOI 10.1016/0304-3940(96)12565-9; Morris R W, 1987, Prog Clin Biol Res, V227B, P451; Mrosovsky N, 1996, BIOL REV, V71, P343, DOI 10.1111/j.1469-185X.1996.tb01278.x; Mukherjee S, 2008, BRAIN RES, V1208, P120, DOI 10.1016/j.brainres.2008.02.079; NIEMEGEERS CJE, 1976, P ROY SOC MED, V69, P3, DOI 10.1177/00359157760690S102; Oyefeso A, 1997, DRUG ALCOHOL DEPEN, V48, P9, DOI 10.1016/S0376-8716(97)00097-5; Pan WJ, 1999, J PHARM SCI, V88, P459, DOI 10.1021/js980282p; PAULSON PE, 1994, BEHAV NEUROSCI, V108, P624, DOI 10.1037/0735-7044.108.3.624; Pecoraro N, 2000, PHYSIOL BEHAV, V71, P95, DOI 10.1016/S0031-9384(00)00306-1; Pelissier AL, 1998, J PHARM PHARMACOL, V50, P929, DOI 10.1111/j.2042-7158.1998.tb04010.x; PENG MT, 1980, J GERONTOL, V35, P339, DOI 10.1093/geronj/35.3.339; RAYMOND RC, 1992, J TOXICOL-CLIN TOXIC, V30, P467; Riviere GJ, 2000, J PHARMACOL EXP THER, V292, P1042; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Roehrs T, 2001, ALCOHOL RES HEALTH, V25, P101; ROSENWASSER AM, 1981, PHYSIOL BEHAV, V27, P33, DOI 10.1016/0031-9384(81)90296-1; RUSAK B, 1979, PHYSIOL REV, V59, P449; SALAMONE JD, 1990, NEUROSCIENCE, V39, P17, DOI 10.1016/0306-4522(90)90218-S; SCHULL J, 1989, PHYSIOL BEHAV, V46, P341, DOI 10.1016/0031-9384(89)90001-2; Sellers Edward M, 2006, J Opioid Manag, V2, P219; Shaw IR, 2005, SLEEP, V28, P677, DOI 10.1093/sleep/28.6.677; Siegel S, 2005, CURR DIR PSYCHOL SCI, V14, P296, DOI 10.1111/j.0963-7214.2005.00384.x; Spanagel R, 2005, NAT MED, V11, P35, DOI 10.1038/nm1163; STEPHAN FK, 1981, J COMP PHYSIOL, V143, P401, DOI 10.1007/BF00609906; Stephan FK, 1998, PHYSIOL BEHAV, V65, P277, DOI 10.1016/S0031-9384(98)00166-8; STEPHAN FK, 1989, PHYSIOL BEHAV, V46, P489, DOI 10.1016/0031-9384(89)90026-7; Tataroglu O, 2006, J BIOL RHYTHM, V21, P185, DOI 10.1177/0748730406287529; Vansteensel MJ, 2005, EUR J NEUROSCI, V21, P2958, DOI 10.1111/j.1460-9568.2005.04131.x; Vansteensel MJ, 2003, J BIOL RHYTHM, V18, P297, DOI 10.1177/0748730403254283; VESCOVI PP, 1992, HORM RES, V37, P221, DOI 10.1159/000182316; Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015; WEDDINGTON WW, 1990, ARCH GEN PSYCHIAT, V47, P861; White W, 1999, AM J PHYSIOL-REG I, V276, pR1276; White W, 2000, BEHAV NEUROSCI, V114, P972, DOI 10.1037//0735-7044.114.5.972; White W, 1999, PHYSIOL BEHAV, V65, P625	83	10	10	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 14	2009	205	1					102	114		10.1016/j.bbr.2009.07.002			13	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	511MY	WOS:000271170700014	19595707	Green Accepted			2020-06-30	J	Bell, JS; Klaukka, T; Ahonen, J; Hartikainen, S				Bell, J. Simon; Klaukka, Timo; Ahonen, Jouni; Hartikainen, Sirpa			National Utilization of Transdermal Fentanyl Among Community-Dwelling Older People in Finland	AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY			English	Article						fentanyl; analgesics; aged; drug utilization; Finland	OPIOID ANALGESICS; CONSUMPTION; TRENDS; PHYSICIANS; PAIN	Background: The use of opioids has increased rapidly in Europe and North America, and older people may be susceptible to opioid-related adverse drug events. The Finnish National Agency for Medicines has recommended that oral opioids be considered the first-line treatment when a strong opioid is required for severe pain. Objective: The objective of this Study was to investigate and describe the age-, indication-, sex-, and geographic-specific utilization of transdermal fentanyl among older people residing in noninstitutional settings in Finland. Methods: Reimbursement data for fentanyl, morphine, oxycodone, and hydromorphone were extracted from the Finnish National Prescription Register for 2008. Age-specific population data were used to calculate the annual prevalence of opioid use for malignant and nonmalignant pain for patients aged 564, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85 to 89, 90 to 94, 95 to 99, and >99 years. The annual prevalence of transdermal fentanyl use was also calculated separately for each of the 21 hospital districts in Finland. Results: Reimbursement for transdermal fentanyl was paid to 2746 people for malignant pain and 6223 people for nonmalignant pain. The annual prevalence of transdermal fentanyl use for nonmalignant pain was lowest among men aged <= 64 years (2.2 users/10,000 men) and highest among women >99 years (539.2 users/10,000 women). The annual prevalence of transdermal fentanyl use was >47 times higher than that of morphine for nonmalignant pain among people aged 85 to 89 years and >97 times higher than that of morphine among people aged 90 to 94 years. A greater than 4-fold variation in the annual prevalence of transdermal fentanyl use was reported among the 21 hospital districts in Finland (range, 9.5-40.6/10,000 inhabitants). Conclusions: The prevalence of transdermal fentanyl use was higher than that of morphine, oxycodone, and hydromorphone among people aged >= 80 years residing in noninstitutional settings in Finland. The variation in use between hospital districts Suggests that organizational culture may have a strong impact on prescribing practices. Our data highlight the need for further education regarding the appropriate use of opioids among older people. (Am J Geriatr Pharmacother. 2009;7:355-361) (C) 2009 Excerpta Medica Inc.	[Bell, J. Simon; Ahonen, Jouni; Hartikainen, Sirpa] Univ Kuopio, Kuopio Res Ctr Geriatr Care, FIN-70211 Kuopio, Finland; [Bell, J. Simon] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland; [Klaukka, Timo] Social Insurance Inst, Social Secur Res Inst, Dept Res, SF-00381 Helsinki, Finland; [Ahonen, Jouni] Univ Kuopio, Fac Pharm, Dept Social Pharm, FIN-70211 Kuopio, Finland; [Ahonen, Jouni] Kuopio Univ Hosp, Dept Pharm, SF-70210 Kuopio, Finland; [Hartikainen, Sirpa] Leppavirta Hlth Ctr, Leppavirta, Finland	Bell, JS (reprint author), Univ Kuopio, Kuopio Res Ctr Geriatr Care, POB 1627, FIN-70211 Kuopio, Finland.	simon.bell@uku.fi	Bell, J Simon/E-7218-2011				[Anonymous], 2009, J AM GERIATR SOC, V57, P1331, DOI [DOI 10.1111/J.1532-5415.2009.02376.X, 10.1111/j.1532-5415.2009.02376.x]; Auret K, 2005, DRUG AGING, V22, P641, DOI 10.2165/00002512-200522080-00002; Berger JT, 2008, ACAD MED, V83, P100, DOI 10.1097/ACM.0b013e31815c6713; Brixner Diana I, 2006, J Pain Palliat Care Pharmacother, V20, P5; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Dosa DM, 2009, J PAIN SYMPTOM MANAG, V38, P515, DOI 10.1016/j.jpainsymman.2008.11.008; Hamilton Hilary J, 2009, BMC Geriatr, V9, P5, DOI 10.1186/1471-2318-9-5; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; HOLDSWORTH MT, 1994, GERONTOLOGY, V40, P32; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Hudec R, 2004, EUR J CLIN PHARMACOL, V60, P445, DOI 10.1007/s00228-004-0793-5; Hughes CM, 2007, DRUG AGING, V24, P81, DOI 10.2165/00002512-200724020-00001; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; KALSO E, 2008, TABU, V6, P10; KALSO E, USE OPIOIDS LONG TER; KALSO E, MED TREATMENT CANC P; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; McLachlan AJ, 2009, CLIN PHARMACOL THER, V85, P431, DOI 10.1038/clpt.2009.1; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P391, DOI 10.1016/j.jpainsymman.2004.02.009; Mercadante S, 2002, LANCET, V360, P1254, DOI 10.1016/S0140-6736(02)11261-X; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; *NAT AG MED, SAL STAT 2008; *NAT AG MED SOC IN, FINN STAT MED; *NPS, FENT PATCH DUR CHRON; Nwokeji ED, 2007, CLIN THER, V29, P2589, DOI 10.1016/j.clinthera.2007.12.007; Nygaard HA, 2003, EUR J CLIN PHARMACOL, V59, P463, DOI 10.1007/s00228-003-0646-7; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Rigler Sally K, 2007, Am J Geriatr Pharmacother, V5, P91, DOI 10.1016/j.amjopharm.2007.05.002; Rochon PA, 2007, ARCH INTERN MED, V167, P676, DOI 10.1001/archinte.167.7.676; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; U. S. Food and Drug Administration, FENT TRANSD PATCH IM; Wilder-Smith OHG, 2005, EUR J PAIN, V9, P137, DOI 10.1016/j.ejpain.2004.07.011	34	11	11	1	7	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	1543-5946			AM J GERIATR PHARMAC	Am. J. Geriatr. Pharmacother.	DEC	2009	7	6					355	361		10.1016/j.amjopharm.2009.11.006			7	Geriatrics & Gerontology; Pharmacology & Pharmacy	Geriatrics & Gerontology; Pharmacology & Pharmacy	544TB	WOS:000273681100004	20129256				2020-06-30	J	Ueyama, Y; Lerche, P; Eppler, CM; Muir, WW				Ueyama, Yukie; Lerche, Phillip; Eppler, C. Mark; Muir, William W., III			Effects of intravenous administration of perzinfotel, fentanyl, and a combination of both drugs on the minimum alveolar concentration of isoflurane in dogs	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							BISPECTRAL INDEX; CONTINUOUS-INFUSION; ANESTHESIA; KETAMINE; PROPOFOL; MEDETOMIDINE; DEPTH; PHARMACOKINETICS; DEXMEDETOMIDINE; HYDROCHLORIDE	Objective-To determine the effects of IV administration of perzinfotel and a perzinfotel-fentanyl combination on the minimum alveolar concentration (MAC) of isoflurane in dogs. Animals-6 healthy sexually intact Beagles (3 males and 3 females). Procedures-All dogs were instrumented with a telemetry device for continuous monitoring of heart rate, arterial blood pressure, and core body temperature (at a femoral artery). Dogs were anesthetized with propofol (6 mg/kg, IV) and isoflurane. Isoflurane MAC values were determined in 3 experiments in each dog, separated by at least 7 days, before (baseline) and after the following treatments: no treatment (anesthetic only), perzinfotel (20 mg/kg, IV), fentanyl (5 mu g/kg bolus, IV, followed by a continuous IV infusion at 0.15 mu g/kg/ min), and a fentanyl-perzinfotel combination (20 mg of perzinfotel/kg, IV plus the fentanyl infusion). Bispectral index and oxygen saturation as measured by pulse oximetry were also monitored throughout anesthesia. Results-Without treatment, the mean +/- SD isoflurane MAC for all 6 dogs was 1.41 +/- 0.10%. Baseline MAC was 1.42 +/- 0.08%. Intravenous administration of perzinfotel, fentanyl, and the perzinfotel-fentanyl combination significantly decreased the MAC by 39%, 35%, and 66%, respectively. Perzinfotel and perzinfotel-fentanyl administration yielded significant increases in the bispectral index. Mean, systolic, and diastolic arterial blood pressures significantly increased from baseline values when perzinfotel was administered. Systolic arterial blood pressure significantly increased from the baseline value when perzinfotel-fentanyl was administered. No adverse effects were detected. Conclusions and Clinical Relevance-IV administration of perzinfotel, fentanyl, or a perzinfotel-fentanyl combination reduced isoflurane MAC in dogs and increased arterial blood pressure. (Am J Vet Res 2009;70:1459-1464)	[Muir, William W., III] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA; Ft Dodge Anim Hlth, Monmouth Jct, NJ 08852 USA	Muir, WW (reprint author), Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA.	bill.muir@amcny.org	Lerche, Phillip/A-8631-2013		Fort Dodge Animal Health	Supported by Fort Dodge Animal Health.	Antognini JF, 2000, VET RES COMMUN, V24, P361, DOI 10.1023/A:1006400315247; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; BAILEY PL, 1987, ANESTH ANALG, V66, P542; Boyce S, 1999, NEUROPHARMACOLOGY, V38, P611, DOI 10.1016/S0028-3908(98)00218-4; Bufalari A, 2007, VET RES COMMUN, V31, P277, DOI 10.1007/s11259-007-0046-z; Campagnol D, 2007, AM J VET RES, V68, P1300, DOI 10.2460/ajvr.68.12.1300; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; Enouri SS, 2008, AM J VET RES, V69, P586, DOI 10.2460/ajvr.69.5.586; Greene SA, 2004, COMPARATIVE MED, V54, P397; Greene SA, 2002, VET ANAESTH ANALG, V29, P59, DOI 10.1046/j.1467-2995.2002.00067.x; Greene SA, 2002, COMPARATIVE MED, V52, P424; GREENWALD SD, 2000, J CLIN MONITOR COMP, V16, P62; Haga H. A., 1999, Journal of Veterinary Anaesthesia, V26, P3; Haga HA, 2002, AM J VET RES, V63, P438, DOI 10.2460/ajvr.2002.63.438; Hellebrekers LJ, 1997, VET REC, V140, P545, DOI 10.1136/vr.140.21.545; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; ILKIW JE, 1994, CAN J VET RES, V58, P248; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; Kinney WA, 1998, J MED CHEM, V41, P236, DOI 10.1021/jm970504g; Kissin I, 2000, ANESTH ANALG, V90, P1114, DOI 10.1097/00000539-200005000-00021; Kushiro T, 2007, AM J VET RES, V68, P1294, DOI 10.2460/ajvr.68.12.1294; Lamont LA, 2001, AM J VET RES, V62, P1745, DOI 10.2460/ajvr.2001.62.1745; Lamont LA, 2005, COMPARATIVE MED, V55, P269; Liehmann L, 2006, VET ANAESTH ANALG, V33, P158, DOI 10.1111/j.1467-2995.2005.00251.x; March PA, 2005, VET ANAESTH ANALG, V32, P241, DOI 10.1111/j.1467-2995.2005.00221.x; Mendes GM, 2003, J AM VET MED ASSOC, V223, P1608, DOI 10.2460/javma.2003.223.1608; Moore PG, 2000, CLIN EXP PHARMACOL P, V27, P1028, DOI 10.1046/j.1440-1681.2000.03371.x; Muir WW, 2003, AM J VET RES, V64, P1155, DOI 10.2460/ajvr.2003.64.1155; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P97, DOI 10.1111/j.1467-2995.2005.00236.x; Pypendop BH, 2007, VET ANAESTH ANALG, V34, P209, DOI 10.1111/j.1467-2995.2006.00324.x; SALMENPERA MT, 1994, ANESTHESIOLOGY, V80, P837, DOI 10.1097/00000542-199404000-00017; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Shafer SL, 2008, ANESTH ANALG, V107, P507, DOI 10.1213/ane.0b013e31817b7140; Solano AM, 2006, AM J VET RES, V67, P21, DOI 10.2460/ajvr.67.1.21; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Sun L, 2004, J PHARMACOL EXP THER, V310, P563, DOI 10.1124/jpet.104.066092; Yackey M, 2004, VET ANAESTH ANALG, V31, P183, DOI 10.1111/j.1467-2987.2004.00125.x	39	24	24	0	3	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	DEC	2009	70	12					1459	1464		10.2460/ajvr.70.12.1459			6	Veterinary Sciences	Veterinary Sciences	526SP	WOS:000272314200003	19951116				2020-06-30	J	Kim, JY; Kim, KB; Shin, CS; Ha, SH; Kim, MK; Lee, JS				Kim, J. Y.; Kim, K. B.; Shin, C. S.; Ha, S. H.; Kim, M. K.; Lee, J. S.			The effect of intrathecal fentanyl on Cerebral State Index-guided sedation during spinal anaesthesia	ANAESTHESIA			English	Article							HYPNOTIC REQUIREMENTS; MIDAZOLAM; BLOCK; ANALGESIA; PROPOFOL; LEVEL	This study investigated the effect of intrathecal fentanyl on the dose of propofol during sedation guided by Cerebral State Index monitoring. Seventy patients were randomly assigned to receive either fentanyl 25 mu g (n = 35) or normal saline (n = 35) with hyperbaric bupivacaine 12.5 mg for spinal anaesthesia. Propofol was infused to maintain a Cerebral State Index value of 65-75 for 30 min. The propofol infusion time and dose required to reach a Cerebral State Index value of 75 were recorded together with the time required to reach a Cerebral State Index value higher than 90 after cessation of sedation. The onset time for sedation was faster and the recovery time was slower in the fentanyl group compared to those in the saline group (p = 0.018 and 0.027, respectively). The propofol doses required for onset and maintenance of sedation were significantly lower in the fentanyl group compared to those in the control group (p = 0.018 and < 0.001, respectively). In conclusion, adding intrathecal fentanyl 25 mu g during spinal anaesthesia significantly reduced the dose of propofol required for sedation and prolonged the subsequent recovery time.	[Kim, J. Y.; Kim, K. B.; Shin, C. S.; Ha, S. H.; Lee, J. S.] Yonsei Univ, Coll Med, Anaesthesia & Pain Res Inst, Dept Anaesthesiol & Pain Med, Seoul, South Korea; [Kim, M. K.] Kyung Hee Univ, Dept Anesthesiol & Pain Med, Sch Med, Seoul, South Korea	Lee, JS (reprint author), Yonsei Univ, Coll Med, Anaesthesia & Pain Res Inst, Dept Anaesthesiol & Pain Med, Seoul, South Korea.	jonglee@yuhs.ac		Kim, Ji Young/0000-0001-5822-0338; SHIN, CHEUNG SOO/0000-0001-7829-8458; Lee, Jong Seok/0000-0002-7945-2530			Bano Fauzia, 2006, J Coll Physicians Surg Pak, V16, P87; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; BENDAVID B, 1995, ANESTH ANALG, V81, P525, DOI 10.1097/00000539-199509000-00017; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Doufas AG, 2004, BRIT J ANAESTH, V93, P228, DOI 10.1093/bja/aeh192; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; Fournier R, 2000, ANESTH ANALG, V90, P918, DOI 10.1213/00000539-200004000-00026; Gentili M, 1998, BRIT J ANAESTH, V81, P970; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; Jensen EW, 2006, ANESTHESIOLOGY, V105, P28, DOI 10.1097/00000542-200607000-00009; Kushida Atsuko, 2006, Masui, V55, P1393; Ozkan-Seyhan T, 2006, BRIT J ANAESTH, V96, P645, DOI 10.1093/bja/ael055; TVERSKOY M, 1994, J CLIN ANESTH, V6, P487, DOI 10.1016/0952-8180(94)90089-2; Tverskoy M, 1996, REGION ANESTH, V21, P209; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011	15	1	1	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	DEC	2009	64	12					1307	1311		10.1111/j.1365-2044.2009.06127.x			5	Anesthesiology	Anesthesiology	517OS	WOS:000271626100008	19832737				2020-06-30	J	Lee, DH; Kwon, IC				Lee, D. H.; Kwon, I. C.			Magnesium sulphate has beneficial effects as an adjuvant during general anaesthesia for Caesarean section	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia; depth; anaesthesia; obstetric; monitoring; bispectral index; pharmacology; magnesium sulphate	BISPECTRAL INDEX; PROPOFOL REQUIREMENTS; PART II; SEDATION; AWARENESS; INFUSION; CHOLECYSTECTOMY; MAINTENANCE; MIDAZOLAM; RESPONSES	The use of low concentrations of volatile anaesthetics with avoidance of opioids may induce intraoperative awareness and adverse haemodynamic responses during Caesarean section. Magnesium is well known to reduce anaesthetic requirements and to block noxious stimuli. We investigated whether i.v. magnesium sulphate modulates anaesthetic depth and analgesic efficacy during Caesarean section. Seventy-two patients undergoing Caesarean section were randomly assigned to receive i.v. saline (control group) or magnesium sulphate 30 mg kg(-1) bolus+10 mg kg(-1) h(-1) continuous infusion (Mg 30 group) or 45 mg kg(-1) bolus+15 mg kg(-1) h(-1) continuous infusion (Mg 45 group) after induction. Bispectral index (BIS) value, mean arterial pressure (MAP), and midazolam, fentanyl, and atracurium consumptions were recorded. BIS values [mean (sd)] at 7.5 and 10 min after surgery and before delivery in the control [64 (9), 66 (8), 67 (8), P < 0.001] and the Mg 30 groups [62 (8), P < 0.01; 64 (7), 63 (9), P < 0.001] were higher than in the Mg 45 group [56 (8), 55 (8), 55 (7)]. MAP was greater in the control group (P < 0.05) than in the Mg 30 and Mg 45 groups during the pre-delivery period. The magnesium groups required less midazolam (P < 0.05), fentanyl (Mg 30, P < 0.05; Mg 45, P < 0.01), and atracurium (P < 0.001) vs the control group. Preoperative i.v. magnesium sulphate attenuated BIS and arterial pressure increases during the pre-delivery period. Magnesium sulphate can be recommended as an adjuvant during general anaesthesia for Caesarean section to avoid perioperative awareness and pressor response resulting from inadequate anaesthesia, analgesia, or both.	[Lee, D. H.; Kwon, I. C.] Yeungnam Univ, Coll Med, Dept Anaesthesiol & Pain Med, Taegu 705717, South Korea	Lee, DH (reprint author), Yeungnam Univ, Coll Med, Dept Anaesthesiol & Pain Med, 317-1 Daemyung Dong, Taegu 705717, South Korea.	dhlee415@ynu.ac.kr			Yeungnam University	This research was supported by the Yeungnam University Research Grants in 2007.	Altan A, 2005, BRIT J ANAESTH, V94, P438, DOI 10.1093/bja/aei070; ALTURA BM, 1978, BLOOD VESSELS, V15, P5; Bhatia A, 2004, J CLIN ANESTH, V16, P262, DOI 10.1016/j.jclinane.2003.08.012; Chin KJ, 2004, ANESTH ANALG, V98, P1140, DOI 10.1213/01.ANE.0000103186.64302.38; Choi JC, 2002, ANESTHESIOLOGY, V97, P1137, DOI 10.1097/00000542-200211000-00017; Flaishon R, 1997, ANESTHESIOLOGY, V86, P613, DOI 10.1097/00000542-199703000-00013; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Gupta K, 2006, ANAESTHESIA, V61, P1058, DOI 10.1111/j.1365-2044.2006.04801.x; Hollmann MW, 2001, ANESTH ANALG, V92, P1182; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; Jee D, 2009, BRIT J ANAESTH, V103, P484, DOI 10.1093/bja/aep196; Kaymak C, 2007, J ENDOUROL, V21, P145, DOI 10.1089/end.2006.0195; Kearse LA, 1998, ANESTHESIOLOGY, V88, P25, DOI 10.1097/00000542-199801000-00007; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Kussman B, 1997, BRIT J ANAESTH, V79, P122; Lee DH, 2006, J INT MED RES, V34, P573, DOI 10.1177/147323000603400602; LISHAJKO F, 1970, ACTA PHYSIOL SCAND, V79, P575, DOI 10.1111/j.1748-1716.1970.tb04760.x; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; McCarthy RJ, 1998, ANESTH ANALG, V86, P830, DOI 10.1097/00000539-199804000-00028; Memis D, 2003, CRIT CARE, V7, pR123, DOI 10.1186/cc2365; Menigaux C, 2002, BRIT J ANAESTH, V89, P857, DOI 10.1093/bja/aef275; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Paech MJ, 2008, INT J OBSTET ANESTH, V17, P298, DOI 10.1016/j.ijoa.2008.01.016; Schulz-Stubner S, 2001, EUR J ANAESTH, V18, P723, DOI 10.1046/j.1365-2346.2001.00921.x; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C; Seyhan TO, 2006, BRIT J ANAESTH, V96, P247, DOI 10.1093/bja/aei291; SIBAI BM, 1984, AM J OBSTET GYNECOL, V150, P728, DOI 10.1016/0002-9378(84)90676-8; Telci L, 2002, BRIT J ANAESTH, V89, P594, DOI 10.1093/bja/aef238; Thwaites CL, 2006, LANCET, V368, P1436, DOI 10.1016/S0140-6736(06)69444-0; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	32	24	24	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	DEC	2009	103	6					861	866		10.1093/bja/aep265			6	Anesthesiology	Anesthesiology	523OQ	WOS:000272084000015	19783538	Green Published, Bronze			2020-06-30	J	Rauck, RL; Tark, M; Reyes, E; Hayes, TG; Bartkowiak, AJ; Hassman, D; Nalamachu, S; Derrick, R; Howell, J				Rauck, Richard L.; Tark, Marvin; Reyes, Eva; Hayes, Teresa G.; Bartkowiak, Anthony J.; Hassman, David; Nalamachu, Srinivas; Derrick, Rob; Howell, Julian			Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrough pain; cancer; fentanyl; opioids; sublingual administration; transmucosal	CITRATE	Background and objectives: Breakthrough cancer pain (BTcP) represents an important clinical challenge in the care of patients with cancer. This trial evaluated the efficacy and long-term tolerability of a sublingual formulation of the fast-acting opioid fentanyl, for the treatment of BTcP in opioid-tolerant patients with cancer. Research design and methods: This was a randomized, placebo-controlled, multi-center, phase III trial, conducted in opioid-tolerant male and female patients (aged >= 17 years) with BTcP. The study was conducted at 36 centers across the USA. The study comprised a 2-week open-label titration phase, followed by a double-blind efficacy phase, during which patients received sublingual fentanyl citrate orally disintegrating tablet (sublingual fentanyl ODT) or placebo, in a random order. The primary efficacy endpoint was the sum of pain intensity difference (SPID) over 30 min post-administration. Secondary efficacy endpoints included pain intensity difference (PID) and pain relief (PR) throughout the 60-min post-dose assessment period. Following efficacy evaluation, patients entered a long-term safety phase of up to 12 months. Adverse events were recorded throughout the study. [Clinical trial registration: NCT00262678] Results: A total of 131 patients entered the titration phase, of whom 61 were included in the primary efficacy analysis. Sublingual fentanyl ODT provided significant improvements in SPID relative to placebo at 30 min (49.5 vs. 36.6, p = 0.0004) and 60 min post-administration (143.0 vs. 104.5, p = 0.0002). Furthermore, sublingual fentanyl ODT provided significant improvements in PID and PR compared to placebo, from 10 min post-dose (p = 0.0055 and p = 0.049 for PID and PR, respectively). Patient recruitment was stopped early, due to positive interim analysis results (significant at prespecified level, p <= 0.0414). Overall, sublingual fentanyl ODT was well-tolerated both systemically and sublingually, with 41 patients experiencing >= 1 study drug-related adverse event (AE). The most common AEs included nausea (12.2%), vomiting (5.3%) and somnolence (4.6%). One serious AE (mild affect lability) was considered possibly related to study medication. The observed pattern of AEs was consistent with that previously observed with fentanyl. Conclusions: Sublingual fentanyl ODT was efficacious and well-tolerated for the treatment of BTcP in opioid-tolerant patients with cancer. Sublingual fentanyl ODT provided significant improvements in pain intensity compared to placebo, from 10 min post-administration and throughout the 60-min post-dose assessment period. Sublingual fentanyl ODT was well tolerated over 12 months of treatment.	[Rauck, Richard L.] Wake Forest Univ Hlth Sci, Carolinas Pain Inst, Clin Res Ctr, Winston Salem, NC USA; [Tark, Marvin] Drug Studies Amer, Marietta, GA USA; [Reyes, Eva] Compassionate Canc Care, Corona, CA USA; [Hayes, Teresa G.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Hayes, Teresa G.] Baylor Coll Med, Houston, TX 77030 USA; [Bartkowiak, Anthony J.] Blair Med Associates, Altoona, PA USA; [Hassman, David] Comprehens Clin Res, Berlin, NJ USA; [Nalamachu, Srinivas] Int Clin Res Inst, Overland Pk, KS USA; [Derrick, Rob; Howell, Julian] ProStrakan Inc, Clin Dev, Bedminster, NJ USA	Derrick, R (reprint author), ProStrakan Grp Plc, Galabank Business Pk, Galashiels TD1 1QH, Scotland.	rob.derrick@prostrakan.com; julian.howell@prostrakan.com			ProStrakan Group Ltd	This study was sponsored by ProStrakan Group Ltd. Preparation and publication of this article was supported by ProStrakan Group Ltd.	BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; *CEPH LTD, ACT SPC; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; LENNERNAS B, 2009, PALLIAT MED IN PRESS; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rauck R, 2009, PAIN PRACT, V9, P93; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; 2004, DATA FILE STUDY SUF	16	94	101	3	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	DEC	2009	25	12					2877	2885		10.1185/03007990903368310			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	541LS	WOS:000273417800007	19814586				2020-06-30	J	Bektas, F; Eken, C; Sayrac, V				Bektas, Firat; Eken, Canker; Sayrac, Vefa			Opioid toxicity as a result of oral/transmucosal administration of transdermal fentanyl patch	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Letter							ABUSE; CITRATE		[Bektas, Firat; Eken, Canker; Sayrac, Vefa] Akdeniz Univ, Dept Emergency Med, Fac Med, TR-07059 Antalya, Turkey	Bektas, F (reprint author), Akdeniz Univ, Dept Emergency Med, Fac Med, TR-07059 Antalya, Turkey.	fbektas@akdeniz.edu.tr	Bektas, Firat Ahmet/C-1686-2016; Eken, Cenker/C-1821-2016	Bektas, Firat Ahmet/0000-0002-0885-8509; Eken, Cenker/0000-0002-2743-5608			Barrueto F, 2004, VET HUM TOXICOL, V46, P30; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Moon JM, 2008, J EMERG MED; NELSON LS, 2002, GOLDFRANKS TOXICOLOG, P901; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	13	2	2	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0969-9546			EUR J EMERG MED	Eur. J. Emerg. Med.	DEC	2009	16	6					344	345		10.1097/MEJ.0b013e3283207fbd			2	Emergency Medicine	Emergency Medicine	528VE	WOS:000272474300014	19904081				2020-06-30	J	Nishiyama, T				Nishiyama, Tomoki			Comparison of the two different auditory evoked potentials index monitors in propofol-fentanyl-nitrous oxide anesthesia	JOURNAL OF CLINICAL ANESTHESIA			English	Article						General anesthesia; Propofol; Fentanyl; Nitrous oxide; Electroencephalogram; Auditory evoked potential	LINE ARX INDEX; BISPECTRAL INDEX; DEPTH	Study Objective: To determine the difference in performance of two different auditory evoked potentials (AEP) monitors, the A-Line AEP (AAI) and the aepEX, and their indices, during general anesthesia. Design: Prospective study. Setting: Operating room at a private hospital. Patients: 40 ASA physical status I and II women, aged 30 to 70 years, scheduled for partial mastectomy. Interventions: Anesthesia was induced with propofol and fentanyl, and a Laryngeal Mask Airway (LMA) was inserted. Anesthesia was maintained with propofol, fentanyl, and nitrous oxide. Measurements and Main Results: The AAI or the aepEX was continuously monitored and their performance was compared at the start of monitoring, at LMA insertion, after disturbance by electric cautery, and during anesthesia. Eighteen of 20 patients had low enough impedance to extract good electroencephalogram signals at the first electrode application with the A-Line AEP, and 14 of 20 patients, with the aepEX. The time to return to good signals after signal disturbance by electric cautery was 14 +/- 3 seconds (SD) with the AAI and 19 +/- 4 seconds (SD) with the aepEX (P = 0.035). Both AAT and aepEX decreased after anesthesia induction, with significantly lower values seen in AAI than the aepEX. Conclusions: The A-Line AEP (AAI) is better detects the response to painful stimuli and during recovering from noise of electric cautery than the aepEX. The aepEX shows higher values than the AM during propofol-fentanyl-nitrous oxide anesthesia. (C) 2009 Elsevier Inc. All rights reserved.	Kamagaya Gen Hosp, Dept Anesthesiol & Crit Care, Chiba 2730121, Japan	Nishiyama, T (reprint author), Kamagaya Gen Hosp, Dept Anesthesiol & Crit Care, 929-6 Hatsutomi, Chiba 2730121, Japan.	nishit-tky@umin.ac.jp					Barr G, 2001, ANAESTHESIA, V56, P888, DOI 10.1046/j.1365-2044.2001.02059-3.x; Doi M, 1997, BRIT J ANAESTH, V78, P180; Ge SJ, 2002, BRIT J ANAESTH, V89, P260, DOI 10.1093/bja/aef187; Jensen EW, 1996, METHOD INFORM MED, V35, P256; Litvan H, 2002, ACTA ANAESTH SCAND, V46, P245, DOI 10.1034/j.1399-6576.2002.t01-1-460304.x; MADLER C, 1991, BRIT J ANAESTH, V66, P81, DOI 10.1093/bja/66.1.81; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; Milne SE, 2003, BRIT J ANAESTH, V90, P127, DOI 10.1093/bja/aeg035; Nishiyama T, 2005, ACTA ANAESTH SCAND, V49, P1326, DOI 10.1111/j.1399-6576.2005.00820.x; Nishiyama T, 2004, ACTA ANAESTH SCAND, V48, P1028, DOI 10.1111/j.0001-5172.2004.00468.x; Nishiyama T, 2004, CAN J ANAESTH, V51, P539, DOI 10.1007/BF03018394; Nishiyama T, 2004, ANESTH ANALG, V98, P1341, DOI 10.1213/01.ANE.0000111109.42728.51; THORNTON C, 1984, BRIT J ANAESTH, V56, P315, DOI 10.1093/bja/56.4.315; Urhonen E, 2000, ACTA ANAESTH SCAND, V44, P743, DOI 10.1034/j.1399-6576.2000.440614.x	14	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2009	21	8					551	554		10.1016/j.jclinane.2008.12.024			4	Anesthesiology	Anesthesiology	584WG	WOS:000276783700002	20122585				2020-06-30	J	DeGasperi, A; Corti, A; Corso, R; Rampoldi, A; Roselli, E; Mazza, E; Fantini, G; Prosperi, M				DeGasperi, Andrea; Corti, Andrea; Corso, Rocco; Rampoldi, Antonio; Roselli, Elena; Mazza, Ernestina; Fantini, Giuliana; Prosperi, Manlio			TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS): THE ANESTHESIOLOGICAL POINT OF VIEW AFTER 150 PROCEDURES MANAGED UNDER TOTAL INTRAVENOUS ANESTHESIA	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Anesthesia; general; Total intravenous anesthesia; TIPS; Fluid management		TIPS is a percutaneous procedure which diverts blood from the portal to the systemic circulation preventing rebleeding from varices and stopping or reducing the formation of ascites. The choice of the anaesthetic technique is still a matter of debate. Since January 2003, 150 consecutive TIPS were performed using total intravenous anesthesia (TIVA), (propofol/fentanyl or remifentanil), endotracheal intubation and mechanical ventilation. Sixty-one patients were classified as ASA 2, 73 ASA 3, and 16 ASA 4. According to CHILD classification, 96 patients were in Class A, 48 in Class B, 6 in Class C. Mean duration f the procedure was 100 +/- 62 min. After TIPS placement Portal vein pressure decreased from 30 +/- 10 to 14 +/- 4 mmHg while RAP increased from 8 +/- 4 to 12 +/- 6 mmHg. Intraoperative fluid management included mainly crystalloids (750 +/- 200 ml, 5.4 +/- 1.5 ml/kg/h). Fresh frozen plasma (median 2 units, range 1-3) was given in 20 patients (13%) if PT INR was >2. Packed red cells (median 2 units, range 1-5) were transfused in 35 patients (23%) to keep haematocrit >25%; platelets were administered before the procedure if platelet count was <50,000 x 10(-9) (20 patients, 13%). Urine output was kept above 4 ml/kg/h with loops diuretics (mean diuresis 700 +/- 200 ml, 5 +/- 1.5 ml/kg/h). Ten patients (6.6%) required ICU after the procedure, because of intraoperative hemodynamic instability. Three patients (2%) died in the early postoperative period because of multiple organ failure associated with the acute deterioration of an already marginal hepatic function.	[DeGasperi, Andrea; Corti, Andrea; Roselli, Elena; Mazza, Ernestina; Fantini, Giuliana; Prosperi, Manlio] Osped Niguarda Ca Granda, Serv Anesthesia & Crit Care Med 2, I-20123 Milan, Italy; [Corso, Rocco; Rampoldi, Antonio] Osped Niguarda Ca Granda, Dept Intervent Radiol, I-20123 Milan, Italy	DeGasperi, A (reprint author), Osped Niguarda Ca Granda, Serv Anesthesia & Crit Care Med 2, Piazza Osped Maggiore 3, I-20123 Milan, Italy.	andrea.degasperi@ospedaleniguarda.it					Boyer TD, 2005, J VASC INTERV RADIOL, V16, P615, DOI 10.1097/01.RVI.0000157297.91510.21; Connolly LA, 1996, ANESTHESIOLOGY, V85, P946, DOI 10.1097/00000542-199610000-00045; Harrod-Kim P, 2006, J VASC INTERV RADIOL, V17, P1605, DOI 10.1097/01.RVI.0000240651.38289.4B; Haskal ZJ, 2001, J VASC INTERV RADIOL, V12, P131, DOI 10.1016/S1051-0443(07)61817-X; Kam PCA, 1997, ANAESTH INTENS CARE, V25, P385, DOI 10.1177/0310057X9702500411; Kelhoffer Eric R, 2003, Int Anesthesiol Clin, V41, P51; Osborn IPA, 2003, ASA REFRESH COURSES, V31, P151; Pivalizza EG, 1996, ANESTHESIOLOGY, V85, P946, DOI 10.1097/00000542-199610000-00044; Rossle M, 2004, BEST PRACT RES CL GA, V18, P99, DOI 10.1053/ybega.2004.437; Sampietro G, 1998, J VASC INTERV RADIOL, V9, P169, DOI 10.1016/S1051-0443(98)70502-0; YonkerSell AE, 1996, ANESTHESIOLOGY, V84, P231, DOI 10.1097/00000542-199601000-00029	11	12	12	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307			J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	DEC	2009	23	6					341	346		10.1007/s10877-009-9167-y			6	Anesthesiology	Anesthesiology	V20PF	WOS:000208151200001	19844796				2020-06-30	J	Khalil, SN; Matuszczak, ME; Maposa, D; Bolos, ME; Lingadevaru, HS; Chuang, AZ				Khalil, Samia N.; Matuszczak, Maria E.; Maposa, Douglas; Bolos, Mariana E.; Lingadevaru, Hemaneth S.; Chuang, Alice Z.			Presurgical fentanyl vs caudal block and the incidence of adverse respiratory events in children after orchidopexy	PEDIATRIC ANESTHESIA			English	Article						early postoperative; hypoxemia; i; v; fentanyl; orchidopexy; postextubation adverse upper airway events; presurgical caudal analgesia	POSTOPERATIVE HYPOXEMIA; DESATURATION; ISOFLURANE	P>Background: There is controversy about the etiology of early postoperative hypoxemia. Age, weight, intubation, surgical procedure, use of muscle relaxants, and/or administration of opioids may affect the incidence of early postoperative hypoxemia. In this prospective, randomized, and single-blinded study, we evaluated whether the administration of caudal analgesia vs i.v. fentanyl affected the number of children who develop postextubation adverse upper airway respiratory events, (upper airway obstruction, laryngospasm) and/or early postoperative hypoxemia. Methods/materials: Institutional approval and written parental informed consents were obtained. Thirty-eight healthy outpatient boys, aged 1-6 years, scheduled for elective orchidopexy were randomized to receive pain relief either with a presurgical caudal block or by i.v. fentanyl. The primary outcome of the study was the number of children who developed postextubation adverse upper airway respiratory events and/or early postoperative hypoxemia. Results: The number of boys who developed postextubation adverse upper airway respiratory events and/or early postoperative hypoxemia in the caudal group was less compared with those in the fentanyl group (P = 0.04). Conclusions: Compared to fentanyl, placement of a presurgical caudal block in boys scheduled for orchidopexy was associated with a lower incidence of postextubation adverse upper airway respiratory events and/or early postoperative hypoxemia.	[Khalil, Samia N.; Matuszczak, Maria E.; Maposa, Douglas; Bolos, Mariana E.; Lingadevaru, Hemaneth S.] Univ Texas Houston, Sch Med, Dept Anesthesiol, Houston, TX 77030 USA; [Chuang, Alice Z.] Univ Texas Houston, Sch Med, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA	Khalil, SN (reprint author), Univ Texas Houston, Sch Med, Dept Anesthesiol, 6431 Fannin St,MSB 5-020, Houston, TX 77030 USA.	Samia.N.Khalil@uth.tmc.edu			Department of Anesthesiology; University of Texas Medical School at Houston, Houston, TX, USA	Financial Support provided by the Department of Anesthesiology, the University of Texas Medical School at Houston, Houston, TX, USA.	CATLEY DM, 1985, ANESTHESIOLOGY, V63, P20, DOI 10.1097/00000542-198507000-00004; Glass PSA, 1997, J CLIN ANESTH, V9, pS18, DOI 10.1016/S0952-8180(97)00122-0; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MOTOYAMA EK, 1986, ANESTH ANALG, V65, P267; PULLERITS J, 1987, CAN J ANAESTH, V34, P470, DOI 10.1007/BF03014352; SOLIMAN IE, 1988, ANESTH ANALG, V67, P53; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Tait AR, 2008, ANESTHESIOLOGY, V108, P375, DOI 10.1097/ALN.0b013e318164ca9b; TOMKINS DP, 1988, ANAESTH INTENS CARE, V16, P177, DOI 10.1177/0310057X8801600208; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23; Xue FS, 1996, PAEDIATR ANAESTH, V6, P21, DOI 10.1111/j.1460-9592.1996.tb00347.x	12	10	11	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	DEC	2009	19	12					1220	1225		10.1111/j.1460-9592.2009.03164.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	522CI	WOS:000271974900012	20017866				2020-06-30	J	Orjales, RN; Carballada, F; Carballas, C; Boquete, M				Orjales, R. N.; Carballada, F.; Carballas, C.; Boquete, M.			Eosinophilic panniculitis: a new form of local reaction with specific immunotherapy	ALLERGY			English	Editorial Material						eosinophilic panniculitis; local reaction; specific immunotherapy; venom allergy	GENERALIZED DERMATITIS; CODEINE		[Orjales, R. N.] Xeral Calde Hosp, Dept Allergy, Lugo, Spain	Orjales, RN (reprint author), Xeral Calde Hosp, Dept Allergy, Lugo, Spain.	ramon.nunez.orjales@sergas.es					DEGROOT AC, 1986, CONTACT DERMATITIS, V14, P209, DOI 10.1111/j.1600-0536.1986.tb01226.x; Estrada JL, 2001, CONTACT DERMATITIS, V44, P185, DOI 10.1034/j.1600-0536.2001.440308-6.x; Gastaminza G, 2005, CONTACT DERMATITIS, V52, P227, DOI 10.1111/j.0105-1873.2005.0566c.x; Rodriguez A, 2005, CONTACT DERMATITIS, V53, P240, DOI 10.1111/j.0105-1873.2005.0670h.x; RODRIGUEZ F, 1995, CONTACT DERMATITIS, V32, P120, DOI 10.1111/j.1600-0536.1995.tb00768.x	5	11	11	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	NOV	2009	64	11					1692	1692		10.1111/j.1398-9995.2009.02113.x			1	Allergy; Immunology	Allergy; Immunology	504SR	WOS:000270638400023	19796218				2020-06-30	J	Koltka, K; Uludag, E; Senturk, M; Yavru, A; Karadeniz, M; Sengul, T; Ozyalcin, S				Koltka, K.; Uludag, E.; Senturk, M.; Yavru, A.; Karadeniz, M.; Sengul, T.; Ozyalcin, S.			Comparison of equipotent doses of ropivacaine-fentanyl and bupivacaine-fentanyl in spinal anaesthesia for lower abdominal surgery	ANAESTHESIA AND INTENSIVE CARE			English	Article						spinal anaesthesia; local anaesthetic; ropivacaine	LOWER-LIMB SURGERY; INTRATHECAL ROPIVACAINE; RELATIVE POTENCIES; HIP FRACTURE; MG ML(-1); ANALGESIA; LABOR; LEVOBUPIVACAINE; LIDOCAINE; EFFICACY	The aim of this randomised, double-blind study was to compare equipotent doses of plain ropivacaine and bupivacaine (19.5 mg and 73 mg respectively), both with fentanyl 20 mu g, for spinal anaesthesia in lower abdominal surgery After written informed consent had been obtained, 52 ASA I to II male patients scheduled for lower abdominal surgery were randomly assigned to receive intrathecal plain ropivacaine 19.5 mg with fentanyl 20 mu g (group R, n = 26) or plain bupivacaine 13 mg with fentanyl 20 mu g (group B, n = 26) in 3 nil. The level and duration of sensory block, intensity and duration of motor block, time to mobilise and patient satisfaction were recorded. All patients achieved sensory block to T10 or higher The level of sensory block was significantly higher in group B (T4 [T3 to T7] vs T7 [T4 to T9], P <0.05). There was no difference in the onset time of motor block. The duration of motor block (Bromage score >0) was shorter in group R (139 +/- 39 minutes vs group B 182 +/- 46 minutes, P <0.05). The duration and intensity of complete motor block (Bromage score=3) were also shorter in group R (90 +/- 25 minutes vs 130 +/- 40 minutes, P <0.05). We conclude that plain ropivacaine 19.5 mg plus fentanyl 20 mu g is associated with a lower level of sensory block and a shorter duration of motor block when compared to bupivacaine 13 mg plus fentanyl 20 mu g for spinal anaesthesia in lower abdominal surgery.	[Koltka, K.; Uludag, E.; Senturk, M.; Yavru, A.; Karadeniz, M.; Sengul, T.; Ozyalcin, S.] Istanbul Univ, Fac Med, Dept Anaesthesiol, TR-34093 Istanbul, Turkey	Koltka, K (reprint author), Istanbul Univ, Fac Med, Dept Anaesthesiol, TR-34093 Istanbul, Turkey.	ahmetkoltka@yahoo.com	Sengul, Turgay/I-4773-2018	yavru, hacer aysen/0000-0003-0669-0324			BADER AM, 1989, ANESTH ANALG, V68, P724; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Camorcia M, 2005, ANESTHESIOLOGY, V102, P646, DOI 10.1097/00000542-200503000-00025; Camorcia M, 2007, ANESTH ANALG, V104, P904, DOI 10.1213/01.ane.0000256912.54023.79; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; Casati A, 2004, ANESTH ANALG, V99, P1387, DOI 10.1213/01.ANE.0000132972.61498.F1; FELDMAN HS, 1988, ANESTH ANALG, V67, P1047, DOI 10.1213/00000539-198867110-00005; Gaiser RR, 2000, J CLIN ANESTH, V12, P476, DOI 10.1016/S0952-8180(00)00186-0; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; Kallio H, 2005, REGION ANESTH PAIN M, V30, P48, DOI 10.1016/j.rapm.2004.11.002; Kallio H, 2004, BRIT J ANAESTH, V93, P664, DOI 10.1093/bja/aeh257; Kallio H, 2004, ANESTH ANALG, V99, P713, DOI 10.1213/01.ANE.0000129976.26455.32; Khaw KS, 2001, ANESTHESIOLOGY, V95, P1346, DOI 10.1097/00000542-200112000-00011; Lee YY, 2005, ACTA ANAESTH SCAND, V49, P1477, DOI 10.1111/j.1399-6576.2005.00864.x; Malinovsky JM, 2000, ANESTH ANALG, V91, P1457, DOI 10.1097/00000539-200012000-00030; Markey JR, 1997, ANESTH ANALG, V85, P1105, DOI 10.1097/00000539-199711000-00026; Martyr JW, 2005, ANAESTH INTENS CARE, V33, P64, DOI 10.1177/0310057X0503300110; McDonald SB, 1999, ANESTHESIOLOGY, V90, P971, DOI 10.1097/00000542-199904000-00007; McNamee DA, 2002, BRIT J ANAESTH, V89, P702, DOI 10.1093/bja/aef259; McNamee DA, 2001, BRIT J ANAESTH, V87, P743, DOI 10.1093/bja/87.5.743; Ogun CO, 2003, BRIT J ANAESTH, V90, P659, DOI 10.1093/bja/aeg123; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; VANKLEEF JW, 1994, ANESTH ANALG, V78, P1125; Wahedi W, 1996, ANAESTHESIST, V45, P737, DOI 10.1007/s001010050306; WILDSMITH JAW, 1989, BRIT J ANAESTH, V63, P444, DOI 10.1093/bja/63.4.444	26	8	11	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	NOV	2009	37	6					923	928		10.1177/0310057X0903700606			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	522LK	WOS:000271999100009	20014598	Bronze			2020-06-30	J	Padmanabhan, U; Leslie, K; Eer, AS; Maruff, P; Silbert, BS				Padmanabhan, Usha; Leslie, Kate; Eer, Audrey SingYi; Maruff, Paul; Silbert, Brendan S.			Early Cognitive Impairment After Sedation for Colonoscopy: The Effect of Adding Midazolam and/or Fentanyl to Propofol	ANESTHESIA AND ANALGESIA			English	Article							RANDOMIZED CONTROLLED-TRIAL; MONITORED ANESTHESIA CARE; TEST-RETEST INTERVALS; GENERAL-ANESTHESIA; AMBULATORY SURGERY; MODERATE SEDATION; CLINICAL-TRIALS; RECOVERY; ALCOHOL; BENZODIAZEPINES	BACKGROUND: The sedative drug combination that produces minimal cognitive impairment and optimal operating conditions during colonoscopy has not been determined. We sought to determine if the use of propofol alone results in less cognitive impairment at discharge than the use of propofol plus midazolam and/or fentanyl in patients presenting for elective outpatient colonoscopy. METHODS: Two hundred adult patients presenting for elective outpatient colonoscopy were randomized to receive propofol alone or propofol plus midazolam, and/or fentanyl for IV sedation. Baseline cognitive function was measured using the computerized CogState test battery (Cogstate(TM), Melbourne Australia) before sedation. During the procedure, sedative drug doses, depth of sedation (via the bispectral index and observer's assessment of alertness/sedation score), complications, and treatability were recorded. Patients were interviewed about recall immediately after emerging from sedation, and cognitive testing was repeated at hospital discharge. Recovery times, quality of recovery, and satisfaction with care were also recorded. RESULTS: In the propofol plus adjuvants group, 84 patients received fentanyl 50 p,g (25-100) (median [range]) and 57 patients received midazolam 2 mg (0.5-10). Patients' cognitive function at discharge was worse than their performance at baseline. However, the changes in cognitive function between discharge and baseline were not significantly different between the two groups. At discharge, 18.5% of patients were cognitively impaired to an extent equivalent to a blood-alcohol concentration of 0.05%. Sedation with propofol plus midazolam and/or fentanyl produced better operating conditions than sedation with propofol alone and was associated with shorter procedure times. Recovery times, recall, dreaming, quality of recovery, and patient satisfaction with care were similar between the groups. Administration of >2 mg of midazolam was a predictor of impaired cognitive function at discharge. CONCLUSIONS: Significant cognitive impairment was common at discharge from elective outpatient colonoscopy. However, the addition of midazolam and/or fentanyl to propofol sedation did not result in more cognitive impairment than the use of propofol alone. Furthermore, the use of adjuvants improved the ease of colonoscopy without increasing the rate of complications or prolonging early recovery times. (Anesth Analg 2009;109:1448-55)	[Padmanabhan, Usha; Leslie, Kate; Eer, Audrey SingYi] Univ Melbourne, Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic 3050, Australia; [Leslie, Kate] Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; [Maruff, Paul] CogState Ltd, Melbourne, Vic, Australia; [Maruff, Paul] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; [Silbert, Brendan S.] St Vincents Hosp, Dept Anaesthesia, Ctr Anaesthesia & Cognit Funct, Melbourne, Vic, Australia; [Silbert, Brendan S.] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia	Leslie, K (reprint author), Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Parkville, Vic 3050, Australia.	kate.leslie@mh.org.au		Leslie, Kate/0000-0001-8512-3517; Maruff, Paul/0000-0002-6947-9537			BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Burgess DC, 2003, MED J AUSTRALIA, V179, P105, DOI 10.5694/j.1326-5377.2003.tb05447.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CHUNG F, 1995, CAN J ANAESTH, V42, P1056, DOI 10.1007/BF03011083; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2007, CONTEMP CLIN TRIALS, V28, P391, DOI 10.1016/j.cct.2006.10.010; Drake LM, 2006, AM J GASTROENTEROL, V101, P2003, DOI 10.1111/j.1572-0241.2006.00806.x; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Fanti L, 2007, DIGEST LIVER DIS, V39, P81, DOI 10.1016/j.dld.2006.09.004; Fredman B, 1999, ANESTH ANALG, V89, P1161, DOI 10.1213/00000539-199911000-00014; Fredrickson A, 2008, HUM PSYCHOPHARM CLIN, V23, P425, DOI 10.1002/hup.942; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; Lubarsky DA, 2007, J CLIN ANESTH, V19, P397, DOI 10.1016/j.jclinane.2006.11.006; Maruff P, 2006, PSYCHOPHARMACOLOGY, V186, P7, DOI 10.1007/s00213-006-0331-5; Maruff P, 2005, J SLEEP RES, V14, P21, DOI 10.1111/j.1365-2869.2004.00438.x; Moerman AT, 2003, EUR J ANAESTH, V20, P461, DOI 10.1097/00003643-200306000-00006; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Padmanabhan U, 2008, ANAESTH INTENS CARE, V36, P436, DOI 10.1177/0310057X0803600316; Richardson MG, 1997, ANESTH ANALG, V85, P301, DOI 10.1097/00000539-199708000-00011; RICHTER JJ, 1981, ANESTHESIOLOGY, V54, P66, DOI 10.1097/00000542-198101000-00013; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Stait ML, 2008, ANAESTH INTENS CARE, V36, P685, DOI 10.1177/0310057X0803600509; THAPAR P, 1995, ANESTHESIOLOGY, V82, P53, DOI 10.1097/00000542-199501000-00008; THAPAR P, 1995, ANESTH ANALG, V80, P1092, DOI 10.1097/00000539-199506000-00005; Theodorou T, 2001, ANAESTH INTENS CARE, V29, P124, DOI 10.1177/0310057X0102900206; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x	28	43	47	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999	1526-7598		ANESTH ANALG	Anesth. Analg.	NOV	2009	109	5					1448	1455		10.1213/ane.0b013e3181a6ad31			8	Anesthesiology	Anesthesiology	509QF	WOS:000271032500019	19617584				2020-06-30	J	de Santiago, J; Santos-Yglesias, J; Giron, J; de Oca, FM; Jimenez, A; Diaz, P				de Santiago, Jesus; Santos-Yglesias, Javier; Giron, Jorge; Montes de Oca, Francisco; Jimenez, Alejandro; Diaz, Pilar			Low-Dose 3 mg Levobupivacaine Plus 10 mu g Fentanyl Selective Spinal Anesthesia for Gynecological Outpatient Laparoscopy	ANESTHESIA AND ANALGESIA			English	Article							LIDOCAINE-FENTANYL; BUPIVACAINE; ROPIVACAINE; SURGERY; STAY	BACKGROUND: Lidocaine selective spinal anesthesia has been effective for short-duration gynecological outpatient laparoscopy. We compared the intraoperative effectiveness, anesthetic recovery tithes, and patient satisfaction after levobupivacainefentanyl versus lidocaine-fentanyl spinal anesthesia during short-duration gynecological laparoscopy. METHODS: In this double-blind study, 52 healthy women scheduled to undergo tubal sterilization were randomly assigned to receive either intrathecal 10 mg lidocaine 2% plus 10 mu g fentanyl (Group I) or intrathecal 3 mg levobupivacaine 0.5% plus 10 P,g fentanyl (Group II), each solution made to a total volume of 3 mL with sterile water. The following variables were monitored intraoperatively: anesthesia onset time, need for anesthesia-analgesia supplementation, depth of sedation, surgical conditions, and occurrence of hemodynamic events. After surgery, motor block, proprioception, vibration sense, light touch, and Romberg's test were performed to evaluate whether the patients could bypass the postanesthesia care unit and be allowed to walk by themselves. Sensory block level was determined at 5, 10, and 15 min after anesthetic injection, and then every 15 min until resolution was complete. A difference of 25 min in sensory block resolution time was considered clinically relevant. RESULTS: Onset time and intraoperative conditions were comparable in both groups. No patient required general anesthesia to complete surgery. All patients from both groups bypassed the postanesthesia care unit. Ambulation took place after 27 (18-45) min in Group I and 30 (18-56) min in Group II (P = 0.24). Complete regression of spinal anesthesia occurred after 93 (65-120) min in Group I and 105 (78-150) min in Group II (P = 0.019); however, no differences were observed in time for home discharge 185 (150-300) min in Group I and 188 (125-300) min in Group II (P = 0.62). Global patient satisfaction was comparable between both groups. CONCLUSIONS: Levobupivacaine 3 mg plus 10 mu g fentanyl may be used as a suitable alternative to 10 mg lidocaine plus 10 mu g fentanyl for spinal anesthesia of short duration. It achieved a clinically equivalent time for resolution of sensory block, similar intraoperative conditions, and comparable patient satisfaction. (Anesth Analg 2009;109:1456-61)	[de Santiago, Jesus; Santos-Yglesias, Javier; Giron, Jorge] Hosp USP La Colina, SC Tenerife, Dept Anesthesiol, Tenerife 38006, Spain; [Montes de Oca, Francisco] Hosp USP La Colina, SC Tenerife, Dept Gynaecol, Tenerife 38006, Spain; [Jimenez, Alejandro] Univ La Laguna, Univ Canarias, Res Unit Hosp, Tenerife, Spain; [Diaz, Pilar] Hosp Univ Nuestra Senora La Candelaria, SC Tenerife, Dept Pharm, Tenerife, Spain	de Santiago, J (reprint author), Hosp USP La Colina, SC Tenerife, Dept Anesthesiol, Tenerife 38006, Spain.	jdesantiago@telefonica.net		Jimenez-Sosa, Alejandro/0000-0001-8732-2616			Alley EA, 2002, ANESTH ANALG, V94, P188, DOI 10.1097/00000539-200201000-00036; Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; Camorcia M, 2007, ANESTH ANALG, V104, P904, DOI 10.1213/01.ane.0000256912.54023.79; Cappelleri G, 2005, ANESTH ANALG, V101, P77, DOI 10.1213/01.ANE.0000155265.79673.56; Casati A, 2004, ANESTH ANALG, V99, P1387, DOI 10.1213/01.ANE.0000132972.61498.F1; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Junger A, 2001, EUR J ANAESTH, V18, P314, DOI 10.1046/j.0265-0215.2000.00837.x; KLEINBAUM DG, 1998, [No title captured], P28; Lennox PH, 2002, ANESTH ANALG, V94, P346; Mulroy MF, 2002, ANESTHESIOLOGY, V97, P315, DOI 10.1097/00000542-200208000-00005; Stewart AVG, 2001, BRIT J ANAESTH, V86, P570, DOI 10.1093/bja/86.4.570; Vaghadia H, 1998, CAN J ANAESTH, V45, pR64, DOI 10.1007/BF03019208; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011; Vaghadia H, 2001, CAN J ANAESTH, V48, P261, DOI 10.1007/BF03019756; Vaghadia H, 2001, CAN J ANAESTH, V48, P256, DOI 10.1007/BF03019755; Werdehausen R, 2007, ANESTHESIOLOGY, V107, P136, DOI 10.1097/01.anes.0000268389.39436.66; Williams BA, 2004, ANESTHESIOLOGY, V101, P3, DOI 10.1097/00000542-200407000-00003; ZARIC D, 2009, COCHRANE DB SYST REV, V15	22	12	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2009	109	5					1456	1461		10.1213/ANE.0b013e3181ba792e			6	Anesthesiology	Anesthesiology	509QF	WOS:000271032500020	19843783				2020-06-30	J	Movafegh, A; Nouralishahi, B; Sadeghi, M; Nabavian, O				Movafegh, Ali; Nouralishahi, Behrang; Sadeghi, Mustafa; Nabavian, Omid			An Ultra-Low Dose of Naloxone Added to Lidocaine or Lidocaine-Fentanyl Mixture Prolongs Axillary Brachial Plexus Blockade	ANESTHESIA AND ANALGESIA			English	Article							INTRAVENOUS REGIONAL ANESTHESIA; EPIDURAL NALOXONE; INTRATHECAL NALOXONE; ANALGESIA; MORPHINE; PRURITUS; NAUSEA; HYPERALGESIA; SUFENTANIL; LIGNOCAINE	INTRODUCTION: In this prospective, randomized, double-blind study, we evaluated the effect of an ultra-low dose of naloxone added to lidocaine and fentanyl mixture on the onset and duration of axillary brachial plexus block. METHODS: One hundred twelve patients scheduled for elective forearm surgery under axillary brachial plexus block were randomly allocated to receive 34 mL lidocaine 1.5% with 3 mL of isotonic saline chloride (control group, n = 28), 34 mL lidocaine 1.5% with 2 mL (100 mu g) of fentanyl and 1 mL of isotonic saline chloride (fentanyl group, n = 28), 34 mL lidocaine 1.5% with 2 mL saline chloride and 100 ng (1 mL) naloxone (naloxone group, n = 28), or 34 mL lidocaine 1.5% with 2 mL (100 mu g) of fentanyl and 100 ng (1 mL) naloxone (naloxone + fentanyl group, n = 28). A multiple stimulation technique was used in all patients. After performing the block, sensory,and motor blockades of radial, median, musculocutaneous, and ulnar nerves were recorded at 5, 15, and 30 min. The onset time of the sensory and motor blockades was defined as the time between the last injection and the total abolition of the pinprick response and complete paralysis, respectively. The duration of sensory and motor blocks was considered as the time interval between the complete block and the first postoperative pain and complete recovery of motor functions. RESULTS: Sensory and motor onset times were longer in the naloxone (sensory onset time: 15 +/- 3, and motor onset time: 21 +/- 4) and naloxone + fentanyl group than control or fentanyl groups (sensory onset time: 10 +/- 3 min in control group, 10 +/- 4 min in fentanyl group, and 17 +/- 3 min in naloxone + fentanyl group, motor onset time: 15 +/- 5 min in control group, 14 +/- 7 min in fentanyl group, and 17.3 +/- 3.4 min in naloxone + fentanyl group) (P < 0.001). The duration of time to first postoperative pain and motor blockade was significantly longer in the naloxone (92 +/- 10 and 115 +/- 10 min) and naloxone + fentanyl groups (98 +/- 12 and 122 +/- 16 min) than control (68 +/- 7 and 89 +/- 11 min) and fentanyl groups (68 +/- 11 and 90 +/- 12 min) (P < 0.001). The time to first postoperative pain was significantly longer in the naloxone and naloxone + fentanyl groups than in the control or fentanyl groups (P < 0.001). CONCLUSIONS: The addition of an ultra-low dose of naloxone to lidocaine 1.5% solution with or without fentanyl solution in axillary brachial plexus block prolongs the time to first postoperative pain and motor blockade but also lengthens the onset time. (Anesth Analg 2009;109:1679-83)	[Movafegh, Ali; Nouralishahi, Behrang; Sadeghi, Mustafa; Nabavian, Omid] Univ Tehran Med Sci, Dr Ali Shariati Hosp, Dept Anesthesiol & Crit Care, Tehran 1411713135, Iran	Sadeghi, M (reprint author), Univ Tehran Med Sci, Dr Ali Shariati Hosp, Dept Anesthesiol & Crit Care, N Karegar St, Tehran 1411713135, Iran.	sadeghi@movafegh.com	Nooralishahi, Behrang/R-8610-2019	Nooralishahi, Behrang/0000-0003-1550-153X; Movafegh, Ali/0000-0002-6346-3657			Alayurt S, 2004, ANAESTH INTENS CARE, V32, P22, DOI 10.1177/0310057X0403200103; Bijur PE, 2006, J PAIN, V7, P75, DOI 10.1016/j.jpain.2005.08.008; Blaise G, 2003, CAN J ANAESTH, V50, P875, DOI 10.1007/BF03018731; Choi JH, 2000, CAN J ANAESTH, V47, P33, DOI 10.1007/BF03020728; COLE DJ, 1989, ANESTHESIOLOGY, V71, P426, DOI 10.1097/00000542-198909000-00019; Crain SM, 2000, PAIN, V84, P121, DOI 10.1016/S0304-3959(99)00223-7; Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Hamann Scott, 2008, J Opioid Manag, V4, P251; Jeon Y, 2005, INT J OBSTET ANESTH, V14, P22, DOI 10.1016/j.ijoa.2004.06.001; Kakinohana M, 2003, ANESTHESIOLOGY, V98, P862, DOI 10.1097/00000542-200304000-00012; Kim ES, 2004, CAN J ANAESTH, V51, P1048, DOI 10.1007/BF03018499; Kim MK, 2007, BRIT J ANAESTH, V99, P270, DOI 10.1093/bja/aem146; Lee J, 2001, CAN J ANAESTH, V48, P54, DOI 10.1007/BF03019815; LEVINE JD, 1979, NATURE, V278, P740, DOI 10.1038/278740a0; LEVINE JD, 1986, BRAIN RES, V365, P377, DOI 10.1016/0006-8993(86)91653-7; Movafegh A, 2006, ANESTH ANALG, V102, P263, DOI 10.1213/01.ane.0000189055.06729.0a; Murphy DB, 2000, ANESTH ANALG, V90, P1122, DOI 10.1097/00000539-200005000-00023; Narang S, 2008, ANAESTH INTENS CARE, V36, P840, DOI 10.1177/0310057X0803600614; Okutomi T, 2003, CAN J ANAESTH, V50, P961, DOI 10.1007/BF03018748; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; SADEGHI A, 2008, RJBS, V10, P1223; Sen S, 2006, ANESTH ANALG, V102, P916, DOI 10.1213/01.ane.0000195581.74190.48; Sinz EH, 2000, ANESTH ANALG, V91, P1443, DOI 10.1097/00000539-200012000-00027; Spencer S. L, 2003, ANESTH ANALG, V96, P263; Wang HY, 2005, NEUROSCIENCE, V135, P247, DOI 10.1016/j.neuroscience.2005.06.003; WOOLF CJ, 1980, BRAIN RES, V189, P593, DOI 10.1016/0006-8993(80)90375-3	26	12	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2009	109	5					1679	1683		10.1213/ANE.0b013e3181b9e904			5	Anesthesiology	Anesthesiology	509QF	WOS:000271032500054	19843808				2020-06-30	J	Lemyre, B; Cheng, R; Gaboury, I				Lemyre, B.; Cheng, R.; Gaboury, I.			Atropine, fentanyl and succinylcholine for non-urgent intubations in newborns	ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION			English	Article							NASOTRACHEAL INTUBATION; TRACHEAL INTUBATION; ENDOTRACHEAL INTUBATION; CONTROLLED-TRIAL; PREMEDICATION; SUXAMETHONIUM; INDUCTION; MORPHINE; PRETERM	Objective: Describe intubation conditions and adverse events when using atropine fentanyl +/- succinylcholine as premedication. Design: Prospective observational study, as part of a quality improvement initiative. Setting: Two level 3 neonatal intensive care units in Ottawa, Canada Patients: 60 infants, median 27 weeks gestation, 1023 g at birth were included. Interventions: Infants received atropine, fentanyl succinycholine prior to the intubation. Succinylcholine was given for all infants >= 34 weeks and at the discretion of the physician for those <34 weeks. Main outcome measures: The primary outcome was the number of attempts. Secondary outcomes were number of attempts and intubation conditions in infants who received and those who did not receive succinylcholine and safety. Results: The median number of attempts was 2. 91.7% had excellent or good conditions. The median number of attempts for infants who received succinylcholine was lower (11 vs 2) than those who did not. No serious adverse events were noted. 2 cases of difficult bag and mask ventilation after administration of fentanyl were noted. Conclusion: Atropine, fentanyl and succinylcholine before non-urgent intubations in newborns has led to a low number of attempts and good intubation conditions with no adverse events.	[Lemyre, B.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Cheng, R.] Nanjing Childrens Hosp, Dept Neonatol, Nanjing, Jiangsu, Peoples R China; [Gaboury, I.] Childrens Hosp Eastern Ontario, Inst Res, Ottawa, ON K1H 8L1, Canada	Lemyre, B (reprint author), Childrens Hosp Eastern Ontario, Div Neonatol, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	blemyre@toh.on.ca	Lemyre, Brigitte/I-2571-2019; Gaboury, Isabelle/B-6868-2011	Lemyre, Brigitte/0000-0003-2743-0417; 			BARRINGTON KJ, 1989, CRIT CARE MED, V17, P1293, DOI 10.1097/00003246-198912000-00009; Barrington KJ, 1998, AM J PERINAT, V15, P213, DOI 10.1055/s-2007-993928; Bhutada A, 2000, ARCH DIS CHILD-FETAL, V82, pF34, DOI 10.1136/fn.82.1.F34; Bonow Fernanda P., 2004, J. Pediatr. (Rio J.), V80, P355, DOI 10.1590/S0021-75572004000600005; Carbajal R, 2007, SEMIN PERINATOL, V31, P309, DOI 10.1053/j.semperi.2007.07.006; Dempsey EM, 2006, ARCH DIS CHILD-FETAL, V91, pF279, DOI 10.1136/adc.2005.087213; Duncan HP, 2001, PAEDIATR ANAESTH, V11, P135, DOI 10.1046/j.1460-9592.2001.00535.x; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; FRIESEN RH, 1987, ANESTH ANALG, V66, P874; Ghanta S, 2007, PEDIATRICS, V119, pE1248, DOI 10.1542/peds.2006-2708; GOLDBERG ME, 1989, ANESTH ANALG, V69, P93; Hamon I, 1996, ACTA PAEDIATR, V85, P361, DOI 10.1111/j.1651-2227.1996.tb14033.x; KELLY MA, 1984, J PEDIATR-US, V105, P303, DOI 10.1016/S0022-3476(84)80137-7; Khammash Hatem M., 1993, Pediatric Research, V33, p218A; Lago P, 2005, PEDIATR ANESTH, V15, P925, DOI 10.1111/j.1460-9592.2005.01688.x; Lemyre Brigitte, 2004, BMC Pediatr, V4, P20, DOI 10.1186/1471-2431-4-20; Oei J, 2000, PEDIATR RES, V47, p421A; POLEKA ML, 1994, ACTA PEDIAT, V83, P151; Roberts KD, 2006, PEDIATRICS, V118, P1583, DOI 10.1542/peds.2006-0590; Sarkar S, 2006, J PERINATOL, V26, P286, DOI 10.1038/sj.jp.7211499; Shah V, 2002, CLIN PERINATOL, V29, P535, DOI 10.1016/S0095-5108(02)00019-2; Simon L, 2004, CRIT CARE MED, V32, P565, DOI 10.1097/01.CCM.0000108883.58081.E3; Walter-Nicolet E, 2007, ARCH PEDIATRIE, V14, P144, DOI 10.1016/j.arcped.2006.10.023; Whyte S, 2000, ARCH DIS CHILD-FETAL, V82, pF38, DOI 10.1136/fn.82.1.F38; ZENK K, 1999, NEONATAL MED NUTR CO; 2007, PAEDIAT CHILD HLTH, V12, P137	26	30	30	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1359-2998	1468-2052		ARCH DIS CHILD-FETAL	Arch. Dis. Child.-Fetal Neonatal Ed.	NOV	2009	94	6					F439	F442		10.1136/adc.2008.146068			4	Pediatrics	Pediatrics	565HH	WOS:000275280200012	19307222				2020-06-30	J	Chhabra, A; Sinha, R; Subramaniam, R; Chandra, P; Narang, D; Garg, SP				Chhabra, A.; Sinha, R.; Subramaniam, R.; Chandra, P.; Narang, D.; Garg, S. P.			Comparison of sub-Tenon's block with i.v. fentanyl for paediatric vitreoretinal surgery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia, paediatric; anaesthetic techniques, regional, sub-Tenon's block; surgery, ophthalmological	RANDOMIZED CONTROLLED-TRIAL; RETINAL-DETACHMENT SURGERY; GENERAL-ANESTHESIA; STRABISMUS SURGERY; CAPSULE INJECTION; ANALGESIA	Background. Vitreoretinal (VR) surgery is associated with moderate to severe pain and significant postoperative nausea and vomiting (PONV). The study aimed to assess the effectiveness of sub-Tenon's block for providing perioperative analgesia in children undergoing VR surgery. Methods. In a randomized, observer-blinded trial, after obtaining institutional ethical committee approval and parental consent, 200 ASA grade I-II children aged 5-16 yr were allocated to receive either a sub-Tenon's block (Group SB) or 2 mu g kg(-1) i.v. fentanyl (Group F) after induction of anaesthesia and topical anaesthesia of the conjunctiva with proparacaine 0.5% drops. Patients in Group F received fentanyl 0.5 mu g kg(-1) and those in Group SB were given a corresponding volume of normal saline i.v. every hour from preloaded syringes. Increases in heart rate or mean arterial pressure by more than 20% of baseline were treated with additional 0.5 mu g kg(-1) i.v. fentanyl boluses in both groups. The incidence of oculocardiac reflex (OCR), need for additional analgesics, postoperative pain, and PONV were recorded for the first 24 h after surgery. Results. More patients in Group F (47.96%) had moderate to severe pain in the first 24 h when compared with Group SB (31.36%) (P=0.023). The need for postoperative ibuprofen was higher in Group F (66.3%) compared with Group SB (47.95%) (P=0.012). The incidence of OCR was significantly higher in Group F (31.6%) compared with Group SB (5.1%) (P<0.001). The incidence of PONV was similar in both groups. Conclusions. Sub-Tenon's block provides more effective analgesia than i.v. fentanyl for paediatric VR surgery.	[Chhabra, A.; Sinha, R.; Subramaniam, R.; Chandra, P.; Narang, D.] All India Inst Med Sci, Dept Anaesthesiol & Intens Care, New Delhi, India; [Garg, S. P.] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India	Chhabra, A (reprint author), 13-61 W Punjabi Bagh, New Delhi 110026, India.	anjolie5@hotmail.com					Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Bergman L, 2007, OPHTHALMOLOGY, V114, P2055, DOI 10.1016/j.ophtha.2006.12.031; Canavan KS, 2003, BRIT J ANAESTH, V90, P787, DOI 10.1093/bja/aeg105; Chhabra A, 2005, REGION ANESTH PAIN M, V30, P43, DOI 10.1016/j.rapm.2004.08.023; Farmery AD, 2003, EUR J ANAESTH, V20, P973, DOI 10.1097/00003643-200312000-00007; Frieman BJ, 2001, AM J OPHTHALMOL, V131, P520, DOI 10.1016/S0002-9394(00)00815-1; Ghai B, 2009, ANESTH ANALG, V108, P1132, DOI 10.1213/ane.0b013e318198a3fd; Henzler D, 2004, EUR J ANAESTH, V21, P101, DOI 10.1017/S0265021504002042; KWOK A, 1999, RETINA, V91, P291; Lai MM, 2005, OPHTHALMOLOGY, V112, P574, DOI 10.1016/j.ophtha.2004.10.043; Li HK, 2000, OPHTHALMOLOGY, V107, P41, DOI 10.1016/S0161-6420(99)00009-3; Olitsky SE, 1997, OPHTHALMIC SURG LAS, V28, P145; PAWAR D, 1994, ANESTHESIA CHILDREN, P127; Ruschen H, 2003, ANESTH ANALG, V96, P273, DOI 10.1213/01.ANE.0000039318.12705.8A; Sheard RM, 2004, J AAPOS, V8, P314, DOI 10.1016/j.jaapos.2004.01.017; Shende D, 2000, ANAESTHESIA, V55, P970, DOI 10.1046/j.1365-2044.2000.01535.x; Sohn HJ, 2008, OPHTHALMOLOGICA, V222, P414, DOI 10.1159/000161556; Steib A, 2005, REGION ANESTH PAIN M, V30, P478, DOI 10.1016/j.rapm.2005.04.011; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Subramaniam R, 2003, REGION ANESTH PAIN M, V28, P43, DOI 10.1053/rapm.2003.50032	20	16	16	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	NOV	2009	103	5					739	743		10.1093/bja/aep230			5	Anesthesiology	Anesthesiology	517NP	WOS:000271622100016	19706631	Bronze			2020-06-30	J	Kim, SY; Cho, JE; Hong, JY; Koo, BN; Kim, JM; Kil, HK				Kim, S. Y.; Cho, J. E.; Hong, J. Y.; Koo, B. N.; Kim, J. M.; Kil, H. K.			Comparison of intrathecal fentanyl and sufentanil in low-dose dilute bupivacaine spinal anaesthesia for transurethral prostatectomy	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques, subarachnoid; anaesthetics local, bupivacaine; analgesics opioid, fentanyl; analgesics opioid, sufentanil; surgery, urological	DURATION OUTPATIENT LAPAROSCOPY; LABOR ANALGESIA; PROLONGING RECOVERY; LOCAL-ANESTHETICS; LIDOCAINE; OPIOIDS; HYPOTENSION; RECEPTORS; RESECTION; SURGERY	Background. The administration of low-dose bupivacaine can limit the distribution of spinal block to reduce adverse haemodynamic effects. Intrathecal opioids can enhance analgesia in combination with subtherapeutic doses of local anaesthetics. We aimed at comparing the efficacy of intrathecal fentanyl and sufentanil with low-dose diluted bupivacaine for transurethral prostatectomy (TURP) in elderly patients. Methods. Seventy patients undergoing TURP were randomly allocated into two groups. Group F (n=35) received fentanyl 25 mu g+bupivacaine 0.5% (0.8 ml)+normal saline 0.3 ml and Group S (n=35) received sufentanil 5 mu g+bupivacaine 0.5% (0.8 ml)+normal saline 0.7 ml-in total, bupivacaine 0.25% (1.6 ml) intrathecally. Onset and duration of the sensory block, the degree of the motor block, side-effects, and the perioperative analgesic requirements were assessed. Results. The median peak level of the sensory block was significantly higher in Group S than in Group F (P=0.049). Group S required fewer perioperative analgesics than Group F (P=0.008). The time to the first analgesic request was longer in Group S (P=0.025). There were no differences between the groups for the onset and recovery time of the sensory block, degree of the motor block, quality of anaesthesia, or adverse effects. Conclusions. Low-dose diluted bupivacaine with fentanyl 25 mu g or sufentanil 5 mu g can provide adequate anaesthesia without haemodynamic instability for TURP in elderly patients. However, sufentanil was superior to fentanyl in the quality of the spinal block produced.	[Kim, S. Y.; Cho, J. E.; Hong, J. Y.; Koo, B. N.; Kim, J. M.; Kil, H. K.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 120752, South Korea; [Hong, J. Y.; Koo, B. N.; Kil, H. K.] Yonsei Univ, Coll Med, Anaesthesia & Pain Res Inst, Seoul 120752, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, 250 Seongsan No, Seoul 120752, South Korea.	hkkil@yuhs.ac		Kim, Jeongmin/0000-0002-0468-8012; Kim, So Yeon/0000-0001-5352-157X; Koo, Bon-Nyeo/0000-0002-3189-1673			Asehnoune K, 2005, ANESTH ANALG, V101, P1512, DOI 10.1213/01.ANE.0000180996.91358.CC; BEERS RA, 1994, CAN J ANAESTH, V41, P807, DOI 10.1007/BF03011588; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; EVANS TI, 1974, ANAESTH INTENS CARE, V2, P240, DOI 10.1177/0310057X7400200307; Gaiser RR, 1998, J CLIN ANESTH, V10, P488, DOI 10.1016/S0952-8180(98)00076-2; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; GREENE NM, 1985, ANESTH ANALG, V64, P715; Hamber Elizabeth A., 1999, Regional Anesthesia and Pain Medicine, V24, P255, DOI 10.1016/S1098-7339(99)90139-6; HANSDOTTIR V, 1991, ANESTHESIOLOGY, V74, P264, DOI 10.1097/00000542-199102000-00012; Herman NL, 1997, ANESTH ANALG, V84, P1256, DOI 10.1097/00000539-199706000-00016; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; LEYSEN JE, 1983, EUR J PHARMACOL, V87, P209, DOI 10.1016/0014-2999(83)90331-X; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Olofsson C, 2004, ACTA ANAESTH SCAND, V48, P1240, DOI 10.1111/j.1399-6576.2004.00504.x; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Parlow JL, 1999, CAN J ANAESTH, V46, P66, DOI 10.1007/BF03012518; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; Riley ET, 1997, ANESTH ANALG, V84, P346, DOI 10.1097/00000539-199702000-00019; Sia ATH, 1999, ANESTH ANALG, V88, P362, DOI 10.1097/00000539-199902000-00026; STIENSTRA R, 1990, REGION ANESTH, V15, P6; TEJWANI GA, 1992, ANESTH ANALG, V74, P726; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011; Yegin A, 2005, ACTA ANAESTH SCAND, V49, P401, DOI 10.1111/j.1399-6576.2005.00607.x	28	30	35	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	NOV	2009	103	5					750	754		10.1093/bja/aep263			5	Anesthesiology	Anesthesiology	517NP	WOS:000271622100018	19797249	Bronze			2020-06-30	J	Mercadante, S; Radbruch, L; Davies, A; Poulain, P; Sitte, T; Perkins, P; Colberg, T; Camba, MA				Mercadante, S.; Radbruch, L.; Davies, A.; Poulain, P.; Sitte, T.; Perkins, P.; Colberg, T.; Camba, M. A.			A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrough cancer pain (BTCP); Breakthrough pain (BTP); Efficacy; Intranasal fentanyl spray (INFS); Opioid treatment; Oral transmucosal fentanyl citrate (OTFC)	DOSE-TITRATION; DOUBLE-BLIND; PREVALENCE; MORPHINE; RECOMMENDATIONS; TOLERABILITY; ASSOCIATION; XEROSTOMIA; MANAGEMENT; EFFICACY	Objective: The efficacy of intranasal fentanyl spray (INFS) was compared with that of oral transmucosal fentanyl citrate (OTFC) for the relief of cancer-related breakthrough pain (BTP) in an open-label, crossover trial. Methods: Adult cancer patients receiving stable background opioid treatment and experiencing BTP episodes were recruited from 44 study centres in seven European countries (Austria, France, Germany, Italy, Poland, Spain and the United Kingdom); of the 196 patients enrolled, 139 were randomised to receive INFS followed by OTFC, or vice versa. Patients were titrated to an effective dose of one agent (50, 100 or 200 mu g INFS; 200, 400, 600, 800, 1200 or 1600 mu g OTFC) to treat six BTP episodes, then titration and treatment were repeated with the other agent. The primary outcome was patient-recorded time to onset of 'meaningful' pain relief. Secondary outcomes included pain intensity difference (PID) at 10 and 30 minutes (PID10, PID30), sum of PID at 15 and 60 minutes (SPID0-15, SPID0-60), ease of administration, treatment preference and relationship between background opioid dose and effective INFS dose. Additional outcome measures included proportions of episodes with >= 33% and >= 50% pain intensity (PI) reduction, and PID at additional time points. Clinical trial registration number: NCT00496392. Results: Among the intention-to-treat population (n = 139), median time to onset of 'meaningful' pain relief was 11 minutes with INFS versus 16 minutes with OTFC; 65.7% of patients attained faster time to 'meaningful' pain-relief onset with INFS (p < 0.001). PID was statistically significantly greater for INFS than OTFC from 5 minutes post-dosing. Significantly more INFS-treated breakthrough pain episodes achieved clinically important pain relief (>= 33% and >= 50% PI reduction) up to 30 minutes post-dosing. The proportions of episodes treated with INFS and OTFC achieving a PI reduction of >= 33% at 5 minutes were 25.3% versus 6.8% (p < 0.001), and at 10 minutes were 51.0% versus 23.6% (p < 0.001), respectively; the proportions of episodes treated with INFS and OTFC achieving a >= 50% PI reduction at 5 minutes were 12.8% versus 2.1% (p < 0.001), and at 10 minutes were 36.9% versus 9.7% (p < 0.001), respectively. Higher SPID0-15 and SPID0-60 scores were achieved with INFS (p < 0.001). More patients preferred INFS than OTFC (p < 0.001) and more patients found it very easy/easy to use. Both treatments were well tolerated. In the safety population (n = 139), 56.8% (n = 79) of patients experienced >= 1 AE during the trial. The only AE that occurred in >= 5% of patients in either treatment group was nausea. Among those patients who experienced serious AEs (13.7%, n = 19), none were considered to be related to either study medication. There was a weak correlation between effective INFS doses and background opioid doses. Conclusion: In this open-label, randomised, crossover trial, significantly more patients attained faster 'meaningful' pain relief with INFS than OTFC, and more patients preferred INFS to OTFC.	[Mercadante, S.] La Maddalena, Casa Cura Ad Alta Specialita Pain Relief & Pallia, Dipartimento Oncol, I-90146 Palermo, Italy; [Radbruch, L.] Univ Klinikum Aachen, RWTH Aachen, Klin Palliativmed, Aachen, Germany; [Davies, A.] Royal Marsden Hosp, Dept Palliat Med, Sutton, Surrey, England; [Poulain, P.] Inst Claudius Regaud, Toulouse & Polyclin Ormeau, Tarbes, France; [Sitte, T.] Schmerz & PalliativZentrum Fulda & PalliativNetz, Fulda, Germany; [Perkins, P.] Sue Ryder Care Leckhampton Court Hospice, Cheltenham, Glos, England; [Perkins, P.] Gloucestershire Hosp NHS Fdn Trust, Cheltenham, Glos, England; [Colberg, T.] Nycomed, Res & Dev, Roskilde, Denmark; [Camba, M. A.] Anesthesiol Serv, Unidad Dolor, La Coruna, Spain	Mercadante, S (reprint author), La Maddalena, Casa Cura Ad Alta Specialita Pain Relief & Pallia, Dipartimento Oncol, Via S Lorenzo Colli 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it					Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BENNETT D, 2005, [No title captured], V30, P354; Chaushu G, 2000, CANCER, V88, P984, DOI 10.1002/(SICI)1097-0142(20000301)88:5<984::AID-CNCR6>3.3.CO;2-S; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies A, 2006, CANC RELATED BREAKTH, P1; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Desjardins P, 2002, EUR J CLIN PHARMACOL, V58, P387, DOI 10.1007/s00228-002-0491-0; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; NAVE R, EFIC 2009 LISB PORT; POPPER L, WCP 2008 GLASG SCOTL; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; PORTENOY RK, 1997, SEMIN ONCOL      S16, V5, P7; Portenoy RK, 2004, OXFORD TXB PALLIATIV, P438; Prescott R, 2006, APPL MIXED MODELS ME; Skinner C, 2006, CANC RELATED BREAKTH, P13; Sunshine A, 2006, CLIN THER, V28, P1107, DOI 10.1016/j.clinthera.2006.08.010; Sweeney MP, 1998, ORAL ONCOL, V34, P123, DOI 10.1016/S1368-8375(97)00076-6; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; *WORLD MED ASS DEC, 1964, ETH PRINC MED RES IN; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	36	104	109	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	NOV	2009	25	11					2805	2815		10.1185/03007990903336135			11	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	541LR	WOS:000273417700025	19792837				2020-06-30	J	Schimke, KE; Greminger, P; Brandle, M				Schimke, K-E.; Greminger, P.; Braendle, M.			Secondary Adrenal Insufficiency due to Opiate Therapy - Another Differential Diagnosis Worth Consideration	EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES			English	Article						secondary adrenal insufficiency; partial anterior pituitary failure; opiate therapy; fentanyl	CRITICAL ILLNESS; OPIOID-PEPTIDES; PITUITARY; SECRETION	We report on a 64-year-old patient in whom fentanyl therapy was found to be responsible for the induction of secondary adrenal insufficiency as clearly demonstrated by re-exposure. We conclude that given the widespread use of opiates in chronic pain management physicians should raise their level of awareness for adrenal insufficiency and look for it generously. Opiates should be added to the list of differential diagnoses to be considered routinely in patients with newly diagnosed secondary adrenal insufficiency.	[Schimke, K-E.; Braendle, M.] Kantonsspital, Dept Internal Med, Div Endocrinol & Diabet, CH-9007 St Gallen, Switzerland	Schimke, KE (reprint author), Kantonsspital, Dept Internal Med, Div Endocrinol & Diabet, Rorschacherstr 95, CH-9007 St Gallen, Switzerland.	katrin.schimke@kssg.ch					Abs R, 2000, J CLIN ENDOCR METAB, V85, P2215, DOI 10.1210/jc.85.6.2215; Arafah BM, 2006, J CLIN ENDOCR METAB, V91, P3725, DOI 10.1210/jc.2006-0674; Bianda T, 2003, QJM-INT J MED, V96, P950, DOI 10.1093/qjmed/hcg156; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; DELITALA G, 1983, NEUROENDOCRINOLOGY, V37, P275, DOI 10.1159/000123558; GROSSMAN A, 1986, NEUROENDOCRINOLOGY, V42, P357, DOI 10.1159/000124463; GROSSMAN A, 1983, CLIN ENDOCRINOL META, V12, P725, DOI 10.1016/S0300-595X(83)80062-0; HOWLETT TA, 1986, ANNU REV PHYSIOL, V48, P527; MORLEY JE, 1981, METABOLISM, V30, P195, DOI 10.1016/0026-0495(81)90172-4; Oltmanns KM, 2005, J INTERN MED, V257, P478, DOI 10.1111/j.1365-2796.2005.01483.x; PENDE A, 1986, BIOMED PHARMACOTHER, V40, P178; ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7; Schuetz P, 2006, ENDOCRIN METAB CLIN, V35, P823, DOI 10.1016/j.ecl.2006.09.013	13	17	17	0	2	JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH	STUTTGART	RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY	0947-7349			EXP CLIN ENDOCR DIAB	Exp. Clin. Endocrinol. Diabet.	NOV	2009	117	10					649	651		10.1055/s-0029-1202851			3	Endocrinology & Metabolism	Endocrinology & Metabolism	525UW	WOS:000272242900017	19373753				2020-06-30	J	Richa, F; Yazigi, A				Richa, Freda; Yazigi, Alexandre			COMPARISON BETWEEN DEXMEDETOMIDINE AND REMIFENTANIL FOR INTRAOPERATIVE CONTROLLED HYPOTENSION	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Letter							TYMPANOPLASTY; SURGERY									Durmus M, 2007, EUR J ANAESTH, V24, P447, DOI 10.1017/S0265021506002122; Farah GJ, 2008, J ORAL MAXIL SURG, V66, P2261, DOI 10.1016/j.joms.2008.06.045; Richa F, 2008, EUR J ANAESTH, V25, P369, DOI 10.1017/S0265021508003761; Richa F, 2007, EUR J ANAESTH, V24, P985, DOI 10.1017/S0265021507001081; Tobias Joseph D, 2002, Paediatr Drugs, V4, P439, DOI 10.2165/00148581-200204070-00003	5	4	5	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	NOV	2009	67	11					2549	2550		10.1016/j.joms.2008.12.060			2	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	512JC	WOS:000271243100039	19837334				2020-06-30	J	Wallace, S; Mecklenburg, B; Hanling, S				Wallace, Scott; Mecklenburg, Brian; Hanling, Steven			Profound Reduction in Sedation and Analgesic Requirements Using Extended Dexmedetomidine Infusions in a Patient With an Open Abdomen	MILITARY MEDICINE			English	Article							HYPERALGESIA	We present a 20-year-old previously healthy male who suffered a gunshot wound to the abdomen and underwent multiple surgeries because of abdominal abscess and fistula formation. Pain control was difficult to achieve despite high-dose opioid therapy. Post-traumatic stress disorder was a confounding factor in treating this patient's pain. Ten months after the original injury, the patient returned to the operating room for an exploratory laparotomy with restoration of bowel continuity and abdominal wall closure. The patient presented to the intensive care unit after a 12-hour operation with an open abdomen and the requirement of mechanical ventilation, sedation, and analgesia. Sedation and analgesia were difficult to achieve and maintain with combinations of extremely high doses of midazolam, lorazepam, propofol, and fentanyl (motor assessment activity scale [MAAS] scores of 5), but profoundly achievable with dexmedetomidine. Dexmedetomidine also improved the patient's mental stability, which resulted in improved patient care through compliance with physicians, nurses, and physical therapists.	[Wallace, Scott; Mecklenburg, Brian; Hanling, Steven] USN, Dept Anesthesiol, San Diego Med Ctr, San Diego, CA 92134 USA	Wallace, S (reprint author), USN, Dept Anesthesiol, San Diego Med Ctr, 34800 Bob Wilson Dr, San Diego, CA 92134 USA.		Hanling, Steven/AAF-9504-2019				Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Chrysostomou C, 2008, EXPERT OPIN DRUG MET, V4, P619, DOI [10.1517/17425255.4.5.619, 10.1517/17425255.4.5.619 ]; CUMMINGS DM, 1982, DRUG INTEL CLIN PHAR, V16, P817, DOI 10.1177/106002808201601102; Davies MF, 2003, ANESTH ANALG, V96, P195, DOI 10.1097/00000539-200301000-00041; Horvath G, 2005, ANESTH ANALG, V101, P812, DOI 10.1213/01.ane.0000166982.19796.ae; *HOSP INC, 2004, PREC DEXM HYDR INJ P; MCMAHON B, 2006, WALL MELZACKS TXB PA, P721; Nasraway SA, 2001, SEM RESP CRIT CARE M, V22, P165, DOI 10.1055/s-2001-13830; PAALZOW G, 1978, N-S ARCH PHARMACOL, V304, P1, DOI 10.1007/BF00501369; Shehabi Y, 2004, INTENS CARE MED, V30, P2188, DOI 10.1007/s00134-004-2417-z; Szumita PM, 2007, AM J HEALTH-SYST PH, V64, P37, DOI 10.2146/ajhp050508; Tobias Joseph D, 2008, J Opioid Manag, V4, P187; Venn RM, 2003, INTENS CARE MED, V29, P201, DOI 10.1007/s00134-002-1579-9	14	7	10	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	NOV	2009	174	11					1228	1230		10.7205/MILMED-D-00-6009			3	Medicine, General & Internal	General & Internal Medicine	601LL	WOS:000278060900018	19960834	Bronze			2020-06-30	J	Mert, T; Gunes, Y; Ozcengiz, D; Gunay, I				Mert, Tufan; Gunes, Yasemin; Ozcengiz, Dilek; Gunay, Ismail			Magnesium modifies fentanyl-induced local antinociception and hyperalgesia	NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY			English	Article						Fentanyl; Magnesium; Intraplantar; Hyperalgesia; Antinociception	OPIOID-INDUCED HYPERALGESIA; LONG-LASTING HYPERALGESIA; PAIN; RATS; KETAMINE; ENHANCEMENT; ANALGESICS; RECEPTORS; TOLERANCE	Fentanyl-induced hyperalgesia and antinociception after systemic administration has been shown in previous clinical and experimental studies. However, there is very little evidence regarding the local possible effects of fentanyl. The purpose of this study was to assess whether local (intraplantar) fentanyl administration can produce antinociception and hyperalgesia. In addition, we examined the effects of magnesium, N-methyl-D-aspartate receptor antagonist, on possible changes produced by fentanyl. The paw withdrawal latencies to radiant heat stimuli were measured to assess the thermal nociceptive actions. Intraplantar administration of fentanyl caused time and dose-dependent increase in the paw withdrawal latencies (antinociception). Coinjection of magnesium with fentanyl markedly enhanced the antinociception. However, fentanyl also markedly decreased paw withdrawal latencies 24 h after intraplantar administration (hyperalgesia). In the presence of magnesium, hyperalgesia after fentanyl administration was not observed. Consequently, following the fentanyl administration, local hyperalgesia after antinociception is a negative effect in pain treatment. Magnesium may not only prevent the hyperalgesia but also enhance antinociceptive effect of fentanyl.	[Mert, Tufan; Gunay, Ismail] Cukurova Univ, Dept Biophys, Fac Med, TR-01330 Balcali, Turkey; [Gunes, Yasemin; Ozcengiz, Dilek] Cukurova Univ, Dept Anaesthesiol, Fac Med, TR-01330 Balcali, Turkey	Mert, T (reprint author), Cukurova Univ, Dept Biophys, Fac Med, TR-01330 Balcali, Turkey.	tufanmert@yahoo.com	Mert, Tufan/AAG-4693-2019; gunay, ismail/G-1625-2018	Mert, Tufan/0000-0002-5926-9210; gunay, ismail/0000-0002-0138-251X	Cukurova University Research FoundationCukurova University	We acknowledge the support given by the Cukurova University Research Foundation.	Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Begon S, 2002, ANESTHESIOLOGY, V96, P627, DOI 10.1097/00000542-200203000-00019; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Dunbar SA, 1998, J PHARMACOL EXP THER, V284, P678; Dupen A, 2007, PAIN MANAG NURS, V8, P113, DOI 10.1016/j.pmn.2007.02.004; Janson W., 2003, Current Pharmaceutical Biotechnology, V4, P270, DOI 10.2174/1389201033489766; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811; Mert T, 2007, EUR J PHARMACOL, V558, P68, DOI 10.1016/j.ejphar.2006.11.055; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Obara I, 2004, NEUROSCI LETT, V360, P85, DOI 10.1016/j.neulet.2004.01.056; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Sawynok J, 2003, PHARMACOL REV, V55, P1, DOI 10.1124/pr.55.1.1; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Stein C, 2001, Curr Opin Pharmacol, V1, P62, DOI 10.1016/S1471-4892(01)00005-4; SUKIENNIK AW, 1995, CURR OPIN ANAESTH, V8, P445; Takano Y, 2000, PAIN, V84, P175, DOI 10.1016/S0304-3959(99)00207-9; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Van Elstracte AC, 2006, CAN J ANAESTH, V53, P1180, DOI 10.1007/BF03021578	25	17	17	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-1298			N-S ARCH PHARMACOL	Naunyn-Schmiedebergs Arch. Pharmacol.	NOV	2009	380	5					415	420		10.1007/s00210-009-0447-3			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	509AZ	WOS:000270984700005	19697012				2020-06-30	J	Jacobsen, R; Moldrup, C; Christrup, L				Jacobsen, Ramune; Moldrup, Claus; Christrup, Lona			Danish Pain Specialists' Rationales behind the Choice of Fentanyl Transdermal Patches and Oral Transmucosal Systems-A Delphi Study	PAIN MEDICINE			English	Article						Fentanyl; Administration Form; Pain Specialists; Rationale; Delphi Survey; Denmark	PRESCRIBING INDICATORS; BREAKTHROUGH PAIN; MANAGEMENT; EFFICACY; CITRATE; PHARMACOKINETICS; INTRANASAL; PRIORITIES; PROVIDERS; OPIOIDS	Objective. The aim of this study was to describe the rationale behind the choice of fentanyl administration forms among Danish pain specialists. Methods. Sixty Danish physicians specializing in pain management were contacted via an Internet survey system to perform a two-phase Delphi survey. Response rates were 45% in the brainstorming and 88% in the rating phases, respectively. Statistical analysis with SPSS for Windows 15.00 included descriptive statistics and factor analysis. Results. The most important rationale to choose fentanyl patches was that patients' clinical condition did not allow them to take analgesia orally, while the main explanations for not choosing a fentanyl patch was a specific chronic pain condition such as nonmalignant or neuropathic pain origin, and price. The foremost rationale behind the choice of oral transmucosal fentanyl citrate (OTFC) were cancer patients' need for the alternative to oral, intravenous or subcutaneous rescue medication, followed by patients' wish and ability to administer pain medication independently. The main reasons for not choosing OTFC were price and the argument that OTFC administration requires much energy and healthy patients' mouth and therefore is inapplicable for terminal pain patients. Conclusion. The study had shown that the rationales behind the choice of administration form with fentanyl reported by a panel of Danish pain specialists partly differed from those overviewed in the literature and those thought to be important while developing fentanyl patches and OTFC.	[Jacobsen, Ramune] Univ Copenhagen, Dept Pharmacol & Pharmacotherapy, Fac Pharmaceut Sci, Sect Social Pharm, DK-2100 Copenhagen, Denmark	Jacobsen, R (reprint author), Univ Copenhagen, Dept Pharmacol & Pharmacotherapy, Fac Pharmaceut Sci, Sect Social Pharm, Univ Pk 2, DK-2100 Copenhagen, Denmark.	raj@farma.ku.dk	Jacobsen, Ramune/AAG-1887-2019	Christrup, Lona/0000-0002-4128-7373; Jacobsen, Ramune/0000-0002-8142-9807	Nycomed A/S, Denmark	This study is a part of the PhD project at the Faculty of Pharmaceutical Sciences, University of Copenhagen, partly supported by Nycomed A/S, Denmark.	Akins Ralitsa B, 2005, BMC Med Res Methodol, V5, P37, DOI 10.1186/1471-2288-5-37; Baker JA, 2007, J PSYCHIATR MENT HLT, V14, P478, DOI 10.1111/j.1365-2850.2007.01112.x; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; Campbell SM, 2000, BRIT MED J, V321, P425, DOI 10.1136/bmj.321.7258.425; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Cook C, 2005, PHYSIOTHER RES INT, V10, P59, DOI 10.1002/pri.27; Crawford SD, 2001, SOC SCI COMPUT REV, V19, P146, DOI 10.1177/089443930101900202; CUDECK R, 1989, PSYCHOL BULL, V105, P317, DOI 10.1037/0033-2909.105.2.317; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Danish Medicine Agency (Laegemiddelstyrelsen), 2007, LIST APPR MED; Delbecq A.L., 1975, GROUP TECHNIQUES PRO; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Efstathiou N, 2007, EUR J ONCOL NURS, V11, P141, DOI 10.1016/j.ejon.2006.06.005; Facione N C, 1994, J Nurs Educ, V33, P345; FASSER CE, 1992, ACAD MED, V67, P696, DOI 10.1097/00001888-199210000-00017; Fayers P, 2007, QUALITY LIFE ASSESSM; Fine P G, 1998, J Palliat Med, V1, P55, DOI 10.1089/jpm.1998.1.55; Gordon DB, 2006, ONCOL NURS FORUM, V33, P257, DOI 10.1188/06.ONF.257-264; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; HAMILTON PA, 1992, PUBLIC HEALTH NURS, V9, P142, DOI 10.1111/j.1525-1446.1992.tb00092.x; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Jensen TS., 2008, PAIN 2008 UPDATED RE, P287; Kilner T, 2004, EMERG MED J, V21, P379, DOI 10.1136/emj.2003.009605; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Mercadante S, 1999, ONCOLOGY-NY, V13, P215; Misener T R, 1997, Image J Nurs Sch, V29, P47; Moldrup C, 2001, TECHNOL FORECAST SOC, V67, P273, DOI 10.1016/S0040-1625(99)00061-X; MOSSER KH, 1992, AM FAM PHYSICIAN, V45, P2289; Mystakidou K, 2004, IN VIVO, V18, P633; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Mystakidou Kyriaki, 2005, Am J Hosp Palliat Care, V22, P228, DOI 10.1177/104990910502200313; Nevo D, 2007, INF MANAGE, V44, P538; Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x; Radovanovic D, 2002, ARCH ONCOL, V10, P263; Rasmussen HMS, 2005, EUR J CLIN PHARMACOL, V61, P237, DOI 10.1007/s00228-004-0870-9; Reddy S K, 2000, Curr Rev Pain, V4, P242; Rees Elizabeth, 2002, Int J Palliat Nurs, V8, P304; Richter A, 2001, CLIN THER, V23, P160, DOI 10.1016/S0149-2918(01)80038-2; Sackman H, 1975, DELPHI CRITIQUE EXPE; Schopper D, 2000, SOC SCI MED, V51, P335, DOI 10.1016/S0277-9536(99)00457-8; SHORE BE, 1986, MED CARE, V24, P580, DOI 10.1097/00005650-198607000-00002; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Stevens Bonnie, 2006, BMC Pediatr, V6, P1, DOI 10.1186/1471-2431-6-1; Stevens J. P., 2002, APPL MULTIVARIATE ST; U. S. Food and Drug Administration, 2007, DUR LAB; U. S. Food and Drug Administration, 2007, MED GUID ACT; ZACNY JP, 1992, PSYCHOPHARMACOLOGY, V107, P319, DOI 10.1007/BF02245155; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	50	2	2	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	NOV-DEC	2009	10	8					1442	1451		10.1111/j.1526-4637.2009.00724.x			10	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	V20FE	WOS:000208125100013	19793344	Bronze			2020-06-30	J	Chrysostomou, C; De Toledo, JS; Avolio, T; Motoa, MV; Berry, D; Morell, VO; Orr, R; Munoz, R				Chrysostomou, Constantinos; De Toledo, Joan Sanchez; Avolio, Tracy; Motoa, Maria V.; Berry, Donald; Morell, Victor O.; Orr, Richard; Munoz, Ricardo			Dexmedetomidine use in a pediatric cardiac intensive care unit: Can we use it in infants after cardiac surgery?	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						sedation; analgesia; infants; dexmedetomidine; cardiac surgery; intensive care unit; neonates	INTRAVENOUS DEXMEDETOMIDINE; SEDATION; CHILDREN; HUMANS; PHARMACOKINETICS; VENTILATION; PROPOFOL; PATIENT; BYPASS	Objective: To assess clinical response of dexmedetomidine alone or in combination with conventional sedatives/analgesics after cardiac surgery. Design: Retrospective study. Setting: Pediatric cardiac intensive care unit. Patients: Infants and neonates after cardiac surgery. Measurements and Main Results: We identified 80 patients including 14 neonates, at mean age and weight of 4.1 +/- 3.1 months and 5.5 +/- 2 kg, respectively, who received dexmedetomidine for 25 +/- 13 hours at an average dose of 0.66 +/- 0.26 mu g.kg(-1)-hr(-1). Overall normal sleep to moderate sedation was documented 94% of the time and no pain to mild pain for 90%. Systolic blood pressure (SBP) decreased from 89 +/- 15 mm Hg to 85 +/- 11 mm Hg (p = .05), heart rate (HR) from 149 +/- 22 bpm to 129 +/- 16 bpm (p < .001), and respiratory rate (RR) remained unchanged. When baseline arterial blood gases were compared with the most abnormal values, pH decreased from 7.4 +/- 0.07 to 7.37 +/- 0.05 (p = .006), PO2 from 91 +/- 67 mm Hg to 66 +/- 29 mm Hg (p = .005), and CO2 increased from 45 +/- 8 mm Hg to 50 +/- 12 mm Hg (p = .001). At the beginning of the study, 37 patients (46%) were mechanically ventilated; and at 48 hours, 13 patients (16%) were still intubated and five patients failed extubation. Three groups of patients were identified: A, dexmedetomidine only (n = 20); B, dexmedetomidine with sedatives/analgesics (n = 38); and C, dexmedetomidine with both sedatives/analgesics and fentanyl infusion (n = 22). The doses of dexmedetomidine and rescue sedatives/analgesics were not significantly different among the three groups but duration of dexmedetomidine was longer in group C vs. A (p = .03) and C vs. B (p = .002). Pain, sedation, SBP, RR, and arterial blood gases were similar. HR was higher in group C vs. B (p = .01). Comparison between neonates and infants showed that infants required higher dexmedetomidine doses, 0.69 +/- 25 mu g.kg(-1)-hr(-1), and vs. 0.47 +/- 21 mu g.kg(-1).hr(-1) (p = .003) and had lower FIR (p = .01), and RR (p = .009), and higher SBP (p < .001). Conclusions: Dexmedetomidine use in infants and neonates after cardiac surgery was well tolerated in both intubated and nonintubated patients. It provides an adequate level of sedation/analgesia either alone or in combination with low-dose conventional agents. (Pediatr Crit Care Med 2009; 10:654-660)	[Chrysostomou, Constantinos; De Toledo, Joan Sanchez; Avolio, Tracy; Motoa, Maria V.; Berry, Donald; Munoz, Ricardo] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat & Crit Care Med, Div Cardiac Intens Care,Med Ctr, Pittsburgh, PA 15213 USA; [Morell, Victor O.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Cardiothorac Surg, Pittsburgh, PA 15213 USA	Chrysostomou, C (reprint author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat & Crit Care Med, Div Cardiac Intens Care,Med Ctr, Pittsburgh, PA 15213 USA.	chrycx@chp.edu		Sanchez-de-Toledo, Joan/0000-0002-9108-4750	Hospira, Inc. Lake Forest	Supported, partially, by Hospira, Inc. Lake Forest, IL.	BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; Berkenbosch John W, 2003, Pediatr Crit Care Med, V4, P203, DOI 10.1097/01.PCC.0000059737.86673.28; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Chrysostomou C, 2005, PEDIATR CARDIOL, V26, P651, DOI 10.1007/s00246-005-0683-3; Chrysostomou C, 2006, PEDIATR CRIT CARE ME, V7, P126, DOI 10.1097/01.PCC.0000200967.76996.07; Diaz SM, 2007, PEDIATR CRIT CARE ME, V8, P419, DOI 10.1097/01.PCC.0000282046.66773.39; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Hammer GB, 2008, ANESTH ANALG, V106, P79, DOI 10.1213/01.ane.0000297421.92857.4e; Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1016/S1053-0770(03)00200-3; Jenkins KJ, 2002, J THORAC CARDIOV SUR, V123, P110, DOI 10.1067/mtc.2002.119064; MAZE M, 2004, [No title captured], P473; Merkel S I, 1997, Pediatr Nurs, V23, P293; Mester R, 2008, AM J THER, V15, P24, DOI 10.1097/MJT.0b013e3180a72255; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Pasero C, 2002, AM J NURS, V102, P61; Petroz GC, 2006, ANESTHESIOLOGY, V105, P1098, DOI 10.1097/00000542-200612000-00009; Sichrovsky TC, 2008, ANESTH ANALG, V106, P1784, DOI 10.1213/ane.0b013e318172fafc; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Walker J, 2006, J BURN CARE RES, V27, P206, DOI 10.1097/01.BCR.0000200910.76019.CF; WERNOVSKY G, 1995, CIRCULATION, V92, P2226, DOI 10.1161/01.CIR.92.8.2226	21	56	58	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	NOV	2009	10	6					654	660		10.1097/PCC.0b013e3181a00b7a			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	517GG	WOS:000271600700005	19295456				2020-06-30	J	Hillier, RJ; Aboud, A; Thind, G; Clark, DI				Hillier, Roxane J.; Aboud, Ahlam; Thind, Gurvinder; Clark, David I.			ORAL TRANSMUCOSAL FENTANYL CITRATE A Novel Analgesic Agent for Use in Retinal Photocoagulation	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						analgesia; diabetes mellitus; fentanyl; photocoagulation; retinopathy	DIABETIC-RETINOPATHY; CONTROLLED-TRIAL; PAIN	Purpose: To evaluate the analgesic effect of 200 mu g oral transmucosal fentanyl citrate during peripheral retinal scatter photocoagulation and to determine the side effect profile. Methods: A prospective, randomized, double-masked crossover study. Consecutive patients (n = 35) undergoing peripheral retinal scatter photocoagulation were randomized into 2 groups. Each attended twice, 1 week apart, and received a standardized laser treatment at each visit. Group one received 200 mu g oral transmucosal fentanyl citrate at Visit 1 and placebo at Visit 2. Group 2 received the lozenges in reverse order. After each visit, each patient completed a 100-mm visual analog scale pain score and rating scale regarding systemic side effects. Results: The mean visual analog scale for patients receiving placebo was 36.4 (SD, 31.5). The mean visual analog scale for patients receiving 200 mu g oral transmucosal fentanyl citrate was 19.2 (SD, 20.5) (P = 0.0014). Overall, 4 patients (11%) reported moderate or severe adverse systemic side effects. No clinically significant changes in systemic observations or adverse events occurred. Conclusion: OTFC at a dosage of 200 mu g is an effective and convenient analgesic for use in peripheral retinal scatter photocoagulation. We found this agent to be well tolerated in the outpatient setting. However, a larger study would be required to ascertain safety across a larger population of opiate-naive patients. RETINA 29:1506-1512, 2009	[Hillier, Roxane J.] Manchester Royal Eye Hosp, Manchester M13 9WH, Lancs, England; [Hillier, Roxane J.; Aboud, Ahlam; Clark, David I.] Aintree Univ Hosp NHS Fdn Trust, Dept Ophthalmol, Liverpool L9 7AL, Merseyside, England; [Thind, Gurvinder] Aintree Univ Hosp NHS Fdn Trust, Dept Anaesthesia, Liverpool L9 7AL, Merseyside, England	Hillier, RJ (reprint author), Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9WH, Lancs, England.	roxanehillier@doctors.org.uk					Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064; Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767; Cook HL, 2002, BRIT J OPHTHALMOL, V86, P1107, DOI 10.1136/bjo.86.10.1107; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; FRIEDBERG MA, 1991, OPHTHALMIC SURG LAS, V22, P619; GERWELS JW, 1994, J DERMATOL SURG ONC, V20, P823, DOI 10.1111/j.1524-4725.1994.tb03712.x; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; Lancaster GA, 2004, J EVAL CLIN PRACT, V10, P307, DOI 10.1111/j..2002.384.doc.x; Landy SH, 2004, HEADACHE, V44, P762, DOI 10.1111/j.1526-4610.2004.04142.x; LIND GH, 1991, ANN EMERG MED, V20, P1117, DOI 10.1016/S0196-0644(05)81387-3; Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; RYSELKOVA A, 2008, AM J PUBLIC HEALTH, V98, P454; Shaiova L, 2004, J NATL MED ASSOC, V96, P984; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; Vaideanu D, 2006, BRIT J OPHTHALMOL, V90, P713, DOI 10.1136/bjo.2005.076091; Weinberger D, 2000, BRIT J OPHTHALMOL, V84, P135, DOI 10.1136/bjo.84.2.135; Wu WC, 2006, EYE, V20, P712, DOI 10.1038/sj.eye.6701989	23	1	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	NOV-DEC	2009	29	10					1506	1512		10.1097/IAE.0b013e3181ae70d4			7	Ophthalmology	Ophthalmology	519SH	WOS:000271787600018	19696704				2020-06-30	J	Andreoni, V; Hughes, JML				Andreoni, Valentina; Hughes, J. M. Lynne			Propofol and fentanyl infusions in dogs of various breeds undergoing surgery	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						dogs; fentanyl; infusion; propofol; TIVA	TOTAL INTRAVENOUS ANESTHESIA; RECOVERY CHARACTERISTICS; ANESTHETIZED DOGS; PHARMACOKINETICS; ISOFLURANE; SEVOFLURANE; GREYHOUNDS; ALFENTANIL; INHALATION; DRUGS	Objective To report the cardiovascular variables, anaesthetic effects and recovery quality of an anaesthesia technique using variable rate infusion propofol combined with constant rate infusion fentanyl in dogs undergoing elective surgery. Study design Prospective clinical trial. Animals A total of 27 dogs, aged 2.7 +/- 2.65 years and weighing 24 +/- 11 kg. Methods Following intramuscular acepromazine (0.03 or 0.05 mg kg-1) and subcutaneous carprofen (4 mg kg-1) pre-medication, anaesthesia was induced with propofol (4.0 +/- 0.5 mg kg-1) intravenously (IV). All dogs were ventilated with 100% oxygen to maintain normocapnia. Propofol was infused at 0.4 mg kg-1 minute-1 for 20 minutes and then at 0.3 mg kg-1 minute-1. If mean arterial blood pressure (MAP) decreased below 70 mmHg, propofol infusion was reduced by 0.1 mg kg-1 minute-1. Five minutes after induction of anaesthesia, fentanyl was administered (2 mu g kg-1) IV followed by the infusion at 0.5 mu g kg-1 minute-1 and atropine (40 mu g kg-1) IV. Heart rate, MAP, respiratory rate, tidal volume, end-tidal carbon dioxide, presence of reflexes, movements and recovery times and quality were recorded. Results Mean anaesthetic duration was 131 +/- 38.5 minutes. Mean heart rate peaked 10 minutes after atropine injection and gradually declined, reaching pre-anaesthetic values at 55 minutes. MAP easily was maintained above 70 mmHg. Mean times to return of spontaneous ventilation, extubation, head lift and sternal recumbency were 21 +/- 10.1, 33 +/- 14.6, 43 +/- 19.7 and 65 +/- 23.4 minutes, respectively. Recovery was smooth and quiet. The time to sternal recumbency was significantly correlated with the duration of anaesthesia and total dose of propofol; time to extubation was correlated to total dose of propofol. Conclusion and clinical relevance Propofol and fentanyl infusions provided stable cardiovascular function and satisfactory conditions for surgery. Some modifications of infusion rates are required to improve the long-recovery times.	[Andreoni, Valentina; Hughes, J. M. Lynne] Natl Univ Ireland Univ Coll Dublin, Univ Vet Hosp, UCD Vet Sci Ctr, Dublin 4, Ireland	Hughes, JML (reprint author), Natl Univ Ireland Univ Coll Dublin, Univ Vet Hosp, UCD Vet Sci Ctr, Dublin 4, Ireland.	lynne.hughes@ucd.ie	Andreoni, Valentina/AAA-3100-2019				ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; ARTRU AA, 1992, J NEUROSURG ANESTH, V4, P99, DOI 10.1097/00008506-199204000-00005; BAKER MT, 1993, ANESTH ANALG, V76, P817; Beths T, 2001, VET REC, V148, P198, DOI 10.1136/vr.148.7.198; Deryck YLJM, 1996, ANESTH ANALG, V83, P958, DOI 10.1097/00000539-199611000-00011; Godet G, 2001, ANESTH ANALG, V93, P560, DOI 10.1097/00000539-200109000-00007; HALL LW, 1987, J SMALL ANIM PRACT, V28, P623, DOI 10.1111/j.1748-5827.1987.tb01277.x; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Joubert KE, 2004, J S AFR VET ASSOC, V75, P85; Love EJ, 2007, VET REC, V161, P217, DOI 10.1136/vr.161.7.217; Mertens MJ, 2001, ANESTHESIOLOGY, V94, P949, DOI 10.1097/00000542-200106000-00006; Meurs KM, 1996, J AM ANIM HOSP ASSOC, V32, P471, DOI 10.5326/15473317-32-6-471; Murrell JC, 2005, VET REC, V156, P804, DOI 10.1136/vr.156.25.804; NOLAN A, 1993, BRIT J ANAESTH, V70, P546, DOI 10.1093/bja/70.5.546; Ozkose Z, 2001, J NEUROSURG ANESTH, V13, P296, DOI 10.1097/00008506-200110000-00003; Raisis AL, 2007, VET ANAESTH ANALG, V34, P171, DOI 10.1111/j.1467-2995.2006.00318.x; Reid J, 2007, ANIM WELFARE, V16, P97; Reid J, 1996, RES VET SCI, V61, P169, DOI 10.1016/S0034-5288(96)90095-8; ROBERTSON SA, 1992, AM J VET RES, V53, P1027; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SAWYER DC, 1991, LAB ANIM SCI, V41, P134; Sear J W, 1991, Rev Esp Anestesiol Reanim, V38, P139; Slingsby LS, 2006, VET REC, V159, P705, DOI 10.1136/vr.159.21.705; Slingsby LS, 2006, VET ANAESTH ANALG, V33, P313, DOI 10.1111/j.1467-2995.2005.00267.x; Tsai YC, 2007, J VET MED SCI, V69, P1179, DOI 10.1292/jvms.69.1179; Voss LJ, 2008, ANESTH ANALG, V107, P1689, DOI 10.1213/ane.0b013e3181852595; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009	29	17	17	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2009	36	6					523	531		10.1111/j.1467-2995.2009.00490.x			9	Veterinary Sciences	Veterinary Sciences	508BV	WOS:000270902700002	19845923				2020-06-30	J	Hung, KC				Hung, K. -C.			The possible mechanism of clonidine to suppress fentanyl-induced coughing	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter									I Shou Univ, Dept Anesthesiol, E DA Hosp, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan	Hung, KC (reprint author), I Shou Univ, Dept Anesthesiol, E DA Hosp, 1 E Da Rd, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan.	billwintw@yahoo.com.tw	Hung, Kuo-chuan/K-8345-2019	Hung, Kuo-chuan/0000-0002-4507-8085			Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; WEINGER MB, 1995, BRAIN RES, V669, P10, DOI 10.1016/0006-8993(94)01216-5; Yemen TA, 1998, ANESTHESIOLOGY, V89, P271, DOI 10.1097/00000542-199807000-00043	7	7	7	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2009	53	9					1227	1228		10.1111/j.1399-6576.2009.02027.x			2	Anesthesiology	Anesthesiology	490VV	WOS:000269537100023	19737186				2020-06-30	J	Hung, KC				Hung, K-C			Incidence of fentanyl-induced cough and injection speed	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter									I Shou Univ, Dept Anesthesiol, E DA Hosp, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan	Hung, KC (reprint author), I Shou Univ, Dept Anesthesiol, E DA Hosp, 1 E Da Rd, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan.	billwintw@yahoo.com.tw	Hung, Kuo-chuan/K-8345-2019	Hung, Kuo-chuan/0000-0002-4507-8085			BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Schapermeier U, 2008, ACTA ANAESTH SCAND, V52, P1071, DOI 10.1111/j.1399-6576.2008.01721.x; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021	5	2	2	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2009	53	9					1227	1227		10.1111/j.1399-6576.2009.02058.x			1	Anesthesiology	Anesthesiology	490VV	WOS:000269537100022	19737185				2020-06-30	J	Uvelin, A; Rakic, G				Uvelin, A.; Rakic, G.			Guidelines for prevention of fentanyl-induced cough	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter							INTRAVENOUS LIDOCAINE; BOLUS; INJECTION			Uvelin, A (reprint author), Augusta Cesarca St 11-62, Novi Sad 21000, Serbia.	auvelin@yahoo.com					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Tweed WA, 2001, ANESTH ANALG, V92, P1442	10	9	14	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2009	53	9					1228	1229		10.1111/j.1399-6576.2009.02041.x			2	Anesthesiology	Anesthesiology	490VV	WOS:000269537100024	19737187				2020-06-30	J	Pereira, LCM; Oliveira, KM; L'Abbate, GL; Sugai, R; Ferreira, JA; da Motta, LA				Modesto Pereira, Luiz Claudio; Oliveira, Karina M.; L'Abbate, Gisele L.; Sugai, Ricardo; Ferreira, Joines A.; da Motta, Luiz A.			Outcome of fully awake craniotomy for lesions near the eloquent cortex: analysis of a prospective surgical series of 79 supratentorial primary brain tumors with long follow-up	ACTA NEUROCHIRURGICA			English	Article						Awake craniotomy; Brain mapping; Cortical stimulation; Eloquent brain area; Frontal operculum; Glioma; Insula; Motor cortex; Parietal cortex; Primary brain tumor; Temporal cortex	LOW-GRADE GLIOMAS; MONITORED CONSCIOUS SEDATION; LANGUAGE LOCALIZATION; LOCAL-ANESTHESIA; ELECTRICAL STIMULATIONS; GLIOBLASTOMA-MULTIFORME; CORTICAL LOCALIZATION; SURGERY; RESECTION; AREAS	Background Despite possible advantages, few surgical series report specifically on awake craniotomy for intrinsic brain tumors in eloquent brain areas. Objectives Primary: To evaluate the safety and efficacy of fully awake craniotomy (FAC) for the resection of primary supratentorial brain tumors (PSBT) near or in eloquent brain areas (EBA) in a developing country. Secondary: To evaluate the impact of previous surgical history and different treatment modalities on outcome. Patients and methods From 1998 to 2007, 79 consecutive FACs for resection PSBT near or in EBA, performed by a single surgeon, were prospectively followed. Two groups were defined based on time period and surgical team: group A operated on from March 1998 to July 2004 without a multidisciplinary team and group B operated on from August 2004 to October 2007 in a multidisciplinary setting. For both time periods, two groups were defined: group I had no previous history of craniotomy, while group II had undergone a previous craniotomy for a PSBT. Forty-six patients were operated on in group A, 46 in group B, 49 in group I and 30 in group II. Psychological assessment and selection were obligatory. The preferred anesthetic procedure was an intravenous high-dose opioid infusion (Fentanil 50 mu g, bolus infusion until a minimum dose of 10 mu g/kg). Generous scalp and periosteous infiltrations were performed. Functional cortical mapping was performed in every case. Continuous somato-sensory evoked potentials (SSEPs) and phase reversal localization were available in 48 cases. Standard microsurgical techniques were performed and monitored by continuous clinical evaluation. Results Clinical data showed differences in time since clinical onset (p < 0.001), slowness of thought (p = 0.02) and memory deficits (p < 0.001) between study periods and also time since recent seizure onset for groups I and II (p = 0.001). Mean tumor volume was 51.2 +/- 48.7 cm(3) and was not different among the four groups. The mean extent of tumor reduction was 90.0 +/- 12.7% and was similar for the whole series. A trend toward a larger incidence of glioblastoma multiforme occurred in group B (p = 0.05) and I (p = 0.04). Recovery of previous motor deficits was observed in 75.0% of patients, while motor worsening in 8.9% of cases. Recovery of semantic language deficits, control of refractory seizures and motor worsening were statistically more frequent in group B (p = 0.01). Satisfaction with the procedure was reported by 89.9% of patients, which was similar for all groups. Clinical complications were minimal, and surgical mortality was 1.3%. Conclusions These data suggest that FAC is safe and effective for the resection of PSBT in EBA as the main technique, and in a multidisciplinary context is associated with greater clinical and physiological monitoring. The previous history of craniotomy for PSBT did not seem to influence the outcome.	[Modesto Pereira, Luiz Claudio; Oliveira, Karina M.; L'Abbate, Gisele L.; Sugai, Ricardo; Ferreira, Joines A.; da Motta, Luiz A.] Hosp Base Distrito Fed, Brasilia, DF, Brazil	Pereira, LCM (reprint author), Hosp Base Distrito Fed, Brasilia, DF, Brazil.	luizpereira@ambr.com.br					Al-Homoud S, 2004, SURG ONCOL, V13, P83, DOI 10.1016/j.suronc.2004.08.006; Ard J, 2003, J NEUROSURG ANESTH, V15, P263, DOI 10.1097/00008506-200307000-00015; Ard JL, 2005, SURG NEUROL, V63, P114, DOI 10.1016/j.surneu.2004.02.029; Bampoe J, 2000, J NEUROSURG, V93, P917, DOI 10.3171/jns.2000.93.6.0917; Bello L, 2007, NEUROSURGERY, V60, P67, DOI 10.1227/01.NEU.0000249206.58601.DE; Bello L, 2006, NEUROSURGERY, V59, P115, DOI 10.1227/01.NEU.0000219241.92246.FB; Berger MS, 2007, NEUROSURGERY, V61, P279, DOI 10.1227/01.NEU.0000255489.88321.18; Berkenstadt H, 2001, J NEUROSURG ANESTH, V13, P246, DOI 10.1097/00008506-200107000-00013; Blanshard HJ, 2001, ANESTH ANALG, V92, P89; Brell M, 2003, NEUROCIRUGIA, V14, P491; Bulsara Ketan R, 2005, Neurosurg Focus, V18, pe5, DOI 10.3171/foc.2005.18.4.6; CABANTOG AM, 1994, CAN J NEUROL SCI, V21, P213, DOI 10.1017/S0317167100041184; Cedzich C, 1996, NEUROSURGERY, V38, P962, DOI 10.1097/00006123-199605000-00023; Danks RA, 2000, J NEURO-ONCOL, V49, P131, DOI 10.1023/A:1026577518902; de Almeida AN, 2005, ARQ NEURO-PSIQUIAT, V63, P748, DOI 10.1590/S0004-282X2005000500005; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Duffau H, 1999, REV NEUROL-FRANCE, V155, P553; Duffau H, 2002, J NEUROL NEUROSUR PS, V73, P733, DOI 10.1136/jnnp.73.6.733; Duffau H, 2002, BRAIN, V125, P199, DOI 10.1093/brain/awf016; Duffau H, 2005, J NEUROL NEUROSUR PS, V76, P845, DOI 10.1136/jnnp.2004.048520; Duffau H, 2003, J NEUROSURG, V98, P764, DOI 10.3171/jns.2003.98.4.0764; Ebel H, 2000, MINIM INVAS NEUROSUR, V43, P192, DOI 10.1055/s-2000-11372; FADUL C, 1988, NEUROLOGY, V38, P1374, DOI 10.1212/WNL.38.9.1374; Farrell DF, 2007, J CLIN NEUROPHYSIOL, V24, P286, DOI 10.1097/WNP.0b013e31803bb59a; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIED I, 1994, NEUROSURGERY, V34, P815, DOI 10.1227/00006123-199405000-00005; Fukaya C, 2001, J CLIN NEUROSCI, V8, P253, DOI 10.1054/jocn.2000.0866; GALASKO D, 1990, ARCH NEUROL-CHICAGO, V47, P49, DOI 10.1001/archneur.1990.00530010061020; GUPTA DK, 2007, CLIN NEUROL NEUROSUR; HAGLUND MM, 1994, NEUROSURGERY, V34, P567, DOI 10.1227/00006123-199404000-00001; Hentschel Stephen J, 2003, Cancer Control, V10, P109; Keles GE, 2001, J NEUROSURG, V95, P735, DOI 10.3171/jns.2001.95.5.0735; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Laws E R Jr, 1995, Clin Neurosurg, V42, P480; Laws ER, 2003, J NEUROSURG, V99, P467, DOI 10.3171/jns.2003.99.3.0467; Laws ER, 2003, ACT NEUR S, V85, P47; Lincoln N B, 1982, Int Rehabil Med, V4, P114; Low D, 2007, ANN ACAD MED SINGAP, V36, P326; Lucas TH, 2004, J NEUROSURG, V101, P449, DOI 10.3171/jns.2004.101.3.0449; Lynch JC, 2004, ARQ NEURO-PSIQUIAT, V62, P507, DOI 10.1590/S0004-282X2004000300024; Mack PF, 2004, J NEUROSURG ANESTH, V16, P20, DOI 10.1097/00008506-200401000-00005; Manninen PH, 2006, ANESTH ANALG, V102, P237, DOI 10.1213/01.ANE.0000181287.86811.5C; Meyer RB, 2001, MAYO CLIN PROC, V76, P677, DOI 10.4065/76.7.677; Nomiya T, 2007, J NEUROSURG, V106, P575, DOI 10.3171/jns.2007.106.4.575; OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316; OJEMANN GA, 1978, BRAIN LANG, V6, P239, DOI 10.1016/0093-934X(78)90061-5; OJEMANN GA, 1979, J NEUROSURG, V50, P164, DOI 10.3171/jns.1979.50.2.0164; Otani N, 2005, NEUROL MED-CHIR, V45, P501, DOI 10.2176/nmc.45.501; PENFIELD W, 1986, INT ANESTHESIOL CLIN, V24, P1, DOI 10.1097/00004311-198602430-00004; Pinaud M, 2002, ARCH MAL COEUR VAISS, V95, P21; Polin RS, 2005, J NEUROSURG, V102, P276, DOI 10.3171/jns.2005.102.2.0276; SALCMAN M, 1994, NEUROSURGERY, V34, P213, DOI 10.1227/00006123-199402000-00002; SALCMAN M, 1980, NEUROSURGERY, V7, P435, DOI 10.1227/00006123-198011000-00001; SALCMAN M, 2001, BRAIN TUMORS ENCY AP, P449; SALCMAN M, 1995, BENIGN CEREBRAL GLIO, V2, P213; Sanai N, 2008, NEW ENGL J MED, V358, P18, DOI 10.1056/NEJMoa067819; Sarang A, 2003, BRIT J ANAESTH, V90, P161, DOI 10.1093/bja/aeg037; Sawaya R, 1998, NEUROSURGERY, V42, P1044, DOI 10.1097/00006123-199805000-00054; Schramm J, 2007, NEUROSURGERY, V60, P285, DOI 10.1227/01.NEU.0000249281.69384.D7; Schreuders T A, 1996, J Hand Ther, V9, P303; Schwab R.S., 1969, 3 S PARK DIS, P152; Serletis D, 2007, J NEUROSURG, V107, P1, DOI 10.3171/JNS-07/07/0001; Souter MJ, 2007, J NEUROSURG ANESTH, V19, P38, DOI 10.1097/01.ana.0000211027.26550.24; Taylor MD, 1999, J NEUROSURG, V90, P35, DOI 10.3171/jns.1999.90.1.0035; Toms SA, 1999, J NEURO-ONCOL, V42, P215, DOI 10.1023/A:1006121817861; Tybor Krzysztof, 2003, Neurol Neurochir Pol, V37, P89; VANDERPLOEG RJO, 1984, J NEUROL, V231, P200; Whittle IR, 2004, J NEUROL NEUROSUR PS, V75, P31, DOI 10.1136/jnnp.2004.040501	68	36	40	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	OCT	2009	151	10					1215	1230		10.1007/s00701-009-0363-9			16	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	505YP	WOS:000270738500005	19730779				2020-06-30	J	Knych, HKD; Steffey, EP; Mama, KR; Stanley, SD				Knych, Heather K. DiMaio; Steffey, Eugene P.; Mama, Khursheed R.; Stanley, Scott D.			Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							GENERAL-ANESTHESIA; ALFENTANIL; HALOTHANE; REDUCTION; ENFLURANE; MORPHINE; PROPOFOL; POTENCY	Objective-To verify the isoflurane anesthetic minimum alveolar concentration (MAC)-sparing effect of a previously administered target plasma fentanyl concentration of 16 ng/mL and characterize an anticipated further sparing in isoflurane MAC associated with higher target plasma fentanyl concentrations. Animals-8 horses. Procedures-Horses were assigned 2 of 3 target plasma fentanyl concentrations (16, 24, and 32 ng/mL), administered in ascending order. Following determination of baseline MAC, horses received a loading dose of fentanyl followed by a constant rate infusion; MAC determination was performed in triplicate at baseline and at each fentanyl concentration. Venous blood samples were collected throughout the study for determination of actual plasma fentanyl concentrations. Recovery from anesthesia was monitored, and behaviors were rated as excellent, good, fair, or poor. Results-Mean +/- SD fentanyl plasma concentrations were 13.9 +/- 2.6 ng/mL, 20.1 +/- 3.6 ng/mL, and 24.1 +/- 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively. The corresponding changes in the MAC of isoflurane were -3.28%, -6.23%, and +1.14%. None of the changes were significant. Recovery behavior was variable and included highly undesirable, potentially injurious excitatory behavior. Conclusions and Clinical Relevance-Results of the study did not verify an isoflurane-sparing effect of fentanyl at a plasma target concentration of 16 ng/mL. Furthermore, a reduction in MAC was not detected at higher fentanyl concentrations. Overall, results did not support the routine use of fentanyl as an anesthetic adjuvant in adult horses. (Am J Vet Res 2009;70:1193-1200)	[Knych, Heather K. DiMaio; Steffey, Eugene P.; Stanley, Scott D.] Univ Calif Davis, Sch Vet Med, Calif Anim Hlth & Food Safety Lab, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA; [Knych, Heather K. DiMaio; Steffey, Eugene P.; Stanley, Scott D.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Mama, Khursheed R.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA	Knych, HKD (reprint author), Univ Calif Davis, Sch Vet Med, Calif Anim Hlth & Food Safety Lab, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA.	hkknych@ucdavis.edu					ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1997, AM J VET RES, V58, P1274; JOHNSTON GM, 1995, EQUINE VET J, V27, P193, DOI 10.1111/j.2042-3306.1995.tb03062.x; Mama KR, 1996, AM J VET RES, V57, P512; MAMA KR, 1995, VET SURG, V24, P188, DOI 10.1111/j.1532-950X.1995.tb01317.x; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; PASCOE PJ, 1993, AM J VET RES, V54, P1327; STEFFEY EP, 1977, AM J VET RES, V38, P1037; STEFFEY EP, 1994, J VET PHARMACOL THER, V17, P202, DOI 10.1111/j.1365-2885.1994.tb00234.x; STEFFEY EP, 1978, AM J VET RES, V39, P611; Steffey EP, 2003, AM J VET RES, V64, P166, DOI 10.2460/ajvr.2003.64.166; STEFFEY EP, 1979, AM J VET RES, V40, P1646; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Thomasy SM, 2008, J ANAL TOXICOL, V32, P754, DOI 10.1093/jat/32.9.754; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23; WHITEHAIR KJ, 1993, AM J VET RES, V54, P1693	18	15	15	0	4	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	OCT	2009	70	10					1193	1200		10.2460/ajvr.70.10.1193			8	Veterinary Sciences	Veterinary Sciences	503YV	WOS:000270579600004	19795933				2020-06-30	J	Sen, H; Kulahci, Y; Bicerer, E; Ozkan, S; Dagli, G; Turan, A				Sen, Huseyin; Kulahci, Yalcin; Bicerer, Enis; Ozkan, Sezai; Dagli, Guner; Turan, Alparslan			The Analgesic Effect of Paracetamol When Added to Lidocaine for Intravenous Regional Anesthesia	ANESTHESIA AND ANALGESIA			English	Article							CANNABINOID RECEPTORS; NEUROPATHIC PAIN; PRILOCAINE; ACETAMINOPHEN; KETOROLAC	BACKGROUND: In this study, we evaluated the effect of paracetamol on sensory and motor block onset time, tourniquet pain, and postoperative analgesia, when added to lidocaine in IV regional anesthesia (IVRA). METHODS: Sixty patients undergoing hand surgery were randomly and blindly. divided into three groups. All groups received IVRA lidocaine (3 mg/kg) diluted with saline to a total volume of 40 mL. Group 1 received IVRA lidocaine plus IV saline, Group 2 received IVRA lidocaine and paracetamol (300 mg) admixture plus IV saline, and Group 3 received IVRA lidocaine plus IV paracetamol (300 mg). Sensory and motor block onset time, tourniquet pain, and analgesic use were assessed during operation. After tourniquet deflation, visual analog scale (VAS) scores at 1, 2, 4, 6, 12, and 24 h, the time to first analgesic requirement, total analgesic consumption in first 24 h, and side effects were noted. RESULTS: Onset of motor block was shorter and recovery of motor and sensory block was significantly longer in Group 2 (P < 0.05). Intraoperative VAS scores at intraoperative 20, 30, and 40 min were significantly lower in Group 2 (P < 0.05). Intraoperative fentanyl consumption (78 +/- 12, 58 +/- 14, 78 +/- 11 mu g, respectively) and the number of patients who required fentanyl for tourniquet pain (13 patients, 3 patients, 9 patients, respectively) were significantly less in Group 2 (P < 0.05). Time to postoperative fentanyl administration was also prolonged (15 +/- 6, 25 +/- 5, 15 +/- 4 min, respectively) in Group 2 (P < 0.05). The quality of surgical anesthesia was better in Group 2 (P < 0.05). Postoperative VAS scores and time of initial analgesic requirement were similar among groups; however, the total amount of diclophenac use was less in Group 2 (P < 0.05). CONCLUSION: The addition of paracetamol during IVRA with lidocaine decreased tourniquet pain, increased anesthesia quality, and decreased postoperative analgesic consumption. (Anesth Analg 2009;109:1327-30)	[Sen, Huseyin; Bicerer, Enis; Ozkan, Sezai; Dagli, Guner] Haydarpasa Training Hosp Uskudar, Gulhane Mil Med Acad, Dept Anesthesiol & Reanimat, Istanbul, Turkey; [Kulahci, Yalcin] Haydarpasa Training Hosp Uskudar, Gulhane Mil Med Acad, Dept Plast & Reconstruct Surg, Istanbul, Turkey; [Turan, Alparslan] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA; [Turan, Alparslan] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA	Turan, A (reprint author), Univ Hosp, Dept Anesthesiol & Perioperat Med, 530 S Jackson St, Louisville, KY 40202 USA.	alparslanturan@yahoo.com	Kulahci, Yalcin/W-5086-2018	Kulahci, Yalcin/0000-0002-6836-2732	institutional and departmental sources at GATA Haydarpacsa Egitim Hastanesi	Supported by institutional and departmental sources at GATA Haydarpacsa Egitim Hastanesi.	ACALOVSCHI I, 1995, ANESTH ANALG, V81, P539, DOI 10.1097/00000539-199509000-00020; Anderson BJ, 2008, PEDIATR ANESTH, V18, P915, DOI 10.1111/j.1460-9592.2008.02764.x; Bertolini A, 2006, CNS DRUG REV, V12, P250, DOI 10.1111/j.1527-3458.2006.00250.x; Canbay O, 2008, BRIT J ANAESTH, V100, P95, DOI 10.1093/bja/aem301; Chan VWS, 2001, ANESTH ANALG, V93, P1181, DOI 10.1097/00000539-200111000-00025; Choyce A, 2002, CAN J ANAESTH, V49, P32, DOI 10.1007/BF03020416; Corpataux JB, 1997, ANESTH ANALG, V84, P1081, DOI 10.1097/00000539-199705000-00023; Dania M, 2007, EUR J PHARMACOL, V573, P214, DOI 10.1016/j.ejphar.2007.07.012; Graham Garry G, 2005, Am J Ther, V12, P46, DOI 10.1097/00045391-200501000-00008; Herrero JF, 2003, CNS DRUG REV, V9, P227; Jones NC, 1996, ANAESTHESIA, V51, P446, DOI 10.1111/j.1365-2044.1996.tb07789.x; Mitrirattanakul S, 2006, PAIN, V126, P102, DOI 10.1016/j.pain.2006.06.016; Ottani A, 2006, EUR J PHARMACOL, V531, P280, DOI 10.1016/j.ejphar.2005.12.015; Perlas A, 2003, REGION ANESTH PAIN M, V28, P98, DOI 10.1053/rapm.2003.50036; REUBEN SS, 1995, ANESTH ANALG, V81, P110, DOI 10.1097/00000539-199507000-00022; Steinberg RB, 1998, ANESTH ANALG, V86, P791, DOI 10.1097/00000539-199804000-00021; Turan A, 2002, ANESTH ANALG, V95, P1419, DOI 10.1097/00000539-200211000-00058	17	27	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2009	109	4					1327	1330		10.1213/ane.0b013e3181b0fedb			4	Anesthesiology	Anesthesiology	499HL	WOS:000270209100052	19762765				2020-06-30	J	Fahy, CJ				Fahy, Cormac J.			Blind Enough? Sham Subtenon Block in Pediatric Patients	ANESTHESIA AND ANALGESIA			English	Letter							SURGERY		Womens & Childrens Hosp, Dept Childrens Anaesthesia, Adelaide, SA, Australia	Fahy, CJ (reprint author), Womens & Childrens Hosp, Dept Childrens Anaesthesia, Adelaide, SA, Australia.	cormac.fahy@cywhs.sa.gov.au					Ghai B, 2009, ANESTH ANALG, V108, P1132, DOI 10.1213/ane.0b013e318198a3fd; Jaycock PD, 2001, EYE, V15, P583, DOI 10.1038/eye.2001.189; Ruschen H, 2003, ANESTH ANALG, V96, P273, DOI 10.1213/01.ANE.0000039318.12705.8A; Steib A, 2005, REGION ANESTH PAIN M, V30, P478, DOI 10.1016/j.rapm.2005.04.011; World Medical Association, DECL HELS ETH PRINC	5	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2009	109	4					1349	1349		10.1213/ane.0b013e3181b2a72b			1	Anesthesiology	Anesthesiology	499HL	WOS:000270209100063	19762772				2020-06-30	J	van der Lee, R; Ceelie, I; de Wildt, SN				van der Lee, Robin; Ceelie, Ilse; de Wildt, Saskia N.			Morphine-Induced Muscle Rigidity in a Term Neonate	ANNALS OF PHARMACOTHERAPY			English	Article						adverse event; laryngospasm; morphine; muscle rigidity; naloxone	FENTANYL; INFANTS	OBJECTIVE: To describe a potentially fatal adverse drug event after administration of morphine to a term neonate. CASE SUMMARY: A 2-day-old term neonate experienced generalized muscle rigidity and laryngeal spasm resulting in acute respiratory failure on 2 separate occasions after morphine administration. The first occasion was after administration of bolus doses of fentanyl and morphine 100 mu g/kg in the operating theater; administration of intravenous propofol 2 mg/kg resulted in relief of muscle rigidity. The second occasion occurred a few hours later, when the patient received a continuous infusion of morphine 4.4 mu g/kg/h in the intensive care unit and experienced generalized muscle rigidity with respiratory compromise. The opioid antagonist naloxone 30 mu g/kg was administered intravenously, which immediately resulted in a patent airway and spontaneous breathing. An objective causality assessment using the Naranjo probability scale revealed that the likelihood of morphine causing the patient's muscle rigidity on the second occasion was highly probable to definite. It is not clear whether the first occurrence of muscle rigidity was morphine-induced. DISCUSSION: We searched PubMed and EMBASE (through August 2009) for previous reports of morphine-related muscle rigidity and/or laryngeal spasm, using the search terms (muscle rigidity OR chest rigidity OR laryngeal spasm) AND (morphine OR fentanyl OR opioid). Sudden onset of muscle rigidity and laryngeal spasm is described in the literature as a rare but serious adverse event after infusion of fentanyl and similar opioids in both adults and young infants. However, there are no reports of this potentially fatal adverse event after administration of morphine. To our knowledge this is the first case reported of life-threatening muscle rigidity and laryngeal spasm after therapeutic doses of morphine in humans. CONCLUSIONS: A serious adverse event consisting of generalized muscle rigidity and laryngospasm can occur after bolus administration of morphine as well as during continuous infusion. Clinicians should be aware of this possibility.	[van der Lee, Robin; Ceelie, Ilse; de Wildt, Saskia N.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Surg & Intens Care, NL-3015 GJ Rotterdam, Netherlands	van der Lee, R (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Surg & Intens Care, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.	r.vanderlee@vumc.nl	de Wildt, Saskia/A-9589-2008	de Wildt, Saskia/0000-0002-0502-0647			Baris S, 2000, PAEDIATR ANAESTH, V10, P684, DOI 10.1111/j.1460-9592.2000.0566d.x; Bolisetty S, 1999, INTENS CARE MED, V25, P1337, DOI 10.1007/s001340051074; Deshpande G, 2009, EUR J PEDIATR, V168, P115, DOI 10.1007/s00431-008-0720-3; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; HARTLEY R, 1993, ARCH DIS CHILD-FETAL, V69, P55, DOI 10.1136/adc.69.1_Spec_No.55; LEMMEN RJ, 1996, EUR J PEDIATR, V15, P1067; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Vanlersberghe C., 2008, V182, P227, DOI 10.1007/978-3-540-74806-9_11; WEINGER MB, 1995, BRAIN RES, V669, P10, DOI 10.1016/0006-8993(94)01216-5	9	9	10	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	OCT	2009	43	10					1724	1726		10.1345/aph.1M268			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	503YR	WOS:000270579100021	19755623				2020-06-30	J	Love, TM; Stohler, CS; Zubieta, JK				Love, Tiffany M.; Stohler, Christian S.; Zubieta, Jon-Kar			Positron Emission Tomography Measures of Endogenous Opioid Neurotransmission and Impulsiveness Traits in Humans	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							MESSENGER-RNA EXPRESSION; STRESS-INDUCED SENSITIZATION; NUCLEUS-ACCUMBENS; VENTRAL PALLIDUM; INDIVIDUAL-DIFFERENCES; DOPAMINE RELEASE; AFFECTIVE DIMENSIONS; DECISION-MAKING; AMPHETAMINE; COCAINE	Context: The endogenous opioid system and opioid mu receptors (mu-receptors) are known to interface environmental events, positive (eg, relevant emotional stimuli) and negative (eg, stressors), with pertinent behavioral responses and to regulate motivated behavior. Objective: To examine the degree to which trait impulsiveness (the tendency to act on cravings and urges rather than to delay gratification) is predicted by baseline mu-receptor availability or the response of this system to a standardized, experientially matched stressor. Design, Setting, and Patients: Nineteen young healthy male volunteers completed a personality questionnaire (NEO Personality Inventory, Revised) and underwent positron emission tomography scans with the mu-receptor selective radiotracer carfentanil labeled with carbon 11. Measures of receptor concentrations were obtained at rest and during receipt of an experimentally maintained pain stressor of matched intensity between subjects. Main Outcome Measures: Baseline receptor levels and stress-induced activation of mu-opioid system neurotransmission compared between subjects scoring above and below the population median on the NEO Personality Inventory, Revised, impulsiveness subscale and the orthogonal dimension (deliberation) expected to interact with it. Results: High impulsiveness and low deliberation scores were associated with significantly higher regional mu-receptor concentrations and greater stress-induced endogenous opioid system activation. Effects were obtained in the prefrontal and orbitofrontal cortices, anterior cingulate, thalamus, nucleus accumbens, and basolateral amygdala-all regions involved in motivated behavior and the effects of drugs of abuse. Availability of the mu-receptor and the magnitude of stress-induced endogenous opioid activation in these regions accounted for 17% to 49% of the variance in these personality traits. Conclusions: Individual differences in the function of the endogenous mu-receptor system predict personality traits that confer vulnerability to or resiliency against risky behaviors such as the predisposition to develop substance use disorders. These personality traits are also implicated in psychopathological states (eg, personality disorders) in which variations in the function of this neurotransmitter system also may play a role.	[Love, Tiffany M.; Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Stohler, Christian S.] Univ Maryland, Sch Dent, Baltimore, MD 21201 USA	Zubieta, JK (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	STOHLER, CHRISTIAN/AAQ-7539-2020; Love, Tiffany/W-8427-2019	Love, Tiffany/0000-0001-9299-3190	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA 016423]	This study was supported by grant R01 DA 016423 from the National Institute on Drug Abuse.	Alessi SM, 2003, BEHAV PROCESS, V64, P345, DOI 10.1016/S0376-6357(03)00150-5; *AM PSYCH ASS TASK, 2000, DIAGN STAT MAN MENT; AUSTIN MC, 1991, BRAIN RES, V542, P123, DOI 10.1016/0006-8993(91)91005-L; Badiani A, 1999, BEHAV BRAIN RES, V103, P203, DOI 10.1016/S0166-4328(99)00041-8; Badiani A, 1998, J NEUROSCI, V18, P10579; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B; BRY BH, 1982, AM J COMMUN PSYCHOL, V10, P265, DOI 10.1007/BF00896494; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Cardinal RN, 2001, SCIENCE, V292, P2499, DOI 10.1126/science.1060818; CHEN JF, 1993, NEUROSCIENCE, V54, P669, DOI 10.1016/0306-4522(93)90238-B; Clark L, 2006, BIOL PSYCHIAT, V60, P515, DOI 10.1016/j.biopsych.2005.11.007; Costa P. T., 1992, PSYCHOL ASSESSMENT, V4, P5, DOI [DOI 10.1037/1040-3590.4.1.5, 10.1037/1040-3590.4.1.5]; Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073; Day HEW, 2001, J NEUROSCI, V21, P732, DOI 10.1523/JNEUROSCI.21-02-00732.2001; Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305; DEROCHE V, 1993, BRAIN RES, V623, P341, DOI 10.1016/0006-8993(93)91451-W; DEROCHE V, 1994, BRAIN RES, V640, P136, DOI 10.1016/0006-8993(94)91867-8; DEROCHE V, 1992, BRAIN RES, V598, P343, DOI 10.1016/0006-8993(92)90205-N; Diergaarde L, 2008, BIOL PSYCHIAT, V63, P301, DOI 10.1016/j.biopsych.2007.07.011; Dixon MR, 2003, J APPL BEHAV ANAL, V36, P449, DOI 10.1901/jaba.2003.36-449; Dolcos F, 2004, NEUROIMAGE, V23, P64, DOI 10.1016/j.neuroimage.2004.05.015; FAHY T, 1993, BRIT J PSYCHIAT, V162, P193, DOI 10.1192/bjp.162.2.193; Fischer S, 2004, PSYCHOL ADDICT BEHAV, V18, P269, DOI 10.1037/0893-164X.18.3.269; Fischer S, 2004, PERS INDIV DIFFER, V36, P527, DOI 10.1016/S0191-8869(03)00112-0; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; GEORGE SR, 1987, PEPTIDES, V8, P487, DOI 10.1016/0196-9781(87)90014-3; Giordano LA, 2002, PSYCHOPHARMACOLOGY, V163, P174, DOI 10.1007/s00213-002-1159-2; Gong WH, 1996, BRAIN RES, V707, P64, DOI 10.1016/0006-8993(95)01222-2; HABER SN, 1985, J COMP NEUROL, V235, P322, DOI 10.1002/cne.902350304; HIROI N, 1993, NEUROSCI LETT, V156, P9, DOI 10.1016/0304-3940(93)90426-L; INNIS RB, 1992, SYNAPSE, V10, P177, DOI 10.1002/syn.890100302; JOHNSON PI, 1993, NEUROPHARMACOLOGY, V32, P1305, DOI 10.1016/0028-3908(93)90025-X; Kabbaj M, 2001, PSYCHOPHARMACOLOGY, V158, P382, DOI 10.1007/s002130100918; KAGAN J, 1988, SCIENCE, V240, P167, DOI 10.1126/science.3353713; Kalivas PW, 1999, ANN NY ACAD SCI, V877, P64, DOI 10.1111/j.1749-6632.1999.tb09261.x; Kelley AE, 2005, PHYSIOL BEHAV, V86, P773, DOI 10.1016/j.physbeh.2005.08.066; KHACHATURIAN H, 1982, BRAIN RES BULL, V9, P441, DOI 10.1016/0361-9230(82)90154-X; Kieres AK, 2004, PSYCHOPHARMACOLOGY, V173, P167, DOI 10.1007/s00213-003-1697-2; Krueger THC, 2005, NEUROPSYCHOBIOLOGY, V52, P206, DOI 10.1159/000089004; Laakso A, 2003, AM J PSYCHIAT, V160, P904, DOI 10.1176/appi.ajp.160.5.904; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Lucas LR, 1998, EUR J NEUROSCI, V10, P3153, DOI 10.1046/j.1460-9568.1998.00321.x; Madden GJ, 1997, EXP CLIN PSYCHOPHARM, V5, P256, DOI 10.1037/1064-1297.5.3.256; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; MANSOUR A, 1990, PROG CLIN BIOL RES, V328, P227; Marinelli M, 2000, J NEUROSCI, V20, P8876; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MOGENSON GJ, 1991, ADV EXP MED BIOL, V295, P267; NAPIER TC, 1992, NEUROPHARMACOLOGY, V31, P1127, DOI 10.1016/0028-3908(92)90009-E; Napier TC, 1999, ANN NY ACAD SCI, V877, P176, DOI 10.1111/j.1749-6632.1999.tb09268.x; Narendran R, 2004, SYNAPSE, V52, P188, DOI 10.1002/syn.20013; Oswald LM, 2007, NEUROIMAGE, V36, P153, DOI 10.1016/j.neuroimage.2007.01.055; Pecina S, 2005, J NEUROSCI, V25, P11777, DOI 10.1523/JNEUROSCI.2329-05.2005; Perry JL, 2008, EXP CLIN PSYCHOPHARM, V16, P165, DOI 10.1037/1064-1297.16.2.165; Piazza PV, 2000, J NEUROSCI, V20, P4226; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Reuter J, 2005, NAT NEUROSCI, V8, P147, DOI 10.1038/nn1378; Rouge-Pont F, 1998, EUR J NEUROSCI, V10, P3903, DOI 10.1046/j.1460-9568.1998.00438.x; ROUGEPONT F, 1995, J NEUROSCI, V15, P7189; ROUGEPONT F, 1993, BRAIN RES, V602, P169, DOI 10.1016/0006-8993(93)90260-T; Sesia T, 2008, EXP NEUROL, V214, P135, DOI 10.1016/j.expneurol.2008.07.015; Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917; Smith GT, 2007, ASSESSMENT, V14, P155, DOI 10.1177/1073191106295527; Smith KS, 2007, J NEUROSCI, V27, P1594, DOI 10.1523/JNEUROSCI.4205-06.2007; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; Spencer TJ, 2002, J CLIN PSYCHIAT, V63, P3; Steiner H, 1998, EXP BRAIN RES, V123, P60, DOI 10.1007/s002210050545; Stohler CS, 1999, PAIN, V79, P165, DOI 10.1016/S0304-3959(98)00171-7; Swanson JM, 1998, LANCET, V351, P429, DOI 10.1016/S0140-6736(97)11450-7; THIERRY AM, 1976, NATURE, V263, P242, DOI 10.1038/263242a0; Tom SM, 2007, SCIENCE, V315, P515, DOI 10.1126/science.1134239; UNTERWALD EM, 1989, BRAIN RES, V505, P111, DOI 10.1016/0006-8993(89)90120-0; UNTERWALD EM, 1992, BRAIN RES, V584, P314, DOI 10.1016/0006-8993(92)90912-S; UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018; Uslaner J, 2001, BRAIN RES, V920, P106, DOI 10.1016/S0006-8993(01)03040-2; Vogt LJ, 2001, J PHARMACOL EXP THER, V299, P840; Volkow ND, 2004, NEUROPHARMACOLOGY, V47, P3, DOI 10.1016/j.neuropharm.2004.07.019; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Winstanley CA, 2005, NEUROPSYCHOPHARMACOL, V30, P669, DOI 10.1038/sj.npp.1300610; ZHANG X, 1993, IEEE T BIO-MED ENG, V40, P344, DOI 10.1109/10.222327; Zouk H, 2006, J AFFECT DISORDERS, V92, P195, DOI 10.1016/j.jad.2006.01.016; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	89	64	64	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	OCT	2009	66	10					1124	1134		10.1001/archgenpsychiatry.2009.134			11	Psychiatry	Psychiatry	502YE	WOS:000270496100010	19805703	Green Accepted, Bronze			2020-06-30	J	Lesage, S; Drolet, P; Donati, F; Racine, S; Fortier, LP; Audy, D				Lesage, Sandra; Drolet, Pierre; Donati, Francois; Racine, Sebastien; Fortier, Louis-Philippe; Audy, Daniel			Low-dose fentanyl-midazolam combination improves sevoflurane induction in adults	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							LARYNGEAL MASK AIRWAY; INHALATION INDUCTION; TRACHEAL INTUBATION; VITAL CAPACITY; ANESTHETIC INDUCTION; INHALED INDUCTION; NITROUS-OXIDE; PROPOFOL; INSERTION; REMIFENTANIL	We investigated the effects of a combination of low-dose fentanyl-midazolam premedication on the speed of inhaled induction with sevoflurane and ProSeal (TM) laryngeal mask airway (PLMA) insertion conditions. Eighty adult patients undergoing elective surgery were randomized in a double-blind fashion to receive either a normal saline placebo (Group PLAC) or a fentanyl 0.6 mu g center dot A kg(-1) and midazolam 9 mu g center dot A kg(-1) premedication (Group FM) 5 min before tidal volume sevoflurane 8%/O(2) induction. Anxiety levels, times to loss of eyelash reflex (LER) and PLMA insertion, and cardiorespiratory data were recorded. Times to LER (Group PLAC: 66 +/- A 34 sec vs Group FM: 47 +/- A 18 sec, P = 0.0027, difference = 19 sec: 95% confidence interval [CI] 7-31 sec) and to PLMA insertion (Group PLAC: 186 +/- A 80 sec vs Group FM: 119 +/- A 44 sec, P < 0.0001, difference = 68 sec: 95% CI 39-97 sec) were shorter following FM. After PLMA insertion, end-tidal sevoflurane concentration (EtSevo) was lower and end-tidal CO(2) (EtCO(2)) was higher following FM. Respiratory rate (RR) was lower with FM, but there was no difference regarding tidal volume. Adverse events, such as movements and apnea, occurred more often in Group PLAC. Systolic blood pressure (SBP) and heart rate (HR) during induction were both lower with FM. Anxiety level after premedication was lower following FM administration. All participants remembered the face mask being applied in Group PLAC vs 69% in Group FM, P < 0.0001. Administration of a low-dose fentanyl-midazolam combination prior to sevoflurane induction decreases time to LER and allows for more rapid and less eventful PLMA insertion. Both SBP and HR were lower when premedication was administered. Patients receiving premedication were less anxious and less likely to remember the face mask. However, premedication was associated with a lower RR and increased EtCO(2) values following PLMA insertion, in spite of lower EtSevo concentrations. (ClinicalTrials.gov ID NCT00723164).	[Lesage, Sandra; Drolet, Pierre; Donati, Francois; Racine, Sebastien; Fortier, Louis-Philippe; Audy, Daniel] Univ Montreal, Dept Anesthesiol, Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada	Lesage, S (reprint author), Univ Montreal, Dept Anesthesiol, Hop Maison Neuve Rosemont, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	sandra.lesage@umontreal.ca					Baker CE, 1999, ANAESTHESIA, V54, P841; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; BRAIN AIJ, 1993, INTAVENT LARYNGEAL M, P7; Cardinal V, 2004, CAN J ANAESTH, V51, P806, DOI 10.1007/BF03018453; Ganatra SB, 2002, EUR J ANAESTH, V19, P371, DOI 10.1017/S0265021502000601; Hall JE, 1997, ANAESTHESIA, V52, P410, DOI 10.1111/j.1365-2044.1997.091-az0086.x; Hattori J, 2001, J Anesth, V15, P117, DOI 10.1007/s005400170041; INAGAKI Y, 1993, ANESTH ANALG, V76, P613; Joo HS, 2000, ANESTH ANALG, V91, P213, DOI 10.1097/00000539-200007000-00040; Joo HS, 2001, CAN J ANAESTH, V48, P646, DOI 10.1007/BF03016197; Katoh T, 1999, BRIT J ANAESTH, V82, P561; KELLY RE, 1993, ANESTH ANALG, V77, P540; Kurdi O, 2001, BRIT J ANAESTH, V87, P943; Le May S, 1999, ANESTH ANALG, V89, P255, DOI 10.1097/00000539-199907000-00047; Meaudre E, 2004, EUR J ANAESTH, V21, P793, DOI 10.1017/S0265021504000079; Muzi M, 1996, ANESTHESIOLOGY, V85, P536, DOI 10.1097/00000542-199609000-00012; Muzi M, 1997, ANESTH ANALG, V85, P1143, DOI 10.1097/00000539-199711000-00034; Nathan N, 2004, ANN FR ANESTH, V23, P884, DOI 10.1016/j.annfar.2004.07.017; Nathan N, 2004, CAN J ANAESTH, V51, P382, DOI 10.1007/BF03018244; Nishiyama T, 2002, J CLIN ANESTH, V14, P290, DOI 10.1016/S0952-8180(02)00361-6; Pancaro C, 2005, CAN J ANAESTH, V52, P591, DOI 10.1007/BF03015767; Philip BK, 1999, ANESTH ANALG, V89, P623, DOI 10.1097/00000539-199909000-00014; Plastow SE, 2000, ANAESTHESIA, V55, P475, DOI 10.1046/j.1365-2044.2000.01268.x; Siau C, 2002, J CLIN ANESTH, V14, P218, DOI 10.1016/S0952-8180(02)00349-5; Siddik-Sayyid SM, 2005, ANESTH ANALG, V100, P1204, DOI 10.1213/01.ANE.0000148166.29749.3B; Sivalingam P, 1999, ANAESTHESIA, V54, P271, DOI 10.1046/j.1365-2044.1999.00663.x; Ti LK, 1999, ANESTH ANALG, V88, P908, DOI 10.1097/00000539-199904000-00041; Wang J, 1998, BRIT J ANAESTH, V81, P994; Yogendran S, 2005, CAN J ANAESTH, V52, P45, DOI 10.1007/BF03018579	29	6	7	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	OCT	2009	56	10					733	739		10.1007/s12630-009-9150-6			7	Anesthesiology	Anesthesiology	498UD	WOS:000270168700004	19641980	Bronze			2020-06-30	J	Fujii, Y; Itakura, M				Fujii, Yoshitaka; Itakura, Michiyo			A Comparison of Pretreatment With Fentanyl and Lidocaine Preceded by Venous Occlusion for Reducing Pain on Injection of Propofol: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study in Adult Japanese Surgical Patients	CLINICAL THERAPEUTICS			English	Article						complications; pain; propofol LCT; fentanyl; lidocaine	PREVENTION; PHARMACOKINETICS	Background: Pain on injection is a recognized adverse effect of propofol, an agent used to induce general anesthesia in surgical patients. Pretreatment with fentanyl has been reported to be effective in reducing propofol-induced pain. Objective: The aim of this study was to compare the efficacy of intravenous pretreatment with fentanyl 50 mu g, fentanyl 100 mu g, and lidocaine 40 mg, preceded by venous occlusion, for reducing pain on injection of propofol in adult Japanese surgical patients. Methods: This was a prospective, randomized, double-blind, placebo-controlled study. Adult Japanese surgical patients were randomized to 1 of 4 groups to receive intravenous fentanyl 50 mu g, fentanyl 100 mu g, lidocaine 40 mg, or placebo (0.9% isotonic saline). The drug administration was preceded by manual venous occlusion with a rubber tourniquet for 1 minute, followed by administering propofol 0.5 mg/kg injected into the largest dorsal vein of the hand through a 20-gauge intravenous cannula at the rate of 10 mg/sec. Pain on injection of propofol was assessed by an investigator who was blinded to group assignment. Patients were interviewed to assess pain intensity on injection using a 4-point verbal rating scale (0 = none; 1. = mild; 2 = moderate; and 3 = severe). Incidence and severity of pain were determined in each of the 4 study groups. Adverse events related to the study drug were recorded before the induction of anesthesia and after surgery. Patients were monitored for adverse events for 24 hours following surgery. Results: A total of 120 patients (70 men and 50 women; mean [SDI age, 44 [111 years; height, 160 [71 cm; weight, 56 [10] kg) completed the study. Each group comprised 30 patients. No significant between-group differences in demographic characteristics were found. The overall incidence of propofol-Induced pain was 77% (23/30 patients) with fentanyl 50 mu g (P = NS), 37% (11/30 patients) with fentanyl 100 mu g (P = 0.001), and 33% (10/30 patients) with lidocaine 40 mg (P = 0.001) compared with 83% (25/30 patients) with placebo. The median pain score was lower in patients who received fentanyl 50 mu g (1; P = NS), fentanyl 100 mu g (0; P = 0.001), or lidocaine 40 mg (0; P = 0.001) than in those who received placebo (2). The incidence and severity of pain were significantly different between the fentanyl 50-mu g and 100-mu g groups (incidence, P = 0.002; severity, P = 0.001). However, there was no significant difference in the incidence and severity of such pain between the fentanyl 100-mu g and lidocaine 40-mg groups. Both study drugs were well tolerated. Conclusions: Preceded by venous occlusion for 1. minute, fentanyl 100 mu g was not significantly different from lidocaine 40 mg in reducing pain during injection of propofol in these adult Japanese surgical patients. Fentanyl 50 mu g was ineffective in reducing such pain compared with placebo. (Clin Ther. 2009;3 1: 2107-2112) (C) 2009 Excerpta Medica Inc.	[Fujii, Yoshitaka] Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, Tokyo 1438541, Japan; [Itakura, Michiyo] Ushiku Aiwa Gen Hosp, Dept Anesthesiol, Ibaraki, Japan	Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, 6-11-1 Ohmori Nishi, Tokyo 1438541, Japan.	yfujii@med.toho-u.ac.jp					Auerswald K, 2005, ANASTH INTENSIV NOTF, V40, P259, DOI 10.1055/s-2005-861353; Doenicke AW, 1997, ANESTH ANALG, V85, P1399, DOI 10.1097/00000539-199712000-00040; Fujii Y, 2005, CAN J ANAESTH, V52, P474, DOI 10.1007/BF03016525; Fujii Y, 2007, CLIN THER, V29, P856, DOI 10.1016/j.clinthera.2007.05.019; HELMERS JH, 1990, CAN J ANAESTH, V32, P267; HYNYNEN M, 1985, ACTA ANAESTH SCAND, V29, P651, DOI 10.1111/j.1399-6576.1985.tb02274.x; KING SY, 1992, ANESTH ANALG, V74, P246, DOI 10.1213/00000539-199202000-00013; Kobayashi Y, 1998, Masui, V47, P963; Liaw WJ, 1999, ACTA ANAESTH SCAND, V43, P24, DOI 10.1034/j.1399-6576.1999.430106.x; Liljeroth E, 2001, ACTA ANAESTH SCAND, V45, P839, DOI 10.1034/j.1399-6576.2001.045007839.x; Macario A, 1999, ANESTH ANALG, V88, P1085, DOI 10.1097/00000539-199905000-00023; MANGAR D, 1992, ANESTH ANALG, V74, P250, DOI 10.1213/00000539-199202000-00014; MCCRIRRICK A, 1990, ANAESTHESIA, V45, P443, DOI 10.1111/j.1365-2044.1990.tb14329.x; Pang W W, 1997, Acta Anaesthesiol Sin, V35, P217; Picard P, 2000, ANESTH ANALG, V90, P963; POWER I, 1991, REGION ANESTH, V16, P204; SCOTT RPF, 1988, ANAESTHESIA, V43, P492, DOI 10.1111/j.1365-2044.1988.tb06641.x; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; STOKES DN, 1989, BRIT J ANAESTH, V62, P202, DOI 10.1093/bja/62.2.202	19	14	16	0	8	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918			CLIN THER	Clin. Ther.	OCT	2009	31	10					2107	2112		10.1016/j.clinthera.2009.10.012			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	522SG	WOS:000272018300005	19922881				2020-06-30	J	Heitz, JW; Witkowski, TA; Viscusi, ER				Heitz, James W.; Witkowski, Thomas A.; Viscusi, Eugene R.			New and emerging analgesics and analgesic technologies for acute pain management	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						acute pain management; analgesia; drug delivery technology; efficacy and safety	CONTROLLED REGIONAL ANALGESIA; PATIENT-CONTROLLED TECHNIQUES; ACUTE POSTOPERATIVE PAIN; MAJOR ABDOMINAL-SURGERY; TOTAL HIP-ARTHROPLASTY; CONTROLLED TRANSDERMAL SYSTEM; RELEASE EPIDURAL MORPHINE; LIDOCAINE PATCH 5-PERCENT; CONTROLLED DRUG-DELIVERY; ROTATOR CUFF REPAIR	Purpose of review Recent advances in drug delivery technology have provided new means of delivering medications with improved efficacy and safety. This review details developments in drug delivery recently made available or in development with the potential to better deliver analgesia. Recent findings Patient-controlled analgesia of intravenous medications was a major advance in drug delivery technology that allowed opioids to be administered more effectively and more safely. Extension of this technology to medications not administered intravenously has further broadened therapeutic options in the treatment of acute pain. Improvements in sustained-release formulations and patient-controlled analgesia modalities that are not catheter-based confer the potential to deliver analgesia less invasively. Receptor-specific antagonists allow opioids to be administered with fewer untoward side effects. Summary New routes of administration allow familiar medications to be utilized with greater clinical efficacy. Elimination of the need for indwelling catheters may reduce both the frequency of analgesic gaps and catheter-related complications. Physicians need to be familiar with developments in drug delivery technologies to be able to effectively utilize analgesics as part of well designed multimodal regimens to bring effective and well tolerated analgesia to patients with acute pain.	[Heitz, James W.; Witkowski, Thomas A.; Viscusi, Eugene R.] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Heitz, JW (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, 111 S 11th St,Suite 8490, Philadelphia, PA 19107 USA.	james.heitz@jefferson.edu					ARGYRA E, 2005, 9 C EUR ASS PALL CAR, P80; Axelsson K, 2008, ANESTH ANALG, V106, P328, DOI 10.1213/01.ane.0000297297.79822.00; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; BATHEJA P, 2007, DRUG DELIV, P46; Capdevila X, 2006, ANESTHESIOLOGY, V105, P566, DOI 10.1097/00000542-200609000-00022; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Delaney CP, 2005, DIS COLON RECTUM, V48, P1114, DOI 10.1007/s10350-005-0035-7; Delaunay L, 2005, REGION ANESTH PAIN M, V30, P117, DOI 10.1016/j.rapm.2004.11.004; Devers A, 2000, CLIN J PAIN, V16, P205, DOI 10.1097/00002508-200009000-00005; DeWeese FT, 2001, CLIN ORTHOP RELAT R, P226; di Benedetto P, 2002, REGION ANESTH PAIN M, V27, P168, DOI 10.1053/rapm.2002.29741; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Eledjam JJ, 2002, REGION ANESTH PAIN M, V27, P604, DOI 10.1053/rapm.2002.36454; *END PHARM, 2006, PACK INS LID LID PAT; Fredman B, 2000, ANESTH ANALG, V91, P1436, DOI 10.1097/00000539-200012000-00025; Galer BS, 2000, J PAIN SYMPTOM MANAG, V19, P287, DOI 10.1016/S0885-3924(00)00125-1; Gambling D, 2005, ANESTH ANALG, V100, P1065, DOI 10.1213/01.ANE.0000145009.03574.78; Ganapathy S, 2000, CAN J ANAESTH, V47, P897, DOI 10.1007/BF03019672; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Habib AS, 2009, ANESTH ANALG, V108, P1950, DOI 10.1213/ane.0b013e3181a21185; Hammell DC, 2005, J PHARM SCI-US, V94, P828, DOI 10.1002/jps.20238; Hines R, 2002, PAIN MED, V3, P361, DOI 10.1046/j.1526-4637.2002.02051.x; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Ilfeld BM, 2003, ANESTH ANALG, V96, P1089, DOI 10.1213/01.ANE.0000049824.51036.EF; Kapoor S, 2009, J PHYS CHEM C, V113, P7155, DOI 10.1021/jp9000863; Karmarkar A, 2007, BRIT J ANAESTH, V98, P261, DOI 10.1093/bja/ael343; Kim T, 1996, ANESTHESIOLOGY, V85, P331, DOI 10.1097/00000542-199608000-00015; Kleinert R, 2008, ANESTH ANALG, V107, P2048, DOI 10.1213/ane.0b013e31818881ca; Mariano ER, 2008, PEDIATR ANESTH, V18, P598, DOI 10.1111/j.1460-9592.2008.02633.x; Meier T, 2003, PAIN, V106, P151, DOI 10.1016/S0304-3959(03)00317-8; Miller RD, 2009, ANESTHESIOLOGY, V110, P714, DOI 10.1097/ALN.0b013e31819c72f9; Morrow D, 2007, OPEN DRUG DELIV J, V1, P36, DOI DOI 10.2174/1874126600701010036; Nalamachu Srinivas, 2006, MedGenMed, V8, P33; *ORTH INC, 2006, PACK INS IONSYS FENT; Predel HG, 2004, BRIT J SPORT MED, V38, P318, DOI 10.1136/bjsm.2003.005017; Rawal N, 2006, EUR J ANAESTH, V23, P1010, DOI 10.1017/S0265021506000883; Rawal N, 1998, ANESTH ANALG, V86, P86, DOI 10.1097/00000539-199801000-00017; Rosen H, 2005, NAT REV DRUG DISCOV, V4, P381, DOI 10.1038/nrd1721; Rowbotham MC, 1996, PAIN, V65, P39, DOI 10.1016/0304-3959(95)00146-8; Saber AA, 2009, INT J SURG, V7, P36, DOI 10.1016/j.ijsu.2008.09.003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Sinatra RS, 2005, ANESTHESIOLOGY, V102, P822, DOI 10.1097/00000542-200504000-00019; Singelyn FJ, 2001, ANESTH ANALG, V92, P455, DOI 10.1213/00000539-200102000-00033; Singelyn FJ, 2000, ANESTH ANALG, V91, P176; Singelyn FJ, 1999, J CLIN ANESTH, V11, P550, DOI 10.1016/S0952-8180(99)00092-6; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; STRIEBEL HW, 1999, ACUTE PAIN, V2, P36; Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564; Taylor AL, 2008, JAMA-J AM MED ASSOC, V299, P89, DOI 10.1001/jama.2007.25; *TEIK SEIYAK CO LT, 2007, PACK INS FLECT DICL; Tetzlaff JE, 2000, REGION ANESTH PAIN M, V25, P611, DOI 10.1053/rapm.2000.8573; Vintar N, 2005, ANESTH ANALG, V101, P573, DOI 10.1213/01.ANE.0000158608.27411.A9; Vintar N, 2002, CAN J ANAESTH, V49, P481, DOI 10.1007/BF03017925; Viscusi ER, 2006, SURG ENDOSC, V20, P64, DOI 10.1007/s00464-005-0104-y; Viscusi ER, 2005, REGION ANESTH PAIN M, V30, P292, DOI 10.1016/j.rapm.2004.12.002; Viscusi ER, 2005, ANESTHESIOLOGY, V102, P1014, DOI 10.1097/00000542-200505000-00022; Viscusi ER, 2008, REGION ANESTH PAIN M, V33, P146, DOI 10.1016/j.rapm.2007.11.005; Viscusi Eugene R, 2006, Am J Ther, V13, P423, DOI 10.1097/01.mjt.0000178903.72619.ee; Viscusi ER, 2009, ANESTH ANALG, V108, P1811, DOI 10.1213/ane.0b013e31819e0d3a; *VYT INC, 2004, PACK INS LID TOP SYS; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Wolff BG, 2004, ANN SURG, V240, P728, DOI 10.1097/01.sla.0000141158.27977.66; Yuan CS, 2000, JAMA-J AM MED ASSOC, V284, P1383, DOI 10.1001/jama.284.11.1383; Yuan CS, 2000, JAMA-J AM MED ASSOC, V283, P367, DOI 10.1001/jama.283.3.367; Zohar E, 2001, ANESTH ANALG, V93, P482, DOI 10.1097/00000539-200108000-00048; PACKAGE INSERT RELIS	69	12	15	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2009	22	5					608	617		10.1097/ACO.0b013e32833041c9			10	Anesthesiology	Anesthesiology	497ID	WOS:000270051500011	19652596				2020-06-30	J	Suzuki, M				Suzuki, Manzo			Role of N-methyl-D-aspartate receptor antagonists in postoperative pain management	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						acute pain; hyperalgesia; N-methyl-D-aspartate; N-methyl-D-aspartate receptor antagonists	PATIENT-CONTROLLED ANALGESIA; LOW-DOSE KETAMINE; MORPHINE CONSUMPTION; DOUBLE-BLIND; MEMANTINE TREATMENT; SURGERY; DEXTROMETHORPHAN; TONSILLECTOMY; COMBINATION; CHILDREN	Purpose of review In recent years, hundreds of studies have examined the clinical efficacy of N-methyl-D-aspartate (NMDA) receptor antagonists such as ketamine and dextromethorphan as an adjunct to routine postoperative pain management. The purpose of this review is to a describe the detail of the study that successfully demonstrated the efficacy of NMDA receptor antagonists. Recent findings The effect of perioperative ketamine infusion, dextromethorphan, and memantine on postoperative opioid-induced analgesia and prevention of long-term persistent pain is described. Summary The co-administration of ketamine and morphine as a mixture is not recommended for postoperative pain relief. As an adjunct in multimodal analgesia, low-dose ketamine infusion and the administration of dextromethorphan may be able to improve postoperative pain status. Memantine exhibits the greatest potency among NMDA receptor antagonists. In future, research should consider the perioperative infusion of ketamine followed by long-term administration of memantine for the prevention of persistent pain.	Musashikosugi Hosp, Nippon Med Sch, Dept Anesthesiol, Kanagawa 2118533, Japan	Suzuki, M (reprint author), Musashikosugi Hosp, Nippon Med Sch, Dept Anesthesiol, Kanagawa 2118533, Japan.	manzo@nms.ac.jp					Abu-Shahwan I, 2008, CLIN J PAIN, V24, P395, DOI 10.1097/AJP.0b013e3181668aad; Annetta MG, 2005, CURR DRUG TARGETS, V6, P789, DOI 10.2174/138945005774574533; Aoki T, 2006, ORAL SURG ORAL MED O, V102, P591, DOI 10.1016/j.tripleo.2005.10.060; Atangana R, 2007, ACTA ANAESTH BELG, V58, P125; Aubrun F, 2008, EUR J ANAESTH, V25, P97, DOI 10.1017/S0265021507002566; Aydin ON, 2007, J CLIN ANESTH, V19, P115, DOI 10.1016/j.jclinane.2006.06.003; Chau-In W, 2007, PAIN MED, V8, P462, DOI 10.1111/j.1526-4637.2006.00226.x; Da Conceicao MJ, 2006, PEDIATR ANESTH, V16, P962, DOI 10.1111/j.1460-9592.2006.01893.x; Dal D, 2007, PEDIATR ANESTH, V17, P263, DOI 10.1111/j.1460-9592.2006.02095.x; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; De Kock MF, 2007, BEST PRACT RES-CLIN, V21, P85, DOI 10.1016/j.bpa.2006.12.006; Duale C, 2009, EUR J PAIN, V13, P497, DOI 10.1016/j.ejpain.2008.06.013; Duedahl TH, 2006, ACTA ANAESTH SCAND, V50, P1, DOI 10.1111/j.1399-6576.2006.00900.x; Erhan OL, 2007, INT J PEDIATR OTORHI, V71, P735, DOI 10.1016/j.ijporl.2007.01.008; Grande LA, 2008, ANESTH ANALG, V107, P1380, DOI 10.1213/ane.0b013e3181733ddd; Hackworth RJ, 2008, ANESTH ANALG, V107, P1377, DOI 10.1213/ane.0b013e31817f90f1; Lu CH, 2006, CLIN J PAIN, V22, P799, DOI 10.1097/01.ajp.0000210931.20322.da; Maier C, 2003, PAIN, V103, P277, DOI 10.1016/S0304-3959(02)00456-6; Michelet P, 2007, BRIT J ANAESTH, V99, P396, DOI 10.1093/bja/aem168; Nesher N, 2008, PHARMACOL RES, V58, P38, DOI 10.1016/j.phrs.2008.06.003; Nikolajsen L, 2000, ANESTH ANALG, V91, P960, DOI 10.1097/00000539-200010000-00036; Schley M, 2007, EUR J PAIN, V11, P299, DOI 10.1016/j.ejpain.2006.03.003; Sveticic G, 2005, ACTA ANAESTH SCAND, V49, P870, DOI 10.1111/j.1399-6576.2005.00740.x; Sveticic G, 2008, ANESTH ANALG, V106, P287, DOI 10.1213/01.ane.0000289637.11065.8f; TUCKER AP, 2005, [No title captured], V5, P2; Webb AR, 2007, ANESTH ANALG, V104, P912, DOI 10.1213/01.ane.0000256961.01813.da; Wilson JA, 2008, PAIN, V135, P108, DOI 10.1016/j.pain.2007.05.011; Yamauchi M, 2008, ANESTH ANALG, V107, P1041, DOI 10.1213/ane.0b013e31817f1e4a; Yeh CC, 2005, ANESTH ANALG, V100, P1384, DOI 10.1213/01.ANE.0000148687.51613.B5; Zakine J, 2008, ANESTH ANALG, V106, P1856, DOI 10.1213/ane.0b013e3181732776	30	29	30	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2009	22	5					618	622		10.1097/ACO.0b013e32832e7af6			5	Anesthesiology	Anesthesiology	497ID	WOS:000270051500012	19535974				2020-06-30	J	Cole, J; Shepherd, M; Young, P				Cole, Joanne; Shepherd, Michael; Young, Phillip			Intranasal fentanyl in 1-3-year-olds: A prospective study of the effectiveness of intranasal fentanyl as acute analgesia	EMERGENCY MEDICINE AUSTRALASIA			English	Article						analgesia; fentanyl; intranasal; pain; paediatrics	PEDIATRIC-PATIENTS; PAIN ASSESSMENT; CHILDREN; MORPHINE	The primary objective of the present study was to determine the effectiveness of intranasal fentanyl analgesia in children aged 1-3 years with acute moderate to severe pain presenting to the ED. We also aimed to gather information on the safety and acceptability of intranasal fentanyl in this age group. Two paediatric ED enrolled children aged 1-3 years, with acute moderate or severe pain. Intranasal fentanyl was administered (1.5 mu g/kg) via a mucosal atomiser device using a 50 mu g/mL solution of fentanyl. Physiological parameters (heart rate, respiratory rate, oxygen saturations and level of consciousness) were measured at regular intervals. Objective pain assessment was completed using the Faces, Legs, Arms, Cry, Consolability (FLACC) score. Forty-six children presenting with acute moderate to severe pain were included. The median FLACC score before intranasal fentanyl administration was 8 (interquartile range [IQR] 5-10), decreasing to 2 (IQR 0-4) 10 min post fentanyl (P < 0.0001) and 0 (IQR 0-2) 30 min post fentanyl (P < 0.0001). A clinically significant decrease in FLACC scores was seen in 93% of children 10 min post fentanyl administration and 98% of children 30 min post fentanyl. Intranasal fentanyl delivery using a mucosal atomiser was well tolerated by all children. There were no adverse drug reactions or adverse events detected. Intranasal fentanyl is an effective, safe and well-tolerated mode of analgesia for children aged 1-3 years with moderate to severe pain.	[Cole, Joanne; Shepherd, Michael] Starship Childrens Hosp, Childrens Emergency Dept, Auckland 1142, New Zealand; [Young, Phillip] Middlemore Hosp, Kidzfirst Emergency Dept, Auckland 6, New Zealand	Cole, J (reprint author), Starship Childrens Hosp, Childrens Emergency Dept, Private Bag 92024, Auckland 1142, New Zealand.	hoj179@yahoo.co.nz					Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; ARONSON JK, 1995, PRESCRIBERS J, V35, P32; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Brislin Robert P, 2005, Anesthesiol Clin North Am, V23, P789, DOI 10.1016/j.atc.2005.07.002; Kelly A M, 2001, Emerg Med (Fremantle), V13, P57, DOI 10.1046/j.1442-2026.2001.00179.x; Lander J, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Malviya S, 2006, PEDIATR ANESTH, V16, P258, DOI 10.1111/j.1460-9592.2005.01773.x; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Maurice SC, 2002, EMERG MED J, V19, P4, DOI 10.1136/emj.19.1.4; Merkel S, 2002, AM J NURS, V102, P55; O'Brien Lisa, 2005, Paediatr Drugs, V7, P41, DOI 10.2165/00148581-200507010-00004; Powell CV, 2001, ANN EMERG MED, V37, P28; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; SHEPHERD M, 2007, STARSHIP CHILDRENS H; Watkins Nicholas, 2006, Emerg Med Australas, V18, P51, DOI 10.1111/j.1742-6723.2006.00808.x; Young KD, 2005, ANN EMERG MED, V45, P160, DOI 10.1016/j.annemergmed.2004.09.019; Younge P, 1999, EMERGEN MED, V11, P90; Zempsky WT, 2004, PEDIATRICS, V114, P1348, DOI 10.1542/peds.2004-1752	23	35	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731	1742-6723		EMERG MED AUSTRALAS	Emerg. Med. Australas.	OCT	2009	21	5					395	400		10.1111/j.1742-6723.2009.01216.x			6	Emergency Medicine	Emergency Medicine	507CL	WOS:000270828200008	19840089				2020-06-30	J	Jeon, EJ; Park, YS; Park, SS; Lee, SK; Kim, DH				Jeon, Eun-ju; Park, Yong-Soo; Park, Soo Seog; Lee, Seung-Kyun; Kim, Dong-Hyun			The effectiveness of gabapentin on post-tonsillectomy pain control	EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY			English	Article						Gabapentin; Postoperative pain; Tonsillectomy	ABDOMINAL HYSTERECTOMY; MORPHINE CONSUMPTION; POSTOPERATIVE PAIN; NMDA RECEPTOR; PLACEBO; TRIAL	Postoperative pain is one of the most troublesome aspects of tonsillectomy for patients. Although various analgesics have been administered for pain control following tonsillectomy, it has still not been effectively controlled. Therefore, this study was conducted to evaluate the effectiveness of premedication using gabapentin on postoperative pain control in patients undergoing tonsillectomy. A total of 58 adult patients were randomly divided into a control group and a gabapentin group. Patients in the control group received an oral placebo preoperatively, whereas those in the gabapentin group received an oral dose of gabapentin preoperatively. All participants were provided with patient-controlled analgesia using fentanyl for 48 h after surgery. The total amount of fentanyl injected and the number of injections of dicolfenac sodium (75 mg each) requested by each of the group was then compared. Pain assessment was performed using a visual analog scale during resting periods (rVAS) and during swallowing (sVAS) for 9 days after the operation. The number of dicolfenac sodium injections and the total amount of fentanyl injected decreased significantly in the gabapentin group (P < 0.01). The sVAS of the gabapentin group was also significantly lower than that of the control group at 2 and 4 h after surgery, but there were no significant differences in the sVAS observed between the two groups for the remainder of the postoperative period. There were no significant differences in the rVAS observed between the two groups throughout the postoperative period. Thus, premedication with gabapentin decreased post-tonsillectomy pain. So the addition of gabapentin prior to tonsillectomy may have an adjunctive role in pain control.	[Jeon, Eun-ju; Park, Yong-Soo; Lee, Seung-Kyun; Kim, Dong-Hyun] Catholic Univ Korea, Dept Otolaryngol Head & Neck Surg, Incheon St Marys Hosp, Inchon 403720, South Korea; [Park, Soo Seog] Catholic Univ Korea, Dept Anesthesiol & Pain Med, Incheon St Marys Hosp, Inchon 403720, South Korea	Kim, DH (reprint author), Catholic Univ Korea, Dept Otolaryngol Head & Neck Surg, Incheon St Marys Hosp, 665 Bupyung Dong, Inchon 403720, South Korea.	monolithkim@catholic.ac.kr					Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; COLCLASURE J B, 1990, Ear Nose and Throat Journal, V69, P155; Davies A, 2007, TRENDS PHARMACOL SCI, V28, P220, DOI 10.1016/j.tips.2007.03.005; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DICKENSON AH, 1987, NEUROPHARMACOLOGY, V26, P1235, DOI 10.1016/0028-3908(87)90275-9; Dierking G, 2004, ACTA ANAESTH SCAND, V48, P322, DOI 10.1111/j.0001-5172.2004.0329.x; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Gilron I, 2005, PAIN, V113, P191, DOI 10.1016/j.pain.2004.10.008; LOO ZD, 2002, J PHARMACOL EXP THER, V303, P1199; Mikkelsen S, 2006, ACTA ANAESTH SCAND, V50, P809, DOI 10.1111/j.1399-6576.2006.01057.x; Moiniche S, 2003, ANESTH ANALG, V96, P68, DOI 10.1213/01.ANE.0000040583.65135.57; Parsons SP, 2006, OTOLARYNG HEAD NECK, V134, P106, DOI 10.1016/j.otohns.2005.09.027	15	25	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-4477	1434-4726		EUR ARCH OTO-RHINO-L	Eur. Arch. Oto-Rhino-Laryn.	OCT	2009	266	10					1605	1609		10.1007/s00405-008-0897-0			5	Otorhinolaryngology	Otorhinolaryngology	489KR	WOS:000269419500017	19099314				2020-06-30	J	Eer, AS; Padmanabhan, U; Leslie, K				Eer, Audrey SingYi; Padmanabhan, Usha; Leslie, Kate			Propofol dose and incidence of dreaming during sedation	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						colonoscopy; dreaming; fentanyl; midazolam; propofol; sedation	GENERAL-ANESTHESIA; AWARENESS; RECALL; COLONOSCOPY; SURGERY; QUALITY	Background and objective Dreaming is commonly reported after propofol-based sedation. We measured the incidence of dreaming and bispectral index (BIS) values in colonoscopy patients sedated with combinations of propofol, midazolam and fentanyl. Methods Two hundred patients presenting for elective outpatient colonoscopy were sedated with combinations of propofol, midazolam and fentanyl. BIS was monitored throughout the procedure. Patients were interviewed immediately after they emerged from sedation. The primary end point was a report of dreaming during sedation. Results Ninety-seven patients were administered propofol alone, 44 were administered propofol and fentanyl,16 were administered propofol and midazolam and 43 were administered propofol, midazolam and fentanyl. Dreaming was reported by 19% of patients. Dreamers received higher doses of propofol and had lower BIS values during sedation. Age of 50 years or less, preoperative quality of recovery score of less than 14, higher home dream recall, propofol dose of more than 300 mg and time to Observers' Assessment of Alertness/Sedation score equalling 5 of 8 min or less were independent predictors of dreaming. Conclusion Dreaming during sedation is associated with higher propofol dose and lower BIS values. Eur J Anaesthesiol 26:833-836 (C) 2009 European Society of Anaesthesiology.	[Eer, Audrey SingYi; Padmanabhan, Usha; Leslie, Kate] Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Leslie, Kate] Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia	Leslie, K (reprint author), Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Parkville, Vic 3050, Australia.	kate.leslie@mh.org.au		Leslie, Kate/0000-0001-8512-3517			Brandner B, 1997, ANAESTHESIA, V52, P750, DOI 10.1111/j.1365-2044.1997.161-az0171.x; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Drake LM, 2006, AM J GASTROENTEROL, V101, P2003, DOI 10.1111/j.1572-0241.2006.00806.x; Errando CL, 2008, BRIT J ANAESTH, V101, P178, DOI 10.1093/bja/aen144; Hellwagner K, 2003, EUR J ANAESTH, V20, P282, DOI 10.1097/00003643-200304000-00002; HUNTER DN, 1987, ANAESTHESIA, V42, P1128, DOI 10.1111/j.1365-2044.1987.tb05211.x; Kasmacher H, 1996, ANAESTHESIST, V45, P146, DOI 10.1007/s001010050249; Leslie K, 2005, ANAESTHESIA, V60, P239, DOI 10.1111/j.1365-2044.2004.04087.x; Leslie K, 2007, ANESTHESIOLOGY, V106, P33, DOI 10.1097/00000542-200701000-00010; MARSCH SCU, 1992, EUR J ANAESTH, V9, P331; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Pace-Schott EF, 2001, J SLEEP RES, V10, P129, DOI 10.1046/j.1365-2869.2001.00249.x; Padmanabhan U, 2008, ANAESTH INTENS CARE, V36, P436, DOI 10.1177/0310057X0803600316; PADMANABHAN U, ANESTH ANAL IN PRESS; Samuelsson P, 2008, ACTA ANAESTH SCAND, V52, P810, DOI 10.1111/j.1399-6576.2008.01633.x; SCHAER H, 1988, ANAESTHESIST, V37, P187; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C; Stait ML, 2008, ANAESTH INTENS CARE, V36, P685, DOI 10.1177/0310057X0803600509; Toscano A, 2007, ANESTHESIOLOGY, V106, P952, DOI 10.1097/01.anes.0000265154.24685.47; YOUNG PN, 1988, ANAESTHESIA, V43, P170	21	16	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	OCT	2009	26	10					833	836		10.1097/EJA.0b013e32832c500c			4	Anesthesiology	Anesthesiology	499UN	WOS:000270251800005	19528807				2020-06-30	J	Hamunen, K; Paakkari, P; Kalso, E				Hamunen, Katri; Paakkari, Pirkko; Kalso, Eija			Trends in opioid consumption in the Nordic countries 2002-2006	EUROPEAN JOURNAL OF PAIN			English	Article						Opioid consumption; Nordic countries	CANCER PAIN; EUROPEAN COUNTRIES; MEDICAL USE; MORPHINE; METHADONE; RECOMMENDATIONS; ANALGESICS; ABUSE	Objective: The purpose of the study was to examine the trends in opioid consumption in the five Nordic countries between 2002 and 2006 and to explore possible explanations for changes in the quality and quantity of opioids consumed. Methods: Data on opioid consumption were extracted from the databases of the respective national authorities. Six strong and four weak opioids were included in the analysis. Data were presented as DDDs/1000 inhabitants/day. In addition, information on the reimbursement system and opioid prescription regulations in respective countries was obtained. Also, the cost of analgesic medication in the Nordic countries was compared as equipotent doses of CR morphine, CR oxycodone and transdermal fentanyl. Results: During the five year period examined the total use of opioids showed some increase in all countries except Sweden. In Finland and Norway the increase in the total consumption was mainly due to an increase in the consumption of strong opioids while in Denmark the rise was due to increased consumption of weak opioids. The consumption of morphine was stabile or decreased slightly in all countries while the use of transdermal fentanyl increased in Denmark, Finland and Sweden and oxycodone in all countries except Iceland. The consumption of dextropropoxyphene decreased in all countries. Reimbursement policies or prescription regulations do not seem to explain the kind/type of opioids consumed or changes in their consumption. Conclusions: Consumption of opioid analgesics in the Nordic countries showed changes over the five year period that cannot be explained by pharmacology, price, reimbursement or prescription regulations. Marketing has most likely significantly influenced the type and amount of opioids consumed. (C) 2008 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.	[Hamunen, Katri; Kalso, Eija] Univ Helsinki, Cent Hosp, Meilahti Hosp, Pain Clin,Dept Anaesthesiol & Intens Care Med, FIN-00029 Helsinki, HUS, Finland; [Paakkari, Pirkko] Finnish Natl Agcy Med, FIN-00301 Helsinki, Finland	Hamunen, K (reprint author), Univ Helsinki, Cent Hosp, Meilahti Hosp, Pain Clin,Dept Anaesthesiol & Intens Care Med, POB 140, FIN-00029 Helsinki, HUS, Finland.	katri.hamunen@fimnet.fi		Kalso, Eija/0000-0002-4899-605X			*AM PAIN SOC, US OP TREATM CHRON P; Barkin Robert L, 2006, Am J Ther, V13, P534, DOI 10.1097/01.mjt.0000253850.86480.fb; Berbatis CG, 2000, MED J AUSTRALIA, V173, P524, DOI 10.5694/j.1326-5377.2000.tb139320.x; Clausen TG, 1997, ACTA ANAESTH SCAND, V41, P162, DOI 10.1111/j.1399-6576.1997.tb04632.x; Davis MP, 2001, SUPPORT CARE CANCER, V9, P73, DOI 10.1007/s005200000180; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Ehret GB, 2006, ARCH INTERN MED, V166, P1280, DOI 10.1001/archinte.166.12.1280; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; Hamunen K, 2008, EUR J PAIN, V12, P705, DOI 10.1016/j.ejpain.2007.10.012; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; KALSO E, 1999, OPIOIDS CHRONIC NONC; MARTIKAINEN J, 2002, SOCIAL SECURITY HLTH, V54; *MED PROD AG SWED, 2002, INFORM FRAN LAKEMEDE, V13, P17; Morley JS, 2003, PALLIATIVE MED, V17, P576, DOI 10.1191/0269216303pm815oa; *NOMESCO, 2004, [No title captured]; *WHO COLL CTR DRUG, 2006, AN THER CHEM CLASS S	20	87	88	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3801			EUR J PAIN	Eur. J. Pain	OCT	2009	13	9					954	962		10.1016/j.ejpain.2008.11.006			9	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	528UF	WOS:000272471800010	19091608				2020-06-30	J	Balaji, P; Dhillon, P; Russell, IF				Balaji, P.; Dhillon, P.; Russell, I. F.			Low-dose epidural top up for emergency caesarean delivery: a randomised comparison of levobupivacaine versus lidocaine/epinephrine/fentanyl	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Anaesthesia; Obstetric; Epidural; Local anaesthetics; Levobupivacaine; Lidocaine	OBSTETRIC ANESTHESIA; RACEMIC BUPIVACAINE; SECTION; ANALGESIA; LABOR; 0.5-PERCENT; FENTANYL; 0.75-PERCENT; ROPIVACAINE; ADRENALINE	Background: Levobupivacaine has a greater safety margin for cardiotoxicity than bupivacaine; consequently it has been recommended as the agent of choice for extending low-dose epidural analgesia for emergency caesarean section. We wished to compare the onset of levobupivacaine with that of a 2% lidocaine/epinephrine/fentanyl Mixture. Methods: In a prospective, single blind study, we compared the speed of onset and efficacy of 20 mL of plain 0.5% levobupivacaine with 2%, lidocaine/epinephrine 100 mu g/fentanyl 100 mu g for extending a previous low-dose labour epidural for emergency caesarean section in 100 patients. Results: The median [interquartile range] onset time for block of the T7 dermatome to touch from the end of the top up for 2% lidocaine /epiiiephrine/fentanyl mixture and levobupivacaine was 10 [8, 13] vs. 15 [10, 20] min respectively (P < 0.0009). There was a significantly longer preparation time for the 2% lidocaine/epinephrine/fentanyl Mixture than for levobupivacaine (median 145 s [120, 200] vs. 60 s [44, 60] P < 0.0009). Even with the inclusion of the longer preparation time, 2% lidocaine/epineplirine/fentanyl still had a more rapid onset than levobupivacaine: 15 [15, 19] vs. 18 [13.8, 22.4] min (P < 0,05). General anaesthesia was not required for inadequate blocks but additional local anaesthetic or intraoperative analgesic supplements were needed more frequently in the levobupivacaine group: 9% vs. 29%, (P < 0.01). Conclusions: A freshly prepared mixture of 2% lidocaine 20 mL Plus epinephrine 100 mu g and fentanyl 100 mu g provides a more rapid onset and superior quality T7 block to touch than 0.5% levobupivacaine 20 mL. (C) 2009 Elsevier Ltd. All rights reserved.	[Balaji, P.; Dhillon, P.; Russell, I. F.] Hull Royal Infirm, Dept Anaesthesia, Kingston Upon Hull HU3 2JZ, N Humberside, England	Russell, IF (reprint author), Hull Royal Infirm, Dept Anaesthesia, Anlaby Rd, Kingston Upon Hull HU3 2JZ, N Humberside, England.	i.f.russell@hull.ac.uk					Allam J, 2008, ANAESTHESIA, V63, P243, DOI 10.1111/j.1365-2044.2007.05342.x; Bader AM, 1999, ANESTHESIOLOGY, V90, P1596, DOI 10.1097/00000542-199906000-00015; Bardsley H, 1998, BRIT J CLIN PHARMACO, V46, P245, DOI 10.1046/j.1365-2125.1998.00775.x; Checketts MR, 1998, BRIT J ANAESTH, V80, P710, DOI 10.1093/bja/80.6.710; Chen DT, 2002, MED CARE, V40, P20, DOI 10.1097/01.MLR.0000023952.15394.88; Collis RE, 1999, BRIT J ANAESTH, V82, P233, DOI 10.1093/bja/82.2.233; Faccenda KA, 2003, REGION ANESTH PAIN M, V28, P394, DOI 10.1016/S1098-7339(03)00223-2; Goring-Morris J, 2006, INT J OBSTET ANESTH, V15, P109, DOI 10.1016/j.ijoa.2005.11.005; Hollmen A., 1966, ACTA ANAESTHESIOL S, V21, P53; Lam DTC, 2001, ANAESTHESIA, V56, P790; Levy DM, 2006, ANAESTHESIA, V61, P786, DOI 10.1111/j.1365-2044.2006.04711.x; Lucas DN, 1999, ANAESTHESIA, V54, P1173, DOI 10.1046/j.1365-2044.1999.01108.x; Lyons G, 1998, BRIT J ANAESTH, V81, P899; Malhotra S, 2007, ANAESTHESIA, V62, P667, DOI 10.1111/j.1365-2044.2007.05096.x; Ngamprasertwong Pornswan, 2005, Journal of the Medical Association of Thailand, V88, P1563; Sanders RD, 2004, ANAESTHESIA, V59, P988, DOI 10.1111/j.1365-2044.2004.03753.x; Sinclair M, 1999, ANAESTH INTENS CARE, V27, P275, DOI 10.1177/0310057X9902700309; Sng BL, 2008, ANAESTH INTENS CARE, V36, P659, DOI 10.1177/0310057X0803600505; Yentis SM, 2003, INT J OBSTET ANESTH, V12, P246, DOI 10.1016/S0959-289X(03)00009-8	19	7	8	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2009	18	4					335	341		10.1016/j.ijoa.2009.03.011			7	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	511AH	WOS:000271135300007	19733053				2020-06-30	J	Nishikawa, RK; Bell, SC; Kraner, JC; Callery, PS				Nishikawa, Rona K.; Bell, Suzanne C.; Kraner, James C.; Callery, Patrick S.			Potential Biomarkers of Smoked Fentanyl Utilizing Pyrolysis Gas Chromatography-Mass Spectrometry	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Society-of-Forensic-Toxicologists	OCT 29, 2008	Phoenix, AZ	Soc Forens Toxicologists			ABUSE; METABOLITE; EPIDEMIC; PATCHES; MPTP; COUNTY; MISUSE; MPP	Fentanyl is a potent opioid analgesic that is increasingly becoming a choice drug of abuse. Fentanyl transdermal patches (FTPs) are easily obtained and consumed by smoking the reservoir gel and/or the whole patch. This allows for an increased bioavailability when inhaled. A method using analytical pyrolysis was developed to identify possible biomarkers associated with smoked fentanyl and FTPs. Pyrolysis was carried out under anaerobic and aerobic conditions using helium and air coupled to a gas chromatograph-mass spectrometer. The presence of a trap enhanced recovery and afforded a positive identification of pyrolytic products. Anaerobic and aerobic pyrolysis of fentanyl and FTPs consistently yielded propionanilide as the major pyrolytic product along with pyridine and previously reported metabolites (norfentanyl and despropionyl fentanyl). Analysis of fentanyl resulted in chlorine-containing compounds, presumably formed from the HCI salt of fentanyl. Analysis of FTPs showed significant polymeric and hydrocarbon compounds and products likely derived from the gel matrix. Fentanyl in the FTPs was in the citrate salt form; therefore, the chlorine-containing pyrolytic products obtained with the neat drug were not observed. Based on this application, it may be possible to identify what salt form of the drug was smoked based on pyrolytic products and to target distinguishing metabolic products for future research.	[Nishikawa, Rona K.; Bell, Suzanne C.] W Virginia Univ, Eugene C Bennett Dept Chem, Morgantown, WV 26506 USA; [Kraner, James C.] Off Chief Med Examiner, Charleston, WV 25302 USA; [Callery, Patrick S.] W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA	Nishikawa, RK (reprint author), W Virginia Univ, Eugene C Bennett Dept Chem, Morgantown, WV 26506 USA.	rnishika@mix.wvu.edu		Bell, Suzanne/0000-0002-7839-3049			Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Benowitz N L, 1990, NIDA Res Monogr, V99, P12; CHIBA K, 1985, BIOCHEM BIOPH RES CO, V128, P1228, DOI 10.1016/0006-291X(85)91071-X; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; DAMATO RJ, 1986, SCIENCE, V231, P987, DOI 10.1126/science.3080808; Gayton-Ely M, 2007, J FORENSIC SCI, V52, P473, DOI 10.1111/j.1556-4029.2006.00371.x; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LANGSTON JW, 1984, NEUROSCI LETT, V48, P87, DOI 10.1016/0304-3940(84)90293-3; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Meng Y, 1997, NIDA Res Monogr, V173, P201; MOEHRLE H, 1990, ARCH PHARM WEINHEIM, V323, P109; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; THOMSON PDR, 2006, PHYS DESK REFERENCE, P2448; U.S. Department of Justice D.E.A., 2007, FED REGISTER, V72, P20039; Wesson D R, 1990, NIDA Res Monogr, V99, P5; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	22	9	9	1	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2009	33	8			SI		418	422		10.1093/jat/33.8.418			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	502ZN	WOS:000270500000003	19874647	Bronze			2020-06-30	J	Takashina, Y; Naito, T; Mino, Y; Kagawa, Y; Kawakami, J				Takashina, Y.; Naito, T.; Mino, Y.; Kagawa, Y.; Kawakami, J.			Validated LC coupled to ESI-MS/MS analysis for fentanyl in human plasma and UV analysis in applied reservoir transdermal patches using a simple and rapid procedure	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article						absorption rate; clinical application; drug reservoir; fentanyl; plasma concentration; transdermal therapeutic system	CANCER PAIN PATIENTS; MASS-SPECTROMETRY; HUMAN URINE; PHARMACOKINETICS; NORFENTANYL; ABSORPTION; OPIOIDS; TRIAL	P>Background and objectives: Fentanyl has been used for cancer pain in transdermal formulation. The aim of the present study was to establish an analytical method for fentanyl in human plasma and in an applied transdermal reservoir patch (Reservoir-TTS), as well as for therapeutic monitoring of fentanyl in cancer patients. Method: Electro-spray ionization mass spectrometric (ESI-MS/MS) analysis followed solid phase extraction (SPE) from human plasma and drug reservoir extraction from an applied Reservoir-TTS. Each separation was completed within 9 min using an ODS column (particle size, 3 mu m, 2 center dot 0 mm i.d. x 75 mm) with 25% acetonitrile containing 5 mm ammonium acetate at pH 3 center dot 5. In the ESI-MS/MS analysis, the calibration curve for fentanyl was linear over a concentration range of 0 center dot 05-7 center dot 2 ng/mL in human plasma. The extraction efficiency of fentanyl in the human plasma was more than 95%. The intra- and interassay precision and accuracy were within 7% and 97 center dot 3-101 center dot 2%, respectively. The lower LOQ for fentanyl was 0 center dot 05 ng/mL in the human plasma. The extraction of the 25 mu g/h and 50 mu g/h Reservoir-TTS gave reproducible recoveries of 88 center dot 3% and 90 center dot 9%, respectively. The plasma concentration of fentanyl showed large interindividual variation in 31 patients with cancer pain. Conclusion: The method described is simple, accurate, and reproducible, and should be helpful for the therapeutic monitoring of fentanyl in cancer patients.	[Takashina, Y.; Naito, T.; Mino, Y.; Kawakami, J.] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Mino, Y.; Kagawa, Y.] Univ Shizuoka, Fac Pharmaceut Sci, Dept Clin Pharmaceut & Pharm Practice, Suruga Ku, Shizuoka 4228526, Japan	Kawakami, J (reprint author), Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kawakamiham@umin.ac.jp					Agarwal S, 2007, PAIN MED, V8, P554, DOI 10.1111/j.1526-4637.2006.00246.x; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Komurcu S, 2007, EUR J CANCER CARE, V16, P67, DOI 10.1111/j.1365-2354.2006.00707.x; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Quigley C, 2005, BMJ-BRIT MED J, V331, P825, DOI 10.1136/bmj.331.7520.825; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; US Food and Drug Administration, 2001, GUID IND BIOAN METH; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Welsh J, 2005, PALLIATIVE MED, V19, P9, DOI 10.1191/0269216305pm971oa	27	9	10	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-4727	1365-2710		J CLIN PHARM THER	J. Clin. Pharm. Ther.	OCT	2009	34	5					523	529		10.1111/j.1365-2710.2009.01033.x			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	491PO	WOS:000269591600004	19744008				2020-06-30	J	Kim, JA; Kim, TH; Yang, M; Gwak, MS; Kim, GS; Kim, MJ; Cho, HS; Sim, WS				Kim, Jie Ae; Kim, Tae Hyeong; Yang, Mikyung; Gwak, Mi Sook; Kim, Gaab Soo; Kim, Myung Joo; Cho, Hyun Sung; Sim, Woo Seok			Is Intravenous Patient Controlled Analgesia Enough for Pain Control in Patients Who Underwent Thoracoscopy?	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						Analgesia, Patient-Controlled; Pain Measurement; Thoracic Surgery, Video-Assisted	ASSISTED THORACIC-SURGERY; POSTOPERATIVE PAIN; PULMONARY-FUNCTION; EPIDURAL FENTANYL; THORACOTOMY; LOBECTOMY; COMPLICATIONS; SUFENTANIL; EFFICACY; ACCESS	This prospective randomized study was conducted to evaluate the efficacy of two common analgesic techniques, thoracic epidural patent-controlled analgesia (Epidural PCA), and intravenous patient-controlled analgesia (IV PCA), in patients undergoing lobectomy by the video-assisted thoracic surgical (VATS) approach. Fifty-two patients scheduled for VATS lobectomy were randomly allocated into two groups: an Epidural PCA group receiving an epidural infusion of ropivacaine 0.2% + fentanyl 5 mu g/mL combination at a rate of 4 mL/hr, and an IV PCA group receiving an intravenous infusion of ketorolac 0.2 mg/kg + fentanyl 15 mu g/mL combination at a rate of 1 mL/hr. Pain scores were then recorded using the visual analogue scale at rest and during motion (VAS-R and VAS-M, 0-10) for five days following surgery. In addition, we measured the daily morphine consumption, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), satisfaction score, and the incidence of side effects. Thirty-seven patents out of 52 completed the study (18 in the Epidural PCA group, 19 in the IV PCA group). There were no differences in the pain scores, analgesic requirements, pulmonary function, satisfaction score, and the incidence of side effects between groups. This indicates that IV PCA and Epidural PCA are equally effective to control the postoperative pain after VATS lobectomy, which suggests that IV PCA may be used instead of Epidural PCA.	[Kim, Jie Ae; Kim, Tae Hyeong; Yang, Mikyung; Gwak, Mi Sook; Kim, Gaab Soo; Kim, Myung Joo; Cho, Hyun Sung; Sim, Woo Seok] Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, Seoul 135720, South Korea	Yang, M (reprint author), Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, 50 Irwon Dong, Seoul 135720, South Korea.	anesyang@skku.edu					Aygun S, 2004, EUR J GYNAECOL ONCOL, V25, P498; Christie IW, 2007, ANAESTHESIA, V62, P335, DOI 10.1111/j.1365-2044.2007.04992.x; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; Craig SR, 2001, EUR J CARDIO-THORAC, V20, P455, DOI 10.1016/S1010-7940(01)00841-7; Fernandez MI, 2005, EUR J CARDIO-THORAC, V27, P671, DOI 10.1016/j.ejcts.2004.12.045; Furrer M, 1997, EUR J CARDIO-THORAC, V12, P82, DOI 10.1016/S1010-7940(97)00105-X; GELLER E, 1993, ANESTH ANALG, V76, P1243, DOI 10.1213/00000539-199376060-00011; Giebler RM, 1997, ANESTHESIOLOGY, V86, P55, DOI 10.1097/00000542-199701000-00009; GLASS PSA, 1992, ANESTH ANALG, V74, P345; Hill SE, 2006, ANESTHESIOLOGY, V104, P1047, DOI 10.1097/00000542-200605000-00022; KIRBY TJ, 1995, J THORAC CARDIOV SUR, V109, P997, DOI 10.1016/S0022-5223(95)70326-8; LANDRENEAU RJ, 1993, ANN THORAC SURG, V56, P1285, DOI 10.1016/0003-4975(93)90667-7; Li WWL, 2003, EUR J CARDIO-THORAC, V23, P390, DOI 10.1016/S1010-7940(02)00795-9; Miguel R, 1993, J Cardiothorac Vasc Anesth, V7, P529, DOI 10.1016/1053-0770(93)90308-8; Nagahiro I, 2001, ANN THORAC SURG, V72, P362, DOI 10.1016/S0003-4975(01)02804-1; Nakata M, 2000, ANN THORAC SURG, V70, P938, DOI 10.1016/S0003-4975(00)01513-7; Perttunen K, 1999, BRIT J ANAESTH, V82, P221, DOI 10.1093/bja/82.2.221; Richardson J, 1999, J CARDIOVASC SURG, V40, P445; Senagore AJ, 2003, BRIT J SURG, V90, P1195, DOI 10.1002/bjs.4223; Senturk M, 2002, ANESTH ANALG, V94, P11; Tajiri M, 2007, RESPIROLOGY, V12, P207, DOI 10.1111/j.1440-1843.2006.01024.x; Vogt A, 2005, BRIT J ANAESTH, V95, P816, DOI 10.1093/bja/aei250; WU CL, 2005, MILLERS ANESTHESIA, V2, P2732; Yoshioka Masakazu, 2006, Ann Thorac Cardiovasc Surg, V12, P313; ZISER A, 1999, INTERNET J ANESTHESI, V3	25	26	29	0	5	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	OCT	2009	24	5					930	935		10.3346/jkms.2009.24.5.930			6	Medicine, General & Internal	General & Internal Medicine	503GA	WOS:000270520300025	19794994	Green Published, Other Gold			2020-06-30	J	Bolte, C; Newman, G; Schultz, JE				Bolte, Craig; Newman, Gilbert; Schultz, Jo El J.			Kappa and delta opioid receptor signaling is augmented in the failing heart	JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY			English	Article						Cardiomyopathy; Opioids; Cardiac physiology; G-protein signaling; Work-performing heart	PEPTIDE GENE-EXPRESSION; ISOLATED RAT-HEART; PROTEIN-KINASE-C; CARDIOMYOPATHIC HAMSTERS; HEREDITARY CARDIOMYOPATHY; CARDIAC MYOCYTES; SARCOGLYCAN GENE; STIMULATION; CHOLESTEROL; PATHWAYS	The opioidergic system, an endogenous stress pathway, modulates cardiac function. Furthermore, opioid peptide and receptor expression is altered in a number of cardiac pathologies. However, whether the response of myocardial opioid receptor signaling is altered in heart failure progression is currently unknown. Elucidating possible alterations in and effects of opioidergic signaling in the failing myocardium is of critical importance as opioids are commonly used for pain management, including in patients at risk for cardiovascular disease. A hamster model of cardiomyopathy and heart failure (Bio14.6) was used to investigate cardiac opioidergic signaling in heart failure development. This study found an augmented negative inotropic and lusitropic response to administration of agonists selective for the kappa opioid receptor and delta opioid receptor in the failing heart that was mediated by a pertussis toxin-sensitive G-protein. The augmented decrease in cardiac function was manifested by increased inhibition of cAMP accumulation and the amplitude of the systolic Ca2+ transient. Furthermore, increased depression of cardiac function and of two important second messengers, cAMP and intracellular Ca2+, were independent of changes in cardiac opioid peptide or receptor expression. Thus, the cardiomyopathy-induced failing heart experiences increased cardiac depressant effects following opioid receptor stimulation which could exacerbate diminished cardiac function in end-stage heart failure. As cardiac function is already depressed in heart failure patients, administration of opioids could exacerbate the degree of cardiac dysfunction and worsen disease progression. (C) 2009 Elsevier Inc. All rights reserved.	[Bolte, Craig; Newman, Gilbert; Schultz, Jo El J.] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	Schultz, JE (reprint author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert Sabin Way ML0575, Cincinnati, OH 45267 USA.	schuljo@ucmail.uc.edu			American Heart AssociationAmerican Heart Association [SDG 23004N]; Pharmaceutical Research and Manufacturers of America; NIH/NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 (HL075633)]; NIH/NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R21 (DA0804)]	This work was supported by grants from the American Heart Association (SDG 23004N), the Pharmaceutical Research and Manufacturers of America ( Research Starter Grant), NIH/NHLBI R01 (HL075633) and NIH/NIDA R21 (DA0804) to Jo El J. Schultz.	Aitchison KA, 2000, BASIC RES CARDIOL, V95, P1, DOI 10.1007/s003950050001; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424; BAJUSZ E, 1969, AM HEART J, V77, P686, DOI 10.1016/0002-8703(69)90556-0; Barron BA, 2000, P SOC EXP BIOL MED, V224, P1, DOI 10.1046/j.1525-1373.2000.22358.x; Bers DM, 2006, J PHARMACOL SCI, V100, P315, DOI 10.1254/jphs.CPJ06001X; Bian JS, 2000, J PHARMACOL EXP THER, V292, P1065; Bolte C, 2009, AM J PHYSIOL-HEART C, V296, pH967, DOI 10.1152/ajpheart.00909.2008; Clark MJ, 2003, J BIOL CHEM, V278, P9418, DOI 10.1074/jbc.M208885200; FEUERSTEIN G, 1987, HYPERTENSION, V9, P561, DOI 10.1161/01.HYP.9.6.561; FONTANA F, 1993, EUR HEART J, V14, P219, DOI 10.1093/eurheartj/14.2.219; Fryer RM, 2001, AM J PHYSIOL-HEART C, V280, pH1346; Gibofsky A, 2008, AM J THER, V15, P241, DOI 10.1097/MJT.0b013e3181727f68; Hailstones D, 1998, J LIPID RES, V39, P369; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Hnasko Robert, 2003, Mol Interv, V3, P445, DOI 10.1124/mi.3.8.445; Huang P, 2007, BIOCHEM PHARMACOL, V73, P534, DOI 10.1016/j.bcp.2006.10.032; Johnson MJ, 2002, EUR J HEART FAIL, V4, P753, DOI 10.1016/S1388-9842(02)00158-7; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jurynec J, 2007, J CARDIOVASC NURS, V22, P65, DOI 10.1097/00005082-200701000-00010; KASPER E, 1992, LIFE SCI, V50, P2029, DOI 10.1016/0024-3205(92)90568-A; Kawada T, 1999, FEBS LETT, V458, P405, DOI 10.1016/S0014-5793(99)01164-3; KNAPP RJ, 1995, EUR J PHARM-MOLEC PH, V291, P129, DOI 10.1016/0014-2999(95)90088-8; OUELLETTE M, 1988, BIOCHEM BIOPH RES CO, V155, P449, DOI 10.1016/S0006-291X(88)81107-0; Peart JN, 2006, AM J PHYSIOL-HEART C, V291, pH1746, DOI 10.1152/ajpheart.00233.2006; Pepe S, 1997, CIRCULATION, V95, P2122, DOI 10.1161/01.CIR.95.8.2122; POGUE DH, 1995, J PHARMACOL EXP THER, V273, P863; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Schultz JE, 1998, AM J PHYSIOL-HEART C, V275, pH495; Schutt K, 2001, ZBL GYNAKOL, V123, P37, DOI 10.1055/s-2001-12024; SEN L, 1990, CIRC RES, V67, P599, DOI 10.1161/01.RES.67.3.599; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; Ventura C, 1998, TRENDS CARDIOVAS MED, V8, P102, DOI 10.1016/S1050-1738(97)00140-0; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1987, PEPTIDES, V8, P695, DOI 10.1016/0196-9781(87)90045-3; Yatani A, 1997, AM J PHYSIOL-HEART C, V272, pH478; Zimlichman R, 1996, CIRCULATION, V93, P1020, DOI 10.1161/01.CIR.93.5.1020	40	19	21	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0022-2828	1095-8584		J MOL CELL CARDIOL	J. Mol. Cell. Cardiol.	OCT	2009	47	4					493	503		10.1016/j.yjmcc.2009.06.016			11	Cardiac & Cardiovascular Systems; Cell Biology	Cardiovascular System & Cardiology; Cell Biology	526AX	WOS:000272261000009	19573531	Green Accepted			2020-06-30	J	Prommer, E				Prommer, Eric			The Role of Fentanyl in Cancer-Related Pain	JOURNAL OF PALLIATIVE MEDICINE			English	Review							CHEST-WALL RIGIDITY; QUALITY-OF-LIFE; TRANSDERMAL FENTANYL; BREAKTHROUGH PAIN; TRANSMUCOSAL FENTANYL; BUCCAL TABLET; ORAL MUCOSITIS; DOSE-TITRATION; CITRATE OTFC; DOUBLE-BLIND	Fentanyl is a lipophilic, short-acting, synthetic opioid with a piperidine chemical structure. Fentanyl is an effective analgesic for cancer pain, and newer formulations such as the transmucosal and buccal forms have shown efficacy for the management of cancer-related breakthrough pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.	Mayo Clin Arizona, Dept Hematol Oncol Palliat Care, Phoenix, AZ 85054 USA	Prommer, E (reprint author), Mayo Clin Arizona, Dept Hematol Oncol Palliat Care, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA.	prommer.eric@mayo.edu					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Anderson R, 2000, Am J Hosp Palliat Care, V17, P265, DOI 10.1177/104990910001700413; *CEPH INC, 2008, ACT PROD INF; *CEPH INC, 2008, FENTORA OR TABL PROD; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Clarke RW, 2000, PAIN, V85, P239, DOI 10.1016/S0304-3959(99)00272-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; De CF, 2000, J PAIN SYMPTOM MANAG, V25, P499; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Demarosi F, 2004, BONE MARROW TRANSPL, V33, P1247, DOI 10.1038/sj.bmt.1704515; DICKMAN A, 2002, SYRINGE DRIVER CONTI; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Dosen-Micovic L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI 10.1016/j.bmc.2005.12.010; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HANKS GW, 1987, ANAESTHESIA, V42, P840, DOI 10.1111/j.1365-2044.1987.tb04107.x; *JANSS PHARM, 2001, DUR PROD INF; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; Kumar Manoj, 2003, J Perinatol, V23, P425; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; Mercadante S, 2002, J PAIN SYMPTOM MANAG, V24, P284, DOI 10.1016/S0885-3924(02)00477-3; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; Murtagh Fliss E M, 2007, J Pain Palliat Care Pharmacother, V21, P5; NEIDHART P, 1989, ACTA ANAESTH SCAND, V33, P1, DOI 10.1111/j.1399-6576.1989.tb02849.x; Okon TR, 2008, J PAIN SYMPTOM MANAG, V35, P327, DOI 10.1016/j.jpainsymman.2007.04.023; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Pistevou-Gompaki K, 2004, CURR MED RES OPIN, V20, P159, DOI 10.1185/030079903125002829; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Radbruch Lukas, 2004, Keio J Med, V53, P23, DOI 10.2302/kjm.53.23; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Shaiova L, 2004, SUPPORT CARE CANCER, V12, P268, DOI 10.1007/s00520-004-0595-4; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-24; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Takane H, 2005, ANN PHARMACOTHER, V39, P2139, DOI 10.1345/aph.1G370; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Walker Paul W, 2008, J Pain Symptom Manage, V36, pe1, DOI 10.1016/j.jpainsymman.2008.01.006; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500; 2008, PRODUCT INFORM SUFEN	55	27	27	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	OCT	2009	12	10					947	954		10.1089/jpm.2009.0051			8	Health Care Sciences & Services	Health Care Sciences & Services	503EG	WOS:000270515000019	19807240				2020-06-30	J	Yu, H; Yang, XY				Yu, Hai; Yang, Xiao-Yun			Paracervical Compared With Intracervical Lidocaine for Suction Curettage: A Randomized Controlled Trial	OBSTETRICS AND GYNECOLOGY			English	Letter									[Yu, Hai] Sichuan Univ, W China Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China; [Yang, Xiao-Yun] Sichuan Univ, W China Univ Hosp 2, Dept Obstet & Gynecol, Chengdu, Sichuan, Peoples R China	Yu, H (reprint author), Sichuan Univ, W China Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China.						Mankowski JL, 2009, OBSTET GYNECOL, V113, P1052, DOI 10.1097/AOG.0b013e31819ec97e	1	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0029-7844			OBSTET GYNECOL	Obstet. Gynecol.	OCT	2009	114	4					927	928		10.1097/AOG.0b013e3181ba05ba			2	Obstetrics & Gynecology	Obstetrics & Gynecology	503WY	WOS:000270573800031	19888053				2020-06-30	J	Waxman, AR; Arout, C; Caldwell, M; Dahan, A; Kest, B				Waxman, Amanda R.; Arout, Caroline; Caldwell, Megan; Dahan, Albert; Kest, Benjamin			Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice	NEUROSCIENCE LETTERS			English	Article						Fentanyl; Hyperalgesia; NMDA; Opioid receptors; Metabolites	MORPHINE ANALGESIC TOLERANCE; LONG-LASTING HYPERALGESIA; EXCITATORY AMINO-ACID; TRIPLE KNOCKOUT MICE; HIGH-DOSE MORPHINE; ANTINOCICEPTIVE TOLERANCE; POSTOPERATIVE PAIN; ABNORMAL PAIN; RATS; KETAMINE	Although mu-receptor opioids are clinically important analgesics, they can also paradoxically cause hyperalgesia independently of opioid receptor activity, presumably via the action of neuroexcitatory glucoronide metabolites. However, it is unknown whether the commonly used mu-receptor opioid analgesic fentanyl, which is not subject to glucuronidation, can also induce hyperalgesia independently of opioid receptor activity. Thus, here we examined whether fentanyl increases nociception on the tail-withdrawal test in CD-1 mice concurrently treated with the opioid receptor antagonist naltrexone or in opioid receptor triple knock-out mice lacking mu, delta, and kappa opioid receptors. For both groups, an acute fentanyl bolus dose (0.25 mg/kg, s.c.) and continuous fentanyl infusion (cumulative daily dose: 10 mg/kg) did not cause analgesia at any time. Instead, fentanyl significantly decreased withdrawal latencies relative to pre-drug values for the next 15-60 min and for six days, respectively. MK-801 blocked and reversed hyperalgesia caused by the acute injection and continuous infusion of fentanyl, respectively, in naltrexone-treated CD-1 mice, indicating the contribution of NMDA receptors to fentanyl hyperalgesia. These data show that the synthetic opioid fentanyl causes hyperalgesia independently of prior or concurrent opioid receptor activity or analgesia. Since the biotransformation of fentanyl does not yield any known pronociceptive metabolites, these data challenge assumptions regarding the role of neuroexcitatory metabolites in opioid-induced hyperalgesia. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Caldwell, Megan; Kest, Benjamin] CUNY Coll Staten Isl, Dept Psychol, Staten Isl, NY 10314 USA; [Caldwell, Megan; Kest, Benjamin] CUNY Coll Staten Isl, Ctr Dev Neurosci, Staten Isl, NY 10314 USA; [Waxman, Amanda R.; Arout, Caroline; Kest, Benjamin] CUNY Queens Coll, Neuropsychol Program, Flushing, NY 11367 USA; [Dahan, Albert] Leiden Univ, Dept Anesthesiol, Med Ctr, NL-2300 RC Leiden, Netherlands	Kest, B (reprint author), CUNY Coll Staten Isl, Dept Psychol, 2800 Victory Blvd, Staten Isl, NY 10314 USA.	kest@mail.csi.cuny.edu	Dahan, Albert/B-8845-2008	Dahan, Albert/0000-0003-3161-3945			Armstrong SC, 2003, PSYCHOSOMATICS, V44, P167, DOI 10.1176/appi.psy.44.2.167; ARNER S, 1988, ACTA ANAESTH SCAND, V32, P253, DOI 10.1111/j.1399-6576.1988.tb02725.x; BARTLETT SE, 1994, PHARMACOL TOXICOL, V75, P73, DOI 10.1111/j.1600-0773.1994.tb00327.x; BARTLETT SE, 1994, LIFE SCI, V54, P687, DOI 10.1016/0024-3205(94)00552-4; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; CHEN ZR, 1991, LIFE SCI, V48, P2165, DOI 10.1016/0024-3205(91)90150-A; Christrup LL, 1997, ACTA ANAESTH SCAND, V41, P116, DOI 10.1111/j.1399-6576.1997.tb04625.x; Clarke S, 2002, EUR J NEUROSCI, V16, P1705, DOI 10.1046/j.1460-9568.2002.02239.x; Cox V, 2005, NEUROPHARMACOLOGY, V48, P228, DOI 10.1016/j.neuropharm.2004.09.016; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DECONNO F, 1991, PAIN, V47, P337, DOI 10.1016/0304-3959(91)90225-M; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Gardell LR, 2006, NEUROSCI LETT, V396, P44, DOI 10.1016/j.neulet.2005.11.009; Juni A, 2007, NEUROSCIENCE, V147, P439, DOI 10.1016/j.neuroscience.2007.04.030; Juni A, 2006, BRAIN RES, V1070, P35, DOI 10.1016/j.brainres.2005.11.054; Juni A, 2008, NEUROPHARMACOLOGY, V54, P1264, DOI 10.1016/j.neuropharm.2008.04.004; Kest B, 2000, BRAIN RES, V879, P17, DOI 10.1016/S0006-8993(00)02685-8; Kest B, 2002, PHARMACOL BIOCHEM BE, V73, P821, DOI 10.1016/S0091-3057(02)00908-5; Kozela E, 2001, EUR J PHARMACOL, V423, P17, DOI 10.1016/S0014-2999(01)01084-6; KUO CK, 1991, J PHARMACOBIO-DYNAM, V14, P187, DOI 10.1248/bpb1978.14.187; LABELLA FS, 1979, BRAIN RES, V174, P263, DOI 10.1016/0006-8993(79)90849-7; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; LIPKOWSKI AW, 1994, LIFE SCI, V55, P149, DOI 10.1016/0024-3205(94)90106-6; LIU H, 1994, P NATL ACAD SCI USA, V91, P8383, DOI 10.1073/pnas.91.18.8383; Liu HT, 1997, NATURE, V386, P721, DOI 10.1038/386721a0; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, J NEUROSCI, V22, P8312; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Nemmani KVS, 2004, PAIN, V109, P274, DOI 10.1016/j.pain.2004.01.035; Ossipov MH, 2004, J NEUROBIOL, V61, P126, DOI 10.1002/neu.20091; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; van Dorp ELA, 2009, ANESTHESIOLOGY, V110, P1356, DOI 10.1097/ALN.0b013e3181a105de; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; Wahlstrom A, 1986, NIDA Res Monogr, V75, P603; WOOLF CJ, 1981, BRAIN RES, V209, P491, DOI 10.1016/0006-8993(81)90176-1; Xie JY, 2005, J NEUROSCI, V25, P409, DOI 10.1523/JNEUROSCI.4054-04.2005; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P590, DOI 10.1097/00000542-198605000-00008; YOBURN BC, 1986, J PHARMACOL EXP THER, V237, P126; YOSHIMURA H, 1973, BIOCHEM PHARMACOL, V22, P1423, DOI 10.1016/0006-2952(73)90320-1	43	33	36	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 18	2009	462	1					68	72		10.1016/j.neulet.2009.06.061			5	Neurosciences	Neurosciences & Neurology	482TM	WOS:000268911600015	19559072				2020-06-30	J	Gross, ML				Gross, Michael L.			Non-lethal weapons and the civilian death toll in war time	NATURE			English	Letter									Univ Haifa, Sch Polit Sci, Dept Int Relat, IL-31905 Haifa, Israel	Gross, ML (reprint author), Univ Haifa, Sch Polit Sci, Dept Int Relat, IL-31905 Haifa, Israel.	mgross@poli.haifa.ac.il					Dando M, 2009, NATURE, V460, P950, DOI 10.1038/460950a	1	1	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 17	2009	461	7262					340	340		10.1038/461340a			1	Multidisciplinary Sciences	Science & Technology - Other Topics	494QB	WOS:000269828100013	19759597	Bronze			2020-06-30	J	Dutschmann, M; Waki, H; Manzke, T; Simms, AE; Pickering, AE; Richter, DW; Paton, JFR				Dutschmann, M.; Waki, H.; Manzke, T.; Simms, A. E.; Pickering, A. E.; Richter, D. W.; Paton, J. F. R.			The potency of different serotonergic agonists in counteracting opioid evoked cardiorespiratory disturbances	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES			English	Article; Proceedings Paper	Royal-Society Discussion Meeting on Brainstem - Neural Networks Vital for Life	2008	Royal Soc, London, ENGLAND		Royal Soc	cardiovascular control; neural control of breathing; apnoea; apneusis; cardio-sympathetic coupling; in vivo awake	INDUCED RESPIRATORY DEPRESSION; 5-HT4 RECEPTOR AGONISTS; BRAIN-STEM; IN-VIVO; GLYCINERGIC INHIBITION; BARORECEPTOR REFLEX; EXPIRATORY NEURONS; CONSCIOUS RATS; HEART-RATE; MOUSE	Serotonin receptor (5-HTR) agonists that target 5-HT4(a)R and 5-HT1AR can reverse mu-opioid receptor (mu-OR)-evoked respiratory depression. Here, we have tested whether such rescuing by serotonin agonists also applies to the cardiovascular system. In working heart-brainstem preparations in situ, we have recorded phrenic nerve activity, thoracic sympathetic chain activity (SCA), vascular resistance and heart rate (HR) and in conscious rats, diaphragmatic electromyogram, arterial blood pressure (BP) and HR via radio-telemetry. In addition, the distribution of 5-HT4(a)R and 5-HT1AR in ponto-medullary cardiorespiratory networks was identified using histochemistry. Systemic administration of the mu-OR agonist fentanyl in situ decreased HR, vascular resistance, SCA and phrenic nerve activity. Subsequent application of the 5-HT1AR agonist 8-OH-DPAT further enhanced bradycardia, but partially compensated the decrease in vascular resistance, sympathetic activity and restored breathing. By contrast, the 5-HT4(a)R agonist RS67333 further decreased vascular resistance, HR and sympathetic activity, but partially rescued breathing. In conscious rats, administration of remifentanyl caused severe respiratory depression, a decrease in mean BP accompanied by pronounced bradyarrhythmia. 8-OH-DPAT restored breathing and prevented the bradyarrhythmia; however, BP and HR remained below baseline. In contrast, RS67333 further suppressed cardiovascular functions in vivo and only partially recovered breathing in some cases. The better recovery of mu-OR cardiorespiratory disturbance by 5-HT1AR than 5-HT4(a)R is supported by the finding that 5-HT1AR was more densely expressed in key brainstem nuclei for cardiorespiratory control compared with 5-HT4(a)R. We conclude that during treatment of severe pain, 5-HT1AR agonists may provide a useful tool to counteract opioid-mediated cardiorespiratory disturbances.	[Pickering, A. E.; Paton, J. F. R.] Univ Bristol, Sch Med Sci, Bristol Heart Inst, Dept Physiol & Pharmacol, Bristol BS8 1TD, Avon, England; [Richter, D. W.] Univ Gottingen, Dept Neuro & Sensory Physiol, D-37073 Gottingen, Germany; [Dutschmann, M.] Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; [Waki, H.] Wakayama Med Univ, Sch Med, Dept Physiol, Wakayama 6418509, Japan; [Manzke, T.] Univ Gottingen, Dept Child & Adolescent Psychiat, D-37075 Gottingen, Germany; [Simms, A. E.] Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia	Paton, JFR (reprint author), Univ Bristol, Sch Med Sci, Bristol Heart Inst, Dept Physiol & Pharmacol, Bristol BS8 1TD, Avon, England.	julian.f.r.paton@bristol.ac.uk	Pickering, Anthony/A-9929-2011; Paton, Julian/AAM-2121-2020	Paton, Julian/0000-0001-7410-2913; Pickering, Anthony/0000-0003-0345-0456; Dutschmann, Mathias/0000-0002-0692-746X	British Heart FoundationBritish Heart Foundation [RG/07/006/23634]; Wellcome TrustWellcome Trust [074570]		Baekey DM, 2008, EXP PHYSIOL, V93, P803, DOI 10.1113/expphysiol.2007.041400; BAINTON CR, 1985, J AUTONOM NERV SYST, V12, P77, DOI 10.1016/0165-1838(85)90041-4; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Busselberg D, 2003, NEUROSCIENCE, V122, P831, DOI 10.1016/j.neuroscience.2003.07.014; Busselberg D, 2001, PFLUG ARCH EUR J PHY, V441, P444, DOI 10.1007/s004240000453; Chamberlin NL, 1999, BRAIN RES, V827, P198, DOI 10.1016/S0006-8993(99)01168-3; De Maeyer JH, 2008, NEUROGASTROENT MOTIL, V20, P99, DOI 10.1111/j.1365-2982.2007.01059.x; DICK TE, 1994, BRAIN RES, V636, P259, DOI 10.1016/0006-8993(94)91025-1; Dutschmann M, 2002, RESP PHYSIOL NEUROBI, V131, P57, DOI 10.1016/S1569-9048(02)00037-X; Dutschmann M, 2002, J PHYSIOL-LONDON, V543, P643, DOI 10.1113/jphysiol.2001.013466; Dutschmann M, 2006, EUR J NEUROSCI, V24, P1071, DOI 10.1111/j.1460-9568.2006.04981.x; Dutschmann M, 2008, RESP PHYSIOL NEUROBI, V164, P72, DOI 10.1016/j.resp.2008.06.013; El-Khatib Mohamad F, 2003, Respir Care, V48, P956; Elliott P, 2000, ANESTH ANALG, V91, P58, DOI 10.1097/00000539-200007000-00011; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; Ezure K, 2003, J NEUROSCI, V23, P8941; GILBEY MP, 1984, J PHYSIOL-LONDON, V356, P65, DOI 10.1113/jphysiol.1984.sp015453; GOETZ AM, 1994, CRIT CARE MED, V22, P1579; Gomeza J, 2003, NEURON, V40, P797, DOI 10.1016/S0896-6273(03)00673-1; Guenther U, 2009, ANESTH ANALG, V108, P1169, DOI 10.1213/ane.0b013e318198f828; Haji A, 2003, NEUROSCI LETT, V351, P37, DOI 10.1016/S0304-3940(03)00951-0; HOYER D, 1994, PHARMACOL REV, V46, P157; Jordan D, 2005, EXP PHYSIOL, V90, P175, DOI 10.1113/expphysiol.2004.029058; Kaumann AJ, 2006, PHARMACOL THERAPEUT, V111, P674, DOI 10.1016/j.pharmthera.2005.12.004; Kubin L, 2006, J APPL PHYSIOL, V101, P618, DOI 10.1152/japplphysiol.00252.2006; La Rovere MT, 1998, LANCET, V351, P478; LALLEY PM, 1994, NEUROSCI LETT, V172, P59, DOI 10.1016/0304-3940(94)90662-9; Lalley PM, 2006, AM J PHYSIOL-REG I, V290, pR1387, DOI 10.1152/ajpregu.00530.2005; Lalley PM, 1997, J NEUROPHYSIOL, V77, P1119; Lonergan T, 2003, RESP PHYSIOL NEUROBI, V138, P165, DOI 10.1016/S1569-9048(03)00173-3; Lotsch J, 2005, CLIN PHARMACOL THER, V78, P278, DOI 10.1016/j.clpt.2005.05.010; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Manzke T, 2009, PHILOS T R SOC B, V364, P2589, DOI 10.1098/rstb.2009.0068; Mine Y, 1997, J PHARMACOL EXP THER, V283, P1000; Morschel M, 2009, PHILOS T R SOC B, V364, P2517, DOI 10.1098/rstb.2009.0074; Murasato Y, 1998, AM J PHYSIOL-HEART C, V275, pH797; O'Sullivan RJ, 2008, MULT SCLER J, V14, P705, DOI 10.1177/1352458507085802; Oertel BG, 2007, CLIN PHARMACOL THER, V81, P59, DOI 10.1038/sj.clpt.6100018; Paton JFR, 1996, J NEUROSCI METH, V65, P63, DOI 10.1016/0165-0270(95)00147-6; Pickering AE, 2006, J NEUROSCI METH, V155, P260, DOI 10.1016/j.jneumeth.2006.01.011; Pierrefiche O, 1998, J PHYSIOL-LONDON, V509, P245, DOI 10.1111/j.1469-7793.1998.245bo.x; Richter DW, 2003, TRENDS MOL MED, V9, P542, DOI 10.1016/j.molmed.2003.10.010; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; Saito Y, 1999, DEV MED CHILD NEUROL, V41, P560, DOI 10.1017/S0012162299001188; Schmid K, 1996, BRAIN RES, V710, P150, DOI 10.1016/0006-8993(95)01380-6; Simms AE, 2009, J PHYSIOL-LONDON, V587, P597, DOI 10.1113/jphysiol.2008.165902; Smith JC, 2007, J NEUROPHYSIOL, V98, P3370, DOI 10.1152/jn.00985.2007; Stettner GM, 2008, RESP PHYSIOL NEUROBI, V161, P10, DOI 10.1016/j.resp.2007.11.001; Villareal Rollo P, 2002, Curr Atheroscler Rep, V4, P120, DOI 10.1007/s11883-002-0035-1; Waki H, 2003, J PHYSIOL-LONDON, V546, P233, DOI 10.1113/jphysiol.2002.030270; Waki H, 2007, HYPERTENSION, V49, P1321, DOI 10.1161/HYPERTENSIONAHA.106.085589; Wilken B, 1997, J PEDIATR-US, V130, P89, DOI 10.1016/S0022-3476(97)70315-9; Yamauchi M, 2008, RESP PHYSIOL NEUROBI, V162, P117, DOI 10.1016/j.resp.2008.05.003; Yamauchi M, 2008, J APPL PHYSIOL, V105, P518, DOI 10.1152/japplphysiol.00069.2008; Zoccal DB, 2008, J PHYSIOL-LONDON, V586, P3253, DOI 10.1113/jphysiol.2008.154187	56	30	30	0	3	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	0962-8436	1471-2970		PHILOS T R SOC B	Philos. Trans. R. Soc. B-Biol. Sci.	SEP 12	2009	364	1529					2611	2623		10.1098/rstb.2009.0076			13	Biology	Life Sciences & Biomedicine - Other Topics	478DW	WOS:000268569000016	19651661	Green Published, Bronze			2020-06-30	J	Qian, TL; Wang, XH; Liu, S; Ma, L; Lu, Y				Qian, Tao-Lai; Wang, Xin-Hua; Liu, Sheng; Ma, Liang; Lu, Ying			Fentanyl inhibits glucose-stimulated insulin release from beta-cells in rat pancreatic islets	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Fentanyl; Inhibition; Insulin release; Islets	TRANSDERMAL FENTANYL; OPIOID-PEPTIDES; CANCER PAIN; MTT ASSAY; IN-VITRO; SECRETION; MODULATION; ENDORPHIN; ACTIVATION; EXPRESSION	AIM: To explore the effects of fentanyl on insulin release from freshly isolated rat pancreatic islets in static culture. METHODS: Islets were isolated from the pancreas of mature Sprague Dawley rats by common bile duct intraductal collagenase V digestion and were purified by discontinuous Ficoll density gradient centrifugation. The islets were divided into four groups according to the fentanyl concentration: control group (0 ng/mL), group I (0.3 ng/mL), group II (3.0 ng/mL), and group M (30 ng/mL). In each group, the islets were co-cultured for 48 h with drugs under static conditions with fentanyl alone, fentanyl + 0.1 mu g/mL naloxone or fentanyl + 1.0 mu g/mL naloxone. Cell viability was assessed by the MTT assay. Insulin release in response to low and high concentrations (2.8 mmol/L and 16.7 mmol/L, respectively) of glucose was investigated and electron microscopy morphological assessment was performed. RESULTS: Low- and high-glucose-stimulated insulin release in the control group was significantly higher than in groups II and III (62.33 +/- 9.67 mu IU vs 47.75 +/- 8.47 mu IU, 39.67 +/- 6.18 mu IU and 125.5 +/- 22.04 mu IU vs 96.17 +/- 14.17 mu IU, 75.17 +/- 13.57 mu IU, respectively, P < 0.01) and was lowest in group III (P < 0.01). After adding 1 mu g/mL naloxone, insulin release in groups II and III was not different from the control group. Electron microscopy studies showed that the islets were damaged by 30 ng/mL fentanyl, CONCLUSION: Fentanyl inhibited glucose-stimulated insulin release from rat islets, which could be prevented by naloxone. Higher concentrations of fentanyl significantly damaged beta-cells of rat islets. (C) 2009 The WJG Press and Baishideng. All rights reserved.	[Qian, Tao-Lai; Wang, Xin-Hua] Tongji Univ, Dept Pain Management, Shanghai E Hosp, Shanghai 2000120, Peoples R China; [Liu, Sheng] Tongji Univ, Dept Anesthesia, Shanghai E Hosp, Shanghai 200120, Peoples R China; [Ma, Liang] Tongji Univ, Cell Therapy Ctr, Shanghai E Hosp, Shanghai 200120, Peoples R China; [Lu, Ying] Tongji Univ, Cent Lab, Shanghai E Hosp, Shanghai 200120, Peoples R China	Qian, TL (reprint author), Tongji Univ, Dept Pain Management, Shanghai E Hosp, 150 Jimo Rd, Shanghai 2000120, Peoples R China.	qiantaolai@sina.com					AHREN B, 1989, INT J PANCREATOL, V5, P165; Amirshahrokhi K, 2008, TOXICOL APPL PHARM, V232, P119, DOI 10.1016/j.taap.2008.06.020; BANK HL, 1988, IN VITRO CELL DEV B, V24, P266; Bedirli N, 2007, J ANESTH, V21, P94, DOI 10.1007/s00540-006-0457-y; CETIN Y, 1990, CELL TISSUE RES, V259, P313, DOI 10.1007/BF00318454; CURRY DL, 1987, LIFE SCI, V40, P2053, DOI 10.1016/0024-3205(87)90097-X; Reisa MAD, 2008, J NUTR BIOCHEM, V19, P85, DOI 10.1016/j.jnutbio.2007.01.005; de Haan BJ, 2004, PANCREAS, V29, pE15, DOI 10.1097/00006676-200407000-00063; Garcia-Barrado MJ, 2002, EUR J PHARMACOL, V448, P95, DOI 10.1016/S0014-2999(02)01897-6; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; GIUGLIANO D, 1988, DIABETOLOGIA, V31, P3; GIUGLIANO D, 1988, DIABETES, V37, P1265, DOI 10.2337/diabetes.37.9.1265; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hair PI, 2008, DRUGS, V68, P2001, DOI 10.2165/00003495-200868140-00005; HUTTON JC, 1994, DIABETOLOGIA, V37, pS48, DOI 10.1007/BF00400826; Hyder A, 2005, CELL BIOL INT, V29, P831, DOI 10.1016/j.cellbi.2005.05.004; KAMEI J, 1993, LIFE SCI, V52, P53, DOI 10.1016/0024-3205(93)90288-E; KHAWAJA XZ, 1990, BIOCHEM J, V267, P233, DOI 10.1042/bj2670233; Knoch KP, 2006, CELL METAB, V3, P123, DOI 10.1016/j.cmet.2005.12.008; Ko WC, 2006, NEUROSCI LETT, V397, P274, DOI 10.1016/j.neulet.2005.12.047; Kussman BD, 2005, J CARDIOTHOR VASC AN, V19, P316, DOI 10.1053/j.jvca.2005.03.008; LATIF ZA, 1988, TRANSPLANTATION, V45, P827; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Liu IM, 1999, NEUROSCI LETT, V265, P183, DOI 10.1016/S0304-3940(99)00226-8; LOCATELLI A, 1985, ACTA DIABETOL LAT, V22, P25, DOI 10.1007/BF02591089; Novelli M, 2005, TOXICOL LETT, V156, P307, DOI 10.1016/j.toxlet.2004.12.004; SCHLEICHER RL, 1989, ENDOCRINOLOGY, V124, P1254, DOI 10.1210/endo-124-3-1254; Sittl R, 2006, CLIN THER, V28, P1144, DOI 10.1016/j.clinthera.2006.08.002; Skelly RH, 1998, BIOCHEM J, V331, P553, DOI 10.1042/bj3310553; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Stein DT, 1997, J CLIN INVEST, V100, P398, DOI 10.1172/JCI119546; Torres N, 2009, VITAM HORM, V80, P217, DOI 10.1016/S0083-6729(08)00609-2; Vosough-Ghanbari S, 2007, PESTIC BIOCHEM PHYS, V89, P130, DOI 10.1016/j.pestbp.2007.05.001; Wang XF, 2006, ASSAY DRUG DEV TECHN, V4, P203, DOI 10.1089/adt.2006.4.203; WERTHER GA, 1985, METABOLISM, V34, P136, DOI 10.1016/0026-0495(85)90122-2; Wu B, 2008, WORLD J GASTROENTERO, V14, P3064, DOI 10.3748/wjg.14.3064	36	3	4	0	1	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1007-9327	2219-2840		WORLD J GASTROENTERO	World J. Gastroenterol.	SEP 7	2009	15	33					4163	4169		10.3748/wjg.15.4163			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	491VS	WOS:000269610100012	19725151	Green Published, Other Gold			2020-06-30	J	Cho, JE; Kim, JY; Hong, JY; Kil, HK				Cho, J. E.; Kim, J. Y.; Hong, J. Y.; Kil, H. K.			The addition of fentanyl to 1.5 mg/ml ropivacaine has no advantage for paediatric epidural analgesia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							CAUDAL BLOCK; BUPIVACAINE-FENTANYL; CHILDREN; CLONIDINE; EFFICACY; INFUSION	Background Epidural opioids are frequently combined with local anaesthetics for an additive antinociceptive effect. We investigated the efficacy of epidural fentanyl to 1.25 or 1.5 mg/ml ropivacaine for post-operative epidural analgesia in children. Methods One hundred and eight children undergoing hypospadias repair were randomized to receive 1.25 mg/ml ropivacaine (R-1.25 group), 1.25 mg/ml ropivacaine with 0.2 mcg/kg/h of fentanyl (R1.25F group), 1.5 mg/ml ropivacaine (R-1.5 group) or 1.5 mg/ml ropivacaine with 0.2 mcg/kg/h of fentanyl (R1.5F group) for post-operative epidural analgesia. The epidural catheter was threaded caudally through the L4-5 interspace. The face, legs, activity, cry, consolability (FLACC) score was assessed at every hour and at FLACC score > 4, an epidural bolus of 0.5 ml/kg of ropivacaine 1.5 mg/ml was given as the rescue analgesia. The incidence of side effects such as hypoxia, sedation, pruritus, nausea and/or vomiting was recorded. Results The need for rescue analgesia was higher in the R-1.25 group compared with that in the other three groups (all P < 0.05). The incidence of side effects was higher in the R1.5F group compared with that in the R-1.25 and R-1.5 groups (both P=0.010). Conclusion The addition of 0.2 mcg/kg/h fentanyl to 1.5 mg/ml ropivacaine increased the incidence of side effects without improvement of analgesia in infants and children undergoing hypospadias repair. The use of plain 1.25 mg/ml ropivacaine increased the need for rescue analgesia and this could be compensated by addition of fentanyl.	[Kil, H. K.] Yonsei Univ, Coll Med, Anaesthesia & Pain Res Inst, Dept Anaesthesiol & Pain Med, Seoul 120752, South Korea; [Kim, J. Y.; Kil, H. K.] Yonsei Univ, Coll Med, Dept Anesthesiol, Seoul 120752, South Korea; [Kim, J. Y.; Kil, H. K.] Yonsei Univ, Coll Med, Pain Res Inst, Seoul 120752, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Anaesthesia & Pain Res Inst, Dept Anaesthesiol & Pain Med, Seoul 120752, South Korea.	hkkil@yuhs.ac		Kim, Ji Young/0000-0001-5822-0338			Baris S, 2003, PAEDIATR ANAESTH, V13, P126, DOI 10.1046/j.1460-9592.2003.00979.x; Boccara G, 2005, BRIT J ANAESTH, V94, P347, DOI 10.1093/bja/aei056; Bosenberg AT, 2005, PEDIATR ANESTH, V15, P739, DOI 10.1111/j.1460-9592.2004.01550.x; CAMPBELL FA, 1992, CAN J ANAESTH, V39, P661, DOI 10.1007/BF03008226; Constant I, 1998, BRIT J ANAESTH, V80, P294; Cucchiaro G, 2006, ANESTH ANALG, V103, P322, DOI 10.1213/01.ane.0000221047.68114.ad; Deng XM, 2002, ANESTH ANALG, V94, P1465, DOI 10.1097/00000539-200206000-00016; Ivani G, 1998, BRIT J ANAESTH, V81, P247; Joshi W, 1999, PAEDIATR ANAESTH, V9, P317, DOI 10.1046/j.1460-9592.1999.00368.x; Jylli L, 2002, ACTA ANAESTH SCAND, V46, P654, DOI 10.1034/j.1399-6576.2002.460604.x; Kawaraguchi Y, 2006, BRIT J ANAESTH, V97, P858, DOI 10.1093/bja/ael249; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Mazoit Jean-Xavier, 2003, Curr Opin Anaesthesiol, V16, P305, DOI 10.1097/00001503-200306000-00010	14	4	4	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2009	53	8					1084	1087		10.1111/j.1399-6576.2009.02046.x			4	Anesthesiology	Anesthesiology	481ED	WOS:000268789300014	19572930				2020-06-30	J	Dewachter, P; Lefebvre, D; Kalaboka, S; Bloch-Morot, E				Dewachter, P.; Lefebvre, D.; Kalaboka, S.; Bloch-Morot, E.			An anaphylactic reaction to transdermal delivered fentanyl	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							GUIDELINES; MANAGEMENT	Immediate allergic hypersensitivity reactions with fentanyl are rarely reported. We diagnosed a presumably IgE-mediated allergic hypersensitivity reaction comprising generalized erythema and bronchospasm 4 h after the first-time application of transdermal fentanyl. Prick test remained negative with fentanyl whereas an intradermal test (IDT) with fentanyl was positive (dilution 10(-2)). Cross-reactivity was found with sufentanil but not with remifentanil. The diagnosis was supported by the clinical history and a positive IDT with fentanyl. This case report confirms the need for a systematic allergological investigation in case of immediate hypersensitivity reactions for all drugs and all modes of administration.	[Dewachter, P.; Kalaboka, S.] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv Anesthesie Reanimat Chirurg & SAMU Paris, F-75015 Paris, France; [Lefebvre, D.; Bloch-Morot, E.] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Anesthesie Reanimat Chirurg, F-75015 Paris, France	Dewachter, P (reprint author), Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv Anesthesie Reanimat Chirurg & SAMU Paris, 149 Rue Sevres, F-75015 Paris, France.	pascale.dewachter@yahoo.fr					Dewachter P, 2006, ACTA ANAESTH SCAND, V50, P245, DOI 10.1111/j.1399-6576.2006.00912.x; Dewachter P, 2005, ANESTH ANALG, V101, P149, DOI 10.1213/01.ANE.0000153497.60047.80; Dewachter P, 2007, OBES SURG, V17, P1413, DOI 10.1007/s11695-007-9224-x; Dewachter P, 2008, CURR OPIN ANESTHESIO, V21, P363, DOI 10.1097/ACO.0b013e3282ff85e1; *FRENCH SOC AN INT, 2002, ANN FR ANESTH S, V21, P7; Hepner DL, 2003, ANESTH ANALG, V97, P1381, DOI 10.1213/01.ANE.0000082993.84883.7D; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kroigaard M, 2007, ACTA ANAESTH SCAND, V51, P655, DOI 10.1111/j.1399-6576.2007.01313.x; Mirakian R, 2009, CLIN EXP ALLERGY, V39, P43, DOI 10.1111/j.1365-2222.2008.03155.x; RING J, 1977, LANCET, V1, P466	11	13	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2009	53	8					1092	1093		10.1111/j.1399-6576.2009.02022.x			2	Anesthesiology	Anesthesiology	481ED	WOS:000268789300016	19496758				2020-06-30	J	Erdil, F; Bulut, S; Demirbilek, S; Gedik, E; Gulhas, N; Ersoy, MO				Erdil, F.; Bulut, S.; Demirbilek, S.; Gedik, E.; Gulhas, N.; Ersoy, M. O.			The effects of intrathecal levobupivacaine and bupivacaine in the elderly	ANAESTHESIA			English	Article							FENTANYL SPINAL-ANESTHESIA; RACEMIC BUPIVACAINE; ROPIVACAINE; VOLUNTEERS; SURGERY; LABOR	P>The objective of this study was to compare the block durations and haemodynamic effects associated with intrathecal levobupivacaine or bupivacaine in elderly patients undergoing transurethral prostate surgery. Eighty patients were prospectively randomised to receive plain 1.5 ml levobupivacaine 0.5% (group levobupivacaine) or 1.5 ml plain bupivacaine 0.5% (group bupivacaine) in combination with fentanyl 0.3 ml (15 mu g) for spinal anaesthesia. The time to reach T10 and peak sensory block level, and to maximum motor block were significantly shorter in group bupivacaine compared to group levobupivacaine (p < 0.05). Peak sensory block level was also significantly higher in group bupivacaine. In group bupivacaine, mean arterial pressure was significantly lower than group levobupivacaine, starting from 10 min until 30 min after injection (p < 0.05). Hypotension and nausea were less common in group levobupivacaine than group bupivacaine (p < 0.05). Because of the better haemodynamic stability and fewer side-effects associated with levobupivacaine, it may be preferred for spinal anaesthesia in elderly patients.	[Erdil, F.; Bulut, S.; Demirbilek, S.; Gedik, E.; Gulhas, N.; Ersoy, M. O.] Inonu Univ, Sch Med, Dept Anaesthesiol & Reanimat, Malatya, Turkey	Erdil, F (reprint author), Inonu Univ, Sch Med, Dept Anaesthesiol & Reanimat, Malatya, Turkey.	ferdil@inonu.edu.tr					Alley EA, 2002, ANESTH ANALG, V94, P188, DOI 10.1097/00000539-200201000-00036; Bardsley H, 1998, BRIT J CLIN PHARMACO, V46, P245, DOI 10.1046/j.1365-2125.1998.00775.x; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; BROMAGE PR, 1978, EPIDURAL ANALGESIA, P40; Burke D, 1998, BRIT J ANAESTH, V81, P631; CARPENTER RL, 1992, ANESTHESIOLOGY, V76, P906, DOI 10.1097/00000542-199206000-00006; Chow T C, 1994, Acta Anaesthesiol Sin, V32, P165; Cox CR, 1998, BRIT J ANAESTH, V80, P289; DORFMAN LJ, 1979, NEUROLOGY, V29, P38, DOI 10.1212/WNL.29.1.38; ERICKSEN MF, 1978, AM J PHYS ANTHROPOL, V48, P241, DOI 10.1002/ajpa.1330480219; Gautier P, 2003, BRIT J ANAESTH, V91, P684, DOI 10.1093/bja/aeg251; Glaser C, 2002, ANESTH ANALG, V94, P194, DOI 10.1097/00000539-200201000-00037; GREENE NM, 1985, ANESTH ANALG, V64, P715; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Lee YY, 2003, ANAESTH INTENS CARE, V31, P637, DOI 10.1177/0310057X0303100604; Lyons G, 1998, BRIT J ANAESTH, V81, P899; Morrison S, 2000, ANESTH ANALG, V90, P289; Newton DJ, 2005, BRIT J ANAESTH, V94, P662, DOI 10.1093/bja/aei095; van de Velde M, 2007, ANESTHESIOLOGY, V106, P149, DOI 10.1097/00000542-200701000-00024; Zohar E, 2007, ANESTH ANALG, V104, P552, DOI 10.1213/01.ane.0000255329.55037.cd	22	29	32	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0003-2409			ANAESTHESIA	Anaesthesia	SEP	2009	64	9					942	946		10.1111/j.1365-2044.2009.05995.x			5	Anesthesiology	Anesthesiology	479IX	WOS:000268654000004	19686477				2020-06-30	J	van Zundert, A; Maassen, R; Lee, R; Willems, R; Timmerman, M; Siemonsma, M; Buise, M; Wiepking, M				van Zundert, Andre; Maassen, Ralph; Lee, Ruben; Willems, Remi; Timmerman, Michel; Siemonsma, Marc; Buise, Marc; Wiepking, Marco			A Macintosh Laryngoscope Blade for Videolaryngoscopy Reduces Stylet Use in Patients with Normal Airways	ANESTHESIA AND ANALGESIA			English	Article							GLIDESCOPE(R) VIDEO LARYNGOSCOPE; TRACHEAL INTUBATION; MCGRATH(R) VIDEOLARYNGOSCOPE; OROTRACHEAL INTUBATION; CLINICAL-ASSESSMENT; SOFT PALATE; PERFORATION; MANAGEMENT; DIFFICULT; INJURY	BACKGROUND: Although most tracheal intubations with direct laryngoscopy are not performed with a styletted endotracheal tube, it is recommended that a stylet can be used with indirect videolaryngoscopy. Recently, there were several reports of complications associated with styletted endotracheal tubes and videolaryngoscopy. In this, study, we compared three videolaryngoscopes (VLSs) in patients undergoing tracheal intubation for elective surgery: the GlideScope (R) Ranger (TM) (GlideScope, Bothell, WA), die V-MAC (TM) Storz (R) Berci DCI (R) (Karl Storz, Tuttlingen, Germany), and the McGrath (R) (McGrath serics 5, Aircraft medical, Edinburgh, UK) and tested whether it is feasible to intubate the trachea of patients with indirect videolaryngoscopy without using a stylet. METHODS: Four hundred fifty consecutive adults (ASA PS I-II) undergoing tracheal intubation for elective surgery were randomly allocated for airway management with one of the three devices. Anesthesia induction for tracheal intubation consisted of fentanyl-propofol-rocuronium. An independent anesthesiologist used the Cormack-Lehane grading system to score an initial direct laryngoscopic view using a classic metal Macintosh blade. After subsequent positive-pressure ventilation using a face mask and an oxygen-sevoflurane mixture for 1 min, the trachea was intubated using one of the three VLSs. During intubation, the following data were collected: intubation time, number of intubation attempts, use of extra tools to facilitate intubation, and overall satisfaction score of the intubation conditions. RESULTS: The trachea of every patient was intubated using the VLSs, and none of the patients required conversion to the classic Macintosh laryngoscope. All three VLSs offered equal or better view of the glottis as assessed by the mean Cormack-Lehane grade, compared with the traditional Macintosh laryngoscopy, including a larger viewing angle of the glottic entrance. The average intubation time was 34 +/- 20 s for the GlideScope, 18 +/- 12 s for the V-M-AC Storz, and 38 +/- 23 s for the McGrath VLS. Intubation with the Storz was faster (P < 0.05) than the other two VLS tested and necessitated fewer additional tools (P < 0.01), resulting in a higher first-pass successful intubation rate. A stylet had to be used in 7%. of the patients in the Storz group versus about 50% of the patients when the other two VLS were used. CONCLUSIONS: The trachea of a large proportion of patients with normal airways can be intubated successfully with certain VLS blades without using a stylet, although the three studied VLSs clearly differ in outcome. The Storz VLS displaces soft tissues in the fashion of a classic Macintosh scope, affording room for tracheal tube insertion and limiting the need for stylet use compared with the other two scopes. Although VLSs offer several advantages, including better Visualization of the glottic entrance and intubation conditions, a good laryngeal view does not guarantee easy or Successful tracheal tube insertion. We recommend that the geometry of VLSs, including blade design, should be studied in more detail. (Anesth Analg 2009;109:825-31)	[van Zundert, Andre; Buise, Marc; Wiepking, Marco] Catharina Hosp, Brabant Med Sch, Dept Anesthesiol Intens Care & Pain Therapy, NL-5623 EJ Eindhoven, Netherlands; [van Zundert, Andre] Ghent Univ Hosp, Dept Anesthesiol, B-9000 Ghent, Belgium; [Maassen, Ralph; Willems, Remi; Timmerman, Michel; Siemonsma, Marc] Univ Hosp, Dept Anesthesiol, Maastricht, Netherlands; [Lee, Ruben] Delft Univ Technol, Dept Biomech Engn Mech Mat & Maritime Engn, Delft, Netherlands	van Zundert, A (reprint author), Catharina Hosp, Brabant Med Sch, Dept Anesthesiol Intens Care & Pain Therapy, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands.	zundert@iae.nl	van Zundert, Andre/D-6938-2012; Van Zundert, Andre A/G-2436-2015	Van Zundert, Andre A/0000-0001-5483-5941	Catharina Hospital, Eindhoven, the NetherlandsNetherlands Government	Supported by departmental funds of the Catharina Hospital, Eindhoven, the Netherlands. The videolaryngoscopes were made available to the study center, on a temporary basis, at no cost by the respective manufacturers: Ranger (TM) GlideScope (R), Verathon Medical, Bothell, WA; V-Mac (TM) Storz (R) Macintosh, Karl Storz, Tuttlingen, Germany; and McGrath (R) Series 5, Aircraft Medical, Edinborgh, UK.	Choo MKF, 2007, CAN J ANAESTH, V54, P322, DOI 10.1007/BF03022782; Cooper RM, 2007, CAN J ANAESTH, V54, P54, DOI 10.1007/BF03021900; Cooper RM, 2005, CAN J ANAESTH, V52, P191, DOI 10.1007/BF03027728; Cooper RM, 2003, CAN J ANAESTH, V50, P611, DOI 10.1007/BF03018651; Cuchillo JV, 2005, CAN J ANAESTH, V52, P661, DOI 10.1007/BF03015790; Fun WLL, 2007, EUR J ANAESTH, V24, P486, DOI 10.1017/S0265021506002067; Hirabayashi Y, 2007, OTOLARYNG HEAD NECK, V137, P175, DOI 10.1016/j.otohns.2007.02.038; Hirabayashi Y, 2006, CAN J ANAESTH, V53, P1263, DOI 10.1007/BF03021589; Hsu WT, 2007, ANESTH ANALG, V104, P1609, DOI 10.1213/01.ane.0000265490.26332.48; Hsu Wei-Ti, 2008, Acta Anaesthesiol Taiwan, V46, P39; Jones PM, 2007, CAN J ANAESTH, V54, P677, DOI 10.1007/BF03022966; Jones PM, 2007, CAN J ANAESTH, V54, P21, DOI 10.1007/BF03021895; Kaplan MB, 2006, J CLIN ANESTH, V18, P357, DOI 10.1016/j.jclinane.2006.01.002; Kaplan MB, 2006, SURG ENDOSC, V20, P479, DOI 10.1007/s00464-006-0038-z; Kramer DC, 2006, CAN J ANAESTH, V53, P737, DOI 10.1007/BF03021635; Lai HY, 2006, BRIT J ANAESTH, V97, P419, DOI 10.1093/bja/ael133; Malik AM, 2007, ANESTH ANALG, V104, P1610, DOI 10.1213/01.ane.0000264321.04403.06; Muallem M, 2007, CAN J ANAESTH, V54, P77, DOI 10.1007/BF03021905; Shippey B, 2008, BRIT J ANAESTH, V100, P116, DOI 10.1093/bja/aem303; Shippey B, 2007, CAN J ANAESTH, V54, P307, DOI 10.1007/BF03022777; Sun DA, 2005, BRIT J ANAESTH, V94, P381, DOI 10.1093/bja/aei041; Turkstra TP, 2007, CAN J ANAESTH, V54, P891, DOI 10.1007/BF03026792; Van Zundert A, 2007, Acta Anaesthesiol Belg, V58, P129; Vincent RD, 2007, J CLIN ANESTH, V19, P619, DOI 10.1016/j.jclinane.2007.03.010; Xue FS, 2007, MINERVA ANESTESIOL, V73, P451; Xue FS, 2006, J CLIN ANESTH, V18, P611, DOI 10.1016/j.jclinane.2006.03.018	26	71	75	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2009	109	3					825	831		10.1213/ane.0b013e3181ae39db			7	Anesthesiology	Anesthesiology	488EB	WOS:000269330800022	19690253				2020-06-30	J	Narayanaswamy, M				Narayanaswamy, Manu			Decrease in Bispectral Index While Correcting Hyperglycemia and an Increase in Bispectral Index with Correction of Hypoglycemia	ANESTHESIA AND ANALGESIA			English	Letter									Gosford Hosp, Dept Anesthesia, Gosford, NSW, Australia	Narayanaswamy, M (reprint author), Gosford Hosp, Dept Anesthesia, Gosford, NSW, Australia.	manu.swamy@gmail.com					Gilbert TT, 2001, CRIT CARE MED, V29, P1996, DOI 10.1097/00003246-200110000-00024; PRAMMING S, 1988, BRIT MED J, V296, P665, DOI 10.1136/bmj.296.6623.665; Vivien B, 2002, ANESTH ANALG, V95, P1824, DOI 10.1097/00000539-200212000-00082	3	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2009	109	3					995	995		10.1213/ane.0b013e3181adf919			1	Anesthesiology	Anesthesiology	488EB	WOS:000269330800056	19690284				2020-06-30	J	Kerssens, C; Gaither, JR; Sebel, PS				Kerssens, Chantal; Gaither, Julie R.; Sebel, Peter S.			Preserved Memory Function during Bispectral Index-guided Anesthesia with Sevoflurane for Major Orthopedic Surgery	ANESTHESIOLOGY			English	Article							IMPLICIT MEMORY; PROPOFOL; ISOFLURANE; AWARENESS; STATE	Background: Memory function tinder anesthesia is undesired but may arise from light hypnosis as well as stress-enhanced learning during surgery. The bispectral index (BIS, Aspect Medical Systems, Norwood, MA) is a monitor of hypnotic state that can help to avoid light hypnosis (i.e., BIS above 60). This study tested the hypothesis that BIS-guided anesthesia maintaining BIS 50-60 reduces the likelihood of memory function under anesthesia. Methods: After obtaining informed consent, 128 patients scheduled for joint replacement surgery under general anesthesia with sevoflurane were randomly assigned to BIS-guided anesthesia, titrating drugs to BIS 50-60 (BIS group), or a standard practice group in which BIS was recorded but did not guide drug administration. After induction, all patients were repeatedly played a list of 15 words. After recovery from anesthesia, all were interviewed about recall and completed a recognition memory test containing the presented words (targets, 33.3%) and new words (distractors). Preoperatively, patients filled out a stress questionnaire (Spielberger State-Trait Anxiety Inventory). Results: BIS values above 60 were recorded in both groups, but no patient recalled the presented words postoperatively. Only patients in the BIS group selected targets more often than distractors (37.1% vs. 31.5% hit rate, P = 0.001). Target hit rates correlated poorly to stress scores (P > 0.9), but were associated with the amount of fentanyl received preoperatively (P = 0.01) and pain management technique (P < 0.01). Conclusions: BIS titration to BIS 50-60 does not necessarily curb memory function under anesthesia when BIS values higher than 60 occur. Preoperative analgesia attenuated the likelihood of memory function under anesthesia.	[Kerssens, Chantal; Gaither, Julie R.; Sebel, Peter S.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30303 USA	Kerssens, C (reprint author), Emory Univ, Sch Med, Dept Anesthesiol, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.	ckerssens@emory.edu					Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Deeprose C, 2005, BRIT J ANAESTH, V94, P57, DOI 10.1093/bja/aeh289; Deeprose C, 2004, BRIT J ANAESTH, V92, P171, DOI 10.1093/bja/aeh054; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HUDETZ AG, 2006, SEMIN ANESTH PERIO M, V25, P196, DOI DOI 10.1053/j.sane.2006.09.003; Iselin-Chaves IA, 2005, ANESTHESIOLOGY, V103, P925, DOI 10.1097/00000542-200511000-00005; JELICIC M, 1992, EUR J COGN PSYCHOL, V4, P71, DOI 10.1080/09541449208406243; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; Johansen JW, 2000, J CLIN ANESTH, V12, P433, DOI 10.1016/S0952-8180(00)00187-2; Kerssens C, 2005, ANESTHESIOLOGY, V102, P57, DOI 10.1097/00000542-200501000-00012; Kerssens C, 2003, ANESTHESIOLOGY, V99, P570, DOI 10.1097/00000542-200309000-00011; Kerssens C, 2002, ANESTHESIOLOGY, V97, P382, DOI 10.1097/00000542-200208000-00015; Kerssens C, 2001, ANESTH ANALG, V92, P1210; Kerssens C, 2007, ANESTHESIOLOGY, V107, P172, DOI 10.1097/01.anes.0000268505.82823.f3; Lubke GH, 1999, ANESTHESIOLOGY, V90, P670, DOI 10.1097/00000542-199903000-00007; Punjasawadwong Y, 2007, COCHRANE DB SYST REV, V17, P4; ROORDAHRDLICKOV.V, 1990, [No title captured], P151; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; SCHEL PS, 2004, ANESTH ANALG, V99, P833; Spielberger C. D., 1983, STATE TRAIT ANXIETY; Stonell CA, 2006, ANESTHESIOLOGY, V105, P920, DOI 10.1097/00000542-200611000-00012; Struys M, 1998, ANAESTHESIA, V53, P4, DOI 10.1046/j.1365-2044.1998.00279.x	22	25	28	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2009	111	3					518	524		10.1097/ALN.0b013e3181b05f0b			7	Anesthesiology	Anesthesiology	488TA	WOS:000269371600013	19672180	Bronze			2020-06-30	J	Leslie, K; Sleigh, J; Paech, MJ; Voss, L; Lim, CW; Sleigh, C				Leslie, Kate; Sleigh, Jamie; Paech, Michael J.; Voss, Logan; Lim, Chiew Woon; Sleigh, Callum			Dreaming and Electroencephalographic Changes during Anesthesia Maintained with Propofol or Desflurane	ANESTHESIOLOGY			English	Article							GENERAL-ANESTHESIA; SPINDLE OSCILLATIONS; ALPHA-POWER; REM-SLEEP; RECALL; RECOVERY; STAGE-2; ISOFLURANE; SURGERY; INDEX	Background: Dream recall is reportedly more common propofol than after volatile anesthesia, but this may be due to delayed emergence or more amnesia after longer-acting volatiles. The electroencephalographic signs of dreaming during anesthesia and the differences between propofol and desflurane also are unknown. The authors therefore compared dream recall after propofol- or desflurane-maintained anesthesia and analyzed electroencephalographic patterns in dreamers and nondreamers and in propofol and desflurane patients for similarities to rapid eye movement and non-rapid eye movement sleep. Methods: Three hundred patients presenting for noncardiac surgery were randomized to receive propofol- or desflurane-maintained anesthesia. The raw electroencephalogram was recorded from induction until patients were interviewed about dreaming when they became first oriented postoperatively. Using spectral and ordinal methods, the authors quantified the amount of sleep spindle-like activity and high-frequency power in the electroencephalogram. Results: The incidence of dream recall was similar for propofol (27%) and desflurane (28%) patients. Times to interview were similar (median 20 [range 4-114] vs. 17 [7-86] min; P = 0.1029), but bispectral index values at interview were lower (85 [69-98] vs. 92 [40-98]; P < 0.0001) in propofol than in desflurane patients. During surgery, the raw electroencephalogram propofol patients showed more and faster spindle activity than in desflurane patients (P < 0.001). The raw electroencephalogram of dreamers showed fewer spindles and more high-frequency power than in nondreamers in the 5 min before interview (P < 0.05). Conclusions: Anesthetic-related dreaming seems to occur just before awakening and is associated with a rapid eye movement-like electroencephalographic pattern.	Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; Univ Auckland, Dept Anaesthesia, Waikato, New Zealand; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Perth, WA, Australia; King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Perth, WA, Australia	Leslie, K (reprint author), Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Parkville, Vic 3050, Australia.	kate.leslie@mh.org.au		Leslie, Kate/0000-0001-8512-3517; PAECH, MICHAEL/0000-0001-9023-6575	Australian and New Zealand College of Anaesthetists, Melbourne, Victoria, Australia [08/005]	Supported by a Project Grant (no. 08/005) from the Australian and New Zealand College of Anaesthetists, Melbourne, Victoria, Australia. ClinicalTrials. gov identifier NCT00446212: Australian Clinical Trials Registry number 012606000279527.	Aceto P, 2007, NEUROREPORT, V18, P823, DOI 10.1097/WNR.0b013e3280e129f5; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Bertolo H, 2003, COGNITIVE BRAIN RES, V15, P277, DOI 10.1016/S0926-6410(02)00199-4; Brandner B, 1997, ANAESTHESIA, V52, P750, DOI 10.1111/j.1365-2044.1997.161-az0171.x; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Conduit R, 2004, CONSCIOUS COGN, V13, P484, DOI 10.1016/j.concog.2004.06.008; Contreras D, 1997, J NEUROSCI, V17, P1179; Esposito MJ, 2004, PSYCHOPHYSIOLOGY, V41, P288, DOI 10.1111/j.1469-8986.00143.x; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Fuentealba P, 2005, J NEUROPHYSIOL, V93, P294, DOI 10.1152/jn.00552.2004; Grasshoff C, 2006, CURR PHARM DESIGN, V12, P3665, DOI 10.2174/138161206778522038; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Hellwagner K, 2003, EUR J ANAESTH, V20, P282, DOI 10.1097/00003643-200304000-00002; Hong CCH, 1996, SLEEP, V19, P232, DOI 10.1093/sleep/19.3.232; Kasmacher H, 1996, ANAESTHESIST, V45, P146, DOI 10.1007/s001010050249; Kreuer S, 2004, ANESTHESIOLOGY, V101, P847, DOI 10.1097/00000542-200410000-00008; Leslie K, 2007, ANESTHESIOLOGY, V106, P33, DOI 10.1097/00000542-200701000-00010; Lichtor JL, 2002, ANESTHESIOLOGY, V96, P878, DOI 10.1097/00000542-200204000-00015; Luginbuhl M, 2003, ACTA ANAESTH SCAND, V47, P165, DOI 10.1034/j.1399-6576.2003.00041.x; MARSCH SCU, 1992, EUR J ANAESTH, V9, P331; MOREL CR, 1991, CAN J PSYCHOL, V45, P140, DOI 10.1037/h0084276; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Steriade M, 2006, NEUROSCIENCE, V137, P1087, DOI 10.1016/j.neuroscience.2005.10.029; Toscano A, 2007, ANESTHESIOLOGY, V106, P952, DOI 10.1097/01.anes.0000265154.24685.47; WILLIAMSON PC, 1986, BIOL PSYCHIAT, V21, P717, DOI 10.1016/0006-3223(86)90236-2	25	63	63	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	SEP	2009	111	3					547	555		10.1097/ALN.0b013e3181adf768			9	Anesthesiology	Anesthesiology	488TA	WOS:000269371600016	19672164	Bronze			2020-06-30	J	Mukherjee, C; Walther, T; Borger, MA; Kempfert, J; Schuler, G; Mohr, FW; Ender, J				Mukherjee, Chirojit; Walther, Thomas; Borger, Michael Andrew; Kempfert, Joerg; Schuler, Gerhard; Mohr, Friedrich Wilhelm; Ender, Joerg			Awake Transapical Aortic Valve Implantation Using Thoracic Epidural Anesthesia	ANNALS OF THORACIC SURGERY			English	Editorial Material							CORONARY-ARTERY DISEASE	Transapical aortic valve implantation is a minimally invasive, beating-heart procedure that normally requires a general anesthetic. We herein report an 85-year-old patient with impaired pulmonary function who underwent successful transapical aortic valve implantation while awake, using a thoracic epidural anesthetic. (Ann Thorac Surg 2009;88:992-4) (C) 2009 by The Society of Thoracic Surgeons	Univ Leipzig, Dept Anesthesiol, Heart Ctr Leipzig, D-04289 Leipzig, Germany; Univ Leipzig, Dept Cardiac Surg, Heart Ctr Leipzig, D-04289 Leipzig, Germany; Univ Leipzig, Dept Cardiol, Heart Ctr Leipzig, D-04289 Leipzig, Germany	Mukherjee, C (reprint author), Univ Leipzig, Dept Anesthesia & Intens Med 2, Heart Ctr Leipzig, Struempellstr 39, D-04289 Leipzig, Germany.	chirojit.mukherjee@med.uni-leipzig.de	Borger, Michael A/H-3553-2013	Borger, Michael A/0000-0003-0780-6851; Borger, Michael/0000-0003-1046-1364			BLOMBERG S, 1990, ANESTHESIOLOGY, V73, P840, DOI 10.1097/00000542-199011000-00008; Ender J, 2008, ANESTHESIOLOGY, V109, P61, DOI 10.1097/ALN.0b013e31817881b3; Kessler P, 2005, J CARDIOTHOR VASC AN, V19, P32, DOI 10.1053/j.jvca.2004.11.006; KOCK M, 1990, ANESTH ANALG, V71, P625; Walther T, 2008, CURR OPIN CARDIOL, V23, P111, DOI 10.1097/HCO.0b013e3282f47c1b; Walther T, 2007, EUR J CARDIO-THORAC, V31, P9, DOI 10.1016/j.ejcts.2006.10.034	6	32	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	SEP	2009	88	3					992	994		10.1016/j.athoracsur.2009.01.052			4	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	485UO	WOS:000269150500045	19699938				2020-06-30	J	Jiang, Z; Dai, JQ; Shi, C; Zeng, WS; Jiang, RC; Tu, WF				Jiang, Z.; Dai, J. Q.; Shi, C.; Zeng, W. S.; Jiang, R. C.; Tu, W. F.			Influence of patient-controlled i.v. analgesia with opioids on supraventricular arrhythmias after pulmonary resection	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, patient-controlled; analgesics opioid, fentanyl; complications, arrhythmia; surgery, thoracic	THORACIC EPIDURAL-ANESTHESIA; POSTOPERATIVE ATRIAL-FIBRILLATION; CELL LUNG-CANCER; CARDIAC-SURGERY; REDUCTION; ONSET; TONE	Background. Postoperative supraventricular arrhythmias (SVA) are common after pulmonary resection and autonomic imbalance is thought to be one of the triggers. Opioids can increase parasympathetic activity and may balance heightened sympathetic tone after operation. We have examined the effect of postoperative patient-controlled analgesia (PCA) with opioids on postoperative SVA. Methods. Forty-eight patients were randomly assigned to two groups. The GA group received general anaesthesia PCA and PCA with opioids (fentanyl 6 mu g ml(-1) and tramadol 3 mg ml(-1)). The GEA group received combined general/epidural anaesthesia plus patient-controlled epidural analgesia (PCEA). Holter recording was completed for 12 h before operation and 12 and 48 h after operation. The incidence of supraventricular tachycardias (SVT), atrial fibrillation, and supraventricular ectopic beats (SVEBs) was evaluated. Results. The incidence of postoperative SVT was significantly lower in the GA group than in the GEA group (3/22 vs 10/22, P=0.021). The incidence of postoperative SVEBs was not statistically different between the groups, but the frequency of postoperative SVEBs increased less in the GA than the GEA group (7/22 vs 15/22, P=0.016). Conclusions. PCA with opioids (fentanyl and tramadol) can reduce postoperative SVA after pulmonary resection compared with PCEA with ropivacaine.	[Jiang, Z.; Dai, J. Q.; Shi, C.; Tu, W. F.] Liuhuaqiao Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [Jiang, Z.] So Med Univ, Postgrad Inst, Guangzhou, Guangdong, Peoples R China; [Zeng, W. S.; Jiang, R. C.] Liuhuaqiao Hosp, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China	Tu, WF (reprint author), Liuhuaqiao Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China.	wftuyx02@163.com					Ahn HJ, 2005, EUR J CARDIO-THORAC, V28, P19, DOI 10.1016/j.ejcts.2005.01.017; Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0; Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437; Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421; Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Dimmer C, 1998, AM J CARDIOL, V82, P22, DOI 10.1016/S0002-9149(98)00231-8; FROST L, 1995, EUR HEART J, V16, P825, DOI 10.1093/oxfordjournals.eurheartj.a061002; Hogue CW, 1998, CIRCULATION, V98, P429, DOI 10.1161/01.CIR.98.5.429; Jideus L, 2001, ANN THORAC SURG, V72, P65, DOI 10.1016/S0003-4975(01)02631-5; Licker M, 2003, BRIT J ANAESTH, V91, P525, DOI 10.1093/bja/aeg212; Liu LL, 1997, AM J PHYSIOL-HEART C, V273, pH805; Mathew JP, 2004, JAMA-J AM MED ASSOC, V291, P1720, DOI 10.1001/jama.291.14.1720; Oka T, 2001, ANESTH ANALG, V93, P253, DOI 10.1097/00000539-200108000-00003; Patti G, 2006, CIRCULATION, V114, P1455, DOI 10.1161/CIRCULATIONAHA.106.621763; Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003; Scott NB, 2001, ANESTH ANALG, V93, P528, DOI 10.1097/00000539-200109000-00003; Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783; VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X; Waktare JEP, 2001, EUR HEART J, V22, P333, DOI 10.1053/euhj.2000.2517	20	8	11	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	SEP	2009	103	3					364	368		10.1093/bja/aep172			5	Anesthesiology	Anesthesiology	483ZV	WOS:000269013300006	19549643	Bronze			2020-06-30	J	Kaneda, K; Han, TH				Kaneda, Kotaro; Han, Tae-Hyung			Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: Burns vs. non-burns	BURNS			English	Article						Burns; Fentanyl; Population pharmacokinetics; Non-linear mixed effect model	ALFENTANIL; INJURIES; PLASMA; MASS	Objective: Fentanyl is a commonly used analgesic and sedative for the burned in the operating theater as well as the burn care units. The aim of this study was to characterize fentanyl population pharmacokinetics in burns and to identify clinically significant covariates. Method: Twenty adults, aged 37 +/- 3 years, with 49 +/- 4% (mean +/- S.E.) total body surface area burn, were enrolled at 17 +/- 3 days after the injury. Twenty non-burn adults served as controls. After an intravenous bolus of 200 mcg fentanyl, the plasma concentrations were sequentially determined up to 4.5 h. Concentration-time profiles were subjected to nonlinear mixed effect modeling. Cardiac indices were estimated with esophageal Doppler monitor. Results: Burned patients have higher cardiac index than the non-burned. Three-compartment model was the best fit. The volumes of distribution were considerably expanded in all three compartments (27.9 L vs. 63.4 L, 64.7 L vs. 92.9 L,153 L vs. 301 L, respectively) compared to the non-burned. BURN was the single most important covariate significantly improving the model. Conclusion: The primary effect of burn trauma on fentanyl pharmacokinetics is substantially expanded volumes of distribution, i.e., dilutional. Difference in simulation, however, was insufficient to explain the augmented resistance to fentanyl, implying the importance of titrating analgesics to the clinical effect. (C) 2008 Elsevier Ltd and ISBI. All rights reserved.	[Kaneda, Kotaro; Han, Tae-Hyung] Univ Iowa Hosp & Clin, Dept Anesthesia, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	Han, TH (reprint author), Univ Iowa Hosp & Clin, Dept Anesthesia, Roy J & Lucille A Carver Coll Med, 200 Hawkins Dr,5937 JPP, Iowa City, IA 52242 USA.	anthony-han@uiowa.edu					Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Davies G, 1996, CLIN PHARMACOKINET, V31, P410, DOI 10.2165/00003088-199631060-00002; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Glatting G, 2007, MED PHYS, V34, P4285, DOI 10.1118/1.2794176; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; HERNDON TN, 2004, LANCET, V5, P1895; JAEHDE L, 1995, CLIN PHARMACOKINET, V29, P15, DOI 10.2165/00003088-199529010-00003; Jeschke MG, 2007, CRIT CARE MED, V35, pS519, DOI 10.1097/01.CCM.0000282027.10288.10; Kim KM, 2004, J TRAUMA, V57, P1013, DOI 10.1097/01.TA.0000105925.51950.08; Kostopanagiotou G, 2006, EUR J ANAESTH, V23, P598, DOI 10.1017/S0265021506000135; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Parke J, 1999, COMPUT METH PROG BIO, V59, P19, DOI 10.1016/S0169-2607(98)00098-4; Perreault S, 2001, ANN PHARMACOTHER, V35, P1588; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; SHEINER LB, 1981, J PHARMACOKINET BIOP, V9, P635, DOI 10.1007/BF01061030; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; SINGLETON MA, 1988, BRIT J ANAESTH, V60, P619, DOI 10.1093/bja/60.6.619; Summer GJ, 2007, BURNS, V33, P1021, DOI 10.1016/j.burns.2007.02.007; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Wahlby U, 2001, J PHARMACOKINET PHAR, V28, P231, DOI 10.1023/A:1011527125570; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X	23	10	11	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	SEP	2009	35	6					790	797		10.1016/j.burns.2008.12.006			8	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	486DX	WOS:000269177100005	19501972				2020-06-30	J	Shah, H; Smythe, J; Hanafiah, Z; Williams, GJP; Holdcroft, A				Shah, H.; Smythe, J.; Hanafiah, Z.; Williams, G. J. P.; Holdcroft, A.			Factors in the choice of oral transmucosal fentanyl citrate dose for adult burns dressings	BURNS			English	Article						Fentanyl; Transmucosal; Burns; Pain; Wound dressing	WOUND CARE; PAIN; MORPHINE; ANALGESIA; TITRATION; EFFICACY; TRIAL	Factors that influenced the choice of dose of oral transmucosal fentanyl at the time of burns dressing change were investigated in a prospective study. After Ethics committee approval, data was analysed from 29 consecutive patients who had been recruited and consented for a study of pain associated with burns dressings. Patients had completed an 11-point verbal pain intensity score (VRS) prior to and after the dressing change. Analgesic use during for this period was documented. Doses of 600 to 1200 mcg of transmucosal fentanyl (Actiq (R)) were given based on individual assessment. The pre-dressing VRS (median [range]) in the 15 patients who received 600 mcg was 8 [3-10] and was higher than the VRS of 6 [2-9] in the 800-1200 mcg group. The time since the burn was longer in the low dose group at 7 [1-22] days compared with 5 [0-50] days in the higher dose group. In addition 73% of the low dose group was prescribed opioids regularly prior to the dressing compared with 57% of the high dose group. The choice of a lower transmucosal fentanyl dose was based on prior use of opioids and the age of the burn rather than on the patient's pain intensity. (C) 2008 Elsevier Ltd and ISBI. All rights reserved.	[Shah, H.; Smythe, J.; Holdcroft, A.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; [Hanafiah, Z.; Williams, G. J. P.; Holdcroft, A.] Chelsea & Westminster Hosp, NHS Fdn Trust, London, England	Shah, H (reprint author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	drhetulshah@gmail.com			Chelsea and Westminster Hospital, London	The authors thank the Burns Unit staff and patients at Chelsea and Westminster Hospital, London, for their support and Cephalon for a grant towards the study analysis and travel costs for Dr. Shah. Cephalon had no involvement in the study design, analysis and manuscript preparation.	Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005; CHOINIERE M, 1989, J TRAUMA, V29, P1531, DOI 10.1097/00005373-198911000-00013; Coimbra C, 2003, ANESTH ANALG, V97, P839, DOI 10.1213/01.ANE.0000074236.76333.53; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Gallagher G, 2000, ANAESTHESIA, V55, P1159, DOI 10.1046/j.1365-2044.2000.01712.x; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks G., 2001, EUR J PALLIAT CARE, V8, P6; Jonsson CE, 1998, BURNS, V24, P448, DOI 10.1016/S0305-4179(98)00050-3; LATARJET J, 1995, BURNS, V21, P344, DOI 10.1016/0305-4179(95)00003-8; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; MACINTYRE PA, 2007, EUR J ANAESTH, V16, P118; NORMAN AT, 2004, EUR J ANAESTH, V4, P57; Pal SK, 1997, BURNS, V23, P404, DOI 10.1016/S0305-4179(97)00029-6; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Rae CP, 2000, EUR J ANAESTH, V17, P43, DOI 10.1046/j.1365-2346.2000.00600.x; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009	21	3	5	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179			BURNS	Burns	SEP	2009	35	6					798	801		10.1016/j.burns.2008.09.014			4	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	486DX	WOS:000269177100006	19167829				2020-06-30	J	Leung, JW; Salera, R; Toomsen, L; Mann, S; Leung, FW				Leung, Joseph W.; Salera, Rodolei; Toomsen, Lee; Mann, Surinder; Leung, Felix W.			Pilot Feasibility Study of the Method of Water Infusion Without Air Insufflation in Sedated Colonoscopy	DIGESTIVE DISEASES AND SCIENCES			English	Article						Colonoscopy; Water infusion; CRC screening; Medication; Sedation; Warm water infusion	RANDOMIZED CONTROLLED-TRIAL; FLEXIBLE SIGMOIDOSCOPY; UNSEDATED COLONOSCOPY; ASSISTED COLONOSCOPY; SCREENING COLONOSCOPY; MINOR COMPLICATIONS; WARM WATER; ENDOSCOPY; VETERANS; NURSES	One study in sedated patients demonstrated a reduction in pain score but not midazolam dosage when warm water infusion was used to manage colonic spasm. We describe pilot data with a modified warm water infusion technique. We tested the hypothesis that patients receiving even only half of the usual dose of sedation medications would have acceptable cecal intubation and tolerate the procedure well, based on retrospective review of prospectively collected data from a single Veterans Affairs (VA) medical center. Group 1 included 32 consecutive patients who received full-dose and group 2 included 43 consecutive patients who received half-dose premedication. Insertion of colonoscope was aided by warm water infusion in lieu of air insufflation. Pain scores during insertion, cecal intubation rate, and total amount of medications were monitored. The novel technique permitted equal cecal intubation rate at reduced total dose of medications. Pain scores were not significantly different. The uncontrolled nonrandomized observational nature of the data is one limitation. The nonsignificant difference in pain scores may be affected by a type II error. These pilot data suggest that insertion is feasible without air when water infusion is used. The novel technique may be a useful adjunct for minimizing the dosage of sedation medications without adversely affecting cecal intubation. Further study is needed to compare air insufflation and water infusion with regard to patient tolerance and success, particularly in the presence of an on-demand sedation policy.	[Leung, Felix W.] VA Greater Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA; [Leung, Joseph W.; Salera, Rodolei; Toomsen, Lee; Mann, Surinder] VANCHCS, Sacramento VA Med Ctr, Gastroenterol Sect, Mather, CA USA; [Leung, Joseph W.] UC Davis Med Ctr, Div Gastroenterol & Hepatol, Sacramento, CA USA; [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	Leung, FW (reprint author), VA Greater Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, 16111 Plummer St, North Hills, CA 91343 USA.	felix.leung@va.gov			Veterans Affairs Medical Research FundsUS Department of Veterans Affairs	Supported in part by the Veterans Affairs Medical Research Funds.	ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; Baumann UA, 1999, ENDOSCOPY, V31, P314; Brocchi E, 2008, AM J GASTROENTEROL, V103, P581, DOI 10.1111/j.1572-0241.2007.01693.x; Chak A, 1996, GASTROINTEST ENDOSC, V44, P54, DOI 10.1016/S0016-5107(96)70229-8; Church JM, 2002, GASTROINTEST ENDOSC, V56, P672, DOI 10.1067/mge.2002.128916; COHAN CF, 1992, GASTROINTEST ENDOSC, V38, P575, DOI 10.1016/S0016-5107(92)70520-3; COTTON PB, 1990, PRACTICAL GASTROINTE, P160; Eckardt VF, 1999, GASTROINTEST ENDOSC, V49, P560, DOI 10.1016/S0016-5107(99)70382-2; Eickhoff A, 2007, AM J GASTROENTEROL, V102, P261, DOI 10.1111/j.1572-0241.2006.01002.x; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; Friedland S, 2007, WORLD J GASTROENTERO, V13, P5933, DOI 10.3748/wjg.v13.i44.5933; Hamamoto N, 2002, GASTROINTEST ENDOSC, V56, P825, DOI 10.1067/mge.2002.129608; Hayes A, 2001, Gastroenterol Nurs, V24, P54, DOI 10.1097/00001610-200103000-00002; Hirota WK, 2007, GASTROINTEST ENDOSC, V65, P657, DOI 10.1016/j.gie.2006.08.021; Hoff G, 2000, SCAND J GASTROENTERO, V35, P225, DOI 10.1080/003655200750024056; HULL T, 1994, SURG ENDOSC-ULTRAS, V8, P784, DOI 10.1007/BF00593441; *JOINT COMM ACCR H, 2001, COMPR ACCR MAN HOSP; *JOINT COMM ACCR H, 2005, COMPR ACCR MAN HOSP; KEEFFE E B, 1990, Gastrointestinal Endoscopy, V36, pS13; Knox L, 2007, J AM BOARD FAM MED, V20, P444, DOI 10.3122/jabfm.2007.05.060175; Ko CW, 2007, GASTROINTEST ENDOSC, V65, P648, DOI 10.1016/j.gie.2006.06.020; Lee JG, 2006, ALIMENT PHARM THER, V23, P945, DOI 10.1111/j.1365-2036.2006.02838.x; Lee JG, 2001, AM J GASTROENTEROL, V96, P95; Leo RA, 2004, SOUTH MED J, V97, P797, DOI 10.1097/01.SMJ.0000136287.03289.3D; Leung FW, 2008, DIGEST DIS SCI, V53, P2719, DOI 10.1007/s10620-007-0192-8; Leung FW, 2008, GASTROINTEST ENDOSC, V67, P712, DOI 10.1016/j.gie.2007.10.028; Leung FW, 2008, GASTROINTEST ENDOSC, V67, P718, DOI 10.1016/j.gie.2007.11.040; Leung JV, 2007, ALIMENT PHARM THERAP, V26, P627, DOI 10.1111/j.1365-2036.2007.03404.x; Levenson D, 2001, Rep Med Guidel Outcomes Res, V12, P9; Madan A, 2004, SOUTH MED J, V97, P800, DOI 10.1097/01.SMJ.0000129794.97798.A5; NIVATVONGS S, 1991, GASTROINTEST ENDOSC, V27, P127; Ramakrishnan S, 2004, J ROY SOC MED, V97, P432, DOI 10.1258/jrsm.97.9.432; Redelmeier DA, 1996, PAIN, V66, P3, DOI 10.1016/0304-3959(96)02994-6; Rex DK, 1999, GASTROINTEST ENDOSC, V49, P554, DOI 10.1016/S0016-5107(99)70381-0; Rubin DT, 2007, GASTROINTEST ENDOSC, V66, P108, DOI 10.1016/j.gie.2006.12.056; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; Terruzzi V, 2001, GASTROINTEST ENDOSC, V54, P169, DOI 10.1067/mge.2001.113923; Tu RH, 2006, GASTROINTEST ENDOSC, V63, P87, DOI 10.1016/j.gie.2005.08.015; Ylinen ER, 2007, J CLIN NURS, V16, P1125, DOI 10.1111/j.1365-2702.2006.01668.x	39	15	15	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	SEP	2009	54	9					1997	2001		10.1007/s10620-008-0576-4			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	474ZP	WOS:000268324000027	19058003				2020-06-30	J	Bonfreschi, V; Giuliani, E; Malagnino, FC; Navi, A; Coppi, G; Silingardi, R; D'Amico, R; Barbieri, A				Bonfreschi, Veronica; Giuliani, Enrico; Malagnino, Francesco C.; Navi, Angela; Coppi, Gioachino; Silingardi, Roberto; D'Amico, Roberto; Barbieri, Alberto			Analgesia during abdominal aortic aneurysm endovascular repair: remifentanil vs. fentanyl-midazolam - a randomized controlled trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						abdominal aortic aneurysm; analgesia; fentanyl; midazolam; remifentanil; sedation	INTENSIVE-CARE-UNIT; CAROTID-ENDARTERECTOMY; REGIONAL ANESTHESIA; CONSCIOUS SEDATION; PATIENT; SAFETY; SYSTEM	Background and objective Endovascular repair offers a less surgically invasive procedure for abdominal aortic aneurysms but nevertheless, still requires analgesic sedative cover to ensure an acceptable level of patient comfort and cardiorespiratory stability. The peculiarity of this kind of operation is that painful stimuli are concentrated in specific moments separated by intervals devoid of pain, so the insurgence of pain can be predicted and prevented with a bolus of analgesic, making a continuous infusion not essential, but potentially useful in achieving a better analgesic stability. The primary objective of the study was pain control measured by Visual Analogue Scale; secondary endpoints were cardiorespiratory stability and an acceptable level of sedation. Methods The sedative analgesic protocols of two groups of randomly allocated patients, undergoing abdominal aortic aneurysm endovascular repair, were compared. The experimental group received remifentanil infusion (0.03-0.1 mu g kg(-1) min(-1)) and the control group received intravenous doses of fentanyl and midazolam (1-3 mu g kg(-1) and 0.05-0.1 mg kg(-1), respectively). Results Fifty patients were investigated out of 60 enrolled. There were no relevant differences concerning cardiorespiratory stability and level of sedation, but pain levels were significantly lower in the experimental group: mean Visual Analogue Scale 0.35 +/- 0.40 vs. 1.49 +/- 0.62 (P<0.001) and area under the curve 17.48 +/- 5.09 vs. 33.05 +/- 8.19 (P<0.001). Conclusion Both techniques were shown to be safe and most importantly effective in offering cardiovascular stability and analgesia for American Society of Anaesthesiologists III-IV patients undergoing endovascular abdominal aortic aneurysm repair. However, remifentanil continuous infusion proved to offer significantly more stable pain control compared with the currently used combination fentanyl-midazolam. Eur J Anaesthesiol 26:782-787 (C) 2009 European Society of Anaesthesiology.	[Bonfreschi, Veronica; Malagnino, Francesco C.] Univ Modena, Dept Anaesthesiol & Intens Care, Azienda Osped, I-41100 Modena, Italy; [Giuliani, Enrico; Barbieri, Alberto] Univ Modena & Reggio Emilia, Dept Anaesthesiol & Intens Care, Modena, Italy; [Navi, Angela] Nuovo Osped S Agostino Estense, Dept Anaesthesiol & Intens Care, Modena, Italy; [Coppi, Gioachino; Silingardi, Roberto] Nuovo Osped S Agostino Estense, Dept Vasc Surg, Modena, Italy; [D'Amico, Roberto] Nuovo Osped S Agostino Estense, Dept Haematol & Oncol, Modena, Italy	Barbieri, A (reprint author), Via Pozzo 71, I-41100 Modena, Italy.	alberto.barbieri@unimore.it	D'Amico, Roberto/I-8106-2014; Barbieri, Alberto/L-1427-2016; Giuliani, Enrico/L-2158-2016	D'Amico, Roberto/0000-0002-3211-6687; Barbieri, Alberto/0000-0002-3904-1323; Giuliani, Enrico/0000-0001-7140-7850; Silingardi, Roberto/0000-0002-5082-6957	University of Modena and Reggio Emilia	The study was subsidized by University of Modena and Reggio Emilia research funds.	Absalom AR, 2001, BRIT J ANAESTH, V87, P778, DOI 10.1093/bja/87.5.778; Allison MA, 2008, J VASC SURG, V48, P121, DOI 10.1016/j.jvs.2008.02.031; Baumgartner I, 2008, J VASC SURG, V48, P808, DOI 10.1016/j.jvs.2008.05.026; Beers R, 2004, CNS DRUGS, V18, P1085, DOI 10.2165/00023210-200418150-00004; Cigada M, 2008, J CRIT CARE, V23, P349, DOI 10.1016/j.jcrc.2007.04.003; Coppi G, 2005, J CARDIOVASC SURG, V46, P431; Coppi G, 2008, J VASC SURG, V48, P795, DOI 10.1016/j.jvs.2008.05.011; Dilger JA, 2004, CAN J ANAESTH, V51, P20, DOI 10.1007/BF03018541; Doyle PW, 2001, EUR J ANAESTH, V18, P13, DOI 10.1046/j.1365-2346.2001.00763.x; Godet G, 2004, BRIT J ANAESTH, V92, P329, DOI 10.1093/bja/aeh057; Henretta JP, 1999, J VASC SURG, V29, P793, DOI 10.1016/S0741-5214(99)70205-3; Hohener D, 2008, BRIT J ANAESTH, V100, P8, DOI 10.1093/bja/aem342; Krenn H, 2002, BRIT J ANAESTH, V89, P637, DOI 10.1093/bja/aef233; Lippmann M, 2003, ANESTH ANALG, V97, P981, DOI 10.1213/01.ANE.0000081791.02404.F7; Marrocco-Trischitta MM, 2001, EUR J VASC ENDOVASC, V22, P405, DOI 10.1053/ejvs.2001.1502; McCutcheon CA, 2006, ANESTH ANALG, V102, P668, DOI 10.1213/01.ane.0000197777.62397.d5; Muellejans B, 2006, CRIT CARE, V10, DOI 10.1186/cc4939; Park G, 2007, BRIT J ANAESTH, V98, P76, DOI 10.1093/bja/ael320	18	7	9	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	SEP	2009	26	9					782	787		10.1097/EJA.0b013e32832bcc9b			6	Anesthesiology	Anesthesiology	500GO	WOS:000270287000012	19412108				2020-06-30	J	Leung, JW; Mann, SK; Siao-Salera, R; Ransibrahmanakul, K; Lim, B; Cabrera, H; Canete, W; Barredo, P; Gutierrez, R; Leung, FW				Leung, Joseph W.; Mann, Surinder K.; Siao-Salera, Rodelei; Ransibrahmanakul, Kanat; Lim, Brian; Cabrera, Hazel; Canete, Wilhemina; Barredo, Paul; Gutierrez, Rebeck; Leung, Felix W.			A randomized, controlled comparison of warm water infusion in lieu of air insufflation versus air insufflation for aiding colonoscopy insertion in sedated patients undergoing colorectal cancer screening and surveillance	GASTROINTESTINAL ENDOSCOPY			English	Article; Proceedings Paper	73rd Annual Meeting of the American-College-of-Gastroenterology	OCT 03-08, 2008	Orlando, FL	Amer Coll Gastroenterol			UNSEDATED COLONOSCOPY; ENDOSCOPY; VETERANS	Background: Pilot studies using a novel water method to perform screening colonoscopy allowed patients to complete colonoscopy without sedation medications and also significantly increased the cecal intubation success rate. Objective: To perform a randomized, controlled trial comparing air insufflation (conventional method) and water infusion in lieu of air insufflation(study method) colonoscopy in minimally sedated patients. Hypothesis: Compared with the conventional method, patients examined by the study method had lower pain scores and required less medication but had a similar cecal intubation rate and willingness to undergo colonoscopy in the future. Setting: Outpatient colonoscopy in a single Veterans Affairs hospital. Methods: After informed consent and standard bowel preparation, patients received premedications administered as 0.5-increments of fentanyl (25 mu g) and 0.5-increments of Versed (midazolam) (1 mg) plus 50 mg of diphenhydramine. The conventional and the study methods for colonoscopy were implemented as previously described. Additional pain medications were administered at the patients' request. Main Outcome Measurements: Increments of medications, pain scores, cecal intubation, and willingness to repeat colonoscopy. Results: Increments of medications Used before reaching the cecum (1.6 +/- 0.2 vs 2.4 +/- 0.2, P < .0027), total increments used (1.8 +/- 0.2 vs 2.5 +/- 0.2, P <.014), and the maximum pain scores (1.3 +/- 0.3 vs 4.1 +/- 0.6, P <.0002) were significantly lower with the water method. Cecal intubation rate (100%) and willingness to undergo a repeat colonoscopy (96%) were similar. Limitations: Single Veterans Affairs hospital, older male population. Conclusion: Water infusion in lieu of air insufflation is superior to air insufflation during colonoscopy in the minimally sedated patients (ClinicalTrials.gov identifier NCT00785889). (Gastrointest Endosc 2009;70:505-10.)	[Leung, Joseph W.; Mann, Surinder K.; Siao-Salera, Rodelei; Cabrera, Hazel; Canete, Wilhemina; Barredo, Paul; Gutierrez, Rebeck] Sacramento VA Med Ctr, Gastroenterol Sect, Mather, CA 95655 USA; [Leung, Joseph W.; Mann, Surinder K.; Ransibrahmanakul, Kanat] Univ Calif, Davis Med Ctr, Sacramento, CA USA; [Leung, Felix W.] Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda ACC, Los Angeles, CA USA	Leung, JW (reprint author), Sacramento VA Med Ctr, Gastroenterol Sect, 10535 Hosp Way, Mather, CA 95655 USA.	jwleung@ucdavis.edu					Baumann UA, 1999, ENDOSCOPY, V31, P314; Church JM, 2002, GASTROINTEST ENDOSC, V56, P672, DOI 10.1067/mge.2002.128916; COTTON PB, 1990, COLONOSCOPY PRACTICA, P160; FALCHUK ZM, 1984, NEW ENGL J MED, V310, P598; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; Hamamoto N, 2002, GASTROINTEST ENDOSC, V56, P825, DOI 10.1067/mge.2002.129608; Henry SG, 2007, J GEN INTERN MED, V22, P1415, DOI 10.1007/s11606-007-0281-6; Jonas DE, 2007, AM J GASTROENTEROL, V102, P2401, DOI 10.1111/j.1572-0241.2007.01387.x; Ko CW, 2007, GASTROINTEST ENDOSC, V65, P648, DOI 10.1016/j.gie.2006.06.020; Leung FW, 2008, DIGEST DIS SCI, V53, P2847, DOI 10.1007/s10620-008-0259-1; Leung FW, 2008, GASTROINTEST ENDOSC, V67, P718, DOI 10.1016/j.gie.2007.11.040; Leung FW, 2009, GASTROINTEST ENDOSC, V69, P546, DOI 10.1016/j.gie.2008.08.014; Leung JV, 2007, ALIMENT PHARM THERAP, V26, P627, DOI 10.1111/j.1365-2036.2007.03404.x; LEUNG JW, 2008, DIG DIS SCI     1205; Ramakrishnan S, 2004, J ROY SOC MED, V97, P432, DOI 10.1258/jrsm.97.9.432; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; Tu RH, 2006, GASTROINTEST ENDOSC, V63, P87, DOI 10.1016/j.gie.2005.08.015; Vargo JJ, 2007, J CLIN GASTROENTEROL, V41, P591, DOI 10.1097/01.mcg.0000225634.52780.0e; WAYE JD, 1972, SURG CLIN N AM, V52, P1013; WILLIAMS C, 1973, GUT, V14, P990, DOI 10.1136/gut.14.12.990; WOLFF WI, 1971, J AMER MED ASSOC, V217, P1509, DOI 10.1001/jama.217.11.1509	21	57	57	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2009	70	3					505	510		10.1016/j.gie.2008.12.253			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	490QN	WOS:000269516500016	19555938				2020-06-30	J	Balci, C; Karabekir, HS; Kahraman, F; Sivaci, RG				Balci, C.; Karabekir, H. S.; Kahraman, F.; Sivaci, R. G.			Comparison of Entropy and Bispectral Index during Propofol and Fentanyl Sedation in Monitored Anaesthesia Care	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						PROPOFOL; FENTANYL; SEDATION; EEG; BISPECTRAL INDEX; ENTROPY; MONITORED ANAESTHESIA CARE	APPROXIMATE ENTROPY; REMIFENTANIL; SUPPRESSION; MIDAZOLAM	Comparison of entropy (state entropy [SE] and response entropy [RE]) with the bispectral index (BIS) during propofol sedation in monitored anaesthesia care (MAC) was carried out in patients undergoing hand surgery. Thirty candidates for elective hand surgery were pre-medicated with midazolam 0.06 mg/kg and atropine 0.01 mg/kg. Sedation was induced with intravenous propofol and fentanyl was also administered. The Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) was used to determine sedation level and pain was maintained at < 4 on a 0 - 10 verbal rating scale. The BIS, entropy, MOAA/S and pain values were recorded before initiation of sedation (control), during initiation of sedation, during surgery, and for 30 min after the end of surgery and anaesthesia. On initiation of sedation, entropy decreased more rapidly than BIS. At 10 min after initiation of sedation, the mean +/- SD values for MOAA/S, BIS, RE and SE were 3.00 +/- 0.36, 85.45 +/- 0.15, 74.00 +/- 0.60 and 72.02 +/- 0.12, respectively. During recovery, BIS and RE and SE increased in parallel with MOAA/S. It is concluded that entropy monitoring is as reliable as BIS monitoring in MAC.	[Balci, C.] Afyon Kocatepe Univ, Sch Med, Dept Anaesthesiol, TR-03200 Afyon, Turkey; [Karabekir, H. S.] Afyon Kocatepe Univ, Dept Neurosurg, TR-03200 Afyon, Turkey	Balci, C (reprint author), Afyon Kocatepe Univ, Sch Med, Dept Anaesthesiol, Ali Cetinkaya Kampusu, TR-03200 Afyon, Turkey.						Anderson RE, 2004, ANAESTHESIA, V59, P52, DOI 10.1111/j.1365-2044.2004.03523.x; Badrinath S, 2000, ANESTH ANALG, V90, P858, DOI 10.1213/00000539-200004000-00016; BARASH PG, 2001, HDB CLIN ANESTHESIA, V54, P14; Bruhn J, 2003, ANESTHESIOLOGY, V98, P621, DOI 10.1097/00000542-200303000-00008; Bruhn J, 2001, ANESTHESIOLOGY, V95, P30, DOI 10.1097/00000542-200107000-00010; Bruhn J, 2001, BRIT J ANAESTH, V87, P505, DOI 10.1093/bja/87.3.505; Bruhn J, 2000, ANESTHESIOLOGY, V92, P715, DOI 10.1097/00000542-200003000-00016; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Ellerkmann RK, 2004, ANESTHESIOLOGY, V101, P1275; Ghisi D, 2005, Minerva Anestesiol, V71, P533; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Herrick IA, 1997, ANESTH ANALG, V84, P1285, DOI 10.1097/00000539-199706000-00021; Iannuzzi M, 2005, BRIT J ANAESTH, V95, P117, DOI 10.1093/bja/aei176; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; KEARSE LA, 1994, ANESTHESIOLOGY, V81, P1365, DOI 10.1097/00000542-199412000-00010; LESLIE K, 1995, ANESTH ANALG, V81, P1269, DOI 10.1097/00000539-199512000-00025; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Rego MMS, 1999, ANESTH ANALG, V88, P518; Rudner R, 2003, GASTROINTEST ENDOSC, V57, P657, DOI 10.1067/mge.2003.207; Schmidt GN, 2004, ANESTHESIOLOGY, V101, P1283; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; SILVA L, 1993, ANESTHESIOLOGY, V79, P95; Soto R, 2005, ANESTH ANALG, V100, P1059, DOI 10.1213/01.ANE.0000146435.58751.17; Viertio-Oja H, 2004, ACTA ANAESTH SCAND, V48, P154, DOI 10.1111/j.0001-5172.2004.00322.x	24	9	12	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	SEP-OCT	2009	37	5					1336	1342		10.1177/147323000903700508			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	537SD	WOS:000273133200008	19930838				2020-06-30	J	Smith, TJ; Coyne, P; French, W; Ramakrishnan, V; Corrigan, P				Smith, Thomas J.; Coyne, Patrick; French, Wendy; Ramakrishnan, Viswanathan; Corrigan, Patricia			Failure to Accrue to a Study of Nebulized Fentanyl for Dyspnea: Lessons Learned	JOURNAL OF PALLIATIVE MEDICINE			English	Letter							CITRATE; PAIN		[Smith, Thomas J.] Virginia Commonwealth Univ, Dept Med, Massey Canc Ctr, Richmond, VA 23298 USA; [Coyne, Patrick] Virginia Commonwealth Univ, Dept Nursing, Thomas Palliat Care Unit, Richmond, VA 23298 USA; [Ramakrishnan, Viswanathan] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Corrigan, Patricia] Virginia Commonwealth Univ, Dept Pharmacol, Richmond, VA 23298 USA	Smith, TJ (reprint author), Virginia Commonwealth Univ, Dept Med, Massey Canc Ctr, 1101 E Marshall St,Sanger Hall 6-030, Richmond, VA 23298 USA.	tsmith@hsc.vcu.edu	Coyne, Patrick/AAH-7098-2019	Smith, Thomas/0000-0003-3040-6434			Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Dy SM, 2008, J CLIN ONCOL, V26, P3886, DOI 10.1200/JCO.2007.15.9525; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Miner JR, 2007, ACAD EMERG MED, V14, P895, DOI 10.1197/j.aem.2007.06.036; POLOSA R, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002872	6	14	14	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	SEP	2009	12	9					771	772		10.1089/jpm.2009.0113			2	Health Care Sciences & Services	Health Care Sciences & Services	489NR	WOS:000269427500005	19719370				2020-06-30	J	Minami, K; Hasegawa, M; Ito, H; Nakamura, A; Tomii, T; Matsumoto, M; Orita, S; Matsushima, S; Miyoshi, T; Masuno, K; Torii, M; Koike, K; Shimada, S; Kanemasa, T; Kihara, T; Narita, M; Suzuki, T; Kato, A				Minami, Kazuhisa; Hasegawa, Minoru; Ito, Hisanori; Nakamura, Atsushi; Tomii, Takako; Matsumoto, Mitsunobu; Orita, Satoshi; Matsushima, Syuichi; Miyoshi, Takako; Masuno, Koichi; Torii, Mikinori; Koike, Katsumi; Shimada, Shinji; Kanemasa, Toshiyuki; Kihara, Tsuyoshi; Narita, Minoru; Suzuki, Tsutomu; Kato, Akira			Morphine, Oxycodone, and Fentanyl Exhibit Different Analgesic Profiles in Mouse Pain Models	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						oxycodone; morphine; fentanyl; neuropathic pain-like state; bone cancer pain	BONE CANCER PAIN; CONTROLLED-RELEASE OXYCODONE; NEUROPATHIC PAIN; PHARMACOLOGICAL PROFILES; BREAKTHROUGH PAIN; RANDOMIZED-TRIAL; NERVE-FIBERS; MURINE MODEL; MICE; DESTRUCTION	Morphine, oxycodone, and fentanyl are clinically prescribed drugs for the management of severe pain. We investigated whether these opioids possess different efficacy profiles on several types of pain in mouse pain models. When the three opioids were tested in the femur bone cancer model, all of them significantly reversed guarding behavior, whereas the effects on limb-use abnormality and allodynia-like behavior differed among the opioids. Particularly, although oxycodone (5 - 20 mg/kg) and fentanyl (0.2 mg/kg) significantly reversed limb-use abnormality, not even a high dose of morphine (50 mg/kg) could reverse it. When the effects of these opioids were examined in a sciatic nerve ligation (SNL) model of neuropathic pain, oxycodone was the most effective, producing an antinociceptive effect without affecting the withdrawal threshold of sham-treated animals. When the effects of these opioids were examined with the tail-flick test using naive animals, oxycodone, morphine, and fentanyl exhibited antinociceptive effects on thermal nociception. These results show that the three opioids exhibit different efficacy outcomes in multiple pain models and that the efficacy profile of oxycodone does not overlap those of morphine and fentanyl.	[Minami, Kazuhisa; Hasegawa, Minoru; Ito, Hisanori; Nakamura, Atsushi; Tomii, Takako; Koike, Katsumi; Shimada, Shinji; Kanemasa, Toshiyuki; Kihara, Tsuyoshi; Kato, Akira] Shionogi & Co Ltd, Discovery Res Labs, Pain & Neurol, Koka, Shiga 5203423, Japan; [Matsumoto, Mitsunobu; Orita, Satoshi] Shionogi & Co Ltd, Discovery Res Labs, Allergy & Canc, Fukushima Ku, Osaka 5530002, Japan; [Matsushima, Syuichi; Miyoshi, Takako; Masuno, Koichi; Torii, Mikinori] Shionogi & Co Ltd, Dev Res Labs, Drug Safety Evaluat, Osaka 5610825, Japan; [Narita, Minoru; Suzuki, Tsutomu] Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Shinagawa Ku, Tokyo 1428501, Japan	Kato, A (reprint author), Shionogi & Co Ltd, Discovery Res Labs, Pain & Neurol, 1405 Gotanda,Koka Cho, Koka, Shiga 5203423, Japan.	akira_kato@shionogi.co.jp					Becker R, 2000, STEREOT FUNCT NEUROS, V75, P16, DOI 10.1159/000048379; Bercovitch Michaela, 2006, J Pain Palliat Care Pharmacother, V20, P33, DOI 10.1300/J354v20n04_06; Cherny N, 2000, J Oncol Manag, V9, P8; CHERNY NI, 1994, NEUROLOGY, V44, P857, DOI 10.1212/WNL.44.5.857; El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016; Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005; Genf World Health Organization, 1986, CANC PAIN REL; Gilchrist LS, 2005, BRAIN RES, V1044, P197, DOI 10.1016/j.brainres.2005.02.081; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hara S, 2008, ONCOLOGY-BASEL, V74, P52, DOI 10.1159/000143219; Hasbi A, 2007, BIOCHEMISTRY-US, V46, P12997, DOI 10.1021/bi701436w; Hojo M, 2008, J PHARMACOL SCI, V108, P308, DOI 10.1254/jphs.08244FP; Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; Kato A, 2008, ONCOLOGY-BASEL, V74, P55, DOI 10.1159/000143220; Kirou-Mauro AN, 2009, J PAIN SYMPTOM MANAG, V37, P77, DOI 10.1016/j.jpainsymman.2007.12.014; Komiya S, 1999, ARCH ORTHOP TRAUM SU, V119, P22, DOI 10.1007/s004020050349; Lemberg K, 2006, ANESTH ANALG, V102, P1768, DOI 10.1213/01.ane.0000205751.88422.41; Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1; Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Narita M, 2008, NEUROPSYCHOPHARMACOL, V33, P1097, DOI 10.1038/sj.npp.1301471; Narita M, 2007, LIFE SCI, V80, P2015, DOI 10.1016/j.lfs.2007.02.045; Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022; Pan YX, 2005, MOL PHARMACOL, V68, P866, DOI 10.1124/mol.105.011858; Pandit-Taskar N, 2004, J NUCL MED, V45, P1358; Peters CM, 2005, EXP NEUROL, V193, P85, DOI 10.1016/j.expneurol.2004.11.028; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022; Smith T, 2007, VASC HEALTH RISK MAN, V3, P833; Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011; Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X; Watson CPN, 1998, NEUROLOGY, V50, P1837; WATSON CPN, 1999, PAIN RES MANAG, V4, P168; Zhao C, 2007, J PAIN, V8, P931, DOI 10.1016/j.jpain.2007.06.008	36	43	45	0	8	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613	1347-8648		J PHARMACOL SCI	J. Pharmacol. Sci.	SEP	2009	111	1					60	72		10.1254/jphs.09139FP			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	501IR	WOS:000270375600007	19729873	Bronze			2020-06-30	J	Pennington, P; Caminiti, S; Schein, JR; Hewitt, DJ; Nelson, WW				Pennington, Peg; Caminiti, Stephanie; Schein, Jeff R.; Hewitt, David J.; Nelson, Winnie W.			Patients' Assessment of the Convenience of Fentanyl HCl Iontophoretic Transdermal System (ITS) Versus Morphine Intravenous Patient-Controlled Analgesia (IV PCA) in the Management of Postoperative Pain After Major Surgery	PAIN MANAGEMENT NURSING			English	Article							EFFICACY; CARE; SAFETY; SATISFACTION; MULTICENTER; QUALITY	The patient-controlled fentanyl HCl iontophoretic transdermal system (ITS) is a compact, self-contained, needle-free system that has been approved for acute postoperative pain management in hospitalized adults. The objective of the present analysis was to evaluate patients' assessment of fentanyl ITS and morphine intravenous patient-controlled analgesia (IV PCA) convenience on 7 different subscales, using a validated patient ease of care (EOC) questionnaire in 2 prospective, open-label, randomized, phase IIIb clinical trials. Patients received fentanyl ITS or morphine IV PCA (N = 1,305) for up to 72 h after total hip replacement surgery (THR study) or abdominal or pelvic surgery (APS study). For the majority of items on the patient EOC questionnaire, trends suggest that greater percentages of patients reported the most positive response for fentanyl ITS than they did for morphine IV PCA in both studies; differences were particularly noteworthy for items on the Movement subscale. In the THR study, more patients in the fentanyl ITS group were responders compared with those in the morphine IV PCA group for the subscales Confidence with Device, Pain Control, Knowledge/Understanding, and Satisfaction. In the APS study, responder rates for these subscales did not differ between treatment-groups. These findings indicate that patients assessed the EOC associated with fentanyl ITS higher compared with morphine IV PCA for the management of acute postoperative pain and suggest that fentanyl ITS has the potential to improve acute Postoperative pain care for patients and nurses. (C) 2009 by the American Society for Pain Management Nursing	[Pennington, Peg] Helen Keller Hosp, Sheffield, AL 35660 USA; [Caminiti, Stephanie] Orthoped Associates Hartford, Hartford, CT USA; [Schein, Jeff R.; Hewitt, David J.] Ortho McNeil Janssen Sci Affairs, Raritan, NJ USA; [Nelson, Winnie W.] Johnson & Johnson Pharmaceut Serv LLC, Raritan, NJ USA	Pennington, P (reprint author), Helen Keller Hosp, 1300 S Montgomery, Sheffield, AL 35660 USA.	ppenn35633@yahoo.com			PriCara, a Unit of Ortho-McNeil, Raritan, New Jersey	Supported by PriCara, a Unit of Ortho-McNeil, Raritan, New Jersey.	Aiken LH, 2001, HEALTH AFFAIR, V20, P43, DOI 10.1377/hlthaff.20.3.43; *AM PAIN SOC, 2003, [No title captured]; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Bertolini G, 2002, EUR J CLIN PHARMACOL, V58, P73, DOI 10.1007/s00228-002-0432-y; Carr DB, 2005, REGION ANESTH PAIN M, V30, P286, DOI 10.1016/j.rapm.2004.10.009; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Chen PP, 2001, ANESTH ANALG, V92, P224; Chumbley GM, 1999, ANAESTHESIA, V54, P386, DOI 10.1046/j.1365-2044.1999.00836.x; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Doyle DJ, 2003, CAN J ANAESTH, V50, P855; EISENACH JC, 2002, CAN J ANAESTH, V49, pR1; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; FERRANTE FM, 1988, ANESTH ANALG, V67, P457; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hicks Rodney W, 2004, J Perianesth Nurs, V19, P18, DOI 10.1016/j.jopan.2003.11.007; Ivanova A, 2001, BIOMETRICS, V57, P567, DOI 10.1111/j.0006-341X.2001.00567.x; JAMISON RN, 1993, ANESTH ANALG, V77, P121; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Lewis JA, 2004, PHARM STAT, V3, P77, DOI 10.1002/pst.107; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MAGNANI B, 1989, PAIN, V39, P23, DOI 10.1016/0304-3959(89)90171-1; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Nixon J, 2000, INT J NURS STUD, V37, P279, DOI 10.1016/S0020-7489(99)00059-0; Puig MM, 2001, ACTA ANAESTH SCAND, V45, P465, DOI 10.1034/j.1399-6576.2001.045004465.x; Ramzi DW, 2004, AM FAM PHYSICIAN, V69, P2829; Rathmell JP, 2006, REGION ANESTH PAIN M, V31, P1, DOI 10.1016/j.rapm.2006.05.002; Ritchey R Michael, 2006, Cleve Clin J Med, V73 Suppl 1, pS72; Roos EM, 2003, CURR OPIN RHEUMATOL, V15, P160, DOI 10.1097/00002281-200303000-00014; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Thomas T, 1998, PAIN, V75, P177, DOI 10.1016/S0304-3959(97)00218-2; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; VISCUSI ER, 2006, 25 ANN SCI M AM PAIN; WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542-199511000-00023; Weill-Engerer S, 2004, J AM GERIATR SOC, V52, P1299, DOI 10.1111/j.1532-5415.2004.52359.x; WILBURN SQ, 2004, ONLINE J ISSUES NURS, V9	42	14	17	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1524-9042	1532-8635		PAIN MANAG NURS	Pain Manag. Nurs.	SEP	2009	10	3					124	133		10.1016/j.pmn.2007.09.001			10	Nursing	Nursing	493UD	WOS:000269762700004	19706349				2020-06-30	J	Papadima, A; Lagoudianakis, EE; Antonakis, P; Filis, K; Makri, I; Markogiannakis, H; Katergiannakis, V; Manouras, A				Papadima, Artemisia; Lagoudianakis, Emmanuel E.; Antonakis, Pantelis; Filis, Konstantinos; Makri, Ira; Markogiannakis, Haridimos; Katergiannakis, Vaggelogiannis; Manouras, Andreas			Repeated intraperitoneal instillation of levobupivacaine for the management of pain after laparoscopic cholecystectomy	SURGERY			English	Article							LOCAL-ANESTHETIC INFILTRATION; POSTOPERATIVE PAIN; DOUBLE-BLIND; PREEMPTIVE ANALGESIA; RACEMIC BUPIVACAINE; CONTROLLED-TRIAL; ROPIVACAINE; RELIEF; LAPAROTOMY; CATHETER	Background. Laparoscopic cholecystectomy is the treatment of choice for symptomatic cholelithiasis. Postoperative pain, however, can prolong hospital stay and Lead to increased morbidity. In the context Of a multimodal approach to analgesia, intraperitoneal local anesthetic administration optimizes analgesia and facilitates early postoperative recovery, and it may be associated with a decreased risk of side effects. Methods. A total of 71 patients was randomized to receive either intraperitoneal analgesic (IPA group) or not (controls). At the completion of cholecystectomy, 10 mL of levobupivacaine 0.5% were infused intraperitoneally in the IPA group and 8 h postoperatively, whereas in the controls, 10 mL of 0.9% NaCl were administered in the corresponding points of time. Differences in pain scores between groups were the primary endpoints. Opioid consumption and adverse effects were the secondary endpoints. Results. The 2 groups were homogenous in respect to age, sex, body mass index (BMI), and duration of operation. No conversion, complication, or mortality was recorded. The IPA group had a lesser visual analog scale score at rest and at movement compared with controls at all points of time measured. Moreover, fentanyl consumption in the recovery room was significantly greater in the control group, and the consumption of meperidine and the percentage of the patients that requested rescue analgesia in the word was significantly greater in the control group. Local analgesic intraperitoneal injection as well as Parecoxib for Postoperative analgesia had no significant adverse effects. Conclusion. Our study showed. that 2 separate doses of intraperitoneally administered levobupivacaine significantly decreased postoperative pain and the need for opioids compared with placebo. This technique is simple, safe, and without adverse effects. (Surgery 2009;146:475-82.)	[Lagoudianakis, Emmanuel E.; Antonakis, Pantelis; Filis, Konstantinos; Markogiannakis, Haridimos; Katergiannakis, Vaggelogiannis; Manouras, Andreas] Univ Athens, Dept Propaedeut Surg 1, Hippocrate Hosp, Athens Med Sch, Athens 11527, Greece; [Papadima, Artemisia; Makri, Ira] Univ Athens, Dept Anesthesiol, Hippocrate Hosp, Athens Med Sch, Athens 11527, Greece	Manouras, A (reprint author), Univ Athens, Dept Propaedeut Surg 1, Hippocrate Hosp, Athens Med Sch, V Sophias 114 Av, Athens 11527, Greece.	amanouras@hippocratio.gr		Filis, Konstantinos/0000-0001-6309-5201			Alexander JI, 1997, BRIT J ANAESTH, V79, P369, DOI 10.1093/bja/79.3.369; Barczynski M, 2006, SURG ENDOSC, V20, P1088, DOI 10.1007/s00464-005-0458-1; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Bisgaard T, 1999, ANESTH ANALG, V89, P1017, DOI 10.1097/00000539-199910000-00036; Bisgaard T, 2001, EUR J SURG, V167, P84; Boddy AP, 2006, ANESTH ANALG, V103, P682, DOI 10.1213/01.ane.0000226268.06279.5a; Casati A, 2003, J CLIN ANESTH, V15, P126, DOI 10.1016/S0952-8180(02)00513-5; Casati A, 2005, BEST PRACT RES-CLIN, V19, P247, DOI 10.1016/j.bpa.2004.12.003; Glaser C, 2002, ANESTH ANALG, V94, P194, DOI 10.1097/00000539-200201000-00037; Gupta A, 2002, ANESTH ANALG, V95, P450, DOI 10.1097/00000539-200208000-00040; Gupta A, 2005, BEST PRACT RES-CLIN, V19, P275, DOI 10.1016/j.bpa.2004.12.007; JORIS J, 1995, ANESTH ANALG, V81, P379, DOI 10.1097/00000539-199508000-00029; JORIS J, 1992, BRIT J ANAESTH, V69, P341, DOI 10.1093/bja/69.4.341; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; Kehlet H, 1996, J CLIN ANESTH, V8, P441, DOI 10.1016/0952-8180(96)00131-6; Kehlet H, 2005, SURG ENDOSC, V19, P1396, DOI 10.1007/s00464-004-2173-8; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kucuk C, 2007, SURG TODAY, V37, P396, DOI 10.1007/s00595-006-3408-1; Labaille T, 2002, ANESTH ANALG, V94, P100, DOI 10.1097/00000539-200201000-00019; Moiniche S, 2000, ANESTH ANALG, V90, P899; Moiniche S, 1998, BRIT J ANAESTH, V81, P377, DOI 10.1093/bja/81.3.377; Mraovic B, 1997, ACTA ANAESTH SCAND, V41, P193, DOI 10.1111/j.1399-6576.1997.tb04664.x; NARCHI P, 1991, LANCET, V338, P1569, DOI 10.1016/0140-6736(91)92384-E; Ozer Y, 2005, EUR J ANAESTH, V22, P442, DOI 10.1017/S026502150500075X; Papadima A, 2007, EUR J ANAESTH, V24, P154, DOI 10.1017/S0265021506001293; Papagiannopoulou P, 2003, SURG ENDOSC, V17, P1961, DOI 10.1007/s00464-002-9256-1; Pappas-Gogos G, 2008, SURG ENDOSC, V22, P2036, DOI 10.1007/s00464-008-9762-x; Pasqualucci A, 1996, ANESTHESIOLOGY, V85, P11, DOI 10.1097/00000542-199607000-00003; PUTENSENHIMMER G, 1992, ANESTHESIOLOGY, V77, P675, DOI 10.1097/00000542-199210000-00010; RICHMOND CE, 1993, LANCET, V342, P73, DOI 10.1016/0140-6736(93)91284-S; SCHEININ B, 1995, ACTA ANAESTH SCAND, V39, P195, DOI 10.1111/j.1399-6576.1995.tb04042.x; URE BM, 1994, SURG ENDOSC-ULTRAS, V8, P90, DOI 10.1007/BF00316616; Wills VL, 2000, BRIT J SURG, V87, P273, DOI 10.1046/j.1365-2168.2000.01374.x	34	27	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	SEP	2009	146	3					475	482		10.1016/j.surg.2009.04.010			8	Surgery	Surgery	492SU	WOS:000269680600012	19715804				2020-06-30	J	Saunders, AB; Hanzlicek, AS; Martinez, EA; Stickney, MJ; Steiner, JM; Suchodolski, JS; Fosgate, GT				Saunders, Ashley B.; Hanzlicek, Andrew S.; Martinez, Elizabeth A.; Stickney, Mark J.; Steiner, Joerg M.; Suchodolski, Jan S.; Fosgate, Geoffery T.			Assessment of cardiac troponin I and C-reactive protein concentrations associated with anesthetic protocols using sevoflurane or a combination of fentanyl, midazolam, and sevoflurane in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anesthesia; biomarker; canine	CHRONICALLY INSTRUMENTED DOGS; MYOCARDIAL INFARCT SIZE; RAT-HEART; ISOFLURANE; INJURY; SURGERY; BIOMARKER; DISEASE; REPERFUSION; HALOTHANE	Objective To report serum cardiac troponin I (cTnI) and C-reactive protein (CRP) concentrations in dogs anesthetized for elective surgery using two anesthetic protocols. Study design Prospective, randomized clinical study. Animals Twenty client-owned dogs presenting for elective ovariohysterectomy or castration. Methods The dogs were randomized into two groups. All dogs were premedicated with glycopyrrolate (0.011 mg kg(-1)) and hydromorphone (0.1 mg kg(-1)) IM approximately 30 minutes prior to induction of anesthesia. Anesthesia in dogs in group 1 was induced with propofol (6 mg kg(-1)) IV to effect and in dogs in group 2 with diazepam (0.2 mg kg(-1)) IV followed by etomidate (2 mg kg(-1)) IV to effect. For maintenance of anesthesia, group 1 received sevoflurane (adjustable vaporizer setting 0.5-4%) and group 2 received a combination of fentanyl (0.8 mu g kg(-1) minute(-1)) and midazolam (8.0 mu g kg(-1) minute(-1)) IV plus sevoflurane (adjustable vaporizer setting 0.5-4%) to maintain anesthesia. Serum cTnI and CRP concentrations were measured at baseline and 6, 18, and 24 hours post-anesthetic induction. Biochemical analysis was performed at baseline. Lactate was obtained at baseline and 6 hours post-anesthetic induction. Heart rate and mean arterial blood pressure were measured intra-operatively. Results Baseline serum cTnI and CRP concentrations were comparable between groups. A significant difference in serum cTnI or CRP concentrations was not detected post-operatively between groups at any time point. Serum CRP concentrations were significantly increased post-anesthetic induction in both groups, which was attributed to surgical trauma. Conclusions and clinical relevance There was no significant difference in serum cTnI and CRP concentrations between anesthetic protocols. Further investigation in a larger number of dogs is necessary to confirm the current findings.	[Saunders, Ashley B.; Hanzlicek, Andrew S.; Martinez, Elizabeth A.; Stickney, Mark J.; Steiner, Joerg M.; Suchodolski, Jan S.] Texas A&M Univ, Dept Small Anim Clin Sci, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Fosgate, Geoffery T.] Texas A&M Univ, Dept Vet Integrat Biosci, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA	Saunders, AB (reprint author), Texas A&M Univ, Dept Small Anim Clin Sci, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA.	asaunders@cvm.tamu.edu	Fosgate, Geoffrey T/N-8700-2014; Hanzlicek, Andrew/AAN-7498-2020	Fosgate, Geoffrey T/0000-0002-9432-0042; Suchodolski, Jan/0000-0002-2176-6932; Saunders, Ashley/0000-0001-9908-3894			Adin DB, 2006, J VET INTERN MED, V20, P1136, DOI 10.1892/0891-6640(2006)20[1136:COCCTI]2.0.CO;2; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; Barr SC, 2005, ANTIMICROB AGENTS CH, V49, P5160, DOI 10.1128/AAC.49.12.5160-5161.2005; BERNARD JM, 1990, ANESTHESIOLOGY, V72, P659, DOI 10.1097/00000542-199004000-00014; Brix-Christensen V, 1998, ACTA ANAESTH SCAND, V42, P63, DOI 10.1111/j.1399-6576.1998.tb05082.x; Burgener IA, 2006, J VET INTERN MED, V20, P277; Buyukkocak U, 2005, MEDIAT INFLAMM, P312, DOI 10.1155/MI.2005.312; Buyukkocak U, 2006, CROAT MED J, V47, P862; Cason BA, 1997, ANESTHESIOLOGY, V87, P1182, DOI 10.1097/00000542-199711000-00023; CHARLSON ME, 1990, ANN SURG, V212, P567, DOI 10.1097/00000658-199011000-00003; Corcoran TB, 2006, BRIT J ANAESTH, V97, P825, DOI 10.1093/bja/ael270; Cromheecke S, 2006, ANESTH ANALG, V103, P289, DOI 10.1213/01.ane.0000226097.22384.f4; EKINS R, 1991, SCAND J CLIN LAB INV, V51, P33, DOI 10.3109/00365519109104600; EVANS GO, 1987, AM J VET RES, V30, P840; Hagman R, 2007, ACTA VET SCAND, V49, DOI 10.1186/1751-0147-49-6; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; ILKIW JE, 1994, CAN J VET RES, V58, P248; Karagiannis MH, 2006, COMP CONT EDUC PRACT, V28, P287; Lobetti R, 2002, J VET INTERN MED, V16, P63, DOI 10.1892/0891-6640(2002)016&lt;0063:CTICB&gt;2.3.CO;2; MAIR J, 1995, EUR J CLIN CHEM CLIN, V33, P869; Malagon I, 2005, BRIT J ANAESTH, V94, P805, DOI 10.1093/bja/aei142; Mastrorilli C, 2007, J VET INTERN MED, V21, P3, DOI 10.1111/j.1939-1676.2007.tb02921.x; McGrotty YL, 2004, VET REC, V154, P175, DOI 10.1136/vr.154.6.175; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; O'Brien PJ, 2006, LAB ANIM-UK, V40, P153, DOI 10.1258/002367706776319042; Osman R, 2006, VASC HEALTH RISK MAN, V2, P221; OVIZE M, 1992, CIRC RES, V71, P1165, DOI 10.1161/01.RES.71.5.1165; Oyama MA, 2004, J VET INTERN MED, V18, P831, DOI 10.1892/0891-6640(2004)18&lt;831:CTCIDW&gt;2.0.CO;2; Pang DS, 2007, J AM ANIM HOSP ASSOC, V43, P270, DOI 10.5326/0430270; Pelander L, 2002, EUR J COMP ANIM PRAC, V12, P66; Pelander L, 2008, ACTA VET SCAND, V50, DOI 10.1186/1751-0147-50-35; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Ricchiuti V, 1998, AM J CLIN PATHOL, V110, P241; Rush JE, 2006, J VET INTERN MED, V20, P635, DOI 10.1892/0891-6640(2006)20[635:CPCIDW]2.0.CO;2; Schlack W, 1998, BRIT J ANAESTH, V81, P913; Schober KE, 2002, J AM VET MED ASSOC, V221, P381, DOI 10.2460/javma.2002.221.381; SCHOBER KE, 2005, TXB VET INTERNAL MED, P940; Schultz JJ, 1997, J MOL CELL CARDIOL, V29, P2187, DOI 10.1006/jmcc.1997.0454; SHIH AC, 2009, J VET CARDIOL S, V11, P587; SHIZUKUDA Y, 1992, CARD RES, V26, pS34; Spratt DP, 2005, J SMALL ANIM PRACT, V46, P139, DOI 10.1111/j.1748-5827.2005.tb00304.x; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Toller WG, 1999, ANESTHESIOLOGY, V91, P1437, DOI 10.1097/00000542-199911000-00037; WARLTIER DC, 1988, ANESTHESIOLOGY, V69, P552, DOI 10.1097/00000542-198810000-00016; Zaugg M, 2004, BRIT J ANAESTH, V93, P21, DOI 10.1093/bja/aeh150	45	15	15	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	SEP	2009	36	5					449	456		10.1111/j.1467-2995.2009.00483.x			8	Veterinary Sciences	Veterinary Sciences	486JM	WOS:000269192300007	19709049				2020-06-30	J	Greer, JJ; Ren, J				Greer, John J.; Ren, Jun			Ampakine therapy to counter fentanyl-induced respiratory depression	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Ampakines; CX717; Fentanyl	INDUCED MUSCULAR RIGIDITY; EXCITATORY AMINO-ACIDS; PRE-BOTZINGER COMPLEX; PREBOTZINGER COMPLEX; NEURONS; RATS; BUPRENORPHINE; TRANSMISSION; INVOLVEMENT; MODULATION	Opioid analgesics are the most widely used and effective pharmacological agents for the treatment of acute, postoperative and chronic pain. However, activation of opiate receptors leads to significant depression of respiratory frequency in a subpopulation of patients. Here we test the hypothesis that the AMPAKINE CX717 is effective for alleviating fentanyl-induced respiratory depression without interfering with analgesia. Ampakines are a relatively new class of compounds that are in Phase 11 clinical trials as potential treatments for cognitive disorders and the enhancement of memory and attentiveness. They function by allosterically binding to amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors (AMPA)-type glutamate receptors and modulating the kinetics of channel closing, transmitter dissociation and desensitization. AMPA receptor mediated conductances play a central role in controlling respiratory rhythmogenesis and drive to motoneurons. Here, we demonstrate that CX717 counters fentanyl-induced respiratory depression without significantly altering analgesia and sedation, or noticeably affecting the animals' behavior. Collectively, the preclinical data demonstrate the significant potential for the use of ampakines in respiratory medicine. (C) 2009 Elsevier B.V. All rights reserved.	[Greer, John J.] Univ Alberta, Ctr Neurosci, HMRC 513, Div Neurosci,Dept Physiol, Edmonton, AB T6G 2S2, Canada	Greer, JJ (reprint author), Univ Alberta, Ctr Neurosci, HMRC 513, Div Neurosci,Dept Physiol, Edmonton, AB T6G 2S2, Canada.	john.greer@ualberta.ca			Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Cortex Pharmaceuticals (Irvine, CA); Alberta Science and Research Authority (ASRA)	Research was supported by the Canadian Institutes for Health Research (CIHR), Cortex Pharmaceuticals (Irvine, CA) and the Alberta Science and Research Authority (ASRA). JR received Studentships from the Alberta Heritage Foundation for Medical Research (AHFMR) and CIHR. JJG is a Scientist of the AHFMR.	ADLER LA, 2006, P 53 ANN M AM AC CHI, P208; Arai AC, 2004, NEUROSCIENCE, V123, P1011, DOI 10.1016/j.neuroscience.2003.10.033; BENVENGA MJ, 1992, J PHARMACOL TOXICOL, V27, P45, DOI 10.1016/1056-8719(92)90020-2; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Desrosiers Gyslaine, 2006, Perspect Infirm, V4, P6; Doraiswamy PM, 2006, EXPERT OPIN PHARMACO, V7, P1, DOI 10.1517/14656566.7.1.1; Feldman JL, 2006, NAT REV NEUROSCI, V7, P232, DOI 10.1038/nrn1871; Ferguson LM, 2006, BRIT J ANAESTH, V96, P384, DOI 10.1093/bja/ael011; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497; Gray PA, 2001, NAT NEUROSCI, V4, P927, DOI 10.1038/nn0901-927; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; JERUSSI TP, 1987, PHARMACOL BIOCHEM BE, V28, P283, DOI 10.1016/0091-3057(87)90226-7; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; LENAL FC, 2007, ANN SOC NEUR ABS, V17, P597; Lynch G, 2006, CURR OPIN PHARMACOL, V6, P82, DOI 10.1016/j.coph.2005.09.005; Pace RW, 2007, J PHYSIOL-LONDON, V582, P113, DOI 10.1113/jphysiol.2007.133660; Porrino LJ, 2005, PLOS BIOL, V3, P1639, DOI 10.1371/journal.pbio.0030299; REN J, ANESTHESIOL IN PRESS; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Solomon IC, 1999, J NEUROPHYSIOL, V81, P1150; Swarm RA, 2001, CURR PROB SURG, V38, P845, DOI 10.1067/msg.20011.118495; Wesensten NJ, 2007, AVIAT SPACE ENVIR MD, V78, P937, DOI 10.3357/ASEM.2055.2007; Yassen A, 2006, J PHARMACOL EXP THER, V319, P682, DOI 10.1124/jpet.106.107953	27	29	32	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	AUG 31	2009	168	1-2			SI		153	157		10.1016/j.resp.2009.02.011			5	Physiology; Respiratory System	Physiology; Respiratory System	498OF	WOS:000270150300019	19712906				2020-06-30	J	Dando, M				Dando, Malcolm			Biologists napping while work militarized	NATURE			English	Editorial Material									Univ Bradford, Wellcome Trust Project Bldg Sustainable Capac Dua, Dept Peace Studies, Bradford BD7 1DP, W Yorkshire, England	Dando, M (reprint author), Univ Bradford, Wellcome Trust Project Bldg Sustainable Capac Dua, Dept Peace Studies, Richmond Rd, Bradford BD7 1DP, W Yorkshire, England.	mrdando@bradford.ac.uk					*CHEM COMM, 1959, 32 M 5 MARCH 1959; HESS L, 2007, P 4 EUR S NONL WEAP; Lakoski J. M., 2000, ADVANTAGES LIMITATIO; Petro James B, 2003, Biosecur Bioterror, V1, P161, DOI 10.1089/153871303769201815; WHITBRED G, 2006, OFFENSIVE USE CHEM T	5	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 20	2009	460	7258					950	951		10.1038/460950a			2	Multidisciplinary Sciences	Science & Technology - Other Topics	484YC	WOS:000269085500015	19693065				2020-06-30	J	Dai, H; Xu, HF; Wu, XP; Chi, YW; Chen, GN				Dai, Hong; Xu, Huifeng; Wu, Xiaoping; Chi, Yuwu; Chen, Guonan			Fabrication of a new electrochemiluminescent sensor for fentanyl citrate based on glassy carbon microspheres and ionic liquid composite paste electrode	ANALYTICA CHIMICA ACTA			English	Article						Electrochemiluminescence; Glassy carbon microsphere; N-octylpyridium tetrafluoroborate; Ru(bpy)(3)Cl-2; Fentanyl citrate	ELECTROGENERATED CHEMILUMINESCENCE; GOLD NANOPARTICLES; EMISSION; SURFACTANT; MONOLAYERS; GLUCOSE; LIGHT; FILMS; DNA	Due to the high performance of glassy carbon in the aspects of mechanical strength, electrical conductivity and high corrosion resistance, etc., glassy carbon has been widely used in the electrochemistry. A new form of glassy carbon, glassy carbon microsphere, was utilized to couple with ionic liquid in preparing a new electrochemiluminescent platform for Ru(bpy)(3)Cl-2. Room temperature ionic liquid has been proposed to be very interesting and efficient pasting binder to replace the non conductive organic binders for the fabrication of composite paste electrode. Attributed to the special characteristics of glassy carbon microspheres and room temperature ionic liquid [N-octylpyridium tetrafluoroborate (OPFP)], this new electrochemiluminescent sensor exhibited excellent electrochemiluminescent performance in Ru(bpy)(3)(2+) solution. We first found that fentanyl citrate could increase the ECL of Ru(bpy)(3)(2+), hence an ECL approach was developed for the determination of fentanyl citrate based on this glassy carbon microspheres based electrochemiluminescent platform with high sensitivity. Under the optimized conditions, the enhanced electrochemiluminescent intensity versus fentanyl citrate concentration was linear in the range of 1.0 x 10(-8) to 1.0 x 10(-4) mol L-1 with a detection limit of 8.5 x 10(-9) mol L-1, and the relative standard deviation for 1.0 x 10(-6) mol L-1 fentanyl citrate was 1.90% (n = 10). This protocol has extended the application scopes of glassy carbon material and promoted the application of glassy carbon microspheres in electroanalysis. (C) 2009 Elsevier B.V. All rights reserved.	[Chen, Guonan] Fuzhou Univ, Minist Educ, Key Lab Analy & Detect Food Safety, Fuzhou 350002, Fujian, Peoples R China; Fuzhou Univ, Dept Chem, Fuzhou 350002, Fujian, Peoples R China	Chen, GN (reprint author), Fuzhou Univ, Minist Educ, Key Lab Analy & Detect Food Safety, Fuzhou 350002, Fujian, Peoples R China.	gnchen@fzu.edu.cn			National Nature Sciences Foundation of ChinaNational Natural Science Foundation of China [20735002, 20877019]; Science and Technology Development Foundation of Fuzhou University [826249]	This project was financially supported by the National Nature Sciences Foundation of China (20735002 and 20877019) and the Science and Technology Development Foundation of Fuzhou University (826249).	Bard A.J., 1982, ELECTROCHEMICAL METH; BRETT CMA, 1993, ELECTROCHEMISTRY PRI; Carpani I, 2008, ELECTROANAL, V20, P84, DOI 10.1002/elan.200704054; Crespilho FN, 2006, J PHYS CHEM B, V110, P17478, DOI 10.1021/jp062098v; Dai H, 2008, ELECTROCHIM ACTA, V53, P5113, DOI 10.1016/j.electacta.2008.02.044; Dai H, 2009, BIOSENS BIOELECTRON, V24, P1230, DOI 10.1016/j.bios.2008.07.025; Dai X, 2006, ANAL CHEM, V78, P6102, DOI 10.1021/ac060582o; Dekanski A, 2001, CARBON, V39, P1195, DOI 10.1016/S0008-6223(00)00228-1; Dennany L, 2003, J AM CHEM SOC, V125, P5213, DOI 10.1021/ja0296529; Fang LY, 2008, BIOSENS BIOELECTRON, V23, P1645, DOI 10.1016/j.bios.2008.01.023; Jie GF, 2008, BIOSENS BIOELECTRON, V23, P1896, DOI 10.1016/j.bios.2008.02.028; Lambropoulos J, 2000, J PHARMACEUT BIOMED, V23, P421, DOI 10.1016/S0731-7085(00)00312-5; LELAND JK, 1990, J ELECTROCHEM SOC, V137, P3127, DOI 10.1149/1.2086171; Liang PY, 2003, J ELECTROANAL CHEM, V560, P151, DOI 10.1016/j.jelechem.2003.07.010; MILLER CJ, 1991, LANGMUIR, V7, P2781, DOI 10.1021/la00059a061; Musameh M, 2008, ANAL CHIM ACTA, V606, P45, DOI 10.1016/j.aca.2007.11.012; OBENG YS, 1991, LANGMUIR, V7, P195, DOI 10.1021/la00049a035; Pittet P, 2008, MAT SCI ENG C-BIO S, V28, P891, DOI 10.1016/j.msec.2007.10.030; Ricci F, 2003, ELECTROANAL, V15, P1204, DOI 10.1002/elan.200390148; Ricci F, 2003, ELECTROANAL, V15, P175, DOI 10.1002/elan.200390021; Tennison SR, 1998, APPL CATAL A-GEN, V173, P289, DOI 10.1016/S0926-860X(98)00186-0; WANG WL, 1993, FORENSIC SCI INT, V61, P65, DOI 10.1016/0379-0738(93)90250-E; Wei H, 2007, CHEM LETT, V36, P210, DOI 10.1246/cl.2007.210; WILSON TD, 1998, J CHROMATOGR, V445, P299; ZHANG X, 1988, J PHYS CHEM-US, V92, P5566, DOI 10.1021/j100331a007; Zu YB, 2001, ANAL CHEM, V73, P3960, DOI 10.1021/ac010230b	26	13	13	0	45	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0003-2670	1873-4324		ANAL CHIM ACTA	Anal. Chim. Acta	AUG 4	2009	647	1					60	65		10.1016/j.aca.2009.05.032			6	Chemistry, Analytical	Chemistry	475FG	WOS:000268343300007	19576386				2020-06-30	J	Hayee, B; Rowbotham, D; Saxena, V; McNair, A				Hayee, B.; Rowbotham, D.; Saxena, V.; McNair, A.			Fentanyl vs. pethidine as sedation for gastrointestinal endoscopy	ALIMENTARY PHARMACOLOGY & THERAPEUTICS			English	Letter							MEPERIDINE; TRIAL		[Hayee, B.; Rowbotham, D.; Saxena, V.; McNair, A.] Queen Elizabeth Hosp, Dept Gastroenterol, London, England	Hayee, B (reprint author), Queen Elizabeth Hosp, Dept Gastroenterol, London, England.	bu@doctors.org.uk					Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; Robertson DJ, 2009, ALIMENT PHARM THER, V29, P817, DOI 10.1111/j.1365-2036.2009.03943.x	2	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-2813	1365-2036		ALIMENT PHARM THER	Aliment. Pharmacol. Ther.	AUG 1	2009	30	3					312	313		10.1111/j.1365-2036.2009.04030.x			3	Gastroenterology & Hepatology; Pharmacology & Pharmacy	Gastroenterology & Hepatology; Pharmacology & Pharmacy	469DB	WOS:000267874600017	19624467				2020-06-30	J	Ocon, FJM; Carcel, I				Morera Ocon, Francisco J.; Carcel, Inmaculada			Feasibility of spinal anesthesia in laparoscopic ventral hernia repair: is it worth it?	AMERICAN JOURNAL OF SURGERY			English	Letter									[Morera Ocon, Francisco J.] Hosp Requena, Dept Gen Surg, Valencia, Spain; [Carcel, Inmaculada] Hosp Requena, Dept Anesthesiol, Valencia, Spain	Ocon, FJM (reprint author), Hosp Requena, Dept Gen Surg, Valencia, Spain.						GONZALEZSERNA DB, 2006, CIR ESPAN, V80, P168; Tzovaras G, 2008, AM J SURG, V196, P191, DOI 10.1016/j.amjsurg.2007.07.028	2	0	0	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610			AM J SURG	Am. J. Surg.	AUG	2009	198	2					299	300		10.1016/j.amjsurg.2008.09.024			2	Surgery	Surgery	481GK	WOS:000268795300031	19285300				2020-06-30	J	Sykes, JM; Cox, S; Ramsay, EC				Sykes, John M.; Cox, Sherry; Ramsay, Edward C.			Evaluation of an osmotic pump for fentanyl administration in cats as a model for nondomestic felids	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article; Proceedings Paper	Annual Conference of the American-Association-of-Zoo-Veterinarians	SEP, 2006	Tampa, FL	Amer Assoc Zoo Vet			TRANSDERMALLY ADMINISTERED FENTANYL; PLASMA-CONCENTRATIONS; INTRAVENOUS FENTANYL; ANALGESIA; PHARMACOKINETICS; PATCHES; DOGS; OVARIOHYSTERECTOMY; DISPOSITION; ONYCHECTOMY	Objective-To evaluate the reliability of an SC implanted osmotic pump (OP) for fentanyl administration in cats and to compare serum concentrations of fentanyl delivered via an OP and a transdermal patch (TP). Animals-8 spayed female cats. Procedures-In a crossover design, cats received fentanyl at 25 mu g/h via a TP or an OP All cats were anesthetized for the pump or patch placement (0 hours) and again when it was removed (96 hours). Venous blood samples were collected for measurement of serum fentanyl concentrations at 0, 6, 12, 24, 36, 48, 72, and 96 hours and at 24 and 48 hours after device removal. After a 3-week washout period, the experiment was repeated with each cat receiving the other treatment. Results-Mean serum fentanyl concentrations at 24, 36, 72, and 96 hours were greater when the OP was used than when the TP was used. Mean residence time and half-life were greater when the TP was used. Fentanyl concentration changed significantly faster in initial and elimination phases when the OP was used. Marked interindividual variation in serum fentanyl concentrations was evident with both administration methods. No adverse effects were evident with either method. Conclusions and Clinical Relevance-Use of the OP to administer fentanyl to cats resulted in a shorter initial lag phase to a therapeutic serum concentration, higher bioavailability, and faster elimination after removal, compared with use of a TP These advantages, in addition to the inability of cats to remove the OP may make OPs useful for fentanyl administration in nondomestic felids. (Am J Vet Res 2009,70:950-955)	[Sykes, John M.; Ramsay, Edward C.] Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci, Knoxville, TN 37996 USA; [Cox, Sherry] Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA	Sykes, JM (reprint author), Wildlife Conservat Soc Bronx Zoo, Global Hlth Program, 2300 Southern Blvd, Bronx, NY 10460 USA.			Cox, Sherry/0000-0002-5184-900X			BASKIN DS, 1994, STROKE, V25, P2047, DOI 10.1161/01.STR.25.10.2047; Carroll GL, 1999, AM J VET RES, V60, P986; Davidson CD, 2004, JAVMA-J AM VET MED A, V224, P700, DOI 10.2460/javma.2004.224.700; DEROJAS TC, 1990, TOXICOL APPL PHARM, V103, P354, DOI 10.1016/0041-008X(90)90235-M; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; Foley PL, 2001, COMPARATIVE MED, V51, P239; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Glerum LE, 2001, VET SURG, V30, P351, DOI 10.1053/jvet.2001.24387; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; Isaza Ramiro, 2007, P61, DOI 10.1002/9780470376478.ch4; Kasamatsu T, 1997, BRAIN RES PROTOC, V1, P57, DOI 10.1016/S1385-299X(96)00008-6; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; LERCHE P, 2008, SMALL ANIMAL ANESTHE, P123; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; REILLY CS, 1985, ANAESTHESIA, V40, P837, DOI 10.1111/j.1365-2044.1985.tb11043.x; Robertson SA, 2005, J VET PHARMACOL THER, V28, P87, DOI 10.1111/j.1365-2885.2004.00628.x; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12; Yackey M, 2004, VET ANAESTH ANALG, V31, P183, DOI 10.1111/j.1467-2987.2004.00125.x	25	3	4	0	4	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	AUG	2009	70	8					950	955		10.2460/ajvr.70.8.950			6	Veterinary Sciences	Veterinary Sciences	478SM	WOS:000268608600002	19645575				2020-06-30	J	Groban, L; Butterworth, J				Groban, Leanne; Butterworth, John			Fentanyl: Destiny or Devil?	ANESTHESIA AND ANALGESIA			English	Editorial Material							INFLAMMATORY RESPONSE; CARDIAC-SURGERY; CARDIOVASCULAR-RESPONSE; CARDIOPULMONARY BYPASS; MORPHINE; ANESTHESIA		[Butterworth, John] Indiana Univ, Sch Med, Dept Anesthesia, Indianapolis, IN 46202 USA; [Groban, Leanne] Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC USA	Butterworth, J (reprint author), Indiana Univ, Sch Med, Dept Anesthesia, 1120 South Dr,FH 204, Indianapolis, IN 46202 USA.	jfbutter@iupui.edu		Groban, Leanne/0000-0001-8934-7358			Agnew NM, 2002, ANAESTHESIA, V57, P338, DOI 10.1046/j.1365-2044.2002.02469.x; ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Cheng DCH, 1998, ANESTHESIOLOGY, V88, P1429, DOI 10.1097/00000542-199806000-00002; JOHNSTONE M, 1956, BRIT J ANAESTH, V28, P392, DOI 10.1093/bja/28.9.392; Laffey JG, 2002, ANESTHESIOLOGY, V97, P215; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; Lowenstein E, 2004, ANESTHESIOLOGY, V100, P1013, DOI 10.1097/00000542-200404000-00036; Murphy GS, 2007, ANESTH ANALG, V104, P1334, DOI 10.1213/01.ane.0000264108.47280.f5; Murphy GS, 2009, ANESTH ANALG, V109, P311, DOI 10.1213/ane.0b013e3181a90adc; Myles PS, 2000, BRIT J ANAESTH, V84, P11; Peart JN, 2008, VASC PHARMACOL, V49, P63, DOI 10.1016/j.vph.2008.07.001; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676; Weber N. C., 2008, V182, P187, DOI 10.1007/978-3-540-74806-9_9	14	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2009	109	2					301	302		10.1213/ane.0b013e3181a91944			2	Anesthesiology	Anesthesiology	474QH	WOS:000268298600004	19608795				2020-06-30	J	Murphy, GS; Szokol, JW; Marymont, JH; Greenberg, SB; Avram, MJ; Vender, JS; Sherwani, SS; Nisman, M; Doroski, V				Murphy, Glenn S.; Szokol, Joseph W.; Marymont, Jesse H.; Greenberg, Steven B.; Avram, Michael J.; Vender, Jeffery S.; Sherwani, Saadia S.; Nisman, Margarita; Doroski, Victoria			Morphine-Based Cardiac Anesthesia Provides Superior Early Recovery Compared Cardiac Surgery Patients	ANESTHESIA AND ANALGESIA			English	Editorial Material							CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; CONTROLLED ANALGESIA; OPIOID ANALGESICS; IN-VIVO; FENTANYL; QUALITY; CARDIOPROTECTION; INVOLVEMENT; SUFENTANIL	BACKGROUND: Experimental and clinical data Suggest that morphine possesses unique cardioprotective and antiinflammatory properties. In this clinical investigation, we sought to determine whether the choice of intraoperative opioid (morphine or fentanyl) influences early recovery after cardiac surgery. METHODS: Ninety patients undergoing cardiac surgery with cardiopulmonary by pass were randomized to receive either morphine (4 mg) or fentanyl (600 mu g) as part of a standardized opioid-isoflurane anesthetic. Quality of recovery was assessed using the QoR-40 questionnaire administered preoperatively and daily oil postoperative days 1-3. During the first three postoperative days, pain was measured using a 100-mm visual analog scale, and the use Of IV and oral pain medications (morphine or acetaminophen/hydrocodone) was quantified. Hemodynamic variables, duration of tracheal intubation, postoperative febrile reactions, organ morbidities, and intensive care unit (ICU) and hospital length of stay were evaluated. RESULTS: Compared with patients given fentanyl, those receiving morphine had higher global QoR-40 scores on postoperative days 1 (173 vs 160, P < 0.0001), 2 (174 vs 164, P < 0.0001), and 3 (177 vs 167, P < 0.001). Differences between the groups were observed in the QoR-40 dimensions of emotional state, physical comfort, and pain (all P < 0.01-0.0001). Postoperative visual analog scale pain scores, use of pain medication in the ICU and surgical ward, and postoperative febrile reactions were reduced significantly in the morphine group (all P < 0.01). No differences between the groups were noted in duration of tracheal intubation, ICU and hospital length of stay, or postoperative complications. CONCLUSIONS: In patients undergoing elective cardiac surgery with cardiopulmonary bypass, postoperative quality-of-life measures and pain control during recovery were enhanced, when morphine (40 mg) was administered intraoperatively as part of a balanced anesthetic technique compared with fentanyl. (Anesth Analg 2009;109:311-9)	[Murphy, Glenn S.; Szokol, Joseph W.; Marymont, Jesse H.; Greenberg, Steven B.; Avram, Michael J.; Vender, Jeffery S.; Sherwani, Saadia S.; Nisman, Margarita; Doroski, Victoria] N Shore Univ Hlth Syst, Dept Anesthesiol, Evanston, IL USA	Murphy, GS (reprint author), Univ Hlth Syst, N Shore Dept Anesthesiol, 2650 Ridge Ave, Evanston, IL 60201 USA.	dgmurphy@yahoo.com	Avram, Michael/M-7681-2019				Abdel-Wahab M, 2008, J INTERV CARDIOL, V21, P232, DOI 10.1111/j.1540-8183.2008.00355.x; Bencsics A, 1997, J NEUROIMMUNOL, V73, P1, DOI 10.1016/S0165-5728(96)00163-4; Benedict PE, 1999, CIRCULATION, V100, P357; BENNETT GM, 1979, ANESTH ANALG, V58, P179; Bilfinger TV, 1996, INT J CARDIOL, V53, pS39, DOI 10.1016/0167-5273(96)02574-0; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; Clark JD, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-28; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; FLACKE JW, 1985, ANESTH ANALG, V64, P897; Frassdorf J, 2005, ANESTH ANALG, V101, P934, DOI 10.1213/01.ane.0000172130.70274.84; GHONEIM MM, 1984, ANESTH ANALG, V63, P405; GIMENO D, 2008, PSYCHOL MED, V4, P1; Hansdottir V, 2006, ANESTHESIOLOGY, V104, P142, DOI 10.1097/00000542-200601000-00020; Herrera FJ, 2007, ANESTH ANALG, V105, P63, DOI 10.1213/01.ane.0000265534.73169.95; JASINSKI DR, 1986, DRUG ALCOHOL DEPEN, V17, P301, DOI 10.1016/0376-8716(86)90079-7; KRUMHOLZ W, 1993, ACTA ANAESTH SCAND, V37, P386, DOI 10.1111/j.1399-6576.1993.tb03734.x; Leslie K, 2003, ANESTHESIOLOGY, V99, P1158, DOI 10.1097/00000542-200311000-00024; Lisowska Barbara, 2006, Ortop Traumatol Rehabil, V8, P547; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; McPherson BC, 2001, CIRCULATION, V103, P290; Mitchell JD, 2007, CYTOKINE, V38, P37, DOI 10.1016/j.cyto.2007.04.009; Murphy GS, 2007, ANESTH ANALG, V104, P1334, DOI 10.1213/01.ane.0000264108.47280.f5; Murphy GS, 2006, J CARDIOTHOR VASC AN, V20, P493, DOI 10.1053/j.jvca.2005.07.036; Myles PS, 2001, ANESTHESIOLOGY, V95, P862, DOI 10.1097/00000542-200110000-00013; Myles PS, 2000, BRIT J ANAESTH, V84, P11; Romano MA, 2004, J SURG RES, V119, P46, DOI 10.1016/j.jss.2004.01.006; SANFORD TJ, 1986, ANESTH ANALG, V65, P259; Scott BH, 1998, INT J CARDIOL, V64, pS35, DOI 10.1016/S0167-5273(98)00034-5; STANLEY TH, 1978, ANESTH ANALG, V57, P411; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; Tomai F, 1999, CIRCULATION, V100, P559, DOI 10.1161/01.CIR.100.5.559; Tsueda K, 1998, ANESTHESIOLOGY, V88, P885, DOI 10.1097/00000542-199804000-00006; VAUPEL DB, 1993, J PHARMACOL EXP THER, V267, P1386; VESELIS RA, 1994, ANESTH ANALG, V79, P952; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; ZACNY JP, 1992, PSYCHOPHARMACOLOGY, V107, P319, DOI 10.1007/BF02245155	37	16	17	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2009	109	2					311	319		10.1213/ane.0b013e3181a90adc			9	Anesthesiology	Anesthesiology	474QH	WOS:000268298600006	19608797				2020-06-30	J	Laboureyras, E; Chateauraynaud, J; Richebe, P; Simonnet, G				Laboureyras, Emilie; Chateauraynaud, Jeremy; Richebe, Philippe; Simonnet, Guy			Long-Term Pain Vulnerability After Surgery in Rats: Prevention by Nefopam, an Analgesic with Antihyperalgesic Properties	ANESTHESIA AND ANALGESIA			English	Article							NEONATAL PERIPHERAL INFLAMMATION; OPIOID-INDUCED HYPERALGESIA; POSTOPERATIVE PAIN; INDUCED ANTINOCICEPTION; CENTRAL SENSITIZATION; LASTING HYPERALGESIA; RECEPTOR ANTAGONIST; KETAMINE; MORPHINE; TOLERANCE	BACKGROUND: Tissue damage associated with Surgery often produces peripheral and central sensitization that may outlast the stimuli, leading to exaggerated postoperative pain. Paradoxically, the use of opioid analgesia, which is essential for surgical pain management may induce pain sensitization leading to enhanced postoperative pain and an increased risk of developing chronic pain. We Studied whether a surgical incision in the rat hindpaw may favor the development of long-term pain vulnerability by estimating hyperalgesia induced by an inflammatory stimulation of the unlesioned contralateral hindpaw 3 wk later. We also evaluated the ability of nefopam, an analgesic drug commonly used in postoperative pain management, to prevent not only exaggerated postoperative pain but also long-term pain vulnerability. The efficacy of morphine was assessed 1 day after surgical incision. METHODS: On Day 0, a surgical plantar incision was performed in one hindpaw, of rats treated or untreated with fentanyl (4 X 100 mu g/kg, one injection every 15 min). Nefopam (10 mg/kg) or saline was subcutaneously injected 30 min before injury. Three weeks later, once pain measures had returned to basal values, a subsequent nociceptive stimulus, specifically intraplantar carrageenan injection, was performed to evaluate pain sensitivity in incision- and fentanyl-experienced rats. Pain was,vas measured by the paw-pressure vocalization test and the weight bearing test. RESULTS: Surgical incision in rats induced latent and long-term pain hypersensitivity, which was manifested by exaggerated hyperalgesia on carrageenan injection. Administering fentanyl in association with the surgical incision induced exaggerated postoperative pain. When injected before incision, nefopam reduced the exaggerated postoperative pain induced by perioperative fentanyl treatment and prevented the development of long-term pain hypersensitivity. Preoperative nefopam administration also improved morphine analgesic efficacy in the context of fentanyl-induced postoperative hyperalgesia. CONCLUSIONS: Given preemptively, nefopam may be effective at improving postoperative pain management and at reducing the risk of developing postoperative chronic pain, because the drug has both analgesic and antihyperalgesic properties. (Anesth Analg 2009;109:623-31)	[Simonnet, Guy] Univ Bordeaux 2, CNRS, UMR 5227, Mouvement Adapat Cognit Team Homeostasie Allostas, F-33076 Bordeaux, France; [Richebe, Philippe] CHU Bordeaux, Hop Cardiol Haut Leveque, Serv Prof Gerard Janvier, Dept Anesthesia & Intens Care 2, Bordeaux, France	Simonnet, G (reprint author), Univ Bordeaux 2, CNRS, UMR 5227, Mouvement Adapat Cognit Team Homeostasie Allostas, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	gsimonnet@yahoo.com			Universite Victor Segalen Bordeaux 2, Universite Bordeaux 1, Bordeaux, France	Supported by Universite Victor Segalen Bordeaux 2, Universite Bordeaux 1, Bordeaux, France; CNRS, Paris, France; and Biocodex, Gentilly, France.	Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; BEAVER WT, 1977, J CLIN PHARMACOL, V17, P579, DOI 10.1177/009127007701701005; Biella GEM, 2003, J NEUROTRAUM, V20, P593, DOI 10.1089/089771503767168519; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Chu YC, 2007, ANESTHESIOLOGY, V106, P1204, DOI 10.1097/01.anes.0000267604.40258.d1; CODERRE TJ, 1993, MOL NEUROBIOL, V7, P229, DOI 10.1007/BF02769177; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Fernandez-Sanchez MT, 2001, NEUROPHARMACOLOGY, V41, P935, DOI 10.1016/S0028-3908(01)00139-3; Fletcher D, 1997, PAIN, V69, P303, DOI 10.1016/S0304-3959(96)03227-7; FULLER RW, 1993, NEUROPHARMACOLOGY, V32, P995, DOI 10.1016/0028-3908(93)90064-A; Girard P, 2001, PHARMACOL RES, V44, P541, DOI 10.1006/phrs.2001.0886; Girard P, 2006, PHARMACOL RES, V54, P195, DOI 10.1016/j.phrs.2006.04.008; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; HUNSKAAR S, 1987, EUR J PHARMACOL, V138, P77, DOI 10.1016/0014-2999(87)90339-6; IRIKURA T, 1981, JPN J PHARMACOL, V31, P815, DOI 10.1254/jjp.31.815; Kapfer B, 2005, ANESTH ANALG, V100, P169, DOI 10.1213/01.ANE.0000138037.19757.ED; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; KAYSER V, 1990, BRAIN RES, V508, P329, DOI 10.1016/0006-8993(90)90418-B; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kissin I, 2006, ANESTH ANALG, V103, P721, DOI 10.1213/01.ane.0000230604.00934.a1; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; OHKUBO Y, 1991, EUR J PHARMACOL, V204, P121; PHILLIPS G, 1979, BRIT J ANAESTH, V51, P961, DOI 10.1093/bja/51.10.961; PIERCEY MF, 1981, EUR J PHARMACOL, V74, P135, DOI 10.1016/0014-2999(81)90523-9; Ren K, 2004, PAIN, V110, P588, DOI 10.1016/j.pain.2004.04.006; Richebe P, 2005, ANESTHESIOLOGY, V103, P845, DOI 10.1097/00000542-200510000-00024; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Rivat C, 2007, NEUROPSYCHOPHARMACOL, V32, P2217, DOI 10.1038/sj.npp.1301340; ROSLAND JH, 1990, J PHARM PHARMACOL, V42, P437, DOI 10.1111/j.2042-7158.1990.tb06587.x; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Tirault M, 2006, ANESTH ANALG, V102, P110, DOI 10.1213/01.ANE.0000181103.07170.15; TRESNAKRUSTAD NJ, 1981, BIOCHEM PHARMACOL, V30, P2847, DOI 10.1016/0006-2952(81)90424-X; Verleye M, 2004, BRAIN RES, V1013, P249, DOI 10.1016/j.brainres.2004.04.035; Walker SM, 2009, PAIN, V141, P79, DOI 10.1016/j.pain.2008.10.012; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Wilder-Smith OHG, 2006, ANESTHESIOLOGY, V104, P601, DOI 10.1097/00000542-200603000-00028; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	47	30	30	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2009	109	2					623	631		10.1213/ane.0b013e3181aa956b			9	Anesthesiology	Anesthesiology	474QH	WOS:000268298600051	19608840				2020-06-30	J	McQueen, A; Wright, RO; Kido, MM; Kaye, E; Krauss, B				McQueen, Alisa; Wright, Robert O.; Kido, Maya M.; Kaye, Erica; Krauss, Baruch			Procedural Sedation and Analgesia Outcomes in Children After Discharge From the Emergency Department: Ketamine Versus Fentanyl/Midazolam	ANNALS OF EMERGENCY MEDICINE			English	Article							POSTOPERATIVE BEHAVIORAL OUTCOMES; PLACEBO-CONTROLLED TRIAL; PREOPERATIVE ANXIETY; INTRAVENOUS KETAMINE; ADVERSE EVENTS; DOUBLE-BLIND; PEDIATRIC SEDATION; SAFETY PROFILE; MIDAZOLAM; HOSPITALIZATION	Study objective: Although the safety and efficacy of procedural sedation and analgesia in the pediatric emergency department (ED) has been established, the prevalence of adverse events after discharge has not been well studied. We compare the postdischarge incidence of adverse behavioral events and vomiting and hypothesize that ketamine would be associated with increased adverse behaviors. Methods: We conducted a prospective observational study of postdischarge behavioral changes and vomiting after sedation with ketamine, ketamine/midazolam, or fentanyl/midazolam. Families were administered a Post Hospital Behavior Questionnaire (PHBQ), with higher scores indicating more adverse behaviors (anxiety, sleep disturbances). We used linear and logistic regression to model PHBQ scores and logistic regression to model vomiting risk adjusting for age, sex, procedure, length of procedure, and parental presence as potential confounders. Results: Seven hundred eighty-six children were enrolled and 554 children (61% boys; mean age 7.5 +/- 4.5 years) were contacted. The prevalence of postdischarge vomiting was 18%, but the prevalence of adverse behavioral changes was low. When adjusted for potential confounders, the odds of a higher PHBQ score increased among patients receiving fentanyl/midazolam (fentanyl/midazolam odds ratio [OR] 2.6, 95% confidence interval [Cl] 1.08 to 6.03, P=.03; ketamine OR 1.7, 95% Cl 0.84 to 3.57; ketamine/midazolam OR 0.5, 95% Cl 0.26 to 1.07). Conclusion: Procedural sedation and analgesia in the ED is well tolerated. Though postdischarge vomiting occurs with some frequency, there is a low prevalence of adverse behavioral events after discharge. The use of fentanyl/midazolam was associated with higher adverse behavioral scores. [Ann Emerg Med. 2009;54: 191-197.]	[McQueen, Alisa] Univ Chicago, Sect Pediat Emergency Med, Chicago, IL 60637 USA; [Wright, Robert O.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Wright, Robert O.; Krauss, Baruch] Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Wright, Robert O.; Kaye, Erica; Krauss, Baruch] Harvard Univ, Sch Med, Boston, MA USA; [Kido, Maya M.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA	McQueen, A (reprint author), Univ Chicago, Sect Pediat Emergency Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	lisa.mcqueen@gmail.com	Kaye, Erica/M-9826-2018	Kaye, Erica/0000-0002-6522-3876	Annals policy	Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement.	Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; Calipel S, 2005, PEDIATR ANESTH, V15, P275, DOI 10.1111/j.1460-9592.2004.01514.x; Evans D, 2005, PEDIATR ANESTH, V15, P131, DOI 10.1111/j.1460-9592.2005.01407.x; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Green SM, 1998, ACAD EMERG MED, V5, P971, DOI 10.1111/j.1553-2712.1998.tb02773.x; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; Kain ZN, 1999, ANESTH ANALG, V88, P1042, DOI 10.1097/00000539-199905000-00013; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kain ZN, 1999, ANESTHESIOLOGY, V90, P758, DOI 10.1097/00000542-199903000-00018; Kain ZN, 2000, ANESTHESIOLOGY, V93, P141, DOI 10.1097/00000542-200007000-00024; Kain ZN, 2002, ANESTHESIOLOGY, V97, P1093, DOI 10.1097/00000542-200211000-00010; Karling M, 2006, ACTA PAEDIATR, V95, P340, DOI 10.1080/08035250500434751; Keaney A, 2004, PEDIATR ANESTH, V14, P866, DOI 10.1111/j.1460-9592.2004.01310.x; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Langston WT, 2008, ANN EMERG MED, V52, P30, DOI 10.1016/j.annemergmed.2008.01.326; Luhmann JD, 2001, ANN EMERG MED, V37, P20, DOI 10.1067/mem.2001.112003; Mamula P, 2007, GASTROINTEST ENDOSC, V65, P203, DOI 10.1016/j.gie.2006.05.002; Marx CM, 1997, J CLIN ONCOL, V15, P94, DOI 10.1200/JCO.1997.15.1.94; Newman DH, 2003, ANN EMERG MED, V42, P627, DOI 10.1016/S0196-0644(03)00446-3; Patel A, 2006, PEDIATR ANESTH, V16, P1019, DOI 10.1111/j.1460-9592.2006.01914.x; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Pitetti R, 2006, ARCH PEDIAT ADOL MED, V160, P211, DOI 10.1001/archpedi.160.2.211; Roback MG, 2006, ANN EMERG MED, V48, P605, DOI 10.1016/j.annemergmed.2006.06.001; Roback MG, 2005, ACAD EMERG MED, V12, P508, DOI 10.1197/j.aem.2004.12.009; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; Stargatt R, 2006, PEDIATR ANESTH, V16, P846, DOI 10.1111/j.1460-9592.2006.01869.x; THOMPSON RH, 1993, J DEV BEHAV PEDIATR, V14, P28; VERNON DTA, 1966, AM J DIS CHILD, V111, P581, DOI 10.1001/archpedi.1966.02090090053003; VERNON DTA, 1993, J DEV BEHAV PEDIATR, V14, P36, DOI 10.1097/00004703-199302000-00006; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Watson AT, 2003, PAEDIATR ANAESTH, V13, P188, DOI 10.1046/j.1460-9592.2003.00848.x	33	20	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2009	54	2					191	197		10.1016/j.annemergmed.2009.04.015			7	Emergency Medicine	Emergency Medicine	479YA	WOS:000268696900011	19464072				2020-06-30	J	Herd, D; Borland, M				Herd, David; Borland, Meredith			Intranasal fentanyl paediatric clinical practice guidelines	EMERGENCY MEDICINE AUSTRALASIA			English	Letter							RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS MORPHINE; EMERGENCY-DEPARTMENT		[Herd, David] Mater Childrens Hosp, Brisbane, Qld, Australia; [Borland, Meredith] Princess Margaret Hosp Children, Emergency Dept, Perth, WA, Australia	Herd, D (reprint author), Mater Childrens Hosp, Brisbane, Qld, Australia.		Herd, David/A-4654-2013	Herd, David/0000-0003-3701-0336			Babl Franz, 2006, Emerg Med Australas, V18, P143, DOI 10.1111/j.1742-6723.2006.00823.x; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Dalton S, 2009, EMERG MED AUSTRALAS, V21, P67, DOI 10.1111/j.1742-6723.2008.01148.x; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027	5	9	9	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1742-6731			EMERG MED AUSTRALAS	Emerg. Med. Australas.	AUG	2009	21	4					335	335		10.1111/j.1742-6723.2009.01207.x			1	Emergency Medicine	Emergency Medicine	478KW	WOS:000268588200015	19682022				2020-06-30	J	Long, JJ; Ma, JY; Leung, LS				Long, Jennifer J.; Ma, Jingyi; Leung, L. Stan			Behavioral depression induced by an amygdala seizure and the opioid fentanyl was mediated through the nucleus accumbens	EPILEPSIA			English	Article						Postictal depression; Kindling; Righting reflex; Catalepsy; Tail pinch; Naloxone	OPIATE ANTAGONISTS; MORPHINE ANALGESIA; GENERAL-ANESTHESIA; FORMALIN TEST; KINDLED RATS; SYSTEM; INVOLVEMENT; RECEPTORS; IMMEDIATE; CATALEPSY	Purpose: To study the behavioral depression induced by a generalized limbic seizure and by an opioid. The hypothesis that an opioid fentanyl and an amygdala-evoked seizure induced behavioral depression through the nucleus accumbens was tested. Methods: The behavioral depression induced by an amygdala-kindled seizure was studied in fully kindled rats, with or without prior injection of fentanyl (0.05 mg/kg, s.c.). Local infusion of a nonspecific opioid antagonist, naloxone, or saline, was made bilaterally in the nucleus accumbens. The durations of loss of righting reflex (LORR), loss of tail-pinch response, and catalepsy were assessed. Results: Fentanyl induced an LORR following a generalized kindled seizure. The combination of fentanyl and a generalized seizure, as compared to fentanyl alone or a generalized seizure alone, resulted in a prolonged duration of LORR, catalepsy, and loss of tail pinch response. Infusion of naloxone as compared to saline in the nucleus accumbens reduced the duration of catalepsy and LORR induced by fentanyl, with or without a generalized seizure. Conclusions: Postictal depression that follows a generalized kindled seizure enhanced the behavioral effects of the opioid fentanyl. Network synaptic depression induced by the seizure acted synergistically with fentanyl to produce analgesia, catalepsy, and LORR, in part through the nucleus accumbens.	[Ma, Jingyi; Leung, L. Stan] Univ Western Ontario, Dept Physiol Pharmacol, London, ON N6A 5C1, Canada; [Long, Jennifer J.; Leung, L. Stan] Univ Western Ontario, Program Neurosci, London, ON N6A 5C1, Canada; [Leung, L. Stan] Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 5C1, Canada	Leung, LS (reprint author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	sleung@uwo.ca			Natural Sciences and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-64433]	We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.; None of the authors has any conflict of interest to disclose.; This work was financially supported by operating grants from the Natural Sciences and Engineering Research Council and the Canadian Institutes of Health Research (MOP-64433). We thank Bixia Shen for technical assistance.	ALBERTSON TE, 1984, J PHARMACOL EXP THER, V228, P620; BERMAN RF, 1990, KINDLING, V4, P423; Brandt C, 2004, EPILEPSY RES, V62, P135, DOI 10.1016/j.eplepsyres.2004.08.008; CAIN DP, 1990, BRAIN RES, V517, P236, DOI 10.1016/0006-8993(90)91032-C; CALDECOTTHAZARD S, 1983, EPILEPSIA, V24, P539, DOI 10.1111/j.1528-1157.1983.tb03418.x; COTTRELL GA, 1987, EUR J PHARMACOL, V141, P417, DOI 10.1016/0014-2999(87)90559-0; COTTRELL GA, 1988, EUR J PHARMACOL, V150, P1, DOI 10.1016/0014-2999(88)90743-1; DILL RE, 1977, NEUROPHARMACOLOGY, V16, P323, DOI 10.1016/0028-3908(77)90068-5; DUNSTAN R, 1981, PHARMACOL BIOCHEM BE, V14, P169, DOI 10.1016/0091-3057(81)90239-2; ENGEL J, 1992, EPILEPSY RES, P341; Fisher RS, 2000, EPILEPSY BEHAV, V1, P52, DOI 10.1006/ebeh.2000.0023; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; FRENK H, 1979, BRAIN RES, V167, P435, DOI 10.1016/0006-8993(79)90842-4; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; Groenewegen HJ, 1996, PROG BRAIN RES, V107, P485; HARDY C, 1980, BRAIN RES, V194, P293, DOI 10.1016/0006-8993(80)91347-5; Hong J S, 1988, NIDA Res Monogr, V82, P48; Kelley AE, 1996, J PHARMACOL EXP THER, V278, P1499; LEUNG LS, 1993, EXP NEUROL, V119, P205, DOI 10.1006/exnr.1993.1022; Leung LS, 2000, NEUROSCI BIOBEHAV R, V24, P763, DOI 10.1016/S0149-7634(00)00035-X; LEUNG LWS, 1990, BRAIN RES, V513, P308, DOI 10.1016/0006-8993(90)90472-N; MA J, 2003, ABSTR SOC NEUR, V29; Ma JY, 2006, NEUROPSYCHOPHARMACOL, V31, P1177, DOI 10.1038/sj.npp.1300909; Ma JY, 2004, BEHAV BRAIN RES, V155, P153, DOI 10.1016/j.bbr.2004.04.010; Ma JY, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0004.2002; MANNING BH, 1994, NEUROSCIENCE, V63, P289, DOI 10.1016/0306-4522(94)90023-X; Manning BH, 1998, BEHAV BRAIN RES, V92, P97, DOI 10.1016/S0166-4328(97)00130-7; McQuiston AR, 2003, J NEUROPHYSIOL, V90, P1936, DOI 10.1152/jn.01150.2002; NARANJO JR, 1986, J NEUROSCI RES, V16, P75, DOI 10.1002/jnr.490160108; Petrov RR, 2006, BIOORG MED CHEM LETT, V16, P4946, DOI 10.1016/j.bmcl.2006.06.040; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; ROSEN JB, 1985, EXP NEUROL, V90, P549, DOI 10.1016/0014-4886(85)90152-9; Saboory E, 2007, ANESTH ANALG, V105, P1729, DOI 10.1213/01.ane.0000287675.15225.0b; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VINDROLA O, 1981, NEUROSCI LETT, V21, P39, DOI 10.1016/0304-3940(81)90054-9; WINKLER M, 1982, N-S ARCH PHARMACOL, V318, P143, DOI 10.1007/BF00500473; Zmarowski A, 2005, EUR J NEUROSCI, V22, P1731, DOI 10.1111/j.1460-9568.2005.04333.x	37	8	8	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	AUG	2009	50	8					1953	1961		10.1111/j.1528-1167.2009.02143.x			9	Clinical Neurology	Neurosciences & Neurology	476YH	WOS:000268482200013	19490038				2020-06-30	J	Nishiyama, T				Nishiyama, Tomoki			Cerebral state index vs. bispectral index during sevoflurane-nitrous oxide anaesthesia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetic; bispectral index; electroencephalogram; inhalational; monitoring; sevoflurane	PROPOFOL; CONSCIOUSNESS; SEDATION; MONITOR; DEPTH	Background and objective The cerebral state index (CSI) is a low-cost and compact electroencephalographic monitor alternative to the bispectral index (BIS). Although both indices are shown as the number between 0 and 100, owing to the different calculation algorithms, both indices might be different during anaesthesia. The present study was performed to compare the BIS and CSI during sevoflurane nitrous oxide anaesthesia. Patients and methods Forty patients scheduled for abdominal surgery aged 30-70 years were enrolled. The electrodes of both the cerebral state monitor and BIS were attached simultaneously. Anaesthesia was induced with midazolam and fentanyl, and was maintained with sevoflurane with 50% nitrous oxide in oxygen and intermittent epidural mepivacaine. During surgery, end-tidal sevoflurane concentration was kept at 0.5, 1.0, and 1.5% for more than 10 min to measure CSI and BIS. Results The duration of signal disturbance by electric cautery was 12.6 +/- 4.2 min in the BIS and 3.9 +/- 1.8 min in the cerebral state monitor (P < 0.05) for 9.5 +/- 4.3 min duration of electric cautery. The recovery time from disturbance by electric cautery was 37 +/- 12 s in the BIS and 4 +/- 2 s in the cerebral state monitor (P < 0.05). The absolute values of the BIS and CSI were not significantly different. Both BIS and CSI decreased significantly when end-tidal sevoflurane concentration increased from 0.5 to 1.0%, but did not significantly change when end-tidal sevoflurane concentration increased from 1.0 to 1.5%. The BIS and CSI correlated well. The Bland-Altman plot showed good agreement between the BIS and CSI. Conclusion During sevoflurane-nitrous oxide anaesthesia, the CSI was not significantly different from the BIS in the awake state and with sevoflurane concentration 0.5-1.5%. Eur J Anaesthesiol 26:638-642 (C) 2009 European Society of Anaesthesiology.	[Nishiyama, Tomoki] Univ Tokyo, Dept Anesthesiol, Tokyo, Japan	Nishiyama, T (reprint author), 3-2-6-603 Kawaguchi, Kawaguchi, Saitama 3320015, Japan.	nishit-tky@umin.ac.jp					Anderson RE, 2006, EUR J ANAESTH, V23, P208, DOI 10.1017/S0265021505002206; Anderson RE, 2005, ACTA ANAESTH SCAND, V49, P750, DOI 10.1111/j.1399-6576.2005.00737.x; Barr G, 1999, BRIT J ANAESTH, V82, P827; Disma N, 2007, PEDIATR ANESTH, V17, P445, DOI 10.1111/j.1460-9592.2006.02146.x; Gajraj RJ, 1998, BRIT J ANAESTH, V80, P46; Hoymork SC, 2007, ACTA ANAESTH SCAND, V51, P210, DOI 10.1111/j.1399-6576.2006.01213.x; Iselin-Chaves Irene A., 1998, Anesthesia and Analgesia, V87, P949, DOI 10.1097/00000539-199810000-00038; Ishiyama T, 2005, ANESTH ANALG, V100, P728, DOI 10.1213/01.ANE.0000159868.06847.47; Jensen EW, 2006, ANESTHESIOLOGY, V105, P28, DOI 10.1097/00000542-200607000-00009; Katoh T, 1998, ANESTHESIOLOGY, V88, P642, DOI 10.1097/00000542-199803000-00014; Nakayama Masayasu, 2002, Masui, V51, P973; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Olofsen E, 1999, ANESTHESIOLOGY, V90, P1345, DOI 10.1097/00000542-199905000-00019; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P671, DOI 10.1097/00000542-199809000-00017; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Zhong T, 2005, BRIT J ANAESTH, V95, P798, DOI 10.1093/bja/aei253	17	11	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2009	26	8					638	642		10.1097/EJA.0b013e328324e946			5	Anesthesiology	Anesthesiology	477NL	WOS:000268525700004	19300270				2020-06-30	J	Duarte, LD; Moises, ECD; Cavalli, RC; Lanchote, VL; Duarte, G; da Cunha, SP				Duarte, Luciana de Barros; Dantas Moises, Elaine Cristine; Cavalli, Ricardo Carvalho; Lanchote, Vera Lucia; Duarte, Geraldo; da Cunha, Sergio Pereira			Distribution of fentanyl in the placental intervillous space and in the different maternal and fetal compartments in term pregnant women	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Fentanyl; Placental transfer; Placental intervillous space; P-glycoprotein	CESAREAN-SECTION; FOLATE LEVELS; BLOOD; GLYCOPROTEIN; PHARMACOKINETICS; SERUM; PARTURIENTS; BUPIVACAINE; NEWBORNS; BINDING	Fentanyl is used in obstetrical practice to promote analgesia and anesthesia during labor and in cesarean delivery, with rapid and short-term effects. To determine fentanyl concentrations in maternal plasma, in the placental intervillous space, and in the umbilical artery and vein in term pregnant women. Ten healthy pregnant women underwent epidural anesthesia with fentanyl plus bupivacaine and lidocaine, and fentanyl concentrations were determined in the various maternal and fetal compartments, including the placental intervillous space, which has not been previously studied in the literature. The ratios of fentanyl concentrations in the various maternal and fetal compartments revealed an 86% rate of placental fentanyl transfer. The highest fentanyl concentrations were detected in the placental intervillous space, being 2.19 times higher than in maternal plasma, 2.8 times higher than in the umbilical vein and 3.6 times higher than in the umbilical artery, with no significant differences between the umbilical vein and artery, demonstrating that there was no drug uptake by fetal tissues nor metabolism of the drug by the fetus despite the high rates of placental transfer. The present study demonstrated that the placental intervillous space acted as a site of fentanyl deposit, a fact that may be explained by two hypotheses: (1) the blood collected from the placental intervillous space is arterial and, according to some investigators, the arterial plasma concentrations of the drugs administered to patients undergoing epidural anesthesia are higher than the venous concentrations, and (2) a possible role of P-glycoprotein (P-gp).	[Duarte, Luciana de Barros] Hosp Clin, Dept Ginecol & Obstet Andar 8, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil; [Duarte, Luciana de Barros; Dantas Moises, Elaine Cristine; Cavalli, Ricardo Carvalho; Duarte, Geraldo; da Cunha, Sergio Pereira] Univ Sao Paulo, Dept Gynecol & Obstet, Fac Med Ribeirao Preto, Ribeirao Preto, Brazil; [Lanchote, Vera Lucia] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, BR-14049 Ribeirao Preto, Brazil	Duarte, LD (reprint author), Hosp Clin, Dept Ginecol & Obstet Andar 8, Fac Med Ribeirao Preto, Av Bandeirantes,3900 Campus USP, BR-14049900 Ribeirao Preto, SP, Brazil.	lbdmedi@msn.com	Moises, Elaine Christine Dantas/N-9522-2019; Moises, Elaine/A-5708-2015; Duarte, Geraldo/J-7906-2012; Lanchote, Vera Lucia/P-5925-2016; Cavalli, Ricardo C/G-2405-2012; Lanchote, Vera/C-1987-2012	Moises, Elaine Christine Dantas/0000-0001-9099-4544; Moises, Elaine/0000-0001-9099-4544; Lanchote, Vera Lucia/0000-0002-0074-4953; Cavalli, Ricardo/0000-0001-5010-4914	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES	The authors are grateful to Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) for financial support and to Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) for granting research fellowships.	BERNARDINI I, 1991, AM J OBSTET GYNECOL, V164, P1481, DOI 10.1016/0002-9378(91)91427-X; BRUNTON L, 2005, GOODMAN GILMANS PHAR; CAMELO JS, 1995, FETAL DIAGN THER, V10, P322, DOI 10.1159/000264252; Camelo JS, 2004, BRAZ J MED BIOL RES, V37, P711, DOI 10.1590/S0100-879X2004000500013; Cooper J, 1999, BRIT J ANAESTH, V82, P929; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P277; DESPRATS R, 1991, EUR J OBSTET GYN R B, V42, P89, DOI 10.1016/0028-2243(91)90167-J; Downing JW, 1997, ANESTH ANALG, V84, P527, DOI 10.1097/00000539-199703000-00011; GIUGLIANI ERJ, 1985, J PERINAT MED, V13, P55, DOI 10.1515/jpme.1985.13.2.55; GIUGLIANI ERJ, 1985, AM J CLIN NUTR, V41, P330; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HULL CJ, 1985, PATIENT CONTROLLED A; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; Lankas GR, 1998, REPROD TOXICOL, V12, P457, DOI 10.1016/S0890-6238(98)00027-6; MARTINEZ FE, 1981, J PEDIATR-US, V99, P298, DOI 10.1016/S0022-3476(81)80482-9; Moises ECD, 2005, EUR J CLIN PHARMACOL, V61, P517, DOI 10.1007/s00228-005-0967-9; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; MOORE K, 1998, WE ARE BORN ESSENTIA; PAECH MJ, 1990, ANAESTH INTENS CARE, V18, P22, DOI 10.1177/0310057X9001800105; PINHEIRO FS, 1992, NUTR RES, V12, P367, DOI 10.1016/S0271-5317(05)80752-3; REYNOLDS F, 1989, OXFORD REV REPROD BI, V11; ROSEAG P, 1992, CAN J ANAESTH, V39, P277; Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2; Shannon C, 1998, HUM REPROD, V13, P2317, DOI 10.1093/humrep/13.8.2317; Smit JW, 1999, J CLIN INVEST, V104, P1441, DOI 10.1172/JCI7963; SUGAWARA I, 1988, CANCER RES, V48, P1926; TUCKER GT, 1988, NEURAL BLOCKADE CLIN, P59; Wiesner G, 1996, ANAESTHESIST, V45, P323, DOI 10.1007/s001010050267	28	16	17	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	AUG	2009	65	8					803	808		10.1007/s00228-009-0645-4			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	474UH	WOS:000268309200008	19330322				2020-06-30	J	Wirz, S; Wittmann, M; Schenk, M; Schroeck, A; Schaefer, N; Mueller, M; Standop, J; Kloecker, N; Nadstawek, J				Wirz, Stefan; Wittmann, Maria; Schenk, Michael; Schroeck, Andreas; Schaefer, Nico; Mueller, Marcus; Standop, Jens; Kloecker, Norbert; Nadstawek, Joachim			Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine	EUROPEAN JOURNAL OF PAIN			English	Article						Hydromorphone; Fentanyl; Buprenorphine; Transdermal; Constipation; Nausea; Emesis; Symptom control; Laxatives; Antiemetics	QUALITY-OF-LIFE; CANCER PAIN; DOSE RATIOS; CONSTIPATION; MORPHINE; EFFICACY; MULTICENTER; ROTATION; PREVALENCE; MANAGEMENT	Introduction: The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation. Patients and methods: Randomly selected outpatients with cancer pain receiving one of the Study medications were enrolled in a prospective, open-labeled, controlled trial (n = 174). Mobility, pain, and gastrointestinal symptoms were assessed directly and per selected item on the ECOG (Eastern Cancer Oncology Group), EORTC (European Organisation for Research and Treatment of Cancer) questionnaires, NRS (Numerical Rating Scales), and analyzed statistically. Results: Demographic and medical data were comparable in all groups. Only 15% of patients suffered from constipation. 59% took the prescribed laxatives. The incidence of stool free periods >72 In was significantly higher with transdermal opioids (transdermal fentanyl: 22%; transdermal buprenorphine: 21%: oral hydromorphone: 2%; p = 0.003). 21% of patients revealed nausea and emesis. The mean NRS for nausea (transdermal fentanyl: 1.3; transdermal buprenorphine: 1.2: oral hydromorphone: 1.5: p = 0.6), the consumption of antiemetics (transdermal fentanyl: 42%; transdermal buprenorphine: 33%: oral hydromorphone: 36%; p = 0.6) and laxatives (transdermal fentanyl:53%: transdermal buprenorphine: 66%: oral hydromorphone: 61%; p = 0.2) did not differ significantly, in contrast to the score for emesis (transdermal fentanyl: 16%; transdermal buprenorphine: 13%; oral hydromorphone: 33%; p = 0.02). Morphine equivalent opioid doses differed (mg/d transdermal fentanyl: 183: transdermal buprenorphine: 89: oral hydromorphone: 143; p = 0.001). because of obvious tolerance varying after long-term treatment. Conclusions: Gastrointestinal symptoms of cancer pain patients undergoing an opioid therapy are related to multifactorial causes. Transdermal opioids showed no benefit over oral controlled-release hydromorphone with regard to gastrointestinal symptoms. The conversion ratios for transdermal fentanyl, transdermal buprenorphine, and oral hydromorphone did not accord to the literature, because of differing occurrences of opioid tolerance after long-term therapy. (C) 2008 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd, All rights reserved.	[Wirz, Stefan] CURA Hosp, Dept Anesthesiol, D-53604 Bad Honnef, Germany; [Wirz, Stefan; Wittmann, Maria; Nadstawek, Joachim] Univ Bonn, Pain Clin, Clin Anesthesiol & Intens Care Med, D-53105 Bonn, Germany; [Schenk, Michael] Palliat Care Ctr, Havelhoehe Clin, D-14089 Berlin, Germany; [Schroeck, Andreas] Univ Bonn, Clin & Outpatients, Dept Otorhinolaryngol, D-53105 Bonn, Germany; [Schaefer, Nico; Mueller, Marcus; Standop, Jens] Univ Bonn, Clin & Outpatients, Dept Gen Abdominal Thorac & Vasc Surg, D-53127 Bonn, Germany; [Kloecker, Norbert] NKST Biostat Inst, D-65719 Kriftel, Germany	Wirz, S (reprint author), CURA Hosp, Dept Anesthesiol, Schuelgen Str 15, D-53604 Bad Honnef, Germany.	s.wirz@web.de	Wittmann, Maria/I-2125-2018	Wittmann, Maria/0000-0003-4786-7712			AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Agachan F, 1996, DIS COLON RECTUM, V39, P681, DOI 10.1007/BF02056950; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Bennett M, 2003, PALLIATIVE MED, V17, P418, DOI 10.1191/0269216303pm773oa; BRUERA E, 1994, J PAIN SYMPTOM MANAG, V9, P515, DOI 10.1016/0885-3924(94)90113-9; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Bruera E, 1991, J Palliat Care, V7, P6; CAMPORA E, 1991, J PAIN SYMPTOM MANAG, V6, P428, DOI 10.1016/0885-3924(91)90041-2; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Davis MP, 2000, SUPPORT CARE CANCER, V8, P444, DOI 10.1007/s005200000151; DERBY S, 1998, TOPICS PALLIATIVE CA, V1, P95; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; Fallon MT, 1999, PALLIATIVE MED, V13, P159, DOI 10.1191/026921699677653615; Glare Paul, 2006, Am J Hosp Palliat Care, V23, P229, DOI 10.1177/1049909106289068; Gralla RJ, 2005, SUPPORT CARE CANCER, V13, P77, DOI 10.1007/s00520-004-0756-5; HAAZEN L, 1999, EUR J PAIN SA, V3, P9; HAYS H, 1994, CANCER-AM CANCER SOC, V74, P1808, DOI 10.1002/1097-0142(19940915)74:6<1808::AID-CNCR2820740625>3.0.CO;2-Y; Lagman RL, 2005, SURG CLIN N AM, V85, P237, DOI 10.1016/j.suc.2004.11.004; Lawlor P, 1997, PAIN, V72, P79, DOI 10.1016/S0304-3959(97)00018-3; LEVY MH, 2003, J NAT COMP CANC N S3, V1, P522; Lindley C M, 1992, Qual Life Res, V1, P331, DOI 10.1007/BF00434947; Lundin E, 2004, Colorectal Dis, V6, P499, DOI 10.1111/j.1463-1318.2004.00694.x; Mancini I L, 2000, J Palliat Med, V3, P49, DOI 10.1089/jpm.2000.3.49; MCSHANE RE, 1985, NURS CLIN N AM, V20, P801; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Mercadante S, 2006, EUR J PAIN, V10, P153, DOI 10.1016/j.ejpain.2005.02.006; Miller MG, 1999, J PAIN SYMPTOM MANAG, V18, P9, DOI 10.1016/S0885-3924(99)00036-6; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; Moriarty M, 1999, J CLIN RES, V2, P1; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pappagallo M, 2001, AM J SURG, V182, p11S, DOI 10.1016/S0002-9610(01)00782-6; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; PORTENOY RK, 1987, MED CLIN N AM, V71, P303, DOI 10.1016/S0025-7125(16)30872-0; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Roila F, 2006, ANN ONCOL, V17, P20, DOI 10.1093/annonc/mdj078; Sarhill N, 2001, SUPPORT CARE CANCER, V9, P84, DOI 10.1007/s005200000183; Sittl R, 2005, CLIN THER, V27, P1022, DOI 10.1016/j.clinthera.2005.06.024; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Sittl R, 2006, CLIN THER, V28, P1144, DOI 10.1016/j.clinthera.2006.08.002; Staats PS, 2004, SOUTH MED J, V97, P129, DOI 10.1097/01.SMJ.0000109215.54052.D8; Sykes NP, 1998, PALLIATIVE MED, V12, P375, DOI 10.1191/026921698674125048; Weinstein SM, 2006, CLIN THER, V28, P86, DOI 10.1016/j.clinthera.2006.01.010; Wirz S, 2006, CLIN J PAIN, V22, P770, DOI 10.1097/01.ajp.0000210925.33783.4d; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	47	47	49	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	AUG	2009	13	7					737	743		10.1016/j.ejpain.2008.09.005			7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	475TQ	WOS:000268384500009	18977159				2020-06-30	J	Turhanoglu, S; Kaya, S; Erdogan, H				Turhanoglu, Selim; Kaya, Sedat; Erdogan, Hulya			Is there an advantage in using low-dose intrathecal bupivacaine for cesarean section?	JOURNAL OF ANESTHESIA			English	Article						Analgesics, fentanyl; Local anesthetics, bupivacaine; Anesthetic techniques, spinal; Cesarean section; Complication, hypotension	SPINAL-EPIDURAL ANESTHESIA; HYPERBARIC BUPIVACAINE; PLUS FENTANYL; DELIVERY; HYPOTENSION; PREVENTION; EPHEDRINE; TRIAL; MG	Spinal anesthesia for cesarean section is associated with a high incidence of maternal hypotension. The aim of this study was to assess the efficacy of low-dose bupivacaine with fentanyl to reduce the incidence of hypotension in spinal anesthesia for cesarean section. Forty pregnant women undergoing elective cesarean section were randomly allocated to two groups; those receiving 10 mg bupivacaine to group B (n = 20) and those receiving 4 mg bupivacaine plus 25 mu g fentanyl to group BF (n = 20); the agents were given intrathecally with patients in the sitting position, with a combined spinal-epidural technique. Sensory block was adequate for surgery in all patients. Hypotension occurred in all patients in group B (100%) and in 15 patients in group BF (75%). The incidence of hypotension, number of ephedrine treatments, and need for ephedrine were significantly greater in group B than group BF. Three patients in group BF required i.v. fentanyl supplementation after delivery. In 1 of these patients, i.v. fentanyl was not adequate, and epidural supplementation of 1% lidocaine was required. The development of hypotension after spinal block in subjects undergoing cesarean section was not prevented despite low-dose (4 mg) bupivacaine plus 25 mu g fentanyl, but the severity of maternal hypotension, and the number of ephedrine treatments and the total dose of ephedrine were decreased.	[Turhanoglu, Selim] Mustafa Kemal Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-31100 Antakya, Turkey; [Kaya, Sedat; Erdogan, Hulya] Dicle Univ, Fac Med, Dept Anesthesiol & Reanimat, Diyarbakir, Turkey	Turhanoglu, S (reprint author), Mustafa Kemal Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-31100 Antakya, Turkey.						Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Cooper DW, 2002, ANESTHESIOLOGY, V97, P1582, DOI 10.1097/00000542-200212000-00034; Faccenda KA, 2001, DRUG SAFETY, V24, P413, DOI 10.2165/00002018-200124060-00002; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; Kang F C, 1998, Acta Anaesthesiol Sin, V36, P207; Kansal A, 2005, ANAESTHESIA, V60, P28, DOI 10.1111/j.1365-2044.2004.03994.x; Kee WDN, 2001, BRIT J ANAESTH, V87, P772, DOI 10.1093/bja/87.5.772; Manullang TR, 2000, ANESTH ANALG, V90, P1162, DOI 10.1097/00000539-200005000-00030; Mendonca C, 2003, ANAESTHESIA, V58, P428, DOI 10.1046/j.1365-2044.2003.03090.x; Morgan PJ, 2001, ANESTH ANALG, V92, P997; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Teoh WHL, 2006, INT J OBSTET ANESTH, V15, P273, DOI 10.1016/j.ijoa.2006.03.004; Turker G, 2003, ACTA ANAESTH SCAND, V47, P986, DOI 10.1034/j.1399-6576.2003.00194.x; Van de Velde M, 2006, ANESTH ANALG, V103, P187, DOI 10.1213/01.ane.0000220877.70380.6e	15	12	12	0	2	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	AUG	2009	23	3					353	357		10.1007/s00540-009-0750-7			5	Anesthesiology	Anesthesiology	483ZC	WOS:000269011200007	19685114				2020-06-30	J	Lorenz, V; Rich, JM; Schebesta, K; Taslakian, S; Mullner, M; Frass, M; Schuster, E; Illievich, UM; Kaye, AD; Vaida, S; Krafft, P				Lorenz, Veit; Rich, James M.; Schebesta, Karl; Taslakian, Sevak; Muellner, Michael; Frass, Michael; Schuster, Ernst; Illievich, Udo M.; Kaye, Alan D.; Vaida, Sonia; Krafft, Peter			Comparison of the EasyTube (R) and endotracheal tube during general anesthesia in fasted adult patients	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Alternative airways; Combitube (R); EasyTube (R), Endotracheal tube, General anesthesia	EMERGENCY AIRWAY MANAGEMENT; LARYNGEAL MASK AIRWAY; DIFFICULT TRACHEAL INTUBATION; COMBITUBE; PRESSURES; DEVICES	Study Objective: To evaluate the effectiveness, safety, case of placement, and ventilatory parameters of a new alternate airway device, the EasyTube (R) (EzT; Teleflex Ruesch, Research Triangle Park, NC), in comparison to the endotracheal tube (ETT). Design: Prospective, randomized controlled trial. Setting: University Hospital. Subjects: 200 adult ASA physical status I and II patients scheduled for surgery. Interventions: Patients were randomized to two groups, one to receive ventilation via the EzT (n = 100) or the ETT (n = 100). After preoxygenation and induction with fentanyl and propofol, patients received muscle relaxation. The respective airway device was then inserted and mechanical ventilation was instituted. Measurements: Ease of insertion, number of insertion maneuvers, time until airtight seal of the airway was achieved, duration of surgery, leak pressure as well as arterial oxygen saturation (SpO(2)), and endtidal carbon dioxide (ETCO2) data, were recorded. Main Results: Mallampati airway class was higher in the EzT group (P < 0.029), while thyromental distance showed no difference between the two groups. Ease of insertion was noted in the EzT group (P < 0.043). Number of insertions was equal in both groups; insertion time was shorter with the EzT (15.5 +/- 3.6 see vs. 19.3 +/- 4.6 see; P < 0.0001). Leak pressure and SPO2 were not significantly different, while ETCO2 was lower with the ETT (P < 0.024). Adjustments had to be made for two EzT group patients. No difference in frequency of laryngo-pharyngeal discomfort was observed in either group. Conclusion: Insertion of an EzT appears to reduce time and facilitate placement of an airway device when compared with direct laryngoscopy and tracheal intubation. (C) 2009 Elsevier Inc. All rights reserved.	[Lorenz, Veit; Schebesta, Karl; Taslakian, Sevak; Krafft, Peter] Med Univ Vienna, Dept Anesthesiol Gen Intens Care & Pain Managemen, A-1090 Vienna, Austria; [Rich, James M.] Baylor Univ, Med Ctr, Dept Anesthesiol & Pain Management, Dallas, TX 75246 USA; [Muellner, Michael; Frass, Michael] Med Univ Vienna, Dept Internal Med 1, Intens Care Unit, A-1090 Vienna, Austria; [Schuster, Ernst] Med Univ Vienna, Core Unit Med Stat & Informat, A-1090 Vienna, Austria; [Illievich, Udo M.] Wagner Jauregg Hosp Linz, Dept Anesthesiol & Gen Intens Care, A-4020 Linz, Austria; [Kaye, Alan D.] Louisiana State Univ, Sch Med, Dept Anesthesiol, New Orleans, LA 70112 USA; [Vaida, Sonia] Penn State Milton S Hershey Med Ctr, Dept Anesthesiol, Hershey, PA 17033 USA	Krafft, P (reprint author), Med Univ Vienna, Dept Anesthesiol Gen Intens Care & Pain Managemen, A-1090 Vienna, Austria.	peter.krafft@meduniwien.ac.at	Schebesta, Karl/V-4626-2019	Schebesta, Karl/0000-0003-4080-0099			Agro F, 2002, J CLIN ANESTH, V14, P307, DOI 10.1016/S0952-8180(02)00356-2; Akca O, 2004, ANESTH ANALG, V99, P272, DOI 10.1213/01.ane.0000117003.60213.e9; Benumof JL, 1996, ANESTHESIOLOGY, V84, P686, DOI 10.1097/00000542-199603000-00024; BENUMOF JL, 1991, ANESTHESIOLOGY, V75, P1087; Bercker S, 2008, ANESTH ANALG, V106, P445, DOI 10.1213/ane.0b013e3181602ae1; FRASS M, 1987, ARCH EMERG MED, V4, P219; Gaitini LA, 1999, ANESTH ANALG, V88, P193, DOI 10.1097/00000539-199901000-00036; Gaitini LA, 2001, ANESTHESIOLOGY, V94, P79, DOI 10.1097/00000542-200101000-00016; Hartmann T, 2000, ANAESTHESIA, V55, P670, DOI 10.1046/j.1365-2044.2000.01376.x; Krafft Peter, 2004, Curr Opin Anaesthesiol, V17, P499, DOI 10.1097/00001503-200412000-00009; Lefrancois DP, 2002, RESUSCITATION, V52, P77, DOI 10.1016/S0300-9572(01)00441-5; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Mort TC, 2006, ANESTH ANALG, V103, P1264, DOI 10.1213/01.ane.0000242521.58073.85; Rabitsch W, 2006, ANESTHESIOLOGY, V105, P696, DOI 10.1097/00000542-200610000-00014; Rich James M, 2004, AANA J, V72, P115; Rich James M, 2004, AANA J, V72, P17; SAMSOON GLT, 1987, ANAESTHESIA, V42, P487, DOI 10.1111/j.1365-2044.1987.tb04039.x; SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007; Thierbach Andreas R, 2005, Prehosp Emerg Care, V9, P445, DOI 10.1080/10903120500254910; Thierbach AR, 2004, RESUSCITATION, V60, P347, DOI 10.1016/j.resuscitation.2003.11.015; TSE JC, 1995, ANESTH ANALG, V81, P254, DOI 10.1097/00000539-199508000-00008; Ulrich-Pur H, 2006, ANESTHESIOLOGY, V104, P933, DOI 10.1097/00000542-200605000-00007	22	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2009	21	5					341	347		10.1016/j.jclinane.2008.09.008			7	Anesthesiology	Anesthesiology	496RM	WOS:000269993500006	19700284				2020-06-30	J	Cohen, RS				Cohen, Ronald S.			Fentanyl Transdermal Analgesia During Pregnancy and Lactation	JOURNAL OF HUMAN LACTATION			English	Article						drug use; human milk; pharmacology	NEONATAL ABSTINENCE SYNDROME; PAIN MANAGEMENT; PHARMACOKINETICS; METHADONE; MORPHINE; CHILDREN; INFANTS; CITRATE; TRIAL; BORN	This report describes an infant who was born to a mother with chronic pain treated with fentanyl 100 mu g/h transdermal patch throughout her pregnancy and during lactation. Oil day of life 27, when the baby was feeding and gaining weight on maternal milk, samples of the baby's blood and maternal milk were sent for analysis. The mother's milk fentanyl level was 6.4 ng/mL. The infant's blood fentanyl level was undetectable. This preliminary report Suggests that fentanyl transdermal patch treatment might be a viable option for managing chronic pain during lactation. J Hum Lact. 25(3):359-361.	[Cohen, Ronald S.] Stanford Univ, Sch Med, Lucile S Packard Childrens Hosp, Palo Alto, CA 94304 USA; [Cohen, Ronald S.] Mothers Milk Bank San Jose, San Jose, CA USA	Cohen, RS (reprint author), Stanford Univ, Sch Med, Lucile S Packard Childrens Hosp, 725 Welch Rd IICN, Palo Alto, CA 94304 USA.	rscohen@stanford.edu					Dashe JS, 2002, OBSTET GYNECOL, V100, P1244, DOI 10.1016/S0029-7844(02)02387-6; DOBERCZAK TM, 1987, AM J DIS CHILD, V141, P1163, DOI 10.1001/archpedi.1987.04460110033016; Ebner N, 2007, DRUG ALCOHOL DEPEN, V87, P131, DOI 10.1016/j.drugalcdep.2006.08.024; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Gadsden J, 2005, ANESTH ANALG, V101, pS62, DOI 10.1213/01.ANE.0000177100.08599.C8; Hunt RW, 2008, EARLY HUM DEV, V84, P29, DOI 10.1016/j.earlhumdev.2007.01.013; Jackson L, 2004, ARCH DIS CHILD-FETAL, V89, pF300, DOI 10.1136/adc.2003.033555; Jansson LM, 2008, PEDIATRICS, V121, P106, DOI 10.1542/peds.2007-1182; Koren G, 2006, LANCET, V368, P704, DOI 10.1016/S0140-6736(06)69255-6; Kuczkowski KM, 2004, J CLIN ANESTH, V16, P1, DOI 10.1016/j.jclinane.2003.08.002; Mahar PJ, 2007, PEDIATR EMERG CARE, V23, P544, DOI 10.1097/PEC.0b013e318128f80b; McCarthy J J, 2000, J Hum Lact, V16, P115, DOI 10.1177/089033440001600206; Nitsun M, 2006, CLIN PHARMACOL THER, V79, P549, DOI 10.1016/j.clpt.2006.02.010; OSTREA EM, 1979, J PEDIATR-US, V94, P292, DOI 10.1016/S0022-3476(79)80847-1; Pan PH, 2006, INT J OBSTET ANESTH, V15, P185, DOI 10.1016/j.ijoa.2006.04.004; Rayburn WF, 2007, CLIN PERINATOL, V34, P559, DOI 10.1016/j.clp.2007.09.001; Regan J, 2000, BRIT J OBSTET GYNAEC, V107, P570, DOI 10.1111/j.1471-0528.2000.tb13282.x; Sabatowski R, 2000, ACTA ANAESTH SCAND, V44, P348, DOI 10.1034/j.1399-6576.2000.440323.x; Seligman NS, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.088; Sharpe C, 2004, ARCH DIS CHILD-FETAL, V89, pF33, DOI 10.1136/fn.89.1.F33; Spigset O, 2000, Paediatr Drugs, V2, P223, DOI 10.2165/00128072-200002030-00006; Taddio A, 2002, CLIN PERINATOL, V29, P493, DOI 10.1016/S0095-5108(02)00017-9; Ward RM, 2001, PEDIATRICS, V108, P1020; Wheeler M, 2004, ANESTH ANALG, V99, P1347, DOI 10.1213/01.ANE.0000132777.00967.A3; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; ZUSPAN FP, 1975, AM J OBSTET GYNECOL, V122, P43, DOI 10.1016/0002-9378(75)90613-4	26	9	12	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0890-3344	1552-5732		J HUM LACT	J. Hum. Lact.	AUG	2009	25	3					359	361		10.1177/0890334409333475			3	Nursing; Obstetrics & Gynecology; Pediatrics	Nursing; Obstetrics & Gynecology; Pediatrics	479NL	WOS:000268666400017	19286842				2020-06-30	J	Morad, AH; Winters, BD; Yaster, M; Stevens, RD; White, EA; Thompson, RE; Weingart, JD; Gottschalk, A				Morad, Athir H.; Winters, Bradford D.; Yaster, Myron; Stevens, Robert D.; White, Elizabeth A.; Thompson, Richard E.; Weingart, Jon D.; Gottschalk, Allan			Efficacy of intravenous patient-controlled analgesia after supratentorial intracranial surgery: a prospective randomized controlled trial Clinical article	JOURNAL OF NEUROSURGERY			English	Article						acute pain; analgesia; craniotomy; neurosurgery; opioids; patient-controlled analgesia	PAIN FOLLOWING CRANIOTOMY; POSTOPERATIVE PAIN; MORPHINE; RECOVERY; HEADACHE; QUALITY; CODEINE; NURSES; NAUSEA; PCA	Object. Opioid administration following major intracranial surgery is often limited by a presumed lack of need and a concern that opioids will adversely affect postoperative Outcome and interfere with the neurological examination. Nevertheless, evidence is accumulating that these patients suffer moderate to severe postoperative pain and that this pain is often undertreated. The authors hypothesized that intravenous patient-controlled analgesia (PCA) would safely and more effectively treat postoperative supratentorial craniotomy pain than conventional as needed (PRN) therapy. Methods. Following a standardized Course of general anesthesia, adult patients who underwent elective supratentorial intracranial surgery were randomized in the neurosciences intensive care unit to receive either PRN intravenous fentanyl 25-50 mu g every 30 minutes or PCA intravenous fentanyl 0.5 mu g/kg every 15 minutes (maximum 4 doses/hour). The authors measured pain (self-reported scale score [0-10]), sedation (Ramsay Sedation Scale score), Glasgow Coma Scale score, fentanyl use, and major adverse events (excessive sedation, respiratory depression, pruritus, nausea, or vomiting) hourly. Results. Sixty-four patients with a mean age of 48 years (range 22-77 years) were randomized to intravenous PCA (29 patients) or PRN fentanyl (35 patients) groups. There were no statistically significant demographic differences between the 2 groups. Patients receiving intravenous PCA had significantly lower pain scores than those receiving intravenous PRN fentanyl (2.53 +/- 1.96 vs 3.62 +/- 2.11 [p = 0.039]) and received significantly more fentanyl than the PRN group (44.1 +/- 34.5 vs 23.6 +/- 23.7 mu g/hour [p = 0.007]). There were no differences between the 2 groups regarding the number of patients with adverse events. Conclusions. Intravenous PCA more effectively treats the pain of supratentorial intracranial surgery than PRN fentanyl, and patients in the former group did not experience any untoward events related to the self-administration of opioids. (DOI: 10.3171/2008.11.JNS08797)	[Morad, Athir H.; Winters, Bradford D.; Yaster, Myron; Stevens, Robert D.; White, Elizabeth A.; Gottschalk, Allan] Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Thompson, Richard E.] Johns Hopkins Univ Hosp, Dept Biostat, Baltimore, MD 21287 USA; [Weingart, Jon D.] Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA	Morad, AH (reprint author), Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, Meyer 8-134,600 N Wolfe St, Baltimore, MD 21287 USA.	morada@jhmi.edu			Jacob and Hilda Blaustein Foundation (Yaster); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS041865]; Richard J. Traystman endowed chair	This study was supported in part by grants from the Jacob and Hilda Blaustein Foundation (Yaster), National Institutes of Health Grant No. NS041865 (Dr. Gottschalk), and Richard J. Traystman endowed chair (Dr. Yaster). The authors report no other conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Bauer C, 2007, ANESTH ANALG, V105, P238, DOI 10.1213/01.ane.0000266441.58308.42; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; COLD GE, 1993, NEUROSURGERY, V32, P327, DOI 10.1097/00006123-199302000-00032; de Gray LC, 2005, ANAESTHESIA, V60, P693, DOI 10.1111/j.1365-2044.2005.03997.x; de Rond MEJ, 2000, PAIN, V89, P25, DOI 10.1016/S0304-3959(00)00344-4; DeBenedittis G, 1996, NEUROSURGERY, V38, P466, DOI 10.1227/00006123-199603000-00008; Dunbar PJ, 1999, ANESTH ANALG, V88, P335, DOI 10.1097/00000539-199902000-00021; Durieux ME, 2007, J NEUROSURG, V106, P207, DOI 10.3171/jns.2007.106.2.207; Fabling JM, 1997, J NEUROSURG ANESTH, V9, P308, DOI 10.1097/00008506-199710000-00003; Gottschalk A, 2007, J NEUROSURG, V106, P210, DOI 10.3171/jns.2007.106.2.210; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Jellish WS, 2006, OTOLARYNG HEAD NECK, V135, P175, DOI 10.1016/j.otohns.2006.02.027; Koperer H, 1999, MINIM INVAS NEUROSUR, V42, P175, DOI 10.1055/s-2008-1053393; Law-Koune JD, 2005, J NEUROSURG ANESTH, V17, P139, DOI 10.1097/01.ana.0000171730.41008.da; Leslie K, 2003, ANESTHESIOLOGY, V99, P1158, DOI 10.1097/00000542-200311000-00024; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; McCaffery M, 2007, AM J NURS, V107, P35, DOI 10.1097/01.NAJ.0000301016.18877.19; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Quiney N, 1996, BRIT J NEUROSURG, V10, P295, DOI 10.1080/02688699650040179; Roberts Gemma, 2004, Nurs Crit Care, V9, P277, DOI 10.1111/j.1362-1017.2004.00087.x; Rocha PAS, 2008, CEPHALALGIA, V28, P41, DOI 10.1111/j.1468-2982.2007.01465.x; SCHESSEL DA, 1992, OTOLARYNG HEAD NECK, V107, P424, DOI 10.1177/019459989210700314; SMYTHE M, 1992, PHARMACOTHERAPY, V12, P132; Stoneham MD, 1996, ANAESTHESIA, V51, P1176, DOI 10.1111/j.1365-2044.1996.tb15065.x; STONEHAM MD, 1995, EUR J ANAESTH, V12, P571; Sudheer PS, 2007, ANAESTHESIA, V62, P555, DOI 10.1111/j.1365-2044.2007.05038.x; Talke PO, 2005, EUR J ANAESTH, V22, P325, DOI 10.1017/S0265021505000542; Tanskanen P, 1999, ACTA ANAESTH SCAND, V43, P42, DOI 10.1034/j.1399-6576.1999.430110.x; YASTER M, 1997, PEDIAT PAIN MANAGEME, P89	31	30	30	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2009	111	2					343	350		10.3171/2008.11.JNS08797			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	475EL	WOS:000268341100024	19249923				2020-06-30	J	Sharma, SS; Sritharan, G; Mogos, M; Roffey, P; Thangathurai, D				Sharma, Shalini S.; Sritharan, Ganan; Mogos, Mariana; Roffey, Peter; Thangathurai, Duraiyah			Fentanyl and Ketamine Used for Postoperative Pain Control in High-Risk Patients with Malignancy	JOURNAL OF PALLIATIVE MEDICINE			English	Letter							LONG-LASTING HYPERALGESIA; RATS		[Sharma, Shalini S.; Sritharan, Ganan; Mogos, Mariana; Roffey, Peter; Thangathurai, Duraiyah] USC, Norris Canc Hosp, Dept Anesthesiol, Los Angeles, CA 90033 USA	Thangathurai, D (reprint author), USC, Norris Canc Hosp, Dept Anesthesiol, 1441 Eastlake Ave,Room 4341, Los Angeles, CA 90033 USA.	thangath@usc.edu					Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025	2	0	0	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	AUG	2009	12	8					675	675		10.1089/jpm.2009.0075			1	Health Care Sciences & Services	Health Care Sciences & Services	480XG	WOS:000268770000006	19663569				2020-06-30	J	Sirohi, S; Dighe, SV; Madia, PA; Yoburn, BC				Sirohi, Sunil; Dighe, Shveta V.; Madia, Priyanka A.; Yoburn, Byron C.			The Relative Potency of Inverse Opioid Agonists and a Neutral Opioid Antagonist in Precipitated Withdrawal and Antagonism of Analgesia and Toxicity	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							BASAL SIGNALING ACTIVITY; NARCOTIC DEPENDENCE; RECEPTOR; 6-BETA-NALTREXOL; NALTREXONE; EFFICACY; NALOXONE; PRETREATMENT; ACTIVATION; TOLERANCE	Opioid antagonists can be classified as inverse agonists and neutral antagonists. In the opioid-dependent state, neutral antagonists are significantly less potent in precipitating withdrawal than inverse agonists. Consequently, neutral opioid antagonists may offer advantages over inverse agonists in the management of opioid overdose. In this study, the relative potency of three opioid antagonists to block opioid analgesia and toxicity and precipitate withdrawal was examined. First, the potency of two opioid inverse agonists (naltrexone and naloxone) and a neutral antagonist (6 beta-naltrexol) to antagonize fentanyl-induced analgesia and lethality was determined. The order of potency to block analgesia was naltrexone > naloxone > 6 beta-naltrexol (17, 4, 1), which was similar to that to block lethality (13, 2, 1). Next, the antagonists were compared using withdrawal jumping in fentanyl-dependent mice. The order of potency to precipitate withdrawal jumping was naltrexone > naloxone >>> 6 beta-naltrexol (1107, 415, 1). The relative potencies to precipitate withdrawal for the inverse agonists compared with the neutral antagonist were dramatically different from that for antagonism of analgesia and lethality. Finally, the effect of 6 beta-naltrexol pretreatment on naloxone-precipitated jumping was determined in morphine and fentanyl-dependent mice. 6 beta-Naltrexol pretreatment decreased naloxone precipitated withdrawal, indicating that 6 beta-naltrexol is a neutral antagonist. These data demonstrate that inverse agonists and neutral antagonists have generally comparable potencies to block opioid analgesia and lethality, whereas the neutral opioid antagonist is substantially less potent in precipitating opioid withdrawal. These results support suggestions that neutral antagonists may have advantages over inverse agonists in the management of opioid overdose.	[Sirohi, Sunil; Dighe, Shveta V.; Madia, Priyanka A.; Yoburn, Byron C.] St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Jamaica, NY 11439 USA	Yoburn, BC (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, 800 Utopia Pkwy, Jamaica, NY 11439 USA.	yoburnb@stjohns.edu	SIROHI, SUNIL/E-1891-2012	SIROHI, SUNIL/0000-0001-7246-9295	National Institutes of Health National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA19959]	This work was supported in part by the National Institutes of Health National Institute on Drug Abuse [Grant DA19959] (to B.C.Y.).	Becker JAJ, 1999, J BIOL CHEM, V274, P27513, DOI 10.1074/jbc.274.39.27513; Burford NT, 2000, BIOCHEM J, V348, P531, DOI 10.1042/0264-6021:3480531; Clarke SFJ, 2005, EMERG MED J, V22, P612, DOI 10.1136/emj.2003.009613; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Divin MF, 2008, EUR J PHARMACOL, V583, P48, DOI 10.1016/j.ejphar.2008.01.004; Finney DJ, 1973, PROBIT ANAL; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Ko MCH, 2006, J PHARMACOL EXP THER, V316, P772, DOI 10.1124/jpet.105.094409; Li JX, 2008, PSYCHOPHARMACOLOGY, V195, P479, DOI 10.1007/s00213-007-0914-9; LING W, 1990, WESTERN J MED, V152, P565; Liu JG, 2001, MOL PHARMACOL, V60, P53; Marczak ED, 2007, J PHARMACOL EXP THER, V323, P374, DOI 10.1124/jpet.107.125807; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)01139-5; Milligan G, 1997, RECEPTOR CHANNEL, V5, P209; PRATHER PL, 2004, SCI STKE, pPE1; Raehal KM, 2005, J PHARMACOL EXP THER, V313, P1150, DOI 10.1124/jpet.104.082966; Sadee W, 2005, LIFE SCI, V76, P1427, DOI 10.1016/j.lfs.2004.10.024; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Sirohi S, 2007, J PHARMACOL EXP THER, V323, P701, DOI 10.1124/jpet.107.127019; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; van Dorp ELA, 2007, EXPERT OPIN DRUG SAF, V6, P125, DOI 10.1517/14740338.6.2.125; Walker EA, 2005, BRIT J PHARMACOL, V145, P975, DOI 10.1038/sj.bjp.0706247; Wang DX, 2007, J PHARMACOL EXP THER, V321, P544, DOI 10.1124/jpet.106.118810; Wang DX, 2004, J PHARMACOL EXP THER, V308, P512, DOI 10.1124/jpet.103.054049; Wang DX, 2001, J NEUROCHEM, V77, P1590, DOI 10.1046/j.1471-4159.2001.00362.x; WANG Z, 1994, LIFE SCI, V54, pPL339, DOI 10.1016/0024-3205(94)90022-1	28	23	25	1	12	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	AUG	2009	330	2					513	519		10.1124/jpet.109.152678			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	472RY	WOS:000268150900016	19435929	Green Published			2020-06-30	J	Lin, H; Higgins, P; Loh, HH; Law, PY; Liao, DZ				Lin, Hang; Higgins, Paul; Loh, Horace H.; Law, Ping-Yee; Liao, Dezhi			Bidirectional Effects of Fentanyl on Dendritic Spines and AMPA Receptors Depend Upon the Internalization of Mu Opioid Receptors	NEUROPSYCHOPHARMACOLOGY			English	Article						fentanyl; dendritic spines; AMPA receptors; receptor internalization; cognitive dysfunctions	VENTRAL TEGMENTAL AREA; MORPHINE-TOLERANCE; SYNAPTIC PLASTICITY; BEHAVIORAL SENSITIZATION; TRANSDERMAL OPIOIDS; HIPPOCAMPAL-NEURONS; OPIATE ANTAGONISTS; ENDOGENOUS OPIATES; NUCLEUS-ACCUMBENS; SILENT SYNAPSES	Fentanyl is a frequently used and abused opioid analgesic and can cause internalization of mu opioid receptors (MORs). Receptor internalization modulates the signaling pathways of opioid receptors. As changes in dendritic spines and synaptic AMPA receptors play important roles in addiction and memory loss, we investigated how fentanyl affects dendritic spines and synaptic AMPA receptors in cultured hippocampal neurons. Fentanyl at low concentrations (0.01 and 0.1 mu M) caused the collapse of dendritic spines and decreased the number of AMPA receptor clusters. In contrast, fentanyl at high concentrations (1 and 10 m=mu M) had opposite effects, inducing the emergence of new spines and increasing the number of AMPA receptor clusters. These dose-dependent bidirectional effects of fentanyl were blocked by a selective MOR antagonist CTOP at 5 mu M. In neurons that had been transfected with HA-tagged or GFP-tagged MORs, fentanyl at high concentrations induced persistent and robust internalization of MORs, whereas fentanyl at lower concentrations induced little or transient receptor internalization. The blockade of receptor internalization with the expression of dominant-negative Dynamin I (the K44E mutant) reversed the effect of fentanyl at high concentrations, supporting a role of receptor internalization in modulating the dose-dependent effects of fentanyl. In contrast to morphine, the effects of fentanyl on dendritic spines are distinctively bidirectional and concentration dependent, probably due to its ability to induce robust internalization of MORs at high concentrations. The characterization of the effects of fentanyl on spines and AMPA receptors may help us understand the roles of MOR internalization in addiction and cognitive deficits. Neuropsychopharmacology (2009) 34, 2097-2111; doi:10.1038/npp.2009.34; published online 18 March 2009	[Lin, Hang; Higgins, Paul; Liao, Dezhi] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; [Lin, Hang] Chengdu Gen Mil Hosp, Dept Neurol, Chengdu, Peoples R China; [Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Liao, DZ (reprint author), Univ Minnesota, Dept Neurosci, 321 Church St SE, Minneapolis, MN 55455 USA.	liaox020@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	National Institute for Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01-DA020582, K02-DA025048]; Chinese government [30570591, 06MA147]; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P50-DA011806, R01-DA007339, R01-DA000564, R01-DA016674, K05-DA070554, K05-DA000513]	We thank Dr George Wilcox and Dr Brian Hoover for their helpful comments, and Mr Eric Nordstrom for his technical support. This study is supported by National Institute for Drug Abuse (NIDA) grants R01-DA020582 and K02-DA025048 to DL; grants from Chinese government (30570591 and 06MA147) to HL; and NIDA grants P50-DA011806, R01-DA007339, R01-DA000564, R01-DA016674, K05-DA070554, and K05-DA000513 to HHL and PYL.	Alvarez V, 2001, NEURON, V32, P761, DOI 10.1016/S0896-6273(01)00530-X; Alvarez VA, 2002, J NEUROSCI, V22, P5769; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Biala G, 2005, EUR J NEUROSCI, V21, P3089, DOI 10.1111/j.1460-9568.2005.04132.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bodnar RJ, 2007, PEPTIDES, V28, P2435, DOI 10.1016/j.peptides.2007.09.002; Bodnar RJ, 2003, PEPTIDES, V24, P1241, DOI 10.1016/j.peptides.2003.08.002; CANLI T, 1990, PHARMACOL BIOCHEM BE, V36, P521, DOI 10.1016/0091-3057(90)90250-L; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; COMETTAMORINI C, 1992, MOL PHARMACOL, V41, P185; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Ersche KD, 2006, NEUROPSYCHOPHARMACOL, V31, P1036, DOI 10.1038/sj.npp.1300889; Fan GH, 1999, MOL PHARMACOL, V56, P39; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Fodale V, 2008, EXPERT OPIN DRUG SAF, V7, P213, DOI [10.1517/14740338.7.3.213, 10.1517/14740338.7.3.213 ]; GALLAGHER M, 1985, BEHAV NEURAL BIOL, V44, P374, DOI 10.1016/S0163-1047(85)90688-0; GOSLIN K, 1991, CULTURING NERVE CELL, P251; Gruber SA, 2007, NEUROPSYCHOL REV, V17, P299, DOI 10.1007/s11065-007-9041-y; Haberstock-Debic H, 2003, J NEUROSCI, V23, P4324; Hanks G, 2005, SUPPORT CARE CANCER, V13, P145, DOI 10.1007/s00520-004-0730-2; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KALIVAS PW, 1993, J PHARMACOL EXP THER, V267, P486; KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3; Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234; Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Lane DA, 2008, J NEUROSCI, V28, P9670, DOI 10.1523/JNEUROSCI.2151-08.2008; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Liao D, 2007, MOL CELL NEUROSCI, V35, P456, DOI 10.1016/j.mcn.2007.04.007; Liao DZ, 2007, J NEUROPHYSIOL, V97, P1485, DOI 10.1152/jn.00790.2006; Liao DH, 1999, NAT NEUROSCI, V2, P37; Liao DZ, 2001, J NEUROSCI, V21, P6008; Lin H, 2004, BIOCHEM BIOPH RES CO, V316, P501, DOI 10.1016/j.bbrc.2004.02.086; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Meilandt WJ, 2008, J NEUROSCI, V28, P5007, DOI 10.1523/JNEUROSCI.0590-08.2008; Mintzer MZ, 2005, DRUG ALCOHOL DEPEN, V78, P225, DOI 10.1016/j.drugalcdep.2004.10.008; Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Prudic J, 1999, NEUROPSYCHOPHARMACOL, V21, P285, DOI 10.1016/S0893-133X(99)00015-9; RANG HP, 1995, PHARMACOLOGY, P609; Robinson TE, 2002, SYNAPSE, V46, P271, DOI 10.1002/syn.10146; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Silbert BS, 2006, ANESTHESIOLOGY, V104, P1137, DOI 10.1097/00000542-200606000-00007; Skaer TL, 2004, DRUGS, V64, P2629, DOI 10.2165/00003495-200464230-00002; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-24; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trescot A, 2008, PAIN PHYSICIAN, V11, pS181; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wiens KM, 2005, J NEUROSCI, V25, P10627, DOI 10.1523/JNEUROSCI.1947-05.2005; Williams JT, 2001, PHYSIOL REV, V81, P299; Wolf Marina E, 2002, Mol Interv, V2, P146, DOI 10.1124/mi.2.3.146; WOLF ME, 1993, BRAIN RES, V613, P291, DOI 10.1016/0006-8993(93)90913-8; Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024	66	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	AUG	2009	34	9					2097	2111		10.1038/npp.2009.34			15	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	471ZM	WOS:000268097200005	19295508	Green Accepted, Bronze			2020-06-30	J	Amornyotin, S; Aanpreung, P; Prakarnrattana, U; Chalayonnavin, W; Chatchawankitkul, S; Srikureja, W				Amornyotin, Somchai; Aanpreung, Prapun; Prakarnrattana, Ungkab; Chalayonnavin, Wiyada; Chatchawankitkul, Sukanda; Srikureja, Wichit			Experience of intravenous sedation for pediatric gastrointestinal endoscopy in a large tertiary referral center in a developing country	PEDIATRIC ANESTHESIA			English	Article						sedation; children; gastrointestinal endoscopy; developing country	DEEP SEDATION; CONSCIOUS SEDATION; GENERAL-ANESTHESIA; PROPOFOL; CHILDREN; FENTANYL; KETAMINE; CARE	Background: The aim of this study was to evaluate the clinical efficacy of intravenous sedation for pediatric gastrointestinal endoscopy (GIE) at a tertiary care teaching hospital in a developing country. Methods: We undertook a retrospective review of the sedation service records of pediatric patients who underwent GIE. All endoscopies were performed by a pediatric gastroenterologist. All of the sedation was administered by staff anesthesiologist or anesthetic personnel in the gastroenterology procedure room. Results: Sedation was provided for 222 procedures in 214 patients ranged in age from younger than 1 to 17 years and in weight from 2.7 to 80.0 kg. Intravenous sedation was provided in 176 patients (82.2%). Of these patients, 185 procedures were performed and reviewed, with 152 (82.2%) procedures were esophagogastroduodenoscopy (EGD) alone, 14 (7.6%) procedures were colonoscopy alone, 18 (9.7%) procedures were EGD and colonoscopy, and one procedure was endoscopic ultrasonography (EUS). Most common indications of the procedure were screening for esophageal varices (25.2%), abdominal pain (15.9%), history of upper gastrointestinal hemorrhage (13.6%), and unexplained anemia (10.3%). The majority of preanesthetic problems were hematologic disease, anemia (38.2%); liver disease, cirrhosis (13.5%); and electrolyte imbalance (13.5%). Propofol (94.0%), fentanyl (87.0%), and midazolam (67.8%) were frequently used. The mean dose of propofol was 7.8 +/- 4.1 mg center dot kg(-1)center dot h(-1), fentanyl 2.3 +/- 1.1 mcg center dot kg(-1)center dot h(-1), and midazolam 0.1 +/- 0.1 mg center dot kg(-1)center dot h(-1). Most of them were used in combination. The combination of propofol, fentanyl, and midazolam was commonly employed (46.4%). The mean sedation time of all procedures was 28.2 min and was different according to procedure type. Complications occurred infrequently (13.5%) and were medication or airway related. All complications were easily treated, with no adverse sequelae. Intravenous sedation was successful except for one patient who required general anesthesia. However, all procedures were completed successfully. Conclusions: In the setting of the developing country, intravenous sedation for pediatric GIE by trained anesthetic personnel with appropriate monitoring was safe and effective. Serious adverse events were rare in our population.	[Amornyotin, Somchai; Prakarnrattana, Ungkab; Chalayonnavin, Wiyada; Chatchawankitkul, Sukanda] Mahidol Univ, Fac Med, Siriraj Hosp, Dept Anesthesiol, Bangkok 10700, Thailand; [Aanpreung, Prapun] Mahidol Univ, Fac Med, Siriraj Hosp, Dept Pediat, Bangkok 10700, Thailand; [Srikureja, Wichit] Mahidol Univ, Fac Med, Siriraj Hosp, Siriraj GI Endoscopy Ctr, Bangkok 10700, Thailand	Amornyotin, S (reprint author), Mahidol Univ, Fac Med, Siriraj Hosp, Dept Anesthesiol, Bangkok 10700, Thailand.	sisam@mahidol.ac.th	Amornyotin, Somchai/E-4438-2012	Amornyotin, Somchai/0000-0002-4345-5836			AMENT ME, 1995, GASTROINTEST ENDOSC, V41, P173, DOI 10.1016/S0016-5107(05)80607-8; Aouad MT, 2008, ACTA ANAESTH SCAND, V52, P561, DOI 10.1111/j.1399-6576.2008.01584.x; Balsells F, 1997, GASTROINTEST ENDOSC, V45, P375, DOI 10.1016/S0016-5107(97)70147-0; Barbi E, 2006, ENDOSCOPY, V38, P368, DOI 10.1055/s-2005-921194; Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; Bishop PR, 2002, GASTROINTEST ENDOSC, V55, P624, DOI 10.1067/mge.2002.123417; BROWN L, 2003, ACAD EMERG MED, V10, P482; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cote CJ, 2008, PEDIATR ANESTH, V18, P3, DOI 10.1111/j.1460-9592.2007.02403.x; Gozal D, 2004, J PEDIATR-US, V145, P47, DOI 10.1016/j.jpeds.2004.01.044; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Heuss LT, 2004, DIGESTION, V69, P20, DOI 10.1159/000076543; *JOINT COMM ACCR H, 2004, COMPL ASS CHECKL AMB, pR5; Kaddu R, 2002, GASTROINTEST ENDOSC, V55, P27, DOI 10.1067/mge.2002.120386; Lamireau T, 1998, J PEDIATR GASTR NUTR, V27, P172, DOI 10.1097/00005176-199808000-00008; Lightdale JR, 2008, GASTROINTEST ENDOSC, V67, P1067, DOI 10.1016/j.gie.2007.11.038; Malviya S, 1997, ANESTH ANALG, V85, P1207, DOI 10.1097/00000539-199712000-00005; *SIGN, 2008, PEDIAT ANESTH, V18, P11; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Sury MRJ, 2008, PEDIATR ANESTH, V18, P18, DOI 10.1111/j.1460-9592.2007.02379.x; Tosun Z, 2007, PEDIATR ANESTH, V17, P983, DOI 10.1111/j.1460-9592.2007.02206.x; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Yildizdas D, 2004, PEDIATR EMERG CARE, V20, P162, DOI 10.1097/01.pec.0000117922.65522.26	25	17	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2009	19	8					784	791		10.1111/j.1460-9592.2009.03063.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	469GO	WOS:000267884600009	19624366				2020-06-30	J	Sedeek, KA; Liu, JB				Sedeek, Khaled A.; Liu, Jiabin			The management of neuraxial anesthesia in Henoch-Schonlein purpura (HSP) patient	PEDIATRIC ANESTHESIA			English	Letter							HEMORRHAGE		[Sedeek, Khaled A.; Liu, Jiabin] Penn State Univ, Milton S Hershey Med Ctr, Dept Anesthesiol, Hershey, PA 17033 USA	Sedeek, KA (reprint author), Penn State Univ, Milton S Hershey Med Ctr, Dept Anesthesiol, Hershey, PA 17033 USA.	Ksedeek@hmc.psu.edu					BISSONNETTE B, 2006, SYNDROMES RAPID RECO, P731; Casonato A, 1996, AM J HEMATOL, V51, P7, DOI 10.1002/(SICI)1096-8652(199601)51:1<7::AID-AJH2>3.0.CO;2-2; Imai T, 2002, BRAIN DEV-JPN, V24, P115, DOI 10.1016/S0387-7604(02)00015-3; KATZ J, 1993, ANESTHESIA UNCOMMON, P542; Usui K, 2007, J DERMATOL, V34, P705, DOI 10.1111/j.1346-8138.2007.00364.x	5	0	0	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	AUG	2009	19	8					811	812		10.1111/j.1460-9592.2009.03075.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	469GO	WOS:000267884600023	19624379				2020-06-30	J	Eberspacher, E; Eckel, B; Engelhard, K; Muller, K; Hoffman, WE; Blobner, M; Werner, C				Eberspaecher, E.; Eckel, B.; Engelhard, K.; Mueller, K.; Hoffman, W. E.; Blobner, M.; Werner, C.			Effects of sevoflurane on cognitive deficit, motor function, and histopathology after cerebral ischemia in rats	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							ARTERY OCCLUSION; FOREBRAIN ISCHEMIA; MEMORY; REPERFUSION; HIPPOCAMPUS; IMPAIRMENT; EXPRESSION; DAMAGE	The volatile anesthetic sevoflurane exhibits neuroprotective properties when assessed for motor function and histopathology after cerebral ischemia in rats. Damage of hippocampal neurons after ischemia relates to a number of cognitive deficits that are not revealed by testing animals for motor function. Therefore, the present study evaluates cognitive and behavioral function as well as hippocampal damage in rats subjected to cerebral ischemia under sevoflurane compared with fentanyl/nitrous oxide (N(2)O)/O(2) anesthesia. Thirty-four rats were trained for 10 days using a hole-board test to detect changes in cognitive and behavioral function. Rats were randomly assigned to the following groups: (A) sham/fentanyl/N(2)O/O(2) (n=7); (B) ischemia/fentanyl/N(2)O/O(2) (n=10); (C) sham/2.0 vol% sevoflurane in O(2)/air (n=7); and (D) ischemia/2.0 vol% sevoflurane in O(2)/air (n=10). Cerebral ischemia was produced by unilateral common carotid artery occlusion combined with hemorrhagic hypotension (mean arterial blood pressure 40 mmHg for 45 min). Temperature, arterial blood gases, and pH were maintained constant. Cerebral blood flow was measured using laser-Doppler flowmetry. After surgery, cognitive and behavioral function was re-evaluated for 10 days. On day 11, the brains were removed for histopathologic evaluation (hematoxylin/eosin-staining). Cognitive testing revealed deficits in declarative and working memory in ischemic rats anesthetized with fentanyl/N(2)O. Rats anesthetized with sevoflurane during ischemia showed a significantly better outcome. Hippocampal damage was significantly worse with fentanyl/N(2)O. The present data add to previous investigations showing that sevoflurane prevents a deficit in cognitive function and histopathological damage induced by cerebral ischemia in rats.	[Eberspaecher, E.] Vet Med Univ Wien, Klin Anasthesiol & Perioperat Intens Med, Dept Kleintiere & Pferde, A-1210 Vienna, Austria; [Eckel, B.; Mueller, K.; Blobner, M.] Tech Univ Munich, Klinikum Rechts Isar, Anasthesiol Klin, D-8000 Munich, Germany; [Engelhard, K.; Werner, C.] Klinikum Johannes Gutenberg Univ, Anasthesiol Klin, Mainz, Germany; [Hoffman, W. E.] Univ Illinois Chicago, Chicago, IL USA	Eberspacher, E (reprint author), Vet Med Univ Wien, Klin Anasthesiol & Perioperat Intens Med, Dept Kleintiere & Pferde, Vet Pl 1, A-1210 Vienna, Austria.	eva.eberspaecher@vu-wien.ac.at	Blobner, Manfred/R-4411-2017	Blobner, Manfred/0000-0002-0370-5247			BADDELEY A, 1998, CR HEBD ACAD SCI, V3, P167; Eberspacher E, 2003, J NEUROSURG ANESTH, V15, P200, DOI 10.1097/00008506-200307000-00007; Engelhard K, 2004, EUR J ANAESTH, V21, P530, DOI 10.1017/S0265021504007057; Engelhard K, 2007, ANESTH ANALG, V104, P898, DOI 10.1213/01.ane.0000255730.73018.31; GOLDMANRAKIC PS, 1994, GEHIRN BEWUSSTSEIN S, P68; Hodges H, 1996, COGNITIVE BRAIN RES, V3, P167, DOI 10.1016/0926-6410(96)00004-3; Hossain M, 2001, INT J RADIAT BIOL, V77, P581, DOI 10.1080/09553000110037394; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MICHEAU J, 1985, BEHAV BRAIN RES, V15, P75, DOI 10.1016/0166-4328(85)90054-3; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Ohl F, 1998, J NEUROSCI METH, V81, P35, DOI 10.1016/S0165-0270(98)00011-9; Ohl F, 2001, BEHAV RES METH INS C, V33, P392, DOI 10.3758/BF03195393; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P1012, DOI 10.1038/jcbfm.1995.127; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P505, DOI 10.1038/jcbfm.1995.62; Pape M, 2006, ANESTH ANALG, V103, P173, DOI 10.1213/01.ane.0000222634.51192.a4; Plaschke K, 2000, ANN NY ACAD SCI, V903, P299, DOI 10.1111/j.1749-6632.2000.tb06380.x; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; SQUIRE LR, 1998, CR HEBD ACAD SCI, V3, P153; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; WARNER DS, 1993, ANESTHESIOLOGY, V79, P985, DOI 10.1097/00000542-199311000-00017; WERNER C, 1995, BRIT J ANAESTH, V75, P756, DOI 10.1093/bja/75.6.756; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	23	14	16	0	5	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2009	53	6					774	782		10.1111/j.1399-6576.2009.01954.x			9	Anesthesiology	Anesthesiology	455VT	WOS:000266796300012	19388889				2020-06-30	J	Tveit, TO; Halvorsen, A; Rosland, JH				Tveit, T. O.; Halvorsen, A.; Rosland, J. H.			Analgesia for labour: a survey of Norwegian practice - with a focus on parenteral opioids	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							PATIENT-CONTROLLED ANALGESIA; PAIN RELIEF; OBSTETRIC ANALGESIA; REMIFENTANIL; FENTANYL; REIMBURSEMENT; ANESTHESIA; COST	During the last two decades, epidural analgesia has become 'a gold standard' for labour pain in most Western countries. Newer short-acting opioids given systemically represent an alternative for adequate pain relief without using regional techniques. With this survey, we wish to explore how Norwegian hospitals practice labour analgesia, especially their use of systemic opioids. A questionnaire was sent to the head of all 46 registered Norwegian labour units in 2005. The questionnaire focused on epidural and the use of systemic opioids. In 2008, the same questionnaire was sent to the 19 largest units reporting > 1000 births a year, seeking updated information. Forty-three of the 46 original questionnaires were returned. An epidural frequency of 25.9% was registered. For epidural treatment, bupivacaine was the preferred local anaesthetic, while sufentanil was the opioid of choice for the majority of units. Pethidine was the most commonly used opioid for systemic administration (77%). All units reported nurse administration of systemic opioids. The intramuscular route was most commonly used, either alone (58%) or in combination with an intravenous (i.v.) administration (34%). Only one unit used i.v. fentanyl. There were only minor changes with the repeated survey, except for one large unit, which reported over a 50% increase in the epidural frequency. In Norway, the frequency of epidural for labour analgesia is still relatively low, but seems to be increasing. Systemic opioids are often used instead of or as a supplement. Clinical practice seems to be conservative, and newer short-acting opioids are seldom used systemically.	[Tveit, T. O.; Halvorsen, A.] Sorlandet Hosp Kristiansand, Dept Anaesthesia & Intens Care, N-4604 Kristiansand, Norway; [Tveit, T. O.; Rosland, J. H.] Univ Bergen, Dept Surg Sci, Bergen, Norway; [Rosland, J. H.] Haraldsplass Deaconess Hosp, Dept Palliat Care, Bergen, Norway	Tveit, TO (reprint author), Sorlandet Hosp Kristiansand, Dept Anaesthesia & Intens Care, N-4604 Kristiansand, Norway.	tor.tveit@sshf.no					Althaus J, 2005, OBSTET GYN CLIN N AM, V32, P231, DOI 10.1016/j.ogc.2005.01.002; Aly EE, 2000, ANAESTHESIA, V55, P419, DOI 10.1046/j.1365-2044.2000.01477.x; Backe Bjorn, 2005, Tidsskr Nor Laegeforen, V125, P606; Barratt-Due Andreas, 2005, Tidsskr Nor Laegeforen, V125, P2504; Bell ED, 2000, ANESTHESIOLOGY, V92, P851, DOI 10.1097/00000542-200003000-00029; CHASSARD D, 2006, ANESTHESIOLOGY, V105, pA899; Gaiser RR, 2005, BEST PRACT RES-CLIN, V19, P1, DOI 10.1016/j.bpa.2004.07.001; Goetzl Laura M, 2002, Obstet Gynecol, V100, P177; Gogarten W, 2002, CAN J ANAESTH, V49, P107, DOI 10.1007/BF03020430; Hill D, 2008, CURR OPIN ANESTHESIO, V21, P270, DOI 10.1097/ACO.0b013e3282f8e26c; Huang C, 2002, PHARMACOECONOMICS, V20, P305, DOI 10.2165/00019053-200220050-00002; Leighton BL, 2001, ANESTHESIOLOGY, V94, P178, DOI 10.1097/00000542-200101000-00037; Loo CC, 2000, INT J OBSTET ANESTH, V9, P99, DOI 10.1054/ijoa.1999.0347; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Olofsson C, 1998, BAILLIERE CLIN OB GY, V12, P409, DOI 10.1016/S0950-3552(98)80075-8; Rayburn W F, 1991, Anesthesiol Rev, V18, P31; Rolfseng OK, 2002, EUR J ANAESTH, V19, P812, DOI 10.1017/S026502150200131X; Saravanakumar K, 2007, INT J OBSTET ANESTH, V16, P221, DOI 10.1016/j.ijoa.2007.01.010; Soontrapa Sukree, 2002, Journal of the Medical Association of Thailand, V85, P1169; Stienstra R, 2003, Acta Anaesthesiol Belg, V54, P141; Tsui MHY, 2004, BJOG-INT J OBSTET GY, V111, P648, DOI 10.1111/j.1471-0528.2004.00160.x; Tveita T, 2008, ACTA ANAESTH SCAND, V52, P920, DOI 10.1111/j.1399-6576.2008.01608.x; Volikas I, 2005, BRIT J ANAESTH, V95, P504, DOI 10.1093/bja/aei219; Volmanen P, 2008, ACTA ANAESTH SCAND, V52, P249, DOI 10.1111/j.1399-6576.2007.01509.x; Volmanen P, 2005, ACTA ANAESTH SCAND, V49, P453, DOI 10.1111/j.1399-6576.2005.00639.x; Volmanen P, 2004, INT J OBSTET ANESTH, V13, P1, DOI 10.1016/j.ijoa.2003.10.002; Wee M, 2007, ANAEST INTENS CARE M, V8, P276, DOI 10.1016/j.mpaic.2007.04.005	27	18	18	0	6	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2009	53	6					794	799		10.1111/j.1399-6576.2009.01988.x			6	Anesthesiology	Anesthesiology	455VT	WOS:000266796300015	19456300				2020-06-30	J	Stamenkovic, D; Geric, V; Djordjevic, M; Raskovic, J; Slavkovic, Z; Randjelovic, I; Karanikolas, M				Stamenkovic, D.; Geric, V.; Djordjevic, M.; Raskovic, J.; Slavkovic, Z.; Randjelovic, I.; Karanikolas, M.			Subarachnoid morphine, bupivacaine and fentanyl as part of combined spinal-epidural analgesia for low anterior resection. A prospective, randomised, double-blind clinical trial	ANAESTHESIA AND INTENSIVE CARE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologist	OCT 18-22, 2008	Orlando, FL	Amer Soc Anesthesiologists		postoperative pain; combined spinal-epidural analgesia; morphine; fentanyl; bupivacaine; tramadol; colorectal surgery	POSTOPERATIVE PAIN; ANESTHESIA; EFFICACY	This study was designed to compare the efficacy of subarachnoid morphine alone or in combination with bupivacaine and fentanyl for combined spinal-epidural analgesia in colorectal surgery. This is a prospective, randomised, double-blind clinical trial. Sixty patients undergoing low anterior resection were assigned to one of three groups: subarachnoid morphine, bupivacaine and fentanyl, subarachnoid morphine and bupivacaine or subarachnoid morphine only. Epidural catheter placement and subarachnoid injection were done via a combined spinal-epidural Epistar (R) needle at L2-3. The epidural catheter was used for scheduled intraoperative bupivacaine and intermittent postoperative bupivacaine and morphine administration. Intraoperative epidural bupivacaine, intraoperative intravenous fentanyl use, time to first analgesia request, postoperative visual analogue scale pain scores, tramadol requirements and side-effects were recorded for 72 hours. Postoperative analgesia was comparable in all groups. Intraoperative fentanyl and bupivacaine consumption was lowest in the morphine, bupivacaine and fentanyl group. Time to first analgesia request was longer in the morphine, bupivacaine and fentanyl compared to the morphine group (P=0.009). Tramadol use was lower in the morphine and bupivacaine group compared to morphine, bupivacaine and fentanyl (P=0.017) on postoperative day two. There were no significant adverse effects. All patients ambulated the morning after surgery. The addition of bupivacaine and fentanyl to subarachnoid morphine did not confer any advantage on postoperative visual analogue scale scores and tramadol use, but lowered the need for additional intraoperative intravenous fentanyl and epidural bupivacaine and prolonged the time to first analgesia request.	[Stamenkovic, D.] Mil Med Acad, Dept Anaesthesia, Med Ctr Bezanijska Kosa, Belgrade 11000, Serbia	Stamenkovic, D (reprint author), Mil Med Acad, Dept Anaesthesia, Med Ctr Bezanijska Kosa, Crnotravska 17, Belgrade 11000, Serbia.		Karanikolas, Menelaos/O-5928-2017; Stamenkovic, Dusica M/A-3319-2008	Karanikolas, Menelaos/0000-0001-8541-7988; Stamenkovic, Dusica/0000-0003-4121-1966			AKERMAN B, 1988, ANESTH ANALG, V67, P943; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Benzon HT, 2007, SPINAL EPIDURAL ANES, P325; Bryant TN, 1998, PEDIATR ALLERGY IMMU, V9, P108, DOI 10.1111/j.1399-3038.1998.tb00355.x; Chrubasik J, 1993, POSTOPERATIVE EPIDUR, P45; DAHL JB, 1990, BRIT J ANAESTH, V64, P518, DOI 10.1093/bja/64.4.518; ELDOR J, 1995, MED HYPOTHESES, V45, P86, DOI 10.1016/0306-9877(95)90209-0; ELLIS H, 1983, ANATOMY ANAESTHETIST, P136; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HANSENFLASCHEN J, 1994, CRIT CARE MED, V22, P732; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Lavand'homme P, 2006, ACTA ANAESTH BELG, V57, P373; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Minty RG, 2007, CAN FAM PHYSICIAN, V53, P437; Moon RE, 2005, MILLERS ANESTHESIA, P1437; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; Rawal N, 2005, CURR OPIN ANESTHESIO, V18, P518, DOI 10.1097/01.aco.0000182565.25057.b3; Sakura S, 2001, ANESTH ANALG, V93, P77; Scott NB, 1996, ACTA ANAESTH SCAND, V40, P691, DOI 10.1111/j.1399-6576.1996.tb04512.x; SOLOMON RE, 1994, ANESTH ANALG, V78, P1164; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; Vasudevan A, 2007, BRIT J ANAESTH, V98, P241, DOI 10.1093/bja/ael346; WU CL, 2005, MILLERS ANESTHESIA, P2729; Yeh HM, 2001, ANESTH ANALG, V92, P665, DOI 10.1097/00000539-200103000-00022	25	4	4	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	JUL	2009	37	4					552	560		10.1177/0310057X0903700410			9	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	481YS	WOS:000268850400006	19681410	Bronze			2020-06-30	J	Erdil, F; Demirbilek, S; Begec, Z; Ozturk, E; Ulger, MH; Ersoy, MO				Erdil, F.; Demirbilek, S.; Begec, Z.; Ozturk, E.; Ulger, M. H.; Ersoy, M. O.			The effects of dexmedetomidine and fentanyl on emergence characteristics after adenoidectomy in children	ANAESTHESIA AND INTENSIVE CARE			English	Article						emergence characteristics; sevoflurane; dexmedetomidine; fentanyl	SEVOFLURANE ANESTHESIA; PEDIATRIC TONSILLECTOMY; INTUBATING CONDITIONS; GENERAL-ANESTHESIA; REDUCES AGITATION; SURGERY; PAIN; DESFLURANE; ACETAMINOPHEN; DEXAMETHASONE	This randomised controlled study evaluated the effects of fentanyl and dexmedetomidine on emergence characteristics of children having adenoidectomy and anaesthetised with sevoflurane. Ninety children, two to seven years of age and ASA physical status I, were studied. Children were randomly assigned to one of three groups of 30 children, with the study intervention injection given intravenously after intubation. Children in Group F received fentanyl 2.5 mu g.kg(-1), children in Group D received dexmedetomidine 0.5 mu g.kg(-1) and children in Group C received saline solution. Anaesthesia was induced with 50% N(2)O and 8% sevoflurane in O(2) by mask and atracurium 0.6 mg.kg(-1) was administered for tracheal intubation. All children received paracetamol 40 mg/kg rectally one hour preoperatively and dexamethasone 0.5 mg.kg(-1) intravenously. The time to extubation was shorter in Group D than Group E The eye-opening time was longer in Group F (161 +/- 5.3 minutes) than in Groups C (12.0 +/- 4.2 minutes) and D (12.7 +/- 3.2 minutes). The proportion of pain-free children in early recovery was significantly higher in Groups D (47%) and F (43%) than Group C (13%) (P < 0.05). The proportion of children with agitation scores > 3 was lower in Groups D 17% (5/30) and F 13% (4/30) than in Group C 47% (14/30) (P < 0.05). Fentanyl 2.5 mu g.kg(-1) and dexmedetomidine 0.5 mu g.kg(-1) had similar haemodynamic effects and emergence characteristics. Fentanyl has been safely used in children for many years. Further studies of dexmedetomidine safety and its interaction with other anaesthetic agents are required before recommending its routine use during general anaesthesia in children.	[Erdil, F.; Demirbilek, S.; Begec, Z.; Ozturk, E.; Ulger, M. H.; Ersoy, M. O.] Inonu Univ, Sch Med, Dept Anaesthesiol & Reanimat, Malatya, Turkey	Erdil, F (reprint author), T Ozal Tip Merkezi Anesteziyol & Reanimasyon AD, TR-44315 Malatya, Turkey.						Afman CE, 2006, OTOLARYNG HEAD NECK, V134, P181, DOI 10.1016/j.otohns.2005.11.010; Berkenbosch John W, 2005, Pediatr Crit Care Med, V6, P435, DOI 10.1097/01.PCC.0000163680.50087.93; Braga ADD, 2001, EUR J ANAESTH, V18, P384, DOI 10.1046/j.0265-0215.2001.00861.x; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2001, ANESTH ANALG, V93, P88; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Deutsch E, 2007, PEDIATR ANESTH, V17, P438, DOI 10.1111/j.1460-9592.2006.02139.x; Elhakim M, 2003, CAN J ANAESTH, V50, P392, DOI 10.1007/BF03021038; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Gupta A, 2006, PEDIATR ANESTH, V16, P399, DOI 10.1111/j.1460-9592.2005.01783.x; Hammer GB, 2005, PEDIATR ANESTH, V15, P616, DOI 10.1111/j.1460-9592.2005.01656.x; Hanasono MM, 2004, ARCH OTOLARYNGOL, V130, P917, DOI 10.1001/archotol.130.8.917; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Koroglu A, 2005, BRIT J ANAESTH, V94, P821, DOI 10.1093/bja/aei119; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Lerman J, 2007, CURR OPIN ANESTHESIO, V20, P221, DOI 10.1097/ACO.0b013e32811e16e7; Mukhtar AM, 2006, ANESTH ANALG, V103, P52, DOI 10.1213/01.ane.0000217204.92904.76; Olutoye O, 2007, PEDIATR ANESTH, V17, P1007, DOI 10.1111/j.1460-9592.2007.02234.x; Petroz GC, 2006, ANESTHESIOLOGY, V105, P1098, DOI 10.1097/00000542-200612000-00009; Schmidt A, 2001, ACTA ANAESTH SCAND, V45, P48, DOI 10.1034/j.1399-6576.2001.450108.x; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Tobin JR, 2006, ANESTH ANALG, V103, P43, DOI 10.1213/01.ane.0000220033.34889.ce; Viitanen H, 2003, BRIT J ANAESTH, V91, P363, DOI 10.1093/bja/aeg196; Vosdoganis F, 1999, ANAESTH INTENS CARE, V27, P489, DOI 10.1177/0310057X9902700509	28	42	50	0	6	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUL	2009	37	4					571	576		10.1177/0310057X0903700405			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	481YS	WOS:000268850400009	19681413	Bronze			2020-06-30	J	Merriman, S; Paech, MJ; Keil, AD				Merriman, S.; Paech, M. J.; Keil, A. D.			Bacterial contamination in solution aspirated from non-sterile packaged fentanyl ampoules: a laboratory study	ANAESTHESIA AND INTENSIVE CARE			English	Article						bacterial contamination; fentanyl; ampoule; drug aspiration	GLASS PARTICLE CONTAMINATION; SPINAL-ANESTHESIA; NEUROLOGICAL COMPLICATIONS; IATROGENIC MENINGITIS; REGIONAL ANESTHESIA; OPIOIDS; STREPTOCOCCI; INFECTION; PUNCTURE	Iatrogenic meningitis is a rare complication of spinal anaesthesia. It is mandatory to use a technique which minimises the risk of introducing bacteria into the subarachnoid space. Currently available fentanyl ampoules require a careful drawing-up technique, as the outside of the ampoule is not sterile and there is potential to contaminate the contents in the drawing-lip process. We designed a pilot laboratory study to determine the extent of bacterial contamination of fentanyl solutions drawn up from non-sterile packaged glass fentanyl ampoules using three different methods: aspirating through a 5 mu m filter needle only, aspirating through a 5 mu m filter needle after swabbing the neck of the ampoule with isopropyl alcohol and aspirating through an antibacterial filter in addition to the 5 mu m filter needle. Ten anaesthetists used each method once, in randomised order, to draw lip solution from three different fentanyl ampoules. Samples underwent bacterial culture in blood agar and enrichment broth for 48 hours. No significant growth was seen in any sample. This pilot study did not identify any bacterial contamination of fentanyl solution irrespective of which of the three methods for aspiration was used.	[Merriman, S.] King Edward Mem Hosp, Dept Anaesthesia & Pain Med, Subiaco, WA 6008, Australia; King Edward Mem Hosp, Dept Microbiol, Subiaco, WA 6008, Australia	Merriman, S (reprint author), King Edward Mem Hosp, Dept Anaesthesia & Pain Med, Bagot Rd, Subiaco, WA 6008, Australia.			PAECH, MICHAEL/0000-0001-9023-6575	King Edward Memorial Hospital Post-Graduate Medical Education and Research Fund	We would like to thank the King Edward Memorial Hospital Post-Graduate Medical Education and Research Fund for their assistance in financing this study.	Baer ET, 2006, ANESTHESIOLOGY, V105, P381, DOI 10.1097/00000542-200608000-00022; Beaman MH, 2002, MED J AUSTRALIA, V176, P389, DOI 10.5694/j.1326-5377.2002.tb04462.x; Benhamou D, 2002, INT J OBSTET ANESTH, V11, P265, DOI 10.1054/ijoa.2002.0973; CHESTNUT DH, 1992, ANESTHESIOLOGY, V76, P667, DOI 10.1097/00000542-199205000-00001; FELDMAN JM, 1994, REGION ANESTH, V19, P43; Green BGJ, 1999, ANAESTHESIA, V54, P511, DOI 10.1046/j.1365-2044.1999.907rr.x; Hemingway CJ, 2007, ANAESTHESIA, V62, P286, DOI 10.1111/j.1365-2044.2007.04977.x; Hiom SJ, 2000, PHARM J, V265, P277; KILPATRICK ME, 1983, ANESTH ANALG, V62, P513; LEPINE G, 1994, MED MICROBIOLOGY, P6; Loo CC, 2000, INT J OBSTET ANESTH, V9, P99, DOI 10.1054/ijoa.1999.0347; Lye ST, 2003, ANAESTHESIA, V58, P93, DOI 10.1046/j.1365-2044.2003.296812.x; McConaghy P, 1996, ANAESTHESIA, V51, P1079; McHutchon A, 1999, ANAESTHESIA, V54, P1119, DOI 10.1046/j.1365-2044.1999.01186.x; McLure HA, 1998, ANAESTHESIA, V53, P624, DOI 10.1046/j.1365-2044.1998.435-az0528.x; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Pandian JD, 2004, J HOSP INFECT, V56, P119, DOI 10.1016/j.jhin.2003.09.023; PINNOCK CA, 1984, ANN ROY COLL SURG, V66, P423; Raedler C, 1999, BRIT J ANAESTH, V83, P657; Reynolds F, 2005, INT J OBSTET ANESTH, V14, P183, DOI 10.1016/j.ijoa.2005.04.001; Rodrigo N, 2007, INT J OBSTET ANESTH, V16, P256, DOI 10.1016/j.ijoa.2006.06.010; SABON RL, 1989, ANESTHESIOLOGY, V70, P859, DOI 10.1097/00000542-198905000-00024; SALZMAN MB, 1993, J CLIN MICROBIOL, V31, P475, DOI 10.1128/JCM.31.3.475-479.1993; Schneeberger PM, 1996, INFECTION, V24, P29, DOI 10.1007/BF01780647; Sellors JE, 2002, ANAESTHESIA, V57, P593; Videira RLR, 2002, ACTA ANAESTH SCAND, V46, P639, DOI 10.1034/j.1399-6576.2002.460602.x; Yaniv LG, 2000, SCAND J INFECT DIS, V32, P693, DOI 10.1080/003655400459658; ZACHER AN, 1991, ANESTHESIOLOGY, V75, P893, DOI 10.1097/00000542-199111000-00022	28	4	5	0	1	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUL	2009	37	4					608	612		10.1177/0310057X0903700413			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	481YS	WOS:000268850400016	19681420	Bronze			2020-06-30	J	Ding, Z; Raffa, RB				Ding, Zhe; Raffa, Robert B.			Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						analgesia (antinociception); buprenorphine; mechanism of action; supraspinal	MU-OPIOID RECEPTOR; SERINE/THREONINE PROTEIN PHOSPHATASES; MORPHINE-THEBAINE GROUP; TAIL-FLICK TEST; OKADAIC-ACID; MOLECULAR-REARRANGEMENTS; INDUCED ANTINOCICEPTION; INTRINSIC EFFICACY; PARTIAL AGONIST; ORL1 RECEPTOR	Background and purpose: Buprenorphine displays attributes of opioids, but also some features distinct from them. We examined spinal and supraspinal signal transduction of buprenorphine-induced anti-nociception in mice compared with morphine and fentanyl. Experimental approach: The opioid receptor antagonist naloxone, Pertussis toxin (PTX), G(z) protein antisense and nociceptin/orphanin-FQ receptor agonist nociceptin, and antagonist, JTC-801, were injected supraspinally (intracerebroventricular) and spinally (intrathecal). Also the cell-permeable Ser/Thr protein phosphatase inhibitor okadaic acid was given supraspinally. Key results: Spinal naloxone (20 mu g) or PTX (1 mu g) attenuated morphine, fentanyl and buprenorphine (s.c.) anti-nociception. Supraspinal naloxone or PTX attenuated morphine and fentanyl, but not buprenorphine anti-nociception. Spinal G(z) protein antisense did not alter buprenorphine, morphine or fentanyl anti-nociception and supraspinal G(z)-antisense did not alter morphine or fentanyl anti-nociception. However, supraspinal G(z)-antisense (not random sense) reduced buprenorphine anti-nociception. Peripheral JTC-801 (1 mg center dot kg(-1), i.p.) enhanced the ascending (3 mg center dot kg(-1)) and descending (30 mg center dot kg(-1)) portions of buprenorphine's dose-response curve, but only spinal, not supraspinal, nociceptin (10 nmol center dot L-1) enhanced buprenorphine anti-nociception. Intracereboventricular okadaic acid (0.001-10 pg) produced a biphasic low-dose attenuation, high-dose enhancement of buprenorphine(3 or 30 mg center dot kg(-1), s.c.) anti-nociception, but did not affect morphine or fentanyl anti-nociception. Conclusions and implications: Buprenorphine has an opioid component to its supraspinal mechanism of analgesic action. Our present results reveal an additional supraspinal component insensitive to naloxone, PTX and nociceptin/orphanin-FQ, but involving G(z) protein and Ser/Thr protein phosphatase. These data might help explain the unique preclinical and clinical profiles of buprenorphine.	[Ding, Zhe; Raffa, Robert B.] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA	Raffa, RB (reprint author), Temple Univ, Sch Pharm, Dept Pharmaceut Sci, 3307 N Broad St, Philadelphia, PA 19140 USA.	robert.raffa@temple.edu			Grunenthal, GmbH	This work was supported by an unrestricted research grant from Grunenthal, GmbH. The authors also wish to thank the reviewers for exceptionally constructive suggestions.	AHLGREN SC, 1994, J NEUROPHYSIOL, V72, P684; Alexander SPH, 2008, BRIT J PHARMACOL, V153, pS1, DOI 10.1038/sj.bjp.0707746; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3281, DOI 10.1021/ja00989a032; BENTLEY KW, 1967, J AM CHEM SOC, V89, P3273, DOI 10.1021/ja00989a031; Bernstein MA, 1998, EUR J PHARMACOL, V341, P173, DOI 10.1016/S0014-2999(97)01502-1; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; BUDD K, 1981, ANAESTHESIA, V36, P900, DOI 10.1111/j.1365-2044.1981.tb08867.x; Budd K, 2005, BUPRENORPHINETHE UNI; Chan JSC, 1998, J NEUROCHEM, V71, P2203; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476-5381.1968.tb00973.x; Cowan Alan, 1995, P31; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dahan A, 2006, BRIT J ANAESTH, V96, P627, DOI 10.1093/bja/ael051; DAHAN A, 2005, BUPRENORPHINE UNIQUE, P22; DUM JE, 1981, BRIT J PHARMACOL, V74, P627, DOI 10.1111/j.1476-5381.1981.tb10473.x; Gabra BH, 2007, BRAIN RES, V1159, P86, DOI 10.1016/j.brainres.2007.05.017; Garzon J, 1998, EUR J NEUROSCI, V10, P2557, DOI 10.1046/j.1460-9568.1998.t01-1-00267.x; Garzon J, 2000, METHOD ENZYMOL, V314, P3; Ge ZJ, 2005, ACTA PHARMACOL SIN, V26, P186, DOI 10.1111/j.1745-7254.2005.00033.x; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gilbert AK, 2002, EUR J PHARMACOL, V449, P75, DOI 10.1016/S0014-2999(02)01974-X; Greenwald MK, 2003, NEUROPSYCHOPHARMACOL, V28, P2000, DOI 10.1038/sj.npp.1300251; Groer CE, 2007, MOL PHARMACOL, V71, P549, DOI 10.1124/mol.106.028258; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Hastie CJ, 1998, FEBS LETT, V431, P357, DOI 10.1016/S0014-5793(98)00775-3; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Ho MKC, 1998, BIOL SIGNAL RECEPT, V7, P80; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Ide S, 2004, NEUROPSYCHOPHARMACOL, V29, P1656, DOI 10.1038/sj.npp.1300463; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; Karim F, 2000, PAIN, V87, P181, DOI 10.1016/S0304-3959(00)00279-7; Khroyan TV, 2007, J PHARMACOL EXP THER, V320, P934, DOI 10.1124/jpet.106.111997; KOSTERLITZ HW, 1975, EUR J PHARMACOL, V32, P10, DOI 10.1016/0014-2999(75)90317-9; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Lutfy K, 2003, J NEUROSCI, V23, P10331; Lutfy Kabirullah, 2004, Current Neuropharmacology, V2, P395, DOI 10.2174/1570159043359477; Maeda T, 2005, BRAIN RES, V1056, P191, DOI 10.1016/j.brainres.2005.07.033; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Mogil JS, 2001, PHARMACOL REV, V53, P381; Moncada A, 2005, PAIN, V114, P212, DOI 10.1016/j.pain.2004.12.017; Moncada A, 2003, EUR J PHARMACOL, V465, P53, DOI 10.1016/S0014-2999(03)01461-4; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; Neilan CL, 2004, EUR J PHARMACOL, V499, P107, DOI 10.1016/j.ejphar.2004.07.097; Ocana M, 2007, PHARMACOL BIOCHEM BE, V86, P21, DOI 10.1016/j.pbb.2006.12.002; PAROLARO D, 1990, PHARMACOL BIOCHEM BE, V35, P137, DOI 10.1016/0091-3057(90)90218-7; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; Price NE, 1999, CURR OPIN NEUROBIOL, V9, P336, DOI 10.1016/S0959-4388(99)80049-X; RAFFA RB, 1994, EUR J PHARMACOL, V258, pR5, DOI 10.1016/0014-2999(94)90073-6; Raffa RB, 2007, ACUTE PAIN, V9, P145; RANCE MJ, 1980, ENDOGENOUS EXOGENOUS, P387; Rizzi A, 2006, PAIN, V124, P100, DOI 10.1016/j.pain.2006.03.021; Rothman Richard B., 1995, P19; SADEE W, 1982, J PHARMACOL EXP THER, V223, P157; Sanchez-Blazquez P, 2001, BRAIN RES BULL, V54, P229, DOI 10.1016/S0361-9230(00)00448-2; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Shinkai H, 2000, J MED CHEM, V43, P4667, DOI 10.1021/jm0002073; Standifer KM, 1996, MOL PHARMACOL, V50, P293; Toll L, 1998, NIDA Res Monogr, V178, P440; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Traynor JR, 2004, REVS ANALGESIA, V8, P11; Tso PH, 2000, J NEUROCHEM, V74, P1685, DOI 10.1046/j.1471-4159.2000.0741685.x; Vanderah TW, 1998, EUR J PAIN, V2, P267, DOI 10.1016/S1090-3801(98)90023-4; VILLIGER JW, 1981, LIFE SCI, V29, P2699, DOI 10.1016/0024-3205(81)90529-4; Wang ZJJ, 2006, LIFE SCI, V79, P1681, DOI 10.1016/j.lfs.2006.05.023; WHEELERACETO H, 1991, EUR J PHARMACOL, V195, P411, DOI 10.1016/0014-2999(91)90485-9; Wnendt S, 1999, MOL PHARMACOL, V56, P334; Womer DE, 1997, PAIN, V70, P223, DOI 10.1016/S0304-3959(97)03329-0; Yamada H, 2002, BRIT J PHARMACOL, V135, P323, DOI 10.1038/sj.bjp.0704478; Yamamoto T, 2006, J PHARMACOL EXP THER, V318, P206, DOI 10.1124/jpet.105.100859; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang RH, 2004, EUR NEUROPSYCHOPHARM, V14, P419, DOI 10.1016/j.euroneuro.2003.12.006	84	25	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	JUL	2009	157	5					831	843		10.1111/j.1476-5381.2009.00209.x			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	462AL	WOS:000267317200015	19422392	Green Published			2020-06-30	J	Vuckovic, S; Prostran, M; Ivanovic, M; Dosen-Micovic, L; Todorovic, Z; Nesic, Z; Stojanovic, R; Divac, N; Mikovic, Z				Vuckovic, S.; Prostran, M.; Ivanovic, M.; Dosen-Micovic, Lj.; Todorovic, Z.; Nesic, Z.; Stojanovic, R.; Divac, N.; Mikovic, Z.			Fentanyl Analogs: Structure-Activity-Relationship Study	CURRENT MEDICINAL CHEMISTRY			English	Review						Fentanyl; analogs; structure-activity-relationship (SAR); analgesic activity; neurotoxicity	PRELIMINARY PHARMACOLOGICAL EVALUATION; 4-ANILIDOPIPERIDINE ANALGESICS; OPIOID AGONIST; IN-VIVO; OPIATE RECEPTORS; MU; BINDING; POTENT; CARFENTANIL; MORPHINE	Fentanyl is the prototype of the 4-anilidopiperidine class of synthetic opioid analgesics. This study was aimed to review the structure-activity-relationship (SAR) of fentanyl analogs substituted in the position 3, or 4 of the piperidine ring. Pharmacological results show that the groups in position 3 of the piperidine ring, which are larger than methyl, severely reduce the analgesic potency compared to fentanyl. It is likely that the steric factor alone (i.e. voluminosity of the group and cis/trans isomerism), rather than the polarity and/or chemical reactivity, plays a crucial role in the analgesic potency of this series. Although the duration of action, in general, does not depend on the stereochemistry, longer action of the most potent 3-alkyl fentanyl analogs such as cis-3-methyl- and cis-3-ethyl fentanyl, is more likely influenced by pharmacodynamic, rather than pharmacokinetic variables. Also, it is possible that the introduction of a functional group such as 3-carbomethoxy reduces the duration of action by altering pharmacokinetic properties. SAR findings obtained by evaluating the neurotoxic effects of fentanyl analogs substituted in the position 3 of the piperidine ring parallel the SAR findings on analgesia in regard to potency and duration of action. This might suggest that similar receptors are involved in producing both antinociceptive and neurotoxic effects of these drugs. It appears that both the potency and the duration of action in the series of fentanyl analogs substituted in position 4 of the piperidine ring is influenced only by the steric requirement and not by the chemical nature of the substituent.	[Vuckovic, S.] Univ Belgrade, Dept Pharmacol Clin Pharmacol & Toxicol, Fac Med, Sch Med, Belgrade 11000, Serbia; [Ivanovic, M.; Dosen-Micovic, Lj.] Univ Belgrade, Fac Chem, Belgrade 11000, Serbia; [Mikovic, Z.] Univ Clin Gynaecol & Obstet Narodni Front, Dept High Risk Pregnancies, Belgrade, Serbia	Vuckovic, S (reprint author), Univ Belgrade, Dept Pharmacol Clin Pharmacol & Toxicol, Fac Med, Sch Med, Doktora Subotica 1,POB 38, Belgrade 11000, Serbia.	svuckovic@med.bg.ac.rs	Ivanovic, Milovan/R-5245-2016	Ivanovic, Milovan/0000-0002-2534-4673	Ministry of Science of SerbiaMinistry of Science, Serbia [145001]	This work was supported by the Ministry of Science of Serbia (grant No. 145001).	Ananthan S, 2006, AAPS J, V8, pE118, DOI 10.1208/aapsj080114; BAGLEY JR, 1991, MED RES REV, V11, P403, DOI 10.1002/med.2610110404; BAGLEY JR, 1989, J MED CHEM, V32, P663, DOI 10.1021/jm00123a028; BAND L, 1990, LIFE SCI, V47, P2231, DOI 10.1016/0024-3205(90)90154-J; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Casy A. F., 1986, OPIOID ANALGESICS CH, P287; CASY AF, 1982, J PHARM PHARMACOL, V34, P210, DOI 10.1111/j.2042-7158.1982.tb04229.x; CASY AF, 1988, J PHARM PHARMACOL, V40, P605, DOI 10.1111/j.2042-7158.1988.tb05318.x; Choi HS, 2006, BIOCHEM BIOPH RES CO, V343, P1132, DOI 10.1016/j.bbrc.2006.03.084; COLAPRET JA, 1989, J MED CHEM, V32, P968, DOI 10.1021/jm00125a008; COOKSON RF, 1983, BRIT J ANAESTH, V55, pS147; COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x; Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102; DEVOS V, 1978, VET REC, V103, P64, DOI 10.1136/vr.103.4.64; Dong N, 2005, ACTA PHARMACOL SIN, V26, P107, DOI 10.1111/j.1745-7254.2005.00014.x; Dosen-Micovic L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI 10.1016/j.bmc.2005.12.010; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; FINNEY ZG, 1980, J MED CHEM, V23, P895, DOI 10.1021/jm00182a016; Freye Enno, 2007, Pain Pract, V7, P123, DOI 10.1111/j.1533-2500.2007.00119.x; Goicoechea C, 2008, EUR J PHARMACOL, V595, P22, DOI 10.1016/j.ejphar.2008.07.052; GOMMEREN W, 1982, ARCH INT PHARMACOD T, V258, P171; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; Henriksen G, 2005, J MED CHEM, V48, P7720, DOI 10.1021/jm0507274; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Husbands SM, 2000, J MED CHEM, V43, P139, DOI 10.1021/jm991165p; Ivanovic MD, 2004, J SERB CHEM SOC, V69, P955, DOI 10.2298/JSC0411955I; Ivanovic MD, 2004, J SERB CHEM SOC, V69, P511, DOI 10.2298/JSC0407511I; IVANOVIC MD, 1995, YUGOSLAV PHYSL PHARM, V31, P195; Janecka A, 2004, CURR TOP MED CHEM, V4, P1, DOI 10.2174/1568026043451618; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; JANSSENS F, 1986, J MED CHEM, V29, P2290, DOI 10.1021/jm00161a027; Jewett DM, 2004, NUCL MED BIOL, V31, P321, DOI 10.1016/j.nucmedbio.2003.10.009; KUDZMA LV, 1989, J MED CHEM, V32, P2534, DOI 10.1021/jm00132a007; LADURON PM, 1985, NEUROPHARMACOLOGY, V24, P617, DOI 10.1016/0028-3908(85)90102-9; LALINDE N, 1990, J MED CHEM, V33, P2876, DOI 10.1021/jm00172a032; LAVECCHIA A, 2005, J MED CHEM, V48, P7720; Lee YS, 2007, BIOORG MED CHEM LETT, V17, P2161, DOI 10.1016/j.bmcl.2007.01.114; Lelas S, 1998, PHARMACOL BIOCHEM BE, V60, P665, DOI 10.1016/S0091-3057(98)00046-X; LEMBECK F, 1985, EUR J PHARMACOL, V114, P241, DOI 10.1016/0014-2999(85)90365-6; Lenard NR, 2007, EUR J PHARMACOL, V566, P75, DOI 10.1016/j.ejphar.2007.02.040; LLAMA EF, 1991, J PHARM PHARMACOL, V43, P68, DOI 10.1111/j.2042-7158.1991.tb05456.x; Lu YF, 1998, SYNAPSE, V28, P117, DOI 10.1002/(SICI)1098-2396(199802)28:2<117::AID-SYN2>3.3.CO;2-8; *MERCK CO INC, 2002, MERCK IND; Micovic IV, 1996, J CHEM SOC PERK T 1, P2041, DOI 10.1039/p19960002041; Micovic IV, 1998, HETEROCYCL COMMUN, V4, P171; Micovic IV, 2000, BIOORG MED CHEM LETT, V10, P2011, DOI 10.1016/S0960-894X(00)00394-2; Narabayashi M, 2008, JPN J CLIN ONCOL, V38, P296, DOI 10.1093/jjco/hyn010; NI Q, 1993, SYNAPSE, V15, P296, DOI 10.1002/syn.890150406; NIEMEGEERS CJE, 1976, ARZNEIMITTEL-FORSCH, V26, P1551; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; Petrov RR, 2006, BIOORG MED CHEM LETT, V16, P4946, DOI 10.1016/j.bmcl.2006.06.040; Prostran M, 2002, EUR NEUROPSYCHOPHARM, V12, pS428; RILEY TN, 1979, J MED CHEM, V22, P1167, DOI 10.1021/jm00196a004; RILEY TN, 1973, J PHARM SCI, V62, P983, DOI 10.1002/jps.2600620627; Sarton E, 2008, ADV EXP MED BIOL, V605, P486; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; Vuckovic S, 2000, JPN J PHARMACOL, V84, P188, DOI 10.1254/jjp.84.188; Vuckovic S, 1998, JPN J PHARMACOL, V78, P523, DOI 10.1254/jjp.78.523; VUCKOVIC S, 1996, ACTA PHYSL PHARM THE, V46, P169; VUCKOVIC S, 2001, EUR J CLIN INVEST, V31, P18; VUCKOVIC S, 2001, PHARMACOL TOXICOL, V89, P98; VUCKOVIC S, 1999, FUND CLIN PHARM, V13, P212; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Williams M, 1999, J MED CHEM, V42, P1481, DOI 10.1021/jm9805034; Wirz S, 2006, CLIN J PAIN, V22, P770, DOI 10.1097/01.ajp.0000210925.33783.4d; XU H, 1991, NEUROPHARMACOLOGY, V30, P455, DOI 10.1016/0028-3908(91)90006-W	70	31	31	0	34	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.	JUL	2009	16	19					2468	2474		10.2174/092986709788682074			7	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	474BV	WOS:000268258200008	19601792				2020-06-30	J	Bryant, CD; Roberts, KW; Culbertson, CS; Le, A; Evans, CJ; Fanselow, MS				Bryant, Carnron D.; Roberts, Kristofer W.; Culbertson, Christopher S.; Le, Alan; Evans, Christopher J.; Fanselow, Michael S.			Pavlovian conditioning of multiple opioid-like responses in mice	DRUG AND ALCOHOL DEPENDENCE			English	Article						Associative learning; Context-dependent; Opiate; Expectancy; Pain; Open field; Cocaine	MORPHINE-TOLERANCE; PLACEBO ANALGESIA; DRUG-DEPENDENCE; TASTE-AVERSION; MU; REWARD; RECEPTOR; SENSITIZATION; EXPECTATION; ADDICTION	Conditional responses in rodents such as locomotion have been reported for drugs of abuse and similar to the placebo response in humans, may be associated with the expectation of reward. We examined several conditional opioid-like responses and the influence of drug expectation on conditioned place preference and concomitant conditional locomotion. Male C57BL/6J mice were conditioned with the selective mu opioid receptor agonist fentanyl (0.2 nng/kg, i.p.) in a novel context and subsequently given a vehicle injection. In separate experiments, locomotor activity, Straub tail, hot plate sensitivity, and conditioned place preference (CPP) were measured. Mice exhibited multiple conditional opioid-like responses including conditional hyperlocomotion, a conditional pattern of opioid-like locomotion, Straub tail, analgesia, and place preference. Modulating drug expectation via administration of fentanyl to "demonstrator" mice in the home cage did not affect the expression of conditioned place preference or the concomitant locomotor activity in "observer" mice. In summary, Pavlovian conditioning of an opioid in a novel context induced multiple conditional opioid-like behaviors and provides a model for studying the neurobiological mechanisms of the placebo response in mice. Published by Elsevier Ireland Ltd.	[Bryant, Carnron D.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Fanselow, Michael S.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Roberts, Kristofer W.; Le, Alan; Evans, Christopher J.] Univ Calif Los Angeles, Hatos Ctr Neuropharmacol, Los Angeles, CA USA; [Roberts, Kristofer W.; Culbertson, Christopher S.; Evans, Christopher J.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA	Bryant, CD (reprint author), Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC Room 501, Chicago, IL 60637 USA.	camron@uchicago.edu; kristo@ucla.edu; culbertson@ucla.edu; cevans@ucla.edu; cevans@ucla.edu; mfanselow@gmail.com	Bryant, Camron D/J-2408-2015	Bryant, Camron D/0000-0003-4505-5809	Shirley and Stefan Hatos Center for Neuropharmacology;  [DA05010];  [MH015795]	Funding for this study was provided by DA05010, MH015795, and the Shirley and Stefan Hatos Center for Neuropharmacology. NIDA and NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Amanzio M, 1999, J NEUROSCI, V19, P484; BARDO MT, 1994, PSYCHOPHARMACOLOGY, V114, P269, DOI 10.1007/BF02244848; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Benedetti F, 2004, NAT NEUROSCI, V7, P587, DOI 10.1038/nn1250; BILBEY DLJ, 1960, BRIT J PHARM CHEMOTH, V15, P540, DOI 10.1111/j.1476-5381.1960.tb00277.x; Bryant CD, 2005, CLIN NEUROSCI RES, V5, P103, DOI 10.1016/j.cnr.2005.08.006; CAREY RJ, 2008, PHARM BIOCH BEHAV; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; CHILDRESS AR, 1986, PSYCHIAT CLIN N AM, V9, P413; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; DUM J, 1984, PHARMACOL BIOCHEM BE, V21, P259, DOI 10.1016/0091-3057(84)90224-7; GOLD LH, 1989, BEHAV PHARMACOL, V1, P209; HAYASHI T, 1980, JPN J PHARMACOL, V30, P93, DOI 10.1254/jjp.30.93; HODGSON S, 2009, J PSYCHOPHARMACOL; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; LEVINE JD, 1984, BRAIN RES, V304, P265, DOI 10.1016/0006-8993(84)90329-9; MICKLEY GA, 1990, PSYCHOPHARMACOLOGY, V101, P332; MILLER JS, 1990, PSYCHOPHARMACOLOGY, V101, P472, DOI 10.1007/BF02244224; MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P274, DOI 10.1007/BF00432213; NATH C, 1994, EUR J PHARMACOL, V263, P203, DOI 10.1016/0014-2999(94)90543-6; OBRIEN CP, 1992, ANN NY ACAD SCI, V654, P400, DOI 10.1111/j.1749-6632.1992.tb25984.x; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Siegel S, 2000, EXP CLIN PSYCHOPHARM, V8, P276, DOI 10.1037/1064-1297.8.3.276; SIEGEL S, 1978, National Institute on Drug Abuse Research Monograph, P27; SIEGEL S, 1975, J COMP PHYSIOL PSYCH, V89, P498, DOI 10.1037/h0077058; SIEGEL S, 1977, J EXP PSYCHOL ANIM B, V3, P1, DOI 10.1037/0097-7403.3.1.1; Skoubis PD, 2001, NEUROSCIENCE, V106, P757, DOI 10.1016/S0306-4522(01)00333-5; STEWART J, 1983, PROG NEURO-PSYCHOPH, V7, P591, DOI 10.1016/0278-5846(83)90030-1; Tirelli E, 1998, BEHAV PHARMACOL, V9, P409, DOI 10.1097/00008877-199809000-00004; Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x; Valone JM, 1998, PHARMACOL BIOCHEM BE, V60, P115, DOI 10.1016/S0091-3057(97)00554-6; VEZINA P, 1987, PSYCHOPHARMACOLOGY, V91, P375, DOI 10.1007/BF00518195; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005	37	19	19	1	15	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	JUL 1	2009	103	1-2					74	83		10.1016/j.drugalcdep.2009.03.016			10	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	455LG	WOS:000266760700011	19419821	Green Accepted			2020-06-30	J	Higginson, I				Higginson, I.			The Livingston paediatric calculator, revision needed	EMERGENCY MEDICINE JOURNAL			English	Letter									Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England	Higginson, I (reprint author), Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England.	ian.higginson@phnt.swest.nhs.uk					Reed MJ, 2007, EMERG MED J, V24, P567, DOI 10.1136/emj.2007.046698	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	JUL	2009	26	7					544	544		10.1136/emj.2008.069757			1	Emergency Medicine	Emergency Medicine	461PJ	WOS:000267280000023	19546288				2020-06-30	J	Tyagi, A; Girotra, G; Kumar, A; Kumar, S; Sethi, AK; Mohta, M				Tyagi, A.; Girotra, G.; Kumar, A.; Kumar, S.; Sethi, A. Kumar; Mohta, M.			Single-shot spinal anaesthesia, combined spinal-epidural and epidural volume extension for elective caesarean section: a randomized comparison	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Single-shot spinal; Combined spinal-epidural; Epidural volume extension	HYPERBARIC BUPIVACAINE; SENSORY BLOCK; SITTING POSITIONS; DOSE REQUIREMENT; DELIVERY; INJECTION; POSTURE; SPREAD; HYPOTENSION; INDUCTION	Background: Single-shot spinal and combined spinal-epidural block, with or without epidural volume extension, can be used for caesarean section. There is no trial comparing their block characteristics and adverse effects under identical conditions. Methods: 60 ASA I or II parturients with gestational age 37 weeks or more, scheduled for elective caesarean section under regional anaesthesia, were included in the trial. Women were randomized to three groups: group SSS: single-shot spinal; group CSE: combined spinal-epidural; group EVE: epidural volume extension of a combined spinal-epidural. Intrathecal injection was identical in the three groups (0.5% hyperbaric bupivacaine 9 mg with fentanyl 10 mu g) and was injected via a 25-gauge pencil-point spinal needle, either as a single-shot spinal or through the spinal needle of the needle-through-needle CSE set. In group EVE, 5 mL of normal saline was injected through the epidural catheter. All blocks were performed with the women sitting. Haemodynamic parameters and block characteristics were assessed. Results: The onset of maximum sensory and motor block was significantly faster in the SSS group than in the other two. Extent and duration of sensory and motor block and the incidence of adverse effects were similar in the three groups (P > 0.05). Conclusions: Intrathecal block is similar in extent and duration whether given as a single-shot spinal or a combined spinal-epidural with or without epidural volume extension when performed for elective caesarean section using hyperbaric bupivacaine in the sitting position. (C) 2009 Elsevier Ltd. All rights reserved.	[Tyagi, A.] Univ Coll Med Sci, Dept Anaesthesiol & Crit Care, Delhi 110095, India; Guru Teg Bahadur Hosp, Delhi 110095, India	Tyagi, A (reprint author), Univ Coll Med Sci, Dept Anaesthesiol & Crit Care, Delhi 110095, India.	drashatyagi@gmail.com					BIRNBACH DJ, 2006, MILLERS ANESTHESIA, P2307; BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; BREEN TW, 1993, ANESTH ANALG, V77, P919; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; Choi DH, 2000, REGION ANESTH PAIN M, V25, P591, DOI 10.1053/rapm.2000.8934; Coppejans HC, 2006, ANESTH ANALG, V102, P243, DOI 10.1213/01.ane.0000189049.11005.26; Goy RWL, 2005, ANESTH ANALG, V100, P1499, DOI 10.1213/01.ANE.0000150941.84786.38; Goy RWL, 2004, ANESTH ANALG, V98, P491, DOI 10.1213/01.ANE.0000097182.DE; Hallworth SP, 2005, ANESTH ANALG, V100, P1159, DOI 10.1213/01.ANE.0000149548.88029.A2; Ithnin F, 2006, ANESTH ANALG, V102, P577, DOI 10.1213/01.ane.0000195440.51717.37; Kohler F, 2002, ACTA ANAESTH SCAND, V46, P441, DOI 10.1034/j.1399-6576.2002.460419.x; Lew E, 2004, ANESTH ANALG, V98, P810; Lim Y, 2006, ANESTH ANALG, V103, P1540, DOI 10.1213/01.ane.0000243392.91765.52; Mardirosoff C, 1998, REGION ANESTH PAIN M, V23, P92, DOI 10.1016/S1098-7339(98)90117-1; McNaught AF, 2007, INT J OBSTET ANESTH, V16, P346, DOI 10.1016/j.ijoa.2007.03.013; PATEL M, 1993, CAN J ANAESTH, V40, P943, DOI 10.1007/BF03010097; Rucklidge MWM, 2005, ANAESTHESIA, V60, P535, DOI 10.1111/j.1365-2044.2005.04178.x; Russell R, 2002, INT J OBSTET ANESTH, V11, P190, DOI 10.1054/ijoa.2002.0964; Stevens R., 1996, REGIONAL ANESTHESIA, P319; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; Takiguchi T, 1997, ANESTH ANALG, V85, P1097, DOI 10.1097/00000539-199711000-00024; Tyagi A, 2008, ANESTH ANALG, V107, P333, DOI 10.1213/ane.0b013e3181734436; WILDSMITH JAW, 1981, BRIT J ANAESTH, V53, P273, DOI 10.1093/bja/53.3.273; Yun EM, 1998, ANESTH ANALG, V87, P614, DOI 10.1097/00000539-199809000-00023	24	12	14	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2009	18	3					231	236		10.1016/j.ijoa.2009.01.007			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	476IA	WOS:000268431600007	19447598				2020-06-30	J	Lindley, P; Pestano, CR; Gargiulo, K				Lindley, Pam; Pestano, Cecile R.; Gargiulo, Kathryn			Comparison of postoperative pain management using two patient-controlled analgesia methods: nursing perspective	JOURNAL OF ADVANCED NURSING			English	Article						fentanyl iontophoretic transdermal system; nursing perspective; patient-controlled analgesia; postoperative pain; randomized controlled trial	IONTOPHORETIC TRANSDERMAL SYSTEM; EFFICACY; MORPHINE; SAFETY; CARE; SURGERY; NURSES; EASE; PCA	Comparison of postoperative pain management using two patient-controlled analgesia methods: nursing perspective. To compare the effect of fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia on the time-efficiency and convenience of postoperative patient care. Intravenous patient-controlled analgesia with morphine is effectively used to manage postoperative pain; however, it takes time to set up and administer. Nurses evaluated patient-care tasks with fentanyl iontophoretic transdermal system and/or morphine intravenous patient-controlled analgesia in two phase IIIb studies (n = 1305) using a nurse ease-of-care questionnaire. A responder for time-efficiency and convenience responded with one of the top three positive choices on all items; for satisfaction, a responder chose one of the top two positive choices on both items. Data were collected between March 2004 and April 2005. In both studies, greater proportions of nurses were responders for fentanyl iontophoretic transdermal system than for morphine intravenous patient-controlled analgesia, respectively, for time-efficiency [total hip replacement surgery, 80.9% (250/309) vs. 57.7% (172/298), P < 0.001; abdominal/pelvic surgery, 84.8% (162/191) vs. 57.7% (113/196), P < 0.001], convenience [total hip replacement surgery, 85.5% (271/317) vs. 64.1% (191/298), P < 0.001; abdominal/pelvic surgery, 89.2% (166/186) vs. 62.8% (123/196), P < 0.001], and satisfaction [total hip replacement surgery, 66.6% (247/371) vs. 33.3% (108/324), P < 0.001; abdominal/pelvic surgery, 67.4% (155/230) vs. 38.2% (84/220), P < 0.001]. Higher proportions of nurses favoured fentanyl iontophoretic transdermal system than morphine intravenous patient-controlled analgesia in both studies (P < 0.001). The fentanyl iontophoretic transdermal system appears to be simpler, easier to use, and more satisfactory for nurses than morphine intravenous patient-controlled analgesia.	[Lindley, Pam] Mem Hermann Mem City Hosp, Houston, TX USA; [Pestano, Cecile R.] William Beaumont Hosp, Royal Oak, MI 48072 USA; [Gargiulo, Kathryn] Ortho McNeil Janssen Sci Affairs LLC, Raritan, NJ USA	Lindley, P (reprint author), Mem Hermann Mem City Hosp, Houston, TX USA.	pam@minkowitzmd.com			Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, New JerseyJohnson & Johnson USAJanssen Biotech Inc	The study was supported by Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, New Jersey (no grant number).	Aiken LH, 2001, HEALTH AFFAIR, V20, P43, DOI 10.1377/hlthaff.20.3.43; Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; [Anonymous], 2002, Health Devices, V31, P342; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Chumbley GM, 1999, ANAESTHESIA, V54, P386, DOI 10.1046/j.1365-2044.1999.00836.x; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; Flynn Fran, 2003, Jt Comm J Qual Saf, V29, P37; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Harding G, 2004, VALUE HEALTH, V7, P728; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Ivanova A, 2001, BIOMETRICS, V57, P567, DOI 10.1111/j.0006-341X.2001.00567.x; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Marck P, 2000, ADV NURS SCI, V23, P62, DOI 10.1097/00012272-200012000-00007; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Pennington P, 2009, PAIN MANAG NURS, V10, P124, DOI 10.1016/j.pmn.2007.09.001; Porter-O'Grady Tim, 2003, J N Y State Nurses Assoc, V34, P4; Roos EM, 2003, CURR OPIN RHEUMATOL, V15, P160, DOI 10.1097/00002281-200303000-00014; Trossman S, 2005, AM J NURS, V105, P75; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; WICHOWSKI HC, 1994, J ADV NURS, V19, P1162; WOMACK D, 2004, TECHNOLOGYS ROLE ADD	26	8	8	0	14	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0309-2402			J ADV NURS	J. Adv. Nurs.	JUL	2009	65	7					1370	1380		10.1111/j.1365-2648.2009.04991.x			11	Nursing	Nursing	453GM	WOS:000266598900003	19456995				2020-06-30	J	Wang, H; Li, EY; Xu, GW; Wang, CS; Gong, YL; Li, P				Wang, H.; Li, E. Y.; Xu, G. W.; Wang, C. S.; Gong, Y. L.; Li, P.			Intravenous Fentanyl is Exhaled and the Concentration Fluctuates with Time	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						FENTANYL; OPIOID; ANAESTHETICS; PHARMACOKINETICS; ELIMINATION; EXHALATION	SOLID-PHASE MICROEXTRACTION; GAS; ALFENTANIL; PROPOFOL; ANESTHESIOLOGISTS; SUFENTANIL; ADDICTION; PLASMA; ABUSE; AIR	Previous studies have reported that fentanyl is eliminated predominantly by hepatic biotransformation, and that some is eliminated unchanged in urine and stools. No reports have described the elimination of fentanyl via the lungs. In this study, exhaled gas samples from eight anaesthetized patients undergoing cardiac surgery were analysed using solid-phase microextraction (SPME) coupled with gas chromatography-mass spectrometry (GC-MS). Results confirmed that fentanyl was exhaled by patients after intravenous administration, that the concentration of exhaled fentanyl fluctuated with time and peak concentrations were reached approximately 15 - 20 min after intravenous fentanyl administration. Thus, in addition to hepatic biotransformation and elimination via urine and faeces, fentanyl is also eliminated unchanged by the lungs. The potential risk to operating theatre personnel from long-term exposure to low levels of exhaled anaesthetic agents following intravenous administration to patients during surgery warrants further research.	[Wang, H.; Li, E. Y.; Wang, C. S.; Gong, Y. L.; Li, P.] Harbin Med Univ, Dept Anaesthesiol, Affiliated Hosp 1, Harbin 150001, Heilongjiang, Peoples R China; [Xu, G. W.] Chinese Acad Sci, Dalian Inst Chem Phys, Natl Chromatog Res & Anal Ctr, Dalian, Liaoning, Peoples R China	Li, EY (reprint author), Harbin Med Univ, Dept Anaesthesiol, Affiliated Hosp 1, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.	enyouli@yahoo.cn	Xu, Guowang/L-6910-2014	Xu, Guowang/0000-0003-4298-3554	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30571783]	The authors gratefully acknowledge the support of the National Natural Science Foundation of China (Grant No. 30571783).	BAGHERI H, 2007, [No title captured], V11, P1763; BALEY PL, 2000, ANESTHESIA, P312; Boer F, 2003, BRIT J ANAESTH, V91, P50, DOI 10.1093/bja/aeg117; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; GRAVENSTEIN JS, 1983, ANESTH ANALG, V62, P467; Grossherr M, 2006, ANESTHESIOLOGY, V104, P786, DOI 10.1097/00000542-200604000-00024; Hornuss C, 2007, ANESTHESIOLOGY, V106, P665, DOI 10.1097/01.anes.0000264746.01393.e0; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Paradis C, 2002, THER DRUG MONIT, V24, P768, DOI 10.1097/00007691-200212000-00014; ROERIG DL, 1987, ANESTHESIOLOGY, V67, P466, DOI 10.1097/00000542-198710000-00004; TAEGER K, 1988, BRIT J ANAESTH, V61, P425, DOI 10.1093/bja/61.4.425; Van Nimmen NFJ, 2004, J CHROMATOGR A, V1035, P249, DOI 10.1016/j.chroma.2004.02.074; Wang CS, 2009, MICROCHEM J, V91, P149, DOI 10.1016/j.microc.2008.09.002; Waters CM, 1999, J PHARMACOL EXP THER, V288, P157; Waters CM, 2000, ANESTHESIOLOGY, V93, P825, DOI 10.1097/00000542-200009000-00033	18	5	6	1	12	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	JUL-AUG	2009	37	4					1158	1166		10.1177/147323000903700421			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	509RQ	WOS:000271036300021	19761699				2020-06-30	J	Singh, D; Rath, GP; Dash, HH; Bithal, PK				Singh, Deepak; Rath, Girija P.; Dash, Hari H.; Bithal, Parmod K.			Sevoflurane Provides Better Recovery as Compared With Isoflurane in Children Undergoing Spinal Surgery	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						spinal dysraphism; spinal surgery; pediatric patient; bispectral index; anesthesia; recovery	AMBULATORY ANESTHESIA; INTERMEDIATE DURATION; EMERGENCE; HALOTHANE; MULTICENTER; DESFLURANE; FENTANYL	Rapid recovery is desirable in pediatric neurosurgical patients to obtain an early neurologic assessment. We compared the recovery characteristics of 2 commonly used anesthetic agents, sevoflurane and isoflurane, under bispectral index-guided anesthesia in children undergoing spinal surgery. Eighty children Who underwent surgery for Occult spinal dysraphism at the lumbar and sacral level were randomized to anesthesia with sevoflurane or isoflurane in oxygen and nitrous oxide. Anesthesia depth was guided by a bispectral index monitor kept between 40 and 60. In addition to time at emergence, extubation and discharge, recovery (modified Aldrete) score, and hemodynamics were compared. The 2 groups did not differ significantly with respect to demographics, duration of surgery and anesthesia, and intraoperative hemodynamic changes. Extubation (6.4 +/- 3.3 vs. 10.7 +/- 4.6) and emergence (7.8 +/- 3.4 vs. 12.8 +/- 5.6) times (minutes) were significantly shorter with sevoflurane (P < 0.001). Time (minutes) to achieve full Aldrete (modified) scores was less with sevoflurane (13.9 +/- 5.3 vs. 20.3 +/- 6.5) than isoflurane (P < 0.001). However, the time (minutes) to achieve discharge criteria from postanesthesia care unit (140.7 +/- 49.3 vs. 146 +/- 43.3) and first dose of postoperative analgesic (60 +/- 24.1 vs. 72 +/- 33.4) in addition to incidence of postoperative agitation were similar in both groups (P > 0.05). Sevoflurane results in an earlier recovery and assessment of modified Aldrete score when compared with isoflurane.	[Singh, Deepak; Rath, Girija P.; Dash, Hari H.; Bithal, Parmod K.] All India Inst Med Sci, Dept Neuroanaesthesiol, Ctr Neurosci, New Delhi 110029, India	Dash, HH (reprint author), All India Inst Med Sci, Dept Neuroanaesthesiol, Ctr Neurosci, New Delhi 110029, India.	dr.harihardash@gmail.com	Rath, Girija Prasad/J-4046-2019	Rath, Girija Prasad/0000-0002-3985-8202			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Bannister CF, 2000, ANESTHESIOLOGY, V93, pU229; Bortone L, 2006, PEDIATR ANESTH, V16, P1138, DOI 10.1111/j.1460-9592.2006.01954.x; CAMPBELL C, 1995, CAN J ANAESTH, V42, P884, DOI 10.1007/BF03011036; Cantillo J, 1997, PHARMACOTHERAPY, V17, P779; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; DEGOUTE WT, 2000, ANESTH ANALG, V90, P872; DENMAN WT, 1998, ANESTH ANALG, V86, P396; Duffy CM, 2000, J NEUROSURG ANESTH, V12, P128, DOI 10.1097/00008506-200004000-00012; Ebert TJ, 1998, ANESTHESIOLOGY, V89, P1524, DOI 10.1097/00000542-199812000-00032; FRINK EJ, 1992, ANESTH ANALG, V74, P241, DOI 10.1213/00000539-199202000-00012; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; HOLLIDAY AM, 1957, PEDIATRICS, V16, P823; JOSEPH PC, 2003, ANESTH ANALG, V97, P364; Le Berre PY, 2001, PAEDIATR ANAESTH, V11, P443, DOI 10.1046/j.1460-9592.2001.00704.x; MALVIYA S, 1990, ANESTHESIOLOGY, V72, P793, DOI 10.1097/00000542-199005000-00003; Meyer RR, 2007, PEDIATR ANESTH, V17, P56, DOI 10.1111/j.1460-9592.2006.01998.x; Norden J, 1991, ANESTH ANALG, V72, pS199; Nordmann GR, 2006, BRIT J ANAESTH, V96, P779, DOI 10.1093/bja/ael092; Philip BK, 1996, ANESTH ANALG, V83, P314, DOI 10.1097/00000539-199608000-00019; Robinson BJ, 1999, ACTA ANAESTH SCAND, V43, P185, DOI 10.1034/j.1399-6576.1999.430211.x; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; Valley RD, 1999, ANESTH ANALG, V88, P742, DOI 10.1097/00000539-199904000-00010; VITTANEN H, 1999, CAN J ANAESTH, V46, P766; YASUDA N, 1989, ANESTH ANALG, V69, P370	27	15	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2009	21	3					202	206		10.1097/ANA.0b013e31819f1ce0			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	464KF	WOS:000267503100003	19542996				2020-06-30	J	Mantadakis, E; Katzilakis, N; Foundoulaki, E; Kalmanti, M				Mantadakis, Elpis; Katzilakis, Nikolaos; Foundoulaki, Eva; Kalmanti, Maria			Moderate Intravenous Sedation With Fentanyl and Midazolam for Invasive Procedures in Children With Acute Lymphoblastic Leukemia	JOURNAL OF PEDIATRIC ONCOLOGY NURSING			English	Article						children; leukemia; puncture; sedation; midazolam; fentanyl	PEDIATRIC ONCOLOGY PATIENTS; CONSCIOUS SEDATION; PAINFUL PROCEDURES; KETAMINE-MIDAZOLAM; GENERAL-ANESTHESIA; LUMBAR PUNCTURE; CANCER; PROPOFOL; AMERICAN; SAFETY	Data were collected prospectively on 100 consecutive invasive procedures, that is, lumbar and bone marrow punctures (alone or in combination), in 16 patients less than 21 years of age with acute lymphoblastic leukemia (ALL). Efficacy of sedation and the need for restraint were graded according to 2 multiple-point scales. All invasive procedures were successfully performed. Oxygen by face mask was needed in 5 cases, whereas no patient required sedation reversal; 92% of the time, the patient was calm, cooperative, and responding to verbal commands, whereas in 97 procedures, there was no or only minimal patient movement that did not interfere with the completion of the procedure. Inpatient administration of midazolam and fentanyl by trained pediatric providers is safe and effective for invasive procedures in children and adolescents with ALL.	[Katzilakis, Nikolaos; Foundoulaki, Eva; Kalmanti, Maria] Univ Hosp Herakl, Dept Pediat Hematol Oncol, Iraklion 71003, Crete, Greece; [Kalmanti, Maria] Univ Crete, Iraklion, Greece	Kalmanti, M (reprint author), Univ Hosp Herakl, Dept Pediat Hematol Oncol, Iraklion 71003, Crete, Greece.	pedhem@med.uoc.gr		Mantadakis, Elpis/0000-0001-7837-9733			Barnes C, 2002, J PAEDIATR CHILD H, V38, P170, DOI 10.1046/j.1440-1754.2002.00761.x; BLANEY SM, 1995, J CLIN ONCOL, V13, P177, DOI 10.1200/JCO.1995.13.1.177; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; Crock C, 2003, ARCH DIS CHILD, V88, P253, DOI 10.1136/adc.88.3.253; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Gottschling S, 2005, J PEDIAT HEMATOL ONC, V27, P471, DOI 10.1097/01.mph.0000179238.37647.91; Green SM, 2002, ANN EMERG MED, V39, P433, DOI 10.1067/mem.2002.122770; Hain RDW, 2001, ARCH DIS CHILD, V85, P12, DOI 10.1136/adc.85.1.12; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Howard SC, 2002, JAMA-J AM MED ASSOC, V288, P2001, DOI 10.1001/jama.288.16.2001; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Klein Scott M, 2003, Pediatr Crit Care Med, V4, P78, DOI 10.1097/00130478-200301000-00016; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Ljungman G, 2001, MED PEDIATR ONCOL, V36, P372, DOI 10.1002/mpo.1088; Marx CM, 1997, J CLIN ONCOL, V15, P94, DOI 10.1200/JCO.1997.15.1.94; MCDOWALL RH, 1995, J CLIN ANESTH, V7, P273, DOI 10.1016/0952-8180(95)00017-C; Parker RI, 1997, PEDIATRICS, V99, P427, DOI 10.1542/peds.99.3.427; Pellier I, 1999, PAEDIATR ANAESTH, V9, P61, DOI 10.1046/j.1460-9592.1999.00280.x; SANDLER ES, 1992, PEDIATRICS, V89, P631; Seigler Robert S., 2001, Pediatr Crit Care Med, V2, P20, DOI 10.1097/00130478-200101000-00005; SIEVERS TD, 1991, PEDIATRICS, V88, P1172	22	9	9	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1043-4542	1532-8457		J PEDIATR ONCOL NURS	J. Pediatr. Oncol. Nurs.	JUL-AUG	2009	26	4					217	222		10.1177/1043454209339733			6	Oncology; Nursing	Oncology; Nursing	490IC	WOS:000269492900005	19726793				2020-06-30	J	Hocker, J; Bohm, R; Meybohm, P; Gruenewald, M; Renner, J; Ohnesorge, H; Scholz, J; Bein, B				Hoecker, Jan; Boehm, Ruwen; Meybohm, Patrick; Gruenewald, Matthias; Renner, Jochen; Ohnesorge, Henning; Scholz, Jens; Bein, Berthold			Interaction of morphine but not fentanyl with cerebral alpha(2)-adrenoceptors in alpha(2)-adrenoceptor knockout mice	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article						alpha(2)-adrenergic receptors; alpha(2)-adrenoceptor knockout mice; binding affinity; morphine; mu-opioid receptors	MORPHINE/CLONIDINE ANTINOCICEPTIVE SYNERGISM; RECEPTOR-LIKE IMMUNOREACTIVITY; ADRENERGIC-OPIOID SYNERGY; ALPHA(2A)-ADRENERGIC RECEPTOR; SPINAL ANALGESIA; TRANSGENIC MICE; NERVOUS-SYSTEM; NITROUS-OXIDE; IN-VIVO; SUBTYPES	Objectives alpha(2)-Adrenergic and mu-opioid receptors belong to the rhodopsin family of G-protein coupled receptors and mediate antinociceptive effects via similar signal transduction pathways. Previous studies have revealed direct functional interactions between both receptor systems including synergistic and additive effects. To evaluate underlying mechanisms. We have Studied whether morphine and fentanyl interacted With alpha(2)-adrenoceptor-subtype in mice lacking one individual alpha(2)-adrenoceptor-subtype (alpha(2)-adrenoceptor knockout). Methods Opioid interaction with alpha(2)-adrenoceptors Was investigated by quantitative receptor autoradiography in brain Slices Of alpha(2A)-, alpha(2B)- or alpha(2C)-adrenoceptor deficient mice. Displacement of the radiolabelled alpha(2)-adrenoceptor agonist [I-125] paraiodoclonidine from alpha(2)-adrenoceptors in different brain regions by increasing concentrations of morphine. fentanyl and naloxone was analysed. The binding affinity of both opioids to alpha(2)-adrenoceptor subtypes in different brain regions Was quantified. Key findings Morphine but not fentanyl or naloxone provoked dose-dependent displacement of [I-125] paraiodoclonidine from all alpha(2)-adrenoceptor subtypes in the brain regions analysed. Binding affinity was highest ill cortex, medulla oblongata and polls of alpha(2A)-adrenoceptor knockout mice. Conclusions Our results indicated that morphine interacted with alpha(2)-adrenoceptors showing higher affinity for the alpha(2B) and alpha(2C) than for the alpha(2A) Subtype. Ill contrast, fentanyl and naloxone did not show any relevant affinity to alpha(2)-adrenoceptors. This effect may have an impact oil the pharmacological actions of morphine.	[Hoecker, Jan; Meybohm, Patrick; Gruenewald, Matthias; Renner, Jochen; Ohnesorge, Henning; Scholz, Jens; Bein, Berthold] Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, D-24105 Kiel, Germany; [Boehm, Ruwen] Univ Hosp Schleswig Holstein, Dept Pharmacol, D-24105 Kiel, Germany	Hocker, J (reprint author), Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, Campus Kiel,Schwanenweg 21, D-24105 Kiel, Germany.	hoecker@anaesthesie.uni-kiel.de	Gruenewald, Matthias/F-9485-2012; Meybohm, Patrick/K-4066-2017	Meybohm, Patrick/0000-0002-2666-8696			Aantaa R, 2006, EUR J ANAESTH, V23, P361, DOI 10.1017/S0265021506000378; AANTAA R, 1995, ANN MED, V27, P439, DOI 10.3109/07853899709002452; Altman JD, 1999, MOL PHARMACOL, V56, P154; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; AOKI C, 1994, BRAIN RES, V650, P181, DOI 10.1016/0006-8993(94)91782-5; Bucheler MM, 2002, NEUROSCIENCE, V109, P819, DOI 10.1016/S0306-4522(01)00531-0; DeKock M, 1997, PHARMACOL BIOCHEM BE, V58, P109, DOI 10.1016/S0091-3057(96)00462-5; DRASNER K, 1988, PAIN, V32, P309, DOI 10.1016/0304-3959(88)90042-5; Fairbanks CA, 2002, J PHARMACOL EXP THER, V300, P282, DOI 10.1124/jpet.300.1.282; FRANKLIN KBJ, 1997, MOUSE BRAIN STEREOTA; Guo TZ, 1999, ANESTHESIOLOGY, V90, P470, DOI 10.1097/00000542-199902000-00022; Hocker J, 2008, EUR J PHARMACOL, V582, P70, DOI 10.1016/j.ejphar.2007.12.022; Holmberg M, 2003, NEUROSCIENCE, V117, P875, DOI 10.1016/S0306-4522(02)00966-1; Hunter JC, 1997, BRIT J PHARMACOL, V122, P1339, DOI 10.1038/sj.bjp.0701520; Jordan BA, 2003, MOL PHARMACOL, V64, P1317, DOI 10.1124/mol.64.6.1317; Kable JW, 2000, J PHARMACOL EXP THER, V293, P1; Lahdesmaki J, 2003, EUR J PHARMACOL, V468, P183, DOI 10.1016/S0014-2999(03)01677-7; Lahdesmaki J, 2002, NEUROSCIENCE, V113, P289, DOI 10.1016/S0306-4522(02)00185-9; Lakhlani PP, 1997, P NATL ACAD SCI USA, V94, P9950, DOI 10.1073/pnas.94.18.9950; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MALLARD NJ, 1992, BRIT J PHARMACOL, V106, P1019, DOI 10.1111/j.1476-5381.1992.tb14450.x; MAZE M, 1991, ANESTHESIOLOGY, V74, P581, DOI 10.1097/00000542-199103000-00029; MEERT TF, 1994, ANESTHESIOLOGY, V81, P677, DOI 10.1097/00000542-199409000-00022; MILLAN MJ, 1992, EUR J PHARMACOL, V215, P355, DOI 10.1016/0014-2999(92)90059-D; Ossipov MH, 1997, ANESTHESIOLOGY, V86, P196, DOI 10.1097/00000542-199701000-00024; Ozdogan UK, 2006, EUR J PHARMACOL, V529, P105, DOI 10.1016/j.ejphar.2005.10.029; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rosin DL, 1996, J COMP NEUROL, V372, P135; SAIZ J, PHARM REP, V60, P391; Sawamura S, 2000, J NEUROSCI, V20, P9242; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; SMITH MS, 1995, MOL BRAIN RES, V34, P109, DOI 10.1016/0169-328X(95)00148-L; Stone LS, 2004, NEUROSCI LETT, V361, P265, DOI 10.1016/j.neulet.2003.12.065; Stone LS, 1997, J NEUROSCI, V17, P7157; Takada K, 2002, ANESTHESIOLOGY, V96, P1420, DOI 10.1097/00000542-200206000-00022; Vilardaga JP, 2008, NAT CHEM BIOL, V4, P126, DOI 10.1038/nchembio.64; Wang R, 1996, NEUROSCIENCE, V74, P199, DOI 10.1016/0306-4522(96)00116-9; Wei ZY, 1996, J PHARMACOL EXP THER, V278, P1392; Wei ZY, 1998, J PHARMACOL EXP THER, V287, P937; Zurn A, 2009, MOL PHARMACOL, V75, P534, DOI 10.1124/mol.108.052399	40	12	12	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	JUL	2009	61	7					901	910		10.1211/jpp/61.07.0009			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	475KZ	WOS:000268358900009	19589232				2020-06-30	J	Yao, LN; Kuai, JK; Liu, XF; Yu, DH; Yang, YH; Tao, L; Zeng, XL; Chai, W				Yao, Linong; Kuai, Jianke; Liu, Xiaofeng; Yu, Daihua; Yang, Yonghui; Tao, Lei; Zeng, Xiaoli; Chai, Wei			Pretreatment With Fentanyl and Propofol Attenuates Myocardial Injury in Rabbits With Acute Hemorrhagic Shock	JOURNAL OF SURGICAL RESEARCH			English	Article						propofol; fentanyl; preconditioning; hemorrhagic shock; troponin I; myocardial protection	MITOCHONDRIAL PERMEABILITY TRANSITION; ISCHEMIA-REPERFUSION INJURY; 15-F-2T-ISOPROSTANE FORMATION; INDUCED CARDIOPROTECTION; OPIOID RECEPTORS; OXIDE SYNTHASE; RAT HEARTS; IN-VIVO; PROTECTION; INHIBITION	Background. Many studies have shown that preconditioning with anesthetics can be used to simulate the myocardial protective effects of ischemic preconditioning. But it is still not certain whether they can protect the myocardium in hemorrhagic shock. This study was designed to examine the myocardial protective effects of propofol and fentanyl in acute hemorrhagic shock. Materials and Methods. Thirty-six white rabbits were randomly divided into a control group (group C), propofol preconditioning group (group P), and fentanyl preconditioning group (group F). The animal model of acute hemorrhagic shock was established according to Wigger's method. The same volumes of saline, propofol (5 mg/kg), or fentanyl (25 mu g/kg) were administered 15 min before bleeding. Left ventricular function parameters were monitored continuously during 90 min of hemorrhagic shock. Serum cardiac troponin I (cTn-I) was detected by chemiluminescence before bleeding and 60 and 90 min after bleeding. Myocardial samples were taken for morphological studies. Results. Compared with group C, the hemodynamic indexes in group F and group P were higher at each time point of shock (P < 0.05). The cTn-I values in group P and group F were lower than in group C (P < 0.05). Electron microscopic examination of the myocardium indicated that the alterations of myocardial structure and mitochondria were less pronounced in both group F and group P. Conclusions. Propofol and fentanyl preconditioning can protect the heart against acute ischemia and promote the recovery of hemodynamics during hemorrhagie shock. (C) 2009 Elsevier Inc. All rights reserved.	[Yao, Linong; Kuai, Jianke; Liu, Xiaofeng; Yu, Daihua; Yang, Yonghui; Tao, Lei; Zeng, Xiaoli; Chai, Wei] Fourth Mil Med Univ, Tangdu Hosp, Dept Anesthesiol, Xian 710038, Peoples R China	Chai, W (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Dept Anesthesiol, Xian 710038, Peoples R China.	tdmzka@fmmu.edu.cn					Bell SP, 2000, J AM COLL CARDIOL, V36, P2296, DOI 10.1016/S0735-1097(00)01011-1; Caruso JM, 2003, J TRAUMA, V55, P531, DOI 10.1097/01.TA.0000025584.46870.95; Frassdorf J, 2005, ANESTH ANALG, V101, P934, DOI 10.1213/01.ane.0000172130.70274.84; Fryer RM, 2001, J PHARMACOL EXP THER, V299, P477; Javadov SA, 2000, CARDIOVASC RES, V45, P360, DOI 10.1016/S0008-6363(99)00365-X; Jiang XJ, 2004, ANESTHESIOLOGY, V101, P82, DOI 10.1097/00000542-200407000-00014; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; Kato R, 2000, BRIT J ANAESTH, V84, P204; Kevin LG, 2003, ANESTHESIOLOGY, V99, P385, DOI 10.1097/00000542-200308000-00020; Ko SH, 1997, ANESTH ANALG, V85, P719, DOI 10.1097/00000539-199710000-00002; Lim SY, 2007, J MOL CELL CARDIOL, V42, pS171, DOI 10.1016/j.yjmcc.2007.03.524; McBride SM, 2005, SHOCK, V23, P264, DOI 10.1097/01.shk.0000155196.25310.9a; Oeltgen PR, 2006, ACAD EMERG MED, V13, P127, DOI 10.1197/j.aem.2005.08.012; Peart JN, 2005, VASC PHARMACOL, V42, P211, DOI 10.1016/j.vph.2005.02.003; Sayin MM, 2002, BRIT J ANAESTH, V89, P242, DOI 10.1093/bja/aef173; Schultz JE, 2001, PHARMACOL THERAPEUT, V89, P123, DOI 10.1016/S0163-7258(00)00106-6; Wiggers CJ, 1942, PHYSIOL REV, V22, P74; Xia ZY, 2003, CARDIOVASC RES, V59, P113, DOI 10.1016/S0008-6363(03)00351-1; Xia ZY, 2003, CAN J PHYSIOL PHARM, V81, P14, DOI 10.1139/Y02-170; Zhang HY, 2002, J PHARMACOL EXP THER, V301, P1012, DOI 10.1124/jpet.301.3.1012	20	9	10	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2009	155	1					25	31		10.1016/j.jss.2008.07.012			7	Surgery	Surgery	463RC	WOS:000267448500005	19059609				2020-06-30	J	Liu, DB; Shao, YB; Luan, XS; Zhang, MK; Shui, CX; Wu, QY				Liu, Debin; Shao, Yanbin; Luan, Xiushu; Zhang, Mingkui; Shui, Chaoxiang; Wu, Qingyu			Comparison of ketamine-pentobarbital anesthesia and fentanyl-pentobarbital anesthesia for open-heart surgery in minipigs	LAB ANIMAL			English	Article								The authors analyzed and compared the cardiovascular effects of two anesthetic combinations in minipigs undergoing open-heart surgery and cardiopulmonary bypass. Pigs in group K (n = 15) were anesthetized with low-dose ketamine combined with pentobarbital (5 mg per kg and 20 mg per kg, respectively, for induction; continuous intravenous infusion of 5 mg per kg per h and 10 mg per kg per h, respectively, for maintenance). Pigs in group F ( n = 15) were treated with fentanyl and pentobarbital (20 mu g per kg and 20 mg per kg, respectively, for induction; continuous intravenous infusion of 20 mu g per kg per h and 10 mg per kg per h, respectively, for maintenance). Most pigs remained stable during the surgical procedures and survived for at least one day after surgery; two pigs in group F died during or soon after surgery. Heart rate and mean arterial pressure after bypass were significantly lower in group F than in group K, and pigs in group F required higher doses of inotropic agents to maintain cardiac function. Results suggest that for open-heart surgery and bypass in minipigs, ketamine-pentobarbital anesthesia is associated with more stable cardiovascular conditions than is fentanyl-pentobarbital anesthesia.	[Liu, Debin; Zhang, Mingkui; Wu, Qingyu] Tsinghua Univ, Hosp 1, Ctr Heart, Beijing 100084, Peoples R China; [Shao, Yanbin; Luan, Xiushu] Tsinghua Univ, Hosp 1, Dept Anaesthesia, Beijing 100084, Peoples R China; [Shui, Chaoxiang] Tsinghua Univ, Hosp 1, Clin Expt Ctr, Beijing 100084, Peoples R China	Liu, DB (reprint author), Tsinghua Univ, Hosp 1, Ctr Heart, Beijing 100084, Peoples R China.	dr.liu.debin@gmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30772152]	This study was supported by grant number 30772152 from the National Natural Science Foundation of China.	Adams HA, 1997, ANAESTHESIST, V46, P1081, DOI 10.1007/s001010050510; Goldmann C, 1999, RES EXP MED, V199, P35, DOI 10.1007/s004330050131; Grund F, 2004, LAB ANIM-UK, V38, P70, DOI 10.1258/00236770460734425; Hubert MB, 2003, J EXP ANIM SCI, V42, P135, DOI 10.1016/S0939-8600(03)80007-X; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; *I LAB AN RES NAT, 1996, [No title captured]; Mazzadi AN, 2006, AM J PHYSIOL-HEART C, V291, pH2570, DOI 10.1152/ajpheart.01249.2005; Parasher PS, 2008, ECHOCARDIOGR-J CARD, V25, P1011, DOI 10.1111/j.1540-8175.2008.00723.x; Schuchard RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243; SHIMADA M, 1993, J CRIT CARE, V8, P109, DOI 10.1016/0883-9441(93)90015-D; STROM J, 1987, ACTA ANAESTH SCAND, V31, P413, DOI 10.1111/j.1399-6576.1987.tb02593.x; SWINDLE MM, 1986, LAB ANIM SCI, V36, P357	12	5	6	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0093-7355	1548-4475		LAB ANIMAL	Lab Anim.	JUL	2009	38	7					234	240		10.1038/laban0709-234			7	Veterinary Sciences	Veterinary Sciences	517KD	WOS:000271611400013	19543261				2020-06-30	J	Schoffmann, G; Winter, P; Palme, R; Pollak, A; Trittenwein, G; Golej, J				Schoeffmann, G.; Winter, P.; Palme, R.; Pollak, A.; Trittenwein, G.; Golej, J.			Haemodynamic changes and stress responses of piglets to surgery during total intravenous anaesthesia with propofol and fentanyl	LABORATORY ANIMALS			English	Article						Total intravenous anaesthesia; fentanyl; propofol; serum amyloid A; cortisol; stress response; piglets	SERUM AMYLOID-A; INDUCED SEDATION; BETA-ENDORPHIN; HEART-RATE; BUTORPHANOL; PIGS; CORTISOL; MEDETOMIDINE; COMBINATION; HAPTOGLOBIN	The purpose of the study was to assess the haemodynamic (blood pressure and heart rate) changes and stress responses (serum cortisol and serum amyloid A [SAA] concentrations) to surgery in piglets during total intravenous anaesthesia (TIVA) with propofol and fentanyl. After preanaesthetic medication with intramuscular midazolam (0.5 mg/kg body mass), ketamine (110 mg/kg) and butorphanol (0.5 mg/kg) anaesthesia was induced in five piglets, with intravenous propofol (1 mg/kg) followed by tracheal intubation and mechanical lung ventilation. Soft tissue surgery was performed in the jugular and inguinal regions during TIVA with propofol (8 mg/kg/h) and fentanyl (35 mu g/kg/h). Anaesthesia was maintained for 300 min after surgery as the piglets were the control group of a project involving extracorporeal membrane oxygenation. Mean plasma cortisol concentration decreased significantly (P < 0.05) from 59 +/- 39.9 nmol/L (mean +/- 1 SID) before surgery to 7.5 +/- 2.5 nmol/L 300 min after end of surgical procedure. The mean SAA concentrations increased over the same period from 1.6 +/- 2.3 mu g/mL to 4.2 +/- 5.6 mu g/mL without statistical significance. The baseline (presurgery) mean arterial pressure (MAP) was 72 +/- 9 mmHg compared with 72 +/- 11 mmHg 300 min after end of surgery. Neither heart rate nor lactate concentrations changed significantly over the same time points: heart rate was 104 +/- 11 and 103 +/- 15 beats/min whereas mean lactate concentrations were reduced from 1.14 +/- 0.45 mmol/L to 0.90 +/- 0.22 mmol/L. Haemodynamic stability, a decrease in serum cortisol and a non-statistically significant rise in mean SAA concentrations suggest that the anaesthetic described suppresses the stress response of piglets to surgery without adverse cardiovascular effects. Therefore, it may prove useful in cardiovascular research.	[Pollak, A.; Trittenwein, G.; Golej, J.] Med Univ Vienna, Div Neonatol & Pediat Intens Care, Dept Pediat, A-1090 Vienna, Austria; [Schoeffmann, G.] Univ Vet Med Vienna, Clin Dept Small Anim & Horses, Clin Anaesthesiol & Perioperat Intens Care, Vienna, Austria; [Winter, P.] Univ Vet Med Vienna, Clin Dept Farm Anim & Heard Hlth Management, Clin Ruminants, Vienna, Austria; [Palme, R.] Univ Vet Med Vienna, Inst Biochem, Dept Nat Sci, Vienna, Austria	Golej, J (reprint author), Med Univ Vienna, Div Neonatol & Pediat Intens Care, Dept Pediat, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	johann.golej@meduniwien.ac.at	Palme, Rupert/A-3499-2008; Palme, Rupert/AAC-7981-2020	Palme, Rupert/0000-0001-9466-3662; Palme, Rupert/0000-0001-9466-3662			AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; ALSEMGEEST SPM, 1995, VET QUART, V17, P9, DOI 10.1080/01652176.1995.9694521; Bollen PJA, 2007, BASIC CLIN PHARMACOL, V101, P192, DOI 10.1111/j.1742-7843.2007.00099.x; BOWDLE TA, 1987, ANESTH ANALG, V66, P517; Briggs SL, 1998, VET SURG, V27, P466, DOI 10.1111/j.1532-950X.1998.tb00158.x; Cancho MFM, 2006, ANESTH ANALG, V102, P1333, DOI 10.1213/01.ane.0000202464.06660.66; Carrasco-Jimenez MS, 2004, AM J VET RES, V65, P1128, DOI 10.2460/ajvr.2004.65.1128; Commiskey S, 2005, J PHARMACOL SCI, V98, P109, DOI 10.1254/jphs.CRJ05001X; DALIN AM, 1993, J ANIM SCI, V71, P1902, DOI 10.2527/1993.7171902x; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655; Gerard H, 1996, VET RES, V27, P219; Golej J, 2003, SHOCK, V20, P110, DOI 10.1097/01.shk.0000075571.93053.2c; HALL GM, 1990, BRIT J ANAESTH, V65, P251, DOI 10.1093/bja/65.2.251; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; HUGHES HC, 1986, LAB ANIM SCI, V36, P348; Hulten C, 2003, VET MICROBIOL, V95, P75, DOI 10.1016/S0378-1135(03)00136-6; Jacobson M, 2001, COMPARATIVE MED, V51, P163; Kajikawa T, 1999, VET IMMUNOL IMMUNOP, V68, P91, DOI 10.1016/S0165-2427(99)00012-4; Kurita T, 2003, BRIT J ANAESTH, V91, P871, DOI 10.1093/bja/aeg259; LACOUMENTA S, 1987, BRIT J ANAESTH, V59, P713, DOI 10.1093/bja/59.6.713; LAFFEY DA, 1984, BRIT J ANAESTH, V56, P363, DOI 10.1093/bja/56.4.363; LEDINGHAM IM, 1983, LANCET, V1, P1270; Martin Maria F, 2001, Vet Anaesth Analg, V28, P132, DOI 10.1046/j.1467-2987.2001.00050.x; Misiolek H, 2000, Med Sci Monit, V6, P319; Miyawaki T, 2004, ACTA ANAESTH SCAND, V48, P384, DOI 10.1111/j.0001-5172.2004.0320a.x; Mohr E, 2002, PHYSIOL BEHAV, V75, P251, DOI 10.1016/S0031-9384(01)00651-5; Murata M, 2003, J VET MED SCI, V65, P511, DOI 10.1292/jvms.65.511; *NIH, 1996, NIH GUID, V25; NISHIMURA R, 1992, J VET MED SCI, V54, P615, DOI 10.1292/jvms.54.615; Osgood P. F., 1995, Journal of Burn Care and Rehabilitation, V16, P394, DOI 10.1097/00004630-199507000-00004; Palme R, 1997, Z SAUGETIERKD, V62, P192; Petersen HH, 2004, VET RES, V35, P163, DOI 10.1051/vetres:2004002; PINEIRO M, 2003, [No title captured], P77; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; SAKAGUCHI M, 1993, J VET MED SCI, V55, P497, DOI 10.1292/jvms.55.497; SAKAGUCHI M, 1992, J VET MED SCI, V54, P1183, DOI 10.1292/jvms.54.1183; Schnoor J, 2005, CAN VET J, V46, P995; Walker B, 2004, J VET MED A, V51, P150, DOI 10.1111/j.1439-0442.2004.00617.x	39	8	8	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	JUL	2009	43	3					243	248		10.1258/la.2008.0080026			6	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	482HF	WOS:000268874700005	19246504				2020-06-30	J	Vilela, SMF; Santos, DJSL; Felix, L; Almeida, JM; Antunes, L; Peixoto, F				Vilela, Sergio M. F.; Santos, Dario J. S. L.; Felix, Luis; Almeida, Jose M.; Antunes, Luis; Peixoto, Francisco			Are fentanyl and remifentanil safe opioids for rat brain mitochondrial bioenergetics?	MITOCHONDRION			English	Article						Analgesic; ATP synthesis; Brain mitochondria; Toxicity; Bioenergetics	ANESTHESIA; PHARMACOKINETICS; PHOSPHORYLATION; INJURY	Fentanyl and remifentanil are potent opioid widely used in routine anesthesia procedures. This study evaluates and compares the effects of fentanyl/remifentanil in isolated brain mitochondria bioenergetic status. Fentanyl and remifentanil in clinical concentrations does not interfere with rat brain isolated mitochondria. Do not withstand, fentanyl concentrations >4 mu g/mL, induces an impairment of the respiratory chain characterized by a decrease in respiratory control ratio, state 3 and uncoupled respiration. Additionally, membrane potential collapses and ADP/O were reduced. Remifentanil follows the same profile but with effects at higher concentrations (>10 mu g/mL). High concentrations of fentanyl and remifentanil interfere with mitochondrial electron chain (complexes III, IV) and on mitochondrial phosphorylation unit (complex V). Mitochondrial permeability transition pore was not induced by both fentanyl and remifentanil in tested concentrations. These data provide the first indication that fentanyl and remifentanil (mu g/mL range) alters mitochondrial metabolism. Fentanyl showed a stronger inhibitory effect on mitochondrial bioenergetics. (C) 2009 Elsevier B.V. and Mitochondria Research Society. All rights reserved.	[Vilela, Sergio M. F.; Felix, Luis; Peixoto, Francisco] Univ Tras Os Montes & Alto Douro, CECAV, Dept Chem, P-5001801 Vila Real, Portugal; [Santos, Dario J. S. L.] Univ Tras Os Montes & Alto Douro, CITAB, DEBA, P-5001801 Vila Real, Portugal; [Almeida, Jose M.; Antunes, Luis] Univ Tras Os Montes & Alto Douro, CECAV Vet & Anim Ctr, P-5001801 Vila Real, Portugal	Peixoto, F (reprint author), Univ Tras Os Montes & Alto Douro, CECAV, Dept Chem, P-5001801 Vila Real, Portugal.	fpeixoto@utad.pt	Felix, Luis/G-5426-2011; Peixoto, Francisco/F-7940-2011; Vilela, Sergio M. F./G-3886-2010; Santos, Dario L/A-4620-2013; Almeida, Jose/H-4475-2011	Felix, Luis/0000-0001-9870-6666; Peixoto, Francisco/0000-0001-9729-7477; Santos, Dario L/0000-0003-2900-6126; Almeida, Jose/0000-0003-4587-0221; Vilela, Sergio/0000-0001-5125-1676; Antunes, Luis/0000-0002-9757-6879	Portuguese Research Council (FCT)Portuguese Foundation for Science and Technology; Center of Animal Science and Veterinary (CECAV) of the University of Tras-os-Montes; POCTI; FEDEREuropean Union (EU);  [POCTI/CVT/59056/2004]	The authors wish to express their grateful acknowledgment to Doctor Delfina Rodrigues for the English revision. This study was supported by Portuguese Research Council (FCT), Center of Animal Science and Veterinary (CECAV) of the University of Tras-os-Montes and Alto Douro, funded by POCTI, co-funded by FEDER and Project POCTI/CVT/59056/2004.	ANAND KJS, 1987, LANCET, V1, P243; Antunes LM, 2003, EUR J ANAESTH, V20, P800, DOI 10.1097/00003643-200310000-00005; BRANCA D, 1995, COMP BIOCHEM PHYS C, V110, P41, DOI 10.1016/0742-8413(94)00078-O; Brautigan D L, 1978, Methods Enzymol, V53, P128; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; CHANCE B, 1956, ADV ENZYMOL, V17, P134; Devin A, 2006, J BIOENERG BIOMEMBR, V38, P137, DOI 10.1007/s10863-006-9013-6; Duthie DJR, 1998, BRIT J ANAESTH, V81, P51; EZE MO, 1990, J CHEM EDUC, V67, P17, DOI 10.1021/ed067p17; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; FERREIRA DA, 2007, ANESTHESIOLOGY, V107, pA3; FREYE E, 2008, OPIOIDS MED, P141; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROUSELLE M, 1990, BIOCHEM J, V271, P269, DOI 10.1042/bj2710269; ISSY AM, 2002, VER BRAS ANESTESIOL, V52, P562; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; LAUWERS MH, 1994, ANAESTHESIA, V49, P876, DOI 10.1111/j.1365-2044.1994.tb04263.x; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; Moreira PI, 2005, NEUROPHARMACOLOGY, V48, P435, DOI 10.1016/j.neuropharm.2004.10.012; MORENO AJM, 1991, BIOCHIM BIOPHYS ACTA, V1060, P166, DOI 10.1016/S0005-2728(09)91004-0; Mouritsen OG, 1998, PHARM RES-DORDR, V15, P1507, DOI 10.1023/A:1011986613392; Muravchick S, 2006, ANESTHESIOLOGY, V105, P819, DOI 10.1097/00000542-200610000-00029; Nouette-Gaulain K, 2007, ANN FR ANESTH, V26, P319, DOI 10.1016/j.annfar.2007.01.012; Okada Y, 1998, PEDIATR SURG INT, V13, P508, DOI 10.1007/s003830050385; PAPPAGALLO M, 2004, NEUROLOGICAL BASIS P, P545; Pasero Chris, 2005, J Perianesth Nurs, V20, P279, DOI 10.1016/j.jopan.2005.03.007; Peixoto F, 2003, ARCH TOXICOL, V77, P403, DOI 10.1007/s00204-003-0456-9; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; Santos DL, 2002, TOXICOL APPL PHARM, V185, P218, DOI 10.1006/taap.2002.9532; Singer T P, 1974, Methods Biochem Anal, V22, P123, DOI 10.1002/9780470110423.ch3; Stevanato R, 2002, BIOCHEM PHARMACOL, V64, P1133, DOI 10.1016/S0006-2952(02)01253-4; Tisdale H., 1967, METHOD ENZYMOL, V10, P213; Videira RA, 2001, TOXICOL APPL PHARM, V175, P209, DOI 10.1006/taap.2001.9246; Zamparelli M, 1999, J PEDIATR SURG, V34, P260, DOI 10.1016/S0022-3468(99)90186-0	36	16	16	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1567-7249	1872-8278		MITOCHONDRION	Mitochondrion	JUL	2009	9	4					247	253		10.1016/j.mito.2009.03.002			7	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	459QH	WOS:000267118000004	19303949				2020-06-30	J	Heiskanen, T; Matzke, S; Haakana, S; Gergov, M; Vuori, E; Kalso, E				Heiskanen, Tarja; Matzke, Sorjo; Haakana, Soile; Gergov, Merja; Vuori, Erkki; Kalso, Eija			Transdermal fentanyl in cachectic cancer patients	PAIN			English	Article						Transdermal fentanyl; Absorption; Cachexia; Cancer pain; Opioid	RELEASE ORAL MORPHINE; PAIN; PHARMACOKINETICS; MULTICENTER; EFFICACY; DELIVERY; CACHEXIA; TRIAL; FOCUS	Fentanyl is an opioid with high lipid solubility, suitable for intravenous, spinal, transmucosal and transdermal administration. The transdermal fentanyl patch has become widely used in the treatment of both malignant and non-malignant chronic pain. The absorption of fentanyl from the patch is governed by the surface area of the patch, by skin permeability and by local blood flow. The aim of this study is to find out whether absorption of fentanyl in cachectic patients with cancer-related pain is different from that of normal weight cancer patients. We recruited ten normal weight (mean body mass index (BMI) 23 kg/m(2)) and ten cachectic (mean BMI 16 kg/m(2)) cancer pain patients. A transdermal fentanyl patch with a dose approximately equianalgesic to the patients' previous opioid dose was administered to the upper arm of the patient for 3 days. Prior to patch application, the height, weight and BMI of the patient, as well as upper arm skin temperature, local sweating, thickness of skin fold and local blood flow were measured. Plasma fentanyl concentrations were analyzed from blood samples taken at baseline, 4, 24, 48 and 72 h. Plasma fentanyl concentrations adjusted to dose were significantly lower at 48 and 72 h in cachectic patients than normal weight patients. The cachectic patients had a significantly thinner upper arm skin fold, but no differences were found in local blood flow, sweating, or skin temperature. Absorption of transdermal fentanyl is impaired in cachectic patients compared with that of normal weight cancer pain patients. (C) 2009 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Heiskanen, Tarja; Haakana, Soile; Kalso, Eija] Univ Helsinki, Cent Hosp, Pain Clin, Dept Anesthesiol & Intens Care Med, Hus Helsinki 00029, Finland; [Matzke, Sorjo] Jorvi Hosp, Dept Clin Physiol, SF-02740 Espoo, Finland; [Gergov, Merja; Vuori, Erkki] Univ Helsinki, Dept Forens Med, SF-00300 Helsinki, Finland; [Kalso, Eija] Univ Helsinki, Inst Clin Med, Helsinki, Finland	Heiskanen, T (reprint author), Univ Helsinki, Cent Hosp, Pain Clin, Dept Anesthesiol & Intens Care Med, POB 140, Hus Helsinki 00029, Finland.	tarja.heiskanen@hus.fi		Kalso, Eija/0000-0002-4899-605X	Finnish Cancer Foundation; Helsinki University Central Hospital Research Funds [T102010066]	This Study received financial support from the Finnish Cancer Foundation (grants to T.H. and to EX) and from the Helsinki University Central Hospital Research Funds (T102010066). We thank Matti Kataja, Doctor of Science (Technology), for assistance in the statistical analysis of the data.	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Baracos VE, 2006, ANNU REV NUTR, V26, P435, DOI 10.1146/annurev.nutr.26.061505.111151; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Eun HC, 1995, CLIN DERMATOL, V13, P337, DOI 10.1016/0738-081X(95)00080-Y; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hadgraft J, 2005, INT J PHARMACEUT, V305, P2, DOI 10.1016/j.ijpharm.2005.07.014; Hediger C, 2000, SCHWEIZ MED WSCHR, V130, P565; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Koltzenburg M, 2006, PAIN, V126, P165, DOI 10.1016/j.pain.2006.06.028; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Morley JE, 2006, AM J CLIN NUTR, V83, P735; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	25	52	51	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	JUL	2009	144	1-2					218	222		10.1016/j.pain.2009.04.012			5	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	470GL	WOS:000267963100034	19442446				2020-06-30	J	Lenkutis, T; Benetis, R; Sirvinskas, E; Raliene, L; Judickaite, L				Lenkutis, Tadas; Benetis, Rimantas; Sirvinskas, Edmundas; Raliene, Laima; Judickaite, Loreta			Effects of epidural anesthesia on intrathoracic blood volume and extravascular lung water during on-pump cardiac surgery	PERFUSION-UK			English	Article						cardiac anesthesia; thoracic epidural anesthesia; cardiopulmonary bypass; extravascular lung water; intrathoracic blood volume	CARDIOPULMONARY BYPASS	Background: The most important side effect of epidural anesthesia is hypotension with functional hypovolemia. Aggressive infusion therapy can reduce the hypotension effect. However, in conjunction with cardiopulmonary bypass, it can increase acute lung injury. We hypothesized that epidural anesthesia, by reducing cardiac sympathetic tonus, with subsequent better pulmonary flow, does not increase lung interstitial fluids. Methods: Sixty patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB) were randomized to combined general anesthesia with epidural anesthesia/analgesia, (EA) group, and to general anesthesia with i/v opiate analgesia, (GA) group. Patients in the EA group received a high thoracic epidural, preoperatively. Intra-operatively, 0.25% bupivacaine 8 mL/h was infused and general anesthesia with sevoflurane was followed by bupivacaine infusion for 48 hours postoperatively. General anesthesia in the GA group was with sevoflurane and fentanyl 10-12 mu g/kg and analgesia with pethidinum 0.1 - 0.4 mg/kg i.v. postoperatively. Global enddiastolic volume index (GEDI), intrathoracic blood volume index (ITBI) and extravascular lung water index (ELWI) were measured before anesthesia, before CPB and 15, 60, 180, 600 min. and 24 hr after CPB. Duration of mechanical lung ventilation was registered in both groups. Results: ITBI and GEDI were significantly higher in the EA group at all time points of measurement (ITBI 945.6 +/- 146.4 ml/m(2) and 870.6 +/- 146.5 ml/m(2) vs. 1118 +/- 153.2 ml/m(2) and 1020 +/- 174.9 ml/m(2); GEDI 720 +/- 96.19 ml/m(2) and 775.0 +/- 159.5 ml/m(2) vs. 805.4 +/- 97.59 ml/m(2) and 888 +/- 117.3 ml/m(2)). GEDI was significantly lower in the GA group compared with baseline (801.9 +/- 132.4 ml/m(2) vs. 695 +/- 169.2 mL/m(2)). ELWI was significantly higher in the GA group (7.233 +/- 1.35 ml/kg and 7.333 +/- 1.32 ml/kg vs. 8.533 +/- 1.45 ml/kg and 8.633 +/- 1.71 ml/kg), but without significant changes in the EA group. Duration of mechanical lung ventilation was shorter in the EA group (663.7 +/- 98.39 min. vs. 362.2 +/- 33.72 min.). Conclusions: Epidural anesthesia /analgesia does not increase interstitial lung fluids by increasing intrathoracic blood volume or the amount of infusion fluids in patients undergoing cardiac surgery under cardiopulmonary bypass. There is, also, a decreased duration of mechanical lung ventilation.	[Lenkutis, Tadas; Benetis, Rimantas] Kaunas Univ Hosp, Clin Cardiothorac & Vasc Surg, LT-50009 Kaunas, Lithuania; [Sirvinskas, Edmundas; Raliene, Laima] Kaunas Univ Med, Inst Biomed Res, Kaunas, Lithuania; [Judickaite, Loreta] Kaunas Univ Med, Dept Anesthesiol, Kaunas, Lithuania	Sirvinskas, E (reprint author), Kaunas Univ Hosp, Dept Cardioanesthesiol, Eiveniu G4, LT-50009 Kaunas, Lithuania.	sirdiskr@kmu.lt					ANDERSEN LW, 1993, CRIT CARE MED, V21, P210, DOI 10.1097/00003246-199302000-00011; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BYRICK RJ, 1977, CAN ANAESTH SOC J, V24, P332; CLEMENTE A, 2008, TECH REG ANESTH PAIN, V12, P41; Gayes JM, 1997, J CARDIOTHOR VASC AN, V11, P625, DOI 10.1016/S1053-0770(97)90019-7; Hachenberg T, 1999, BEST PRACT RES CLIN, V13, P57; Holte K, 2004, ANESTHESIOLOGY, V100, P281, DOI 10.1097/00000542-200402000-00016; Li Yu-hong, 2006, J Zhejiang Univ Sci B, V7, P738, DOI 10.1631/jzus.2006.B0738; Schumacher J, 2004, PERFUSION-UK, V19, P277, DOI 10.1191/0267659104pf753oa; Waurick R, 2005, BEST PRACT RES-CLIN, V19, P201, DOI 10.1016/j.bpa.2004.12.001	10	7	9	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	JUL	2009	24	4					243	248		10.1177/0267659109348724			6	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	525CX	WOS:000272192200005	19808745				2020-06-30	J	Park, KE; Sohn, JT; Jeong, YS; Sung, HJ; Shin, IW; Lee, HK; Chung, YK				Park, Kyeong-Eon; Sohn, Ju-Tae; Jeong, Young Seok; Sung, Hui-Jin; Shin, Il-Woo; Lee, Heon-Keun; Chung, Young-Kyun			Inhibitory Effect of Fentanyl on Phenylephrine-Induced Contraction of the Rat Aorta	YONSEI MEDICAL JOURNAL			English	Article						Fentanyl; phenylephrine; 5-methylurapidil; BMY 7378; prazosin; rat aorta	ALPHA(1)-ADRENOCEPTOR SUBTYPES; MEDIATING CONTRACTIONS; ARTERY; ALPHA(1D)-ADRENOCEPTOR; RECEPTOR; ALPHA-1-ADRENOCEPTORS; DEPRESSION; PLASMA	Purpose: Fentanyl was reported to inhibit the alpha(1)-adrenoceptor agonist-induced contraction. The goal of this in vitro study was to identify the alpha(1)-adrenoceptor subtype primarily involved in the fentanyl-induced attenuation of phenylephrine-induced contraction in isolated endothelium-denuded rat aorta. Materials and Methods: Aortic rings were suspended in order to record isometric tension. Concentration-response curves for phenylephrine (10(-9) to 10(-5) M) were generated in the presence or absence of one of the following drugs: fentanyl (3 x 10(-7), 10(-6), 3 x 10(-6) M), 5-methylurapidil (3 x 10(-8), 10(-7), 3 x 10(-7) M), chloroethylclonidine (10(-5) M) and BMY 7378 (3 x 10(-9), 10(-8), 3 x 10(-8) M). Phenylephrine concentration-response curves were generated in the presence or absence of fentanyl in rings pretreated with either 3 x 10(-1) M prazosin, 10(-9) M 5-methylurapidil or 3 x 10(-9) M BMY 7378. Results: Fentanyl (10(-6), 3 x 10(-6) M) attenuated phenylephrine-induced contraction in the rat aorta. 5-Methylurapidil and BMY 7378 produced a parallel rightward shift in the phenylephrine concentration-response curve. The pA(2) values for 5-methylurapidil and BMY 7378 were estimated to be 7.71 +/- 0.15 and 8.99 +/- 0.24, respectively. Fentanyl (10(-6) M) attenuated phenylephrine-induced contraction in rings pretreated with 10(-9) M 5-methylurapidil, but did not alter the rings when pretreated with 3 x 10(-9) M BMY 7378. Pretreatment of the rings with chloroethylclonidine showed a 72.9 +/- 2.3% reduction in phenylephrine-induced maximal contraction. Conclusion: The results suggest that fentanyl attenuates phenylephrine-induced contraction by inhibiting the pathway involved in the alpha 1D-adrenoceptormediated contraction of the rat aorta.	[Park, Kyeong-Eon; Sohn, Ju-Tae; Jeong, Young Seok; Sung, Hui-Jin; Shin, Il-Woo; Lee, Heon-Keun; Chung, Young-Kyun] Gyeongsang Natl Univ, Sch Med, Dept Anesthesiol & Pain Med, Jinju, South Korea; [Sohn, Ju-Tae] Gyeongsang Natl Univ, Sch Med, Inst Hlth Sci, Jinju, South Korea	Sohn, JT (reprint author), Gyeongsang Natl Univ Hosp, Dept Anesthesiol & Pain Med, 90 Chilam Dong, Jinju 660702, South Korea.	jtsohn@nongae.gsnu.ac.kr					Arevalo-Leon LE, 2003, VASC PHARMACOL, V40, P91, DOI 10.1016/S1537-1891(02)00336-1; Artru AA, 2001, ANESTHESIA NEUROSURG, P84; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Asbun-Bojalil J, 2002, VASC PHARMACOL, V38, P169, DOI 10.1016/S1537-1891(02)00164-7; BLAISE GA, 1990, ANESTHESIOLOGY, V72, P535, DOI 10.1097/00000542-199003000-00023; Buckner SA, 1996, EUR J PHARMACOL, V297, P241, DOI 10.1016/0014-2999(95)00755-5; Christensen KL, 2001, J VASC RES, V38, P1, DOI 10.1159/000051024; Deng XF, 1996, BRIT J PHARMACOL, V119, P269, DOI 10.1111/j.1476-5381.1996.tb15981.x; Errasti AE, 1999, BRIT J PHARMACOL, V126, P437, DOI 10.1038/sj.bjp.0702320; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; Fagura MS, 1997, BRIT J PHARMACOL, V120, P247, DOI 10.1038/sj.bjp.0700917; FLACKE JW, 1985, ANESTH ANALG, V64, P1053; FORRAY C, 1994, MOL PHARMACOL, V45, P703; FREYE E, 1974, ANESTH ANALG, V53, P40; GOETZ AS, 1995, EUR J PHARMACOL, V272, pR5, DOI 10.1016/0014-2999(94)00751-R; GRAVES CL, 1975, ANESTH ANALG, V54, P15; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Hussain MB, 1997, BRIT J PHARMACOL, V122, P849, DOI 10.1038/sj.bjp.0701461; KARASAWA F, 1993, BRIT J ANAESTH, V71, P877, DOI 10.1093/bja/71.6.877; Kawakubo A, 1999, J Anesth, V13, P77; KENNY BA, 1995, BRIT J PHARMACOL, V115, P981, DOI 10.1111/j.1476-5381.1995.tb15907.x; Low AM, 1998, J PHARMACOL EXP THER, V285, P894; Maruyama K, 1998, PHARMACOLOGY, V57, P88, DOI 10.1159/000028229; Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9; Saussy DL, 1996, J PHARMACOL EXP THER, V278, P136; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; Sohn JT, 2005, ANESTHESIOLOGY, V103, P327, DOI 10.1097/00000542-200508000-00016; Sohn JT, 2004, ANESTHESIOLOGY, V101, P89, DOI 10.1097/00000542-200407000-00015; Suzer O, 1998, EUR J ANAESTH, V15, P480; TODA N, 1977, ANESTHESIOLOGY, V46, P411, DOI 10.1097/00000542-197706000-00007; VARGAS HM, 1995, LIFE SCI, V57, P2291, DOI 10.1016/0024-3205(95)02224-7; WYNANDS JE, 1983, ANESTH ANALG, V62, P661	33	4	4	0	1	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	JUN 30	2009	50	3					414	421		10.3349/ymj.2009.50.3.414			8	Medicine, General & Internal	General & Internal Medicine	462DF	WOS:000267325500016	19568605	DOAJ Gold, Green Published			2020-06-30	J	Martinez, MA; Murison, PJ; Love, E				Martinez, M. A.; Murison, P. J.; Love, E.			Induction of anaesthesia with either midazolam or propofol in rabbits premedicated with fentanyl/fluanisone	VETERINARY RECORD			English	Article							ISOFLURANE; BUTORPHANOL; HALOTHANE; DIAZEPAM; FENTANYL	Fifty-four rabbits that were to be neutered were premedicated with 0.1 ml/kg fentanyl/fluanisone and then randomly allocated to be anaesthetised with either midazolam or propofol. Anaesthesia was then maintained with isoflurane. The ease of orotracheal intubation, the rabbits' cardiorespiratory variables, and the speed and quality of recovery from anaesthesia were assessed by the same anaesthetist who was unaware of the induction agent used. Hypotension was common in both groups. The mean (sd) respiratory rates were 30 (12) breaths per minute in the midazolam group and 43 (15) breaths per minute in the propofol group. The mean (sd) time to first head lift was 36 (21) minutes in the midazolam group and 14 (11) minutes in the propofol group, and the mean (sd) times to the return of the righting reflex were 35 (19) minutes and 15 (eight) minutes, respectively. The quality of recovery was better in the propofol group than in the midazolam group.	[Martinez, M. A.; Murison, P. J.; Love, E.] Univ Bristol, Dept Clin Vet Med, Langford BS40 5DU, England	Martinez, MA (reprint author), Chestergates Referral Hosp, Telford Court CH1 6LT, Chestergates, England.	mamfer2000@hotmail.com					AESCHBACHER G, 1993, LAB ANIM SCI, V43, P324; [Anonymous], ASA PHYS STAT CLASS; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Caulkett NA, 1998, VET SURG, V27, P370, DOI 10.1111/j.1532-950X.1998.tb00143.x; EDMONDSSEAL J, 1970, BRIT J ANAESTH, V42, P207, DOI 10.1093/bja/42.3.207; EVERS AS, 2006, GOODMAN GILMANS PHAR, P361; Flecknell P, 2006, BSAVA MANUAL RABBIT, P154; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; Gil AG, 2005, VET REC, V157, P589; Grint NJ, 2008, VET ANAESTH ANALG, V35, P113, DOI 10.1111/j.1467-2995.2007.00362.x; Gross ME, 2002, J AM ANIM HOSP ASSOC, V38, P503, DOI 10.5326/0380503; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P571; HEXEBERG E, 1995, LAB ANIM, V29, P400, DOI 10.1258/002367795780740069; Imai A, 1999, AM J VET RES, V60, P1189; Kim C, 2006, ACTA ANAESTH SCAND, V50, P144, DOI 10.1111/j.1399-6576.2005.00896.x; Ma D, 1998, ACTA ANAESTH SCAND, V42, P670, DOI 10.1111/j.1399-6576.1998.tb05300.x; MURPHY PJ, 1994, ANAESTHESIA, V49, P105, DOI 10.1111/j.1365-2044.1994.tb03363.x; PEETERS ME, 1988, LAB ANIM, V22, P355, DOI 10.1258/002367788780746197; RICHARDSON V, 2000, RABBITS HLTH HUSBAND, P146; Turner PV, 2006, AM J VET RES, V67, P770, DOI 10.2460/ajvr.67.5.770	20	11	11	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0042-4900	2042-7670		VET REC	Vet. Rec.	JUN 27	2009	164	26					803	806		10.1136/vr.164.26.803			4	Veterinary Sciences	Veterinary Sciences	467DJ	WOS:000267716700013	19561349				2020-06-30	J	Bauer, MD; Clark-Price, SC; McFadden, MS				Bauer, Matthew D.; Clark-Price, Stuart C.; McFadden, Michael S.			Anesthesia Case of the Month	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Editorial Material							TRACHEAL RUPTURE; CATS		[Bauer, Matthew D.; Clark-Price, Stuart C.; McFadden, Michael S.] Univ Illinois, Dept Vet Clin Med, Coll Vet Med, Urbana, IL 61801 USA	Clark-Price, SC (reprint author), Univ Illinois, Dept Vet Clin Med, Coll Vet Med, Urbana, IL 61801 USA.						Hardie EM, 1999, J AM VET MED ASSOC, V214, P508; Mitchell SL, 2000, J AM VET MED ASSOC, V216, P1592, DOI 10.2460/javma.2000.216.1592; Roach W, 2009, COMPENDIUM, V31, P86; SEYMOUR C, 2007, BSAVA MANUAL CANINE, P145; TRANQUILLI WJ, 2007, LUMB JONES VET ANEST, P291	5	5	5	0	1	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488	1943-569X		JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	JUN 15	2009	234	12					1539	1541		10.2460/javma.234.12.1539			3	Veterinary Sciences	Veterinary Sciences	457QC	WOS:000266946100021	19527126				2020-06-30	J	Biedrzycki, OJ; Bevan, D; Lucas, S				Biedrzycki, Olaf J.; Bevan, David; Lucas, Sebastian			Fatal Overdose Due to Prescription Fentanyl Patches in a Patient With Sickle Cell/beta-Thalassemia and Acute Chest Syndrome A Case Report and Review of the Literature	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						fentanyl; Duragesic patch; overdose; sickle cell/beta-thalassemia	TRANSDERMAL FENTANYL; DEATHS; ABUSE; DRUG; PHARMACOKINETICS	Introduced into clinical practice in the 1960s, the analgesic fentanyl is 100 times more potent than morphine. Various methods of administration exist including the transdermal Duragesie patch system, widely used in chronic pain and palliative care settings. Numerous, Offers imaginative methods of abuse of fentanyl patches have been reported; the majority of fatal fentanyl overdose cases resulting from deliberate abuse or suicide. We describe the accidental overdose of a young black ale with sickle cell/beta-thalassemia who had been using the Duragesic system for almost 2 years. At autopsy the macroscopic findings were of nonspecific opiate overdose with congested heavy lungs. Histopathological examination revealed severe sickling of red blood cells in the lungs (acute chest syndrome). Toxicological examination revealed blood and urine fentanyl levels of 40 mu g/L and 400 mu g/L (10 fold and 100 told higher than therapeutic levels). The niast cell tryptase was also significantly elevated at 76 mu g/L, (Normal 2-14 mu g/L). We discuss the relevance of these findings with regard to the cause of death, and stress the need to consider fentanyl when confronted with nonspecific signs, of opiate overdose as it is not detected in routine toxicological drug screens.	[Biedrzycki, Olaf J.; Lucas, Sebastian] Kings Coll London, Sch Med, St Thomas Hosp, Dept Histopathol, London SE1, England; [Bevan, David] St George Hosp, Dept Haematol, London, England	Biedrzycki, OJ (reprint author), Kings Coll London, Sch Med, St Thomas Hosp, Dept Histopathol, London SE1, England.	olafbiedrzycki@aol.com					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; ANDREWS CJH, 1983, BRIT J ANAESTH, V55, pS211; Barrueto F, 2004, VET HUM TOXICOL, V46, P30; Blunk JA, 2004, ANESTH ANALG, V98, P364, DOI 10.1213/01.ANE.0000097168.32472.0D; Christensen ML, 1996, J PEDIAT HEMATOL ONC, V18, P372, DOI 10.1097/00043426-199611000-00007; Edston E, 1997, ALLERGY, V52, P950, DOI 10.1111/j.1398-9995.1997.tb01256.x; Fineschi V, 2001, FORENSIC SCI INT, V120, P189, DOI 10.1016/S0379-0738(00)00469-2; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; FUNG DL, 1980, J CLIN PHARMACOL, V20, P652, DOI 10.1002/j.1552-4604.1980.tb01682.x; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; JACKSON FW, 1994, GASTROENTEROLOGY, V106, P820, DOI 10.1016/0016-5085(94)90729-3; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; KARCH SB, 2002, KARCHS PATHOLOGY DRU; Karst M, 2001, PAIN MED, V2, P225, DOI 10.1046/j.1526-4637.2001.01028.x; KISSIN W, 2000, DRUG ABUSE WARNING N; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; LUCAS SB, 2003, CLIN MANAGEMENT HAEM; LUNN JK, 1979, ANESTH ANALG, V58, P390; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Reeves MD, 2003, MED J AUSTRALIA, V178, P526, DOI 10.5694/j.1326-5377.2003.tb05342.x; Shaiova L, 2004, J NATL MED ASSOC, V96, P984; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11	28	19	19	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	JUN	2009	30	2					188	190		10.1097/PAF.0b013e318187de71			3	Medicine, Legal; Pathology	Legal Medicine; Pathology	451PW	WOS:000266483100018	19465816				2020-06-30	J	Ren, J; Ding, XQ; Funk, GD; Greer, JJ				Ren, Jun; Ding, Xiuqing; Funk, Gregory D.; Greer, John J.			Ampakine CX717 Protects against Fentanyl-induced Respiratory Depression and Lethal Apnea in Rats	ANESTHESIOLOGY			English	Article							INDUCED MUSCULAR RIGIDITY; EXCITATORY AMINO-ACIDS; PRE-BOTZINGER COMPLEX; PREBOTZINGER COMPLEX; MODULATION; NEURONS; BUPRENORPHINE; TRANSMISSION; STIMULATION; INVOLVEMENT	Background: The use of fentanyl as a potent analgesic is contradicted by marked respiratory depression among a subpopulation of patients. The commonly used approach of reversing fentanyl-induced respiratory depression with mu-opiate receptor antagonists such as naloxone has the undesirable effect of blocking analgesia. Here, the authors report a clinically feasible pharmacological solution for countering fentanyl-induced respiratory depression via a mechanism that does not interfere with analgesia. Specifically, to determine if the ampakine CX717, which has been proven metabolically stable and safe for human use, can prevent and rescue from severe fentanyl-induced apnea. Methods: Plethsymographic recordings were performed from young and adult rats. Varying doses of fentanyl were administered either intraperitoneally or intravenously to induce moderate to life-threatening apneas. CX717 was administered either before or after fentanyl administration. In addition, phrenic nerve recordings were performed from in situ working heart brainstem preparations from juvenile rats. Results: Preadministration of CX717 markedly attenuated fentanyl-induced respiratory depression. Postadministration of CX717 rescued animals from a lethal dose of fentanyl. Significantly, CX717 countered fentanyl-induced depression of respiratory frequency without suppressing analgesia. The effective dose of CX717 was in the range deemed safe on the basis of clinical trials examining its efficacy for cognitive disorders. lit situ, fentanyl-induced depression in respiratory frequency and amplitude was alleviated by CX717. Conclusions: CX717 is an agent that enhances the safety of using opiate drugs while preserving the analgesic effects. This advancement could significantly improve pain management in a variety of clinical settings.	[Greer, John J.] Univ Alberta, Ctr Neurosci, Dept Physiol, Div Neurosci, Edmonton, AB T6G 2S2, Canada	Greer, JJ (reprint author), Univ Alberta, Ctr Neurosci, Dept Physiol, Div Neurosci, 513 HMRC, Edmonton, AB T6G 2S2, Canada.	john.greer@ualberta.ca		Funk, Gregory/0000-0001-5848-0631	Canadian Institutes for Health Research (Ottawa, Ontario, Canada)Canadian Institutes of Health Research (CIHR); Cortex Pharmaceuticals (Irvine, California); Alberta Science anti Research Authority (Edmonton, Alberta, Canada)	Received from the Department of physiology, Division of Neuroscience, University of Alberta, Edmonton, Alberta, Canada. Submitted for publication June 26, 2008. Accepted for publication December 4, 2008. Supported by the Canadian Institutes for Health Research (Ottawa, Ontario, Canada), Cortex Pharmaceuticals (Irvine, California), and the Alberta Science anti Research Authority (Edmonton, Alberta, Canada). Dr. Ren received Studentships from the Alberta Heritage Foundation for Medical Research (Edmonton. Alberta, Canada) and Canadian Institutes for Health Research. Drs. Greer and Funk are Scientists of the Alberta Heritage Foundation for Medical Research.	ADLER LA, 2006, 53 ANN M AM AC CHI A, V42; Arai AC, 2004, NEUROSCIENCE, V123, P1011, DOI 10.1016/j.neuroscience.2003.10.033; BENVENGA MJ, 1992, J PHARMACOL TOXICOL, V27, P45, DOI 10.1016/1056-8719(92)90020-2; Colman AS, 2001, RESP PHYSIOL, V127, P157, DOI 10.1016/S0034-5687(01)00240-7; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Desrosiers Gyslaine, 2006, Perspect Infirm, V4, P6; Doraiswamy PM, 2006, EXPERT OPIN PHARMACO, V7, P1, DOI 10.1517/14656566.7.1.1; Feldman JL, 2006, NAT REV NEUROSCI, V7, P232, DOI 10.1038/nrn1871; Ferguson LM, 2006, BRIT J ANAESTH, V96, P384, DOI 10.1093/bja/ael011; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497; FUNK GD, 1995, J NEUROSCI, V15, P4046; Gray PA, 2001, NAT NEUROSCI, V4, P927, DOI 10.1038/nn0901-927; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; JERUSSI TP, 1987, PHARMACOL BIOCHEM BE, V28, P283, DOI 10.1016/0091-3057(87)90226-7; Laferriere A, 2005, DEV BRAIN RES, V156, P210, DOI 10.1016/j.devbrainres.2005.03.002; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; LENAL FC, 2007, 37 ANN M SOC NEUR, V597; Lynch G, 2006, CURR OPIN PHARMACOL, V6, P82, DOI 10.1016/j.coph.2005.09.005; Pace RW, 2007, J PHYSIOL-LONDON, V582, P113, DOI 10.1113/jphysiol.2007.133660; Porrino LJ, 2005, PLOS BIOL, V3, P1639, DOI 10.1371/journal.pbio.0030299; Ren J, 2006, AM J RESP CRIT CARE, V174, P1384, DOI 10.1164/rccm.200606-778OC; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Solomon IC, 1999, J NEUROPHYSIOL, V81, P1150; Swarm RA, 2001, CURR PROB SURG, V38, P845, DOI 10.1067/msg.20011.118495; Thompson CA, 2007, AM J HEALTH-SYST PH, V64, P798, DOI 10.2146/news070035; Wesensten NJ, 2007, AVIAT SPACE ENVIR MD, V78, P937, DOI 10.3357/ASEM.2055.2007; Yassen A, 2006, J PHARMACOL EXP THER, V319, P682, DOI 10.1124/jpet.106.107953	31	56	58	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUN	2009	110	6					1364	1370		10.1097/ALN.0b013e31819faa2a			7	Anesthesiology	Anesthesiology	450ET	WOS:000266384500024	19461299	Bronze			2020-06-30	J	Rim, JE; Pinsky, PM; van Osdol, WW				Rim, Jee E.; Pinsky, Peter M.; van Osdol, William W.			Multiscale Modeling Framework of Transdermal Drug Delivery	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Fentanyl; Permeation enhancer; Oleic acid; Multiscale; Molecular dynamics; Homogenization; Finite element method	MOLECULAR-DYNAMICS SIMULATIONS; HUMAN STRATUM-CORNEUM; EPIDERMAL PERMEABILITY BARRIER; LIPID BILAYER-MEMBRANES; EFFECTIVE DIFFUSIVITY; LATERAL DIFFUSION; SOLUTE DIFFUSION; HUMAN-SKIN; PERMEATION; ABSORPTION	This study addresses the modeling of transdermal diffusion of drugs to better understand the permeation of molecules through the skin, especially the stratum corneum, which forms the main permeation barrier to percutaneous permeation. In order to ensure reproducibility and predictability of drug permeation through the skin and into the body, a quantitative understanding of the permeation barrier properties of the stratum corneum (SC) is crucial. We propose a multiscale framework of modeling the multicomponent transdermal diffusion of molecules. The problem is divided into subproblems of increasing length scale: microscopic, mesoscopic, and macroscopic. First, the microscopic diffusion coefficient in the lipid bilayers of the SC is found through molecular dynamics (MD) simulations. Then, a homogenization procedure is performed over a model unit cell of the heterogeneous SC, resulting in effective diffusion parameters. These effective parameters are the macroscopic diffusion coefficients for the homogeneous medium that is "equivalent" to the heterogeneous SC, and thus can be used in finite element simulations of the macroscopic diffusion process. The resulting drug flux through the skin shows very reasonable agreement to experimental data.	[Rim, Jee E.] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA; [Pinsky, Peter M.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [van Osdol, William W.] ALZA Corp, Mountain View, CA 94039 USA	Rim, JE (reprint author), Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA.	jrim@ucla.edu			ALZA Corporation	One of the authors (J.E.R.) is grateful for the financial support from ALZA Corporation that permitted this study. The molecular dynamics study was possible due to the computing resources of the Center for Biomedical Computing at Stanford University. The authors thank the reviewers for their detailed comments and suggestions.	ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; ALPER HE, 1995, J PHYS CHEM-US, V99, P5724, DOI 10.1021/j100015a065; Anezo C, 2003, J PHYS CHEM B, V107, P9424, DOI 10.1021/jp0348981; BARRY BW, 1991, J CONTROL RELEASE, V15, P237, DOI 10.1016/0168-3659(91)90115-T; BASSOLINOKLIMAS D, 1993, BIOCHEMISTRY-US, V32, P12624, DOI 10.1021/bi00210a010; BASSOLINOKLIMAS D, 1995, J AM CHEM SOC, V117, P4118, DOI 10.1021/ja00119a028; Berendsen H., 1981, INTERMOLECULAR FORCE, P331, DOI DOI 10.1007/978-94-015-7658-1_21; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; Brannigan G, 2006, EUR BIOPHYS J BIOPHY, V35, P104, DOI 10.1007/s00249-005-0013-y; CHANDRASEKARAN SK, 1976, AICHE J, V22, P828, DOI 10.1002/aic.690220503; Chi SC, 1995, INT J PHARM, V126, P267, DOI 10.1016/0378-5173(95)04137-0; CUSSLER EL, 1988, J MEMBRANE SCI, V38, P161, DOI 10.1016/S0376-7388(00)80877-7; Demmel JW, 1999, SIAM J MATRIX ANAL A, V20, P915, DOI 10.1137/S0895479897317685; ELIAS PM, 1991, ADV LIPID RES, V24, P1; Falla WR, 1996, J MEMBRANE SCI, V119, P129, DOI 10.1016/0376-7388(96)00106-8; Flynn GL, 1985, PERCUTANEOUS ABSORPT, P17; Frasch HF, 2003, J PHARM SCI-US, V92, P2196, DOI 10.1002/jps.10466; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Holtje M, 2001, BBA-BIOMEMBRANES, V1511, P156, DOI 10.1016/S0005-2736(01)00270-X; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Johnson ME, 1997, J PHARM SCI, V86, P1162, DOI 10.1021/js960198e; Johnson ME, 1996, BIOPHYS J, V71, P2656, DOI 10.1016/S0006-3495(96)79457-2; KITSON N, 1994, BIOCHEMISTRY-US, V33, P6707, DOI 10.1021/bi00187a042; KUBOTA K, 1985, J PHARMACOKINET BIOP, V13, P55, DOI 10.1007/BF01073656; KUBOTA K, 1992, MATH BIOSCI, V108, P157, DOI 10.1016/0025-5564(92)90054-Z; LIECKFELDT R, 1995, J PHARM PHARMACOL, V47, P26, DOI 10.1111/j.2042-7158.1995.tb05728.x; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Marrink SJ, 1996, J PHYS CHEM-US, V100, P16729, DOI 10.1021/jp952956f; MICHAELS AS, 1975, AICHE J, V21, P985, DOI 10.1002/aic.690210522; ONGPIPATTANAKUL B, 1994, BBA-BIOMEMBRANES, V1190, P115, DOI 10.1016/0005-2736(94)90040-X; PHIPPS B, 2004, ENCY BIOMATERIALS BI; POTTS RO, 1991, J INVEST DERMATOL, V96, P495, DOI 10.1111/1523-1747.ep12470197; Rim JE, 2005, ANN BIOMED ENG, V33, P1422, DOI 10.1007/s10439-005-5788-6; Rim JE, 2008, J BIOMECH, V41, P788, DOI 10.1016/j.jbiomech.2007.11.011; Rim JE, 2007, J MEMBRANE SCI, V293, P174, DOI 10.1016/j.memsci.2007.02.018; Scheuplein KJ, 1983, BIOCH PHYSL SKIN, V11, P1255; Sinha VR, 2000, DRUG DEV IND PHARM, V26, P1131, DOI 10.1081/DDC-100100984; SMIT B, 1996, [No title captured]; SWARTZENDRUBER DC, 1989, J INVEST DERMATOL, V92, P251, DOI 10.1111/1523-1747.ep12276794; Talreja PS, 2001, AAPS PHARMSCI, V3; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WANG TF, 2003, THESIS STATE U NEW Y	43	30	30	1	24	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964			ANN BIOMED ENG	Ann. Biomed. Eng.	JUN	2009	37	6					1217	1229		10.1007/s10439-009-9678-1			13	Engineering, Biomedical	Engineering	441RC	WOS:000265787100015	19319682	Other Gold			2020-06-30	J	Hennebry, MC; Stocks, GM; Belavadi, P; Barnes, J; Wray, S; Columb, MO; Lyons, G				Hennebry, M. C.; Stocks, G. M.; Belavadi, P.; Barnes, J.; Wray, S.; Columb, M. O.; Lyons, G.			Effect of i.v. phenylephrine or ephedrine on the ED50 of intrathecal bupivacaine with fentanyl for Caesarean section	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques; subarachnoid; surgery; Caesarean section; sympathetic nervous system; phenylephrine; sympathetic nervous system; ephedrine	PROPHYLACTIC INTRAVENOUS EPHEDRINE; SPINAL-ANESTHESIA; HYPOTENSION; DELIVERY; INFUSION; SPREAD; FETAL; VASOPRESSOR; METARAMINOL; PREVENTION	Prophylactic infusion of phenylephrine to prevent hypotension at Caesarean section has been shown to decrease the rostral spread of intrathecal plain levobupivacaine and intrathecal hyperbaric bupivacaine by a median of two dermatomes compared with ephedrine. The aim of this study was to determine the median effective dose (ED50) of intrathecal bupivacaine required to achieve a block to touch at the xiphisternum in patients undergoing Caesarean section when phenylephrine or ephedrine are used to prevent hypotension. Seventy women were randomized in two groups to receive either phenylephrine at a rate of 16.6 mu g min(-1) (concentration 1 mu g ml(-1)) or ephedrine at a rate of 1.5 mg min(-1) (concentration 90 mu g ml(-1)). Patients received varying doses of hyperbaric bupivacaine with fentanyl 25 mu g using a double-blinded, up-down sequential allocation design. Effective doses were defined as anaesthesia to touch with ethyl chloride spray to the xiphisternum within 20 min. The ED50 estimates of bupivacaine were similar in the two groups: 7.8 mg [95% confidence interval (CI) 6.7-8.9] with phenylephrine and 7.6 mg (95% CI 6.8-8.4) with ephedrine. Systolic blood pressure control was similar (P=0.18) with vasopressors but heart rate was higher with ephedrine (P=0.0014). Under the conditions of this study, we have shown that when phenylephrine or ephedrine were used to prevent post-spinal hypotension, the dosing requirement of hyperbaric bupivacaine was similar for intrathecal anaesthesia.	[Hennebry, M. C.; Stocks, G. M.; Belavadi, P.; Barnes, J.; Wray, S.] Queen Charlottes & Chelsea Hosp, Dept Anaesthesia, London W12 0HS, England; [Columb, M. O.] Univ S Manchester Hosp, Wythenshawe, England; [Lyons, G.] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England	Stocks, GM (reprint author), Queen Charlottes & Chelsea Hosp, Dept Anaesthesia, Du Cane Rd, London W12 0HS, England.	gary.stocks@imperial.nhs.uk	Columb, Malachy/F-9588-2016	Columb, Malachy/0000-0001-7837-4262	UK National Institute for Health Research Biomedical Research CentreNational Institute for Health Research (NIHR); Obstetric Anaesthetists Association	The authors are grateful for the support of the UK National Institute for Health Research Biomedical Research Centre Funding Scheme and to the Obstetric Anaesthetists Association for a research grant.	Beale N, 2005, BRIT J ANAESTH, V95, P500, DOI 10.1093/bja/aei200; Cooper DW, 2007, BRIT J ANAESTH, V98, P649, DOI 10.1093/bja/aem056; Cooper DW, 2004, ANESTHESIOLOGY, V101, P28, DOI 10.1097/00000542-200407000-00007; Cooper DW, 2002, ANESTHESIOLOGY, V97, P1582, DOI 10.1097/00000542-200212000-00034; HALL PA, 1994, BRIT J ANAESTH, V73, P471, DOI 10.1093/bja/73.4.471; Hirabayashi Y, 1997, BRIT J ANAESTH, V78, P317; Igarashi T, 2000, ANESTHESIOLOGY, V92, P1631, DOI 10.1097/00000542-200006000-00021; JAMES FM, 1970, ANESTHESIOLOGY, V33, P25, DOI 10.1097/00000542-197007000-00010; KANG YG, 1982, ANESTH ANALG, V61, P839; Kee WDN, 2004, ANESTH ANALG, V98, P815; Kee WDN, 2003, ANAESTHESIA, V58, P125, DOI 10.1046/j.1365-2044.2003.02888.x; Kee WDN, 2001, ANESTHESIOLOGY, V95, P307; Kee WDN, 2000, ANESTH ANALG, V90, P1390, DOI 10.1097/00000539-200006000-00024; Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028; Ngan Kee WD, 2008, ANESTH ANALG, V107, P1295, DOI 10.1213/ane.0b013e31818065bc; Panni MK, 2006, BRIT J ANAESTH, V96, P106, DOI 10.1093/bja/aei284; PITKANEN MT, 1987, ANESTH ANALG, V66, P127, DOI 10.1213/00000539-198702000-00005; RALSTON DH, 1974, ANESTHESIOLOGY, V40, P354, DOI 10.1097/00000542-197404000-00009; Saravanan S, 2006, BRIT J ANAESTH, V96, P95, DOI 10.1093/bja/aei265	19	9	16	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JUN	2009	102	6					806	811		10.1093/bja/aep095			6	Anesthesiology	Anesthesiology	449QG	WOS:000266344500014	19411667	Bronze			2020-06-30	J	Weinstein, SM; Messina, J; Xie, F				Weinstein, Sharon M.; Messina, John; Xie, Fang			Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Cancer Pain A Long-term, Open-Label Safety Study	CANCER			English	Article						breakthrough pain; cancer pain; fentanyl buccal tablet; opioid; long-term therapy; safety; tolerability	PREVALENCE	BACKGROUND: This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients). METHODS: Patients who were FBT-naive underwent titration to find a successful FBT dose. Rollover patients used a previously identified successful dose of FBT. Patients who achieved a successful dose were eligible to enter a maintenance phase (>= 12 months). Safety assessments included adverse events (AEs), physical and neurologic examinations, and clinical laboratory tests. RESULTS: Two hundred thirty-two patients were enrolled. A total of 112 entered titration; 79 identified a successful FBT dose, and 77 of these patients entered the maintenance phase along with 120 rollover patients (n=197). AEs resulted in discontinuation of therapy for 33% of patients. The most common AEs were generally typical of opioids administered to cancer patients. All serious AEs were considered to be related to the patients' underlying conditions, except for I incident of FBT-related drug withdrawal syndrome. Sixty patients died after enrollment because of disease progression. Fifteen (6%) patients experienced >= 1 application-site AE, all of which were considered by investigators to be related to FBT. CONCLUSIONS: FBT was generally well tolerated and had a favorable safety profile in the long-term (>= 12 months) management of patients with persistent cancer pain and BTP. No unexpected AEs occurred. Safety and tolerability was similar to that observed in short-term studies. Cancer 2009;115:2571-9. (C) 2009 American Cancer Society.	[Weinstein, Sharon M.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Messina, John; Xie, Fang] Cephalon Inc, Frazer, PA USA	Weinstein, SM (reprint author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Room 2151, Salt Lake City, UT 84112 USA.	sharon.weinstein@hci.utah.edu			Cephalon, Inc.	This study was sponsored by Cephalon, Inc. Writing assistance was provided by Embryon. Drs. Messina and Xie are both employees of Cephalon, Inc.	[Anonymous], 1996, ICH HARM TRIP GUID G; BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Collett BJ, 1998, BRIT J ANAESTH, V81, P58; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; MIASKOWSKI C, 2005, [No title captured], V3; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	16	49	52	0	1	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0008-543X			CANCER	Cancer	JUN 1	2009	115	11					2571	2579		10.1002/cncr.24279			9	Oncology	Oncology	448ZJ	WOS:000266300200024	19373888				2020-06-30	J	Kress, HG; Oronska, A; Kaczmarek, Z; Kaasa, S; Colberg, T; Nolte, T				Kress, Hans Georg; Oronska, Anna; Kaczmarek, Zbigniew; Kaasa, Stein; Colberg, Torben; Nolte, Thomas			Efficacy and Tolerability of Intranasal Fentanyl Spray 50 to 200 mu g for Breakthrough Pain in Patients With Cancer: A Phase III, Multinational, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial With a 10-Month, Open-Label Extension Treatment Period	CLINICAL THERAPEUTICS			English	Article						breakthrough cancer pain; fentanyl; intranasal administration; pain reduction	POSTOPERATIVE PAIN; ORAL MORPHINE; EUROPEAN-ASSOCIATION; NASAL FENTANYL; ANALGESIA; MANAGEMENT; PREVALENCE; CITRATE; PHARMACOKINETICS; ACCEPTABILITY	Objective: This trial investigated the efficacy and long-term tolerability of intranasal fentanyl spray (INFS) 50 to 200 mu g in the treatment of breakthrough pain in opioid-tolerant patients with cancer. Methods: This Phase III, double-blind, randomized, placebo-controlled, crossover trial was conducted at pain centers, anesthesiology departments, palliative care units, and oncology clinics in Austria, Denmark, France, German),, and Poland. Eligible patients were adults with cancer receiving a stable dose of long-term opioid treatment for the control of background pain. Patients were treated at home with their effective dose of INFS (50, 100, or 200 mu g) or inactive spray (placebo) in a randomized sequence for 3 weeks, followed by a 10-month, open-label tolerability phase during which they received their effective dose of INFS. Throughout the Study, patients were allowed to use their usual rescue medication, which was recorded in patient diaries. The primary efficacy end point was the pain intensity difference at 10 minutes after study drug administration (PID10), as assessed using an 11-point numeric rating scale (0 = no pain to 10 = worst pain imaginable). An effect size of 0.5 for PID was considered clinically relevant. The rate of response, defined as PID10 >2, was also assessed. Adverse events (AEs) were recorded in patient diaries during the efficacy period and reported in monthly clinic visits and follow-up weekly telephone contacts during the extension period. Results: In all, 120 patients were enrolled and achieved an effective dose; 113) were randomized and 111 were Included in the intent-to-treat analysis set (56 men, 55 women; mean [SD] age, 60.6 [9.45] years; mean weight, 70.3 kg [men] and 65.3 kg [women]; white race, 107 [96.4%]; INFS 50 [mu g, 18; INFS 100 mu g, 48; INFS 200 mu g, 45; placebo, 110). PID10 with INFS was 2-fold that with placebo (adjusted means, 2.36 vs 1.10; adjusted difference, 1.26 [greater than the clinically relevant difference of 0.5]; P < 0.001). Additional analysis revealed that the mean response rate with all 3 doses of INFS was 51.1% versus 20.9% with placebo. The prevalence of AEs was 22/111 (19.8%)) during the efficacy period, during which the most frequently reported AEs were nausea (5 [4.5%]) and vertigo (2 [1.8%]). No serious AEs were considered related to the study drugs. In all, 108 patients entered the extension period, with a mean duration of exposure to INFS of 134.9 days. Progression Of Underlying malignant disease was the most common AE reported during this period (55 [50.9%]); this event was not considered treatment related. Conclusions: In these opioid-tolerant patients with cancer, INFS at doses of 50, 100, and 200 mu g was associated with all onset of activity at 10 minutes and effective treatment of breakthrough pain compared with placebo. All doses were generally well tolerated and clinically efficacious. (Clin Ther. 2009;31:1177-1191) (C) 2009 Excerpta Medica Inc.	[Kress, Hans Georg] Med Univ, AKH Vienna, Dept Special Anesthesia & Pain Therapy, A-1090 Vienna, Austria; [Oronska, Anna] Outpatient Ctr, Dolnoslaskie Oncol Ctr, Wroclaw, Poland; [Kaczmarek, Zbigniew] Polish Palliat Assoc, Wloclawek, Poland; [Kaasa, Stein] St Olavs Hosp, Sect Palliat Care Kreftavdelingen, Trondheim, Norway; [Kaasa, Stein] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7034 Trondheim, Norway; [Colberg, Torben] Nycomed Danmark, Res & Dev, Roskilde, Denmark; [Nolte, Thomas] Med Specialists Ctr, Ctr Pain Therapy & Palliat Care, Wiesbaden, Germany	Kress, HG (reprint author), Med Univ, AKH Vienna, Dept Special Anesthesia & Pain Therapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	hans-georg.kress@meduniwien.ac.at			Ny-comed Danmark	This research and Its publication were funded by Ny-comed Danmark.	*ACT, [No title captured]; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; BREITBART W, 2000, ONCOLOGY HUNTINGT, V14, P705; Breitbart W, 2000, ONCOLOGY HUNTINGT, V14, P9; Chaushu G, 2000, CANCER, V88, P984, DOI 10.1002/(SICI)1097-0142(20000301)88:5<984::AID-CNCR6>3.3.CO;2-S; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Collins SL, 2001, PAIN, V91, P189, DOI 10.1016/S0304-3959(00)00435-8; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; *FENT, FENT MED GUID FENT B; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Klepstad P, 2005, PALLIATIVE MED, V19, P477, DOI 10.1191/0269216305pm1054oa; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Prescott R, 2006, APPL MIXED MODELS ME; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; Sweeney MP, 1998, ORAL ONCOL, V34, P123, DOI 10.1016/S1368-8375(97)00076-6; THOMPSON J, 1990, CLIN PHARM OPIOID AG, P117; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; *US FDA, MED DICT REG ACT; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; *WORLD MED ASS DEC, 1964, ETH PRINC MED RES IN; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500; Zeppetella G, 2001, J PAIN SYMPTOM MANAG, V21, P265; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	49	98	99	0	10	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	JUN	2009	31	6					1177	1191		10.1016/j.clinthera.2009.05.022			15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	475HF	WOS:000268348500004	19695386				2020-06-30	J	Rothman, M; Vallow, S; Damaraju, CV; Hewitt, DJ				Rothman, Margaret; Vallow, Sue; Damaraju, C. V.; Hewitt, David J.			Using the patient global assessment of the method of pain control to assess new analgesic modalities in clinical trials	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Outcome measure; Patient-controlled analgesia; Validation study	IONTOPHORETIC TRANSDERMAL SYSTEM; PLACEBO-CONTROLLED TRIAL; POSTOPERATIVE PAIN; ORTHOPEDIC-SURGERY; DOUBLE-BLIND; MANAGEMENT; FENTANYL; SATISFACTION; EFFICACY; SAFETY	Objective: To assess the validity of the patient global assessment (PGA) of the method of pain control, a single-item patient-reported outcome measure of a method of pain control for patients experiencing postoperative pain. Research design and methods: Content validity of the PGA of the method of pain control was assessed using cognitive debriefing interviews. Construct validity was evaluated using data from six clinical trials that compared the efficacy of the fentanyl HCl iontophoretic transdermal system (fentanyl ITS) with morphine intravenous patientcontrolled analgesia or placebo fentanyl ITS for acute postoperative pain management. Main outcome measures: To assess the construct validity of the PGA rating scale, four hypotheses were developed that related positive PGA ratings ('good' or 'excellent') to (1) lower pain intensity scores, (2) higher satisfaction ratings, (3) a greater propensity to select the assigned pain control method in the future, and (4) favorable ratings of ease of use/convenience on the Patient Ease-of-Care Questionnaire. Descriptive statistics were used to evaluate the association of pain intensity and Overall Ease-of-Care scores with PGA ratings. An exact linear-by-linear association test was conducted to evaluate the association of satisfaction ratings and propensity to select the pain control method in the future with PGA ratings. Results: Results of cognitive debriefing interviews indicated that the PGA incorporates patient perceptions of several aspects of treatment with an analgesic modality, including level of pain, ease of use, and control of administration. PGA ratings were associated in the expected direction with other patient-reported outcomes used in several clinical studies. Conclusions: Findings suggest that both the content and construct validity of the PGA of the method of pain control in clinical trial settings are supported. However, this conclusion is potentially limited by the use of a narrow range of therapeutic interventions and, in some cases, small sample sizes in the clinical trials used to assess construct validity. The PGA of the method of pain control is an informative and useful measure for assessing pain control provided by different drug delivery systems for patients experiencing postoperative pain.	[Rothman, Margaret; Vallow, Sue] Johnson & Johnson Pharmaceut Serv LLC, Raritan, NJ 08869 USA; [Damaraju, C. V.] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA; [Hewitt, David J.] Ortho McNeil Inc, Raritan, NJ USA	Rothman, M (reprint author), Johnson & Johnson Pharmaceut Serv LLC, 700 Route 202 South, Raritan, NJ 08869 USA.	mrothman@its.jnj.com			Johnson and Johnson Pharmaceutical Services, LLCJohnson & Johnson USA; Ortho-McNeil Janssen Scientific Affairs, LLCJohnson & Johnson USAJanssen Biotech Inc	This study was financially supported by Johnson and Johnson Pharmaceutical Services, LLC and Ortho-McNeil Janssen Scientific Affairs, LLC.	AGRESTI A, 1990, J AM STAT ASSOC, V85, P453, DOI 10.2307/2289783; *AM ED RES ASS AM, 2000, STAND ED PSYCH TEST; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Calvin A, 1999, J PAIN SYMPTOM MANAG, V18, P17, DOI 10.1016/S0885-3924(99)00025-1; Camilleri M, 2007, CLIN GASTROENTEROL H, V5, P534, DOI 10.1016/j.cgh.2007.03.004; Capdevila X, 2005, ANESTHESIOLOGY, V103, P1035, DOI 10.1097/00000542-200511000-00018; Chapman SL, 1996, PAIN, V68, P349, DOI 10.1016/S0304-3959(96)03217-4; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Cheville A, 2001, J BONE JOINT SURG AM, V83A, P572, DOI 10.2106/00004623-200104000-00013; Chung Joanne W Y, 2003, Nurs Health Sci, V5, P13, DOI 10.1046/j.1442-2018.2003.00130.x; COE A, 1991, ANAESTHESIA, V46, P918, DOI 10.1111/j.1365-2044.1991.tb09846.x; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Fisher CG, 2003, SPINE, V28, P739, DOI 10.1097/00007632-200304150-00002; Gordon Debra B, 2002, Pain Manag Nurs, V3, P116, DOI 10.1053/jpmn.2002.127570; Harding G, 2004, VALUE HEALTH, V7, P728; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Jensen MP, 2004, PAIN, V110, P480, DOI 10.1016/j.pain.2004.04.036; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; LYONS JS, 2004, USE PSYCHOL TESTING, V2; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Senturk M, 2002, ANESTH ANALG, V94, P11; SHIKIAR R, 1996, PSYCHOMETRIC EVALUAT; Svensson I, 2001, EUR J PAIN, V5, P125, DOI 10.1053/eujp.2001.0227; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77	27	20	20	0	7	LIBRAPHARM/INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	JUN	2009	25	6					1433	1443		10.1185/03007990902862032			11	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	469XC	WOS:000267933600012	19419336				2020-06-30	J	Furyk, JS; Grabowski, WJ; Black, LH				Furyk, Jeremy S.; Grabowski, Walter J.; Black, Lisa H.			Nebulized fentanyl versus intravenous morphine in children with suspected limb fractures in the emergency department: A randomized controlled trial	EMERGENCY MEDICINE AUSTRALASIA			English	Article						analgesia; fentanyl; opioid; paediatric; pain	FACES PAIN SCALE; CLINICALLY SIGNIFICANT DIFFERENCE; INTRANASAL FENTANYL; PEDIATRIC EMERGENCY; ANALGESIC USE; SEVERITY; DIAMORPHINE; VALIDATION; MANAGEMENT; PROVISION	Objective: To compare the efficacy of nebulized fentanyl (NF) with i.v. morphine (IVM) in paediatric patients presenting to the ED with clinically suspected limb fractures. Methods: A convenience sample of patients aged 4-13 years, presenting with clinically suspected limb fractures, were randomized to receive either NF at 4 mu g/kg or IVM at 0.1 mg/kg. Pain scores were assessed at 0, 15 and 30 min using the Wong and Baker faces pain scale (0-10). Vital signs and adverse effects were also recorded. Results: Of the 77 patients enrolled in the study, data were available for analysis on 73 patients. Of those, 36 received NF and 37 received IVM. The two groups were similar in terms of demographics and initial pain scores. Mean pain score at 15 min was decreased by 3.06 (NF) and by 1.97 (IVM) (difference 1.09; 95% CI 2.32 to -0.32). At 30 min the decreases were 3.6 (NF) and 3.0 (IVM), respectively (difference 0.6; 95% CI 1.89 to -0.65). Decreases in pain scores for both NF and IVM were statistically significant (P < 0.0001), but the difference in the effect of NF and IVM did not reach statistical significance. There was no significant change in any vital signs or serious adverse events in either group. Conclusion: NF in a dose of 4 mu g/kg given via a standard nebulizer provided clinically significant improvements in pain scores, comparable to IVM. NF should be considered as a treatment option for use in children presenting in acute pain.	[Furyk, Jeremy S.; Black, Lisa H.] Townsville Hosp, Emergency Dept, Townsville, Qld 4810, Australia; [Grabowski, Walter J.] Brockton Hosp, Emergency Dept, Brockton, MA USA	Furyk, JS (reprint author), Townsville Hosp, Emergency Dept, Angus Smith Dr, Townsville, Qld 4810, Australia.	jeremy_furyk@health.qld.gov.au		Furyk, Jeremy/0000-0002-9503-0928			Alexander-Williams JM, 1998, BRIT J ANAESTH, V81, P3; Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Baumann BM, 2007, ACAD EMERG MED, V14, P47, DOI 10.1197/j.aem.2006.06.057; Belville RG, 2005, PEDIATR EMERG CARE, V21, P90, DOI 10.1097/01.pec.0000159051.26812.8b; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Bosenberg A, 2003, PAEDIATR ANAESTH, V13, P708, DOI 10.1046/j.1460-9592.2003.01142.x; Boyd RJ, 2005, EMERG MED J, V22, P30, DOI 10.1136/emj.2002.003574; Bulloch B, 2002, ACAD EMERG MED, V9, P199, DOI 10.1197/aemj.9.3.199; Chambers CT, 1999, PAIN, V83, P25, DOI 10.1016/S0304-3959(99)00086-X; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; Cimpello LB, 2004, PEDIATR EMERG CARE, V20, P228, DOI 10.1097/01.pec.0000121242.99242.e0; Drendel AL, 2006, PEDIATRICS, V117, P1511, DOI 10.1542/peds.2005-2046; FRIEDLAND LR, 1994, ANN EMERG MED, V23, P203, DOI 10.1016/S0196-0644(94)70031-1; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; Hunter M, 2000, J PAIN SYMPTOM MANAG, V20, P122, DOI 10.1016/S0885-3924(00)00171-8; KAULT D, 2007, PUBLIC DOMIAN STAT 2; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Kendall JM, 2003, CLIN PHARMACOKINET, V42, P501, DOI 10.2165/00003088-200342060-00001; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Miner JR, 2007, ACAD EMERG MED, V14, P895, DOI 10.1197/j.aem.2007.06.036; PAUT O, 2003, ANESTHESIOLOGY, V99, P490; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Powell CV, 2001, ANN EMERG MED, V37, P28; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Wong DL, 1997, WHALEY WONGS ESSENTI, P1215; World Medical Association, 2004, WORLD MED ASS DECL H; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x	38	34	34	0	6	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1742-6731			EMERG MED AUSTRALAS	Emerg. Med. Australas.	JUN	2009	21	3					203	209		10.1111/j.1742-6723.2009.01183.x			7	Emergency Medicine	Emergency Medicine	457ZJ	WOS:000266977900007	19527280				2020-06-30	J	Inkster, T; Grant, P; Roberts, J				Inkster, Teresa; Grant, Patrick; Roberts, Jason			An unusual cause of septic arthritis in a 16-year-old girl	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Letter							FUSOBACTERIUM-NECROPHORUM; LEMIERRES-SYNDROME		[Inkster, Teresa] Univ Glasgow, Western Infirm, Dept Microbiol, Glasgow G11 6NT, Lanark, Scotland; [Grant, Patrick] Univ Glasgow, Western Infirm, Dept Emergency Med, Glasgow G11 6NT, Lanark, Scotland; [Roberts, Jason] Univ Glasgow, Western Infirm, Dept Trauma & Orthopaed, Glasgow G11 6NT, Lanark, Scotland	Inkster, T (reprint author), Univ Glasgow, Western Infirm, Dept Microbiol, Dumbarton Rd, Glasgow G11 6NT, Lanark, Scotland.	teresaink@hotmail.com	Inkster, Teresa/AAM-4286-2020				Brazier JS, 2006, ANAEROBE, V12, P165, DOI 10.1016/j.anaerobe.2005.11.003; Chirinos JA, 2002, MEDICINE, V81, P458, DOI 10.1097/00005792-200211000-00006; KAKOS PD, 2004, EUR J EMERG MED, V11, P228; Riordan T, 2004, POSTGRAD MED J, V80, P328, DOI 10.1136/pgmj.2003.014274; Riordan T, 2007, CLIN MICROBIOL REV, V20, P622, DOI 10.1128/CMR.00011-07; Wallace J, 2007, LASER FOCUS WORLD, V43, P51	6	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0969-9546			EUR J EMERG MED	Eur. J. Emerg. Med.	JUN	2009	16	3					166	167		10.1097/MEJ.0b013e3283207fbd			2	Emergency Medicine	Emergency Medicine	444GC	WOS:000265967700014	19417573				2020-06-30	J	Maglinte, DDT; Applegate, KE; Rajesh, A; Jennings, SG; Ford, JM; Savabi, MS; Lappas, JC				Maglinte, Dean D. T.; Applegate, Kimberly E.; Rajesh, Arumugam; Jennings, S. Gregory; Ford, Jason M.; Savabi, Mojgan Sarah; Lappas, John C.			Conscious sedation for patients undergoing enteroclysis: Comparing the safety and patient-reported effectiveness of two protocols	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						CT enteroclysis; Radiologic sedation/analgesia	ENDOSCOPY; RADIOLOGY; PAIN	Objective: To compare the safety and patient-reported effectiveness of two regimens for conscious sedation during enteroclysis. Materials and methods: We surveyed two groups of outpatients and retrospectively reviewed procedure records for conscious sedation and complications. Patients were divided into Group One (received sedative/amnesic diazepam), and Group Two, (received amnesic/sedative, midazolam and analgesic fentanyl). Results: All enteroclyses were successfully completed; there were no hospital admissions due to complications. In Group One (n = 106), mean dose of diazepam was 12.7 mg. 25% had oxygen desaturation (n = 25), and post-procedure vomiting without aspiration (n = 1). 56% of outpatients completed phone surveys, and 68% recalled procedural discomfort. In Group Two (n = 45), mean doses were 3.9 mg midazolam and 108 mcg fentanyl. 31% had desaturation (n = 13), and post-procedure vomiting without aspiration (n = 1). 87% had only a vague recall of the procedure or of any discomfort. Conclusion: A combination of amnesic and fentanyl prevented the recall of discomfort of nasoenteric intubation and infusion in most patients who had enteroclysis compared to diazepam. Most of the patients would undergo the procedure again, if needed. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Maglinte, Dean D. T.; Applegate, Kimberly E.; Rajesh, Arumugam; Jennings, S. Gregory; Ford, Jason M.; Lappas, John C.] Indiana Univ, Med Ctr, Dept Radiol, Indianapolis, IN 46202 USA; [Savabi, Mojgan Sarah] Indiana Univ, Sch Med, Dept Med, Div Gastroenterol, Indianapolis, IN 46202 USA	Maglinte, DDT (reprint author), Indiana Univ, Med Ctr, Dept Radiol, 550 N,Univ Blvd,Univ Hosp Room 0279, Indianapolis, IN 46202 USA.	dmaglint@iupui.edu		applegate, kimberly/0000-0001-7716-1636			*ACR, 2000, AM COLL RAD ACR STAN, P123; BARLOON TJ, 1988, GASTROINTEST RADIOL, V13, P203, DOI 10.1007/BF01889060; Berlin L, 2001, AM J ROENTGENOL, V177, P293, DOI 10.2214/ajr.177.2.1770293; Bluemke DA, 2000, RADIOLOGY, V216, P645, DOI 10.1148/radiology.216.3.r00se45645; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Karian VE, 2002, PEDIATR RADIOL, V32, P348, DOI 10.1007/s00247-001-0653-8; Lang EV, 1998, J VASC INTERV RADIOL, V9, P407, DOI 10.1016/S1051-0443(98)70291-X; Lang EV, 2002, RADIOLOGY, V222, P375, DOI 10.1148/radiol.2222010528; Madan A, 2004, SOUTH MED J, V97, P800, DOI 10.1097/01.SMJ.0000129794.97798.A5; Maglinte DDT, 2005, RADIOGRAPHICS, V25, P711, DOI 10.1148/radiographics.25.3.0250711; Maglinte DDT, 2005, RADIOLOGY, V236, P763, DOI 10.1148/radiol.2363041868; MAGLINTE DDT, 1988, AM J ROENTGENOL, V151, P951, DOI 10.2214/ajr.151.5.951; Maglinte DDT, 1999, ACAD EMERG MED, V6, P166, DOI 10.1111/j.1553-2712.1999.tb00149.x; Mueller PR, 1997, RADIOLOGY, V202, P339, DOI 10.1148/radiology.202.2.9015053; REDMOND PL, 1983, RADIOLOGY, V165, P195; Singer AJ, 1999, ANN EMERG MED, V33, P652, DOI 10.1016/S0196-0644(99)70194-0; Thanvi BR, 2003, POSTGRAD MED J, V79, P650, DOI 10.1136/pmj.79.937.650; Trevisani L, 2004, WORLD J GASTROENTERO, V10, P3313, DOI 10.3748/wjg.v10.i22.3313; Zaman A, 1999, GASTROINTEST ENDOSC, V49, P279, DOI 10.1016/S0016-5107(99)70001-5	19	7	7	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	JUN	2009	70	3					512	516		10.1016/j.ejrad.2008.02.013			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	468XK	WOS:000267857600019	18375082				2020-06-30	J	Matsui, T; Kojima, T; Kojima, H; Iwamoto, N; Kure, S; Uemura, T; Fujimitsu, Y; Sakamoto, J				Matsui, Takanori; Kojima, Taiki; Kojima, Hiroshi; Iwamoto, Naoko; Kure, Shigehiro; Uemura, Takanori; Fujimitsu, Yasunobu; Sakamoto, Junichi			Feasibility study of direct fentanyl patch introduction without prior opioid titration	INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY			English	Article						Fentanyl patch (FP); Opioid-induced bowel dysfunction (OBD); Direct introduction; Prospective feasibility study	PAIN	Opioids are key drugs for cancer pain relief, but some patients, especially those who have gastroenterological cancers, suffer from severe opioid-induced bowel dysfunction (OBD), which reduces their quality of life. In order to achieve better pain relief, efforts to minimize OBD are required. Between September 2006 and December 2007, 18 patients were enrolled in this feasibility study. All patients had gastroenterological cancer pain. The patients received direct fentanyl patch introduction starting from 12.5 mu g/h, with additional opioid treatment for the first 12 h. Adverse events, changes of medications, pain scale, and patients' satisfaction scores were recorded for 9 days after fentanyl patch introduction. All patients completed the protocol treatment without interruption by adverse events. Eight patients (44%) showed adverse events that were presumed to be related to the treatment. However, all events were grade 1 and had a minimal effect on patients' quality of life. According to subjective evaluation on day 9, only 4 patients (22%) mentioned that they had felt adverse events during the treatment course. Seventeen patients (94%) had pain score scale improvements evaluated on day 9. Satisfaction scores on days 9 and day 27 were excellent or good for all but one of the patients. This prospective study showed the safety and efficacy of direct fentanyl patch introduction in Japanese gastroenterological cancer patients, and the treatment had good feasibility. This model should help cancer pain management for patients with a high risk of features of OBD such as constipation, subileus, or postabdominal surgery.	[Matsui, Takanori; Kojima, Taiki; Kojima, Hiroshi; Iwamoto, Naoko; Kure, Shigehiro; Uemura, Takanori; Fujimitsu, Yasunobu] Aichi Hosp, Aichi Canc Ctr, Dept Surg Gastroenterol, Aichi 4440011, Japan; [Sakamoto, Junichi] Nagoya Univ, Grad Sch Med, Young Leaders Program, Nagoya, Aichi 4648601, Japan	Matsui, T (reprint author), Aichi Hosp, Aichi Canc Ctr, Dept Surg Gastroenterol, 18 Kuriyado, Aichi 4440011, Japan.	matsui-ngy@umin.ac.jp			ECRIN (Epidemiological and Clinical Research Information Network)	We would like to thank Ms Maiko Yamamoto, Ms Mayumi Izumichi, Ms Satoko Hagiwara, and Ms Kumi Takeyama for their data management assistance. This study was partly supported by ECRIN (Epidemiological and Clinical Research Information Network).	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; *AM SOC CLIN ONC, 2001, [No title captured]; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Genf World Health Organization, 1986, CANC PAIN REL; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; JACOX A, 1994, [No title captured]; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; MANARA L, 1986, J PHARMACOL EXP THER, V237, P945; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Narita M, 2003, EUR J NEUROSCI, V18, P3193, DOI 10.1111/j.1460-9568.2003.03052.x; Pappagallo M, 2001, AM J SURG, V182, p11S, DOI 10.1016/S0002-9610(01)00782-6; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Thomas J, 2008, J PAIN SYMPTOM MANAG, V35, P103, DOI 10.1016/j.jpainsymman.2007.01.017; World Health Organization, 1996, CANC PAIN REL	15	4	4	0	0	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	1341-9625	1437-7772		INT J CLIN ONCOL	Int. J. Clin. Oncol.	JUN	2009	14	3					202	207		10.1007/s10147-008-0829-4			6	Oncology	Oncology	469KL	WOS:000267896800005	19593610				2020-06-30	J	Shiiba, M; Takei, M; Nakatsuru, M; Bukawa, H; Yokoe, H; Uzawa, K; Tanzawa, H				Shiiba, M.; Takei, M.; Nakatsuru, M.; Bukawa, H.; Yokoe, H.; Uzawa, K.; Tanzawa, H.			Clinical observations of postoperative delirium after surgery for oral carcinoma	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						delirium; oral carcinoma; patient-controlled analgesia; fentanyl	PATIENT-CONTROLLED ANALGESIA; NECK-CANCER SURGERY; RISK-FACTORS; PREOPERATIVE PREDICTORS; CARDIAC-SURGERY; HEAD	The aim of the present study was to clarify the clinical characteristics of postoperative delirium and to determine appropriate postoperative management for its prevention. The authors analysed 132 cases of primary surgery for oral carcinoma and observed 24 (18%) cases of postoperative delirium. Univariate analysis revealed that significant risk factors for postoperative delirium were older age, male gender, extensive surgery and morphine pain control. Logistic regression analysis showed that older age and male gender were significant risk factors for postoperative delirium, while patient-controlled analgesia with fentanyl was effective for prevention of postoperative delirium. There was a trend for postoperative delirium to be associated with extensive surgery. In those who had delirium, blood tests revealed that alkaline phosphatase, total protein, sodium, chlorine, red blood cell Count, haemoglobin and haematocrit were significantly diminished after Surgery. These results indicate that general condition is closely related to the onset of postoperative delirium, and Suggest that appropriate postoperative management can reduce the incidence of this complication.	[Shiiba, M.; Takei, M.; Nakatsuru, M.; Bukawa, H.; Yokoe, H.; Uzawa, K.; Tanzawa, H.] Chiba Univ, Chiba Univ Hosp, Dept Dent & Oral Surg, Chiba 2608677, Japan	Shiiba, M (reprint author), 1-8-1 Inohana, Chiba 2608677, Japan.	m.shiiba@faculty.chiba-u.jp		Uzawa, Katsuhiro/0000-0002-7036-0859			Aldemir M, 2001, CRIT CARE, V5, P265, DOI 10.1186/cc1044; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P135; Benoit AG, 2005, J VASC SURG, V42, P884, DOI 10.1016/j.jvs.2005.07.032; Bohner H, 2003, ANN SURG, V238, P149, DOI 10.1097/00000658-200307000-00019; Herrick IA, 1996, ANAESTHESIA, V51, P356, DOI 10.1111/j.1365-2044.1996.tb07748.x; Kazmierski J, 2006, GEN HOSP PSYCHIAT, V28, P536, DOI 10.1016/j.genhosppsych.2006.08.007; Kunimatsu Teruhito, 2004, J Oral Sci, V46, P71, DOI 10.2334/josnusd.46.71; Merchant RA, 2005, ANN ACAD MED SINGAP, V34, P163; OWEN H, 1988, ANAESTH INTENS CARE, V16, P437, DOI 10.1177/0310057X8801600409; Santos FS, 2004, INT PSYCHOGERIATR, V16, P175, DOI 10.1017/S1041610204000365; SVEINSSON IS, 1975, J THORAC CARDIOV SUR, V70, P717; van der Mast RC, 1999, J PSYCHOSOM RES, V46, P479, DOI 10.1016/S0022-3999(99)00002-1; Vaurio LE, 2006, ANESTH ANALG, V102, P1267, DOI 10.1213/01.ane.0000199156.59226.af; WEED HG, 1995, LARYNGOSCOPE, V105, P1066, DOI 10.1288/00005537-199510000-00011; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; Yamagata K, 2005, INT J ORAL MAX SURG, V34, P33, DOI 10.1016/j.ijom.2004.03.005; Zakriya KJ, 2002, ANESTH ANALG, V94, P1628, DOI 10.1097/00000539-200206000-00050	17	26	26	0	5	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027			INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	JUN	2009	38	6					661	665		10.1016/j.ijom.2009.01.011			5	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	467FP	WOS:000267723800007	19237264				2020-06-30	J	Bushnaq, M; Al-Shoubaki, M; Milhem, M				Bushnaq, Mohammad; Al-Shoubaki, Muhannad; Milhem, Mohammed			The Feasibility of Using Intravenous Fentanyl as Sublingual Drops in the Treatment of Incidental Pain in Patients with Cancer	JOURNAL OF PALLIATIVE MEDICINE			English	Letter							ORAL TRANSMUCOSAL FENTANYL; PHARMACOKINETICS; VARIABILITY; ANALGESICS		[Bushnaq, Mohammad; Al-Shoubaki, Muhannad] King Hussein Canc Ctr, Palliat Care Program, Amman, Jordan; [Milhem, Mohammed] Univ Iowa, Div Hematol & Oncol & Blood Marrow Transplantat, Iowa City, IA USA	Bushnaq, M (reprint author), King Hussein Canc Ctr, Palliat Care Program, Amman, Jordan.	mbushnaq@KHCC.JO		Milhem, Mohammed/0000-0003-4663-6824			COLLUZI PH, 1998, AM J HOSP PALLIAT CA, V15, P13; DOLLERY C, 1991, THERAPEUTIC DRUGS, V1, pF26; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; HANKS G, 1998, OXFORD TXB PALLIATIV; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; McMillan C, 2001, Br J Nurs, V10, P860; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	12	4	4	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	JUN	2009	12	6					511	514		10.1089/jpm.2009.9618			4	Health Care Sciences & Services	Health Care Sciences & Services	456FD	WOS:000266826100003	19508134				2020-06-30	J	Hajiha, M; DuBord, MA; Liu, H; Horner, RL				Hajiha, Mohammad; DuBord, Marq-Andre; Liu, Hattie; Horner, Richard L.			Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							ISOLATED RESPIRATORY NETWORK; EXCITATORY AMINO-ACIDS; GENIOGLOSSUS MUSCLE; VENTILATORY RESPONSE; BRAIN-STEM; RATS; SLEEP; DEPRESSION; NUCLEUS; MOTONEURONS	Opioids can modulate breathing and predispose to respiratory depression by actions at various central nervous system sites, but the mechanisms operating at respiratory motor nuclei have not been studied. This study tests the hypotheses that (i) local delivery of the mu-opioid receptor agonist fentanyl into the hypoglossal motor nucleus (HMN) will suppress genioglossus activity in vivo, (ii) a component of this suppression is mediated by opioid-induced acetylcholine release acting at muscarinic receptors, and (iii) delta- and kappa-opioid receptors also modulate genioglossus activity. Seventy-two isoflurane-anaesthetised, tracheotomised, spontaneously breathing rats were studied during microdialysis perfusion into the HMN of (i) fentanyl and naloxone (mu-opioid receptor antagonist), (ii) fentanyl with and without co-application of muscarinic receptor antagonists, and (iii) delta- and kappa-opioid receptor agonists and antagonists. The results showed (i) that fentanyl at the HMN caused a suppression of genioglossus activity (P < 0.001) that reversed with naloxone (P < 0.001), (ii) that neither atropine nor scopolamine affected the fentanyl-induced suppression of genioglossus activity, and (iii) that delta-, but not kappa-, opioid receptor stimulation also suppressed genioglossus activity (P = 0.036 and P = 0.402 respectively). We conclude that mu-opioid receptor stimulation suppresses motor output from a central respiratory motoneuronal pool that activates genioglossus muscle, and this suppression does not involve muscarinic receptor-mediated inhibition. This mu-opioid receptor-induced suppression of tongue muscle activity by effects at the hypoglossal motor pool may underlie the clinical concern regarding adverse upper airway function with mu-opioid analgesics. The inhibitory effects of mu- and delta-opioid receptors at the HMN also indicate an influence of endogenous enkephalins and endorphins in respiratory motor control.	[Hajiha, Mohammad; DuBord, Marq-Andre; Liu, Hattie; Horner, Richard L.] Univ Toronto, Dept Physiol & Med, Toronto, ON M5S 1A8, Canada	Horner, RL (reprint author), Room 7308,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON, Canada.	richard.horner@utoronto.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MT-15563]; Ontario Thoracic Society	This work was supported by funds from the Canadian Institutes of Health Research (CIHR, Grant MT-15563) and the Ontario Thoracic Society. RLH is supported by a Tier I Canada Research Chair in Sleep and Respiratory Neurobiology. The authors thank Dr. Karen Brown MD, Associate Professor, Department of Anesthesia, Montreal Children's Hospital for her clinical interest and input, and the stimulation to perform this work.	Aldes LD, 1998, BRAIN RES, V780, P67, DOI 10.1016/S0006-8993(97)01126-8; Bailey PL, 2000, NEW ENGL J MED, V343, P1228, DOI 10.1056/NEJM200010263431705; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; BARTLETT D, 1986, RESP PHYSIOL, V64, P289, DOI 10.1016/0034-5687(86)90122-2; Bouryi VA, 2004, NEUROSCIENCE, V129, P55, DOI 10.1016/j.neuroscience.2004.07.023; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; Burke RE, 2007, BRAIN, V130, P887, DOI 10.1093/brain/awm022; CONNAUGHTON M, 1986, NEUROSCIENCE, V17, P205, DOI 10.1016/0306-4522(86)90237-X; DAHAN A, 2007, SEMIN ANESTH PERIO M, V26, P58, DOI DOI 10.1053/j.sane.2007.04.003; Dahan Albert, 2007, J Pain Palliat Care Pharmacother, V21, P63, DOI 10.1300/J354v21n01_15; Eikermann M, 2008, BRIT J ANAESTH, V101, P344, DOI 10.1093/bja/aen176; Eikermann M, 2007, ANESTHESIOLOGY, V107, P621, DOI 10.1097/01.anes.0000281928.88997.95; Fort P, 1998, Sleep Res Online, V1, P102; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; HENKE KG, 1990, J APPL PHYSIOL, V69, P617; HENKE KG, 1992, J APPL PHYSIOL, V72, P1221; Hoglund AU, 2000, J PHARMACOL EXP THER, V295, P100; Jelev A, 2001, J PHYSIOL-LONDON, V532, P467, DOI 10.1111/j.1469-7793.2001.0467f.x; Kryger MH, 2000, PRINCIPLES PRACTICE, P940; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Lerman Jerrold, 2006, Anesthesiology, V105, P645, DOI 10.1097/00000542-200610000-00004; Liu X, 2005, J PHYSIOL-LONDON, V565, P965, DOI 10.1113/jphysiol.2005.084657; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; McCrimmon DR, 2003, AM J PHYSIOL-REG I, V285, pR1274, DOI 10.1152/ajpregu.00428.2003; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; Morrison JL, 2002, J APPL PHYSIOL, V93, P1786, DOI 10.1152/japplphysiol.00464.2002; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Paxinos G., 1998, RAT BRAIN STEREOTAXI; Rekling JC, 2000, PHYSIOL REV, V80, P767; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931; Richardson KA, 2005, BRAIN RES, V1032, P23, DOI 10.1016/j.brainres.2004.10.045; Roda F, 2004, J COMP NEUROL, V468, P571, DOI 10.1002/cne.10974; SALES N, 1985, BRAIN RES, V344, P382, DOI 10.1016/0006-8993(85)90820-0; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; Sherrington C.S., 1906, INTEGRATIVE ACTION N; Skulsky EM, 2007, SLEEP, V30, P566, DOI 10.1093/sleep/30.5.566; Sood S, 2005, AM J RESP CRIT CARE, V172, P1338, DOI 10.1164/rccm.200502-258OC; Sood S, 2006, J APPL PHYSIOL, V100, P1807, DOI 10.1152/japplphysiol.01508.2005; Steenland HW, 2008, J NEUROSCI, V28, P6826, DOI 10.1523/JNEUROSCI.1019-08.2008; Steenland HW, 2006, NEUROSCIENCE, V138, P1407, DOI 10.1016/j.neuroscience.2005.12.040; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Teichtahl H, 2007, EXPERT OPIN DRUG SAF, V6, P641, DOI 10.1517/14740338.6.6.641; Travers Joseph B., 1995, P239; Wang D, 2007, SLEEP MED REV, V11, P35, DOI 10.1016/j.smrv.2006.03.006; XIA Y, 1991, BRAIN RES, V549, P181, DOI 10.1016/0006-8993(91)90457-7; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; Zhang ZX, 2007, ANESTHESIOLOGY, V107, P288, DOI 10.1097/01.anes.0000270760.46821.67	52	61	61	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JUN 1	2009	587	11					2677	2692		10.1113/jphysiol.2009.171678			16	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	451TD	WOS:000266492200026	19403616	Green Published			2020-06-30	J	Prodduturi, S; Smith, GJ; Wokovich, AM; Doub, WH; Westenberger, BJ; Buhse, L				Prodduturi, Suneela; Smith, Glen J.; Wokovich, Anna M.; Doub, William H.; Westenberger, Benjamin J.; Buhse, Lucinda			Reservoir Based Fentanyl Transdermal Drug Delivery Systems: Effect of Patch Age on Drug Release and Skin Permeation	PHARMACEUTICAL RESEARCH			English	Article						fentanyl; reservoir systems; skin permeation; stability; transdermal drug delivery		To understand and evaluate the stability and skin permeation profiles of fentanyl reservoir systems as a function of patch age. Drug release and skin permeation studies were performed using a modified USP apparatus 5 with a novel sample preparation technique. The amount of fentanyl present in the EVA/adhesive layer (EAL) increased from about 17% of label claim (LC) at 5 months to 25% LC at 22 months. The increase in the drug concentration was mainly observed in the peripheral EAL. Simultaneously, the alcohol content of the patch decreased as a function of patch age. A significant effect of patch age on the drug content in the EAL and the drug release from the system was observed; however, skin permeation studies did not indicate an increase in drug delivery rate. Novel sample preparation technique with USP Apparatus 5 allowed determination of in vitro skin permeation rates for fentanyl transdermal patches with different designs. Permeation rates with cadaver skin as substrate were found not to change with patch age despite changing drug concentration in the EAL.	[Prodduturi, Suneela; Wokovich, Anna M.; Doub, William H.; Westenberger, Benjamin J.; Buhse, Lucinda] US FDA, Div Pharmaceut Anal, St Louis, MO 63101 USA; [Smith, Glen J.] US FDA, Off Gener Drugs, Rockville, MD 20857 USA	Prodduturi, S (reprint author), US FDA, Div Pharmaceut Anal, 1114 Market St Rm 1002, St Louis, MO 63101 USA.	suneela.prodduturi@fda.hhs.gov					AGUIAR A, 2005, BRAZ J FOOD TECHNOL, V5, P52; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018; Mehdizadeh Amir, 2004, Acta Pharmaceutica (Zagreb), V54, P301; Moore TW, 1996, DISSOLUT TECHNOL, V3, P3; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; NAYLOR TD, 1988, COMPREHENSIVE POLYM	7	15	16	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741			PHARM RES-DORD	Pharm. Res.	JUN	2009	26	6					1344	1352		10.1007/s11095-009-9843-0			9	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	442IJ	WOS:000265834600006	19229594				2020-06-30	J	Mercadante, S; Casuccio, A; Tirelli, W; Giarratano, A				Mercadante, Sebastiano; Casuccio, Alessandra; Tirelli, Walter; Giarratano, Antonello			Equipotent doses to switch from high doses of opioids to transdermal buprenorphine	SUPPORTIVE CARE IN CANCER			English	Article						Cancer pain; Opioid switching; Transdermal buprenorphine	CHRONIC PAIN; CANCER PAIN; MORPHINE; FENTANYL	The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 A mu g of TD fentanyl, reporting adequate pain and symptom control. Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl-BUP ratio of 0.6:0.8 and an oral morphine-BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakthrough medication were recorded before switching (T0), 3 days after (T3), and 6 days after (T6). Eleven patients were recruited in a period of 1 year, and data were complete for ten patients. The mean age was 61.6 (SD 9.5), and five patients were males. No significant changes in pain and symptom intensity were found, except improvement in reported constipation (p = 0.014), as well as in global satisfaction with the analgesic treatment. No significant changes in breakthrough pain medication were observed. The results of this study suggest that stable patients receiving relatively high doses of oral morphine or TD fentanyl could be safely switched to TD BUP, by using a ratio of 70:1 and 0.6:0.8, respectively, maintaining the same level of analgesia.	[Mercadante, Sebastiano] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Mercadante, Sebastiano; Casuccio, Alessandra; Giarratano, Antonello] Univ Palermo, I-90146 Palermo, Italy; [Tirelli, Walter] Hosp Sacro Cuore, Rome, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013; Cortegiani, Andrea/H-4902-2016; Giarratano, Antonino/D-2346-2012	casuccio, alessandra/0000-0002-5676-9535; Cortegiani, Andrea/0000-0003-1416-9993; GIARRATANO, Antonino/0000-0001-9344-8311			Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Davis MP, 2005, SUPPORT CARE CANCER, V13, P878, DOI 10.1007/s00520-005-0849-9; Freye Enno, 2007, Pain Pract, V7, P123, DOI 10.1111/j.1533-2500.2007.00119.x; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Likar R, 2008, INT J CLIN PRACT, V62, P152, DOI 10.1111/j.1742-1241.2007.01531.x; Mercadante S, 2007, J PAIN SYMPTOM MANAG, V34, P532, DOI 10.1016/j.jpainsymman.2007.01.006; Mercadante S, 2007, SUPPORT CARE CANCER, V15, P441, DOI 10.1007/s00520-006-0169-8; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1	10	21	21	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	JUN	2009	17	6					715	718		10.1007/s00520-008-0546-6			4	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	442IO	WOS:000265835100012	19104845				2020-06-30	J	Saeki, H; Ishimura, H; Higashi, H; Kitagawa, D; Tanaka, J; Maruyama, R; Katoh, H; Shimazoe, H; Yamauchi, K; Ayabe, H; Kakeji, Y; Morita, M; Maehara, Y				Saeki, Hiroshi; Ishimura, Hiroshi; Higashi, Hidefumi; Kitagawa, Dai; Tanaka, Junko; Maruyama, Riichiroh; Katoh, Hidenori; Shimazoe, Hirofumi; Yamauchi, Kouta; Ayabe, Hitoshi; Kakeji, Yoshihiro; Morita, Masaru; Maehara, Yoshihiko			Postoperative management using intensive patient-controlled epidural analgesia and early rehabilitation after an esophagectomy	SURGERY TODAY			English	Article						Esophagectomy; Thoracic epidural analgesia; Patient-controlled analgesia; Postoperative complications; Hospital stay	THORACIC ESOPHAGECTOMY; VASCULAR-SURGERY; PAIN RELIEF; ANESTHESIA; INHIBITOR; CANCER; MORBIDITY	Patient-controlled epidural analgesia (PCEA) was developed for use after surgery for thoracic esophageal cancer to relieve wound pain, introduce early rehabilitation, and provide an uneventful postoperative recovery. This retrospective study investigated 22 patients who underwent esophageal surgery to determine the efficacy of postoperative management with PCEA. In the PCEA group (n = 12), patients had two epidural catheters inserted to cover both the thoracic and abdominal incision with a patient-controlled bolus capability. Postoperative mechanical ventilation was administered in all cases in the control group (n = 10). On the other hand, this was only necessary in two patients in the PCEA group. The amount of time the patients stayed in the intensive care unit and the hospital was significantly shorter in the PCEA group than in the control group (P < 0.001 and P < 0.01, respectively). Respiratory complications occurred in four patients in the control group, and none in the PCEA group. The mean number of supplemental analgesics administered for breakthrough pain until the 7th postoperative day was 5.5 in the control group, and 1.3 in the PCEA group (P < 0.001). Early rehabilitation is facilitated with intensive PCEA, while it also improves postoperative management and reduces hospitalization after esophageal surgery.	[Saeki, Hiroshi; Kakeji, Yoshihiro; Morita, Masaru; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, Fukuoka 8128582, Japan; [Saeki, Hiroshi; Higashi, Hidefumi; Kitagawa, Dai; Tanaka, Junko; Maruyama, Riichiroh; Katoh, Hidenori] Nippon Steel Yawata Mem Hosp, Dept Surg, Kitakyushu, Fukuoka, Japan; [Ishimura, Hiroshi] Nippon Steel Yawata Mem Hosp, Dept Anesthesia, Kitakyushu, Fukuoka, Japan; [Shimazoe, Hirofumi; Yamauchi, Kouta; Ayabe, Hitoshi] Nippon Steel Yawata Mem Hosp, Dept Rehabil, Kitakyushu, Fukuoka, Japan	Saeki, H (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Maehara, Yoshihiko/A-4867-2010	kang tai, shan nei/0000-0002-8998-7555			Akamoto S, 2007, SURG TODAY, V37, P359, DOI 10.1007/s00595-006-3409-0; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; Flisberg P, 2001, J CARDIOTHOR VASC AN, V15, P282, DOI 10.1053/jcan.2001.23270; Luketich JD, 2005, ANN THORAC SURG, V79, P1845, DOI 10.1016/j.athoracsur.2004.10.055; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; Morita M, 2008, SURGERY, V143, P499, DOI 10.1016/j.surg.2007.12.007; Ono S, 1999, AM J SURG, V177, P78, DOI 10.1016/S0002-9610(98)00300-6; Priestley MC, 2002, ANESTH ANALG, V94, P275, DOI 10.1097/00000539-200202000-00009; Sato A, 2005, DIS ESOPHAGUS, V18, P151, DOI 10.1111/j.1442-2050.2005.00485.x; Sato N, 2002, ANN SURG, V236, P184, DOI 10.1097/00000658-200208000-00006; Senagore AJ, 2003, BRIT J SURG, V90, P1195, DOI 10.1002/bjs.4223; Suda K, 2007, DIS ESOPHAGUS, V20, P478, DOI 10.1111/j.1442-2050.2007.00699.x; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; WATSON A, 1994, SURGERY, V115, P429; Weber T, 2007, J THORAC CARDIOV SUR, V134, P865, DOI 10.1016/j.jtcvs.2007.05.050; Weinbroum AA, 2005, SURGERY, V138, P869, DOI 10.1016/j.surg.2005.05.004	16	16	18	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291			SURG TODAY	Surg. Today	JUN	2009	39	6					476	480		10.1007/s00595-008-3924-2			5	Surgery	Surgery	450IM	WOS:000266394200003	19468802				2020-06-30	J	Aurilio, C; Pace, MC; Pota, V; Sansone, P; Barbarisi, M; Grella, E; Passavanti, MB				Aurilio, C.; Pace, M. C.; Pota, V.; Sansone, P.; Barbarisi, M.; Grella, E.; Passavanti, M. B.			Opioids Switching with Transdermal Systems in Chronic Cancer Pain	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH			English	Article							CLINICAL-ASPECTS; FENTANYL; ROTATION; BUPRENORPHINE; TOLERANCE	Background: Due to tolerance development and adverse side effects, chronic pain patients frequently need to be switched to alternative opioid therapy Objective: To assess the efficacy and tolerability of an alternative transdermally applied (TDS) opioid in patients with chronic cancer pain receiving insufficient analgesia using their present treatment. Methods: A total of 32 patients received alternative opioid therapy, 16 were switched from buprenorphine to fentanyl and 16 were switched from fentanyl to buprenorphine. The dosage used was 50% of that indicated in equipotency conversion tables. Pain relief was assessed at weekly intervals for the next 3 weeks Results: Pain relief as assessed by VAS, PPI, and PRI significantly improved (p < 0.0001) in all patients at all 3 follow up visits. After 3 weeks of treatment, the reduction in the mean VAS, PPI, and PRI scores in the fentanyl and buprenorphine groups was 68, 77, 74, and 69, 79, and 62%, respectively. Over the same time period the use of oral morphine as rescue medication was reduced from 27.5 +/- 20.5 (mean +/- SD) to 3.75 +/- 8.06, and 33.8 +/- 18.9 to 3.75 +/- 10.9 mg/day in the fentanyl and buprenorphine groups, respectively. There was no significant difference in either pain relief or rescue medication use between the two patient groups The number of patient with adverse events fell during the study. After the third week of the treatment the number of patients with constipation was reduced from 11 to 5, and 10 to 4 patients in the fentanyl and buprenorphine groups, respectively. There was a similar reduction in the incidence of nausea and vomiting. No sedation was seen in any patient after one week of treatment. Conclusion: Opioid switching at 50% of the calculated equianalgesic dose produced a significant reduction in pain levels and rescue medication. The incidence of side effects decreased and no new side effects were noted. Further studies are required to provide individualized treatment for patients according to their different types of cancer.	[Aurilio, C.; Pace, M. C.; Pota, V.; Sansone, P.; Barbarisi, M.; Passavanti, M. B.] Univ Naples 2, Dept Anesthesiol Surg & Emergency Sci, Naples, Italy; [Grella, E.] Univ Naples 2, Dept Plast Surg, Naples, Italy	Aurilio, C (reprint author), Univ Naples 2, Dept Anesthesiol Surg & Emergency Sci, Naples, Italy.	caterina.aurilio@unina2.it; caterina.pace@libero.it; vincenzo.pota@inwind.it; pasquale.sansone@unina2.it; manlio.barbarisi@unina2.it; elisa.grella@unina2.it; beatrice.passavanti@unina2.it	POTA, VINCENZO/C-4837-2013; Pace, Maria Caterina/L-5452-2016; Sansone, Pasquale/H-3286-2012; Sansone, Pasquale/AAL-4368-2020	POTA, VINCENZO/0000-0001-9999-3388; Pace, Maria Caterina/0000-0002-9352-4780; Sansone, Pasquale/0000-0003-0873-3586; 			BRUERA E, 1989, PAIN, V37, P203, DOI 10.1016/0304-3959(89)90131-0; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donovan HS, 2008, J PAIN SYMPTOM MANAG, V35, P242, DOI 10.1016/j.jpainsymman.2007.04.017; Dupen A, 2007, PAIN MANAG NURS, V8, P113, DOI 10.1016/j.pmn.2007.02.004; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mercadante S, 2007, J PAIN SYMPTOM MANAG, V34, P532, DOI 10.1016/j.jpainsymman.2007.01.006; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; PORTENOY RK, 1994, CANCER SURV, V21, P49; QUIGLEY C, 2004, [No title captured]; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; Vallerand AH, 2003, NURS CLIN N AM, V38, P435, DOI 10.1016/S0029-6465(02)00094-4; Ward S, 2001, SUPPORT CARE CANCER, V9, P148, DOI 10.1007/s005200000176; Ward S, 2008, HEALTH PSYCHOL, V27, P59, DOI 10.1037/0278-6133.27.1.59; *WHO, 1999, J MOFFITT CANC CTR, V6, P191; Williams RL, 2002, CLIN PHARMACOL THER, V72, P229, DOI 10.1067/mcp.2002.126705	20	20	20	0	2	BIOMED CENTRAL LTD	LONDON	CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1756-9966			J EXP CLIN CANC RES	J. Exp. Clin. Cancer Res.	MAY 7	2009	28								61	10.1186/1756-9966-28-61			7	Oncology	Oncology	447AJ	WOS:000266163700001	19422676	DOAJ Gold, Green Published			2020-06-30	J	Massicotte, L; Chalaoui, KD; Beaulieu, D; Roy, JD; Bissonnette, F				Massicotte, L.; Chalaoui, K. D.; Beaulieu, D.; Roy, J. -D.; Bissonnette, F.			Comparison of spinal anesthesia with general anesthesia on morphine requirement after abdominal hysterectomy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							INTRATHECAL MORPHINE; POSTOPERATIVE PAIN; CESAREAN DELIVERY; ANALGESIA; EFFICACY; FENTANYL; SECTION; RELIEF; SAFETY	The aim of this study was to compare morphine consumption with patient-controlled analgesia (PCA) between spinal anesthesia (SA) (bupivacaine, morphine and fentanyl) and general anesthesia (GA) (sufentanil) after an abdominal hysterectomy. Forty women were randomly assigned to receive SA with bupivacaine 15 mg, 0.15 mg of intrathecal morphine and 15 mu g of fentanyl or GA with sufentanil, both combined with PCA. The primary outcome was morphine consumption with the PCA device. The secondary outcomes were post-operative pain at rest and under stress on a visual analog scale, nausea, pruritus and respiratory depression on a standardized scale. Outcome measures were recorded at 6, 12, 18, 24 and 48 h post-anesthesia. The duration of post-anesthesia care unit (PACU) and hospital stay were recorded. Patients in the SA group consumed at least two times less morphine at each time interval than the GA group: at 48 h, they used 19 +/- 17 vs. 81 +/- 31 mg (P < 0.0001). Post-operative pain at rest was lower in the SA group until the 18th hour and under stress until the 48th. There was more sedation in the GA group until the 18th hour. Little difference was observed in the incidence of pruritus. Nausea was more intense at the 6th hour in the GA group. There was no difference in the respiratory rate. The duration of PACU stay was shorter for the SA group (52 +/- 9 vs. 73 +/- 11 min, P < 0.0001) as was the duration of hospital stay (2.2 +/- 0.4 vs. 3.3 +/- 0.7 days, P=0.01). It is concluded that intrathecal morphine 0.15 mg with 15 mu g of fentanyl decreases post-operative pain and morphine consumption by PCA without increasing adverse reactions for women undergoing an abdominal hysterectomy.	[Massicotte, L.; Beaulieu, D.; Roy, J. -D.] CHUM Hop St Luc, Dept Anesthesiol, Montreal, PQ H2X 3J4, Canada; [Chalaoui, K. D.] Univ Montreal, Dept Obstet & Gynecol, Montreal, PQ, Canada; [Bissonnette, F.] CHUM Hop St Luc, Dept Obstet & Gynecol, Montreal, PQ H2X 3J4, Canada	Massicotte, L (reprint author), CHUM Hop St Luc, Dept Anesthesiol, 1058 Rue St Denis, Montreal, PQ H2X 3J4, Canada.	luc.massicotte@umontreal.ca					ABBOUD TK, 1988, ANESTH ANALG, V67, P137; Bogra J, 2005, BMC ANESTHESIOL, V5, P5, DOI DOI 10.1186/1471-2253-5-5; Callesen T, 1999, BRIT J ANAESTH, V82, P881; Cardoso MMSC, 1998, ANESTH ANALG, V86, P538, DOI 10.1097/00000539-199803000-00017; Celeski D C, 1999, AANA J, V67, P239; Choiniere M, 1996, J PAIN SYMPTOM MANAG, V11, P299, DOI 10.1016/0885-3924(95)00204-9; Fournier R, 2000, ANESTH ANALG, V90, P918, DOI 10.1213/00000539-200004000-00026; Ghirardini Giuseppe, 1998, Clinical and Experimental Obstetrics and Gynecology, V25, P105; GUSTAFSSON LL, 1982, BRIT J ANAESTH, V54, P479, DOI 10.1093/bja/54.5.479; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Habib AS, 2005, ANESTH ANALG, V100, P239, DOI 10.1213/01.ANE.0000143955.37182.09; Jain K, 2004, INT J OBSTET ANESTH, V13, P215, DOI 10.1016/j.ijoa.2004.04.006; LEFEBVRE G, 2002, JOGC, V104, P1; Melzack R, 1989, J Pain Symptom Manage, V4, P157, DOI 10.1016/0885-3924(89)90010-9; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RIGG JR, LANCET, V13, P1276; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Roy JD, 2006, ANESTH ANALG, V103, P990, DOI 10.1213/01.ane.0000238040.41872.7e; Shapiro A, 2005, J CLIN ANESTH, V17, P537, DOI 10.1016/j.jclinane.2005.01.006; Swart M, 1997, ANAESTHESIA, V52, P373, DOI 10.1111/j.1365-2044.1997.az0083c.x; Wang JJ, 1996, REGION ANESTH, V21, P281; WAY JD, 1979, ANESTHESIOLOGY, V50, P149	22	28	30	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2009	53	5					641	647		10.1111/j.1399-6576.2009.01930.x			7	Anesthesiology	Anesthesiology	433DL	WOS:000265184400015	19419359				2020-06-30	J	McCluskey, SV; Graner, KK; Kemp, J; Aloumanis, V; Ben, M; Kupiec, T; Vu, N				McCluskey, Susan V.; Graner, Kevin K.; Kemp, Jesse; Aloumanis, Vasileios; Ben, Michel; Kupiec, Thomas; Vu, Nicole			Stability of fentanyl 5 mu g/mL diluted with 0.9% sodium chloride injection and stored in polypropylene syringes	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article						Chromatography, liquid; Color; Concentration; Diluents; Fentanyl citrate; Hydrogen ion concentration; Injections; Opiates; Polymers; Polypropylene; Sodium; Stability; Storage; Syringes		Purpose. The stability of fentanyl 5 mu g/mL in 0.9% sodium chloride solution packaged in polypropylene syringes was studied. Methods. Samples of fentanyl 5 mu g (as the citrate) per milliliter in 0.9% sodium chloride injection were prepared and assessed for chemical stability using a validated, stability-indicating high-performance liquid chromatographic (HPLC) assay. A total of 12 syringe samples were submitted for chemical stability testing by HPLC. The syringes were protected from light and stored in controlled ambient conditions (23-27 degrees C and 55-65% relative humidity) in an environmental chamber. Three samples were tested initially and at each 30-day interval. Each syringe sample was tested with two determinations, using the average of the determinations for the assay result. Samples were assessed for pH and inspected for color and visible particulate matter. Stability was defined as the retention of 90-110% of the initial drug concentration at 30, 60, and 90 days. Results. Fentanyl citrate injection maintained the appearance of a clear, colorless solution, with mean +/- S.D. pH values ranging from 4.13 +/- 0.01 to 4.52 +/- 0.02 throughout the study period, Recovery of fentanyl ranged from 99.86% +/- 0.29% to 102.74% +/- 1.60% of the initial concentration, with no detectable changes in the chromatographic profiles of all tested samples. Conclusion. Fentanyl 5 mu g (as the citrate) per milliliter in 0.9% sodium chloride injection, packaged in polypropylene syringes and stored protected from light, was stable for at least 90 days in controlled ambient conditions.	[McCluskey, Susan V.] Mayo Clin, Ei Pharm Serv 1 420, Rochester, MN 55902 USA; [Vu, Nicole] Analyt Res Labs, Oklahoma City, OK USA	McCluskey, SV (reprint author), Mayo Clin, Ei Pharm Serv 1 420, 201 W Ctr St, Rochester, MN 55902 USA.	mccluskey.susan@mayo.edu					Akers MJ, 1994, PARENTERAL QUALITY C, V2nd, P3; ALLEN LV, 1990, AM J HOSP PHARM, V47, P1572, DOI 10.1093/ajhp/47.7.1572; [Anonymous], 2007, US PHARM 30 REV NAT, P334; BING CM, 2005, EXTENDED STABLITY PA, P132; Jappinen Annalisa Msc Pharm, 2002, Int J Pharm Compd, V6, P471; TRISSEL LA, 2005, TRISSELS STABILITY C, P172; TRISSEL LA, 2007, HDB INJ DRUGS, P699; *US PHARM CONV, 2007, US PHARM 30 REV NAT, P97; *US PHARM CONV, 2007, US PHARM, P680; *US PHARM CONV, 2007, US PHARM 30 REV NAT, P2123	10	6	6	0	6	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082			AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	MAY 1	2009	66	9					860	863		10.2146/ajhp080255			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	437RD	WOS:000265503700018	19386950				2020-06-30	J	Jahanbakhsh, S; Bameshki, A; Khashayar, P				Jahanbakhsh, S.; Bameshki, A.; Khashayar, P.			Remifentanil-induced abdominal pain: a randomised clinical trial	ANAESTHESIA AND INTENSIVE CARE			English	Article						remifentanil; side-effect; abdominal pain; cataract surgery	SMALL-DOSE KETAMINE; TRACHEAL INTUBATION; INDUCED ANALGESIA; HYPERALGESIA; MODULATION; PROPOFOL; HUMANS	Remifentanil is all ultra-short-acting opioid, widely used for induction and maintainance of anaesthesia in various types of operations. We recently noted that a great number of patients receiving remifentanil in their anaesthetic regimen experienced postoperative abdominal pain. As a result, we performed this study to investigate its incidence. This randomised single-blinded clinical trial was conducted oil 300 patients who were undergoing elective cataract surgery under general anaesthesia. The patients were randomly divided into two groups. In the control group (n = 150), anaesthesia was induced with fentanyl and propofol and maintained with propofol by infusion and 60% N2O. In the remifentanil group, anaesthesia was induced with remifentanil and propofol and maintained with remifentanil infusion and inhalation of 60% N2O. Atracurium was used for muscle relaxation in both groups. Abdominal pain was observed in 79 patients (52.6%) in the remifentanil and group, 10 of whom required a therapeutic intervention, but in only three patients in the control group, none of whom required an intervention (P value=0.001). Postoperative nausea and vomiting were reported in seven and 10 patients (4.7%) in the remifentanil and control group, respectively. These findings indicate that abdominal pain is very common in patients receiving remifentanil by infusion for cataract surgery.	[Jahanbakhsh, S.; Bameshki, A.] Med Sci Univ Mashhad, Dept Anesthesiol, Imam Reza Hosp, Tehran, Iran; [Khashayar, P.] Univ Tehran Med Sci, Sina Hosp, Ctr Res & Dev, Tehran 11397, Iran	Khashayar, P (reprint author), Univ Tehran Med Sci, Sina Hosp, Ctr Res & Dev, Imam Khomeini St, Tehran 11397, Iran.		Khashayar, Patricia/C-2738-2009	Khashayar, Patricia/0000-0001-7525-8418			Albertin A, 2000, Minerva Anestesiol, V66, P691; Barclay K, 2000, ANAESTH INTENS CARE, V28, P403; Cohen J, 2001, Curr Opin Crit Care, V7, P227, DOI 10.1097/00075198-200108000-00003; Hall AP, 2000, BRIT J ANAESTH, V84, P100; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Luginbuhl M, 2003, ANESTH ANALG, V96, P726, DOI 10.1213/01.ANE.0000048086.58161.18; Patel SS, 1996, DRUGS, V52, P417, DOI 10.2165/00003495-199652030-00009; Scholz J, 1996, Anasthesiol Intensivmed Notfallmed Schmerzther, V31, P592, DOI 10.1055/s-2007-995993; VUYK J, 1995, ANESTHESIOLOGY, V83, P8, DOI 10.1097/00000542-199507000-00003; Yarmush J, 1997, ANESTHESIOLOGY, V87, P235, DOI 10.1097/00000542-199708000-00009	11	0	0	0	2	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	MAY	2009	37	3					447	449		10.1177/0310057X0903700302			3	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	448QA	WOS:000266275900014	19499866	Bronze			2020-06-30	J	McKenzie, A; Sherwood, M				McKenzie, A.; Sherwood, M.			Continuous spinal analgesia after extensive lumbar spine surgery	ANAESTHESIA AND INTENSIVE CARE			English	Article						spinal analgesia; lumbar spine surgery; post-dural puncture headache; intrathecal morphine	SELECTIVE DORSAL RHIZOTOMY; INTRATHECAL PAIN TREATMENT; MORPHINE; CATHETER; CHILDREN; BUPIVACAINE; MANAGEMENT; DRAINAGE; FUSION	A 77-year-old male underwent L-1 to S-1 spine decompression and fusion from L-3 to S-1. A 25 G spinal catheter was placed intraoperatively, and bupivacaine 1.25 mg/ml, fentanyl 2 mu g/ml and morphine 3 mu g/ml infused. The patient was pain-free for the duration of the infusion. Continuous spinal analgesia was effective after extensive spinal surgery The risks of post-dural puncture headache, infection of wound and/or meninges and the optimum drug doses and combinations are yet to be quantified in this setting.	[McKenzie, A.; Sherwood, M.] Wakefield Hosp, Wellington, New Zealand; [McKenzie, A.] Wellington Hosp, Dept Anaesthesia & Pain Management, Wellington, New Zealand; [Sherwood, M.] Pacific Orthopaed, Wellington, New Zealand	McKenzie, A (reprint author), Wakefield Hosp, Wellington, New Zealand.						BAILEY PL, 1993, ANESTHESIOLOGY, V79, P49, DOI 10.1097/00000542-199307000-00010; BEVACQUA BK, 1994, ANESTHESIOLOGY, V80, P1234, DOI 10.1097/00000542-199406000-00010; Bevacqua Brian K, 2003, Best Pract Res Clin Anaesthesiol, V17, P393, DOI 10.1016/S1521-6896(02)00117-9; Brown MD, 2004, SPINE, V29, P1066, DOI 10.1097/00007632-200405150-00003; COLPLIN WM, 1999, J NEUROL NEUROSUR PS, V67, P468; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; France JC, 1997, SPINE, V22, P2272, DOI 10.1097/00007632-199710010-00015; Gottschalk A, 2004, ANESTHESIOLOGY, V101, P175, DOI 10.1097/00000542-200407000-00027; Harney D, 2005, REGION ANESTH PAIN M, V30, P317, DOI 10.1016/j.rapm.2005.03.005; Hesselgard K, 2006, PEDIATR ANESTH, V16, P436, DOI 10.1111/j.1460-9592.2005.01804.x; Hesselgard K, 2001, PAEDIATR ANAESTH, V11, P75, DOI 10.1046/j.1460-9592.2001.00606.x; Ho C, 2007, SPINE, V32, P2272, DOI 10.1097/BRS.0b013e31814b1c0b; Hughes SA, 2006, SURG NEUROL, V65, P410, DOI 10.1016/j.surneu.2005.11.052; Johnson SM, 2008, SURG INFECT, V9, P205, DOI 10.1089/sur.2007.036; Kroin J. S., 1993, NEUROSURGERY, V33, P30; KROIN JS, 1993, NEUROSURGERY, V33, P226; RATILAL B, 2006, COCHRANE DB SYST REV, V3; Reynolds F, 2001, ANAESTHESIA, V56, P238, DOI 10.1046/j.1365-2044.2001.01422-2.x; Sell A, 2006, ACTA ANAESTH SCAND, V50, P217, DOI 10.1111/j.1399-6576.2006.00918.x; SIMMONS SW, 2007, COCHRANE DB SYST REV, V18; Sin AH, 2006, J NEUROSURG-SPINE, V5, P224, DOI 10.3171/spi.2006.5.3.224; Tobias JD, 2004, ANESTH ANALG, V98, P956, DOI 10.1213/01.ANE.0000107938.80562.75; Wang JC, 1998, J BONE JOINT SURG AM, V80A, P1728, DOI 10.2106/00004623-199812000-00002	23	1	1	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	MAY	2009	37	3					473	476		10.1177/0310057X0903700309			4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	448QA	WOS:000266275900019	19499871	Bronze			2020-06-30	J	Ghrab, BE; Maatoug, M; Kallel, N; Khemakhem, K; Chaari, M; Kolsi, K; Karoui, A				Ghrab, B. E.; Maatoug, M.; Kallel, N.; Khemakhem, K.; Chaari, M.; Kolsi, K.; Karoui, A.			Does combination of intrathecal magnesium sulfate and morphine improve postcaesarean section analgesia?	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						Spinal analgesia; Caesarean section; Magnesium sulphated; Morphine	SPINAL-ANESTHESIA; CESAREAN-SECTION; CONTROLLED-TRIAL; DOUBLE-BLIND; RATS; PAIN; BUPIVACAINE; EFFICACY; KETAMINE; DELIVERY	Background. - Intrathecal morphine (IT) is commonly used for postoperative analgesia after caesarean section. The addition of intrathecal (IT) magnesium to spinal bupivacaine-fentanyl anaesthesia increases the duration of spinal analgesia for labour without additional side effects. In this prospective, randomized, double blind, controlled study, we evaluated whether adding intrathecal niagnesillul Could prolong spinal morphine analgesia after caesarean section. Parturient and methods. - After ethics committee approval and obtaining written consent, one hundred and five (ASA I or II) adult patients undergoing caesarean section were recruited. They were randomly allocated to one of three groups: ( 1) group Morphine (M): 10 mg of isobaric bupivacaine 0.5% (2 ml) + 100 mu g morphine (1 ml) + 10 mu g fentanyl (0.1 ml) + 1 ml of isotonic saline solution, (2) group Magnesium (Mg): 10 mg of isobaric bupivacame 0.5% (2 ml) + 100 mg of magnesium sulphate 10% (1 ml) + 10 mu g fentanyl (0.1 ml) + I nil of isotonic saline solution, (3) group Morphine + Magnesium (MMg): 10 mg of isobaric bupivacaine 0.5% (2 nil) + 100 mg of magnesium sulphate 10% (1 ml) + 100 mu g morphine (1 ml) + 10 Rg fentanyl (0.1 ml). We recorded the following: time to the first analgesic request, pain scores with the visual analogic scale at rest and in movement at h0, h1, h2, h4 and then every 4 h for the first 36 postoperative hours, the occurrence of adverse events and patients' satisfaction. Results. - Time of the first analgesic request was 28 +/- 8 h in group MMg versus 19 6 It in group M and 7 +/- 6 h in group Mg (p < 0.01). Pain scores were statistically lower in group MMg (9 +/- 7 and 17 +/- 9 mm respectively) compared to group M (16 9 and 28 11 mm respectively) and Mg (21 +/- 9 and 37 +/- 13 mm respectively) (p < 0.01). There was no difference in adverse events among the three groups. Patients satisfaction was better in group MMg (p < 0.01). Conclusion. - In patients undergoing caesarean section under spinal anaesthesia, the addition of IT magnesium sulphate (100 mg) to morphine 100 mu g improved the quality and the duration of postoperative analgesia without increasing the incidence of adverse effects. (C) 2009 Elsevier Masson SAS. All rights reserved.	[Ghrab, B. E.; Maatoug, M.; Kallel, N.; Khemakhem, K.; Chaari, M.; Kolsi, K.; Karoui, A.] CHU Habib Bourguiba, Serv Anesthesie Reanimat Chirurg, Sfax, Tunisia	Ghrab, BE (reprint author), CHU Habib Bourguiba, Serv Anesthesie Reanimat Chirurg, Sfax, Tunisia.	dr_badiezzamen@yahoo.fr	MHAMED, MAATOUG/T-6939-2018	MHAMED, MAATOUG/0000-0001-5620-0931			ABBOUD TK, 1988, ANESTH ANALG, V67, P137; ABOULEISH E, 1991, REGION ANESTH, V16, P137; [Anonymous], 1998, ANN FR ANESTH, V17, P445; Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; Bilir A, 2007, BRIT J ANAESTH, V98, P519, DOI 10.1093/bja/aem029; Birbicer H, 2007, PEDIATR SURG INT, V23, P195, DOI 10.1007/s00383-006-1779-4; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dresner MR, 2001, BEST PRACT RES CL OB, V15, P127, DOI 10.1053/beog.2000.0153; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; FuchsBuder T, 1997, J NEUROSURG ANESTH, V9, P324, DOI 10.1097/00008506-199710000-00006; Gogarten Wiebke, 2003, Best Pract Res Clin Anaesthesiol, V17, P377; Haubold HA, 1906, J AMER MED ASSOC, V46, P647; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; LEJUSTE MJLR, 1985, S AFR MED J, V68, P367; Liu HT, 2001, ANESTH ANALG, V92, P1173; LYBECKER H, 1990, ANESTH ANALG, V70, P389; McCarthy RJ, 1998, ANESTH ANALG, V86, P830, DOI 10.1097/00000539-199804000-00028; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; Paech MJ, 2004, ANESTH ANALG, V98, P1460, DOI 10.1213/01.ANE.0000111208.08867.3C; POCKETT S, 1995, ANESTH ANALG, V80, P173, DOI 10.1097/00000539-199501000-00026; Puri GD, 1998, ANESTH ANALG, V87, P808, DOI 10.1097/00000539-199810000-00012; REN K, 1992, PAIN, V50, P331, DOI 10.1016/0304-3959(92)90039-E; Takano Y, 2000, PAIN, V84, P175, DOI 10.1016/S0304-3959(99)00207-9; Unlugenc H, 2006, EUR J ANAESTH, V23, P1018, DOI 10.1017/S0265021506000950; WONG CH, 1994, ANESTH ANALG, V79, P303; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	28	19	19	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	MAY	2009	28	5					454	459		10.1016/j.annfar.2009.03.004			6	Anesthesiology	Anesthesiology	455CI	WOS:000266733800010	19427159				2020-06-30	J	Bandieri, E; Chiarolanza, A; Luppi, M; Magrini, N; Marata, AM; Ripamonti, C				Bandieri, E.; Chiarolanza, A.; Luppi, M.; Magrini, N.; Marata, A. M.; Ripamonti, C.			Prescription of opioids in Italy: everything, but the morphine	ANNALS OF ONCOLOGY			English	Letter									[Bandieri, E.; Chiarolanza, A.; Magrini, N.; Marata, A. M.] Univ Modena & Reggio Emilia, Ctr Evaluat Effectiveness Hlth Care CeVEAS, WHO Collaborating Ctr, Modena, Italy; [Ripamonti, C.] Natl Canc Inst, Palliat Care Unit Pain Therapy & Rehab, I-20133 Milan, Italy; [Luppi, M.] Univ Modena & Reggio Emilia, Dept Oncol Haematol & Resp Dis, Modena, Italy	Bandieri, E (reprint author), Univ Modena & Reggio Emilia, Ctr Evaluat Effectiveness Hlth Care CeVEAS, WHO Collaborating Ctr, Modena, Italy.	carla.ripamonti@istitutotumori.mi.it	Luppi, Mario/J-3668-2016; Ripamonti, Carla/C-4557-2017	Luppi, Mario/0000-0002-0373-1154; Ripamonti, Carla/0000-0001-5495-5054			Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; *ESMO, ANN ONCOL, V19, P119; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Wiffen PJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub2; World Health Organization, 1996, CANC PAIN REL	6	27	28	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534			ANN ONCOL	Ann. Oncol.	MAY	2009	20	5					961	962		10.1093/annonc/mdp041			2	Oncology	Oncology	440ZY	WOS:000265739700026	19282469	Bronze			2020-06-30	J	Hill, LR; Pichel, AC				Hill, Lisar R.; Pichel, Adam C.			Respiratory arrest after cadaveric renal transplant	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							FENTANYL; PHARMACOKINETICS		[Hill, Lisar R.] Royal Perth Hosp, Dept Anaesthesia, Perth, WA 6001, Australia; [Pichel, Adam C.] Manchester Royal Infirm, Dept Anaesthesia, Manchester M13 9WL, Lancs, England	Hill, LR (reprint author), Royal Perth Hosp, Dept Anaesthesia, GPO Box X2213, Perth, WA 6001, Australia.	lisarachelhill@googlemail.com					ALAZIA M, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P465, DOI 10.1016/S0750-7658(87)80376-3; BOVILL JG, 1980, BRIT J ANAESTH, V52, P795, DOI 10.1093/bja/52.8.795; CORALL IM, 1980, BRIT J ANAESTH, V52, P101; Koehntop DE, 1997, PHARMACOTHERAPY, V17, P746; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; SEAR JW, 2000, BRIT J ANAESTH, V84, P285; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741	7	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	MAY	2009	26	5					435	436		10.1097/EJA.0b013e32831dccf4			2	Anesthesiology	Anesthesiology	438NH	WOS:000265561700013	19521299				2020-06-30	J	Garg, R				Garg, Rakesh			Does fentanyl really need to be omitted in favour of sevoflurane in day care surgery?	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							NITROUS-OXIDE; NAUSEA		[Garg, Rakesh] All India Inst Med Sci, Dept Anaesthesiolgy & Intens Care, New Delhi, India	Garg, R (reprint author), 58-E Kavita Colony, Delhi 110041, India.	drrgarg@hotmail.com					Albertin A, 2005, EUR J ANAESTH, V22, P431, DOI 10.1017/S0265021505000736; Kjetil H, 2007, ANESTH ANALG, V105, P481, DOI 10.1213/01.ane.0000267261.61444.69; Mraovic B, 2008, ANESTH ANALG, V107, P818, DOI 10.1213/ane.0b013e318181f4aa; Smith ER, 2003, GYNECOL ONCOL, V91, P1, DOI 10.1016/S0090-8258(03)00463-3; Smith I, 2008, EUR J ANAESTH, V25, P790, DOI 10.1017/S026502150800464X; TAKASUMI K, 1998, ANESTHESIOLOGY, V88, P18; TAKASUMI K, 1999, ANESTHESIOLOGY, V90, P398; Zhang Y, 1999, Zhonghua Yi Xue Za Zhi, V79, P187	8	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAY	2009	26	5					436	438		10.1097/EJA.0b013e32831f3486			3	Anesthesiology	Anesthesiology	438NH	WOS:000265561700014	19295438				2020-06-30	J	Watts, P; Smith, A				Watts, Peter; Smith, Alan			PecSys: in situ gelling system for optimised nasal drug delivery	EXPERT OPINION ON DRUG DELIVERY			English	Article						buprenorphine; fentanyl; gel; modified release; mucosal; nasal; pain; pectin	HUMAN GROWTH-HORMONE; INTRANASAL HYDROMORPHONE; BIOAVAILABILITY; FENTANYL; CHITOSAN; PECTIN; VITRO; PAIN; PHARMACOKINETICS; FORMULATIONS	PecSys (TM) (pS) is a proprietary pectin-based drug delivery system designed to gel when applied to mucosal surfaces and with potential areas of application for drugs used in local and systemic disease therapy. The current area of focus is intranasal drug delivery where PS is being used to optimise absorption of lipophilic drugs into the systemic circulation. Pectin is described as GRAS (generally regarded as safe) with an excellent regulatory position through its long history of pharmaceutical and food usage. Tests to measure the functional gelling properties of pectin raw material and PS have been devised and validated. The PS-based products at the most advanced stages of development are intranasal formulations containing opioid analgesics intended to provide rapid pain relief with simple and convenient dosing and minimal side effects. The profile of such drugs may not be optimal through current routes of delivery and the ability of PS to modulate their pharmacokinetic profiles, such as attenuation of the peak plasma concentration (C-max), has been demonstrated in clinical testing. The lead product using PS is a fentanyl nasal spray formulation (NasalFent (R)), which has successfully met the primary objective in a pivotal Phase III clinical study and is scheduled for regulatory filings in the first half of 2009.	[Watts, Peter; Smith, Alan] Archimedes Dev Ltd, Albert Einstein Ctr, Nottingham NG7 2TN, England	Watts, P (reprint author), Archimedes Dev Ltd, Albert Einstein Ctr, Nottingham Sci & Technol Pk,Univ Blvd, Nottingham NG7 2TN, England.	peterwatts@archimedespharma.com					[Anonymous], 2006, US PHARM 30 NAT FORM; *ARCH PHARM, ARCH PHARM ANN POST; Axelos M. A. V., 1991, CHEM TECHNOLOGY PECT, P109, DOI DOI 10.1016/B978-0-08-092644-5.50011-X; Badve SS, 2007, EUR J PHARM BIOPHARM, V65, P85, DOI 10.1016/j.ejpb.2006.07.010; *BRIT PHARM, AP NAS; Cao SL, 2009, INT J PHARMACEUT, V365, P109, DOI 10.1016/j.ijpharm.2008.08.042; Charlton S, 2007, EUR J PHARM SCI, V30, P295, DOI 10.1016/j.ejps.2006.11.018; Charlton ST, 2007, J CONTROL RELEASE, V118, P225, DOI 10.1016/j.jconrel.2006.12.014; Cheng YH, 2005, EUR J PHARM SCI, V26, P9, DOI 10.1016/j.ejps.2005.03.014; Christensen KS, 2008, ANESTH ANALG, V107, P2018, DOI 10.1213/ane.0b013e318187b952; Costantino HR, 2007, INT J PHARMACEUT, V337, P1, DOI 10.1016/j.ijpharm.2007.03.025; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; DAVIES G, 2007, P 10 C EUR ASS PALL; Davis GA, 2004, CLIN DRUG INVEST, V24, P633, DOI 10.2165/00044011-200424110-00002; Davis GA, 2004, PHARMACOTHERAPY, V24, P26, DOI 10.1592/phco.24.1.26.34810; DILORENZO C, 1988, GASTROENTEROLOGY, V95, P1211, DOI 10.1016/0016-5085(88)90352-6; EICHNER H, 1983, LARYNG RHINOL OTOL V, V62, P561, DOI 10.1055/s-2007-1008498; Ghosh PK, 2006, AAPS PHARMSCITECH, V7; Greiff L, 2002, CLIN PHYSIOL FUNCT I, V22, P55, DOI 10.1046/j.1475-097X.2002.00401.x; GUYTON AC, 2000, TXB MED PHYSL, P899; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; *IK THER INC, MID; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; ILLUM L, 1996, Patent No. 5554388; Illum LC, 2008, Patent No. [US 7,323,183, 7323183]; *IPPA, SAF LEG STAT PECT; Itoh K, 2007, INT J PHARM, V335, P90, DOI 10.1016/j.ijpharm.2006.10.042; Klas SD, 2008, VACCINE, V26, P5494, DOI 10.1016/j.vaccine.2008.07.062; LEARY AC, 2008, DIABETES SCI TECHNOL, V2, P1054; Leitner VM, 2004, J CONTROL RELEASE, V100, P87, DOI 10.1016/j.jconrel.2004.08.001; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; LORIN MI, 1972, J LAB CLIN MED, V80, P275; MAY CD, 1990, CARBOHYD POLYM, V12, P79, DOI 10.1016/0144-8617(90)90105-2; McNeela EA, 2004, VACCINE, V22, P909, DOI 10.1016/j.vaccine.2003.09.012; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; *NASC, NASC CYAN USP NAS SP; Ni Y, 1999, United States patent, Patent No. 5929051; PIETRUSKO RG, 1979, AM J HOSP PHARM, V36, P757, DOI 10.1093/ajhp/36.6.757; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Rapoport A, 2006, HEADACHE, V46, pS192, DOI 10.1111/j.1526-4610.2006.00603.x; Rennie P, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-38; Rolin C., 1993, IND GUMS POLYSACCHAR, P257, DOI DOI 10.1016/B978-0-08-092654-4.50014-0; ROWE RC, 2006, HDB PHARM EXCIPIENT, P507; Soane RJ, 1999, INT J PHARMACEUT, V178, P55, DOI 10.1016/S0378-5173(98)00367-6; Sriamornsak P, 2007, EUR J PHARM BIOPHARM, V67, P211, DOI 10.1016/j.ejpb.2006.12.014; *STABL MICR, TEXT AN; Thakur BR, 1997, CRIT REV FOOD SCI, V37, P47, DOI 10.1080/10408399709527767; TOMBS MP, 1998, INTRO POLYSACCHARIDE, P47; Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004; *VERN R D CTR, POST PAIN V1003; WASHINGTON N, 2001, PHYSL PHARM BARRIER, P211; WEST PHARM SERV DRUG, 2002, Patent No. 6432440; Wu J, 2007, BIOMATERIALS, V28, P2220, DOI 10.1016/j.biomaterials.2006.12.024	54	66	67	1	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1742-5247	1744-7593		EXPERT OPIN DRUG DEL	Expert Opin. Drug Deliv.	MAY	2009	6	5					543	552		10.1517/17425240902939135			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	448RX	WOS:000266280800008	19413461				2020-06-30	J	Laim, A; Jaggy, A; Forterre, F; Doherr, MG; Aeschbacher, G; Glardon, O				Laim, Annina; Jaggy, Andre; Forterre, Franck; Doherr, Marcus G.; Aeschbacher, Gina; Glardon, Olivier			Effects of adjunct electroacupuncture on severity of postoperative pain in dogs undergoing hemilaminectomy because of acute thoracolumbar intervertebral disk disease	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							ACUPUNCTURE; STIMULATION; ANALGESIA; MECHANISMS	Objective-To compare severity of postoperative pain in dogs undergoing hemilaminectomy because of acute thoracolumbar intervertebral disk disease treated with a combination of conventional analgesics and electroacupuncture (EAP) or with conventional analgesics alone. Design-Controlled clinical trial. Animals-15 dogs undergoing surgery because of acute thoracolumbar disk disease. Procedures-Dogs were alternately assigned to treatment (conventional analgesics and adjunct EAP) and control (conventional analgesics alone) groups. Analgesic treatment was adjusted as necessary by the attending clinician, who was not aware of group assignment. Pain scores were assigned 1, 3, and 12 hours after surgery and every 12 hours thereafter for 72 hours by the same individual who performed acupuncture treatments. Results-Total dose of fentanyl administered during the first 12 hours after surgery was significantly lower in the treatment group than in the control group, but dosages of analgesics administered from 12 through 72 hours after surgery did not differ between groups. Pain score was significantly lower in the treatment group than in the control group 36 hours after surgery, but did not differ significantly between groups at any other time. Conclusions and Clinical Relevance-Results provided equivocal evidence that adjunct EAP might provide some mild benefit in regard to severity of postoperative pain in dogs undergoing hemilaminectomy because of acute thoracolumbar intervertebral disk disease. (J Am Vet Med Assoc 2009;234:1141-1146)	[Laim, Annina; Jaggy, Andre; Forterre, Franck; Doherr, Marcus G.; Aeschbacher, Gina; Glardon, Olivier] Univ Bern, Dept Clin Vet Med, Vetsuisse Fac, CH-3001 Bern, Switzerland	Laim, A (reprint author), Clin Small Anim, Rothusstr 2B, CH-6331 Hunenberg, Switzerland.			Doherr, Marcus/0000-0003-0064-1708			Adams H. R., 2001, VET PHARM THERAPEUTI, P268; Cassu RN, 2008, VET ANAESTH ANALG, V35, P52, DOI 10.1111/j.1467-2995.2007.00347.x; DRAEHMPAEHL D, 1998, AKUPUNKTUR BEI HUND, P48; Farber PL, 1997, ACUPUNCTURE ELECTRO, V22, P109, DOI 10.3727/036012997816356725; FLECKNELL PA, 2000, SAUNDERS MANUAL SMAL, P21; FUKAZAWA Y, 1999, J PHARM SCI, V99, P408; HAB JS, 1992, NEWS PHYSIOL SCI, V7, P176; Hardie EM, 1997, J AM VET MED ASSOC, V211, P977; Hayashi AM, 2007, JAVMA-J AM VET MED A, V231, P913, DOI 10.2460/javma.231.6.913; Holton LL, 1998, J SMALL ANIM PRACT, V39, P469, DOI 10.1111/j.1748-5827.1998.tb03681.x; Hsieh CL, 2000, AM J CHINESE MED, V28, P291, DOI 10.1142/S0192415X00000349; Irnich D, 2002, SCHMERZ, V16, P93, DOI 10.1007/s004820100094; Jaeger GT, 2006, VET REC, V158, P722, DOI 10.1136/vr.158.21.722; JIANREN M, 2008, PAIN, V2, P1; KAJIWARA M, 1986, JPN J PHARMACOL, V40, P95, DOI 10.1254/jjp.40.95; Kapatkin AS, 2006, JAVMA-J AM VET MED A, V228, P1350, DOI 10.2460/javma.228.9.1350; KASPAR M, 2007, GANZHEITLICHE SCHMER, P254; Lewith GT, 2005, EVID-BASED COMPL ALT, V2, P315, DOI 10.1093/ecam/neh110; LUC AAJ, 2003, AKUPUNKTUR TIERMEDIZ, V14, P203; RYTZ U, 2007, ALTAS LEHRBUCH KLEIN, P206; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; STILL J, 1989, J SMALL ANIM PRACT, V30, P298, DOI 10.1111/j.1748-5827.1989.tb01562.x; Tousignant-Laflamme Y, 2005, J PAIN, V6, P341, DOI 10.1016/j.jpain.2005.01.351; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; VANDEVELDE M, 1981, PATHOPHYSIOLOGY SMAL, P228; Wang RR, 2000, AM J CHINESE MED, V28, P25, DOI 10.1142/S0192415X00000052; WHEELER SJ, 2005, SMALL ANIMAL SPINAL, P121; Yang Jung-whan, 2003, J Vet Sci, V4, P97; YIM YK, 2006, EVID-BASED COMPL ALT, V3, P1; Zhi Liang-Xi, 2007, Zhen Ci Yan Jiu, V32, P342	30	18	18	1	20	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488	1943-569X		JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	MAY 1	2009	234	9					1141	1146		10.2460/javma.234.9.1141			6	Veterinary Sciences	Veterinary Sciences	437UP	WOS:000265512700009	19405884				2020-06-30	J	Yamamoto, Y; Watanabe, S; Kano, T				Yamamoto, Yosuke; Watanabe, Seiji; Kano, Tatsuhiko			Gradient of bronchial end-tidal CO2 during two-lung ventilation in lateral decubitus position is predictive of oxygenation disorder during subsequent one-lung ventilation	JOURNAL OF ANESTHESIA			English	Article						One-lung ventilation; Hypoxemia; Bronchial end-tidal ventilation; Lateral decubitus position	BLOOD-FLOW; ANESTHESIA; VASOCONSTRICTION; TENSION	Purpose. Hypoxemia is one of the major problems during one-lung ventilation (OLV). During two-lung ventilation (TLV) using a double-lumen bronchial tube, bronchial end-tidal carbon dioxide partial pressure (ETbr(CO2)) can be determined on both sides, independently. The ETbr(CO2) is mainly dependent on the pulmonary perfusion to each lung. If the degree of oxygenation disorder during OLV were to be predictable before starting OLV, this could provide time to prepare for any subsequent hypoxemia. The aim of this study was to investigate whether the difference of ETbr(CO2) (D-ETbr(CO2)) between the dependent and the nondependent lungs during TLV in the lateral decubitus position (LP) could be a predictive factor for the severity of oxygenation disorder under subsequent OLV. Methods. Eighteen patients undergoing lung surgery were enrolled in this study. Anesthesia was induced with intravenous thiopental and fentanyl, supplemented by the inhalation of sevoflurane. A left-sided double-lumen bronchial tube was placed. The ETbr(CO2) was independently determined on each side during TLV in the supine position (SP) and at 10 min after changing the position from SP to LP. Pa-O2/inspiratory fraction of oxygen (FIO2) was taken at 15 min after switching from TLV to OLV in LP. Results. The decrease of Pa-O2/FIO2 at 15 min during OLV in LP correlated with the reduction of the D-ETbr(CO2) predetermined during TLV in LP (r = 0.698; P < 0.01). Conclusion. The D-ETbr(CO2) predetermined during TLV in LP could be a predictive factor for the severity of oxygenation disorder after starting OLV in LP.	[Yamamoto, Yosuke; Watanabe, Seiji; Kano, Tatsuhiko] Kurume Univ, Sch Med, Dept Anesthesiol, Kurume, Fukuoka 8300011, Japan	Yamamoto, Y (reprint author), Kurume Univ, Sch Med, Dept Anesthesiol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.				Japanese Ministry of Education, Culture, Sports, Science and Technology for Young ScientistsMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [19791093]	This work was supported by a Grant-in-Aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology for Young Scientists (B, 19791093).	Abe Kazuo, 2006, J Anesth, V20, P1, DOI 10.1007/s00540-005-0352-y; CARLSSON AJ, 1987, ANESTHESIOLOGY, V67, P240, DOI 10.1097/00000542-198708000-00015; EISENKRAFT JB, 1990, BRIT J ANAESTH, V65, P63, DOI 10.1093/bja/65.1.63; Guenoun T, 2002, J CARDIOTHOR VASC AN, V16, P199, DOI 10.1053/jcan.2002.31067; Hoka S, 1997, J CLIN ANESTH, V9, P457, DOI 10.1016/S0952-8180(97)00100-1; HURFORD WE, 1987, ANESTHESIOLOGY, V67, P841, DOI 10.1097/00000542-198711000-00045; Inoue S, 2004, BRIT J ANAESTH, V92, P195, DOI 10.1093/bja/aeh055; JENSEN KS, 1992, J APPL PHYSIOL, V72, P2018; MORRELL NW, 1995, RESP PHYSIOL, V100, P271, DOI 10.1016/0034-5687(95)00002-U; NOMOTO Y, 1987, CAN J ANAESTH, V34, P447, DOI 10.1007/BF03014346; Ribas J, 2001, CHEST, V120, P852, DOI 10.1378/chest.120.3.852; SIMMONS DH, 1961, CIRC RES, V9, P465, DOI 10.1161/01.RES.9.2.465; SLINGER P, 1992, CAN J ANAESTH, V39, P1030, DOI 10.1007/BF03008370; Watanabe S, 2000, ANESTH ANALG, V90, P28, DOI 10.1097/00000539-200001000-00007; WULFF KE, 1972, ACTA ANAESTH SCAND, V16, P195, DOI 10.1111/j.1399-6576.1972.tb00974.x	15	2	2	0	2	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	MAY	2009	23	2					192	197		10.1007/s00540-008-0737-9			6	Anesthesiology	Anesthesiology	445ZG	WOS:000266089400004	19444556				2020-06-30	J	Yumura, J; Koukita, Y; Fukuda, K; Kaneko, Y; Ichinohe, T				Yumura, Junko; Koukita, Yoshihiko; Fukuda, Ken-ichi; Kaneko, Yuzuru; Ichinohe, Tatsuya			Low dose of fentanyl reduces predicted effect-site concentration of propofol for flexible laryngeal mask airway insertion	JOURNAL OF ANESTHESIA			English	Article						Flexible laryngeal mask airway; Propofol; Fentanyl; Bispectral index	HEMODYNAMIC-RESPONSES; BISPECTRAL INDEX; SKIN INCISION; ANESTHESIA; REMIFENTANIL; THIOPENTONE; RATS; EC50	Purpose. In contrast to reports on the classical laryngeal mask airway (classical LMA; CLMA), no report has calculated the 50% and 95% effect-site concentrations (EC(50) and EC(95), respectively) of propofol required for flexible LMA (FLMA) insertion. This study was designed to determine the EC(50) and EC(95) of propofol for FLMA insertion, using probit analysis, and to investigate whether supplemental 0.25 mu g.kg(-1) fentanyl decreased these concentrations. Methods. Fifty-nine unpremedicated patients who were scheduled for elective minor oral surgery were randomly allocated to a saline-propofol group (S-P group; n = 30) or a fentanyl-propofol group (F-P group; n = 29). Each group was further divided into four subgroups, in which the propofol EC for FLMA insertion was set at 2.5, 3.0, 3.5, and 4.0 mu g.ml(-1), respectively, in the S-P group and 1.8, 2.0, 2.5, and 3.0 mu g.ml(-1), respectively, in the F-P group,. The experiment was assessed as "successful" when FLMA insertion within 1 min was possible. Results. The EC(50) and EC(95) in the S-P group were 3.29 (95% confidence interval [CI], 2.83-3.93) and 4.73 (95% CI, 3.94-12.22) mu g.ml(-1), and those in the F-P group were 2.13 (95% CI, 1.42-2.60) and 3.54 95% CI, (2.78-34.78) mu g.ml(-1), respectively. The EC(50) in the F-P group was significantly lower than that in the S-P group. There were no significant differences in bispectral index (BIS), hemodynamic variables, respiratory rate, and arterial oxygen saturation (Sp(O2)) between the S-P and F-P groups. Conclusion. The propofol EC(50) for FLMA insertion was decreased by supplemental 0.25 mu g.kg(-1) fentanyl without BIS, hemodynamic, or respiratory depression.	[Yumura, Junko; Kaneko, Yuzuru; Ichinohe, Tatsuya] Tokyo Dent Coll, Dept Dent Anesthesiol, Mihama Ku, Chiba 2618502, Japan; [Koukita, Yoshihiko; Fukuda, Ken-ichi] Tokyo Dent Coll, Div Dent Anesthesiol, Dept Oral Hlth & Clin Sci, Tokyo, Japan	Yumura, J (reprint author), Tokyo Dent Coll, Dept Dent Anesthesiol, Mihama Ku, 1-2-2 Masago, Chiba 2618502, Japan.						BARKER P, 1992, BRIT J ANAESTH, V69, P23, DOI 10.1093/bja/69.1.23; Brimacombe J, 1999, CAN J ANAESTH, V46, P558, DOI 10.1007/BF03013546; BROWN GW, 1991, ANAESTHESIA, V46, P771, DOI 10.1111/j.1365-2044.1991.tb09776.x; Casati A, 1999, ANESTH ANALG, V88, P917, DOI 10.1097/00000539-199904000-00043; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; GEPTS E, 1987, ANESTH ANALG, V66, P1256; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Iannuzzi M, 2005, BRIT J ANAESTH, V94, P613, DOI 10.1093/bja/aei097; KAMEI J, 1990, EUR J PHARMACOL, V187, P281, DOI 10.1016/0014-2999(90)90014-W; KAMEI J, 1991, EUR J PHARMACOL, V203, P153, DOI 10.1016/0014-2999(91)90807-3; Kazama T, 1998, ANESTHESIOLOGY, V89, P894, DOI 10.1097/00000542-199810000-00014; Kazama T, 1998, ANESTH ANALG, V86, P872, DOI 10.1097/00000539-199804000-00036; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; Kodaka M, 2004, BRIT J ANAESTH, V92, P238, DOI 10.1093/bja/aeh033; Krasowski MD, 2001, NEUROPHARMACOLOGY, V41, P952, DOI 10.1016/S0028-3908(01)00141-1; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; TSUTSUI F, 2005, J CLIN ANESTH, V17, P344; Wang LP, 2007, ANESTH ANALG, V104, P325, DOI 10.1213/01.ane.0000252966.03103.89	21	5	5	0	0	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	MAY	2009	23	2					203	208		10.1007/s00540-008-0728-x			6	Anesthesiology	Anesthesiology	445ZG	WOS:000266089400006	19444558				2020-06-30	J	Shin, HY; Lim, JA; Kim, SH; Baek, SW; Kim, DK				Shin, Hwa-Yong; Lim, Jung-Ae; Kim, Seong-Hyop; Baek, Seung-Woo; Kim, Duk-Kyung			Desflurane requirements for laryngeal mask airway insertion during inhalation induction	JOURNAL OF ANESTHESIA			English	Article						Desflurane; Inhalation induction; Laryngeal mask airway	MINIMUM ALVEOLAR CONCENTRATION; TRANSIENT CARDIOVASCULAR STIMULATION; DAY-CASE ANESTHESIA; DOWN METHOD; SEVOFLURANE; HUMANS; IRRITATION; FENTANYL; SMOKING	We hypothesized that the simultaneous use of low concentrations (< 6%) of desflurane, nitrous oxide (N2O), and fentanyl would allow a laryngeal mask airway (LMA) to be inserted safely with inhalation induction of desflurane, even in nonparalyzed patients. This prospective, observational study was performed to determine the 50% effective concentration (EC50) of desflurane for LMA insertion in such patients. Twenty-two adult patients undergoing ambulatory surgical procedures under general anesthesia using an LMA were included in the study. Fentanyl was administered intravenously at 1.5 mu g center dot kg(-1), and anesthesia was induced with desflurane in 50% N2O and oxygen, using a normal tidal volume breathing technique. Subsequently, a preselected steady-state end-tidal desflurane concentration was maintained for 10 min before insertion of the LMA. Successful LMA insertion was defined as the absence of adverse airway responses until cuff inflation. Target concentrations of desflurane for LMA insertion were determined using a modified Dixon's up-and-down method (starting dose, 5%; step size, 0.5%). All 22 patients completed the study without adverse events related to airway irritation. The EC50 of desflurane for insertion of the LMA was determined to be 3.61 +/- 0.31%, and the 95% confidence interval (CI) of the EC50 obtained using probit analysis was 3.13-3.90. We demonstrated that N2O-desflurane inhalation induction with a normal tidal breathing technique after premedication with fentanyl can be used safely without any adverse airway events in nonparalyzed patients. In such patients, the EC50 of desflurane for successful LMA insertion was 3.61 +/- 0.31% (95% CI, 3.13-3.90).	[Shin, Hwa-Yong; Lim, Jung-Ae; Kim, Seong-Hyop; Baek, Seung-Woo; Kim, Duk-Kyung] Konkuk Univ, Sch Med, Dept Anesthesiol & Pain Med, Seoul 143701, South Korea	Kim, DK (reprint author), Konkuk Univ, Sch Med, Dept Anesthesiol & Pain Med, 1 Hwayang Dong, Seoul 143701, South Korea.						Bailey JM, 1997, ANESTH ANALG, V85, P681, DOI 10.1097/00000539-199709000-00036; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; Bonnin M, 2007, ACTA ANAESTH SCAND, V51, P54, DOI 10.1111/j.1399-6576.2006.01186.x; BUNTING HE, 1995, BRIT J ANAESTH, V75, P631, DOI 10.1093/bja/75.5.631; CHOI SC, 1990, BIOMETRICS, V46, P485, DOI 10.2307/2531453; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; Ghatge S, 2003, ACTA ANAESTH SCAND, V47, P917, DOI 10.1034/j.1399-6576.2003.00196.x; GOLD MI, 1993, ANESTHESIOLOGY, V79, P710; JONES RM, 1990, BRIT J ANAESTH, V65, P527, DOI 10.1093/bja/65.4.527; KELLY RE, 1993, ANESTH ANALG, V77, P540; Kihara S, 2003, ANESTHESIOLOGY, V99, P1055, DOI 10.1097/00000542-200311000-00008; Kong CF, 2000, BRIT J ANAESTH, V85, P364, DOI 10.1093/bja/85.3.364; Leong Wai May, 2005, J Anesth, V19, P112, DOI 10.1007/s00540-004-0300-2; Lichtman AH, 1998, J PHARMACOL TOXICOL, V40, P81, DOI 10.1016/S1056-8719(98)00041-0; Mahmoud NA, 2001, ANAESTHESIA, V56, P171, DOI 10.1046/j.1365-2044.2001.01528.x; Mckay RE, 2006, ANESTH ANALG, V103, P1147, DOI 10.1213/01.ane.0000237293.39466.65; Mendonca C, 2001, ANAESTHESIA, V56, P19, DOI 10.1046/j.1365-2044.2001.01790.x; Saros GB, 2006, ACTA ANAESTH SCAND, V50, P549, DOI 10.1111/j.1399-6576.2006.001022.x; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Wadhwa A, 2003, ANESTHESIOLOGY, V99, P1062, DOI 10.1097/00000542-200311000-00010; WEISKOPF RB, 1994, ANESTHESIOLOGY, V81, P1350, DOI 10.1097/00000542-199412000-00008; WEISKOPF RB, 1994, ANESTHESIOLOGY, V80, P1035; Wilkes AR, 2000, ANAESTHESIA, V55, P685, DOI 10.1046/j.1365-2044.2000.01469.x	23	1	1	0	4	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	MAY	2009	23	2					209	214		10.1007/s00540-008-0730-3			6	Anesthesiology	Anesthesiology	445ZG	WOS:000266089400007	19444559				2020-06-30	J	Kunisawa, T; Nagata, O; Nagashima, M; Mitamura, S; Ueno, M; Suzuki, A; Takahata, O; Iwasaki, H				Kunisawa, Takayuki; Nagata, Osamu; Nagashima, Michio; Mitamura, Sayuri; Ueno, Megumi; Suzuki, Akihiro; Takahata, Osamu; Iwasaki, Hiroshi			Dexmedetomidine suppresses the decrease in blood pressure during anesthetic induction and blunts the cardiovascular response to tracheal intubation	JOURNAL OF CLINICAL ANESTHESIA			English	Article	Annual Meeting of the Japan-Society-for-Clinical-Anesthesia	OCT 27, 2006	Asahikawa, JAPAN	Japan Soc Clin Anesthesia		Anesthesia induction; Adjuvant anesthetic sparing effect; Dexmedetomidine	PERIOPERATIVE HEMODYNAMICS; ABDOMINAL HYSTERECTOMY; CARDIAC-ARREST; REQUIREMENTS; INFUSION; HUMANS; AGONIST; ARTERY	Study Objective: To evaluate the effect of dexmedetomidine combined with fentanyl on hemodynamics. Design: Prospective, double-blinded, randomized study. Setting: Operating room of a university hospital. Patients: 30 ASA physical status II and III patients with mild-to-moderate cardiovascular disease. Interventions: Patients were assigned to one of three groups: Group D-F2 [dexmedetomidine, effect-site concentration (ESC) of fentanyl = two ng/mL]; Group F2 (placebo, ESC of fentanyl = two ng/mL), or Group F4 (placebo, ESC of fentanyl = 4 ng/mL). Measurements: Dexmedetomidine (an initial dose of 1.0 mu g/kg for 10 min, followed by a continuous infusion of 0.7 mu g-kg(-1.)hr(-1)) or placebo saline was administered 15 minutes before anesthetic induction. Anesthesia was induced with propofal and fentanyl using a target-controlled infusion system. Hemodynamic parameters: systolic (SBP) and diastolic blood pressures (DBP), and heart rate (HR) during anesthetic induction were measured and the percent changes were calculated for both induction and intubation. Main Results: After inducing anesthesia, SBP was significantly higher in Group D-F2 (127 24 mmHg) than Group F2 (90 +/- 20 mmHg) or Group F4 (77 +/- 21 mmHg). The SBP in Groups F2 and F4 reached 160 +/- 31 mmHg and 123 +/- 36 mmHg, respectively, after intubation, but no significant change in SBP was noted in Group D-F2. The percent increase in SBP due to tracheal intubation in Group D-F2 was 3% +/- 4% and was significantly lower than that of Group F2 (70% +/- 34%) or Group F4 (45% +/- 36%). Conclusion: Dexmedetomidine combined with fentanyl during anesthetic induction suppresses the decrease in blood pressure due to anesthetic induction and also blunts the cardiovascular response to tracheal intubation. (C) 2009 Elsevier Inc. All rights reserved.	[Kunisawa, Takayuki; Mitamura, Sayuri; Ueno, Megumi; Suzuki, Akihiro; Takahata, Osamu; Iwasaki, Hiroshi] Asahikawa Med Coll, Dept Anesthesiol & Crit Care Med, Asahikawa, Hokkaido 0788510, Japan; [Nagata, Osamu] Tokyo Metropolitan Police Hosp, Dept Anesthesia, Tokyo, Japan; [Nagashima, Michio] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; [Nagashima, Michio] Harvard Univ, Sch Med, Boston, MA USA	Kunisawa, T (reprint author), Asahikawa Med Coll, Dept Anesthesiol & Crit Care Med, Asahikawa, Hokkaido 0788510, Japan.	taka.kunisawa@nifty.ne.jp		Nagashima, Michio/0000-0001-7416-5367			AANTAA R, 1991, PHARMACOL TOXICOL, V68, P394, DOI 10.1111/j.1600-0773.1991.tb01259.x; AHO M, 1992, ANESTH ANALG, V75, P940; AHO M, 1991, ANESTHESIOLOGY, V74, P997, DOI 10.1097/00000542-199106000-00005; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Gray JM, 1998, ANAESTHESIA, V53, P22, DOI 10.1111/j.1365-2044.1998.53s114.x; Hall JE, 2001, BRIT J ANAESTH, V86, P5, DOI 10.1093/bja/86.1.5; Ingersoll-Weng E, 2004, ANESTHESIOLOGY, V100, P738, DOI 10.1097/00000542-200403000-00040; Jalonen J, 1997, ANESTHESIOLOGY, V86, P331; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Koroglu A, 2006, ANESTH ANALG, V103, P63, DOI 10.1213/01.ane.0000219592.82598.AA; Kunisawa Takayuki, 2006, Masui, V55, P995; Muntazar M, 2004, ANESTHESIOLOGY, V101, P1478; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; SEGAL IS, 1988, ANESTHESIOLOGY, V69, P818, DOI 10.1097/00000542-198812000-00004; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; TALKE P, 1995, ANESTHESIOLOGY, V82, P620, DOI 10.1097/00000542-199503000-00003; Yildiz Munise, 2006, Drugs R D, V7, P43, DOI 10.2165/00126839-200607010-00004; Yildiz O, 2007, J CARDIOTHOR VASC AN, V21, P696, DOI 10.1053/j.jvca.2006.11.005	19	36	65	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAY	2009	21	3					194	199		10.1016/j.jclinane.2008.08.015			6	Anesthesiology	Anesthesiology	454MW	WOS:000266687300008	19464613				2020-06-30	J	Wu, Y; Wang, YL; Zhan, J				Wu, Yun; Wang, Yanlin; Zhan, Jia			Effects of remifentanyl and fentanyl on LPS-induced cytokine release in human whole blood in vitro	MOLECULAR BIOLOGY REPORTS			English	Article						Inflammatory response; Remifentanyl; Fentanyl	NECROSIS-FACTOR; SEPSIS; INTERLEUKIN-6; ANESTHESIA; ENDOTOXIN; IL-10; SHOCK	Aim The present study sought insight into the effects of remifentanyl and fentanyl on LPS-induced release of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and IL-10 in human whole blood. Methods Whole blood was incubated in the presence and absence of remifentanyl and fentanyl. Effects of remifentanyl and fentanyl on spontaneous and endotoxin (lipopolysaccharide; 100 ng ml(-1))-stimulated cytokine release were studied in whole blood from volunteers (n = 10) cultured for 6 h. Results IL-6, TNF-alpha and IL-10 concentrations in groups added with LPS were significantly higher than those in control group (P < 0.01). IL-6, TNF-alpha and IL-10 concentrations in activation groups treated with remifentanyl or fentanyl were significantly lower than those in LPS treated group (P < 0.05). There were no significant differences on IL-6,TNF-alpha and IL-10 concentrations in drug-alone groups compared with control group (P > 0.05). Conclusion Remifentanyl or fentanyl alone has no effects on IL-6, TNF-alpha and IL-10 production, but could attenuate LPS-induced IL-6,TNF-alpha and IL-10 production in human whole blood. Remifentanyl and fentanyl could inhibit the expressions of IL-6, TNF-alpha and IL-10 induced by LPS.	[Wu, Yun; Wang, Yanlin; Zhan, Jia] Wuhan Univ, Zhongnan Hosp, Dept Anesthesiol, Wuhan 430071, Hubei Province, Peoples R China	Wang, YL (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Anesthesiol, E Lake Rd 169, Wuhan 430071, Hubei Province, Peoples R China.	wangyanlin0510@yahoo.com			Yichang Renfu Corporation (Yichang, China)	We thank Yichang Renfu Corporation (Yichang, China) for their excellent assistance in fund support.	Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783; Cavaillon JM, 2006, J ENDOTOXIN RES, V12, P151, DOI 10.1179/096805106X102246; Conti P, 2003, IMMUNOL LETT, V86, P123, DOI 10.1016/S0165-2478(03)00002-6; Cortinez LI, 2005, EUR J ANAESTH, V22, P56, DOI 10.1017/S0265021505000128; DEFORGE LE, 1992, J IMMUNOL, V148, P2133; Kawasaki Takashi, 1999, Anesthesia and Analgesia, V89, P665, DOI 10.1097/00000539-199909000-00024; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Mason Paula, 2002, Intensive Crit Care Nurs, V18, P355, DOI 10.1016/S0964-3397(02)00087-3; MOORE CM, 1994, BRIT J ANAESTH, V72, P272, DOI 10.1093/bja/72.3.272; Opal SM, 2007, INT J MED MICROBIOL, V297, P365, DOI 10.1016/j.ijmm.2007.03.006; Peterson PK, 1998, J NEUROIMMUNOL, V83, P63, DOI 10.1016/S0165-5728(97)00222-1; Rao Y, 2004, CHINESE MED J-PEKING, V117, P303; ROSOW CE, 1999, ANESTH ANALG, V89, P451, DOI DOI 10.1097/00000539-199910001-00001; Sacerdote P, 2001, INT IMMUNOPHARMACOL, V1, P713, DOI 10.1016/S1567-5769(01)00005-4; Sheeran P, 1997, BRIT J ANAESTH, V78, P201; Vallejo Ricardo, 2004, Am J Ther, V11, P354, DOI 10.1097/01.mjt.0000132250.95650.85; Wei G, 2003, BIOCHEM PHARMACOL, V65, P1761, DOI 10.1016/S0006-2952(03)00085-6; XINMIN W, 2003, CHIN J ANESTHESIOL, V23, P245; Zanotti S, 2002, EXPERT OPIN INV DRUG, V11, P1061, DOI 10.1517/13543784.11.8.1061	20	16	16	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-4851	1573-4978		MOL BIOL REP	Mol. Biol. Rep.	MAY	2009	36	5					1113	1117		10.1007/s11033-008-9286-4			5	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	428ME	WOS:000264851600035	18575957				2020-06-30	J	Pandin, P; Haentjens, L; Salengros, JC; Quintin, J; Barvais, L				Pandin, Pierre; Haentjens, Lionel; Salengros, Jean Corentin; Quintin, Jeam; Barvais, Luc			Combined Ultrasound and Nerve Stimulation-Guided Thoracic Epidural Catheter Placement for Analgesia Following Anterior Spine Fusion in Scoliosis	PAIN PRACTICE			English	Article						scoliosis; epidural; nerve stimulation; ultrasound-guided		Anterior spine fusion by thoracotomy is indicated for the treatment of idiopathic scoliosis. Although epidural (EP) analgesia represents the most effective way to provide adequate analgesia after thoracotomy, scoliosis patients have substantial anatomic variations that make EP catheter placement more difficult and often contraindicated. This case report describes a safe, effective technique for placing a thoracic EP catheter in a young patient undergoing anterior spine fusion surgery by thoracotomy. The procedure was guided by both ultrasound (US) and electrical stimulation of the Tuohy needle and catheter. The combination of US and nerve stimulation in this setting may be associated with easier, potentially safer, and more accurate insertion.	[Pandin, Pierre; Haentjens, Lionel; Salengros, Jean Corentin] Free Univ Brussels, Erasmus Hosp, Dept Anesthesiol, B-1070 Brussels, Belgium; [Quintin, Jeam; Barvais, Luc] Univ Libre Bruxelles, Hop Erasme, Dept Orthoped & Traumatol Surg, Brussels, Belgium	Pandin, P (reprint author), Free Univ Brussels, Erasmus Hosp, Dept Anesthesiol, Lennik Dr 808, B-1070 Brussels, Belgium.	ppandin@ulb.ac.be					Aebi M, 2005, EUR SPINE J, V14, P925, DOI 10.1007/s00586-005-1053-9; Andersen MO, 2006, SPINE, V31, P350, DOI 10.1097/01.brs.0000197649.29712.de; Arms DM, 1998, ORTHOPEDICS, V21, P539; Blumenthal S, 2005, ANESTHESIOLOGY, V102, P175, DOI 10.1097/00000542-200501000-00026; Bong CL, 2005, J CARDIOTHOR VASC AN, V19, P786, DOI 10.1053/j.jvca.2005.08.012; Cohen BE, 1997, SPINE, V22, P1892, DOI 10.1097/00007632-199708150-00016; Ekatodramis G, 2002, CAN J ANAESTH, V49, P173, DOI 10.1007/BF03020491; Goobie SM, 2003, ANESTH ANALG, V97, P984, DOI 10.1213/01.ANE.0000080609.05942.38; Grau T, 2002, REGION ANESTH PAIN M, V27, P200, DOI 10.1053/rapm.2002.29239; Grau T, 2001, ACTA ANAESTH SCAND, V45, P766, DOI 10.1034/j.1399-6576.2001.045006766.x; Grau T, 2001, J CLIN ANESTH, V13, P213, DOI 10.1016/S0952-8180(01)00245-8; LONSTEIN JE, 1982, J BONE JOINT SURG AM, V64, P481, DOI 10.2106/00004623-198264040-00002; O'Hara JF, 2004, PEDIATR ANESTH, V14, P1009, DOI 10.1111/j.1460-9592.2004.01387.x; Rapp HJ, 2005, ANESTH ANALG, V101, P333, DOI 10.1213/01.ANE.0000156579.11254.D1; Shaw BA, 1996, J PEDIATR ORTHOPED, V16, P374, DOI 10.1097/01241398-199605000-00016; Tobias JD, 2001, PAEDIATR ANAESTH, V11, P199, DOI 10.1046/j.1460-9592.2001.00632.x; Turner A, 2000, ANAESTHESIA, V55, P370, DOI 10.1046/j.1365-2044.2000.01117.x; Van Boerum DH, 2000, SPINE, V25, P2355, DOI 10.1097/00007632-200009150-00014	18	5	6	0	2	WILEY PERIODICALS, INC	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA	1530-7085			PAIN PRACT	Pain Pract.	MAY-JUN	2009	9	3					230	234		10.1111/j.1533-2500.2009.00275.x			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	V19YM	WOS:000208107700010	19298362				2020-06-30	J	Erden, IA; Pamuk, AG; Akinci, SB; Koseoglu, A; Aypar, U				Erden, I. Aydin; Pamuk, A. Gulsun; Akinci, Seda B.; Koseoglu, Ayhan; Aypar, Ulku			Comparison of propofol-fentanyl with propofol-fentanyl-ketamine combination in pediatric patients undergoing interventional radiology procedures	PEDIATRIC ANESTHESIA			English	Article						anesthetics; intravenous; propofol; ketamine; radiology; interventional; child	MONITORED ANESTHESIA CARE; EMERGENCY-DEPARTMENT; DOUBLE-BLIND; SEDATION; CHILDREN; MIDAZOLAM; TRIAL; PROPOFOL/FENTANYL; ALFENTANIL	With an increase in the frequency of interventional radiology procedures in pediatrics, there has been a corresponding increase in demand for procedural sedation to facilitate them. The purpose of our study was to compare the frequency of adverse effects, sedation level, patient recovery characteristics in pediatric patients receiving intravenous propofol fentanyl combination with or without ketamine for interventional radiology procedures. Our main hypothesis was that the addition of ketamine would decrease propofol/fentanyl associated desaturation. Sixty consenting American Society of Anesthesia physical status I-III pediatric patients undergoing interventional radiology procedures under sedation were studied according to a randomized, double-blinded, institutional review board approved protocol. Group 1 received propofol 0.5 mg.kg(-1) + fentanyl 1 mu g.kg(-1) + ketamine 0.5 mg.kg(-1), and group 2 received propofol 0.5 mg.kg(-1) + fentanyl 1 mu g.kg(-1) + same volume of %0.9 NaCl intravenously. While apnea was not observed in any of the groups, there were three cases (10%) in group 1, and nine cases (30%) in group 2 with oxygen desaturation (P = 0.052). In group 1, 12 (40%) patients and, in group 2, 21 (70%) patients required supplemental propofol during the procedure (P = 0.021). There was no evidence for difference between groups in terms of other side effects except nystagmus. In conclusion, addition of low dose ketamine to propofol-fentanyl combination decreased the risk of desaturation and it also decreased the need for supplemental propofol dosage in pediatric patients at interventional radiology procedures.	[Erden, I. Aydin; Pamuk, A. Gulsun; Akinci, Seda B.; Koseoglu, Ayhan; Aypar, Ulku] Hacettepe Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-06100 Ankara, Turkey	Erden, IA (reprint author), Hacettepe Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-06100 Ankara, Turkey.	aydinerden@yahoo.com	Erden, I. Aydin/J-2525-2013; pamuk, almila gulsun/O-4672-2016				Akin A, 2005, INT J PEDIATR OTORHI, V69, P1541, DOI 10.1016/j.ijporl.2005.04.011; Akin A, 2005, PEDIATR CARDIOL, V26, P553, DOI 10.1007/s00246-004-0707-4; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Avramov MN, 1997, ANESTH ANALG, V85, P566, DOI 10.1097/00000539-199709000-00015; Badrinath S, 2000, ANESTH ANALG, V90, P858, DOI 10.1213/00000539-200004000-00016; Erden IA, 2007, SAUDI MED J, V28, P364; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Green SM, 2000, ANN EMERG MED, V35, P35, DOI 10.1016/S0196-0644(00)70102-8; GUIT JBM, 1991, ANAESTHESIA, V46, P24, DOI 10.1111/j.1365-2044.1991.tb09308.x; Haslam PJ, 2000, CARDIOVASC INTER RAD, V23, P256, DOI 10.1007/s002700010065; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; LANGLEY MS, 1988, DRUGS, V35, P334, DOI 10.2165/00003495-198835040-00002; Mason KP, 2002, RADIOLOGY, V225, P457, DOI 10.1148/radiol.2252011786; Mortero RF, 2001, ANESTH ANALG, V92, P1465; Petrack EM, 2000, CLIN PED EMERG MED, V1, P281; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; Skokan EG, 2001, CLIN PEDIATR, V40, P663, DOI 10.1177/000992280104001204; Vardi A, 2002, CRIT CARE MED, V30, P1231, DOI 10.1097/00003246-200206000-00010; VUYK J, 1995, ANESTHESIOLOGY, V83, P8, DOI 10.1097/00000542-199507000-00003; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	23	40	40	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAY	2009	19	5					500	506		10.1111/j.1460-9592.2009.02971.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	437UF	WOS:000265511700013	19453582				2020-06-30	J	Konig, MW; Mahmoud, MA; Fujiwara, H; Hemasilpin, N; Lee, KH; Rose, DF				Koenig, Matthias W.; Mahmoud, Mohamed A.; Fujiwara, Hisako; Hemasilpin, Nat; Lee, Ki H.; Rose, Douglas F.			Influence of anesthetic management on quality of magnetoencephalography scan data in pediatric patients: a case series	PEDIATRIC ANESTHESIA			English	Article	Winter Meeting of the Society-of-Pediatric-Anesthesia	APR 03-06, 2008	San Diego, CA	Soc Pediat Anesthes		magnetoencephalography; dexmedetomidine; propofol; epilepsy	DOSE DEXMEDETOMIDINE; CHILDREN; SEDATION; EPILEPSY; ELECTROCORTICOGRAPHY	Magnetoencephalography (MEG) is increasingly used in the presurgical evaluation of pediatric seizure patients. Many pediatric patients require sedation or anesthesia to tolerate these exams. However, the available literature on anesthetic management in this population is very limited. We retrospectively reviewed the records of all patients who underwent MEG scanning at our institution with regard to the interaction of anesthetic management and quality of scan data. High-dose propofol infusions (>= 200 mu g.kg(-1).min(-1)) were associated with high frequency artifacts that interfered with the identification of epileptiform discharges. Lower-dose propofol infusions (<= 100 mu g.kg(-1).min(-1)) did not produce artifacts but required co-administration of fentanyl to prevent patient motion. Dexmedetomidine infusions were not associated with signal artifacts and prevented patient motion very well in our initial patients and became our standard technique. In our experience, dexmedetomidine infusions are preferable to propofol-based techniques for pediatric MEG scans due to the absence of adverse effect on interictal activity.	[Koenig, Matthias W.; Mahmoud, Mohamed A.] Cincinnati Childrens Hosp, Med Ctr, Dept Anesthesiol, Cincinnati, OH 45229 USA; [Fujiwara, Hisako; Lee, Ki H.; Rose, Douglas F.] Cincinnati Childrens Hosp, Med Ctr, Dept Neurol, Cincinnati, OH 45229 USA; [Hemasilpin, Nat] Cincinnati Childrens Hosp, Med Ctr, Dept Clin Engn, Cincinnati, OH 45229 USA	Konig, MW (reprint author), Cincinnati Childrens Hosp, Med Ctr, Dept Anesthesiol, 3333 Burnet Ave,MLC 2001, Cincinnati, OH 45229 USA.	matthias.konig@cchmc.org					Karol M. D., 2000, BEST PRACT RES CL AN, V14, P261, DOI DOI 10.1053/BEAN.2000.0081; Koroglu A, 2006, ANESTH ANALG, V103, P63, DOI 10.1213/01.ane.0000219592.82598.AA; Mason KP, 2008, PEDIATR ANESTH, V18, P403, DOI 10.1111/j.1460-9592.2008.02468.x; Mehta UC, 2004, J DEV BEHAV PEDIATR, V25, P102, DOI 10.1097/00004703-200404000-00005; Oda Y, 2007, ANESTH ANALG, V105, P1272, DOI 10.1213/01.ane.0000281075.77316.98; Papanicolaou AC, 2005, INT REV NEUROBIOL, V68, P223, DOI 10.1016/S0074-7742(05)68009-9; Pataraia E, 2002, NEUROSURG REV, V25, P141, DOI 10.1007/s10143-001-0197-2; Popat K, 2006, ADV ANESTH, V24, P177; Rosen DA, 2006, ANESTH ANALG, V103, P68, DOI 10.1213/01.ane.0000216289.52261.5e; Souter MJ, 2007, J NEUROSURG ANESTH, V19, P38, DOI 10.1097/01.ana.0000211027.26550.24; Szmuk P, 2003, PAEDIATR ANAESTH, V13, P811, DOI 10.1046/j.1460-9592.2003.01159.x; Talke P, 2007, J NEUROSURG ANESTH, V19, P195, DOI 10.1097/ANA.0b013e318060d281; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Vilo S, 2008, BRIT J ANAESTH, V100, P697, DOI 10.1093/bja/aen070	14	11	11	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAY	2009	19	5					507	512		10.1111/j.1460-9592.2009.02983.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	437UF	WOS:000265511700014	19453583				2020-06-30	J	Long, LS; Ved, S; Koh, JL				Long, Lawrence S.; Ved, Sudha; Koh, Jeffrey L.			Intraoperative opioid dosing in children with and without cerebral palsy	PEDIATRIC ANESTHESIA			English	Article						cerebral palsy; children; opioids; pain management; orthopedic surgery	COGNITIVE IMPAIRMENT; PAIN ASSESSMENT; POSTOPERATIVE PAIN; SURGERY; MANAGEMENT	To describe the differences in intraoperative opioid dosing and associated outcomes in children with and without cerebral palsy (CP). Previous work on children with cognitive impairment has suggested that they receive less intraoperative opioid than children without cognitive impairment. This finding may be due to a common concern that impaired children are hypersensitive to the adverse effects of opioids. Patterns in intraoperative opioid dosing have yet to be studied in children with motor impairment (e.g. CP). We examined the medical records of pediatric patients with CP who underwent orthopedic surgery over the last decade at our institution, as well as the records of a randomly selected group of pediatric orthopedic patients without CP (non-CP). Outcome variables were intraoperative opioid dosing, postoperative intensive care unit (ICU) admission, and postoperative oxygen desaturation. We collected demographic, surgical, and medical data for covariate analysis. A stepwise multivariate regression was used for each outcome. Seventy-one (71) CP and 77 non-CP charts were included in the study. CP children received significantly less intraoperative opioid (3.26 +/- 3.01 mu g.kg(-1) fentanyl dose equivalents) than non-CP children (4.58 +/- 3.79 mu g.kg(-1)) (P = 0.02), and this difference was corroborated by the regression analysis, which significantly associated CP with decreased opioid dosing (P < 0.001). In addition, intraoperative opioid dosing, but not CP, predicted ICU admission (odds ratio: 1.463, 95% CI: 1.042-2.054, P = 0.03) and postoperative oxygen desaturation (odds ratio: 1.174, 95% CI: 1.031-1.338, P = 0.02). Similar to prior research on children with cognitive impairment, a reduction in intraoperative opioid dosing was found in children with CP. Given the discrepant doses of intraoperative opioid between groups, it is unclear whether children with CP are at any greater risk for untoward opioid-related events.	[Long, Lawrence S.; Ved, Sudha] Georgetown Univ, Med Ctr, Washington, DC 20007 USA; [Koh, Jeffrey L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Ved, S (reprint author), Georgetown Univ Hosp, Dept Anesthesia, Bldg CCC,Room CL 60,3800 Reservoir Rd NW, Washington, DC 20007 USA.	l.stephen.long@gmail.com					Fanurik D, 1999, CLIN J PAIN, V15, P304, DOI 10.1097/00002508-199912000-00007; Fanurik D, 1998, Clin Nurs Res, V7, P103, DOI 10.1177/105477389800700202; Ghai B, 2008, PEDIATR ANESTH, V18, P462, DOI 10.1111/j.1460-9592.2008.02433.x; Hardman J.G., 2001, GOODMAN GILMANS PHAR; Kain ZN, 2006, PEDIATRICS, V118, P651, DOI 10.1542/peds.2005-2920; Koh JL, 2004, PAIN, V111, P239, DOI 10.1016/j.pain.2004.07.005; Kuperminc MN, 2008, DEV DISABIL RES REV, V14, P137, DOI 10.1002/ddrr.14; Malviya S, 2001, PAEDIATR ANAESTH, V11, P453, DOI 10.1046/j.1460-9592.2001.00686.x; Malviya S, 2005, ACUTE PAIN, V7, P27; McGrath PJ, 1998, DEV MED CHILD NEUROL, V40, P340; Megens JHAM, 2008, PEDIATR ANESTH, V18, P620, DOI 10.1111/j.1460-9592.2008.02601.x; Odding E, 2006, DISABIL REHABIL, V28, P183, DOI 10.1080/09638280500158422; Scheufler KM, 2002, J NEUROSURG, V96, P571, DOI 10.3171/jns.2002.96.3.0571; Thees C, 1999, J NEUROSURG ANESTH, V11, P112, DOI 10.1097/00008506-199904000-00007; Voepel-Lewis T, 2008, ANESTH ANALG, V106, P72, DOI 10.1213/01.ane.0000287680.21212.d0; Wong D L, 1988, Pediatr Nurs, V14, P9	16	15	17	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAY	2009	19	5					513	520		10.1111/j.1460-9592.2009.02980.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	437UF	WOS:000265511700015	19453584				2020-06-30	J	Robertson, DJ; Jacobs, DP; Mackenzie, TA; Oringer, JA; Rothstein, RI				Robertson, D. J.; Jacobs, D. P.; Mackenzie, T. A.; Oringer, J. A.; Rothstein, R. I.			Clinical trial: a randomized, study comparing meperidine (pethidine) and fentanyl in adult gastrointestinal endoscopy	ALIMENTARY PHARMACOLOGY & THERAPEUTICS			English	Article							CONSCIOUS SEDATION; GI ENDOSCOPY; PROPOFOL; COLONOSCOPY; MIDAZOLAM; ANALGESIA; SAFETY	There is little evidence to guide choice between meperidine (pethidine) and fentanyl for sedation for gastrointestinal endoscopy. To compare meperidine with fentanyl in terms of procedure time and analgesia. Single centre randomized controlled trial. Patients received narcotic doses and midazolam at the discretion of the attending endoscopist who was unaware of narcotic assignment. Endoscopy and recovery times were then recorded. The main outcome was total procedure time, defined as endoscopy time plus recovery time. Patient discomfort was assessed prior to discharge via visual analogue scale (VAS). In total, 55 patients were randomized to meperidine [44 colonoscopy and 11 esophagogastroduodenoscopy (EGD)] and 56 to fentanyl (45 colonoscopy and 11 EGD). Total procedure time was shorter for those receiving fentanyl (mean = 87.7 min) than for those receiving meperidine (mean = 102.9 min) (P = 0.05). The difference between the groups was explained by a shorter mean recovery time in the fentanyl group (63.0 min) than in the meperidine group (76.2 min) (P = 0.07). Based on post procedure pain scores, examinations with meperidine (mean = 1.99) were less painful when compared with those receiving fentanyl (mean = 2.86, P = 0.03). Fentanyl shortened total procedure time by reducing recovery time. A simple change in narcotic choice could increase endoscopy unit efficiency.	[Robertson, D. J.; Rothstein, R. I.] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA; [Jacobs, D. P.] LeBauer Healthcare, Greensboro, NC USA; [Jacobs, D. P.] UNC Chapel Hill Sch Med, Chapel Hill, NC USA; [Mackenzie, T. A.] Dartmouth Hitchcock Med Ctr, Gen Internal Med Sect, Lebanon, NH 03766 USA; [Oringer, J. A.] N Shore Med Ctr, Salem, MA USA; [Robertson, D. J.] VA Med Ctr, White River Jct, VT USA		douglas.robertson@med.va.gov			VA HSR&D Career Development Award	Declaration of personal interests: The other authors have no conflict of interest or disclosure to make with regard to the manuscript. Declaration of funding interests: Dr Robertson is supported by a VA HSR&D Career Development Award.	Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; BELL GD, 1990, ALIMENT PHARM THERAP, V4, P103; Cataldo PA, 1996, DIS COLON RECTUM, V39, P257, DOI 10.1007/BF02049463; CHOKHAVATIA S, 1993, AM J GASTROENTEROL, V88, P393; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; FLACKE JW, 1987, ANESTH ANALG, V66, P723; Horn Ed, 2004, Gastrointest Endosc Clin N Am, V14, P247, DOI 10.1016/j.giec.2004.01.001; ISHIDO S, 1992, GASTROINTEST ENDOSC, V38, P689, DOI 10.1016/S0016-5107(92)70565-3; Katzung B. G., 1998, BASIC CLIN PHARM; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Mamula P, 2007, GASTROINTEST ENDOSC, V65, P203, DOI 10.1016/j.gie.2006.05.002; Rex DK, 2004, AM J GASTROENTEROL, V99, P2080, DOI 10.1111/j.1572-0241.2004.41325.x; Rex DK, 2002, AM J GASTROENTEROL, V97, P1159; Ristikankare M, 1999, GASTROINTEST ENDOSC, V49, P566, DOI 10.1016/S0016-5107(99)70383-4; SEOWCHOEN F, 1994, GASTROINTEST ENDOSC, V40, P661, DOI 10.1016/S0016-5107(94)70105-9; Vicari Joseph J, 2002, Gastrointest Endosc Clin N Am, V12, P297, DOI 10.1016/S1052-5157(01)00011-3; Walker JA, 2003, AM J GASTROENTEROL, V98, P1744, DOI 10.1016/S0002-9270(03)00496-9	18	17	18	0	3	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0269-2813			ALIMENT PHARM THER	Aliment. Pharmacol. Ther.	APR 15	2009	29	8					817	823		10.1111/j.1365-2036.2009.03943.x			7	Gastroenterology & Hepatology; Pharmacology & Pharmacy	Gastroenterology & Hepatology; Pharmacology & Pharmacy	421QC	WOS:000264372400003	19154568				2020-06-30	J	Citerio, G; Franzosi, MG; Latini, R; Masson, S; Barlera, S; Guzzetti, S; Pesenti, A				Citerio, Giuseppe; Franzosi, Maria Grazia; Latini, Roberto; Masson, Serge; Barlera, Simona; Guzzetti, Stefano; Pesenti, Antonio			Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial - The NeuroMorfeo trial	TRIALS			English	Article							ISOFLURANE-NITROUS-OXIDE; DOSE FENTANYL ANESTHESIA; HEART-RATE-VARIABILITY; STRESS-RESPONSE; NONINFERIORITY; REMIFENTANIL; CATECHOLAMINE; SURGERY; QUALITY; CARE	Background: Many studies have attempted to determine the "best" anaesthetic technique for neurosurgical procedures in patients without intracranial hypertension. So far, no study comparing intravenous (IA) with volatile-based neuroanaesthesia (VA) has been able to demonstrate major outcome differences nor a superiority of one of the two strategies in patients undergoing elective supratentorial neurosurgery. Therefore, current practice varies and includes the use of either volatile or intravenous anaesthetics in addition to narcotics. Actually the choice of the anaestesiological strategy depends only on the anaesthetists' preferences or institutional policies. This trial, named NeuroMorfeo, aims to assess the equivalence between volatile and intravenous anaesthetics for neurosurgical procedures. Methods/Design: NeuroMorfeo is a multicenter, randomized, open label, controlled trial, based on an equivalence design. Patients aged between 18 and 75 years, scheduled for elective craniotomy for supratentorial lesion without signs of intracranial hypertension, in good physical state (ASA I-III) and Glasgow Coma Scale (GCS) equal to 15, are randomly assigned to one of three anaesthesiological strategies ( two VA arms, sevoflurane + fentanyl or sevoflurane + remifentanil, and one IA, propofol + remifentanil). The equivalence between intravenous and volatile-based neuroanaesthesia will be evaluated by comparing the intervals required to reach, after anaesthesia discontinuation, a modified Aldrete score >= 9 (primary end-point). Two statistical comparisons have been planned: 1) sevoflurane + fentanyl vs. propofol + remifentanil; 2) sevoflurane + remifentanil vs. propofol + remifentanil. Secondary end-points include: an assessment of neurovegetative stress based on (a) measurement of urinary catecholamines and plasma and urinary cortisol and (b) estimate of sympathetic/parasympathetic balance by power spectrum analyses of electrocardiographic tracings recorded during anaesthesia; intraoperative adverse events; evaluation of surgical field; postoperative adverse events; patient's satisfaction and analysis of costs. 411 patients will be recruited in 14 Italian centers during an 18-month period. Discussion: We presented the development phase of this anaesthesiological on-going trial. The recruitment started December 4(th), 2007 and up to 4(th), December 2008, 314 patients have been enrolled.	[Citerio, Giuseppe; Pesenti, Antonio] San Gerardo Hosp, Neuroanaesthesia & Neurointens Care Unit, Dept Perioperat Med & Intens Care, Milan, Italy; [Franzosi, Maria Grazia; Latini, Roberto; Masson, Serge; Barlera, Simona] Ist Ric Farmacol Mario Negri, Dept Cardiovasc Res, Milan, Italy; [Pesenti, Antonio] Univ Milano Bicocca, Dept Expt Med, Milan, Italy; [Guzzetti, Stefano] Osped L Sacco, Dept Clin Sci, I-20157 Milan, Italy	Citerio, G (reprint author), San Gerardo Hosp, Neuroanaesthesia & Neurointens Care Unit, Dept Perioperat Med & Intens Care, Milan, Italy.	g.citerio@hsgerardo.org; franzosi@marionegri.it; latini@marionegri.it; masson@marionegri.it; simo@marionegri.it; stefanoguzzetti@yahoo.it; antonio.pesenti@unimib.it	Pesenti, Antonio/H-7483-2012; Latini, Roberto/AAB-1410-2020; Citerio, Giuseppe/B-1839-2015	Pesenti, Antonio/0000-0003-2593-729X; Latini, Roberto/0000-0002-3729-4650; Citerio, Giuseppe/0000-0002-5374-3161	AIFA (Agenzia Italiana del Farmaco); Eudract [2007-005279-32]	AIFA (Agenzia Italiana del Farmaco) fully financed the trial ( year 2006, FARM6FKJKK) that has been registered at Eudract (2007-005279-32) and on http://www.clinicaltrials.gov (NCT00741351).	ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Balakrishnan G, 2000, ANESTH ANALG, V91, P163, DOI 10.1097/00000539-200007000-00030; BENT JM, 1984, ANAESTHESIA, V39, P19, DOI 10.1111/j.1365-2044.1984.tb09447.x; Boztug N, 2006, J NEUROSURG ANESTH, V18, P1, DOI 10.1097/01.ana.0000188028.80960.dd; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; Citerio G, 2007, INTENS CARE MED, V33, P1580, DOI 10.1007/s00134-007-0700-5; Del Gaudio A, 2006, MINERVA ANESTESIOL, V72, P309; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Dinsmore J, 2007, BRIT J ANAESTH, V99, P68, DOI 10.1093/bja/aem132; Engelhard K, 2006, CURR OPIN ANESTHESIO, V19, P504, DOI 10.1097/01.aco.0000245275.76916.87; Fung D, 2005, ANESTH ANALG, V100, P1637, DOI 10.1213/01.ANE.0000154203.00434.23; Gomberg-Maitland M, 2003, AM HEART J, V146, P398, DOI 10.1016/S0002-8703(03)00324-7; Guzzetti S, 2005, CIRCULATION, V112, P465, DOI 10.1161/CIRCULATIONAHA.104.518449; HALL GM, 1978, ANAESTHESIA, V33, P924; Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; Kaul S, 2006, ANN INTERN MED, V145, P62, DOI 10.7326/0003-4819-145-1-200607040-00011; KLINGSTEDT C, 1987, BRIT J ANAESTH, V59, P184, DOI 10.1093/bja/59.2.184; LAUTA E, 2003, SNACC 2003 ABSTR, pA44; Le Henanff A, 2006, JAMA-J AM MED ASSOC, V295, P1147, DOI 10.1001/jama.295.10.1147; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Leslie K, 2002, J CLIN NEUROSCI, V9, P231, DOI 10.1054/jocn.2001.0934; Magni G, 2005, J NEUROSURG ANESTH, V17, P134, DOI 10.1097/01.ana.0000167447.33969.16; Nishiyama T, 2005, J CLIN ANESTH, V17, P586, DOI 10.1016/j.jclinane.2005.03.009; Olsen KS, 2002, J NEUROSURG ANESTH, V14, P171, DOI 10.1097/00008506-200207000-00001; PARKER SD, 1995, CRIT CARE MED, V23, P1954, DOI 10.1097/00003246-199512000-00003; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Talke P, 2002, ANESTH ANALG, V95, P430, DOI 10.1097/00000539-200208000-00036; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002	30	16	16	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	APR 6	2009	10								19	10.1186/1745-6215-10-19			10	Medicine, Research & Experimental	Research & Experimental Medicine	438BK	WOS:000265530700001	19348675	DOAJ Gold, Green Published			2020-06-30	J	Fujiwara, Y; Kurokawa, S; Shibata, Y; Asakura, Y; Harado, M; Komatsu, T				Fujiwara, Y.; Kurokawa, S.; Shibata, Y.; Asakura, Y.; Harado, M.; Komatsu, T.			Sympathovagal effects of spinal anaesthesia with intrathecal or intravenous fentanyl assessed by heart rate variability	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							SYMPATHETIC-NERVOUS-SYSTEM; CESAREAN DELIVERY; GENERAL-ANESTHESIA; BUPIVACAINE; ANALGESIA; SEDATION; FLUCTUATION; PROPOFOL; INTERVAL; ENTROPY	Although many investigators previously reported the sympathovagal effect of spinal anaesthesia, there is no information about the sympathovagal effects of supplementation with fentanyl. The aim of this study was to evaluate the sympathovagal effects of intrathecal or intravenous fentanyl added to spinal anaesthesia. One hundred and twenty patients undergoing elective transurethral surgery under spinal anaesthesia were randomly allocated to receive intrathecally either isobaric bupivacaine alone (Group B), bupivacaine supplemented with intrathecal (Group Ft) or with intravenous fentanyl (Group Fv). Heart rate variability was estimated using the MemCalc method (Tarawa, Suwa Trust, Japan) before and after spinal anaesthesia. In all groups, spinal anaesthesia significantly decreased low frequency/high frequency (LF/HF) as a marker of sympathovagal balance. However, patients in Group B with a low block height developed a marked increase in LF/HF after spinal anaesthesia, which was attenuated in Group Ft. Meanwhile, intravenous fentanyl did not attenuate this response. We conclude that sympathetic activation observed in patients with a low block height was attenuated by intrathecal fentanyl but not by intravenous fentanyl.	[Fujiwara, Y.] Aichi Med Univ, Dept Anaesthesiol, Sch Med, Aichi 4801195, Japan	Fujiwara, Y (reprint author), Aichi Med Univ, Dept Anaesthesiol, Sch Med, 21 Karimata Yazako, Aichi 4801195, Japan.	yyoshiff@aichi-med-u.ac.jp					AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; BENGTSSON M, 1983, ACTA ANAESTH SCAND, V27, P206, DOI 10.1111/j.1399-6576.1983.tb01936.x; Camm AJ, 1996, EUR HEART J, V17, P354; CHAMBERLAIN DP, 1986, ANESTHESIOLOGY, V65, P139, DOI 10.1097/00000542-198608000-00002; COOK PR, 1990, ACTA ANAESTH SCAND, V34, P271, DOI 10.1111/j.1399-6576.1990.tb03084.x; FLEISHER LA, 1994, ANESTH ANALG, V79, P165; Fujiwara Y, 2007, ACTA ANAESTH SCAND, V51, P1161, DOI 10.1111/j.1399-6576.2007.01435.x; Fujiwara Y, 2007, ANAESTHESIA, V62, P117, DOI 10.1111/j.1365-2044.2006.04933.x; Gentili M, 1998, BRIT J ANAESTH, V81, P970; Gratadour P, 1997, ANESTHESIOLOGY, V87, P1359, DOI 10.1097/00000542-199712000-00015; Haney MF, 2007, ACTA ANAESTH SCAND, V51, P1289, DOI 10.1111/j.1399-6576.2007.01517.x; Hanss R, 2007, ACTA ANAESTH SCAND, V51, P1297, DOI 10.1111/j.1399-6576.2007.01455.x; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; INTRONA R, 1995, ANESTH ANALG, V80, P315, DOI 10.1097/00000539-199502000-00019; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; Kararmaz A, 2003, ACTA ANAESTH SCAND, V47, P1096, DOI 10.1034/j.1399-6576.2003.00231.x; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; KAWAMOTO M, 1993, BRIT J ANAESTH, V71, P523; Kushida Atsuko, 2006, Masui, V55, P1393; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Marucci M, 2003, Minerva Anestesiol, V69, P809; MARUCCI M, 2003, MINERVA ANESTESIOL, V69, P819; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Owczuk R, 2005, REGION ANESTH PAIN M, V30, P548, DOI 10.1016/j.rapm.2005.06.005; Patterson L, 2001, CAN J ANAESTH, V48, P768, DOI 10.1007/BF03016692; PODRID PJ, 1990, CIRCULATION, V82, P103; Pollock JE, 2000, ANESTHESIOLOGY, V93, P728, DOI 10.1097/00000542-200009000-00022; Remme WJ, 1998, EUR HEART J, V19, pF62; Sawada Y, 1997, MED BIOL ENG COMPUT, V35, P318, DOI 10.1007/BF02534083; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; Taniguchi M, 1997, ANESTH ANALG, V84, P391, DOI 10.1097/00000539-199702000-00029; Taylor JA, 2006, J APPL PHYSIOL, V101, P690; Win NN, 2005, ANESTH ANALG, V101, P97, DOI 10.1213/01.ANE.0000156204.89879.5C	36	8	8	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2009	53	4					476	482		10.1111/j.1399-6576.2008.01800.x			7	Anesthesiology	Anesthesiology	418QD	WOS:000264162400010	19226297				2020-06-30	J	Ghai, B; Ram, J; Makkar, JK; Wig, J; Kaushik, S				Ghai, Babita; Ram, Jagat; Makkar, Jeetinder Kaur; Wig, Jyotsna; Kaushik, Sushmita			Subtenon Block Compared to Intravenous Fentanyl for Perioperative Analgesia in Pediatric Cataract Surgery	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	12th World Congress on Pain/International-Association-for-the-Study-of-Pain	AUG 17-22, 2008	Glasgow, SCOTLAND	Int Assoc Study Pain			POSTOPERATIVE PAIN RELIEF; SUB-TENONS BLOCK; STRABISMUS SURGERY; GENERAL-ANESTHESIA; REGIONAL ANESTHESIA; VITREORETINAL SURGERY; LIDOCAINE INJECTION; OPHTHALMIC SURGERY; PERIBULBAR BLOCK; CHILDREN	BACKGROUND: General anesthesia with opioids provides good operative conditions for ocular surgery in children; however, postoperative pain management remains a significant problem. Regional anesthesia is commonly used as an adjunct to general anesthesia in children. We compared the efficacy and safety of subtenon block (SB) versus IV fentanyl for perioperative analgesia in pediatric cataract surgery. We hypothesized that perioperative analgesia using SB may reduce the requirement of postoperative rescue analgesia compared with fentanyl. METHODS: This was a prospective, randomized, controlled double-blind trial. One hundred fourteen ASA I and II children (6 mo-6 yr) undergoing elective cataract surgery in one eye under general anesthesia were studied. Children were randomly allocated to one of the two groups, i.e., Group SB (n = 58) or Group F (n = 56) after securing the airway. Children in Group SB received SB with 0.06-0.08 mL/kg of 2% lidocaine and 0.5% bupivacaine (50:50) mixture and simultaneous 0.2 mL/kg normal saline IV, whereas children in Group F received 1 mu g/kg (0.2 mL/kg of 5 mu g/kg) of fentanyl IV and simultaneous subtenon injection with normal saline (0.06-0.08 mL/kg). Surgery started after 5 min of study drug administration. Postoperative assessment for pain, sedation, and nausea/vomiting was done at 0.5,1, 2, 3, 4, and 24 h. The primary outcome was number of patients requiring rescue analgesia during the 24-h study period. Secondary outcomes assessed were pain and sedation scores, time to first rescue analgesia, incidence of occulocardiac reflex, and nausea/vomiting. RESULTS: The number of patients requiring rescue analgesia during the 24 h was significantly less in Group SB (n = 17/58, 29.3%) compared with Group F (n = 39/56, 69.6%, P < 0.001). The postoperative pain scores were statistically lower in Group SB at all time intervals. The median (range) time to first analgesic requirement was significantly prolonged in Group SB (16 [2-13] vs 4 [0.5-8.5] h in Group F) (P < 0.001). Sedation scores at 1/2 h were comparable, after which significantly more children were anxious or crying in Group F compared with Group SB in which more children were calm, sitting, or lying with eyes open and relaxed (P < 0.05). A significantly higher incidence of oculocardiac reflex was recorded in Group F versus Group SB (P = 0.019). No complication related to SB was noticed. CONCLUSIONS: SB is a safe and superior alternative to IV fentanyl for perioperative analgesia in pediatric cataract surgery.	[Ghai, Babita; Makkar, Jeetinder Kaur; Wig, Jyotsna] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India; [Ram, Jagat; Kaushik, Sushmita] Postgrad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh 160012, India	Makkar, JK (reprint author), 447-2,Sector 45A, Chandigarh 160012, India.	jeet1516@gmail.com	Kaushik, Sushmita/AAE-3806-2019	Kaushik, Sushmita/0000-0002-9175-5497			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Ates Y, 1998, REGION ANESTH PAIN M, V23, P569; Bergman L, 2007, OPHTHALMOLOGY, V114, P2055, DOI 10.1016/j.ophtha.2006.12.031; Chambers CT, 1996, PAIN, V68, P307, DOI 10.1016/S0304-3959(96)03209-5; DAVIS DB, 1994, J CATARACT REFR SURG, V20, P327, DOI 10.1016/S0886-3350(13)80586-X; Deb K, 2001, PAEDIATR ANAESTH, V11, P161, DOI 10.1046/j.1460-9592.2001.00623.x; Eke T, 1999, EYE, V13, P196, DOI 10.1038/eye.1999.50; Farmery AD, 2003, EUR J ANAESTH, V20, P973, DOI 10.1097/00003643-200312000-00007; Frieman BJ, 2001, AM J OPHTHALMOL, V131, P520, DOI 10.1016/S0002-9394(00)00815-1; Guise PA, 2003, ANESTHESIOLOGY, V98, P964, DOI 10.1097/00000542-200304000-00025; HAMILTON RC, 1988, CAN J ANAESTH, V35, P615, DOI 10.1007/BF03020350; Jaycock PD, 2001, EYE, V15, P583, DOI 10.1038/eye.2001.189; Kumar CM, 2005, EUR J ANAESTH, V22, P567, DOI 10.1017/S0265021505000967; McGoldrick KE, 1996, SMITHS ANESTHESIA IN, P633; Merkel S I, 1997, Pediatr Nurs, V23, P293; Nouvellon E, 2004, ANESTHESIOLOGY, V100, P370, DOI 10.1097/00000542-200402000-00028; Olitsky SE, 1997, OPHTHALMIC SURG LAS, V28, P145; Parulekar MV, 2002, PAEDIATR ANAESTH, V12, P85, DOI 10.1046/j.1460-9592.2002.0787a.x; Ruschen H, 2003, ANESTH ANALG, V96, P273, DOI 10.1213/01.ANE.0000039318.12705.8A; Sheard RM, 2004, J AAPOS, V8, P314, DOI 10.1016/j.jaapos.2004.01.017; Sheard RM, 2003, J AAPOS, V7, P38, DOI 10.1016/S1091-8531(03)00054-5; Spierer A, 1999, J CATARACT REFR SURG, V25, P144, DOI 10.1016/S0886-3350(99)80025-X; Steib A, 2005, REGION ANESTH PAIN M, V30, P478, DOI 10.1016/j.rapm.2005.04.011; Subramaniam R, 2003, REGION ANESTH PAIN M, V28, P43, DOI 10.1053/rapm.2003.50032; Suresh Santhanam, 2002, Anesthesiol Clin North Am, V20, P83, DOI 10.1016/S0889-8537(03)00056-7; WILTON NCT, 1988, ANESTHESIOLOGY, V69, P972, DOI 10.1097/00000542-198812000-00032	26	32	32	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2009	108	4					1132	1138		10.1213/ane.0b013e318198a3fd			7	Anesthesiology	Anesthesiology	423ZG	WOS:000264534700016	19299775				2020-06-30	J	White, PF; Tufanogullari, B; Taylor, J; Klein, K				White, Paul F.; Tufanogullari, Burcu; Taylor, Jimmie; Klein, Kevin			The Effect of Pregabalin on Preoperative Anxiety and Sedation Levels: A Dose-Ranging Study	ANESTHESIA AND ANALGESIA			English	Article							PLACEBO-CONTROLLED TRIAL; POSTOPERATIVE ANALGESIA; DOUBLE-BLIND; PAIN; GABAPENTIN; EFFICACY; PREMEDICATION; COMBINATION; RECOVERY; INFUSION	BACKGROUND: Pregabalin is a gabapentinoid compound, which has been alleged to possess anxiolytic, analgesic, and anticonvulsant properties. We hypothesized that premedication with oral pregabalin would produce dose-related reductions in acute (state) anxiety and increases in sedation (sleepiness) before induction of general anesthesia. A secondary objective was to determine if premedication with pregabalin would reduce postoperative pain. METHODS: One hundred eight ASA I-III outpatients undergoing elective surgery were randomly assigned to one of the four premedication treatment groups: 1) control group received placebo capsules, 2) pregabalin 75 group received pregabalin 75 mg, po, 3) pregabalin 150 group received pregabalin 150 mg, po, and 4) pregabalin 300 group received pregabalin 300 mg, po. The effects of the study drug on the patients' level of anxiety, sedation, and pain were assessed at baseline (immediately before study drug administration), at 30 and 60 min after drug administration, and immediately before induction of anesthesia, as well as at 30-min intervals in the postanesthesia care unit (PACU) using standardized 11-point verbal rating scales, with 0 = none to 10 = maximal effect. The need for postoperative opioid analgesic medication, incidence of nausea and vomiting requirement for rescue antiemetics, and times to discharge from the PACU and hospital, as well as the patients' quality of recovery scores, and late recovery outcomes (e.g., resumption of dietary intake and recovery of bowel function) were assessed at a 7-day follow-up interview. RESULTS: Demographic characteristics, times between study drug administration to anesthetic induction, type of surgical procedures, duration of anesthesia, PACU and hospital discharge time, as well as the requirement for fentanyl in the PACU, did not differ among the four study groups. Anxiety levels remained unchanged during the preoperative evaluation period, and did not differ among the four study groups. Sedation scores were significantly higher in the pregabalin 300 group at the preinduction assessment interval and at 90 and 120 min after surgery compared with the control group (5 +/- 3 vs 3 +/- 2, 7 +/- 4 vs 5 +/- 3, 8 +/- 4 vs 4 +/- 4, respectively, P < 0.05). CONCLUSION: Preoperative pregabalin administration (75-300 mg po) increased perioperative sedation in a dose-related fashion, but failed to reduce preoperative state anxiety, postoperative pain, or to improve the recovery process after minor elective surgery procedures.	[White, Paul F.; Tufanogullari, Burcu; Taylor, Jimmie; Klein, Kevin] Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA	White, PF (reprint author), Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	paul.white@utsouthwestem.edu			Pfizer (New York, NY)Pfizer; Margaret Milam McDermott Distinguished Chair in Anesthesiology; White Mountain Institute	Supported, in part, by an unrestricted educational grant from Pfizer (New York, NY), endowment funds from the Margaret Milam McDermott Distinguished Chair in Anesthesiology, and the White Mountain Institute, a nonprofit private foundation (Paul F. White, President).	Aasvang EK, 2008, ANESTH ANALG, V107, P282, DOI 10.1213/ane.0b013e31816b94c9; Adam F, 2005, ANESTH ANALG, V100, P475, DOI 10.1213/01.ANE.0000142117.82241.DC; Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Collard V, 2007, ANESTH ANALG, V105, P1255, DOI 10.1213/01.ane.0000282822.07437.02; Gajraj NM, 2007, ANESTH ANALG, V105, P1805, DOI 10.1213/01.ane.0000287643.13410.5e; Gilron I, 2005, PAIN, V113, P191, DOI 10.1016/j.pain.2004.10.008; Hill CM, 2001, EUR J PAIN, V5, P119, DOI 10.1053/eujp.2001.0235; Jokela R, 2008, PAIN, V134, P106, DOI 10.1016/j.pain.2007.04.002; Kavoussi R, 2006, EUR NEUROPSYCHOPHARM, V16, pS128, DOI 10.1016/j.euroneuro.2006.04.005; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Paech MF, 2007, ANESTH ANALG, V105, P1449, DOI 10.1213/01.ane.0000286227.13306.d7; Pavlin DJ, 2002, ANESTH ANALG, V95, P627, DOI 10.1097/00000539-200209000-00025; Randinitis EJ, 2003, J CLIN PHARMACOL, V43, P277, DOI 10.1177/0091270003251119; Reuben SS, 2006, ANESTH ANALG, V103, P1271, DOI 10.1213/01.ane.0000237279.08847.2d; Rickels K, 2005, ARCH GEN PSYCHIAT, V62, P1022, DOI 10.1001/archpsyc.62.9.1022; SHAFER A, 1989, ANESTHESIOLOGY, V71, P495, DOI 10.1097/00000542-198910000-00004; Tiippana EM, 2007, ANESTH ANALG, V104, P1545, DOI 10.1213/01.ane.0000261517.27532.80; Turan A, 2006, ANESTH ANALG, V102, P175, DOI 10.1213/01.ane.0000184824.43411.63; Turan A, 2007, ANESTH ANALG, V104, P97, DOI 10.1213/01.ane.0000250408.56586.88; White PF, 2008, CURR OPIN INVEST DR, V9, P76; White PF, 2007, ANESTH ANALG, V105, P10, DOI 10.1213/01.ane.0000268392.05157.a8; White PF, 2005, ANESTH ANALG, V101, pS5, DOI 10.1213/01.ANE.0000177099.28914.A7	22	85	88	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2009	108	4					1140	1145		10.1213/ane.0b013e31818d40ce			6	Anesthesiology	Anesthesiology	423ZG	WOS:000264534700017	19299776				2020-06-30	J	Guenther, U; Manzke, T; Wrigge, H; Utschmann, M; Zinserling, J; Putensen, C; Hoeft, A				Guenther, Ulf; Manzke, Till; Wrigge, Hermann; Utschmann, Matthias; Zinserling, Joerg; Putensen, Christian; Hoeft, Andreas			The Counteraction of Opioid-Induced Ventilatory Depression by the Serotonin 1A-Agonist 8-OH-DPAT Does Not Antagonize Antinociception in Rats In Situ and In Vivo	ANESTHESIA AND ANALGESIA			English	Article							INDUCED RESPIRATORY DEPRESSION; POSTOPERATIVE PAIN MANAGEMENT; PRESSURE RELEASE VENTILATION; 5-HT1A AGONIST F-13640; WITHDRAWAL REFLEX; FORMALIN MODEL; RECEPTORS; ANALGESIA; NEURONS; STIMULATION	BACKGROUND: Spontaneous breathing during mechanical ventilation is gaining increasing importance during intensive care but is depressed by narcotics, such as opioids. Serotonin 1A-receptor (5-HT1A-R) agonists have been shown to antagonize opioid-induced ventilatory depression, but both enhancement and attenuation of nociceptive reflexes have been found with different experimental models. To clarify contradictory findings, we simultaneously determined dose-response functions of the standard 5-HT1A-R-agonist 8-OH-DPAT and two different opioids for spontaneous ventilation and nociception. Two hypotheses were tested: 1) 8-OH-DPAT at a dose to stimulate spontaneous breathing does not activate nociceptive reflexes. 2) 8-OH-DPAT does not diminish opioid-induced antinociception. METHODS: (A) A dose-response relationship of 8-OH-DPAT, spontaneous phrenic nerve activity and a nociceptive C-fiber reflex (CFR) were established simultaneously in an in situ perfused, nonanesthetized, rat brainstem-spinal cord preparation. (B) Fentanyl was administered in situ to investigate the interaction with 8-OH-DPAT on phrenic nerve activity and nociceptive CFR. Additional experiments involved the selective 5-HT1A-R-antagonist WAY 100 635 to exclude effects of receptors other than 5-HT1A-R. (C) The effects of 8-OH-DPAT on spontaneous ventilation and nociceptive tail-flick reflex with and without morphine were verified in in viva anesthetized rats. RESULTS: Low-dose 8-OH-DPAT (0.001 and 0.01 mu M in situ, 0.1 mu g/kg in vivo) enhanced nociceptive reflexes but did not activate spontaneous ventilation. On the contrary, high doses of 8-OH-DPAT (1 mu M in situ and 10-100 mu g/kg in viva) stimulated ventilation, whereas nociceptive CFR amplitude in situ returned to baseline and tail-flick reflex was depressed in viva. Opioid-induced ventilatory depression was antagonized by 8-OH-DPAT (1 mu M in situ, and 1.0 mu g/kg in viva), whereas antinociception sustained. Selective 5-HT1A-R-antagonist WAY 100 635 (1 AM) prevented the effects of 8-OH-DPAT in situ. CONCLUSION: 5-HT1A-R-agonist 8-OH-DPAT activates spontaneous breathing without diminishing opioid-induced antinociception in rats. (Anesth Analg 2009;108:1169-76)	[Guenther, Ulf; Wrigge, Hermann; Zinserling, Joerg; Putensen, Christian; Hoeft, Andreas] Univ Bonn, Clin Anesthesiol & Intens Care Med, D-5300 Bonn, Germany; [Manzke, Till; Utschmann, Matthias] CMPB, DFG Res, Gottingen, Germany	Guenther, U (reprint author), Univ Hosp Bonn, Clin Anesthesiol & Intens Care, Sigmund Freud St 25, D-53105 Bonn, Germany.	ulf.guenther@ukb.uni-bonn.de		Dutschmann, Mathias/0000-0002-0692-746X	Departmental Funds	Supported by Departmental Funds.	Bardin L, 2005, J PHARMACOL EXP THER, V312, P1034, DOI 10.1124/jpet.104.077669; Bardin L, 2004, EUR J PAIN, V8, P253, DOI 10.1016/j.ejpain.2003.09.002; Bardin L, 2003, PHARMACOLOGY, V67, P182, DOI 10.1159/000068404; Bardin L, 2001, EUR J PHARMACOL, V421, P109, DOI 10.1016/S0014-2999(01)01029-9; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Clarke RW, 1996, BRIT J PHARMACOL, V119, P1167, DOI 10.1111/j.1476-5381.1996.tb16019.x; Clarke RW, 1997, BRIT J PHARMACOL, V122, P631, DOI 10.1038/sj.bjp.0701430; Clarke RW, 2000, PAIN, V85, P239, DOI 10.1016/S0304-3959(99)00272-9; Colpaert FC, 2004, EUR J PHARMACOL, V497, P29, DOI 10.1016/j.ejphar.2004.06.026; Dong JM, 1998, J PHARMACOL EXP THER, V286, P1239; Dutschmann M, 2002, AM J PHYSIOL-REG I, V282, pR999, DOI 10.1152/ajpregu.00502.2001; Dutschmann M, 2002, PFLUG ARCH EUR J PHY, V444, P227, DOI 10.1007/s00424-002-0797-x; El-Khatib Mohamad F, 2003, Respir Care, V48, P956; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; Galeotti N, 1997, PHARMACOL BIOCHEM BE, V57, P835, DOI 10.1016/S0091-3057(96)00401-7; GARNER SJ, 1989, AM REV RESPIR DIS, V139, P946, DOI 10.1164/ajrccm/139.4.946; GARRIOTT JC, 1983, J TOXICOL-CLIN TOXIC, V19, P987, DOI 10.3109/15563658208992530; GERBER N, 1993, J PEDIATR-US, V123, P322, DOI 10.1016/S0022-3476(05)81713-5; Gjerstad J, 1996, EUR J PHARMACOL, V318, P315, DOI 10.1016/S0014-2999(96)00819-9; GOETZ AM, 1994, CRIT CARE MED, V22, P1579; Gold MS, 1999, P NATL ACAD SCI USA, V96, P7645, DOI 10.1073/pnas.96.14.7645; Graeff FG, 2004, NEUROSCI BIOBEHAV R, V28, P239, DOI 10.1016/j.neubiorev.2003.12.004; Guenther U, 2002, MOLECULAR AND BASIC MECHANISMS OF ANESTHESIA, P400; Hering R, 2002, INTENS CARE MED, V28, P1426, DOI 10.1007/s00134-002-1442-z; Hering R, 2008, INTENS CARE MED, V34, P523, DOI 10.1007/s00134-007-0957-8; Holden JE, 2005, NEUROSCIENCE, V135, P1255, DOI 10.1016/j.neuroscience.2005.07.023; HOOVER CA, 1996, J CARDIOVASC PHARM T, V1, P255; Kayser V, 2007, PAIN, V130, P235, DOI 10.1016/j.pain.2006.11.015; Kiss I, 2005, EUR J PHARMACOL, V523, P29, DOI 10.1016/j.ejphar.2005.09.003; Liu FY, 2007, J PHARMACOL EXP THER, V321, P1046, DOI 10.1124/jpet.106.115204; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Meyer LCR, 2006, AM J PHYSIOL-REG I, V290, pR405; Millan MJ, 1998, NEUROPHARMACOLOGY, V37, P953, DOI 10.1016/S0028-3908(98)00078-1; MOTULSKY HJ, 1999, ANAL DATA GRAPHPAD P; Nadeson R, 2002, BRIT J ANAESTH, V88, P679, DOI 10.1093/bja/88.5.679; Oertel BG, 2007, CLIN PHARMACOL THER, V81, P59, DOI 10.1038/sj.clpt.6100018; Paton JFR, 1996, J NEUROSCI METH, V65, P63, DOI 10.1016/0165-0270(95)00147-6; Piquet CY, 1998, ANN PHARMACOTHER, V32, P653, DOI 10.1345/aph.17182; Putensen C, 2001, AM J RESP CRIT CARE, V164, P43, DOI 10.1164/ajrccm.164.1.2001078; Putensen Christian, 2002, Curr Opin Crit Care, V8, P51, DOI 10.1097/00075198-200202000-00009; Richter DW, 2003, TRENDS MOL MED, V9, P542, DOI 10.1016/j.molmed.2003.10.010; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; Sauget D, 2002, THERAPIE, V57, P309; Schomburg ED, 2000, NEUROSCI RES, V37, P277, DOI 10.1016/S0168-0102(00)00129-2; St John WA, 2007, RESP PHYSIOL NEUROBI, V155, P97, DOI 10.1016/j.resp.2006.04.018; St-John WM, 2000, RESP PHYSIOL, V123, P201, DOI 10.1016/S0034-5687(00)00177-8; Steffens H, 2001, NEUROSCI RES, V39, P413, DOI 10.1016/S0168-0102(01)00198-5; Szereda-Przestaszewska M, 2007, EXP PHYSIOL, V92, P953, DOI 10.1113/expphysiol.2007.037333; Wei H, 2006, EUR J PHARMACOL, V535, P157, DOI 10.1016/j.ejphar.2006.02.019; Wilken B, 1997, J PEDIATR-US, V130, P89, DOI 10.1016/S0022-3476(97)70315-9; Wysowski DK, 1996, NEW ENGL J MED, V335, P290, DOI 10.1056/NEJM199607253350416; ZIMMERMANN DL, 1993, CAN J ANAESTH, V40, P568, DOI 10.1007/BF03009742	53	23	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2009	108	4					1169	1176		10.1213/ane.0b013e318198f828			8	Anesthesiology	Anesthesiology	423ZG	WOS:000264534700022	19299781				2020-06-30	J	Gentile, A; Tran-Van, D; Dardare, E; Fritsch, N; Benois, A; Fontaine, B				Gentile, A.; Tran-Van, D.; Dardare, E.; Fritsch, N.; Benois, A.; Fontaine, B.			Management of transdermal therapeutics in perioperative care	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						Transdermal therapeutic; Phamacokinetics; Anaesthesia; Surgery; Nicotine; Fentanyl; Nitroglycerin; Scopolamine; Estradiol	POSTOPERATIVE PAIN MANAGEMENT; PATTERN SKIN FLAPS; NICOTINE PATCH; REPLACEMENT THERAPY; ISCHEMIC NECROSIS; DELIVERY-SYSTEM; FENTANYL PATCH; RISK-FACTORS; PHARMACOKINETICS; EFFICACY	Objective. To provide guidance on perioperative management of most frequently encountered transdermal therapeutics in anaesthesiology; nicotine, fentanyl, nitroglycerin, scopolamine and estradiol. Data sources. - A review of the last decade literature was carried out on the Pubmed database using the following keywords (transcutaneous or percutaneous or transdermal or transdermic or skin or dermal) and (drug delivery systems or therapeutic systems or drug administration) grouped under the Mesh terms cutaneous administration, perioperative care, surgery, pharmacokinetics, nicotine, fentanyl, nitroglycerin, scopolamine. estradiol. Study selection. - Original articles. general articles reviews, guidelines, letters to the editor and case reports have been selected. Dam extraction. Articles were analyzed for each transdermal treatment in terms of pharmacokinetics as well as anaesthetics and surgical interactions. Data synthesis. - Transdermal nicotine must be removed before anaesthesia of patients with coronary disease or with high risk of inhalation and in case of reconstructive surgery. Transdermal fentanyl must be maintained during the perioperative period and associated with preventive treatments of hyperalgesia. Transdermal administration of fentanyl by iontophoresis is a promising system for postoperative analgesia. Transdermal nitroglycerin must be maintained before scheduled surgery of a coronary patient. Transdermal scopolamine must he removed the day before surgery because of its side effects. It could have an interest in the prevention of postoperative nausea and vomiting, but its therapeutic method remain to be defined. Transdermal estradiol can be maintained during the perioperative period. Conclusion. - The management of transdermal therapeutics in peri operative care can be adapted for each treatment and for each patient by knowing pharmacokinetics as well as anaesthetics and Surgical interactions. In emergency situations, the actions to be taken do not generally differ, but one must be aware that the effects of trandermal treatments do not disappear immediately when removed, due to their pharmacokinetics properties. (C) 2009 Elsevier Masson SAS. All rights reserved.	[Gentile, A.; Tran-Van, D.; Dardare, E.; Fritsch, N.; Benois, A.; Fontaine, B.] HIA Robert Picque, Federat Anesthesie Reanimat Urgences Citera, F-33998 Bordeaux, France	Tran-Van, D (reprint author), HIA Robert Picque, Federat Anesthesie Reanimat Urgences Citera, BP 28, F-33998 Bordeaux, France.	david.tranvan@yahoo.fr					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Baillard C, 2005, ANN FR ANESTH, V24, P1360, DOI 10.1016/j.annfar.2005.06.013; Caumo W, 2001, ACTA ANAESTH SCAND, V45, P298, DOI 10.1034/j.1399-6576.2001.045003298.x; Caumo W, 2001, ANAESTHESIA, V56, P720, DOI 10.1046/j.1365-2044.2001.01842.x; Chalhoub V, 2008, ANN FR ANESTH, V27, P405, DOI 10.1016/j.annfar.2008.04.002; CULLANDER C, 1991, PREDICTION OF PERCUTANEOUS PENETRATION : METHODS, MEASUREMENTS, MODELLING, VOL 2, P229; Diemunsch P, 2008, Ann Fr Anesth Reanim, V27, P866, DOI 10.1016/j.annfar.2008.09.004; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; Fletcher D., 2002, C ACT 44 C NAT AN RE, P197; FORREST CR, 1994, CAN J PHYSIOL PHARM, V72, P30, DOI 10.1139/y94-006; FORREST CR, 1987, BRIT J PLAST SURG, V40, P295, DOI 10.1016/0007-1226(87)90126-3; FORREST CR, 1991, PLAST RECONSTR SURG, V87, P518, DOI 10.1097/00006534-199103000-00020; Frolich M, 2001, ANESTH ANALG, V93, P647; GONZALES F, 2002, C ACT 39 C NAT AN RE, P11; Greenland S, 1998, DRUG SAFETY, V18, P297, DOI 10.2165/00002018-199818040-00005; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUY RH, 1989, PERCUTANEOUS ABSORPT, P13; HABIB AS, 2007, ANESTHESIOLOGY, V107, pA462; HABIB AS, 2007, ANESTHESIOLOGY, V107, pA494; Haddox JD, 1997, CLIN J PAIN, V13, P6; HADGRAFT J, 2001, SKIN PHARMACOL APPL, V15, pS72; Harnett MJP, 2007, ANESTH ANALG, V105, P764, DOI 10.1213/01.ane.0000277494.30502.db; Herndon CM, 2007, PHARMACOTHERAPY, V27, P745, DOI 10.1592/phco.27.5.745; Kadakia SC, 1996, DIGEST DIS SCI, V41, P2130, DOI 10.1007/BF02071391; Kazemi AP, 2006, J CLIN ANESTH, V18, P495, DOI 10.1016/j.jclinane.2006.02.015; Kelton MC, 2000, BRAIN COGNITION, V43, P274; Kimmel SE, 2001, J AM COLL CARDIOL, V37, P1297, DOI 10.1016/S0735-1097(01)01124-X; Koo PJS, 2005, AM J HEALTH-SYST PH, V62, P1171, DOI 10.1093/ajhp/62.11.1171; Kranke P, 2002, ANESTH ANALG, V95, P133, DOI 10.1097/00000539-200207000-00024; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; LADEMANN J, 2001, SKIN PHARMACOL APPL, V14, pS17; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P734, DOI 10.1097/00000542-199903000-00015; Lauretti GR, 2000, ANESTHESIOLOGY, V93, P943, DOI 10.1097/00000542-200010000-00011; LAURETTI GR, 2007, ANESTHESIOLOGY, V107, pA463; LAVRIJSEN APM, 1995, J INVEST DERMATOL, V105, P619, DOI 10.1111/1523-1747.ep12323752; LEMAY S, 2004, BIOL PSYCHIAT, V28, P31; MINKOWITZ HS, 2006, ANESTHESIOLOGY A, V105, P1645; MOE G, 1986, AM J MED, V81, P765, DOI 10.1016/0002-9343(86)90341-4; Morioka N, 1998, Masui, V47, P1459; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; MURPHY M, 2001, [No title captured], V1, P361; Paut O, 2000, ANAESTHESIA, V55, P1202, DOI 10.1046/j.1365-2044.2000.01615-3.x; Puura A, 2003, METHOD FIND EXP CLIN, V25, P383, DOI 10.1358/mf.2003.25.5.769661; Puura AIE, 1998, ANESTH ANALG, V87, P430, DOI 10.1097/00000539-199808000-00037; RAPP SE, 1995, PAIN, V61, P195, DOI 10.1016/0304-3959(94)00168-E; RENNARD S, 1994, ARCH INTERN MED, V154, P989; Renner UD, 2005, THER DRUG MONIT, V27, P655, DOI 10.1097/01.ftd.0000168293.48226.57; Roth JV, 1997, ANESTHESIOLOGY, V86, P1208, DOI 10.1097/00000542-199705000-00024; RUPREHT J, 1990, ANN FR ANESTH, V9, P295, DOI 10.1016/S0750-7658(05)80190-X; Samama CM, 2005, ANN FR ANESTH, V24, P853, DOI 10.1016/j.annfar.2005.06.011; SCHAEFER P, 2001, SKILL PHARM APPL SKI, V14, pS23; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Warnakulasuriya S, 2005, ORAL ONCOL, V1, P46, DOI 10.1016/S1744-7895(05)80058-6; White HK, 2004, PSYCHOPHARMACOLOGY, V171, P465, DOI 10.1007/s00213-003-1614-8; WILLIAMS EL, 1993, ANESTH ANALG, V76, P907; Wong PWK, 1999, DIGEST DIS SCI, V44, P2165, DOI 10.1023/A:1026680031346; YANG CY, 1992, PSYCHOPHARMACOLOGY, V106, P417, DOI 10.1007/BF02245428; Zhai HB, 2001, SKIN PHARMACOL APPL, V14, P1, DOI 10.1159/000056328; 2006, [No title captured], V25, P479	66	0	1	0	6	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	APR	2009	28	4					311	320		10.1016/j.annfar.2009.01.019			10	Anesthesiology	Anesthesiology	444YT	WOS:000266017500006	19304449				2020-06-30	J	Demmy, TL; Nwogu, C; Solan, P; Yendamuri, S; Wilding, G; DeLeon, O				Demmy, Todd L.; Nwogu, Chukwumere; Solan, Patrick; Yendamuri, Saikrishna; Wilding, Gregory; DeLeon, Oscar			Chest Tube-Delivered Bupivacaine Improves Pain and Decreases Opioid Use After Thoracoscopy	ANNALS OF THORACIC SURGERY			English	Article; Proceedings Paper	55th Annual Meeting of the Southern-Thoracic-Surgical-Association	NOV 05-08, 2008	Austin, TX	SE Thorac Surg Assoc			POSTTHORACOTOMY PAIN; INTRAPLEURAL BUPIVACAINE; THORACIC-SURGERY; INTERPLEURAL BUPIVACAINE; POSTOPERATIVE ANALGESIA; THORACOTOMY; CHOLECYSTECTOMY; LOBECTOMY	Background. This study compared a simplified method of intrapleural bupivacaine administration with traditional analgesic therapy to decrease postoperative pain and opioid usage in patients after thoracoscopy. Methods. Thirty patients who had non-rib-spreading thoracoscopic operations under general anesthesia were prospectively randomized to no local anesthetic infusion (control), intermittent bolus (30 mL every 6 hours), or continuous infusion (5 mL/h). Bupivacaine (0.25%) was delivered through the pleural infusion channel of a specially designed single silicone 28F chest tube. Total intravenous fentanyl patient-controlled analgesia (boluses with basal rate) infused in the first 24 hours postoperatively was the designated primary study end point. Escalations of analgesic therapy, including ketorolac administration, were standardized across all groups. Nurses assessed pain control at onset and every 6 hours by visual analog pain scales (VAPS, 100 mm). VAPS were repeated 10 minutes later to assess any opioid or bupivacaine bolus effects. Results. No study-related adverse events occurred. Compared with controls, pooled VAPS scores and 24-hour fentanyl consumption were significantly lower for the intermittent and continuous administration groups (1753 vs 1180 vs 1177 mu g/24 h, respective median; p = 0.04) Early (6-hour) VAPS analgesic responses were more certain for intermittent (10 of 10) and continuous (10 of 10) patients than controls (7 of 10, p = .04). Five continuous patients successfully maintained VAPS scores below 20 mm throughout the study vs 3 intermittent and 2 controls (p = .045). Conclusions. Intermittent or continuous intrapleural bupivacaine infused through the chest tube reliably reduces postoperative pain and 24-hour opioid usage in thoracoscopy patients.	[Demmy, Todd L.] Roswell Pk Canc Inst, Dept Thorac Surg, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Biostat, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Anesthesiol & Pain Med, Buffalo, NY 14263 USA; SUNY Buffalo, Buffalo, NY 14260 USA	Demmy, TL (reprint author), Roswell Pk Canc Inst, Dept Thorac Surg, Elm & Carlton Sts, Buffalo, NY 14263 USA.	todd.demmy@roswellpark.org					Alex J, 2003, ANN THORAC SURG, V76, P1046, DOI 10.1016/S0003-4975(03)00884-1; BROCKMEIER V, 1994, ACTA ANAESTH SCAND, V38, P317, DOI 10.1111/j.1399-6576.1994.tb03900.x; Demmy TL, 2005, ANN THORAC SURG, V79, P1744, DOI 10.1016/j.athoracsur.2004.05.015; ELMAN A, 1993, J CLIN ANESTH, V5, P118, DOI 10.1016/0952-8180(93)90138-5; KAMBAM JR, 1989, CAN J ANAESTH, V36, P106, DOI 10.1007/BF03011428; Karakaya D, 2004, J CARDIOTHOR VASC AN, V18, P461, DOI 10.1053/j.jvca.2004.05.026; Katz J, 1996, CLIN J PAIN, V12, P50, DOI 10.1097/00002508-199603000-00009; MANN LJ, 1992, ANN THORAC SURG, V53, P449, DOI 10.1016/0003-4975(92)90267-8; Miguel R, 1993, J Cardiothorac Vasc Anesth, V7, P529, DOI 10.1016/1053-0770(93)90308-8; Pompeo E, 2003, ANN THORAC SURG, V76, P1821, DOI 10.1016/S0003-4975(03)01302-X; RICHARDSON J, 1995, BRIT J ANAESTH, V75, P405, DOI 10.1093/bja/75.4.405; SCHNEIDER RF, 1993, CHEST, V103, P414, DOI 10.1378/chest.103.2.414; SHAFEI H, 1990, THORAC CARDIOV SURG, V38, P38, DOI 10.1055/s-2007-1013989; Silomon M, 2000, ANESTH ANALG, V91, P44, DOI 10.1097/00000539-200007000-00009; STROMSKAG KE, 1988, ANESTH ANALG, V67, P430; Symreng T, 1989, J Cardiothorac Anesth, V3, P144, DOI 10.1016/S0888-6296(89)92306-5; TURNER D, 1989, REGION ANESTH, V14, P128; VADEBONCOUER TR, 1989, ANESTHESIOLOGY, V71, P339, DOI 10.1097/00000542-198909000-00003; VANKLEEF JW, 1992, ANESTH ANALG, V75, P268	19	22	22	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	APR	2009	87	4					1040	1047		10.1016/j.athoracsur.2008.12.099			8	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	423OQ	WOS:000264506000007	19324125				2020-06-30	J	Shao, X; Kilbourn, MR				Shao, Xia; Kilbourn, Michael R.			A simple modification of GE tracerlab FX C Pro for rapid sequential preparation of [(11)C]carfentanil and [(11)C]raclopride	APPLIED RADIATION AND ISOTOPES			English	Article						[(11)C]Raclopride; [(11)C]Carfentanil; PET; GE tracerlab FX C Pro; [(11)C]Methylation	C-11 METHYL TRIFLATE	A simple modification of the GE Tracerlab FX C Pro system which enabled performance of both solvent capture (loop method) and conventional solution phase [(11)C]methylation in the same module is described. By the quick setup and automated method, [(11)C]carfentanil and [(11)C]raclopride could be prepared in rapid succession without opening the hot cell. The radiochemical yields were over 40% and 30% (decay-corrected and based on [(11)C]methyl iodide) for [(11)C]carfentanil and [(11)C]raclopride, respectively. The radiochemical purities were greater than 95% and specific activities over 5 Ci/mmol for both tracers. The modification is extremely easy and can be utilized for multiple syntheses of other (11)C-labeled radiopharmaceuticals in a fast and reliable manner. (C) 2009 Elsevier Ltd. All rights reserved.	[Shao, Xia; Kilbourn, Michael R.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA	Shao, X (reprint author), Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA.	xshao@umich.edu					Elsinga PH, 2006, CURR MED CHEM, V13, P2139, DOI 10.2174/092986706777935258; Iwata R, 2001, APPL RADIAT ISOTOPES, V55, P17, DOI 10.1016/S0969-8043(00)00368-7; JEWETT DM, 1992, APPL RADIAT ISOTOPES, V43, P1383; Koeppe RA, 2001, J CEREBR BLOOD F MET, V21, P1480, DOI 10.1097/00004647-200112000-00013; Ravert HT, 2004, CURR PHARM DESIGN, V10, P759, DOI 10.2174/1381612043452992; Scott DJ, 2007, SYNAPSE, V61, P707, DOI 10.1002/syn.20404; Scott DJ, 2007, NEUROPSYCHOPHARMACOL, V32, P450, DOI 10.1038/sj.npp.1301238	7	13	15	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0969-8043			APPL RADIAT ISOTOPES	Appl. Radiat. Isot.	APR	2009	67	4					602	605		10.1016/j.apradiso.2008.12.013			4	Chemistry, Inorganic & Nuclear; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Chemistry; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	420QY	WOS:000264305500020	19162491				2020-06-30	J	Maslekar, S; Gardiner, A; Hughes, M; Culbert, B; Duthie, GS				Maslekar, S.; Gardiner, A.; Hughes, M.; Culbert, B.; Duthie, G. S.			Randomized clinical trial of Entonox (R) versus midazolam-fentanyl sedation for colonoscopy	BRITISH JOURNAL OF SURGERY			English	Article							NITROUS-OXIDE; GASTROINTESTINAL ENDOSCOPY; FLEXIBLE SIGMOIDOSCOPY; ANALGESIA; RECOVERY; QUALITY	Background: Intravenous sedation for colonoscopy is associated with cardiorespiratory complications and delayed recovery. The aim of this randomized clinical trial was to compare the efficacy of Entonox (R) (50 per cent nitrous oxide and 50 per cent oxygen) and intravenous sedation using midazolam-fentanyl for colonoscopy. Methods: Some 131 patients undergoing elective colonoscopy were included. Patients completed a Hospital Anxiety and Depression questionnaire, letter cancellation tests and pain scores on a 100-mm visual analogue scale before, immediately after the procedure and at discharge. They also completed a satisfaction survey at discharge and 24 h after the procedure. Results: Sixty-five patients were randomized to receive Entonox (R) and 66 to midazolam-fentanyl. Completion rates were similar (94 versus 92 per cent respectively; P = 0.513). Patients receiving Entonox (R) had a shorter time to discharge. They reported significantly less pain (mean score 16.7 versus 40.1; P < 0.001), and showed better recovery of psychomotor function immediately after the procedure and at discharge. Patient satisfaction was higher among patients who received Entonox (R) (median score 96 versus 89; P = 0.001). Conclusion: Entonox (R) provides better pain relief and faster recovery than midazolam-fentanyl and so is more effective for colonoscopy. Registration number: ISRCTN81142957 (http://www.controlled-trials.com).	[Duthie, G. S.] Univ Hull, Acad Surg Unit, Castle Hill Hosp, Cottingham HU16 5JQ, England	Duthie, GS (reprint author), Univ Hull, Acad Surg Unit, Castle Hill Hosp, Castle Rd, Cottingham HU16 5JQ, England.	g.s.duthie@hull.ac.uk	Gardiner, Angela/B-6941-2014	Gardiner, Angela/0000-0001-6209-8275			ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BELL GD, 1990, ALIMENT PHARM THERAP, V4, P103; *CDC, 2001, MMWR SURVEILL SUMM, V52, P193; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Forbes GM, 2000, GASTROINTEST ENDOSC, V51, P271, DOI 10.1016/S0016-5107(00)70354-3; FROEHLICH F, 1994, ENDOSCOPY, V26, P231, DOI 10.1055/s-2007-1008949; Harding TA, 2000, ENDOSCOPY, V32, P457, DOI 10.1055/s-2000-652; Johanson JF, 2000, GASTROINTEST ENDOSC, V52, P827, DOI 10.1016/S0016-5107(00)70218-5; KEEFFE E B, 1990, Gastrointestinal Endoscopy, V36, pS13; KEEFFE EB, 1995, GASTROENTEROLOGY, V108, P932, DOI 10.1016/0016-5085(95)90471-9; LAWRENCE B, 2005, GASTROINTEST ENDOSC, V61, pAB111; LINDBLOM A, 1994, ENDOSCOPY, V26, P283, DOI 10.1055/s-2007-1008968; LINDSAY DC, 1988, BRIT MED J, V296, P167, DOI 10.1136/bmj.296.6616.167; Martin JP, 2000, GASTROINTEST ENDOSC, V51, P701, DOI 10.1067/mge.2000.106113; NotiniGudmarsson AK, 1996, ENDOSCOPY, V28, P283, DOI 10.1055/s-2007-1005454; O'CONNOR K W, 1990, Gastrointestinal Endoscopy, V36, pS2; RIMMER KP, 1989, J CLIN GASTROENTEROL, V11, P17, DOI 10.1097/00004836-198902000-00005; SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012; Trojan J, 1997, ENDOSCOPY, V29, P17, DOI 10.1055/s-2007-1004055; Vargo JJ, 2007, J CLIN GASTROENTEROL, V41, P591, DOI 10.1097/01.mcg.0000225634.52780.0e; Willey J, 2002, GASTROINTEST ENDOSC, V56, P810, DOI 10.1067/mge.2002.129609; WILLIAMS CB, 1994, GASTROINTEST ENDOSC, V40, P769, DOI 10.1016/S0016-5107(94)70127-X; Wootton F T 3rd, 1998, Am J Gastroenterol, V93, P660; SAFETY SEDATION DURI; ENTONOX DATA SHEET	26	25	28	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1323	1365-2168		BRIT J SURG	Br. J. Surg.	APR	2009	96	4					361	368		10.1002/bjs.6467			8	Surgery	Surgery	426EV	WOS:000264691700006	19283736				2020-06-30	J	Manral, L; Muniappan, N; Gupta, PK; Ganesan, K; Malhotral, RC; Vijayaraghavan, R				Manral, Laxmi; Muniappan, Natrajan; Gupta, Pradeep K.; Ganesan, Kumaran; Malhotral, Ramesh Chandra; Vijayaraghavan, Rajagopalan			Effect of exposure to fentanyl aerosol in mice on breathing pattern and respiratory variables	DRUG AND CHEMICAL TOXICOLOGY			English	Article						Fentanyl; aerosol; RD50; LC50; TLV; mice	AIRBORNE CHEMICALS; TRACT; DELIVERY	The breathing pattern of mice that were exposed to fentanyl aerosol was studied (2.7, 5.7, 6.0, 10.0, and 23.6 mu g/m(3); for 1 hour), using dimethyl sulfoxide as a vehicle. This study was conducted in a head-only exposure assembly. Body plethysmographs connected to a volumetric pressure transducer were used to capture the respiratory signals, and an on-line computer program capable of recognizing the changes in the breathing pattern was used for monitoring the respiratory pattern. The response of mice to fentanyl exposure was found to be concentration dependent. A lower concentration (2.7 mu g/m(3)) showed fast recovery and no mortality, while 100% mortality was observed at a higher concentration (23.6 mu g/m(3)). No sensory, pulmonary irritation, and airway limitation in mice was observed, and death occurred probably due to respiratory depression. The concentration that decreased 50% of the respiratory frequency (RD50) was estimated to be 6.4 mu g/m(3). The extrapolated human threshold limit value, calculated from the RD50 value, was found to be 0.192 mu g/m(3). The concentration that caused 50% mortality in exposed mice (LC50) was estimated to be 8.8 mu g/m(3). This study shows that aerosolized fentanyl does not cause sensory and pulmonary irritation, and since the RD50 and LC50 are very close with a low safety margin, this type of sedative should not be used as an incapacitating agent.	[Manral, Laxmi; Gupta, Pradeep K.; Ganesan, Kumaran; Malhotral, Ramesh Chandra] Def Res & Dev Estab, Synthet Chem Div, Gwalior 474002, India; [Muniappan, Natrajan; Vijayaraghavan, Rajagopalan] Def Res & Dev Estab, Div Pharmacol & Toxicol, Gwalior 474002, India	Manral, L (reprint author), Def Res & Dev Estab, Synthet Chem Div, Jhansi Rd, Gwalior 474002, India.	luxmimanral@yahoo.com					ALARIE Y, 1966, ARCH ENVIRON HEALTH, V13, P433, DOI 10.1080/00039896.1966.10664593; ALARIE Y, 1986, TOXICOLOGY NASAL PAS, P91; ALARIE Y, 1973, CRC CRIT R TOXICOL, V2, P229; ALARIE Y, 2000, INDOOR AIR QUALITY H, P231; BALLANTYNE B, 1977, CURRENT APPROACHES T, P105; CAPSI J, 1988, CRIT CARE MED, V16, P238; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; GHOSH MN, 1984, FUNDAMENTALS EXPT PH, P187; Gupta PK, 2005, J CHEM RES, P452; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; HU H, 1992, CHEM WARFARE AGENTS, P271; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Micovic IV, 2000, BIOORG MED CHEM LETT, V10, P2011, DOI 10.1016/S0960-894X(00)00394-2; Rabinowitz JD, 2004, J PHARMACOL EXP THER, V309, P769, DOI 10.1124/jpet.103.062893; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; SCHAPER M, 1993, AM IND HYG ASSOC J, V54, P488, DOI 10.1202/0002-8894(1993)054<0488:DOADFS>2.0.CO;2; SPRUNG J, 1992, J CLIN ANESTH, V4, P504, DOI 10.1016/0952-8180(92)90230-X; Vijayaraghavan R, 1997, ARCH TOXICOL, V71, P157, DOI 10.1007/s002040050370; VIJAYARAGHAVAN R, 1994, ARCH TOXICOL, V68, P490, DOI 10.1007/s002040050101; VIJAYARAGHAVAN R, 1993, ARCH TOXICOL, V67, P478, DOI 10.1007/BF01969919; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	21	5	5	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0148-0545	1525-6014		DRUG CHEM TOXICOL	Drug Chem. Toxicol.	APR	2009	32	2					108	113		10.1080/01480540802587214			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology	Chemistry; Pharmacology & Pharmacy; Toxicology	453DL	WOS:000266590300003	19514946				2020-06-30	J	Casuccio, A; Mercadante, S; Fulfaro, F				Casuccio, Alessandra; Mercadante, Sebastiano; Fulfaro, Fabio			Treatment strategies for cancer patients with breakthrough pain	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						breakthrough pain; cancer pain; pharmacotherapy; treatment strategies	TRANSMUCOSAL FENTANYL CITRATE; BONE METASTASES; INCIDENT PAIN; INTRAVENOUS MORPHINE; BUCCAL TABLET; PALLIATIVE-CARE; DOSE-TITRATION; RECOMMENDATIONS; ASSOCIATION; MULTICENTER	Background: Breakthrough pain (BTP) is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids. It is normally severe in intensity, has a rapid onset, has a variable duration (on average 30 min) and is considered a negative prognostic factor. Objective: To verify the data in the literature about therapy strategies for BTP in cancer patients. Methods: To find clinical trials investigating drug therapy for BTP. Conclusion: The treatment of BTP in cancer patients receiving opioids is principally based on the use of opioids, preferentially with a short onset. Fentanyl delivered by recently developed systems seems to be the best option to cover the temporal pattern of BTP, although the treatment should be highly personalized to provide the best in individuals, balancing patients' preferences and clinical needs. The doses to be administered is still a matter of controversy in the literature; additional studies with specific designs should be conducted to settle the question.	[Casuccio, Alessandra] Univ Palermo, Dept Clin Neurosci, I-90127 Palermo, Italy; [Mercadante, Sebastiano] La Maddalena Canc Ctr, Intens Care Unit, Palermo, Italy; [Mercadante, Sebastiano] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Palermo, Italy; [Fulfaro, Fabio] Univ Palermo, Operat Unit Med Oncol, Dept Oncol, I-90127 Palermo, Italy	Casuccio, A (reprint author), Univ Palermo, Dept Clin Neurosci, Via Liborio Giuffre 13, I-90127 Palermo, Italy.	casuccio@unipa.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535			Agarawal JP, 2006, CLIN ONCOL-UK, V18, P747, DOI 10.1016/j.clon.2006.09.007; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; BRUERA E, 1992, PAIN, V50, P75, DOI 10.1016/0304-3959(92)90114-Q; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; MERCADANTE S, 1992, PAIN, V50, P151, DOI 10.1016/0304-3959(92)90155-5; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P505, DOI 10.1016/j.jpainsymman.2004.02.024; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V22, P630, DOI 10.1016/S0885-3924(01)00322-0; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2006, DRUGS, V66, P2394, DOI 10.2165/00003495-200666180-00015; Overhoff KA, 2008, DRUG DEV IND PHARM, V34, P960, DOI [10.1080/03639040802154897, 10.1080/03639040802154897 ]; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Ripamonti C, 2007, SUPPORT CARE CANCER, V15, P1177, DOI 10.1007/s00520-007-0230-2; Ripamonti C, 2007, SUPPORT CARE CANCER, V15, P339, DOI 10.1007/s00520-006-0131-9; Taylor DR, 2007, EXPERT OPIN PHARMACO, V8, P3043, DOI 10.1517/14656566.8.17.3043; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	33	8	10	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1465-6566			EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	APR	2009	10	6					947	953		10.1517/14656560902851510			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	447LC	WOS:000266191600004	19351277	Green Published			2020-06-30	J	Weissman, A; Torkhov, O; Weissman, AI; Drugan, A				Weissman, A.; Torkhov, O.; Weissman, A. I.; Drugan, A.			The effects of meperidine and epidural analgesia in labor on maternal heart rate variability	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Analgesia; Labor; Epidural analgesia; Meperidine; Heart rate variability	APPROXIMATE ENTROPY; SPINAL-ANESTHESIA; POINCARE PLOT; COMPLEXITY; BIRTH; PAIN	Background: Epidural and parenteral opioid analgesia are two common methods of pain relief in labor that may influence the autonomic nervous system. However, these effects on laboring women have not yet been adequately studied. The aim of our study was to assess the effects of these two methods of analgesia on autonomic nervous system modulation of maternal heart rate variability in laboring women. Methods: A prospective observational study was conducted on 64 laboring women; 33 received epidural analgesia with bupivacaine and fentanyl and 31 intravenous meperidine and promethazine. Power spectral analysis and nonlinear methods were applied to digitized electrocardiograms performed before and after administration of analgesia, to assess maternal heart rate variability and autonomic equilibrium. Results: Maternal heart rate significantly increased in women who received meperidine compared to those who had epidural analgesia. There was a significant increase in the low-frequency to high-frequency ratio (3.7 +/- 3.9 vs. 1.8 +/- 1.6, P < 0.05), and a significant decrease of high-frequency spectral power in women who had meperidine compared to those who received epidural analgesia (163 +/- 91 vs. 98 +/- 100 ms(2)/Hz, P < 0.05). Conclusions: Meperidine caused an autonomic nervous system shift towards sympathetic activation with abolition of respiratory sinus arrhythmia high-frequency spectral band. Conversely epidural analgesia had no significant effect on autonomic nervous system control of heart rate. (C) 2008 Elsevier Ltd. All rights reserved.	[Weissman, A.; Torkhov, O.; Drugan, A.] Rambam Med Ctr, Dept Obstet & Gynecol, IL-31096 Haifa, Israel; [Weissman, A. I.] Rambam Med Ctr, Dept Anesthesiol, IL-31096 Haifa, Israel; [Weissman, A. I.; Drugan, A.] Technion Israel Inst Technol, Fac Med, Haifa, Israel	Weissman, A (reprint author), Rambam Med Ctr, Dept Obstet & Gynecol, POB 9602, IL-31096 Haifa, Israel.	wamir@netvision.net.il					AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Brennan M, 2001, IEEE T BIO-MED ENG, V48, P1342, DOI 10.1109/10.959330; Brown TE, 1997, J PHARMACOL EXP THER, V282, P839; Camm AJ, 1996, CIRCULATION, V93, P1043, DOI 10.1016/0044-8486(94)90048-5; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Deschamps A, 2004, ANESTHESIOLOGY, V101, P21, DOI 10.1097/00000542-200407000-00006; Goldberger AL, 2002, NEUROBIOL AGING, V23, P23, DOI 10.1016/S0197-4580(01)00266-4; Herbst A, 1997, OBSTET GYNECOL, V90, P125, DOI 10.1016/S0029-7844(97)00177-4; Hill JB, 2003, OBSTET GYNECOL, V102, P333, DOI 10.1016/S0029-7844(03)00567-2; INTRONA R, 1995, ANESTH ANALG, V80, P315, DOI 10.1097/00000539-199502000-00019; KAMEN PW, 1995, AUST NZ J MED, V25, P18, DOI 10.1111/j.1445-5994.1995.tb00573.x; LANDRY DP, 1994, REGION ANESTH, V19, P189; Latta Kenneth S, 2002, Am J Ther, V9, P53, DOI 10.1097/00045391-200201000-00010; Lowe NK, 2002, AM J OBSTET GYNECOL, V186, pS16, DOI 10.1067/mob.2002.121427; PINCUS SM, 1992, OBSTET GYNECOL, V79, P249; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; Sosa CG, 2006, EUR J OBSTET GYN R B, V129, P135, DOI 10.1016/j.ejogrb.2005.11.033; SPIELMAN FJ, 1987, CLIN OBSTET GYNECOL, V30, P495, DOI 10.1097/00003081-198709000-00005; Weissman A, 2006, DIABETES CARE, V29, P571, DOI 10.2337/diacare.29.03.06.dc05-2009; Weissman A, 2009, NEONATOLOGY, V95, P41, DOI 10.1159/000151754	21	5	5	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2009	18	2					118	124		10.1016/j.ijoa.2008.09.006			7	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	438FV	WOS:000265542200004	19157851				2020-06-30	J	Arpino, PA; Thompson, BT				Arpino, P. A.; Thompson, B. T.			Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article; Proceedings Paper	42nd Midyear Clinical Meeting of the American-Society-of-Health-System-Pharmacists	DEC 02-06, 2007	Las Vegas, NV	Amer Soc Hlth Syst Pharmacists		constipation; intensive care unit; naloxone; safety	OPIOID-INDUCED CONSTIPATION; ORAL NALOXONE; ANALGESIA; PATIENT	Background: Opiates are the mainstay of analgesia in the intensive care unit (ICU). Unfortunately, constipation is a common adverse effect associated with opioid use. Naloxone is a pure opiate antagonist that is frequently utilized in practice for the prophylaxis or treatment of opiate-induced constipation in the ICU. Despite extensive first pass metabolism in the liver there remains the potential for opiate reversal after oral administration. We sought to assess the safety of enteral naloxone in the ICU for the treatment of opiate-induced constipation. Methods: Patients who were ordered enteral naloxone while in the ICU were identified through the Pharmacy's computer system. Patients were included in the data analysis if they had received at least one dose of enteral naloxone and had received standing opiates for at least 48 h prior to the initial naloxone dose. Patients were excluded from data analysis if the Richmond agitation-sedation scale (RASS) score was not utilized, they were paralysed or the medical record indicated that extubation was planned within the following 24 h. Data points were recorder at the following times with respect to each naloxone dose administered; time -2, -1, 0, 1, 2 and 4 h. The following data points were collected before and after each naloxone dose; blood pressure, heart rate, respiratory rate, RASS score, pain assessment score (recorded as present or absent), midazolam dose, propofol dose and fentanyl dose. In order to assess for possible opiate reversal the peak fentanyl, propofol and midazolam dose, vital sign value, RASS score and pain score were compared before and after each dose of naloxone. Results: The mean naloxone dose was 3.6 +/- 0.9 mg. There was no significant change in RASS score around the naloxone doses, -2.9 +/- 1.4 before and -2.8 +/- 1.6 after (P = 0.28). There were no significant changes in mean fentanyl, propofol or midazolam dose around naloxone administration. There were also no significant changes in heart rate, blood pressure and respiratory rate or in the presence of pain. Conclusion: These results demonstrate that the administration of enteral naloxone to patients on intravenous opiates in the ICU setting was not associated with changes in sedation score, vital signs, fentanyl dose, midazolam dose or propofol dose.	[Arpino, P. A.] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA; [Thompson, B. T.] Massachusetts Gen Hosp, Dept Med, Med Intens Care Unit, Pulm & Crit Care Unit, Boston, MA 02114 USA	Arpino, PA (reprint author), 55 Fruit St, Boston, MA 02114 USA.	parpino@partners.org					Culpepper-Morgan J A, 1989, NIDA Res Monogr, V95, P399; CULPEPPERMORGAN JA, 1992, CLIN PHARMACOL THER, V52, P90, DOI 10.1038/clpt.1992.106; FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575; Hall G R, 1995, Medsurg Nurs, V4, P11; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; Liu MW, 2002, J PAIN SYMPTOM MANAG, V23, P48, DOI 10.1016/S0885-3924(01)00369-4; MANARA L, 1985, ANNU REV PHARMACOL, V25, P249, DOI 10.1146/annurev.pa.25.040185.001341; Meissner W, 2003, CRIT CARE MED, V31, P776, DOI 10.1097/01.CCM.0000053652.80849.9F; Meissner W, 2000, PAIN, V84, P105, DOI 10.1016/S0304-3959(99)00185-2; Mostafa SM, 2003, BRIT J ANAESTH, V91, P815, DOI 10.1093/bja/aeg275; SCHANG JC, 1985, AM J GASTROENTEROL, V80, P407; Thomas MC, 2003, AM J HEALTH-SYST PH, V60, P1264, DOI 10.1093/ajhp/60.12.1264	12	6	6	0	3	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0269-4727			J CLIN PHARM THER	J. Clin. Pharm. Ther.	APR	2009	34	2					171	175		10.1111/j.1365-2710.2008.00982.x			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	452OR	WOS:000266551300004	19250137				2020-06-30	J	Mercadante, S; Ferrera, P; Villari, P; Casuccio, A; Intravaia, G; Mangione, S				Mercadante, Sebastiano; Ferrera, Patrizia; Villari, Patrizia; Casuccio, Alessandra; Intravaia, Giuseppe; Mangione, Salvatore			Frequency, Indications, Outcomes, and Predictive Factors of Opioid Switching in an Acute Palliative Care Unit	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Opioid switching; cancer pain; palliative care	RESPONSIVE CANCER PAIN; TRANSDERMAL FENTANYL; ORAL METHADONE; DOSE RATIO; MORPHINE; ROTATION; MANAGEMENT; ANALGESIA; EFFICACY; NEED	The aim of this study was to prospectively evaluate the frequency, indications, outcomes, and predictive factors associated with opioid switching, using a protocol that. had been clinically applied and viewed as effective for many years. A prospective study was carried out on a cohort of consecutive cancer patients who were receiving opioids bill had an unacceptable balance between. analgesia and adverse effects, despite symptomatic treatment of side effects. The initial conversion, ratio between opioids and routes was (as follows (mg/day): oral morphine 100 = intravenous morphine 33 = transdermal fentanyl 1 = intravenous fentanyl 1 = oral methadone 20 = intravenous methadone 16 = oral oxycodone 70 = transdermal buprenorphine 1.3. The switch was assisted by opioids used as needed, and doses were changed after the initial conversion according to clinical response in an acute care selling. Intensity of pain and symptoms associated with opioid therapy were recorded. A distress score (DS) was calculated as a sum, of symptom intensity. A switch was considered successful when. the intensity of pain and/or DS, or the principal symptom. necessitating the switch, decreased to at least 33% of the value recorded before switching. One hundred eighteen patients underwent opioid substitutions. The indications for opioid switching we're uncontrolled pain and adverse effects (50.8%), adverse effects (28.8%), uncontrolled pain (15.2%), and convenience (4.2%). Overall, 103 substitutions were successful. Ninety-six substitutions were successful after the first switching, and a further substitution was successful in seven patients who did not respond, to the first switch. The mean time to achieve dose stabilization after switching was 3.2 days. The presence of both poor pain control and adverse effects was related to unsuccessful switching (P < 0.004). No relationship was identified between unsuccessful switching and the opioid dose, opioid sequence, pain mechanism., or use of adjuvant, medications. Opioid switching was an effective method to improve the balance between analgesia and adverse effects in more than 80% of cancer patients with a poor response to an opioid. The presence of both poor pain relief and adverse effects is a negative factor for switching prognosis, whereas renal failure is not. J Pain Symptom Manage 2009;37:632-641. (C) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Mercadante, Sebastiano; Ferrera, Patrizia; Villari, Patrizia; Intravaia, Giuseppe] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Mangione, Salvatore] Univ Palermo, Dept Anesthesiol & Intens Care, Palermo, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@la-maddalena.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Ashby MA, 1999, MED J AUSTRALIA, V170, P68, DOI 10.5694/j.1326-5377.1999.tb126885.x; Benitez-Rosario MA, 2004, CANCER-AM CANCER SOC, V101, P2866, DOI 10.1002/cncr.20712; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Cherny N. J., 1995, CANCER, V76, P1288; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Gagnon B, 1999, J PAIN SYMPTOM MANAG, V18, P120, DOI 10.1016/S0885-3924(99)00049-4; Hagen N, 1997, J PAIN SYMPTOM MANAG, V14, P51, DOI 10.1016/S0885-3924(97)00001-8; Kloke M, 2000, SUPPORT CARE CANCER, V8, P479, DOI 10.1007/s005200000153; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Mercadante S, 1999, J CLIN ONCOL, V17, P3307, DOI 10.1200/JCO.1999.17.10.3307; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P144, DOI 10.1016/S0885-3924(00)00228-1; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P255, DOI 10.1016/S0885-3924(00)00236-0; Mercadante S, 2007, J PAIN SYMPTOM MANAG, V34, P532, DOI 10.1016/j.jpainsymman.2007.01.006; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Muller-Busch HC, 2005, EUR J PAIN, V9, P571, DOI 10.1016/j.ejpain.2004.12.003; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2; Riley J, 2004, PALLIATIVE MED, V18, P19, DOI 10.1191/0269216304pm856oa; Ripamonti C, 2006, SUPPORT CARE CANCER, V14, P400, DOI 10.1007/s00520-005-0918-0; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G	27	91	91	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	APR	2009	37	4					632	641		10.1016/j.jpainsymman.2007.12.024			10	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	433SH	WOS:000265225600003	19345298	Bronze			2020-06-30	J	Ko, JS; Choi, SJ; Gwak, MS; Kim, GS; Ahn, HJ; Kim, JA; Hahm, TS; Cho, HS; Kim, KM; Joh, JW				Ko, Justin Sangwook; Choi, Soo Joo; Gwak, Mi Sook; Kim, Gaab Soo; Ahn, Hyun Joo; Kim, Jie Ae; Hahm, Tae Soo; Cho, Hyun Sung; Kim, Kyoung Mi; Joh, Jae Won			Intrathecal Morphine Combined with Intravenous Patient-Controlled Analgesia Is an Effective and Safe Method for Immediate Postoperative Pain Control in Live Liver Donors	LIVER TRANSPLANTATION			English	Article							INCREASED PROTHROMBIN TIME; LIVING-DONOR; EPIDURAL-ANESTHESIA; CESAREAN DELIVERY; OPIOID ANALGESIA; INDUCED PRURITUS; RESECTION; HEPATECTOMY; EFFICACY; COMPLICATIONS	The healthy condition of living donors makes their tolerance to pain particularly low, and clinicians are often challenged to come up with an analgesic technique that is effective yet ensures donor safety. This study compared, in donor right hepatectomy, the efficacy and safety of preoperative intrathecal morphine (ITM) combined with intravenous patient-controlled analgesia (IV-PCA) with IV-PCA alone. Forty adult patients were randomly allocated into 2 groups: ITM+IV-PCA group (n = 20) and IV-PCA-only group (n = 20). Patients in the ITM+IV-PCA group received morphine sulfate (400 mu g). The visual analog scale (VAS) at rest and when coughing and supplementary meperidine and IV-PCA (fentanyl) consumption were assessed at 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, 42, 48 56, 64, and 72 hours after surgery. Also, side effects such as sedation, dizziness, nausea, vomiting, pruritus, and respiratory depression were evaluated. The ITM+IV-PCA group showed significantly less pain at rest and when coughing for up to 30 hours and 24 hours, respectively. Cumulative postoperative consumption of meperidine and IV-PCA (fentanyl) were significantly less in the ITM+IV-PCA group. The incidence of side effects were comparable between the 2 groups except for pruritus; its incidence was significantly higher in the ITM+IV-PCA group during the first 24 hours, but no treatment was required due to its mild severity. The results of our study suggest that preoperative ITM combined with IV-PCA may be considered as an effective and safe pain management regimen in living liver donors who have characteristics of low tolerance to pain and postoperative coagulation derangement. Liver Transpl 15:381-389, 2009. (C) 2009 AASLD.	[Ko, Justin Sangwook; Choi, Soo Joo; Gwak, Mi Sook; Kim, Gaab Soo; Ahn, Hyun Joo; Kim, Jie Ae; Hahm, Tae Soo; Cho, Hyun Sung; Kim, Kyoung Mi] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul 135710, South Korea; [Joh, Jae Won] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea	Choi, SJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, 50 Ilwon Dong, Seoul 135710, South Korea.	csjoo@skku.edu		Joh, Jae-Won/0000-0003-1732-6210	IN-SUNG Foundation for Medical Research	Supported by an unrestricted educational grant from the IN-SUNG Foundation for Medical Research.	ABBOUD TK, 1984, BRIT J ANAESTH, V56, P1351, DOI 10.1093/bja/56.12.1351; Akpek EA, 2003, TRANSPL INT, V16, P584, DOI 10.1111/j.1432-2277.2003.tb00353.x; Bailey PL, 2000, NEW ENGL J MED, V343, P1228, DOI 10.1056/NEJM200010263431705; BARAKA A, 1981, ANESTHESIOLOGY, V54, P136, DOI 10.1097/00000542-198102000-00007; Borromeo CJ, 2000, ANESTH ANALG, V91, P1139, DOI 10.1097/00000539-200011000-00018; Cammu G, 2002, EUR J ANAESTH, V19, P93, DOI 10.1017/S0265021502000169; Charuluxananan S, 2003, ANESTH ANALG, V96, P1789, DOI 10.1213/01.ANE.0000066015.21364.7D; Choi SJ, 2005, TRANSPL INT, V18, P548, DOI 10.1111/j.1432-2277.2005.00087.x; Choi SJ, 2007, LIVER TRANSPLANT, V13, P62, DOI 10.1002/lt.20933; Christie IW, 2007, ANAESTHESIA, V62, P335, DOI 10.1111/j.1365-2044.2007.04992.x; Cole PJ, 2000, BRIT J ANAESTH, V85, P233, DOI 10.1093/bja/85.2.233; Cywinski JB, 2004, ANESTH ANALG, V99, P1747, DOI 10.1213/01.ANE.0000136423.17446.5D; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; De Pietri L, 2006, ANESTH ANALG, V102, P1157, DOI 10.1213/01.ane.0000198567.85040.ce; DELEONCASASOLA OA, 1994, ANESTHESIOLOGY, V81, P368, DOI 10.1097/00000542-199408000-00015; Fournier R, 2000, ACTA ANAESTH SCAND, V44, P940, DOI 10.1034/j.1399-6576.2000.440808.x; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Ho AMH, 2000, CHEST, V117, P551, DOI 10.1378/chest.117.2.551; HORLOCKER TT, 1995, ANESTH ANALG, V80, P303, DOI 10.1097/00000539-199502000-00017; JACOBSON L, 1988, ANESTH ANALG, V67, P1082, DOI 10.1213/00000539-198867110-00011; Jones RM, 1998, BRIT J SURG, V85, P1058; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Matot I, 2002, ANESTH ANALG, V95, P1179, DOI 10.1097/00000539-200211000-00009; MILLER R, 2005, ANESTHESIA, P2729; MILLER R, 2005, ANESTHESIA, P2231; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Pomfret EA, 2003, LIVER TRANSPLANT, V9, pS45, DOI 10.1053/jlts.2003.50231; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Roy JD, 2006, ANESTH ANALG, V103, P990, DOI 10.1213/01.ane.0000238040.41872.7e; Salame E, 2002, AM J TRANSPLANT, V2, P780, DOI 10.1034/j.1600-6143.2002.20813.x; Siniscalchi A, 2004, LIVER TRANSPLANT, V10, P1144, DOI 10.1002/lt.20235; VANDERMEULEN EP, 1994, ANESTH ANALG, V79, P1165; Varitimidis SE, 2007, J BONE JOINT SURG AM, V89A, P2048, DOI 10.2106/JBJS.F.00895; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652; White PF, 2006, CLIN ANESTH, P334; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	38	26	26	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6465	1527-6473		LIVER TRANSPLANT	Liver Transplant.	APR	2009	15	4					381	389		10.1002/lt.21625			9	Gastroenterology & Hepatology; Surgery; Transplantation	Gastroenterology & Hepatology; Surgery; Transplantation	430LV	WOS:000264991500004	19326422				2020-06-30	J	Newberg, AB; Ray, R; Scheuermann, J; Wintering, N; Saffer, J; Schmitz, A; Freifelder, R; Karp, J; Lerman, C; Divgi, C				Newberg, Andrew B.; Ray, Riju; Scheuermann, Joshua; Wintering, Nancy; Saffer, Janet; Schmitz, Alexander; Freifelder, Richard; Karp, Joel; Lerman, Caryn; Divgi, Chaitanya			Dosimetry of C-11-carfentanil, a mu-opioid receptor imaging agent	NUCLEAR MEDICINE COMMUNICATIONS			English	Article						mu-opiate receptors; C-11-carfentanil; brain; dosimetry; positron emission tomography	BINDING; BIODISTRIBUTION; AVAILABILITY	Objective C-11-carfentanil is a radiopharmaceutical that selectively binds the p-opiate receptor of the central nervous system. However, its dosimetry throughout the body and other organs has never been reported in the literature. The purpose of this study was to measure the radiation dosimetry of C-11-carfentanil in healthy human volunteers. The study was conducted within a regulatory framework that required its pharmacological safety to be assessed simultaneously. Methods The sample included two male and three female participants ranging in age from 28 to 49 years. Three to four scans were obtained over approximately 2 h starting immediately after the intravenous administration of 0.03 mu g/kg of [C-11]carfentanil injected as a slow bolus (mean activity injected was 280 +/- 68 M 13q). The fraction of the administered dose in 10 regions of interest was quantified from the attenuation-corrected counts obtained on the axial images. Monoexponential functions were fit to each time-activity curve using a nonlinear, least-squares regression algorithm. These curves were numerically integrated to yield the number of disintegrations per unit activity administered in source organs. Sex-specific radiation doses were then estimated with the medical internal radiation dose technique. Results A few participants reported mild pharmacological effects of the radiotracer, primarily mild drowsiness, which is an expected side effect. The dose-limiting organ was the bladder wall, which received a mean of 3.65E-02 mGy/MBq. The mean effective dose equivalent and effective dose for C-11-carfentanil were 5.38E-03 and 4.59E-03 mSv/MBq, respectively. Conclusion The observed dosimetry values for C-11-carfentanil indicate that it is safe for imaging p-opiate receptors in the central nervous system and periphery. Nucl Med Commun 30:314-318 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.	[Newberg, Andrew B.; Scheuermann, Joshua; Wintering, Nancy; Saffer, Janet; Schmitz, Alexander; Freifelder, Richard; Karp, Joel; Divgi, Chaitanya] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Ray, Riju; Lerman, Caryn] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; [Lerman, Caryn; Divgi, Chaitanya] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA	Newberg, AB (reprint author), 110 Donner Bldg,HUP,3400 Spruce St, Philadelphia, PA 19104 USA.	Andrew.newberg@uphs.upenn.edu		Newberg, Andrew/0000-0001-8230-1752	National Institutes on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [RO1 DA18755]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA/DA84718]	This research was supported by grants from the National Institutes on Drug Abuse (RO1 DA18755) and the National Cancer Institute (P50 CA/DA84718) (to C.L.).	Bencherif B, 2005, J NUCL MED, V46, P1349; Cristy M, 1987, ORNLTM8381V1; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Greenwald M, 2007, BIOL PSYCHIAT, V61, P101, DOI 10.1016/j.biopsych.2006.04.043; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; *INT COMM RAD PROT, 1979, ANN ICRP ICRP PUBL 1, V30; Liberzon I, 2007, BIOL PSYCHIAT, V61, P1030, DOI 10.1016/j.biopsych.2006.06.021; Mozley PD, 1996, J NUCL MED, V37, P151; MOZLEY PD, 1993, J NUCL MED, V34, P1910; MOZLEY PD, 1995, J NUCL MED, V35, P1322; Newberg AB, 2004, J NUCL MED, V45, P834; Scott DJ, 2007, NEUROPSYCHOPHARMACOL, V32, P450, DOI 10.1038/sj.npp.1301238; SORENSON JA, 1987, PHYS NUCL MED; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842	15	5	5	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0143-3636			NUCL MED COMMUN	Nucl. Med. Commun.	APR	2009	30	4					314	318		10.1097/MNM.0b013e328329a0ec			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	426FE	WOS:000264692600011	19242386				2020-06-30	J	Sinha, R; Subramaniam, R; Chhabra, A; Pandey, R; Nandi, B; Jyoti, B				Sinha, Renu; Subramaniam, Rajeshwari; Chhabra, Anjolie; Pandey, Ravindra; Nandi, Biswajit; Jyoti, Bikram			Comparison of topical lignocaine gel and fentanyl for perioperative analgesia in children undergoing cataract surgery	PEDIATRIC ANESTHESIA			English	Article						lignocaine gel; pediatric; cataract surgery; fentanyl	LIDOCAINE 2-PERCENT GEL; ANESTHESIA	Opioids continue to remain the primary analgesics in children undergoing ophthalmic surgery, and their use may be associated with adverse effects like vomiting and respiratory depression. Topical anesthesia avoids these adverse effects and also complications of regional blocks. We designed this study to verify whether topical anesthesia with lignocaine gel is a feasible alternative to intravenous (IV) fentanyl for pediatric cataract surgery. One hundred ASA I and II children aged 3-12 years, scheduled for cataract surgery were included in this study. After induction of anesthesia, children were randomized to Group F (fentanyl), who received 2 mcg.kg(-1) IV fentanyl for analgesia and Group G (lignocaine gel), who received 2% lignocaine gel applied over the cornea of the operative eye. Anesthesia was maintained with isoflurane and oxygen in nitrous oxide. All children received intramuscular ketorolac. Intraoperative supplementary analgesia was provided with 0.5 mcg.kg(-1) IV fentanyl to manage increases in heart rate or blood pressure of 20% above baseline. In the postoperative period, Aldrete score and objective pain score were assessed. Rescue analgesia was provided with fentanyl in the postanesthesia care unit and syrup ibuprofen in the ward. Significantly more children in group F (8/48) required intraoperative supplementary fentanyl as compared with group G (1/48) (P = 0.0291). In the PACU, 7/48 children of group G needed fentanyl as compared with 5/48 children in group F. Time to reach Aldrete 10 was significantly longer in group F (P = 0.01). Topical lignocaine gel is an effective analgesic and may be used as an adjunct to fentanyl during cataract surgery in children.	[Sinha, Renu; Subramaniam, Rajeshwari; Chhabra, Anjolie; Pandey, Ravindra; Nandi, Biswajit; Jyoti, Bikram] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Anesthesiol, New Delhi 110029, India	Sinha, R (reprint author), All India Inst Med Sci, RP Ctr, Dept Anesthesiol, S-6, 1st Floor OPD Block, New Delhi 110029, India.	renuagarwal4@rediffmail.com					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Bardocci A, 2003, OPHTHALMOLOGY, V110, P144, DOI 10.1016/S0161-6420(02)01562-2; Barequet IS, 1999, J CATARACT REFR SURG, V25, P626, DOI 10.1016/S0886-3350(99)00004-8; HANALLAH RS, 1987, [No title captured], V66, P832; Leaming DV, 2000, J CATARACT REFR SURG, V26, P913, DOI 10.1016/S0886-3350(00)00469-7; Soliman MM, 2004, J CATARACT REFR SURG, V30, P1716, DOI 10.1016/j.jcrs.2003.12.034; Sun R, 1999, J CATARACT REFR SURG, V25, P1232, DOI 10.1016/S0886-3350(99)00150-9; ZETTERSTROM C, 2000, CATARACT SURG COMPLI, P1	8	6	6	0	5	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2009	19	4					371	375		10.1111/j.1460-9592.2008.02902.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	418RK	WOS:000264165900012	19143950				2020-06-30	J	Briggs, SL; Rech, RH				Briggs, Shannon L.; Rech, Richard H.			Antinociceptive interactions of mu- and kappa-opioid agonists in the colorectal distension assay in rats	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Mu and kappa opioids; CRD; Fentanyl; Spiradoline; Opioid antagonists; Visceral Pain	VISCERAL NOCICEPTIVE THRESHOLD; MORPHINE-TOLERANCE; SPINAL-CORD; OPIATE RECEPTORS; DOSE-RESPONSE; PAIN; ANALGESIA; BUTORPHANOL; MODULATION; SYNERGY	Interactions of opioid agonists, fentanyl and oxymorphone (mu-selective) and spiradoline and enadoline (kappa-selective), were examined for additive, sub-additive, or supra-additive antinociception in the colorectal distension (CRD) assay. Single-dose values (mg/kg. 0.006-0.016 for fentanyl, 0.25-1.26 for spiradoline, etc.) were summed to formulate theoretical additive-dose plots for comparison with actual combined-dose effects. Combined fentanyl and spiradoline yielded additive (low-dose levels) or supra-additive (high-close levels) effects. Single and combined doses of fentanyl (0.012 mg/kg) and spiradoline (0.3 mg/kg) were tested after pretreatment with saline, beta-funaltrexamine (b-FNA, mu-selective antagonist), or nor-binaltorphimine (n-BNI, kappa-selective antagonist). Supra-additive effects of combined agonists were attenuated by either antagonist (greater with n-BNI). But paradoxical patterns of antagonism of single-close effects Occurred: the fentanyl antinociception was not antagonized by b-FNA, whereas the spiradoline antinociception was. The results indicate complex interactions of agonists in this visceral pain model and potential for combined agonists to improve pain relief with decreased side effects. (C) 2009 Elsevier Inc. All rights reserved.	[Rech, Richard H.] Michigan State Univ, Dept Pharmacol Toxicol, E Lansing, MI 48824 USA; [Briggs, Shannon L.] Dept Environm Qual, Lansing, MI 48909 USA	Rech, RH (reprint author), 1474 Mercer Dr, Okemos, MI 48864 USA.	rech@msu.edu					ALLERTON CA, 1989, BRAIN RES, V502, P149, DOI 10.1016/0006-8993(89)90470-8; ATWEH SF, 1977, BRAIN RES, V124, P53, DOI 10.1016/0006-8993(77)90863-0; Bie BH, 2003, J NEUROSCI, V23, P7262; Black D, 1998, GUT, V43, P312, DOI 10.1136/gut.43.3.312; BONICA JJ, 1990, MANAGEMENT PAIN, P28; Briggs SL, 1998, VET SURG, V27, P466, DOI 10.1111/j.1532-950X.1998.tb00158.x; Briggs SL, 1998, PHARMACOL BIOCHEM BE, V60, P467, DOI 10.1016/S0091-3057(98)00017-3; BRIGGS SL, 1996, THESIS MICH STATE U; Christianson JA, 2007, NAT PROTOC, V2, P2624, DOI 10.1038/nprot.2007.392; COOP A, 2002, AM J PHARM EDUC, V24, P198; Fundytus ME, 2001, CNS DRUGS, V15, P29, DOI 10.2165/00023210-200115010-00004; Gebhart G.F., 1992, ANIMAL PAIN, P81; HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P524; HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141; He L, 1997, J PHARMACOL EXP THER, V280, P1210; Herraez-Baranda LA, 2005, MOL BRAIN RES, V137, P166, DOI 10.1016/j.molbrainres.2005.03.003; HOUGHTON KJ, 1991, P SOC EXP BIOL MED, V197, P290; Jang S, 2006, ARCH PHARM RES, V29, P677, DOI 10.1007/BF02968252; JANIG W, 1986, FUNCTIONAL PROPERTIE, P87; JONES DN, 1998, EUR J PHARMACOL, V215, P345; Joshi S K, 2000, Curr Rev Pain, V4, P499; Khotib J, 2004, NEUROPHARMACOLOGY, V46, P531, DOI 10.1016/j.neuropharm.2003.11.003; Larsson M, 2003, NEUROGASTROENT MOTIL, V15, P371, DOI 10.1046/j.1365-2982.2003.00418.x; Margolis EB, 2005, J NEUROPHYSIOL, V93, P3086, DOI 10.1152/jn.00855.2004; MIASKOWSKI C, 1993, BRAIN RES, V608, P87, DOI 10.1016/0006-8993(93)90777-K; Narita M, 2005, NEUROPSYCHOPHARMACOL, V30, P111, DOI 10.1038/sj.npp.1300527; Negus SS, 2008, EXP CLIN PSYCHOPHARM, V16, P386, DOI 10.1037/a0013088; Nemmani KVS, 2003, NEUROPHARMACOLOGY, V44, P304, DOI 10.1016/S0028-3908(02)00374-X; NESS TJ, 1990, PAIN, V41, P167, DOI 10.1016/0304-3959(90)90021-5; PASTERNAK GW, 1986, LIFE SCI, V38, P1889, DOI 10.1016/0024-3205(86)90217-1; Pearl SM, 1996, NEUROSCI LETT, V213, P5, DOI 10.1016/0304-3940(96)12822-6; PRESTON KL, 1993, J PHARMACOL EXP THER, V264, P813; REN MF, 1985, PEPTIDES, V6, P1015, DOI 10.1016/0196-9781(85)90423-1; Ross FB, 2000, PAIN, V84, P421, DOI 10.1016/S0304-3959(99)00230-4; SAWYER DC, 1991, AM J VET RES, V52, P1826; SAWYER DC, 1987, J AM ANIM HOSP ASSOC, V23, P438; SAWYER DC, 1990, STATUS OF KETAMINE IN ANESTHESIOLOGY, P247; SCHMAUSS C, 1987, EUR J PHARMACOL, V135, P429, DOI 10.1016/0014-2999(87)90695-9; SCHMAUSS C, 1984, J PHARMACOL EXP THER, V228, P1; Smith HS, 2008, PAIN PHYSICIAN, V11, P201; SONG ZH, 1992, LIFE SCI, V51, P107, DOI 10.1016/0024-3205(92)90003-8; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006; Stachura Zdzislaw, 1994, Polish Journal of Pharmacology, V46, P37; STEEL RGD, 1984, PRINCIPLES PROCEDURE, P41; SUTTERS KA, 1990, BRAIN RES, V530, P290, DOI 10.1016/0006-8993(90)91297-T; TAO PL, 1994, EUR J PHARMACOL, V256, P281, DOI 10.1016/0014-2999(94)90553-3; Verborgh CML, 1997, ACTA ANAESTH SCAND, V41, P895, DOI 10.1111/j.1399-6576.1997.tb04806.x; VONVOIGTLANDER PF, 1988, J PHARMACOL EXP THER, V246, P259; Walker DJ, 2001, PSYCHOPHARMACOLOGY, V155, P362, DOI 10.1007/s002130100723; WARD SJ, 1982, J PHARMACOL EXP THER, V220, P494; WERZ MA, 1987, J PHARMACOL EXP THER, V243, P258; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x; YAMAMOTO T, 1988, EUR J PHARMACOL, V156, P173, DOI 10.1016/0014-2999(88)90162-8	54	6	6	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	APR	2009	92	2					343	350		10.1016/j.pbb.2008.12.023			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	419YJ	WOS:000264255300022	19353808				2020-06-30	J	Hashimoto, K; Amano, T; Kasakura, A; Uhl, GR; Sora, I; Sakai, N; Kuzumaki, N; Suzuki, T; Narita, M				Hashimoto, Keisuke; Amano, Taku; Kasakura, Akiko; Uhl, George R.; Sora, Ichiro; Sakai, Norio; Kuzumaki, Naoko; Suzuki, Tsutomu; Narita, Minoru			mu-Opioid receptor-independent fashion of the suppression of sodium currents by mu-opioid analgesics in thalamic neurons	NEUROSCIENCE LETTERS			English	Article						Morphine; Fentanyl; Oxycodone; Lidocaine; Voltage-gated sodium channels	LOCAL-ANESTHETICS; MYELINATED NERVE; LIDOCAINE BLOCK; PHOSPHOLIPASE-C; SPINAL-CORD; CHANNELS; MORPHINE; MICE; RAT; INHIBITION	Most reports in the literature have shown that the effects of opioid analgesics are primarily mediated by mu-opioid receptor (MOR), whereas other potential targets of opioid analgesics have not been thoroughly characterized. In this study, we found that extracellular application of morphine, fentanyl or oxycodone,which are all considered to be MOR agonists, at relatively high concentrations, but not endogenous mu-opioid peptides, produced a concentration-dependent suppression of sodium currents in cultured thalamic neurons. These effects of opioids were not affected by either a MOR antagonist naloxone or a deletion of MOR gene. Among these opioids, fentanyl strongly suppressed sodium currents to the same degree as lidocaine, and both morphine and oxycodone slightly but significantly reduced sodium currents when they were present extracellularly. In contrast, the intracellular application of morphine, but not oxycodone, fentanyl or lidocaine, reduced sodium currents. These results suggest that morphine, fentanyl and oxycodone each produce the MOR-independent suppression of sodium currents by distinct mechanisms in thalamic neurons. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Hashimoto, Keisuke; Amano, Taku; Kasakura, Akiko; Kuzumaki, Naoko; Suzuki, Tsutomu; Narita, Minoru] Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Shinagawa Ku, Tokyo 1428501, Japan; [Amano, Taku; Sakai, Norio] Hiroshima Univ, Dept Mol & Pharmacol Neurosci, Div Integrated Med Sci, Grad Sch Biomed Sci,Minami Ku, Hiroshima 7348551, Japan; [Uhl, George R.] NIDA, Intramural Res Program, Baltimore, MD 21224 USA; [Sora, Ichiro] Tohoku Univ, Grad Sch Med, Dept Biol Psychiat, Sendai, Miyagi 9808574, Japan	Suzuki, T (reprint author), Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	suzuki@hoshi.ac.jp; narita@hoshi.ac.jp	Kuzumaki, Naoko/L-1287-2013		Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 DA000492-03, Z01 DA000406-10, Z01 DA000401-10, Z01 DA000165-13]		BEAN BP, 1983, J GEN PHYSIOL, V81, P613, DOI 10.1085/jgp.81.5.613; CAHALAN MD, 1979, BIOPHYS J, V27, P39, DOI 10.1016/S0006-3495(79)85201-7; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; CHRISTIE MJ, 1988, BRIT J PHARMACOL, V95, P896, DOI 10.1111/j.1476-5381.1988.tb11719.x; COURTNEY KR, 1975, J PHARMACOL EXP THER, V195, P225; FRAZIER DT, 1970, J PHARMACOL EXP THER, V171, P45; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; Liu HJ, 2003, J GEN PHYSIOL, V121, P199, DOI 10.1085/jgp.20028723; Mizoguchi H, 2003, J PHARMACOL SCI, V93, P423, DOI 10.1254/jphs.93.423; Narahashi T, 1971, Neurosci Res (N Y), V4, P65; Narita M, 2000, NEUROSCIENCE, V99, P327, DOI 10.1016/S0306-4522(00)00202-5; Narita M, 2008, NEUROPSYCHOPHARMACOL, V33, P1097, DOI 10.1038/sj.npp.1301471; Narita M, 2008, J NEUROCHEM, V104, P469, DOI 10.1111/j.1471-4159.2007.05059.x; RHIM H, 1994, J NEUROSCI, V14, P7608; SMART D, 1995, BIOCHEM J, V305, P577, DOI 10.1042/bj3050577; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37	17	6	6	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 27	2009	453	1					62	67		10.1016/j.neulet.2009.01.066			6	Neurosciences	Neurosciences & Neurology	426HM	WOS:000264698600015	19429017	Green Accepted			2020-06-30	J	Lafreniere, NM; Watterson, JH				Lafreniere, Nelson M.; Watterson, James H.			Detection of acute fentanyl exposure in fresh and decomposed skeletal tissues	FORENSIC SCIENCE INTERNATIONAL			English	Article						Forensic toxicology; Bone; Fentanyl; Drug; ELISA; Immunoassay	BONE-MARROW; OPIATES; DEATH; BLOOD; ELISA; HAIR	The detection of acute fentanyl exposure in fresh and decomposed skeletal tissues (marrow and bone), by automated enzyme-linked immunosorbent assay (ELISA) is described. Rats (n = 15) were administered fentanyl acutely at a dose of 0 (n = 3), 15 (n = 3), 30 (n = 3) or 60 mu g/kg (n = 6) by intraperitoneal injection, and euthanized within 20 min. Femora and tibiae were extracted from the fresh corpses and marrow was isolated from the femoral and tibial medullary cavities. The remains were then allowed to decompose outdoors to the point of complete skeletonization, and vertebrae and pelvi were recovered for analysis. In all cases, bones were cleaned in alkaline solution and then ground into a fine powder. Marrow was homogenized in alkaline solution. Fentanyl was extracted from ground bone by methanolic extraction. Extracts were adjusted to pH 6 and analyzed by ELISA. Perimortem heart blood was also collected and diluted in phosphate buffer prior to screening by ELISA. The effect of tissue type on ELISA response was examined through determination of binary classification test sensitivity and the relative decrease in absorbance (%DA, drug-positive tissues vs drug-free controls) in each tissue type. Overall, the %DA varied significantly between extracts from different skeletal tissues under a given dose condition, according to the general order of marrow > vertebrae similar to pelvi > epiphyseal bone diaphyseal bone. Binary classification test sensitivity values for fentanyl in marrow, fresh epiphyseal (femoral and tibial) bone, fresh diaphyseal (femoral and tibial) bone, decomposed vertebrae and decomposed pelvic bone were 100%, 16-33%, 0-16%, 0-33% and 66-100%, respectively. at the 60 mu g/kg dose level. While mean %DA values showed a strong positive correlation with those in marrow and blood measurements and the administered dose (r = 0.997 and 0.986), such a correlation was not observed in assays of decomposed tissues (r = -0.157 and -0.315). These results suggest that the type of skeletal tissue sampled and position within a given bone may be important considerations in the choice of substrate for fentanyl screening in skeletal tissues, but that quantitative analysis of drugs in decomposed bones may be of limited interpretive value. (c) 2009 Elsevier Ireland Ltd. All rights reserved.	[Lafreniere, Nelson M.; Watterson, James H.] Laurentian Univ, Dept Forens Sci, Forens Toxicol Res Lab, Sudbury, ON P3E 2C6, Canada	Watterson, JH (reprint author), Laurentian Univ, Dept Forens Sci, Forens Toxicol Res Lab, 935 Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.	jwatterson@laurentian.ca	Watterson, James/F-7168-2013		Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada	The authors would like to acknowledge the Natural Sciences and Engineering Research Council of Canada (NSERC) and Nathalie Desrosiers, for her generous assistance throughout these experiments.	Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Kemp P, 2002, J ANAL TOXICOL, V26, P504, DOI 10.1093/jat/26.7.504; KERRIGAN S, 2006, PRINCIPLES FORENSIC, P230; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Moore C, 2008, FORENSIC SCI INT, V176, P47, DOI 10.1016/j.forsciint.2007.06.027; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; RAIKOS N, 2006, FORENSIC SCI INT, V13, P140; SCHNEIDER E, 1985, ARCH PHARM, V331, P359; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; Stout PR, 1998, DRUG METAB DISPOS, V26, P689; Watterson J, 2006, ANALYST, V131, P961, DOI 10.1039/b609130j; Watterson JH, 2008, J ANAL TOXICOL, V32, P631, DOI 10.1093/jat/32.8.631; WATTERSON JH, J FORENSIC IN PRESS; WINEK CL, 1983, FORENSIC SCI INT, V22, P151, DOI 10.1016/0379-0738(83)90008-7; WINEK CL, 1990, FORENSIC SCI INT, V48, P49, DOI 10.1016/0379-0738(90)90271-Y; WINEK CL, 1993, J ANAL TOXICOL, V17, P93, DOI 10.1093/jat/17.2.93	16	26	26	0	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	MAR 10	2009	185	1-3					100	106		10.1016/j.forsciint.2008.12.019			7	Medicine, Legal	Legal Medicine	420BI	WOS:000264263000013	19201558				2020-06-30	J	Unlugenc, H; Ozalevli, M; Gunduz, M; Gunasti, S; Urunsak, IF; Guler, T; Isik, G				Unlugenc, H.; Ozalevli, M.; Gunduz, M.; Gunasti, S.; Urunsak, I. F.; Guler, T.; Isik, G.			Comparison of intrathecal magnesium, fentanyl, or placebo combined with bupivacaine 0.5% for parturients undergoing elective cesarean delivery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							SPINAL-ANESTHESIA; DOUBLE-BLIND; SULFATE; ROPIVACAINE; MORPHINE; INJURY; CORD	Intrathecal (i.t.) administration of magnesium has been reported to potentiate opioid antinociception in rats and humans. In this prospective, randomized, double-blind, study, we investigated the sensory, motor, and analgesic block characteristics of i.t. magnesium 50 mg compared with fentanyl 25 mu g and saline when added to 0.5% bupivacaine (10 mg). Ninety ASA I or II adult patients undergoing cesarean section were randomly allocated to receive 1.0 ml of 0.9% sodium chloride in group S, 50 mg of magnesium sulfate (1.0 ml) 5% in group M, or 25 mu g of fentanyl (1.0 ml) in group F following 10 mg of bupivacaine 0.5% i.t. We recorded the following: onset and duration of sensory and motor block, maximal sensory block height, the time to reach the maximal dermatomal level of sensory block, and the duration of spinal anesthesia. Magnesium did not shorten the onset time of sensory and motor blockade or prolong the duration of spinal anesthesia. The duration of sensory (P < 0.032) and motor (P < 0.002) blockade was significantly shorter in M and S groups than in the F group. The time to reach the maximal dermatomal level of sensory block was significantly shorter in the F group than in the S and M groups (P < 0.002). In patients undergoing cesarean section with spinal anesthesia, the addition of magnesium sulfate (50 mg) i.t. to 10 mg of spinal bupivacaine (0.5%) did not shorten the onset time of sensory and motor blockade or prolong the duration of spinal anesthesia, as seen with fentanyl.	[Unlugenc, H.; Ozalevli, M.; Gunduz, M.; Gunasti, S.; Guler, T.; Isik, G.] Cukurova Univ, Dept Anesthesiol, Fac Med, TR-01330 Adana, Turkey; [Urunsak, I. F.] Cukurova Univ, Dept Obstet & Gynecol, Fac Med, TR-01330 Adana, Turkey	Unlugenc, H (reprint author), Cukurova Univ, Dept Anesthesiol, Fac Med, TR-01330 Adana, Turkey.	unlugenc@cu.edu.tr	Unlugenc, Hakki/W-9586-2018	Unlugenc, Hakki/0000-0003-0164-8258			Arai YCP, 2006, ACTA ANAESTH SCAND, V50, P364, DOI 10.1111/j.1399-6576.2006.00961.x; Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; ASHBURN MA, 1994, CLIN J PAIN, V10, P52, DOI 10.1097/00002508-199403000-00007; Bahar M, 1996, ANAESTHESIA, V51, P627, DOI 10.1111/j.1365-2044.1996.tb07843.x; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BROCKWAY MS, 1990, BRIT J ANAESTH, V64, P243, DOI 10.1093/bja/64.2.243; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; CAMPORA E, 1991, J PAIN SYMPTOM MANAG, V6, P428, DOI 10.1016/0885-3924(91)90041-2; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Cowan CM, 2002, BRIT J ANAESTH, V89, P452; Danelli G, 2004, REGION ANESTH PAIN M, V29, P221, DOI 10.1016/j.rapm.2004.02.003; Dickenson AH, 1997, ACTA ANAESTH SCAND, V41, P112, DOI 10.1111/j.1399-6576.1997.tb04624.x; Hung YC, 2007, REGION ANESTH PAIN M, V32, P288, DOI 10.1016/j.rapm.2007.03.008; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; Maenpaa J, 1998, PHARMACOGENETICS, V8, P137; Ogun CO, 2003, BRIT J ANAESTH, V90, P659, DOI 10.1093/bja/aeg123; Okutomi T, 2004, CAN J ANAESTH, V51, P93, DOI 10.1007/BF03018565; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Saeki H, 2004, ANESTH ANALG, V99, P1805, DOI 10.1213/01.ANE.0000138039.04548.3D; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; Takano Y, 2000, PAIN, V84, P175, DOI 10.1016/S0304-3959(99)00207-9; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; WilderSmith CH, 1997, ACTA ANAESTH SCAND, V41, P1023, DOI 10.1111/j.1399-6576.1997.tb04830.x; Witlin AG, 1998, OBSTET GYNECOL, V92, P883, DOI 10.1016/S0029-7844(98)00277-4; XIAO WH, 1994, BRAIN RES, V666, P168, DOI 10.1016/0006-8993(94)90768-4; YAMAMOTO T, 1992, NEUROSCI LETT, V135, P67, DOI 10.1016/0304-3940(92)90137-V; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020	34	37	40	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2009	53	3					346	353		10.1111/j.1399-6576.2008.01864.x			8	Anesthesiology	Anesthesiology	407GM	WOS:000263351600011	19173689				2020-06-30	J	Baumgartner, CM; Koenighaus, H; Ebner, JK; Henke, J; Schuster, T; Erhardt, WD				Baumgartner, Christine M.; Koenighaus, Hilke; Ebner, Johanna K.; Henke, Julia; Schuster, Tibor; Erhardt, Wolf D.			Cardiovascular effects of fentanyl and propofol on hemodynamic function in rabbits	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							HEART-RATE; RAT; MORPHINE; ANESTHESIA; SUFENTANIL; ALFENTANIL; POTENTIATION; STIMULATION; KETAMINE; MYOCYTES	Objective-To evaluate short-term cardiovascular effects after IV administration of boluses of fentanyl in rabbits. Animals-6 healthy New Zealand White rabbits. Procedures-Each rabbit was anesthetized with propofol (4.0 to 8.0 mg/kg, IV); anesthesia was maintained by administration of propofol (1.2 to 1.3 mg/kg/min, IV). Subsequently, 3 injections of fentanyl (0.0053 mg/kg) were administered. Before and for 10 minutes after injections, the following variables were measured: vessel diameter, peak systolic blood flow velocity, minimum diastolic blood flow velocity, end-diastolic blood flow velocity, time-average blood flow velocity, mean volumetric flow (VFmean), resistance index (RI), and pulsatility index for the left common carotid artery after the first injection and abdominal aorta after the third injection; mean arterial pressure (MAP); heart rate (HR); arterial oxygen saturation; end-tidal partial pressure of carbon dioxide; and body temperature. Echocardiography was performed after the second injection. Results-Fentanyl injections caused a transient and significant decrease in diameter and VFmean of the abdominal aorta and end-diastolic blood flow velocity of the left common carotid artery and an increase in peak systolic blood flow velocity and RI of the left common carotid artery. Also, MAP HR, and body temperature decreased significantly after injections. Conclusions and Clinical Relevance-Fentanyl injections induced a short-term decrease of vessel diameter in the abdominal aorta and increased resistance in the distal distribution area of the left common carotid artery. Results revealed decreases in MAP HR, and body temperature, with an increasing effect after the third bolus injection, which indicated a cumulative drug effect. (Am J Vet Res 2009;70:409-417)	[Baumgartner, Christine M.; Henke, Julia] Tech Univ Munich, Klinikum Rechts Isar, Ctr Preclin Res, D-8000 Munich, Germany; [Koenighaus, Hilke; Erhardt, Wolf D.] Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Oncol & Therapeut Res, D-8000 Munich, Germany; [Schuster, Tibor] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Stat & Epidemiol, D-8000 Munich, Germany; [Baumgartner, Christine M.; Ebner, Johanna K.] Trigen GmbH, D-82152 Martinsried, Germany	Baumgartner, CM (reprint author), Tech Univ Munich, Klinikum Rechts Isar, Ctr Preclin Res, D-8000 Munich, Germany.						Bailey P.L., 2000, ANESTHESIA, P273; Ban K, 2005, CIRC J, V69, P688, DOI 10.1253/circj.69.688; Baumgartner C, 2008, VET ANAESTH ANALG, V35, P100, DOI 10.1111/j.1467-2995.2007.00360.x; BLAIR JR, 1989, ANESTHESIOLOGY, V71, P565, DOI 10.1097/00000542-198910000-00015; BUHRE W, 2000, CARDIOVASCULAR PHYSL, P331; CULLEN PM, 1987, ANESTH ANALG, V66, P1115; ELA C, 1993, J MOL CELL CARDIOL, V25, P599, DOI 10.1006/jmcc.1993.1069; ERHARDT W, 1989, BERL MUNCH TIERARZTL, V102, P289; ERHARDT W, 2004, ANASTHESIE ANALGESIE, P43; Haberstroh J, 2004, ANASTHESIE ANALGESIE, P629; Kanaya N, 1998, ANESTHESIOLOGY, V89, P1532, DOI 10.1097/00000542-199812000-00033; KLEWS R, 1993, FARBKODIERTE DUPLEXS, P1; Koehler E, 1992, ZWEIDIMENSIONALE ECH, P1; Kucewicz JC, 2004, ULTRASOUND MED BIOL, V30, P773, DOI 10.1016/j.ultrasmedbio.2004.04.002; LEDDA F, 1984, EUR J PHARMACOL, V102, P443, DOI 10.1016/0014-2999(84)90565-X; Lightbown ID, 2001, BRIT J PHARMACOL, V132, P197, DOI 10.1038/sj.bjp.0703823; Lin GS, 1997, RADIOLOGY, V204, P870, DOI 10.1148/radiology.204.3.9280274; Luo S, 2004, J ELECTROCARDIOL, V37, P81, DOI 10.1016/j.jelectrocard.2004.08.030; Mastronardi P, 2001, Minerva Anestesiol, V67, P332; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MAYER M, 1990, ANAESTHESIST, V39, P609; MILLER DR, 1988, CAN J ANAESTH, V35, P219, DOI 10.1007/BF03010615; MOISE N, 1999, TXB CANINE FELINE CA, P140; MOLNAR J, 1995, AM J CARDIOL, V75, P537, DOI 10.1016/S0002-9149(99)80603-1; Mueck-Weymann M, 1999, SONOGRAPHIE GEFAESSE, P21; PATSCHKE D, 1976, ANAESTHESIST, V25, P10; REITAN JA, 1978, ANESTH ANALG, V57, P31; ROCCHICCIOLI C, 1989, J CARDIOVASC PHARM, V14, P631, DOI 10.1097/00005344-198910000-00015; ROMERO M, 1992, GEN PHARMACOL, V23, P1135, DOI 10.1016/0306-3623(92)90300-9; RORIE DK, 1981, ANESTH ANALG, V60, P21; RUCQUOI M, 1983, BRIT J ANAESTH, V55, pS223; SCHAEBERLE W, 1998, ULTRASCHALL GEFAESSD, P1; STIEGLER H, 2002, FARBKODIERTE DUPLEXS, P93; Suzer O, 1998, EUR J ANAESTH, V15, P480; THURSTON CL, 1993, BRAIN RES, V612, P70, DOI 10.1016/0006-8993(93)91645-9; Tobias R, 2001, ATLAS LEHRBUCH ULTRA, P127; Wandless AL, 1996, BRIT J ANAESTH, V76, P461; WEBER G, 1995, ACTA ANAESTH SCAND, V39, P1071, DOI 10.1111/j.1399-6576.1995.tb04232.x; Xiao RP, 1997, AM J PHYSIOL-HEART C, V272, pH797	39	1	1	0	6	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	MAR	2009	70	3					409	417		10.2460/ajvr.70.3.409			9	Veterinary Sciences	Veterinary Sciences	419FL	WOS:000264204400014	19254155				2020-06-30	J	Ahern, BJ; Soma, LR; Boston, RC; Schaer, TP				Ahern, Benjamin J.; Soma, Lawrance R.; Boston, Raymond C.; Schaer, Thomas P.			Comparison of the analgesic properties of transdermally administered fentanyl and intramuscularly administered buprenorphine during and following experimental orthopedic surgery in sheep	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							SERUM CONCENTRATIONS; OVINE MODEL; PHARMACOKINETICS; CATS; HORSES	Objective-To evaluate the analgesic properties of transdermally administered fentanyl and IM administered buprenorphine in sheep undergoing unilateral tibial osteotomy. Animals-20 mature sheep. Procedures-Fentanyl patches (n = 15 sheep) or placebo patches (5 sheep) were applied 12 hours before sheep underwent general anesthesia and a unilateral tibial osteotomy. Buprenorphine was administered to the placebo group every 6 hours commencing at time of induction. Signs of pain were assessed every 12 hours after surgery by 2 independent observers unaware of treatment groups. Results-There were no differences in preoperative and intraoperative physiologic data between the 2 groups. Sheep treated with fentanyl required less preoperative administration of diazepam for sedation and had significantly lower postoperative pain scores, compared with those treated with buprenorphine. No complications associated with the antebrachium at the site of patch application were detected. Conclusions and Clinical Relevance-Under the conditions of this study, transdermally administered fentanyl was a superior option to IM administered buprenorphine for alleviation of postoperative orthopedic pain in sheep. This information can be used to assist clinicians in the development of a rational analgesic regimen for research and clinical patients. (Am J Vet Res'2009;70:418-422)	[Ahern, Benjamin J.; Schaer, Thomas P.] Univ Penn, Sch Vet Med, Comparat Orthopaed Res Lab, Kennett Sq, PA 19348 USA; [Soma, Lawrance R.; Boston, Raymond C.] Univ Penn, Sch Vet Med, Dept Clin Studies, Kennett Sq, PA 19348 USA	Schaer, TP (reprint author), Univ Penn, Sch Vet Med, Comparat Orthopaed Res Lab, Kennett Sq, PA 19348 USA.		Ahern, Benjamin/J-2602-2016; Schaer, Thomas/F-4519-2010; Ahern, Benjamin J/M-1193-2015	Ahern, Benjamin/0000-0001-5527-8964; Schaer, Thomas/0000-0002-4340-8212; Ahern, Benjamin J/0000-0001-5527-8964			*AN RES CTR, YAL U WEB SIT; Carroll GL, 1999, AM J VET RES, V60, P986; Challis MJ, 2006, J BONE JOINT SURG BR, V88B, P411, DOI 10.1302/0301-620X.88B3.16856; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; Eufinger H, 2007, BIOMATERIALS, V28, P475, DOI 10.1016/j.biomaterials.2006.08.055; Grubb TL, 2005, AM J VET RES, V66, P907, DOI 10.2460/ajvr.2005.66.907; JAFFE JH, 1990, [No title captured], P485; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Otto KA, 2000, J EXP ANIM SCI, V41, P133, DOI 10.1016/S0939-8600(00)80005-X; Pettifer GR, 2003, AM J VET RES, V64, P1557, DOI 10.2460/ajvr.2003.64.1557; PLUMB D, 2005, PLUMBS VET DRUG HDB, P327; Posner LP, 2007, VET ANAESTH ANALG, V34, P40, DOI 10.1111/j.1467-2995.2006.00287.x; Romans CW, 2005, JAVMA-J AM VET MED A, V227, P89, DOI 10.2460/javma.2005.227.89; Shafford HL, 2004, VET ANAESTH ANALG, V31, P20, DOI 10.1111/j.1467-2995.2004.00126.x; Tate MLK, 2007, J BONE JOINT SURG AM, V89A, P307, DOI 10.2106/JBJS.E.00512; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; *U MT I AN CAR US, POST SHEEP GUID	18	26	27	0	21	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	MAR	2009	70	3					418	422		10.2460/ajvr.70.3.418			5	Veterinary Sciences	Veterinary Sciences	419FL	WOS:000264204400016	19254157				2020-06-30	J	Erdil, F; Demirbilek, S; Begec, Z; Ozturk, E; But, A; Ozcan Ersoy, M				Erdil, F.; Demirbilek, S.; Begec, Z.; Ozturk, E.; But, A.; Ozcan Ersoy, M.			The effect of esmolol on the QTc interval during induction of anaesthesia in patients with coronary artery disease	ANAESTHESIA			English	Article							TRACHEAL INTUBATION; HEMODYNAMIC-RESPONSES; HEART-RATE; DISPERSION; COMBINATION; ALFENTANIL; PRESSURE; PROPOFOL; FENTANYL; TRIAL	The aim of this study was to evaluate whether esmolol has an effect on QT interval during induction of anaesthesia using etomidate and fentanyl in patients with known coronary artery disease. Sixty patients were prospectively randomised to either a control group or the esmolol group. Esmolol was administered as a bolus 1 mg.kg(-1), followed by a continuous infusion at 250 mu g.kg(-1)min(-1). All patients received etomidate 0.3 mg.kg(-1) and fentanyl 15 mu g.kg(-1). The ECG was recorded prior to induction of anaesthesia (T0), 5 min following the start of drug infusions (T1), 1 min following etomidate (T2), 3 min following vecuronium (T3), 30 s (T4), 2 min (T5) and 4 min (T6) after intubation. In the esmolol group, QTc interval was significantly shorter at T1, T2 and T4 compared to the control group (p < 0.05). In conclusion, QTc interval increased following tracheal intubation during induction of anaesthesia using etomidate and fentanyl. An infusion of Esmolol attenuated the QTc interval prolongation associated with tracheal intubation.	[Erdil, F.; Demirbilek, S.; Begec, Z.; Ozturk, E.; But, A.; Ozcan Ersoy, M.] Inonu Univ, Sch Med, Dept Anaesthesiol & Reanimat, Malatya, Turkey	Erdil, F (reprint author), Inonu Univ, Sch Med, Dept Anaesthesiol & Reanimat, Malatya, Turkey.	ferdil@inonu.edu.tr					ALEXANDER R, 1994, BRIT J ANAESTH, V72, P594, DOI 10.1093/bja/72.5.594; ANNILA P, 1993, BRIT J ANAESTH, V71, P736, DOI 10.1093/bja/71.5.736; Ay B, 2003, J ELECTROCARDIOL, V36, P99, DOI 10.1054/jelc.2003.50017; CHUNG KS, 1992, CAN J ANAESTH, V39, P774, DOI 10.1007/BF03008287; Figueredo E, 2001, ACTA ANAESTH SCAND, V45, P1011, DOI 10.1034/j.1399-6576.2001.450815.x; KORPINEN R, 1995, CAN J ANAESTH, V42, P298, DOI 10.1007/BF03010706; Korpinen R, 2006, ACTA ANAESTH SCAND, V50, P188, DOI 10.1111/j.1399-6576.2006.00911.x; Korpinen R, 1998, Acta Anaesthesiol Belg, V49, P123; KORPINEN R, 1995, ACTA ANAESTH SCAND, V39, P809, DOI 10.1111/j.1399-6576.1995.tb04175.x; Korpinen R, 1997, ACTA ANAESTH SCAND, V41, P371, DOI 10.1111/j.1399-6576.1997.tb04701.x; Kweon TD, 2008, ANAESTHESIA, V63, P347, DOI 10.1111/j.1365-2044.2007.05372.x; LISCHKE V, 1994, ACTA ANAESTH SCAND, V38, P144, DOI 10.1111/j.1399-6576.1994.tb03856.x; Luo S, 2004, J ELECTROCARDIOL, V37, P81, DOI 10.1016/j.jelectrocard.2004.08.030; MILLER DR, 1991, CAN J ANAESTH, V38, P849, DOI 10.1007/BF03036959; MOSS A J, 1986, Journal of the American Medical Association, V256, P2985, DOI 10.1001/jama.256.21.2985; MOSS AJ, 1993, AM J CARDIOL, V72, P23; REILLY CS, 1985, CLIN PHARMACOL THER, V38, P579, DOI 10.1038/clpt.1985.227; Roukema G, 1998, AM HEART J, V135, P88, DOI 10.1016/S0002-8703(98)70347-3; Sharma S, 1996, CAN J ANAESTH, V43, P778, DOI 10.1007/BF03013028; Tanskanen PE, 2002, EUR J ANAESTH, V19, P749, DOI 10.1017/S0265021502001217; WILTON NCT, 1987, ANESTH ANALG, V66, P357; ZAREBA W, 1994, AM J CARDIOL, V74, P550, DOI 10.1016/0002-9149(94)90742-0	22	16	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2009	64	3					246	250		10.1111/j.1365-2044.2008.05754.x			5	Anesthesiology	Anesthesiology	405RV	WOS:000263242800003	19302635				2020-06-30	J	Wilson, MJA; MacArthur, C; Cooper, GM; Shennan, A				Wilson, M. J. A.; MacArthur, C.; Cooper, G. M.; Shennan, A.		COMET Study Grp UK	Ambulation in labour and delivery mode: a randomised controlled trial of high-dose vs mobile epidural analgesia	ANAESTHESIA			English	Article							ANESTHESIA	Compared to high-dose epidurals where mobility is impossible, mobile epidurals have been shown to reduce instrumental vaginal delivery rates. The mechanism for this benefit may depend on women walking or adopting upright postures during labour. We investigated maternal motor power and ambulation of 1052 primparous women randomised to high-dose epidural (Control), Combined Spinal Epidural (CSE) or Low-Dose Infusion (LDI) as a pre-specified, secondary outcome of the Comparative Obstetric Mobile Epidural Trial. Modified Bromage power scores and the level of mobility a woman actually achieved were recorded each hour after epidural placement during first and second stage, until delivery. Relative to control, significantly more women maintained normal leg power throughout labour in both mobile groups and significantly more women with CSE maintained superior leg power for longer than with LDI. Observational analysis did not demonstrate an association between the level of ambulation a woman actually achieved after epidural placement and delivery mode.	[Wilson, M. J. A.] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; [MacArthur, C.; Cooper, G. M.] Univ Birmingham, Birmingham, W Midlands, England; [Shennan, A.] Kings & St Thomas Sch Med, London, England	Wilson, MJA (reprint author), Royal Hallamshire Hosp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	matthew.wilson@sth.nhs.uk					Ami-Somuah M, 2000, COCHRANE DB SYST REV, V2; Bloom SL, 1998, NEW ENGL J MED, V339, P76, DOI 10.1056/NEJM199807093390203; Collis RE, 1999, ANAESTHESIA, V54, P535, DOI 10.1046/j.1365-2044.1999.00802.x; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Frenea S, 2004, ANESTH ANALG, V98, P224, DOI 10.1213/01.ANE.0000090317.01876.D9; Gupta JK, 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002006.PUB2; Karraz MA, 2003, INT J GYNECOL OBSTET, V80, P117, DOI 10.1016/S0020-7292(02)00339-9; MacArthur C, 2002, ANESTHESIOLOGY, V97, P1567; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MacArthur C, 2001, LANCET, V358, P19; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; Roberts CL, 2005, ACTA OBSTET GYN SCAN, V84, P794; Thornton JG, 2001, LANCET, V358, P2, DOI 10.1016/S0140-6736(00)05295-8; Vallejo MC, 2001, ANESTHESIOLOGY, V95, P857, DOI 10.1097/00000542-200110000-00012	14	21	22	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2009	64	3					266	272		10.1111/j.1365-2044.2008.05756.x			7	Anesthesiology	Anesthesiology	405RV	WOS:000263242800006	19302638				2020-06-30	J	Park, EY; Kil, HK; Park, WS; Lee, NH; Hong, JY				Park, E. Y.; Kil, H. K.; Park, W. S.; Lee, N. -H.; Hong, J. -Y.			Effect of epidural saline washout on regression of sensory and motor block after epidural anaesthesia with 2% lidocaine and fentanyl in elderly patients	ANAESTHESIA			English	Article							REVERSAL; INJECTIONS; ANALGESIA	Seventy elderly males received lumbar epidural anaesthesia with 12 ml of 2% lidocaine containing fentanyl 50 mu g. At the end of transurethral surgery, the washout group (n = 33) received an epidural bolus of 30 ml saline while the control group (n = 34) did not. Mean (SD) times to 1-grade (17.2 (11.9) vs 32.7 (11.3) min) and 2-grade regression (23.8 (12.2) vs 56.0 (23.9) min) of motor block, 3-dermatomal sensory regression (31.4 (11.6) vs 42.2 (14.4) min for cold and 30.8 (15.6) vs 40.6 (14.2) min for pinprick), and regression to S1 (57.7 (16.1) vs 76.2 (20.2) min for cold and 56.8 (17.3) vs 69.2 (16.2) min for pinprick) were significantly shorter in the washout group than the control group. There were no differences in postoperative pain scores and side effects between the two groups. We concluded that epidural washout facilitates regression of both motor and sensory block following epidural anaesthesia without reducing the postoperative analgesic benefit.	[Park, E. Y.; Kil, H. K.; Park, W. S.; Lee, N. -H.; Hong, J. -Y.] Yonsei Univ, Coll Med, Severance Hosp, Anaesthesia & Pain Res Inst,Dept Anaesthesiol & P, Seoul 120749, South Korea	Hong, JY (reprint author), Yonsei Univ, Coll Med, Severance Hosp, Anaesthesia & Pain Res Inst,Dept Anaesthesiol & P, Seoul 120749, South Korea.	jenyhongg@yuhs.ac		PARK, WON SUN/0000-0003-3856-3987			BIRNBACH DJ, 1989, ANESTH ANALG, V68, P808; Brock-Utne JG, 1998, REGION ANESTH PAIN M, V23, P247, DOI 10.1016/S1098-7339(98)90049-9; Chan VWS, 1999, ANESTH ANALG, V89, P1006, DOI 10.1097/00000539-199910000-00034; GISSEN D, 1985, ANESTHESIOLOGY, V62, P822, DOI 10.1097/00000542-198506000-00028; HILT H, 1986, BRIT J ANAESTH, V58, P676, DOI 10.1093/bja/58.6.676; HIRABAYASHI Y, 1990, BRIT J ANAESTH, V65, P508, DOI 10.1093/bja/65.4.508; JOHNSON MD, 1990, ANESTH ANALG, V70, P395; Katircioglu K, 2007, REGION ANESTH PAIN M, V32, P389, DOI 10.1016/j.rapm.2007.06.004; Rodriguez J, 2001, ACTA ANAESTH SCAND, V45, P893, DOI 10.1034/j.1399-6576.2001.045007893.x; Sitzman BT, 2001, REGION ANESTH PAIN M, V26, P246, DOI 10.1053/rapm.2001.22587; WEEKS SK, 1994, OBSTETRIC ANESTHESIA, P611	11	5	6	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2009	64	3					273	276		10.1111/j.1365-2044.2008.05746.x			4	Anesthesiology	Anesthesiology	405RV	WOS:000263242800007	19302639				2020-06-30	J	Kim, KS; Kim, KN; Hwang, KG; Park, CJ				Kim, Kyo S.; Kim, Kyu N.; Hwang, Kyung G.; Park, Chang J.			Capsicum Plaster at the Hegu Point Reduces Postoperative Analgesic Requirement After Orthognathic Surgery	ANESTHESIA AND ANALGESIA			English	Article							HAND ACUPUNCTURE POINT; ABDOMINAL HYSTERECTOMY; PAIN; STIMULATION; ACUPOINT; PREVENTION; EXTUBATION; BRAIN	BACKGROUND: Capsicum plaster at classical Chinese acupoints is an alternative to acupuncture, which has been used as an effective method for preventing postoperative nausea and vomiting sore throat, and pain. In this study, we investigated the postoperative analgesic efficacy of capsicum plaster at Hegu (LI 4) acupoints in patients after bilateral sagittal split ramus osteotomy. METHODS: A double-blind, sham-controlled study was conducted with 84 patients undergoing orthognathic surgery, and who were randomly assigned to three treatment regimens (n = 28 each): Hegu group = capsicum plaster at Hegu acupoints and placebo tape on the shoulders as a nonacupoint; sham group = capsicum plaster on the shoulders and placebo tape at Hegu acupoints; and control group = placebo tape at Hegu acupoints and on the shoulders. The capsicum plaster was applied before induction of anesthesia and maintained for 8 h per day for 3 postoperative days. RESULTS: The total amount of patient-controlled analgesia, containing 6.5 mu g/mL fentanyl and 1.2 mg/mL ketorolac, administered in the first 24 h after the operation was decreased in the Hegu group (26.8 +/- 3.4 mL) compared with the control (44.2 +/- 7.3 mL) and sham (42.1 +/- 6.9 mL) groups (P < 0.01). The incidence of postoperative nausea and vomiting and the need for rescue medication were reduced, and the overall satisfaction score was greater in the Hegu group compared with other groups (P < 0.01). CONCLUSION: The capsicum plaster at the Hegu acupoints decreased the postoperative opioid requirements and opioid-related side effects in patients after orthognathic surgery.	[Kim, Kyo S.; Kim, Kyu N.] Hanyang Univ Hosp, Dept Anesthesiol, Seoul 133792, South Korea; [Hwang, Kyung G.; Park, Chang J.] Hanyang Univ Hosp, Dept Dent Surg, Seoul 133792, South Korea	Kim, KS (reprint author), Hanyang Univ Hosp, Dept Anesthesiol, 17 Haengdang Dong, Seoul 133792, South Korea.	kimks@hanyang.ac.kr		KIM, KYO SANG/0000-0002-2186-3484			Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028; Creac'h C, 2000, AM J NEURORADIOL, V21, P1402; DRYLAND K, 1989, CLIN PLAST SURG, V16, P645; Francon D, 2008, ANN FR ANESTH, V27, P46, DOI 10.1016/j.annfar.2007.10.026; HABERCOHEN A, 1988, J ORAL MAXIL SURG, V46, P269, DOI 10.1016/0278-2391(88)90006-7; Keitel WG, 2001, ARZNEIMITTELFORSCH, V51, P896; Kim KS, 2002, ANESTH ANALG, V95, P1103, DOI 10.1097/00000539-200210000-00059; Kim KS, 2006, PEDIATR ANESTH, V16, P1036, DOI 10.1111/j.1460-9592.2006.01927.x; Kim KS, 2006, ANESTH ANALG, V103, P709, DOI 10.1213/01.ane.0000228864.74691.9f; Kitade T, 2000, ACUPUNCTURE ELECTRO, V25, P109, DOI 10.3727/036012900816356172; Kuhn FA, 1997, AM J RHINOL, V11, P313, DOI 10.2500/105065897781446649; Lao LX, 1999, ARCH OTOLARYNGOL, V125, P567, DOI 10.1001/archotol.125.5.567; Misra MN, 2005, CAN J ANAESTH, V52, P485, DOI 10.1007/BF03016527; NAMSAN, 1999, MIRACLE PAS METHOD; Niederhagen B, 1997, Mund Kiefer Gesichtschir, V1, P229; Park HS, 2004, ANAESTHESIA, V59, P647, DOI 10.1111/j.1365-2044.2004.03739.x; Pohodenko-Chudakova IO, 2005, J CRANIO MAXILL SURG, V33, P118, DOI 10.1016/j.jcms.2004.10.003; Precious DS, 1997, J ORAL MAXIL SURG, V55, P33, DOI 10.1016/S0278-2391(97)90442-0; Tuzuner AM, 2007, J ORAL MAXIL SURG, V65, P2453, DOI 10.1016/j.joms.2007.06.622; VINCENT CA, 1989, J PSYCHOSOM RES, V33, P489, DOI 10.1016/0022-3999(89)90010-X; Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029; Yan B, 2005, NEUROSCI LETT, V383, P236, DOI 10.1016/j.neulet.2005.04.021; YANG ZL, 1995, ACUPUNCTURE ELECTRO, V20, P15, DOI 10.3727/036012995816357186	23	14	16	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2009	108	3					992	996		10.1213/ane.0b013e318195b78f			5	Anesthesiology	Anesthesiology	409WU	WOS:000263537300053	19224815				2020-06-30	J	Pranevicius, M; Pranevicius, O				Pranevicius, Mindaugas; Pranevicius, Osvaldas			Non-Opioid Anesthesia with Esmolol Avoids Opioid-Induced Hyperalgesia and Reduces Fentanyl Requirement After Laparoscopy	ANESTHESIA AND ANALGESIA			English	Letter							POSTINFUSION HYPERALGESIA; REMIFENTANIL; MODULATION; INFUSION		[Pranevicius, Mindaugas] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Anesthesiol, Bronx, NY 10467 USA; [Pranevicius, Osvaldas] New York Hosp Queens, Dept Anesthesiol, Flushing, NY USA	Pranevicius, M (reprint author), Albert Einstein Coll Med, Jacobi Med Ctr, Dept Anesthesiol, Bronx, NY 10467 USA.	Pranevicius@gmail.com					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Collard V, 2007, ANESTH ANALG, V105, P1255, DOI 10.1213/01.ane.0000282822.07437.02; Cortinez LI, 2001, BRIT J ANAESTH, V87, P866, DOI 10.1093/bja/87.6.866; Koppert W, 2007, BEST PRACT RES-CLIN, V21, P65, DOI 10.1016/j.bpa.2006.12.004; Lange M, 2007, ANESTHESIOLOGY, V106, P884, DOI 10.1097/01.anes.0000264787.22478.d7; Singler B, 2007, ANESTH ANALG, V104, P1397, DOI 10.1213/01.ane.0000261305.22324.f3; Troster A, 2006, ANESTHESIOLOGY, V105, P1016; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044	9	7	9	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2009	108	3					1048	1048		10.1213/ane.0b013e3181938f3f			1	Anesthesiology	Anesthesiology	409WU	WOS:000263537300070	19224829				2020-06-30	J	Okutomi, T; Saito, M; Mochizuki, J; Kuczkowski, K				Okutomi, Toshiyuki; Saito, Miwako; Mochizuki, Junko; Kuczkowski, Krzysztof M.			Combined spinal-epidural analgesia for labor pain: best timing of epidural infusion following spinal dose	ARCHIVES OF GYNECOLOGY AND OBSTETRICS			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 23-27, 2004	Las Vegas, NV	Amer Soc Anesthesiologists		Labor pain; Labor analgesia; Combined spinal-epidural; Timing of epidural infusion; Ropivacaine; Fentanyl; Obstetric anesthesia	0.0002-PERCENT FENTANYL; INTRATHECAL FENTANYL; BUPIVACAINE; 0.125-PERCENT	The combined spinal-epidural analgesia (CSEA) technique for labor pain has attained wide spread popularity in obstetric anesthesia. The onset of analgesia is rapid and reliable, and maternal satisfaction is very high. However, the best timing of an epidural infusion following the spinal dose and its effect on the total local anesthetics consumption has not been well determined. A total of 144 consenting healthy nulliparous parturients whose labor was induced and who labored under regional analgesia were enrolled in this study. Following induction of the CSEA with intrathecal injection of bupivacaine, 2.5 mg and fentanyl, 25 mu g, the patients were randomized into one of four groups to receive a subsequent continuous epidural infusion [E (3), E (30), E (60) and E (90)], depending on the timing of the initiation of epidural infusion of 0.1% ropivacaine, 0.0002% fentanyl and 1:500,000 epinephrine at the rate of 10 ml/h. In study Groups E (3), E (30), E (60) and E (90), epidural infusion was initiated 3, 30, 60 and 90 min, respectively following spinal induction dose. Patients requesting additional labor analgesia were given an epidural bolus (8 ml) of ropivacaine, 0.2%. The number of parturients requesting additional boluses of ropivacaine and the total dose of ropivacaine required for labor analgesia were registered. The numbers of patients who required additional boluses of ropivacaine in Group E (3) and Group E (30) were significantly less than those in Group E (60) and Group E (90). The total dose of ropivacaine required for labor pain in Group E (3) and Group E (30) was insignificantly smaller than the total dose required in Group E (60) and Group E (90). Our results suggest that the best timing of epidural infusion following spinal dose was within 30 min of spinal induction dose.	[Okutomi, Toshiyuki; Saito, Miwako] Kitasato Univ, Sch Med, Dept Anesthesiol, Kanagawa 2288555, Japan; [Mochizuki, Junko] Kitasato Univ, Sch Med, Dept Obstet & Gynecol, Kanagawa 2288555, Japan; [Kuczkowski, Krzysztof M.] Univ Calif San Diego, Dept Anesthesiol & Reprod Med, San Diego, CA 92103 USA	Okutomi, T (reprint author), Kitasato Univ, Sch Med, Dept Anesthesiol, 1-15-1 Kitasato, Kanagawa 2288555, Japan.	toshiyukiokutomi@hotmail.com					Atienzar MC, 2004, EUR J ANAESTH, V21, P770; CHESTNUT DH, 1988, ANESTHESIOLOGY, V68, P754, DOI 10.1097/00000542-198805000-00013; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Gaiser RR, 2000, REGION ANESTH PAIN M, V25, P223, DOI 10.1016/S1098-7339(00)90002-6; Goodman SR, 2002, REGION ANESTH PAIN M, V27, P374, DOI 10.1053/rapm.2002.33283; James KS, 1998, BRIT J ANAESTH, V81, P507, DOI 10.1093/bja/81.4.507; Kuczkowski K M, 2004, Acta Anaesthesiol Belg, V55, P29; Kuczkowski Krzysztof M., 2007, Archives of Gynecology and Obstetrics, V275, P183, DOI 10.1007/s00404-006-0204-5; Lee BB, 2002, REGION ANESTH PAIN M, V27, P31, DOI 10.1053/rapm.2002.27836; Norris MC, 2000, INT J OBSTET ANESTH, V9, P3, DOI 10.1054/ijoa.1999.0301; OKUTOMI T, 2004, ANESTHESIOLOGY, V101, pA1225, DOI DOI 10.1097/00000542-200411000-00024; Pace MC, 2004, ANN NY ACAD SCI, V1034, P356, DOI 10.1196/annals.1335.037; Sah N, 2005, J CLIN ANESTH, V17, P91, DOI 10.1016/j.jclinane.2004.05.004; Sia ATH, 1999, CAN J ANAESTH, V46, P1019, DOI 10.1007/BF03013195; Teoh WHL, 2003, ANESTH ANALG, V97, P873, DOI 10.1213/01.ANE.0000076388.17223.37; Yeh HM, 2001, ANESTH ANALG, V92, P665, DOI 10.1097/00000539-200103000-00022	17	6	7	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-0067	1432-0711		ARCH GYNECOL OBSTET	Arch. Gynecol. Obstet.	MAR	2009	279	3					329	334		10.1007/s00404-008-0725-1			6	Obstetrics & Gynecology	Obstetrics & Gynecology	399FA	WOS:000262784600010	18629529				2020-06-30	J	Hube, R; Troger, M; Rickerl, F; Muench, EO; von Eisenhart-Rothe, R; Hein, W; Mayr, HO				Hube, R.; Troeger, M.; Rickerl, F.; Muench, E. O.; von Eisenhart-Rothe, R.; Hein, W.; Mayr, H. O.			Pre-emptive intra-articular administration of local anaesthetics/opiates versus postoperative local anaesthetics/opiates or local anaesthetics in arthroscopic surgery of the knee joint: a prospective randomized trial	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Knee arthroscopy; Pre-emptive analgesia; Pre-emptive fentanyl; Co-analgesic effect; Intra-articular analgesia	CRUCIATE LIGAMENT RECONSTRUCTION; FEMORAL NERVE BLOCK; PAIN-CONTROL; REGIONAL ANESTHESIA; MORPHINE; BUPIVACAINE; ANALGESIA; REPAIR; REQUIREMENTS; CATHETER	Arthroscopic surgery on the knee joint is increasingly being performed as day-case surgery. This necessitates adequate postoperative pain therapy. We performed a study to compare three different intra-articular regimens of pain treatment. The hypothesis was that preoperative intra-articular pain management is superior to postoperative procedures. In this study we compared the preoperative administration of 0.1 mg fentanyl + 5 ml bupivacaine 0.5% with the postoperative administration of either 0.1 mg fentanyl + 5 ml bupivacaine 0.5% or 5 ml bupivacaine 0.5% alone in a total of 564 patients. Participants were randomly assigned to three groups. Each group was subdivided into patients with and without synovitis. The preoperative administration of fentanyl and bupivacaine significantly decreased the perceived pain. The efficiency increased with major arthroscopic procedures. Postoperative administration of bupivacaine alone had the least effect. There was variation within each group depending on whether synovitis was present or not. This study demonstrated the superiority of the preoperative intra-articular administration of a combination of fentanyl and local anaesthetic over postoperative fentanyl and local anaesthetic or postoperative local anaesthetic alone.	[Hube, R.; Rickerl, F.; Muench, E. O.; Mayr, H. O.] OCM Klin, D-81369 Munich, Germany; [Hube, R.; Hein, W.; Mayr, H. O.] Univ Halle Wittenberg, Orthopad Klin & Poliklin, D-06112 Halle, Germany; [Troeger, M.] Klin Unfall & Wiederherstellungschirurg Henriette, D-30171 Hannover, Germany; [von Eisenhart-Rothe, R.] Asclepios Orthopad Klin, D-92421 Schwandorf, Germany	Hube, R (reprint author), OCM Klin, Steiner Str 6, D-81369 Munich, Germany.	robert.hube@ocm-muenchen.de	von Eisenhart-Rothe, Ruediger/E-4839-2017				Atchabahian A, 2001, ANESTHESIOLOGY, V94, P534, DOI 10.1097/00000542-200103000-00029; Butterfield NN, 2001, CAN J ANAESTH, V48, P245, DOI 10.1007/BF03019753; Cappellino A, 1996, ARTHROSCOPY, V12, P120, DOI 10.1016/S0749-8063(96)90233-9; Cepeda MS, 1997, REGION ANESTH, V22, P233, DOI 10.1016/S1098-7339(06)80007-6; Cuvillon P, 2001, ANESTH ANALG, V93, P1045, DOI 10.1097/00000539-200110000-00050; Dauri M, 2003, ACTA ANAESTH SCAND, V47, P20, DOI 10.1034/j.1399-6576.2003.470104.x; Denti M, 1997, Knee Surg Sports Traumatol Arthrosc, V5, P206, DOI 10.1007/s001670050051; Goranson BD, 1997, CAN J ANAESTH, V44, P371, DOI 10.1007/BF03014456; Iskandar H, 2003, REGION ANESTH PAIN M, V28, P29, DOI 10.1053/rapm.2003.50019; JOSHI GP, 1993, REGION ANESTH, V18, P254; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608; Lundin O, 1998, ARTHROSCOPY, V14, P192, DOI 10.1016/S0749-8063(98)70040-4; Lynch J, 1991, Acta Anaesthesiol Belg, V42, P207; Mayr HO, 2007, ARCH ORTHOP TRAUM SU, V127, P241, DOI 10.1007/s00402-006-0147-0; Mehdi SA, 2004, KNEE SURG SPORT TR A, V12, P180, DOI 10.1007/s00167-003-0464-6; Rosseland LA, 2005, REGION ANESTH PAIN M, V30, P83, DOI 10.1016/j.rapm.2004.08.022; Shaw A, 1997, EUR J ANAESTH, V14, P635, DOI 10.1046/j.1365-2346.1994.00203.x; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Tetzlaff JE, 1997, J CLIN ANESTH, V9, P542, DOI 10.1016/S0952-8180(97)00141-4; Tetzlaff JE, 1999, REGION ANESTH PAIN M, V24, P220, DOI 10.1016/S1098-7339(99)90131-1; Uysalel A, 1995, ARTHROSCOPY, V11, P660, DOI 10.1016/0749-8063(95)90105-1; Varkel V, 1999, CAN J ANAESTH, V46, P867, DOI 10.1007/BF03012977; Woods GW, 2006, AM J SPORT MED, V34, P1328, DOI 10.1177/0363546505286145	25	0	0	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051			ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	MAR	2009	129	3					343	348		10.1007/s00402-008-0614-x			6	Orthopedics; Surgery	Orthopedics; Surgery	407GO	WOS:000263351800009	18365222				2020-06-30	J	Hayee, B; Dunn, J; Loganayagam, A; Wong, M; Saxena, V; Rowbotham, D; McNair, A				Hayee, Bu'Hussain; Dunn, Jason; Loganayagam, Aathavan; Wong, Mandy; Saxena, Vishal; Rowbotham, David; McNair, Alistair			Midazolam with meperidine or fentanyl for colonoscopy: results of a randomized trial	GASTROINTESTINAL ENDOSCOPY			English	Article							SEDATION-FREE COLONOSCOPY; GASTROINTESTINAL ENDOSCOPY; CLINICAL PHARMACOKINETICS; DIFFICULTY; PETHIDINE; PAIN	Background: A combination of midazolant and opioid is usually used to achieve sedation and analgesia during colonoscopy Two commonly used opioids are meperidine and fentanyl, but few studies have compared their efficacy. Objective: This randomized trial aimed to compare the efficacy and recovery time of 2 sedation regimens consisting of midazolam in combination with either meperidine or fentanyl. Design, Setting, and Patients: A total of 300 Consecutive, unselected adults attending Outpatient colonoscopy at a District General Hospital were enrolled with informed consent and randomized to receive midazolam with meperidine or fentanyl. Data for procedure times, perceived discomfort (according to standard 100-mm visual analog scales [VAS]), and recovery time were collected. Patients and all endoscopy staff directly involved with the procedure were blinded to the regimen used. Main Outcome Measurements: Primary: patients' experience of pain (postrecovery VAS score); secondary: recovery time. Results: A total of 287 patients (150 female, mean [SD] age 54 [17] years) were studied. Recovery time (in minutes) was significantly shorter in patients receiving fentanyl (n = 138) than in those receiving meperidine (n = 149, mean +/- SE: 13.7 +/- 1.8 vs 18.7 +/- 1.7, P = .03), whereas there was no difference in the patients', endoscopists', or nurses' perception of pain during the procedure between the 2 groups. Both groups received a median dose of 3 mg of midazolam (range 2-5 mg). In patients receiving lower closes (2-2.5 and 3-3.5 mg), recovery times were significantly faster with fentanyl (P < .01 and < .05, respectively), whereas at higher closes of midazolam (>= 4 mg) there was no difference between the 2 groups. Limitations: The use of VAS scores and nurse assessment of recovery time were chosen in this study because, despite their subjectivity, these measures were felt to most closely reflect true clinical practice. Conclusions: The use of fentanyl in combination with low-close midazolam results in significantly faster recovery from sedation compared with meperidine, without any apparent loss of analgesic effect. (Gastrointest Endosc 2009;69:681-7.)	[Hayee, Bu'Hussain; Dunn, Jason; Loganayagam, Aathavan; Wong, Mandy; Saxena, Vishal; Rowbotham, David; McNair, Alistair] Queen Elizabeth NHS Trust, Dept Gastroenterol, London SE18 4QH, England	Hayee, B (reprint author), Queen Elizabeth NHS Trust, Dept Gastroenterol, Stadium Rd, London SE18 4QH, England.	bu@doctors.org.uk					Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; *AM SOC GASTR END, PUBL AM SOC GASTR EN; British Society of Gastroenterology, BRIT SOC GASTR GUID; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; CHUANG E, 1995, GASTROINTEST ENDOSC, V42, P156, DOI 10.1016/S0016-5107(95)70073-0; Chung YW, 2007, DIGEST LIVER DIS, V39, P872, DOI 10.1016/j.dld.2007.04.019; FLACKE JW, 1987, ANESTH ANALG, V66, P723; Galletly NP, 2006, GUT, V55, pA55; Hayee BH, 2006, GUT, V55, pA4; LORD DA, SEDATION GASTROINTES; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MATHER LE, 1978, CLIN PHARMACOKINET, V3, P352, DOI 10.2165/00003088-197803050-00002; McPhillips J, 2006, GUT, V55, pA57; MOSTERT JW, 1968, J CLIN PHARMACOL N D, V8, P382, DOI 10.1002/j.1552-4604.1968.tb00114.x; *NAT CONF ENQ PAT, SCOP OUR PRACT; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Takahashi Y, 2005, DIS COLON RECTUM, V48, P1295, DOI 10.1007/s10350-004-0940-1	17	28	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	MAR	2009	69	3	2				681	687		10.1016/j.gie.2008.09.033			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	416NG	WOS:000264012200013	19251010				2020-06-30	J	Aneiros, F; Vazquez, M; Valino, C; Taboada, M; Sabate, S; Otero, P; Costa, J; Carceller, J; Vazquez, R; Diaz-Vieito, M; Rodriguez, A; Alvarez, J				Aneiros, Francisco; Vazquez, Miriam; Valino, Cristina; Taboada, Manuel; Sabate, Sergi; Otero, Pablo; Costa, Jose; Carceller, Javier; Vazquez, Rocio; Diaz-Vieito, Maria; Rodriguez, Alfonso; Alvarez, Julian			Does epidural versus combined spinal-epidural analgesia prolong labor and increase the risk of instrumental and cesarean delivery in nulliparous women?	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Analgesia; Obstetrical; Analgesic techniques; Combined spinal-epidural; Epidural; Subarachnoid	BUPIVACAINE; LEVOBUPIVACAINE; ROPIVACAINE; SUFENTANIL; INFUSION	Study Objective: To compare duration of labor, mode of delivery, and local anesthetic consumed in women who received labor analgesia with epidural or combined spinal-epidural technique. Design: Retrospective, observational study. Setting: Delivery room of a university hospital. patients: 788 nulliparous women in labor at term with cervical dilation between three and 5 cm. Interventions: In Group E (epidural alone), parturients received an epidural solution of 8 mL (levobupivacaine 0.125% with fentanyl 5 mu g/mL). In Group CSE (combined spinal-epidural), parturients received a spinal injection of levobupivacaine two mg with fentanyl 15 mu g (total volume two mL). Then an epidural catheter was placed in all patients and connected to a patient-controlled analgesia pump (basal infusion rate of 8 mL/hr of 0.1% levobupivacaine and fentanyl two mu g/mL, patient-controlled bolus dose of three mL, and lockout time of 30 min). Measurements: Labor duration, mode of delivery (spontaneous vaginal vs. instrumental delivery vs. cesarean section), and local anesthetic consumed, were recorded. Main Results: Labor analgesia was performed with an epidural technique in 322 patients (40.9%), and a combined spinal-epidural technique in 466 patients (59.1%), of whom 39 Group E women (12.1%) and 46 Group CSE women (9.9%) required cesarean section (P=ns). No differences in the mode of delivery were observed between the groups. Time from analgesia to delivery (Group E: 217 +/- 111 min vs. Group CSE: 213 +/- 115 min; P=ns), and epidural local anesthetic consumed (Group E: 35 +/- 20 mL vs. Group CSE: 33 20 mL; P=ns), were similar in both groups. Conclusions: No significant differences were observed between epidural and combined spinal-epidural given for labor analgesia in nulliparous women in duration of labor, mode of delivery, or local anesthetic consumed. (c) 2009 Elsevier Inc. All rights reserved.	[Aneiros, Francisco; Vazquez, Miriam; Valino, Cristina; Taboada, Manuel; Otero, Pablo; Costa, Jose; Carceller, Javier; Vazquez, Rocio; Diaz-Vieito, Maria; Rodriguez, Alfonso; Alvarez, Julian] Univ Santiago de Compostela, Dept Anesthesiol, Santiago De Compostela 15706, Spain; [Aneiros, Francisco; Vazquez, Miriam; Valino, Cristina; Taboada, Manuel; Otero, Pablo; Costa, Jose; Carceller, Javier; Vazquez, Rocio; Diaz-Vieito, Maria; Rodriguez, Alfonso; Alvarez, Julian] Hosp Clin Univ Santiago, Santiago De Compostela 15706, Spain; [Sabate, Sergi] Fdn Puigvert INUA, Dept Anesthesiol, Barcelona 08025, Spain	Taboada, M (reprint author), Univ Santiago de Compostela, Dept Anesthesiol, Santiago De Compostela 15706, Spain.	manutabo@yahoo.es	Sabate, Sergi/AAC-2619-2019; Julian, Alvarez/D-5716-2011	Julian, Alvarez/0000-0002-2518-0891; Sabate, Sergi/0000-0001-7582-2832	institutional and departmental sources	Support was provided solely from institutional and departmental sources.	Camorcia M, 2005, ANESTHESIOLOGY, V102, P646, DOI 10.1097/00000542-200503000-00025; CAYACON N, 2006, J INT MED RES, V34, P596; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Dresner M, 1999, BRIT J ANAESTH, V83, P756; Hepner DL, 2000, CAN J ANAESTH, V47, P232, DOI 10.1007/BF03018918; MacArthur C, 2001, LANCET, V358, P19; Missant C, 2005, ANAESTH INTENS CARE, V33, P452, DOI 10.1177/0310057X0503300405; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; Norris MC, 2001, ANESTHESIOLOGY, V95, P913, DOI 10.1097/00000542-200110000-00020; Price C, 1998, ANAESTHESIA, V53, P951, DOI 10.1046/j.1365-2044.1998.00523.x; Sah N, 2005, J CLIN ANESTH, V17, P91, DOI 10.1016/j.jclinane.2004.05.004; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; Van de Velde M, 1999, Acta Anaesthesiol Belg, V50, P129; van de Velde M, 2007, ANESTHESIOLOGY, V106, P149, DOI 10.1097/00000542-200701000-00024; Vernis L, 2004, EUR J ANAESTH, V21, P186, DOI 10.1017/S0265021504003047	15	3	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAR	2009	21	2					94	97		10.1016/j.jclinane.2008.06.020			4	Anesthesiology	Anesthesiology	432LC	WOS:000265133500003	19329011				2020-06-30	J	Lilker, S; Rofaeel, A; Balki, M; Carvalho, JCA				Lilker, Suzanne; Rofaeel, Ayman; Balki, Mrinalini; Carvalho, Jose C. A.			Comparison of fentanyl and sufentanil as adjuncts to bupivacaine for labor epidural analgesia	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Epidural analgesia; Fentanyl; Labor; Sufentanil	INFUSION; 0.125-PERCENT; DELIVERY	Study Objective: To compare the clinical efficacy of theoretically equipotent doses of fentanyl and sufentanil, each in combination with bupivacaine, for patient-controlled epidural analgesia (PCEA) for labor. Design: Single-blinded, randomized study. Setting: University hospital. Patients: 48 ASA physical status I and II term parturients in active labor, with cervical dilatation equal to or less than 5 cm, and requesting epidural analgesia. Interventions: Patients received a loading dose of 10 mL of 0.125% bupivacaine with either 30 mu g of fentanyl or 5 mu g of sufentanil. PCEA was maintained with 0.0625% bupivacaine with either fentanyl two mu g/mL or sufentanil 0.35 mu g/mL. The PCEA settings were: bolus 5 mL, lockout 10 minutes, infusion 10 mL/hr, and maximum dose 40 mL/hr. Standardized rescue doses of bupivacaine were administered as necessary. Measurements: The bupivacaine requirement in mg/hr was calculated from the time of initiation of the epidural until the patient had had 4 to 6 hours of PCEA. The hourly pain score, sensory and motor block, and side effects were documented. Overall patient satisfaction was assessed at the end of the study. Main Results: The mean (standard deviation) bupivacaine requirement was 12.4 mg/hr (3.2) and 11.0 mg/hr (2.4) for the fentanyl and sufentanil groups, respectively (P = 0.08). There was evidence of higher maternal satisfaction (P = 0.01), and weak evidence of lower pain scores (P = 0.10) in the sufentanil group. The side effects were similar in both groups. Conclusions: At the assumed equipotent sufentanil to fentanyl ratio of 6:1, there is some evidence that sufentanil is clinically superior to fentanyl as an adjunct to bupivacaine in labor epidurals, although the advantages are subtle. (c) 2009 Elsevier Inc. All rights reserved.	[Lilker, Suzanne; Rofaeel, Ayman; Balki, Mrinalini; Carvalho, Jose C. A.] Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada; [Carvalho, Jose C. A.] Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynecol, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada	Carvalho, JCA (reprint author), Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada.	jose.carvalho@uhn.on.ca	Balki, Mrinalini/A-2669-2015				BADER AM, 1995, ANESTH ANALG, V81, P829, DOI 10.1097/00000539-199510000-00029; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Capogna G, 2003, ANESTH ANALG, V96, P1178, DOI 10.1213/01.ANE.0000054003.03645.CF; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; Cohen S, 1996, CAN J ANAESTH, V43, P341, DOI 10.1007/BF03011711; Connelly NR, 2000, ANESTH ANALG, V91, P374, DOI 10.1097/00000539-200008000-00026; ELLIOTT RD, 1991, CAN J ANAESTH, V38, P303, DOI 10.1007/BF03007619; Herman NL, 1998, J CLIN ANESTH, V10, P670, DOI 10.1016/S0952-8180(98)00113-5; Le Guen H, 2001, J CLIN ANESTH, V13, P98, DOI 10.1016/S0952-8180(01)00221-5; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Lyons G, 1997, BRIT J ANAESTH, V78, P493; Pan P. H., 2005, ANESTHESIOLOGY, V103, pA572; Polley LS, 1998, ANESTHESIOLOGY, V89, P626, DOI 10.1097/00000542-199809000-00011; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Porter J, 1998, ANESTHESIOLOGY, V89, P79, DOI 10.1097/00000542-199807000-00014; STODDART AP, 1994, ANAESTHESIA, V49, P1087, DOI 10.1111/j.1365-2044.1994.tb04362.x; VERTOMMEN JD, 1991, ANESTHESIOLOGY, V74, P809, DOI 10.1097/00000542-199105000-00002	17	10	15	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAR	2009	21	2					108	112		10.1016/j.jclinane.2008.06.027			5	Anesthesiology	Anesthesiology	432LC	WOS:000265133500006	19329014				2020-06-30	J	Stricker, PA; Kraemer, FW; Ganesh, A				Stricker, Paul A.; Kraemer, F. Wickham; Ganesh, Arjunan			Severe remifentanil-induced acute opioid tolerance following awake craniotomy in an adolescent	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Acute opioid tolerance; Hyperalgesia; Remifentanil; Awake craniotomy	FENTANYL-OXYGEN ANESTHESIA; AWARENESS	Anesthetic goals for procedures involving resections close to the motor cortex include immobility, analgesia, and a level of consciousness that allows for the ability to follow motor commands. Remifentanil as a single agent is an attractive choice, particularly when ventilation is controlled. The successful use of large-dose remifentanil infusion during an awake craniotomy in a 16 year-old man and the subsequent severe acute opioid tolerance is presented. (c) 2009 Elsevier Inc. All rights reserved.	[Stricker, Paul A.; Kraemer, F. Wickham; Ganesh, Arjunan] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Stricker, PA (reprint author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	strickerp@email.chop.edu					Ard J, 2003, J NEUROSURG ANESTH, V15, P263, DOI 10.1097/00008506-200307000-00015; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hagberg CA, 2004, J CLIN ANESTH, V16, P43, DOI 10.1016/j.jclinane.2003.02.011; HILGENBERG JC, 1981, ANESTHESIOLOGY, V54, P341, DOI 10.1097/00000542-198104000-00018; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Klimek M, 2004, ANAESTHESIA, V59, P607, DOI 10.1111/j.1365-2044.2004.03675.x; MUMMANENI N, 1980, ANESTH ANALG, V59, P948; Tobias JD, 1997, PAEDIATR ANAESTH, V7, P341, DOI 10.1046/j.1460-9592.1997.d01-86.x; VINIK HR, 1998, ANESTH ANALG, V86, P49	9	10	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAR	2009	21	2					124	126		10.1016/j.jclinane.2008.06.032			3	Anesthesiology	Anesthesiology	432LC	WOS:000265133500009	19329017				2020-06-30	J	Liang, BA				Liang, Bryan A.			Responsibility for anesthesiologist suicide relating to drug abuse	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material									[Liang, Bryan A.] Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA 92101 USA; [Liang, Bryan A.] Univ Calif San Diego, San Diego Ctr Patient Safety, Sch Med, San Diego, CA 92103 USA	Liang, BA (reprint author), Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA 92101 USA.	baliang@alum.mit.edu						0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAR	2009	21	2					135	136		10.1016/j.jclinane.2008.11.002			2	Anesthesiology	Anesthesiology	432LC	WOS:000265133500012	19329020				2020-06-30	J	Paterson, JM; Caulkett, NA; Woodbury, MR				Paterson, Jessica M.; Caulkett, Nigel A.; Woodbury, Murray R.			PHYSIOLOGIC EFFECTS OF NASAL OXYGEN OR MEDICAL AIR ADMINISTERED PRIOR TO AND DURING CARFENTANIL-XYLAZINE ANESTHESIA IN NORTH AMERICAN ELK (CERVUS CANADENSIS MANITOBENSIS)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Review						Cervus canadensis manitobensis; immobilization; carfentanil-xylazine; hypoxemia; hypercarbia; oxygen	SHEEP OVIS-OVIS; MEDETOMIDINE-KETAMINE; TAILED DEER; ANESTHETIZED HORSES; ELAPHUS-NELSONI; CARBON-DIOXIDE; MULE DEER; IMMOBILIZATION; NALTREXONE; HYPOXEMIA	This study compared the physiologic effects of carfentanil-xylazine anesthesia in elk administered nasal oxygen or medical air. Eight female 5 +/- 2-yr-old (mean +/- SD) captive elk (Cervus canadensis manitobensis) weighing 245 +/- 20 kg and habituated to chute restraint were studied in a randomized crossover. Nasal insufflation of oxygen Or medical air (10 L/min) was provided prior to and throughout anesthesia. Baseline data were collected before i.m. injection of carfentanil (10 mu g/kg) and xylazine (0.2 mg/kg). Arterial blood gases (PaO2 and PaCO2), arterial blood pressure, heart and respiratory rate, and observation,, of muscle rigidity and movement were collected every 3 min for 30 min. Drugs were antagonized at 30 min with i.m. naltrexone (1 mg/kg) and tolazoline (2 mg/kg). Induction and recovery were significantly faster (mean SD) in elk receiving oxygen (208 39 and 333 63 sec, respectively), vs. medical air (306 +/- 84 and 532 +/- 201 sec). Elk receiving oxygen had a significantly higher PaO2 and PaCO2, and significantly lower pH and heart rate. Minimum PaO, was 75 +/- 30 mm Hg (oxygen), and 28 +/- 6 mm Hg (air). Maximum PaCO2 was 89 +/- 5 mm Hg (oxygen), and 64 +/- 4 mm Hg (air). Frequency of rigidity and movement decreased when PaO2 >= 70 mm Hg. Animals breathing air demonstrated slower inductions and recoveries, severe hypoxemia, and increased rigidity and movement. Oxygen administration reduced hypoxemia and improved anesthesia quality. but caused prolonged periods of apnea, and moderate to severe hypercarbia and respiratory acidosis.	[Caulkett, Nigel A.] Univ Calgary, Dept Clin Diagnost Sci, Fac Vet Med, Calgary, AB T2N 4N1, Canada; [Paterson, Jessica M.] Univ Saskatchewan, Dept Small Anim Clin Sci, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada; [Woodbury, Murray R.] Univ Saskatchewan, Dept Large Anim Clin Sci, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada	Caulkett, NA (reprint author), Univ Calgary, Dept Clin Diagnost Sci, Fac Vet Med, Calgary, AB T2N 4N1, Canada.	nacaulke@ucalgary.ca			Western College of Veterinary Medicine Research Fund; Saskatchewan Canada Agrifood Innovation Fund Specialized Livestock Research Trust	The authors extend their appreciation to the Western College of Veterinary Medicine Research Fund, and the Saskatchewan Canada Agrifood Innovation Fund Specialized Livestock Research Trust for funding this project. The authors also express their appreciation to Dr. Rob McCorkell for his invaluable assistance during the study.	ALLEN JL, 1989, J ZOO WILDLIFE MED, V20, P423; BAILEY PL, 1985, J WILDLIFE MANAGE, V49, P931, DOI 10.2307/3801373; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Baraka AS, 1999, ANESTHESIOLOGY, V91, P612, DOI 10.1097/00000542-199909000-00009; Bateman NT, 1998, BRIT MED J, V317, P798, DOI 10.1136/bmj.317.7161.798; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; CARROLL GC, 1992, CHEST, V102, P986, DOI 10.1378/chest.102.4.986; CAULKETT NA, 1994, J ZOO WILDLIFE MED, V25, P376; Caulkett NA, 2000, CAN J VET RES, V64, P64; Caulkett NA, 1996, J ZOO WILDLIFE MED, V27, P217; Caulkett NA, 2000, CAN VET J, V41, P49; Cole A, 2006, J ZOO WILDLIFE MED, V37, P318, DOI 10.1638/05-070.1; CROSS JP, 1994, COMP HAEMATOL INT, V4, P76, DOI 10.1007/BF00368273; HAIGH JC, 1991, J ZOO WILDLIFE MED, V22, P318; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Heard DJ, 1996, AM J VET RES, V57, P87; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; JACOBSEN NK, 1983, J WILDLIFE MANAGE, V47, P252, DOI 10.2307/3808079; JESSUP DA, 1985, J AM VET MED ASSOC, V187, P1253; JESSUP DA, 1984, J ZOO ANIM MED, V15, P8, DOI 10.2307/20094672; JUAN G, 1984, NEW ENGL J MED, V310, P874, DOI 10.1056/NEJM198404053101402; Marntell S, 2005, VET ANAESTH ANALG, V32, P338, DOI 10.1111/j.1467-2995.2005.00199.x; McDonell W, 1996, LUMB JONES VET ANEST, V1, P115; MEULEMAN T, 1984, J WILDLIFE MANAGE, V48, P258, DOI 10.2307/3808484; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; Read MR, 2003, J ZOO WILDLIFE MED, V34, P134, DOI 10.1638/1042-7260(2003)034[0134:AROAAA]2.0.CO;2; Read MR, 2001, CAN VET J, V42, P861; Rosef Oav, 2004, Rangifer, V24, P79; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; Schumacher J, 1997, J ZOO WILDLIFE MED, V28, P166; Schumacher J, 1997, AM J VET RES, V58, P157; SEAL US, 1985, J WILDLIFE DIS, V21, P48, DOI 10.7589/0090-3558-21.1.48; STEFFEY EP, 1992, AM J VET RES, V53, P1850; STOELTING RK, 1999, PHARM PHYSL ANESTHET, P698; Storms TN, 2005, J WILDLIFE DIS, V41, P559, DOI 10.7589/0090-3558-41.3.559; WIENSNER H, 1984, J ZOO ANIM MED, V15, P18, DOI 10.2307/20094674	38	25	25	0	9	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	MAR	2009	40	1					39	50		10.1638/2007-0107.1			12	Veterinary Sciences	Veterinary Sciences	427JO	WOS:000264775800006	19368239				2020-06-30	J	Kannikeswaran, N; Mahajan, PV; Sethuraman, U; Groebe, A; Chen, XG				Kannikeswaran, Nirupama; Mahajan, Prashant V.; Sethuraman, Usha; Groebe, Anna; Chen, Xinguang			Sedation medication received and adverse events related to sedation for brain MRI in children with and without developmental disabilities	PEDIATRIC ANESTHESIA			English	Article						sedation; magnetic resonance imaging; adverse events; developmental disabilities; children	PROCEDURAL SEDATION; PEDIATRIC-SEDATION; REDUCTION	There are few studies on sedation medication requirements and sedation related adverse events in developmentally disabled children. The objectives of our study were to compare sedation medication received and sedation related adverse events for brain magnetic resonance imaging (MRI) between children with and without developmental disabilities. We hypothesized that developmentally disabled children would require increased doses of sedative medications and will have increased frequency of adverse events when compared with normal children. We conducted a retrospective chart review on children 1-18 years, who required sedation for an elective brain MRI. Children were excluded if they required sedation for diagnostic imaging other than brain MRI, belonged to ASA category > 3, or required general anesthesia. Data on developmental status, demographics and details of sedation medications received along with adverse events were collected. About 53.5% (260/486) of the patients were classified as developmentally disabled. Pentobarbital and fentanyl were the two most common medications used for sedation in children with and without developmental disability. There was no difference in the mean dosages of pentobarbital (3.02 mg.kg(-1) vs 3.06 mg.kg(-1); P = 0.2) and fentanyl (1.01 mcg.kg(-1) vs 1.02 mcg.kg(-1); P = 0.81) in the two groups. There was a threefold increased incidence of hypoxia noted in children with developmental disability (11.9% vs 4.9%; P < 0.01). Presence of developmental disability alone was significantly associated with sedation related hypoxia (OR = 3.2, 95% CI: 1.8, 6.94; P < 0.01). Children with developmental disabilities have similar requirements for sedation medications but are three times more likely to experience hypoxia when compared with normal children.	[Kannikeswaran, Nirupama; Mahajan, Prashant V.; Sethuraman, Usha] Wayne State Univ, Childrens Hosp Michigan, Div Emergency Med, Carman & Ann Adams Dept Pediat, Detroit, MI 48201 USA; [Chen, Xinguang] Wayne State Univ, Dept Pediat, Detroit, MI 48201 USA	Kannikeswaran, N (reprint author), Wayne State Univ, Childrens Hosp Michigan, Div Emergency Med, Carman & Ann Adams Dept Pediat, 3901 Beaubien Blvd, Detroit, MI 48201 USA.	nkannike@dmc.org		Chen, Xinguang/0000-0001-8263-643X			Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; [Anonymous], 1985, PEDIATRICS, V76, P317; Bluemke DA, 2000, RADIOLOGY, V216, P645, DOI 10.1148/radiology.216.3.r00se45645; Boswinkel JP, 2005, PEDIATR ANN, V34, P650, DOI 10.3928/0090-4481-20050801-13; Cortellazzi P, 2007, PEDIATR ANESTH, V17, P630, DOI 10.1111/j.1460-9592.2006.02178.x; Cutter KO, 2007, AM J EMERG MED, V25, P654, DOI 10.1016/j.ajem.2006.11.043; Elwood T, 2001, J CLIN ANESTH, V13, P482, DOI 10.1016/S0952-8180(01)00312-9; Frei FJ, 1997, ANAESTHESIA, V52, P1056, DOI 10.1111/j.1365-2044.1997.257-az0376.x; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; King WK, 2006, ACAD EMERG MED, V13, P673, DOI 10.1197/j.aem.2006.01.022; Lowrie L, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e30; Malviya S, 2000, BRIT J ANAESTH, V84, P743; Malviya S, 1997, ANESTH ANALG, V85, P1207, DOI 10.1097/00000539-199712000-00005; Mehta UC, 2004, J DEV BEHAV PEDIATR, V25, P102, DOI 10.1097/00004703-200404000-00005; Osborn Irene P, 2002, Curr Opin Anaesthesiol, V15, P443, DOI 10.1097/00001503-200208000-00006; RABEY PG, 1992, BRIT J ANAESTH, V69, pS40, DOI 10.1093/bja/69.supplement_1.40S; Ross AK, 2005, PEDIATR RADIOL, V35, P867, DOI 10.1007/s00247-005-1499-2; Sanborn PA, 2005, RADIOLOGY, V237, P288, DOI 10.1148/radiol.2371041415; Schmerler BL, 2008, AM J EMERG MED, V26, P661, DOI 10.1016/j.ajem.2007.10.001; Shevell M, 2003, NEUROLOGY, V60, P367, DOI 10.1212/01.WNL.0000031431.81555.16; Van der Walt JH, 2001, PAEDIATR ANAESTH, V11, P401, DOI 10.1046/j.1460-9592.2001.00688.x; Volle E, 1996, PEDIATR RADIOL, V26, P280, DOI 10.1007/BF01372113	23	37	40	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAR	2009	19	3					250	256		10.1111/j.1460-9592.2008.02900.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	406NP	WOS:000263302500009	19143958				2020-06-30	J	Matsota, FK; Markantonis, SL; Fousteri, MZF; Pandazi, AK; Manikis, DE; Christodoulopoulou, TC; Loizou, MM; Kostopanagiotou, GG				Matsota, Faraskevi K.; Markantonis, Sophia L.; Fousteri, Marina-Zoi F.; Pandazi, Ageliki K.; Manikis, Dimitris E.; Christodoulopoulou, Theodora C.; Loizou, Marilia M.; Kostopanagiotou, Georgia G.			Excretion of Ropivacaine in Breast Milk During Patient-Controlled Epidural Analgesia After Cesarean Delivery	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							BUPIVACAINE; ANESTHESIA; SECTION; PLASMA; LIDOCAINE; FENTANYL	Background: Few studies have been published concerning the excretion of bupivacaine and lidocaine into the breast milk and none concerning ropivacaine. Aim: The aim of this study was to determine the levels of ropivacaine in plasma and breast milk after combined spinal-epidural anesthesia for cesarean delivery and postoperative patient-controlled epidural analgesia (PCEA), as well as possible adverse effects from these levels on the neonate. Methods: Twenty-five parturients admitted for cesarean delivery under combined spinal-epidural anesthesia participated in the study. The PCEA regimen was prepared as 0.15% ropivacame and fentanyl 2 mu g/mL (basal rate, 6 mL/h; demand dose, 4 mL/20 min). Blood samples were collected before anesthesia and from the umbilical cord immediately after birth, followed by blood and breast milk samples 18 and 24 hrs after initiation of PCEA. The newborns were clinically appraised with the Apgar score at delivery and Neurological and Adaptive Capacity Score 24 hrs later. Local anesthetic side effects were recorded. Ropivacaine levels were determined by high-performance liquid chromatography with a UV detector. Results: Ropivacaine excretion into the breast milk produced concentrations that significantly correlated with those in the plasma 18 and 24 hrs after administration, achieving milk-plasma ratios (mean SD) of 0.25 +/- 0.08 and 0.23 +/- 10.07, respectively. Most newborns had maximal Apgar and Neurological and Adaptive Capacity Scores. No adverse effects from ropivacame were noted in mothers or neonates. Conclusions: The milk-plasma concentration ratio of ropivacame was found to be lower than that reported for other local anesthetics It seems that PCEA with ropivacaine/fentanyl after cesarean delivery is not associated with excessive milk-plasma concentrations of ropivacame.	[Matsota, Faraskevi K.; Pandazi, Ageliki K.; Kostopanagiotou, Georgia G.] Univ Athens, Sch Med, Dept Anaesthesiol, Athens 13231, Greece; [Markantonis, Sophia L.; Fousteri, Marina-Zoi F.] Sch Pharm, Dept Biopharmaceut & Pharmacokinet, Athens, Greece	Matsota, FK (reprint author), Univ Athens, Sch Med, Dept Anaesthesiol, 122 Athanassiou Diakou Str, Athens 13231, Greece.	matsota@yahoo.gr	Matsota, Paraskevi/AAD-8073-2019	Matsota, Paraskevi/0000-0003-0971-4483; Pandazi, Ageliki/0000-0002-6187-6431			ALAHUHTA S, 1995, ANESTHESIOLOGY, V83, P23, DOI 10.1097/00000542-199507000-00004; AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P340, DOI 10.1097/00000542-198205000-00003; Anderson JW, 1999, AM J CLIN NUTR, V70, P525; BEGG EJ, 1993, PHARMACOL THERAPEUT, V59, P301, DOI 10.1016/0163-7258(93)90072-L; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; BISSONNETTE JM, 1995, PRINCIPLES PRACTICE, P225; Buggy DJ, 2000, BRIT J ANAESTH, V85, P468, DOI 10.1093/bja/85.3.468; DATTA S, 1995, ANESTHESIOLOGY, V82, P1346, DOI 10.1097/00000542-199506000-00004; Earle S, 2002, HEALTH PROMOT INT, V17, P205, DOI 10.1093/heapro/17.3.205; FLEISHAKER JC, 1987, J PHARM SCI, V76, P189, DOI 10.1002/jps.2600760302; Giuliani M, 2001, J PEDIATR GASTR NUTR, V32, P142, DOI 10.1097/00005176-200102000-00009; Hirose M, 1996, ANESTH ANALG, V82, P1166, DOI 10.1097/00000539-199606000-00011; Kee WDN, 1997, ANAESTH INTENS CARE, V25, P126, DOI 10.1177/0310057X9702500203; LEBEDEVS TH, 1993, J CLIN PERIODONTOL, V20, P606, DOI 10.1111/j.1600-051X.1993.tb00779.x; Leung AY, 2004, J CLIN ANESTH, V16, P57, DOI 10.1016/j.jclinane.2003.02.012; Littleford J, 2004, CAN J ANAESTH, V51, P586, DOI 10.1007/BF03018403; Lyons G, 2005, Minerva Anestesiol, V71, P27; MORISHIMA HO, 1989, ANESTHESIOLOGY, V71, P110, DOI 10.1097/00000542-198907000-00019; Ortega D, 1999, ACTA ANAESTH SCAND, V43, P394, DOI 10.1034/j.1399-6576.1999.430405.x; Reif S, 1998, J CHROMATOGR B, V719, P239, DOI 10.1016/S0378-4347(98)00442-3; Zhang Yong-fu, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P224	21	12	14	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAR-APR	2009	34	2					126	129		10.1097/AAP.0b013e3181958f39			4	Anesthesiology	Anesthesiology	418DY	WOS:000264128600009	19282712				2020-06-30	J	Ogawa, J; Nakamura, K; Iizuka, K; Sekizuka, M; Yamamoto, K; Horiuchi, R				Ogawa, Junji; Nakamura, Katsunori; Iizuka, Keiko; Sekizuka, Masayuki; Yamamoto, Koujirou; Horiuchi, Ryuya			Optimal Conversion Ratio of Oral Morphine to Transdermal Fentanyl Patches to the Cancer Pain	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			Japanese	Article						fentanyl patch; pain control; conversion ratio; opioid rotation		In Japan, the initial dose of 2.5 mg/3 d is recommended in the package insert of the fentanyl patch preparation to substitute for oral morphine in the dose range of 45-135 mg/d (90 mg/d at the midpoint), while a higher dose is recommended in other countries. To validate the recommended dose of this drug in Japan, we investigated how long the initial recommended dose of the fentanyl patch could control the pain of cancer patients after the switch from other opioids. The dose of the fentanyl patch was increased on the 20th day after the switch from prior opioids at a lower dose than the midpoint of the indicated range, while it was increased on the 3rd day after the switch from the higher dose of prior opioids. Regression analysis showed that the efficacy ratio of the fentanyl patch : oral morphine-80 : 1, suggesting that oral morphine of 25-75 mg/d should be substituted for by the fentanyl patch preparation at a dose of 2.5 mg/3 d.	[Ogawa, Junji; Nakamura, Katsunori; Iizuka, Keiko; Sekizuka, Masayuki; Yamamoto, Koujirou; Horiuchi, Ryuya] Gunma Univ Hosp, Dept Pharm, Gunma 3718511, Japan; [Nakamura, Katsunori; Yamamoto, Koujirou; Horiuchi, Ryuya] Gunma Univ, Dept Clin Pharmacol, Grad Sch Med, Gunma 3718511, Japan	Yamamoto, K (reprint author), Gunma Univ Hosp, Dept Pharm, 3-39-15 Showa Machi, Gunma 3718511, Japan.	koujirou@med.gunma-u.ac.jp					Curtis GB, 1999, EUR J CLIN PHARMACOL, V55, P425, DOI 10.1007/s002280050651; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; *DUROTEP PATCH, PACK INS; Kato K, 2004, YAKUGAKU ZASSHI, V124, P287, DOI 10.1248/yakushi.124.287; MATOBA M, 2004, RECIPE CANC PAIN MAN, P96; Narita M, 2003, EUR J NEUROSCI, V18, P3193, DOI 10.1111/j.1460-9568.2003.03052.x; SUZUKI T, 2002, PHARM PROFILE FENTAN, P129; 2000, CHAPTER JAPANESE PAL, P54	8	3	3	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAR	2009	129	3					335	340		10.1248/yakushi.129.335			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	413DA	WOS:000263771900009	19252390	Bronze			2020-06-30	J	Lurie, IS; Iio, R				Lurie, Ira S.; Iio, Reiko			Use of multiple-reaction monitoring ratios for identifying incompletely resolved fentanyl homologs and analogs via ultra-high-pressure liquid chromatography-tandem mass spectrometry	JOURNAL OF CHROMATOGRAPHY A			English	Article						UHPLC; MRM; Fentanyl; Analog; Homolog	GAS-CHROMATOGRAPHY; DISCRIMINATION; IDENTIFICATION; DERIVATIVES; SEPARATION	Fentanyl and 16 of its corresponding homologs and analogs were distinguished using ultra-high-pressure liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). A 1.7 mu m Acquity BEH C18 column (150 mm x 2.1 mm) was used with a 1% formic acid (pH 2.2), methanol gradient. Multiple-reaction monitoring (MRM) was employed for MS/MS detection. All selected fentanyl-related compounds, including incompletely resolved compounds, were uniquely identified using retention times and dual MRMs. Published by Elsevier B.V.	[Lurie, Ira S.] US Drug Enforcement Adm, Special Testing & Res Lab, Dulles, VA 20166 USA; [Iio, Reiko] Ishikawa Prefectural Police Headquarters, Forens Sci Lab, Kanazawa, Ishikawa, Japan	Lurie, IS (reprint author), US Drug Enforcement Adm, Special Testing & Res Lab, Dulles, VA 20166 USA.	islurie@comcast.net		Lurie, Ira/0000-0003-3844-5120			BRINE GA, 1989, J HETEROCYCLIC CHEM, V26, P677, DOI 10.1002/jhet.5570260329; COOPER D, 1986, J FORENSIC SCI, V31, P511; FINCH JS, 1967, J CLIN PHARMACOL N D, V7, P46, DOI 10.1002/j.1552-4604.1967.tb00029.x; LURIE IS, 1984, J LIQ CHROMATOGR, V7, P463, DOI 10.1080/01483918408073979; LURIE IS, 1984, J CHROMATOGR, V292, P283, DOI 10.1016/S0021-9673(01)83609-8; Lurie IS, 2005, J CHROMATOGR A, V1100, P168, DOI 10.1016/j.chroma.2005.09.054; MOORE JM, 1986, ANAL CHEM, V58, P1656, DOI 10.1021/ac00121a013; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; SUZUKI S, 1989, FORENSIC SCI INT, V43, P15, DOI 10.1016/0379-0738(89)90117-5; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761	10	25	26	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0021-9673			J CHROMATOGR A	J. Chromatogr. A	FEB 27	2009	1216	9					1515	1519		10.1016/j.chroma.2008.12.097			5	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	410XB	WOS:000263610500033	19167002				2020-06-30	J	Turock, MK; Watts, DJ; Mude, H; Prestosh, J; Stoltzfus, J				Turock, Melanie K.; Watts, David J.; Mude, Hannah; Prestosh, John; Stoltzfus, Jill			Fentanyl-laced heroin: a report from an unexpected place	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter									[Turock, Melanie K.; Watts, David J.; Mude, Hannah; Prestosh, John] St Lukes Hosp, Dept Emergency Med, Bethlehem, PA 18015 USA; [Stoltzfus, Jill] St Lukes Hosp, Res Ctr, Bethlehem, PA 18015 USA	Turock, MK (reprint author), St Lukes Hosp, Dept Emergency Med, Bethlehem, PA 18015 USA.	drmelanieturock@hotmail.com					RANNAZZISI J, 2006, EX OFF PRES OFF NAT; *US CENS, 2000, BETHL PENNS POP DEM; 2006, FENTANYL LACED HEROI	3	8	8	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	FEB	2009	27	2					237	239		10.1016/j.ajem.2008.09.043			3	Emergency Medicine	Emergency Medicine	416DN	WOS:000263985600018	19371535				2020-06-30	J	Fujii, K; Iranami, H; Nakamura, Y; Hatano, Y				Fujii, Keisuke; Iranami, Hiroshi; Nakamura, Yoshihide; Hatano, Yoshio			Fentanyl Added to Propofol Anesthesia Elongates Sinus Node Recovery Time in Pediatric Patients with Paroxysmal Supraventricular Tachycardia	ANESTHESIA AND ANALGESIA			English	Article							HEART-RATE-VARIABILITY; RADIOFREQUENCY CATHETER ABLATION; ACCESSORY PATHWAY CONDUCTION; CHRONIC ATRIAL-FIBRILLATION; PARKINSON-WHITE-SYNDROME; SINOATRIAL NODE; CARDIAC CONDUCTION; AUTONOMIC BLOCKADE; CHILDREN; INDUCTION	BACKGROUND: In some types of pediatric supraventricular tachycardia, reentrant mechanisms are sensitive to enhanced vagal tone. Propofol is a feasible anesthetic for pediatric electrophysiological study and radiofrequency catheter ablation. Although fentanyl and propofol infusions both enhance cardiac vagal tone, it is unclear whether the combination of propofol and fentanyl has a potential to enhance it. In this study, we evaluated the hypothesis that fentanyl combined with propofol could alter cardiac electrophysiological activities in pediatric patients undergoing electrophysiological study and radiofrequency catheter ablation. METHODS: Twenty-seven pediatric patients (9 Wolff-Parkinson-White syndrome, 7 concealed accessory pathway and 11 atrioventricular nodal reentry tachycardia) were enrolled in this study. Anesthesia was induced with propofol 2.0 mg/kg and was maintained with a continuous infusion of propofol at a rate of 100-167 mu g . kg(-1) . min(-1). During a stable anesthetic state, the calculated sinoatrial conduction time and corrected sinus node recovery time (CSNRT) were measured before and after fentanyl administration. The fentanyl dose consisted of an initial 2.0 mu g/kg IV bolus and subsequent continuous infusion of 0.075 . mu g . kg(-1) . min(-1). RESULTS: Bispectral Index scores and systemic blood pressure remained unchanged throughout the examinations. Fentanyl administration significantly prolonged CSNRT (P = 0.005) but not calculated sinoatrial conduction time (P = 0.35). CONCLUSION: Since an enhanced cardiac vagal tone is one of the causative factors for prolonged CSNRT, our findings greatly support the hypothesis that fentanyl combined with propofol has a potential to enhance cardiac vagal tone.	[Fujii, Keisuke; Iranami, Hiroshi] Japanese Red Cross Soc Wakayama Med Ctr, Dept Anesthesiol, Wakayama, Japan; [Iranami, Hiroshi; Hatano, Yoshio] Wakayama Med Univ, Dept Anesthesiol, Wakayama, Japan; [Nakamura, Yoshihide] Japanese Red Cross Soc Wakayama Med Ctr, Dept Pediat Cardiol, Wakayama, Japan	Fujii, K (reprint author), 4-20 Komatsubara Dori, Wakayama 6408558, Japan.	fujiik@topaz.ocn.ne.jp					Brembilla-Perrot B, 2001, INT J CARDIOL, V78, P293, DOI 10.1016/S0167-5273(01)00392-8; CARLSON MD, 1992, CIRCULATION, V85, P1311, DOI 10.1161/01.CIR.85.4.1311; Chen YJ, 1998, J AM COLL CARDIOL, V32, P732, DOI 10.1016/S0735-1097(98)00305-2; Chiou CW, 2003, CIRCULATION, V107, P2583, DOI 10.1161/01.CIR.0000068339.04731.4D; DEBENEDITTIS G, 1994, INT J CLIN EXP HYP, V42, P140, DOI 10.1080/00207149408409347; DEMARNEFFE M, 1986, EUR HEART J, V7, P662, DOI 10.1093/oxfordjournals.eurheartj.a062120; DEUTSCHMAN CS, 1994, ANESTH ANALG, V79, P373; EHLERT FA, 1994, J CARDIOVASC ELECTR, V5, P485, DOI 10.1111/j.1540-8167.1994.tb01289.x; Elvan A, 1996, CIRCULATION, V94, P2953, DOI 10.1161/01.CIR.94.11.2953; Fattorini F, 2003, Minerva Anestesiol, V69, P673; Gaita F, 2004, J CARDIOVASC ELECTR, V15, P263, DOI 10.1046/j.1540-8167.2004.03426.x; GOMES JAC, 1982, CIRCULATION, V66, P864, DOI 10.1161/01.CIR.66.4.864; Hamer ME, 1995, PACE, V18, P2155, DOI 10.1111/j.1540-8159.1995.tb04641.x; HLUCHY J, 1991, INT J CARDIOL, V33, P357, DOI 10.1016/0167-5273(91)90064-V; Ikeno S, 1999, CAN J ANAESTH, V46, P148, DOI 10.1007/BF03012549; IWAI M, 1995, PAEDIATR ANAESTH, V5, P233; KERIN NZ, 1983, AM HEART J, V105, P215, DOI 10.1016/0002-8703(83)90516-1; KUGLER JD, 1979, AM J CARDIOL, V44, P1344, DOI 10.1016/0002-9149(79)90451-X; KUGLER JD, 1994, NEW ENGL J MED, V330, P1481, DOI 10.1056/NEJM199405263302103; KUMAGAI K, 1991, CIRCULATION, V84, P1662, DOI 10.1161/01.CIR.84.4.1662; Kurzidim K, 2005, J CARDIOVASC ELECTR, V16, P366, DOI 10.1046/j.1540-8167.2005.40571.x; LATSON TW, 1992, J CLIN ANESTH, V4, P265, DOI 10.1016/0952-8180(92)90127-M; LAVOIE J, 1995, ANESTHESIOLOGY, V82, P884, DOI 10.1097/00000542-199504000-00010; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Lee SJ, 2000, CARDIOLOGY, V94, P44, DOI 10.1159/000007045; Lowe MD, 2003, PACE, V26, P500, DOI 10.1046/j.1460-9592.2003.00081.x; Manios EG, 2001, J CARDIOVASC ELECTR, V12, P800, DOI 10.1046/j.1540-8167.2001.00800.x; NARULA OS, 1978, CIRCULATION, V58, P706, DOI 10.1161/01.CIR.58.4.706; NARULA OS, 1972, CIRCULATION, V45, P140, DOI 10.1161/01.CIR.45.1.140; Porter MJ, 2004, HEART RHYTHM, V1, P393, DOI 10.1016/j.hrthm.2004.05.007; PRYSTOWSKY EN, 1981, CIRC RES, V49, P511, DOI 10.1161/01.RES.49.2.511; Riznyk L, 2005, PHARMACOL REP, V57, P128; ROBINSON BJ, 1994, BRIT J ANAESTH, V73, P167, DOI 10.1093/bja/73.2.167; Sanders P, 2004, CIRCULATION, V109, P1514, DOI 10.1161/01.CIR.0000121734.47409.AA; Schaffer MS, 2000, PAEDIATR ANAESTH, V10, P155, DOI 10.1046/j.1460-9592.2000.00465.x; SHARPE MD, 1995, ANESTHESIOLOGY, V82, P888, DOI 10.1097/00000542-199504000-00011; Sharpe MD, 1999, ANESTHESIOLOGY, V90, P60, DOI 10.1097/00000542-199901000-00010; Tanel RE, 1997, J PEDIATR-US, V131, P878, DOI 10.1016/S0022-3476(97)70037-4; Tyndall A, 1997, Am J Crit Care, V6, P437; WAXMAN MB, 1980, AM J CARDIOL, V46, P655, DOI 10.1016/0002-9149(80)90517-2; Win NN, 2005, ANESTH ANALG, V101, P97, DOI 10.1213/01.ANE.0000156204.89879.5C; YABEK SM, 1982, AM HEART J, V104, P612, DOI 10.1016/0002-8703(82)90235-6; Yu WC, 1996, AM J CARDIOL, V78, P1299	43	9	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2009	108	2					456	460		10.1213/ane.0b013e31819002d4			5	Anesthesiology	Anesthesiology	396KG	WOS:000262590000012	19151272				2020-06-30	J	Awab, A; Alilou, M; El Moussaoui, R; El Hijri, A; Azzouzi, A				Awab, A.; Alilou, M.; El Moussaoui, R.; El Hijri, A.; Azzouzi, A.			Rhabdomyolysis in severe acute asthma	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Letter						Rhabdomyolysis; Severe acute asthma			[Awab, A.; Alilou, M.; El Moussaoui, R.; El Hijri, A.; Azzouzi, A.] Hop Ibn Sina, Serv Reanimat Chirurg, Rabat 10000, Morocco	Azzouzi, A (reprint author), Hop Ibn Sina, Serv Reanimat Chirurg, Rabat 10000, Morocco.	azzouzi59@yahoo.fr					Bando T, 1996, RESPIRATION, V63, P309; BARRETT SA, 1993, CRIT CARE MED, V21, P151, DOI 10.1097/00003246-199301000-00026; CHUGH KS, 1978, CHEST, V73, P879, DOI 10.1378/chest.73.6.879; CLAVELOU P, 1993, ANN FR ANESTH, V12, P326, DOI 10.1016/S0750-7658(05)80661-6; Goh A Y, 1999, Respirology, V4, P97, DOI 10.1046/j.1440-1843.1999.00158.x	5	1	1	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	FEB	2009	28	2					171	172		10.1016/j.annfar.2008.11.017			2	Anesthesiology	Anesthesiology	422IG	WOS:000264420300011	19157772				2020-06-30	J	Richebe, P; Rivalan, B; Rivat, C; Laulin, JP; Janvier, G; Maurette, P; Simonnet, G				Richebe, Philippe; Rivalan, Bertrand; Rivat, Cyril; Laulin, Jean-Paul; Janvier, Gerard; Maurette, Pierre; Simonnet, Guy			Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							OPIOID-INDUCED HYPERALGESIA; LONG-LASTING HYPERALGESIA; SMALL-DOSE KETAMINE; POSTOPERATIVE PAIN; VOLATILE ANESTHETICS; MORPHINE-TOLERANCE; HALOTHANE; REMIFENTANIL; ISOFLURANE; REQUIREMENTS	Opioids are widely used for anesthesia but paradoxically induce postoperative pain hypersensitivity via N-methyl-d-aspartate (NMDA) receptor modulation. Sevoflurane effects on opioid-induced hyperalgesia have not been yet evaluated in vivo. Nevertheless, some experimental in vitro studies reported anti-NMDA receptor properties for sevoflurane. The aim of this study was to evaluate sevoflurane effects on fentanyl-induced hyperalgesia in opioid-naive rats and in rats with inflammatory pain. Sevoflurane effects on hyperalgesia were evaluated in Sprague-Dawley rats: opioid-naive rats, rats treated with fentanyl (4 x 60 mu g kg(-1)) and rats with inflammatory pain (carrageenan) treated with fentanyl (4 x 60 mu g kg(-1)). On day zero, subcutaneous fentanyl injections were administered and inflammatory pain was induced with one carrageenan injection in one hind paw. Rats were exposed to low concentrations of sevoflurane (1.0 or 1.5%) on day zero prior to fentanyl injections and inflammatory pain induction, and for the duration of the fentanyl analgesic effect. The nociceptive threshold (Randall-Selitto test) was evaluated daily for 7 days. On day seven, naloxone was injected and the nociceptive threshold was assessed 5 min later. In rats without inflammatory pain but treated with fentanyl on day zero, sevoflurane 1.0% reversed the early (day zero) and long-lasting (day zero to day three) hyperalgesia classically described after high-doses of fentanyl (P < 0.05). This sevoflurane concentration antagonized the hyperalgesia induced by naloxone on day seven (P = 0.33). In a second experiment in rats with inflammatory pain, exposure to low concentrations of sevoflurane (1.0 and 1.5%) did not reduce fentanyl-induced hyperalgesia (P > 0.05), but nevertheless antagonized the naloxone induced hyperalgesia on day seven (P = 0.061). Relatively low sevoflurane concentrations (1.0%) reverse fentanyl-induced hyperalgesia in rats without inflammatory pain. Nevertheless, the lack of effect of sevoflurane concentrations of 1.0% and 1.5% to oppose hyperalgesia following high-dose fentanyl and inflammatory pain suggests that sevoflurane anti-hyperalgesic properties are weak.	[Richebe, Philippe; Rivat, Cyril; Laulin, Jean-Paul; Simonnet, Guy] Univ Bordeaux 1, Univ Bordeaux 2, CNRS,UMR 5227, Lab Homeostasie Allostasie Pathol Rehabiltat, F-33076 Bordeaux, France; [Richebe, Philippe; Janvier, Gerard] Univ Hosp Bordeaux, Dept Anesthesia & Intens Care 2, Bordeaux, France; [Rivalan, Bertrand; Maurette, Pierre] Univ Hosp Bordeaux, Dept Anesthesia & Intens Care 3, Bordeaux, France	Richebe, P (reprint author), Univ Bordeaux 1, Univ Bordeaux 2, CNRS,UMR 5227, Lab Homeostasie Allostasie Pathol Rehabiltat, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	philippe.richebe@u-bordeaux2.fr	RIVAT, Cyril/B-5697-2008; Rivat, Cyril/F-8482-2019	Rivat, Cyril/0000-0002-7491-6113	Universite Victor Segalen Bordeaux 2, Bordeaux, France; Ministere de l'Education nationale, de l'Enseignement superieur et de la Recherche, Paris, France; Conseil Regional d' Aquitaine, Bordeaux, FranceRegion Nouvelle-Aquitaine	This work was supported by the Universite Victor Segalen Bordeaux 2, Bordeaux, France, the Ministere de l'Education nationale, de l'Enseignement superieur et de la Recherche, Paris, France, the Conseil Regional d' Aquitaine, Bordeaux, France.	Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Cesare P, 1997, CURR OPIN NEUROBIOL, V7, P493, DOI 10.1016/S0959-4388(97)80028-1; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Cuellar JM, 2005, BRIT J ANAESTH, V94, P617, DOI 10.1093/bja/aei107; Dahl JB, 2004, ACTA ANAESTH SCAND, V48, P1130, DOI 10.1111/j.1399-6576.2004.00484.x; Dahl JB, 2004, BRIT MED BULL, V71, P13, DOI 10.1093/bmb/ldh030; Drasner K, 2001, ANESTHESIOLOGY, V94, P298, DOI 10.1097/00000542-200102000-00020; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; Hollmann MW, 2001, ANESTH ANALG, V92, P1182; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; Katz J, 1996, CLIN J PAIN, V12, P50, DOI 10.1097/00002508-199603000-00009; Kawamata M, 2005, ANESTHESIOLOGY, V102, P165, DOI 10.1097/00000542-200501000-00025; KAYSER V, 1990, BRAIN RES, V508, P329, DOI 10.1016/0006-8993(90)90418-B; Kingery WS, 2002, ANESTHESIOLOGY, V96, P367, DOI 10.1097/00000542-200202000-00023; KISSIN I, 1984, ANESTHESIOLOGY, V61, P671, DOI 10.1097/00000542-198412000-00008; Kissin I, 2000, ANESTH ANALG, V91, P110, DOI 10.1097/00000539-200007000-00021; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; MARTIN DC, 1995, BIOCHEM PHARMACOL, V49, P809, DOI 10.1016/0006-2952(94)00519-R; Matute E, 2003, NEUROPHARMACOLOGY, V44, P811, DOI 10.1016/S0028-3908(03)00055-8; Nishikawa K, 2000, ANESTHESIOLOGY, V92, P228, DOI 10.1097/00000542-200001000-00035; Richebe P, 2005, ANESTHESIOLOGY, V103, P845, DOI 10.1097/00000542-200510000-00024; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Tasmuth T, 1996, PAIN, V68, P343, DOI 10.1016/S0304-3959(96)03219-8; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; You HJ, 2005, EUR J NEUROSCI, V22, P354, DOI 10.1111/j.1460-9568.2005.04234.x; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044	38	13	13	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	FEB	2009	56	2					126	135		10.1007/s12630-008-9023-4			10	Anesthesiology	Anesthesiology	409AH	WOS:000263478100006	19247760	Bronze			2020-06-30	J	Wilson, LC; Chen, BA; Creinin, MD				Wilson, Leah C.; Chen, Beatrice A.; Creinin, Mitchell D.			Low-dose fentanyl and midazolam in outpatient surgical abortion up to 18 weeks of gestation	CONTRACEPTION			English	Article						Abortion; Sedation; Fentanyl; Midazolam; Aspiration	CONSCIOUS SEDATION; INTRAVENOUS SEDATION; LOCAL-ANESTHESIA; DOUBLE-BLIND; GUIDELINES; ANALGESIA; PAIN	Background: We investigated the safety of a conscious sedation protocol using intravenous fentanyl and midazolam by direct venous injection in women who underwent outpatient surgical abortion up to 18 weeks of gestation. Study Design: This retrospective cohort study evaluated 1433 abortion procedures performed on women who received intravenous conscious sedation between April 1, 200 1, and December 31, 2006. Women were allowed oral intake before the procedure. De-identified data were abstracted from charts using a standardized extraction form. Primary outcomes evaluated were need for reversal agents, need to obtain emergency intravenous access, pulmonary aspiration, need for oxygen supplementation and hospitalization for any reason. Results: Of the 1433 procedures, 410 women received sedation with continuous intravenous access, and 1023 women received sedation by direct venous injection. More than 95% of women received fentanyl 100 mcg combined with 1-2 mg of midazolam. We identified four (0.3%) instances of adverse events, none of which occurred as a result of oversedation. No women experienced oral content aspiration. Conclusions: Intravenous conscious sedation with fentanyl and midazolam is safe for outpatient surgical abortion in women Without cardiovascular compromise up to 18 weeks of gestation. The risk of aspiration or oversedation requiring reversal agents is rare and does not warrant universal direct venous access or restriction of oral intake. (C) 2009 Elsevier Inc. All rights reserved.	[Wilson, Leah C.; Chen, Beatrice A.; Creinin, Mitchell D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; [Creinin, Mitchell D.] Magee Womens Res Inst, Pittsburgh, PA 15213 USA; [Creinin, Mitchell D.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA	Creinin, MD (reprint author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Magee Womens Hosp, Pittsburgh, PA 15213 USA.	mcreinin@upmc.edu	Creinin, Mitchell/AAH-3488-2020	Creinin, Mitchell/0000-0001-5967-8180			Allen RH, 2006, CONTRACEPTION, V74, P407, DOI 10.1016/j.contraception.2006.06.002; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Dionne RA, 2001, J AM DENT ASSOC, V132, P740, DOI 10.14219/jada.archive.2001.0271; Finer LB, 2003, PERSPECT SEX REPRO H, V35, P6, DOI 10.1111/j.1931-2393.2003.tb00079.x; Green SM, 2007, ANN EMERG MED, V49, P454, DOI 10.1016/j.annemergmed.2006.08.017; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Lichtenberg ES, 2001, CONTRACEPTION, V64, P345, DOI 10.1016/S0010-7824(01)00279-7; Miller L, 1996, OBSTET GYNECOL, V87, P600, DOI 10.1016/0029-7844(95)00463-7; Sakai T, 2006, ANESTH ANALG, V103, P941, DOI 10.1213/01.ane.0000237296.57941.e7; Sedgh G, 2007, INT FAM PLAN PERSPEC, V33, P106, DOI 10.1363/3310607; Trout SW, 1998, FERTIL STERIL, V69, P799, DOI 10.1016/S0015-0282(98)00031-4; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Wong CYG, 2002, HUM REPROD, V17, P1222, DOI 10.1093/humrep/17.5.1222; Zullo F, 2000, FERTIL STERIL, V74, P376, DOI 10.1016/S0015-0282(00)00611-7	14	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0010-7824	1879-0518		CONTRACEPTION	Contraception	FEB	2009	79	2					122	128		10.1016/j.contraception.2008.08.005			7	Obstetrics & Gynecology	Obstetrics & Gynecology	397UN	WOS:000262687700008	19135569	Green Published			2020-06-30	J	Bonnet, F; Eberhart, L; Wennberg, E; Dodds, SJ; Van Bellinghen, L; Annemans, L; Kavanagh, S; Choe, Y				Bonnet, F.; Eberhart, L.; Wennberg, E.; Dodds, S. J.; Van Bellinghen, L.; Annemans, L.; Kavanagh, S.; Choe, Y.			Fentanyl HCl iontophoretic transdermal system versus morphine IV-PCA for postoperative pain management: survey of healthcare provider opinion	CURRENT MEDICAL RESEARCH AND OPINION			English	Article; Proceedings Paper	5th Congress of the European Federation Chapter of the International-Association-for-the-Study-of-Pain	SEP 13-16, 2006	Istanbul, TURKEY	Int Assoc Study Pain, European Federat Chapter		Delphi panel; Fentanyl ITS; IV-PCA; Postoperative pain; Staff time estimation	PATIENT-CONTROLLED ANALGESIA; DELIVERY-SYSTEM; SURGERY; SAFETY; EFFICACY; OUTCOMES; NURSES	Objective: This survey estimated differences in staff time requirements between fentanyl HCl iontophoretic transdermal system (fentanyl ITS) and intravenous patient-controlled analgesia (IV-PCA) in post-operative pain management. Research design and methods: European Delphi panels of nurses and anaesthesiologists, who had practical experience with both fentanyl ITS and IV-PCA, were provided a task list, developed from a previous clinical trial, associated with each modality. The panellists were asked to estimate time spent on each task. Estimates were calculated by multiplying the estimated patient proportion for whom the task was performed by the expected frequency of task performance, by the estimated task time. Results: Data is presented as mean minutes (standard deviation). Fentanyl ITS use was estimated to save an average of 68.7 min total staff time per patient per treatment period compared to IV-PCA 86.5 (20.3)) vs. 156.4 (55.2); respectively; p<0.001), the largest amount of savings being in the 'Setup' category (19.4 (6.7) vs. 47.8 (17.5), respectively; p<0.001), and mostly due to IV-PCA task elimination. Significant time savings were estimated using fentanyl ITS over IV- PCA in the 'Discontinuation' category (4.8 (2.4) vs. 20.6 (3.3), respectively; p<0.001). Panellists agreed that fentanyl ITS use would decrease staff assistance time required for helping patients during self- care routines and it may also decrease the patient's time to ambulation. Survey limitations included: possible recall bias due to the observational nature of the data; task list descriptions resulting in possible double-counting of data; no sensitivity analyses; and the declarative nature of the responses possibly leading to a dilution of survey findings. Conclusions: Fentanyl ITS use was estimated, by expert opinion, to require 44% less staff time than IV-PCA use.	[Bonnet, F.] Univ Paris 06, Hop Tenon, Serv Anesthesie Reanimat, F-75970 Paris 20, France; [Eberhart, L.] Univ Marburg, Marburg, Germany; [Wennberg, E.] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Dodds, S. J.] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Van Bellinghen, L.] IMS Hlth, Brussels, Belgium; [Annemans, L.] Univ Ghent, B-9000 Ghent, Belgium; [Annemans, L.] Univ Brussels, Ghent, Belgium; [Kavanagh, S.] Janssen Pharmaceut NV, Beerse, Belgium; [Choe, Y.] Johnson & Johnson Pharmaceut Serv LLC, Raritan, NJ USA	Bonnet, F (reprint author), Univ Paris 06, Hop Tenon, Serv Anesthesie Reanimat, 4 Rue Chine, F-75970 Paris 20, France.	francis.bonnet@tnn.aphp.fr					Aiken LH, 2001, HEALTH AFFAIR, V20, P43, DOI 10.1377/hlthaff.20.3.43; Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; Asch Steven M, 2005, BMC Cardiovasc Disord, V5, P1, DOI 10.1186/1471-2261-5-1; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; *CTR EV BAS MED, 2001, [No title captured]; Dalkey NC, 1969, DELPHI METHOD EXPT S; Evans C, 2007, PAIN MANAG NURS, V8, P86, DOI 10.1016/j.pmn.2007.03.004; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Guevara Edilma B., 2002, Rev Panam Salud Publica, V12, P347, DOI 10.1590/S1020-49892002001100009; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; *HENR J KAIS FAM F, 1999, SURV PHYS NURS; Iavicoli S, 2005, OCCUP ENVIRON MED, V62, P71, DOI 10.1136/oem.2004.015487; Koo PJS, 2005, AM J HEALTH-SYST PH, V62, P1171, DOI 10.1093/ajhp/62.11.1171; Lankshear AJ, 2005, ADV NURS SCI, V28, P163, DOI 10.1097/00012272-200504000-00008; Linstone H.A., 1975, DELPHI METHOD TECHNI; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Mordin Margaret, 2007, J Perianesth Nurs, V22, P243, DOI 10.1016/j.jopan.2007.05.007; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; PESTANO C, 2006, ANN C NAT ASS ORTH N; PHILLIPS S, 2005, ANN FALL PAIN M WORK; Quintana JM, 2006, BMC HEALTH SERV RES, V6, DOI [10.1186/1471-213X-6-24, 10.1186/1472-6963-6-24]; Rogers AE, 2004, HEALTH AFFAIR, V23, P202, DOI 10.1377/hlthaff.23.4.202; Sheward Louisa, 2005, J Nurs Manag, V13, P51, DOI 10.1111/j.1365-2834.2004.00460.x; Strassels SA, 2005, AM J HEALTH-SYST PH, V62, P1904, DOI 10.2146/ajhp040490.p1; van der Linde H, 2005, J REHABIL RES DEV, V42, P693, DOI 10.1682/JRRD.2003.11.0172; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Wagenaar Deborah, 2003, Journal of the American Osteopathic Association, V103, P465; YARMUSH J, 2005, ANN FALL PAIN M WORK	30	10	11	0	4	LIBRAPHARM/INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	FEB	2009	25	2					293	301		10.1185/03007990802631321			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	412JJ	WOS:000263720800002	19192974				2020-06-30	J	Sathyan, G; Phipps, B; Gupta, SK				Sathyan, Gayatri; Phipps, Brad; Gupta, Suneel K.			Passive absorption of fentanyl from the fentanyl HCl iontophoretic transdermal system	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Fentanyl ITS; Passive absorption; Transdermal	PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PHARMACOKINETICS; MORPHINE; MANAGEMENT; SURGERY	Background: The fentanyl HCl iontophoretic transdermal system (ITS) is a patient-controlled analgesic delivery system that actively administers bolus doses of fentanyl transdermally upon patient activation. Objective: To determine the amount of fentanyl absorbed from fentanyl ITS via passive absorption over a 24.5-h period. Methods: Serial blood samples for pharmacokinetic analyses were obtained from healthy adults who received fentanyl ITS for 24 h. Findings: The average absorption rate was 2.3 mu g/h. An average total of 57.4 mg fentanyl was absorbed during the study. The mean maximum observed serum fentanyl concentration was 0.06 ng/mL. Conclusions: Results indicate that the average amount of fentanyl absorbed passively or via passive delivery from fentanyl ITS is minimal. Maximum serum fentanyl concentrations fell below the range associated with analgesia and respiratory depression. The variability in fentanyl exposure was likely exaggerated by the low amounts of drug absorption resulting in overall fairly low fentanyl concentrations.	[Sathyan, Gayatri; Phipps, Brad; Gupta, Suneel K.] ALZA Corp, Mountain View, CA USA	Phipps, B (reprint author), 1900 Charleston Rd, Mountain View, CA 94043 USA.	BPHIPPS@its.jnj.com					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ANDERSON LS, 2002, AAPS PHARMSCI, V4; CUTLER DJ, 1978, J PHARMACOKINET BIOP, V6, P265, DOI 10.1007/BF01312266; GILLESPIE WR, 1991, PCDCON MANUAL DECONV; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 1998, J PHARM SCI, V87, P976, DOI 10.1021/js970437d; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; *ORTH MCNEIL JANSS, 2008, DURAGESIC FENT TRANS; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; VENGPEDERSEN P, 1988, J PHARMACOKINET BIOP, V16, P413, DOI 10.1007/BF01062554; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	16	5	5	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	FEB	2009	25	2					363	366		10.1185/03007990802594941			4	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	412JJ	WOS:000263720800008	19192980				2020-06-30	J	Rivat, C; Vera-Portocarrero, LP; Ibrahim, MM; Mata, HP; Stagg, NJ; Felice, M; Porreca, F; Malan, TP				Rivat, Cyril; Vera-Portocarrero, Louis P.; Ibrahim, Mohab M.; Mata, Heriberto P.; Stagg, Nicola J.; De Felice, Milena; Porreca, Frank; Malan, T. P.			Spinal NK-1 receptor-expressing neurons and descending pathways support fentanyl-induced pain hypersensitivity in a rat model of postoperative pain	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						dynorphin; neurokinin-1 receptors; opioid; pain hypersensitivity; rostral ventromedial medulla	OPIOID-INDUCED HYPERALGESIA; ROSTRAL VENTROMEDIAL MEDULLA; SUBSTANCE-P RECEPTOR; LONG-LASTING HYPERALGESIA; AMINO-ACID RECEPTORS; SMALL-DOSE KETAMINE; NEUROPATHIC PAIN; ANTINOCICEPTIVE TOLERANCE; CUTANEOUS HYPERALGESIA; MORPHINE-TOLERANCE	The clinically important opioid fentanyl, administered acutely, enhances mechanical hypersensitivity in a model of surgical pain induced by plantar incision. Activity of neurokinin-1 (NK-1) receptor-expressing ascending spinal neurons, descending pathways originating in the rostral ventromedial medulla (RVM), and spinal dynorphin are necessary for the development and maintenance of hyperalgesia during sustained morphine exposure, suggesting that these mechanisms may also be important in opioid enhancement of surgical pain. Therefore, we examined the roles of these mechanisms in sensory hypersensitivity produced by acute fentanyl administration in rats not undergoing surgical incision and in rats undergoing plantar incision. In non-operated rats, fentanyl induced analgesia followed by immediate and long-lasting sensory hypersensitivity, as previously described. Fentanyl also enhanced pain sensitivity induced by plantar incision. Ablation of NK-1-expressing spinal neurons by pre-treatment with substance P-Saporin reduced sensory hypersensitivity in fentanyl-treated rats and, to a lesser extent, in fentanyl-treated rats with a surgical incision. Microinjection of lidocaine into the RVM completely reversed fentanyl-induced sensory hypersensitivity and fentanyl enhancement of incision-induced sensory hypersensitivity. RVM lidocaine injection resulted in a slight reduction of incision-induced sensory hypersensitivity in the absence of fentanyl pre-treatment. Spinal dynorphin content increased by 30 +/- 7% and 66 +/- 17% in fentanyl- and fentanyl/incision-treated rats. Spinal administration of antiserum to dynorphin attenuated sensory hypersensitivity in fentanyl-treated rats. These data support a partial role of NK-1 receptor-containing ascending pathways and a crucial role of descending facilitatory pathways in fentanyl-induced hyperalgesia and in the enhanced hyperalgesia produced by fentanyl treatment following surgical incision.	[Rivat, Cyril; Ibrahim, Mohab M.; Mata, Heriberto P.; Porreca, Frank; Malan, T. P.] Univ Arizona, Coll Med, Dept Anesthesiol, Tucson, AZ USA; [Vera-Portocarrero, Louis P.; Stagg, Nicola J.; De Felice, Milena; Porreca, Frank; Malan, T. P.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA; [Stagg, Nicola J.] Univ Arizona, Coll Med, IDP Pharmacol & Toxicol, Tucson, AZ 85724 USA	Rivat, C (reprint author), Univ Paris 06, INSERM, U713, 91 Blvd Hop, F-75013 Paris, France.	cyril.rivat@upmc.fr	RIVAT, Cyril/B-5697-2008; Rivat, Cyril/F-8482-2019	Rivat, Cyril/0000-0002-7491-6113	Department of Anesthesiology and Pharmacology of University of Arizon	This work was supported by the Department of Anesthesiology and Pharmacology of University of Arizona.	Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Burgess SE, 2002, J NEUROSCI, V22, P5129, DOI 10.1523/JNEUROSCI.22-12-05129.2002; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chizh BA, 2007, J PSYCHOPHARMACOL, V21, P259, DOI 10.1177/0269881105062484; ERICSON AC, 1995, EUR J NEUROSCI, V7, P305, DOI 10.1111/j.1460-9568.1995.tb01066.x; Fields H., 1999, TXB PAIN, P309; FIELDS HL, 1978, ANNU REV PHYSIOL, V40, P217, DOI 10.1146/annurev.ph.40.030178.001245; Gardell LR, 2004, NEUROSCIENCE, V123, P43, DOI 10.1016/j.neuroscience.2003.08.021; Gardell LR, 2002, J NEUROSCI, V22, P6747; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; HARDY JD, 1950, J CLIN INVEST, V29, P115, DOI 10.1172/JCI102227; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Jones CK, 2006, J PHARMACOL EXP THER, V319, P396, DOI 10.1124/jpet.106.105601; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Khasabov SG, 2002, J NEUROSCI, V22, P9086; King T, 2005, PAIN, V116, P276, DOI 10.1016/j.pain.2005.04.014; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; LAKKE EAJ, 1997, [No title captured], V135, P1, DOI DOI 10.1007/978-3-642-60601-4; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; Liang DY, 2006, ANESTHESIOLOGY, V104, P1054, DOI 10.1097/00000542-200605000-00023; Ma W, 2003, NEUROSCIENCE, V121, P681, DOI 10.1016/S0306-4522(03)00497-4; Malan TP, 2000, PAIN, V86, P185, DOI 10.1016/S0304-3959(00)00243-8; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MAO J, 1994, J NEUROSCI, V14, P2301; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Nichols ML, 1999, SCIENCE, V286, P1558, DOI 10.1126/science.286.5444.1558; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Ossipov MH, 2003, LIFE SCI, V73, P783, DOI 10.1016/S0024-3205(03)00410-7; Paxinos G. T., 1986, RAT BRAIN STEREOTAXI; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Ren K, 2002, PAIN, V100, P1, DOI 10.1016/S0304-3959(02)00368-8; Ren K, 1996, J NEUROPHYSIOL, V76, P3025; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Rivat C, 2007, NEUROPSYCHOPHARMACOL, V32, P2217, DOI 10.1038/sj.npp.1301340; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Simons CT, 2002, BRAIN RES, V945, P139, DOI 10.1016/S0006-8993(02)02913-X; Suzuki R, 2002, NAT NEUROSCI, V5, P1319, DOI 10.1038/nn966; Suzuki R, 2005, PAIN, V117, P292, DOI 10.1016/j.pain.2005.06.015; Tan-No K, 2005, PAIN, V113, P301, DOI 10.1016/j.pain.2004.11.004; Todd AJ, 2002, EXP PHYSIOL, V87, P245, DOI 10.1113/eph8702351; TOLLE TR, 1993, J NEUROSCI, V13, P5009; TREEDE RD, 1992, BRAIN, V115, P607, DOI 10.1093/brain/115.2.607; TREEDE RD, 1992, PROG NEUROBIOL, V38, P397, DOI 10.1016/0301-0082(92)90027-C; Urban MO, 1999, P NATL ACAD SCI USA, V96, P7687, DOI 10.1073/pnas.96.14.7687; Urban MO, 1999, PAIN, V81, P45, DOI 10.1016/S0304-3959(98)00265-6; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20-18-07074.2000; Vera-Portocarrero LP, 2007, PAIN, V129, P35, DOI 10.1016/j.pain.2006.09.033; Wang ZJ, 2001, J NEUROSCI, V21, P1779; WATKINS LR, 1980, BRAIN RES, V181, P1, DOI 10.1016/0006-8993(80)91255-X; Wu CR, 2007, ANESTHESIOLOGY, V107, P128, DOI 10.1097/01.anes.0000267512.08619.bd; YAKSH TL, 1976, SCIENCE, V192, P1357, DOI 10.1126/science.1273597; Yamamoto T, 1999, ANESTH ANALG, V89, P1203, DOI 10.1213/00000539-199911000-00022; Zhang RX, 2004, NEUROSCI LETT, V359, P85, DOI 10.1016/j.neulet.2004.02.014; Zhu XY, 2006, PAIN, V125, P43, DOI 10.1016/j.pain.2006.04.027	64	39	39	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2009	29	4					727	737		10.1111/j.1460-9568.2009.06616.x			11	Neurosciences	Neurosciences & Neurology	408RF	WOS:000263451700007	19200067				2020-06-30	J	Hirvonen, J; Aalto, S; Hagelberg, N; Maksimow, A; Ingman, K; Oikonen, V; Virkkala, J; Nagren, K; Scheinin, H				Hirvonen, Jussi; Aalto, Sargo; Hagelberg, Nora; Maksimow, Anu; Ingman, Kimmo; Oikonen, Vesa; Virkkala, Jussi; Nagren, Kjell; Scheinin, Harry			Measurement of central mu-opioid receptor binding in vivo with PET and [C-11] carfentanil: a test-retest study in healthy subjects	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING			English	Article						(11C)carfentanil; Mu opioid receptor; Positron emission tomography; Imaging	QUANTIFICATION; PARAMETERS; DERIVATION; MODELS; LIGAND	Purpose [C-11] Carfentanil has been widely used in positron emission tomography ( PET) studies for measuring mu-opioid receptor binding in humans, but the reproducibility of the binding parameter estimates is unknown. Materials and methods Eight healthy volunteers were scanned twice during the same day with [C-11] carfentanil PET, and binding to receptors was assessed with both reference tissue and arterial plasma input-based models using region of interest (ROI) and voxel-based quantification. Results The two-tissue compartmental model distribution volume (V-T) was highly reproducible as indicated by low variability (VAR<6%) and high intraclass correlation coefficients (ICC>0.93). BPND (BP relative to the nondisplaceable tissue compartment) was also highly reproducible (VAR<10%, ICC>0.90) both at ROI- and voxel-level, and reference tissue-based models provided stable estimates after 40 min. Conclusions The reproducibility of [C-11] carfentanil binding parameter estimates is excellent with outcome measures based on both arterial plasma and reference tissue input, and a scanning time of 40 min appears sufficient.	[Hirvonen, Jussi; Aalto, Sargo; Hagelberg, Nora; Maksimow, Anu; Oikonen, Vesa; Nagren, Kjell; Scheinin, Harry] Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland; [Hagelberg, Nora; Scheinin, Harry] Turku Univ, Cent Hosp, Dept Anaesthesiol Intens Care Emergency Care & Pa, Turku, Finland; [Ingman, Kimmo] Univ Turku, Dept Pharmacol Drug Dev & Therapeut, FIN-20520 Turku, Finland; [Virkkala, Jussi] Med Imaging Ctr, Dept Clin Neurophysiol, Tampere, Finland	Hirvonen, J (reprint author), Univ Turku, Turku PET Ctr, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	jueshi@utu.fi	Aalto, Sargo/K-1757-2013; Hirvonen, Jussi/AAC-1864-2020; Nagren, Kjell/AAE-7039-2019	Aalto, Sargo/0000-0002-8924-5447; Oikonen, Vesa/0000-0002-1947-0219; Scheinin, Harry/0000-0002-1171-3511			Contet C, 2004, CURR OPIN NEUROBIOL, V14, P370, DOI 10.1016/j.conb.2004.05.005; Dhawan BN, 1996, PHARMACOL REV, V48, P567; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; Hirvonen J, 2008, J CEREBR BLOOD F MET, V28, P1059, DOI 10.1038/sj.jcbfm.9600607; Ingman K, 2005, NEUROPSYCHOPHARMACOL, V30, P2245, DOI 10.1038/sj.npp.1300790; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Kemppainen NM, 2006, NEUROLOGY, V67, P1575, DOI 10.1212/01.wnl.0000240117.55680.0a; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Larsen P, 1997, APPL RADIAT ISOTOPES, V48, P153, DOI 10.1016/S0969-8043(96)00177-7; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Meyer JH, 1999, NEUROIMAGE, V9, P545, DOI 10.1006/nimg.1999.0431; Nagren K., 2003, Journal of Labelled Compounds and Radiopharmaceuticals, V46, pS76; Salmi E, 2008, ANESTH ANALG, V106, P129, DOI 10.1213/01.ane.0000287658.14763.13; Slifstein M, 2000, NUCL MED BIOL, V27, P487, DOI 10.1016/S0969-8051(00)00117-7; Slifstein M, 2001, NUCL MED BIOL, V28, P595, DOI 10.1016/S0969-8051(01)00214-1; Sprenger T, 2005, EUR J PAIN, V9, P117, DOI 10.1016/j.ejpain.2004.07.010; Zhou Y, 2002, NEUROIMAGE, V16, pS91; Zhou Y, 2004, NEUROIMAGE, V22, pT98; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	26	39	39	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1619-7070	1619-7089		EUR J NUCL MED MOL I	Eur. J. Nucl. Med. Mol. Imaging	FEB	2009	36	2					275	286		10.1007/s00259-008-0935-6			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	417TL	WOS:000264101300015	18779961				2020-06-30	J	Dayioglu, H; Baykara, ZN; Salbes, A; Solak, M; Toker, K				Dayioglu, Hueban; Baykara, Zehra N.; Salbes, Asena; Solak, Mine; Toker, Kamil			Effects of adding magnesium to bupivacaine and fentanyl for spinal anesthesia in knee arthroscopy	JOURNAL OF ANESTHESIA			English	Article						Anesthetic techniques; Intrathecal; Drugs; Magnesium sulfate; Bupivacaine; Fentanyl	GENERAL-ANESTHESIA; SULFATE; PAIN; ANALGESIA; BLOCK; RECOVERY; INJURY; CORD	Purpose. The aim of the study was to investigate the effects of adding intrathecal magnesium sulfate 50 mg to low-dose bupivacaine-fentanyl on the spread, duration, regression of spinal block, and postoperative analgesia in patients undergoing knee arthroscopy. Methods. This study was designed in a prospective, randomized, and double-blinded manner. Sixty American Society of Anesthesiologists (ASA) physical status I or II patients were randomly allocated to receive 50 mg magnesium sulfate (3 ml) or 3 ml of preservative-free 0.9% NaCl following 6 mg bupivacaine 0.5% plus 10 mu g fentanyl intrathecally. Date were collected regarding the highest level of dermatomal sensory blockade, the time to reach this level from the time of injection of the spinal anesthetic, Bromage scale of motor blockade at the time of reaching maximum sensory level, time for regression of two segments in the maximum block height, time to L-2 regression, time to ambulation, and postoperative analgesic consumption. Results. The addition of intrathecal magnesium (50 mg) to spinal anesthesia prolonged the time for regression of two segments in the maximum block height and time to L-2 regression, but did not affect maximum sensory level or the time to reach the highest level of sensory block. Even though the mean times to complete recovery of motor function were similar in the two groups, time to ambulation was significantly longer in the magnesium group than in the saline group. Total analgesic consumption in the first 24 h was not decreased significantly with the addition of magnesium to spinal anesthesia, but the time to first analgesic requirement was prolonged significantly. Conclusion. Even though the time to first analgesic requirement was prolonged significantly by magnesium, the addition of intrathecal magnesium sulfate to spinal anesthesia is not desirable in patients undergoing knee arthroscopy due to the prolonged time to ambulation and the lack of effect of magnesium on postoperative analgesic consumption.	[Dayioglu, Hueban; Baykara, Zehra N.; Salbes, Asena; Solak, Mine; Toker, Kamil] Kocaeli Univ, Fac Med, Dept Anesthesiol, Kocaeli, Turkey	Baykara, ZN (reprint author), Tubitak MAM Loj, 4A Gebze,POB 41470, Kocaeli, Turkey.						Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; BACIGALUPO G, 1990, J PERINAT MED, V18, P289, DOI 10.1515/jpme.1990.18.4.289; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Borghi B, 2003, J CLIN ANESTH, V15, P351, DOI 10.1016/S0952-8180(03)00078-3; BUGGY D, 1994, BRIT J ANAESTH, V73, P540, DOI 10.1093/bja/73.4.540; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Chanimov M, 1997, ANAESTHESIA, V52, P223, DOI 10.1111/j.1365-2044.1997.034-az0057.x; Fassoulaki A, 1999, ANESTH ANALG, V88, P398, DOI 10.1097/00000539-199902000-00033; Gurkan Y, 2004, ACTA ANAESTH SCAND, V48, P513, DOI 10.1111/j.1399-6576.2004.00353.x; Haubold HA, 1906, J AMER MED ASSOC, V46, P647; Imarengiaye CO, 2003, ANESTHESIOLOGY, V98, P511, DOI 10.1097/00000542-200302000-00033; Ishizaki K, 1999, ANAESTHESIA, V54, P241, DOI 10.1046/j.1365-2044.1999.00741.x; Jacobson E, 2000, ARTHROSCOPY, V16, P183, DOI 10.1016/S0749-8063(00)90034-3; Jankowski CJ, 2003, ANESTH ANALG, V97, P1003, DOI 10.1213/01.ANE.0000081798.89853.E7; Kawamata YT, 2003, ANESTH ANALG, V96, P881, DOI 10.1213/01.ANE.0000048825.491890.B3; Knoerl D V, 2001, J Perianesth Nurs, V16, P11, DOI 10.1016/S1089-9472(01)60701-9; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; LEJUSTE MJLR, 1985, S AFR MED J, V68, P367; Menigaux C, 2001, ANESTH ANALG, V93, P606, DOI 10.1097/00000539-200109000-00016; Mulroy MF, 2000, ANESTH ANALG, V91, P860, DOI 10.1097/00000539-200010000-00017; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; PARNASS SM, 1993, ARTHROSCOPY, V9, P91, DOI 10.1016/S0749-8063(05)80351-2; Pogatzki EM, 2000, ANESTHESIOLOGY, V93, P489, DOI 10.1097/00000542-200008000-00029; Pollock JE, 2003, ANESTH ANALG, V97, P397, DOI 10.1213/01.ANE.0000070226.10440.3A; Saeki H, 2004, ANESTH ANALG, V99, P1805, DOI 10.1213/01.ANE.0000138039.04548.3D; Shah J, 2000, BRIT J ANAESTH, V84, P399; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; Wong J, 2001, CAN J ANAESTH, V48, P369, DOI 10.1007/BF03014965; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Zahn PK, 1998, ANESTHESIOLOGY, V88, P143, DOI 10.1097/00000542-199801000-00022; Zahn PK, 1999, ANESTHESIOLOGY, V90, P863, DOI 10.1097/00000542-199903000-00030	34	24	25	0	1	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2009	23	1					19	25		10.1007/s00540-008-0677-4			7	Anesthesiology	Anesthesiology	441OU	WOS:000265779300004	19234817				2020-06-30	J	Oshima, M; Aoyama, K; Warabi, K; Akazawa, T; Inada, E				Oshima, Masayuki; Aoyama, Kazuyoshi; Warabi, Kengo; Akazawa, Toshimasa; Inada, Eiichi			Electrogastrography during and after cesarean delivery	JOURNAL OF ANESTHESIA			English	Article						Electrogastrography; Cesarean section	PREGNANCY; MOTILITY; ABSORPTION; AGONISTS; ANXIETY; TERM	Purpose. Although it has been generally believed that parturients have delayed gastric emptying during anesthesia, the most recent reports suggest that gastric emptying is not delayed during pregnancy except during labor. Electrical slow waves in the stomach determine the frequency and the peristaltic nature of gastric contractions. In this study we performed electrogastrography during and after elective cesarean section (CS) in an attempt to evaluate gastric motility. Methods. Sixteen American Society of Anesthesiologists physical status I or II term parturients undergoing elective CS were enrolled. Combined spinal-epidural anesthesia was initiated with 10 mg of bupivacaine plus 10 mu g of fentanyl. Four-channel electrogastrography was obtained for 10 min prior to venous catheter insertion (baseline), 10 min following spinal injection of bupivacaine and fentanyl (Sp-1), 10 to 20 min following spinal injection (Sp-2), 10 min prior to the end of operation (end), and finally 10 min on the seventh postoperative day (POD 7). Results. The mean +/- SD values for dominant frequency of electrogastrography (DF) were determined as: 1.57 +/- 0.36 cpm (baseline), 1.81 +/- 0.32 cpm (Sp-1), 2.08 +/- 0.36 cpm (Sp-2), 1.96 +/- 0.36 cpm (end), and 3.02 +/- 0.28 cpm (POD 7). The DF of Sp-1, Sp-2, and end were significantly higher than that of baseline (P < 0.05). The DF of POD 7 was significantly higher than that of baseline, Sp-1, Sp-2, and end (P < 0.01). Conclusion. Electrogastrography analysis suggests that the frequency of gastric contractions during CS was less than that in the postpartum period.	[Oshima, Masayuki; Aoyama, Kazuyoshi; Warabi, Kengo; Akazawa, Toshimasa; Inada, Eiichi] Juntendo Univ, Sch Med, Dept Anesthesiol & Pain Med, Bunkyo Ku, Tokyo 1138421, Japan	Oshima, M (reprint author), Juntendo Univ, Sch Med, Dept Anesthesiol & Pain Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.		OSHIMA, Masayuki/AAI-4280-2020	Aoyama, Kazuyoshi/0000-0002-7502-0896			Camilleri M, 1998, GASTROENTEROLOGY, V115, P747, DOI 10.1016/S0016-5085(98)70155-6; Chang FY, 2005, J GASTROEN HEPATOL, V20, P502, DOI 10.1111/j.1440-1746.2004.03751.x; Chiloiro M, 2001, J GASTROENTEROL, V36, P538, DOI 10.1007/s005350170056; IMPROTA G, 1994, NEUROPHARMACOLOGY, V33, P977, DOI 10.1016/0028-3908(94)90155-4; KELLY KA, 1992, GASTROENTEROLOGY, V103, P1967, DOI 10.1016/0016-5085(92)91457-F; Kelly MC, 1997, ANESTH ANALG, V85, P834, DOI 10.1097/00000539-199710000-00022; Lydon A, 1998, BRIT J ANAESTH, V81, P522, DOI 10.1093/bja/81.4.522; Lydon AM, 1999, CAN J ANAESTH, V46, P544, DOI 10.1007/BF03013544; MACFIE AG, 1991, BRIT J ANAESTH, V67, P54, DOI 10.1093/bja/67.1.54; MARSH RHK, 1984, BRIT J ANAESTH, V56, P161, DOI 10.1093/bja/56.2.161; NYGREN J, 1995, ANN SURG, V222, P728, DOI 10.1097/00000658-199512000-00006; OSULLIVAN GM, 1987, ANESTH ANALG, V66, P505; Parkman HP, 2003, NEUROGASTROENT MOTIL, V15, P89, DOI 10.1046/j.1365-2982.2003.00396.x; RUCKEBUSCH Y, 1984, LIFE SCI, V35, P1731, DOI 10.1016/0024-3205(84)90269-8; SANDHAR BK, 1992, ANAESTHESIA, V47, P196, DOI 10.1111/j.1365-2044.1992.tb02116.x; THOMPSON DG, 1983, GUT, V24, P277, DOI 10.1136/gut.24.4.277; Tsuchida D, 2004, BRAIN RES, V1024, P244, DOI 10.1016/j.brainres.2004.07.081; VANNER RG, 1989, ANAESTHESIA, V44, P808, DOI 10.1111/j.1365-2044.1989.tb09096.x; VOLANS GN, 1974, BRIT MED J, V4, P265, DOI 10.1136/bmj.4.5939.265; WHITEHEAD EM, 1993, ANAESTHESIA, V48, P53; Wong CA, 2002, ANESTHESIOLOGY, V96, P1395, DOI 10.1097/00000542-200206000-00019	21	5	5	0	2	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	FEB	2009	23	1					75	79		10.1007/s00540-008-0692-5			5	Anesthesiology	Anesthesiology	441OU	WOS:000265779300014	19234827				2020-06-30	J	Sato, H; Yamakage, M; Okuyama, K; Imai, Y; Iwashita, H; Masamune, T; Ishimaya, T; Matsukawa, T				Sato, Hiroaki; Yamakage, Michiaki; Okuyama, Katsumi; Imai, Yusuke; Iwashita, Hironobu; Masamune, Taishi; Ishimaya, Tadahiko; Matsukawa, Takashi			Intravenous famotidine does not always change core temperature during general anesthesia	JOURNAL OF ANESTHESIA			English	Article						Famotidine; Core temperature; Thermoregulation	HUMANS; ISOFLURANE; THRESHOLD	It has been reported that oral premedication with the H-2 receptor antagonist famotidine augmented intraoperative hypothermia. We again investigated whether the H-2 receptor antagonist famotidine significantly affected body temperature during open abdominal surgery under general anesthesia. We studied 20 female patients undergoing elective gynecological surgery. Participating patients were assigned randomly to one of two regimens: (1) 10 ml saline given intravenously just before induction of general anesthesia or (2) 20 mg famotidine in 10 ml saline given just before induction of general anesthesia. General anesthesia was induced by 2 mg.kg(-1) propofol and 0.1 mg.kg(-1) vecuronium. After tracheal intubation, anesthesia was maintained with sevoflurane (1%-2%) in nitrous oxide (2 l.min(-1)) and oxygen (1 l.min(-1)) along with 1-2 mu g.kg(-1) fentanyl as needed. Tympanic temperature (T-Tym) was measured as the core temperature, and arteriovenous perfusion of the fingertip was evaluated using the forearm-minus-fingertip skin-surface temperature gradient (Grad(a-f)). T-Tym gradually and significantly decreased in both groups during anesthesia, and no significant differences in these values were observed between the two groups. Grad(a-f) did not differ significantly between the two groups during anesthesia. We conclude that intravenous famotidine does not always change the core temperature during general anesthesia.	[Yamakage, Michiaki] Sapporo Med Univ, Dept Anesthesiol, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; [Sato, Hiroaki; Okuyama, Katsumi; Imai, Yusuke; Iwashita, Hironobu; Masamune, Taishi; Ishimaya, Tadahiko; Matsukawa, Takashi] Univ Yamanashi, Fac Med, Dept Anesthesiol, Chuo, Japan	Yamakage, M (reprint author), Sapporo Med Univ, Dept Anesthesiol, Sch Med, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.						BELANI K, 1993, ANESTHESIOLOGY, V78, P856, DOI 10.1097/00000542-199305000-00008; CLARK WG, 1976, J PHYSIOL-LONDON, V261, P235, DOI 10.1113/jphysiol.1976.sp011556; HIROSE M, 1995, ANESTHESIOLOGY, V83, P1179, DOI 10.1097/00000542-199512000-00008; Lin C S, 1995, Acta Anaesthesiol Sin, V33, P15; LOMAX P, 1981, FED PROC, V40, P2741; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; OZAKI M, 1995, ANESTH ANALG, V80, P1212, DOI 10.1097/00000539-199506000-00025; SESSLER DI, 1993, FASEB J, V7, P638; SESSLER DI, 1988, ANESTHESIOLOGY, V69, P357, DOI 10.1097/00000542-198809000-00012	9	0	0	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2009	23	1					151	153		10.1007/s00540-008-0673-8			3	Anesthesiology	Anesthesiology	441OU	WOS:000265779300031	19234844				2020-06-30	J	Olivecrona, M; Zetterlund, B; Rodling-Wahlstrom, M; Naredi, S; Koskinen, LOD				Olivecrona, Magnus; Zetterlund, Bo; Rodling-Wahlstrom, Marie; Naredi, Silvana; Koskinen, Lars-Owe D.			Absence of electroencephalographic seizure activity in patients treated for head injury with an intracranial pressure-targeted therapy	JOURNAL OF NEUROSURGERY			English	Article						continuous EEG; head injury; seizure	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; CONTINUOUS EEG; HEMORRHAGE; PRINCIPLES; EDEMA	Object. The authors prospectively studied the occurrence of clinical and nonclinical electroencephalographically verified seizures during treatment with an intracranial pressure (ICP)-targeted protocol in patients with traumatic brain injury (TBI). Methods. All patients treated for TBI at the Department of Neurosurgery, University Hospital Umea, Sweden, were eligible for the stud. The inclusion was consecutive and based on the availability of the electroencephalographic (EEG) monitoring equipment. Patients were included irrespective of pupil size, pupil reaction, or level of consciousness as long as their first measured cerebral perfusion pressure was > 10 mm Hg. The patients were treated in a protocol-guided manner with an ICP-targeted treatment based on the Lund concept. The patients were continuously sedated with midazolam, fentanyl, propofol, or thiopental, or combinations thereof. Five-lead continuous EEG monitoring was performed with the electrodes at F3, F4, P3, P4, and a midline reference. Sensitivity was set at 100 mu V per cm and filter settings 0.5-70 Hz. Amplitude-integrated EEG recording and relative band power trends were displayed. The trends were analyzed offline by trained clinical neurophysiologists. Results. Forty-seven patients (mean age 40 years) were studied. Their median Glasgow Coma Scale score at the time of sedation and intubation was 6 (range 3-15). In 8.5% of the patients clinical seizures were observed before sedation and intubation. Continuous EEG monitoring was performed for a total of 7334 hours. During this time neither EEG nor clinical seizures were observed. Conclusions. Our protocol-guided ICP targeted treatment seems to protect patients with severe TBI from clinical and subclinical seizures and thus reduces the risk of secondary brain injury. (DOI: 10.3171/2008.4.17538)	[Olivecrona, Magnus; Koskinen, Lars-Owe D.] Univ Hosp, Dept Neurosurg, SE-90185 Umea, Sweden; [Zetterlund, Bo] Univ Hosp, Dept Clin Neurophysiol, SE-90185 Umea, Sweden; [Rodling-Wahlstrom, Marie; Naredi, Silvana] Univ Hosp, Dept Anaesthesiol, SE-90185 Umea, Sweden	Olivecrona, M (reprint author), Univ Hosp, Dept Neurosurg, SE-90185 Umea, Sweden.	magnus.olivecrona@vll.se		Koskinen, Lars-Owe/0000-0003-3528-8502; Naredi, Silvana/0000-0002-4409-6089	Department of Neurosciences at Umea University; Umea University Hospital General Foundation; Capio Research Foundation; Tore Nilssons Foundation	This study was supported by grants from the Department of Neurosciences at Umea University, Umea University Hospital General Foundation, Capio Research Foundation, and Tore Nilssons Foundation.	ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen Jan, 2002, Curr Neurol Neurosci Rep, V2, P534, DOI 10.1007/s11910-002-0042-1; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kollevold T, 1976, J Oslo City Hosp, V26, P99; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; LOWENSTEIN DH, 1992, NEUROLOGY, V42, P100, DOI 10.1212/WNL.42.1.100; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Privitera Michael D., 1994, Emergency Medicine Clinics of North America, V12, P1089; Procaccio F, 2001, Curr Opin Crit Care, V7, P74, DOI 10.1097/00075198-200104000-00004; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Scheuer ML, 2002, EPILEPSIA, V43, P114, DOI 10.1046/j.1528-1157.43.s.3.7.x; Spencer E M, 1990, Intensive Care World, V7, P34; SYNEK VM, 1988, CLIN ELECTROENCEPHAL, V19, P160, DOI 10.1177/155005948801900310; Theilen HJ, 2000, CRIT CARE MED, V28, P3522, DOI 10.1097/00003246-200010000-00029; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Young GB, 1996, NEUROLOGY, V47, P83	39	23	24	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2009	110	2					300	305		10.3171/2008.4.17538			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	399GI	WOS:000262788000015	18759609				2020-06-30	J	Steward, DJ				Steward, David J.			Awareness in children	PEDIATRIC ANESTHESIA			English	Letter									Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Steward, DJ (reprint author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.	davidjsteward@comcast.net					CAMERON CB, 1984, ANESTH ANALG, V63, P418; JONMARKER C, 1987, ANESTHESIOLOGY, V67, P104, DOI 10.1097/00000542-198707000-00020; Van Oud-Alblas HJB, 2008, PEDIATR ANESTH, V18, P654, DOI 10.1111/j.1460-9592.2008.02576.x	3	0	0	0	0	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	FEB	2009	19	2					168	168		10.1111/j.1460-9592.2008.02907.x			1	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	397VH	WOS:000262689800013	19207902				2020-06-30	J	Eyigor, C; Uyar, M; Pirildar, S; Coker, M				Eyigor, Can; Uyar, Meltem; Pirildar, Sebnem; Coker, Mahmut			Combination therapy in treatment of peripheral diabetic neuropathy with severe pain in an adolescent patient	PEDIATRIC ANESTHESIA			English	Letter							TRIAL		[Eyigor, Can; Uyar, Meltem] Ege Univ, Dept Anesthesiol, Pain Clin, Fac Med, Izmir, Turkey; [Pirildar, Sebnem] Ege Univ, Fac Med, Dept Psychiat, Izmir, Turkey; [Coker, Mahmut] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey	Eyigor, C (reprint author), Ege Univ, Dept Anesthesiol, Pain Clin, Fac Med, Izmir, Turkey.	can.eyigor@yahoo.com.tr					Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; Duby JJ, 2004, AM J HEALTH-SYST PH, V61, P160, DOI 10.1093/ajhp/61.2.160; Harati Y, 1998, NEUROLOGY, V50, P1842, DOI 10.1212/WNL.50.6.1842; Vinik A, 2005, J CLIN ENDOCR METAB, V90, P4936, DOI 10.1210/jc.2004-2376; WATSON CP, 2000, J PAIN SYMPTOM MANAG, V20, P449	5	2	2	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	FEB	2009	19	2					193	194		10.1111/j.1460-9592.2008.02819.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	397VH	WOS:000262689800032	19207920				2020-06-30	J	Negus, SS; Bear, AE; Folk, JE; Rice, KC				Negus, S. Stevens; Bear, Ashley E.; Folk, John E.; Rice, Kenner C.			Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Delta opioid receptor; Mu opioid receptor; Interaction; Antinociception; Efficacy; Rhesus monkey	MU-MEDIATED ANTINOCICEPTION; SPRAGUE-DAWLEY RATS; AGONIST SNC80; THERMAL NOCICEPTION; RECEPTOR; MORPHINE; LIGANDS; BINDING; TRAFFICKING; COMBINATION	Delta opioid agonists can selectively enhance the antinociceptive effects of mu opioid agonists without enhancing some other, potentially undesirable mu agonist effects. However, the degree of delta receptor efficacy required to produce this profile of interactions is unknown. To address this issue, the present study examined interactions produced by the mu agonist fentanyl and the intermediate-efficacy delta opioid MSF61 in rhesus monkeys. For comparison, interactions were also examined between fentanyl and the relatively high-efficacy delta agonist SNC243A and the delta antagonist naltrindole, which has negligible efficacy at delta receptors. Two different behavioral procedures were used: (a) a warm-water tail-withdrawal assay of thermal nociception, and (b) an assay of schedule-controlled responding for food reinforcement. Drug interactions within each procedure were evaluated using dose-addition analysis to compare experimental results with expected additivity. Drug interactions across procedures were evaluated using dose-ratio analysis to assess relative potencies to produce antinociception vs. response-rate suppression. As expected, dose-addition analysis found that fentanyl/SNC243A interactions were superadditive in the assay of antinociception but additive in the assay of schedule-controlled responding. Conversely, fentanyl/MSF61 interactions were generally additive in both procedures, and fentanyl/naltrindole interactions were additive or subadditive in both procedures. Dose-ratio analysis found that fentanyl alone produced antinociception and rate suppression with similar potencies. Some fentanyl/SNC243A mixtures produced antinociception with up to 4-fold greater potency than rate-suppression. However, fentanyl/MSF61 and fentanyl/naltrindole mixtures produced antinociception with lower potency than rate suppression. These results suggest that relatively high delta receptor efficacy is required for mu/delta antinociceptive synergy. (C) 2008 Elsevier B.V. All rights reserved.	[Negus, S. Stevens] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Negus, S. Stevens; Bear, Ashley E.; Folk, John E.] Harvard Univ, McLean Hosp, Sch Med, Alcohol & Drug Abuse Res Ctr, Belmont, MA 02178 USA; [Rice, Kenner C.] Natl Inst Drug Abuse, Chem Biol Res Branch, Bethesda, MD USA; [Rice, Kenner C.] NIAAA, NIH, DHHS, Bethesda, MD USA	Negus, SS (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, 410 N 12th St,POB 980613, Richmond, VA 23298 USA.	ssnegus@vcu.edu			National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [Grant RO1-DA11460]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	This work was supported by Grant RO1-DA11460 from the National Institute on Drug Abuse, National Institutes of Health. A portion of this work was also supported by the Intramural Research Programs of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism. The authors would like to thank Joe Pocher, D.V.M., for expert veterinary assistance.	ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; ADAMS JU, 1993, J PHARMACOL EXP THER, V266, P1261; Ananthan S, 2006, AAPS J, V8, pE118, DOI 10.1208/aapsj080114; Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939; Cahill CM, 2003, PAIN, V101, P199, DOI 10.1016/S0304-3959(02)00333-0; Calderon SN, 1997, J MED CHEM, V40, P695, DOI 10.1021/jm960319n; Clark MJ, 1997, J PHARMACOL EXP THER, V283, P501; Danielsson I, 2006, PHARMACOL BIOCHEM BE, V85, P428, DOI 10.1016/j.pbb.2006.09.012; Dykstra L A, 1988, Psychopharmacol Ser, V4, P107; Dykstra LA, 2002, PSYCHOPHARMACOLOGY, V163, P420, DOI 10.1007/s00213-002-1100-8; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Furness MS, 2000, J MED CHEM, V43, P3193, DOI 10.1021/jm0001222; GERAK LR, 1994, J PHARMACOL EXP THER, V271, P993; GUTSTEIN H, 2005, PHARMACOL BASIS THER, P547; HEYMAN JS, 1989, EUR J PHARMACOL, V165, P1, DOI 10.1016/0014-2999(89)90764-4; HEYMAN JS, 1989, EUR J PHARMACOL, V169, P43, DOI 10.1016/0014-2999(89)90815-7; Jordan BA, 2000, NEUROPSYCHOPHARMACOL, V23, pS5, DOI 10.1016/S0893-133X(00)00143-3; Jutkiewicz EM, 2005, J PHARMACOL EXP THER, V312, P1314, DOI 10.1124/jpet.104.078741; Jutkiewicz EM, 2004, J PHARMACOL EXP THER, V309, P173, DOI 10.1124/jpet.103.061242; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Morgan D, 1999, J PHARMACOL EXP THER, V289, P965; Negus SS, 2008, EXP CLIN PSYCHOPHARM, V16, P386, DOI 10.1037/a0013088; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 1998, NEUROPSYCHOPHARMACOL, V18, P325; Negus SS, 1998, J PHARMACOL EXP THER, V286, P362; NEGUS SS, 1994, J PHARMACOL EXP THER, V270, P1025; NEGUS SS, 2002, NIDA RES MONOGR, V182, P20; Patwardhan AM, 2005, J NEUROSCI, V25, P8825, DOI 10.1523/JNEUROSCI.0160-05.2005; PORTOGHESE PS, 1988, EUR J PHARMACOL, V146, P185, DOI 10.1016/0014-2999(88)90502-X; ROTHMAN RB, 2004, DELTA RECEPTOR, P373; RUFFOLO RR, 1982, J AUTON PHARMACOL, V2, P277, DOI 10.1111/j.1474-8673.1982.tb00520.x; Stevenson GW, 2005, J PHARMACOL EXP THER, V314, P221, DOI 10.1124/jpet.104.082685; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; Su YF, 1998, J PHARMACOL EXP THER, V287, P815; TALLARIDA R, 2000, DRUG SYNERGISM DOSE; VAUGHT JL, 1979, J PHARMACOL EXP THER, V208, P86; WALKER EA, 1993, J PHARMACOL EXP THER, V267, P280; WESSINGER WD, 1986, NEUROSCI BIOBEHAV R, V10, P103, DOI 10.1016/0149-7634(86)90021-7; WOODS JH, 1982, FED PROC, V41, P221; WOOLVERTON WL, 1987, NEUROBEHAVIORAL PHAR, P275; Zhang X, 1998, NEUROSCIENCE, V82, P1225	44	27	28	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	JAN 5	2009	602	1					92	100		10.1016/j.ejphar.2008.11.004			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	401WD	WOS:000262972300015	19027735	Green Accepted			2020-06-30	J	Pesonen, A; Suojaranta-Ylinen, R; Hammaren, E; Tarkkila, P; Seppala, T; Rosenberg, PH				Pesonen, A.; Suojaranta-Ylinen, R.; Hammaren, E.; Tarkkila, P.; Seppala, T.; Rosenberg, P. H.			Comparison of effects and plasma concentrations of opioids between elderly and middle-aged patients after cardiac surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							ARTERY-BYPASS SURGERY; POSTOPERATIVE PAIN; CHINESE PATIENTS; FENTANYL; REQUIREMENTS; ANALGESIA; MORPHINE; PHARMACODYNAMICS; PHARMACOKINETICS; APPLICABILITY	In elderly patients, opioids may cause prominent postoperative sedation and respiratory depression. We evaluated the influence of age on the effects of opioids and plasma concentrations of fentanyl and oxycodone in cardiac surgery patients. Thirty (>= 75 years, gender M9/F21) and 20 (<= 60 years, gender M20/F0) patients scheduled to undergo cardiac surgery. A standard anesthesia with fentanyl as an opioid was used. Fentanyl plasma concentrations were measured at the end of surgery and 2 h later. After tracheal extubation, when the pain intensity was at least moderate, blood samples for fentanyl and oxycodone plasma concentration measurements were taken. Thereafter, oxycodone hydrochloride 0.05 mg/kg i.v. was administered. After 15 and 45 min, pain intensity, sedation and oxycodone plasma concentration were determined. This test protocol was repeated twice. The elderly had a higher plasma concentration of fentanyl at the end of surgery than younger patients (5.7 +/- 2.2 vs. 3.8 +/- 1.2 ng/ml, P=0.001). The plasma concentrations of oxycodone were comparable between the groups. The interval between the second and the third oxycodone dose was longer in the elderly patients (P=0.036). Pain intensity on the verbal rating scale was lower at the 45-min assessment point after all three oxycodone test doses (P=0.008) and sedation scores were significantly higher after the third dose in the elderly patients (P=0.035). In elderly patients, the plasma concentration of fentanyl was higher but plasma levels of oxycodone were at a similar level compared with middle-aged patients. However, the elderly patients had less pain and were more sedated after doses of oxycodone.	[Pesonen, A.; Suojaranta-Ylinen, R.; Hammaren, E.; Tarkkila, P.; Rosenberg, P. H.] Helsinki Univ Hosp, Dept Anesthesiol & Intens Care Med, FI-00029 Helsinki, Finland; [Seppala, T.] Natl Inst Hlth Finland, Helsinki, Finland	Pesonen, A (reprint author), Helsinki Univ Hosp, Dept Anaesthesiol, POB 340, FI-00029 Helsinki, Finland.	Anne.Pesonen@hus.fi			Helsinki University Hospital Research Fund; Finska Lakaresallskapet, Finland	This work was supported by the Helsinki University Hospital Research Fund and Finska Lakaresallskapet, Finland.	Ahonen J, 2000, BRIT J ANAESTH, V85, P533, DOI 10.1093/bja/85.4.533; Aubrun F, 2005, ANESTHESIOLOGY, V103, P156, DOI 10.1097/00000542-200507000-00023; Bowie Mark W, 2007, Am J Geriatr Pharmacother, V5, P263, DOI 10.1016/j.amjopharm.2007.10.001; Cepeda MS, 2003, ANESTH ANALG, V97, P1464, DOI 10.1213/01.ANE.0000080153.36643.83; Chia YY, 2002, CAN J ANAESTH, V49, P249, DOI 10.1007/BF03020523; GAGLIESE L, 1997, PAIN RES MANAG, V103, P11; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hadjistavropoulos T, 2007, CLIN J PAIN, V23, pS1, DOI 10.1097/AJP.0b013e31802be869; Hudson RJ, 2002, CAN J ANAESTH, V49, P388, DOI 10.1007/BF03017328; Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004; Kaiko RF, 1996, CLIN PHARMACOL THER, V59, P52, DOI 10.1016/S0009-9236(96)90024-7; Kokubun H, 2007, BIOL PHARM BULL, V30, P2173, DOI 10.1248/bpb.30.2173; Lahtinen P, 2006, ANESTHESIOLOGY, V105, P794, DOI 10.1097/00000542-200610000-00026; Liu YT, 2007, DRUG METAB REV, V39, P699, DOI 10.1080/03602530701690374; LIUKAS A, 2008, CLIN PHARMACOL THER, V64, P1; Lugo Ralph A, 2004, J Pain Palliat Care Pharmacother, V18, P17; Macintyre PE, 1996, PAIN, V64, P357, DOI 10.1016/0304-3959(95)00128-X; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Pesonen A, 2008, ACTA ANAESTH SCAND, V52, P267, DOI 10.1111/j.1399-6576.2007.01480.x; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Silbert BS, 2006, ANESTHESIOLOGY, V104, P1137, DOI 10.1097/00000542-200606000-00007; Suojaranta-Ylinen RT, 2006, J CARDIOTHOR VASC AN, V20, P526, DOI 10.1053/j.jvca.2005.11.016; Swift CG, 2003, BRIT J CLIN PHARMACO, V56, P249, DOI 10.1046/j.1365-2125.2003.01938.x; TIGERSTEDT I, 1988, SCHMERZ PAIN DOULEUR, V9, P27; Tsui SL, 1996, ANAESTH INTENS CARE, V24, P658, DOI 10.1177/0310057X9602400604; Wilder-Smith OHG, 2005, EUR J PAIN, V9, P137, DOI 10.1016/j.ejpain.2004.07.011	27	15	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2009	53	1					101	108		10.1111/j.1399-6576.2008.01819.x			8	Anesthesiology	Anesthesiology	384YO	WOS:000261780300016	19032559				2020-06-30	J	Unoki, T; Grap, MJ; Sessler, CN; Best, AM; Wetzel, P; Hamilton, A; Mellott, KG; Munro, CL				Unoki, Takeshi; Grap, Mary Jo; Sessler, Curtis N.; Best, Al M.; Wetzel, Paul; Hamilton, Anne; Mellott, Karen G.; Munro, Cindy L.			AUTONOMIC NERVOUS SYSTEM FUNCTION AND DEPTH OF SEDATION IN ADULTS RECEIVING MECHANICAL VENTILATION	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							HEART-RATE-VARIABILITY; ORGAN DYSFUNCTION SYNDROME; PATIENT STATE INDEX; SPECTRAL-ANALYSIS; MIDAZOLAM SEDATION; ARTERIAL-PRESSURE; PROPOFOL; HUMANS; CARE; ANESTHESIA	Background The effect of the depth of sedation on the function of the autonomic nervous system is not well known. Objectives To describe the effect of level of sedation on heart rate variability as a marker of the function of the autonomic nervous system in patients receiving mechanical ventilation. Methods This pilot study was part of a larger study in which sedation level was measured continuously for up to 24 hours. The sample consisted of 14 patients receiving mechanical ventilation. The R-R interval was measured continuously via electrocardiography. Sedation level was determined by using the Patient State Index and was categorized as deep (<60) or light (>= 60). Continuous heart rate data of 5 to 10 minutes for each sedation level for each patient were analyzed. Results Parasympathetic activity as indicated by root mean square of successive difference of the R-R interval, the high-frequency component, and the percentage of differences of successive N-N intervals (intervals due to normal sinus depolarization) that differed more than 50 milliseconds was significantly lower for deep sedation than for light sedation. The markers indicating sympathetic activity, including the low-frequency component and the ratio of the low-frequency component to the high-frequency component, did not differ significantly between the 2 levels of sedation. Most patients were receiving benzodiazepines. Conclusions Deep sedation may be associated with depression of parasympathetic function in patients receiving mechanical ventilation. Use of benzodiazepines most likely contributed to this finding. (American Journal of Critical Care. 2009;18:42-51)	[Unoki, Takeshi] St Lukes Coll Nursing, Dept Adult Nursing, Sch Nursing, Tokyo, Japan; [Grap, Mary Jo; Hamilton, Anne; Mellott, Karen G.; Munro, Cindy L.] Virginia Commonwealth Univ, Sch Nursing, Richmond, VA USA; [Best, Al M.] Virginia Commonwealth Univ, Dept Internal Med, Sch Med, Richmond, VA USA; [Best, Al M.] Virginia Commonwealth Univ, Sch Med, Dept Biostat, Richmond, VA USA; [Wetzel, Paul] Virginia Commonwealth Univ, Sch Engn, Dept Biomed Engn, Richmond, VA USA	Unoki, T (reprint author), St Lukes Coll Nursing, Dept Adult Nursing, Sch Nursing, Tokyo, Japan.	tunoki@slcn.ac.jp	Best, Al/F-6425-2012	Best, Al/0000-0002-6300-3925	Physiometrix Inc; North Billerica; Massachusetts; National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31-NR009623]	This study was supported by Physiometrix Inc, North Billerica, Massachusetts, and grant F31-NR009623 from the National Institute of Nursing Research to Karen Mellott.	Agelink MW, 2002, CRIT CARE MED, V30, P997, DOI 10.1097/00003246-200205000-00008; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; Bilan A, 2005, J ELECTROCARDIOL, V38, P239, DOI 10.1016/j.jelectrocard.2005.01.012; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; BROWN TE, 1993, J APPL PHYSIOL, V75, P2310; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Camm AJ, 1996, EUR HEART J, V17, P354; Chase JG, 2004, COMPUT METH PROG BIO, V76, P131, DOI 10.1016/j.cmpb.2004.03.005; Chen GY, 1997, ANAESTHESIA, V52, P653, DOI 10.1111/j.1365-2044.1997.114-az0106.x; Chen XG, 2002, ANESTH ANALG, V95, P1669, DOI 10.1097/00000539-200212000-00036; Ebert TJ, 2005, ANESTHESIOLOGY, V103, P20, DOI 10.1097/00000542-200507000-00007; ECKBERG DL, 1983, J APPL PHYSIOL, V54, P961; FEI L, 1994, J AM COLL CARDIOL, V24, P1515, DOI 10.1016/0735-1097(94)90148-1; FORSTER A, 1980, ANESTHESIOLOGY, V53, P494, DOI 10.1097/00000542-198012000-00010; FURLAN R, 1990, CIRCULATION, V81, P537, DOI 10.1161/01.CIR.81.2.537; Galletly DC, 1996, BRIT J ANAESTH, V76, P503; Haberthur C, 1996, INTENS CARE MED, V22, P1385, DOI 10.1007/s001340050268; Hogarth D Kyle, 2004, Curr Opin Crit Care, V10, P40, DOI 10.1097/00075198-200402000-00007; HUIKURI HV, 1995, AM J CARDIOL, V76, P56, DOI 10.1016/S0002-9149(99)80801-7; Jacobsohn Eric, 2005, J Clin Monit Comput, V19, P219, DOI 10.1007/s10877-005-3546-9; Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009; Korach M, 2001, CRIT CARE MED, V29, P1380, DOI 10.1097/00003246-200107000-00013; Kress JP, 2006, CRIT CARE MED, V34, P2541, DOI 10.1097/01.CCM.0000239117.39890.E3; LATSON TW, 1993, BRIT J ANAESTH, V70, P301, DOI 10.1093/bja/70.3.301; Li D, 2004, CRIT CARE NURSE, V68, P72; LI D, 2004, CRIT CARE NURSE, V24, P70; Li Denise, 2004, Crit Care Nurse, V24, P72; Lombardi Federico, 2002, Card Electrophysiol Rev, V6, P245, DOI 10.1023/A:1016329008921; LUMB BL, 2000, NUNNS APPL RESPIRATO, P420; MALLIANI A, 1994, J CARDIOVASC ELECTR, V5, P274, DOI 10.1111/j.1540-8167.1994.tb01164.x; Munro CL, 2006, AM J CRIT CARE, V15, P453; Nishiyama T, 2002, J CLIN ANESTH, V14, P344, DOI 10.1016/S0952-8180(02)00370-7; OFLAHERTY D, 1993, EUR J ANAESTH, V10, P419; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; Pontet J, 2003, J CRIT CARE, V18, P156, DOI 10.1016/j.jcrc.2003.08.005; Poyhonen M, 2004, ACTA ANAESTH SCAND, V48, P93, DOI 10.1111/j.1399-6576.2004.00272.x; Pruvot E, 2000, CIRCULATION, V101, P2398, DOI 10.1161/01.CIR.101.20.2398; Robinson BJ, 1997, ANESTHESIOLOGY, V86, P64, DOI 10.1097/00000542-199701000-00010; Schmidt H B, 2001, Curr Opin Crit Care, V7, P314, DOI 10.1097/00075198-200110000-00002; Schmidt H, 2005, CRIT CARE MED, V33, P1994, DOI 10.1097/01.CCM.0000178181.91250.99; Schneider G, 2004, INTENS CARE MED, V30, P213, DOI 10.1007/s00134-003-2092-5; Sessler CN, 2005, CHEST, V128, p151S, DOI 10.1378/chest.128.3.1101; Sessler CN, 2001, SEMIN RESP CRIT CARE, V22, P211, DOI 10.1055/s-2001-13834; Stein PK, 2001, CRIT CARE MED, V29, P1738, DOI 10.1097/00003246-200109000-00014; Sztajzel J, 2004, SWISS MED WKLY, V134, P514; Uemura S, 1997, JPN CIRC J, V61, P819, DOI 10.1253/jcj.61.819; Win NN, 2005, ANESTH ANALG, V101, P97, DOI 10.1213/01.ANE.0000156204.89879.5C; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011	48	19	19	1	1	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264	1937-710X		AM J CRIT CARE	Am. J. Crit. Care	JAN 1	2009	18	1					42	50		10.4037/ajcc2009509			9	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	389LP	WOS:000262094400013	19116404	Green Accepted			2020-06-30	J	Elkiweri, IA; Zhang, YL; Christians, U; Ng, KY; van Patot, MCT; Henthorn, TK				Elkiweri, Iman A.; Zhang, Yan Ling; Christians, Uwe; Ng, Ka-Yun; van Patot, Martha C. Tissot; Henthorn, Thomas K.			Competitive Substrates for P-Glycoprotein and Organic Anion Protein Transporters Differentially Reduce Blood Organ Transport of Fentanyl and Loperamide: Pharmacokinetics and Pharmacodynamics in Sprague-Dawley Rats	ANESTHESIA AND ANALGESIA			English	Article							MU-OPIOID RECEPTOR; BRAIN-BARRIER; POLYPEPTIDES; ALFENTANIL; MEDIATE; MODEL	BACKGROUND: Drug transport proteins may be instrumental in controlling the concentration of fentanyl at mu receptors in the brain and may provide potential therapeutic targets for controlling an individual response to opioid administration. P-glycoprotein (P-gp)) efflux transporter and organic anion transport protein inward transporters (OATP, human; Oatp, rat) have been implicated in fentanyl and verapamil (only P-gp) transport across the blood-brain barrier. We hypothesized that transport proteins P-gp) and Oatp mediate opioid uptake in a drug and organ-specific manner, making them excellent potential targets for therapeutic intervention. METHODS: Opioid (fentanyl or loperamide) was administered by IV infusion to prague- aw ev rats alo e or in combination with competitive Substrates of I-gp (verapamil) or Oatp (pravastatin, naloxone). Plasma, lung, and brain were collected over 10 min and at 60 min after opioid infusion and opioid concentration determined using liquid chromatography/mass spectrometry (LC/LC-MS/MS). Continuous electroencephalogram was used to determine the in vivo response to fentanyl and loperamide in the presence and absence of verapamil. RESULTS: Loperamide brain;plasma (P-B) and lung:plasma (P-L) partitioning was increased two and fivefold, respectively in the presence of verapamil. Verapamil administration was lethal Unless the loperamide dose was reduced by half (0.95-0.475 mg/kg). Fentanyl brain:plasma and lung:plasma were reduced (Our and sixfold, respectively, by pravastatin and naloxone, whereas verapamil had much less effect. Electroencephalogram results indicated that verapamil reduced the fentanyl-induced central nervous system (CNS) effect and increased the loperamide CNS effect. CONCLUSION: Protein transporters appear to be organ and drug-specific in vivo, affecting first-pass pulmonary uptake and CNS response to opioid administration. Further, data suggest that transport protein inhibition may prove useful for normalizing an individual response to opioids.	[Zhang, Yan Ling; Christians, Uwe; Ng, Ka-Yun; van Patot, Martha C. Tissot; Henthorn, Thomas K.] Univ Colorado, Hlth Sci Ctr, Dept Anesthesiol, Denver, CO USA; [Elkiweri, Iman A.] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Nursing, Jeddah, Saudi Arabia; [Elkiweri, Iman A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; [Ng, Ka-Yun] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore	van Patot, MCT (reprint author), Univ Colorado Denver, Dept Anesthesiol, Campus Box 8202,Bldg AO1,Room L15-2009,POB 6511,1, Aurora, CO 80045 USA.	martha.tissotvanpatot@ucdenver.edu		Tissot van Patot, Martha/0000-0002-2934-366X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-GM47502.09]; Nema Foundation, Malaysia	Supported by National Institutes of Health Grant R01-GM47502.09 and in part by the Nema Foundation, Malaysia.	Bhatti MM, 1997, BIOPHARM DRUG DISPOS, V18, P387, DOI 10.1002/(SICI)1099-081X(199707)18:5<387::AID-BDD26>3.0.CO;2-X; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; EBLING WF, 1990, ANESTHESIOLOGY, V72, P650, DOI 10.1097/00000542-199004000-00013; Gao B, 2000, J PHARMACOL EXP THER, V294, P73; Gao P, 1999, J HISTOCHEM CYTOCHEM, V47, P1255, DOI 10.1177/002215549904701005; GUSTAFSSON LL, 1992, PHARMACEUT RES, V9, P800, DOI 10.1023/A:1015863824277; Hagenbuch B, 2003, BBA-BIOMEMBRANES, V1609, P1, DOI 10.1016/S0005-2736(02)00633-8; Hagenbuch B, 2002, NEWS PHYSIOL SCI, V17, P231, DOI 10.1152/nips.01402.2002; Hanks G, 2005, SUPPORT CARE CANCER, V13, P145, DOI 10.1007/s00520-004-0730-2; HEEL RC, 1978, DRUGS, V15, P33, DOI 10.2165/00003495-197815010-00003; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Henthorn TK, 1998, INT J CLIN PHARM TH, V36, P74; HEYKANTS J, 1974, ARZNEIMITTEL-FORSCH, V24, P1649; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; LUDDEN TM, 1994, J PHARMACOKINET BIOP, V22, P431, DOI 10.1007/BF02353864; Nozaki-Taguchi N, 1999, ANESTHESIOLOGY, V90, P225, DOI 10.1097/00000542-199901000-00029; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Seithel A, 2007, DRUG METAB DISPOS, V35, P779, DOI 10.1124/dmd.106.014407; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Waters CM, 1999, J PHARMACOL EXP THER, V288, P157; Waters CM, 2000, ANESTHESIOLOGY, V93, P825, DOI 10.1097/00000542-200009000-00033	23	35	36	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2009	108	1					149	159		10.1213/ane.0b013e31818e0bd1			11	Anesthesiology	Anesthesiology	387PB	WOS:000261963000023	19095843	Green Accepted			2020-06-30	J	Horstman, DJ; Riley, ET; Carvalho, B				Horstman, Damian J.; Riley, Edward T.; Carvalho, Brendan			A Randomized Trial of Maximum Cephalad Sensory Blockade with Single-Shot Spinal Compared with Combined Spinal-Epidural Techniques for Cesarean Delivery	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	39th Annual Meeting of the Society-for-Obstetric-Anesthesia-and-Perinatology	MAY 16-19, 2007	Banff, CANADA	Soc Obstet Anesthesia & Perinatol			CEREBROSPINAL-FLUID VOLUME; ANESTHESIA; DURATION; EXTENT; SECTION; SPREAD; LEVEL	BACKGROUND: Previous studies have shown more extensive cephalad sensory blockade in women receiving combined spinal-epidural (CSE) anesthesia compared with single-shot spinal (SSS) anesthesia for elective cesarean delivery. It has been postulated that introduction of the epidural needle during CSE disturbs the negative pressure in the epidural space, resulting in relatively greater cerebrospinal fluid (CSF) pressure and increased spread of intrathecal local anesthetic. We tested the hypothesis that CSE results in more extensive cephalad sensory blockade than SSS anesthesia and that loss-of-resistance during initiation of CSE anesthesia increases CSF pressure compared with SSS. METHODS: Thirty parturients scheduled for elective cesarean delivery were enrolled in this randomized, double-blind study. Patients received either SSS or CSE anesthesia with equal doses of intrathecal anesthetic (hyperbaric bupivacaine 12 mg, fentanyl 10 mu g and morphine 200 mu g). Before the intrathecal injection, the CSF pressure was measured with a fiberoptic pressure sensor. Maximum cephalad touch was measured. The total sensory blockade to pinprick, cold and lose of phenylephrine required to maintain baseline arterial blood pressure was also recorded. RESULTS: There were no significant differences in the median (interquartile range) pinprick sensory block height [T4 (T4-2) vs T3 (T4-1)] or CSF pressures [6 (4-12) vs 9 (8-12) mm Hg] between the SSS and CSE groups, There were no significant correlations between CSF pressure and block height or total dose of phenylephrine. CONCLUSION: The SSS and CSE techniques inserted in the lateral decubitus position resulted in similar extent of sensory blockade and CSF pressure. These findings Suggest that altering the intrathecal dose is not necessary and that any difference in intrathecal pressure associated with initial placement of an epidural needle in the epidural space during CSE anesthesia is clinically inconsequential.	[Horstman, Damian J.; Riley, Edward T.; Carvalho, Brendan] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA	Carvalho, B (reprint author), Stanford Univ, Sch Med, Dept Anesthesia, H3580, Stanford, CA 94305 USA.	bcarvalho@stanford.edu					Bucklin BA, 2005, ANESTHESIOLOGY, V103, P645, DOI 10.1097/00000542-200509000-00030; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; Congreve K, 2006, ANAESTHESIA, V61, P453, DOI 10.1111/j.1365-2044.2006.04609.x; Cooper DW, 2007, BRIT J ANAESTH, V98, P649, DOI 10.1093/bja/aem056; Cooper DW, 2004, ANESTHESIOLOGY, V101, P28, DOI 10.1097/00000542-200407000-00007; Goy RWL, 2004, ANESTH ANALG, V98, P491, DOI 10.1213/01.ANE.0000097182.DE; Higuchi H, 2005, ANESTH ANALG, V101, P555, DOI 10.1213/01.ANE.0000158465.17547.F1; Higuchi H, 2004, ANESTHESIOLOGY, V100, P106, DOI 10.1097/00000542-200401000-00019; Ithnin F, 2006, ANESTH ANALG, V102, P577, DOI 10.1213/01.ane.0000195440.51717.37; Jenkins JG, 2003, ANAESTHESIA, V58, P1114, DOI 10.1046/j.1365-2044.2003.03446.x; Lim PL, 2006, IMMUNOL LETT, V103, P17, DOI 10.1016/j.imlet.2005.10.023; OKUTOMI T, 1993, CAN J ANAESTH, V40, P1044, DOI 10.1007/BF03009475; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; TELFORD RJ, 1991, ANAESTHESIA, V46, P725, DOI 10.1111/j.1365-2044.1991.tb09765.x	15	16	17	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2009	108	1					240	245		10.1213/ane.0b013e31818e0fa6			6	Anesthesiology	Anesthesiology	387PB	WOS:000261963000037	19095857				2020-06-30	